{"generated":"2026-09-04T11:36:38Z","content_changed":"2026-09-03T17:37:17Z","count":4516,"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","note":"Metadata van elk artikel, nieuwste eerst. Volledige tekst: corpus.json of het index.json naast elk artikel.","articles":[{"id":"649e34b9472d","type":"article","url":"https://hartvaat.nl/2026/10/01/emboliebescherming-en-farmacotherapie-bij-tavr-update-over-strokepreventie/","title":"Emboliebescherming en farmacotherapie bij TAVR: update over strokepreventie","title_en":"Neurologic Complications after Transcatheter Aortic Valve Replacement: An Updated Review of Incidence, Current Treatments, and Future Directions.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Interventional cardiology clinics","doi":"10.1016/j.iccl.2026.05.003","source_url":"https://doi.org/10.1016/j.iccl.2026.05.003","authors":["Ritik Patel","Tyler Andrews","Tiberio M Frisoli"],"significance":6,"published":"2026-09-04","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This review summarizes the incidence, timing, and mechanisms of neurological complications following TAVR, focusing on procedural embolization and patient comorbidities. Although cerebral embolic protection devices and pharmacological strategies are increasingly utilized, randomized trials have not yet demonstrated consistent stroke reduction. An individualized prevention strategy that carefully balances thromboembolic and bleeding risks across acute, subacute, and late post-procedural periods remains essential for daily clinical decision-making.","created":"2026-08-29T00:59:40Z","updated":"2026-08-29T00:59:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"83c76dd00bc3","type":"article","url":"https://hartvaat.nl/2026/10/01/il-6-remmers-als-nieuwe-aanpak-bij-chronische-nierziekte-en-hart-en-vaatziekten/","title":"IL-6-remmers als nieuwe aanpak bij chronische nierziekte en hart- en vaatziekten","title_en":"Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106712","source_url":"https://doi.org/10.1016/j.ekir.2026.106712","authors":["Katherine R Tuttle","David Z Cherney","Roberto Pecoits-Filho","Matteo Pirro","Kevin Yau","Manisha Sahay"],"significance":5,"published":"2026-09-04","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This narrative review examines the role of the interleukin-6 (IL-6) pathway in the shared pathophysiology of chronic kidney disease and cardiovascular disease. It synthesizes current clinical evidence on IL-6 upregulation and evaluates the potential of emerging anti-inflammatory therapies, particularly IL-6 inhibitors, to mitigate cardiorenal risk. While standard treatments often fall short in addressing underlying inflammation, the authors emphasize the need for robust trials to establish the efficacy and long-term safety of targeted immunomodulation. The review offers clinicians a concise overview of a promising therapeutic avenue that remains under active investigation.","created":"2026-08-29T00:56:40Z","updated":"2026-08-29T00:56:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56914e23aca6","type":"article","url":"https://hartvaat.nl/2026/10/01/nitraatsuppletie-haalbaar-en-veilig-bij-zwangeren-met-ckd-orchard-beet/","title":"Nitraatsuppletie haalbaar en veilig bij zwangeren met CKD — ORCHARD-BEET","title_en":"Randomized Trial of Dietary Nitrate Supplementation in CKD Pregnancy (ORCHARD-BEET).","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106704","source_url":"https://doi.org/10.1016/j.ekir.2026.106704","authors":["Priscilla Smith","Danielle Ashworth","Rachel Hung","Yanzhong Wang","Andrew J Webb","Kathryn Dalrymple","Katherine Clark","Lucy C Chappell","Kate Wiles","Kate Bramham"],"significance":3,"published":"2026-09-04","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"A multicenter RCT randomised 108 pregnant women with moderate-to-severe chronic kidney disease to daily dietary nitrate supplementation (beetroot juice, 400 mg) or standard care, primarily as a feasibility study. Secondary outcomes suggested lower postpartum creatinine, fewer neonatal intensive care admissions, and fewer serious adverse events in the nitrate group, though efficacy endpoints did not reach statistical significance due to limited sample size. The findings indicate that nitrate supplementation is safe and feasible in this high-risk population, but a larger, adequately powered trial is required to confirm any clinical benefit for maternal or neonatal outcomes.","created":"2026-08-29T00:53:15Z","updated":"2026-08-29T00:53:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"475d32037a16","type":"article","url":"https://hartvaat.nl/2026/12/01/weight-adjusted-waist-index-voorspelt-cardiovasculaire-sterfte-bij-chronische-ni/","title":"Weight-adjusted waist index voorspelt cardiovasculaire sterfte bij chronische nierziekte","title_en":"Weight-adjusted waist index and risk of cardiovascular and all-cause mortality in chronic kidney disease: NHANES 2005-2018 analysis of 5,381 adults.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2718572","source_url":"https://doi.org/10.1080/0886022X.2026.2718572","authors":["Zhendong Wang","Xiumei Li","Xiangrong Zhu","Qiufa Hao","Fanwu Kong","Guangyi Liu"],"significance":5,"published":"2026-09-04","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"In a prospective cohort analysis of 5,381 US adults with chronic kidney disease (CKD), a higher weight-adjusted waist index (WWI) was significantly associated with increased risks of cardiovascular mortality (HR 1.73) and all-cause mortality (HR 1.45) over a median follow-up of 79 months. Systemic inflammation partially mediated this relationship, and WWI demonstrated strong predictive accuracy (AUC 0.793 for CVD mortality). Incorporating WWI into routine risk stratification may help identify high-risk cardio-renal-metabolic phenotypes beyond conventional obesity measures.","created":"2026-08-29T00:49:19Z","updated":"2026-08-29T00:49:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e230137fd84","type":"article","url":"https://hartvaat.nl/2026/12/01/ckd-geassocieerde-jeuk-komt-bij-60-van-dialysepatienten-voor-lage-behandelgraad/","title":"CKD-geassocieerde jeuk komt bij 60% van dialysepatiënten voor — lage behandelgraad","title_en":"Epidemiological characteristics and factors associated with chronic kidney disease-associated pruritus in the Chinese adult dialysis population: a multicenter, cross-sectional study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2702238","source_url":"https://doi.org/10.1080/0886022X.2026.2702238","authors":["Xi Yao","Ping Zhang","Chunping Xu","Xin Lei","Shilong Xiang","Xiaohui Zhang","Yaomin Wang","Liangliang Chen","Qi Guo","Xiaoying Du","Jianghua Chen"],"significance":5,"published":"2026-09-04","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A multicentre cross-sectional study of 9,589 dialysis patients reveals a high prevalence of chronic kidney disease-associated pruritus (60.3%), with only 2.9% receiving potentially effective treatment. Pruritus severity was significantly associated with modifiable and non-modifiable factors, including cardiovascular disease, diabetes, dialysis vintage, eosinophil count, and calcium and phosphorus levels. These findings highlight a substantial treatment gap and point to specific targets for improving symptom management in dialysis care.","created":"2026-08-29T00:45:54Z","updated":"2026-08-29T00:45:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2da342a44b29","type":"article","url":"https://hartvaat.nl/2026/08/26/gestructureerd-overdrachtspad-vermindert-zorgonderbreking-bij-erfelijke-hartritm/","title":"Gestructureerd overdrachtspad vermindert zorgonderbreking bij erfelijke hartritmestoornissen","title_en":"Paediatric-to-adult transition in inherited arrhythmia syndromes.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag610","source_url":"https://doi.org/10.1093/eurheartj/ehag610","authors":["Mayank Sardana","Ciorsti MacIntyre","John R Giudicessi","Michael J Ackerman"],"significance":7,"published":"2026-09-03","source_date":"2026-08-26","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/"],"congress":"","summary_en":"This European Heart Journal review addresses the frequent loss to follow-up and care gaps when transitioning patients with inherited arrhythmia syndromes (LQTS, CPVT, Brugada) from paediatric to adult services. It proposes a pragmatic pathway beginning in early adolescence, utilising a patient-held health passport and one of three transfer models (joint clinic, staged overlap, or virtual co-management) around age 19. A dedicated transition coordinator and standardised handover summaries are highlighted as key to maintaining continuity. Implementing these structured pathways can significantly reduce preventable morbidity and support safe management of lifestyle, pregnancy, and long-term follow-up in this vulnerable population.","created":"2026-08-27T01:32:51Z","updated":"2026-08-27T01:32:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e987b75501ea","type":"article","url":"https://hartvaat.nl/2026/08/26/de-vaguszenuw-bij-myocardinfarct-mechanismen-reflexen-en-klinische-perspectieven/","title":"De vaguszenuw bij myocardinfarct: mechanismen, reflexen en klinische perspectieven","title_en":"The vagus nerve in myocardial infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag674","source_url":"https://doi.org/10.1093/eurheartj/ehag674","authors":["Gerd Heusch","Petra Kleinbongard","Alexander V Gourine"],"significance":5,"published":"2026-09-03","source_date":"2026-08-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ischemie-reperfusieschade/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This review outlines the role of the vagus nerve in myocardial infarction, bridging preclinical mechanisms with early clinical observations. Vagal activation counteracts sympathetic overdrive and may limit infarct size and inflammation via reflexes such as the Bezold-Jarisch response and remote ischaemic conditioning. While experimental data are promising, the clinical efficacy of vagal stimulation in ischaemic heart disease requires validation in larger trials. The article provides a mechanistic overview that may inform future cardioprotective strategies.","created":"2026-08-27T01:28:14Z","updated":"2026-08-27T01:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0c14899e397","type":"article","url":"https://hartvaat.nl/2026/08/26/vutrisiran-stabiliseert-rechterventrikel-functie-bij-attr-cardiomyopathie-helios/","title":"Vutrisiran stabiliseert rechterventrikel-functie bij ATTR-cardiomyopathie — HELIOS-B","title_en":"Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2026.3390","source_url":"https://doi.org/10.1001/jamacardio.2026.3390","authors":["Karola S Jering","Alireza Manafi","Brian L Claggett","Marianna Fontana","Julian D Gillmore","Bernard E Bulwer","Farideh Roshanali","Narayana Prasad","Patrick Y Jay","Scott D Solomon","Hicham Skali"],"significance":7,"published":"2026-09-03","source_date":"2026-08-26","image":"","kennis":[],"congress":"","summary_en":"In a post hoc analysis of the HELIOS-B trial in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), impaired right ventricular free wall strain (RVFWS) was highly prevalent and independently predicted mortality and recurrent cardiovascular events, whereas conventional RV measures lost prognostic significance after adjustment. Vutrisiran treatment stabilized RVFWS and improved RVFWS indexed to pulmonary artery pressure at 30 months. These findings highlight the prognostic value of advanced right ventricular imaging in ATTR-CM and reinforce the cardioprotective effects of vutrisiran beyond left-sided metrics.","created":"2026-08-27T01:23:00Z","updated":"2026-08-27T01:23:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c985c5fc225a","type":"article","url":"https://hartvaat.nl/2026/08/26/grijze-zone-analyse-van-late-gadolinium-enhancement-verbetert-scd-risicoschattin/","title":"Grijze-zone-analyse van late gadolinium enhancement verbetert SCD-risicoschatting bij hypertrofie cardiomyopathie","title_en":"Enhancing risk prediction for sudden cardiac death: quantitative late gadolinium enhancement analysis in hypertrophic cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Insights into imaging","doi":"10.1186/s13244-026-02385-3","source_url":"https://doi.org/10.1186/s13244-026-02385-3","authors":["Lili Wang","Hongbo Zhang","Guanyu Lu","Junjie Zhou","Zhihui Lu","Lanling Wang","Chen Zhang","Xiaohai Ma","Shuang Li","Lei Zhao"],"significance":5,"published":"2026-09-03","source_date":"2026-08-26","image":"https://hartvaat.nl/global/img/4b75b2193592.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/ischemische-cardiomyopathie/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"A single-center retrospective study of 617 patients with hypertrophic cardiomyopathy (HCM) demonstrates that quantitative late gadolinium enhancement (LGE) assessment on cardiac MRI independently predicts sudden cardiac death (SCD). Dual-threshold gray-zone metrics showed stronger prognostic associations than conventional single-threshold methods, and both approaches significantly improved risk discrimination beyond the standard AHA/ACC guideline model. These findings highlight the need for standardized LGE quantification to optimize SCD risk stratification in clinical practice.","created":"2026-08-27T01:18:04Z","updated":"2026-08-27T01:18:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4f1125f4adc","type":"article","url":"https://hartvaat.nl/2026/08/26/dapagliflozin-vermindert-epicardiaal-vetweefsel-onafhankelijk-van-gewichtsverlie/","title":"Dapagliflozin vermindert epicardiaal vetweefsel onafhankelijk van gewichtsverlies — MRI-analyse","title_en":"Impact of Dapagliflozin on MRI-Derived Epicardial Adipose Tissue: Secondary Imaging Analysis of a Randomized Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of magnetic resonance imaging : JMRI","doi":"10.1002/jmri.70526","source_url":"https://doi.org/10.1002/jmri.70526","authors":["Min Jae Cha","Negar Firoozeh","Anna V Naumova","Peter Muzi","Karen G Ordovas","Dennis D Wang","Daniel Isquith","Chuck Maynard","Xue-Qiao Zhao","Francis Kim"],"significance":3,"published":"2026-09-03","source_date":"2026-08-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"In a randomized trial of 56 patients with type 2 diabetes without overt cardiovascular disease, dapagliflozin significantly reduced MRI-derived epicardial adipose tissue (EAT) thickness compared with placebo over 12 months (-0.8 mm vs. 0.1 mm). Mediation analysis indicated this reduction was largely independent of concomitant weight loss. The findings highlight EAT as a responsive imaging biomarker and provide mechanistic insight into the cardiometabolic benefits of SGLT2 inhibitors beyond glycemic control or weight reduction.","created":"2026-08-27T01:12:45Z","updated":"2026-08-27T01:12:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"814f6edb201a","type":"article","url":"https://hartvaat.nl/2026/08/26/glp-1-receptoragonisten-verlagen-nierkankerrisico-na-metabole-bariatrische-chiru/","title":"GLP-1-receptoragonisten verlagen nierkankerrisico na metabole bariatrische chirurgie","title_en":"GLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag197","source_url":"https://doi.org/10.1093/ndt/gfag197","authors":["Jesús Gibran Hernández-Pérez","Omer Abdelgadir","Mohanad Albayyaa","Deepali K Ernest","Jing Chen","Stacia M DeSantis","Arthur S Hong","Lindsay G Cowell","Jaime P Almandoz","Sarah E Messiah","David S Lopez"],"significance":5,"published":"2026-09-02","source_date":"2026-08-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"In a retrospective TriNetX cohort of adults with type 2 diabetes and obesity or overweight status following metabolic bariatric surgery, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were compared with metformin, insulin, SGLT2 inhibitors, or sulfonylureas. Over five years, GLP-1 RA initiation was associated with a lower incidence of kidney cancer across all comparators, with absolute risk differences ranging from -0.18% to -0.22%. These findings, consistent across sensitivity analyses, suggest an additional oncologic safety signal for GLP-1 RAs beyond their established cardiometabolic benefits, which may inform therapeutic selection in post-bariatric patients.","created":"2026-08-27T01:09:34Z","updated":"2026-08-27T01:09:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6b62c0912228","type":"article","url":"https://hartvaat.nl/2026/08/26/microvasculaire-dysfunctie-bij-hfpef-pathofysiologie-en-behandelopties/","title":"Microvasculaire dysfunctie bij HFpEF: pathofysiologie en behandelopties","title_en":"Coronary Microvascular Disease in Heart Failure With Preserved Systolic Function: Pathogenic Mechanisms and Therapeutic Options-A Narrative Review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Cardiology in review","doi":"10.1097/CRD.0000000000001442","source_url":"https://doi.org/10.1097/CRD.0000000000001442","authors":["Shijun Li"],"significance":5,"published":"2026-09-02","source_date":"2026-08-26","image":"https://hartvaat.nl/global/img/6e2cc0469790.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"Coronary microvascular disease affects up to 75% of patients with heart failure with preserved ejection fraction (HFpEF), even in the absence of obstructive epicardial coronary artery disease. This narrative review outlines the shared pathophysiological pathways, including endothelial dysfunction and mitochondrial impairment, positioning microvascular dysfunction as a distinct HFpEF endotype. Clinically, the findings support integrating lifestyle modifications, guideline-directed medical therapy, and SGLT2 inhibitors to target the microvasculature and improve outcomes in this prevalent patient population.","created":"2026-08-27T01:05:07Z","updated":"2026-08-27T01:05:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3a3d86f3533d","type":"article","url":"https://hartvaat.nl/2026/08/26/glp-1-agonisten-verlagen-sterfte-en-mace-bij-patienten-met-ernstige-psychiatrisc/","title":"GLP-1-agonisten verlagen sterfte en MACE bij patiënten met ernstige psychiatrische aandoeningen","title_en":"Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA psychiatry","doi":"10.1001/jamapsychiatry.2026.2574","source_url":"https://doi.org/10.1001/jamapsychiatry.2026.2574","authors":["Roger S McIntyre","Yanli Zhang-James","Angela T H Kwan"],"significance":6,"published":"2026-09-02","source_date":"2026-08-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"In a large retrospective target trial emulation using electronic health records, initiation of GLP-1 receptor agonists versus SGLT2 inhibitors was associated with significantly lower 4-year all-cause mortality (HR 0.76; 4.91% vs 6.45%) and reduced major adverse cardiovascular events in adults with serious mental illness. Among patients with coexisting type 2 diabetes, semaglutide specifically showed lower risks of myocardial infarction, stroke, heart failure, and revascularization compared with SGLT2 inhibitors. These real-world findings highlight a potential cardiometabolic advantage of GLP-1 agonists in a population known to face substantial excess cardiovascular mortality.","created":"2026-08-27T01:01:17Z","updated":"2026-08-27T01:01:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a348db6776ed","type":"article","url":"https://hartvaat.nl/2026/09/01/mechanismen-en-actuele-therapieen-bij-metabool-syndroom/","title":"Mechanismen en actuele therapieën bij metabool syndroom","title_en":"Metabolic Syndrome: From Mechanisms to Therapeutic Interventions.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"MedComm","doi":"10.1002/mco2.70934","source_url":"https://doi.org/10.1002/mco2.70934","authors":["Mengyao Yan","Qian Xiang"],"significance":5,"published":"2026-09-02","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This narrative review outlines the pathophysiology of metabolic syndrome, highlighting insulin resistance, chronic low-grade inflammation, oxidative stress, and the gut-adipose tissue axis. It evaluates current pharmacological standards, including GLP-1 receptor agonists, SGLT2 inhibitors, and RAAS blockers, while also discussing emerging interventions such as microbiome-targeted therapies and lifestyle modifications. The article provides a structured overview for clinicians managing cardiometabolic risk, bridging mechanistic insights with practical therapeutic options.","created":"2026-08-27T00:52:29Z","updated":"2026-08-27T00:52:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc23fad520c2","type":"article","url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","title":"ESH-convenant polshorloges-bloeddrukmeters: acceptabele nauwkeurigheid, maar klinisch bewijs blijft beperkt","title_en":"Wearable wrist-watch type cuff oscillometric blood pressure monitors: consensus statement by the European Society of Hypertension Working Group on blood pressure monitoring.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of hypertension","doi":"10.1097/HJH.0000000000004415","source_url":"https://doi.org/10.1097/HJH.0000000000004415","authors":["George S Stergiou","Ariadni Menti","Kei Asayama","Anastasios Kollias","Gianfranco Parati","Aletta E Schutte","Jiguang Wang","Dagnovar Aristizabal","Roland Asmar","Grzegorz Bilo","Tomas Bothe","Christopher Clark","Kazuomi Kario","Yan Li","Richard McManus","Takayoshi Ohkubo","Paolo Palatini","Dean Picone","Daichi Shimbo","Thomas Tsaganos","Alejandro De La Sierra"],"significance":6,"published":"2026-09-02","source_date":"2026-10-01","image":"https://hartvaat.nl/global/img/6e2cc0469790.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/laboratoriumonderzoek-bij-hypertensie/"],"congress":"","summary_en":"The European Society of Hypertension has issued a consensus statement on wearable wristwatch cuff oscillometric blood pressure monitors. A systematic review identified only two devices (Omron HeartGuide and Huawei Watch D/D2) meeting strict validation standards, with acceptable static accuracy but limited data on 24-hour ambulatory use, sleep BP, and special populations. While these wearables offer potential advantages for home monitoring and stress-related BP episodes, clinicians should exercise caution regarding adherence and measurement accuracy. Further research is needed to establish their clinical utility and role in hypertension management.","created":"2026-08-27T00:47:43Z","updated":"2026-08-27T00:47:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6660aed7d23","type":"article","url":"https://hartvaat.nl/2026/08/24/roux-en-y-maagoperatie-verlaagt-zoutgevoelige-hypertensie-via-glp-1-gemedieerde-/","title":"Roux-en-Y-maagoperatie verlaagt zoutgevoelige hypertensie via GLP-1-gemedieerde remming van de RAS/NHE3-as","title_en":"[Gastrointestinal metabolic surgery improves salt-sensitive hypertension via GLP-1-mediated inhibition of the RAS/NHE3 axis].","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Zhonghua xin xue guan bing za zhi","doi":"10.3760/cma.j.cn112148-20260310-00156","source_url":"https://doi.org/10.3760/cma.j.cn112148-20260310-00156","authors":["D Tong","Q L Peng","L J Wang","H D Zhao","A D Mou","H Wu","F Sun","Z S Lu","Z M Zhu"],"significance":3,"published":"2026-09-01","source_date":"2026-08-24","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A clinical cohort (n=57) combined with animal and in vitro experiments demonstrates that Roux-en-Y gastric bypass (RYGB) significantly reduces systolic and diastolic blood pressure in patients with salt-sensitive hypertension. The blood pressure reduction correlated with preoperative sodium intake, and mechanistic studies revealed that this effect is mediated by GLP-1 receptor activation, which suppresses the RAS/NHE3 axis and mitigates vascular and renal remodeling. While these findings highlight a promising pathophysiological link between metabolic surgery, GLP-1 signaling, and blood pressure control, the small observational clinical sample limits immediate translation to routine antihypertensive therapy.","created":"2026-08-25T01:23:41Z","updated":"2026-08-25T01:23:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"924c96dc3ecd","type":"article","url":"https://hartvaat.nl/2026/08/25/glp-1-en-dual-receptoragonisten-nieuwe-consensus-over-toepassing-bij-type-2-diab/","title":"GLP-1- en dual-receptoragonisten: nieuwe consensus over toepassing bij type 2-diabetes","title_en":"[Expert consensus on the clinical application of nutrient-stimulated hormone receptor agonist in the treatment of type 2 diabetes mellitus (2026 edition)].","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Zhonghua yi xue za zhi","doi":"10.3760/cma.j.cn112137-20260527-01398","source_url":"https://doi.org/10.3760/cma.j.cn112137-20260527-01398","authors":[],"significance":5,"published":"2026-09-01","source_date":"2026-08-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"A 2026 expert consensus provides updated recommendations for the clinical use of glucagon-like peptide-1 (GLP-1) receptor agonists, including GLP-1, GIP/GLP-1, and GCG/GLP-1 receptor agonists, in type 2 diabetes. The guidance outlines optimal patient selection, combination strategies with other antidiabetic agents, and highlights the established cardiovascular, renal, and hepatic benefits of these agents. For clinicians, the consensus offers a practical framework to standardize prescribing and optimize cardiometabolic outcomes in diabetes management.","created":"2026-08-25T01:18:19Z","updated":"2026-08-25T01:18:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"850468ec0418","type":"article","url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","title":"Extracraniale bloedingen komen bij 26% van AF-patiënten op antistolling voor — COMBINE-AF","title_en":"Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.079205","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.079205","authors":["Deborah M Siegal","Marc Carrier","M Cecilia Bahit","Jackie Bosch","Alexander P Benz","Brian Bergmark","Robert P Giugliano","Christopher B Granger","Victorien Monguillon","Martin O'Donnell","Jonas Oldgren","Manesh R Patel","Rohin K Reddy","Lars Wallentin","Qilong Yi","Andre Zimerman","John Eikelboom"],"significance":8,"published":"2026-09-01","source_date":"2026-08-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"A pooled analysis of five pivotal randomized trials (COMBINE-AF; n=73,737) demonstrates that extracranial bleeding occurs in 26% of patients with atrial fibrillation on oral anticoagulants over a mean follow-up of nearly two years, translating to 7.6 events per 100 person-years. Major extracranial bleeds account for 7% of cases, while clinically relevant non-major bleeds make up 19%, with gastrointestinal bleeding representing 49% of major events. These findings highlight that extracranial bleeding better captures the true burden of anticoagulation therapy than major bleeding alone, underscoring the need for comprehensive risk assessment and patient counseling in daily practice.","created":"2026-08-25T01:14:25Z","updated":"2026-08-25T01:14:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"01884c9bbf4b","type":"article","url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","title":"Risicogestuurde AF-screening met machine learning verhoogt detectiegraad — FIND-AF 2.0","title_en":"Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.079391","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.079391","authors":["Ramesh Nadarajah","Jianhua Wu","Ali Wahab","Catherine Reynolds","Mohammad Haris","Tobin Joseph","Keerthenan Raveendra","Ben Hurdus","Khalid Kazi","Sheena Bennett","Chris Hayward","Ben Mercer","Jing Kang","Chenyi Gao","Yoko M Nakao","Koji Kawakami","Carlin Chang","Abraham Wai","Jiandong Zhou","Gary Tse","Talish Razi Benita","Lior Rokach","Ronen Arbel","Moti Haim","Doron Zahger","Dina Labib","Jacqueline Flewitt","James A White","Konsta Teppo","Mika Lehto","Ville Langén","Aleksi K Winstén","K E Juhani Airaksinen","Jari Haukka","Olli Halminen","Jukka Putaala","Juha Hartikainen","Miika Linna","Ben Freedman","Emma Svennberg","A John Camm","Gregory Y H Lip","Chris P Gale"],"significance":7,"published":"2026-09-01","source_date":"2026-08-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"Researchers developed and externally validated FIND-AF 2.0, a machine learning model using electronic health records to identify patients at high risk of developing atrial fibrillation (AF). In a prospective screening study of 1,923 adults, AF was detected in 4.5% of high-risk participants compared to 0.6% of low-risk individuals (OR 8.46; P<0.001), outperforming conventional risk scores like CHA₂DS₂-VASc. Implementing this EHR-driven approach could enable targeted AF screening in primary care and cardiology, catching high-burden AF earlier and reducing the risk of ischemic stroke (6.0 events per 100 patient-years) in untreated patients.","created":"2026-08-25T01:08:52Z","updated":"2026-08-25T01:08:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb7e519f61fc","type":"article","url":"https://hartvaat.nl/2026/09/01/ballonaortakleivalvuloplastie-als-brug-naar-tavr-bij-acuut-klepsyndroom-narrativ/","title":"Ballonaortakleivalvuloplastie als brug naar TAVR bij acuut klepsyndroom — narrative review","title_en":"Balloon Aortic Valvuloplasty as a Bridge Therapy in Acute Valve Syndrome: A Narrative Review of Evidence Gaps and Future Directions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Structural heart : the journal of the Heart Team","doi":"10.1016/j.shj.2026.101059","source_url":"https://doi.org/10.1016/j.shj.2026.101059","authors":["Omar Saleh","Omar Jafar","Nicholas Valle","Shirish Yasa","Saleh Mostafa","Raymond L Benza","Deepak R Talreja","Benjamin D Peterson","Matthew R Summers"],"significance":5,"published":"2026-09-01","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-bloeding/"],"congress":"","summary_en":"Acute valve syndrome, a decompensated presentation of severe aortic stenosis, often requires rapid hemodynamic stabilization before transcatheter aortic valve replacement (TAVR) can be safely performed. This narrative review evaluates balloon aortic valvuloplasty (BAV) as a bridge strategy, comparing registry data and smaller hemodynamic cohorts against direct emergent TAVR. While registries suggest lower mortality with direct TAVR, selected patients stabilized with BAV may achieve comparable outcomes. The authors highlight key evidence gaps and provide practical considerations for Heart Team decision-making in unstable patients.","created":"2026-08-25T01:03:18Z","updated":"2026-08-25T01:03:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e8400ccc6f6","type":"article","url":"https://hartvaat.nl/2026/09/01/tirzepatide-zorgt-voor-sterk-gewichtsverlies-bij-vrouwen-met-pcos-en-obesitas/","title":"Tirzepatide zorgt voor sterk gewichtsverlies bij vrouwen met PCOS en obesitas","title_en":"Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Journal of the Endocrine Society","doi":"10.1210/jendso/bvag177","source_url":"https://doi.org/10.1210/jendso/bvag177","authors":["Ashley Kieran Clift","Dan Reisel","Hans Johnson","Naveed Sattar","David R Huang"],"significance":5,"published":"2026-08-31","source_date":"2026-09-01","image":"","kennis":[],"congress":"","summary_en":"A retrospective open-cohort study of over 54,000 women with obesity in the UK evaluated tirzepatide-induced weight loss, with a specific focus on those with self-reported polycystic ovary syndrome (PCOS). At 10 months, mean weight reduction was 19.4% in the PCOS subgroup, comparable to the 18.7% observed in women without PCOS, with 57.7% of PCOS patients achieving ≥20% total body weight loss. Digital engagement further amplified weight loss outcomes. These findings reinforce tirzepatide as a highly effective therapeutic option for weight management in women with PCOS, offering valuable insights for primary care physicians and internists managing cardiometabolic risk.","created":"2026-08-25T01:00:35Z","updated":"2026-08-25T01:00:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38cc9e989b8f","type":"article","url":"https://hartvaat.nl/2026/12/01/longitudinale-geografische-miss-verhoogt-restenose-na-stentgraft-bij-dialyse-acc/","title":"Longitudinale geografische miss verhoogt restenose na stentgraft bij dialyse-access","title_en":"Geographic miss and stent graft restenosis in hemodialysis access.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2717813","source_url":"https://doi.org/10.1080/0886022X.2026.2717813","authors":["Cheng-Wei Lien","Ming-Chien Hsieh","Mu-Yang Hsieh","Meng-Kan Chen","Chih-Cheng Wu"],"significance":4,"published":"2026-08-31","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"In a cohort of 203 patients with hemodialysis access, longitudinal geographic miss (LGM) — residual stenosis >30% within 5 mm of the stent edge — was strongly associated with early restenosis. LGM was linked to a 2.6- to 2.7-fold higher risk of losing stent graft and access primary patency at one year. The findings suggest that precise stent coverage is a modifiable procedural target to improve access durability, though prospective validation is required.","created":"2026-08-25T00:54:55Z","updated":"2026-08-25T00:54:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21866cbc55b0","type":"article","url":"https://hartvaat.nl/2026/12/01/balloon-assisted-maturation-versnelt-avf-maturatie-zonder-verlies-aan-1-jaar-pat/","title":"Balloon-assisted maturation versnelt AVF-maturatie zonder verlies aan 1-jaar patency","title_en":"Early balloon-assisted-maturation does not reduce patency of mature arteriovenous fistulae.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2679293","source_url":"https://doi.org/10.1080/0886022X.2026.2679293","authors":["Chung-Kuan Wu","Wei-Cheng Tseng","Chia-Hsun Lin"],"significance":4,"published":"2026-08-31","source_date":"2026-12-01","image":"","kennis":[],"congress":"","summary_en":"A single-center retrospective cohort study of 129 hemodialysis patients evaluated whether early balloon-assisted maturation (BAM) of arteriovenous fistulae (AVF) affects 1-year patency. Kaplan-Meier analysis revealed no significant difference in patency between BAM and non-BAM groups (p = 0.238), and the adjusted hazard ratio for primary intervention was 1.25 (95% CI 0.78–2.01; p = 0.346). The findings indicate that early BAM does not compromise fistula longevity and may be safely utilized to accelerate maturation in slow-developing AVFs.","created":"2026-08-25T00:51:38Z","updated":"2026-08-25T00:51:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16a92948a422","type":"article","url":"https://hartvaat.nl/2026/12/01/j-vormige-relatie-tussen-stresshyperglykemie-verhouding-en-sterfte-bij-hypertens/","title":"J-vormige relatie tussen stresshyperglykemië-verhouding en sterfte bij hypertensie — MIMIC-IV","title_en":"J‑shaped link of stress hyperglycaemia ratio with in-hospital and 1-year mortality in hypertension patients: based on the MIMIC-IV database.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Blood pressure","doi":"10.1080/08037051.2026.2709810","source_url":"https://doi.org/10.1080/08037051.2026.2709810","authors":["Dan Zhao","Fan Wang","Yanzhi Ding","Xinshun Gu"],"significance":5,"published":"2026-08-31","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/laboratoriumonderzoek-bij-hypertensie/"],"congress":"","summary_en":"A retrospective analysis of 2,088 hypertensive ICU patients evaluated the association between the stress hyperglycaemia ratio (SHR) and both in-hospital and 1-year mortality. Higher SHR levels demonstrated a J-shaped relationship with adverse outcomes, with each unit increase linked to significantly elevated risks (HR 1.93 for in-hospital and HR 1.66 for 1-year mortality), while the highest SHR quartile carried the greatest mortality risk (HR 3.29 and HR 1.74, respectively). These findings highlight SHR as a potential adjunctive prognostic marker in critically ill hypertensive patients, though external validation is required before routine clinical adoption.","created":"2026-08-25T00:48:01Z","updated":"2026-08-25T00:48:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e3c073ef0ec","type":"article","url":"https://hartvaat.nl/2026/12/31/lvh-voorspelt-ongunstige-moeder-en-foetale-uitkomsten-bij-chronische-hypertensie/","title":"LVH voorspelt ongunstige moeder- en foetale uitkomsten bij chronische hypertensie in de zwangerschap","title_en":"Left ventricular hypertrophy as a predictor of adverse maternal and neonatal outcomes in chronic hypertension in pregnancy: a multicenter study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Hypertension in pregnancy","doi":"10.1080/10641955.2026.2719498","source_url":"https://doi.org/10.1080/10641955.2026.2719498","authors":["Bei Zhang","Guilong Pan","Wei Wang","Kai Zhang","Xiao Song","Wei Tian","Ran Chu","Shuyi Li","Hui An","Shuo Zhang"],"significance":5,"published":"2026-08-31","source_date":"2026-12-31","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"A multicenter retrospective cohort study (n=500) demonstrates that left ventricular hypertrophy (LVH) in women with chronic hypertension during pregnancy is independently associated with higher risks of adverse maternal (OR 2.16) and fetal/neonatal (OR 2.42) outcomes. Additional predictors included NYHA class III–IV, pre-eclampsia, and oligohydramnios. These findings support early-pregnancy echocardiography for improved risk stratification, though prospective external validation is needed before clinical implementation.","created":"2026-08-25T00:45:41Z","updated":"2026-08-25T00:45:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-aspired","type":"article","url":"https://hartvaat.nl/2026/08/31/aspired-twee-weken-plak-ecg-direct-vanaf-de-seh-verdubbelt-de-ritmediagnoses-bij/","title":"ASPIRED: twee weken plak-ECG direct vanaf de SEH verdubbelt de ritmediagnoses bij onverklaarde wegrakingen, maar voorkomt de wegrakingen zelf niet","title_en":"ASPIRED: two weeks of patch ECG straight from the ED doubles rhythm diagnoses in unexplained syncope, but does not prevent the syncope itself","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"","source_url":"","authors":["Reed MJ, et al.; ASPIRED investigators"],"significance":7,"published":"2026-08-31","source_date":"2026-08-31","image":"https://hartvaat.nl/global/img/84d78f4019c7.webp","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"esc-2026","summary_en":"Open-label RCT in 45 UK hospitals: 2,233 patients with acute unexplained syncope randomised to an immediate 14-day leadless waterproof ECG patch or standard management. Primary endpoint, self-reported syncope episodes at one year: 1.37 versus 1.58 (p=0.43), no difference. Secondary: arrhythmia detection 22 versus 9 percent, median time to diagnosis 22 versus 55 days, pacemakers 6.8 versus 4.6 percent, antiarrhythmic therapy 10.8 versus 7.3 percent, all-cause mortality 1.5 versus 2.9 percent. Presented by Matthew Reed (Edinburgh) in Hot Line 10, NEJM.","created":"2026-08-31T06:34:53Z","updated":"2026-08-31T13:02:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-crhcp-dementie","type":"article","url":"https://hartvaat.nl/2026/08/31/crhcp-intensieve-bloeddrukcontrole-door-getrainde-niet-artsen-verlaagt-het-demen/","title":"CRHCP: intensieve bloeddrukcontrole door getrainde niet-artsen verlaagt het dementierisico met 15 procent in zeven jaar","title_en":"CRHCP: intensive blood pressure control by trained non-physicians lowers dementia risk by 15 percent over seven years","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"ESC Congress 2026 (Hot Line 9)","doi":"","source_url":"","authors":["Sun Y, et al.; CRHCP investigators"],"significance":8,"published":"2026-08-31","source_date":"2026-08-31","image":"https://hartvaat.nl/global/img/c42c4e3e1e31.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"esc-2026","summary_en":"Cluster-randomised trial in 326 rural Chinese villages: 33,995 people with hypertension, non-physician community health providers initiating and titrating antihypertensives to below 130/80 versus usual care; four years of intervention plus three of observation. Systolic BP fell 17.6 versus 2.4 mmHg. Dementia 8.85 versus 10.55 percent (adjusted risk ratio 0.85, 95% CI 0.78 to 0.91, p under 0.001); cognitive impairment without dementia 13 percent lower. Presented by Yingxian Sun in Hot Line 9.","created":"2026-08-31T06:03:02Z","updated":"2026-08-31T13:02:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-shasta-3-4","type":"article","url":"https://hartvaat.nl/2026/08/31/shasta-3-en-shasta-4-plozasiran-verlaagt-triglyceriden-met-ruim-80-procent-bij-e/","title":"SHASTA-3 en SHASTA-4: plozasiran verlaagt triglyceriden met ruim 80 procent bij ernstige hypertriglyceridemie en voorkomt driekwart van de pancreatitisaanvallen","title_en":"SHASTA-3 and SHASTA-4: plozasiran lowers triglycerides by over 80 percent in severe hypertriglyceridaemia and prevents three quarters of pancreatitis events","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"ESC Congress 2026 (Hot Line 9)","doi":"","source_url":"","authors":["SHASTA-3 en SHASTA-4 investigators"],"significance":8,"published":"2026-08-31","source_date":"2026-08-31","image":"https://hartvaat.nl/global/img/2b13f01a7395.webp","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"esc-2026","summary_en":"Two double-blind phase 3 trials in 24 countries: 757 patients with triglycerides of 500 mg/dL (5.6 mmol/L) or higher received four quarterly subcutaneous doses of plozasiran 25 mg (an siRNA against APOC3) or placebo for a year. Median triglyceride reduction 79 percent (SHASTA-3) and 81 percent (SHASTA-4) versus about 27 percent on placebo; cumulative acute pancreatitis events down 78 percent, and 100 percent in the highest-risk subgroup (over 880 mg/dL with prior pancreatitis). Discontinuation for treatment-related adverse events 1.4 versus 0.8 percent. Hot Line 9.","created":"2026-08-31T06:03:02Z","updated":"2026-08-31T13:02:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5c2d59aec13","type":"article","url":"https://hartvaat.nl/2026/08/21/allegra-kunstklep-toont-veelbelovende-techniek-en-veiligheidsresultaten-bij-valv/","title":"Allegra-kunstklep toont veelbelovende techniek- en veiligheidsresultaten bij valve-in-valve TAVI","title_en":"Clinical Outcomes of the Allegra Transcatheter System in Bioprosthetic Aortic Valve Failure: A Multicentre Valve-in-Valve Registry.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","doi":"10.1002/ccd.70811","source_url":"https://doi.org/10.1002/ccd.70811","authors":["Hilal Khan","Mohamed Ali","Abdalazeem Ibrahem","Karim Ratib","Nur Ilia Mohd Zaki","Freidoon Keshavarzi","Alok Shah","Hesham Abdelaziz","Ayush Khurana","Alexander Chase","Diana A Gorog","Rajiv Das","Azfar Zaman","Mohammad AlKhalil","Mohamed Farag"],"significance":5,"published":"2026-08-30","source_date":"2026-08-21","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/chirurgische-klepvervanging/"],"congress":"","summary_en":"A retrospective multicentre registry evaluated the Allegra transcatheter heart valve system in 106 high-risk patients undergoing valve-in-valve TAVI for failing bioprosthetic aortic valves. Technical and early safety success rates were both 86.8%, with device success at 75.5%, 30-day mortality at 0%, and a median 15-month all-cause mortality of 6.6%. Post-implant haemodynamics were favourable, with a mean gradient of 12 mmHg. These findings position the Allegra system as a promising option for complex valve-in-valve procedures, though larger randomised trials are required to confirm long-term efficacy and safety.","created":"2026-08-23T01:32:41Z","updated":"2026-08-23T01:32:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3db1e067b68f","type":"article","url":"https://hartvaat.nl/2026/08/21/frailheid-en-laag-bmi-bepalen-sglt2-remmerstopt-bij-ouderen-75-jaar/","title":"Frailheid en laag BMI bepalen SGLT2-remmerstopt bij ouderen ≥75 jaar","title_en":"Frailty and low body mass index as key determinants of sodium-glucose cotransporter 2 inhibitor-specific adverse event-related discontinuation in adults aged ≥75 years: A multicenter real-world retrospective cohort study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of diabetes investigation","doi":"10.1111/jdi.70424","source_url":"https://doi.org/10.1111/jdi.70424","authors":["Taisuke Uchida","Hiroaki Ueno","Ayaka Konagata","Hiroki Nabekura","Yuki Kikuchi","Takumi Beppu","Akari Sekishima","Hirotaka Sekishima","Takayuki Nakamura","Fumiko Kogo","Yudai Uehira","Yuri Tanaka","Hideki Yamaguchi","Kazuya Shimoda"],"significance":5,"published":"2026-08-30","source_date":"2026-08-21","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"A multicenter retrospective cohort study evaluated 616 Japanese adults aged ≥75 years newly initiating an SGLT2 inhibitor. Over 180 days, 9.1% discontinued treatment due to drug-specific adverse events. Multivariable analysis identified clinical frailty (score ≥5; HR 4.67) and low BMI (<22 kg/m²; HR 2.53) as independent predictors of discontinuation, whereas chronological age alone was not. These findings suggest that physiological reserve and nutritional status, rather than age per se, should guide monitoring and support the safe use of SGLT2 inhibitors in older adults.","created":"2026-08-23T01:24:56Z","updated":"2026-08-23T01:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"349fcf95d375","type":"article","url":"https://hartvaat.nl/2026/08/21/bariatrische-chirurgie-remt-nierfunctieverlies-bij-obesitas-gerelateerde-nierzie/","title":"Bariatrische chirurgie remt nierfunctieverlies bij obesitas-gerelateerde nierziekte — overzicht","title_en":"The Role of Bariatric Surgery in Kidney Disease: Evidence, Controversies, and Future Needs.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Obesity surgery","doi":"10.1007/s11695-026-08901-0","source_url":"https://doi.org/10.1007/s11695-026-08901-0","authors":["Ernesto Calderon Martinez","Jonathan Victor Salazar Ore","Patricia Elena Ghattas Hasbun","Bana Khalil","Hrachya Ajamyan","Gabriela Vanessa Flores Monar","Jose Carlos Del Castillo Miranda","Bansi Sutariya"],"significance":5,"published":"2026-08-30","source_date":"2026-08-21","image":"https://hartvaat.nl/global/img/fe0fe42c035e.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This narrative review examines the role of bariatric surgery in preventing and treating chronic kidney disease (CKD) in patients with severe obesity. Observational studies and meta-analyses indicate that significant weight loss following procedures like sleeve gastrectomy and gastric bypass reduces albuminuria, stabilizes eGFR decline, and lowers the risk of kidney failure. For internists and cardiologists, these findings highlight bariatric surgery as a potent non-pharmacological strategy to mitigate cardiorenal risk in obesity, provided careful patient selection and postoperative monitoring are maintained.","created":"2026-08-23T01:21:28Z","updated":"2026-08-23T01:21:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2688ad709815","type":"article","url":"https://hartvaat.nl/2026/08/21/lipidparadox-bij-kanker-ldl-c-dekt-de-lading-niet-voor-cardiovasculair-risico/","title":"Lipidparadox bij kanker: LDL-C dekt de lading niet voor cardiovasculair risico","title_en":"The Cancer-Associated Lipid Paradox: Implications for Cardiovascular Risk and Lipid Management.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"The American journal of cardiology","doi":"10.1016/j.amjcard.2026.08.022","source_url":"https://doi.org/10.1016/j.amjcard.2026.08.022","authors":["Nicole Prescott","Victoria J Eichten","Vishal Ahuja","Courtney M Campbell","Anand Gupta","Catherine A Raver","Michael D Duncan","Javed Butler","Byron Cryer","Ronan J Kelly","Subhash Banerjee"],"significance":5,"published":"2026-08-30","source_date":"2026-08-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This review explores the cancer-associated lipid paradox, where cardiovascular events frequently occur despite low or well-controlled LDL-C levels in oncology patients. Systemic inflammation, treatment-related vascular injury, and tumor-driven metabolic shifts decouple circulating lipid concentrations from actual cardiovascular risk. Clinicians should recognize that LDL-centric prevention strategies are insufficient for cancer survivors, necessitating a dynamic, longitudinal risk-assessment framework in cardio-oncology to better mitigate cardiovascular morbidity.","created":"2026-08-23T01:16:29Z","updated":"2026-08-23T01:16:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a0d8de2e472","type":"article","url":"https://hartvaat.nl/2026/08/21/doac-s-verlagen-risico-op-hersenbloeding-en-beroerte-bij-af-met-eerdere-ich-meta/","title":"DOAC's verlagen risico op hersenbloeding en beroerte bij AF met eerdere ICH — meta-analyse","title_en":"Walking a tightrope: the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open heart","doi":"10.1136/openhrt-2026-004264","source_url":"https://doi.org/10.1136/openhrt-2026-004264","authors":["Andreas Mercyan Anggitama","Edwin Pranata Laban","Christien Carla Bambuta","Christian Stefanny Gerungan","Arya Taksya Bagaskara","Kristin Purnama Dewi","Ivana Purnama Dewi"],"significance":6,"published":"2026-08-30","source_date":"2026-08-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage. Based on five observational studies, DOACs were associated with a lower risk of recurrent intracranial haemorrhage (HR 0.65) and ischaemic stroke (HR 0.80), although evidence certainty ranged from moderate to very low and sensitivity analyses attenuated the stroke and mortality benefits. While DOACs appear preferable for clinical decision-making in this high-risk population, the authors caution that practice-changing guidelines await prospective randomised trials.","created":"2026-08-23T01:09:25Z","updated":"2026-08-23T01:09:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-hcp-preventie","type":"article","url":"https://hartvaat.nl/2026/08/30/de-zorgprofessional-als-patient-1-300-esc-congresgangers-gemeten-met-overgewicht/","title":"De zorgprofessional als patiënt: 1.300 ESC-congresgangers gemeten, met overgewicht bij 47 procent, onbehandelde hypertensie en stille atherosclerose bij een op de vijf","title_en":"The clinician as patient: 1,300 ESC congress delegates measured, with excess weight in 47 percent, untreated hypertension and silent atherosclerosis in one in five","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag736","source_url":"https://doi.org/10.1093/eurheartj/ehag736","authors":["Wenzl FA, et al.; ESC Congress Cardiovascular Health Check 2025"],"significance":6,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/0969533a7e32.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"esc-2026","summary_en":"Cross-sectional health check of more than 1,300 healthcare professionals at ESC Congress 2025 with age- and sex-matched general-population controls. Excess weight 46.8 percent, hypertension 23.2 percent, high cholesterol 22.7 percent; subclinical atherosclerosis in about 20 percent without known disease; only 27.6 percent of eligible professionals on blood pressure medication versus 46.5 percent of controls, though those treated reached targets more often; in secondary prevention only 22.2 percent on lipid-lowering therapy at LDL target. Presented by Florian Wenzl (Zurich/Oxford), European Heart Journal.","created":"2026-08-30T15:57:41Z","updated":"2026-08-31T13:02:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-statine-dementie","type":"article","url":"https://hartvaat.nl/2026/08/30/vroeg-starten-met-een-statine-na-de-diagnose-type-2-diabetes-hangt-samen-met-15-/","title":"Vroeg starten met een statine na de diagnose type 2 diabetes hangt samen met 15 procent minder dementie in tien jaar, in een Deense registerstudie van 132.585 mensen","title_en":"Starting a statin early after a type 2 diabetes diagnosis is associated with 15 percent less dementia over ten years in a Danish register study of 132,585 people","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["esc-2026"],"journal":"The Lancet Regional Health, Europe","doi":"","source_url":"","authors":["Ternhamar T, et al."],"significance":6,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/3d6eab0ed02c.webp","kennis":["https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"esc-2026","summary_en":"Nationwide Danish register study (2006 to 2019, follow-up to 2021) using a clone-censor-weight design to emulate a trial in 132,585 statin-naive people with new type 2 diabetes. Dementia incidence 2.7 percent over a median 7.1 years; statin start within a year of diagnosis was associated with a 15 percent lower ten-year relative risk of dementia, start at one to five years with 10 percent lower; similar in men and women. Observational; presented by Tummas Ternhamar (Copenhagen), The Lancet Regional Health, Europe.","created":"2026-08-30T15:57:41Z","updated":"2026-08-31T13:02:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-luminara","type":"article","url":"https://hartvaat.nl/2026/08/30/luminara-de-orale-relaxine-receptoragonist-azd5462-laat-in-fase-2b-tekenen-van-b/","title":"LUMINARA: de orale relaxine-receptoragonist AZD5462 laat in fase 2b tekenen van betere hartfunctie zien bij HFrEF en een lagere vaatweerstand bij HFpEF","title_en":"LUMINARA: the oral relaxin receptor agonist AZD5462 shows signs of better cardiac function in HFrEF and lower vascular resistance in HFpEF in phase 2b","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.082763","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.082763","authors":["Januzzi JL, et al.; LUMINARA investigators"],"significance":6,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/a6e2373388d6.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/ace-remmers-bij-hartfalen/"],"congress":"esc-2026","summary_en":"Double-blind dose-ranging phase 2b trial in 69 sites in 10 countries, 24 weeks: 235 patients with LVEF 35 percent or lower and 140 with LVEF 41 to 55 percent. HFrEF: end-systolic volume index minus 5.4 mL/m2 at the lowest dose (p=0.054 versus placebo), LVEF gains largest at 20 mg. HFpEF cohort: systemic vascular resistance index down 19 to 21 percent (p 0.021 or lower). Mild BP lowering, no excess adverse events. Presented by James Januzzi in Hot Line 6, Circulation.","created":"2026-08-30T15:57:41Z","updated":"2026-08-31T13:02:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-h-heft","type":"article","url":"https://hartvaat.nl/2026/08/30/h-heft-hydralazine-plus-isosorbidedinitraat-bovenop-moderne-hfref-therapie-mist-/","title":"H-HeFT: hydralazine plus isosorbidedinitraat bovenop moderne HFrEF-therapie mist het primaire eindpunt, met een sterftesignaal dat om een nieuwe trial vraagt","title_en":"H-HeFT: hydralazine plus isosorbide dinitrate on top of modern HFrEF therapy misses its primary endpoint, with a mortality signal that calls for a new trial","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"ESC Congress 2026 (Hot Line 6, DANHEART)","doi":"","source_url":"","authors":["Køber L, et al.; DANHEART investigators"],"significance":7,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/b0ceeb6e82f5.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/ace-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"esc-2026","summary_en":"Double-blind investigator-initiated trial in 23 Danish centres (DANHEART): 592 patients with symptomatic HFrEF, systolic BP 100 or higher and raised natriuretic peptides, randomised to hydralazine 37.5 mg plus isosorbide dinitrate 20 mg twice daily (uptitrated) or placebo. Primary composite (death, worsening HF, urgent IV therapy, transplant or LVAD) 8.6 versus 9.3 per 100 patient-years (HR 0.90, 95% CI 0.67 to 1.21); all-cause mortality 19.4 versus 24.2 percent (HR 0.72, 0.51 to 1.02). Presented by Lars Køber in Hot Line 6.","created":"2026-08-30T15:57:41Z","updated":"2026-08-31T13:02:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-met-heft","type":"article","url":"https://hartvaat.nl/2026/08/30/met-heft-metformine-geeft-geen-cardiovasculaire-bescherming-bij-hfref-met-diabet/","title":"Met-HeFT: metformine geeft geen cardiovasculaire bescherming bij HFrEF met diabetes of prediabetes, wel blijft het veilig","title_en":"Met-HeFT: metformin gives no cardiovascular protection in HFrEF with diabetes or prediabetes, but remains safe","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"ESC Congress 2026 (Hot Line 6, DANHEART)","doi":"","source_url":"","authors":["Wiggers H, et al.; DANHEART investigators"],"significance":7,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/8de4409eabbf.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"esc-2026","summary_en":"Investigator-initiated, double-blind factorial trial in 23 Danish centres (DANHEART): 940 patients with symptomatic HFrEF (LVEF 40 percent or lower) and type 2 diabetes, prediabetes or high diabetes risk, randomised to metformin or placebo, mean follow-up 3.7 years. Death, worsening HF, MI or stroke 25.1 versus 23.4 percent (HR 1.10, 95% CI 0.84 to 1.42, p=0.48); no differences in mortality, HF events, new diabetes or NT-proBNP. Presented by Henrik Wiggers (Aarhus) in Hot Line 6.","created":"2026-08-30T15:57:41Z","updated":"2026-08-31T13:02:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-time-hf","type":"article","url":"https://hartvaat.nl/2026/08/30/time-hf-verpleegkundig-gecoordineerde-digitaal-ondersteunde-hartfalenzorg-verlaa/","title":"TIME-HF: verpleegkundig gecoördineerde, digitaal ondersteunde hartfalenzorg verlaagt sterfte met 22 procent en verdubbelt bijna de richtlijntherapie in India","title_en":"TIME-HF: nurse-coordinated, digitally supported heart failure care lowers mortality by 22 percent and nearly doubles guideline therapy in India","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.082490","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.082490","authors":["Jeemon P, et al.; TIME-HF investigators"],"significance":7,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/12f570366dba.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"esc-2026","summary_en":"Cluster-randomised trial in 22 Indian centres (57 percent rural): 1,507 adults with HFrEF, nurse-coordinated collaborative care with mobile health, structured counselling and real-time communication versus usual care. Days alive and out of hospital at two years: probability of survival without hospitalisation 84.0 versus 79.4 percent (p under 0.001), mortality minus 22 percent (p=0.028), guideline-directed therapy at two years 37.3 versus 22.1 percent. Presented by Panniyammakal Jeemon in Hot Line 6, Circulation.","created":"2026-08-30T15:57:40Z","updated":"2026-08-31T13:02:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-nexaf","type":"article","url":"https://hartvaat.nl/2026/08/30/nexaf-een-trainingsprogramma-met-acht-begeleide-intervalsessies-en-een-jaar-thui/","title":"NEXAF: een trainingsprogramma met acht begeleide intervalsessies en een jaar thuistraining verlaagt de AF-last met 45 procent en de AF-opnames met 46 procent","title_en":"NEXAF: an exercise programme of eight supervised interval sessions and a year of home training lowers AF burden by 45 percent and AF hospitalisations by 46 percent","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"","source_url":"","authors":["Nes BM, et al.; NEXAF investigators"],"significance":7,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/79da52b2512a.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"esc-2026","summary_en":"RCT in three Norwegian centres: 295 patients with AF randomised to eight supervised high-intensity sessions over 4 to 6 weeks followed by home-based exercise for a year with smartwatch, app and web monitoring, or usual care. AF burden 3.9 versus 7.1 percent of monitored time (45 percent relative reduction, p=0.016); AFEQT no difference (+5.6 versus +4.4, p=0.43); total hospitalisations minus 37 percent, AF-related minus 46 percent; fitness improved. Presented by Bjarne Nes (NTNU Trondheim) in Hot Line 8, European Heart Journal.","created":"2026-08-30T15:57:40Z","updated":"2026-08-31T13:02:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-acasa-tavi","type":"article","url":"https://hartvaat.nl/2026/08/30/acasa-tavi-een-doac-in-plaats-van-aspirine-na-tavi-halveert-de-klepbladtrombose-/","title":"ACASA-TAVI: een DOAC in plaats van aspirine na TAVI halveert de klepbladtrombose op CT en is even veilig, met levensbedreigende bloedingen alleen in de aspirinegroep","title_en":"ACASA-TAVI: a DOAC instead of aspirin after TAVI halves CT leaflet thrombosis and is as safe, with life-threatening bleeds only in the aspirin group","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"JAMA","doi":"10.1001/jama.2026.17327","source_url":"https://doi.org/10.1001/jama.2026.17327","authors":["Lie ØH, et al.; ACASA-TAVI investigators"],"significance":7,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/9f003cec52db.webp","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"esc-2026","summary_en":"Investigator-initiated head-to-head trial in three Norwegian hospitals: 360 patients aged 65 to 80 after TAVI randomised to DOAC monotherapy (apixaban, edoxaban or rivaroxaban) or aspirin monotherapy. Hypo-attenuated leaflet thickening at 12 months 17.2 versus 32.6 percent (RR 0.55, p=0.004); safety composite of VARC-3 bleeding, thromboembolism or death 7.5 versus 10.6 percent (non-inferior); life-threatening or fatal bleeding only in the aspirin arm. Hot Line 7, JAMA.","created":"2026-08-30T15:57:40Z","updated":"2026-08-31T13:02:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-pvi-sham-af","type":"article","url":"https://hartvaat.nl/2026/08/30/pvi-sham-af-pulmonaalvene-isolatie-verbetert-de-af-gerelateerde-kwaliteit-van-le/","title":"PVI-SHAM-AF: pulmonaalvene-isolatie verbetert de AF-gerelateerde kwaliteit van leven niet meer dan een schijnprocedure, ondanks minder atriumfibrilleren","title_en":"PVI-SHAM-AF: pulmonary vein isolation does not improve AF-related quality of life more than a sham procedure, despite less atrial fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"The Lancet","doi":"","source_url":"","authors":["Wachter R, et al.; PVI-SHAM-AF investigators"],"significance":8,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/77231166d0dd.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"esc-2026","summary_en":"The first double-blind, sham-controlled ablation trial in AF: 262 symptomatic patients with paroxysmal or persistent AF randomised to pulmonary vein isolation or a sham procedure (sedation, vascular access, no catheter). AFEQT summary score at six months improved in both groups without difference (61.3 to 81.1 versus 59.2 to 74.9, p=0.36), while freedom from AF was 73 versus 52 percent. Six versus four serious adverse events. Presented by Rolf Wachter (Leipzig) in Hot Line 8, The Lancet.","created":"2026-08-30T15:57:40Z","updated":"2026-08-31T13:02:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-tavi-pci","type":"article","url":"https://hartvaat.nl/2026/08/30/tavi-pci-eerst-de-klep-en-dan-de-stent-is-non-inferieur-aan-eerst-de-stent-bij-e/","title":"TAVI PCI: eerst de klep en dan de stent is non-inferieur aan eerst de stent bij ernstige aortastenose met coronairlijden, met minder ernstige bloedingen","title_en":"TAVI PCI: valve first then stent is non-inferior to stent first in severe aortic stenosis with coronary disease, with fewer major bleeds","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"","source_url":"","authors":["Stähli BE, et al.; TAVI PCI investigators"],"significance":8,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/9920ad115901.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/"],"congress":"esc-2026","summary_en":"Open-label non-inferiority trial in 48 centres in Austria, France, Germany, Italy, the Netherlands and Switzerland: 986 patients (mean 82, 34 percent women) with severe aortic stenosis and coronary artery disease, randomised to TAVI followed by angiography-guided PCI or PCI followed by TAVI, both within 1 to 45 days. Composite of death, MI, ischaemia-driven revascularisation, rehospitalisation or major bleeding at one year 22.2 versus 24.2 percent (difference minus 2.0 points, 95% CI minus 7.4 to 3.4, non-inferior); major bleeding 6.6 versus 9.7 percent. Hot Line 7, NEJM.","created":"2026-08-30T15:57:40Z","updated":"2026-08-31T13:02:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-tric-i-hf","type":"article","url":"https://hartvaat.nl/2026/08/30/tric-i-hf-transcatheter-tricuspidalisklepherstel-bovenop-medicatie-verlaagt-ster/","title":"TRIC-I-HF: transcatheter tricuspidalisklepherstel bovenop medicatie verlaagt sterfte of hartfalenopname na drie jaar met 60 procent bij ernstige tricuspidalisinsufficiëntie","title_en":"TRIC-I-HF: transcatheter tricuspid repair on top of medical therapy lowers death or heart failure hospitalisation at three years by 60 percent in severe tricuspid regurgitation","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2606934","source_url":"https://doi.org/10.1056/NEJMoa2606934","authors":["Hausleiter J, Stocker T, et al.; TRIC-I-HF investigators"],"significance":9,"published":"2026-08-30","source_date":"2026-08-30","image":"https://hartvaat.nl/global/img/417a79819738.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"esc-2026","summary_en":"The hard-endpoint trial the tricuspid field lacked: 360 patients (mean 80 years, 56 percent women) with heart failure and severe tricuspid regurgitation in 29 German centres, randomised 2:1 to transcatheter edge-to-edge repair (98 percent) plus medical therapy or medical therapy alone. One-year hierarchical endpoint win ratio 2.42 (95% CI 1.76 to 3.33, p under 0.001); freedom from death or HF hospitalisation at three years 52.4 versus 21.0 percent (HR 0.40, 0.29 to 0.55). Hot Line 7, NEJM.","created":"2026-08-30T15:57:39Z","updated":"2026-08-31T13:02:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80d959d23724","type":"article","url":"https://hartvaat.nl/2026/08/21/scd-bij-ckd-en-dialyse-heterogene-aritmieen-en-mechanisme-gestuurde-preventie/","title":"SCD bij CKD en dialyse: heterogene aritmieën en mechanisme-gestuurde preventie","title_en":"Sudden cardiac death in chronic kidney disease and dialysis: From descriptive epidemiology to mechanism-driven prevention.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of internal medicine","doi":"10.1111/joim.70127","source_url":"https://doi.org/10.1111/joim.70127","authors":["Carmine Zoccali","Mehmet Kanbay","Andrzej Wiecek","Sophie Liabeuf","Francesca Mallamaci"],"significance":6,"published":"2026-08-29","source_date":"2026-08-21","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This narrative review examines sudden cardiac death (SCD) in chronic kidney disease and dialysis, challenging the traditional focus on ventricular tachyarrhythmias by highlighting that bradyarrhythmias, pauses, and conduction disease are equally prevalent. Device-based monitoring data reveal a heterogeneous arrhythmic spectrum, shifting the clinical paradigm toward mechanism-driven prevention. Effective risk reduction now requires integrating contemporary cardiorenal pharmacotherapy, tailored dialysis prescriptions, and selective device therapy. The proposed framework offers cardiologists and internists a structured approach to phenotyping, continuous monitoring, and modifiable trigger management in this high-risk population.","created":"2026-08-23T01:06:09Z","updated":"2026-08-23T01:06:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5773e49f229","type":"article","url":"https://hartvaat.nl/2026/08/21/lvad-implantatie-voor-destination-therapy-toont-vergelijkbare-uitkomsten-als-bru/","title":"LVAD-implantatie voor destination therapy toont vergelijkbare uitkomsten als brug naar transplantatie","title_en":"Clinical differences between destination therapy and bridge-to-transplant left ventricular assist device implantation: a 17-year single-center experience in Japan.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs","doi":"10.1007/s10047-026-01581-8","source_url":"https://doi.org/10.1007/s10047-026-01581-8","authors":["Koichi Inoue","Daisuke Yoshioka","Yusuke Misumi","Ai Kawamura","Shin Yajima","Takuji Kawamura","Shunsuke Saito","Takashi Yamauchi","Shigeru Miyagawa"],"significance":4,"published":"2026-08-29","source_date":"2026-08-21","image":"https://hartvaat.nl/global/img/7f8062705c8a.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/"],"congress":"","summary_en":"In a single-center retrospective study of 40 patients in Japan, clinical outcomes of left ventricular assist device (LVAD) implantation for destination therapy (DT) were compared with those for bridge-to-transplant (BTT). Five-year on-device survival was 49.8%, with 90.6% of patients experiencing rehospitalization, primarily due to device-related infections. No significant differences were observed between DT and BTT groups in survival or complication rates. These findings support LVAD implantation as a viable option for patients ineligible for heart transplantation.","created":"2026-08-23T00:57:04Z","updated":"2026-08-23T00:57:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c51b09254ed9","type":"article","url":"https://hartvaat.nl/2026/08/22/lipidenzorg-bij-ascvd-preventie-cac-scoren-lp-a-en-niet-statine-remmers/","title":"Lipidenzorg bij ASCVD-preventie: CAC-scoren, Lp(a) en niet-statine-remmers","title_en":"Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Cardiology and therapy","doi":"10.1007/s40119-026-00473-5","source_url":"https://doi.org/10.1007/s40119-026-00473-5","authors":["Andrew Carlson","Zaid A Zayyad","Stefanie Driesenga","Peter Boxley","Atreya Mishra","Omar Uraizee","Rediat Ephrem","Runze Zhang","Zachary Natsheh","Adhir R Shroff"],"significance":6,"published":"2026-08-29","source_date":"2026-08-22","image":"https://hartvaat.nl/global/img/d3d102d0a2c9.webp","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This narrative review outlines the evolving landscape of lipid management for atherosclerotic cardiovascular disease (ASCVD) prevention in primary care and cardiology. Beyond traditional risk scores, clinicians are increasingly using lifetime risk assessment, lipoprotein(a), apolipoprotein B, and coronary artery calcification (CAC) scoring to identify residual risk and guide therapy. While statins remain foundational, recent ACC/AHA and ESC/EAS guidelines emphasize early treatment intensification and the strategic use of non-statin agents. The article provides a practical, guideline-aligned framework for optimizing secondary and primary prevention strategies.","created":"2026-08-23T00:52:36Z","updated":"2026-08-23T00:52:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3110950d5ab6","type":"article","url":"https://hartvaat.nl/2026/08/22/menopauze-verstoort-lever-nier-metabool-evenwicht-hormoontherapie-niet-bewezen-v/","title":"Menopauze verstoort lever-nier-metabool evenwicht; hormoontherapie niet bewezen voor MASLD- of CKD-preventie","title_en":"Impact of Menopause and Menopausal Hormone Therapy on Liver-Kidney-Metabolic Health.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Advances in therapy","doi":"10.1007/s12325-026-03758-2","source_url":"https://doi.org/10.1007/s12325-026-03758-2","authors":["Mohamad Jamalinia","Amedeo Lonardo","Ralf Weiskirchen"],"significance":4,"published":"2026-08-29","source_date":"2026-08-22","image":"https://hartvaat.nl/global/img/4cb5550ab72a.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This narrative review outlines how menopause disrupts the liver-kidney-metabolic (LKM) axis through shifts in fat distribution, insulin sensitivity, and inflammation, thereby increasing the risk of MASLD and chronic kidney disease. While menopausal hormone therapy may partially mitigate some metabolic changes, current evidence does not support its use for preventing or treating MASLD or CKD. For clinicians, this reinforces that cardiovascular and renal risk management in peri- and postmenopausal women should remain guideline-driven, with hormone therapy reserved for established indications rather than metabolic protection.","created":"2026-08-23T00:49:27Z","updated":"2026-08-23T00:49:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"177e5b9f7045","type":"article","url":"https://hartvaat.nl/2026/09/01/doorbraakstroke-onder-doac-s-bij-atriumfibrilleren-vaak-door-niet-naleving-of-ni/","title":"Doorbraakstroke onder DOAC's bij atriumfibrilleren vaak door niet-naleving of niet-cardioembolische oorzaken","title_en":"Etiologic spectrum of direct oral anticoagulant breakthrough stroke in atrial fibrillation: The role of pseudo-failure and non-cardioembolic mechanisms.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","doi":"10.1016/j.jstrokecerebrovasdis.2026.108706","source_url":"https://doi.org/10.1016/j.jstrokecerebrovasdis.2026.108706","authors":["Lóránd Hegyi","Alex Beke","József Norbert Nemes","Nikoletta Szabó","Péter Klivényi","Tibor Gellért Hortobágyi","Ádám Annus"],"significance":5,"published":"2026-08-29","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"A retrospective cohort of 246 atrial fibrillation patients experiencing ischemic stroke while on DOAC therapy revealed that over 60% of events were classified as pseudo-failure, primarily driven by non-adherence or off-label underdosing. True DOAC failure accounted for 38% of cases and was strongly associated with competing non-cardioembolic mechanisms, particularly large-artery atherosclerosis (41.5%), whereas cardioembolism was less common (27.7%). True failure remained independently linked to non-cardioembolic stroke (adjusted OR 7.15; 95% CI 3.85–13.29; p < 0.001). These findings highlight that breakthrough strokes on DOACs often reflect medication issues or alternative vascular pathologies, underscoring the need for thorough etiologic reassessment and mechanism-specific secondary prevention before altering anticoagulant regimens.","created":"2026-08-23T00:46:00Z","updated":"2026-08-23T00:46:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-tranquility","type":"article","url":"https://hartvaat.nl/2026/08/29/tranquility-het-il-6-antilichaam-pacibekitug-verlaagt-hs-crp-tot-89-procent-bij-/","title":"TRANQUILITY: het IL-6-antilichaam pacibekitug verlaagt hs-CRP tot 89 procent bij chronische nierschade, met infrequente dosering en zonder nieuwe veiligheidssignalen","title_en":"TRANQUILITY: the IL-6 antibody pacibekitug lowers hs-CRP by up to 89 percent in chronic kidney disease, with infrequent dosing and no new safety signals","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"ESC Congress 2026 (Hot Line 2, fase 2)","doi":"","source_url":"","authors":["Bhatt DL, et al.; TRANQUILITY investigators"],"significance":6,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/f4669e9f7e30.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"esc-2026","summary_en":"Phase 2, placebo-controlled, 49 US centres: 143 patients with CKD stage 3 to 4 and hs-CRP 2 to under 15 mg/L. Median hs-CRP change through day 180: plus 7 percent on placebo versus minus 76 to minus 89 percent on pacibekitug (p under 0.0001), dose-dependent, reached by day 30 and sustained; fibrinogen and lipoprotein(a) also fell. Discontinuations 1.9 percent, no dose-related safety signal. Presented by Deepak Bhatt in Hot Line 2. Biomarker trial; the outcomes trial is what matters.","created":"2026-08-29T16:03:59Z","updated":"2026-08-31T13:02:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-react","type":"article","url":"https://hartvaat.nl/2026/08/29/react-beeldvorming-vindt-stille-atherosclerose-bij-57-procent-van-16-808-volwass/","title":"REACT: beeldvorming vindt stille atherosclerose bij 57 procent van 16.808 volwassenen zonder hartziekte, en SCORE2 mist de meesten","title_en":"REACT: imaging finds silent atherosclerosis in 57 percent of 16,808 adults without heart disease, and SCORE2 misses most of them","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2609059","source_url":"https://doi.org/10.1056/NEJMoa2609059","authors":["Bundgaard H, Ibanez B, et al.; REACT investigators"],"significance":8,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/b35b2dbb94f4.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/preventie/screeningsprogramma-hart-en-vaatziekten/"],"congress":"esc-2026","summary_en":"Prospective cross-sectional study in Denmark and Spain: 16,808 adults aged 18 to 70 without known cardiovascular disease, balanced by decade and sex, imaged with 3D vascular ultrasound of carotid and femoral arteries and coronary CT angiography. Silent atherosclerosis in 57.1 percent: about 1 in 13 at 18 to 29, 9 in 10 at 60 to 70, an S-shaped age curve, men 5 to 10 years ahead of women, women with a steep rise around the menopause. Only a minority of those with silent disease were high risk on SCORE2. Presented by Henning Bundgaard and Borja Ibanez in Hot Line 2, NEJM.","created":"2026-08-29T16:03:58Z","updated":"2026-08-31T13:02:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-epidaurus","type":"article","url":"https://hartvaat.nl/2026/08/29/epidaurus-prasugrel-of-ticagrelor-bij-een-doac-na-infarct-met-atriumfibrilleren-/","title":"EPIDAURUS: prasugrel of ticagrelor bij een DOAC na infarct met atriumfibrilleren verdrievoudigt de ernstige bloedingen, de trial is voortijdig gestopt","title_en":"EPIDAURUS: prasugrel or ticagrelor with a DOAC after infarction in atrial fibrillation triples major bleeding, the trial was stopped early","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"Nature Medicine","doi":"10.1038/s41591-026-04629-7","source_url":"https://doi.org/10.1038/s41591-026-04629-7","authors":["Rizas KD, et al.; EPIDAURUS investigators"],"significance":7,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/ab2c388172b5.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"esc-2026","summary_en":"Randomised trial stopped early for safety after 602 of 1,474 planned patients with AF and myocardial infarction: DOAC plus one month of prasugrel or ticagrelor versus DOAC plus clopidogrel (with in-hospital aspirin). BARC 3 or higher bleeding HR 3.54 (95% CI 1.15 to 10.85, p=0.028) within six weeks, with no difference in ischaemic outcomes at six weeks or six months. Presented by Konstantinos Rizas (LMU Munich) in Hot Line 3, Nature Medicine.","created":"2026-08-29T16:03:58Z","updated":"2026-08-31T13:02:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-a-close","type":"article","url":"https://hartvaat.nl/2026/08/29/a-close-na-twaalf-maanden-dapt-bij-hoog-ischemisch-risico-is-clopidogrel-alleen-/","title":"A-CLOSE: na twaalf maanden DAPT bij hoog ischemisch risico is clopidogrel alleen non-inferieur op het netto-eindpunt, maar met meer infarcten en sterfte en minder bloedingen","title_en":"A-CLOSE: after twelve months of DAPT in high ischaemic risk, clopidogrel alone is non-inferior on the net endpoint, but with more infarctions and deaths and less bleeding","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2608533","source_url":"https://doi.org/10.1056/NEJMoa2608533","authors":["Kim BK, et al.; A-CLOSE investigators"],"significance":7,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/440e3855248e.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"esc-2026","summary_en":"RCT in 19 South Korean centres: 3,203 patients who completed 12 months of DAPT after high-risk drug-eluting stent PCI, randomised to clopidogrel monotherapy or 24 further months of DAPT. Net primary endpoint (death, MI, stent thrombosis, stroke or BARC 2, 3 or 5 bleeding) 5.0 versus 5.1 percent (non-inferior, p=0.001); ischaemic endpoint 3.7 versus 1.6 percent (p under 0.001), all-cause death 1.3 versus 0.4 percent; bleeding 1.8 versus 4.1 percent. Hot Line 3, NEJM.","created":"2026-08-29T16:03:58Z","updated":"2026-08-31T13:02:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-premium","type":"article","url":"https://hartvaat.nl/2026/08/29/premium-aspirine-weglaten-vanaf-de-primaire-pci-bij-stemi-haalt-non-inferioritei/","title":"PREMIUM: aspirine weglaten vanaf de primaire PCI bij STEMI haalt non-inferioriteit niet, ondanks minder bloedingen","title_en":"PREMIUM: omitting aspirin from primary PCI onwards in STEMI fails non-inferiority, despite less bleeding","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2606997","source_url":"https://doi.org/10.1056/NEJMoa2606997","authors":["Nakazawa G, et al.; PREMIUM investigators"],"significance":7,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/0338717e2e9a.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"esc-2026","summary_en":"Open-label non-inferiority trial in 69 Japanese centres: 2,280 STEMI patients randomised to prasugrel monotherapy (20 mg loading, 3.75 mg daily, Japanese dosing) started before PCI, or 12 months of DAPT. Death, MI or stroke at 12 months 11.0 versus 8.5 percent (HR 1.34, 95% CI 1.02 to 1.75; non-inferiority not met); BARC 3 or 5 bleeding 5.6 versus 8.4 percent (HR 0.66). Presented by Gaku Nakazawa in Hot Line 3, NEJM.","created":"2026-08-29T16:03:58Z","updated":"2026-08-31T13:02:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-air-stemi","type":"article","url":"https://hartvaat.nl/2026/08/29/air-stemi-complete-revascularisatie-op-geleide-van-angiografisch-afgeleide-ffr-v/","title":"AIR-STEMI: complete revascularisatie op geleide van angiografisch afgeleide FFR verlaagt events met 38 procent na STEMI met meervatslijden","title_en":"AIR-STEMI: complete revascularisation guided by angiography-derived FFR lowers events by 38 percent after STEMI with multivessel disease","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2605373","source_url":"https://doi.org/10.1056/NEJMoa2605373","authors":["Biscaglia S, et al.; AIR-STEMI investigators"],"significance":8,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/828737b11b64.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/","https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/"],"congress":"esc-2026","summary_en":"Investigator-initiated RCT in 21 centres in Italy and Pakistan: 1,823 STEMI patients with multivessel disease randomised to complete revascularisation guided by angiography-derived FFR (non-culprit lesions treated only if FFR 0.80 or lower) versus angiography-guided PCI of every lesion of 50 percent or more. Death, MI, stroke or ischaemia-driven revascularisation at median 17.9 months 8.9 versus 13.7 percent (HR 0.62, 95% CI 0.47 to 0.83, p under 0.001); contrast nephropathy or major bleeding 4.6 versus 7.1 percent. Hot Line 4, NEJM.","created":"2026-08-29T16:03:58Z","updated":"2026-08-31T13:02:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-amundsen","type":"article","url":"https://hartvaat.nl/2026/08/29/amundsen-evolocumab-in-de-katheterisatiekamer-brengt-82-procent-van-de-infarctpa/","title":"AMUNDSEN: evolocumab in de katheterisatiekamer brengt 82 procent van de infarctpatiënten binnen een jaar op LDL-doel, zonder aantoonbaar klinisch verschil","title_en":"AMUNDSEN: evolocumab in the cath lab gets 82 percent of infarct patients to LDL target within a year, without a demonstrable clinical difference","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"JAMA","doi":"10.1001/jama.2026.17302","source_url":"https://doi.org/10.1001/jama.2026.17302","authors":["Montalescot G, et al.; AMUNDSEN investigators"],"significance":7,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/b5a862760b62.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"esc-2026","summary_en":"International open-label phase 4 trial: 2,161 patients with high-risk acute MI undergoing PCI, evolocumab 140 mg every two weeks for one year with the first dose given before PCI, versus standard care. LDL-C under 55 mg/dL plus at least 50 percent reduction at 12 months: 82 versus 40 percent (adjusted OR 5.54, 95% CI 4.50 to 6.82, p under 0.001). Death or unplanned cardiovascular hospitalisation 14.6 versus 15.4 percent (OR 0.94, p=0.59). Hot Line 2, JAMA.","created":"2026-08-29T16:03:57Z","updated":"2026-08-31T13:02:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-presc1se-mi","type":"article","url":"https://hartvaat.nl/2026/08/29/presc1se-mi-het-esc-0-1-uur-troponine-algoritme-is-even-veilig-als-0-3-uur-maar-/","title":"PRESC1SE-MI: het ESC 0/1-uur troponine-algoritme is even veilig als 0/3 uur, maar verkort het SEH-verblijf met geen minuut","title_en":"PRESC1SE-MI: the ESC 0/1-hour troponin algorithm is as safe as 0/3 hours but shortens emergency department stay by not a single minute","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"The Lancet","doi":"","source_url":"","authors":["Boeddinghaus J, et al.; PRESC1SE-MI investigators"],"significance":8,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/16bcff2b3a07.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/"],"congress":"esc-2026","summary_en":"The largest diagnostic trial ever in suspected MI: a stepped-wedge cluster-randomised trial in 20 hospitals in 11 countries, 67,624 consecutive emergency presentations, 0/1-hour versus 0/3-hour high-sensitivity troponin pathways. Death or new type 1 MI within 30 days 1.1 versus 1.2 percent (adjusted OR 0.93, 95% CI 0.77 to 1.13, non-inferior); median ED length of stay 309 minutes in both arms (p=0.65). Presented by Jasper Boeddinghaus in Hot Line 4, simultaneously in The Lancet.","created":"2026-08-29T16:03:57Z","updated":"2026-08-31T13:02:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-switch-swedeheart","type":"article","url":"https://hartvaat.nl/2026/08/29/switch-swedeheart-een-regiobreed-beleid-van-prasugrel-in-plaats-van-ticagrelor-n/","title":"SWITCH SWEDEHEART: een regiobreed beleid van prasugrel in plaats van ticagrelor na PCI geeft gelijke bescherming en minder bloedingen bij 17.095 ACS-patiënten","title_en":"SWITCH SWEDEHEART: a region-wide policy of prasugrel instead of ticagrelor after PCI gives equal protection and less bleeding in 17,095 ACS patients","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2609057","source_url":"https://doi.org/10.1056/NEJMoa2609057","authors":["Omerovic E, et al.; SWITCH SWEDEHEART investigators"],"significance":8,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/20245692a61b.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"esc-2026","summary_en":"A registry-based stepped-wedge randomised trial: seven Swedish regions switched their default P2Y12 inhibitor from ticagrelor to prasugrel at staggered dates, covering 17,095 consecutive ACS patients undergoing PCI. Death, MI or stroke at one year 11.1 versus 11.8 percent (adjusted OR 0.90, 95% CI 0.77 to 1.06); major bleeding 4.2 versus 4.4 percent (OR 0.80, 0.64 to 0.99). Presented by Elmir Omerovic in Hot Line 3, NEJM.","created":"2026-08-29T16:03:57Z","updated":"2026-08-31T13:02:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-librexia-acs","type":"article","url":"https://hartvaat.nl/2026/08/29/librexia-acs-milvexian-voorkomt-geen-events-na-een-acuut-coronair-syndroom-en-bl/","title":"LIBREXIA ACS: milvexian voorkomt geen events na een acuut coronair syndroom en bloedt niet minder, een klap voor de factor XI-hypothese in het ACS-domein","title_en":"LIBREXIA ACS: milvexian prevents no events after an acute coronary syndrome and does not bleed less, a blow to the factor XI hypothesis in ACS","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2608717","source_url":"https://doi.org/10.1056/NEJMoa2608717","authors":["Steg PG, et al.; LIBREXIA ACS investigators"],"significance":8,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/ff212ed9235b.webp","kennis":["https://hartvaat.nl/kennis/antistolling/rivaroxaban/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"esc-2026","summary_en":"The full results of the trial stopped for futility in November 2025: 14,194 patients within 7 days of an ACS with at least two risk factors, milvexian 25 mg twice daily or placebo on top of antiplatelet therapy, median 10 months. Cardiovascular death, MI or ischaemic stroke 5.4 versus 5.1 percent (HR 1.05, 95% CI 0.91 to 1.21, p=0.50); BARC 3c or 5 bleeding 0.3 percent in both arms (HR 1.04). Presented by Gabriel Steg in Hot Line 3, NEJM. LIBREXIA AF and LIBREXIA Stroke continue.","created":"2026-08-29T16:03:57Z","updated":"2026-08-31T13:02:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-staree","type":"article","url":"https://hartvaat.nl/2026/08/29/staree-atorvastatine-40-mg-bij-gezonde-70-plussers-voorkomt-30-procent-van-de-ca/","title":"STAREE: atorvastatine 40 mg bij gezonde 70-plussers voorkomt 30 procent van de cardiovasculaire events, maar verlengt de invaliditeitsvrije overleving niet","title_en":"STAREE: atorvastatin 40 mg in healthy adults over 70 prevents 30 percent of cardiovascular events but does not extend disability-free survival","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2607314","source_url":"https://doi.org/10.1056/NEJMoa2607314","authors":["Zoungas S, et al.; STAREE investigators"],"significance":9,"published":"2026-08-29","source_date":"2026-08-29","image":"https://hartvaat.nl/global/img/fdd2d16f581d.webp","kennis":["https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"esc-2026","summary_en":"The trial the primary-care question has waited for: 9,971 healthy Australians aged 70 and over (mean 74.7, 52 percent women) randomised to atorvastatin 40 mg or placebo, median follow-up 5.9 years. Major cardiovascular events 6.0 versus 8.3 percent (HR 0.70, 95% CI 0.61 to 0.82, p under 0.001). The co-primary disability-free survival endpoint (death, dementia or persistent disability) was not improved: 12.8 versus 13.6 percent (HR 0.94, 0.84 to 1.05, p=0.25). Muscle, liver and diabetes events more frequent on atorvastatin; serious adverse events 2.7 percent in both arms. Hot Line 2, NEJM.","created":"2026-08-29T16:03:56Z","updated":"2026-08-31T13:02:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5abf53b54879","type":"article","url":"https://hartvaat.nl/2026/08/20/deep-learning-op-mobiele-ecg-voorspelt-atriumfibrilleren-binnen-30-dagen/","title":"Deep learning op mobiele ECG voorspelt atriumfibrilleren binnen 30 dagen","title_en":"Prediction of Atrial Fibrillation Occurrence With Handheld Mobile Electrocardiogram: Deep Learning Model Development Using Real-World Data.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JMIR medical informatics","doi":"10.2196/87142","source_url":"https://doi.org/10.2196/87142","authors":["Minje Park","Hyun Jin Ahn","Yeongyeon Na","Sunghoon Joo","Young Ho Lee","Seongwoo Han","Myung Soo Park","Dae Young Cheon","Jeen Hwa Lee","Ki Hong Lee"],"significance":5,"published":"2026-08-28","source_date":"2026-08-20","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/","https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"Researchers developed a deep learning model that predicts the short-term occurrence of atrial fibrillation (AF) within 7, 14, and 31 days using a single resting ECG recording from a handheld mobile device. In a real-world cohort of over 386,000 recordings from 8,200 users, the model achieved an AUROC of 0.79 for 31-day prediction, significantly outperforming single-lead approaches. These findings suggest that AI-driven risk stratification from consumer-grade ECGs could serve as a practical tool for opportunistic AF screening, enabling targeted follow-up in primary care and cardiology.","created":"2026-08-21T01:42:07Z","updated":"2026-08-21T01:42:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5ab6489b60c3","type":"article","url":"https://hartvaat.nl/2026/08/20/risicofactoren-voor-vroege-tussen-en-late-hartfalenheropnames-na-ontslag/","title":"Risicofactoren voor vroege, tussen- en late hartfalenheropnames na ontslag","title_en":"Timing-Specific Factors Associated With Early, Intermediate, and Late Readmission After Heart Failure Hospitalisation.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag219","source_url":"https://doi.org/10.1093/eschf/xvag219","authors":["Gen Li","Zhanyue Shi","Tengfei Gu","Guanghui Li","Ziniu Zhao","Lili Shi"],"significance":4,"published":"2026-08-28","source_date":"2026-08-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This secondary analysis of 1,992 patients discharged from a single-centre heart failure cohort identified distinct risk factors for readmissions within 180 days. Early readmissions (≤28 days) were linked to advanced heart failure severity, reduced eGFR, and hyponatraemia, whereas late readmissions (91-180 days) showed stronger associations with dementia, chronic kidney disease, and diabetes. Predictive models showed modest discrimination (AUC 0.63–0.68). The findings suggest that post-discharge follow-up strategies should be tailored to the specific time window and the patient’s comorbidity profile.","created":"2026-08-21T01:38:31Z","updated":"2026-08-21T01:38:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b1c0b70e8a8","type":"article","url":"https://hartvaat.nl/2026/08/20/long-covid-verhoogt-risico-op-hart-nier-en-longcomplicaties-trinetx-cohort/","title":"Long COVID verhoogt risico op hart-, nier- en longcomplicaties — TriNetX-cohort","title_en":"Cardiovascular, Renal, and Pulmonary Risks of Long COVID: A Retrospective Cohort Study Stratified by Age and Sex.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.126.049226","source_url":"https://doi.org/10.1161/JAHA.126.049226","authors":["Akash Pradeep","Izola Ramalho","Martha L Carvour","Srija M Sivamurugan","Upinder Singh","Alejandro P Comellas","Sanjana Dayal"],"significance":5,"published":"2026-08-28","source_date":"2026-08-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"In a retrospective cohort of over 300,000 propensity-matched COVID-19 patients, Long COVID was associated with an elevated risk of cardiovascular, renal, and pulmonary complications. The relative risk was disproportionately higher in younger adults, particularly young women for cardiovascular and renal outcomes, and young men for pulmonary outcomes. These findings highlight the need for structured follow-up and risk-reduction strategies for Long COVID patients in routine clinical practice.","created":"2026-08-21T01:34:49Z","updated":"2026-08-21T01:34:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b7b49d4bf8e","type":"article","url":"https://hartvaat.nl/2026/08/20/ouderlijke-obesitas-verhoogt-cardiorenale-risico-s-bij-nakomelingen-review/","title":"Ouderlijke obesitas verhoogt cardiorenale risico's bij nakomelingen — review","title_en":"Parental Obesity and Offspring Risk for Cardiorenal Diseases.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Current hypertension reports","doi":"10.1007/s11906-026-01379-2","source_url":"https://doi.org/10.1007/s11906-026-01379-2","authors":["Jussara M do Carmo","John E Hall","Zhen Wang","Alan J Mouton","Ana C M Omoto","Luciana Jorge","Alexandre A da Silva"],"significance":4,"published":"2026-08-28","source_date":"2026-08-20","image":"https://hartvaat.nl/global/img/94feed139c1f.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This narrative review examines evidence linking parental obesity, particularly maternal obesity, to an increased risk of cardiorenal and metabolic dysfunction in offspring. Emerging data suggest that intrauterine exposures, chronic inflammation, mitochondrial dysfunction, and altered intercellular signaling contribute to transgenerational disease programming. For clinical practice, these findings reinforce the importance of preconception counseling, weight management during pregnancy, and early-life interventions to mitigate long-term cardiovascular risk in the next generation.","created":"2026-08-21T01:31:55Z","updated":"2026-08-21T01:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4de32c788b1","type":"article","url":"https://hartvaat.nl/2026/08/20/aangetaste-tubulaire-secretiecapaciteit-verhoogt-cardiovasculaire-sterfte-hunt-s/","title":"Aangetaste tubulaire secretiecapaciteit verhoogt cardiovasculaire sterfte — HUNT-studie","title_en":"Kidney Tubular Secretion Capacity and Risk of Cardiovascular Mortality in the General Population: The HUNT Study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Clinical journal of the American Society of Nephrology : CJASN","doi":"10.2215/CJN.0000001183","source_url":"https://doi.org/10.2215/CJN.0000001183","authors":["Alexander L Bullen","Ronit Katz","Simon B Ascher","Pranav S Garimella","Yngvar Haaskjold","Marius Altern Øvrehus","Michael G Shlipak","Joachim H Ix","Stein Hallan"],"significance":5,"published":"2026-08-28","source_date":"2026-08-20","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Researchers from the HUNT study investigated the association between kidney tubular secretion capacity and cardiovascular mortality in a general community-dwelling population. After adjusting for eGFR, albuminuria, and traditional risk factors, each standard deviation decrease in a composite tubular secretion score was linked to a 27% higher risk of cardiovascular death (HR 1.27; 95% CI 1.03–1.56). The findings indicate that impaired tubular function independently predicts cardiovascular mortality, even in individuals with preserved kidney filtration and no significant albuminuria.","created":"2026-08-21T01:27:50Z","updated":"2026-08-21T01:27:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-revalidatie-richtlijn","type":"article","url":"https://hartvaat.nl/2026/08/28/eerste-esc-richtlijn-hartrevalidatie-multidisciplinair-ook-thuis-en-digitaal-en-/","title":"Eerste ESC-richtlijn hartrevalidatie: multidisciplinair, ook thuis en digitaal, en voor veel meer patiënten dan alleen na een infarct","title_en":"First ESC guideline on cardiac rehabilitation: multidisciplinary, also home-based and digital, and for far more patients than the post-infarction group","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag099","source_url":"https://doi.org/10.1093/eurheartj/ehag099","authors":["Bäck M, Wilhelm M, Hansen D, et al.; ESC Task Force on cardiac rehabilitation"],"significance":7,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/725d53a67e0f.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/"],"congress":"esc-2026","summary_en":"Published today in the European Heart Journal ahead of its Monday presentation: the first dedicated ESC guideline on cardiac rehabilitation, chaired by Maria Bäck (Gothenburg), Matthias Wilhelm (Bern) and Dominique Hansen (Hasselt). Core components are exercise training, psychological support and personalised education on lifestyle and adherence, delivered by a multidisciplinary team, in hospital or through digitally supported home-based programmes with remote monitoring. Indications extend beyond myocardial infarction to heart failure, congenital heart disease, atrial fibrillation, valve replacement and patients receiving cardiotoxic cancer therapy. The guideline calls out the under-use of one of the most effective and cost-effective treatments in cardiology.","created":"2026-08-28T15:15:18Z","updated":"2026-08-31T13:02:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-mi-definitie","type":"article","url":"https://hartvaat.nl/2026/08/28/vijfde-universele-definitie-van-het-myocardinfarct-de-typenummers-verdwijnen-voo/","title":"Vijfde universele definitie van het myocardinfarct: de typenummers verdwijnen, voortaan primair, secundair of procedureel infarct","title_en":"Fifth Universal Definition of Myocardial Infarction: the type numbers go, replaced by primary, secondary and procedure-related infarction","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag101","source_url":"https://doi.org/10.1093/eurheartj/ehag101","authors":["Mills NL, Newby LK, Zaman S, et al.; ESC/ACC/AHA/WHF Joint Task Force"],"significance":8,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/7a3c030db637.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/","https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/"],"congress":"esc-2026","summary_en":"ESC, ACC, AHA and WHF published the Fifth Universal Definition of MI today in the European Heart Journal, simultaneously in Circulation and Global Heart. The numbered types (1 to 5, 4a to 4c) are replaced by three clinical categories: primary MI (plaque rupture, spontaneous coronary artery dissection, spasm, thrombosis), secondary MI (supply-demand mismatch) and procedure-related MI (within 30 days of a cardiac procedure or surgery). The aim is a language patients understand and a research frame for underdiagnosed causes such as SCAD, which predominantly affects women. Chairs: Nicholas Mills (ESC), Kristin Newby (ACC/AHA), Sarah Zaman (WHF).","created":"2026-08-28T15:15:17Z","updated":"2026-08-31T13:02:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-cmr-guide","type":"article","url":"https://hartvaat.nl/2026/08/28/cmr-guide-icd-bij-littekenweefsel-en-lvef-36-tot-50-procent-mist-het-primaire-ei/","title":"CMR GUIDE: ICD bij littekenweefsel en LVEF 36 tot 50 procent mist het primaire eindpunt, maar halveert plotse hartdood en helpt vooral onder de 70","title_en":"CMR GUIDE: an ICD for scar on CMR with LVEF 36 to 50 percent misses its primary endpoint but reduces sudden cardiac death, with benefit confined to patients under 70","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"JAMA","doi":"10.1001/jama.2026.17078","source_url":"https://doi.org/10.1001/jama.2026.17078","authors":["Selvanayagam JB, et al.; CMR GUIDE investigators"],"significance":7,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/916cc48f7fac.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"esc-2026","summary_en":"353 patients with LVEF 36 to 50 percent on optimal therapy and myocardial scar on cardiovascular magnetic resonance (ischaemic or non-ischaemic, 18 centres in Australia, Germany and the UK) were randomised to an ICD or an implantable loop recorder. The primary composite of sudden cardiac death or haemodynamically significant ventricular arrhythmia was 7.8 versus 9.2 percent (HR 0.76, 95% CI 0.37 to 1.58). Sudden cardiac death alone: 1.7 versus 5.8 percent (HR 0.26, 95% CI 0.07 to 0.95). Under 70 the primary endpoint fell by 72 percent; at 70 and over there was no benefit. Hot Line 1, JAMA.","created":"2026-08-28T15:15:17Z","updated":"2026-08-31T13:02:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-poet-ii","type":"article","url":"https://hartvaat.nl/2026/08/28/poet-ii-responsgestuurde-antibioticaduur-bij-linkszijdige-endocarditis-scheelt-t/","title":"POET-II: responsgestuurde antibioticaduur bij linkszijdige endocarditis scheelt twee weken en is niet-inferieur, maar geeft meer recidieven","title_en":"POET-II: response-tailored antibiotic duration in left-sided endocarditis saves two weeks and is non-inferior, at the cost of more relapses","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2607887","source_url":"https://doi.org/10.1056/NEJMoa2607887","authors":["Bundgaard H, et al.; POET-II investigators"],"significance":7,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/5091fde596d2.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"esc-2026","summary_en":"Investigator-initiated open-label trial in 508 clinically stable patients with left-sided endocarditis due to S. aureus, E. faecalis or streptococci (13 centres, Denmark, Sweden, US). Stopping antibiotics once stabilisation criteria were met after a minimum of 2 to 4 weeks yielded 183 versus 169 days alive without antibiotics within 6 months (p under 0.001), median 26 versus 41 days of treatment; the safety composite of death, unplanned valve surgery or symptomatic embolism was 8.2 versus 10.7 percent, meeting non-inferiority. Relapse was more frequent: 5.1 versus 1.6 percent (p=0.04). Hot Line 1, NEJM.","created":"2026-08-28T15:15:17Z","updated":"2026-08-31T13:02:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-cvd-ckd-richtlijn","type":"article","url":"https://hartvaat.nl/2026/08/28/nieuwe-esc-richtlijn-hart-en-nier-2026-egfr-en-albuminurie-bij-elke-hartpatient-/","title":"Nieuwe ESC-richtlijn hart en nier 2026: eGFR en albuminurie bij elke hartpatiënt, SGLT2-remmer ongeacht ejectiefractie, en een Groningse voorzitter","title_en":"New 2026 ESC guideline on cardiovascular disease and chronic kidney disease: eGFR and albuminuria for every cardiac patient, an SGLT2 inhibitor regardless of ejection fraction, and a chair from Groningen","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag098","source_url":"https://doi.org/10.1093/eurheartj/ehag098","authors":["Damman K, Herrington WG, ter Maaten JM, Mayne KJ, et al.; ESC Task Force on cardiovascular disease and chronic kidney disease"],"significance":9,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/a1f088a1ad8f.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"esc-2026","summary_en":"Published today in the European Heart Journal ahead of its Saturday presentation: the first ESC guideline that treats cardiovascular disease and chronic kidney disease as one condition, endorsed by the European Renal Association and chaired by Kevin Damman (UMC Groningen) with William Herrington (Oxford); Jozine ter Maaten (UMCG) co-ordinated. Class I: every patient with CVD is tested for CKD with creatinine-based eGFR and a spot morning urine albumin-to-creatinine ratio, classified by GFR and albuminuria, confirmed over three months. SGLT2 inhibitors across CKD stages and in heart failure regardless of LVEF, early RAS inhibition, finerenone, GLP-1 receptor agonists in diabetes, statins, DOACs over VKA down to an eGFR of 15. The STAMP framework: Screen, Triage, Address CKD risk, Modify CVD management, Plan services.","created":"2026-08-28T15:15:17Z","updated":"2026-08-31T13:02:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-single-af","type":"article","url":"https://hartvaat.nl/2026/08/28/single-af-doac-beschermt-patienten-met-atriumfibrilleren-en-een-risicofactor-zon/","title":"SINGLE-AF: DOAC beschermt patiënten met atriumfibrilleren en één risicofactor, zonder meer ernstige bloedingen","title_en":"SINGLE-AF: a DOAC protects patients with atrial fibrillation and a single stroke risk factor, without excess major bleeding","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2607978","source_url":"https://doi.org/10.1056/NEJMoa2607978","authors":["Joung B, et al.; SINGLE-AF investigators"],"significance":8,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/451bf0377cb7.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-ouderen/"],"congress":"esc-2026","summary_en":"The first randomised trial in the guideline grey zone: 1,803 Korean patients with AF and a CHA2DS2-VASc score of 1 (men) or 2 (women) were randomised to apixaban or rivaroxaban versus no anticoagulation. At 24 months the composite of stroke, systemic embolism, major bleeding or cardiovascular death occurred in 0.5 percent versus 1.5 percent (HR 0.31, 95% CI 0.10 to 0.94, p=0.028); ischaemic stroke 0.1 versus 1.1 percent; major bleeding 0.3 versus 0.5 percent. Hot Line 1, NEJM.","created":"2026-08-28T15:15:17Z","updated":"2026-08-31T13:02:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-cardio-ttransform","type":"article","url":"https://hartvaat.nl/2026/08/28/cardio-ttransform-eplontersen-mist-het-primaire-eindpunt-bij-attr-cardiomyopathi/","title":"CARDIO-TTRansform: eplontersen mist het primaire eindpunt bij ATTR-cardiomyopathie, alleen zonder stabilisator een nominaal signaal","title_en":"CARDIO-TTRansform: eplontersen misses its primary endpoint in ATTR cardiomyopathy, with only a nominal signal in patients not on a stabiliser","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2608510","source_url":"https://doi.org/10.1056/NEJMoa2608510","authors":["Fontana M, Maurer MS, et al.; CARDIO-TTRansform investigators"],"significance":8,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/cf3d8f8b409a.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"esc-2026","summary_en":"The largest ATTR-CM trial to date (1,432 patients, 130 centres) randomised eplontersen 45 mg every four weeks against placebo. The primary composite of cardiovascular death and recurrent cardiovascular events through week 140 was not reduced (rate ratio 0.89, 95% CI 0.73 to 1.09, p=0.277). In the prespecified 43 percent without a baseline stabiliser the signal was nominally positive; on top of tafamidis or acoramidis there was no added benefit. Serum TTR was suppressed throughout. Presented in Hot Line 1 by Mathew Maurer and published in the NEJM.","created":"2026-08-28T15:15:16Z","updated":"2026-08-31T13:02:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-hf-richtlijn","type":"article","url":"https://hartvaat.nl/2026/08/28/nieuwe-esc-hartfalenrichtlijn-2026-twee-fenotypes-in-plaats-van-drie-mra-voor-ie/","title":"Nieuwe ESC-hartfalenrichtlijn 2026: twee fenotypes in plaats van drie, MRA voor iedereen, stadia A tot D en semaglutide bij HFpEF met obesitas","title_en":"New 2026 ESC heart failure guideline: two phenotypes instead of three, an MRA for everyone, stages A to D and semaglutide for HFpEF with obesity","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag100","source_url":"https://doi.org/10.1093/eurheartj/ehag100","authors":["Køber L, Adamo M, et al.; ESC Task Force for the management of heart failure"],"significance":9,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/d4be9352a29b.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"esc-2026","summary_en":"Presented in Munich on 28 August 2026 and published in the European Heart Journal: the first full revision of the ESC heart failure guideline since 2021. HFmrEF disappears (HFrEF now means LVEF below 50 percent, HFpEF 50 percent and above), a stage A to D framework puts prevention on the map, 'acute' becomes 'decompensated', and GDMT is replaced by foundational, additional and interventional therapy. New class I recommendations: an MRA for symptomatic HF regardless of LVEF (finerenone for HFpEF), in-hospital SGLT2 inhibitor start after stabilisation, uptitration every 1 to 2 weeks, IV iron, early advanced-HF referral and palliative care access. Class IIa: semaglutide or tirzepatide for HF with LVEF 45 percent or higher and BMI 30 or higher, digoxin or digitoxin for symptomatic HFrEF. Four Dutch task force members.","created":"2026-08-28T14:19:38Z","updated":"2026-08-31T13:02:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-live-acacia-hcm","type":"article","url":"https://hartvaat.nl/2026/08/28/acacia-hcm-aficamten-verbetert-symptomen-en-inspanningscapaciteit-bij-niet-obstr/","title":"ACACIA-HCM: aficamten verbetert symptomen en inspanningscapaciteit bij niet-obstructieve HCM, de eerste positieve trial ooit in deze groep","title_en":"ACACIA-HCM: aficamten improves symptoms and exercise capacity in non-obstructive HCM, the first positive trial ever in this population","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa2603021","source_url":"https://doi.org/10.1056/NEJMoa2603021","authors":["Masri A, et al.; ACACIA-HCM investigators"],"significance":8,"published":"2026-08-28","source_date":"2026-08-28","image":"https://hartvaat.nl/global/img/dfaa13f3d926.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"esc-2026","summary_en":"Presented in Hot Line 1 at ESC Congress 2026 in Munich and published simultaneously in the NEJM: in 517 patients with symptomatic non-obstructive hypertrophic cardiomyopathy, aficamten improved both KCCQ-CSS (difference 3.0 points, p=0.021) and peak VO2 (difference 0.67 mL/kg/min, p=0.003) at 36 weeks versus placebo. NYHA class improved in 42 percent versus 28 percent, NT-proBNP fell by more than half, and 53 percent versus 13 percent responded in three or more domains. The price: LVEF below 50 percent in 10.5 percent versus 0.8 percent, and more serious adverse events. A first drug for a third of the HCM population, with a modest effect size and a safety signal that demands echo-guided titration.","created":"2026-08-28T14:19:38Z","updated":"2026-08-31T13:02:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa6d3b15179a","type":"article","url":"https://hartvaat.nl/2026/08/22/clopidogrel-superieur-aan-aspirine-na-pci-10-jaar-host-exam/","title":"Clopidogrel superieur aan aspirine na PCI — 10-jaar HOST-EXAM","title_en":"Reappraising long-term antiplatelet therapy after percutaneous coronary intervention","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"The Lancet","doi":"10.1016/S0140-6736(26)01206-7","source_url":"https://doi.org/10.1016/S0140-6736(26)01206-7","authors":["Shaun Khanna","Patrick W Surreys","Aditya Bhat"],"significance":9,"published":"2026-08-27","source_date":"2026-08-22","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"The 10-year follow-up of the HOST-EXAM trial compares clopidogrel versus aspirin monotherapy in patients after percutaneous coronary intervention (PCI). Results demonstrate sustained reductions in composite ischaemic and bleeding outcomes with clopidogrel, with no mortality difference between the two agents. These long-term data challenge the historical primacy of aspirin in chronic secondary prevention post-PCI. Clinicians should consider clopidogrel as a preferred monotherapy option for long-term management following PCI.","created":"2026-08-21T01:19:27Z","updated":"2026-08-21T01:19:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa7f427c644c","type":"article","url":"https://hartvaat.nl/2026/09/01/verhoogd-10-jaar-ascvd-risico-gekoppeld-aan-linkerventrikelhypertrofie-bij-hyper/","title":"Verhoogd 10-jaar ASCVD-risico gekoppeld aan linkerventrikelhypertrofie bij hypertensiepatiënten","title_en":"Association of 10-year Cardiovascular Risk with Left Ventricular Hypertrophy in a Population of Nigerian Hypertensives.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"The Nigerian postgraduate medical journal","doi":"10.4103/npmj.npmj_580_25","source_url":"https://doi.org/10.4103/npmj.npmj_580_25","authors":["Olugbenga Olusola Abiodun","Tina Anya"],"significance":4,"published":"2026-08-27","source_date":"2026-09-01","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"In a cohort of 934 hypertensive patients, an elevated 10-year ASCVD risk score (≥7.5%) was associated with a two-fold higher odds of left ventricular hypertrophy (LVH) on both echocardiography and ECG. Patients with high ASCVD risk had a significantly higher prevalence of LVH compared to those with low risk (42.1% vs 32.3% for echo; 26.3% vs 19.6% for ECG; p < 0.05). These findings suggest that routine ASCVD risk stratification could help identify patients needing timely LVH evaluation, particularly in resource-limited settings.","created":"2026-08-21T00:57:08Z","updated":"2026-08-21T00:57:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9509e699108","type":"article","url":"https://hartvaat.nl/2026/09/22/ldl-c-reductie-50-verlaagt-risico-op-secundaire-cardiovasculaire-gebeurtenissen-/","title":"LDL-C-reductie ≥50% verlaagt risico op secundaire cardiovasculaire gebeurtenissen na ischemische stroke","title_en":"Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Neurology","doi":"10.1212/WNL.0000000000218491","source_url":"https://doi.org/10.1212/WNL.0000000000218491","authors":["Minyoul Baik","Jimin Jeon","Joonsang Yoo","Jinkwon Kim"],"significance":5,"published":"2026-08-27","source_date":"2026-09-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"A retrospective cohort study of 89,414 patients following an acute ischemic stroke found that achieving a ≥50% reduction in LDL-C from baseline independently lowers the risk of recurrent stroke, myocardial infarction, and all-cause mortality, regardless of whether an absolute LDL-C target of <70 mg/dL is met. Patients failing to reach the relative reduction threshold had a significantly higher risk of the primary outcome (adjusted HR 1.12 if LDL-C was <70 mg/dL, and HR 1.28 if ≥70 mg/dL). These findings reinforce current guidelines advocating for intensive lipid-lowering strategies that target both absolute and relative LDL-C reductions to optimize secondary prevention in stroke survivors.","created":"2026-08-21T00:54:03Z","updated":"2026-08-21T00:54:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5a71cfa9a8c","type":"article","url":"https://hartvaat.nl/2026/10/01/cardiale-amyloidose-komt-bij-9-van-tavi-patienten-voor-ongeacht-stromingspatroon/","title":"Cardiale amyloidose komt bij 9% van TAVI-patiënten voor — ongeacht stromingspatroon","title_en":"Dual pathology in aortic stenosis: Identifying transthyretin amyloidosis likelihood in patients referred for transcatheter aortic valve implantation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"International journal of cardiology. Heart & vasculature","doi":"10.1016/j.ijcha.2026.101991","source_url":"https://doi.org/10.1016/j.ijcha.2026.101991","authors":["Stéphanie Kristina Schwarting","Selen Alieva","Mohammad Usama Chaudhry","Kornelia Löw","Sergio Grosu","Steffen Massberg","Simon Deseive","Julius Steffen"],"significance":5,"published":"2026-08-27","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"A retrospective analysis of 2,764 patients undergoing TAVI for severe aortic stenosis found a high likelihood of coexisting transthyretin cardiac amyloidosis in 9% of cases, regardless of the aortic stenosis flow pattern. While procedural success was similar, patients with dual pathology had a higher 3-year all-cause mortality (44% vs 29%), an association that was largely attenuated after adjustment for baseline surgical risk (STS score). These findings suggest that cardiac amyloidosis is relatively common in the TAVI population and contributes to long-term mortality primarily through underlying patient risk rather than procedural complications. Routine consideration of amyloidosis screening may improve prognostic stratification, though it does not currently alter TAVI technique.","created":"2026-08-21T00:50:59Z","updated":"2026-08-21T00:50:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bd46fe688be5","type":"article","url":"https://hartvaat.nl/2026/10/01/masld-verhoogt-sterfte-en-cv-risico-onafhankelijk-van-lipoproteine-a/","title":"MASLD verhoogt sterfte- en CV-risico, onafhankelijk van lipoproteïne(a)","title_en":"The association of MASLD, lipoprotein(a) and long-term outcomes: Results from the multi-ethnic study of atherosclerosis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Metabolism: clinical and experimental","doi":"10.1016/j.metabol.2026.156723","source_url":"https://doi.org/10.1016/j.metabol.2026.156723","authors":["Gomathy Nageswaran","Vignesh Chidambaram","Amudha Kumar","Rami Doukky","Thorsten Leucker","Subhi J Al'Aref","Ragesh Thandassery"],"significance":5,"published":"2026-08-27","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"A secondary analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) demonstrates that metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to lower lipoprotein(a) [Lp(a)] levels but independently increases long-term mortality and cardiovascular risk. Patients with MASLD and elevated Lp(a) faced a twofold higher risk of hard cardiovascular events (HR 2.07), while those with MASLD and low Lp(a) still had a 28% higher all-cause mortality risk (HR 1.28). These findings highlight MASLD as an independent predictor of poor long-term outcomes, suggesting that Lp(a) measurement may refine risk stratification in patients with fatty liver disease.","created":"2026-08-21T00:47:53Z","updated":"2026-08-21T00:47:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8b67fccf2b2d","type":"article","url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","title":"Finerenone blijft effectief bij CKM-patiënten met kankeranamnese — FINE-HEART","title_en":"Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag522","source_url":"https://doi.org/10.1093/eurheartj/ehag522","authors":["Mihály Ruppert","Muthiah Vaduganathan","Brian L Claggett","Akshay S Desai","Pardeep S Jhund","Alasdair Henderson","James Lay-Flurrie","Meike Brinker","Lucas Hofmeister","Markus S Anker","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Peter Rossing","Luis M Ruilope","Bertram Pitt","Rajiv Agarwal","John J V McMurray","Scott D Solomon","Stefan D Anker","Gerasimos Filippatos"],"significance":7,"published":"2026-08-26","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/metformine-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/metabool-syndroom/"],"congress":"","summary_en":"A pooled analysis of three major RCTs (FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF) including 18,991 patients with cardio-renal-metabolic (CKM) syndrome found that 7.3% had a history of cancer. Finerenone consistently reduced all-cause mortality, heart failure, hospitalizations, and composite kidney and cardiovascular outcomes regardless of cancer status, with a consistent safety profile despite slightly higher adverse event rates in the cancer subgroup. The findings reassure clinicians that a prior cancer diagnosis does not diminish the cardiorenal and cardiovascular benefits of finerenone, supporting its use in this complex patient population.","created":"2026-08-19T01:26:44Z","updated":"2026-08-19T01:26:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62f7193f44e4","type":"article","url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","title":"Tafamidis bij ATTR-cardiomyopathie kosteffectiviteit onder de maat in vier Europese landen","title_en":"Deterministic Economic Modelling Study of Tafamidis in Transthyretin Amyloid Cardiomyopathy Across Four European Healthcare Systems.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal. Quality of care & clinical outcomes","doi":"10.1093/ehjqcco/qcag129","source_url":"https://doi.org/10.1093/ehjqcco/qcag129","authors":["Kossar Hosseini","Nicolas Girerd","François Roubille","Luca Monzo","Guillaume Baudry","Jonathan Epstein","Francis Guillemin","Jean-Marc Boivin"],"significance":4,"published":"2026-08-26","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A deterministic modelling study indicates that tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM) is unlikely to be cost-effective in France, Spain, Germany, and the UK against a €100,000/QALY threshold. Incremental cost-effectiveness ratios ranged from €398,136 to €1,398,706 per QALY, with sensitivity analyses showing less than 13% probability of meeting the acceptability threshold. While tafamidis improves survival and quality of life in ATTR-CM, these findings raise significant concerns regarding the funding and accessibility of this high-cost therapy across European healthcare systems.","created":"2026-08-19T01:22:20Z","updated":"2026-08-19T01:22:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb9fb839e3dc","type":"article","url":"https://hartvaat.nl/2026/08/18/echocardiografie-overschatte-drukgradienten-na-tav-in-tav-met-ballon-expandable-/","title":"Echocardiografie overschatte drukgradiënten na TAV-in-TAV met ballon-expandable kleppen","title_en":"Invasive and echocardiographic gradients of self- and balloon-expandable valves in failing aortic bioprostheses.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","doi":"10.1007/s12471-026-02061-7","source_url":"https://doi.org/10.1007/s12471-026-02061-7","authors":["Sraman Chatterjee","Mark van den Dorpel","Rik Adrichem","Claire Ben Ren","Isabella Kardys","Rutger-Jan Nuis","Joost Daemen","Alexander Hirsch","Marcel L Geleijnse","Nicolas M Van Mieghem"],"significance":5,"published":"2026-08-26","source_date":"2026-08-18","image":"https://hartvaat.nl/global/img/0d47193307ad.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"A study of 56 patients undergoing TAV-in-TAV or TAV-in-SAV compared hemodynamics of self-expanding versus balloon-expandable valves. While invasive mean gradients were similar between valve types (6.0 vs 7.0 mmHg), transthoracic echocardiography consistently showed higher gradients for balloon-expandable devices, leading to a significantly larger echo-invasive discrepancy. This highlights the need for cardiologists and imaging specialists to account for valve type when interpreting post-procedural echocardiographic data to avoid misdiagnosing prosthetic dysfunction.","created":"2026-08-19T01:15:23Z","updated":"2026-08-19T01:15:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2608955c262b","type":"article","url":"https://hartvaat.nl/2026/08/18/sheath-to-artery-ratio-voorspelt-access-site-complicaties-bij-femoraal-ingrijpen/","title":"Sheath-to-artery ratio voorspelt access-site complicaties bij femoraal ingrijpen","title_en":"Sheath-to-Artery Diameter Ratio: A Robust Predictor of Early Access-Site Adverse Events in Percutaneous Procedures.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","doi":"10.1002/ccd.70808","source_url":"https://doi.org/10.1002/ccd.70808","authors":["Eduardo Ismael Arteaga Chan","Claudia Lerma","Adriana Torres-Machorro"],"significance":5,"published":"2026-08-26","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"A retrospective nested case-control study of 2,660 patients undergoing femoral percutaneous procedures with sheaths >6 Fr. identified the sheath-to-artery diameter (SHAD) ratio as a strong independent predictor of early vascular access site complications. A SHAD ratio ≥ 1.07 optimally predicted adverse events (OR 6.71; AUC 0.83), while ultrasound- or fluoroscopy-guided puncture significantly reduced complication risk. For interventionalists, these findings support routine pre-procedural vessel assessment and image-guided access to minimize access-site morbidity.","created":"2026-08-19T01:11:34Z","updated":"2026-08-19T01:11:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ca00e216ae0","type":"article","url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","title":"Semaglutide verlaagt hsCRP en ontstekingsactiviteit bij ASCVD-patiënten met overgewicht — SELECT","title_en":"Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.074482","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.074482","authors":["Jorge Plutzky","Paweł Bogdański","Helen M Colhoun","Selcuk Dagdelen","John E Deanfield","Scott S Emerson","G Kees Hovingh","Steven E Kahn","Kathrine Ekström","Gustavs Latkovskis","Michael Lehrke","Søren Hardt-Lindberg","Ildiko Lingvay","Stephen J Nicholls","Tugce Kalayci Oral","Paula P Terns","Søren Rasmussen","Paul M Ridker","Donna H Ryan","A Michael Lincoff"],"significance":8,"published":"2026-08-26","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"In a prespecified secondary analysis of the SELECT trial, researchers evaluated the effect of semaglutide on high-sensitivity C-reactive protein (hsCRP) in 17,604 patients with established atherosclerotic cardiovascular disease and overweight/obesity without diabetes. Semaglutide reduced hsCRP by 37.8% at 104 weeks, with reductions evident as early as 4 weeks and independent of weight loss or statin use. The magnitude of hsCRP reduction correlated with lower major adverse cardiovascular event (MACE) risk, suggesting that anti-inflammatory effects partially mediate the cardiovascular benefits of semaglutide in this high-risk population.","created":"2026-08-19T01:07:59Z","updated":"2026-08-19T01:07:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee7bb936618f","type":"article","url":"https://hartvaat.nl/2026/08/18/glp-1-agonisten-verlagen-cardiovasculaire-risicos-bij-diabetes-en-obesitas-overz/","title":"GLP-1-agonisten verlagen cardiovasculaire risico’s bij diabetes en obesitas — overzicht","title_en":"Glucagon-Like Peptide-1-Based Therapies in Cardiovascular Disease: Evidence, Mechanisms, and Emerging Clinical Applications.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag430","source_url":"https://doi.org/10.1093/eurjpc/zwag430","authors":["Placido Maria Mazzone","Daniele Giacoppo","Nicola Ammirabile","Maria Sara Mauro","Francesco Spagna","Davide Capodanno"],"significance":7,"published":"2026-08-25","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"GLP-1 receptor agonists and emerging dual GIP/GLP-1 agonists have evolved into key cardiometabolic therapies with proven cardiovascular benefits. Large outcome trials demonstrate that these agents significantly reduce major adverse cardiovascular events in patients with type 2 diabetes and elevated risk, with effects extending well beyond glycaemic control. Recent evidence also indicates a reduction in cardiovascular events in obesity without diabetes, alongside promising signals in heart failure with preserved ejection fraction. Clinicians across primary care, internal medicine, and cardiology should integrate these agents into risk management strategies, weighing their metabolic, anti-inflammatory, and haemodynamic benefits against safety considerations.","created":"2026-08-19T01:04:12Z","updated":"2026-08-19T01:04:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b26440917450","type":"article","url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","title":"C-MIC-apparaat vermindert hartfalen-ernst onafhankelijk van GDMT-aanpassingen — C-MIC II","title_en":"Differential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag220","source_url":"https://doi.org/10.1093/eschf/xvag220","authors":["Marat Fudim","Tamara Kovacevic-Preradovic","Dragana N Kosevic","Sasko Jovev","Nermir Granov","Tanja Popov","Igor Rudez","Petar Vukovic","Velibor Ristic","Annette Holtdirk","Miodrag Peric","Faouzi Kallel","Javed Butler","J Eduardo Rame","Stefan D Anker","Marija Zdravkovic"],"significance":5,"published":"2026-08-25","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"A secondary analysis of the C-MIC II trial evaluated whether the benefits of C-MIC device therapy in HFrEF patients were independent of background guideline-directed medical therapy (GDMT) adjustments. While GDMT intensity slightly increased in the control group—likely reflecting clinical deterioration—it decreased in the C-MIC group. Despite this, C-MIC therapy consistently improved left ventricular ejection fraction, patient-reported outcomes, and exercise capacity regardless of baseline SGLT2 inhibitor use. These findings indicate that the device provides clinical benefits independent of pharmacological intensification, supporting its role as an effective add-on strategy in HFrEF management.","created":"2026-08-19T01:01:19Z","updated":"2026-08-19T01:01:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"327a9109fae5","type":"article","url":"https://hartvaat.nl/2026/08/18/fgf23-niveaus-correleren-met-vaatcalcificatie-en-cv-risico-bij-peritonealdialyse/","title":"FGF23-niveaus correleren met vaatcalcificatie en CV-risico bij peritonealdialysepatiënten","title_en":"Clinical association between fibroblast growth factor 23 (FGF23) levels and the severity of vascular calcification and cardiovascular event risk in peritoneal dialysis patients.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Clinical nephrology","doi":"10.5414/CN111818","source_url":"https://doi.org/10.5414/CN111818","authors":["Zhou Meiyang","Huang Haole","Zhou Canxin"],"significance":4,"published":"2026-08-25","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"In a retrospective cohort of 150 peritoneal dialysis patients, higher circulating intact FGF23 levels were independently associated with greater vascular calcification burden and an increased risk of cardiovascular events. After full adjustment, each unit increase in log-transformed FGF23 corresponded to a 74% higher hazard for cardiovascular events (HR 1.74; 95% CI 1.18–2.56; p=0.005). Adding FGF23 to a baseline model modestly improved risk reclassification, suggesting its potential utility for refined cardiovascular risk stratification in dialysis patients, though prospective validation is still required.","created":"2026-08-19T00:55:54Z","updated":"2026-08-19T00:55:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d1442dc3232f","type":"article","url":"https://hartvaat.nl/2026/08/18/hif-stabilisatoren-als-orale-alternatief-voor-esas-bij-anemie-bij-chronische-nie/","title":"HIF-stabilisatoren als orale alternatief voor ESAs bij anemie bij chronische nierziekte","title_en":"Beyond erythropoiesis-stimulating agents: The evolving role of hypoxia-inducible factor stabilizers in anemia of chronic kidney disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Clinical nephrology","doi":"10.5414/CN112100","source_url":"https://doi.org/10.5414/CN112100","authors":["Joel Shah","William Wells-Gatnik","Kunal Sharma","Sidhartha Senapati","Lakshmi Kattamuri","Aimee Hechanova","Fernanda Payan-Schober","Biff F Palmer"],"significance":6,"published":"2026-08-25","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This narrative review evaluates hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) as an oral treatment for anemia in chronic kidney disease (CKD). Phase 3 trials demonstrate that HIF-PHIs are non-inferior to erythropoiesis-stimulating agents (ESAs) and effectively maintain hemoglobin levels, while also improving iron mobilization by lowering hepcidin. However, emerging safety signals regarding major adverse cardiovascular events and thromboembolism, particularly in non-dialysis patients, have prompted divergent regulatory approvals across regions. Clinicians should consider HIF-PHIs a promising alternative to ESAs, but therapy initiation requires individualized cardiovascular risk assessment and ongoing post-marketing surveillance.","created":"2026-08-19T00:51:16Z","updated":"2026-08-19T00:51:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"43b8dcf7203e","type":"article","url":"https://hartvaat.nl/2026/08/18/combinatietherapie-bij-t2dm-en-chronische-nierziekte-evidence-naar-praktijk/","title":"Combinatietherapie bij T2DM en chronische nierziekte — evidence naar praktijk","title_en":"Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag136","source_url":"https://doi.org/10.1093/ndt/gfag136","authors":["Julie A Lovshin"],"significance":6,"published":"2026-08-25","source_date":"2026-08-18","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Chronic kidney disease in type 2 diabetes affects 30–40% of patients and substantially increases cardiovascular risk and mortality. Recent evidence supports the simultaneous use of SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and RAAS blockade to target distinct pathophysiological pathways. This combination strategy reduces cardiovascular events, delays progression to end-stage renal disease, and improves survival. Clinically, it underscores the importance of early, mechanism-driven combination pharmacotherapy in patients with T2DM and CKD.","created":"2026-08-19T00:48:20Z","updated":"2026-08-19T00:48:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"07d788a3ca2d","type":"article","url":"https://hartvaat.nl/2026/08/15/geautomatiseerde-lipidenmonitoring-en-risicoclassificatie-in-de-huisartspraktijk/","title":"Geautomatiseerde lipidenmonitoring en risicoclassificatie in de huisartspraktijk — real-world studie","title_en":"Longitudinal automated lipid target monitoring integrated into a laboratory-based clinical decision support system: a real-world cardiovascular risk management approach.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"Clinica chimica acta; international journal of clinical chemistry","doi":"10.1016/j.cca.2026.121283","source_url":"https://doi.org/10.1016/j.cca.2026.121283","authors":["Jordi Tortosa-Carreres","Mónica Piqueras","Ana Vañó-Bellver","Diana Domingo-Valero","Eugenia Avelino-Hidalgo","Teresa Claramunt-Carbonell","Luís Martínez-Dolz","Begoña Laiz-Marro"],"significance":4,"published":"2026-08-24","source_date":"2026-08-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-doelwaarden-risicostratificatie/"],"congress":"","summary_en":"A laboratory-integrated clinical decision support system (CDSS) was evaluated for automated cardiovascular risk stratification and longitudinal lipid monitoring across 9,507 primary care patients. Despite high exposure to lipid-lowering therapy, target attainment remained low, particularly in very high and high-risk groups (14.9% and 7.8%, respectively). These real-world findings highlight the need for automated, longitudinal monitoring tools in primary care to bridge the gap between guideline-directed therapy and actual lipid control.","created":"2026-08-17T01:23:00Z","updated":"2026-08-17T01:23:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"24adbbb10f40","type":"article","url":"https://hartvaat.nl/2026/08/15/fib-4-en-fni-duiden-op-cardiorenale-en-metabole-belasting-bij-t2dm-en-masld/","title":"FIB-4 en FNI duiden op cardiorenale en metabole belasting bij T2DM en MASLD","title_en":"Association of non-invasive liver-related scores with cardiovascular disease and a four-domain cardiovascular-renal-hepatic-metabolic phenotype in patients with type 2 diabetes mellitus and MASLD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Endocrine","doi":"10.1007/s12020-026-04751-z","source_url":"https://doi.org/10.1007/s12020-026-04751-z","authors":["Katerina Stefanaki","Dimitrios S Karagiannakis","Maria Manolakopoulou","Stefania Magkou","Georgios Georgiopoulos","Michalis Liontos","Andromachi Vryonidou","Melpomeni Peppa","Evanthia Kassi","Theodora Psaltopoulou","Stavroula A Paschou"],"significance":4,"published":"2026-08-24","source_date":"2026-08-15","image":"https://hartvaat.nl/global/img/6bc4538e900e.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"In a retrospective analysis of 216 patients with type 2 diabetes and MASLD, non-invasive liver scores were evaluated for their association with cardiovascular disease and a four-domain cardiorenal-hepatic-metabolic (CRHM) phenotype. Patients with CVD had significantly higher FNI and Hellenic Score II values, while the CRHM phenotype was independently associated with elevated FIB-4 (OR 5.4; 95% CI 1.6-18.6), with combined scores reaching an AUROC of 0.81. These exploratory findings suggest that routine liver scores may help identify systemic cardiorenal and metabolic burden in this population, though external validation is needed before clinical implementation.","created":"2026-08-17T01:17:21Z","updated":"2026-08-17T01:17:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5e6701686fc","type":"article","url":"https://hartvaat.nl/2026/08/15/injecteerbare-lipidendalers-bij-gevorderde-chronische-nierziekte-en-dialyse-narr/","title":"Injecteerbare lipidendalers bij gevorderde chronische nierziekte en dialyse — narratieve review","title_en":"Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Cardiovascular drugs and therapy","doi":"10.1007/s10557-026-07934-y","source_url":"https://doi.org/10.1007/s10557-026-07934-y","authors":["Aikaterini Damianaki","Emelina Stambolliu","Panagiotis Iliakis","Panagiotis Theofilis","Aggeliki Vakka","Evangelia Kalliakouda","Polykarpos Christos Patsalis","Dimitrios Konstantinidis","Dimitrios Petras"],"significance":6,"published":"2026-08-24","source_date":"2026-08-15","image":"https://hartvaat.nl/global/img/d869f6f0c3f9.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This narrative review evaluates injectable lipid-lowering therapies (PCSK9 inhibitors, inclisiran, and emerging agents) in patients with advanced chronic kidney disease (CKD) and dialysis dependence. While these agents achieve substantial LDL reductions without renal toxicity, dialysis patients remain critically underrepresented in trials, contributing to divergent guidelines and the dialysis paradox. Integrating these therapies warrants serious consideration for their ability to target multiple cardiorenal risk pathways beyond LDL alone, though dedicated studies are needed to clarify their role in this high-risk population.","created":"2026-08-17T01:13:11Z","updated":"2026-08-17T01:13:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8fa4c2348db4","type":"article","url":"https://hartvaat.nl/2026/08/15/tirzepatide-verlaagt-hypertensierisico-maar-verhoogt-hypotensie-meta-analyse/","title":"Tirzepatide verlaagt hypertensierisico maar verhoogt hypotensie — meta-analyse","title_en":"Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Endocrine","doi":"10.1007/s12020-026-04757-7","source_url":"https://doi.org/10.1007/s12020-026-04757-7","authors":["Qing-Xin Chen","Xiao-Yu Zhou","Qi Wu","Jia-Jie Xie","Yong Xu","Fang-Yuan Teng","Man Guo"],"significance":6,"published":"2026-08-24","source_date":"2026-08-15","image":"https://hartvaat.nl/global/img/8082309e5398.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A meta-analysis of 32 RCTs (47,332 participants) compared the blood pressure-related safety profiles of tirzepatide and semaglutide in patients with type 2 diabetes or obesity. Tirzepatide significantly reduced the risk of hypertension-related adverse events (RR 0.40) but increased the risk of dose-dependent hypotension (RR 2.45), whereas semaglutide demonstrated a neutral profile. These distinct hemodynamic effects highlight the need for individualized dosing and careful blood pressure monitoring, particularly in patients with low baseline readings.","created":"2026-08-17T01:09:44Z","updated":"2026-08-17T01:09:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b277517fda21","type":"article","url":"https://hartvaat.nl/2026/09/01/pm2-5-blootstelling-versnelt-daling-van-egfr-bij-volwassenen/","title":"PM2.5-blootstelling versnelt daling van eGFR bij volwassenen","title_en":"Long Term Exposure to Ambient Particulate Matter","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106693","source_url":"https://doi.org/10.1016/j.ekir.2026.106693","authors":["Siddhartha Mandal","Ram Jagannathan","Shuchi Anand","Mohammed K Ali","Poornima Prabhakaran","Sailesh Mohan","Ruby Gupta","K M Venkat Narayan","Viswanathan Mohan","Joel D Schwartz","Nikhil Tandon","Dorairaj Prabhakaran"],"significance":5,"published":"2026-08-24","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"In a longitudinal cohort of 12,271 adults from Chennai and Delhi (2010–2016), researchers examined the association between long-term ambient PM2.5 exposure and estimated glomerular filtration rate (eGFR). Each 5 μg/m³ increase in annual PM2.5 was significantly associated with a decline in eGFR (-0.32 ml/min/1.73m² in Chennai and -0.42 ml/min/1.73m² in Delhi). These findings highlight sustained air pollution as a key modifiable risk factor for progressive kidney dysfunction, underscoring the importance of environmental prevention strategies in chronic kidney disease management.","created":"2026-08-17T01:03:05Z","updated":"2026-08-17T01:03:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"962816aec390","type":"article","url":"https://hartvaat.nl/2026/09/01/vrouwen-met-perifeer-arterieel-vaatlijden-presenteren-later-met-meer-distale-zie/","title":"Vrouwen met perifeer arterieel vaatlijden presenteren later met meer distale ziekte — overzicht","title_en":"Sex Differences in Peripheral Arterial Disease: Presentation, Treatment, and Outcomes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts"],"tags":[],"journal":"The International journal of angiology : official publication of the International College of Angiology, Inc","doi":"10.1055/a-2886-6566","source_url":"https://doi.org/10.1055/a-2886-6566","authors":["Nicolas W Shammas"],"significance":5,"published":"2026-08-23","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This narrative review synthesizes current evidence on sex-related differences in peripheral arterial disease (PAD), drawing from observational studies, registries, and randomized trials. Women typically present at an older age with more comorbidities, atypical symptoms, and more diffuse distal disease, leading to delayed diagnosis and higher procedural complexity. While contemporary limb salvage rates are comparable to men, women experience more repeat revascularizations and periprocedural complications, likely driven by smaller vessel diameter and higher comorbidity burden. These findings highlight the need for earlier detection, equitable guideline-directed medical therapy, and sex-specific management strategies in PAD.","created":"2026-08-17T00:58:57Z","updated":"2026-08-17T00:58:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"48d9e3dab1ab","type":"article","url":"https://hartvaat.nl/2026/10/01/cardiale-ct-als-standaard-in-de-electrophysiologie-planning-en-veiligheid-bij-af/","title":"Cardiale CT als standaard in de electrophysiologie — planning en veiligheid bij AF-ablatie en CIED-behandeling","title_en":"Your map to the heart - Cardiac CT applications in modern electrophysiology.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Clinical imaging","doi":"10.1016/j.clinimag.2026.110898","source_url":"https://doi.org/10.1016/j.clinimag.2026.110898","authors":["Stephanie Tan","Blandine Mondesert","Linda B Haramati"],"significance":5,"published":"2026-08-23","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"This narrative review outlines the expanding role of cardiac CT in modern electrophysiology, particularly for atrial fibrillation ablation, cardiac implantable electronic device (CIED) management, and left atrial appendage closure. Optimized CT protocols provide high-resolution, low-radiation imaging that is essential for anatomical mapping, thrombus exclusion, device sizing, and early detection of procedural complications. For electrophysiologists and cardiologists, integrating cardiac CT into routine planning enhances procedural efficiency, improves patient safety, and supports personalized care pathways.","created":"2026-08-17T00:55:00Z","updated":"2026-08-17T00:55:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"467bc22cee44","type":"article","url":"https://hartvaat.nl/2026/10/01/hepcidine-heeft-beperkte-waarde-voor-het-sturen-van-anemietherapie-bij-ckd/","title":"Hepcidine heeft beperkte waarde voor het sturen van anemietherapie bij CKD","title_en":"Hepcidin and Cardiovascular Events in CKD With and Without Dialysis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106703","source_url":"https://doi.org/10.1016/j.ekir.2026.106703","authors":["Yudai Fujimoto","Yuya Matsue","Taisuke Nakade","Yu Suresvar Singh","Yuka Akama","Yutaka Nakamura","Junzhe Cao","Tadao Aikawa","Kentaro Sakamaki","Tohru Minamino"],"significance":4,"published":"2026-08-23","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"A post hoc analysis of two phase 3 trials evaluated the prognostic value of baseline hepcidin levels for major adverse cardiovascular events (MACE) in CKD patients, both on and off dialysis. Non-dialysis patients showed a nonlinear association with MACE (lowest risk in the second quartile), whereas no link was observed in dialysis patients. These findings indicate limited utility of hepcidin measurement for guiding anemia treatment selection between daprodustat and conventional ESAs in routine care.","created":"2026-08-17T00:51:52Z","updated":"2026-08-17T00:51:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72a1ba04d12c","type":"article","url":"https://hartvaat.nl/2026/11/01/risicotool-identificeert-attr-cardiomyopathie-bij-patienten-met-carpaaltunnelsyn/","title":"Risicotool identificeert ATTR-cardiomyopathie bij patiënten met carpaaltunnelsyndroom","title_en":"Development of a Three-Source Convergent Risk Assessment Tool for Amyloidosis Screening in Carpal Tunnel Syndrome Patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of hand surgery global online","doi":"10.1016/j.jhsg.2026.101102","source_url":"https://doi.org/10.1016/j.jhsg.2026.101102","authors":["Komatsu David Edward","Badalamente Marie Anne","Grabowski Kathryn","Paulus Megan","Muhlrad Samantha","Meo Ann Marie","Gorevic Peter Dov","Vlay Stephen","Hurst Lawrence Colwyn"],"significance":4,"published":"2026-08-23","source_date":"2026-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Researchers developed a weighted risk assessment tool to screen for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with carpal tunnel syndrome (CTS). By integrating data from three independent sources—including a TriNetX cohort of 800,662 patients, clinical cohorts, and tenosynovial biopsy findings—the team established a four-tier risk stratification system. Key predictors included arrhythmias, chronic fatigue, and dyspnea. This tool may help clinicians identify CTS patients warranting targeted ATTR-CM screening or biopsy during surgical release.","created":"2026-08-17T00:49:26Z","updated":"2026-08-17T00:49:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68d2e865f70b","type":"article","url":"https://hartvaat.nl/2026/12/01/kort-slapen-6-uur-verhoogt-kans-op-hypertensie-bij-ouderen-clhls/","title":"Kort slapen (<6 uur) verhoogt kans op hypertensie bij ouderen — CLHLS","title_en":"Association of sleep duration and hypertension in older adults: a cross-sectional study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Blood pressure","doi":"10.1080/08037051.2026.2717792","source_url":"https://doi.org/10.1080/08037051.2026.2717792","authors":["Xiang Wang","Cailing Chen","Jianbang Shi","Weiyun Zhao","Miao Dai"],"significance":4,"published":"2026-08-23","source_date":"2026-12-01","image":"https://hartvaat.nl/global/img/e3f5fb401a32.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This cross-sectional study examined the association between sleep duration and hypertension in 15,650 Chinese older adults (mean age 87.1 years). Participants reporting less than 6 hours of sleep had a 30% higher odds of hypertension compared to those sleeping 6–8 hours (OR 1.30; 95% CI 1.17–1.44), while sleep duration of 9 hours or more showed no significant association. The findings highlight sleep assessment as a practical, low-cost tool for identifying older adults at elevated cardiovascular risk, though longitudinal studies are needed to establish causality.","created":"2026-08-17T00:46:13Z","updated":"2026-08-17T00:46:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7fd2a2fa28b","type":"article","url":"https://hartvaat.nl/2026/08/14/hogere-hu-drempels-voegen-geen-waarde-toe-aan-ct-calciumscoring-voor-aortaklepst/","title":"Hogere HU-drempels voegen geen waarde toe aan CT-calciumscoring voor aortaklepstenose","title_en":"CT-based multi-threshold calcium scoring for aortic valve assessment: comparable predictive performance across HU thresholds in a pre-TAVI cohort.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The international journal of cardiovascular imaging","doi":"10.1007/s10554-026-03800-y","source_url":"https://doi.org/10.1007/s10554-026-03800-y","authors":["Michael Welt","Mohammad Alnees","Yazan Hamdan","Khaled Khalilia","Tamar Shalmon","Jebrin Alkrinawi","Ramon Cohen","Mustafa Abu Teer","Elias Hellou","Nizar Abu Hamdeh","Amir Haim","Omar Ayyad","Adam Hasan","Mohammad Masu'd","Duha Najajra","Alex Blatt","Haitham Abu Khadija"],"significance":3,"published":"2026-08-22","source_date":"2026-08-14","image":"https://hartvaat.nl/global/img/7a234098d6e2.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-coronaire-calcium-score/"],"congress":"","summary_en":"In a single-center retrospective cohort of 63 patients with severe aortic stenosis, researchers evaluated whether higher Hounsfield unit (HU) thresholds for CT calcium scoring offer additional value beyond the conventional 130-HU Agatston method. While calcium scores at all thresholds correlated with transvalvular gradients, higher thresholds (up to 1000 HU) did not outperform the standard 130-HU scoring and showed only modest discrimination for very severe hemodynamic burden. These findings reinforce that the conventional 130-HU threshold remains sufficient for clinical aortic valve assessment, with higher thresholds serving only as complementary densitometric tools rather than alternative diagnostic cut-offs.","created":"2026-08-15T01:33:47Z","updated":"2026-08-15T01:33:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"291329581677","type":"article","url":"https://hartvaat.nl/2026/08/14/biotechnologie-en-ai-veranderen-precisielipidenmanagement-van-pcsk9-tot-crispr/","title":"Biotechnologie en AI veranderen precisielipidenmanagement — van PCSK9 tot CRISPR","title_en":"Precision Lipid Management in the Era of Biotechnology and Artificial Intelligence: From Gene Editing to Smart Drug Delivery.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Therapeutic innovation & regulatory science","doi":"10.1007/s43441-026-01033-8","source_url":"https://doi.org/10.1007/s43441-026-01033-8","authors":["Esra Palabiyik"],"significance":4,"published":"2026-08-22","source_date":"2026-08-14","image":"https://hartvaat.nl/global/img/97b2a8e2959b.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This narrative review examines how biotechnology and artificial intelligence are reshaping precision lipid management for hyperlipidemia and ASCVD. While PCSK9 monoclonal antibodies demonstrate established cardiovascular outcome benefits and inclisiran offers durable LDL-C lowering with infrequent dosing, emerging approaches like CRISPR gene editing, nanoparticle delivery, and AI-driven optimization remain largely preclinical or early-stage, constrained by delivery efficiency, algorithmic bias, and validation challenges. For clinical practice, the review underscores that current biologic therapies are ready for use, whereas next-generation platforms require long-term safety data, standardized delivery, and adaptive regulatory frameworks before routine implementation.","created":"2026-08-15T01:27:56Z","updated":"2026-08-15T01:27:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"331929812489","type":"article","url":"https://hartvaat.nl/2026/08/14/dapagliflozin-verlaagt-serum-klotho-bij-dialysepatienten-zonder-effect-op-botbio/","title":"Dapagliflozin verlaagt serum-Klotho bij dialysepatiënten zonder effect op botbiomarkers of fracturen — post-hoc RCT","title_en":"Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Calcified tissue international","doi":"10.1007/s00223-026-01587-7","source_url":"https://doi.org/10.1007/s00223-026-01587-7","authors":["Lauter E Pelepenko","Joaquim Barreto","Marília P Martins","Pedro B Chiteculo","Jessica M Camargo","Mariana C de Oliveira","Eric A Corrêa","Mauro Pascoa","Gil Guerra-Junior","Wagner Vasques Dominguez","Cinthia E M Carbonara","Loïc Louvet","Rosa M A Moyses","Makoto Kuro-O","Andrei C Sposito","Rodrigo Bueno de Oliveira"],"significance":3,"published":"2026-08-22","source_date":"2026-08-14","image":"https://hartvaat.nl/global/img/a5dae736affe.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"A post-hoc analysis of an RCT evaluated the effects of dapagliflozin 10 mg daily on bone biomarkers in 79 dialysis-dependent CKD patients over 24 weeks. While dapagliflozin significantly lowered serum Klotho levels compared to standard care (p=0.03), it had no impact on FGF23, other bone markers, osteopenia/osteoporosis prevalence, or fracture rates. These findings indicate that short-term dapagliflozin use does not confer clinically relevant benefits for bone health in this population, despite modulating the Klotho pathway.","created":"2026-08-15T01:22:36Z","updated":"2026-08-15T01:22:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e50d85f984f","type":"article","url":"https://hartvaat.nl/2026/08/14/kaliumbinders-ondersteunen-raasi-gebruik-bij-ckd-maar-terugkeer-van-hyperkaliemi/","title":"Kaliumbinders ondersteunen RAASi-gebruik bij CKD, maar terugkeer van hyperkaliëmie versnelt nierfunctieverlies","title_en":"Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of nephrology","doi":"10.1093/joneph/aajag149","source_url":"https://doi.org/10.1093/joneph/aajag149","authors":["María Marques","Paula López-Sánchez","Enrique Morales","M Auxiliadora Bajo","Antolina Rodriguez","Milagros Fernández Lucas","Vicente Paraiso","Laura Bucalo","Yolanda Hernandez","José C De La Flor","Maite Padrón","Hanane Bouarich","Fabio Procaccini","Coraima Nava Chavez","Jose Herrero","Fernando Tornero"],"significance":5,"published":"2026-08-22","source_date":"2026-08-14","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"A prospective multicenter observational study (n=429) evaluated real-world management of hyperkalemia in patients with chronic kidney disease (CKD). Hyperkalemia recurred in 43.8% of patients over two years, a pattern associated with a significantly faster eGFR decline of 2.4 ml/min/year. While potassium binders (patiromer and sodium zirconium cyclosilicate) facilitate the continuation of RAAS inhibitors and MRAs, recurrent episodes remain common and may accelerate renal deterioration. Clinicians should consider early integration of potassium binders to sustain guideline-directed cardiorenal therapies and mitigate kidney function loss.","created":"2026-08-15T01:17:28Z","updated":"2026-08-15T01:17:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"49cf19811014","type":"article","url":"https://hartvaat.nl/2026/08/14/crp-en-albuminurie-duiden-op-hoog-risico-op-herhalende-hart-en-vaatziekten-bij-c/","title":"CRP en albuminurie duiden op hoog risico op herhalende hart- en vaatziekten bij chronische nierziekte — KNOW-CKD","title_en":"Risk factors for recurrent cardiovascular events in CKD: results from the KNOW-CKD study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of nephrology","doi":"10.1093/joneph/aajag150","source_url":"https://doi.org/10.1093/joneph/aajag150","authors":["Eunjeong Kang","Dah Woon Im","Minsang Kim","Yaeni Kim","Tae-Hyun Yoo","Soo Wan Kim","Jayoun Kim","Kook-Hwan Oh"],"significance":5,"published":"2026-08-22","source_date":"2026-08-14","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"The prospective KNOW-CKD cohort followed 2,099 non-dialysis patients with chronic kidney disease for a median of 8.3 years to assess predictors of first and recurrent non-fatal cardiovascular events. Nine point seven percent of participants experienced at least one event; older age, diabetes, prior cardiovascular disease, elevated CRP, albuminuria, and lower BMI were consistently linked to recurrence, with CRP and albuminuria showing a particularly strong association with repeated events compared to initial ones. These findings highlight that cardiovascular risk stratification in CKD should extend beyond traditional metabolic factors to include markers of vascular injury and systemic inflammation, informing more comprehensive preventive strategies.","created":"2026-08-15T01:14:30Z","updated":"2026-08-15T01:14:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46a86f33b7d7","type":"article","url":"https://hartvaat.nl/2026/08/14/infectie-is-belangrijkste-doodsoorzaak-bij-dialysepatienten-retrospectieve-analy/","title":"Infectie is belangrijkste doodsoorzaak bij dialysepatiënten — retrospectieve analyse","title_en":"Analysis of adjudicated causes of death in a large cohort of Brazilian patients undergoing dialysis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of nephrology","doi":"10.1093/joneph/aajag152","source_url":"https://doi.org/10.1093/joneph/aajag152","authors":["Cristiane de Magalhães Rosa Ribeiro","Jorge Paulo Strogoff-de-Matos","Ana Beatriz Lesqueves Barra","Maria Eugenia Fernandes Canziani"],"significance":5,"published":"2026-08-21","source_date":"2026-08-14","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A retrospective analysis of 1,742 adjudicated deaths among dialysis patients in Brazil identified infection as the leading cause of mortality (41%), followed by cardiovascular disease (30%). Most deaths occurred in hospital settings (84%), with over half classified as unexpected, highlighting gaps in end-of-life care and prevention strategies. These findings underscore the need for structured mortality reviews and targeted interventions to reduce both infectious and cardiovascular risks in dialysis populations.","created":"2026-08-15T01:08:23Z","updated":"2026-08-15T01:08:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8962d45e297d","type":"article","url":"https://hartvaat.nl/2026/08/14/vereenvoudigd-crt-systeem-zonder-atriale-pacing-niet-slechter-dan-conventioneel-/","title":"Vereenvoudigd CRT-systeem zonder atriale pacing niet slechter dan conventioneel — CRT-NEXT","title_en":"Rethinking atrial pacing support in cardiac resynchronization therapy: insights from the CRT-NEXT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart failure reviews","doi":"10.1007/s10741-026-10664-w","source_url":"https://doi.org/10.1007/s10741-026-10664-w","authors":["Arman Soltani Moghadam","Saman Soltani Moghadam","Mandana Ebrahimzade","Yasaman Daryabari","Aida Zeinali","Toshiki Kuno","Kaveh Hosseini"],"significance":6,"published":"2026-08-21","source_date":"2026-08-14","image":"https://hartvaat.nl/global/img/c7632da5e52b.webp","kennis":[],"congress":"","summary_en":"The CRT-NEXT trial demonstrated that a simplified two-lead CRT-DX system, which enables atrial sensing without active pacing, is non-inferior to conventional three-lead CRT-D. At 12 months, the composite endpoint of all-cause mortality, cardiovascular hospitalization, and lead-related complications was comparable between groups, with the DX system showing shorter procedure times and fewer atrial lead complications. These findings suggest that reliable atrial sensing may suffice for most patients without sinus node dysfunction, potentially eliminating the need for routine atrial lead implantation and reducing device-related risks.","created":"2026-08-15T01:05:00Z","updated":"2026-08-15T01:05:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b68d8e419204","type":"article","url":"https://hartvaat.nl/2026/10/01/sglt2-remmers-geassocieerd-met-lagere-sterfte-bij-attr-cardiomyopathie-meta-anal/","title":"SGLT2-remmers geassocieerd met lagere sterfte bij ATTR-cardiomyopathie — meta-analyse","title_en":"Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Current problems in cardiology","doi":"10.1016/j.cpcardiol.2026.103409","source_url":"https://doi.org/10.1016/j.cpcardiol.2026.103409","authors":["Roberta Magnano","Davide Rossi","Silvio Saraullo","Vittoria Zuardi","Laura Pezzi","Alberto D'Alleva","Mario Di Marino","Claudio Scollo","Eugenio Genovesi","Stefano Guarracini","Daniele Forlani","Piergiusto Vitulli","Giulia Renda","Sabina Gallina","Massimo Di Marco"],"significance":5,"published":"2026-08-21","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"A systematic review and stratified meta-analysis of 18 observational studies (n≈24,000) indicates that SGLT2 inhibitors are associated with reduced all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) (HR 0.65; 95% CI 0.56–0.76). Benefits were also observed for composite mortality and heart failure events, with a favorable safety profile and low discontinuation rates. However, the evidence remains limited by the observational design, endpoint heterogeneity, and potential database overlap. While promising for cardiologists and internists managing this rare cardiomyopathy, dedicated randomized trials are required before SGLT2 inhibitors can be routinely recommended in this population.","created":"2026-08-15T00:57:34Z","updated":"2026-08-15T00:57:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d8b3789e522","type":"article","url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","title":"Voorgebruik van opioïden verhoogt sterfte en ziekenhuisopnames na TAVI — Deens cohort","title_en":"Associated prognostic impact of opioid use before Transcatheter aortic valve implantation - A Danish nationwide cohort study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"International journal of cardiology. Heart & vasculature","doi":"10.1016/j.ijcha.2026.101981","source_url":"https://doi.org/10.1016/j.ijcha.2026.101981","authors":["Martha Meibom","Jeppe K Petersen","Victoria Mikkelsen","Louise Marqvard Sørensen","Jonas Agerlund Povlsen","Christian Juhl Terkelsen","Ashkan Eftekhari","Morten Schou","Lars Køber","Ole de Backer","Emil Fosbøl"],"significance":5,"published":"2026-08-21","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-ouderen/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"In a Danish nationwide cohort of 6,505 patients undergoing TAVI between 2015 and 2022, pre-procedural opioid use was associated with worse one-year outcomes compared to non-users. Opioid users had a significantly higher risk of all-cause mortality (10.4% vs 6.9%; adjusted HR 1.35) and increased hospitalization burden, with mortality rising in a dose-dependent manner. These findings highlight pre-procedural opioid use as an important prognostic marker in TAVI candidates, likely reflecting underlying comorbidities. Clinicians should consider this factor when assessing perioperative risk and planning post-procedural care.","created":"2026-08-15T00:52:59Z","updated":"2026-08-15T00:52:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6318df214e86","type":"article","url":"https://hartvaat.nl/2026/12/01/verhoogde-bloeddruk-bij-jonge-volwassenen-verdubbelt-sterftekans-nhanes-cohort/","title":"Verhoogde bloeddruk bij jonge volwassenen verdubbelt sterftekans — NHANES-cohort","title_en":"Burden of high blood pressure and associated risk for all-cause and cardiovascular mortality among US young adults.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":[],"journal":"Blood pressure","doi":"10.1080/08037051.2026.2715846","source_url":"https://doi.org/10.1080/08037051.2026.2715846","authors":["Ming Ying","Kunming Bao","Dongjun Bao","Zhiyuan Wu","Junhao He","Zhidong Huang","Lixin Ye","Wenjun Gu"],"significance":4,"published":"2026-08-21","source_date":"2026-12-01","image":"https://hartvaat.nl/global/img/e3f5fb401a32.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A cohort analysis of NHANES data (1999–2016) reveals that 23.9% of US young adults (mean age 28.6) have prehypertension and 14.3% have hypertension. Compared with normotensive peers, adjusted hazard ratios for all-cause mortality were 1.82 for prehypertension and 2.39 for hypertension, rising to 4.17 for cardiovascular mortality in those with hypertension. These findings underscore the importance of early blood pressure screening and management in young adults to mitigate long-term mortality risk.","created":"2026-08-15T00:48:16Z","updated":"2026-08-15T00:48:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97c5853ff1d4","type":"article","url":"https://hartvaat.nl/2026/08/12/clonale-hematopoiese-voorspelt-nierfunctievermindering-en-sterfte-bij-cytopenie-/","title":"Clonale hematopoïese voorspelt nierfunctievermindering en sterfte bij cytopenie met chronische nierziekte","title_en":"Clonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Blood research","doi":"10.1007/s44313-026-00161-2","source_url":"https://doi.org/10.1007/s44313-026-00161-2","authors":["Suwannaporn Yaophrukchai","Chantana Polprasert","Sirorat Kobbuaklee","Ponlapat Rojnuckarin","Sunisa Kongkiatkamon"],"significance":4,"published":"2026-08-20","source_date":"2026-08-12","image":"https://hartvaat.nl/global/img/51137ab74ed6.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"In a retrospective cohort study of 67 patients with cytopenia and chronic kidney disease (CKD), clonal hematopoiesis (CH) was present in 53.7% and independently predicted CKD progression (adjusted HR 2.83) and higher mortality (adjusted HR 3.90) over a median follow-up of 43.5 months. The association was most pronounced in patients with myelodysplastic syndromes. Identifying CH in this population may improve risk stratification and guide closer monitoring of renal decline and survival outcomes.","created":"2026-08-13T01:42:26Z","updated":"2026-08-13T01:42:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3eefff6acb2","type":"article","url":"https://hartvaat.nl/2026/08/12/romosozumab-vermindert-wervelfracturen-en-mace-bij-osteoporose-met-chronische-ni/","title":"Romosozumab vermindert wervelfracturen en MACE bij osteoporose met chronische nierziekte — TriNetX-cohort","title_en":"Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Clinical journal of the American Society of Nephrology : CJASN","doi":"10.2215/CJN.0000001168","source_url":"https://doi.org/10.2215/CJN.0000001168","authors":["Cheng-Hsien Hung","Fu-Yu Yang","Hung-En Huang","James Cheng-Chung Wei"],"significance":6,"published":"2026-08-20","source_date":"2026-08-12","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"A retrospective target trial emulation using TriNetX real-world data compared romosozumab and teriparatide in patients aged ≥40 with osteoporosis and CKD (eGFR <60). Romosozumab was associated with a significantly lower risk of vertebral fractures (HR 0.64) and improved cardiovascular safety, showing reduced MACE (HR 0.82) and myocardial infarction (HR 0.77) compared to teriparatide. These findings suggest a potential dual benefit of romosozumab in high-risk CKD patients, though prospective trials are needed to confirm efficacy and safety in advanced kidney disease.","created":"2026-08-13T01:37:05Z","updated":"2026-08-13T01:37:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3abb43a3c3a5","type":"article","url":"https://hartvaat.nl/2026/08/12/ivf-gebruik-niet-geassocieerd-met-hart-en-vaatziekten-behalve-herseninfarct/","title":"IVF-gebruik niet geassocieerd met hart- en vaatziekten — behalve herseninfarct","title_en":"Long-term risk of cardiovascular disease after assisted reproductive technology and infertility: A cohort study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"PLoS medicine","doi":"10.1371/journal.pmed.1005120","source_url":"https://doi.org/10.1371/journal.pmed.1005120","authors":["Angelo Giosuè Mezzoiuso","Peter Henriksson","Márta Radó","Kenny A Rodriguez-Wallberg","Anna Sara Oberg"],"significance":5,"published":"2026-08-20","source_date":"2026-08-12","image":"https://hartvaat.nl/global/img/6e8d54f2b2f3.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"A Swedish nationwide cohort study of nearly 380,000 women found that long-term use of assisted reproductive technology (ART) is not associated with an increased risk of cardiovascular or metabolic diseases, except for a 44% higher risk of cerebral ischemia over 30 years (RR 1.44). Women with a history of infertility, however, consistently showed elevated risks for heart failure, type 2 diabetes, and chronic kidney disease, reinforcing infertility as a marker for underlying cardiometabolic risk. These findings reassure regarding the long-term cardiovascular safety of ART while highlighting the need for proactive cardiovascular risk assessment in women with infertility.","created":"2026-08-13T01:32:18Z","updated":"2026-08-13T01:32:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c633c1fb00b5","type":"article","url":"https://hartvaat.nl/2026/08/13/hdl-eiwitten-bepalen-cvd-en-ontstekingsrisico-onafhankelijk-van-hdl-c/","title":"HDL-eiwitten bepalen CVD- en ontstekingsrisico — onafhankelijk van HDL-C","title_en":"HDL-associated proteins affecting CVD and systemic inflammation.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Current opinion in lipidology","doi":"10.1097/MOL.0000000000001052","source_url":"https://doi.org/10.1097/MOL.0000000000001052","authors":["Samuel C Delk","Srinivasa T Reddy"],"significance":5,"published":"2026-08-20","source_date":"2026-08-13","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This narrative review explains why elevated HDL-C is a poor predictor of cardiovascular protection, emphasizing that HDL function depends on its associated proteins. Key molecules like ApoM, ApoA-I, and SR-B1 modulate inflammation, LDL deposition, and endotoxin clearance, with ApoM showing a protective association in chronic kidney disease. While CETP inhibition improved survival in a murine sepsis model, clinical translation remains pending as key trials continue. The authors advocate shifting focus from HDL-cholesterol levels to HDL functionality in both research and clinical practice.","created":"2026-08-13T01:25:24Z","updated":"2026-08-13T01:25:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db79f13475f0","type":"article","url":"https://hartvaat.nl/2026/09/01/metformin-verlaagt-risico-op-buikaorta-aneurysma-mr-en-cohortanalyse/","title":"Metformin verlaagt risico op buikaorta-aneurysma — MR- en cohortanalyse","title_en":"Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"Annals of human genetics","doi":"10.1111/ahg.70049","source_url":"https://doi.org/10.1111/ahg.70049","authors":["Katie Louise Saxby","Svetlana Stoma","Frank Dudbridge","Nilesh J Samani","Matthew J Bown","Christopher P Nelson"],"significance":5,"published":"2026-08-20","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Combining a large UK Biobank cohort study with a two-sample Mendelian randomisation analysis, researchers investigated whether metformin use causally reduces the risk of abdominal aortic aneurysm (AAA). Observational data showed a strong protective association (OR 0.49), which was corroborated by genetic analysis indicating a 43% risk reduction per standard deviation decrease in HbA1c via metformin targets (OR 0.57; p = 0.010). While the findings suggest a potential causal link, they remain observational and genetically inferred. Dedicated clinical trials are required to evaluate whether metformin can effectively slow AAA progression or prevent rupture in patients.","created":"2026-08-13T01:17:51Z","updated":"2026-08-13T01:17:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b99ab4bae3eb","type":"article","url":"https://hartvaat.nl/2026/09/01/pre-existent-pfo-of-asd-verhoogt-risico-op-recidief-en-stroke-na-ablatie-bij-atr/","title":"Pre-existent PFO of ASD verhoogt risico op recidief en stroke na ablatie bij atriumfibrilleren","title_en":"Patients With Patent Foramen Ovale or Atrial Septal Defect Have Worse Outcomes After Pulmonary Vein Isolation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"The American journal of cardiology","doi":"10.1016/j.amjcard.2026.06.030","source_url":"https://doi.org/10.1016/j.amjcard.2026.06.030","authors":["Suraj S Patel","Sakshum Chadha","Sandi Bajrami","Thomas P Fedrigoni","David T Zhang"],"significance":5,"published":"2026-08-19","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"A propensity-matched cohort study using TriNetX claims data compared outcomes in 2,804 patients with a pre-existing PFO or ASD versus 2,804 without these defects following pulmonary vein isolation for atrial fibrillation. Over two years, patients with a septal defect had significantly higher rates of hospitalization (HR 1.14), direct-current cardioversion (HR 1.18), antiarrhythmic drug use (HR 1.12), and stroke (HR 1.36), with no difference in mortality or redo ablation. These real-world findings suggest that EP specialists should counsel patients with PFO or ASD about their elevated risk of arrhythmia recurrence and stroke following catheter ablation.","created":"2026-08-13T01:12:35Z","updated":"2026-08-13T01:12:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f8fa609f50f","type":"article","url":"https://hartvaat.nl/2026/09/01/perioperatieve-opioiden-bij-hartfalen-lokale-cardiale-routes-en-klinische-risico/","title":"Perioperatieve opioiden bij hartfalen: lokale cardiale routes en klinische risico’s","title_en":"Cardiac Opioid System and Its Role in Heart Failure and Ischemia-Reperfusion Injury.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Anesthesiology","doi":"10.1097/ALN.0000000000006139","source_url":"https://doi.org/10.1097/ALN.0000000000006139","authors":["Alexandra Lasch","Melih Özgür Celik","Carolin Torregroza","Ragnar Huhn","Michael Schäfer","Sascha Treskatsch"],"significance":4,"published":"2026-08-19","source_date":"2026-09-01","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"This review outlines the local cardiac opioid system and its contrasting roles in heart failure versus ischemia-reperfusion injury. While preclinical models indicate cardioprotective effects during ischemia-reperfusion, clinical opioid administration in heart failure is associated with higher in-hospital mortality and increased ventilatory support. Clinicians should account for these hemodynamic and prognostic risks when selecting perioperative analgesia.","created":"2026-08-13T01:03:53Z","updated":"2026-08-13T01:03:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8b203d990267","type":"article","url":"https://hartvaat.nl/2026/09/08/gepersonaliseerde-bloeddrukregeling-tijdens-thrombectomie-verbetert-functionele-/","title":"Gepersonaliseerde bloeddrukregeling tijdens thrombectomie verbetert functionele uitkomst niet — DETERMINE","title_en":"Individualized vs Standard Blood Pressure Control During Thrombectomy for Ischemic Stroke: The DETERMINE Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Neurology","doi":"10.1212/WNL.0000000000218420","source_url":"https://doi.org/10.1212/WNL.0000000000218420","authors":["Benjamin Maïer","Benjamin Gory","Russell Chabanne","Benoit Tavernier","Alice Jacquens","Baptiste Balanca","Maxime Pommier","Morgan Le Guen","Laurie-Anne Thion","Simon Clariot","Bertrand Lapergue","Adrien Guyot","Omer F Eker","Lionel Bapteste","Jean Marc Olivot","Lionel Calviere","Gabriela Julean","Pauline Bourst","Gérard Audibert","Vincent Degos","Julie Dupont","Erwan Robichon","Simon Escalard","Jean-Philippe Desilles","Stanislas Smajda","Hocine Redjem","William Boisseau","Amira Al Raaisi","Raphael Blanc","Michel Piotin","Pierre Seners","François Delvoye","Pierre-Olivier Comby","Perrine Boursin","Amélie Yavchitz","Célia Nekrouf","Chloé Le Cossec","Mikael Mazighi","Etienne Gayat"],"significance":6,"published":"2026-08-19","source_date":"2026-09-08","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/"],"congress":"","summary_en":"A multicenter randomized trial evaluated whether individualized mean arterial pressure (MAP) management during mechanical thrombectomy for acute anterior large vessel occlusion improves 90-day functional outcomes compared with standard systolic BP control (140–180 mmHg). Among 433 patients, individualized MAP targeting (within 10% of baseline) did not increase the rate of favorable functional outcomes at 90 days (44.2% vs 48.8%; aOR 0.82; p=0.34), with no differences in symptomatic intracranial hemorrhage or mortality. These results support maintaining current standard BP protocols during thrombectomy, as individualized targeting offers no additional clinical benefit in this acute setting.","created":"2026-08-13T00:57:59Z","updated":"2026-08-13T00:57:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa7a75a687a6","type":"article","url":"https://hartvaat.nl/2026/12/01/higs-score-voorspelt-pacemaker-implantatie-en-sterfte-na-tavi/","title":"HIGS-score voorspelt pacemaker-implantatie en sterfte na TAVI","title_en":"Association of the HIGS score with permanent pacemaker implantation and mortality after transcatheter aortic valve implantation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Annals of medicine","doi":"10.1080/07853890.2026.2715272","source_url":"https://doi.org/10.1080/07853890.2026.2715272","authors":["Özkan Karaca","Burak Toprak","Nihat Söylemez","Mustafa Ekici","Abdulkadir Bilgiç","Ahmet Turhan Kılıç","Samet Yımaz","Ali Orçun Sürmeli","Sonay Oğuz","Mehmet Ballı","Rıdvan Bora","Serdar Keçeoğlu"],"significance":5,"published":"2026-08-19","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"In a retrospective single-center study of 196 TAVI patients, the Hematological Inflammatory Global Score (HIGS) derived from routine blood parameters was independently associated with permanent pacemaker implantation (PPI) and in-hospital mortality. Higher HIGS values correlated with a significantly increased risk of PPI (OR 3.96) and death (OR 4.92), while also improving the predictive performance of conventional clinical models. Although HIGS shows promise as a readily available risk-stratification tool, prospective multicenter validation is needed before routine clinical adoption.","created":"2026-08-13T00:52:09Z","updated":"2026-08-13T00:52:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf203669ae6c","type":"article","url":"https://hartvaat.nl/2026/12/01/antitrombotica-veilig-bij-incidentele-ongescheurde-intracraniele-aneurysmas-na-i/","title":"Antitrombotica veilig bij incidentele ongescheurde intracraniële aneurysma’s na ischemisch beroerte","title_en":"Impact of antithrombotic therapy on outcomes of incidental unruptured intracranial aneurysms in patients with ischemic stroke.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Annals of medicine","doi":"10.1080/07853890.2026.2705593","source_url":"https://doi.org/10.1080/07853890.2026.2705593","authors":["Chao Chen","Yiya Xu","Yingchao He","Ting Chen","Xingyong Chen"],"significance":4,"published":"2026-08-19","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A single-center retrospective cohort study evaluated whether standard antithrombotic regimens increase the risk of rupture in patients with ischemic stroke and concomitant incidental unruptured intracranial aneurysms. Among 197 patients followed for a mean of 28.6 months, only two experienced aneurysm rupture (1.0%), with no statistically significant difference between single antiplatelet therapy, anticoagulation, or no regular therapy. These findings suggest that standard secondary stroke prevention can be safely continued in this population, though the low event rate warrants cautious interpretation and individualized risk assessment.","created":"2026-08-13T00:47:22Z","updated":"2026-08-13T00:47:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fbf607852598","type":"article","url":"https://hartvaat.nl/2026/08/10/urine-albumine-en-natrium-hebben-prognostische-waarde-bij-hartfalen-experimentel/","title":"Urine-albumine en natrium hebben prognostische waarde bij hartfalen — experimentele biomarkers nog onvoldoende onderbouwd","title_en":"Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Current heart failure reports","doi":"10.1007/s11897-026-00774-9","source_url":"https://doi.org/10.1007/s11897-026-00774-9","authors":["Bethany Roehm","Yash Vaggar","Justin L Grodin","Robert D Toto"],"significance":5,"published":"2026-08-18","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/6cb8034713a3.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This narrative review evaluates the clinical utility of urinary biomarkers in heart failure management. While urine albumin and sodium offer established prognostic and diagnostic value for guiding medication prioritization and diuretic therapy, experimental markers such as NGAL, KIM-1, and IGFBP7/TIMP-2 currently lack evidence of superior kidney injury prediction compared to serum creatinine. For clinical practice, this reinforces the role of routine urine parameters in cardiorenal risk stratification, while highlighting that novel biomarkers remain primarily of research and mechanistic interest at this time.","created":"2026-08-11T01:24:16Z","updated":"2026-08-11T01:24:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f5af9e720e8","type":"article","url":"https://hartvaat.nl/2026/08/10/voedingspatronen-en-macronutrientenvervanging-verlagen-triglyceriden-bij-hypertr/","title":"Voedingspatronen en macronutriëntenvervanging verlagen triglyceriden bij hypertriglyceridemie","title_en":"Dietary Interventions for Hypertriglyceridemia.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Current atherosclerosis reports","doi":"10.1007/s11883-026-01444-w","source_url":"https://doi.org/10.1007/s11883-026-01444-w","authors":["Carol F Kirkpatrick","Kristina S Petersen","Penny M Kris-Etherton","Kevin C Maki"],"significance":5,"published":"2026-08-18","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4444c1fb12db.webp","kennis":["https://hartvaat.nl/kennis/lipiden/fibraten-bij-hypertriglyceridemie/"],"congress":"","summary_en":"This narrative review outlines the pathophysiology of hypertriglyceridemia (HTG) and evaluates dietary strategies for its management. Guideline recommendations stress individualized dietary patterns based on triglyceride severity and underlying etiology, emphasizing partial carbohydrate replacement with unsaturated fats or protein, alongside limiting added sugars and alcohol. Combined with physical activity and weight management, these interventions form a cornerstone of cardioprotective lifestyle therapy. Clinicians can use these tailored dietary approaches to optimize lipid profiles and reduce cardiometabolic risk.","created":"2026-08-11T01:20:45Z","updated":"2026-08-11T01:20:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64311db3d18a","type":"article","url":"https://hartvaat.nl/2026/09/01/anemie-verergert-mortaliteit-en-hartfalenheropnames-na-tavr-bij-patienten-boven-/","title":"Anemie verergert mortaliteit en hartfalenheropnames na TAVR bij patiënten boven de 80 jaar","title_en":"The Impact of Anemia on Clinical Outcomes of Patients Above 80 Years Old Following Transcatheter Aortic Valve Replacement.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Structural heart : the journal of the Heart Team","doi":"10.1016/j.shj.2026.101057","source_url":"https://doi.org/10.1016/j.shj.2026.101057","authors":["Besir Besir","Carl Ammoury","Alexander Egoavil","Sada Babazade","Wajeh Abuirmaileh","Osamah Badwan","Chadi Tabaja","Issam Motairek","Akiva Rosenzveig","Taha Hatab","Ali Hamam","Radwan Alkhatib","Tamari Lomaia","James J Yun","Serge C Harb","Rhonda Miyasaka","Grant W Reed","Rishi Puri","Amar Krishnaswamy","Samir R Kapadia"],"significance":5,"published":"2026-08-18","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"An observational study shows that anemia is highly prevalent in patients over 80 years undergoing transcatheter aortic valve replacement (TAVR) and is linked to a higher burden of cardiovascular and non-cardiovascular comorbidities. Baseline anemia predicts worse long-term outcomes, including increased all-cause mortality and heart failure rehospitalization. These findings reinforce anemia as a key prognostic marker and potential therapeutic target in this high-risk elderly population.","created":"2026-08-11T01:15:33Z","updated":"2026-08-11T01:15:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0cd8f93ab87","type":"article","url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","title":"Posteriorcirculatie-infarcten na doorbraakstroke op anticoagulantia duiden op slechtere prognose","title_en":"Posterior versus anterior circulation infarct location and outcomes after breakthrough ischemic stroke in orally anticoagulated patients for atrial fibrillation: An ASPERA-R inverse probability-weighted analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the neurological sciences","doi":"10.1016/j.jns.2026.126100","source_url":"https://doi.org/10.1016/j.jns.2026.126100","authors":["Matteo Foschi","Lucio D'Anna","Francesca Gabriele","Raffaele Ornello","Andrea Zini","Matteo Paolucci","Stefano Forlivesi","Ludovica Migliaccio","Maria Maddalena Viola","Angelo Cascio Rizzo","Maria Sessa","Ghil Schwarz","Rachele Tortorella","Muhammad Jaffar","Gabriele Prandin","Leonardo Pantoni","Francesco Mele","Giuseppe Scopelliti","Ilaria Cova","Mariarosaria Valente","Domenico Maisano","Luca Antonelli","Maria Rosaria Bagnato","Giovanni Di Mauro","Francesca Bernocchi","Martina Gaia Di Donna","Barbara Casolla","Antonio Ciacciarelli","Chiara Bruno","Baptiste Alvarez","Laura González-Martín","Ricardo Rigual","Blanca Fuentes","Carlos Hervás","Paolo Candelaresi","Vincenzo Andreone","Antonio De Mase","Emanuele Spina","Diana Aguiar de Sousa","Mariana Almudi Souza","Alberto Fior","Miguel Serôdio","Pietro Caliandro","Aurelia Zauli","Giuseppe Reale","Ahmed Abdelalim","Sandra Ahmed","Nourhan Mohamed Soliman","Liqun Zhang","Tara Latimer","Muhammad Elboghday","Ahmed Aly Elbassiouny","Tamer Roushdy","Hossam Shokri","Federica Ferrari","Nicola Davide Loizzo","Federico Mazzacane","Maria Guarino","Valentina Barone","Paola Forti","Giuseppe Rinaldi","Marco Vito Rossi","Vincenzo Laterza","Giovanni Frisullo","Pier Andrea Rizzo","Aldobrando Broccolini","Marina Mannino","Valeria Terruso","Marcella Caggiula","Annalisa Rizzo","Ana Catarina Fonseca","Bernardo Antunes","Ana M Barbosa","Hrvoje Budincevic","Petra Crnac","Giovanna Viticchi","Mauro Silvestrini","Lorenzo Barba","Viktoria Musienko","Markus Otto","Piergiorgio Lochner","Benjamin Landau","Sandeep Buddha","Roumeisa Khalil","Ludovica Maria Miserocchi","Giorgia Balducci","Maria Grazia Piscaglia","Elena Minguzzi","Marialuisa Zedde","Ahmed Nasreldein","Luisa Vinciguerra","Luis Costa","Ahmed Elsaid Elsayed","Mona AlBanna","Laura Tudisco","Giovanni Merlino","Alexandros Polymeris","Federico De Santis","Simona Sacco"],"significance":5,"published":"2026-08-18","source_date":"2026-10-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"A retrospective multicentre analysis of 1,649 atrial fibrillation patients experiencing an ischemic stroke despite continuous oral anticoagulation demonstrates that infarct location significantly influences prognosis. Patients with posterior circulation infarcts faced a higher risk of a 90-day composite endpoint (recurrent stroke, MI, or vascular death; aHR 1.50), greater all-cause mortality (aHR 1.85), and worse functional outcomes (mRS shift) compared to those with anterior circulation infarcts. These findings highlight infarct location as a valuable prognostic marker, aiding risk stratification and follow-up intensity for AF patients experiencing breakthrough strokes on anticoagulation.","created":"2026-08-11T01:11:17Z","updated":"2026-08-11T01:11:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a3fb55576706","type":"article","url":"https://hartvaat.nl/2026/10/15/vroege-bloeddrukverlaging-bij-acute-ischemische-stroke-verbetert-functioneel-her/","title":"Vroege bloeddrukverlaging bij acute ischemische stroke verbetert functioneel herstel niet — meta-analyse","title_en":"Early antihypertensive therapy in acute ischemic stroke: A Meta-analysis of randomized controlled trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the neurological sciences","doi":"10.1016/j.jns.2026.126125","source_url":"https://doi.org/10.1016/j.jns.2026.126125","authors":["Gabriela Argollo Fernandes","Lorrany Larisse Costa Rodrigues","Maria Eduarda Sulzbacher E Lima","Ahmad Alareed"],"significance":6,"published":"2026-08-18","source_date":"2026-10-15","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"A meta-analysis of seven RCTs involving 15,521 patients found that initiating antihypertensive therapy within 48 hours of an acute ischemic stroke effectively lowers blood pressure but does not improve mortality or functional outcomes. Pooled risk ratios for all-cause mortality (RR 0.97) and death or functional dependency (RR 1.01) showed no significant benefit compared with placebo or usual care. These results reinforce current guidelines against routine early blood pressure lowering in the general acute stroke population and highlight the need for individualized hemodynamic management.","created":"2026-08-11T01:07:04Z","updated":"2026-08-11T01:07:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c021f5785d8","type":"article","url":"https://hartvaat.nl/2026/12/01/ras-remmers-verlagen-risico-op-nieuwe-ckd-bij-diabetes-type-2-met-behoudende-nie/","title":"RAS-remmers verlagen risico op nieuwe CKD bij diabetes type 2 met behoudende nierfunctie","title_en":"Prevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2711459","source_url":"https://doi.org/10.1080/0886022X.2026.2711459","authors":["Wan-Chia Hsu","Shih-Yuan Hung","Sheng-Hsiang Lin","Yuan-Yow Chiou","Yu-Ling Lin","Hsi-Hao Wang","Li-Chun Ho","Yi-Che Lee"],"significance":5,"published":"2026-08-17","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"In a multicenter retrospective cohort study of 3,316 patients with type 2 diabetes, newly diagnosed hypertension, and preserved kidney function, researchers evaluated the impact of ACE inhibitors or ARBs on the development of new-onset chronic kidney disease. RAS blocker therapy was associated with a significantly reduced risk of new-onset CKD (HR 0.72; 95% CI 0.60-0.86), with consistent results in competing-risk and time-dependent analyses. These findings support the early use of RAS blockade for renal protection in this population, even when baseline kidney function remains normal.","created":"2026-08-11T00:58:55Z","updated":"2026-08-11T00:58:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bcbfa7cf81fb","type":"article","url":"https://hartvaat.nl/2026/12/01/positieve-levensorientatie-en-bloeddruk-bij-ouderen-nauwelijks-klinisch-relevant/","title":"Positieve levensoriëntatie en bloeddruk bij ouderen: nauwelijks klinisch relevant verband — TUVA/UTUVA","title_en":"Positive life orientation and blood pressure in older adults: evidence from two Finnish generational cohorts born 20 years apart.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"Blood pressure","doi":"10.1080/08037051.2026.2692239","source_url":"https://doi.org/10.1080/08037051.2026.2692239","authors":["Adriana Lääti","Konsta Teppo","Jenni Vire","Matti Viitanen","Ville Langén"],"significance":3,"published":"2026-08-17","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"An observational study in two Finnish cohorts of 70-year-olds (n=1,554) examined the association between positive life orientation and blood pressure. After adjustment for age, sex, smoking, and BMI, no significant association was found between life orientation and systolic or diastolic blood pressure. The findings suggest that psychosocial well-being alone does not substantially influence blood pressure levels, particularly in populations with widespread antihypertensive treatment.","created":"2026-08-11T00:54:42Z","updated":"2026-08-11T00:54:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b5e12e2006a","type":"article","url":"https://hartvaat.nl/2026/12/01/lage-richtlijnconformiteit-en-zorgcontinuiteit-bij-hypertensie-in-uruguay/","title":"Lage richtlijnconformiteit en zorgcontinuïteit bij hypertensie in Uruguay","title_en":"Health system competence and care continuity in patients with hypertension: electronic cohort in Uruguay.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":[],"journal":"Blood pressure","doi":"10.1080/08037051.2026.2702689","source_url":"https://doi.org/10.1080/08037051.2026.2702689","authors":["Marina Guglielmino","Javier Roberti","Agustina Mazzoni","Carolina Prado","Laura Gutiérrez","Candela Stella","Emilse Vitar","Jacqueline Ponzo","Natalia Cristoforone","Hannah Leslie","Vilma Irazola","Ezequiel García-Elorrio"],"significance":3,"published":"2026-08-17","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A longitudinal cohort study of 200 adults in Uruguay reveals that only 42% had controlled blood pressure at baseline and merely 11.5% received all guideline-recommended interventions. Overall blood pressure control reached 34.4%, with notably lower continuity of care and guideline adherence among newly diagnosed patients. These findings highlight systemic gaps in hypertension management and underscore the need for structured follow-up and quality improvement initiatives in primary care settings.","created":"2026-08-11T00:51:53Z","updated":"2026-08-11T00:51:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21679f9c93cb","type":"article","url":"https://hartvaat.nl/2026/12/01/optimale-cardiometabole-gezondheid-tijdens-zwangerschap-verlaagt-risico-op-compl/","title":"Optimale cardiometabole gezondheid tijdens zwangerschap verlaagt risico op complicaties","title_en":"Gestational cardiovascular health and adverse pregnancy outcomes: a prospective cohort study in China.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"Annals of medicine","doi":"10.1080/07853890.2026.2703887","source_url":"https://doi.org/10.1080/07853890.2026.2703887","authors":["Qi Wu","Hao Ma","Yihui Wu","Shuqi Zhu","Jiayue Tang","Mengjia Hu","Yibo Tang","Luyao Hu","Lixia Zhang","Xiaolin Xu","Danqing Chen","Lu Qi","Zhaoxia Liang"],"significance":4,"published":"2026-08-17","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"A prospective cohort study of 2,775 pregnant women in China evaluated the association between gestational cardiovascular health metrics and adverse maternal and neonatal outcomes. Each one-point increase in the composite health score was linked to a 7% lower risk of maternal complications and a 4% lower risk of neonatal complications, with women achieving an ideal score showing 21% and 12% reduced risks, respectively. The findings highlight the potential value of integrating cardiometabolic risk assessment into routine prenatal care to improve short-term pregnancy outcomes and long-term cardiovascular health.","created":"2026-08-11T00:49:05Z","updated":"2026-08-11T00:49:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"810625634896","type":"article","url":"https://hartvaat.nl/2026/12/31/inter-enkel-bloeddrukverschil-correleert-met-microalbuminurie-bij-hypertensiepat/","title":"Inter-enkel bloeddrukverschil correleert met microalbuminurie bij hypertensiepatiënten","title_en":"Inter-ankle systolic blood pressure difference is associated with microalbuminuria in non-diabetic hypertension patients: A cross-sectional study from two cohorts.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Clinical and experimental hypertension (New York, N.Y. : 1993)","doi":"10.1080/10641963.2026.2712543","source_url":"https://doi.org/10.1080/10641963.2026.2712543","authors":["Yuanyuan Shi","Pengjie Gao","Xingyue Lin","Molei Zhang","Danni Wang","Kamila Kamili","Xiyang Li","Suining Xu","Gang Tian"],"significance":4,"published":"2026-08-17","source_date":"2026-12-31","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"A cross-sectional analysis of 2,500 nondiabetic hypertensive patients found that an inter-ankle systolic blood pressure difference is independently associated with microalbuminuria (UACR > 30 mg/g). Receiver operating characteristic curves demonstrated that this simple physical examination finding effectively identifies subclinical renal damage. The results suggest that measuring ankle blood pressure differences could serve as a practical, low-cost tool for risk stratification and early renal assessment in primary care and cardiology practice.","created":"2026-08-11T00:45:48Z","updated":"2026-08-11T00:45:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cfbc0b432c13","type":"article","url":"https://hartvaat.nl/2026/07/30/vad-implantatie-bij-enkelventrikelhart-overleving-verbetert-maar-complicaties-bl/","title":"VAD-implantatie bij enkelventrikelhart: overleving verbetert maar complicaties blijven frequent","title_en":"Ventricular Assist Device Use in Single Ventricle Heart Disease: Current Outcomes and Considerations.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Current cardiology reports","doi":"10.1007/s11886-026-02396-y","source_url":"https://doi.org/10.1007/s11886-026-02396-y","authors":["T Miller Sisson","Erin V Shea"],"significance":5,"published":"2026-08-16","source_date":"2026-07-30","image":"https://hartvaat.nl/global/img/bf9bc1eb13dd.webp","kennis":[],"congress":"","summary_en":"This narrative review outlines current outcomes and clinical considerations for ventricular assist device (VAD) therapy in patients with single-ventricle congenital heart disease. Although survival historically lagged behind biventricular physiology, recent evidence suggests this gap is narrowing, despite a persistently high rate of adverse events across all palliation stages. Many available devices lack pediatric regulatory approval, underscoring the need for careful patient selection and monitoring. Cardiologists managing complex congenital heart failure must integrate a thorough understanding of both disease physiology and device mechanics to optimize clinical outcomes.","created":"2026-08-09T01:57:59Z","updated":"2026-08-10T10:35:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e2f9f340a0e9","type":"article","url":"https://hartvaat.nl/2026/07/30/hfpef-bij-vrouwen-vereist-geslachtsspecifieke-diagnostiek-en-behandelstrategieen/","title":"HFpEF bij vrouwen vereist geslachtsspecifieke diagnostiek en behandelstrategieën","title_en":"Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Current cardiology reports","doi":"10.1007/s11886-026-02392-2","source_url":"https://doi.org/10.1007/s11886-026-02392-2","authors":["Sharon Andrade-Bucknor","Shiva Barforoshi","D Elizabeth Le","Radmila Lyubarova","Jina Chung"],"significance":6,"published":"2026-08-16","source_date":"2026-07-30","image":"https://hartvaat.nl/global/img/80e309ecfaf6.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This narrative review examines sex-specific differences in the pathophysiology, diagnostic challenges, and therapeutic responses of heart failure with preserved ejection fraction (HFpEF) in women. Women face a twofold higher lifetime risk of HFpEF compared to HFrEF, with obesity and microvascular dysfunction playing key roles. Current echocardiographic parameters for assessing diastolic dysfunction and filling pressures may require sex-specific refinements to improve diagnostic accuracy. Enhancing outcomes will depend on greater female representation in cardiovascular trials and further investigation into sex-targeted diagnostic and treatment approaches.","created":"2026-08-09T01:54:39Z","updated":"2026-08-10T10:35:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26bd7b14c65f","type":"article","url":"https://hartvaat.nl/2026/07/30/visinname-en-visgerelateerde-metabolieten-geassocieerd-met-lagere-triglyceriden-/","title":"Visinname en visgerelateerde metabolieten geassocieerd met lagere triglyceriden en bloeddruk","title_en":"Association between fish-related metabolites and metabolic syndrome risk factors in Japan: INTERLIPID metabolome -wide association study.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"European journal of nutrition","doi":"10.1007/s00394-026-04068-7","source_url":"https://doi.org/10.1007/s00394-026-04068-7","authors":["Tserenlkham Byambajav","Queenie Chan","Yukiko Okami","Aya Kadota","Naoko Miyagawa","Nagako Okuda","Hideaki Nakagawa","Kiyomi Sakata","Shigeyuki Saitoh","Akira Okayama","Katsushi Yoshita","Kamal Masaki","Chung-Ho E Lau","Timothy M Ebbels","Linda Van Horn","Elaine Holmes","Paul Elliott","Jeremiah Stamler","Hirotsugu Ueshima","Katsuyuki Miura"],"significance":3,"published":"2026-08-16","source_date":"2026-07-30","image":"https://hartvaat.nl/global/img/86584cdaf8b2.webp","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/"],"congress":"","summary_en":"A cross-sectional study of 1,047 Japanese adults examined the relationship between fish intake, fish-related metabolites, and metabolic syndrome risk factors. Higher consumption of fish and shellfish was significantly associated with lower triglycerides, lower systolic blood pressure, and a more favorable HDL cholesterol profile. The results suggest that cooking methods may modulate the metabolic impact of seafood, offering nuanced insights for dietary counseling in cardiovascular and metabolic risk prevention.","created":"2026-08-09T01:39:11Z","updated":"2026-08-10T10:35:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7af1ba3f5882","type":"article","url":"https://hartvaat.nl/2026/07/31/uit-het-hospitaal-hartstilstand-komt-12-keer-vaker-voor-bij-niet-ischemische-car/","title":"Uit-het-hospitaal hartstilstand komt 12 keer vaker voor bij niet-ischemische cardiomyopathie — registerstudie","title_en":"Incidence, Analysis and Risk of Out-of-Hospital Cardiac Arrest in Individuals with Non-Ischaemic Dilated Cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag207","source_url":"https://doi.org/10.1093/eschf/xvag207","authors":["Leo Henry Mansell","Peder Emil Warming","Rasmus Bork Dinesen","Rodrigue Garcia","Reza Jabbari","Gunnar Gislason","Bo Gregers Winkel","Jacob Tfelt-Hansen"],"significance":5,"published":"2026-08-16","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ischemische-cardiomyopathie/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"A nationwide Danish register study spanning two decades reveals that patients with non-ischaemic dilated cardiomyopathy (NIDCM) face a substantially higher risk of out-of-hospital cardiac arrest (OHCA) compared to the general population. The incidence rate is approximately 12 times higher (532 vs 45 per 100,000 person-years), with a 10-year cumulative risk of 3.4% in men and 2.1% in women. Although NIDCM-related arrests more frequently present with a shockable rhythm, 30-day and 1-year mortality remain comparable to non-NIDCM cases. These epidemiological insights assist cardiologists and primary care physicians in refining sudden cardiac death risk stratification and guiding preventive strategies, such as implantable cardioverter-defibrillator placement, in this distinct heart failure cohort.","created":"2026-08-09T01:35:12Z","updated":"2026-08-10T10:35:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e64612704b9","type":"article","url":"https://hartvaat.nl/2026/07/31/finerenone-verhoogt-complete-nierremissie-bij-niet-diabetische-iga-nefropatie/","title":"Finerenone verhoogt complete nierremissie bij niet-diabetische IgA-nefropatie","title_en":"Efficacy and safety of finerenone in non-diabetic patients with IgA nephropathy.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag023","source_url":"https://doi.org/10.1093/ndt/gfag023","authors":["Ju'an Wang","Yuanmao Tu","Zige Chen","Zhaochen Guo","Jinglei Chen","Bian Wu","Zhihong Liu","Hao Bao"],"significance":6,"published":"2026-08-16","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"A retrospective cohort study of 382 patients with non-diabetic IgA nephropathy demonstrates that finerenone significantly improves complete renal remission rates (HR 2.58; p < 0.001) and reduces the risk of a ≥30% eGFR decline (HR 0.30; p = 0.036) compared to standard care alone. Potassium levels remained stable, and adding finerenone to an SGLT2 inhibitor yielded the highest remission rates. These findings support the nephroprotective role of finerenone in non-diabetic IgA nephropathy, particularly when combined with SGLT2 inhibitors.","created":"2026-08-09T01:30:28Z","updated":"2026-08-10T10:35:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1a5f2aeadce4","type":"article","url":"https://hartvaat.nl/2026/07/31/15-mg-edoxaban-na-pci-bij-atriumfibrilleren-met-hoog-bloedingrisico-geen-superie/","title":"15 mg edoxaban na PCI bij atriumfibrilleren met hoog bloedingrisico — geen superieure uitkomst","title_en":"Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"International heart journal","doi":"10.1536/ihj.25-558","source_url":"https://doi.org/10.1536/ihj.25-558","authors":["Takao Sato","Yoshifusa Aizawa","Toshihiro Miyamoto","Ryoma Fukuoka","Kazumasa Sugimoto","Yoko Tanimoto","Takashi Nakayama","Kojiro Tanimoto","Koichiro Sugimura","Yoshihide Fujimoto","Takahiko Kiyooka","Akio Kawamura"],"significance":4,"published":"2026-08-15","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A retrospective analysis of 148 patients with atrial fibrillation undergoing PCI compared 15 mg versus 30 mg edoxaban in those at high bleeding risk. Although the 15 mg dose showed numerically lower rates of major bleeding (6.8% vs 19.7%) and thrombotic events (3.0% vs 7.4%), these differences did not reach statistical significance. Clinicians should note that current evidence does not support switching to the lower edoxaban dose over the standard 30 mg regimen in this high-risk population.","created":"2026-08-09T01:18:42Z","updated":"2026-08-10T10:35:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef47e9e07df9","type":"article","url":"https://hartvaat.nl/2026/07/31/atenolol-vermindert-postoperatief-atriumfibrilleren-na-hartchirurgie/","title":"Atenolol vermindert postoperatief atriumfibrilleren na hartchirurgie","title_en":"A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Medicine","doi":"10.1097/MD.0000000000050029","source_url":"https://doi.org/10.1097/MD.0000000000050029","authors":["Jin-He Deng","Fan-Rong He","Yun-Tai Yao"],"significance":5,"published":"2026-08-15","source_date":"2026-07-31","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A meta-analysis of six randomized controlled trials (870 patients) demonstrates that atenolol significantly reduces the incidence of postoperative atrial fibrillation following cardiac surgery (RR 0.55; 95% CI 0.32-0.93). However, atenolol showed no superiority over sotalol and performed similarly to other control agents such as metoprolol and propafenone. These findings reinforce the established role of beta-blockers in POAF prophylaxis, without providing evidence to favor atenolol over alternative antiarrhythmic or beta-blocking strategies.","created":"2026-08-09T01:14:12Z","updated":"2026-08-10T10:35:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"117b2521339d","type":"article","url":"https://hartvaat.nl/2026/10/01/sglt2-remmers-bij-zeer-oude-hartfalenpatienten-nierfunctie-en-palliatieve-zorg-b/","title":"SGLT2-remmers bij zeer oude hartfalenpatiënten: nierfunctie en palliatieve zorg bepalen voorschrijfpatroon","title_en":"SGLT2 inhibitor prescription at discharge in very old adults with heart failure irrespective of diabetes status.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"International journal of cardiology. Heart & vasculature","doi":"10.1016/j.ijcha.2026.101980","source_url":"https://doi.org/10.1016/j.ijcha.2026.101980","authors":["Rémi Esser","Marc Harboun","Marine Larbaneix","Alejandro Mondragon","Sophie Balesdent","Marlène Esteban","Jennifer Corny","Christine Farges","Vincenzo Palermo","Nicolas Pages","Sophie Nisse Durgeat","Olivier Maurou"],"significance":4,"published":"2026-08-15","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"A single-centre retrospective study of 1,235 hospitalisations in a cardiogeriatric unit found that SGLT2 inhibitors were prescribed at discharge in 82.3% of very old heart failure patients (median age 88.6 years), regardless of diabetes status. Non-prescription was strongly associated with advanced chronic kidney disease (CKD stages 4–5) and palliative care orientation, but not with age or comorbidity burden. These patterns highlight that renal function and care goals, rather than diabetes or frailty alone, currently drive SGLT2 inhibitor use in this vulnerable population, informing discharge prescribing decisions.","created":"2026-08-09T01:00:21Z","updated":"2026-08-10T10:35:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4392a5674782","type":"article","url":"https://hartvaat.nl/2026/10/01/biomarker-gestuurde-farmacotherapie-biedt-raamwerk-voor-precisiebehandeling-bij-/","title":"Biomarker-gestuurde farmacotherapie biedt raamwerk voor precisiebehandeling bij CKM-syndroom","title_en":"Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Pharmacology & therapeutics","doi":"10.1016/j.pharmthera.2026.109089","source_url":"https://doi.org/10.1016/j.pharmthera.2026.109089","authors":["Yafeng Li","Wenzhu Song","Chengyu Huan","Keman Xu","Juan Sun","Xin Zhen","Hua Ouyang","Hairong Tang","Qiuxia Fan","Wenqiang Zhi","Yuanmin Chai","Ruilin Li","Hong Wang","Xiaofeng Yang"],"significance":6,"published":"2026-08-15","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This review proposes a three-dimensional framework for biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic (CKM) syndrome. It maps organ-specific biomarkers to drug targets, identifies cross-system markers like hs-CRP and IL-6 for targeting inflammatory and metabolic pathways, and emphasizes serial biomarker trajectories to distinguish drug effects from disease progression. Central to the approach is 'pharmacological phenotyping,' using multi-biomarker panels to define drug-responsive states and guide therapeutic selection. The framework offers a practical roadmap for clinicians to navigate the expanding arsenal of cardiorenal and metabolic agents with greater precision and monitoring.","created":"2026-08-09T00:55:36Z","updated":"2026-08-10T10:35:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fce87e0996f7","type":"article","url":"https://hartvaat.nl/2026/09/01/drinkfrequentie-bepaalt-hdl-c-niveau-meer-dan-hoeveelheid-per-keer-troms-studie/","title":"Drinkfrequentie bepaalt HDL-C-niveau meer dan hoeveelheid per keer — Tromsø-studie","title_en":"The impact of drinking patterns on the relationship between alcohol use and levels of serum high-density lipoprotein cholesterol (HDL-C).","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"Alcohol (Fayetteville, N.Y.)","doi":"10.1016/j.alcohol.2026.07.003","source_url":"https://doi.org/10.1016/j.alcohol.2026.07.003","authors":["Jørgen G Bramness","Jørg Mørland","Torgeir Gilje Lid","Anne Høye","Gudrun Høiseth"],"significance":3,"published":"2026-08-15","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-doelwaarden-risicostratificatie/"],"congress":"","summary_en":"In a cross-sectional study of 18,614 adults (aged 40–79), the frequency of alcohol consumption showed a stronger positive association with HDL-C levels than the amount consumed per occasion. Each additional gram of alcohol per day was associated with a 0.005 mmol/L increase in HDL-C, whereas large amounts per drinking occasion were linked to lower HDL-C, particularly among infrequent drinkers. These findings highlight that drinking patterns influence HDL-C interpretation and cardiovascular risk assessment, though they do not support recommending alcohol for prevention.","created":"2026-08-09T00:47:18Z","updated":"2026-08-10T10:35:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa09028359de","type":"article","url":"https://hartvaat.nl/2026/07/31/steilere-egfr-daling-voorspelt-nierfalen-en-cardiovasculaire-mortaliteit-narrati/","title":"Steilere eGFR-daling voorspelt nierfalen en cardiovasculaire mortaliteit — narratieve review","title_en":"Estimated glomerular filtration rate slope and clinical outcomes: a narrative review.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Diabetes research and clinical practice","doi":"10.1016/j.diabres.2026.113477","source_url":"https://doi.org/10.1016/j.diabres.2026.113477","authors":["Fan Zhang","Yue Xing","Wanhaier Abudoureheman","Yifei Zhong"],"significance":5,"published":"2026-08-14","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This narrative review synthesizes current evidence on the prognostic value of the estimated glomerular filtration rate (eGFR) slope for kidney failure, cardiovascular events, and all-cause mortality. A steeper decline over three years is consistently associated with higher risks of end-stage kidney disease, hospitalization, and death, with a notable U-shaped relationship observed for mortality. Incorporating eGFR slope into routine clinical assessment can improve risk stratification, support personalized management, and serve as a reliable surrogate endpoint for evaluating renoprotective therapies like SGLT2 inhibitors.","created":"2026-08-07T01:40:05Z","updated":"2026-08-10T10:35:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af8ddedf3661","type":"article","url":"https://hartvaat.nl/2026/07/31/verhoogde-serumketonen-verlagen-niercomplicaties-bij-type-2-diabetes-prospectief/","title":"Verhoogde serumketonen verlagen niercomplicaties bij type 2-diabetes — prospectief cohort","title_en":"Serum ketone body levels and risk of incident kidney and cardiovascular events among patients with type 2 diabetes: a prospective cohort study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Diabetes research and clinical practice","doi":"10.1016/j.diabres.2026.113476","source_url":"https://doi.org/10.1016/j.diabres.2026.113476","authors":["Soo Myoung Shin","Jiyoon Lee","Young-Eun Kim","Jung A Kim","Kyoung Jin Kim","Kyeong Jin Kim","Hee Young Kim","Sin Gon Kim","Nam Hoon Kim"],"significance":4,"published":"2026-08-14","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"A prospective cohort study of 1,392 stable patients with type 2 diabetes found that mildly elevated serum ketone levels were independently associated with a reduced risk of kidney complications. Over a median follow-up of 23.2 months, participants in the highest ketone tertile had a 54% lower risk of a ≥40% decline in eGFR (adjusted HR 0.46) and a 37% lower risk of a composite kidney outcome (aHR 0.63) compared to the lowest tertile, with similar non-significant trends for cardiovascular events. While these findings highlight ketones as a potential biomarker for renal risk, they do not yet translate into specific clinical interventions.","created":"2026-08-07T01:36:24Z","updated":"2026-08-10T10:35:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"439079c1382f","type":"article","url":"https://hartvaat.nl/2026/07/31/hoge-serumbicarbonaat-bij-opname-voorspelt-diuretische-resistentie-bij-acute-har/","title":"Hoge serumbicarbonaat bij opname voorspelt diuretische resistentie bij acute hartfalenexacerbatie","title_en":"Admission serum bicarbonate is associated with early diuretic resistance in acute decompensated heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Cardiovascular journal of Africa","doi":"10.5830/CVJA-2026-021","source_url":"https://doi.org/10.5830/CVJA-2026-021","authors":["Kayıhan Karaman","Sefa Erdi Ömür"],"significance":4,"published":"2026-08-14","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"A retrospective single-centre cohort of 1,000 patients with acute decompensated heart failure found that elevated admission serum bicarbonate (>28 mmol/L) is independently associated with early diuretic resistance and less effective decongestion. Patients with this alkalosis phenotype required earlier diuretic escalation, had smaller 24- to 48-hour fluid losses, and exhibited lower early urine sodium levels. Incorporating bicarbonate into urine-sodium-guided decongestion protocols may enable faster, more objective diuretic titration, though prospective trials are needed to confirm impact on clinical outcomes.","created":"2026-08-07T01:32:00Z","updated":"2026-08-10T10:35:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b18f02764cd","type":"article","url":"https://hartvaat.nl/2026/07/31/ontstekingsrijke-voeding-verhoogt-sterfterisico-bij-ckm-syndroom-nhanes-cohort/","title":"Ontstekingsrijke voeding verhoogt sterfterisico bij CKM-syndroom — NHANES-cohort","title_en":"Associations of dietary inflammatory and antioxidant indices with mortality in adults with cardiovascular-kidney-metabolic syndrome: A mediation analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Medicine","doi":"10.1097/MD.0000000000050040","source_url":"https://doi.org/10.1097/MD.0000000000050040","authors":["Yuefeng Li","Jing Kang"],"significance":5,"published":"2026-08-14","source_date":"2026-07-31","image":"https://hartvaat.nl/global/img/0155cc89a708.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"In a cohort of 21,420 NHANES participants with cardiovascular-kidney-metabolic (CKM) syndrome, higher dietary inflammatory index (DII) and lower composite dietary antioxidant index (CDAI) scores were independently associated with increased all-cause and cardiovascular mortality. The highest versus lowest DII tertile corresponded to a hazard ratio of 1.27, while a high CDAI reduced mortality risk to HRs of 0.84 and 0.78, respectively. Mediation analysis indicated that obesity and systemic inflammation indices accounted for only 4–9% of this association. These findings reinforce the potential role of anti-inflammatory, antioxidant-rich dietary patterns in reducing mortality risk among patients with CKM syndrome.","created":"2026-08-07T01:27:47Z","updated":"2026-08-10T10:35:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8b9b33cfaa5f","type":"article","url":"https://hartvaat.nl/2026/07/31/draagbare-sensoren-voor-comorbiditeit-osa-en-hypertensie-huidige-stand-van-zaken/","title":"Draagbare sensoren voor comorbiditeit OSA en hypertensie: huidige stand van zaken en beperkingen","title_en":"Wearable Devices for Monitoring and Management of Comorbid Obstructive Sleep Apnea and Hypertension: Scoping Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JMIR mHealth and uHealth","doi":"10.2196/84506","source_url":"https://doi.org/10.2196/84506","authors":["Hongyi Wang","Anran Cheng","Yusheng Li","Haining Zhang","Shun Fan","Rong Shen","Wei Zhang","Huanan Li","Jingui Wang"],"significance":3,"published":"2026-08-14","source_date":"2026-07-31","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/laboratoriumonderzoek-bij-hypertensie/"],"congress":"","summary_en":"This scoping review synthesizes 13 studies on wearable sensors for patients with comorbid obstructive sleep apnea (OSA) and hypertension. Current devices, primarily wrist- and patch-based, focus on screening, risk stratification, and nocturnal blood pressure monitoring, but exhibit substantial variability in validation and diagnostic thresholds. Clinically, wearables currently serve only as adjunctive tools for risk warning and cannot replace standard sleep studies or conventional blood pressure monitoring. Large-scale prospective multicenter trials are required to establish definitive clinical utility.","created":"2026-08-07T01:21:33Z","updated":"2026-08-10T10:35:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"845e56618583","type":"article","url":"https://hartvaat.nl/2026/06/01/glp-1-agonisten-verlagen-mace-met-14-bij-diabetes-type-2-meta-analyse/","title":"GLP-1-agonisten verlagen MACE met 14% bij diabetes type 2 — meta-analyse","title_en":"Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Cureus","doi":"10.7759/cureus.111723","source_url":"https://doi.org/10.7759/cureus.111723","authors":["Samih Abdelmutalab Mohamed Abdalla","Hind Osman Ali Mohammed","Eltayeb Osman E Omer","Ibrahim Obied Ibrahim Ahmed","Wadah Ahmed Osman Ahmed","Khalid Omer Taha Ginawi","Riham Elgaali Mohamed Abdelfattah","Ahmed Abdalla Zarrouq Yousif","Khadija Ibrahim Ahmed Ismail"],"significance":5,"published":"2026-08-13","source_date":"2026-06-01","image":"https://hartvaat.nl/global/img/4c69482a1671.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A systematic review and meta-analysis of nine placebo-controlled cardiovascular outcome trials (n = 69,730) demonstrates that GLP-1 receptor agonists significantly reduce major adverse cardiovascular events in patients with type 2 diabetes. The pooled hazard ratio was 0.86 (95% CI: 0.82–0.92; p < 0.001), representing a 14% relative risk reduction driven primarily by fewer myocardial infarctions and strokes. While gastrointestinal events and a mild increase in gallbladder disease were noted, the overall safety profile remains acceptable. These findings reinforce current guidelines recommending GLP-1 receptor agonists as a cornerstone of cardiovascular risk reduction in diabetes, though heterogeneity across trials prevents definitive ranking of individual agents.","created":"2026-08-07T01:11:18Z","updated":"2026-08-10T10:35:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56beb909698a","type":"article","url":"https://hartvaat.nl/2026/06/01/glp-1-polyagonisten-verbeteren-leverhistologie-en-vetgehalte-bij-masld-mash-meta/","title":"GLP-1-polyagonisten verbeteren leverhistologie en vetgehalte bij MASLD/MASH — meta-analyse","title_en":"Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["huisarts","internist"],"tags":[],"journal":"Cureus","doi":"10.7759/cureus.111728","source_url":"https://doi.org/10.7759/cureus.111728","authors":["Rogelio Santos Solis","Armando A Baeza-Zapata","Juan P Negrete-Najar"],"significance":5,"published":"2026-08-13","source_date":"2026-06-01","image":"https://hartvaat.nl/global/img/16acb30c4750.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"A meta-analysis of six randomized controlled trials (n=961) demonstrates that dual and triple GLP-1-based polyagonists significantly improve histological resolution of MASLD and MASH (RR 3.32) and reduce liver fat content by over 44 percentage points compared with placebo. While gastrointestinal adverse events are more common, serious adverse events and treatment discontinuation rates remain comparable to placebo. These findings reinforce the cardiometabolic and hepatic benefits of next-generation GLP-1 agonists, though high heterogeneity in weight loss outcomes and limited follow-up duration warrant cautious interpretation until larger phase 3 trials clarify long-term efficacy and cardiovascular impact.","created":"2026-08-07T01:06:03Z","updated":"2026-08-10T10:35:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bdcc8ad43963","type":"article","url":"https://hartvaat.nl/2026/06/01/cardiovasculair-risico-van-adt-en-arpi-s-bij-prostaatkanker-narrative-review/","title":"Cardiovasculair risico van ADT en ARPI's bij prostaatkanker — narrative review","title_en":"Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"Archivos espanoles de urologia","doi":"10.56434/j.arch.esp.urol.20267905.87","source_url":"https://doi.org/10.56434/j.arch.esp.urol.20267905.87","authors":["Sandra Fernández Alonso","Fernando López Campos","David Büchser","Sandra Guardado","Jon Andreescu","Walter Vásquez","Ana Castaño","Javier Gil Moradillo","Lucía García González","Andrew Loblaw","Felipe Couñago"],"significance":5,"published":"2026-08-13","source_date":"2026-06-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A narrative review examines the cardiovascular toxicity of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) in patients with prostate cancer. ADT induces metabolic and vascular alterations that promote a proatherogenic state; GnRH antagonists appear to carry a lower early risk of major adverse cardiovascular events compared to agonists, while darolutamide demonstrates a more favorable cardiovascular safety profile than abiraterone or apalutamide. Routine cardiovascular risk assessment, aggressive management of modifiable risk factors, and a multidisciplinary cardio-oncology approach are essential to optimize long-term outcomes in this population.","created":"2026-08-07T00:54:42Z","updated":"2026-08-10T10:35:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f8e6d9d54c0c","type":"article","url":"https://hartvaat.nl/2026/09/01/tavr-met-ballon-expanderbare-klep-heeft-vergelijkbare-overleving-en-minder-compl/","title":"TAVR met ballon-expanderbare klep heeft vergelijkbare overleving en minder complicaties dan chirurgische vervanging bij laag-risico aortastenose","title_en":"Transcatheter versus surgical aortic valve replacement for severe aortic stenosis in low-risk adults: a network meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Indian journal of thoracic and cardiovascular surgery","doi":"10.1007/s12055-026-02245-1","source_url":"https://doi.org/10.1007/s12055-026-02245-1","authors":["Kanandya Kizzandy","Yehezkiel Gian Pradipta Pahu","Satria Rafi Ratmandhika","Krisanto Tanjaya","Elsafira Rana Rinanada","Muhammad Yusuf","Muhammad Reva Aditya","Imam Suseno Bayuadi"],"significance":6,"published":"2026-08-13","source_date":"2026-09-01","image":"https://hartvaat.nl/global/img/4ae9c5687fce.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"A network meta-analysis of 31 studies (37,741 patients) compared transcatheter (TAVR) and surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis. TAVR, particularly with balloon-expandable valves, demonstrated comparable short- and intermediate-term survival while significantly reducing 30-day stroke, major bleeding, acute kidney injury, and readmission rates, and shortening hospital stays by approximately four days. SAVR remained associated with lower rates of paravalvular regurgitation and permanent pacemaker implantation across all time horizons. These findings support platform-specific, individualized decision-making, positioning balloon-expandable TAVR as a safe and efficient alternative to surgery in low-risk patients.","created":"2026-08-07T00:50:01Z","updated":"2026-08-10T10:35:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b8a020b8ef15","type":"article","url":"https://hartvaat.nl/2026/09/01/perioperatieve-empagliflozin-verlaagt-trend-postoperatieve-boezemfibrilleren-na-/","title":"Perioperatieve empagliflozin verlaagt trend postoperatieve boezemfibrilleren na klepsurgery — RCT","title_en":"Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart valve surgery: a double-blind, randomized, placebo-controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Indian journal of thoracic and cardiovascular surgery","doi":"10.1007/s12055-026-02240-6","source_url":"https://doi.org/10.1007/s12055-026-02240-6","authors":["Mahdi YazdFazeli","Sahar Samimi","Mohammad Abbasi Teshnizi","Hamid Hoseinikhah","Aliasghar Moeinipour","Omid Javedanfar","Vahid Ghavami","Farshad Abedi","Shahram Amini","Benyamin Fazli","Amir Hooshang Mohammadpour"],"significance":3,"published":"2026-08-13","source_date":"2026-09-01","image":"https://hartvaat.nl/global/img/0225e929308c.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"A double-blind RCT (n=110) evaluated whether perioperative empagliflozin (10 mg daily) prevents postoperative atrial fibrillation (POAF) following elective heart valve surgery. Among 81 patients in the modified intention-to-treat analysis, POAF occurred in 20% of the empagliflozin group versus 39% in the placebo group (49% relative risk reduction, p=0.088). Although the primary endpoint did not reach statistical significance, the trend toward reduced arrhythmia incidence, combined with improved postoperative glycemic control and a favorable safety profile, warrants further investigation. Larger trials are needed before perioperative SGLT2 inhibitor use can be recommended for POAF prevention.","created":"2026-08-07T00:46:44Z","updated":"2026-08-10T10:35:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"875ff3095acb","type":"article","url":"https://hartvaat.nl/2026/06/01/vis-score-voorspelt-28-daagse-mortaliteit-bij-atriumfibrilleren-met-hemodynamisc/","title":"VIS-score voorspelt 28-daagse mortaliteit bij atriumfibrilleren met hemodynamische instabiliteit op de IC","title_en":"[Predictive value of the Vasoactive Inotropic Score for 28-day mortality in patients with atrial fibrillation-related hemodynamic deterioration in the intensive care unit].","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Zhonghua wei zhong bing ji jiu yi xue","doi":"10.3760/cma.j.cn121430-20260108-00018","source_url":"https://doi.org/10.3760/cma.j.cn121430-20260108-00018","authors":["Zhaoxuan Guo","Xiujun Chang","Xian Qin","Jiayu Fang","Xingfu Shi","Yunping Lan"],"significance":4,"published":"2026-08-12","source_date":"2026-06-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"In a single-center retrospective cohort of 123 ICU patients with atrial fibrillation and hemodynamic deterioration, the vasoactive inotropic score (VIS) showed good predictive value for 28-day mortality (AUC 0.801). A VIS ≥ 129.7 was an independent risk factor for death (OR 70.5), while anticoagulation therapy was protective (OR 0.073). These findings support VIS as a practical risk-stratification tool in critically ill patients with AF, though results are limited to a single center and require external validation.","created":"2026-08-05T01:31:19Z","updated":"2026-08-10T10:35:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ca9fcee22aa","type":"article","url":"https://hartvaat.nl/2026/06/01/oudere-stemi-patienten-hebben-meer-complicaties-en-hogere-sterfte-dan-jongeren-e/","title":"Oudere STEMI-patiënten hebben meer complicaties en hogere sterfte dan jongeren — een prospectieve cohortstudie","title_en":"Comparison of In-Hospital Outcomes of Acute ST Segment Elevation Myocardial Infarction in Young Versus Older Patients.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Cureus","doi":"10.7759/cureus.111767","source_url":"https://doi.org/10.7759/cureus.111767","authors":["Yasotha Gnanakaran","Muhammad Hassaan Qayyum","Samar Raza","Hafiz Zunair Iqbal","Saba Arshad Ali","Umaima Jawad","Ammar Noor","Muhammad Ayoob Memon","Fnu Qurat-Ul-Ain","Muhammad Irfan Jamil"],"significance":4,"published":"2026-08-12","source_date":"2026-06-01","image":"https://hartvaat.nl/global/img/940a0e091a4a.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Among 300 STEMI patients, those over 40 had significantly higher rates of heart failure, cardiogenic shock, acute kidney injury, and in-hospital death (11.3% vs 4.0%; p=0.017). Multivariable analysis revealed that mortality was independently predicted by mechanical complications, ventricular arrhythmias, shock, and AKI, rather than age itself. These findings reinforce that the higher burden of comorbidities and acute complications in older patients drives worse outcomes, underscoring the need for vigilant monitoring and early intervention in this population.","created":"2026-08-05T01:27:34Z","updated":"2026-08-10T10:35:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae54e79edc23","type":"article","url":"https://hartvaat.nl/2026/06/02/smartphone-app-voor-symptoomregistratie-na-ablatie-bij-atriumfibrilleren-isolati/","title":"Smartphone-app voor symptoomregistratie na ablatie bij atriumfibrilleren — ISOLATION","title_en":"Symptom severity assessment in patients with atrial fibrillation after catheter ablation using a smartphone application.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag139","source_url":"https://doi.org/10.1093/europace/euag139","authors":["Emma Sandgren","Konstanze Betz","Monika Gawalko","Astrid Hermans","Zarina Habibi","Dominique Verhaert","Suzanne Philippens","Bianca Vorstermans","Mandy Kessels","David Bovenkerk","Ben J M Hermans","Jeroen M Hendriks","Dennis den Uijl","Sevasti-Maria Chaldoupi","Justin Luermans","Theo Lankveld","Ulrich Schotten","Kevin Vernooy","Dominik Linz"],"significance":3,"published":"2026-08-12","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"An analysis of the ISOLATION study evaluated a smartphone-based photoplethysmography app for daily symptom severity tracking in 140 patients following catheter ablation for atrial fibrillation. Among 8,575 recordings, 11% showed active AF, with nearly half of these episodes being asymptomatic. Symptom severity was higher during AF, in women, and at higher heart rates. This digital approach offers clinicians a more precise assessment of patient burden beyond rhythm status alone, potentially refining post-ablation follow-up.","created":"2026-08-05T01:18:11Z","updated":"2026-08-10T10:35:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6125ec63bbc","type":"article","url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","title":"Pulsfield-ablatie levert betere vrijwaring van recidief dan cryoballoon bij paroxysmale AF — SINGLE SHOT CHAMPION","title_en":"Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag152","source_url":"https://doi.org/10.1093/europace/euag152","authors":["Laurent Roten","Thomas Kueffer","Patrick Badertscher","Peter Jüni","Sven Knecht","Gregor Thalmann","Nikola Kozhuharov","Philipp Krisai","Salik Ur Rehman Iqbal","Corinne Jufer","Jens Maurhofer","Dik Heg","Tiago V Pereira","Felix Mahfoud","Helge Servatius","Hildegard Tanner","Michael Kühne","Christian Sticherling","Tobias Reichlin"],"significance":6,"published":"2026-08-12","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/pathofysiologie-af/"],"congress":"","summary_en":"In this substudy of a multicentre RCT, 210 patients with symptomatic paroxysmal atrial fibrillation underwent pulmonary vein isolation using either pulsed field ablation (PFA) or cryoballoon ablation (CBA). At 12 months, freedom from arrhythmia recurrence was significantly higher with PFA than CBA (63% vs 49%, p=0.046), accompanied by higher heart rate variability and lower resting heart rates in the PFA group. Although PFA exerts less autonomic nervous system modulation, these results suggest that autonomic effects are not critical for successful paroxysmal AF ablation. The findings reinforce PFA as a highly effective first-line ablation strategy.","created":"2026-08-05T01:12:42Z","updated":"2026-08-10T10:36:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1c983b9212f","type":"article","url":"https://hartvaat.nl/2026/06/02/vroege-katheterablatie-even-effectief-als-antiaritmica-bij-ischemische-ventricul/","title":"Vroege katheterablatie even effectief als antiaritmica bij ischemische ventriculaire tachycardie — meta-analyse","title_en":"Early catheter ablation vs. antiarrhythmic drugs in treatment-naïve ischaemic ventricular tachyarrhythmias: a meta-analysis of randomized controlled trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag073","source_url":"https://doi.org/10.1093/europace/euag073","authors":["Tiago Moura Façanha","Anna Isabelle Gomes Pereira","Maria Fernanda Carvalho Garcia","Enzo Tunala Mendonça","João Vitor Jacobsen Ramos","Leonardo Antunes Mesquita"],"significance":6,"published":"2026-08-12","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/"],"congress":"","summary_en":"A meta-analysis of three randomized controlled trials (n=618) evaluated early catheter ablation versus antiarrhythmic drugs as initial therapy for ventricular tachycardia in patients with prior myocardial infarction. Both strategies demonstrated comparable efficacy for all-cause mortality, appropriate ICD therapies, and VT storm, while ablation showed a trend toward fewer hospitalizations and adverse events, though largely driven by a single study. These results support considering early ablation as a first-line option in selected patients, pending further confirmation in larger trials.","created":"2026-08-05T01:07:47Z","updated":"2026-08-10T10:36:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e5431aaff01","type":"article","url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","title":"Catheterablatie bij atriumfibrilleren in cardiale amyloïdose levert 42% ritmievrije patiënten op — AMYL-AF","title_en":"Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag143","source_url":"https://doi.org/10.1093/europace/euag143","authors":["Daniele Faccenda","Marco Bergonti","Tom De Potter","Michel Haïssaguerre","Johan Saenen","Carlo De Asmundis","Giuseppe Ciconte","Marta De Riva","Michela Casella","Jacopo Costantino","Daniel Scherr","Mikael Laredo","Patrizio Mazzone","Avi Sabbag","Matteo Anselmino","Andrea Rossi","Matteo Bertini","Lia Crotti","Christian-Hendrik Heeger","Claudio Tondo","Elena Arbelo","Moises Levinstein","Sebastiaan R D Piers","Maria L Caputo","Carlo Pappone","Domenico G Della Rocca","Olivier Van Leuven","Paolo Compagnucci","Tardu Özkartal","Raffaele Salerno","Chiara Pavone","Valeria Rella","Katharina I Gölly","Lorenzo Gigli","Cristina Balla","Cristina Chimenti","Nicolas Johner","Alessandro Laschera","Manuela Averaimo","Esther Scheirlynck","Marco Schiavone","Cinzia Monaco","Giulio Conte"],"significance":5,"published":"2026-08-11","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"The multicentre AMYL-AF registry evaluated catheter ablation outcomes in 109 patients with transthyretin (ATTR) or light-chain (AL) cardiac amyloidosis and atrial fibrillation. After a median follow-up of 22.7 months, 42% remained arrhythmia-free, while 25% experienced the composite endpoint of all-cause mortality or heart failure hospitalisation. Recurrent persistent AF was associated with a three-fold higher risk of these adverse outcomes. These real-world data assist cardiologists and internists in counselling patients and selecting appropriate rhythm-control strategies in this high-risk population.","created":"2026-08-05T01:04:07Z","updated":"2026-08-10T10:36:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de817b7f9e23","type":"article","url":"https://hartvaat.nl/2026/06/02/autonoom-remodelling-vormt-onafhankelijk-domein-binnen-atriale-cardiomyopathie/","title":"Autonoom remodelling vormt onafhankelijk domein binnen atriale cardiomyopathie","title_en":"Atrial cardiomyopathy as a multidomain disease: longitudinal evidence for autonomic remodelling.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag132","source_url":"https://doi.org/10.1093/europace/euag132","authors":["Jean-Baptiste Guichard","David Hupin","Vincent Pichot","Sébastien Celle","Inés Martínez Saludes","Ahmed El-Medany","Joseph Barker","Ivo Roca-Luque","Lluís Mont","Antoine Da Costa","Adelina Doltra","Fu Siong Ng","Eduard Guasch","Linda S Johnson","Frédéric Roche"],"significance":6,"published":"2026-08-11","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/pathofysiologie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"A prospective cohort study of 670 adults aged 65 years without prior atrial fibrillation demonstrates that autonomic remodelling, assessed via longitudinal heart rate variability, constitutes an independent domain of atrial cardiomyopathy. Involvement of two or more remodelling axes (autonomic, electrical, and structural) was associated with a more than twofold higher risk of incident AF (HR 2.43) and increased rates of major cardiovascular events and mortality. These findings support a multidimensional framework for atrial substrate assessment, suggesting that longitudinal autonomic monitoring may help identify high-risk individuals before clinical arrhythmia onset.","created":"2026-08-05T01:00:34Z","updated":"2026-08-10T10:36:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"502ab223879c","type":"article","url":"https://hartvaat.nl/2026/06/02/doac-gebruik-na-ablatie-voor-atriumfibrilleren-aanhouderij-daalt-na-drie-jaar/","title":"DOAC-gebruik na ablatie voor atriumfibrilleren: aanhouderij daalt na drie jaar","title_en":"Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag151","source_url":"https://doi.org/10.1093/europace/euag151","authors":["Bjarke Sihm Stender","Victor Kjær Eskildsen","Anders Kramer","Maja Hellfritzsch Poulsen","Kasper Korsholm","Kasper Bonnesen","Morten Schmidt","Mads Brix Kronborg","Jens Erik Nielsen-Kudsk"],"significance":5,"published":"2026-08-11","source_date":"2026-06-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"A nationwide Danish cohort of 13,438 patients undergoing first-time catheter ablation for atrial fibrillation was analysed for DOAC adherence and persistence, focusing on those with a CHA₂DS₂-VASc score ≥2. After three years, 87.6% met the adherence threshold (PDC ≥80%), but persistence dropped to 73.0%, indicating that over 20% had discontinued therapy. Thromboembolic and major bleeding rates remained low. The findings highlight a need for structured follow-up and adherence support to maintain long-term stroke prevention after AF ablation.","created":"2026-08-05T00:56:48Z","updated":"2026-08-10T10:36:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2cabf36716d0","type":"article","url":"https://hartvaat.nl/2026/06/30/catheterablatie-verlaagt-sterfte-en-complicaties-bij-af-in-cardiale-amyloidose-t/","title":"Catheterablatie verlaagt sterfte en complicaties bij AF in cardiale amyloïdose — TriNetX-cohort","title_en":"Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: a propensity-matched cohort study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Global cardiology science & practice","doi":"10.21542/gcsp.2026.26","source_url":"https://doi.org/10.21542/gcsp.2026.26","authors":["Joud Fahed","Mohammad Hamza","Azka Naeem","Asad Ur Rab","Muhammad Hashim Khan","Mohammad Ali Sheffeh","Jawad Basit","Salem Assiri","M Chadi Alraies"],"significance":5,"published":"2026-08-11","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"In a propensity-matched cohort of nearly 1,800 patients with cardiac amyloidosis and atrial fibrillation, catheter ablation combined with antiarrhythmic drugs significantly reduced a composite endpoint of all-cause mortality, stroke, bleeding, and myocardial infarction at 12 months compared to medical therapy alone (8.3% vs 13.2%; HR 0.59). Although the ablation group experienced more repeat procedures and device implantations, it also showed a lower mortality rate without differences in new-onset heart failure or hospitalizations. These findings suggest that ablation may be a viable option for carefully selected patients, particularly those with earlier-stage disease or significant symptom burden.","created":"2026-08-05T00:50:38Z","updated":"2026-08-10T10:36:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35d3006b7e26","type":"article","url":"https://hartvaat.nl/2026/06/30/vutrisiran-remt-ttr-en-vermindert-valrisico-bij-attr-cardiomyopathie-meta-analys/","title":"Vutrisiran remt TTR en vermindert valrisico bij ATTR-cardiomyopathie — meta-analyse","title_en":"Clinical outcomes with vutrisiran in transthyretin amyloidosis: a systematic review and meta-analysis of randomized trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Global cardiology science & practice","doi":"10.21542/gcsp.2026.25","source_url":"https://doi.org/10.21542/gcsp.2026.25","authors":["Faizan Ahmed","Faseeh Haider","Ayesha Zulfiqar","Tooba Nihal","Maliha Khalid","Areej Dar","Saman Rauf","Noor Ul Ain Saleem","Hassan Farooq","Haris Bin Tahir","Ramsha Ali","Haider Hussain Shah","Swapnil Patel","Mohammad Hossain","Fawaz Alenezi"],"significance":6,"published":"2026-08-11","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"A systematic review and meta-analysis of three RCTs (HELIOS-A, HELIOS-B, and a phase-1 trial, n=976) demonstrates that vutrisiran, an RNA interference therapy, reduces transthyretin (TTR) levels by up to 97% with durable suppression. While the analysis suggests trends toward improved quality of life, functional capacity, and mortality (RR 0.51; p=0.29), these did not reach statistical significance. Vutrisiran significantly reduced fall risk (RR 0.62; p=0.001) without increasing overall adverse events, indicating a favourable safety profile. These findings confirm robust biomarker suppression and safety, but larger long-term trials are required to definitively establish clinical and survival benefits in transthyretin amyloidosis.","created":"2026-08-05T00:46:58Z","updated":"2026-08-10T10:36:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1bf561be1fc9","type":"article","url":"https://hartvaat.nl/2026/06/11/longultrasongrafie-onthult-subklinische-longcongestie-bij-stabiele-hfpef-in-de-h/","title":"Longultrasongrafie onthult subklinische longcongestie bij stabiele HFpEF in de huisartspraktijk","title_en":"Pulmonary congestion assessed by lung ultrasound in stable ambulatory patients with heart failure and preserved ejection fraction in primary care.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Family practice","doi":"10.1093/fampra/cmag050","source_url":"https://doi.org/10.1093/fampra/cmag050","authors":["Eva Leceaga-Gaztambide","Mar Domingo","Josep M Manresa","Maria Iniguez-Cruz","Laura Conangla-Ferrin","Carla Chacón","Galadriel Diez-Fadrique","Raquel Garcia","Hajar El Jaouhari Khlifi","Marc Juviña","Maria Alpiste","Daniel Jorba","David Jara","Pere Torán-Montserrat"],"significance":4,"published":"2026-08-10","source_date":"2026-06-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"In a prospective observational study of 188 stable HFpEF patients managed in primary care, lung ultrasound detected subclinical pulmonary congestion (B-lines) in 86.5% of participants, with one-third having ≥5 B-lines despite clinical stability. B-line counts correlated with higher systolic blood pressure, pulmonary crackles, and elevated NT-proBNP and CA-125 levels, but not with functional capacity or quality of life. These findings suggest that lung ultrasound may help identify occult congestion in clinically stable HFpEF patients, potentially refining monitoring and diuretic titration in primary care settings.","created":"2026-08-03T01:23:15Z","updated":"2026-08-10T10:36:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2a21b430eaed","type":"article","url":"https://hartvaat.nl/2026/06/13/ml-modellen-voorspellen-sterfte-bij-post-cardiotomisch-shock-op-ecmo-elso-regist/","title":"ML-modellen voorspellen sterfte bij post-cardiotomisch shock op ECMO — ELSO-registry","title_en":"Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag145","source_url":"https://doi.org/10.1093/eschf/xvag145","authors":["Ahmad Mahajna","Michal Kawczynski","Silvia Mariani","Bas C T van Bussel","Maria Elena De Piero","Gaik Narsesian","Gil Bolotin","Graeme MacLaren","Joseph E Tonna","Edward Soltesz","Giles Peek","Daniel Brodie","Christian Bermudez","Jonathan Haft","Hiroo Takayama","Milan Milojevic","Daniel Goldstein","Daniel Engelman","Koji Takeda","Daniel Zimpfer","Dominik Wiedemann","Jae-Seung Jung","Yoan Lamarche","Vivek Rao","Gloria Faerber","Bart Meyns","Udo Boeken","Evgenij Potapov","Scott Silvestry","Louis Stein","Glenn Whitman","Rakesh Arora","Roberto Lorusso"],"significance":5,"published":"2026-08-10","source_date":"2026-06-13","image":"","kennis":[],"congress":"","summary_en":"A retrospective cohort analysis of 5,982 adults with post-cardiotomy cardiogenic shock on ECMO from the ELSO registry demonstrates that machine learning models can predict in-hospital mortality. The boosting algorithm achieved the highest discrimination (AUC 0.759), with lactate, arterial pH, age, and BMI as key predictors. While the model shows promise as a tool for dynamic risk assessment in the cardiac ICU, external validation and calibration are required before clinical implementation.","created":"2026-08-03T01:16:39Z","updated":"2026-08-10T10:36:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38beb9b2c5d7","type":"article","url":"https://hartvaat.nl/2026/06/16/rivaroxaban-verlaagt-dvt-risico-na-gewrichtsvervanging-maar-verhoogt-bloedingen/","title":"Rivaroxaban verlaagt DVT-risico na gewrichtsvervanging, maar verhoogt bloedingen","title_en":"Multifactorial Risk Assessment and Anticoagulation Strategy Optimization for Deep Vein Thrombosis After Major Joint Surgery: A Retrospective Study.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of visualized experiments : JoVE","doi":"10.3791/70890","source_url":"https://doi.org/10.3791/70890","authors":["Gengwu Li","Chunyu Chen","Hongping Wang","Mingguo Xu","Shiwei Xie","Heng Xiao"],"significance":5,"published":"2026-08-10","source_date":"2026-06-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"A multicenter retrospective cohort study of 32,512 patients undergoing total hip or knee arthroplasty found that rivaroxaban reduced 30-day deep vein thrombosis incidence compared with low-molecular-weight heparin (2.3% vs 3.6%; aOR 0.62). This efficacy benefit was accompanied by a modestly higher rate of major bleeding (1.48% vs 1.08%). The results highlight the importance of individualized anticoagulation strategies that balance thrombotic and hemorrhagic risks, particularly in patients with obesity, advanced age, or prior venous thromboembolism.","created":"2026-08-03T01:12:38Z","updated":"2026-08-10T10:36:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"81792b922e62","type":"article","url":"https://hartvaat.nl/2026/06/19/vrouwen-met-ckd-krijgen-minder-vaak-ras-remmers-en-sglt2-remmers-dan-mannen/","title":"Vrouwen met CKD krijgen minder vaak RAS-remmers en SGLT2-remmers dan mannen","title_en":"Sex disparities in receiving evidence-based medications in patients with CKD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag135","source_url":"https://doi.org/10.1093/ndt/gfag135","authors":["Rui Du","Hannah Wallace","Jeffrey T Ha","Ben Talbot","Vlado Perkovic","Ian H de Boer","Meg Jardine","Adeera Levin","Jose L Górriz","Hiddo L Heerspink","Sradha Kotwal"],"significance":5,"published":"2026-08-10","source_date":"2026-06-19","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"An international observational cohort of 4,192 patients with chronic kidney disease (CKD) revealed that women were significantly less likely to receive evidence-based medications, including renin-angiotensin system inhibitors (OR 0.75) and SGLT2 inhibitors (OR 0.79), compared to men after multivariable adjustment. This prescribing gap persisted across all high-risk subgroups and age categories. The findings highlight a persistent global inequity in cardiorenal care, underscoring the need for clinicians to actively ensure equitable initiation of guideline-directed therapies in female CKD patients.","created":"2026-08-03T01:08:52Z","updated":"2026-08-10T10:36:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18bd191ef755","type":"article","url":"https://hartvaat.nl/2026/06/22/cardiale-amyloidose-komt-frequent-voor-bij-hfpef-aortastenose-en-lvh-meta-analys/","title":"Cardiale amyloïdose komt frequent voor bij HFpEF, aortastenose en LVH — meta-analyse","title_en":"Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag172","source_url":"https://doi.org/10.1093/eschf/xvag172","authors":["Alberto Aimo","Vincenzo Castiglione","Giorgia Panichella","Marianna Fontana","Michele Emdin","Giuseppe Vergaro"],"significance":7,"published":"2026-08-10","source_date":"2026-06-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/"],"congress":"esc-2026","summary_en":"A meta-analysis of 83 studies reveals that cardiac amyloidosis (CA) is relatively prevalent in patients with HFpEF/HFmrEF (12.6%), severe aortic stenosis (9.6%), and left ventricular hypertrophy (15.1%). Prevalence estimates rise substantially when only patients meeting confirmatory testing criteria are evaluated, reaching up to 35.4% in LVH/HCM cohorts. Clinically, the findings underscore the need for structured screening pathways and clear referral criteria rather than selective testing based on clinical suspicion alone.","created":"2026-08-03T01:05:28Z","updated":"2026-08-10T11:07:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-ai","type":"article","url":"https://hartvaat.nl/2026/08/10/ai-als-co-piloot-wat-het-spotlightthema-van-esc-2026-concreet-betekent/","title":"AI als co-piloot: wat het spotlightthema van ESC 2026 concreet betekent","title_en":"AI as co-pilot: what the ESC 2026 spotlight theme actually means","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":6,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/vasculair/enkel-arm-index/","https://hartvaat.nl/kennis/ritmestoornissen/wolff-parkinson-white/"],"congress":"esc-2026","summary_en":"ESC Congress 2026 puts artificial intelligence in the spotlight, framed as a co-pilot from diagnostics to care delivery, with two dedicated programme tracks and hands-on demonstrations. The theme reflects a field moving past research: AI already reads echos, filters rhythm-monitoring alerts and sharpens risk prediction, while the congress rightly programmes the reliability, accountability and equity questions alongside.","created":"2026-08-10T11:55:45Z","updated":"2026-08-10T11:55:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-nhcm","type":"article","url":"https://hartvaat.nl/2026/08/10/niet-obstructieve-hcm-waarom-acacia-hcm-de-eerste-echte-kans-op-een-medicijn-is/","title":"Niet-obstructieve HCM: waarom ACACIA-HCM de eerste echte kans op een medicijn is","title_en":"Non-obstructive HCM: why ACACIA-HCM is the first real shot at a drug","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":6,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"esc-2026","summary_en":"Myosin inhibitors transformed obstructive hypertrophic cardiomyopathy, but the non-obstructive third of patients still has no approved disease-targeted therapy, and mavacamten failed to deliver there. ACACIA-HCM, opening the Hot Line programme at ESC Congress 2026 on Friday 28 August, met both primary endpoints (KCCQ-CSS and pVO2 at week 36) in its 5 May topline; Munich brings the effect sizes, the LVEF safety signals and the MAPLE-HCM comparison.","created":"2026-08-10T11:55:45Z","updated":"2026-08-27T05:20:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-attr","type":"article","url":"https://hartvaat.nl/2026/08/10/attr-cardiomyopathie-aan-de-vooravond-van-cardio-ttransform/","title":"ATTR-cardiomyopathie aan de vooravond van CARDIO-TTRansform","title_en":"ATTR cardiomyopathy on the eve of CARDIO-TTRansform","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":6,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"esc-2026","summary_en":"Transthyretin amyloid cardiomyopathy has moved from rare diagnosis to recognised cause of heart failure in older adults. CARDIO-TTRansform, presented in Hot Line 1 on Friday 28 August, tested the antisense agent eplontersen in 1,432 patients and, as announced by AstraZeneca and Ionis, missed its primary endpoint of CV death plus recurrent CV events to week 140. A prespecified monotherapy subgroup showed a nominally significant HR of 0.71, with no added effect on top of stabilisers: Munich has to explain why.","created":"2026-08-10T11:55:45Z","updated":"2026-08-27T05:20:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-factor-xi","type":"article","url":"https://hartvaat.nl/2026/08/10/factor-xi-remming-de-hypothese-de-belofte-en-de-les-van-librexia-acs/","title":"Factor XI-remming: de hypothese, de belofte en de les van LIBREXIA ACS","title_en":"Factor XI inhibition: the hypothesis, the promise and the LIBREXIA ACS lesson","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":6,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"esc-2026","summary_en":"Factor XI inhibition promises antithrombotic effect without the bleeding cost, but the field keeps hitting reality: after asundexian, the 14,000-patient LIBREXIA ACS trial of milvexian was halted for futility in November 2025. The full results, presented at ESC Congress 2026, will determine what remains of the factor XI hypothesis in ACS, while the AF and stroke programmes continue.","created":"2026-08-10T11:55:45Z","updated":"2026-08-10T11:55:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-cvd-ckd","type":"article","url":"https://hartvaat.nl/2026/08/10/hart-en-nier-in-een-richtlijn-waarom-de-esc-ze-samen-behandelt/","title":"Hart en nier in één richtlijn: waarom de ESC ze samen behandelt","title_en":"Heart and kidney in one guideline: why the ESC now treats them together","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":7,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"esc-2026","summary_en":"ESC Congress 2026 delivers the first dedicated ESC guideline on cardiovascular disease in chronic kidney disease, presented Saturday 29 August. It formalises care for a huge overlap population long excluded from trials, arriving exactly as SGLT2 inhibitors, finerenone and GLP-1 agonists have turned cardio-renal protection into a treatable continuum.","created":"2026-08-10T11:55:44Z","updated":"2026-08-28T15:15:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-hf-richtlijn","type":"article","url":"https://hartvaat.nl/2026/08/10/de-nieuwe-esc-hartfalenrichtlijn-wat-er-op-28-augustus-op-tafel-ligt/","title":"De nieuwe ESC-hartfalenrichtlijn: wat er op 28 augustus op tafel ligt","title_en":"The new ESC heart failure guideline: what lands on 28 August","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":7,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"esc-2026","summary_en":"The new ESC heart failure guideline, the first full revision since 2021, is presented on Friday 28 August at ESC Congress 2026, followed by an Ask the Task Force session. Expect consolidation of four-pillar HFrEF therapy and its rapid initiation, a firmer evidence base for HFpEF treatment, and close alignment with the simultaneously released guideline on cardiovascular disease and chronic kidney disease.","created":"2026-08-10T11:55:44Z","updated":"2026-08-10T11:55:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esc26-staree","type":"article","url":"https://hartvaat.nl/2026/08/10/statines-na-je-zeventigste-wat-staree-wel-en-niet-gaat-beantwoorden/","title":"Statines na je zeventigste: wat STAREE wel en niet gaat beantwoorden","title_en":"Statins beyond seventy: what STAREE will and will not answer","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"HartVaat congresredactie","doi":"","source_url":"","authors":[],"significance":7,"published":"2026-08-10","source_date":"2026-08-10","image":"https://hartvaat.nl/global/img/4b1c1141f4af.webp","kennis":["https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"esc-2026","summary_en":"STAREE randomised almost 10,000 healthy Australians aged 70 and over to atorvastatin or placebo, with disability-free survival as its primary endpoint. Presented in Hot Line 2 at ESC Congress 2026, it addresses the largest remaining evidence gap in primary prevention: whether statins help healthy older adults live longer without disability or dementia. Either outcome will directly change everyday consultations about starting, or stopping, statins in older age.","created":"2026-08-10T11:55:44Z","updated":"2026-08-10T11:55:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3edc8ae0829a","type":"article","url":"https://hartvaat.nl/2026/06/23/zwangerschapsgeassocieerd-acuut-nierfalen-pathofysiologie-en-verhoogd-langetermi/","title":"Zwangerschapsgeassocieerd acuut nierfalen: pathofysiologie en verhoogd langetermijnrisico op hart- en vaatziekten","title_en":"Pathophysiology of pregnancy-associated acute kidney injury.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag142","source_url":"https://doi.org/10.1093/ndt/gfag142","authors":["Kianoush B Kashani","Lizemarie Wium","Marlies Ostermann","Ravindra L Mehta","Claudio Ronco","Cathy Nelson-Piercy","Carlos E Poli-de-Figueiredo","Manisha Sahay"],"significance":5,"published":"2026-08-09","source_date":"2026-06-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This narrative review outlines the pathophysiology of pregnancy-associated acute kidney injury (PrAKI), which affects an estimated 40–100 per 10,000 pregnancies. The authors highlight how pregnancy-specific hemodynamic shifts, placental ischemia, and immune dysregulation impair renal reserve and endothelial function, leading to long-term risks of chronic kidney disease and cardiovascular disease. Recognizing these mechanisms underscores the need for structured long-term follow-up and cardiovascular risk management in women who have experienced PrAKI.","created":"2026-08-03T01:01:14Z","updated":"2026-08-10T10:36:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7abceeb0c198","type":"article","url":"https://hartvaat.nl/2026/06/23/lifestyle-modificatie-en-metabole-therapieen-bij-cardiometabole-hfpef-overzicht/","title":"Lifestyle-modificatie en metabole therapieën bij cardiometabole HFpEF — overzicht","title_en":"Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of cardiovascular development and disease","doi":"10.3390/jcdd13070291","source_url":"https://doi.org/10.3390/jcdd13070291","authors":["Daniel G Yang","Shaleen Thakur","Harriet Akunor","Richard B Stacey","Bharathi Upadhya"],"significance":5,"published":"2026-08-09","source_date":"2026-06-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"Cardiometabolic HFpEF is increasingly recognized as a systemic syndrome driven by visceral adiposity and chronic inflammation. This narrative review highlights that combined aerobic and resistance exercise training, with or without caloric restriction, significantly improves exercise capacity, physical function, and quality of life in clinically stable patients. The authors also emphasize that SGLT2 inhibitors and GLP-1 receptor agonists exert beneficial effects largely through metabolic pathways. For clinicians, the findings reinforce lifestyle modification and early metabolic pharmacotherapy as cornerstone strategies in the management of cardiometabolic HFpEF.","created":"2026-08-03T00:57:43Z","updated":"2026-08-10T10:36:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"818c83788913","type":"article","url":"https://hartvaat.nl/2026/06/23/rhbnp-therapie-vermindert-congestie-en-dyspnoe-bij-rechterhartfalen-door-longhyp/","title":"rhBNP-therapie vermindert congestie en dyspnoe bij rechterhartfalen door longhypertensie","title_en":"Retrospective Evaluation of Recombinant Human Brain Natriuretic Peptide Therapy for Decompensated Right Heart Failure Across Pulmonary Hypertension Groups.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62071213","source_url":"https://doi.org/10.3390/medicina62071213","authors":["Lixing Hu","Qing Zhao","Zhihui Zhao","Qin Luo","Li Deng","Zhihong Liu"],"significance":4,"published":"2026-08-09","source_date":"2026-06-23","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"A retrospective evaluation of 763 patients with pulmonary hypertension (groups 1, 2, and 4) demonstrates that adding recombinant human brain natriuretic peptide (rhBNP) to conventional therapy significantly reduces markers of cardiac congestion, including NT-proBNP, bilirubin, and body weight. Clinical improvement in dyspnea and lower limb edema was observed in 49.9% and 66.6% of cases, respectively, with a low overall adverse event rate (0.66%). While these findings support rhBNP as a useful adjunct for decompensated right heart failure, the authors emphasize the need for close blood pressure monitoring, particularly in high-risk group 1 pulmonary arterial hypertension patients.","created":"2026-08-03T00:53:44Z","updated":"2026-08-10T10:36:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5cf84598dd8","type":"article","url":"https://hartvaat.nl/2026/06/23/vldl-en-hdl-tg-verhoogd-bij-overgewicht-bij-kinderen-geavanceerd-lipoproteinepro/","title":"VLDL en HDL-tg verhoogd bij overgewicht bij kinderen — geavanceerd lipoproteïneprofiel toont extra informatie","title_en":"Composition and Characterization of the Different Lipoproteins in Overweight/Obese Children vs. Normal-Weight Children.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"Biomolecules","doi":"10.3390/biom16070927","source_url":"https://doi.org/10.3390/biom16070927","authors":["Jose Cuenca-Alcocel","Lorena Villalba-Heredia","Daiana Ibarretxe","Jose A Casajús","Jose M Arbonés-Mainar","Pilar Calmarza"],"significance":3,"published":"2026-08-09","source_date":"2026-06-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"An observational study compared advanced lipoprotein profiling via 1H-NMR in overweight/obese children versus normal-weight peers. The overweight/obese group showed significantly higher levels of VLDL-C, VLDL-TG, IDL-TG, HDL-TG, total VLDL particle count, and REM-C, alongside smaller mean LDL particle size. These findings highlight early metabolic alterations associated with childhood excess weight. Advanced lipoprotein profiling may provide incremental risk information beyond standard lipid panels.","created":"2026-08-03T00:48:40Z","updated":"2026-08-10T10:36:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6015b144b7a","type":"article","url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","title":"Inclisiran als monotherapie verlaagt LDL-C met 47,5% in Chinese volwassenen — VICTORION-Mono","title_en":"Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.06.016","source_url":"https://doi.org/10.1016/j.jacl.2026.06.016","authors":["Yong Huo","Janna Sand Dejmek","Zuyi Yuan","Daoquan Peng","Jorge Mena-Madrazo","Karen X Liu","Mengli Zhang","Yuan Ji","Xiaochun Xing","Zhuhua Yao","Yuyang Liu","Weihong Jiang","Lingyan Bai"],"significance":5,"published":"2026-08-09","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The phase-3 VICTORION-Mono trial evaluated inclisiran monotherapy in 207 Chinese adults with elevated LDL-C and low-to-moderate ASCVD risk. At day 150, inclisiran reduced LDL-C by 47.5% compared with placebo, with sustained lipid-lowering effects and significant reductions in Lp(a) and ApoB through day 360. The treatment was well-tolerated, supporting inclisiran as a viable monotherapy option for dyslipidemia management in this population.","created":"2026-08-03T00:45:51Z","updated":"2026-08-10T10:36:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de2d080bcdfe","type":"article","url":"https://hartvaat.nl/2026/06/24/meer-kip-dan-rundvlees-of-vis-bij-avondmaaltijd-gekoppeld-aan-grotere-bloeddrukd/","title":"Meer kip dan rundvlees of vis bij avondmaaltijd gekoppeld aan grotere bloeddrukdaling — MED-HDP","title_en":"Observational Assessments of Chicken, Beef, and Seafood Proportions with a Mediterranean-Style Healthy Dietary Pattern and Cardiovascular Risk Factor Changes: Post Hoc Analysis of a Controlled Feeding Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Nutrients","doi":"10.3390/nu18132062","source_url":"https://doi.org/10.3390/nu18132062","authors":["Eric M Davis","Robert E Bergia","Austin S Hartman","Rikard Landberg","Gabriele Riccardi","Wayne W Campbell"],"significance":4,"published":"2026-08-08","source_date":"2026-06-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/preventie/leefstijladvisering-cardiologie/"],"congress":"","summary_en":"A post hoc analysis of a 12-week controlled feeding trial (n=52) in adults with metabolic syndrome found that a Mediterranean-style dietary pattern improved blood pressure and lipid profiles. Within the diet, higher consumption of chicken at dinner was modestly associated with greater reductions in systolic and diastolic blood pressure compared to beef or seafood, with no significant differences observed for lipid parameters. These results reinforce the cardiovascular benefits of a Mediterranean diet, though the specific association with chicken requires independent validation before influencing clinical dietary advice.","created":"2026-08-01T01:24:19Z","updated":"2026-08-10T10:36:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2f27d43301c1","type":"article","url":"https://hartvaat.nl/2026/06/24/vexus-scoring-biedt-completer-beeld-van-congestie-bij-hartfalen/","title":"VExUS-scoring biedt completer beeld van congestie bij hartfalen","title_en":"Rethinking Congestion in Heart Failure from Volume Overload to Venous Pressure and Organ Disfunction with VExUS.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62071224","source_url":"https://doi.org/10.3390/medicina62071224","authors":["Marcello Marchetta","Lucio Giuseppe Granata","Anna Rosa Napoli","Fabiana Cipolla","Giuseppe Massimo Sangiorgi","Giuseppina Maura Francese","Simona Giubilato"],"significance":5,"published":"2026-08-08","source_date":"2026-06-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/","https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"Congestion drives symptoms and hospitalizations in heart failure, yet bedside assessment remains challenging. This narrative review discusses the Venous Excess Ultrasound (VExUS) score, which integrates inferior vena cava, hepatic, portal, and intrarenal Doppler assessments to better capture venous pressure transmission and end-organ impact. Observational data link VExUS abnormalities to invasive hemodynamics, acute kidney injury, and mortality, but randomized trials are still lacking. The authors recommend VExUS as a complementary tool within a multimodal congestion assessment strategy.","created":"2026-08-01T01:20:22Z","updated":"2026-08-10T10:36:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"92cbe1082232","type":"article","url":"https://hartvaat.nl/2026/06/24/sglt2-remmers-en-bloeddrukdoelen-bij-hypertensief-hfpef-een-overzicht-van-richtl/","title":"SGLT2-remmers en bloeddrukdoelen bij hypertensief HFpEF — een overzicht van richtlijnen en bewijs","title_en":"Hypertensive Heart Failure with Preserved Ejection Fraction: Guidelines vs. Randomized Controlled Trials Evidence Gaps.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62071222","source_url":"https://doi.org/10.3390/medicina62071222","authors":["Georgios Mavraganis","Christos Fragoulis","Georgios Georgiopoulos","Kyriaki Mavromoustakou","Kyriakos Dimitriadis","Konstantinos Aznaouridis","Christina Chrysohoou","Kimon Stamatelopoulos","Konstantinos Tsioufis"],"significance":5,"published":"2026-08-08","source_date":"2026-06-24","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/betablokkers-hypertensie/"],"congress":"","summary_en":"This narrative review evaluates current evidence for blood pressure targets (<130/80 mmHg) and SGLT2 inhibitor therapy in patients with hypertensive heart failure with preserved ejection fraction (HFpEF). Post-hoc analyses from EMPEROR-Preserved and DELIVER demonstrate consistent reductions in heart failure events with SGLT2 inhibitors (pooled HR 0.79), alongside modest systolic blood pressure lowering. While biomarkers such as sST2 and NT-proBNP aid risk stratification, significant evidence gaps remain regarding guideline harmonisation, device therapies like renal denervation, and real-world adherence. The review underscores the need for phenotype-driven management and dedicated randomised trials to translate current recommendations into routine clinical practice for this growing patient population.","created":"2026-08-01T01:16:53Z","updated":"2026-08-10T10:36:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb315e578da1","type":"article","url":"https://hartvaat.nl/2026/10/01/parodontitis-kan-via-systemische-ontsteking-bijdragen-aan-hartfalen-narratieve-r/","title":"Parodontitis kan via systemische ontsteking bijdragen aan hartfalen — narratieve review","title_en":"Association between periodontitis and heart failure: Mechanisms and clinical implications (Review).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Molecular medicine reports","doi":"10.3892/mmr.2026.13974","source_url":"https://doi.org/10.3892/mmr.2026.13974","authors":["Xinyue Zhang","Xiaoli An"],"significance":3,"published":"2026-08-08","source_date":"2026-10-01","image":"https://hartvaat.nl/global/img/1246efe56d5a.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This narrative review explores the potential mechanisms linking periodontitis to heart failure, including systemic inflammation, microbial dysbiosis, and immune dysregulation. While observational data suggest an association, current evidence is insufficient to establish causality or demonstrate that dental interventions improve heart failure outcomes. Clinically, routine periodontal screening is not yet recommended, but oral health assessment may be considered as part of a comprehensive, multidisciplinary heart failure management strategy.","created":"2026-08-01T01:13:01Z","updated":"2026-08-10T10:36:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ffec8564847","type":"article","url":"https://hartvaat.nl/2026/10/15/lage-voorspelde-adherentie-verhoogt-stroke-risico-bij-af-patienten-die-starten-m/","title":"Lage voorspelde adherentie verhoogt stroke-risico bij AF-patiënten die starten met orale anticoagulatie","title_en":"Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134660","source_url":"https://doi.org/10.1016/j.ijcard.2026.134660","authors":["Jos Perdeck","Reinoud E Knops","Joris R de Groot","Martin C Burke","Vivek Y Reddy","Tom F Brouwer"],"significance":5,"published":"2026-08-08","source_date":"2026-10-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"In a retrospective cohort study of 11,233 AF patients with a CHA₂DS₂-VASc score ≥ 2 initiating oral anticoagulation, a validated Medication Adherence Score (MAS) was used to predict adherence levels. Patients with low predicted adherence faced a significantly higher 12-month risk of ischemic stroke compared to those with high adherence (subdistribution HR 0.67; 95% CI 0.56-0.80; cumulative incidence 5.08% vs. 7.97%). These findings suggest that applying the MAS at OAC initiation could help clinicians identify high-risk patients for targeted adherence support, potentially improving stroke prevention in routine practice.","created":"2026-08-01T01:09:42Z","updated":"2026-08-10T10:36:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b90eb3d21c41","type":"article","url":"https://hartvaat.nl/2026/10/15/ice-gestuurde-laac-toont-lage-stroke-en-bloedingsrisicos-op-lange-termijn/","title":"ICE-gestuurde LAAC toont lage stroke- en bloedingsrisico’s op lange termijn","title_en":"Long-term outcomes of ICE-guided left atrial appendage occlusion from a large single-center experience.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134664","source_url":"https://doi.org/10.1016/j.ijcard.2026.134664","authors":["Luigi Emilio Pastormerlo","Angela Buonpane","Giancarlo Trimarchi","Francesco Orazi","Giovanni Benedetti","Marta Casula","Augusto Esposito","Massimiliano Mariani","Andreina D'Agostino","Federica Marchi","Simone Sorbo","Alessio Lilli","Fausto Pizzino","Umberto Paradossi","Sergio Berti"],"significance":5,"published":"2026-08-07","source_date":"2026-10-15","image":"","kennis":[],"congress":"","summary_en":"A single-center retrospective cohort of 411 patients undergoing intracardiac echocardiography (ICE)-guided left atrial appendage closure (LAAC) between 2009 and 2024 demonstrated a 99.8% technical success rate and a 5.1% major adverse event rate. Over a mean follow-up of 44 months, the annualized stroke/TIA rate was 1.7% (73% lower than CHA₂DS₂-VASc predicted) and major bleeding occurred at 1.1% per year. These findings support ICE guidance as a safe and effective alternative to TEE for LAAC, offering favorable long-term ischemic and bleeding outcomes in a high-risk atrial fibrillation population.","created":"2026-08-01T01:04:58Z","updated":"2026-08-10T10:36:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82c0179fd940","type":"article","url":"https://hartvaat.nl/2026/09/01/cardiorenale-bescherming-door-sglt2-remmers-glp-1-agonisten-en-mra-s-bij-type-1-/","title":"Cardiorenale bescherming door SGLT2-remmers, GLP-1-agonisten en MRA's bij type 1-diabetes","title_en":"Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.007","source_url":"https://doi.org/10.1016/j.ecl.2026.04.007","authors":["Stuti Fernandes","Barbara Hettinger","Lynn Ang","Rodica Pop-Busui"],"significance":5,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This narrative review synthesizes current evidence on the cardiorenal benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists in patients with type 1 diabetes. While these drug classes have fundamentally transformed cardiovascular and renal care in type 2 diabetes, robust long-term outcome data in type 1 diabetes remain limited. Clinicians should consider these agents on a case-by-case basis for cardiorenal risk reduction, pending further dedicated trials to establish definitive safety and efficacy profiles in this population.","created":"2026-08-01T00:57:48Z","updated":"2026-08-10T10:36:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"96c77cc79366","type":"article","url":"https://hartvaat.nl/2026/09/01/naast-insuline-zijn-nieuwe-medicijnen-nodig-om-het-hart-en-vaatrisico-bij-type-1/","title":"Naast insuline zijn nieuwe medicijnen nodig om het hart- en vaatrisico bij type 1-diabetes te verlagen","title_en":"Beyond Insulin: Why Type 1 Diabetes Mellitus Needs More?","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.001","source_url":"https://doi.org/10.1016/j.ecl.2026.04.001","authors":["Huajing Ni","Jennifer R Snaith","Jerry R Greenfield"],"significance":5,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Patients with type 1 diabetes continue to face elevated cardiovascular risk and mortality that cannot be fully explained by traditional risk factors or dysglycemia alone. This narrative review highlights the contribution of glycemic variability, insulin-related weight gain, and insulin resistance, emphasizing the need for additional pharmacological agents targeting these pathways. However, data on long-term outcomes and hard cardiovascular endpoints remain sparse. Clinicians should be aware of these mechanisms and the current evidence gap when managing cardiometabolic risk in type 1 diabetes.","created":"2026-08-01T00:52:17Z","updated":"2026-08-10T10:36:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a3b9d306fc8a","type":"article","url":"https://hartvaat.nl/2026/09/01/cardiorenale-risicos-bij-type-1-diabetes-een-overzicht-van-de-huidige-stand-van-/","title":"Cardiorenale risico’s bij type 1-diabetes — een overzicht van de huidige stand van zaken","title_en":"Current State of Cardiorenal Disease in People with Type 1 Diabetes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.004","source_url":"https://doi.org/10.1016/j.ecl.2026.04.004","authors":["Stuti Fernandes","Barbara Hettinger","Lynn Ang","Rodica Pop-Busui"],"significance":3,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"Individuals with type 1 diabetes (T1D) face a substantially elevated risk of cardiovascular disease, heart failure, and chronic kidney disease. While novel glucose-lowering agents have demonstrated significant cardiorenal protection in type 2 diabetes, patients with T1D have historically been excluded from most outcome trials. This review synthesizes current evidence on the high cardiorenal burden in T1D and highlights the clinical need for targeted risk management and dedicated research in this population.","created":"2026-08-01T00:49:05Z","updated":"2026-08-10T10:36:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c84a3a24334","type":"article","url":"https://hartvaat.nl/2026/09/01/sglt2-remmers-glp-1-agonisten-en-finerenone-voor-nierbescherming-bij-type-1-diab/","title":"SGLT2-remmers, GLP-1-agonisten en finerenone voor nierbescherming bij type 1-diabetes","title_en":"Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.015","source_url":"https://doi.org/10.1016/j.ecl.2026.04.015","authors":["Michael S Hughes","Francisco J Pasquel"],"significance":5,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/"],"congress":"","summary_en":"This narrative review outlines the pathophysiology of diabetic kidney disease in type 1 diabetes and evaluates the emerging evidence for adjunctive kidney-protective agents, including SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone. While large-scale outcome trials specific to type 1 diabetes are still maturing, current mechanistic data and early clinical findings support their potential role in mitigating hyperfiltration and inflammatory injury. Clinicians should anticipate a shift toward integrating these cardiorenal therapies into standard management protocols for type 1 diabetes as evidence continues to accumulate.","created":"2026-08-01T00:45:35Z","updated":"2026-08-10T10:36:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e81cc95daa37","type":"article","url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","title":"Machine learning voorspelt diureticumrespons bij acuut hartfalen — DRC-AHF","title_en":"A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag185","source_url":"https://doi.org/10.1093/eschf/xvag185","authors":["Gracjan Iwanek","Mateusz Guzik","Amadeusz Oleszczak","Iga Karbowiak","Dominik Marciniak","Matteo Pagnesi","Julio Nuñez","Robert Zymliński","Piotr Ponikowski","Jan Biegus"],"significance":5,"published":"2026-08-06","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"A prospective single-centre study developed a machine learning model to predict 6-hour urine output after intravenous furosemide in acute heart failure, using eGFR and spot urine sodium/creatinine measured two hours post-dose. In an external validation cohort (n=50), the model showed strong correlation with observed output (r=0.90) and correctly classified diuresis response in 88% of patients, outperforming the standard NRPE equation (58%). While the tool offers a promising approach to personalizing diuretic therapy in diuretic-resistant AHF, its single-centre derivation and small validation sample warrant multicentre external validation before routine clinical adoption.","created":"2026-07-30T01:35:07Z","updated":"2026-08-10T10:36:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37d67c5c974c","type":"article","url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","title":"Finerenone verlaagt hart- en vaatrisico via vroege daling van UACR en systolische bloeddruk — FIDELITY-analyse","title_en":"Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag150","source_url":"https://doi.org/10.1093/ndt/gfag150","authors":["Rajiv Agarwal","Ambarish Pandey","Scott D Solomon","Muthiah Vaduganathan","Faiez Zannad"],"significance":6,"published":"2026-08-06","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A causal mediation analysis of the pooled FIDELITY trial data (n = 12,143) demonstrates that the cardiovascular benefit of finerenone in patients with type 2 diabetes and chronic kidney disease is largely driven by early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure. Within four months, UACR and systolic blood pressure changes accounted for 39% and 21% of the long-term cardiovascular risk reduction, respectively, while shifts in body weight and serum potassium did not mediate outcomes. These findings highlight UACR and blood pressure as complementary early markers to monitor cardiovascular efficacy when initiating finerenone therapy.","created":"2026-07-30T01:30:57Z","updated":"2026-08-10T10:36:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0638ff453ccc","type":"article","url":"https://hartvaat.nl/2026/06/26/peptidehormooncombinaties-bieden-superieure-effectiviteit-bij-metabole-multimorb/","title":"Peptidehormooncombinaties bieden superieure effectiviteit bij metabole multimorbiditeit","title_en":"Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Pharmacological reviews","doi":"10.1016/j.pharmr.2026.100150","source_url":"https://doi.org/10.1016/j.pharmr.2026.100150","authors":["Zara Siu Wa Chui","Yaqian Xue","Xiaoping Wu","Aimin Xu"],"significance":6,"published":"2026-08-06","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/farmacologie/drug-drug-interacties-cardiologie/"],"congress":"","summary_en":"This narrative review evaluates the pharmacological and clinical advances of combination therapies using peptide hormone co-agonists, such as GLP-1 combined with FGF21 or GDF15 analogs, for chronic metabolic diseases including obesity, type 2 diabetes, MASLD, and cardiovascular disease. The authors highlight that synergistic targeting of multiple metabolic pathways yields superior efficacy over monotherapy, addressing the growing burden of metabolic multimorbidity. For clinicians, these findings outline the evolving therapeutic landscape and underscore the potential of next-generation co-agonists to transform cardiometabolic care, while noting ongoing challenges in clinical development and safety profiling.","created":"2026-07-30T01:24:20Z","updated":"2026-08-10T10:36:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9098f972e08b","type":"article","url":"https://hartvaat.nl/2026/06/26/sglt2-remmers-kunnen-hyperkaliemie-gerelateerd-stoppen-van-raas-remmers-voorkome/","title":"SGLT2-remmers kunnen hyperkaliëmie-gerelateerd stoppen van RAAS-remmers voorkomen bij MRA-gebruik","title_en":"Sodium-Glucose Co-Transporter 2 Inhibitors and Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors During Mineralocorticoid Receptor Antagonist Therapy: A Real-World Cohort Study.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Pharmacy (Basel, Switzerland)","doi":"10.3390/pharmacy14040091","source_url":"https://doi.org/10.3390/pharmacy14040091","authors":["Abdullah Hashim Almalki","Nourah Abdulaziz Alorainan","Muhjah Abdulhakim Bukhari","Fahad Ali Dokhaikh","Salma Mohamed Abbas Quqandi","Reyan Hatem Merdad","Laila Fahad Sadagah"],"significance":5,"published":"2026-08-06","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"In a retrospective cohort of 905 patients, adding a mineralocorticoid receptor antagonist (MRA) to RAAS inhibition doubled the risk of hyperkalemia. However, co-prescription of an SGLT2 inhibitor neutralized the association between MRA use and hyperkalemia-driven RAAS inhibitor discontinuation: discontinuation rates increased more than fivefold without an SGLT2 inhibitor, but remained low in those receiving one. This real-world data suggests that SGLT2 inhibitors may help preserve RAASi and MRA therapy in patients prone to hyperkalemia, supporting their early integration in cardiorenal management.","created":"2026-07-30T01:20:27Z","updated":"2026-08-10T10:36:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ff8acaccc32f","type":"article","url":"https://hartvaat.nl/2026/06/26/correctie-van-ldl-c-voor-lipoproteine-a-verbetert-diagnose-familiaire-hyperchole/","title":"Correctie van LDL-C voor lipoproteïne(a) verbetert diagnose familiaire hypercholesterolemie","title_en":"Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohort.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.06.017","source_url":"https://doi.org/10.1016/j.jacl.2026.06.017","authors":["Rasmus Barkowski","Lorenz Rieck","Valentin Max Vetter","Thomas Grenkowitz","Dominik Spira","Knut Mai","Thomas Bobbert","Ursula Kassner","Ilja Demuth"],"significance":5,"published":"2026-08-06","source_date":"2026-06-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/"],"congress":"","summary_en":"A German cohort study of 384 patients suspected of familial hypercholesterolemia (FH) demonstrates that adjusting LDL-C for lipoprotein(a) improves diagnostic accuracy. Correcting LDL-C by 17.3% of the measured Lp(a) level significantly increased specificity for both the DLCN score and a fixed LDL-C cutoff, primarily by reclassifying false positives among genetically unconfirmed patients without compromising sensitivity. Implementing this simple correction could streamline FH screening, reduce unnecessary genetic testing, and minimize overdiagnosis in routine lipid management.","created":"2026-07-30T01:16:18Z","updated":"2026-08-10T10:36:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"172253cf7b60","type":"article","url":"https://hartvaat.nl/2026/06/27/laag-cachexie-index-voorspelt-overleving-en-heropname-bij-hartfalenpatienten/","title":"Laag cachexie-index voorspelt overleving en heropname bij hartfalenpatiënten","title_en":"The Prognostic Impact of the Cachexia Index in Patients Hospitalized with Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62071246","source_url":"https://doi.org/10.3390/medicina62071246","authors":["Vahit Can Cavdar","Hidayet Ozan Arabaci","Zafer Guven","Emine Meltem","Hatice Ozkul","Ayse Satilmisoglu","Kader Onay","Elif Kilic Dinler","Ismail Can Ciftci","Yalcin Gokmen","Mert Aric","Ayli Heydari","Cagdas Kaya","Veysi Kapagan","Eser Onur Cakir","Ahmet Oz"],"significance":4,"published":"2026-08-05","source_date":"2026-06-27","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-coronaire-calcium-score/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"In a retrospective single-center cohort of 127 patients hospitalized for decompensated heart failure, a low cachexia index (CXI)—calculated from skeletal muscle mass, serum albumin, and the neutrophil-to-lymphocyte ratio—was strongly associated with all-cause mortality and recurrent hospitalizations. Patients with a CXI below 20.87 had a mortality rate of 80.5% and a median of 4 heart failure-related readmissions, compared to 4.7% mortality and 0.5 readmissions in those with a high CXI. While the CXI shows promise as an integrative prognostic tool for risk stratification, its clinical utility requires validation in larger, multicenter prospective studies.","created":"2026-07-30T01:08:29Z","updated":"2026-08-10T10:36:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"551c740a1134","type":"article","url":"https://hartvaat.nl/2026/06/29/functioneel-nierreservoir-als-aanvulling-op-kdigo-cga-bij-chronische-nierziekte/","title":"Functioneel nierreservoir als aanvulling op KDIGO-CGA bij chronische nierziekte","title_en":"Renal Functional Reserve-Informed Personalized Renoprotection in Chronic Kidney Disease: A Proposed Extension of the KDIGO CGA Framework.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Biomedicines","doi":"10.3390/biomedicines14071478","source_url":"https://doi.org/10.3390/biomedicines14071478","authors":["Dmytro D Ivanov","Anatoliy I Gozhenko","Volodymyr V Bezruk","Mariia D Ivanova"],"significance":3,"published":"2026-08-05","source_date":"2026-06-29","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This narrative review proposes a functional-hemodynamic extension to the standard KDIGO CGA framework for chronic kidney disease by integrating renal functional reserve (RFR), blood pressure, volume status, and tubular markers. The authors distinguish established renoprotective therapies (RAASi, SGLT2i, non-steroidal MRAs) from conceptual treatment sequencing hypotheses, while clarifying that the model remains a hypothesis-generating tool rather than a validated clinical algorithm. This framework aids clinicians in physiological phenotyping and interpreting early eGFR changes, ultimately guiding the design of prospective studies to test RFR's independent prognostic value.","created":"2026-07-30T01:04:12Z","updated":"2026-08-10T10:36:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d7562a57093","type":"article","url":"https://hartvaat.nl/2026/10/01/dapagliflozin-kosteneffectief-bij-chronisch-hartfalen-economische-evaluatie-in-a/","title":"Dapagliflozin kosteneffectief bij chronisch hartfalen — economische evaluatie in Argentinië","title_en":"Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Lancet regional health. Americas","doi":"10.1016/j.lana.2026.101571","source_url":"https://doi.org/10.1016/j.lana.2026.101571","authors":["Javier Santiago Araujo","Francisco Moioni","Diego Sebastián Novielli","Germán Andrés Jelusic","Sofía Inés Lucini","Jeremías Augusto Zabalo","José Alberto Spala","María Celeste Piervincenzi"],"significance":5,"published":"2026-08-05","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"A cost-utility analysis in Argentina demonstrates that adding dapagliflozin to standard therapy for chronic heart failure is cost-effective. Based on DAPA-HF and DELIVER trial data, dapagliflozin yielded an incremental gain of 0.76 and 0.44 QALYs, with ICERs of US$6,672 and US$10,371 per QALY, respectively. At a willingness-to-pay threshold of 1 GDP per capita, the probability of cost-effectiveness was 97% for HFrEF and 73% for HFpEF/mHFrEF. While region-specific, these findings reinforce the established value of SGLT2 inhibitors in heart failure and highlight the importance of pricing strategies and reimbursement policies for equitable patient access.","created":"2026-07-30T00:54:28Z","updated":"2026-08-10T10:37:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95d07304f716","type":"article","url":"https://hartvaat.nl/2026/09/01/hogere-ziekenhuisvolumes-verbeteren-efficientie-bij-transcarotide-tavr-maar-mort/","title":"Hogere ziekenhuisvolumes verbeteren efficiëntie bij transcarotide TAVR — maar mortaliteit blijft gelijk","title_en":"Hospital volume and efficiency in transcarotid transcatheter aortic valve replacement: Insights from a national database of 10,000+ cases.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JTCVS structural and endovascular","doi":"10.1016/j.xjse.2026.100123","source_url":"https://doi.org/10.1016/j.xjse.2026.100123","authors":["Gloria Zacharias","Connor Moynihan","Daohai Yu","Xiaoning Lu","Karan Patel","William Moser","Suyog Mokashi"],"significance":5,"published":"2026-08-05","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"A retrospective analysis of over 10,000 transcarotid TAVR procedures across 118 US academic centers reveals that higher hospital volumes are associated with greater resource efficiency, including shorter length of stay (4.9 vs 7.5 days) and reduced ICU admissions (42.5% vs 70.7%). Mortality and complication rates, however, remain comparable across volume quartiles, likely reflecting lower baseline patient complexity at high-volume sites. These findings suggest that procedural volume primarily impacts logistical efficiency rather than short-term safety outcomes for transcarotid TAVR.","created":"2026-07-30T00:48:48Z","updated":"2026-08-10T10:37:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef5c63a10afb","type":"article","url":"https://hartvaat.nl/2026/09/01/menopauze-en-cardiovasculaire-veroudering-preventiekansen-in-de-middenleeftijd/","title":"Menopauze en cardiovasculaire veroudering: preventiekansen in de middenleeftijd","title_en":"The Menopausal Transition and Cardiovascular Aging: Implications for Prevention in Midlife.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Obstetrics and gynecology clinics of North America","doi":"10.1016/j.ogc.2026.04.003","source_url":"https://doi.org/10.1016/j.ogc.2026.04.003","authors":["Ziyuan Wang","Samar R El Khoudary"],"significance":5,"published":"2026-08-05","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"The menopausal transition marks a critical window for cardiovascular health, as normal age-related vascular and myocardial changes can accelerate in the presence of cardiometabolic risk factors and unhealthy lifestyles. This narrative review highlights how modifiable targets, particularly lifestyle modification and standardized cardiovascular health scores, offer a practical framework for early risk stratification in midlife women. Implementing proactive preventive strategies during this period can significantly reduce the long-term burden of cardiovascular disease in women.","created":"2026-07-30T00:45:16Z","updated":"2026-08-10T10:37:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"659193548e64","type":"article","url":"https://hartvaat.nl/2026/06/27/frailte-versnelt-hartfalenprogressie-en-vermindert-therapietolerantie/","title":"Frailte versnelt hartfalenprogressie en vermindert therapietolerantie","title_en":"Frailty and Heart Failure: An Integrated Review of a Bidirectional Relationship.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag178","source_url":"https://doi.org/10.1093/eschf/xvag178","authors":["Izabella Uchmanowicz","Ercole Vellone","Christopher S Lee","Robbert J J Gobbens","Camilla Hage","Ekaterini Lambrinou","Bartosz Uchmanowicz","Cristiana Vitale","Michał Czapla"],"significance":6,"published":"2026-08-04","source_date":"2026-06-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This integrated review examines the bidirectional relationship between frailty and heart failure in older adults, highlighting how frailty independently predicts incident HF while HF accelerates frailty progression through inflammation, sarcopenia, and deconditioning. Frailty is strongly associated with higher mortality, reduced quality of life, and poorer tolerance of guideline-directed medical therapy, with the newly proposed Heart Failure Frailty Score (HFFS) offering a dedicated assessment tool. Clinically, routine frailty screening and targeted interventions—including exercise rehabilitation, nutritional support, and structured medication review—are essential to optimise outcomes in this vulnerable population.","created":"2026-07-29T01:12:37Z","updated":"2026-08-10T10:37:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eba2370ffd2a","type":"article","url":"https://hartvaat.nl/2026/06/27/tavr-bij-patienten-65-jaar-hogere-sterfte-en-heropnames-dan-chirurgie-maar-onvol/","title":"TAVR bij patiënten ≤65 jaar: hogere sterfte en heropnames dan chirurgie, maar onvoldoende bewijs — overzicht","title_en":"Transcatheter Aortic Valve Replacement in Patients Aged 65 Years and Younger: Unresolved Issues and Future Directions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Life (Basel, Switzerland)","doi":"10.3390/life16071075","source_url":"https://doi.org/10.3390/life16071075","authors":["Julius Jelisejevas","Giacomo Maria Cioffi","Ioannis Skalidis","Serban Puricel","Ali Husain","David A Wood","Mariama Akodad","Peter Wenaweser","Pascal Meier","Mario Togni","Stéphane Cook"],"significance":5,"published":"2026-08-04","source_date":"2026-06-27","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/farmacologie/p2y12-remmers-vergelijking/"],"congress":"","summary_en":"This narrative review examines transcatheter aortic valve replacement (TAVR) in patients aged 65 and younger, a population where guidelines still prefer surgical aortic valve replacement (SAVR). Observational data indicate higher mid-term mortality and heart failure readmissions following TAVR compared with SAVR, though these outcomes are likely confounded by the higher comorbidity burden and surgical risk in patients selected for the procedure. With no dedicated randomized trials and unresolved questions regarding valve durability and future redo interventions, the choice between TAVR and SAVR in younger patients remains highly centre-dependent and requires careful individualized assessment.","created":"2026-07-29T01:08:51Z","updated":"2026-08-10T10:37:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b2681c4afc1","type":"article","url":"https://hartvaat.nl/2026/06/29/familiaire-hypercholesterolemie-en-hypertriglyceridemie-nieuw-diagnostisch-algor/","title":"Familiaire hypercholesterolemie en hypertriglyceridemie: nieuw diagnostisch algoritme combineert genetica, ApoB en Lp(a)","title_en":"From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62071257","source_url":"https://doi.org/10.3390/medicina62071257","authors":["Dragos Cozma","Daniel Florin Lighezan","Cristina Tudoran","Oana Raluca Voinescu","Cristian Mornos"],"significance":5,"published":"2026-08-04","source_date":"2026-06-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/"],"congress":"","summary_en":"This narrative review highlights the limitations of current phenotypic diagnostic criteria for familial hypercholesterolemia (FH) and familial hypertriglyceridemia (FHTG), such as the DLCN score, and proposes a new four-step algorithm integrating genetic testing, ApoB quantification, and lifetime Lp(a) screening. Evidence from Mendelian randomization studies confirms that cardiovascular risk in these conditions is driven by ApoB-containing particles and remnant cholesterol rather than LDL-C or triglycerides alone. For clinical practice, this underscores the need to shift from LDL-C-centric to particle- and genotype-driven diagnostic pathways, improving early detection and cascade screening in primary care and lipid clinics.","created":"2026-07-29T01:03:02Z","updated":"2026-08-10T10:37:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9911af4b1d4a","type":"article","url":"https://hartvaat.nl/2026/06/30/infectieuze-endocarditis-verschuiving-naar-oudere-patienten-met-comorbiditeiten-/","title":"Infectieuze endocarditis: verschuiving naar oudere patiënten met comorbiditeiten en medische hulpmiddelen","title_en":"Changing Patterns in Infective Endocarditis: A Contemporary Epidemiological Perspective.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Pathogens (Basel, Switzerland)","doi":"10.3390/pathogens15070697","source_url":"https://doi.org/10.3390/pathogens15070697","authors":["Vasiliki Rapti","Anna-Pelagia Magiorakos","Efthymia Giannitsioti","Garyfallia Poulakou"],"significance":4,"published":"2026-08-04","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/","https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"This narrative review outlines the shifting epidemiology of infective endocarditis (IE), highlighting a transition from younger patients with structural heart disease to older individuals with multiple comorbidities and frequent healthcare exposure. The increasing prevalence of end-stage renal disease, immunosuppression, intravenous drug use, and implanted cardiac devices has broadened the susceptible population and altered microbiological patterns, with staphylococci and enterococci now dominating. Clinicians should recognize this evolving risk profile, as it necessitates targeted prevention strategies around prosthetic valves and cardiac devices, alongside a heightened index of suspicion in complex, multimorbid patients.","created":"2026-07-29T00:58:27Z","updated":"2026-08-10T10:37:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f2570a7cdb9e","type":"article","url":"https://hartvaat.nl/2026/05/01/hartfalen-als-belangrijkste-risicofactor-voor-amyloidose-bij-carpaaltunnelsyndro/","title":"Hartfalen als belangrijkste risicofactor voor amyloidose bij carpaaltunnelsyndroom","title_en":"Carpal Tunnel Syndrome and Other Predictors of Amyloidosis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of hand surgery global online","doi":"10.1016/j.jhsg.2026.100952","source_url":"https://doi.org/10.1016/j.jhsg.2026.100952","authors":["Kathryn E Grabowski","Stephen C Vlay","Peter Gorevic","Marie A Badalamente","David E Komatsu","Lawrence C Hurst"],"significance":5,"published":"2026-08-04","source_date":"2026-05-01","image":"","kennis":[],"congress":"","summary_en":"A retrospective cohort study of carpal tunnel syndrome (CTS) patients identifies heart failure as the strongest associated risk factor for developing amyloidosis within six years. The absolute risk difference was 702 per 100,000 in men and 261 per 100,000 in women. These findings may help clinicians identify CTS patients with heart failure who should be considered for tenosynovial biopsy to screen for ATTR amyloidosis.","created":"2026-07-29T00:53:42Z","updated":"2026-08-10T10:37:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b0db95a8ccc3","type":"article","url":"https://hartvaat.nl/2026/08/01/lipoproteine-afseparatie-bij-refractaire-fh-en-lp-a-verschuivende-rol-naar-vaat-/","title":"Lipoproteïne-afseparatie bij refractaire FH en Lp(a) — verschuivende rol naar vaat- en nierziekten","title_en":"Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","doi":"10.1016/j.transci.2026.104483","source_url":"https://doi.org/10.1016/j.transci.2026.104483","authors":["Menatalla Nadim","Yamac Akgun"],"significance":5,"published":"2026-08-03","source_date":"2026-08-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Lipoprotein apheresis (LA) acutely lowers LDL-C and Lp(a) by 60–80% through extracorporeal removal of apoB-containing particles, remaining the cornerstone therapy for homozygous and severe refractory heterozygous familial hypercholesterolemia. While long-term registry data demonstrate consistent reductions in major adverse cardiovascular events, LA utilization is declining due to PCSK9 inhibitors and inclisiran, with novel RNA-based Lp(a) agents poised to further reshape its role. Emerging observational evidence also supports LA in peripheral arterial disease and steroid-resistant focal segmental glomerulosclerosis via pleiotropic rheologic and anti-inflammatory mechanisms. Clinicians should anticipate a gradual contraction of LA in LDL-centric management, a sustained niche in Lp(a)-driven disease until RNA therapies demonstrate outcome benefits, and a mechanistically plausible but evidence-limited application in select vascular and renal phenotypes.","created":"2026-07-27T01:39:40Z","updated":"2026-08-10T10:37:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b968467af98f","type":"article","url":"https://hartvaat.nl/2026/06/27/oac-monotherapie-is-superieur-aan-combinatie-met-antiplatelets-bij-stabiele-ccs-/","title":"OAC-monotherapie is superieur aan combinatie met antiplatelets bij stabiele CCS en atriumfibrilleren","title_en":"Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Current cardiology reports","doi":"10.1007/s11886-026-02384-2","source_url":"https://doi.org/10.1007/s11886-026-02384-2","authors":["Hubert Dromas","Dany Janah","Basile Verdier","Guillaume Schurtz","Thomas de Saint Nicolas","Gilles Lemesle"],"significance":7,"published":"2026-08-03","source_date":"2026-06-27","image":"https://hartvaat.nl/global/img/fa566d493f88.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A recent narrative review synthesizes evidence on antithrombotic management in patients with stable chronic coronary syndrome (CCS) and atrial fibrillation (AF). Trials including AFIRE, EPIC-CAD, AQUATIC, and ADAPT-AF-DES demonstrate that oral anticoagulant (OAC) monotherapy is superior to combination therapy with antiplatelets, resulting in significantly fewer major bleeding events without an increase in ischemic complications, and even showing excess mortality with prolonged combination regimens. For clinical practice, this supports OAC monotherapy as the preferred long-term strategy, effectively balancing ischemic protection with bleeding risk reduction.","created":"2026-07-27T01:35:19Z","updated":"2026-08-10T10:37:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"10b3c25ae044","type":"article","url":"https://hartvaat.nl/2026/06/28/cryoballoonablatie-resulteert-in-meer-linkeratrium-uitzetting-dan-radiofrequente/","title":"Cryoballoonablatie resulteert in meer linkeratrium-uitzetting dan radiofrequente ablatie na longaderisolatie","title_en":"Left Atrial Structural and Functional Changes After Pulmonary Vein Isolation Using Different Energy Sources.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Sensors (Basel, Switzerland)","doi":"10.3390/s26134103","source_url":"https://doi.org/10.3390/s26134103","authors":["Jonasz Kozielski","Monika Olczyk","Ewa Świerżyńska-Wodarska","Michał Orczykowski","Bronisław Sulkowski","Łukasz Szumowski","Maciej Sterliński","Marek Szołkiewicz"],"significance":3,"published":"2026-08-03","source_date":"2026-06-28","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"A prospective study of 42 patients evaluated whether pulmonary vein isolation (PVI) for atrial fibrillation induces different short-term structural and functional changes in the left atrium when using cryoballoon ablation (CBA) versus radiofrequency catheter ablation (RFCA). At 12-month follow-up, the CBA group showed a significantly greater increase in left atrial diameter (p = 0.0017) compared with RFCA, with no significant differences in volumetric indices or mechanical function. Given the small sample size and exploratory nature of the findings, the results do not currently support a change in ablation strategy in routine clinical practice.","created":"2026-07-27T01:31:51Z","updated":"2026-08-10T10:37:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1a918e17576","type":"article","url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","title":"Nieuwe universele definitie van hartfalen vervangt vaste EF-cutoffs door verbeterde, behouden en verminderde fenotypes","title_en":"AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag500","source_url":"https://doi.org/10.1093/eurheartj/ehag500","authors":["Mary Norine Walsh","Lars Kober","Karen Sliwa","Marianna Adamo","Anubha Agarwal","Amitava Banerjee","Biykem Bozkurt","Maja Cikes","Albertino Damasceno","Akshay S Desai","G Michael Felker","Gail Hogan","Koichiro Kinugawa","Michelle Kittleson","Carolyn S P Lam","Theresa McDonagh","Marco Metra","Wilfried Mullens","Antonio Luiz P Ribeiro","Yolanda Vaughn","Amanda Vest"],"significance":9,"published":"2026-08-03","source_date":"2026-06-29","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/"],"congress":"","summary_en":"A joint expert consensus from the AHA, ACC, ESC, and WHF introduces the second universal definition of heart failure to resolve longstanding diagnostic ambiguities and standardize global surveillance. The updated framework replaces rigid left ventricular ejection fraction cutoffs with dynamic categories of reduced, preserved, and improved ejection fraction, while formally integrating pre-heart failure (stage B), recovery trajectories, and social determinants into clinical classification. This standardized nomenclature will streamline early detection, guide prevention strategies, and align research and practice across primary care, cardiology, and health systems worldwide.","created":"2026-07-27T01:23:28Z","updated":"2026-08-10T10:37:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"15bddfa879bf","type":"article","url":"https://hartvaat.nl/2026/06/30/kfre-aangepast-voor-multimorbiditeit-verbetert-schatting-nierfalenrisico/","title":"KFRE aangepast voor multimorbiditeit verbetert schatting nierfalenrisico","title_en":"The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfaf252","source_url":"https://doi.org/10.1093/ndt/gfaf252","authors":["Heather Walker","Juan-Jesus Carrero","Michael K Sullivan","Ryan Field","Anne-Laure Faucon","Jennifer S Lees","Edouard L Fu","Bhautesh Dinesh Jani","Katie Gallacher","Patrick B Mark"],"significance":6,"published":"2026-08-03","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"A large cohort study using UK Biobank and SCREAM data demonstrates that the standard Kidney Failure Risk Equation (KFRE) underestimates kidney failure risk in chronic kidney disease patients with multimorbidity. An updated model that accounts for competing mortality risks significantly improved calibration (O/E ratio 0.98 versus 1.75 for the original KFRE), while cystatin C-based eGFR did not enhance performance. This refined risk stratification tool offers clinicians a more accurate basis for timing nephrology referral and managing complex multimorbid patients.","created":"2026-07-27T01:14:35Z","updated":"2026-08-10T10:37:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f8aac4918f6","type":"article","url":"https://hartvaat.nl/2026/06/30/icodextrin-verlaagt-sterfte-en-mace-bij-dialysepatienten-met-hartfalen/","title":"Icodextrin verlaagt sterfte en MACE bij dialysepatiënten met hartfalen","title_en":"The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfaf265","source_url":"https://doi.org/10.1093/ndt/gfaf265","authors":["Li-Yi Ma","Yi-Ran Tu","Ming-Jen Chan","Chan Ip Chan","Jia-Jin Chen","Cheng-Chia Lee","Victor Chien-Chia Wu","Pao-Hsien Chu","Hsiang-Hao Hsu","Chih-Hsiang Chang"],"significance":5,"published":"2026-08-02","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"A retrospective cohort study of 1,800 peritoneal dialysis patients with congestive heart failure found that icodextrin use was associated with significantly lower risks of all-cause mortality (HR 0.16), cardiovascular mortality (HR 0.20), and MACE (HR 0.68). Using time-varying exposure modeling and target trial emulation, the authors suggest icodextrin improves fluid management and survival in this high-risk group, though transplantation rates were lower. These findings support prioritizing icodextrin in dialysis patients with heart failure, but prospective validation is warranted.","created":"2026-07-27T01:08:43Z","updated":"2026-08-10T10:37:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eeadffe8a0fc","type":"article","url":"https://hartvaat.nl/2026/06/30/combinatietherapie-met-vier-pilaren-verlaagt-nierfalenrisico-bij-ckd/","title":"Combinatietherapie met vier pilaren verlaagt nierfalenrisico bij CKD","title_en":"Trends in nephrology: from \"supportive care\" to CKD combination therapy.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag003","source_url":"https://doi.org/10.1093/ndt/gfag003","authors":["Kaiyu He","Yuanrong Guo","Changyuan Yang","David W Johnson","Guobin Su"],"significance":6,"published":"2026-08-02","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This narrative review outlines the shift in chronic kidney disease (CKD) management from renin-angiotensin system inhibitor monotherapy to a four-pillar combination approach incorporating SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists. Evidence and the 2024 KDIGO guidelines indicate that these complementary therapies significantly reduce kidney failure risk in diabetic patients while improving safety and tolerability, notably by mitigating hyperkalemia. Clinicians should consider early integration of this multimodal strategy, with ongoing research focusing on non-diabetic CKD populations and novel agents like aldosterone synthase inhibitors.","created":"2026-07-27T01:04:01Z","updated":"2026-08-10T10:37:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8ad4fb7c69aa","type":"article","url":"https://hartvaat.nl/2026/08/01/verhoogde-lp-a-komt-vaker-voor-bij-kinderen-met-familiaire-hypercholesterolemie-/","title":"Verhoogde Lp(a) komt vaker voor bij kinderen met familiaire hypercholesterolemie — systematische review","title_en":"Distribution of Lipoprotein(a) concentrations in children and young people with Familial Hypercholesterolemia (FH) compared to those without FH: A systematic review and narrative synthesis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2026.120823","source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.120823","authors":["Lorraine Priestley-Barnham","Steve E Humphries","Jo Wray","Tina Khan"],"significance":5,"published":"2026-08-02","source_date":"2026-08-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This systematic review evaluated Lipoprotein(a) [Lp(a)] concentrations in children and young people with familial hypercholesterolaemia (FH) compared with non-FH peers. While most non-FH children remained below adult risk thresholds, 20–40% of those with FH exhibited elevated Lp(a), indicating a substantially higher lifetime atherosclerotic burden from an early age. These findings support the integration of targeted Lp(a) screening in paediatric FH to refine early cardiovascular risk stratification and guide preventive strategies.","created":"2026-07-27T00:59:44Z","updated":"2026-08-10T10:37:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fbe8a4a3dfb","type":"article","url":"https://hartvaat.nl/2026/09/01/combinatie-glp-1ra-en-sglt2-remmer-verlaagt-hartritmestoornissen-bij-niet-diabet/","title":"Combinatie GLP-1RA en SGLT2-remmer verlaagt hartritmestoornissen bij niet-diabetische obese patiënten","title_en":"Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"International journal of cardiology. Cardiovascular risk and prevention","doi":"10.1016/j.ijcrp.2026.200681","source_url":"https://doi.org/10.1016/j.ijcrp.2026.200681","authors":["George A Blankson","Irene A Acheampong","Abraham K Carboo","Dennis D Kumi","Joseph Amoah","Abdi Nawal","Stephen Nii-Ashie Djanie","Isaac Prempeh","Adama Seidu","Richmond K E Buckner"],"significance":5,"published":"2026-08-02","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"A retrospective real-world cohort study evaluated arrhythmia outcomes in non-diabetic obese adults treated with combined GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy. At 60 months, combination therapy was associated with a 17.5% lower odds of composite arrhythmia (OR 0.825), primarily driven by a reduced incidence of atrial fibrillation/flutter. Although ventricular tachycardia was initially more frequent in the combination group, this difference normalized over time. The findings suggest a favorable long-term electrophysiological profile for dual cardiometabolic therapy in obesity, informing arrhythmia monitoring in clinical practice.","created":"2026-07-27T00:49:11Z","updated":"2026-08-10T10:37:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb744356ec2b","type":"article","url":"https://hartvaat.nl/2026/09/01/hydrocortison-verhoogt-sterfte-en-cardiorenale-uitkomsten-bij-ckd-met-septische-/","title":"Hydrocortison verhoogt sterfte en cardiorenale uitkomsten bij CKD met septische shock","title_en":"Hydrocortisone Use for Septic Shock in Patients With CKD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international reports","doi":"10.1016/j.ekir.2026.106686","source_url":"https://doi.org/10.1016/j.ekir.2026.106686","authors":["Parth Dhamelia","Hashane Abeyagunawardene","Rajshekhar A Kore","Deepa Raghavan","John M Arthur","Keyur Vyas","Ninad Khandekar","Nishank Jain"],"significance":5,"published":"2026-08-02","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"In a large propensity-matched cohort of 26,282 patients with nondialysis CKD and septic shock, hydrocortisone use was associated with higher 90-day mortality (HR 1.31), major adverse kidney events (HR 1.08), and major adverse cardiovascular events (HR 1.19). While reinfection rates were slightly lower, there were no significant differences in hyperglycemia or delirium. These observational findings highlight potential cardiorenal and survival risks with hydrocortisone in CKD patients with sepsis, underscoring the need for rigorous randomized trials to guide therapy in this high-risk population.","created":"2026-07-27T00:45:39Z","updated":"2026-08-10T10:37:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90dab6e81d67","type":"article","url":"https://hartvaat.nl/2026/06/30/sglt2-remmers-breiden-indicatie-uit-naar-niet-diabetische-nier-en-hartfalenziekt/","title":"SGLT2-remmers breiden indicatie uit naar niet-diabetische nier- en hartfalenziekte","title_en":"[Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): A Therapeutic Revolution Beyond Diabetes. New Indications in Non-Diabetic Chronic Kidney Disease and Heart Failure].","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","doi":"10.69097/43-03-2026-09","source_url":"https://doi.org/10.69097/43-03-2026-09","authors":["Fabio Pio Gentile"],"significance":5,"published":"2026-08-01","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This narrative review synthesizes evidence on sodium-glucose cotransporter 2 inhibitors (SGLT2i) for non-diabetic chronic kidney disease and heart failure with reduced or preserved ejection fraction. Large trials demonstrate that SGLT2i improve renal and cardiac outcomes independent of diabetes status, primarily through restoration of tubuloglomerular feedback and favorable shifts in myocardial metabolism. The review provides practical guidance for clinicians on dose adjustment, monitoring the expected initial eGFR decline, and preventing euglycemic ketoacidosis.","created":"2026-07-24T01:24:41Z","updated":"2026-08-10T10:37:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f9c28fa47f0","type":"article","url":"https://hartvaat.nl/2026/06/30/erectiestoornis-komt-bij-twee-op-drie-hypertensieve-mannen-voor-in-afrika-meta-a/","title":"Erectiestoornis komt bij twee op drie hypertensieve mannen voor in Afrika — meta-analyse","title_en":"Prevalence of erectile dysfunction and its associated factors among hypertensive men in Africa: a systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Sexual medicine reviews","doi":"10.1093/sxmrev/qeag046","source_url":"https://doi.org/10.1093/sxmrev/qeag046","authors":["Eshet Gebrie","Elias Chane","Berihun A Mengistie","Getasew Kibralew","Henok Worku","Birhan Mulugeta","Amanuale Zayede"],"significance":5,"published":"2026-08-01","source_date":"2026-06-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A systematic review and meta-analysis of 18 studies (3,648 men) reveals a pooled prevalence of erectile dysfunction of 65% among hypertensive men in Africa. Risk factors significantly associated with ED include older age, hypertension duration over 10 years, stage II hypertension, depression, comorbidities, and antihypertensive polytherapy. These findings highlight the need for routine ED screening in hypertensive patients and underscore the importance of medication review and integrated cardiometabolic care.","created":"2026-07-24T01:20:13Z","updated":"2026-08-10T10:37:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"88c6340765d6","type":"article","url":"https://hartvaat.nl/2026/05/01/spect-en-cmri-bij-attr-cardiomyopathie-beeldvorming-toont-beperkte-segmentale-na/","title":"SPECT en cMRI bij ATTR-cardiomyopathie: beeldvorming toont beperkte segmentale nauwkeurigheid","title_en":"Segmental and global amyloid burden and myocardial mechanics: a multimodality imaging comparison.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of medicine and life","doi":"10.25122/jml-2026-0071","source_url":"https://doi.org/10.25122/jml-2026-0071","authors":["Claudiu Stan","Gabriela Neculae","Sebastian Onciul","Robert Daniel Adam","Laura Andrei","Razvan Capşa","Andreea Jercan","Sorina Badelita","Daniel Coriu","Ruxandra Jurcuţ"],"significance":4,"published":"2026-08-01","source_date":"2026-05-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This retrospective study of 16 patients with ATTR-CM compared bisphosphonate SPECT, cMRI-derived extracellular volume (ECV), and echocardiography. Segmental amyloid burden on SPECT significantly correlated with ECV, but global amyloid burden showed only a weak, nonsignificant association with global longitudinal strain. ECV remained independently linked to impaired myocardial mechanics, whereas radiotracer uptake lost significance in combined models. These findings indicate that conventional SPECT can estimate global amyloid burden but lacks the segmental precision of cMRI, limiting its utility for detailed regional disease monitoring.","created":"2026-07-24T01:15:39Z","updated":"2026-08-10T10:37:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e38f4be89867","type":"article","url":"https://hartvaat.nl/2026/05/01/inr-zelftest-verbetert-ttr-en-vermindert-bloedingen-bij-patienten-met-atriumfibr/","title":"INR-zelftest verbetert TTR en vermindert bloedingen bij patiënten met atriumfibrilleren","title_en":"Self-testing and clinical outcomes in Black and White patients on warfarin for atrial fibrillation or venous thromboembolism.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Research and practice in thrombosis and haemostasis","doi":"10.1016/j.rpth.2026.106801","source_url":"https://doi.org/10.1016/j.rpth.2026.106801","authors":["Brindha Rajakumar","Xiaowen Kong","Brian Haymart","Scott Kaatz","Gregory Krol","Mona Ali","Noelle Ryan","Stacy Ellsworth","Beverly Stallings","Tina Alexandris-Souphis","Amy DeLellis","Josh Errickson","James B Froehlich","Geoffrey D Barnes"],"significance":5,"published":"2026-08-01","source_date":"2026-05-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This retrospective registry study of 5,903 patients with atrial fibrillation or venous thromboembolism compared clinical outcomes between patients using INR self-testing and those receiving traditional clinic-based monitoring. Self-testers achieved a significantly higher time in therapeutic range (65.3% vs 59.8%) and experienced fewer non-major bleeding events (20.9 vs 29.9 per 100 patient-years), with benefits observed across both Black and White racial groups. Despite low utilization rates, particularly among Black patients, the findings reinforce the clinical value of INR self-testing for optimizing anticoagulation control and reducing bleeding risk.","created":"2026-07-24T01:08:39Z","updated":"2026-08-10T10:37:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5b64801b43d","type":"article","url":"https://hartvaat.nl/2026/05/01/cardioselectieve-betablokkers-veilig-en-nuttig-bij-copd-systematische-review/","title":"Cardioselectieve bètablokkers veilig en nuttig bij COPD — systematische review","title_en":"Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Current medical research and opinion","doi":"10.1080/03007995.2026.2692171","source_url":"https://doi.org/10.1080/03007995.2026.2692171","authors":["Elisa Perger","Fabrizio Luppi","Paola Faverio","Laura Pini","Gianfranco Parati"],"significance":6,"published":"2026-08-01","source_date":"2026-05-01","image":"https://hartvaat.nl/global/img/9d6e133ce0bb.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This systematic review evaluates the safety and efficacy of cardioselective beta-blockers (bisoprolol, metoprolol, nebivolol) in patients with COPD and concomitant cardiovascular disease. Contrary to historical concerns about bronchoconstriction, recent trials and meta-analyses demonstrate that cardioselective agents are safe and provide significant cardiovascular benefits without clinically relevant deterioration in lung function. These findings reinforce current guidelines, confirming that cardioselective beta-blockers should be used as first-line therapy in patients with heart failure, coronary artery disease, or hypertension who also have COPD.","created":"2026-07-24T01:05:38Z","updated":"2026-08-10T10:37:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4594c10f7bc6","type":"article","url":"https://hartvaat.nl/2026/05/05/grote-variatie-in-diureticabeleid-en-zeldzame-natriummeting-bij-acuut-hartfalen/","title":"Grote variatie in diureticabeleid en zeldzame natriummeting bij acuut hartfalen","title_en":"Reported decision-making regarding diuretic use and urinary sodium monitoring in acute heart failure: a vignette-based survey in three European countries.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag161","source_url":"https://doi.org/10.1093/eschf/xvag161","authors":["Niclas Geldermann","Noemi Filidoro","Matthias Paul","Stefan Venturini","Andrea Bürgi","Michael Christ"],"significance":5,"published":"2026-07-31","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"A multinational vignette survey of 787 clinicians in Switzerland, Germany, and Austria reveals substantial variability in diuretic management and monitoring for acute heart failure. Only 16.9% reported routinely using urinary sodium measurement, while 64.6% preferred sequential nephron blockade for inadequate diuretic response. These findings highlight a significant gap between guideline recommendations and real-world practice. Targeted educational initiatives may be needed to standardize monitoring and optimize acute heart failure care.","created":"2026-07-24T00:59:55Z","updated":"2026-08-10T10:37:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"426c7104af7b","type":"article","url":"https://hartvaat.nl/2026/05/05/perifere-zuurstofextractie-bepaalt-belasting-bij-arrhythmogene-cardiomyopathie-f/","title":"Perifere zuurstofextractie bepaalt belasting bij arrhythmogene cardiomyopathie — fysiologisch pleidooi voor veilige training","title_en":"Oxygen utilization during moderate-intensity resistance and aerobic exercise in arrhythmogenic cardiomyopathy: the central role of the periphery.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag163","source_url":"https://doi.org/10.1093/eschf/xvag163","authors":["Simon Wernhart","Manuel Rattka","Marwin Shir","Karl-Ludwig Laugwitz","Martin Halle","Mark J Haykowsky"],"significance":4,"published":"2026-07-31","source_date":"2026-05-05","image":"","kennis":[],"congress":"","summary_en":"In a small mechanistic study (n=19), researchers quantified central oxygen delivery and peripheral extraction during resistance and aerobic exercise in patients with arrhythmogenic cardiomyopathy (ACM). While central oxygen delivery increased only modestly, peripheral oxygen extraction and diffusive conductance rose significantly and accounted for 77% of the variance in whole-body oxygen uptake. These findings suggest that moderate exercise imposes predominantly peripheral, rather than central, physiological stress in ACM, providing a physiological rationale for prescribing safe exercise training in this population.","created":"2026-07-24T00:55:54Z","updated":"2026-08-10T10:37:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5d7d5148d3e","type":"article","url":"https://hartvaat.nl/2026/09/01/langdurige-lvad-behandeling-klinisch-beheer-en-uitkomsten-in-de-heartmate-3-erat/","title":"Langdurige LVAD-behandeling: klinisch beheer en uitkomsten in de HeartMate 3-eratie","title_en":"Permanent Left Ventricular Assist Devices: Long-Term Management and Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Clinics in chest medicine","doi":"10.1016/j.ccm.2026.04.014","source_url":"https://doi.org/10.1016/j.ccm.2026.04.014","authors":["Ruben Crespo-Diaz"],"significance":5,"published":"2026-07-31","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This review outlines the physiological principles and long-term clinical management of durable left ventricular assist devices (LVAD), with a focus on the HeartMate 3 era. While major complications such as pump thrombosis and stroke have declined, gastrointestinal bleeding, right ventricular failure, infection, and arrhythmias remain significant clinical challenges. The article emphasizes that LVAD therapy continues to be a vital strategy for bridge-to-transplant, destination therapy, and potential myocardial recovery amid ongoing organ shortages.","created":"2026-07-24T00:52:58Z","updated":"2026-08-10T10:37:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af930377e4c8","type":"article","url":"https://hartvaat.nl/2026/09/01/lvad-patienten-op-de-intensive-care-richtlijnen-voor-monitoring-en-acute-zorg/","title":"LVAD-patiënten op de intensive care: richtlijnen voor monitoring en acute zorg","title_en":"The Left Ventricular Assist Device Patient in the Intensive Care Unit: A Clinically Focused Guide for Intensivists.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Clinics in chest medicine","doi":"10.1016/j.ccm.2026.04.015","source_url":"https://doi.org/10.1016/j.ccm.2026.04.015","authors":["Charlotte Starling","Jonathan D Moreno","Adam May"],"significance":4,"published":"2026-07-31","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This narrative review outlines the critical care management of patients with left ventricular assist devices (LVADs), focusing on the unique physiological interactions and common ICU complications. It provides practical guidance on device monitoring, hemodynamic management, and the treatment of acute pathophysiological states in this growing patient population. The review offers cardiologists and intensivists a structured approach to optimizing care for LVAD recipients presenting with acute decompensation or critical illness.","created":"2026-07-24T00:49:58Z","updated":"2026-08-10T10:37:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc88f977c403","type":"article","url":"https://hartvaat.nl/2026/09/01/lvad-beheer-in-de-icu-praktische-richtlijnen-voor-intensivisten/","title":"LVAD-beheer in de ICU — praktische richtlijnen voor intensivisten","title_en":"Device Management of Patients on Left Ventricular Assist Device Support: A Practical Review for the ICU Clinician.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Clinics in chest medicine","doi":"10.1016/j.ccm.2026.04.016","source_url":"https://doi.org/10.1016/j.ccm.2026.04.016","authors":["Sara S Inglis","Sarah D Schettle","Andrew N Rosenbaum"],"significance":5,"published":"2026-07-31","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This practical review outlines the physiological challenges and clinical management of patients supported by continuous-flow left ventricular assist devices (LVADs). It highlights increased preload and afterload sensitivity, reduced systemic pulsatility, and right ventricular implications, providing actionable guidance for troubleshooting alarms and managing common complications. The article serves as a concise reference for intensivists and cardiologists caring for complex heart failure patients.","created":"2026-07-24T00:46:21Z","updated":"2026-08-10T10:37:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae5014faccd5","type":"article","url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","title":"Off-label dosering van sacubitril-valsartan wijdverspreid in de praktijk","title_en":"Global trend and predictors of non-labelled sacubitril-valsartan dosing: results from IKNOW-HF survey.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag162","source_url":"https://doi.org/10.1093/eschf/xvag162","authors":["Israa Fadhil Yaseen","Hasan Ali Farhan","Justin Paul Gnanaraj","Hidehira Fukaya","Hawani Sasmaya Prameswari","Clara Saldarriaga","Tuğba Kemaloğlu Öz","Somaya Aref Elhout","Pablo Díez-Villanueva","Maria Rosa Costanzo","Mustafa Toma","Nafisa Omar Elsammani Elsheikh Ibrahim","Zainab Atiyah Dakhil","Nathan Mewton","Wilfried Mullens"],"significance":5,"published":"2026-07-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A global survey of 1,285 clinicians reveals that 86.1% prescribe sacubitril-valsartan at unlabelled doses in heart failure patients, often as a pragmatic strategy for advanced disease. Prescribing patterns vary significantly by region and experience, with HF specialists more likely to deviate from standard dosing while pharmacist involvement shows a trend toward reduced non-labelled use. These findings highlight a substantial gap between guideline recommendations and real-world practice, underscoring the need for targeted education and greater integration of clinical pharmacists to optimize GDMT.","created":"2026-07-22T01:22:50Z","updated":"2026-08-10T10:37:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55792f40b6a1","type":"article","url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","title":"APTURE-shunt verlaagt hartfalen-heropnames bij patiënten met HFpEF/HFmrEF — ALT-FLOW","title_en":"Predicted versus observed outcomes in the ALT-FLOW early feasibility study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag101","source_url":"https://doi.org/10.1093/eschf/xvag101","authors":["Francesco Fioretti","William A Gray","Benjamin Hibbert","JoAnn Lindenfeld","Ryan J Tedford","Firas Zahr","Javed Butler"],"significance":5,"published":"2026-07-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"In a post-hoc analysis of the ALT-FLOW early feasibility study, patients with heart failure with preserved or mildly reduced ejection fraction (LVEF >40%) who received an APTURE left atrial-to-coronary sinus shunt showed higher 1-year survival than predicted by the MAGGIC score (94.7% vs 87.0%; P=0.04). Heart failure hospitalizations dropped significantly from 37.9% before to 9.6% after implantation (P<0,0001), with consistent benefits across SGLT2 inhibitor subgroups and NT-proBNP strata. While these hypothesis-generating results are promising, confirmation in the ongoing sham-controlled ALT-FLOW II randomized trial is required before clinical adoption.","created":"2026-07-22T01:19:21Z","updated":"2026-08-10T10:37:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"50161c2d7226","type":"article","url":"https://hartvaat.nl/2026/05/05/cmr-parameters-voorspellen-nieuwe-hartklachten-bij-hypertrofische-cardiomyopathi/","title":"CMR-parameters voorspellen nieuwe hartklachten bij hypertrofische cardiomyopathie","title_en":"Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag160","source_url":"https://doi.org/10.1093/eschf/xvag160","authors":["Danuzia S da Silva","Vanessa Karlinski Vizentin","Iuri Ferreira Felix","Maren Maanja","Simmy A Lahori","Kalyan S Pasupathy","Steve R Ommen","Jeffrey B Geske","John R Giudicessi","Philip A Araoz","Michael J Ackerman","Adelaide M Arruda-Olson","J Martijn Bos"],"significance":4,"published":"2026-07-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/dilaterende-cardiomyopathie/"],"congress":"","summary_en":"In a single-centre retrospective cohort study of 276 asymptomatic hypertrophic cardiomyopathy (HCM) patients, 93 developed heart failure symptoms (NYHA class II–IV) over a median 6.3-year follow-up. Multivariable analysis identified left atrial enlargement (HR 1.63), higher LV mass index (HR 1.014), and male sex (HR 1.7) as independent predictors of new-onset HF symptoms. These findings highlight the role of cardiac MRI in refining risk stratification and guiding follow-up intensity for HCM patients in clinical practice.","created":"2026-07-22T01:15:27Z","updated":"2026-08-10T10:37:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"244cb94326af","type":"article","url":"https://hartvaat.nl/2026/05/05/harttransplantatie-bij-hoogste-urgentie-meer-vroege-infecties-en-sterfte-mede-do/","title":"Harttransplantatie bij hoogste urgentie: meer vroege infecties en sterfte, mede door langdurige beademing","title_en":"High-urgency heart transplantation and outcome trade-offs: early post-transplant infection and mortality.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag167","source_url":"https://doi.org/10.1093/eschf/xvag167","authors":["Kyu-Sun Lee","Darae Kim","Jin-Oh Choi","Hae-Young Lee","Myoung Soo Kim","Hyungseop Kim","Dong-Ju Choi","Sang Eun Lee","Seok-Min Kang","Soo Yong Lee","Hyun-Jai Cho"],"significance":5,"published":"2026-07-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"A retrospective cohort study of 801 adult heart transplant recipients in South Korea found that patients listed at the highest urgency status (Status 0) had a significantly higher five-year mortality rate compared to lower-urgency patients (28.0% vs. 13.5%). Early post-transplant infections were more frequent in the highest-urgency group and mediated nearly half of the excess mortality risk. After adjustment for clinical severity, prolonged mechanical ventilation (>24 hours) emerged as the strongest independent predictor of infection. These findings highlight the need for targeted infection prevention and optimized perioperative ventilation strategies in critically ill transplant candidates.","created":"2026-07-22T01:12:28Z","updated":"2026-08-10T10:37:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1a11e66a9fd5","type":"article","url":"https://hartvaat.nl/2026/05/05/sterftecijfers-in-controle-armen-van-hartfalen-rcts-dalen-niet-ondanks-betere-ac/","title":"Sterftecijfers in controle-armen van hartfalen-RCTs dalen niet ondanks betere achtergrondtherapie","title_en":"Event rates in major Phase 3 heart failure trials over the last 20 years.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag169","source_url":"https://doi.org/10.1093/eschf/xvag169","authors":["Alberto Aimo","Giorgia Panichella","Andrea Ripoli","Guiomar Mendieta Badimon","Faiez Zannad","Michele Emdin"],"significance":6,"published":"2026-07-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"An analysis of 38 phase 3 heart failure RCTs published in the NEJM between 2004 and 2024 reveals that control-arm mortality rates have not declined, despite increased use of evidence-based background therapies such as beta-blockers and MRAs. After adjusting for follow-up duration, cardiovascular mortality and the composite of death or HF hospitalization remained stable over time, while the adoption of natriuretic peptide cut-offs for patient selection increased significantly. These findings suggest that risk-enriched enrolment and shorter follow-up periods may offset therapeutic gains in modern trials, highlighting key considerations for interpreting control arms and designing future cardiovascular research.","created":"2026-07-22T01:08:40Z","updated":"2026-08-10T10:37:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d80f9a43525a","type":"article","url":"https://hartvaat.nl/2026/05/05/vroege-harttoxiciteit-na-doxorubicine-bij-jongvolwassenen-met-sarcoom/","title":"Vroege harttoxiciteit na doxorubicine bij jongvolwassenen met sarcoom","title_en":"Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag143","source_url":"https://doi.org/10.1093/eschf/xvag143","authors":["Efstratios Koutroumpakis","Efthymios Triantafyllou","John Andrew Livingston","Juhee Song","Claire Viguet","Andres Hughes","Savannah V Rauschendorfer","Prince Jeyabal","Theresa A Honey","Joya Chandra","Najat C Daw","Michelle A T Hildebrandt","Jose Banchs","Susan C Gilchrist","Michael E Roth","Anita Deswal","Eugenie S Kleinerman"],"significance":5,"published":"2026-07-29","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/"],"congress":"","summary_en":"A prospective cohort study of 70 adolescents and young adults (15–39 years) with sarcoma receiving high-dose doxorubicin evaluated early echocardiographic changes. At one year, 44.4% met the primary endpoint, primarily driven by a decline in the LVWT/D ratio, with significant subclinical reductions in LVEF and global longitudinal strain also observed. Approximately half of these abnormalities persisted at two years, and one patient developed symptomatic heart failure. These findings highlight the need for routine echocardiographic and strain monitoring to detect subclinical cardiotoxicity early in this vulnerable population.","created":"2026-07-22T01:04:41Z","updated":"2026-08-10T10:38:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce13ed16e358","type":"article","url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","title":"Transseptale punctie bij linkshartinterventies: nieuwe ESC-consensus over techniek, beeldvorming en complicaties","title_en":"Transseptal puncture in cardiovascular interventions: a clinical consensus statement of the European Heart Rhythm Association, the Heart Failure Association, the European Association of Percutaneous Cardiovascular Interventions, the European Association of Cardiovascular Imaging of the ESC, and the Association for European Paediatric and Congenital Cardiology.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag021","source_url":"https://doi.org/10.1093/europace/euag021","authors":["Isabel Deisenhofer","Magdy Abdelhamid","Marianna Adamo","Nina Ajmone Marsan","Nicolas Amabile","Caterina Bisceglia","Lucas Boersma","Belen Cid Alvarez","Stefano Cornara","Victoria Delgado","Dhiraj Gupta","Ulrich Krause","Philipp Sommer","Stylianos Tzeis","Dan Wichterle","Marta de Riva"],"significance":8,"published":"2026-07-29","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"A multi-society ESC working group has released a clinical consensus on transseptal puncture (TSP), a foundational technique for over 250,000 annual atrial fibrillation ablations and various structural heart interventions. The statement emphasizes the critical role of echocardiographic guidance for precise fossa ovalis targeting, outlines standardized techniques, and provides clear algorithms for preventing and managing life-threatening complications such as cardiac tamponade and aortic puncture. This consensus offers interventional cardiologists and electrophysiologists a practical, evidence-based framework to enhance procedural safety and outcomes across routine and complex cases.","created":"2026-07-22T01:00:39Z","updated":"2026-08-10T10:38:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d27b8a1b9f81","type":"article","url":"https://hartvaat.nl/2026/05/06/vereenvoudigde-linkervoorhoofdaanhangsel-occlusie-onder-fluoroscopie-met-watchma/","title":"Vereenvoudigde linkervoorhoofdaanhangsel-occlusie onder fluoroscopie met WATCHMAN FLX is veilig en haalbaar","title_en":"Outcomes of simplified left atrial appendage occlusion using the WATCHMAN FLX device: the ROSE-FLX study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag045","source_url":"https://doi.org/10.1093/europace/euag045","authors":["Wei Zhou","Qian Tang","Anning Zeng","Jiulin Chen","Fang Wang","Jing Wang","Jingjing Chen","LinYan Shi","Ji Li","Yirong Zhang","Dawei Tian","Dandan Chen","Fuliang Luo","Zheyi Wu","Na Deng","Fei Yan","Qianjiang Pan","Zhongrong Liao","Yongxian Tian","Yifan Mao","Huimin Lu","Xing Zhou","Ya Yang","ZhenFa Zhang","Runze Huang","Wei Li"],"significance":5,"published":"2026-07-29","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/transesofageale-echo-bij-af/","https://hartvaat.nl/kennis/atriumfibrilleren/hasbled-score/"],"congress":"","summary_en":"The prospective multicentre ROSE-FLX registry evaluated simplified left atrial appendage occlusion (LAAO) using the WATCHMAN FLX device under exclusive fluoroscopic guidance and local anaesthesia in 400 patients with non-valvular atrial fibrillation at high thromboembolic and bleeding risk. Procedural success was 100%, with low rates of pericardial effusion (0.5%), access-site complications (1.3%), and major bleeding (0.8%). Over a median follow-up of 194.5 days, all-cause mortality was 0.8%, TIA 3.3%, and device-related thrombosis 0.3%, with COPD and higher CHA2DS2-VASc scores independently predicting adverse events. These findings suggest that fluoroscopy-only LAAO is a safe, feasible, and resource-efficient alternative for centres lacking advanced echocardiographic or anaesthetic support, pending confirmation from head-to-head trials.","created":"2026-07-22T00:57:17Z","updated":"2026-08-10T10:38:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ac0e7e11488f","type":"article","url":"https://hartvaat.nl/2026/05/12/matige-koffiedrinken-waarschijnlijk-veilig-en-mogelijk-gunstig-bij-chronische-ni/","title":"Matige koffiedrinken waarschijnlijk veilig en mogelijk gunstig bij chronische nierziekte","title_en":"Coffee consumption and chronic kidney disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag107","source_url":"https://doi.org/10.1093/ndt/gfag107","authors":["Miguel Bigotte Vieira","Carla Nicolau","Andreia Curto","Rita Magriço","Finnian R Mc Causland","João Sérgio Neves"],"significance":5,"published":"2026-07-29","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This narrative review synthesises current evidence on the relationship between caffeine intake, chronic kidney disease (CKD), and cardiovascular outcomes. The authors conclude that moderate coffee consumption is likely safe for patients with CKD and may offer potential renal and cardioprotective benefits. While these findings are reassuring, the evidence base remains largely observational, highlighting the need for more robust studies before formal clinical recommendations can be established. In practice, moderate coffee intake does not need to be restricted in most patients with chronic kidney disease.","created":"2026-07-22T00:52:53Z","updated":"2026-08-10T10:38:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"11711d232ef9","type":"article","url":"https://hartvaat.nl/2026/05/15/verhoogde-albuminurie-drijft-hypercholesterolemie-bij-patienten-met-het-syndroom/","title":"Verhoogde albuminurie drijft hypercholesterolemie bij patiënten met het syndroom van Alport","title_en":"Albuminuria drives hyperlipidemia in patients with Alport syndrome.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag100","source_url":"https://doi.org/10.1093/ndt/gfag100","authors":["Oliver Gross","Annika Jens","Agne Cerkauskaite-Kerpauskiene","Valentine Gillion","Mira Choi","Jan Halbritter","Yanqin Zhang","Fang Wang","Jie Ding","Ilva Bever","Jana Wenzlitschke","Kathleen J Claes","Manuel Wallbach","Jan Boeckhaus"],"significance":5,"published":"2026-07-29","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"In a multicenter retrospective cohort of 459 patients with Alport syndrome, 59.3% had hypercholesterolemia and 58.5% elevated LDL-C. Multivariable analysis identified albuminuria as the primary independent driver of total cholesterol and LDL-C levels, whereas eGFR and BMI were not significant predictors. These findings highlight a critical gap in current management and support routine lipid screening and risk-adapted therapy to mitigate long-term cardiovascular risk in this population.","created":"2026-07-22T00:50:13Z","updated":"2026-08-10T10:38:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d875fa878f5","type":"article","url":"https://hartvaat.nl/2026/05/25/multimodale-beeldvorming-verheldert-atriumfibrilleren-bij-infiltratieve-cardiomy/","title":"Multimodale beeldvorming verheldert atriumfibrilleren bij infiltratieve cardiomyopathieën","title_en":"Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62061023","source_url":"https://doi.org/10.3390/medicina62061023","authors":["Matteo Brusamolino","Francesco Catagnano","Maria Lo Monaco","Silvia Malara","Matteo De Carli","Margherita Licastro","Valentina Rossi","Gaspare Maranzano","Federica Frascaro","Stefano Frittella","Flavia Nicoli","Rocco Mollace","Erika Bertella"],"significance":4,"published":"2026-07-28","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/pathofysiologie-af/"],"congress":"","summary_en":"This narrative review explores the pathophysiological link between infiltrative cardiomyopathies and atrial fibrillation, highlighting atrial cardiomyopathy as a common underlying substrate. Multimodality cardiac imaging is discussed as a key tool for characterizing this atrial substrate, potentially guiding patient stratification and targeted management. The review provides cardiologists and internists with a practical overview on integrating imaging insights into the clinical care of these complex patients.","created":"2026-07-20T01:21:47Z","updated":"2026-08-10T10:38:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"243209fb9ed1","type":"article","url":"https://hartvaat.nl/2026/05/27/inflammatoire-biomarkers-verbeteren-risicostratificatie-bij-perifeer-arterieel-v/","title":"Inflammatoire biomarkers verbeteren risicostratificatie bij perifeer arterieel vaatlijden","title_en":"Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Biomolecules","doi":"10.3390/biom16060789","source_url":"https://doi.org/10.3390/biom16060789","authors":["Andreea Tudurachi","Bogdan-Sorin Tudurachi","Larisa Anghel","Radu Andy Sascău","Mircea Ovanez Balasanian","Cristina Prisacariu","Amin Bazyani","Cristian Stătescu"],"significance":5,"published":"2026-07-28","source_date":"2026-05-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"This narrative review evaluates the prognostic value of classical and emerging inflammatory biomarkers in peripheral arterial disease (PAD). Elevated levels of markers such as CRP, GDF-15, galectin-3, and composite indices like the neutrophil-to-lymphocyte ratio are consistently associated with disease severity and adverse cardiovascular and limb outcomes. Incorporating these biomarkers into routine risk assessment may help identify high-risk patients who could benefit from targeted anti-inflammatory strategies, including colchicine and PCSK9 inhibitors, to mitigate residual cardiovascular risk.","created":"2026-07-20T01:18:51Z","updated":"2026-08-10T10:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c6cd95c27493","type":"article","url":"https://hartvaat.nl/2026/05/27/cardiotoxiciteit-van-her2-remmers-en-multikinaseremmers-mechanismen-en-klinisch-/","title":"Cardiotoxiciteit van HER2-remmers en multikinaseremmers — mechanismen en klinisch beleid","title_en":"Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Pharmaceuticals (Basel, Switzerland)","doi":"10.3390/ph19060833","source_url":"https://doi.org/10.3390/ph19060833","authors":["Amro Abu Suleiman","Vincenzo Quagliariello","Luigi Spadafora","Federico Russo","Nicola Maurea"],"significance":4,"published":"2026-07-28","source_date":"2026-05-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This narrative review examines the cardiovascular toxicity associated with novel HER2-targeted therapies and multikinase inhibitors in oncology. It outlines key mechanisms such as mitochondrial dysfunction and endothelial damage, while summarizing real-world incidence rates and current management strategies. The authors advocate for standardized cardiotoxicity definitions, biomarker-guided monitoring, and multidisciplinary cardio-oncology care to mitigate cardiovascular risk in cancer patients.","created":"2026-07-20T01:15:28Z","updated":"2026-08-10T10:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78b504a8eab6","type":"article","url":"https://hartvaat.nl/2026/05/28/atriumfibrilleren-en-hartfalen-versterken-elkaar-en-verhogen-sterfte-aanzienlijk/","title":"Atriumfibrilleren en hartfalen versterken elkaar en verhogen sterfte aanzienlijk — UK Biobank","title_en":"Development of Atrial Fibrillation in patients with Heart Failure and vice versa: Incidence, risk factors, and their impact on survival.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag152","source_url":"https://doi.org/10.1093/eschf/xvag152","authors":["Arietje J L Zandijk","Hailun Qin","Jasper Tromp","Michiel Rienstra","Adriaan A Voors"],"significance":5,"published":"2026-07-28","source_date":"2026-05-28","image":"","kennis":[],"congress":"","summary_en":"A UK Biobank cohort study of 31,374 participants demonstrates a strong bidirectional relationship between atrial fibrillation (AF) and heart failure (HF): AF increases the risk of subsequent HF by threefold, while HF raises the risk of AF by 2.75 times. Patients with both conditions face a substantially higher mortality risk compared to those with either condition alone, regardless of which disease developed first. These findings highlight the need for proactive prevention strategies and close monitoring in both AF and HF populations to interrupt this harmful cycle.","created":"2026-07-20T01:12:25Z","updated":"2026-08-10T10:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"003091226ae3","type":"article","url":"https://hartvaat.nl/2026/05/29/cardiovasculaire-ziekte-blijft-leidend-na-niertransplantatie-overzicht-van-uitda/","title":"Cardiovasculaire ziekte blijft leidend na niertransplantatie — overzicht van uitdagingen en nieuwe therapieën","title_en":"New kidneys, old risks: cardiovascular challenges after transplantation.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfaf239","source_url":"https://doi.org/10.1093/ndt/gfaf239","authors":["Amaryllis H Van Craenenbroeck","Shanmugakumar Chinnappa","Evangelia Dounousi","Beatriz Fernandez-Fernandez","Fotini Iatridi","Patrick B Mark","Nejc Piko","Johannes Stegbauer","Claudia Torino","Liffert Vogt","Jose Manuel Valdivielso"],"significance":6,"published":"2026-07-28","source_date":"2026-05-29","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Kidney transplantation significantly improves survival, yet cardiovascular disease remains the leading cause of morbidity and mortality in transplant recipients. This review highlights how traditional risk factors, immunosuppressive therapies, and post-transplant metabolic complications sustain a high cardiovascular burden, while evidence for targeted interventions remains largely extrapolated from non-transplant populations. For clinical practice, this underscores the need for rigorous risk stratification and cautious adoption of emerging cardiorenal therapies like SGLT2 inhibitors and GLP-1 receptor agonists, alongside a strong push for transplant-specific randomized trials.","created":"2026-07-20T01:09:06Z","updated":"2026-08-10T10:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d67dd979b398","type":"article","url":"https://hartvaat.nl/2026/05/29/lichaamsrondheidsindex-bri-voorspelt-sterfte-bij-nierpatienten-beter-dan-bmi/","title":"Lichaamsrondheidsindex (BRI) voorspelt sterfte bij nierpatiënten beter dan BMI","title_en":"Body roundness index and mortality risk in patients with chronic kidney disease: moving beyond the obesity paradox.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfaf237","source_url":"https://doi.org/10.1093/ndt/gfaf237","authors":["Changyuan Yang","Biyi Liao","Priya Vart","David W Johnson","Ron T Gansevoort","Guobin Su"],"significance":5,"published":"2026-07-27","source_date":"2026-05-29","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"An observational cohort study using NHANES data evaluated the prognostic value of the body roundness index (BRI) compared with BMI and waist circumference in 6,240 patients with chronic kidney disease (CKD). A BRI >10 was independently associated with a significantly higher risk of all-cause mortality (aHR 1.82) and cardiovascular mortality (aHR 2.15), whereas a BMI >30 paradoxically correlated with lower mortality rates. These findings suggest that BRI may offer superior risk stratification over traditional BMI thresholds in CKD populations, particularly among patients under 65 years or with elevated albuminuria.","created":"2026-07-20T01:05:28Z","updated":"2026-08-10T10:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d3dfde1d0df","type":"article","url":"https://hartvaat.nl/2026/05/29/rna-remmers-verlagen-lp-a-en-triglyceriden-bij-residual-risico-scoping-review/","title":"RNA-remmers verlagen Lp(a) en triglyceriden bij residual risico — scoping review","title_en":"Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Biomolecules","doi":"10.3390/biom16060807","source_url":"https://doi.org/10.3390/biom16060807","authors":["Diana Tatarciuc","Irina Mihaela Esanu","Mioara Florentina Trandafirescu","Ana Maria Raluca Pauna","Teodor Flaviu Vasilcu","Iolanda Foia","Adina Oana Armencia","Magda Ecaterina Antohe","Dragos Catalin Ghica","Ovidiu Stamatin","Roxana Ionela Vasluianu"],"significance":5,"published":"2026-07-27","source_date":"2026-05-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This scoping review maps the molecular mechanisms and pharmacodynamic profiles of RNA-based lipid-lowering therapies targeting residual cardiovascular risk in patients inadequately controlled on standard care. GalNAc-conjugated siRNAs and ASOs demonstrate substantial efficacy, achieving 80–98% reductions in Lp(a), 50–80% in triglycerides, and 36–44% in LDL-C, with sustained effects every 3–6 months and a favorable safety profile. The analysis highlights how these novel agents address pathways beyond traditional statins and ezetimibe, offering clinicians a structured overview of emerging options for high-risk cardiometabolic patients.","created":"2026-07-20T01:00:46Z","updated":"2026-08-10T10:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d0a826a30f6","type":"article","url":"https://hartvaat.nl/2026/05/31/hfpef-fenotype-duidt-op-hogere-sterfte-na-tavi-bij-laagstroom-laaggradient-aorta/","title":"HFpEF-fenotype duidt op hogere sterfte na TAVI bij laagstroom, laaggradient aortaklepstenose","title_en":"Phenotyping patients with a low-flow, low-gradient aortic stenosis and a preserved ejection fraction undergoing TAVI.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["esc-2026"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag146","source_url":"https://doi.org/10.1093/eschf/xvag146","authors":["K H van Bergeijk","F Roski","C S Venema","T Rheude","Ophuis","J Tromp","Y M Hummel","Wouter Ouwerkerk","A F M van den Heuvel","H W van der Werf","Y L Douglas","M Adamo","A A Voors","T Trenkwalder","M Joner","J J Wykrzykowska"],"significance":6,"published":"2026-07-27","source_date":"2026-05-31","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"esc-2026","summary_en":"In a cohort of 827 patients undergoing TAVI, unsupervised clustering of AI-assessed echocardiographic parameters identified two distinct phenotypes among the 35% with paradoxical low-flow, low-gradient aortic stenosis and preserved ejection fraction. Patients exhibiting a HFpEF and atrial fibrillation phenotype faced a significantly higher risk of cardiovascular mortality and heart failure hospitalisation at 1 and 5 years. These findings suggest that targeted guideline-directed medical therapy for HFpEF, including SGLT2 inhibitors and MRAs, may improve outcomes in this high-risk subgroup.","created":"2026-07-20T00:57:29Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b229eef7de1a","type":"article","url":"https://hartvaat.nl/2026/10/01/cpap-therapie-verlaagt-diastolische-bloeddruk-bij-niet-slaapige-osa-systematisch/","title":"CPAP-therapie verlaagt diastolische bloeddruk bij niet-slaapige OSA — systematische review","title_en":"Does treatment of nonsleepy OSA with CPAP therapy change CVD risk? A systematic review.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Sleep medicine","doi":"10.1016/j.sleep.2026.109093","source_url":"https://doi.org/10.1016/j.sleep.2026.109093","authors":["Kiran Abraham-Aggarwal","Christie Hung","Xiaoxuan Chen","Shriya Suresh","Meghana Ramineni","Ashutosh Kacker"],"significance":5,"published":"2026-07-27","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A PRISMA-guided systematic review of 11 randomized trials evaluated the cardiovascular impact of CPAP therapy in adults with non-sleepy obstructive sleep apnea (OSA). Pooled analysis demonstrated a significant reduction in diastolic blood pressure by 2.33 mmHg, whereas systolic blood pressure and hard cardiovascular endpoints showed no significant benefit. For clinical practice, this suggests CPAP offers only a modest effect on diastolic pressure in this population, highlighting the need for longer follow-up and standardized endpoints to confirm hard cardiovascular outcomes.","created":"2026-07-20T00:54:49Z","updated":"2026-08-10T10:38:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"96b2f1ea737c","type":"article","url":"https://hartvaat.nl/2026/10/01/rusteloze-benen-en-slaapbewegingen-bepalen-lipidenprofiel-bij-slaapapneu/","title":"Rusteloze benen en slaapbewegingen bepalen lipidenprofiel bij slaapapneu","title_en":"Restless legs syndrome determines whether periodic limb movements are associated with altered lipid profiles in sleep-disordered breathing.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Sleep medicine","doi":"10.1016/j.sleep.2026.109109","source_url":"https://doi.org/10.1016/j.sleep.2026.109109","authors":["Alen Juginovic","Laura Rodman"],"significance":4,"published":"2026-07-27","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/"],"congress":"","summary_en":"A cross-sectional analysis of 643 adults with sleep-disordered breathing evaluated whether periodic limb movements (PLM) independently associate with lipid profiles, and whether restless legs syndrome (RLS) modifies this relationship. While PLM alone showed no significant association with cardiometabolic markers, RLS status fundamentally altered the pattern: in RLS-positive patients, higher PLM frequency correlated with elevated HDL, LDL, and total cholesterol, whereas an inverse trend appeared in RLS-negative individuals. These findings suggest that the co-occurrence of RLS and PLM identifies a distinct cardiometabolic phenotype that may benefit from targeted lipid screening in clinical practice.","created":"2026-07-20T00:50:51Z","updated":"2026-08-10T10:38:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9998fea5a2e1","type":"article","url":"https://hartvaat.nl/2026/09/01/tcl-biopsie-tijdens-carpaaltunneloperatie-heeft-lage-diagnostische-yield-voor-at/","title":"TCL-biopsie tijdens carpaaltunneloperatie heeft lage diagnostische yield voor ATTR-CM","title_en":"Tenosynovial and Transverse Carpal Ligament Biopsy for Early Transthyretin Amyloidosis Cardiomyopathy Detection: A Systematic Review and African American Retrospective Cohort Study","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of hand surgery global online","doi":"10.1016/j.jhsg.2026.101020","source_url":"https://doi.org/10.1016/j.jhsg.2026.101020","authors":["Shireen Dogar","Punn Punnakanta","Marcus D Williams","Youssef Al Hamda","Somjade Songcharoen","Mark A Dodson","Marc E Walker"],"significance":3,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/kanteltest-bij-syncope/"],"congress":"","summary_en":"A systematic review and retrospective cohort study evaluated the diagnostic yield of transverse carpal ligament (TCL) biopsy during carpal tunnel release for early detection of transthyretin amyloid cardiomyopathy (ATTR-CM). While pooled literature reports an amyloid detection rate of 10% to 30%, the institutional cohort of 89 patients (61.8% African American) showed a 0% yield. These negative findings highlight the need to refine patient selection criteria and standardize sampling techniques before TCL biopsy can be reliably integrated into ATTR-CM screening pathways.","created":"2026-07-04T15:56:54Z","updated":"2026-08-10T10:38:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"068746c80bb8","type":"article","url":"https://hartvaat.nl/2026/09/01/glp-1-agonisten-verlagen-mace-en-hartfalen-heropnames-bij-diabetes-en-ascvd-meta/","title":"GLP-1-agonisten verlagen MACE en hartfalen-heropnames bij diabetes en ASCVD — meta-analyse","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Cardiovascular endocrinology & metabolism","doi":"10.1097/XCE.0000000000000360","source_url":"https://doi.org/10.1097/XCE.0000000000000360","authors":["Alejandro Montenegro-Avila","Abelardo Montenegro-Cantillo","Jheyson Fuentes","Jennifer Cifuentes","German Camilo Giraldo-Gonzalez"],"significance":6,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"A systematic review and meta-analysis of seven randomised trials (n=56,191) demonstrates that GLP-1 receptor agonists significantly reduce major adverse cardiovascular events by 11% (HR 0.89; 95% CI 0.83–0.96) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The intervention also lowered all-cause mortality by 11% (HR 0.89; 95% CI 0.82–0.97) and heart failure hospitalisations by 7% (HR 0.93; 95% CI 0.89–0.98), with high-certainty evidence across outcomes. Incorporating recent data from the SOUL trial and oral formulations, these findings reinforce the established cardiovascular benefits of GLP-1RAs and support their continued integration into cardiometabolic care pathways.","created":"2026-07-04T15:52:23Z","updated":"2026-08-10T10:38:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9ed467d9966","type":"article","url":"https://hartvaat.nl/2026/09/01/verhoogd-lp-a-gekoppeld-aan-ernstiger-coronaire-ziekte-en-pci-uitkomsten-scoping/","title":"Verhoogd Lp(a) gekoppeld aan ernstiger coronaire ziekte en PCI-uitkomsten — scoping review","title_en":"Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"International journal of cardiology. Cardiovascular risk and prevention","doi":"10.1016/j.ijcrp.2026.200657","source_url":"https://doi.org/10.1016/j.ijcrp.2026.200657","authors":["Santosh Mohanlal Modani","Shravan Kumar Rampelly","Shafi Palagiri","Samiya Begum Ibrahim","Sivaramakrishnan Ramachandiran"],"significance":5,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"A structured scoping review with exploratory meta-analysis evaluated the association between elevated lipoprotein(a) [Lp(a)] and premature acute myocardial infarction, focusing on PCI outcomes and South Asian populations. Although the quantitative synthesis was limited to three studies (pooled RR 1.16 for MACE; 95% CI 0.93–1.43), qualitative data consistently linked higher Lp(a) levels to multivessel disease, higher SYNTAX scores, increased thrombus burden, and recurrent post-PCI events. These findings reinforce the value of routine Lp(a) screening in high-risk patients, particularly among South Asian cohorts who experience earlier and more severe coronary disease.","created":"2026-07-04T15:44:00Z","updated":"2026-08-10T10:38:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16341f39540b","type":"article","url":"https://hartvaat.nl/2026/09/01/afstand-tot-ldl-doelwaarde-stuurt-keuze-lipiddalende-therapie/","title":"Afstand tot LDL-doelwaarde stuurt keuze lipiddalende therapie","title_en":"LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["esc-2026"],"journal":"Atherosclerosis plus","doi":"10.1016/j.athplu.2026.100574","source_url":"https://doi.org/10.1016/j.athplu.2026.100574","authors":["Maria Chiara Palloni","Teresa Farella","Andrea Faggiano","Marco Vatri","Francesco Fattirolli","Elisabetta Angelino","Marco Ambrosetti","Massimiliano Ruscica","Alberto Corsini","Stefano Carugo","Andrea Poli","Pompilio Faggiano"],"significance":5,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/","https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"esc-2026","summary_en":"This practical review proposes calculating the 'distance to target'—the percentage reduction in LDL-C required from baseline—as a streamlined tool for selecting lipid-lowering therapy in patients with atherosclerotic cardiovascular disease. Despite stringent 2025 ESC/EAS guidelines and strong evidence linking cumulative LDL exposure to cardiovascular risk, less than one-third of secondary prevention patients achieve target levels due to therapeutic inertia. By aligning the expected efficacy of available agents (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran) with individual patient needs, this framework helps clinicians overcome treatment gaps and optimize early, intensive lipid lowering.","created":"2026-07-04T15:38:44Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7e2d978241f","type":"article","url":"https://hartvaat.nl/2026/09/01/inflammatie-als-risicofactor-krijgt-onvoldoende-ruimte-in-de-ascvd-en-ckd-prakti/","title":"Inflammatie als risicofactor krijgt onvoldoende ruimte in de ASCVD- en CKD-praktijk — SPARK-CVD","title_en":"Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Atherosclerosis plus","doi":"10.1016/j.athplu.2026.100570","source_url":"https://doi.org/10.1016/j.athplu.2026.100570","authors":["Xiaoxia Liu","Yuanlin Guo","Ban Zhao","Haobo Teng","Wenyan Liu","Kun Xiao","Changsheng Ma"],"significance":4,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"A nationwide survey of 1,500 Chinese cardiologists and nephrologists reveals a significant knowledge-practice gap regarding systemic inflammation and hsCRP in patients with ASCVD and CKD. While 73.3% recognize inflammation as a key cardiovascular risk factor, only 35.2% discuss it with patients, and barriers such as limited experience and safety concerns hinder the use of anti-inflammatory therapies like colchicine. Conversely, the cardiorenal and anti-inflammatory benefits of GLP-1 receptor agonists are widely acknowledged (97.9%). These findings highlight an urgent need for targeted physician education and clearer guideline recommendations to integrate inflammation-guided care into routine cardiorenal practice.","created":"2026-07-04T15:35:21Z","updated":"2026-08-10T10:38:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46099","type":"article","url":"https://hartvaat.nl/2026/04/03/hoe-nauwkeurig-is-bloeddrukmeting-bij-opgenomen-patienten-vaak-slordig-blijkt-ui/","title":"Hoe nauwkeurig is bloeddrukmeting bij opgenomen patiënten? Vaak slordig, blijkt uit observatie","title_en":"How Accurate Is Inpatient Blood Pressure Measurement?","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26355","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26355","authors":["Alexandra Gallagher"],"significance":5,"published":"2026-07-25","source_date":"2026-04-03","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"Accurate blood-pressure measurement depends on good technique, but no guidelines exist for inpatient BP measurement. In a major teaching hospital, 278 measurements in 153 patients across three non-critical wards were observed and assessed against ten consensus criteria for an ideal measurement. Concordance was high for device calibration (92%), uncrossed legs (82%), correct cuff size (77%) and back support (75%), but poor for the highest-ranked criteria: seated position (26%), no talking (23%), cuff at heart height (15%) and at least two measurements (7%). No measurement met all ten criteria. Routine inpatient BP measurement thus deviates substantially from optimal technique, which may cause inaccurate and biased readings — standardised, hospital-specific guidelines and training are needed.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:26:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46098","type":"article","url":"https://hartvaat.nl/2026/04/03/machine-learningmodel-voorspelt-periprocedurele-complicaties-bij-tavi-voor-bicus/","title":"Machine-learningmodel voorspelt periprocedurele complicaties bij TAVI voor bicuspide aortaklepstenose","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003749?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003749?rss=1","authors":["Mao","Y.","Chen","Y.","Zhai","M.","Jin","P.","Li","W.","Gou","Y.","Liu","Y.","Zhang","J.","Yang","J."],"significance":6,"published":"2026-07-25","source_date":"2026-04-03","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"Transcatheter aortic valve replacement (TAVR) is increasingly used for severe bicuspid aortic valve (BAV) stenosis, but these patients face multiple procedural challenges. In this multicentre study (1,266 patients with BAV stenosis), a machine-learning model was developed to predict the risk of periprocedural adverse events (PAEs). Five predictors were identified: Type 0 bicuspid valve, aortic-root calcification volume, horizontal aorta, annular ellipticity and prior atrial fibrillation. The risk model had good discrimination (AUC 0.80), with a clearly graded PAE risk by quartile (0.6%, 1.7%, 3.2% and 9.6%). A nomogram enables individual risk calculation. The model can thus individualise procedural planning and in-hospital care for bicuspid TAVR.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:09:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46097","type":"article","url":"https://hartvaat.nl/2026/04/07/voor-het-voorspellen-van-hypertensie-na-de-zwangerschap-telt-de-obstetrische-voo/","title":"Voor het voorspellen van hypertensie na de zwangerschap telt de obstetrische voorgeschiedenis zwaarder dan biomarkers","title_en":"Obstetric History Versus Biomarkers: Hypertension Risk Up to 15 Years Postpartum","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25552","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25552","authors":["Tooba Anwer"],"significance":6,"published":"2026-07-25","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/therapietrouw-hypertensie/"],"congress":"","summary_en":"The sFlt-1/PlGF ratio predicts severe preeclampsia, but its link to long-term hypertension was unclear. In this retrospective cohort (LIFECODES biobank, 993 participants; sFlt-1 and PlGF measured in the second half of pregnancy), 29% developed stage 1 and 17% stage 2 hypertension over 15 years. A history of preeclampsia or gestational hypertension was strongly associated with later hypertension (adjusted HR 2.17 and 3.50, respectively), whereas the sFlt-1/PlGF ratio showed no association. PlGF levels were, however, lower in women who later developed hypertension. For long-term prediction of hypertension, obstetric history is thus more informative than pregnancy biomarkers — a simple basis for follow-up after a hypertensive pregnancy.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:26:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46096","type":"article","url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","title":"WARRIOR-trial: intensieve medicamenteuze behandeling verbetert de uitkomsten niet bij vrouwen met ANOCA/INOCA","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004115?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004115?rss=1","authors":["Pepine","C. J.","Handberg","E.","Cooper-DeHoff","R.","Cook-Wiens","G.","Diniz","M. A.","Frayne","S.","Lo","M. C.","Smith","S. M.","Harris","B.","Wei","J.","Chaitman","B. R.","Spertus","J. A.","Berry","C.","Weintraub","W.","Bairey Merz","C. N."],"significance":7,"published":"2026-07-24","source_date":"2026-04-03","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"Women with angina referred for coronary angiography often have no obstructive coronary artery disease (ANOCA/INOCA). The randomised WARRIOR trial (2,476 women, 71 US sites) tested whether intensive medical treatment (IMT: high-intensity statin, ACE inhibitor or ARB, and aspirin) reduces cardiovascular events (MACE) versus usual care. Recruitment was lower than planned, yielding an older population with well-controlled BP and LDL at baseline. At 2.5 years, 421 events occurred, with no difference in the primary endpoint (HR 1.13; p=0.20) or secondary outcomes; angina hospitalisations were the dominant contributor to MACE. IMT thus did not improve outcomes, though the trial was underpowered to exclude a possible benefit. The findings underscore the high disease burden and the need for better research in this population.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:09:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46095","type":"article","url":"https://hartvaat.nl/2026/04/07/hoge-bloeddruk-op-de-tienerleeftijd-voorspelt-hart-en-vaatziekten-voor-het-50e-j/","title":"Hoge bloeddruk op de tienerleeftijd voorspelt hart- en vaatziekten vóór het 50e jaar","title_en":"Adolescent Blood Pressure and Cardiovascular Disease Before Age 50 Years","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26414","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26414","authors":[],"significance":7,"published":"2026-07-24","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"Adolescent blood-pressure guidelines rely largely on expert consensus, as evidence on hard cardiovascular outcomes is lacking. In this cohort of 902,741 adolescents (aged 16-19, evaluated for mandatory service, 1979-2019, without pre-existing cardiometabolic conditions), participants were followed to age 50. Over more than 18 million person-years, 6,305 cardiovascular events occurred (ischaemic heart or cerebrovascular disease). Higher systolic, diastolic and mean arterial blood pressure were associated with higher risk: compared with normal BP, the adjusted hazard ratio was 1.14 for stage 1, 1.31 for stage 2 and 2.42 for hypertension, with stage 1 particularly sensitive to diastolic pressure. Elevated blood pressure in adolescence is thus strongly associated with early cardiovascular disease — arguing for refining current guidelines.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:26:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46093","type":"article","url":"https://hartvaat.nl/2026/04/07/bij-2-3-miljoen-amerikaanse-veteranen-was-de-sterfte-het-laagst-bij-een-systolis/","title":"Bij 2,3 miljoen Amerikaanse veteranen was de sterfte het laagst bij een systolische bloeddruk van 130-139 mmHg","title_en":"Blood Pressure Control and Mortality Among US Veterans","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25787","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25787","authors":["Masaaki Yamada"],"significance":7,"published":"2026-07-24","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"Intensive blood-pressure lowering reduces mortality and cardiovascular disease in clinical trials, but real-world BP measurements often differ from standardised protocols. In this retrospective cohort of over 2.3 million US Veterans with hypertension (mean age 66; 36% diabetes, 22% cardiovascular disease, 19% kidney disease), systolic BP was treated as a time-dependent variable across seven categories. Lowest mortality was seen at a systolic BP of 130-139 mmHg. Compared with a year at BP ≥160 mmHg, adjusted hazard ratios included 1.29 at <110, 0.83 at 130-139 and 0.86 at 140-149 mmHg — a J-shaped relationship consistent across patients with and without cardiovascular or kidney disease. In routine practice, a somewhat higher BP target thus appears appropriate, especially for older patients with comorbidity.","created":"2026-07-03T20:27:19Z","updated":"2026-07-04T19:26:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46092","type":"article","url":"https://hartvaat.nl/2026/04/09/sterftereductie-of-uitstel-van-overlijden-waarom-de-taal-in-cardiovasculaire-tri/","title":"'Sterftereductie' of uitstel van overlijden? Waarom de taal in cardiovasculaire trials ertoe doet","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004039?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004039?rss=1","authors":["Tona","F."],"significance":5,"published":"2026-07-24","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"In cardiology, 'mortality reduction' is often used to summarise the benefit of modern therapies — a powerful phrasing suggesting deaths have been prevented and lives saved. This Open Heart viewpoint shows that many cardiovascular trials, however, rely on time-to-event analyses that, within a limited follow-up, mainly demonstrate a difference in the timing of death. Such findings are frequently translated as 'reduced mortality', whereas the effect is in reality more a modest extension of survival than the prevention of death. Although statistically correct within the predefined time horizon, this framing may overstate clinical benefit and obscure its time-dependent nature. The authors argue for interpretive precision: distinguishing survival extension from mortality reduction makes communication more transparent and supports shared decision-making aligned with what patients actually experience.","created":"2026-07-03T20:27:18Z","updated":"2026-07-04T19:09:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46091","type":"article","url":"https://hartvaat.nl/2026/04/10/risicostratificatie-bij-longembolie-hoe-bruikbaar-zijn-de-huidige-instrumenten/","title":"Risicostratificatie bij longembolie: hoe bruikbaar zijn de huidige instrumenten?","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/9/480?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/9/480?rss=1","authors":["Stenger","W. J. E.","den Uil","C. A.","Rietdijk","W. J. R.","Kraaijeveld","A. O.","Klok","F. A."],"significance":5,"published":"2026-07-24","source_date":"2026-04-10","image":"https://hartvaat.nl/global/img/5e97691e9888.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"International guidelines recommend risk stratification of acute pulmonary embolism (PE) to guide treatment. Key prognostic factors include clinical presentation, comorbidities, (imaging) biomarkers and haemodynamic status. The most widely used algorithm, from the 2019 ESC/ERS guideline, classifies patients as high-risk (massive), intermediate-risk (submassive, high or low) and low-risk (non-massive), with the risk of adverse outcomes rising at each level. Yet leading guidelines differ substantially in their risk classification and corresponding treatment recommendations, owing to a lack of top-level (1A) evidence. This review evaluates current stratification tools and identifies the main knowledge gaps — relevant to the everyday choice between outpatient treatment, admission or reperfusion in PE.","created":"2026-07-03T20:27:18Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46089","type":"article","url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-secundaire-preventie-na-acs-vrouwen-halen-minder-vaak-hun-ld/","title":"Sekseverschillen in secundaire preventie na ACS: vrouwen halen minder vaak hun LDL-doel (TEXTMEDS)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003856?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003856?rss=1","authors":["Mishra","S. R.","Marschner","S.","Min","H.","Mahendran","S.","Thiagalingam","A.","Poulter","R.","Redfern","J.","Brieger","D. B.","Thompson","P. L.","Hillis","G. S.","Collins","N.","Shetty","P.","McGrady","M.","Hamilton-Craig","C.","Kangaharan","N.","Atherton","J.","Maiorana","A.","Klimis","H.","Juergens","C.","Chow","C. K."],"significance":6,"published":"2026-07-23","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Good risk-factor control and medication adherence after an acute coronary syndrome (ACS) help determine long-term prognosis, and sex plays a role. In this secondary analysis of the randomised TEXTMEDS trial (1,379 patients post-ACS, 79% male), sex differences in secondary-prevention targets were examined. Women were less likely to reach the LDL-cholesterol target (<1.8 mmol/L; aOR 0.61) and to exercise regularly (aOR 0.61), but more likely to achieve a healthy BMI (aOR 1.47). Women were also less adherent to medication (aOR 0.68), though this association weakened and lost significance after adjustment for socioeconomic factors. The findings argue for sex-sensitive strategies for risk-factor control and adherence to improve cardiovascular outcomes.","created":"2026-07-03T20:27:18Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46088","type":"article","url":"https://hartvaat.nl/2026/04/09/aanvullende-ablatie-van-het-aorticorenale-ganglion-versterkt-het-bloeddrukeffect/","title":"Aanvullende ablatie van het aorticorenale ganglion versterkt het bloeddrukeffect van renale denervatie","title_en":"Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26719","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26719","authors":["Yuxiang Long"],"significance":6,"published":"2026-07-23","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"The aorticorenal ganglion (ARG) is an upstream component of renal sympathetic fibres and a possible new target in hypertension. In this exploratory study, patients with uncontrolled hypertension underwent renal denervation (RDN); if blood pressure rose during high-frequency stimulation at the ARG, that ganglion was additionally ablated (RDN+ARG). In 41 patients (20 RDN, 21 RDN+ARG), mean 24-hour systolic blood pressure at three months fell by 9.7 mmHg after RDN alone and by 18.2 mmHg after RDN+ARG — a difference of 7.5 mmHg, with no major complications. In a canine model, ARG ablation reduced renal and systemic sympathetic activity more than RDN alone. The ARG thus appears a key regulator of sympathetic tone and a promising target; adjunctive ARG ablation with RDN warrants validation in larger trials.","created":"2026-07-03T20:27:18Z","updated":"2026-07-04T19:26:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46087","type":"article","url":"https://hartvaat.nl/2026/04/10/zuinig-machine-learningmodel-voorspelt-1-jaarssterfte-en-zinloosheid-na-tavi/","title":"Zuinig machine-learningmodel voorspelt 1-jaarssterfte en zinloosheid na TAVI","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/9/488?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/9/488?rss=1","authors":["Bharucha","A. H.","Brown","S.","Theofilatos","K.","Singh","B.","Galusko","V.","Rashid","H.","Abdelgawad","H.","Dworakowski","R.","Papachristidis","A.","Patterson","T.","Redwood","S. R.","Prendergast","B.","Byrne","J. A.","MacCarthy","P. A.","OGallagher","K.","Eskandari","M."],"significance":6,"published":"2026-07-23","source_date":"2026-04-10","image":"https://hartvaat.nl/global/img/5e97691e9888.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"Existing risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), hampering decisions about procedural futility. The investigators developed a machine-learning model using only preprocedural variables to predict 1-year all-cause mortality. The model was trained on 1,025 TAVR patients with 52 clinical and echocardiographic variables; via an evolutionary algorithm it was reduced to 13 variables while preserving performance and simplicity. The final model was externally validated in an independent cohort of 270 patients and compared with EuroSCORE II, FRANCE-2 and TAVI2-SCORE. A simple, preprocedural-data-based model can thus identify patients with high 1-year mortality — useful to support decision-making around TAVR.","created":"2026-07-03T20:27:17Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46086","type":"article","url":"https://hartvaat.nl/2026/04/09/grootschalige-proteomics-van-bloeddruk-en-hypertensie-wijst-nherf2-aan-als-mogel/","title":"Grootschalige proteomics van bloeddruk en hypertensie wijst NHERF2 aan als mogelijk doelwit","title_en":"Integrative Proteomic Profiling of Blood Pressure and Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26407","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26407","authors":["Mohit Aggarwal"],"significance":7,"published":"2026-07-23","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"Hypertension affects one-third of adults worldwide and is largely idiopathic; protein biomarkers may reveal underlying mechanisms and treatment targets. This study linked 2,922 plasma proteins to blood pressure (systolic and diastolic) and hypertension in 45,991 UK Biobank participants, validated in 5,759 Framingham Heart Study participants. In the UK Biobank, 342 proteins were associated with systolic and 276 with diastolic blood pressure; new-onset hypertension was associated with 60 proteins. Mendelian randomisation identified hundreds of proteins with a causal signal, involved in blood-vessel and cardiac-muscle morphogenesis, vasoconstriction and inflammation; BP-related proteins were enriched for atherosclerotic, liver and kidney diseases. NHERF2 emerged as a putatively causal protein and promising therapeutic target. The study thus provides a comprehensive protein signature of blood pressure and hypertension risk.","created":"2026-07-03T20:27:17Z","updated":"2026-07-04T19:26:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46085","type":"article","url":"https://hartvaat.nl/2026/04/15/mitralisklepreparatie-bij-endocarditis-geeft-betere-langetermijnoverleving-dan-k/","title":"Mitralisklepreparatie bij endocarditis geeft betere langetermijnoverleving dan klepvervanging","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004008?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004008?rss=1","authors":["Momin","A.","Ranjan","R.","Sowden","W.","Sarsam","M.","Chandrasekaran","V."],"significance":5,"published":"2026-07-23","source_date":"2026-04-15","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The optimal surgical strategy for mitral valve (MV) endocarditis is uncertain: although repair is increasingly advocated, replacement is often performed, and good comparative long-term data are lacking. In this retrospective single-centre study (88 consecutive patients undergoing MV surgery for endocarditis-related mitral regurgitation, 2011-2025), replacement was performed in 51%; these patients were older (median 62 vs 51 years). In-hospital mortality was 4.5% (no deaths in the repair group) and long-term mortality 14.8%. In the replacement group, older age and diabetes (OR 7.8) independently predicted mortality. Mean survival was significantly longer after repair than replacement (161 vs 130 months). MV repair for endocarditis is thus safe and associated with better long-term survival; diabetes is a strong risk factor in replacement.","created":"2026-07-03T20:27:17Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46084","type":"article","url":"https://hartvaat.nl/2026/04/17/direct-naar-ct-coronairangiografie-bij-verdenking-angina-snellere-diagnose-en-mi/","title":"Direct naar CT-coronairangiografie bij verdenking angina: snellere diagnose en minder polibezoeken","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003948?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003948?rss=1","authors":["Ahmad","F.","Galvin","J.","Cruickshanks","W.","Miller","L.","Hunter","A.","Murdoch","D.","Campbell","R. T.","Connolly","E.","Mangion","K."],"significance":5,"published":"2026-07-22","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-angiografie/"],"congress":"","summary_en":"Rapid-access chest pain (RACP) clinics suffer delays from sequential consultations and tests. In this prospective single-centre pilot (149 primary-care referrals, June 2024-January 2025), a 'test-first' pathway was tested in which eligible patients with suspected angina and no known coronary disease went directly to CT coronary angiography (CTCA). Median referral-to-diagnosis time fell from 88 to 29 days. CTCA showed no or mild coronary disease in 70%; only 32% needed a face-to-face consultation. Follow-up testing comprised exercise ECG (17%), echocardiography (8%) and invasive angiography (7%); incidental findings occurred in 30%. An estimated 102 outpatient visits per year were avoided (saving about £32,620). A direct-to-CTCA pathway is thus feasible, speeds diagnosis and aligns with NICE guidelines, without loss of diagnostic quality.","created":"2026-07-03T20:27:17Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46083","type":"article","url":"https://hartvaat.nl/2026/04/17/langetermijnuitkomsten-na-de-ross-operatie-een-op-de-vier-krijgt-een-heroperatie/","title":"Langetermijnuitkomsten na de Ross-operatie: één op de vier krijgt een heroperatie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003782?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003782?rss=1","authors":["Mahmoud","M.","Johansson","B.","Rinnstro&#x0308;m","D.","Sandberg","C.","Christersson","C.","So&#x0308;rensson","P.","Trzebiatowska-Krzynska","A.","Mandalenakis","Z.","Hlebowicz","J.","Ljungberg","J."],"significance":5,"published":"2026-07-22","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"In aortic valve disease, the Ross procedure — transposing the patient's own pulmonary valve to the aortic position with a homograft in the pulmonary position — remains an alternative for young patients or those avoiding long-term anticoagulation. Long-term prognosis, however, was largely unknown. In the Swedish congenital heart disease registry, 82 adults after a Ross procedure were identified (mean age at the procedure 23.6 years). After a mean of 16.8 years, 24.4% had undergone a first reoperation — cumulative incidence about 15% at 10 years and 30% at 20 years — mostly on the pulmonary valve (85%). Mortality was low (2.3%). In selected patients the Ross procedure thus remains a viable option, provided late morbidity is considered; secondary Ross surgery was associated with better left ventricular function.","created":"2026-07-03T20:27:17Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46082","type":"article","url":"https://hartvaat.nl/2026/04/10/subklinische-atherosclerose-bij-vrouwen-na-pre-eclampsie-systematische-review-en/","title":"Subklinische atherosclerose bij vrouwen na pre-eclampsie: systematische review en meta-analyse","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/9/473?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/9/473?rss=1","authors":["Yao","J. V.","Wang","B.","Ganes","A.","Peters","S.","Taylor","A.","Brennecke","S.","Winship","I.","Zentner","D."],"significance":6,"published":"2026-07-22","source_date":"2026-04-10","image":"https://hartvaat.nl/global/img/5e97691e9888.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Women who experienced pre-eclampsia have an increased later-life risk of cardiovascular disease (CVD), but uniform screening recommendations are lacking. Subclinical atherosclerosis offers a window to identify and treat at-risk women, measurable by coronary artery calcium scoring (CAC), carotid intima-media thickness (CIMT) and ankle-brachial index (ABI). This systematic review and meta-analysis (MEDLINE, EMBASE, CINAHL) examined the association between a history of pre-eclampsia and the presence of subclinical atherosclerosis, and how this relates to the timing of measurement. The findings support that prior pre-eclampsia is associated with more subclinical atherosclerosis and underscore the importance of cardiovascular risk evaluation in these women.","created":"2026-07-03T20:27:16Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46081","type":"article","url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","title":"Proteomics onthult vier subgroepen van acuut HFpEF met eigen biologische routes (PURSUIT-HFpEF)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/9/504?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/9/504?rss=1","authors":["Sotomi","Y.","Matsuoka","Y.","Ebert","C.","Wang","Z.","Ohtani","T.","Kammerhoff","K.","Liu","L.","Schafer","P.","Chang","C.-P.","Gordon","D.","Hikoso","S.","Chirinos","J. A.","Zhao","L.","Sakata","Y."],"significance":6,"published":"2026-07-22","source_date":"2026-04-10","image":"https://hartvaat.nl/global/img/5e97691e9888.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/ischemie-reperfusieschade/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The marked heterogeneity of heart failure with preserved ejection fraction (HFpEF) hampers treatment development; distinguishing phenogroups may help tailor therapy. This post-hoc analysis of the prospective, multicentre PURSUIT-HFpEF study (patients hospitalised with acute decompensated HFpEF) examined, in 198 patients with available proteomics data, the protein patterns of phenogroups identified by a machine-learning clustering model. Patients were classified into four phenogroups, each with distinct biological pathways. The study shows that proteomics-driven phenotyping of HFpEF can uncover specific pathophysiological mechanisms per subgroup — a step toward more targeted treatment strategies.","created":"2026-07-03T20:27:16Z","updated":"2026-07-04T19:09:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46080","type":"article","url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","title":"Tweelingzwangerschap bij vrouwen met een hartaandoening geeft een hoog risico op hartfalen (ROPAC)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/9/514?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/9/514?rss=1","authors":["Wander","G.","van der Zande","J. A.","Canpolat","U.","Bouchardy","J.","Furena&#x0308;s","E.","Agata","B. D.","Diller","G. P.","Morissens","M.","Mekonnen","D.","Hall","R.","Roos-Hesselink","J. W.","Johnson","M. R.","EORP Oversight Committee","ROPAC Executive Committee","Investigators","Ferrari","IT","Alonso","ES","Bax","NL","Blomstro&#x0308;m-Lundqvist","SE","Gielen","DE","Lancellotti","BE","Maggioni","IT","Maniadakis","GR","Pinto","PT","Ruschitzka","CH","Tavazzi","IT","Vardas","GR","Weidinger","AT","Zeymer","DE","Vahanian","FR","Budaj","PL","DE","Danchin","FR","Delgado","NL","Emberson","GB","Friberg","SE","Gale","GB","Heyndrickx","BE","Iung","FR","James","SE","Kappetein","NL","Maggioni","IT","Maniadakis","GR","Nagy","HUt","Parati","IT","Petronio","IT","Pietila","FI","Prescott","DK","Ruschitzka","CH","Van de Werf","BE","Weidinger","AT","Zeymer","DE","Gale","GB","Beleslin","RS","Budaj","PL","Chioncel","RO","Dagres","DE","Danchin","FR","Emberson","GB","Erlinge","SE","Glikson","IL","Gray","GB","Kayikcioglu","TR","Maggioni","IT","Nagy","HU","Nedoshivin","RU","Petronio","IT","Roos-Hesselink","NL","Wallentin","SE","Zeymer","DE","Popescu","RO","Adlam","GB","Caforio","IT","Capodanno","IT","Dweck","GB","Erlinge","SE","Glikson","IL","Hausleiter","DE","Iung","FR","Kayikcioglu","TR","Ludman","GB","Lund","SE","Maggioni","IT","Matskeplishvili","RU","Meder","DE","Nagy","HU","Nedoshivin","RU","Neglia","IT","Pasquet","BE","Roos-Hesselink","NL","Rossello","ES","Shaheen","EG","Torbica","IT","ROPAC Executive Committee","Roos-Hesselink","Hall","Parsonage","Budts","Backer","Grewal","Marelli","Jondeau","Johnson","Otto","Sliwa","Maggioni","Yerevan","Vardanyan","Melkonyan","Lachikyan","Hakobyan","Mazmanian","Hayrapetyan","Tavaracyan","Poghosyan","Hovhannisyan","Sahakyan","Martirosyan","Harris","Pasquet","Morissens","Besse-Hammer","Dumoulin","De Backer","Campens","Demulier","De Hosson","Budts","Van de Bruaene","Rampelberg","Troost","Roggen","De Meester","Mwita","Tefera","Kontle","Marelli","Malhame","Grewal","Janzen","Roman Rubio","Vasallo Peraza","Vazquez Hernandez","Perez Torga","Gil Jimenez","Meluza Martin","Almaleh","Youssef","Sorour","Abebe","Mekonnen","Fekadu","Yadeta","Dupuis-Girod","Delagrange","Richardson","Ghesquiere","Domanski","Gonzalez Estevez","Ould Hamoud","Gautier","Marsili","Bal-Theoleyre","Palazzolo","Ladouceur","Jondeau","Bourgeois Moine","Eliaou","Milleron","Tchitchinadze","Dulac","Karsenty","Souletie","Bajanca","Rickers","Blankenberg","Sinning","Magnussen","Zengin","Mueller","Schnabel","Von Kodolitsch","Kozlik-Feldmann","Baumgartner","Schmidt","Hellige","Rietko&#x0308;tter","Spartalis","Frogoudaki","Arvanitaki","Baroutidou","Giannakoulas","Karvounis","Gnanaraj","Steaphen","Ethirajan","Kannan","Subramanian","Surendran","Gnanasekaran","Natarajalingam","Balasubramani","Ali Farhan","Yaseen","Mariucci","Ciuca","Marchi","Benedetti","Baroni","Festa","Parlanti","Scognamiglio","Fusco","Sarubbi","Merlo","D'Agata Mottolese","Carriere","Sinagra","Bobbo","Ramani","Comoglio","Bordese","Pagano","Montali","Donvito","Remolif","Petey","Bouma","Chamuleau","Robbers-Visser","Konings","Dronkert","Dronkert","Segers","Van Kimmenade","Van Der Zwaan","Tjalling Sieswerda","Evers","Schaap","Bano","Yasmeen","Amir","Patel","Akhter","Khan","Shakeel","Mahar","Habib","Lelonek","Hoffman","Lipczynska","De Sousa","Ferreira","Mano","Selas","Cruz Ferreira","Shlyakhto","Irtyuga","Sefieva","Malikov","Pervunina","Shadrina","Kinsara","Galzerano","Al Sergani","Kurdi","Kholaif","Vriz","Alhamshari","Alsaigh","Ahmad","Alzaher","Alamro","Sliwa","Jakoet-Bassier","Galian-Gay","Pijuan-Domenech","Miranda-Barrio","Gordon","Furena&#x0308;s","Hlebowicz","Wedlund","Nagy","Mattsson","Majczuk Sennstrom","So&#x0308;rensson","Christersson","Lutvica","Jo&#x0308;nelid","Achter","Junus","Ga&#x0308;rdesten Wall","Andreasson","Tobler","Bouchardy","Brand","Blanche","Bouchardy","Rutz","Brand","Canpolat","Sener","Ozer","Ayduk Go&#x0308;vdeli","Bugra","Umman","Karaca O&#x0308;zer","Baykiz","Mutlu","Yalman","Kilickiran Avci","Catirli Enar","Batukan Esen","Oksen","Lazoryshynets","Siromakha","Davydova","Limanska","Zinovchyk","Kravchenko","Kravchuk","Kravets","Volkova","Mazur","Beregovyi","Salih","Al Mahmeed","Wani","Mohamed Farook","Al Mansoori","Prakash","Afifi","Milewicz","Cecchi","Wells","Sparks","Wagner","Bigelow","Colicchia","Jentink","Loichinger","Saxena","Wunderlich","Longtin","Klopper","Gobar","Chou","Campbell","Elder","Halpern","Hausvater","Reynolds","Bhalla","Small","Feinberg","Panday","Awerbach","Porche","Stack","Mcgrath","Khan","Pare","Woods","Broberg","Gibbins","Brookfield","Al-Sadawi","Cove","Mann"],"significance":6,"published":"2026-07-22","source_date":"2026-04-10","image":"https://hartvaat.nl/global/img/5e97691e9888.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/metabool-syndroom/"],"congress":"","summary_en":"Cardiovascular adaptation to pregnancy is more marked in twin than singleton pregnancies and may cause more cardiac events in women with heart disease. In the global, prospective ROPAC registry (Registry Of Pregnancy And Cardiac disease, 2007-2018), outcomes of 96 twin pregnancies were compared with 5,643 singleton pregnancies in women with heart disease. Twin mothers were older (32.1 vs 29.5 years) and had fewer prior cardiac interventions, while cardiac diagnosis, NYHA class, modified WHO class and risk factors were comparable. The risk of heart failure was clearly higher in twin pregnancies. The findings are important for pre-pregnancy counselling and antenatal management of women with heart disease.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46078","type":"article","url":"https://hartvaat.nl/2026/04/17/verhoogd-crp-voorspelt-hartfalen-bij-kankeroverlevenden-uk-biobank/","title":"Verhoogd CRP voorspelt hartfalen bij kankeroverlevenden (UK Biobank)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003513?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003513?rss=1","authors":["Yang","Q.","Zheng","J.","Zhao","C.","Lin","Q.","Li","W.","Wu","M.","Wang","R.","Liu","M.","Yiu","K. H."],"significance":6,"published":"2026-07-21","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"Cancer survivors are at risk of heart failure (HF), partly from prior cancer therapy, but early predictors are scarce. Chronic low-grade inflammation has been linked to both cancer and HF. In this UK Biobank analysis (20,244 participants with cancer at baseline, mean age 60), 2.0% developed incident HF over a median 10.5-year follow-up. After adjustment for sociodemographic, lifestyle and clinical factors, CRP above 2 mg/L was associated with a 53% higher HF risk (sHR 1.53). Subgroup analyses confirmed this trend, which was strongest among survivors of cutaneous malignancies. A simple inflammatory marker may thus help identify cancer survivors at elevated HF risk; future research should determine whether reducing inflammation lowers that risk.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46077","type":"article","url":"https://hartvaat.nl/2026/04/17/restrictief-vullingspatroon-voorspelt-heropname-bij-acuut-gedecompenseerd-hfpef-/","title":"Restrictief vullingspatroon voorspelt heropname bij acuut gedecompenseerd HFpEF (KCHF-register)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004093?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004093?rss=1","authors":["Miyoshi","Y.","Kato","T.","Morimoto","T.","Ozasa","N.","Yaku","H.","Inuzuka","Y.","Tamaki","Y.","Yamamoto","E.","Yoshikawa","Y.","Kitai","T.","Iguchi","M.","Nagao","K.","Kawase","Y.","Morinaga","T.","Furukawa","Y.","Ando","K.","Sato","Y.","Kuwahara","K.","Ono","K.","Kimura","T."],"significance":6,"published":"2026-07-21","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"A restrictive transmitral inflow pattern (E/A ratio ≥2) predicts poor prognosis in HF with reduced ejection fraction and after infarction, but its significance in HFpEF was unclear. From the Kyoto Congestive Heart Failure registry, 830 patients with acute decompensated HFpEF and available echo data were analysed. A restrictive filling pattern was present in 17.3%; these patients more often had prior atrial fibrillation, a supranormal ejection fraction (>65%) and higher BNP at discharge. The 1-year incidence of HF hospitalisation was clearly higher with a restrictive pattern (31.0% vs 18.1%), while all-cause death did not differ. After adjustment, the restrictive pattern remained independently associated with HF hospitalisation (HR 1.58) but not death. Transmitral inflow pattern is thus a simple echo marker of rehospitalisation risk in HFpEF.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46076","type":"article","url":"https://hartvaat.nl/2026/04/17/niet-invasieve-endotypering-met-stress-mri-verbetert-de-behandeling-van-angina-z/","title":"Niet-invasieve endotypering met stress-MRI verbetert de behandeling van angina zonder vernauwingen (ANOCA)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004135?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004135?rss=1","authors":["Bradley","C. P.","McKinley","G.","Orchard","V.","Tiller","C.","Stanley","B.","Ang","D.","Morrow","A. J.","Sykes","R.","Gildea","P.","Petty","M.","Brogan","R.","Carrick","D.","Collison","D.","Eteiba","H.","Ghattas","A.","Good","R.","Joshi","F.","Lindsay","M.","McCartney","P.","McGowan","J.","McGeoch","R.","Robertson","K. E.","Rocchiccioli","J. P.","Shaukat","A.","Watkins","S.","Kellman","P.","McConnachie","A.","Berry","C."],"significance":7,"published":"2026-07-21","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Patients with angina and no obstructive coronary artery disease (ANOCA) often receive empirical antianginal therapy that misses the underlying mechanism. In this randomised trial (Coronary Microvascular Angina CMR Imaging Trial; 250 patients with ANOCA after non-obstructive coronary angiography), stress perfusion CMR with myocardial blood-flow quantification (intervention) was compared with angiography-guided care (control). Stress CMR led to a new diagnosis in 53%, with microvascular angina in 51%. At 12 months, treatment satisfaction (TSQM-9) was substantially higher in the intervention group (difference 19.3 points), with more appropriate prescribing: more preventive therapy (86% vs 68%) and more targeted antianginals (more calcium channel blockers and long-acting nitrates). Non-invasive CMR-guided endotyping thus improves satisfaction and leads to more mechanism-targeted medication in ANOCA.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46075","type":"article","url":"https://hartvaat.nl/2026/04/21/delphi-consensus-over-uitgestelde-en-gemiste-diagnose-van-coronairlijden/","title":"Delphi-consensus over 'uitgestelde' en 'gemiste' diagnose van coronairlijden","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003998?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003998?rss=1","authors":["Van Schalkwijk","D. L.","Dobbe","A. S. M.","Mommersteeg","P. M. C.","Erkelens","D. C.","Zwart","D. L. M.","Meeder","J. G.","Rutten","F. H.","On behalf of the IMPRESS Consortium"],"significance":5,"published":"2026-07-21","source_date":"2026-04-21","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"A clear definition of delayed or missed coronary artery disease (CAD) diagnosis is lacking, hampering research into its scale and causes. Using a modified Delphi method, a panel of cardiologists (19), general practitioners (35), patients (55) and healthy citizens (34) developed consensus definitions for two domains: acute coronary syndrome (ACS) and chronic coronary syndrome (CCS). After four rounds, two definitions for delayed ACS were highly recommended and thirteen recommended; for missed ACS none reached the highest threshold. For CCS, two definitions for delayed diagnosis and one for missed diagnosis were highly recommended. No one-size-fits-all definition proved possible, reflecting the complexity and context-dependence of diagnostic pathways. The resulting framework and recommended definitions nonetheless provide a basis for comparable future research into delayed and missed CAD diagnoses.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46074","type":"article","url":"https://hartvaat.nl/2026/04/22/een-op-de-tien-volwassenen-met-een-aangeboren-hartafwijking-heeft-een-syndroom-e/","title":"Eén op de tien volwassenen met een aangeboren hartafwijking heeft een syndroom — en dat verhoogt de sterfte","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003971?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003971?rss=1","authors":["Umei","M.","Diller","G. P.","Brida","M.","Aw","T.-C.","Hoschtitzky","A.","Kempny","A.","Gatzoulis","M. A."],"significance":5,"published":"2026-07-21","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/","https://hartvaat.nl/kennis/cardiometabool/metabool-syndroom/"],"congress":"","summary_en":"Syndromic conditions frequently accompany congenital heart disease (CHD), but their distribution and prognostic impact in adults (ACHD) are poorly characterised. In this retrospective study of 9,826 ACHD patients from a tertiary centre, 10.9% had a syndromic diagnosis — most often Marfan syndrome (4.1%) and Down syndrome (3.6%), followed by Noonan and 22q11.2 deletion syndromes. Syndromic patients were younger, more often had pulmonary arterial hypertension (15% vs 6%) and sleep apnoea, but fewer traditional risk factors. Down syndrome clustered with atrioventricular septal defect and 22q11.2 deletion with conotruncal defects. In Tetralogy of Fallot, 22q11.2 deletion was often neither recognised nor tested in adulthood. A syndromic diagnosis was independently associated with higher all-cause mortality (HR 2.06). Better recognition and broader genetic screening may improve risk assessment in this growing patient population.","created":"2026-07-03T20:27:15Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46072","type":"article","url":"https://hartvaat.nl/2026/04/21/chirurgie-voor-aortaklependocarditis-blijft-hoogrisico-spoed-en-inotropie-sterks/","title":"Chirurgie voor aortaklependocarditis blijft hoogrisico: spoed en inotropie sterkste voorspellers van sterfte","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003997?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003997?rss=1","authors":["Narayan","P.","Dong","T.","Chan","J.","Fudulu","D. P.","Angelini","G. D."],"significance":6,"published":"2026-07-20","source_date":"2026-04-21","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"Native aortic valve endocarditis is often complicated by heart failure, peri-annular extension and conduction disturbances, making surgery challenging. In this retrospective analysis of the UK NICOR registry, 3,694 patients underwent aortic valve replacement (AVR) for endocarditis (1996-2019; mean age 58, 22% female). In-hospital mortality was 7.8%. Non-survivors were older and more often had chronic kidney disease, diabetes, pulmonary disease, cardiogenic shock and poor ventricular function. On multivariable analysis, operative urgency (OR 2.49) and preoperative inotropic support (OR 2.24) were the strongest predictors of mortality, alongside NYHA III-IV, age, kidney disease and atrial fibrillation. More recent years of surgery were associated with better survival. Surgery for aortic valve endocarditis thus remains high risk, though outcomes have improved over time.","created":"2026-07-03T20:27:14Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46070","type":"article","url":"https://hartvaat.nl/2026/04/24/sekseverschillen-bij-infectieuze-endocarditis-vrouwen-vaker-conservatief-behande/","title":"Sekseverschillen bij infectieuze endocarditis: vrouwen vaker conservatief behandeld, slechtere overleving","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004026?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004026?rss=1","authors":["Dalebout","E. M.","Budde","R. P. J.","Galema","T. W.","Wahadat","A. R.","Swart","L. E.","Veen","K. M.","Verkaik","N. J.","Hirsch","A.","Kluin","J.","Roos-Hesselink","J. W."],"significance":6,"published":"2026-07-20","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/"],"congress":"","summary_en":"Although interest in male-female differences in cardiovascular disease is growing, evidence in infective endocarditis (IE) is limited and contradictory. This prospective study included 791 patients with definite or possible IE discussed by the endocarditis team (2016-2025; 73% male, 27% female). Women more often had mitral-valve IE, men more often aortic-valve IE, more predisposing conditions and more Cutibacterium. Although the indication for surgery did not differ, men were operated on more often (41% vs 29%), and women with a surgical indication were more often treated conservatively (37% vs 23%). Over a median 2.1-year follow-up, women had higher adjusted mortality (HR 1.39); after excluding non-operated patients with an indication, surgery appeared more protective in women than men. The findings point to sex differences in surgical decision-making and a less favourable prognosis in women.","created":"2026-07-03T20:27:14Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46069","type":"article","url":"https://hartvaat.nl/2026/04/22/eiwithandtekening-voorspelt-nierschade-bij-hypertensie-uk-biobank-nieuwe-risicos/","title":"Eiwithandtekening voorspelt nierschade bij hypertensie (UK Biobank): nieuwe risicoscore en doelwitten","title_en":"Proteomics Signatures of Chronic Kidney Disease in Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26477","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26477","authors":["Yu Huang"],"significance":7,"published":"2026-07-20","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"Hypertension is a major modifiable risk factor for chronic kidney disease (CKD), but predicting which patients will progress remains difficult. Using the UK Biobank Pharma Proteomics Project (22,258 hypertensive participants without baseline CKD), a plasma protein-based risk score was developed and validated (internal and external Scotland/Wales). A 13-protein score (C-index ~0.78) predicted incident CKD, with a simplified 3-protein panel (RNASE1, IGFBP4, GDF15) retaining most of the predictive power. Adding the score to the clinical model significantly improved discrimination, whereas a genetic (polygenic) eGFR score added nothing. Mendelian randomisation identified seven proteins with a causal signal, nominating FOLR1 and STC1 as potential treatment targets. The study thus provides a robust protein signature for hypertensive kidney disease and novel therapeutic targets.","created":"2026-07-03T20:27:14Z","updated":"2026-07-04T19:26:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46068","type":"article","url":"https://hartvaat.nl/2026/04/24/relatieve-apicale-sparing-op-strain-echo-voor-cardiale-amyloidose-meta-analyse-v/","title":"Relatieve apicale sparing op strain-echo voor cardiale amyloïdose: meta-analyse van 41 studies","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004143?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004143?rss=1","authors":["Ahmad","O.","Khan","M. I.","Omer","M. H.","Alzahrani","T.","Janjua","M.","Echahidi","Z.","Kharabsheh","S. M.","Tournoux","F.","AlSergani","H.","Damy","T.","Lairez","O.","Vieira","R. J.","Mohty","D."],"significance":7,"published":"2026-07-20","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"Cardiac amyloidosis (CA) is often missed due to non-specific clinical and echocardiographic features. This systematic review and meta-analysis (41 studies, 3,473 CA patients and 4,525 comparators) evaluated the diagnostic accuracy of the relative apical sparing (RELAPS) pattern on speckle-tracking echocardiography — apical longitudinal strain divided by the sum of basal and mid-ventricular strain. Pooled AUC was 0.82, with sensitivity 66% and specificity 83%. The AL subtype had the highest specificity (93%) and ATTR 84%, with no significant difference between subtypes. Performance varied clearly by analysis software (GE EchoPAC and Philips QLAB better than TomTec). RELAPS thus offers moderate diagnostic accuracy with good specificity but modest sensitivity — useful as a red flag, provided standardised measurement and prespecified cut-offs are used.","created":"2026-07-03T20:27:14Z","updated":"2026-07-04T19:09:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46067","type":"article","url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","title":"CONFIDENT-HFpEF: machine-learning voorspelt sterfte en opname beter dan bestaande risicoscores","title_en":"CONFIDENT-HFpEF: A Machine Learning-Based Risk Stratification for Mortality and Hospitalization Using Multimodal Real-World Data.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag097","source_url":"https://doi.org/10.1093/eschf/xvag097","authors":["Marat Fudim","Vanessa Van Empel","Tobias Zehnder","Benoit Sauty","Christian Esposito","Félix Balazard","Imke Mayer","Mohammad Hallal","Nicolas Loiseau","Jerremy Weerts","Manesh Patel","Suresh Balu","Bradley Hintze","Francisco Torres","Mariann Micsinai","Marzia Rigolli","Paul Kessler","Maxime Touzot","Lars H Lund","Aruna Pradhan","Javed Butler"],"significance":6,"published":"2026-07-20","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"Heart failure with preserved ejection fraction (HFpEF) is heterogeneous, with high morbidity and mortality; accurate risk stratification matters for both care and drug development. The observational CONFIDENT study included 1,208 HFpEF patients (HFA-PEFF criteria) across three centres in Europe and the US (2013-2022), using electronic health records, labs, echocardiography and ECG. Machine-learning models were developed for all-cause mortality and HF hospitalisation. The mortality model achieved fair-to-good discrimination (C-index 0.68-0.72) and performed significantly better than the validated PREDICT-HFpEF and MAGGIC scores across cohorts; the hospitalisation model also outperformed both, including MAGGIC plus natriuretic peptide. Using routinely collected variables, these models can thus reliably predict outcomes and may support personalised care and trial recruitment in HFpEF.","created":"2026-07-03T20:27:14Z","updated":"2026-07-04T19:26:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46065","type":"article","url":"https://hartvaat.nl/2026/04/14/sporten-op-je-eigen-bioritme-verlaagt-de-bloeddruk-meer-een-gerandomiseerde-stud/","title":"Sporten op je eigen bioritme verlaagt de bloeddruk meer: een gerandomiseerde studie","title_en":"Chronotype-aligned exercise timing in middle-aged adults at cardiometabolic risk: a randomised controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open heart","doi":"10.1136/openhrt-2025-003573","source_url":"https://doi.org/10.1136/openhrt-2025-003573","authors":["Arsalan Tariq","Mohammed Harris Khalid","Muhammad Ammar"],"significance":6,"published":"2026-07-19","source_date":"2026-04-14","image":"https://hartvaat.nl/global/img/372e0e9f682d.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"Aligning the timing of exercise with chronotype ('morning' or 'evening' type) may yield greater cardiometabolic benefit. In this 12-week randomised trial (Lahore, Pakistan; 150 sedentary adults aged 40-60 with at least one cardiovascular risk factor), chronotype was determined by questionnaire and confirmed with 48-hour core body-temperature monitoring. Participants trained supervised (5×/week, 40 min moderate intensity) either at their preferred time (chronotype-aligned, CAE) or at their non-preferred time (CME). The CAE group improved significantly more in systolic blood pressure (-10.8 vs -5.5 mmHg), diastolic blood pressure, heart-rate variability (RMSSD), peak VO2, LDL, fasting glucose and sleep quality (PSQI). Matching exercise to individual chronotype could thus be a low-cost, personalised way to improve cardiovascular health.","created":"2026-07-03T20:27:13Z","updated":"2026-07-04T19:26:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46063","type":"article","url":"https://hartvaat.nl/2026/04/12/lipidenmanagement-bij-type-2-diabetes-richt-je-op-alle-atherogene-lipoproteinen-/","title":"Lipidenmanagement bij type 2-diabetes: richt je op álle atherogene lipoproteïnen (non-HDL-cholesterol)","title_en":"Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03166-4","source_url":"https://doi.org/10.1186/s12933-026-03166-4","authors":["Julia Brandts","Marlo Verket","Alberto Zambon","Nikolaus Marx","Dirk Müller-Wieland","Massimo Federici"],"significance":6,"published":"2026-07-19","source_date":"2026-04-12","image":"https://hartvaat.nl/global/img/cccce4a31502.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in diabetes, partly driven by dyslipidaemia. Although LDL cholesterol (LDL-C) is the primary treatment target, many patients with diabetes have mixed dyslipidaemia with elevated triglycerides and atherogenic remnant lipoproteins, better captured by non-HDL cholesterol (non-HDL-C). Guidelines from the ADA, AACE and ESC recommend both LDL-C and non-HDL-C targets based on individual risk, yet target attainment remains suboptimal in practice. Statins, ezetimibe, bempedoic acid and PCSK9 inhibitors effectively lower LDL-C and non-HDL-C and reduce cardiovascular risk; triglyceride-lowering agents (omega-3, fibrates) lower triglycerides but their effect on hard outcomes remains uncertain. This review argues for using non-HDL-C and apolipoprotein B (apoB) alongside LDL-C as measures of atherogenic burden, and for more targeted treatment of residual atherogenic particles in diabetes.","created":"2026-07-03T20:27:13Z","updated":"2026-07-04T19:26:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46062","type":"article","url":"https://hartvaat.nl/2026/04/09/prefers-stockholm-nieuw-ontstaan-hfpef-heeft-slechtere-langetermijnuitkomsten-da/","title":"PREFERS Stockholm: nieuw ontstaan HFpEF heeft slechtere langetermijnuitkomsten dan HFrEF en HFmrEF","title_en":"Worse Long-Term Outcomes in New-Onset HFpEF vs HFrEF and HFmrEF: Findings from the Stockholm PREFERS Study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag105","source_url":"https://doi.org/10.1093/eschf/xvag105","authors":["Hans Persson","Anton Winderud","Camilla Hage","Carin Corovic Cabrera","Ulrika Löfström","Patrik Lyngå","Taner Arslan","Karin Knudsen-Malmqvist","Maria J Eriksson","Bengt Persson","Håkan Wallen","Mattias Ekström","Cecilia Linde"],"significance":7,"published":"2026-07-19","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Prospective outcome data for new-onset heart failure (HF) by ejection-fraction category are scarce. The Stockholm PREFERS study followed 547 patients with new-onset HF treated in specialised HF clinics (HFpEF 25%, HFmrEF 11%, HFrEF 64%; median EF 55%, 45% and 30%). The primary endpoint was cardiovascular death or first HF hospitalisation. Over a median 3.8-year follow-up, HFpEF patients had a higher risk of the primary endpoint than HFmrEF and HFrEF combined (adjusted HR 1.7). Moreover, at one year NT-proBNP fell markedly in HFmrEF (-42%) and HFrEF (-55%) with rising EF, whereas in HFpEF the EF actually fell by 5 percentage points and NT-proBNP was unchanged. The study underscores the severity of HFpEF — often underestimated — and the need for more effective treatment strategies.","created":"2026-07-03T20:27:12Z","updated":"2026-07-04T19:26:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46060","type":"article","url":"https://hartvaat.nl/2026/04/15/opleidingsniveau-verandert-het-effect-van-diabetes-op-de-sterfte-bij-hartfalen-i/","title":"Opleidingsniveau verandert het effect van diabetes op de sterfte bij hartfalen (India)","title_en":"Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open heart","doi":"10.1136/openhrt-2025-003833","source_url":"https://doi.org/10.1136/openhrt-2025-003833","authors":["Panniyammakal Jeemon","Sunu C Thomas","Ajay Bahl","Ambuj Roy","Animesh Mishra","Jayesh Prajapati","Manjunath C Nanjappa","Rishi Sethi","Santanu Guha","Satheesh Santhosh","Rupinder S Dhaliwal","Meenakshi Sharma","Sanjay Ganapathi","Girish Palleda","Nirav Kumar","Susheel Malani","Prakash Negi","Aditya Kapoor","Dharmendra Jain","Sandeep Chowdhary","Smit Shrivastava","Balbir Singh Yadav","Sivadasanpillai Harikrishnan"],"significance":6,"published":"2026-07-19","source_date":"2026-04-15","image":"https://hartvaat.nl/global/img/5855ca4721f7.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"Patients with both heart failure (HF) and diabetes are often prescribed complex regimens, but their impact may depend on social determinants such as educational attainment. This analysis of India's National Heart Failure Registry (10,850 patients, 53 hospitals, 21 states) followed patients for one year. Cumulative 1-year mortality was 22.1%. Diabetes was associated with 10% higher mortality (HR 1.10), and higher education independently with lower mortality. Compared with patients without diabetes and low education, those with both diabetes and low education had 25% higher risk of death (HR 1.25), whereas those with diabetes and higher education had 22% lower risk (HR 0.78). A significant interaction was found: the adverse effect of diabetes is greater among the less educated. The findings underscore the importance of health literacy and equitable access to care to reduce disparities in heart failure.","created":"2026-07-03T20:27:12Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46058","type":"article","url":"https://hartvaat.nl/2026/04/17/atriumfibrilleren-in-catalonie-prevalentie-gestabiliseerd-incidentie-gedaald-2-v/","title":"Atriumfibrilleren in Catalonië: prevalentie gestabiliseerd, incidentie gedaald, 2% van het zorgbudget","title_en":"Epidemiology, economic burden and mortality of atrial fibrillation in a region with very high life expectancy: a contemporary, population-based analysis in Catalonia.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open heart","doi":"10.1136/openhrt-2026-004007","source_url":"https://doi.org/10.1136/openhrt-2026-004007","authors":["Benjamin Casteigt","Emili Vela","Ermengol Valles","Carlos Eduardo González-Matos","Jesus Jimenez Lopez","Pasquale Valerio Falzone","Gianluca Guelfand Crignola","Giulia Garosi","Josep Comin-Colet","Josepa Mauri","Helena Tizón-Marcos","Miguel Cainzos-Achirica"],"significance":6,"published":"2026-07-19","source_date":"2026-04-17","image":"https://hartvaat.nl/global/img/27c554ca82e8.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"The high prevalence of atrial fibrillation (AF) is a public-health challenge, especially in ageing societies. This retrospective population-based study used the Catalan public health system database (8 million people, 2019-2023). Age-standardised AF prevalence remained stable at 2.5%, while incidence fell slightly (from 3.8 to 3.6 per 1,000). The 2023 AF population had a median age of 77.6 years and a high comorbidity burden: heart failure (37.6%), obesity (33.8%) and coronary disease (26.7%). Low socioeconomic status was associated with higher AF prevalence. AF was modestly associated with all-cause mortality (OR 1.25), and its healthcare costs were estimated at 2% of the annual Catalan health budget. In a high-life-expectancy region, AF prevalence thus appears to be plateauing, with a high disease burden and substantial economic impact.","created":"2026-07-03T20:27:11Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46057","type":"article","url":"https://hartvaat.nl/2026/04/21/jacc-beschouwing-placebo-in-trials-met-incretine-therapie-bij-hartfalen-wetensch/","title":"JACC-beschouwing: placebo in trials met incretine-therapie bij hartfalen — wetenschap versus ethiek","title_en":"Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2026.02.5086","source_url":"https://doi.org/10.1016/j.jacc.2026.02.5086","authors":["Francesco Fioretti","Mark C Petrie","Neal W Dickert","Javed Butler"],"significance":5,"published":"2026-07-18","source_date":"2026-04-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"GLP-1 receptor agonists and dual GIP/GLP-1 agonists improve symptoms and function in heart failure with preserved ejection fraction (HFpEF) and obesity, but the trials were small with few hard events. At the same time, these drugs have proven cardiovascular and renal benefits in obesity, diabetes and kidney disease, raising questions about placebo use in future heart-failure trials. In this JACC viewpoint, the authors weigh the scientific, practical and ethical considerations: placebo ensures methodologic rigour but may be ethically problematic given the cardiometabolic benefit, whereas abandoning placebo risks incomplete safety and efficacy data. They introduce a structured framework for when placebo remains appropriate, when active comparison is needed, and how trial design can address the ethical and operational challenges — aiming for definitive evidence to inform guidelines and reimbursement.","created":"2026-07-03T20:27:11Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46056","type":"article","url":"https://hartvaat.nl/2026/04/21/lp-a-bepaling-sterk-onderbenut-bij-patienten-met-atherosclerotische-hart-en-vaat/","title":"Lp(a)-bepaling sterk onderbenut bij patiënten met atherosclerotische hart- en vaatziekten (Australië)","title_en":"Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology Network.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":[],"journal":"Heart, lung & circulation","doi":"10.1016/j.hlc.2025.11.017","source_url":"https://doi.org/10.1016/j.hlc.2025.11.017","authors":["David Eccleston","Enayet K Chowdhury","Anna Williamson","Meherin Rahman","Catherine Sciascia","Ravi Santani","Renae Deans"],"significance":5,"published":"2026-07-18","source_date":"2026-04-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Elevated lipoprotein(a) (Lp(a)) is a genetically determined causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This retrospective study analysed over 1.1 million de-identified records from a large Australian cardiology network (2011-2022) using natural language processing. Lp(a) testing in ASCVD patients was rare but rising: from 0.9% in the historical cohort to 2.6% in 2022. Of tested patients with a recorded value, 25% had Lp(a) >90 mg/dL (historical) and 30% ≥70 mg/dL (recent), while 87% were already on lipid-lowering therapy. Despite guidelines recommending testing, Lp(a) measurement remains markedly underused — a missed opportunity to identify high-risk patients, especially as targeted Lp(a)-lowering therapies are in development.","created":"2026-07-03T20:27:11Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46054","type":"article","url":"https://hartvaat.nl/2026/04/27/consensus-breid-het-cardio-renaal-metabool-syndroom-uit-met-de-lever-cklms-in-de/","title":"Consensus: breid het cardio-renaal-metabool syndroom uit met de lever (CKLMS) in de eerste lijn","title_en":"Assessment and management of cardiovascular-kidney-liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European journal of internal medicine","doi":"10.1016/j.ejim.2026.106902","source_url":"https://doi.org/10.1016/j.ejim.2026.106902","authors":["Reinhold Kreutz","Ali Canbay","Martin Haluzik","Andrzej Januszewicz","Juan M Mendive","Pantelis Sarafidis","Jörn M Schattenberg"],"significance":7,"published":"2026-07-18","source_date":"2026-04-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"The recently introduced cardiovascular-kidney-metabolic (CKM) syndrome captures the close interplay between metabolic risk factors, chronic kidney disease and cardiovascular disease, but underestimates the role of the liver. Metabolic dysfunction-associated steatotic liver disease (MASLD) — the world's most prevalent chronic liver disease — is strongly linked to cardiovascular events, kidney-disease progression and mortality, yet is often missed in practice. This multidisciplinary consensus statement proposes the concept of a cardiovascular-kidney-liver-metabolic syndrome (CKLMS) and offers a practical, primary-care-centred framework. Using accessible, validated tools — blood pressure and lipid profiling, kidney function and albuminuria, non-invasive liver fibrosis testing, and screening for diabetes and obesity — cardiovascular, renal, hepatic and metabolic risk are stratified together. It emphasises early lifestyle intervention, drugs with multi-organ benefit, and clear referral pathways, positioning the primary-care physician as coordinator of longitudinal, patient-centred care.","created":"2026-07-03T20:27:11Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46053","type":"article","url":"https://hartvaat.nl/2026/04/07/kosteneffectiviteit-van-stapsgewijze-lipidenverlaging-na-coronaire-bypasschirurg/","title":"Kosteneffectiviteit van stapsgewijze lipidenverlaging na coronaire bypasschirurgie","title_en":"Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.124.040272","source_url":"https://doi.org/10.1161/JAHA.124.040272","authors":["Salil V Deo","Giorgio Ciminata","Gauranga Mahalwar","Pedro R V O Salerno","David A McAllister","Yakov E Elgudin","Ariela Orkaby","Salim Virani","Stephen Fremes","Sanjay Rajagopalan","Naveed Sattar","Jill P Pell"],"significance":6,"published":"2026-07-18","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/statines-overzicht/","https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"","summary_en":"Lipid-lowering therapy (LLT) is important after coronary artery bypass grafting (CABG), but cost limits wider use of PCSK9 inhibitors and newer agents. In a nationwide cohort of US veterans after CABG, the investigators used Monte Carlo simulations to model stepwise initiation of high-intensity statins, ezetimibe and a PCSK9 inhibitor toward LDL targets, followed by a lifetime Markov model with events (stroke, myocardial infarction, revascularisation and death). The aim was to compare the cost-effectiveness of this stepwise LLT approach with observed practice from the health-care perspective. The study provides a framework to inform targeted, stepwise use of costlier lipid-lowering agents.","created":"2026-07-03T20:27:11Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46051","type":"article","url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","title":"Zorgpaden na nieuw vastgesteld atriumfibrilleren: rol van de elektrofysioloog en uitkomsten","title_en":"Patient Care Pathways and Outcomes Following Newly Diagnosed Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046111","source_url":"https://doi.org/10.1161/JAHA.125.046111","authors":["Emily P Zeitler","Larry R Jackson","Andrea Natale","Jonathan P Piccini","Sean D Pokorney","Andrea M Russo","Roopinder K Sandhu","Rahul Khanna","Maximiliano Iglesias","Yiran Rong","T Jared Bunch"],"significance":6,"published":"2026-07-18","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"Care pathways in atrial fibrillation (AF) are poorly characterised and may influence guideline-concordant treatment. In the Optum database (37,370 patients with incident AF, 2015–2023), 20.6% had a pathway including an electrophysiologist visit. Older patients and those with a higher CHA2DS2-VASc score were less likely to see an electrophysiologist. An electrophysiologist visit was associated with more antiarrhythmic therapy and oral anticoagulation, and in patients aged 80+ with lower stroke risk (HR 0.63). Guideline-concordant care and better outcomes — especially in the highest stroke-risk groups — were thus associated with electrophysiology pathways, even though high-risk groups received that care less often.","created":"2026-07-03T20:27:10Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46049","type":"article","url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","title":"Vrouwen hebben slechtere uitkomsten na een herseninfarct ondanks antistolling bij atriumfibrilleren (ASPERA-R)","title_en":"Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted Analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.047064","source_url":"https://doi.org/10.1161/JAHA.125.047064","authors":["Matteo Foschi","Lucio D'Anna","Francesca Gabriele","Raffaele Ornello","Andrea Zini","Matteo Paolucci","Stefano Forlivesi","Ludovica Migliaccio","Maria Maddalena Viola","Angelo Cascio Rizzo","Maria Sessa","Ghil Schwarz","Rachele Tortorella","Soma Banerjee","Gaurav Desai","Muhammad Jaffar","Gabriele Prandin","Leonardo Pantoni","Francesco Mele","Giuseppe Scopelliti","Ilaria Cova","Mariarosaria Valente","Domenico Maisano","Luca Antonelli","Maria Rosaria Bagnato","Giovanni Di Mauro","Francesca Bernocchi","Martina Gaia Di Donna","Barbara Casolla","Perla Mazloum","Chiara Bruno","Baptiste Alvarez","Laura González-Martín","Ricardo Rigual","Blanca Fuentes","Carlos Hervás","Paolo Candelaresi","Vincenzo Andreone","Antonio De Mase","Emanuele Spina","Diana Aguiar de Sousa","Mariana Almudi Souza","Alberto Fior","Miguel Serôdio","Pietro Caliandro","Aurelia Zauli","Giuseppe Reale","Ahmed Abdelalim","Sandra Ahmed","Nourhan Mohamed Soliman","Liqun Zhang","Tara Latimer","Muhammad Elboghday","Ahmed Aly Elbassiouny","Tamer Roushdy","Hossam Shokri","Federica Ferrari","Nicola Davide Loizzo","Federico Mazzacane","Maria Guarino","Valentina Barone","Paola Forti","Giuseppe Rinaldi","Marco Vito Rossi","Vincenzo Laterza","Giovanni Frisullo","Pier Andrea Rizzo","Aldobrando Broccolini","Marina Mannino","Valeria Terruso","Marcella Caggiula","Guglielmo Lucchese","Ana Catarina Fonseca","Bernardo Antunes","Ana M Barbosa","Hrvoje Budincevic","Petra Crnac","Giovanna Viticchi","Mauro Silvestrini","Lorenzo Barba","Viktoria Musienko","Markus Otto","Piergiorgio Lochner","Benjamin Landau","Sandeep Buddha","Roumeisa Khalil","Maria Grazia Piscaglia","Elena Minguzzi","Marialuisa Zedde","Ahmed Nasreldein","Luisa Vinciguerra","Luis Costa","Ahmed Elsaid Elsayed","Mona AlBanna","Laura Tudisco","Maria Giulia Mosconi","Giovanni Merlino","Alexandros Polymeris","Federico De Santis","Simona Sacco"],"significance":7,"published":"2026-07-17","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-ckd/"],"congress":"","summary_en":"Sex-specific outcomes after breakthrough ischaemic stroke on oral anticoagulation (OAC) in atrial fibrillation were unknown. In the international retrospective ASPERA-R study (1,649 patients, 52% women, mean age 78), women were older and had more severe baseline impairment. After inverse-probability weighting, women were less likely to return to baseline neurologic function (35.2% vs 42.7%; adjusted RR 0.82), had a worse mRS distribution and more recurrent stroke/TIA (adjusted HR 1.70), with a trend toward more major bleeding. Significant sex interactions were seen for OAC type, endovascular treatment and OAC restart. The findings argue for sex-aware management.","created":"2026-07-03T20:27:10Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46048","type":"article","url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-lipiden-en-lipoproteinen-en-het-cardiovasculaire-risico-uk-b/","title":"Sekseverschillen in lipiden en lipoproteïnen en het cardiovasculaire risico (UK Biobank)","title_en":"Sex Differences in Lipids and Lipoproteins and Their Relationship With Cardiovascular Disease: A Prospective Study of UK Biobank Participants.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.045533","source_url":"https://doi.org/10.1161/JAHA.125.045533","authors":["Rebecca K Kelly","Katie Harris","Paul Muntner","Mark Woodward"],"significance":7,"published":"2026-07-17","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Sex differences in serum lipids are recognised, but their relationship with cardiovascular disease has not been reliably quantified. In 432,092 UK Biobank participants without cardiovascular disease (median follow-up 13.3 years; 10,699 events in women, 18,950 in men), sex-specific associations of lipids and apolipoproteins with incident CVD were examined. LDL cholesterol, apoB and log-Lp(a) were more strongly associated with risk in men than women (women-to-men HR ratios ~0.94–0.96), whereas triglycerides were more strongly associated with risk in women (ratio 1.06). ApoA1 was less protective in women. Men had higher absolute risk overall. These sex differences argue for sex-specific interpretation of the lipid profile.","created":"2026-07-03T20:27:10Z","updated":"2026-07-04T19:26:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46046","type":"article","url":"https://hartvaat.nl/2026/04/16/lp-a-en-hscrp-voorspellen-ascvd-bij-mensen-zonder-klassieke-risicofactoren/","title":"Lp(a) én hsCRP voorspellen ASCVD bij mensen zónder klassieke risicofactoren","title_en":"Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag221","source_url":"https://doi.org/10.1093/eurjpc/zwag221","authors":["Richard Kazibwe","Christopher L Schaich","Jeff A Kingsley","Parag Chevli","Saeid Mirzai","Rishi Rikhi","Soroush Masrouri","Leandro Slipczuk","Michael D Shapiro"],"significance":7,"published":"2026-07-17","source_date":"2026-04-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"The combined value of lipoprotein(a) [Lp(a)] and high-sensitivity CRP (hsCRP) in primary prevention among people without standard modifiable risk factors (SMuRF-less: no smoking, obesity, hypertension, dyslipidaemia or diabetes) was unclear. In 50,450 SMuRF-less UK Biobank participants, 1,104 (2.2%) ASCVD events occurred over 15 years. Both elevated hsCRP (sHR 1.35) and elevated Lp(a) (sHR 1.24) were independently associated with ASCVD; risk was highest with concurrent elevation of both (sHR 1.64, and 1.74 using clinical cutoffs Lp(a) ≥125 nmol/L and hsCRP ≥2.0 mg/L). Combined Lp(a) and hsCRP assessment thus provides complementary risk information, even in apparently low-risk individuals.","created":"2026-07-03T20:27:10Z","updated":"2026-07-04T19:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46045","type":"article","url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","title":"PANDORA-register: supra- versus intra-annulaire kleppen bij TAVR-in-TAVR","title_en":"Supra-Annular Versus Intra-Annular Devices for Transcatheter Aortic Valve-in-Valve Replacement: The PANDORA International Registry.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046180","source_url":"https://doi.org/10.1161/JAHA.125.046180","authors":["Antonio Popolo Rubbio","Antonio Sisinni","Enrico Criscione","Enrico Poletti","Nicolas Van Mieghem","Gaspare S Cannone","Didier Tchétché","Azeem Latib","Andrea Scotti","Ole De Backer","Michele Morosato","Damiano Regazzoli","Ignacio A Santos","Michiel Voskuil","Matjaz Bunc","David Hildick-Smith","Joachim Schofer","Christina Brinkmann","Kush P Patel","Andreas Baumbach","Francesco Bedogni","Luca Testa"],"significance":7,"published":"2026-07-17","source_date":"2026-04-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"As transcatheter aortic valve replacement (TAVR) extends to younger, lower-risk patients, the need for repeat procedures (TAVR-in-TAVR) is rising. The international PANDORA registry (172 TAVR-in-TAVR procedures from ~30,000 TAVRs; median interval 1,401 days) compared supra-annular (SAV) and intra-annular (IAV) valve combinations. Structural valve deterioration was the leading failure mechanism (78%). VARC-3 technical success was 91% and 30-day device success 68% — limited by elevated residual gradients (≥20 mmHg in 13%) and 30-day mortality of 7.3%. The IAV-IAV combination had the numerically lowest 1-year freedom from death or heart-failure hospitalisation. Male sex and CKD predicted mortality. TAVR-in-TAVR is feasible, but the valve combination affects outcomes.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46044","type":"article","url":"https://hartvaat.nl/2026/04/17/lagere-kaliuminname-hangt-samen-met-meer-hart-en-vaatziekte-bij-ckd-vooral-bij-v/","title":"Lagere kaliuminname hangt samen met meer hart- en vaatziekte bij CKD — vooral bij vrouwen","title_en":"Sex-Specific Cardiovascular Risk of Lower Potassium Intake in Patients with CKD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag226","source_url":"https://doi.org/10.1093/eurjpc/zwag226","authors":["Tatsuya Suenaga","Shigeru Tanaka","Hiromasa Kitamura","Kazuhiro Okamura","Shunsuke Yamada","Kazuhiko Tsuruya","Toshiaki Nakano","Tetsuro Ago"],"significance":6,"published":"2026-07-17","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Lower potassium intake is associated with more cardiovascular disease (CVD) in the general population, with sex differences. In this Japanese prospective study (Fukuoka Kidney Disease Registry; 4,314 patients with chronic kidney disease, 5-year follow-up), estimated potassium intake (from spot urine) was related to cardiovascular events. Over five years, 431 patients had an event. There was a significant interaction with sex (p<0.001): in women, lower potassium intake was strongly associated with more events (HR 2.97), but not in men (HR 0.98). In CKD, low potassium intake thus appears to be a risk particularly in women — though potassium management in CKD requires caution because of hyperkalaemia risk.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46043","type":"article","url":"https://hartvaat.nl/2026/04/20/biomarkers-voorspellen-coronairlijden-bij-atriumfibrilleren-regards/","title":"Biomarkers voorspellen coronairlijden bij atriumfibrilleren (REGARDS)","title_en":"Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.045735","source_url":"https://doi.org/10.1161/JAHA.125.045735","authors":["Andres Cordova Sanchez","Katherine Wilkinson","Samuel A P Short","Virginia J Howard","Suzanne E Judd","Parag Goyal","Elsayed Z Soliman","Emily B Levitan","Monika M Safford","Mary Cushman"],"significance":7,"published":"2026-07-16","source_date":"2026-04-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Atrial fibrillation (AF) was recently identified as a risk factor for coronary heart disease (CHD), but the pathophysiology is unclear. In the REGARDS cohort, 13 cardiovascular biomarkers were measured in 1,818 participants with AF (no prior stroke or CHD). Over nine years, 201 (11%) developed CHD. Several markers were associated with incident CHD (NT-proBNP, GDF-15, CRP, IL-6, D-dimer, cholesterol, Lp(a), triglycerides, LDL and GGT; HR 1.17–1.69 per SD), strongest for NT-proBNP (HR 1.69) and GDF-15 (HR 1.45). Top-versus-bottom tertile, NT-proBNP, IL-6 and GDF-15 were strongest. Myocardial strain (NT-proBNP) and inflammation appear to drive CHD risk in AF.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46041","type":"article","url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","title":"Nierfunctiestoornis verergert pulmonale vaatziekte bij HFpEF","title_en":"Kidney Dysfunction and Pulmonary Vascular Disease in Heart Failure with preserved Ejection Fraction.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"European journal of heart failure","doi":"10.1093/ejhf/xuag140","source_url":"https://doi.org/10.1093/ejhf/xuag140","authors":["Matthew B Amdahl","Jwan A Naser","Atsushi Tada","Shunichi Doi","Tomonari Harada","Tatsuro Ibe","Jeffrey M Testani","Vojtech Melenovsky","Yogesh N V Reddy","Barry A Borlaug"],"significance":7,"published":"2026-07-16","source_date":"2026-04-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Chronic kidney disease (CKD) is common in heart failure with preserved ejection fraction (HFpEF) and is linked to worse outcomes via unclear mechanisms. In this cohort of 925 HFpEF patients undergoing invasive haemodynamic exercise testing (34.5% with eGFR <60), worse kidney function was associated with higher biventricular filling pressures, lower cardiac output and — most strikingly — increasing pulmonary vascular disease: pulmonary vascular resistance rose and pulmonary arterial compliance fell as kidney function declined. During exercise these differences became even more pronounced, with the greatest cardiac-output limitation in the worst kidney function. CKD thus contributes to progressive pulmonary vascular disease in HFpEF.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46040","type":"article","url":"https://hartvaat.nl/2026/04/02/aha-verklaring-geavanceerde-karakterisering-van-rechterventrikelfalen/","title":"AHA-verklaring: geavanceerde karakterisering van rechterventrikelfalen","title_en":"Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001422","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001422","authors":["Soni Savai Pullamsetti"],"significance":7,"published":"2026-07-16","source_date":"2026-04-02","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortaregurgitatie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Right ventricular (RV) dysfunction is a major predictor of outcomes in pulmonary hypertension and beyond. This American Heart Association scientific statement describes how chronic pressure overload first drives adaptive RV hypertrophy and then maladaptive remodelling with dilation, fibrosis, stiffness and RV–pulmonary arterial uncoupling, ultimately causing right heart failure. It synthesises advanced molecular, metabolic and imaging approaches to characterising RV failure — relevant not only to (pulmonary arterial) hypertension but also to HFpEF, congenital heart disease and other systemic conditions.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46038","type":"article","url":"https://hartvaat.nl/2026/04/07/multi-orgaan-inspanningstekorten-kenmerken-de-aanleg-voor-hfpef/","title":"Multi-orgaan inspanningstekorten kenmerken de aanleg voor HFpEF","title_en":"Multiorgan Physiological Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure With Preserved Ejection Fraction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077579","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077579","authors":["Isabela Landsteiner"],"significance":7,"published":"2026-07-16","source_date":"2026-04-07","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/invasieve-hemodynamiek-rechts-hartkatheterisatie/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Exercise unmasks the limited multi-organ reserve characteristic of heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary exercise testing (iCPET), metabolite profiling and genomics, the investigators characterised seven exercise physiologic deficits in HFpEF patients: reduced exercise stroke volume and heart rate, a steep PCWP/cardiac-output slope, elevated pulmonary vascular resistance, pulmonary mechanical limitation, impaired peripheral oxygen extraction, and the obesity-related exaggerated metabolic cost of exercise. They mapped the distribution and the functional and prognostic significance of these deficits and linked them to molecular (metabolite and genetic) signatures — a step toward more targeted HFpEF phenotyping and risk assessment.","created":"2026-07-03T20:27:09Z","updated":"2026-07-04T19:26:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46037","type":"article","url":"https://hartvaat.nl/2026/04/09/pings-telefonische-verpleegkundig-geleide-bloeddrukcontrole-na-een-beroerte-ghan/","title":"PINGS: telefonische, verpleegkundig geleide bloeddrukcontrole na een beroerte (Ghana)","title_en":"Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077424","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077424","authors":["Fred Stephen Sarfo"],"significance":7,"published":"2026-07-16","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"In low-income countries, fewer than 10% of people with hypertension ever achieve blood-pressure control. The PINGS trial (Ghana, 10 hospitals, 500 patients with recent stroke and elevated blood pressure) compared usual care with a 12-month intervention: home blood-pressure self-monitoring with nurse case management, phone-alarm medication reminders, and weekly audio messages on risk reduction in local dialects. At 12 months, systolic blood pressure was a mean of 5.5 mmHg lower, and 67% of the intervention group reached a systolic below 140 mmHg versus 43% with usual care (24% difference). Low-tech mHealth with task-shifting to nurses can safely improve blood-pressure control in stroke survivors in low-resource settings.","created":"2026-07-03T20:27:08Z","updated":"2026-07-04T19:27:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46035","type":"article","url":"https://hartvaat.nl/2026/04/17/massieve-linkerventrikelhypertrofie-bij-kinderen-met-hypertrofische-cardiomyopat/","title":"Massieve linkerventrikelhypertrofie bij kinderen met hypertrofische cardiomyopathie (multiregisteranalyse)","title_en":"The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.078843","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.078843","authors":["Robert Przybylski"],"significance":8,"published":"2026-07-15","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Massive left ventricular hypertrophy (LVH) is a risk factor for sudden cardiac death in children with hypertrophic cardiomyopathy (HCM), but its natural history is poorly understood. This analysis from two large international registries (SHaRe and IPHCC) compares children with HCM with and without massive LVH — defined as maximal wall thickness ≥30 mm or a z-score ≥+20 before age 18 — using serial wall-thickness measurements and composite outcomes for major ventricular arrhythmia events (sudden cardiac death, aborted sudden cardiac death or appropriate ICD therapy) and heart failure. The study characterises the course and risk profile of this severe phenotype to support risk stratification and treatment decisions such as ICD implantation.","created":"2026-07-03T20:27:08Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46034","type":"article","url":"https://hartvaat.nl/2026/04/01/prevent-risicoscore-presteert-robuust-in-de-dagelijkse-ehr-praktijk/","title":"PREVENT-risicoscore presteert robuust in de dagelijkse EHR-praktijk","title_en":"Performance of PREVENT Cardiovascular Risk in Electronic Health Record-Based Clinical Practice.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2026.6838","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.6838","authors":["Chuan Hong","Mu Niu","Haoyuan Wang","Daniel M Wojdyla","Nicoleta Economou-Zavlanos","Matthew M Engelhard","Michael Pignone","Manesh R Patel","Michael J Pencina"],"significance":7,"published":"2026-07-15","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"The PREVENT equations (AHA, 2023) estimate cardiovascular risk in a race-free, sex-specific manner. In this retrospective cohort from the Duke health system (406,230 patients in the relaxed cohort; 127,151 with complete records), PREVENT showed good discrimination (C-index 0.75–0.77) that remained robust to missing laboratory and vital-sign data when imputation was applied. Calibration was better in the complete-record cohort; local adaptations modestly improved calibration. PREVENT thus appears reliable for risk estimation in routine practice.","created":"2026-07-03T20:27:08Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46032","type":"article","url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","title":"VISION: postoperatief atriumfibrilleren na hartchirurgie verhoogt sterfte na een jaar","title_en":"New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag236","source_url":"https://doi.org/10.1093/eurheartj/ehag236","authors":["William F McIntyre","P J Devereaux","Emilie P Belley-Cote","Jessica D Spence","Robin Zhao","Matthew T V Chan","Vladimir V Lomivorotov","Giovanni Landoni","Domenico Paparella","Graham S Hillis","Nicholas L Mills","Joel Parlow","Katheryn Brady","S Ming Chen","Leah Hayward","Clara Healey","Amna Ismaili","Ryan Louie","Charlotte McEwen","Courtney Mullen","Maia Shen","Charlotte Tan","Sandra Ofori","Jeff S Healey","Andre Lamy","Richard P Whitlock"],"significance":7,"published":"2026-07-15","source_date":"2026-04-08","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/"],"congress":"","summary_en":"In the prospective VISION Cardiac Surgery cohort (12,234 patients, 12 countries), new-onset postoperative atrial fibrillation (POAF) occurred in 31.8% within 30 days of cardiac surgery. Antithrombotic and antiarrhythmic management varied widely: 15.6% received anticoagulation alone, 54.3% antiplatelets alone, 24% both, and 49% amiodarone. At one year, clinical AF was detected in 6.9% of POAF patients versus 0.6% without (aHR 11.3), and all-cause mortality was higher (3.0% vs 1.7%; aHR 1.54). POAF after cardiac surgery is thus common and associated with both more AF and higher mortality in the first year.","created":"2026-07-03T20:27:08Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46031","type":"article","url":"https://hartvaat.nl/2026/04/09/cardiale-screening-van-jonge-sporters-eerste-eapc-aepc-consensus-voor-kinderen/","title":"Cardiale screening van jonge sporters: eerste EAPC/AEPC-consensus voor kinderen","title_en":"Cardiac evaluation of paediatric athletes.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag188","source_url":"https://doi.org/10.1093/eurheartj/ehag188","authors":["Guido E Pieles","Elena Cavarretta","Jessica J Orchard","Mark Abela","Elena Arbelo","Werner Budts","Silvia Castelletti","Guido Claessen","Domenico Corrado","Giovanni Di Salvo","Gherardo Finocchiaro","Peter Fritsch","Sabiha Gati","Stephan Gerling","M Cecilia Gonzalez-Corcia","Aneil Malhotra","Viviana Maestrini","Josef Niebauer","David Niederseer","Michael Papadakis","Renate Oberhoffer","Antonio Pelliccia","Nathan Riding","María Sanz-de la Garza","Georgia Sarquella-Brugada","Sanjay Sharma","Alan Graham Stuart","Monica Tiberi","Alessandro Zorzi","Flavio D'Ascenzi"],"significance":7,"published":"2026-07-15","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"Children are not simply 'mini-adults': existing athlete-screening recommendations are based on adults. This joint consensus document from the EAPC (ESC) and AEPC provides, for the first time, specific advice for athletes under 16. It recommends cardiac screening with personal and family history, physical examination and a 12-lead resting ECG, starting no later than age 12; an echocardiogram may be appropriate to detect structural disease missed by ECG. The document includes age-specific definitions of normal, borderline and abnormal ECG findings and stresses the need for more research and for training in paediatric sports cardiology.","created":"2026-07-03T20:27:08Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46029","type":"article","url":"https://hartvaat.nl/2026/04/10/genprobcad-gecombineerde-monogene-en-polygene-risicobepaling-voor-coronairlijden/","title":"GenProbCAD: gecombineerde monogene én polygene risicobepaling voor coronairlijden","title_en":"Development of an Integrated Monogenic and Polygenic Risk Assessment Tool for Coronary Artery Disease and Its Application in a Community-Based Health Care Biobank.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation. Genomic and precision medicine","doi":"10.1161/CIRCGEN.125.005494","source_url":"https://doi.org/10.1161/CIRCGEN.125.005494","authors":["Jianfeng Xu","Zhuqing Shi","Sumeet A Khetarpal","Ashley J Mulford","Osama Siddiqui","Huy Tran","Jun Wei","Annabelle Ashworth","S Lilly Zheng","David Duggan","Brian T Helfand","Henry M Dunnenberger","Peter J Hulick","David J Davidson","Amit V Khera","Aniruddh P Patel","Alan R Sanders","Arman Qamar"],"significance":8,"published":"2026-07-15","source_date":"2026-04-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Current genetic testing for coronary artery disease (CAD) mainly targets monogenic variants in severe hypercholesterolaemia. GenProbCAD combines monogenic pathogenic variants with polygenic risk scores for CAD and for lipoprotein(a), developed and validated in the UK Biobank (two cohorts of 226,145) and applied in a community biobank (20,477). The integrated score predicted CAD better than monogenic variants or the polygenic score alone and flagged 16% as high-risk — 46-fold more than monogenic carriers — with comparable CAD prevalence and consistent prediction across all LDL strata and ancestries. A universal strategy would hypothetically capture ~21% of all incident CAD, versus 0.3% with current monogenic testing.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46028","type":"article","url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","title":"Transkatheter-tricuspidalisreparatie bij hoogrisicopatiënten: real-world toets van de ESC/EACTS-aanbevelingen","title_en":"Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"JACC. Cardiovascular interventions","doi":"10.1016/j.jcin.2026.02.024","source_url":"https://doi.org/10.1016/j.jcin.2026.02.024","authors":["Lukas Stolz","Karl-Patrik Kresoja","Jennifer von Stein","Vera Fortmeier","Christoph Pauschinger","Wolfgang Rottbauer","Mohammad Kassar","Bjoern Goebel","Paolo Denti","Paul Achouh","Tienush Rassaf","Manuel Barreiro-Perez","Peter Boekstegers","Andreas Rück","Monika Zdanyte","Marianna Adamo","Flavien Vincent","Philipp Schlegel","Sebastian Rosch","Mirjam G Wild","Christian Besler","Stefan Toggweiler","Stephanie Brunner","Julia Grapsa","Tiffany Patterson","Holger Thiele","Tobias Kister","Giuseppe Tarantini","Giulia Masiero","Hannah Kempton","Marco De Carlo","Cristina Giannini","Fabian Voss","Amin Polzin","Antonio Popolo Rubbio","Francesco Bedogni","Thorald Stolte","Thomas Nestelberger","Tomás Benito-González","Enrique Sánchez-Muñóz","Martijn Vrijkorte","Martin Swaans","Mathias H Konstandin","Eric Van Belle","Marco Metra","Tobias Geisler","Rodrigo Estévez-Loureiro","Amir Abbas Mahabadi","Nicole Karam","Francesco Maisano","Philipp Lauten","Mirjam Kessler","Daniel Kalbacher","Volker Rudolph","Christos Iliadis","Philipp Lurz","Fabien Praz","Jörg Hausleiter"],"significance":7,"published":"2026-07-14","source_date":"2026-04-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"The 2025 ESC/EACTS guideline gives transcatheter tricuspid interventions a Class IIa recommendation but advises optimal medical therapy first in severe left- or right-ventricular dysfunction or precapillary pulmonary hypertension because of futility risk. In the EuroTR registry (1,626 patients with edge-to-edge repair, T-TEER), these 'OMT candidates' (13.1%) had lower 2-year survival free of heart-failure hospitalisation (58.7% vs 74.3%) but comparable symptomatic improvement (≥1 NYHA class in 56% vs 60%). T-TEER may thus offer symptomatic relief in selected high-risk patients; multidisciplinary evaluation at experienced valve centres remains essential.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46027","type":"article","url":"https://hartvaat.nl/2026/04/14/left-bundle-crt-linkerbundeltak-pacing-niet-aantoonbaar-non-inferieur-aan-bivent/","title":"LEFT-BUNDLE-CRT: linkerbundeltak-pacing niet aantoonbaar non-inferieur aan biventriculaire CRT","title_en":"Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag225","source_url":"https://doi.org/10.1093/eurheartj/ehag225","authors":["Óscar Cano","Víctor Pérez-Roselló","Andrea Di Marco","Javier Ramos-Maqueda","Pablo Moriña","Thomas Brouzet","Daniel Rodríguez-Muñoz","Víctor Castro","Sebastian Giacoman","Pablo Peñafiel","María Rodríguez-Serrano","Manuel Molina-Lerma"],"significance":7,"published":"2026-07-14","source_date":"2026-04-14","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/bundeltakblok/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized non-inferiority trial compared left-bundle branch area pacing (LBBAP) with biventricular pacing (BiVP) for cardiac resynchronization therapy in 176 patients with a CRT indication and typical left bundle branch block. The primary endpoint (CRT response at six months) was met in 94.6% with BiVP and 89.7% with LBBAP; non-inferiority of LBBAP was not demonstrated (RR 0.95; 95% CI 0.88–1.02). Both strategies yielded high response rates and similar clinical outcomes and complications. LBBAP remains a reasonable alternative, but this evidence does not support non-inferiority to BiVP.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46026","type":"article","url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","title":"ULYSSES: echogeleide venapunctie halveert toegangscomplicaties bij AF-ablatie","title_en":"Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag291","source_url":"https://doi.org/10.1093/eurheartj/ehag291","authors":["David Schaack","K R Julian Chun","Kars Neven","Andreas Metzner","Christian Heeger","Reza Wakili","Arian Sultan","Andrea Urbani","Nico Reinsch","Andreas Rillig","Henning Rolfes","Laura Rottner","Julia Vogler","Lukas Urbanek","Stefan Hartl","Joseph Kheir","Julia Alexandra Marx","Julia Lurz","Melanie A Gunawardene","Stefano Bordignon","Anna Fueting","Katharina Govorov","Fariba Rafiee","Matthias Hölzl","Matteo Rocchetti","Shota Tohoku","Boris Schmidt"],"significance":7,"published":"2026-07-14","source_date":"2026-04-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"The ULYSSES trial randomized 986 patients undergoing catheter ablation for atrial fibrillation or left atrial tachycardia to ultrasound-guided or conventional (palpation-based) femoral venous puncture. The trial stopped early for efficacy: vascular access-site complications occurred in 0.6% with ultrasound guidance versus 3.3% conventionally (risk ratio 0.19). Unintended arterial punctures (2% vs 16%) and failed venous access (0.2% vs 8.2%) also fell sharply. Ultrasound-guided venous puncture is therefore preferable for AF ablation procedures.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46025","type":"article","url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","title":"CAAN-AF: AV-knoopablatie verbetert CRT-uitkomsten bij permanent atriumfibrilleren niet","title_en":"Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag206","source_url":"https://doi.org/10.1093/eurheartj/ehag206","authors":["Prashanthan Sanders","Jonathan P Ariyaratnam","Martin K Stiles","Alexis Puvrez","Stephen J Nicholls","Walter P Abhayaratna","Mark J Perrin","Jeff Alison","Rajeev K Pathak","Anand Ganesan","Vincent Paul","Stuart P Thomas","Gijo Thomas","Melissa E Middeldorp","Elnaz Shahmohamadi","Adrian D Elliott","Robert Park","Haris Haqqani","Dean Boddington","Peter M Kistler","Paul Martin","Raymond W Sy","Stephan Willems","Paul Stobie","Matthew Webber","Gerald Kaye","Paul MacIntyre","Bobby John","Daniel Steven","Azlan Hussin","Suresh Singarayar","David Whalley","David O'Donnell","Nigel Lever","Rajiv Mahajan","Daniel Ninio","John Amerena","Adrian Esterman","Derek P Chew","Matthew Worthley","Andrew Tonkin","Carmine G De Pasquale","Jonathan M Kalman"],"significance":7,"published":"2026-07-14","source_date":"2026-04-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/"],"congress":"","summary_en":"The CAAN-AF trial tested whether atrioventricular node ablation (AVNA) added to cardiac resynchronisation therapy (CRT-D) improves outcomes in patients with heart failure with reduced ejection fraction and permanent atrial fibrillation, versus medical rate control. The trial stopped early for futility: among 143 randomized patients there was no difference in the primary endpoint (all-cause mortality plus non-fatal heart-failure events; IRR 1.16) or in secondary outcomes. In this randomized setting AVNA showed no benefit over medical rate control.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46024","type":"article","url":"https://hartvaat.nl/2026/04/16/winteropname-voor-acuut-hartfalen-gaat-gepaard-met-hogere-sterfte/","title":"Winteropname voor acuut hartfalen gaat gepaard met hogere sterfte","title_en":"Clinical Impact of Seasonal and Environmental Factors in Patients with Acute Heart Failure.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal. Acute cardiovascular care","doi":"10.1093/ehjacc/zuag059","source_url":"https://doi.org/10.1093/ehjacc/zuag059","authors":["Akito Okabe","Akiomi Yoshihisa","Yu Sato","Naoto Ohashi","Satoshi Okochi","Toranosuke Sekine","Ryo Ogawara","Yukiko Sugawara","Akihiko Sato","Shunsuke Miura","Tetsuro Yokokawa","Takeshi Shimizu","Tomofumi Misaka","Takamasa Sato","Takashi Kaneshiro","Masayoshi Oikawa","Atsushi Kobayashi","Kazuhiko Nakazato","Yasuchika Takeishi"],"significance":6,"published":"2026-07-14","source_date":"2026-04-16","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"In a cohort of 2,857 patients hospitalised for heart failure, seasonal and environmental factors were examined. The winter group was older, had more comorbidity and higher in-hospital and 90-day mortality than the autumn group (odds ratios 1.7–2.1). Lower temperature was associated with 90-day mortality, shorter sunshine duration with all-cause mortality, and higher PM2.5 with in-hospital cardiac mortality; atmospheric pressure, humidity and influenza activity were not. The findings suggest a role for cold and limited sunlight in winter heart-failure mortality.","created":"2026-07-03T20:27:07Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46022","type":"article","url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","title":"PCSK9-remmers verlagen events bij ASCVD zónder eerder infarct of beroerte (real-world)","title_en":"PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag176","source_url":"https://doi.org/10.1093/eurheartj/ehag176","authors":["Deepak L Bhatt","Pasquale Perrone Filardi","Irfan Khan","José Tuñón","Nikolaus Marx","Manuel Castro Cabezas","Katherine Andrade","Alexandra Koumas","Zhouyang Lou","Lale Tokgözoğlu"],"significance":8,"published":"2026-07-13","source_date":"2026-04-16","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This real-world study (Optum database; 19,670 patients with atherosclerotic cardiovascular disease and no prior ischaemic event) compared PCSK9 monoclonal-antibody initiators with matched non-initiators. Over five years, the composite of non-fatal myocardial infarction, non-fatal ischaemic stroke or death was lower with a PCSK9 inhibitor (17.5% vs 25.4%): a 31% relative and 7.8% absolute risk reduction. LDL cholesterol fell by a mean of 54% (from 118 to 55 mg/dL). The data support early, intensive LDL lowering even before a first event.","created":"2026-07-03T20:27:06Z","updated":"2026-07-04T19:27:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46021","type":"article","url":"https://hartvaat.nl/2026/04/17/schildklierdisfunctie-en-hart-en-vaatziekten-ehj-overzicht/","title":"Schildklierdisfunctie en hart- en vaatziekten (EHJ-overzicht)","title_en":"Thyroid dysfunction and cardiovascular disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag248","source_url":"https://doi.org/10.1093/eurheartj/ehag248","authors":["Heba Alwan","Ola Hysaj","Baris Gencer","Leonidas Duntas","Nicolas Rodondi"],"significance":7,"published":"2026-07-13","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Thyroid hormones regulate the cardiovascular system; both hypo- and hyperthyroidism are linked to dyslipidaemia, blood-pressure dysregulation, endothelial dysfunction, impaired cardiac function and arrhythmias. This EHJ review summarises the molecular and pathophysiological mechanisms and discusses the effect of levothyroxine in subclinical hypothyroidism on cardiovascular outcomes, which remains uncertain: the largest trial (TRUST) was underpowered but suggested a trend toward benefit. Recent omics and Mendelian-randomisation studies are also covered.","created":"2026-07-03T20:27:06Z","updated":"2026-07-04T19:27:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46019","type":"article","url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","title":"Bloeddrukverlaging beschermt over het hele spectrum van chronische nierschade (Lancet IPD-meta-analyse)","title_en":"Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(26)00367-3","source_url":"https://doi.org/10.1016/S0140-6736(26)00367-3","authors":["Guyu Zeng","Zeinab Bidel","Qianqian Yang","Dexter Canoy","Mark Woodward","Julia Lewis","Sverre E Kjeldsen","William C Cushman","Jinqing Yuan","Koon Teo","Barry R Davis","John Chalmers","Carl J Pepine","Kazem Rahimi","Milad Nazarzadeh"],"significance":9,"published":"2026-07-13","source_date":"2026-04-25","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This individual-participant-data meta-analysis from the Blood Pressure Lowering Treatment Trialists' Collaboration (46 trials, 285,124 participants) examined blood-pressure lowering across all stages of chronic kidney disease (CKD). A 5 mmHg systolic reduction lowered major cardiovascular event risk similarly in people with (HR 0.91) and without CKD (HR 0.90), consistent across all CKD stages (including stages 4–5), blood-pressure thresholds (down to <120/70 mmHg) and proteinuria status. However, the relative benefit was attenuated in CKD with concomitant diabetes (HR 0.96), underscoring the need for adapted strategies in that high-risk subgroup.","created":"2026-07-03T20:27:06Z","updated":"2026-07-04T19:27:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46017","type":"article","url":"https://hartvaat.nl/2026/05/07/cerebrale-amyloidangiopathie-nejm-state-of-the-art-overzicht/","title":"Cerebrale amyloïdangiopathie: NEJM state-of-the-art overzicht","title_en":"Cerebral Amyloid Angiopathy.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMra2411298","source_url":"https://doi.org/10.1056/NEJMra2411298","authors":["Steven M Greenberg"],"significance":8,"published":"2026-07-13","source_date":"2026-05-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"Cerebral amyloid angiopathy (CAA) — deposition of beta-amyloid in the brain's small vessels — is a major cause of haemorrhagic stroke and contributes to cognitive decline and to complications of anti-amyloid immunotherapy. Diagnosis usually rests on MRI showing multiple (micro)bleeds or cortical/leptomeningeal blood products. For cardiovascular practice the key issue is the high recurrence risk: in patients with an indication for antithrombotic therapy, CAA demands a carefully individualised weighing of bleeding versus thrombotic risk. Research focuses on risk prediction, early markers and disease-modifying therapy.","created":"2026-07-03T20:27:06Z","updated":"2026-07-04T19:27:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46015","type":"article","url":"https://hartvaat.nl/2026/04/29/cardiale-revalidatie-verbetering-depressie-hangt-samen-met-betere-loopconditie-p/","title":"Cardiale revalidatie: verbetering depressie hangt samen met betere loopconditie — pleidooi voor geïntegreerde aanpak","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004051?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004051?rss=1","authors":["Sever","S.","Harrison","A.","Doherty","P."],"significance":6,"published":"2026-07-13","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"Retrospective observational study on data from the UK National Audit of Cardiac Rehabilitation: 4,585 patients with acute coronary syndrome who underwent both a valid Incremental Shuttle Walk Test and the Hospital Anxiety and Depression Scale before and after cardiac rehabilitation between January 2021 and June 2024. Patients who achieved a minimum clinically important difference (MCID) for depression (>1.7-point HADS improvement) had 23% higher odds of also achieving the MCID for walking fitness (>70 m improvement; OR 1.23; 95% CI 1.01-1.49). Compared with home-based programmes, centre-based group programmes and hybrid programmes had higher odds of clinically meaningful improvement in walking fitness. Older age, female sex, physical inactivity, obesity, and longer waiting time were associated with lower likelihood of MCID improvement. The findings underscore the importance of integrating depression care within cardiac rehabilitation.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:09:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46013","type":"article","url":"https://hartvaat.nl/2026/04/29/geleidingssysteem-pacing-slaat-rechterventrikel-pacing-bij-av-blok-70-hartfalen-/","title":"Geleidingssysteem-pacing slaat rechterventrikel-pacing bij AV-blok: -70% hartfalen-opnames in RCT-meta-analyse","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003954?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003954?rss=1","authors":["Mojica","J. C.","Interior","J.","Virata","M. C.","Kasimieh","O.","Guingon","A.","Faizan","M. A.","Rehman","T.","Fernandez","F. C."],"significance":8,"published":"2026-07-12","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/hartgeruisen-herkenning/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"Systematic review and meta-analysis of randomised trials only — 5 RCTs with 985 patients with atrioventricular (AV) block — comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The composite endpoint significantly favoured CSP (HR 0.54; 95% CI 0.31-0.95; p=0.03), with markedly reduced risk of HF hospitalisation (RR 0.30; 95% CI 0.17-0.54; p<0.0001). No significant difference in all-cause mortality (RR 0.69; 95% CI 0.36-1.30; p=0.25). Secondary outcomes: significantly greater LVEF improvement (p=0.008) and shorter QRS duration (p=0.002) with CSP. In AV block, CSP therefore yields cardiac and clinical benefit over RVP — mainly through reduced HF hospitalisation and preservation of physiological activation. Mortality evidence remains uncertain. A practice shift toward CSP in pacemaker selection is supported by these data.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:09:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46012","type":"article","url":"https://hartvaat.nl/2026/04/29/black-women-s-health-study-dagelijks-en-institutioneel-racisme-verhogen-pre-ecla/","title":"Black Women's Health Study: dagelijks en institutioneel racisme verhogen pre-eclampsie-risico met 47-50%","title_en":"Experiences of Racism and Risk of Preeclampsia in the Black Women’s Health Study","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26454","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26454","authors":[],"significance":7,"published":"2026-07-12","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"Cohort study within the Black Women's Health Study (n≈59,000 Black women in the US, initiated 1995). Nulliparous women at enrolment with their first birth between 1995 and 2009 were included. Racism was measured as a total daily racism score (interpersonal racism) and an institutional racism summary score (unfair treatment due to race in policing, housing, or employment). Logistic regression adjusted for demographic, reproductive, and health factors. Women in the highest quartile of daily racism had 50% higher odds of preeclampsia versus the lowest quartile (aOR 1.50; 95% CI 1.13-1.99). Women reporting institutional racism in 2 domains had 47% higher odds (aOR 1.47; 95% CI 1.14-1.91). The findings suggest racism contributes to the disproportionate burden of preeclampsia in Black women in the US — relevant to addressing structural cardiovascular disparities.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:27:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46011","type":"article","url":"https://hartvaat.nl/2026/04/29/fibromusculaire-dysplasie-nieuwe-inzichten-voorbij-de-2019-consensus-bredere-cla/","title":"Fibromusculaire dysplasie: nieuwe inzichten voorbij de 2019-consensus — bredere classificatie en biomarkers in zicht","title_en":"Fibromuscular Dysplasia: Emerging Concepts Beyond the International Consensus","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25633","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25633","authors":["Tom Robberechts"],"significance":6,"published":"2026-07-12","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/"],"congress":"","summary_en":"Hypertension review of recent developments in fibromuscular dysplasia (FMD) since the First International Consensus document of 2019. The authors discuss: (1) a more detailed classification of FMD beyond the multifocal-versus-focal distinction, as a common language for research and clinical practice; (2) new insights into FMD-related phenotypes; (3) emerging imaging and proteomic biomarkers for improved detection, diagnosis, and classification, as well as prognosis and treatment response prediction; and (4) quantitative imaging with computational fluid dynamics (AI-enhanced or not) to assess the haemodynamic significance of FMD lesions. Combined with genetic studies and animal models, these developments pave the way for a more definitive and personalised approach to FMD.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:27:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46010","type":"article","url":"https://hartvaat.nl/2026/04/29/geisoleerde-secundaire-tricuspidalisinsufficientie-na-linkszijdige-klepchirurgie/","title":"Geïsoleerde secundaire tricuspidalisinsufficiëntie na linkszijdige klepchirurgie verhoogt sterfte met 29%","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004063?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004063?rss=1","authors":["Dregoesc","M. I.","Yucel","E.","Dal-Bianco","J.","Dahan","S.","Zeng","X.","Cramariuc","D.","Kolte","D.","Inglessis-Azuaje","I.","Passeri","J. J.","Danik","J.","Osho","A. A.","Kreso","A.","Grayburn","P. A.","Hung","J. W."],"significance":7,"published":"2026-07-12","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Single-centre observational cohort study in 2,487 patients (mean age 68 years; median follow-up 3 years) who underwent left-sided valve surgery with less than moderate preoperative tricuspid regurgitation (TR) and follow-up echocardiography between 2002 and 2024. All-cause mortality and HF hospitalisations increased with the grade of postoperative TR (p<0.001). Postoperative TR was independently associated with the composite endpoint (death/HFH), adjusted for CV risk factors and comorbidities (aHR 1.29; 95% CI 1.18-1.41; p<0.001), and even after adjustment for RV remodelling and moderate mitral regurgitation (aHR 1.40; 95% CI 1.28-1.53). An increase in TR by ≥2 grades from preoperative occurred in 12.5% and was strongly associated with adverse outcome. Predictors of TR progression: age, sex, myocardial infarction, CABG, atrial fibrillation, and RV remodelling. The findings argue for systematic TR surveillance after left-sided valve surgery.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:09:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46009","type":"article","url":"https://hartvaat.nl/2026/04/29/centrale-versus-brachiale-ambulante-bloeddruk-brachiaal-volstaat-voor-mortalitei/","title":"Centrale versus brachiale ambulante bloeddruk: brachiaal volstaat voor mortaliteit-stratificatie (n=36.594)","title_en":"Mortality in Relation to Brachial Versus Central Ambulatory Blood Pressure","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26778","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26778","authors":[],"significance":7,"published":"2026-07-12","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"Analysis of 36,594 patients from the Shanghai Ruijin Ambulatory BP Monitoring Registry (2017-2023) who underwent 24-hour ambulatory blood pressure monitoring with an oscillometric cuff monitor, measuring both brachial (bSBP) and central systolic BP (cSBP, calibrated on brachial or on mean arterial pressure). Median age 53.4 years; 52.8% female. During 4 years of follow-up, 505 participants died, including 174 from cardiovascular causes. Non-linear Cox models fitted better than linear (p<0.001) for both endpoints, regardless of time-of-day or calibration. Adding 24-hour SBP to the base model improved C-statistics for all-cause and cardiovascular mortality (0.003≤p≤0.06). Adding cSBP on top of bSBP did not yield statistically significant improvement (0.054≤p≤0.22). Central BP measurement on top of brachial ambulatory monitoring therefore adds little value for mortality stratification — simple brachial ambulant measurement suffices.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:27:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46008","type":"article","url":"https://hartvaat.nl/2026/04/29/erasmus-mc-linkeratrium-strain-voorspelt-aritmieen-na-chirurgische-correctie-van/","title":"Erasmus MC: linkeratrium-strain voorspelt aritmieën na chirurgische correctie van rechtszijdige ACHD","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004033?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004033?rss=1","authors":["U&#x0308;nlu&#x0308;tu&#x0308;rk","S.","Linderhof","M. H. C.","Cuypers","J. A. A. E.","Bowen","D. J.","de Groot","N. M. S.","Roos-Hesselink","J. W.","Kauling","R. M.","van den Bosch","A. E."],"significance":6,"published":"2026-07-11","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/"],"congress":"","summary_en":"Dutch longitudinal study within the Erasmus MC Quality of Life cohort in 195 adults with congenital heart disease and right-sided pathology — atrial septal defect (n=78, 40%), pulmonary stenosis (n=45, 23%), or Tetralogy of Fallot (n=72, 37%) — who underwent surgical repair as children between 1968 and 1980. At follow-up in 2012 (mean age 40.7 years), speckle-tracking echocardiography evaluated left atrial reservoir (LASr), conduit, and contractile (LASct) function; clinical outcomes were followed for 10 years. ToF patients had more frequent interventricular conduction abnormalities at baseline and 2.7-fold higher odds of the composite endpoint versus ASD patients. In Cox regression, LASr and LASct were independently associated with symptomatic tachyarrhythmias (LASr HR 0.952; p=0.013; LASct HR 0.936; p=0.046), even after adjustment for LVEF, LA volume index, or NT-proBNP. LA strain therefore provides additional prognostic information in ACHD follow-up — relevant to the growing Dutch ACHD population.","created":"2026-07-03T20:27:05Z","updated":"2026-07-04T19:09:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46007","type":"article","url":"https://hartvaat.nl/2026/04/30/hanzhong-cohort-36-jaar-follow-up-snelle-bloeddrukstijging-in-kindertijd-voorspe/","title":"Hanzhong-cohort (36 jaar follow-up): snelle bloeddrukstijging in kindertijd voorspelt orgaanschade in middelbare leeftijd","title_en":"Blood Pressure Change and Subclinical Target Organ Damage in Mid-Adulthood","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26364","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26364","authors":["Tongshuai Guo"],"significance":7,"published":"2026-07-11","source_date":"2026-04-30","image":"","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"Cohort study within the Hanzhong Adolescent Hypertension Study in 2,508 participants with ≥4 BP measurements between 1987 and 2023. Growth models constructed age-specific BP levels and rates of change (slopes) and related them to subclinical end-organ damage in mid-adulthood (arterial stiffness, left ventricular hypertrophy, albuminuria). Rates of change at each age point were positively associated with arterial stiffness and albuminuria, independent of BP level itself. The associations rose from childhood, peaked in adolescence, and declined thereafter: per 1 SD increase in systolic BP rate of change, the OR for arterial stiffness was 1.94 at age 6, 2.11 at age 13, and fell to 1.13 by age 52. In childhood and adolescence, the rate of BP increase was more important than the concurrent level; from young adulthood onwards this reversed. Similar patterns for LVH. Early monitoring of the pace of BP rise — not only the level — may therefore be essential for cardiovascular prevention.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:27:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46006","type":"article","url":"https://hartvaat.nl/2026/04/30/etnische-verschillen-in-sterfte-na-acuut-coronair-syndroom-hogere-mortaliteit-bi/","title":"Etnische verschillen in sterfte na acuut coronair syndroom: hogere mortaliteit bij zwarte STEMI-patiënten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004072?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004072?rss=1","authors":["Mayet","Y.","Wasan","D.","Sesia","D.","Shah","A. S. V.","Johnson","T.","Kaura","A."],"significance":7,"published":"2026-07-11","source_date":"2026-04-30","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/ecg-bij-acs/"],"congress":"","summary_en":"Systematic review and meta-analysis of 40 cohort and registry studies (total 14 million patients from the USA, UK, and Canada) on ethnic disparities in mortality after acute coronary syndrome (ACS). Overall mortality was similar between Black and White patients (RR 0.99; 95% CI 0.94-1.03) and between Asian and White patients (RR 1.06; 95% CI 0.95-1.17); however, in US-based studies, Asian patients had higher mortality (RR 1.14; 95% CI 1.03-1.27). Subgroup analysis showed significantly higher mortality in Black patients after STEMI (RR 1.09; 95% CI 1.02-1.17). Meta-regression demonstrated an age-modifying effect for Black-versus-White comparisons: differences attenuated in older populations. Pooled risk of major bleeding was comparable between groups. The findings suggest ethnic disparities in ACS outcomes persist in specific contexts and may be more pronounced in younger patients — though interpretation requires caution due to heterogeneity.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:09:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46005","type":"article","url":"https://hartvaat.nl/2026/04/30/peri-arteriele-zenuwdissectie-tijdens-bijniechirurgie-geeft-renale-denervatie-ef/","title":"Peri-arteriële zenuwdissectie tijdens bijniechirurgie geeft renale-denervatie-effect: betere bloeddrukcontrole en minder medicatie","title_en":"Peri-Arterial Neural Dissection During Adrenal Surgery Provides a Denervation-Like Benefit in Hypertension Control","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26495","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26495","authors":["Liqi Yi"],"significance":6,"published":"2026-07-11","source_date":"2026-04-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"Retrospective analysis of 127 hypertensive patients who underwent adrenal surgery between January 2022 and March 2025, classified by surgical peri-arterial neural dissection (PAND) — a surgical manoeuvre that interrupts sympathetic nerve bundles surrounding the renal artery — versus no dissection. After 1:2 matching by age, sex, and hypertension duration, 54 patients remained for analysis. The PAND group had a higher postoperative hypertension remission rate (50.0% vs 16.1%; p=0.008). In multivariable logistic regression, PAND was independently associated with lower odds of non-remission (OR 0.150; 95% CI 0.030-0.744; p=0.020). The dissection group also showed greater reduction in antihypertensive medication use (median defined-daily-dose change -1.0 vs 0.0; p=0.006). Renal function (creatinine, urea) and adrenal hormones (cortisol, ACTH) were comparable between groups. The manoeuvre therefore appears to produce a renal-denervation-like effect without compromising renal or adrenal function.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:27:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46004","type":"article","url":"https://hartvaat.nl/2026/05/01/finse-hypertensie-curve-vlakt-af-vooruitgang-gestopt-zoutinname-30-boven-aanbeve/","title":"Finse hypertensie-curve vlakt af: vooruitgang gestopt, zoutinname 30% boven aanbeveling","title_en":"From Progress to Plateau: 50-Year Trends in Hypertension Prevalence and Salt Intake in the Finnish Population","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25982","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25982","authors":["Annika Santalahti"],"significance":7,"published":"2026-07-11","source_date":"2026-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"Analysis of 12 cross-sectional health surveys in Finland between 1972 and 2023 (77,418 randomly selected adults aged 25-64). BP was measured in all; a subsample of 5,035 provided 24-hour urine for salt intake. Hypertension prevalence (SBP ≥140, DBP ≥90, or antihypertensive use) declined in men from 1972 to 2002 and in women until 1997; thereafter declines slowed and in 2023 prevalence remained high (42.6% men, 31.8% women). Median salt intake fell until the early 2000s (men 13.9→9.7 g/day, women 11.1→7.6 g/day) but plateaued thereafter; in 2023 intake remained well above the recommended level (men 10.3 g/day, women 7.6 g/day). The declining trend in hypertension has therefore stalled, paralleling stagnating salt intake — arguing for renewed public-health action on salt reduction.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:27:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46003","type":"article","url":"https://hartvaat.nl/2026/05/04/angina-toevoegen-aan-de-h2fpef-score-verbetert-hfpef-diagnose-bij-vrouwen-geen-w/","title":"Angina toevoegen aan de H2FPEF-score verbetert HFpEF-diagnose bij vrouwen — geen winst bij mannen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004054?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004054?rss=1","authors":["Qu","K.","Onland-Moret","N. C.","de Vos","A.","van Ommen","A. M. L. N.","van Mourik","Y.","van Riet","E. E.","Boonman - de Winter","L.","Handoko","M. L.","Cramer","M. J.","Teske","A. J.","Menken","R.","Rutten","F.","den Ruijter","H. M.","Dal Canto","E."],"significance":6,"published":"2026-07-10","source_date":"2026-05-04","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/vasculair/pulmonale-hypertensie/"],"congress":"","summary_en":"Diagnostic study in 515 patients from the UHFO-DM cohort with suspected HFpEF, plus 751 patients from three additional cohorts (UHFO-COPD, STRETCH, TREE). Symptoms, including angina by WHO questionnaire, were collected in standardised fashion; HFpEF was adjudicated by expert panel. HFpEF prevalence 24% in UHFO-DM. The H2FPEF score had an overall AUC of 0.72 (0.69 in women, 0.74 in men). Angina was independently associated with HFpEF in women (OR 3.96; 95% CI 1.72-9.11; p=0.001) but not in men (OR 1.90; p=0.10). Adding one point for angina to H2FPEF in women improved AUC from 0.69 to 0.71 (DeLong p=0.030), sensitivity from 0.53 to 0.60, and NPV from 0.80 to 0.82, with continuous net reclassification improvement 0.449. No gain in men. A simple sex-specific modification of H2FPEF — for women only — therefore improves diagnostic precision for HFpEF.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:09:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46001","type":"article","url":"https://hartvaat.nl/2026/05/04/stami-linkerventrikel-trombus-komt-na-voorwand-stemi-voor-8-bij-takotsubo-nooit-/","title":"STAMI: linkerventrikel-trombus komt na voorwand-STEMI voor (8%), bij Takotsubo nooit — ondanks slechtere LVEF","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004154?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004154?rss=1","authors":["Jha","S.","Simonsson","M.","Poller","A.","Molander","L.","Thorleifsson","S.","Pirazzi","C.","Bentzel","S.","Torild","P.","Andersson","E. A.","Shekka Espinosa","A.","Sevastianova","V.","Salahuddin","S.","Zeijlon","R.","Elmahdy","A.","Skoglund","K.","Omerovic","E.","Redfors","B."],"significance":6,"published":"2026-07-10","source_date":"2026-05-04","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Prospective cohort study at Sahlgrenska University Hospital in 314 patients with Takotsubo syndrome (TS, n=68), anterior STEMI (n=148), or non-anterior STEMI (n=98), with serial echocardiography on admission and days 1, 2, 3, 7, 14, and 30. Mean LVEF at admission: 39% in TS (lowest), 47% in anterior STEMI, and 53% in non-anterior STEMI. Despite the poorest LV function, no TS patient developed a left ventricular thrombus, while 20 of 246 STEMI patients (8.1%) did — almost exclusively anterior STEMI. All LV thrombi in anterior STEMI were detected within 7 days; the single non-anterior thrombus appeared at day 30. All patients received anticoagulation. Predictors: lower LVEF and higher troponin. The findings underscore pathophysiological differences between TS and STEMI and argue for distinct post-acute surveillance strategies.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:09:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46000","type":"article","url":"https://hartvaat.nl/2026/05/04/noorse-nationale-validatie-myocarditis-na-mrna-covid-vaccinatie-4-5-per-100-000-/","title":"Noorse nationale validatie: myocarditis na mRNA-COVID-vaccinatie 4,5 per 100.000 — meest klinisch mild","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004112?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004112?rss=1","authors":["Hagen","B. S.","Vlaisavljevic","K.","Oppedal","L. S.","Endresen","J.","Mohn","V. S.","Fladseth","K.","Lysaker","T. M.","Ribe","M. P.","Mo&#x0308;ller","T. F.","Hole","T. L.","Dahl","J.","Karlstad","O.","Gulseth","H. L.","Olsen","D. B.","Greve-Isdahl","M.","Watle","S. V.","Estensen","M.-E.","Broch","K.","Haugaa","K. H.","Hasselberg","N. E."],"significance":7,"published":"2026-07-10","source_date":"2026-05-04","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/klepprothese-mechanisch-biologisch/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Norwegian nationwide population-based validation study of myocarditis after BNT162b2 or mRNA-1273 vaccination (27 December 2020 - 30 April 2022). Among 4.1 million vaccinated individuals (10.9 million doses), 367 potential cases were identified via linked registries; of 349 reviewed, 177 (51%) were validated as vaccine-associated myocarditis by Brighton Collaboration criteria — equating to 4.5 per 100,000 vaccinated individuals. 110 (62%) occurred after the second dose. 79% of validated cases were in men; median age 30 years in men and 54 years in women. Only 3 (2%) were under 18 years. Median hospital stay 4 days; median LVEF 55%. 7 (4%) patients required intensive care; 2 older patients died. None required mechanical circulatory support or heart transplantation. The acute course was generally mild. National surveillance and systematic validation are essential for reliable incidence estimates.","created":"2026-07-03T20:27:04Z","updated":"2026-07-04T19:09:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45999","type":"article","url":"https://hartvaat.nl/2026/05/06/haiti-cohort-n-2-073-bloeddrukbehandeling-in-extreme-armoede-haalbaar-vier-50-ma/","title":"Haïti-cohort (n=2.073): bloeddrukbehandeling in extreme armoede haalbaar — vier 50-maands BD-trajecten geïdentificeerd","title_en":"Blood Pressure Trajectories Among Adults Living in Extreme Poverty: A Population-Based Cohort in Port-au-Prince, Haiti","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26295","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26295","authors":["Anju Ogyu"],"significance":5,"published":"2026-07-10","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"Population-based cohort study in Port-au-Prince, Haiti, of 2,073 adults with ≥3 BP measurements between March 2019 and April 2025 (median age 43 years; 60% female; 100% Black Haitian; 69% lived on <US$1/day). Latent class growth mixture modelling identified four systolic BP trajectories by baseline BP: normal-rising (107 mm Hg, 39.2%, +0.7 mm Hg/y), moderate-rising (126 mm Hg, 34.7%, +1.3 mm Hg/y), high-reduction (151 mm Hg, 19.2%, -1.6 mm Hg/y), and very high-rebound (173 mm Hg, 6.9%, -0.8 mm Hg/y). During follow-up, antihypertensive medication use and BP control improved among hypertensive participants. Older age, lower education, and obesity were associated with the high/very high-rebound trajectories. The data show that structured BP care is feasible and effective even in extreme poverty — an important message for global hypertension control.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45998","type":"article","url":"https://hartvaat.nl/2026/05/06/dolichoectasie-van-hersenarterien-niet-stenose-drijft-lacunair-cva-en-cerebrale-/","title":"Dolichoectasie van hersenarteriën — niet stenose — drijft lacunair CVA en cerebrale small-vessel-ziekte","title_en":"Implications of Cranial Arterial Stenosis and Dolichoectasia for Cerebral Small-Vessel Disease Etiopathogenesis: Findings From a Prospective Mild Stroke Cohort","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079493","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079493","authors":["Fei Han"],"significance":7,"published":"2026-07-10","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-endocarditis-2023/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"Prospective cohort study in 229 patients (mean age 65.9 years; 57.2% lacunar stroke) with MRI at baseline and 1 year, plus systematic review. Large-artery stenosis (LAS, ≥50%) was present in 20.5% and basilar artery dolichoectasia in 15.7%. After adjustment, LAS was associated with lower odds of lacunar versus non-lacunar stroke (OR 0.49; 95% CI 0.23-0.99) and not with cSVD markers or incident infarcts. By contrast, basilar artery dolichoectasia was strongly associated with lacunar stroke (OR 4.67; 95% CI 1.87-13.14), higher cSVD scores (OR 2.57), incident infarcts (75% subcortical; OR 2.29), and greater progression of white matter hyperintensities over 1 year. Similar associations for wider intracranial arteries. The findings support a non-atheromatous, intrinsic microvascular pathology — particularly segmental arteriolar disorganisation — as the principal mechanism of lacunar stroke and cSVD, with mechanism-specific diagnostic and therapeutic strategies as the logical implication.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45997","type":"article","url":"https://hartvaat.nl/2026/05/06/rasi-verlost-adrenale-veneuze-sampling-van-de-bilaterale-selectiviteit-flessenha/","title":"RASI verlost adrenale veneuze sampling van de bilaterale-selectiviteit-flessenhals bij primair aldosteronisme","title_en":"Subtyping of Primary Aldosteronism in Partial Adrenal Vein Sampling: The Relative Aldosterone Secretion Index","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26988","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26988","authors":["Federico Bernardo Rossi"],"significance":7,"published":"2026-07-09","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"Hypertension review of the Relative Aldosterone Secretion Index (RASI), a physiologically grounded strategy for interpreting partially successful adrenal venous sampling (AVS) in subtyping primary aldosteronism. AVS frequently fails to achieve bilateral selectivity, precluding calculation of the lateralisation index and diverting patients to lifelong medical therapy when surgical cure is possible. RASI quantifies aldosterone secretion from each adrenal gland relative to peripheral values and incorporates contralateral suppression — with 80% concordance with the conventional lateralisation index when available. Postoperative outcomes after RASI-guided adrenalectomy approximate those after fully selective AVS: biochemical cure 85-90% and blood pressure improvement 65-75%. Recent data clarify performance-modifying factors (cosyntropin stimulation, aldosterone variability) and the limited utility of imaging alone. RASI should be integrated into contemporary AVS interpretation algorithms to broaden access to adrenalectomy and its cardiovascular benefits.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45995","type":"article","url":"https://hartvaat.nl/2026/05/08/orbita-fire-fysiologische-angina-drempel-ligt-veel-lager-dan-klinische-ffr-grens/","title":"ORBITA-FIRE: fysiologische angina-drempel ligt veel lager dan klinische FFR-grens — pleidooi voor individuele revascularisatie-strategie","title_en":"Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078738","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078738","authors":["Fiyyaz Ahmed"],"significance":8,"published":"2026-07-09","source_date":"2026-05-08","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"Multicenter, double-blind, randomised, placebo-controlled study in 65 patients with stable angina and single-vessel coronary disease. After image-guided PCI, an in-stent balloon was incrementally inflated until angina occurred, verified against placebo inflation; FFR-angina and RFR-angina were recorded at symptom onset, also during low- and high-intensity exercise. Median pre-PCI FFR was 0.59 (IQR 0.46-0.70). Median FFR-angina at rest was 0.29 (IQR 0.23-0.35), during low-intensity exercise 0.38, and during high-intensity exercise 0.45. RFR-angina followed parallel values: 0.22 at rest, 0.26 at low, and 0.32 at high intensity. All thresholds were significantly lower than clinical ischaemia cut-offs (p<0.001). Lower FFR-angina thresholds were associated with greater baseline angina burden and greater symptom relief from PCI. The physiological angina threshold is therefore highly individualised, varies with cardiac workload, and lies well below universal cut-offs — arguing for symptom-led, personalised revascularisation strategy.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45994","type":"article","url":"https://hartvaat.nl/2026/05/08/primaire-aldosteronisme-tijdens-zwangerschap-56-gecompliceerd-36-pre-eclampsie-o/","title":"Primaire aldosteronisme tijdens zwangerschap: 56% gecompliceerd, 36% pre-eclampsie — onmiskenbaar pleidooi voor vroege diagnose","title_en":"Pregnancy-Related Complications in Primary Aldosteronism: A European Survey","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25339","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25339","authors":["Vittorio Forestiero"],"significance":6,"published":"2026-07-09","source_date":"2026-05-08","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"International survey at 5 European hypertension centres (2000-2022) in 102 women aged 18-45 diagnosed with primary aldosteronism (PA) who were pregnant after, or <1 year before, the PA diagnosis. 56% of pregnancies were complicated: preeclampsia 36%, preterm birth 30%, low birth weight 30%, NICU admission 22%; hypokalaemia 31%. Pregnancies before PA diagnosis had worse BP control and higher complication rates than those after established PA diagnosis. Independent predictors of complications: uncontrolled BP during pregnancy (OR 7.05), undiagnosed PA (OR 4.37), North/Black African ethnicity (OR 3.69), higher BMI (OR 1.09), and treatment with more antihypertensives at PA diagnosis (OR 2.18). The findings underscore that early identification and optimal BP control in women with PA are crucial for maternal and fetal outcomes.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45992","type":"article","url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamica-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril/valsartan verbetert inspanningshemodynamica bij HFpEF met atriale functionele mitralis-insufficiëntie","title_en":"Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080833","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080833","authors":["Sebastiaan Dhont"],"significance":8,"published":"2026-07-09","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tricuspidalisregurgitatie/","https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"Multicenter open-label randomised trial with blinded primary endpoint in 84 patients with symptomatic HFpEF and ≥moderate atrial functional mitral regurgitation (AFMR), randomised to sacubitril/valsartan (n=41) or standard of care (n=43). The primary endpoint was change in exercise mPAP/CO slope (mean pulmonary arterial pressure to cardiac output) measured via cardiopulmonary exercise testing with simultaneous echocardiography. At 6 months, mPAP/CO slope significantly improved with sacubitril/valsartan (adjusted between-group difference -0.93 mm Hg/L/min; 95% CI -1.80 to -0.07; p=0.035). Accompanying benefits: higher peak VO2 (+0.9 vs -0.6 mL/kg/min; p=0.002), higher KCCQ score (+10 vs +2 points; p=0.002), significantly lower NT-proBNP and LA volume (both p<0.001), and attenuation of the dynamic MR increase during exercise (p=0.020). Target dose was achieved in 60%; symptomatic hypotension was the main titration-limiting factor. A phenotype-specific benefit warranting confirmation in larger outcome trials.","created":"2026-07-03T20:27:03Z","updated":"2026-07-04T19:27:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45990","type":"article","url":"https://hartvaat.nl/2026/05/11/wisdom-hmod-nachtelijke-pols-bloeddrukmeting-voorspelt-onafhankelijk-linkerventr/","title":"WISDOM-HMOD: nachtelijke pols-bloeddrukmeting voorspelt onafhankelijk linkerventrikelhypertrofie","title_en":"Wrist-Measured Nighttime Home BP and Left Ventricular Hypertrophy: The WISDOM-HMOD Study","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26510","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26510","authors":["Kazuomi Kario"],"significance":7,"published":"2026-07-09","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"WISDOM-Night substudy in 1,218 patients with hypertension or heart failure (mean age 67.2 years; 53.9% men) using a wrist-type oscillometric home BP monitor (HEM9601T, Omron) to measure nighttime BP at 2:00, 3:00, and 4:00 am plus 4 hours after bedtime, alongside morning/evening BPs over 7 days. Mean nighttime SBP/DBP 110.5/63.5 mm Hg; 70.4% had well-controlled nighttime BP (<120/70). Echo-derived LV mass index: 90.1 g/m² in men, 80.3 g/m² in women. An increase in nighttime SBP was significantly associated with higher LV mass index, independent of office, morning, and evening home BP. Per 10 mm Hg increase in nighttime SBP, the OR for LVH was 1.36 (95% CI 1.15-1.60) overall, 1.54 in men, and 1.27 in women — sex-specific thresholds. Less sleep-disturbing wrist home monitors make nighttime BP monitoring accessible and clinically relevant.","created":"2026-07-03T20:27:02Z","updated":"2026-07-04T19:27:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45988","type":"article","url":"https://hartvaat.nl/2026/05/15/crossover-trial-amlodipine-geeft-bij-hfpef-hypertensie-betere-bloeddruk-hogere-v/","title":"Crossover-trial: amlodipine geeft bij HFpEF + hypertensie betere bloeddruk, hogere VO2 én lager NT-proBNP dan metoprolol","title_en":"Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover Trial","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26801","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26801","authors":[],"significance":8,"published":"2026-07-08","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Double-blind randomised crossover trial in 50 adults with HFpEF and hypertension, who received in random order 4 weeks of amlodipine 5-10 mg and 4 weeks of metoprolol succinate 100-200 mg (equipotent antihypertensive doses). Mean age 72 years, 68% women, 66% Black, baseline BP 144/78 mm Hg, 46% already on beta-blockers. Amlodipine produced significantly lower home systolic BP (-4 mm Hg; 95% CI -7 to -1; p=0.017), higher peak oxygen uptake during exercise (+1.2 mL/min/kg; p=0.008), higher physical activity (+0.1 MET-h/day; p=0.019), and lower NT-proBNP (-200 pg/mL; p<0.0001) than metoprolol. No difference in septal E/e', myocardial strain, or systemic vasodilatory reserve. Adverse events comparable. The results support dihydropyridine calcium channel blockers as a preferred alternative to beta-blockers for managing hypertension in HFpEF.","created":"2026-07-03T20:27:02Z","updated":"2026-07-04T19:27:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45987","type":"article","url":"https://hartvaat.nl/2026/05/18/mint-post-hoc-bloedtransfusie-strategie-bij-infarct-anemie-heeft-geen-sekse-spec/","title":"MINT post-hoc: bloedtransfusie-strategie bij infarct + anemie heeft geen sekse-specifiek effect","title_en":"Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078320","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078320","authors":[],"significance":7,"published":"2026-07-08","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"Prespecified secondary analysis of the MINT trial in 3,504 patients with acute myocardial infarction (AMI) and anaemia randomised to restrictive or liberal transfusion thresholds. 1,593 (45.4%) were women. Women received fewer transfusions on average. The primary endpoint (30-day death or MI) occurred in 15.4% of both women and men — no significant sex interaction (p=0.60). 180-day mortality was lower in women (11.0% vs 13.5%; p=0.04). For 30-day cardiac death, men had higher risk in the restrictive arm (RR 2.34; 95% CI 1.48-3.70; interaction p=0.05) — a suggestion that men may be more vulnerable to a restrictive transfusion strategy in AMI. Overall, the findings support sex-neutral transfusion thresholds in current practice.","created":"2026-07-03T20:27:02Z","updated":"2026-07-04T19:27:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45986","type":"article","url":"https://hartvaat.nl/2026/05/18/trajectory-van-eind-expiratoire-co2-bij-ohca-monitor-7-21-minuten-voor-betrouwba/","title":"Trajectory van eind-expiratoire CO2 bij OHCA: monitor 7-21 minuten voor betrouwbare ROSC-voorspelling","title_en":"Resuscitation From Out-of-Hospital Cardiac Arrest When Is EtCO\n                    <sub>2</sub>\n                    Reliably Associated With ROSC?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077980","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077980","authors":[],"significance":7,"published":"2026-07-08","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"Secondary analysis of the cluster-randomised Pragmatic Airway Resuscitation Trial (PART) in 1,168 patients with out-of-hospital cardiac arrest (OHCA). Mean end-tidal CO2 (EtCO2) per 1-minute epoch was classified by trajectory modelling into upward versus downward patterns, stratified by witnessed/unwitnessed status and initial EtCO2 (low ≤30, moderate 31-49, high ≥50 mm Hg). Overall ROSC 18.2% (30.5% witnessed vs 10.5% unwitnessed). In witnessed arrests, the 95% CIs between upward and downward trajectories became non-overlapping at 8 minutes for low initial EtCO2 (RR 3.06), 12 minutes for moderate (RR 1.95), and 21 minutes for high (RR 2.12). In unwitnessed arrests, already at 7 minutes (RR 3.56). Dynamic EtCO2 trajectory monitoring therefore provides early prognostic information during resuscitation, but the minimum required observation time depends on witness status and initial EtCO2 level.","created":"2026-07-03T20:27:02Z","updated":"2026-07-04T19:27:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45984","type":"article","url":"https://hartvaat.nl/2026/05/19/vesalius-cv-subgroep-prior-pci-zonder-eerder-mi-evolocumab-halveert-hartinfarct-/","title":"VESALIUS-CV subgroep prior PCI zonder eerder MI: evolocumab halveert hartinfarct-risico (n=3.627)","title_en":"Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080616","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080616","authors":[],"significance":8,"published":"2026-07-08","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Prespecified subgroup analysis of VESALIUS-CV in 3,627 patients (29.6% of the total study population) with prior PCI but no prior myocardial infarction or stroke, randomised to evolocumab or placebo (median follow-up 4.6 years). Median age 66 years, 30.7% women, median time since PCI 4 years. At 48 weeks, median LDL-C was 41.5 versus 107.0 mg/dL with evolocumab versus placebo. Evolocumab reduced 3-point MACE by 30% (5-year KM 7.0% vs 9.5%; HR 0.70; 95% CI 0.56-0.89; p=0.004), 4-point MACE by 18%, MI risk by 50% (3.0% vs 6.1%; HR 0.50; p<0.001), and urgent coronary revascularisation by 39%. The effect was apparent within 6 months. Numerically lower cardiovascular mortality (HR 0.66) and all-cause mortality (HR 0.76). The findings support intensive LDL-C lowering with evolocumab in stable patients with prior PCI even without prior MI — a substantial practical expansion of the indication.","created":"2026-07-03T20:27:01Z","updated":"2026-07-04T19:27:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45983","type":"article","url":"https://hartvaat.nl/2026/05/19/nyc-4h-cohort-sociale-problemen-verviervoudigen-sterfterisico-bij-hiv-patienten-/","title":"NYC 4H-cohort: sociale problemen verviervoudigen sterfterisico bij hiv-patiënten met hartfalen","title_en":"Multidimensional Social Adversity and Mortality in People With HIV Infection and Heart Failure: Insights From NYC Health + Hospitals HIV–Heart Failure Cohort","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.078897","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.078897","authors":[],"significance":7,"published":"2026-07-08","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"Cohort study of the NYC Health + Hospitals HIV-Heart Failure (NYC 4H) registry in 1,044 participants (62.9% male, mean age 61.6 years). At baseline, multidimensional social adversity (SA) was assessed by licensed clinical social workers across 5 domains: economic hardship, healthcare access barriers, unstable neighbourhood/housing, social support challenges, and psychobehavioural instability. 58% had at least one SA domain, most often psychobehavioural instability (n=438). During 3.8 years of follow-up, any SA exposure was associated with higher all-cause mortality (HR 4.32), cardiovascular mortality (HR 4.05), and infection-related mortality (HR 2.37). Domain-specific associations: social support challenges and psychobehavioural instability predicted CV mortality; economic hardship and social support predicted infection mortality. Patients with environmental instability, psychobehavioural instability, or social support challenges had 73%, 75%, and 44% higher 6-month rehospitalisation risk respectively. Multidimensional SA assessment can support domain-specific risk stratification in HIV + heart failure.","created":"2026-07-03T20:27:01Z","updated":"2026-07-04T19:27:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45982","type":"article","url":"https://hartvaat.nl/2026/05/20/cardiale-mri-bij-dystrofinopathie-consensus-voor-dmd-bmd-en-vrouwelijke-draagste/","title":"Cardiale MRI bij dystrofinopathie: consensus voor DMD, BMD en vrouwelijke draagsters","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004037?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004037?rss=1","authors":["McDiarmid","A.","Augustine","D.","Coats","C.","Myerson","S. G.","Hughes","M.","Villa","C.","Soslow","J.","Kadhim","K.","Kerr","A.","Kuhwald","L.","Sado","D. M.","Swoboda","P.","Turner","C.","Guglieri","M.","Bourke","J.","Members of the CMR focus group of DMD Care UK"],"significance":6,"published":"2026-07-07","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"Consensus document from a UK-US expert working group (paediatric cardiologists, neuromuscular specialists, and patient representatives) on the use of cardiac MRI (CMR) in patients with Duchenne (DMD) and Becker (BMD) muscular dystrophy and in female carriers of DMD-gene variants. Heart failure progresses in all DMD patients, but symptoms appear late — making regular imaging essential. Echocardiography remains the first-line modality in the UK, but CMR detects myocardial tissue changes before pump function declines and maintains accuracy as the disease progresses. Recommendation: wider use of CMR in DMD patients >10 years at key decision points, plus in BMD males and female carriers. This would allow earlier detection of cardiac involvement and more timely initiation or adjustment of cardiac medication.","created":"2026-07-03T20:27:01Z","updated":"2026-07-04T19:09:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45981","type":"article","url":"https://hartvaat.nl/2026/05/20/ecog-acrin-eaq191-intensieve-bloeddrukcontrole-tijdens-vegfr-tki-therapie-haalba/","title":"ECOG-ACRIN EAQ191: intensieve bloeddrukcontrole tijdens VEGFR-TKI-therapie haalbaar en veilig bij kankerpatiënten","title_en":"Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26016","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26016","authors":["Bonnie Ky"],"significance":6,"published":"2026-07-07","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/farmacologie/ace-remmers-bijwerkingen/"],"congress":"","summary_en":"Phase 2 cluster-randomised trial in 61 patients with renal cell or thyroid cancer starting VEGFR tyrosine kinase inhibitors (TKIs), randomised at site level (10 sites) to intensive systolic blood pressure control (SBP <120 mm Hg) or usual care (SBP <140 mm Hg), with central BP advisory support. Patients underwent home BP monitoring and study visits at baseline, 1, 2, 3, and 6 months. The intensive arm achieved significantly lower SBP (-12.2 mm Hg at 1 month; -7.6 mm Hg at 3 months; -6.9 mm Hg at 6 months). Grade 3 adverse events were numerically lower with intensive control: kidney injury (1 vs 4), hypotension (2 vs 3), and dyspnoea (0 vs 2). Patient-reported outcomes were largely similar. The first-ever RCT of BP control in active cancer patients on TKI therapy demonstrates the feasibility, safety, and tolerability of the intensive approach.","created":"2026-07-03T20:27:01Z","updated":"2026-07-04T19:27:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45979","type":"article","url":"https://hartvaat.nl/2026/05/20/scapis-cohort-diastolische-dysfunctie-even-vaak-bij-prediabetes-als-diabetes-ple/","title":"SCAPIS-cohort: diastolische dysfunctie even vaak bij prediabetes als diabetes — pleidooi tegen 'diabetische cardiomyopathie'","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004052?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004052?rss=1","authors":["Kylhammar","D.","Hult","L.","Blomstrand","P.","Holm Isholth","H.","Jujic","A.","Magnusson","M.","O&#x0308;stgren","C. J.","Engvall","J.","Hedman","K."],"significance":7,"published":"2026-07-07","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Cross-sectional study within the Swedish CArdioPulmonary bioImage Study (SCAPIS) in 3,840 men and women aged 50-64 years with transthoracic echocardiography, anthropometry, blood pressure, biochemistry, and coronary CT calcium scoring. Normoglycaemia 82%, pre-diabetes 12%, diabetes 6%. Diastolic dysfunction was significantly more common in pre-diabetes (30%) and diabetes (33%) than in normoglycaemia (21%); prevalence was therefore equivalent between pre-diabetes and diabetes. In dysglycaemic individuals, diastolic dysfunction was associated with hypertension and more severe coronary atherosclerosis. In multivariable analysis, waist circumference (OR 1.034) and high CAC score (OR 2.90) were independent predictors — even after excluding ischaemic heart disease. In individuals without coronary atherosclerosis and hypertension, systolic blood pressure remained the only independent predictor. The findings challenge the concept of an 'isolated diabetic cardiomyopathy' and argue for early, integrated cardiometabolic risk management to prevent HFpEF.","created":"2026-07-03T20:27:01Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45977","type":"article","url":"https://hartvaat.nl/2026/05/20/bloeddrukeffecten-van-nitraat-hangen-af-van-de-bron-planten-verlagen-vlees-verho/","title":"Bloeddrukeffecten van nitraat hangen af van de bron: planten verlagen, vlees verhoogt","title_en":"Dietary Intakes of Plant and Animal Nitrate and 5-Year Blood Pressure Changes","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26894","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26894","authors":["Yuanyuan Cao"],"significance":7,"published":"2026-07-07","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"Cohort study in 2,942 Chinese adults analysing plant- versus animal-sourced nitrate intake via a validated food frequency questionnaire in relation to 5-year blood pressure changes and arterial stiffness (brachial-ankle pulse wave velocity). Higher plant nitrate intake was associated with greater 5-year SBP decline (β -3.51; 95% CI -5.89 to -1.13) and lower arterial stiffness (OR 0.59; 95% CI 0.35-0.98). Higher animal nitrate intake was conversely associated with DBP increase (β +1.95; 95% CI 0.54-3.37). In 2×2 analyses, plant nitrate + polyphenols or vitamin C gave the strongest BP decline, while animal nitrate + heme iron gave the strongest DBP rise. The BP effect of nitrate therefore depends strongly on the dietary context — an argument for actively promoting plant nitrate sources (green vegetables, beetroot) over animal sources (processed meat).","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:27:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45976","type":"article","url":"https://hartvaat.nl/2026/05/20/diffuse-myocardfibrose-bij-ernstige-aortastenose-is-ongelijk-verdeeld-vooral-aan/","title":"Diffuse myocardfibrose bij ernstige aortastenose is ongelijk verdeeld — vooral aan de basis van het hart","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003583?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003583?rss=1","authors":["Holmberg","E.","Engvall","J.","Nylander","E.","Granfeldt","H.","Tamas","E."],"significance":5,"published":"2026-07-07","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"Study in 43 patients with severe aortic stenosis who underwent cardiac MRI (cine, T1 relaxometry, and extracellular volume) and transthoracic echocardiography within one week before surgical aortic valve replacement. Endomyocardial biopsies were sampled during surgery. Histological analysis of 192 biopsies showed a median LV collagen volume fraction (CVF) of 19%, peaking in segment 1 (base) per the AHA segment model. Significant moderate correlations between CVF and extracellular volume in AHA segments 1 (r²=0.54) and 16 (r²=0.44) — the segments with the highest fibrosis prevalence. Functional parameters correlated with CVF: global circumferential strain (r²=0.31), radial strain (r²=-0.33), LVEF (r²=-0.34); T1 relaxation correlated with GLS (r²=0.42), MAPSE (r²=-0.39), and S' velocity (r²=-0.45). Fibrosis therefore begins at the base and relates to systolic function — CMR can quantify this regional heterogeneity.","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45975","type":"article","url":"https://hartvaat.nl/2026/05/20/hypochloremie-bij-opname-voor-acuut-hartfalen-voorspelt-onafhankelijk-30-daagse-/","title":"Hypochloremie bij opname voor acuut hartfalen voorspelt onafhankelijk 30-daagse sterfte (Vietnamees cohort)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003635?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003635?rss=1","authors":["Tran","D. H.","Truyen","T. T. T. T.","Pham","V. N. A.","Nhut Do","C.-M.","Vo","P. D.","Phan","T. C.","Nguyen Le","H. M.","Tran","H. N. T.","Luu","B. M. T.","Nguyen","T. H.-D.","Tran","T. P.","Nguyen","V. K.","Truong","D. T.","Pham","T. P.","Nguyen","M. V.","Nguyen","M. N."],"significance":5,"published":"2026-07-06","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"Cross-sectional study at Can Tho Central General Hospital (Vietnam, May-December 2024) in 423 patients ≥18 years with acute heart failure and NT-proBNP ≥300 pg/mL (mean age 69.7 years; 48% male). During hospitalisation, 5.0% died; of 252 discharged patients who completed 30-day phone follow-up, 17.1% died. After adjustment for age, sex, coronary disease, chronic HF, LVEF, and serum sodium, hypochloraemia was an independent predictor of both in-hospital mortality (aOR 4.9; 95% CI 1.3-18.5) and 30-day mortality (aRR 1.9; 95% CI 1.1-3.6). Each 1 mmol/L increase in chloride was associated with 5% lower 30-day mortality (RR 0.95; p=0.007). The findings confirm admission serum chloride as a valuable prognostic biomarker in AHF in a population where Western data are scarce.","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45973","type":"article","url":"https://hartvaat.nl/2026/05/20/infectieuze-endocarditis-na-tavi-diabetes-belangrijkste-risicofactor-e-faecalis-/","title":"Infectieuze endocarditis na TAVI: diabetes belangrijkste risicofactor, E. faecalis dominante verwekker, 2× mortaliteit","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004079?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004079?rss=1","authors":["Jordal","S.","Dingen","H.","Wasim","D.","Hoem","E. L.","Skaar","E.","Kommedal","O.","Mohamed Ali","A.","Giil","L. M.","Haaverstad","R.","Bleie","O.","Kittang","B. R.","Saeed","S."],"significance":6,"published":"2026-07-06","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Case-control study at Haukeland University Hospital (Norway, 2012-2023) comparing 71 patients with TAVI-related infective endocarditis (TAVI-IE) to 213 age- and sex-matched controls without IE (1:3 ratio). Incidence was 1.2% per patient-year; median time from TAVI to infection was 13 months (IQR 4-29). Diabetes mellitus was the only independent predictor of TAVI-IE in multivariable competing-risk analysis (SHR 2.08; 95% CI 1.19-3.65). Obesity (27% vs 15%) and balloon-expandable valve use (28% vs 13%) were more frequent in IE patients. Enterococcus faecalis was the most common pathogen (30%). TAVI-IE was associated with approximately twofold higher all-cause mortality (aHR 2.13; 95% CI 1.48-3.07), with the highest risk in early infections. The findings can guide targeted monitoring and prevention in high-risk patients.","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45972","type":"article","url":"https://hartvaat.nl/2026/05/20/klinisch-en-genetisch-risico-op-atriumfibrilleren-versterken-elkaar-additief-13-/","title":"Klinisch en genetisch risico op atriumfibrilleren versterken elkaar additief — 13× risico bij beide hoog","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004078?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004078?rss=1","authors":["Frederiksen","T. C.","Nadarajah","R.","Christiansen","M. K.","Wu","J.","Gale","C. P.","Benjamin","E. J.","Olsen","A.","Andersen","M. K.","Hansen","T.","Grarup","N.","Dahm","C. C.","Jensen","H. K."],"significance":7,"published":"2026-07-06","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"Case-cohort study within the Danish Diet, Cancer and Health cohort (subcohort n=4,040 plus AF cases) combining the FIND-AF clinical risk score (low 0-3, high 4-6, very high 7-14 points) with a genetic risk score (GRS) based on 142 variants, categorised as low (Q1), intermediate (Q2-4), or high (Q5) genetic risk. Over a median follow-up of 12.9 years, 3,094 participants developed AF. Compared with those at low clinical and genetic risk, the adjusted hazard ratio for AF was 3.47 with high clinical + high genetic risk, and 12.76 with very high clinical + high genetic risk. The relative excess risk due to interaction (RERI) was 0.56 — a positive additive interaction between GRS and FIND-AF. Combining clinical and genetic risk stratification can therefore better target future AF prevention and screening.","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45971","type":"article","url":"https://hartvaat.nl/2026/05/20/aric-over-35-jaar-hogere-bloeddruk-niet-alleen-lage-staande-bd-verklaart-syncope/","title":"ARIC over 35 jaar: hogere bloeddruk — niet alleen lage staande BD — verklaart syncope, vallen én CHD","title_en":"Orthostatic Blood Pressure, Cardiovascular Disease, and Hypotensive Events","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25773","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25773","authors":[],"significance":7,"published":"2026-07-06","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"Analysis of the Atherosclerosis Risk in Communities (ARIC) study: in 11,386 participants (mean age 54 years; 56% female; 25% Black), supine and standing BP were measured once at baseline, with over 35 years of follow-up for coronary heart disease, mortality, falls, and syncope. Drops in systolic BP on standing (absolute or relative) were associated with coronary heart disease, syncope, and mortality. In untreated participants, higher supine systolic BP and mean arterial pressure were associated with syncope. An increase in systolic BP ≥20 mm Hg on standing was associated with more falls (HR 1.52) and syncope (HR 1.40). In treated participants, lower standing BP did predict more syncope (HR 1.55). Regardless of treatment, higher pulse pressure was associated with CHD and mortality, but not with falls or syncope. The findings nuance the view that only low standing BP is the problem: higher BP appears an important risk factor for both cardiovascular and hypotension-related events, particularly in untreated adults.","created":"2026-07-03T20:27:00Z","updated":"2026-07-04T19:27:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45970","type":"article","url":"https://hartvaat.nl/2026/05/20/pulmonale-hypertensie-screenen-met-echo-cut-off-trv-2-7-m-s-beter-dan-2-9-onder-/","title":"Pulmonale hypertensie screenen met echo: cut-off TRV 2,7 m/s beter dan 2,9 onder nieuwe PH-definitie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004185?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004185?rss=1","authors":["Fukuda","Y.","Akagi","S.","Taya","S.","Ejiri","K.","Takaya","Y.","Dohi","Y.","Yuasa","S."],"significance":6,"published":"2026-07-06","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/pulmonale-hypertensie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-endocarditis-2023/"],"congress":"","summary_en":"Retrospective study in 755 patients at two general hospitals who underwent both transthoracic echocardiography and right heart catheterisation to determine optimal echocardiographic cut-offs for pulmonary hypertension (PH) under the revised definition (mPAP >20 mm Hg). The c-statistic for peak tricuspid regurgitation velocity (TRV) was 0.82 (95% CI 0.79-0.85). An optimal TRV cut-off of 2.7 m/s provided higher sensitivity (72%) than the conventional 2.9 m/s (60%) while maintaining specificity (82%). In 681 patients with available estimated right atrial pressure (eRAP, derived from IVC diameter and respiratory variation), adding eRAP improved discrimination (c-statistic 0.83 vs 0.80; net reclassification improvement 0.14; p=0.002). eRAP ≥5 mm Hg was associated with higher PH risk, and combining it with elevated TRV provided the strongest association. Under the new PH definition, a TRV cut-off of 2.7 m/s is a more useful screening threshold; adding eRAP further refines diagnosis.","created":"2026-07-03T20:26:59Z","updated":"2026-07-03T20:26:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45969","type":"article","url":"https://hartvaat.nl/2026/05/20/ct-ffr-voorspelt-mace-4-hoger-bij-waarde-0-80-bijgewerkte-meta-analyse-van-20-06/","title":"CT-FFR voorspelt MACE 4× hoger bij waarde ≤0,80: bijgewerkte meta-analyse van 20.067 patiënten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003979?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003979?rss=1","authors":["Biswas","S.","Srivastava","Y.","Hamadttu","A."],"significance":7,"published":"2026-07-05","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"Systematic review and meta-analysis of 22 studies (n=20,067) on the prognostic value of CT-derived fractional flow reserve (FFR-CT) in patients with suspected or known coronary artery disease, comparing FFR-CT ≤0.80 versus >0.80 — a fourfold expansion of the 2022 Nørgaard meta-analysis. Patients with FFR-CT ≤0.80 had significantly higher MACE risk (HR 3.94; 95% CI 2.92-5.31; p<0.0001) with substantial heterogeneity (I²=79.9%). Restricting to hard endpoints (death/myocardial infarction, k=6) yielded HR 3.28 (95% CI 2.25-4.79) with zero heterogeneity (I²=0%). No significant differences across FFR-CT technologies (HeartFlow, machine-learning, deep-learning algorithms; p=0.81). Trim-and-fill suggested possible publication bias (adjusted HR 2.35). GRADE certainty moderate. The findings support FFR-CT as a reliable non-invasive prognostic marker — relevant for non-invasive coronary work-up.","created":"2026-07-03T20:26:59Z","updated":"2026-07-04T19:09:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45967","type":"article","url":"https://hartvaat.nl/2026/05/21/hoge-jeugdige-conditie-en-af-risico-trade-off-verdwijnt-na-correctie-voor-famili/","title":"Hoge jeugdige conditie en AF-risico: trade-off verdwijnt na correctie voor familiaire factoren (1,1 miljoen Zweden)","title_en":"Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: A Nationwide Sibling-Controlled Cohort Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078250","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078250","authors":["Marcel Ballin"],"significance":8,"published":"2026-07-05","source_date":"2026-05-21","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Nationwide Swedish cohort with sibling-controlled analysis of 1,124,049 men (mean age 18.3 years) who underwent mandatory military fitness testing between 1972 and 1995, followed until December 2023. 45,179 (4.0%) developed atrial fibrillation and 96,404 (8.6%) had non-AF cardiovascular disease (median events around age 55 years). In population-wide analysis, the fittest men (highest decile) had a small excess of AF in early adulthood but greater reductions in non-AF CVD from age 45. In full-sibling comparison (controlling for shared familial factors), the trade-off disappeared entirely: from age 35 the reduction in non-AF CVD was already larger (RD -0.11%) than the AF excess (RD +0.06%); at age 65, respectively -3.91% versus +2.30%. High youth fitness therefore confers no net cardiovascular disadvantage — supporting public-health efforts to improve youth fitness and reassuring about the safety of high fitness levels.","created":"2026-07-03T20:26:59Z","updated":"2026-07-04T19:27:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45965","type":"article","url":"https://hartvaat.nl/2026/05/21/swedeheart-na-een-eerste-hartinfarct-is-fysieke-fitheid-bij-start-cardiale-reval/","title":"SWEDEHEART: na een eerste hartinfarct is fysieke fitheid bij start cardiale revalidatie ver onder de norm","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004046?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004046?rss=1","authors":["Hedin","K.","Carlen","A.","Hadziosmaniovic","N.","Hagstro&#x0308;m","E.","Jernberg","T.","Leosdottir","M.","Ravn-Fischer","A.","Sandberg","C.","Ahlund","K.","Urell","C.","Ba&#x0308;ck","M."],"significance":6,"published":"2026-07-05","source_date":"2026-05-21","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"Registry study from the Swedish SWEDEHEART post-MI register (2016-2019) in 15,105 patients with first-time myocardial infarction (mean age 62.5 years; 78.4% male) who underwent physiotherapist-led assessments of exercise capacity (symptom-limited cycle ergometry) and muscular endurance (unilateral heel-rise test) at the start of cardiac rehabilitation. Results were compared with Swedish age- and sex-stratified reference values (Kalmar dataset). Mean exercise capacity was only 64.7% of predicted in men and 68.4% in women; muscular endurance 78.4% in men and 61.7% in women. Women showed a steeper age-related decline in heel-rise performance. The results underscore the importance of systematic baseline assessment and tailored rehabilitation targeting both exercise capacity and muscle strength.","created":"2026-07-03T20:26:59Z","updated":"2026-07-04T14:56:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45963","type":"article","url":"https://hartvaat.nl/2026/05/21/million-women-study-ernstige-obesitas-verviervoudigt-risico-op-af-en-hartfalen-s/","title":"Million Women Study: ernstige obesitas verviervoudigt risico op AF én hartfalen samen bij vrouwen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003950?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003950?rss=1","authors":["Suh","J. W.","Floud","S.","Reeves","G. K.","Cairns","B. J.","Wright","F. L."],"significance":7,"published":"2026-07-05","source_date":"2026-05-21","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Prospective cohort within the UK Million Women Study: 1.3 million women aged 50-64 recruited in 1996-2001, with baseline data on demographics, BMI, smoking, alcohol, physical activity, and treatment for hypertension, diabetes, and hypercholesterolaemia. Through linked hospital and death records, 19 cardiovascular disease subtypes were tracked. Cardiovascular multimorbidity (CVM, ≥2 diagnoses) and complex CVM (≥4 diagnoses) were analysed. Obesity, smoking, and treated diabetes or hypertension were each independently associated with 2-3× higher CVM risk; severe obesity, heavy smoking, and diabetes with 3-4× higher complex-CVM risk. Strongest associations: severe obesity with fivefold risk of atrial fibrillation + heart failure together, and diabetes with fivefold risk of ischaemic heart disease + heart failure together. Alcohol and physical activity showed weak associations. Targeted risk-factor management is particularly important in women to prevent CV multimorbidity.","created":"2026-07-03T20:26:58Z","updated":"2026-07-04T14:56:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45962","type":"article","url":"https://hartvaat.nl/2026/05/25/patientspecifieke-3d-hartmodellen-bij-congenitale-hartchirurgie-18-minuten-korte/","title":"Patiëntspecifieke 3D-hartmodellen bij congenitale hartchirurgie: 18 minuten korter opereren en minder complicaties (meta-analyse)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004011?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004011?rss=1","authors":["Arero","G.","Jarsso","G.","Wako","A.","Fekadu","D.","Mardasa","K.","Godana","H."],"significance":5,"published":"2026-07-05","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/cardiometabool/metformine-cardiovasculair/"],"congress":"","summary_en":"Systematic review and meta-analysis of 32 comparative studies (n=1,842) on the impact of patient-specific 3D heart models — printed or virtual — on surgical planning and outcomes in congenital heart surgery, compared with conventional imaging. Use of 3D models was associated with: more frequent modification of the operative plan (RR 1.42; 95% CI 1.21-1.67), shorter operative time (mean -18.4 minutes), fewer postoperative complications (RR 0.74), fewer re-operations (RR 0.52), shorter hospital stay (-1.8 days), and higher self-reported surgeon confidence (SMD 0.88). Certainty of evidence ranged from low to moderate due to non-experimental study designs and heterogeneity. 3D models appear useful in complex congenital anomalies; confirmation in larger, methodologically stronger studies is desirable.","created":"2026-07-03T20:26:58Z","updated":"2026-07-03T20:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45961","type":"article","url":"https://hartvaat.nl/2026/05/25/laparoscopische-pericardio-peritoneale-window-kleine-prospectieve-serie-van-24-p/","title":"Laparoscopische pericardio-peritoneale window: kleine prospectieve serie van 24 patiënten zonder recidief in 12 maanden","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004047?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004047?rss=1","authors":["Alhames","S.","Ghabally","M.","Bayda","A.","Marta","E."],"significance":5,"published":"2026-07-04","source_date":"2026-05-25","image":"","kennis":[],"congress":"","summary_en":"Single-centre prospective study (2022-2024) in 24 patients with recurrent pericardial effusion requiring surgical intervention. In all, a pericardio-peritoneal window was created via laparoscopy for continuous drainage as a minimally invasive alternative to repeated drainage. The procedure was technically successful in all 24 patients, produced immediate symptomatic improvement, required no postoperative drainage, and allowed next-day discharge; no postoperative complications occurred. At 12 months, there was no clinical or radiological recurrence. The results suggest that a laparoscopic pericardio-peritoneal window is a safe, effective, and durable alternative for patients with recurrent pericardial effusion — though larger randomised trials are needed for definitive confirmation of safety and long-term outcome.","created":"2026-07-03T20:26:58Z","updated":"2026-07-03T20:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45960","type":"article","url":"https://hartvaat.nl/2026/05/26/acute-bloeddrukverhoging-tijdens-ziekenhuisopname-hoe-te-handelen-bij-asymptomat/","title":"Acute bloeddrukverhoging tijdens ziekenhuisopname: hoe te handelen bij asymptomatische 'hypertensieve urgentie'?","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/658?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/658?rss=1","authors":["Etemadi","A.","Kumar","P.","Anderson","T. S.","Chang","T. I."],"significance":6,"published":"2026-07-04","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"Heart BMJ review of pragmatic management of acute blood pressure elevations during hospitalisation. True hypertensive emergencies (with end-organ damage) are relatively rare and have clear guidelines; asymptomatic acute BP elevations are far more frequent and lack consensus on appropriate management. Contributing factors: fear of missing true emergencies, limitations in inpatient BP measurement accuracy, and inconsistent data on short- and long-term effects of inpatient BP elevations. Practice varies widely — even within a single hospital — between observation, intravenous or oral antihypertensives, and adjustment of home medication. Some clinicians discharge patients on intensified therapy based on inpatient values. The review synthesises the available evidence and provides a practical, holistic framework for evaluation and treatment.","created":"2026-07-03T20:26:58Z","updated":"2026-07-03T20:26:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45959","type":"article","url":"https://hartvaat.nl/2026/05/26/12-leads-ecg-onderscheidt-rasopathie-hcm-van-sarcomere-hcm-bij-kinderen-superieu/","title":"12-leads ECG onderscheidt RASopathie-HCM van sarcomere HCM bij kinderen — superieure asdeviatie en rechterventrikel-hypertrofie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/692?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/692?rss=1","authors":["Boleti","O.","Sunjaya","A.","Field","E.","Norrish","G.","Tollit","J.","Cervi","E.","Kaski","J. P."],"significance":5,"published":"2026-07-04","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/ritmestoornissen/ventrikelfibrilleren/"],"congress":"","summary_en":"Retrospective single-centre cohort study in 84 children with RASopathy-associated hypertrophic cardiomyopathy (RAS-HCM, e.g. Noonan syndrome) versus 113 children with sarcomeric HCM (s-HCM). RAS-HCM ECGs showed significantly more superior axis deviation (29.8% vs 2.5%; p<0.001) and voltage criteria for right ventricular hypertrophy (52.4% vs 28.3%; p<0.001), and significantly fewer pathological Q waves (27.4% vs 47.8%; p<0.001). Over a median follow-up of 6.8 years, 19 (22.6%) RAS-HCM patients experienced major adverse cardiovascular events (cardiovascular death, resuscitation, haemodynamically relevant ventricular arrhythmias, ICD shock, or HF hospitalisation). ST-segment changes >2 mm remained associated with MACE after adjustment (aRR 2.33; 95% CI 1.12-4.86; p=0.024). The 12-lead ECG may therefore serve as a simple discriminating test between RAS-HCM and s-HCM with additional prognostic value.","created":"2026-07-03T20:26:58Z","updated":"2026-07-04T11:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9ab832c60eaf","type":"article","url":"https://hartvaat.nl/2026/05/26/recidief-linkerventrikel-trombus-12-recidief-actieve-eerdere-maligniteit-verzesv/","title":"Recidief linkerventrikel-trombus: 12% recidief — actieve/eerdere maligniteit verzesvoudigt het risico","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/684?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/684?rss=1","authors":["Leow","A. S.-T.","Low","C. J.","Goh","F.-Q.","Seah","A. W.-J.","Tan","B. Y.-Q.","Kong","W. K. F.","Poh","K.-K.","Chan","M. Y.","Yeo","L. L. L.","Chai","P.","Yeo","T.-C.","Zhou","X.","Lip","G. Y. H.","Sia","C.-H."],"significance":6,"published":"2026-07-03","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"Retrospective cohort of 346 patients with resolved left ventricular thrombus (LVT) at a tertiary centre (2011-2021; mean age 59.9 years, 86.4% male, median follow-up 4.4 years). LVT recurrence occurred in 11.8% (41/346) of all cases and 12.0% (23/192) after post-AMI LVT. In multivariable analysis with competing risks, active or previous malignancy was a strong predictor of recurrence — both overall (aSHR 5.59; 95% CI 2.02-15.5) and in post-AMI LVT (aSHR 13.9; 95% CI 4.05-47.7). Initial LVT characteristics also predicted recurrence: thrombus size (per cm; aSHR 1.42) and protrusion into the LV lumen (aSHR 5.46). LVT recurrence was associated with more composite outcomes (MI, ischaemic stroke, acute HF, mortality; aHR 3.04 overall; aHR 2.77 post-AMI). Active malignancy warrants extra screening and prevention strategy in patients with prior LVT.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"389aab64e20a","type":"article","url":"https://hartvaat.nl/2026/05/26/routine-huisarts-emd-voorspelt-5-jaars-cardiovasculair-risico-betrouwbaar-austra/","title":"Routine huisarts-EMD voorspelt 5-jaars cardiovasculair risico betrouwbaar — Australische validatie bij 850.000 patiënten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","farmaco-economie","fractional-flow-reserve","hartrevalidatie","laminopathie","obesitas","ouderen","pathfinder-trial","perifeer-vaatlijden","richtlijnen-esc","secundaire-preventie","slaapapneu","stride-trial","supraventriculaire-tachycardie","ventrikelfibrilleren","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/674?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/674?rss=1","authors":["Kuo","N. I.-H.","Barbieri","S.","Arnott","C.","Gallego","B.","Gandomkar","Z.","Ferdousi","S.","Douglas","K.","Woodward","M.","Jorm","L."],"significance":7,"published":"2026-07-03","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Study using routinely collected electronic medical records (EMRs) from 680 Australian general practices (Lumos programme, linked to hospital and death records) in 850,216 patients aged 30-74 years without prior CVD. Over a mean follow-up of 4.9 years, 33,578 cardiovascular events occurred. Sex-specific Cox models with 28 predictors achieved Harrell's C 0.803 (95% CI 0.801-0.804) in females and 0.772 (95% CI 0.770-0.773) in males; simpler LASSO models with 12-15 predictors performed similarly. Models were well calibrated across age, socioeconomic strata, and smoking status, with consistent discrimination across 10 regional Primary Health Networks. Net reclassification improvement up to 0.185 versus existing AusCVDRisk variables. EMR-based models are suitable for automated integration into primary-care software for real-time CVD risk assessment — an important scalability step for primary prevention.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T18:39:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb3e689a9d18","type":"article","url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","title":"Asymptomatische matige/ernstige aortaklepinsufficiëntie níet benigne — meta-analyse pleit voor vroege interventie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["abelacimab","aortainsufficiëntie","atherosclerose","fractional-flow-reserve","select-trial","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/646?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/646?rss=1","authors":["Naser","J. A.","Massad","F.","Al-Abcha","A.","Gerberi","D.","Pislaru","S. V.","Nkomo","V. T.","Thaden","J. J.","Wang","Z.","Cavalcante","J. L.","Pellikka","P. A.","Michelena","H. I.","Enriquez-Sarano","M."],"significance":8,"published":"2026-07-03","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/"],"congress":"","summary_en":"Systematic review and meta-analysis of 27 cohort studies (4,720 patients; mean age 49 years; median follow-up 3.9 years) on the natural history of asymptomatic moderate or severe aortic regurgitation (AR). Pooled incidence per 100 person-years: all-cause mortality 1.75 (95% CI 1.27-2.41), cardiac death 1.29, sudden death 0.29, new symptoms 4.30, and aortic valve replacement/repair (AVR) 7.01. Asymptomatic LV dysfunction occurred at only 0.9 per 100 person-years. Mortality rates were more than double those of the general population irrespective of age — 2.45 per 100 person-years in cohorts ≥50 years versus 0.59 in younger cohorts. Early AVR was associated with lower mortality (pooled HR 0.33; 95% CI 0.30-0.37). The findings contradict the historical view of AR as a 'benign' valvular lesion and argue for earlier intervention guided by more sensitive markers of LV damage.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97e5b6f4cbfd","type":"article","url":"https://hartvaat.nl/2026/05/26/accurhythm-ai-vermindert-valse-alarmen-bij-ilr-met-62-bespaart-honderden-klinisc/","title":"AccuRhythm AI vermindert valse alarmen bij ILR met 62% — bespaart honderden klinische uren","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/12/667?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/12/667?rss=1","authors":["Cocchiara","L.","Brescia","B.","Marchese","P.","Nardi","S.","Arabia","G.","Salucci","A.","Gennaro","F.","Mazzotta","G.","Addeo","L.","Calvi","E.","Mitacchione","G.","Strisciuglio","T.","Vergara","P.","Esposito","G.","Rapacciuolo","A."],"significance":6,"published":"2026-07-02","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"Multicenter retrospective study in 800 patients with an implantable loop recorder (Reveal LINQ or LINQ II) evaluating the cloud-based AI filtering algorithm AccuRhythm AI for false-positive alerts and clinical workload. AI filtering reduced false pause alerts by 62% and false AF alerts by 33%, saving 210 clinician hours over 6 months. At the patient level (n=465 Reveal LINQ users), the proportion of patients with ≥1 false-positive transmission fell from 55.5% to 15.1% (p<0.001), saving 1,128 hours. All residual false alerts occurred in patients with R-wave amplitudes <0.4 mV. AccuRhythm AI thus reduces workload without compromising diagnostic accuracy, with R-wave amplitude as the critical factor — underscoring the importance of optimal device implantation and signal quality.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47fc1c24d252","type":"article","url":"https://hartvaat.nl/2026/05/26/pfa-sham-pulsed-field-ablatie-verslaat-sham-procedure-overtuigend-bij-atriumfibr/","title":"PFA-SHAM: pulsed field-ablatie verslaat sham-procedure overtuigend bij atriumfibrilleren — placebo-effect uitgesloten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079484","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079484","authors":["Pavel Osmancik"],"significance":9,"published":"2026-07-02","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Prospective, sham-controlled, single-blind randomised trial in 60 patients with highly symptomatic atrial fibrillation (AFEQT score <50), assigned 1:1 to pulsed field ablation (PFA) or a sham procedure. All participants received implantable rhythm monitors for continuous rhythm monitoring. At 6 months: AF recurrence occurred in 6.7% (PFA) versus 83.3% (sham); posterior HR 19.6 (95% Bayesian credible interval 6.7-76.9; posterior superiority probability >0.99). Quality of life (AFEQT) improved +43.9 points with PFA versus +11.3 with sham (difference +32.6 points). AF burden was significantly lower with PFA (median 0% vs 0.43%). Anxiety/depression score (HADS) improved -4 points with PFA versus -0.5 with sham. This first sham-controlled PFA trial excludes a placebo effect and confirms PFA as robustly effective in symptomatic AF — both objectively (rhythm) and subjectively (quality of life, psychological distress).","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T18:39:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ec3b66881d6","type":"article","url":"https://hartvaat.nl/2026/04/30/kp-chemo-cumulatieve-incidentie-cancer-therapy-related-cardiac-dysfunction-8-4-h/","title":"KP CHEMO: cumulatieve incidentie cancer-therapy-related cardiac dysfunction 8,4% — hoogste bij HER2-remmers","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["kanker-en-hart"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag113","source_url":"https://doi.org/10.1093/eschf/xvag113","authors":["Samir R Thadani","Alan S Go","Jane Y Liu","Rishi V Parikh","Elisha A Garcia","Elizabeth M Cespedes Feliciano","Ankeet S Bhatt","Sirtaz Adatya","Marilyn L Kwan","Amy Y Lin","Raymond Liu","Alfredo Lopez","Joshua R Nugent","David Ouyang","Alberta H Yen","Jonathan G Zaroff","Andrew P Ambrosy"],"significance":8,"published":"2026-07-02","source_date":"2026-04-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Retrospective cohort study within Kaiser Permanente Northern California: 26,646 adults diagnosed with malignant tumours between 2012-2022 who received anthracyclines, HER2 inhibitors, immune checkpoint inhibitors (ICIs), or tyrosine kinase inhibitors (TKIs). Mean age 62 years, 64% women. Cancer therapy-related cardiac dysfunction (CTRCD) — defined as >10% LVEF decline to <53% or incident heart failure — occurred in 8.4% (95% CI 7.7-9.1) cumulative. Highest incidence with HER2 inhibitors (10.7%), lowest with ICIs (5.2%) (p<0.001). Nearly half of all events occurred within the first year. The cohort supports early risk prediction models and targeted cardiology surveillance during oncologic therapy to reduce downstream HF risk — a key message for cardio-oncology practice.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bcba630de750","type":"article","url":"https://hartvaat.nl/2026/08/15/3d-ct-fluoroscopie-fusie-maakt-laac-efficienter-minder-contrast-minder-straling-/","title":"3D CT-fluoroscopie-fusie maakt LAAC efficiënter: minder contrast, minder straling, korte procedure","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134536","source_url":"https://doi.org/10.1016/j.ijcard.2026.134536","authors":["Xiancun Yang","Youwei Sun","Nan Zhang","Jianle Xu","Baocheng Geng","Ying Wang"],"significance":5,"published":"2026-07-01","source_date":"2026-08-15","image":"","kennis":[],"congress":"","summary_en":"Retrospective comparative study of 109 consecutive patients undergoing left atrial appendage closure (LAAC) using 3D CT-fluoroscopy fusion (n=51) versus the Real-time Operation Guidance Planning System (ROGPS, n=58). The fusion group required significantly less contrast (60.2 vs 75.3 mL; p<0.001), shorter fluoroscopy time (8.0 vs 10.2 min; p=0.002), and shorter total procedure time (62.2 vs 68.5 min; p=0.005). Radiation dose (DAP) was also lower (29.8 vs 42.2 Gy·cm²; p=0.01). Procedural success was 100% in both groups. Device-related thrombosis and peridevice leak did not differ significantly. 3D CT-fluoroscopy fusion thus improves LAAC efficiency without compromising safety.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f12f3596f4f7","type":"article","url":"https://hartvaat.nl/2026/05/01/doac-s-cox-2-selectieve-nsaid-s-geven-37-minder-gi-bloedingen-dan-doac-s-niet-se/","title":"DOAC's + COX-2-selectieve NSAID's geven 37% minder GI-bloedingen dan DOAC's + niet-selectieve NSAID's","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aspirine"],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2026.13941","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.13941","authors":["Fabian Maximilian Meinert","Jenny Dimakos","Ying Cui","Kristian B Filion","Christel Renoux","Antonios Douros"],"significance":7,"published":"2026-07-01","source_date":"2026-05-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"Multinational cohort study (UK EHR + Quebec claims, 2011-2020) in 30,240 patients with nonvalvular atrial fibrillation initiating concomitant DOAC and NSAID (37,833 episodes; 45.2% COX-2-selective, 54.8% nonselective). Mean age 72.1 years, 56.7% male. Pooled weighted analysis with inverse-probability-of-treatment weighting showed that COX-2-selective NSAIDs combined with DOACs were associated with fewer gastrointestinal bleeds (HR 0.63; 95% CI 0.46-0.87; I²=56%) and fewer non-GI bleeds (HR 0.54; 95% CI 0.40-0.74; I²=0%) versus nonselective NSAIDs. The effect was stronger in women (HR 0.50 for GI bleeding) than in men (HR 0.85). No major effect modification by age, order of initiation, baseline bleeding risk, or specific DOAC. COX-2-selective NSAIDs thus retain their GI-protective benefit during DOAC therapy; future research should clarify the relationship with stroke risk.","created":"2026-07-03T10:33:09Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93830a5ca5d2","type":"article","url":"https://hartvaat.nl/2026/05/04/congestie-bij-chronisch-hartfalen-echografie-vult-klinisch-onderzoek-aan-en-voor/","title":"Congestie bij chronisch hartfalen: echografie vult klinisch onderzoek aan en voorspelt slechte prognose","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","hfpef","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag126","source_url":"https://doi.org/10.1093/eschf/xvag126","authors":["Ahmad Alsaeed","Htet Htet Ei Khin","Elisabetta Caiazzo","Moustafa I Morsy","Joe Cuthbert","Andrew L Clark","John G F Cleland","Pasquale Maffia","Pierpaolo Pellicori"],"significance":6,"published":"2026-07-01","source_date":"2026-05-04","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"Study in 342 patients with chronic heart failure (CHF) during routine clinic visits. Clinical congestion (elevated JVP, pulmonary congestion, or peripheral oedema) was assessed unblinded versus ultrasonographic congestion (inferior vena cava diameter, jugular vein Valsalva/rest ratio, lung B-lines). eGFR was calculated with CKD-EPI 2021. eGFR distribution: <30 in 9%, 30-44 in 18%, 45-59 in 26%, >60 in 47%. Many patients — particularly with low eGFR — had both clinical and ultrasound congestion (51%, 30%, 39%, 25% per eGFR group). Isolated ultrasound congestion was also common (19-34%); isolated clinical congestion was rarer. Congestion, especially when both methods agreed, was associated with higher NT-proBNP and greater risk of HF hospitalisation or death (aHR 2.16; 95% CI 1.25-3.75; p=0.006 vs no congestion). The role of ultrasound congestion assessment in routine HF management warrants further study.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T18:39:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7da9721e277e","type":"article","url":"https://hartvaat.nl/2026/05/04/microbioom-vriendelijk-dieet-di-gm-geassocieerd-met-27-minder-hartfalen-bij-pred/","title":"Microbioom-vriendelijk dieet (DI-GM) geassocieerd met 27% minder hartfalen bij prediabetes (NHANES n=15.219)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-1","microbioom","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag125","source_url":"https://doi.org/10.1093/eschf/xvag125","authors":["Yuqing Huang","Yuling Yang","Jia Feng","Qiming Gong","Yueli Pu","Xia Fang","Yong Xu"],"significance":6,"published":"2026-06-30","source_date":"2026-05-04","image":"","kennis":[],"congress":"","summary_en":"Cross-sectional analysis of NHANES 2007-2018 data in 15,219 US adults with diabetes or prediabetes. The Dietary Index for Gut Microbiota (DI-GM) was calculated from two 24-hour dietary recalls covering 14 food groups linked to gut microbiota. Higher DI-GM scores were independently associated with lower heart failure risk (aOR 0.93 per point; 95% CI 0.89-0.98; p=0.005). Compared with scores 0-3, DI-GM ≥6 was associated with 27% lower HF risk (OR 0.73; 95% CI 0.58-0.92; p=0.007). The inverse association was stronger in prediabetes (OR 0.89 per point; p=0.004) but not significant in diabetes. Microbiota-related dietary patterns may thus play a role in HF prevention in metabolically vulnerable populations.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b77fc97db822","type":"article","url":"https://hartvaat.nl/2026/05/05/apicale-myocardfibrose-bij-lvad-implantatie-voorspelt-cardiale-mortaliteit-singl/","title":"Apicale myocardfibrose bij LVAD-implantatie voorspelt cardiale mortaliteit (single-center, n=47)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag135","source_url":"https://doi.org/10.1093/eschf/xvag135","authors":["İbrahim Demir","Bilge Ecemiş","Ayşe Zorba","Işık İkbal Barış","Berhan Keskin","Emir Cantürk","Yahya Yıldız","İbrahim Oğuz Karaca","Korhan Erkanlı"],"significance":5,"published":"2026-06-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Single-centre retrospective cohort of 47 consecutive patients undergoing durable LVAD implantation (2019-2025; median age 63 years, 14.9% female). At implantation, tissue from the apical LV core was analysed by structured histopathology (THS-10 score) and digital morphometry (QuPath). Median follow-up 1,513 days; 27 deaths (16 cardiovascular, 11 non-cardiac). A threshold of 33.7% collagen-positive area gave the best discrimination for overall mortality (AUC 0.739). On univariable Cox analysis, fibrosis burden (HR 39.4) and THS-10 score (HR 1.51) were strongly associated with mortality. After adjustment for clinical severity (including INTERMACS profile), the all-cause-mortality association attenuated, but fibrosis burden independently predicted cardiac mortality (sHR ≈ 4.1; p=0.02). The cohort-derived threshold for cardiac death was 39.6% (AUC 0.752). The results support myocardial-substrate assessment in LVAD selection; external validation in larger cohorts is needed.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87c65d7bc11a","type":"article","url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","title":"CMR-LACI ≥21% identificeert hoogrisicopatiënten met HFrEF — onafhankelijk van LVEF en LGE","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag130","source_url":"https://doi.org/10.1093/eschf/xvag130","authors":["Marco Guglielmo","Damiano Fedele","Luca Bergamaschi","Matteo Armillotta","Francesco Angeli","Mariachiara Ciarlantini","Ilaria Buccella","Carmine Pizzi","Theo Pezel","Giovanni Donato Aquaro","Andrea Baggiano","Andrea Barison","Jan Bogaert","Leonardo Calò","Giovanni Camastra","Samuela Carigi","Nazario Carrabba","Grazia Casavecchia","Stefano Censi","Gloria Cicala","Carlo N De Cecco","Manuel De Lazzari","Gabriella Di Giovine","Monica Dobrovie","Marta Focardi","Laura Fusini","Nicola Gaibazzi","Annalaura Gismondi","Matteo Gravina","Pim van der Harst","Chiara Lanzillo","Massimo Lombardi","Valentina Lorenzoni","Jordi Lorano-Torres","Davide Margonato","Chiara Martini","Francesca Marzo","Pier-Giorgio Masci","Ambra Masi","Claudio Moro","Giuseppe Muscogiuri","Saima Mushtaq","Alberto Nese","Alessandro Palumbo","Patrizia Pedrotti","Martina Perazzolo Marra","Silvia Pradella","Cristina Presicci","Mark G Rabbat","Claudia Raineri","Jose' F Rodriguez-Palomares","Stefano Sbarbati","Angelo Squeri","Nicola Sverzellati","Rolf Symons","Emily Tat","Mauro Timpani","Giancarlo Todiere","Adele Valentini","Akos Varga-Szemes","Alessandra Volpe","Andrea Igoren Guaricci","Juerg Schwitter","Anna Giulia Pavon","Gianluca Pontone"],"significance":6,"published":"2026-06-30","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/","https://hartvaat.nl/kennis/hartfalen/ischemische-cardiomyopathie/"],"congress":"","summary_en":"Analysis within the multicenter DERIVATE registry: 2,170 patients with LVEF <50% who underwent cardiac MRI (mean age 59.8 years, 24.7% women, median LVEF 31.6%). LACI (left atrioventricular coupling index) was calculated as the ratio of left atrial to left ventricular end-diastolic volume. Median LACI 19.4%. During a median follow-up of 1,016 days, all-cause mortality occurred in 8.8%, mortality/HF in 26.0%, and HF in 20.4%. After adjustment for clinical and CMR parameters (including LVEF and late gadolinium enhancement), each 5% increase in LACI was associated with greater all-cause mortality (HR 1.06), mortality/HF (HR 1.09), and HF (HR 1.09). The optimal cut-off for all-cause mortality was LACI ≥21% (AUC 0.617). LACI provides incremental prognostic information beyond LVEF and LGE in HFrEF.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"888df5e9edf2","type":"article","url":"https://hartvaat.nl/2026/05/05/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","title":"UK Biobank: na ischemisch CVA of TIA is het risico op hartfalen groter dan dat op hartinfarct","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["cerebrovasculair"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag123","source_url":"https://doi.org/10.1093/eschf/xvag123","authors":["Rahul G Muthalaly","Nitesh Nerlekar","Sean Tan","Andrew Lin","Adam J Nelson","Thanh Phan","Henry Ma","Stephen J Nicholls"],"significance":7,"published":"2026-06-29","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"Prospective cohort study within UK Biobank (n=405,406, ages 40-69; 45.6% male). Patients with prior heart failure were excluded and stratified by history of ischaemic stroke/TIA. Over 13.7 years of follow-up, 15,565 incident HF events occurred. Stroke survivors had an unadjusted HR of 3.6 (95% CI 3.3-3.8) for HF hospitalisation and adjusted HR of 1.4 (95% CI 1.3-1.5). Notably, the risk of incident HF exceeded the risk of recurrent MI (12.6% vs 5.4%). Stroke survivors who developed HF had lower LVEF and higher LV mass on CMR. Incident HF in this group was associated with aHR 1.8 for mortality. The findings suggest stroke survivors are an underrecognised high-risk population for HF, predominantly with a low-EF phenotype — supporting future preventive HF trials in this group.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bec0da3faee0","type":"article","url":"https://hartvaat.nl/2026/05/05/coronaire-embolie-bij-atriumfibrilleren-hoog-rest-trombo-embolisch-risico-ondank/","title":"Coronaire embolie bij atriumfibrilleren: hoog rest-trombo-embolisch risico ondanks antistolling","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["aperitif-trial","slaapapneu"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.045749","source_url":"https://doi.org/10.1161/JAHA.125.045749","authors":["Jinsong Cheng","Hengyi Mao","Minfang Guan","Hanbin Cui"],"significance":7,"published":"2026-06-29","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/linkerhartoorkluiting/"],"congress":"","summary_en":"Retrospective cohort study (China, 2014-2023, n=4,777 with acute myocardial infarction) in which coronary embolism (CE) was diagnosed via a 3-step validation process (Shibata criteria, angiographic core lab, final adjudication). Patients were grouped: CE with AF (n=78), non-CE AMI with AF (n=205), and non-CE AMI without AF (n=3,937), with propensity-score overlap weighting. CE accounted for 1.6% of all AMIs and 14.7-27.6% of AF-related AMIs. Compared with non-CE AMI without AF, CE+AF patients had significantly higher all-cause mortality (aHR 1.77; 95% CI 1.15-2.71) and ischaemic stroke (aHR 4.45; 95% CI 2.34-8.45), despite 79.2% receiving therapeutic anticoagulation. CE in AF is therefore an underrecognised high-risk phenotype with residual thromboembolic risk. The authors advocate multimodal imaging, embolism-targeted reperfusion, and optimisation of antithrombotic therapy including standard-dose DOACs.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T18:39:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d6a6e0bbd4b1","type":"article","url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","title":"DAPA-HD: eerste gerandomiseerde studie naar dapagliflozin bij hemodialyse-patiënten — opzet en achtergrond","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","dapa-hf","dapagliflozine","dubbele-trombocytenremming","fidelio-dkd","figaro-dkd"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag104","source_url":"https://doi.org/10.1093/eschf/xvag104","authors":["Thomas A Zelniker","Christopher Paschen","Christopher Mann","Manfred Eigner","Hildegard Hafner-Gießauf","Josef Kletzmayr","Matthias Lorenz","Bernhard Ludvik","Thomas Stulnig","Ingmar Waller","Johannes Werzowa","Sebastian Hödlmoser","Christian Hengstenberg","Rainer Oberbauer","Manfred Hecking"],"significance":5,"published":"2026-06-29","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"Design of the academic multicenter, double-blind, placebo-controlled DAPA-HD trial (NCT05179668) in 220 patients with kidney failure on maintenance haemodialysis. Background: SGLT2 inhibitors reduce cardiovascular events across a wide range of kidney function, but evidence is lacking for patients on haemodialysis. Stratified block randomisation by patient-reported residual urine volume. Primary outcome is change in left ventricular mass index (echocardiographic) at 6 months. A prespecified subgroup analysis compares patients with residual urine output >200 mL/24 h versus ≤200 mL/24 h. Secondary outcomes: additional echocardiographic parameters, biomarkers, quality of life, and clinical events. The first trial to specifically address the cardiovascular and haemodynamic effects of dapagliflozin in dialysis patients — will close an important evidence gap.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T18:39:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3398e1549f94","type":"article","url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","title":"Reduce-MFA DZHK25: trial naar antifibrotische therapie tegen myocardfibrose na TAVI — opzet en achtergrond","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag083","source_url":"https://doi.org/10.1093/eschf/xvag083","authors":["Miriam Puls","Elisabeth M Zeisberg","Marius Placzek","Bo E Beuthner","Christoph F Jacob","Kristin E Steinhaus","Torben Lange","Ralf Tostmann","Moritz Schnelle","Andreas Schuster","Gerd Hasenfuß","Tim Friede"],"significance":5,"published":"2026-06-28","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Trial design of the German Reduce-MFA DZHK25 trial: prospective, multicenter, randomised, open-label study with blinded outcome assessment (PROBE design) in patients with severe aortic stenosis and high baseline myocardial fibrosis undergoing TAVI. Only patients with cardiac MRI ECV ≥25.9% (independent mortality predictor) are randomised to 3 arms: (i) standard care, (ii) + spironolactone, (iii) + spironolactone + low-dose dihydralazine (epigenetic reactivation of anti-fibrotic genes), for 12 months. Primary outcome is fibrosis regression by CMR-T1 mapping (ECV-derived LV matrix volume); secondary outcomes include reverse remodelling, KCCQ, 6MWT, NT-proBNP, NYHA class, mortality, and cardiac hospitalisations. Enrolment is complete with 384 screened and 153 randomised. Results may open a new adjuvant treatment route after TAVI for patients with high fibrotic burden.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dbefaefd5346","type":"article","url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","title":"Wereldwijde HF-registry (28 landen): FEV1 is een onafhankelijke prognostische factor — pleidooi voor spirometrie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag128","source_url":"https://doi.org/10.1093/eschf/xvag128","authors":["MyLinh Duong","Shofiqul Islam","Philip Joseph","Darryl Leong","Alex Grinvalds","Tara McCready","Kelley R Branch","Andrzej Budaj","Albertino Damasceno","Juan Manuel Dominguez","Anastase Dzudie","Camilla Hage","Charles Mondo","Julius Chacha Mwita","Francesco Orso","Alexander Parkhomenko","Jeffrey Probstfield","Jean Rouleau","Sanjib Kumar Sharma","Jose Silva-Cardoso","Stefan Störk","Thomas Wittlinger","Gerald Yonga","Jun Zhu","Salim Yusuf"],"significance":7,"published":"2026-06-28","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Substudy within the Global Congestive Heart Failure registry, which collected clinical data and spirometry from 3,359 HF patients across 28 high-, middle-, and low-income countries (mean age 61.9 years, 66.4% male; median follow-up 3.8 years). Baseline FEV1 was converted to z-scores standardised for age, sex, and height. Lower FEV1 — even within the 'normal' range — was associated with greater HF burden, more cardiac structural/functional abnormalities, and lower quality of life. FEV1 z-score ≤-2 was independently associated with higher all-cause mortality (HR 2.20; 95% CI 1.61-3.01), CV mortality (HR 2.45), and all-cause hospitalisation (HR 1.40). The effect was comparable to other major HF prognostic factors and consistent across income levels, HF aetiology, HF type, and airflow obstruction. Spirometry therefore deserves a place in routine HF evaluation.","created":"2026-07-03T10:33:08Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b962f9e2aae","type":"article","url":"https://hartvaat.nl/2026/05/05/thuis-bio-impedantie-voor-hartfalen-haalbaar-en-acceptabel-klinische-winst-nog-n/","title":"Thuis-bio-impedantie voor hartfalen: haalbaar en acceptabel, klinische winst (nog) niet aangetoond","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag106","source_url":"https://doi.org/10.1093/eschf/xvag106","authors":["Min Gyu Kong","Inki Moon","Jon Suh","Jah Yeon Choi","Jin Oh Na","Hwan-Seok Yong","Chi Young Shim","Seong-Mi Park","Eung Ju Kim"],"significance":5,"published":"2026-06-28","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"Multicenter open-label randomised feasibility trial (n=40) in heart failure patients on loop diuretics, randomised to standard care or a home bioelectrical impedance analysis (BIA) device with a paired app providing weekly diuretic guidance. BIA-measurement adherence was 82.5%, completion 100%, and acceptability high (4.21/5 usability, 3.90/5 acceptability). No significant differences in NT-proBNP or oedema index between groups. NYHA worsening occurred less often in the BIA group (10% vs 31.6%; p=0.095). Changes in oedema index correlated more strongly with NT-proBNP (r=0.54) than changes in body weight (r=0.24). No HF hospitalisations or deaths during follow-up. Home BIA monitoring with pre-emptive diuretic management is feasible and safe, but larger trials are needed to demonstrate clinical effect.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T13:32:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44651b83f9f9","type":"article","url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","title":"EuroTR-register: co-existente linkszijdige kleplek verhoogt sterfte na transcatheter-tricuspidalis-edge-to-edge repair","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["esc-2026","mitraclip","tricuspidalisinsufficiëntie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag103","source_url":"https://doi.org/10.1093/eschf/xvag103","authors":["Jonas Gmeiner","Lukas Stolz","Karl-Patrik Kresoja","Jennifer von Stein","Vera Fortmeier","Christoph Pauschinger","Wolfgang Rottbauer","Mohammad Kassar","Bjoern Goebel","Paolo Denti","Paul Achouh","Tienush Rassaf","Manuel Barreiro-Perez","Peter Boekstegers","Andreas Rück","Monika Zdanyte","Marianna Adamo","Flavien Vincent","Philipp Schlegel","Sebastian Rosch","Mirjam G Wild","Christian Besler","Stefan Toggweiler","Stephanie Brunner","Julia Grapsa","Tiffany Patterson","Holger Thiele","Tobias Kister","Giuseppe Tarantini","Giulia Masiero","Marco De Carlo","Alessandro Sticchi","Fabian Voss","Amin Polzin","Antonio Popolo Rubbio","Francesco Bedogni","Thorald Stolte","Thomas Nestelberger","Thomas Benito-Gonzales","Enrique Sánchez-Muñóz","Mathias H Konstandin","Eric Van Belle","Marco Metra","Tobias Geisler","Rodrigo Estévez-Loureiro","Amir Abbas Mahabadi","Nicole Karam","Francesco Maisano","Philipp Lauten","Fabien Praz","Mirjam Kessler","Daniel Kalbacher","Volker Rudolph","Christos Iliadis","Philipp Lurz","Jörg Hausleiter"],"significance":7,"published":"2026-06-27","source_date":"2026-05-05","image":"","kennis":[],"congress":"esc-2026","summary_en":"Analysis of the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR) in 1,647 patients undergoing T-TEER. Concomitant left-sided valve disease (VHD) ≥mild was present in 95.8%, ≥moderate in 35.6%, and severe in 3.8%. ≥moderate VHD was associated with significantly lower 2-year survival (p<0.001) and HF-hospitalisation-free survival (p=0.005). Multivariable analysis confirmed ≥moderate VHD as an independent mortality predictor (HR 1.54; 95% CI 1.21-1.96; p<0.001). Despite worse baseline TR and NYHA in patients with ≥moderate VHD, T-TEER delivered significant TR reduction and symptomatic improvement in both groups. Conclusion: left-sided valvular disease should be weighed in the prognosis of T-TEER candidates, while symptomatic benefit is generally preserved.","created":"2026-07-03T10:33:07Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aadc13fa7773","type":"article","url":"https://hartvaat.nl/2026/05/05/mavacamten-in-de-praktijk-zwarte-patienten-krijgen-55-minder-vaak-toegang-atrium/","title":"Mavacamten in de praktijk: zwarte patiënten krijgen 55% minder vaak toegang — atriumfibrilleren voorspelt slechtere uitkomst","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","esc-2026","hypertrofische-cardiomyopathie","slaapapneu","supraventriculaire-tachycardie","vrouwen"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.045994","source_url":"https://doi.org/10.1161/JAHA.125.045994","authors":["Ayman R Fath","Amro Aglan","Srihari S Naidu","Michael J Mader","Robert J Chilton","Islam Y Elgendy","Martin S Maron","Ethan J Rowin"],"significance":7,"published":"2026-06-27","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"esc-2026","summary_en":"Multicenter observational analysis on TriNetX data (2011-2023) in 15,145 patients with obstructive hypertrophic cardiomyopathy, of whom 509 (3.5%) received mavacamten. After propensity matching (502 mavacamten vs 1,475 weighted controls 1:3), access was sharply stratified: Black patients had 55% lower odds of receiving mavacamten than White patients (OR 0.45; 95% CI 0.33-0.63). Among mavacamten recipients, 4.8% had acute heart failure, 8.3% systolic dysfunction, 10.8% cardiovascular hospitalisation, 6.4% new-onset AF, and 1.4% died. Outcomes were largely similar to controls, except for higher incidence of systolic dysfunction with mavacamten (log-rank p<0.001). Patients with baseline AF (28%) had significantly worse outcomes within the mavacamten group: more acute heart failure (7.8% vs 3.6%), systolic dysfunction (12.8% vs 6.4%), CV hospitalisation (27.7% vs 4.2%), and mortality (5% vs 0%). The equity gap and elevated risk with pre-existing AF are important practice signals.","created":"2026-07-03T10:33:07Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9e6d68e53b3","type":"article","url":"https://hartvaat.nl/2026/05/05/nederlandse-huisartsenpost-1-op-20-contacten-voor-benauwdheid-betreft-hartfalen-/","title":"Nederlandse huisartsenpost: 1 op 20 contacten voor benauwdheid betreft hartfalen — 6-maands sterfte 32%","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag124","source_url":"https://doi.org/10.1093/eschf/xvag124","authors":["Anne P Nelissen","Sander van Doorn","Carline J van den Dries","Michelle Spek","Dorien L M Zwart","Roderick P Venekamp","Linda W van Laake","Frans H Rutten","Geert-Jan Geersing"],"significance":7,"published":"2026-06-27","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Dutch observational study of out-of-hours primary care (OHS-PC) contacts for acute shortness of breath (Sep 2020-Aug 2021). Of 1,833 calls, 102 (5.1%) involved patients in whom heart failure was deemed the cause (mean age 79.6 years, 53% women). 10 (9.8%) were referred directly to the emergency department; of the remaining 92, 60.8% were assessed by home visit, 14.7% at the clinic, and 14.7% by telephone advice. Subsequently 44.6% were referred to the ED and 42.4% received loop diuretics at home (new or up-titrated). Of the 51 ED-referred patients, 82.4% were admitted. The 6-month all-cause mortality was 32.3%. The findings underscore that heart failure patients in out-of-hours primary care are a high-risk subgroup with substantial heterogeneity in care pathway — relevant for triage and long-term outcomes in primary-care acute services.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5ed0809e24a6","type":"article","url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","title":"EXPANDed: bij 73% verbetert tricuspidalisinsufficiëntie binnen 30 dagen na M-TEER — zonder directe TR-interventie","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["gedilateerde-cardiomyopathie","mitraclip","tricuspidalisinsufficiëntie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag108","source_url":"https://doi.org/10.1093/eschf/xvag108","authors":["Rodrigo Estevez-Loureiro","Mark J Ricciardi","Wolfgang Rottbauer","Matthew J Price","Philip Raake","Mathew Williams","Federico M Asch","Jose L Zamorano","Melody Dong","Kelli Peterman","Evelio Rodriguez","Saibal Kar","Ralph Stephan von Bardeleben","Francesco Maisano"],"significance":7,"published":"2026-06-26","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"Pooled analysis of the EXPAND and EXPAND G4 studies in 160 patients with mitral and tricuspid regurgitation who underwent mitral transcatheter edge-to-edge repair (M-TEER, MitraClip) and received NO direct TR intervention. Echo assessment was by independent core lab. At 30 days, 73% (n=116) improved to ≤moderate TR; 28% (n=44) remained ≥severe. The ≤moderate TR group had less atrial fibrillation (68% vs 89%, p=0.009), slightly lower LVEF (49% vs 56%, p=0.07), and larger LV dimensions (LVEDV 137.5 vs 107.9 mL, p=0.01). TR reduction persisted at 1 year in 86% of the ≤moderate group; 45% of the ≥severe group improved later. Significantly greater NYHA and KCCQ-OS improvements in the ≤moderate group. 1-year mortality was numerically lower with ≤moderate TR (12.4% vs 22.3%; HR 1.92; p=0.16). LV dilation and lower LVEF predicted TR improvement — relevant for selecting patients who may not need an additional TR procedure.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"407438d8a54c","type":"article","url":"https://hartvaat.nl/2026/05/05/vericiguat-en-sgc-stimulatoren-bij-hartfalen-werkingsmechanisme-en-plaats-na-vic/","title":"Vericiguat en sGC-stimulatoren bij hartfalen: werkingsmechanisme en plaats na VICTORIA/VICTOR","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["bloeddrukbehandeling","laminopathie","supraventriculaire-tachycardie","ventrikelfibrilleren","vericiguat"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag117","source_url":"https://doi.org/10.1093/eschf/xvag117","authors":["Frank Ruschitzka","Robert Lukowski","Stefano Corda","Christian Meier","Peter Sandner"],"significance":6,"published":"2026-06-26","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"Review in ESC HF on the pharmacological rationale for soluble guanylyl cyclase (sGC) stimulators in chronic heart failure. Intact NO-sGC-cGMP signalling is essential to cardiovascular homeostasis; its impairment is regarded as a key pathomechanism in HF. The review describes the molecular mode of action of NO-independent, haem-dependent sGC stimulators and discusses preclinical and clinical evidence for broad cardiovascular effects, as well as effects on other organs that contribute to clinical outcomes. The sGC stimulator vericiguat has a place — on top of standard therapy — in adults with symptomatic HFrEF after a recent worsening event; this recommendation rests on the phase 3 VICTORIA and VICTOR trials. Outstanding research questions around vericiguat and related drugs are outlined.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T13:32:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"60a6c3ee1e51","type":"article","url":"https://hartvaat.nl/2026/05/08/car-t-therapie-en-cardiovasculaire-uitkomsten-in-duitsland-en-vs-ernstige-events/","title":"CAR-T-therapie en cardiovasculaire uitkomsten in Duitsland en VS: ernstige events zeldzaam acuut, hoger op lange termijn bij pre-existente hartziekte","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","farmaco-economie","select-trial","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag132","source_url":"https://doi.org/10.1093/eschf/xvag132","authors":["Jakob Christoph Voran","Lars Fransecky","Hatim Seoudy","Manuel Hecht","Oliver Müller","Philipp Berning","Alexander Pohlmann","Cornelia Baden","Tim Versteegen","Claudia D Baldus","Friedrich Stölzel","Derk Frank","David Baden"],"significance":7,"published":"2026-06-26","source_date":"2026-05-08","image":"","kennis":[],"congress":"","summary_en":"Analysis of two independent CAR-T cell therapy registries: 2,545 German patients (DESTATIS) and 1,335 US patients (TriNetX). Acutely severe cardiac events were relatively rare (51 and 20 cases respectively); 5% of German and 1.2% of US patients died shortly after CAR-T. Patients with pre-existing cardiac disease had no increased risk for immune-mediated complications (cytokine release syndrome OR 1.19; neurotoxicity OR 1.59) but higher long-term risk for major cardiovascular events (OR 1.89; 95% CI 1.23-2.91) and kidney failure (OR 2.98; 95% CI 1.85-4.81). The cumulative evidence underscores the need for risk-adapted follow-up and cardiological assessment in CAR-T patients with cardiac comorbidity. Interpretation is subject to potential under- and over-reporting in registries.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T13:32:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"60240e3a5873","type":"article","url":"https://hartvaat.nl/2026/05/09/uf-care-trial-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-geen-significante-/","title":"UF-CARE-trial: ultrafiltratie bij type-2 cardiorenaal syndroom geen significante winst (kleine, onderpowered RCT)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","flow-trial","ijzertekort","step-hfpef","summit-trial"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag133","source_url":"https://doi.org/10.1093/eschf/xvag133","authors":["Maxime Schleef","Florence Sens","Laurent Magaud","Julie Haesebaert","Carole Langlois-Jacques","Laurent Juillard","Eric Bonnefoy","Guillaume Baudry"],"significance":6,"published":"2026-06-25","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"UF-CARE was a multicenter, open-label randomised trial in 15 French centres in adults with severe heart failure, persistent or recurrent congestion despite high-dose diuretics and guideline-directed therapy, and mild-to-severe CKD (type 2 cardiorenal syndrome). 46 of 108 screened patients were randomised: 24 control (optimal medical therapy alone) and 22 ultrafiltration (peritoneal dialysis, haemodialysis, or isolated ultrafiltration based on clinical judgment, patient preference, and availability). The composite primary outcome (mortality or unplanned HF hospitalisation within 12 months) occurred in 63% of the ultrafiltration group and 87% of controls (p=0.144), after a median follow-up of 262 days. Quality of life improved slightly more with ultrafiltration; one technique-related death occurred. Conclusion: in this underpowered cohort, adding ultrafiltration did not significantly improve outcomes; larger trials are needed.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d5baa45bf758","type":"article","url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","title":"DECISION-trial: digoxine staken bij hartfalen leidt tot zevenvoudige stijging in HF-events binnen 6 weken","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dapa-hf","pathfinder-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag385","source_url":"https://doi.org/10.1093/eurheartj/ehag385","authors":["Peter van der Meer","Dirk J van Veldhuisen","Geert H D Voordes","Jan Tijssen","Marco Alings","M L Bouvy","Henk P Swart","H Jaco Houtgraaf","H G Reinhart Dorman","Michiel Rienstra","Kevin Damman","Arend Mosterd"],"significance":8,"published":"2026-06-25","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"Prespecified analysis of the DECISION trial: 1,001 heart failure patients on contemporary guideline therapy were randomised to low-dose digoxin or placebo, with a median treatment of 36.5 months. At study end, 587 patients on active treatment (288 digoxin, 299 placebo) underwent blinded withdrawal with 6-week follow-up. During the 100 days before withdrawal, cardiovascular death/HF event rates were similar (5.7 vs 6.5 events per 100 patient-years). After withdrawal, the rate rose sharply in the digoxin arm but not in the placebo arm (42.8 vs 5.9 per 100 patient-years; time-by-treatment interaction p=0.036). 14 events occurred in the digoxin withdrawal arm (12 hospitalisations, 2 urgent HF visits) versus 2 in the placebo withdrawal arm (RR 7.37; 95% CI 1.56-34.88; p=0.012). Withdrawal was accompanied by higher heart rate, lower systolic BP, and rising NT-proBNP. Conclusion: caution is warranted when stopping long-standing digoxin in HF with (mildly) reduced ejection fraction.","created":"2026-07-03T10:33:07Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1838bfae319e","type":"article","url":"https://hartvaat.nl/2026/05/11/emerge-laa-amulet-occluder-in-12-180-patienten-96-succes-1-jaars-beroerte-1-6-re/","title":"EMERGE LAA: Amulet-occluder in 12.180 patiënten — 96% succes, 1-jaars beroerte 1,6% (real-world register)","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting"],"journal":"JACC. Cardiovascular interventions","doi":"10.1016/j.jcin.2026.02.016","source_url":"https://doi.org/10.1016/j.jcin.2026.02.016","authors":["Dhanunjaya Lakkireddy","Atman P Shah","Himanshu Agarwal","Christopher R Ellis","Akash Makkar","Megan Coylewright","Jordan A Anderson","Ryan Gage","Mohamad Alkhouli","James V Freeman"],"significance":8,"published":"2026-06-25","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Postapproval registry (EMERGE LAA) of the first 12,180 patients with attempted Amulet occluder implantation for left atrial appendage occlusion (LAAO) in nonvalvular atrial fibrillation, captured in the US NCDR LAAO Registry between August 2021 and December 2023. Implantation success was 96.0% — 88.9% in patients with prior failed LAAO attempt. Clinically relevant closure (peridevice leak ≤3 mm) at day 45 was 97.2%. The composite safety endpoint (death, ischaemic stroke, embolism, device-/procedure-related events) occurred in 0.9%. Major adverse events at day 45 decreased with operator experience (8.4% at <10 cases to 5.8% at ≥30; p<0.001). At 1 year: 1.6% all stroke, 6.3% major bleeding, 2.9% CV/unknown-cause death, 7.9% all-cause death. The real-world data confirm safety and effectiveness of the Amulet occluder and highlight the impact of the learning curve on procedural outcomes.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T13:32:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73e72751a658","type":"article","url":"https://hartvaat.nl/2026/05/11/evolocumab-effectief-en-veilig-bij-ckd-stadium-3-4-56-ldl-zonder-nierfunctiedali/","title":"Evolocumab effectief en veilig bij CKD stadium 3-4: -56% LDL zonder nierfunctiedaling","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["anemie-ckd","bempedoïnezuur","chronische-nierziekte","cystatine-c","dyslipidemie","ezetimibe","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","statines","yellow-iii"],"journal":"International journal of clinical pharmacology and therapeutics","doi":"10.5414/CP204964","source_url":"https://doi.org/10.5414/CP204964","authors":["Hongxu Zhu","Yufeng Chang","Qi Jin"],"significance":6,"published":"2026-06-24","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"Single-centre retrospective study in 200 patients with chronic kidney disease stage 3-4 and hyperlipidaemia treated with evolocumab, with lipids, renal function, and liver enzymes assessed at baseline and 3, 6, and 12 months. After 12 months, LDL cholesterol fell significantly by 56.3 ± 10.5%, with similar reductions in stage 3 and stage 4. Non-HDL and total cholesterol also fell significantly; HDL and triglycerides did not change meaningfully. Renal function (eGFR, serum creatinine, urea) showed no significant deterioration, and no clinically relevant hepatic adverse events occurred. Baseline LDL and age predicted the magnitude of LDL reduction. Public transcriptomic data show that PCSK9 expression is largely liver-specific and minimal in renal tissue — a biological explanation for preserved kidney function. The results support evolocumab as a practical LDL-lowering option in CKD patients.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T13:32:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4169163ec9f2","type":"article","url":"https://hartvaat.nl/2026/05/11/invasieve-drukvolumelussen-onthullen-mechanisme-van-tricuspidalisinsufficientie-/","title":"Invasieve drukvolumelussen onthullen mechanisme van tricuspidalisinsufficiëntie bij HFrEF: RV-PA-ontkoppeling en sMR","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","fractional-flow-reserve","hfpef","hfref","ouderen","rechterventrikelfalen","tricuspidalisinsufficiëntie","ventrikelfibrilleren"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag134","source_url":"https://doi.org/10.1093/eschf/xvag134","authors":["Alexander Schmeisser","Thomas Rauwolf","Thomas Groscheck","Tarek Bekfani","Katharina Fischbach","Blerim Luani","Ivan Tanev","Michael Hansen","Saskia Meißler","Paul Steendijk","Ruediger C Braun-Dullaeus"],"significance":6,"published":"2026-06-24","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Retrospective study integrating right ventricular pressure-volume loops and Swan-Ganz catheter data with RV/LV imaging in 134 patients with heart failure with reduced ejection fraction (HFrEF). Independent predictors of moderate-to-severe ventricular tricuspid regurgitation (vTR2/3) were: (1) presence of secondary mitral regurgitation (sMR; aOR 1.67), (2) elevated pulsatile RV loads with lower PA compliance (aOR 0.43; AUC 0.82; threshold <2.24 ml/mmHg), largely driven by sMR2/3 (aOR 4.56), and (3) progressive uncoupling of RV elastance/contractility relative to pulmonary elastance (Ees/Ea aOR 0.024; AUC 0.84; threshold <0.6). This RV-PA uncoupling occurred across the entire afterload range and was associated with higher all-cause mortality. The work identifies sMR and RV-PA uncoupling as core drivers of vTR in HFrEF — relevant for determining which patients may benefit from mechanical TR reduction.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T13:32:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4ecbe3fa217","type":"article","url":"https://hartvaat.nl/2026/05/11/volwassenen-met-aangeboren-hartafwijking-hebben-vergelijkbare-overleving-na-hart/","title":"Volwassenen met aangeboren hartafwijking hebben vergelijkbare overleving na hartinfarct als de algemene populatie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","aperitif-trial","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","ouderen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag216","source_url":"https://doi.org/10.1093/eurheartj/ehag216","authors":["Love Holmgren","Sacharias von Koch","Pontus Andell","Peder Sörensson","Christina Christersson","Aleksandra Trzebiatowska-Krzynska","Maria Fedchenko","Zacharias Mandelanakis","Bengt Johansson","Moman A Mohammad","Joanna Hlebowicz"],"significance":6,"published":"2026-06-24","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"Nationwide case-control study (2000-2022) of 214 adults with congenital heart disease (ACHD) and their first acute myocardial infarction, matched to 2,092 controls without ACHD on age, sex, hypertension, diabetes, hyperlipidaemia, and previous PCI/CABG. ACHD patients were younger at first infarction (58 vs 70 years). Over a mean follow-up of 6.5 (ACHD) and 7.3 years (controls), no difference emerged in mortality or recurrent MI at 1 year. At 10 years, mortality appeared higher in ACHD (HR 1.4; 95% CI 1.0-1.9) but lost significance after adjustment. The findings suggest ACHD patients have survival similar to the general population after MI. Since they share the same cardiovascular risk factors, healthy lifestyle and proactive risk management remain essential to prevent acquired heart disease in this growing population.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4329e90649a1","type":"article","url":"https://hartvaat.nl/2026/05/11/thoracoscopische-af-ablatie-met-bipolaire-clamp-5-jaars-ritmevrijheid-52-met-ant/","title":"Thoracoscopische AF-ablatie met bipolaire clamp: 5-jaars ritmevrijheid 52% met antiaritmica — multicenter register","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery","doi":"10.1093/ejcts/ezag161","source_url":"https://doi.org/10.1093/ejcts/ezag161","authors":["Luca Aerts","Michal J Kawczynski","Niels J Verberkmoes","Thomas Van Brakel","Justin G L M Luermans","Samuel Heuts","Eva Verbeek","Ricardo Cocchieri","Sacha P Salzberg","Henri Gruwez","Herbert Gutermann","Laurent Pison","Dmitry Elesin","Alexander Bogachev-Prokophiev","Oleg Shelest","Alexandr Troitskiy","Robert Khabazov","Aleksander Zotov","Bart Maesen"],"significance":6,"published":"2026-06-23","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/"],"congress":"","summary_en":"Retrospective multicenter registry of 678 patients undergoing isolated or hybrid thoracoscopic atrial fibrillation (AF) ablation with a bipolar irrigated radiofrequency clamp (Gemini Clamp) between 2010 and 2023. Most had longstanding persistent AF (66.7%, mean AF duration 61 months), and 33.3% had prior catheter ablation. Freedom from atrial tachyarrhythmias (allowing class I/III antiarrhythmic use) was 82.3% at 1 year, 71.5% at 3 years, and 52.4% at 5 years. Without antiarrhythmics, this declined from 71.7% (year 1) to 44.2% (year 5), underscoring AF's progressive nature. Women presented with greater comorbidity and higher CHA2DS2-VA scores, but long-term rhythm outcomes did not differ by sex or by paroxysmal vs non-paroxysmal AF. Complication rates were low. Variability in arrhythmia-detection methods across centres may have affected outcomes.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"260c5e452b5a","type":"article","url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","title":"EHJ-overzicht: mechanische complicaties na hartinfarct — zeldzaam (<1%) maar acuut levensbedreigend","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag164","source_url":"https://doi.org/10.1093/eurheartj/ehag164","authors":["Roberto Lorusso","Matteo Matteucci","Daniele Ronco","Giulio Massimi","Susanna Price","Martin Czerny","Rodrigo Estévez-Loureiro","Matthias Siepe","Gianluca Pontone","Christian Hassager","Ovidiu Chioncel","Marco Zuin","Constantinos H Davos","Marianna Adamo","Finn Gustafsson","George Giannakoulas","Nicolas Amabile","Alessandro Sionis","Matthias Thielmann","Steffen Erhard Petersen","Bernard Cosyns","Kurt Huber","Mariya Tokmakova","Davide Pacini","Frederikus A Klok","Francesco Saia","Ana Abreu","Michael Grimm","Marc J Claeys","Ana García-Álvarez","Bernhard Gerber","Carlos A Mestres","Stephan Rosenkranz","Stamatis Adamopoulos","Nikolaos Bonaros"],"significance":7,"published":"2026-06-23","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"EHJ review of the three most serious mechanical complications after acute myocardial infarction: free-wall rupture, ventricular pseudoaneurysm, and papillary muscle rupture. With rapid revascularization, incidence has declined to <1% of infarctions, but severe haemodynamic compromise may already be present at admission, requiring immediate diagnosis and intervention. Until recently, surgical repair was the only option, with non-negligible in-hospital mortality, especially with acute circulatory collapse. Transcatheter percutaneous procedures now offer alternatives for high-risk or inoperable patients. Recurrences after repair markedly impact outcome and require careful monitoring. The role of concomitant revascularization remains controversial. Temporary mechanical circulatory support shows promise as 'bridge-to-procedure' or 'bridge-to-recovery'. Optimal management requires a multidisciplinary Heart Team — including a Shock Team — with palliative care integrated where appropriate.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T13:32:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7211cc4b547","type":"article","url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","title":"NHLBI-workshop: bloeddrukmeting verfijnen door de hele levensloop heen — knelpunten en kansen","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2026.02.5124","source_url":"https://doi.org/10.1016/j.jacc.2026.02.5124","authors":["Marwah Abdalla","Stephen P Juraschek","Italo Biaggioni","C Barrett Bowling","Ravi C Balijepalli","Tammy M Brady","Adam P Bress","Robert D Brook","Jordana B Cohen","Yvonne Commodore-Mensah","Richard A Dart","Patrice Desvigne-Nickens","Paul Drawz","Keith C Ferdinand","Joseph T Flynn","Kathryn Foti","Beverley B Green","Kara K Hoppe","Kate Kirley","Lewis Lipsitz","Young S Oh","Jesus D Melgarejo","Ramakrishna Mukkamala","Paul Muntner","Joseph Ravenell","Daichi Shimbo","Andrew M South","Raymond R Townsend","Jasmina Varagic","Hilary K Wall","Paul Wang","Paula Einhorn","Michael Wolz"],"significance":7,"published":"2026-06-23","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Report from a 2-day workshop convened by the US National Heart, Lung, and Blood Institute (NHLBI, December 2024) on the state of blood pressure assessment. Hypertension remains the principal modifiable cardiovascular risk factor, yet adequate characterisation of BP is challenging due to lifespan, comorbidity, and environmental influences. Uncertainty in BP measurement contributes to underdiagnosis, undertreatment, and preventable morbidity/mortality. Recent technological developments — home and ambulatory monitoring, wearables — enable richer BP characterisation that could dramatically improve hypertension management and cardiovascular risk reduction. The report summarises the latest evidence, identifies knowledge gaps, and sets research and practice priorities for advancing BP assessment.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"884f8db70342","type":"article","url":"https://hartvaat.nl/2026/05/13/evoque-transcatheter-tricuspidalisklep-mogelijk-kosteneffectief-bij-ernstige-tr-/","title":"Evoque transcatheter-tricuspidalisklep mogelijk kosteneffectief bij ernstige TR — maar resultaten leunen sterk op extrapolatie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["farmaco-economie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag137","source_url":"https://doi.org/10.1093/eschf/xvag137","authors":["Apolline Grangeon","Martin Connock","Peter Auguste","Jean François Obadia","Maurice Enriquez-Sarano","Benjamin Essayagh","Xavier Armoiry"],"significance":6,"published":"2026-06-22","source_date":"2026-05-13","image":"","kennis":[],"congress":"","summary_en":"Markov model from a French payer perspective on the cost-effectiveness of the Evoque transcatheter tricuspid valve replacement (TTVR) versus optimal medical therapy (OMT) in severe tricuspid regurgitation, based on TRISCEND II. Over a lifetime horizon, TTVR yielded 1.76 additional life-years and 1.63 additional QALYs at €39,382 incremental costs, giving an ICER of €22,327/life-year and €24,109/QALY — below the French threshold. However: when no mortality difference is assumed in the extrapolation, the ICER rises to €86,428/QALY (+258%). Results are highly sensitive to time horizon, utility, discount rate, and post-trial mortality extrapolation. Conclusion: Evoque-TTVR appears potentially cost-effective, but the long-term benefit is largely model-driven rather than empirically demonstrated — longer follow-up is needed.","created":"2026-07-03T10:33:06Z","updated":"2026-07-03T13:32:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4cc12ed4162","type":"article","url":"https://hartvaat.nl/2026/05/13/ai-echo-verslaat-ai-ecg-en-klinische-score-voor-diagnose-cardiale-amyloidose-aur/","title":"AI-Echo verslaat AI-ECG en klinische score voor diagnose cardiale amyloïdose (AUROC 0,93)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-amyloidose","echocardiografie","esc-2026","supraventriculaire-tachycardie"],"journal":"Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography","doi":"10.1016/j.echo.2026.05.007","source_url":"https://doi.org/10.1016/j.echo.2026.05.007","authors":["Armin Garmany","Jose K James","Gregorio Tersalvi","Patricia Carey","Christopher G Scott","Will Hawkes","Ashley Akerman","Ross Upton","Angela Dispenzieri","Martha Grogan","Omar F AbouEzzeddine","Patricia A Pellikka"],"significance":7,"published":"2026-06-22","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/","https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"esc-2026","summary_en":"Retrospective cohort study in 598 patients referred for cardiac scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA), comparing three risk models: the ATTR-CM clinical score, AI-ECG, and AI-Echo. Median age 76 years; 30% had confirmed ATTR-CA. AI-Echo performed best: AUROC 0.93 (95% CI 0.91-0.95) versus 0.79 for AI-ECG and 0.87 for the ATTR-CM score (p<0.001). Sensitivity/specificity were 86%/85% (AI-Echo), 80%/64% (AI-ECG), and 86%/69% (clinical score). At a threshold of 0.25, AI-Echo avoided the most unnecessary scintigraphies (45 per 100 referrals vs 24 for AI-ECG and 37 for ATTR-CM). AI-Echo appears the most valuable screening tool for ATTR-CA in high-risk populations and may prevent unnecessary nuclear imaging.","created":"2026-07-03T10:33:05Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47c10d795da1","type":"article","url":"https://hartvaat.nl/2026/05/13/mtmr4-modifier-heeft-tegenovergestelde-invloed-op-aritmierisico-bij-lqt1-en-lqt2/","title":"MTMR4-modifier heeft tegenovergestelde invloed op aritmierisico bij LQT1 en LQT2","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["gepersonaliseerde-geneeskunde","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag294","source_url":"https://doi.org/10.1093/eurheartj/ehag294","authors":["Peter J Schwartz","Annika Winbo","Luca Sala","Lia Crotti","Giulia Musu","Federica Dagradi","Fulvio L F Giovenzana","Davide F Dragani","Kotryna Simonyté Sjödin","Jenny Lundström","Chiara Alberio","Matteo Pedrazzini","Bruce D Nearing","Annika Rydberg","Hung-Fat Tse","Fabio Badilini","Richard L Verrier","Carla Spazzolini","Massimiliano Gnecchi"],"significance":6,"published":"2026-06-22","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/ritmestoornissen/lang-qt-syndroom/"],"congress":"","summary_en":"Study in 1,192 long-QT syndrome (LQTS) patients (LQT1 n=638, LQT2 n=432, plus 122 Swedish carriers of the p.Y111C-LQT1 mutation), investigating the impact of MTMR4 modifier-gene variants on severe clinical outcomes (cardiac arrest or syncope on beta-blockers). In the LQT1 cohort, the percentage of cardiac events decreased significantly with increasing aa-genotype frequency (AA 15.9% → Aa 11.6% → aa 6.3%); in LQT2 the pattern was reversed (AA 16.5% → Aa 18.2% → aa 27.6%). In combined LQT1, aa was present in 15% of mild/asymptomatic vs 1.7% of severe cases (p=0.002); in LQT2, 24.1% vs 11.9% (p=0.014). QTc did not differ, but repolarization markers (Tpeak-Tend) supported the gene-specific directionality. The MTMR4 minor-allele homozygosity has a gene-specific, opposite impact on arrhythmic risk — relevant for risk stratification.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:32:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f4ef4132cc7","type":"article","url":"https://hartvaat.nl/2026/05/13/verisec-register-vericiguat-halveert-hartfalen-decompensaties-bij-hfref-in-dagel/","title":"VERISEC-register: vericiguat halveert hartfalen-decompensaties bij HFrEF in dagelijkse Spaanse praktijk","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag138","source_url":"https://doi.org/10.1093/eschf/xvag138","authors":["Alberto Esteban-Fernández","Beatriz Calvo-Bernal","Raquel López-Vilella","Gregorio de Lara","Laia C Belarte-Tornero","Moisés Barrantes-Castillo","Inés Gómez-Otero","Julio Nuñez-Villota","Carolina Robles-Gamboa","José López-Aguilera","Ana Torremocha-López","María Melendo-Viu","Clara Simón-Ramón","Paula Fluvià-Burgués","Francisco J Pastor-Pérez","Gonzalo Alonso-Salinas","José Manuel García-Pinilla","Antonia Pomares-Varó","Jara Gayán-Ordás","David González-Calle","Pablo Díez-Villanueva","Mario Galván-Ruiz","Carolina Ortiz-Cortés","Pedro Caravaca-Pérez","Cristina Goena-Vives","Julia Seller","Marta Jiménez-Blanco","Pau Codina","José María Vietiez","Laura Jordán-Martínez","Maria Thiscal López-Lluva","Elisabet Mena-Sebastià","Pedro Pájaro","Alejandro Recio-Mayoral"],"significance":7,"published":"2026-06-21","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"Prospective multicenter registry (VERISEC) of 835 consecutive patients with HFrEF after recent decompensation initiating vericiguat at 41 Spanish centres (mean age 71.3 years, 78.9% male). Baseline therapy was highly optimised: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAAS inhibitors, 79.8% MRAs; quadruple therapy was 61.7-63.0% throughout follow-up. At 1 year, NT-proBNP fell from 3,532 to 2,292 pg/mL (p<0.001), LVEF rose from 30.3% to 35.4% (p<0.001), and NYHA class improved. HF decompensations requiring IV diuretics halved (1.34 → 0.65/year); non-HF cardiovascular hospitalisations fell from 0.98 to 0.39/year. Vericiguat was discontinued in 13.4%, mostly for symptomatic hypotension (49.4%); higher baseline NT-proBNP predicted discontinuation (OR 1.06 per 1,000 pg/mL). The real-world data confirm clinical utility and safety of vericiguat on top of quadruple therapy.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T18:39:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97f17625cc1c","type":"article","url":"https://hartvaat.nl/2026/05/13/hypothese-falen-van-het-raas-verklaart-inappropriate-vasodilatatie-bij-cardiogen/","title":"Hypothese: falen van het RAAS verklaart inappropriate vasodilatatie bij cardiogene shock","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","cardiogene-shock","supraventriculaire-tachycardie","troponine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag292","source_url":"https://doi.org/10.1093/eurheartj/ehag292","authors":["Adrien Picod","Susanna Price","Thomas Hanff"],"significance":6,"published":"2026-06-21","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"Conceptual paper in EHJ on an underappreciated aspect of cardiogenic shock (CS): a subgroup of patients — without concurrent sepsis — develop a mixed shock phenotype with unexpected vasodilation on top of the primary myocardial failure, which portends a worse prognosis. The authors propose that failure of the renin-angiotensin-aldosterone system (RAAS), analogous to recent findings in septic shock, plays a key role: through defective angiotensin II generation, enhanced peptide degradation, and/or receptor unavailability, angiotensin II signalling at the AT1 receptor becomes impaired. Recognising RAAS failure in CS could justify new therapeutic strategies to restore vascular tone and improve outcomes in mixed cardiogenic-vasodilatory shock.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e82d0391a444","type":"article","url":"https://hartvaat.nl/2026/05/13/aasi-is-geen-betrouwbare-maat-voor-arteriele-stijfheid-bij-kinderen-met-risico-o/","title":"AASI is geen betrouwbare maat voor arteriële stijfheid bij kinderen met risico op secundaire hypertensie","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","aperitif-trial","bloeddrukbehandeling","perifeer-vaatlijden","sacubitril-valsartan","voeding-hart","vrouwen"],"journal":"European journal of pediatrics","doi":"10.1007/s00431-026-07057-4","source_url":"https://doi.org/10.1007/s00431-026-07057-4","authors":["Plamen Bokov","Elodie Surget","Cherine Benzouid","Benjamin Dudoigon","Julien Hogan","Christophe Delclaux"],"significance":5,"published":"2026-06-21","source_date":"2026-05-13","image":"https://hartvaat.nl/global/img/cfa5359c05fb.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"Cross-sectional study in 75 children and adolescents (8-18 years, mean 12.3; 34 girls) at risk of secondary hypertension: vascular remodeling context (preterm birth n=44, CKD n=7) or hyperkinetic causes (congenital central hypoventilation syndrome n=14, psychostimulant treatment n=10). Alongside 24-hour ambulatory BP monitoring (ABPM), arterial stiffness was measured by several methods: carotid-femoral and heart-finger pulse wave velocity, augmentation index (AIx75), and systemic arterial stiffness via pulse-contour analysis. AASI correlated with none of the direct stiffness measures, only with systolic and diastolic nocturnal BP dipping. In ABPM-hypertensive children (20%), cf-PWV was elevated (5.64 vs 4.92 m/s) but AASI was not. Conclusion: AASI does not reflect true arterial stiffness in children and should not be used as such.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"85d72343586c","type":"article","url":"https://hartvaat.nl/2026/05/14/sprint-accord-gepoold-bloeddrukvariabiliteit-is-even-prognostisch-als-gemiddelde/","title":"SPRINT + ACCORD gepoold: bloeddrukvariabiliteit is even prognostisch als gemiddelde bloeddruk — J-vormige curve","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag330","source_url":"https://doi.org/10.1093/eurheartj/ehag330","authors":["Wenbo Zhao","Yue Qiao","Lupei Cai","Eric L Harshfield","Zihan Sun","Robin B Brown","Junwei Hao","Xunming Ji","Hugh S Markus"],"significance":7,"published":"2026-06-20","source_date":"2026-05-14","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Pooled individual-patient analysis of SPRINT and ACCORD in 18,415 participants (median 12 BP measurements, 3.6-year follow-up), in which visit-to-visit blood pressure variability (BPV) from month 3 onward was assessed using multiple metrics (including variation-independent-of-mean, VIM). 1,244 participants (6.8%) experienced a major cardiovascular event. After multivariable adjustment, higher SBP-VIM (highest vs lowest tertile) was associated with greater MCE risk (HR 1.15; 95% CI 1.00-1.32), particularly myocardial infarction and cardiovascular death. Restricted cubic spline analyses revealed a J-shaped relationship: both low and high BPV appear harmful. The prognostic value of SBP-VIM was comparable to mean systolic BP. The findings underscore the importance of defining optimal BPV targets and interventions that modulate BPV.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39cb30419c7f","type":"article","url":"https://hartvaat.nl/2026/05/14/mendeliaanse-randomisatie-hmgcr-remming-verhoogt-diabetesrisico-andere-lipidendo/","title":"Mendeliaanse randomisatie: HMGCR-remming verhoogt diabetesrisico, andere lipidendoelen niet","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-2","dyslipidemie","familiaire-hypercholesterolemie-screening","lipidenverlaging","statines","vrouwen"],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03209-w","source_url":"https://doi.org/10.1186/s12933-026-03209-w","authors":["Zekai Chen","Rima D Triatin","Li Luo","Harold Snieder","A Floriaan Schmidt","Marc Ditmarsch","John J P Kastelein","Robin P F Dullaart","Jan Albert Kuivenhoven","Chris H L Thio"],"significance":7,"published":"2026-06-20","source_date":"2026-05-14","image":"https://hartvaat.nl/global/img/68c087ef7113.webp","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"Cis-Mendelian randomisation study using individual-level data from UK Biobank, Lifelines, and publicly available GWAS sources, examining 13 lipid-related drug targets (including ACLY, ANGPTL3/4, APOB, APOC3, CETP, HMGCR, LDLR, LIPG, LPA, MTTP, NPC1L1, and PCSK9). Lipid modification via HMGCR (statins) was predicted to reduce CAD risk but increase type 2 diabetes risk — a known statin side-effect. Modification via APOC3, LDLR, LPA, MTTP, NPC1L1, and PCSK9 reduced CAD risk without changing T2D risk. ANGPTL4 and CETP reduced risk of both CAD and T2D. For ACLY, ANGPTL3, APOB, and LIPG, no genetic evidence was found for either CAD or T2D effects. The findings suggest substantial variation in diabetes risk between lipid-lowering classes and may guide future drug development and individual therapy decisions.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2a15b09d4e68","type":"article","url":"https://hartvaat.nl/2026/05/14/lipidegerelateerd-cv-risico-voorbij-ldl-focus-verschuift-naar-remnant-cholestero/","title":"Lipidegerelateerd CV-risico voorbij LDL: focus verschuift naar remnant-cholesterol en Lp(a)","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","statines"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-326404","source_url":"https://doi.org/10.1136/heartjnl-2025-326404","authors":["Mie Balling","Karen Hvid","Anette Varbo","Anne Langsted","Borge G Nordestgaard","Shoaib Afzal"],"significance":6,"published":"2026-06-20","source_date":"2026-05-14","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Heart review of lipid-related cardiovascular risk beyond LDL cholesterol. While LDL lowering has been the dominant target for decades, mechanistic, observational, and genetic studies support a causal role for remnant particles and lipoprotein(a) in ASCVD development. Multiple new drugs targeting these are now in development with RCT results expected. Lipoprotein(a) is largely genetically determined; remnant cholesterol correlates strongly with overeating, obesity, and diabetes. The global obesity epidemic is driving an increase in metabolic dyslipidaemias and related ASCVD risk. The era of LDL-only risk management is over — targeted approaches to metabolically dysregulated and genetically driven lipid fractions are becoming increasingly important.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9dcba1a5f462","type":"article","url":"https://hartvaat.nl/2026/05/15/aspirine-voor-primaire-preventie-bij-verhoogd-lp-a-of-lpa-varianten-levert-geen-/","title":"Aspirine voor primaire preventie bij verhoogd Lp(a) of LPA-varianten levert geen significante winst op","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aspirine","bisoprolol","clear-outcomes","dyslipidemie","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","primaire-preventie","statines","vrouwen"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag207","source_url":"https://doi.org/10.1093/eurjpc/zwag207","authors":["Rodolfo A Lopes","Carlos A Vergara Sanchez","Alfredo Perez Tagle Tejeda","Jordan Khorsandi","Christian K Fukunaga","Eric Katsuyama","Juan Armando Talavera","Eugene Yang","Michael D Shapiro"],"significance":7,"published":"2026-06-19","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/"],"congress":"","summary_en":"Systematic review and meta-analysis of 6 studies (total 6,628 participants) on aspirin for primary prevention in adults without ASCVD with elevated lipoprotein(a) (≥50 mg/dL), high-risk LPA genotypes, or elevated genetic risk scores. Pooled analysis showed no significant reduction in major adverse cardiovascular events (HR 0.60; 95% CI 0.31-1.17; p=0.10) and no significant increase in clinical bleeding (HR 1.24; p=0.18). Subgroup analyses showed a non-significant reduction with elevated Lp(a) (HR 0.63) and a statistically significant reduction in LPA rs3798220 carriers (HR 0.37; 95% CI 0.19-0.71), but the latter was inconsistent on sensitivity analysis and likely reflects small-sample bias. The evidence does not support routine aspirin in asymptomatic adults with high Lp(a) or risk-LPA variants.","created":"2026-07-03T10:33:05Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4333d2d365b1","type":"article","url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","title":"EAPCI/EBC-consensus: intracoronaire beeldvorming als standaard bij PCI van hoofdstam","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag353","source_url":"https://doi.org/10.1093/eurheartj/ehag353","authors":["Thomas W Johnson","Nieves Gonzalo","Jose M de la Torre Hernandez","Nicolas Amabile","Peter O'Kane","Mirvat Alasnag","Robert-Jan van Geuns","Niels Ramsing Holm","Salvatore Brugaletta","Lorenz Raber","Remo Albiero","Miroslaw Ferenc","Manuel Pan","Valeria Paradies","Ziad A Ali","Haibo Jia","Pedro Lemos","Rony Mathew","Jun Jie Zhang","Joo-Yoong Hahn","Yiannis S Chiatzizisis","Francesco Burzotta","Adrian P Banning","Giulio Guagliumi","David Hildick-Smith","Alaide Chieffo","Takashi Akasaka","Gary Mintz","Yves Louvard","Jens Flensted Lassen","Goran Stankovic"],"significance":8,"published":"2026-06-19","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"Joint clinical consensus statement from EAPCI and the European Bifurcation Club (EBC) on intracoronary imaging for left main percutaneous coronary intervention. The document underpins recent American and European guideline recommendations to use intravascular ultrasound (IVUS) or optical coherence tomography (OCT) for planning, guidance, and optimisation of left main bifurcation PCI in both chronic and acute coronary syndromes. The authors emphasise that benefit will only be realised when the interventional community routinely deploys intracoronary imaging for these complex high-risk lesions. The document provides practical guidance to maximise the benefit of IVUS and OCT in left main bifurcation disease.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"77edf9d349cf","type":"article","url":"https://hartvaat.nl/2026/05/15/laroprovstat-eerste-orale-pcsk9-remmer-haalt-80-ldl-reductie-in-combinatie-met-r/","title":"Laroprovstat: eerste orale PCSK9-remmer haalt -80% LDL-reductie in combinatie met rosuvastatine (fase 1)","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["atorvastatine","enlicitide","ezetimibe","hdl-cholesterol","lipidenverlaging","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","ramipril","rosuvastatine","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.075973","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.075973","authors":["Rick B Vega","Gavin O'Mahony","April M Barbour","Hongtao Yu","Jane Knöchel","Johan Brengdahl","Thomas Hochdörfer","Linnéa Bergenholm","Eva Töppner Carlsson","Andrea Ahnmark","Christina Rye Underwood","Anna Rudvik","Debra Carter","Johanna Laru","Aspen Gutgsell","Lee Twaddle","Pavlo Garkaviy","Anna Bogstedt","Eva Hurt-Camejo","Tasso Miliotis","Maria Ryaboshapkina","Andrease Hober","Brian Hubbard","Michael Serrano-Wu","Virendar Kaushik","Stefan Geschwindner","Michael C McCarthy","Daniel Lindén","Jaya B Rosenmeier"],"significance":8,"published":"2026-06-19","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"Phase 1 randomised, single-blind, placebo-controlled trial of laroprovstat (AZD0780), the first oral small-molecule PCSK9 inhibitor. Unlike injectable PCSK9 antibodies, laroprovstat does not block the PCSK9-LDLR interaction but stabilises the PCSK9 C-terminal domain, preventing lysosomal degradation of the LDL receptor. In healthy participants with LDL-C ≥70 and ≤190 mg/dL, pharmacokinetics were dose-proportional and suitable for once-daily dosing (half-life ~40 hours), with no food interaction. After a 3-week run-in with rosuvastatin 20 mg, laroprovstat 1 mg reduced LDL by 29% and 30 mg by 51% versus baseline. Combined rosuvastatin + laroprovstat resulted in total LDL reductions of ~70% and ~80%. Safety was favourable with no concerning signals. The results support further development as the first oral PCSK9 inhibitor.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c77198e4a334","type":"article","url":"https://hartvaat.nl/2026/05/15/non-invasieve-veneuze-return-cardiac-output-mismatch-onthult-gebufferde-staat-vo/","title":"Non-invasieve veneuze return/cardiac output-mismatch onthult 'gebufferde' staat vóór klinische hartfalen-decompensatie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfmref","hfpef","hfref","ventrikelfibrilleren"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag139","source_url":"https://doi.org/10.1093/eschf/xvag139","authors":["Hiroshi Morishita"],"significance":5,"published":"2026-06-18","source_date":"2026-05-15","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Study in 193 patients with chronic heart failure, hypertensive heart disease, or acute heart failure (AHF) using noninvasive estimation of mean circulatory filling pressure (via IVC diameter indexed to BSA) and right atrial pressure (via extracellular-to-total-body-water ratio). The calculated venous return / cardiac output (VR-CO) mismatch showed a bimodal pattern with two Gaussian components (means 2.25 and 5.25). All overt AHF cases fell within the higher-mismatch cluster. Intermediate states with increasing mismatch but preserved forward flow were interpreted as buffered states; a subgroup with marked mismatch but no clinical congestion represents a 'highly buffered pre-decompensated state'. AHF can thus be viewed as a failure of circulatory compensation, and this VR-CO framework may aid earlier detection and risk stratification.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"743b58657669","type":"article","url":"https://hartvaat.nl/2026/05/17/langetermijnoverleving-na-icd-implantatie-verschilt-sterk-per-cardiomyopathie-pl/","title":"Langetermijnoverleving na ICD-implantatie verschilt sterk per cardiomyopathie: pleit voor etiologie-gestuurde selectie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","diabetes-en-hart","farmaco-economie","gedilateerde-cardiomyopathie","harttransplantatie","hypertrofische-cardiomyopathie","iaso-dcm","icd-implantatie","immunoadsorptie","inflammatie","laminopathie","obesitas","ouderen","vrouwen"],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134561","source_url":"https://doi.org/10.1016/j.ijcard.2026.134561","authors":["Rebeca Lorca","Paula Bouzón","Fernando López","María Salgado","Rosana González-Mesa","Francisco González-Urbistondo","Cristina Helguera","Alberto Alen","Alvaro Lorente","Rut Alvarez-Velasco","José Manuel Rubín","Pablo Avanzas"],"significance":7,"published":"2026-06-18","source_date":"2026-05-17","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/","https://hartvaat.nl/kennis/hartfalen/dilaterende-cardiomyopathie/"],"congress":"","summary_en":"Retrospective cohort study of 1,091 adults who underwent ICD implantation at the regional referral centre in Asturias, Spain, between 2015 and 2024 (82.1% male, mean age 63 years, mean LVEF 38%). 75.6% received the ICD for primary prevention. Patients were classified by underlying cardiomyopathy: ischaemic (ICM, n=588), non-ischaemic dilated (NI-DCM, n=332), or other arrhythmogenic conditions (ACC, n=171; including HCM). Observed survival was compared with expected survival from age- and sex-matched national life tables. ICM patients had the worst prognosis with excess mortality versus the general population, NI-DCM had intermediate outcomes, and ACC closely matched expected population survival. Findings support an aetiology-informed approach to risk stratification and ICD selection, beyond a purely LVEF-driven strategy.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc1b21d61ae0","type":"article","url":"https://hartvaat.nl/2026/05/18/naar-precisiecardiologie-na-het-hartinfarct-opkomende-biomarkers-voor-risicostra/","title":"Naar precisiecardiologie na het hartinfarct: opkomende biomarkers voor risicostratificatie","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","inflammatie","laminopathie","lipoproteïne-a","menopauze","myocardinfarct","nt-probnp","troponine","vrouwen"],"journal":"European heart journal. Quality of care & clinical outcomes","doi":"10.1093/ehjqcco/qcag086","source_url":"https://doi.org/10.1093/ehjqcco/qcag086","authors":["Simón Rodríguez-Moar","Carmen Neiro-Rey","David García-Molinero","José M García-Acuña","Pedro Rigueiro-Veloso","Diego Iglesias-Álvarez","Brais Díaz-Fernández","Miguel Souto-Bayarri","José R González-Juanatey","Ezequiel Álvarez","Rosa M Agra-Bermejo"],"significance":6,"published":"2026-06-18","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"EHJ Quality of Care review of biomarkers for prognosis after myocardial infarction (MI). Despite significant advances in acute MI care, long-term prediction and risk stratification remain challenging. Cardiac troponins and natriuretic peptides remain standard for diagnosis and initial risk evaluation. Emerging biomarkers — galectin-3, lipoprotein(a), receptor for advanced glycation end-products (RAGE), and non-coding RNAs — are associated with higher mortality and major adverse cardiovascular events. Further exploration of their biological roles may yield new therapeutic targets. Combined with omics, imaging modalities, and digital monitoring, refined phenotypic characterisation enables personalised post-MI management.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b4c83196531","type":"article","url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","title":"Global HICC-register: 950+ HoFH-patiënten uit 45 landen — slechts 4% haalt LDL-doelen, mediane sterfteleeftijd 37 jaar","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag357","source_url":"https://doi.org/10.1093/eurheartj/ehag357","authors":["Willemijn A M Schonck","Janneke W C M Mulder","Marina Cuchel","Laurens F Reeskamp","Fahad Alnouri","Iulia Iatan","Tomas Freiberger","Meral Kayıkçıoğlu","Tycho R Tromp","M Doortje Reijman","Albert Wiegman","G Kees Hovingh","Jeanine E Roeters van Lennep","Frederick J Raal","Dirk J Blom","Alberico L Catapano"],"significance":8,"published":"2026-06-17","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/ritmestoornissen/wolff-parkinson-white/"],"congress":"","summary_en":"Data from the Global HoFH International Clinical Collaborators (HICC) registry, which has now included over 950 patients with homozygous familial hypercholesterolaemia (HoFH) from 45 countries. HoFH is characterised by extremely elevated LDL cholesterol from birth and very high risk of premature atherosclerotic CVD. Median age at diagnosis was 12 years (IQR 5.5-27.0), with untreated LDL cholesterol at median 14.7 mmol/L. At diagnosis 9% already had ASCVD or (supra)aortic valve disease; despite widespread lipid-lowering therapy, only 4% reached guideline LDL goals. Early initiation of lipoprotein apheresis was associated with greater LDL reductions and delayed ASCVD onset. Median age at death is just 37 years [20-50]. No sex differences emerged at diagnosis or in treatment, and the usual sex gap in CVD onset is absent. Global disparities in genetic screening and access to therapy are profound, with earlier events in low-income countries.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abcbf02673f4","type":"article","url":"https://hartvaat.nl/2026/05/18/helios-b-post-hoc-vutrisiran-effectief-bij-oost-aziatische-attr-cm-patienten-hr-/","title":"HELIOS-B post-hoc: vutrisiran effectief bij Oost-Aziatische ATTR-CM-patiënten (HR 0,20 voor mortaliteit/CV-events)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"JACC. Asia","doi":"10.1016/j.jacasi.2026.03.031","source_url":"https://doi.org/10.1016/j.jacasi.2026.03.031","authors":["Jin Endo","Tetsuo Minamino","Jaewon Oh","Nobuhiro Tahara","Kenichi Tsujita","Chisato Izumi","Takahiro Okumura","Kenji Onoue","Hiroaki Kitaoka","Chongshu Chen","Amy Chan-Daniels","Darae Kim"],"significance":6,"published":"2026-06-17","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"Post-hoc analysis of 32 East Asian participants (Japan and South Korea) from the phase 3 HELIOS-B trial of vutrisiran in transthyretin amyloidosis cardiomyopathy (ATTR-CM), randomised to vutrisiran (n=17) or placebo (n=15). Baseline tafamidis use was lower than in the overall population. Vutrisiran reduced the composite primary endpoint of all-cause mortality and recurrent cardiovascular events (HR 0.20; 95% CI 0.04-0.93). Attenuated declines in 6-minute walk distance and KCCQ-OS scores were observed, and a greater proportion maintained or improved NYHA functional class. NT-proBNP and troponin I increases were smaller with vutrisiran. Similar trends were seen in patients not on baseline tafamidis. Safety matched the overall population. Vutrisiran is thus effective and safe in East Asian ATTR-CM patients.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"953ff314a109","type":"article","url":"https://hartvaat.nl/2026/05/19/finacaf-n-229-565-hartfalen-verhoogt-cva-risico-bij-af-vooral-bij-jongere-patien/","title":"FinACAF (n=229.565): hartfalen verhoogt CVA-risico bij AF vooral bij jongere patiënten","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","nt-probnp","pathfinder-trial","primaire-preventie","vrouwen"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.047961","source_url":"https://doi.org/10.1161/JAHA.125.047961","authors":["Eero Jalli","Ville Langén","Jussi Jaakkola","K E Juhani Airaksinen","Olli Halminen","Jukka Putaala","Pirjo Mustonen","Jari Haukka","Juha Hartikainen","Miika Linna","Elis Kouki","Mika Lehto","Konsta Teppo"],"significance":7,"published":"2026-06-17","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"Nationwide Finnish retrospective cohort study (FinACAF) of 229,565 patients with new-onset atrial fibrillation (AF) between 2007 and 2018. Prevalence of heart failure was much higher in older than younger patients (38.7% vs 4.3%). The relative association between heart failure and ischaemic stroke was age-dependent: in patients <60 years the incidence rate ratio was ≥2.0, falling to ≈1.0 in the oldest group (p<0.001 for interaction). The adjusted absolute event-rate difference remained stable at ≈1 event per 100 patient-years across all age categories. The findings argue for extra weight on heart failure when deciding on oral anticoagulation in younger AF patients — co-existing HF is prognostically more important in this group than in older patients.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1019ac7283b1","type":"article","url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","title":"Clopidogrel versus aspirine bij chronisch coronair syndroom: meta-analyse toont winst — maar vooral bij Oost-Aziaten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["trombocytenaggregatieremmers"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag351","source_url":"https://doi.org/10.1093/eurheartj/ehag351","authors":["Claudio Laudani","Giovanni Occhipinti","Francesco Costa","Domenico D'Amario","Tullio Palmerini","Sebastiano Sciarretta","Charles Michael Gibson","Behnood Bikdeli","Felicita Andreotti","Young-Hoon Jeong","Takeshi Kimura","Diana A Gorog","Dirk Sibbing","Davide Capodanno","Jurrien Ten Berg","Raffaele De Caterina","Mattia Galli"],"significance":7,"published":"2026-06-16","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"Systematic review and meta-analysis of 7 randomised trials (30,165 patients; 75.1% East Asian, median follow-up 36 months) comparing clopidogrel versus aspirin for secondary prevention in chronic coronary syndrome. Overall, clopidogrel reduced the composite MACE (IRR 0.83; 95% CI 0.69-0.99) and net adverse clinical events (IRR 0.83), with no difference in major bleeding, myocardial infarction, or mortality. However, there was a significant ethnicity interaction: in East Asians, clopidogrel clearly reduced MACE (IRR 0.76; 95% CI 0.59-0.98), while in non-East Asians it did not (IRR 1.00; Pint=0.010), with similar interaction for mortality (Pint=0.014). Evidence favouring clopidogrel over aspirin in chronic coronary syndrome is therefore robust in East Asian populations; further research is needed before generalising to other ethnic groups.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"064f895c7758","type":"article","url":"https://hartvaat.nl/2026/05/19/gezond-eetpatroon-verlaagt-cv-risico-bij-kankeroverlevenden-los-van-genetisch-ri/","title":"Gezond eetpatroon verlaagt CV-risico bij kankeroverlevenden — los van genetisch risico (UK Biobank, n=10.414)","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["voeding-hart","vrouwen"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.048476","source_url":"https://doi.org/10.1161/JAHA.125.048476","authors":["Shaojie Han","Zenghui Zhang","Lishan Li","Siqi Gao","Bin Li","Chuxian Guo","Can Lu","Xianwu Lan","Zhaoyu Liu","Jun Guo"],"significance":6,"published":"2026-06-16","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Prospective cohort study in UK Biobank of 10,414 cancer survivors free of prior CVD who had completed ≥2 dietary recalls (mean age 59.5 years, 37% men). Over a median follow-up of 13.1 years, 1,331 incident CV events occurred. Higher adherence to four healthy dietary patterns reduced CV risk (highest vs lowest tertile): alternate Mediterranean diet HR 0.83, Alternative Healthy Eating Index 2010 HR 0.76, Dietary Approaches to Stop Hypertension HR 0.82, EAT-Lancet HR 0.85. Effects were consistent for ischaemic heart disease (HR 0.77-0.85); AHEI-2010, DASH, and EAT-Lancet also reduced heart failure risk (HR 0.74-0.88); AHEI-2010 and EAT-Lancet also reduced stroke risk. There was no interaction with genetic CVD risk. Healthy eating thus benefits cancer survivors regardless of genetic predisposition — a growing high-risk population.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"044874b3d763","type":"article","url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","title":"ELDERCARE-AF post-hoc: edoxaban-spiegel én PT >13s voorspellen bloedingsrisico bij zeer oude AF-patiënten","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","anemie-ckd","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","ouderen"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.042950","source_url":"https://doi.org/10.1161/JAHA.125.042950","authors":["Ken Okumura","Masaharu Akao","Masayuki Fukuzawa","Yoshiyuki Igawa","Takuya Hayashi","Takeshi Yamashita"],"significance":6,"published":"2026-06-16","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/hasbled-score/"],"congress":"","summary_en":"Post-hoc analysis of the randomised double-blind ELDERCARE-AF trial (Japanese patients ≥80 years with atrial fibrillation and high bleeding risk), in which 427 patients received edoxaban 15 mg/day or placebo. After 8 weeks, trough edoxaban concentration (E-trough) and prothrombin time (PT) were measured. Older age, lower body weight, lower creatinine clearance, and congestive heart failure were independent predictors of higher E-trough. Higher E-trough was associated with more major bleeding (0.8%, 1.9%, 3.4%, 4.7% per year across quartiles; p=0.04). E-trough correlated strongly with PT (r=0.43; p<0.0001). At PT >13 seconds, significantly more major bleeding occurred (4.61% vs 0.98%/year; p=0.006). PT may thus serve as a simple bedside marker to identify bleeding risk in very old edoxaban patients.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87ba765d89cd","type":"article","url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","title":"SGLT2-remmers bij oudere patiënten opgenomen voor HFrEF: -24% sterfte en -16% heropname bij start vóór ontslag","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.126.049161","source_url":"https://doi.org/10.1161/JAHA.126.049161","authors":["Nicholas Brownell","Nicole Solomon","Stephen J Greene","Karen Chiswell","Muthiah Vaduganathan","Clyde Yancy","Priscilla Hsue","Boback Ziaeian","Gregg C Fonarow"],"significance":7,"published":"2026-06-15","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"Analysis of Medicare data from Get with the Guidelines-Heart Failure: 8,847 patients aged ≥65 years hospitalised for HFrEF between July 2021 and June 2023, eligible for SGLT2 inhibitors but not yet receiving them (median age 77 years, 40% women, median LVEF 28%). 16.5% (n=1,464) initiated an SGLT2 inhibitor at discharge. After overlap weighting via propensity score, SGLT2i initiation was independently associated with lower 12-month all-cause mortality (aHR 0.76; 95% CI 0.67-0.86), all-cause readmission (aHR 0.89), and HF readmission (aHR 0.84). Findings were consistent across age, sex, race/ethnicity, diabetes status, CKD status, and LVEF. Early in-hospital initiation of SGLT2 inhibitors thus improves prognosis in older HFrEF patients in routine practice — a population previously underrepresented in RCTs.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31ec0732baf0","type":"article","url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-head-to-head-empagliflozin-licht-beter-dan-canagliflozin-bij-matig/","title":"SGLT2-remmers head-to-head: empagliflozin licht beter dan canagliflozin bij matig CV-risico (target trial van 137.232 patiënten)","title_en":"","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","farmaco-economie","fidelio-dkd","pcsk9-remmers-nieuwe-generatie","sglt2-remmers","soul-trial"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046238","source_url":"https://doi.org/10.1161/JAHA.125.046238","authors":["Anum Zehra","Yihong Deng","Kavya Sindhu Swarna","Jeph Herrin","Eric C Polley","Joshua J Neumiller","Rodolfo J Galindo","Guillermo E Umpierrez","Joseph S Ross","Juan P Brito","Victor M Montori","Bijan J Borah","Bradley A Maron","Mindy M Mickelson","Rozalina G McCoy"],"significance":7,"published":"2026-06-15","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"Target trial emulation on US claims data (commercial + Medicare) of adults with type 2 diabetes and moderate cardiovascular risk who started canagliflozin (n=42,877), dapagliflozin (n=17,871), or empagliflozin (n=7,648) between 2015 and 2020. In the weighted cohort (n=137,232; mean age 65.7 years, 81.9% on metformin), MACE risk was slightly lower with empagliflozin versus canagliflozin (HR 0.92; 95% CI 0.87-0.97), driven by reduced all-cause mortality (HR 0.86). Empagliflozin versus dapagliflozin and dapagliflozin versus canagliflozin did not differ. No differences in hyperglycaemic or hypoglycaemic crises between the three drugs. The three most commonly used SGLT2 inhibitors show comparable cardiovascular effectiveness; clinicians and health systems should prioritise enhancing access to this class rather than drug selection.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae8ec1a48b72","type":"article","url":"https://hartvaat.nl/2026/05/19/tirzepatide-bij-hfpef-obesitas-niet-kosteneffectief-en-niet-betaalbaar-tegen-hui/","title":"Tirzepatide bij HFpEF + obesitas: niet kosteneffectief en niet betaalbaar tegen huidige prijs in Duitsland","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["farmaco-economie","step-hfpef","summit-trial"],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134560","source_url":"https://doi.org/10.1016/j.ijcard.2026.134560","authors":["Bent Estler","Hanna Fröhlich","Tobias Täger","Jannick Heins","Norbert Frey","Lutz Frankenstein"],"significance":6,"published":"2026-06-15","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"Markov model of tirzepatide versus placebo (both on top of standard care) in the SUMMIT population (HFpEF + obesity) from the German payer perspective, with monthly cycles over 5 years and four KCCQ-defined health states plus death. Discounted per-patient costs: €5,827 (placebo) versus €31,052 (tirzepatide), with QALYs of 3.539 versus 3.638. Tirzepatide yielded 0.100 additional QALYs at incremental costs of €25,225, ICER €252,611/QALY — far above the €100,000/QALY threshold. Five-year budget impact: €1.9-6.2 billion under SUMMIT criteria and €3.8-12.6 billion under broad eligibility, depending on uptake (30/50/100%). Substantial price reduction would be needed for tirzepatide to be both cost-effective and affordable at population scale.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"753ab21d9fe2","type":"article","url":"https://hartvaat.nl/2026/05/19/vertraagde-intracraniele-bloeding-na-trombectomie-geassocieerd-met-slechtere-fun/","title":"Vertraagde intracraniële bloeding na trombectomie geassocieerd met slechtere functionele uitkomst en SBP >150 mmHg","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","dubbele-trombocytenremming"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.048272","source_url":"https://doi.org/10.1161/JAHA.125.048272","authors":["Jae Wook Jung","Byungjae Kim","Eun Lee Ko","JoonNyung Heo","Hyungwoo Lee","Young Dae Kim","Haram Joo","Byung Moon Kim","Dong Joon Kim","Hyo Suk Nam"],"significance":7,"published":"2026-06-14","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"Retrospective study of 268 patients undergoing endovascular thrombectomy, with dual-energy CT immediately post-procedure and follow-up imaging. Early intracranial haemorrhage (ICH) occurred in 11.9%, delayed ICH in 36.9%, and no ICH in 51.1%. Delayed ICH was associated with lower 90-day functional independence (mRS 0-2; aOR 0.49; 95% CI 0.25-0.94), without elevated mortality. Within delayed ICH, haemorrhagic infarction was mainly associated with functional dependence, while parenchymal haematoma was also linked to death. Higher postprocedural systolic blood pressure predicted delayed ICH, with thresholds at mean >150 mm Hg and peak >166 mm Hg. Optimised BP management may help prevent delayed ICH.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db68b936f104","type":"article","url":"https://hartvaat.nl/2026/05/19/team-gebaseerde-telehealth-bloeddrukbehandeling-acceptabel-en-haalbaar-in-achter/","title":"Team-gebaseerde telehealth-bloeddrukbehandeling acceptabel en haalbaar in achterstandsklinieken — mixed-methods evaluatie","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.047236","source_url":"https://doi.org/10.1161/JAHA.125.047236","authors":["Sunit Chhetri","Srista Manandhar","Austin L Seals","Justin Kramer","Yashashwi Pokharel"],"significance":5,"published":"2026-06-14","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"Implementation evaluation of a team-based telehealth blood pressure management program using home BP monitoring, self-management, and social support in underserved patient populations. Mixed-methods approach with 20 patients and 16 clinic staff from 2 safety-net clinics in North Carolina, framed by EPIS and Health Equity Implementation Frameworks. Five themes emerged: (1) staffing barriers and coordinated teamwork with user-friendly tools, (2) patient- and provider-centred approach, (3) ease of home BP monitoring, (4) personalised self-management calls, (5) social support. Both patients and clinic staff rated the program highly on acceptability (4.42/5), appropriateness (4.42/5), and feasibility (4.40/5). Successful implementation depends on tailoring, trust-building, and financial sustainability.","created":"2026-07-03T10:33:03Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"348ea979bb2b","type":"article","url":"https://hartvaat.nl/2026/05/19/ehj-review-dyslipidemie-bij-kankerpatienten-verhoogd-ascvd-risico-beperkte-data-/","title":"EHJ-review: dyslipidemie bij kankerpatiënten — verhoogd ASCVD-risico, beperkte data, behoefte aan kankerspecifieke risicoscores","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","ouderen","statines","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag265","source_url":"https://doi.org/10.1093/eurheartj/ehag265","authors":["Muhummad Sohaib Nazir","Jaimini Cegla","Maria Sol Andres","Kausik K Ray","Alexander R Lyon"],"significance":7,"published":"2026-06-14","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"EHJ review of the challenges of dyslipidaemia in cancer patients and survivors. As cancer survival improves, more patients face cardiovascular complications: both dyslipidaemia and cancer therapy elevate atherosclerotic CVD risk. Most ASCVD risk scores do not incorporate cancer factors and underestimate true risk. Some cancer therapies cause transient elevations in LDL, triglycerides, or HDL reductions, sometimes to extreme levels. Lipid-lowering therapy: reliable data exist for statins and ezetimibe (LDL) and fibrates and omega-3 (hypertriglyceridaemia); newer agents (PCSK9 inhibitors, inclisiran, bempedoic acid) are insufficiently studied in this population. Initiation requires integration of ASCVD risk, drug-drug interactions, side-effects, and prognosis. Statins as cardioprotection in anthracycline therapy opens an additional research avenue.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc15d042418b","type":"article","url":"https://hartvaat.nl/2026/05/19/peulvruchten-in-de-voeding-verlagen-ldl-en-non-hdl-dose-response-meta-analyse-va/","title":"Peulvruchten in de voeding verlagen LDL en non-HDL: dose-response meta-analyse van 38 RCT's","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","hdl-cholesterol","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","soul-trial","statines"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046659","source_url":"https://doi.org/10.1161/JAHA.125.046659","authors":["Songhee Back","Shuting Yang","Antonio Rossi","Sabrina Ayoub-Charette","Shannan M Grant","Victoria Chen","Erika J Lin","Lukas Haintz","Yue-Tong Chen","Elmirah Ahmad","Jacqueline Gahagan","Christopher P F Marinangeli","Vanessa Ha","Tauseef Ahmad Khan","Sonia Blanco Meji","Andreea Zurbau","Russell J de Souza","Joseph Beyene","Marcia M English","Vladimir Vuksan","Robert G Josse","Lawrence A Leiter","Cyril W C Kendall","David J A Jenkins","John L Sievenpiper","Laura Chiavaroli"],"significance":7,"published":"2026-06-13","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"Systematic review and dose-response meta-analysis of 38 randomised trials (52 comparisons, n=2,095) on the effect of whole dietary pulses on lipid targets. Median duration 6 weeks, median dose 130 g/day (0.5-0.67 cup). Pulses reduced LDL cholesterol by -0.14 mmol/L (95% CI -0.19 to -0.08), non-HDL cholesterol by -0.22 mmol/L, apoB by -0.08 g/L, and HDL by -0.03 mmol/L (the last clinically trivial). No effect on other lipids. Results were consistent across pulse types. For beans, a linear inverse relationship was demonstrated up to 1 cup/day for LDL (-0.25 mmol/L per 0.5 cup) and non-HDL (-0.45 mmol/L per 0.5 cup). GRADE certainty was moderate-to-high for most outcomes. Effects are small-to-moderate but clinically meaningful, supporting dietary guidelines on pulses as a lipid-lowering strategy.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1cd52093e901","type":"article","url":"https://hartvaat.nl/2026/05/19/clear-taiwan-bempedoinezuur-verlaagt-ldl-met-19-in-real-world-aziatische-populat/","title":"CLEAR Taiwan: bempedoïnezuur verlaagt LDL met 19% in real-world Aziatische populatie","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","clear-outcomes","dyslipidemie","ezetimibe","ldl-cholesterol","niet-statine-therapie"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.126.049917","source_url":"https://doi.org/10.1161/JAHA.126.049917","authors":["I-Chang Hsieh","Dong-Yi Chen","Chih-Sheng Chu","Yi-Yao Chang","Bing-Hsiean Tzeng","Tien-Chi Huang","Heng-Hsu Lin","Wen-Po Chuang","Chi-Cheng Huang","Jih-Kai Yeh","Chun-Yuan Chu","Ming-Yun Ho","Ching-Ya Huang","Yu-Wen Chen","Wei-Chen Yang","Tsung-Hsien Lin","Yen-Wen Wu"],"significance":6,"published":"2026-06-13","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"Pragmatic phase 4 study in 180 Taiwanese patients with inadequately controlled hypercholesterolaemia who received bempedoic acid for 12 weeks added to their existing lipid-lowering therapy. Of 180 patients, 88.9% (n=160) completed the study. Median LDL reduction from baseline was -19% (IQR -36.4 to -3.6), with a decrease from 117.5 to 92 mg/dL (p<0.01). Other parameters also fell: non-HDL cholesterol -13.3%, total cholesterol -10.8%, apolipoprotein B -11.5%, and hs-CRP -34.0% (all p<0.01). Effects on triglycerides, HDL and Lp(a) were minimal. At week 12, 31.3% met the LDL target. Safety profile matched the Taiwanese label, with no new signals. Bempedoic acid offers an effective and safe oral add-on for patients who do not reach LDL targets on statins alone.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"33964fe6d581","type":"article","url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","title":"ESC Atlas 2025: 3 miljoen CVD-doden per jaar in Europa — middeninkomenlanden hebben dubbele sterfte","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag345","source_url":"https://doi.org/10.1093/eurheartj/ehag345","authors":["Adam Timmis","Steffen E Petersen","Eric Van Belle","Nick Townsend","Nathalie Conrad","Agnieszka Kaplon-Cieslicka","Denis Kazakiewicz","Maryam Kavousi","Marta Cvijic","Barbara Ignatiuk","Aleksandra Torbica","Daniel Scherr","Giuseppe Boriani","Alaide Chieffo","Efstratios Karagiannidis","Susanna Price","Helmut Puererfellner","Angela Wood","Thomas F Lüscher","Panos E Vardas"],"significance":8,"published":"2026-06-13","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"Fifth biennial ESC Atlas report presenting cardiovascular disease statistics from more than 50 ESC member countries for 2024. CVD causes over 3 million deaths and 68 million disability-adjusted life years annually in the region, remaining the leading cause of death. Substantial variation exists by national income: middle-income countries show age-standardised mortality roughly twice that of high-income countries, with major disparities in workforce capacity and access to advanced interventions. The report informs the EU Safe Hearts Plan (adopted December 2025) and highlights new threats — particularly the obesity and diabetes epidemic — that risk reversing progress in CVD reduction. Ageing and socioeconomic inequality call for coordinated European policy to safeguard further progress.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2694caa74d58","type":"article","url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","title":"Lipoproteïne-aferese blijft relevant in het tijdperk van PCSK9-remmers en siRNA","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["abelacimab","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag328","source_url":"https://doi.org/10.1093/eurheartj/ehag328","authors":["Francesco Sbrana","Beatrice Dal Pino","Volker J J Schettler","Eri Muso","Mariko Harada-Shiba","Maria Di Mola","Maki Kagitani","Eleanor Pineda","Nathalie Selke","Sebastian Jenke","Thomas Zimmermann","Wanja Bernhardt","Federico Bigazzi","Franz Heigl","Peter Grützmacher","Iris Löhlein","Reinhard Klingel","Carmen Corciulo","Bernd Hohenstein","Wolfang Ramlow","Anja Vogt","Alfonso Ramunni","Michele Emdin","Tiziana Sampietro","Ulrich Julius","Georg Schlieper","Claudia Stefanutti","Patrick M Moriarty"],"significance":6,"published":"2026-06-12","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"Review of lipoprotein apheresis (LA) in the era of modern lipid-lowering therapies. LA selectively removes atherogenic apoB100-containing lipoproteins — LDL, VLDL, and lipoprotein(a) — from blood. Proven effects: protection of endothelium and microcirculation, prevention of new aortic and coronary lesions in homozygous familial hypercholesterolaemia (HoFH), reduction of cardiovascular events, and adjunct in secondary prevention for patients who fail LDL targets or have elevated Lp(a). Despite the rise of PCSK9 inhibitors, antisense oligonucleotides, and siRNA therapies, LA remains a safe option for patients with severe lipid disorders. Barriers to broader use: HoFH and high-Lp(a) underdiagnosis, therapeutic inertia, and limited availability of qualified LA centres. Future research is directed at kidney disease, peripheral arterial disease, pre-eclampsia, macular degeneration, and sudden sensorineural hearing loss.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6dd1ec85a03","type":"article","url":"https://hartvaat.nl/2026/05/19/therapietrouw-trajecten-na-ischemisch-cva-vroeg-dubbel-staken-verhoogt-sterfte-e/","title":"Therapietrouw-trajecten na ischemisch CVA: vroeg dubbel staken verhoogt sterfte en recidief met ~50%","title_en":"","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.048456","source_url":"https://doi.org/10.1161/JAHA.125.048456","authors":["Shih-Wei Wang","Hung-Sheng Lin","Che-Wei Hsu","Chung-Yu Chen","Hiroshi Saito","Fu-Shih Chen"],"significance":7,"published":"2026-06-12","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Cohort study using Taiwanese registry data (Chang Gung Research Database linked to nationwide claims) of 13,299 patients with first-ever ischaemic stroke or TIA between 2012 and 2018 who survived ≥1 year and initiated secondary prevention. Monthly adherence (proportion of days covered) was modelled into four trajectories: high dual adherence (46.7%), antithrombotic-only (35.1%), early dual discontinuation (12.2%), and gradual dual decline (6.0%). High dual adherence achieved the greatest LDL reduction (-24.3%) and lowest mortality. Early dual discontinuation was associated with higher composite outcome (aHR 1.57), recurrent stroke/embolism (aHR 1.60), myocardial infarction (aHR 1.48), and all-cause death (aHR 1.56). Poor adherence had greater impact in patients with baseline LDL ≥100 mg/dL, younger adults, and men. Sustained dual adherence confers substantial protection; early discontinuation markedly elevates recurrence and mortality risk.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a560c0d1dfcd","type":"article","url":"https://hartvaat.nl/2026/05/19/victorion-inception-vroege-inclisiran-na-acuut-coronair-syndroom-verviervoudigt-/","title":"VICTORION-INCEPTION: vroege inclisiran na acuut coronair syndroom verviervoudigt het halen van LDL-doel","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","lipidenverlaging"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.043655","source_url":"https://doi.org/10.1161/JAHA.125.043655","authors":["Kirk U Knowlton","Ann Marie Navar","Jeffrey L Anderson","Alan S Brown","Joseph B Muhlestein","Kelly Kleeman","Samiha Sarwat","Cheryl A Abbas","Mary Ann Ramirez","Cindy L Grines","Wael S Abo-Auda","Nihar R Desai"],"significance":8,"published":"2026-06-12","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"","summary_en":"Open-label phase 3b multicenter randomised trial in 400 patients ≤5 weeks after acute coronary syndrome with LDL-C ≥70 mg/dL (or non-HDL ≥100 mg/dL) on statin therapy or statin-intolerant. 1:1 randomisation to inclisiran 300 mg (days 0, 90, 270) plus usual care versus usual care alone, with 330 days of follow-up. At day 90, 74.6% of inclisiran patients reached LDL <70 mg/dL versus 26.6% with usual care (OR 10.84); for LDL <55 mg/dL it was 63.2% vs 8.5% (OR 26.58). At day 330 the gap persisted: 66.7% vs 28.1% for LDL <70 (OR 5.42; p<0.001) and 54.2% vs 13.6% for LDL <55. Mean LDL reduction from baseline was -46.9% greater with inclisiran. Adverse events were comparable between arms (58.6% vs 53.3%). The first inclisiran trial in recent ACS — early addition rapidly and durably achieves guideline LDL targets.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce1259213061","type":"article","url":"https://hartvaat.nl/2026/05/19/mobiele-screeningseenheid-in-detroit-70-van-inwoners-in-achtergestelde-wijken-he/","title":"Mobiele screeningseenheid in Detroit: 70% van inwoners in achtergestelde wijken heeft minstens één onbeheerste cardiometabole risicofactor","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["primaire-preventie"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.047852","source_url":"https://doi.org/10.1161/JAHA.125.047852","authors":["Robert D Brook","Steven J Korzeniewski","Bethany Foster","Paul Kurian","Brian Reed","Anna Steinberg-Abreu","James L Young","Phillip D Levy"],"significance":6,"published":"2026-06-11","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Cross-sectional analysis of the Wayne State University/Wayne Health mobile health unit program, which conducted screening at over 1,000 locations across metropolitan Detroit between July 2021 and September 2025. In voluntary adult participants: median BP 122/75 mm Hg, LDL cholesterol 103 mg/dL, HbA1c 5.7%. About half had elevated BP (48%; n=6,182/12,821) or LDL ≥100 mg/dL (54%; n=3,860/7,115); 16% had HbA1c ≥6.5%. Among 5,393 participants with all four measurements, only 4% had an ideal cardiometabolic risk profile (SBP <120, LDL <70, HbA1c <5.7%), while 70% had at least one uncontrolled risk factor. Older age predicted all four; Black race predicted uncontrolled BP; male sex predicted uncontrolled BP and HbA1c. Mobile units are a valuable tool for detection and targeted intervention in socioeconomically disadvantaged populations.","created":"2026-07-03T10:33:02Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"369ae417479a","type":"article","url":"https://hartvaat.nl/2026/05/19/life-s-essential-8-lichaamsbeweging-is-de-sterkste-schakel-tussen-laag-inkomen-e/","title":"Life's Essential 8: lichaamsbeweging is de sterkste schakel tussen laag inkomen en cardiovasculair risico","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":["lichaamsbeweging"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.043789","source_url":"https://doi.org/10.1161/JAHA.125.043789","authors":["Donya Nemati","Parvati Naliyatthaliyazchayil","Louis Bherer","Kenneth Lim","NiCole Keith","Navin Kaushal"],"significance":5,"published":"2026-06-11","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Mediation analysis of NHANES data (2021-2023) in 3,345 US adults, framed by Life's Essential 8. Low income was associated with lower moderate-to-vigorous physical activity (MVPA), poorer nutrition, and more smoking. Via these behaviours, the path extended to higher fasting glucose, BMI, and systolic blood pressure. Low MVPA was independently associated with higher systolic blood pressure, fasting glucose, and BMI. MVPA showed the strongest mediator effects, suggesting it as a leverage point for reducing income-related cardiovascular risk through population- and community-level interventions.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4553ef153821","type":"article","url":"https://hartvaat.nl/2026/05/19/beste-bewegingsvorm-voor-bloeddruk-combinatietraining-en-hiit-geven-12-6-mmhg-in/","title":"Beste bewegingsvorm voor bloeddruk: combinatietraining en HIIT geven -12/-6 mmHg in netwerk-meta-analyse","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.044003","source_url":"https://doi.org/10.1161/JAHA.125.044003","authors":["Xianyang Xin","Yongqing Guo","Mei Wang","Zhongxu Hu","Jiu Chen","Jun Xie"],"significance":7,"published":"2026-06-11","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/"],"congress":"","summary_en":"Bayesian network meta-analysis of 105 randomised trials examining different exercise modalities and doses on blood pressure in prehypertension and established hypertension. Combined training (strength + aerobic) reduced systolic blood pressure by -12.05 mm Hg (95% CrI -15.08 to -9.05) and diastolic by -6.20 mm Hg; high-intensity interval training reduced systolic by -10.97 mm Hg and diastolic by -6.42 mm Hg. Yoga and tai chi had moderate effects; aerobic, isometric, and resistance training were relatively weaker as single modalities. Dose-response was non-linear and U-shaped, with greatest benefit at ~830 metabolic-equivalent minutes per week (optimal dose varying by modality). Conclusion: all modalities lower BP; combined training and HIIT are most effective, with diminishing returns beyond ~830 MET-min/week.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6bcfe08b3b44","type":"article","url":"https://hartvaat.nl/2026/05/19/stop-cad-1-op-6-cervicale-arteriedissecties-wordt-aanvankelijk-verkeerd-gediagno/","title":"STOP-CAD: 1 op 6 cervicale arteriedissecties wordt aanvankelijk verkeerd gediagnosticeerd","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046408","source_url":"https://doi.org/10.1161/JAHA.125.046408","authors":["Ekaterina Bakradze","Liqi Shu","Shadi Yaghi","Thanh Lam Ngoc Tran","Ross Curtiss Crandal","Evan Lester","Daniel M Mandel","James Ernest Siegler","Mary Penckofer","Ava Leigh Liberman","Thalia S Field","Farhan Khan","Wayneho Kam","Brian Mac Grory","Faddi G Saleh Velez","Nils Henninger","Cheran Elangovan","Balaji Krishnaiah","Preet Gandhi","Reza Bavarsad Shahripour","Malik Ghannam","Mirjam Rachel Heldner","Kateryna Antonenko","Aaron Rothstein","Ronen R Leker","Issa Metanis","Edgar Samaniego","Michele Romoli","Marialuisa Zedde","Rosario Pascarella","Thanh N Nguyen","Piers Klein","Farid Khasiyev","Ossama Khazaal","Mohammad Almajali","Adeel S Zubair","Marwa Elnazeir","João Pedro Marto","Ahmad Nehme","James Anthony Giles","Stefan T Engelter","Christoph Stretz","Setareh Salehi Omran"],"significance":6,"published":"2026-06-10","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"Secondary analysis of the STOP-CAD study in 4,012 patients with cervical artery dissection (CeAD; mean age 47.5 years; 44.6% female). Possible diagnostic error — defined as CeAD symptoms within 30 days before the eventual diagnosis — occurred in 663 (16.5%); 33.8% of these had an ischaemic stroke before diagnosis. Patients with diagnostic delay were younger (OR 0.89), more often had a migraine history (OR 1.35) and presented with headache (OR 1.43) but less often with focal neurological signs (OR 0.68). After adjustment, there were no differences in ischaemic stroke after diagnosis, 90-day mRS <2 or mortality between groups. Heightened differential-diagnostic awareness in younger patients with headache (especially with migraine history) and no focal signs could speed diagnosis.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00aca3311f30","type":"article","url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","title":"SALAMANDER-register: 95,5% technisch succes bij stand-alone linker-hartoor-occlusie in Europese praktijk","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046625","source_url":"https://doi.org/10.1161/JAHA.125.046625","authors":["Wojciech Wańha","Łukasz Kuźma","Mariusz Kowalewski","Sylwia Iwańczyk","Joanna Grygier","Jan Jeske","Marco Frazzetto","Radosław Litwinowicz","Marian Burysz","Ewa Gaszewska-Żurek","Claudio Sanfilippo","Tomasz Bochenek","Michał Lelek","Krystian Wita","Zenon Huczek","Agnieszka Kapłon-Cieślicka","Tomasz Mazurek","Piotr Scisło","Jerzy Sacha","Krzysztof Struniawski","Brunon Tomasiewicz","Facehauwe Mezque","Wiktor Kuliczkowski","Krzysztof Bartuś","Sławomir Dobrzycki","Michał Święczkowski","Anna Kurasz","Paweł Kralisz","Dawid Miśkowiec","Jarosław D Kasprzak","Marta Chamera","Maksymilian Mielczarek","Piotr Drewla","Rafał Gałąska","Fabrizio Ugo","Marco Franzino","Bernardo Cortese","Filippo L Gurgoglione","Luigi Vignali","Giorgio Benatti","Federico Barocelli","Piotr Waciński","Piotr Niezgoda","Adam Sukiennik","Jacek Kubica","Mario Iannacone","Klaudia Kowalska","Łukasz Lewicki","Carmelo Grasso","Davide Capodanno","Fabrizio D'Ascenzo","Ovidio de Filippo","Francesco Bruno","Radosław Gocoł","Zbigniew Kalarus","Piotr Suwalski","Marek Grygier","Grzegorz Smolka","Gregory Y H Lip","Wojciech Wojakowski"],"significance":7,"published":"2026-06-10","source_date":"2026-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Prospective multicenter observational cohort of 1,660 patients with non-valvular atrial fibrillation undergoing stand-alone left atrial appendage occlusion (LAAO) at 16 European centres between 2010 and 2024. Median age 76 years (IQR 70-81); 38% women; median CHA2DS2-VASc 4. Indication was significant bleeding in 83.7% — most often on DOAC (68.8%) and less often VKAs (24.9%); main bleeding sites were lower (27.9%) and upper (21.7%) GI tract, with 17.4% history of haemorrhagic stroke. Technical success 95.5% (limited mainly by residual leak 2.2% and tamponade 1.4%); procedural success 90.5% (vascular complications 3.7%, periprocedural death 1.1%). Results were comparable across devices. Virtually all patients received dual antiplatelet therapy post-procedure.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2dc2400593de","type":"article","url":"https://hartvaat.nl/2026/05/20/nutrinet-sante-voedselconserveermiddelen-geassocieerd-met-meer-hypertensie-en-ca/","title":"NutriNet-Santé: voedselconserveermiddelen geassocieerd met meer hypertensie en cardiovasculaire ziekte","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","bloeddrukbehandeling","farmaco-economie","obesitas","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag308","source_url":"https://doi.org/10.1093/eurheartj/ehag308","authors":["Anaïs Hasenböhler","Guillaume Javaux","Marie Payen de la Garanderie","Fabien Szabo de Edelenyi","Paola Yvroud-Hoyos","Cédric Agaësse","Alexandre De Sa","Inge Huybrechts","Fabrice Pierre","Xavier Coumoul","Léopold K Fezeu","Pilar Galan","Jacques Blacher","Chantal Julia","Benjamin Allès","Serge Hercberg","Benoit Chassaing","Mélanie Deschasaux-Tanguy","Bernard Srour","Mathilde Touvier"],"significance":7,"published":"2026-06-10","source_date":"2026-05-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/vasculair/d-dimeer-interpretatie/"],"congress":"","summary_en":"Prospective French cohort study (NutriNet-Santé, 2009-2024) in 112,395 participants (78.7% women; mean age 42.8 years; median follow-up 7.9 years). Dietary intake was assessed via repeated 24-hour dietary records (up to 96 per participant); exposure to food additives was analysed using multiple composition databases and laboratory assays. Total non-antioxidant preservatives were associated with increased incident hypertension (n=5,544; HR highest vs lowest consumers 1.29; 95% CI 1.20-1.39) and cardiovascular disease (n=2,450; HR 1.16). Antioxidant preservatives were linked only to hypertension (HR 1.22). Of 17 individually examined additives (consumed by ≥10%), eight were associated with hypertension and one with CVD after multiple-testing correction. If confirmed experimentally, the findings call for re-evaluation of regulations on industrial food additives.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"afa8667c5436","type":"article","url":"https://hartvaat.nl/2026/05/21/glp-1-agonisten-kosten-geen-spiermassa-tijdens-intensieve-hartrevalidatie/","title":"GLP-1-agonisten kosten geen spiermassa tijdens intensieve hartrevalidatie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide","vrouwen"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag279","source_url":"https://doi.org/10.1093/eurjpc/zwag279","authors":["Ian Jennings","Kristine Ly","Mariam Marooki","Marissa Dzotsi","Gavin McLaren","Raphael E Cuomo","Shady Abohashem","Pam R Taub"],"significance":6,"published":"2026-06-09","source_date":"2026-05-21","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"Retrospective cohort of 468 patients enrolled in a structured Pritikin intensive cardiac rehabilitation program (UC San Diego, 2017-2024), 67 of whom were taking GLP-1 receptor agonists for a median of 231 days. Body composition was assessed by bioelectrical impedance at baseline and program completion. GLP-1 RA users had higher baseline BMI and body fat but similar skeletal muscle mass (SMM). After adjustment for age, sex, BMI, diabetes, and fitness, there was no significant difference in percent change in SMM (β 0.62%; 95% CI -0.62 to 1.86; p=0.33) or fat mass (p=0.20) between users and non-users. Both groups improved METs significantly. The findings counter — in this setting — the concern that GLP-1 therapy drives clinically relevant sarcopenia and support combining it with structured exercise.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T13:31:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04bfe2b30f23","type":"article","url":"https://hartvaat.nl/2026/05/21/1-op-10-patienten-heroptname-binnen-30-dagen-na-tavi-sterfterisico-na-1-jaar-ver/","title":"1 op 10 patiënten heroptname binnen 30 dagen na TAVI — sterfterisico na 1 jaar verdrievoudigd","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"Open heart","doi":"10.1136/openhrt-2026-004059","source_url":"https://doi.org/10.1136/openhrt-2026-004059","authors":["Polyxeni Alexiou","Federico Moccetti","Indra Bat-Ochir","Lorena Niederberger","Stephanie Brunner","Urs Jeker","Matthias Paul","Florim Cuculi","Mathias Wolfrum","Stefan Toggweiler"],"significance":7,"published":"2026-06-09","source_date":"2026-05-21","image":"https://hartvaat.nl/global/img/3b29446e6e22.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Retrospective analysis of 1,347 consecutive TAVI patients (43.8% women, mean age 81 years; 2012-2025). 9.7% (n=131) were readmitted within 30 days, most commonly for infection (22.9%), heart failure (19.8%) and bradycardia (9.9%). Independent predictors of infection readmission: chronic HF (OR 2.60), COPD (OR 3.18) and contrast volume (OR 1.25 per 25 mL). HF readmission was predicted by chronic HF (OR 3.82), paravalvular leak ≥mild (OR 5.05) and reduced post-procedure LVEF (OR 3.85). Discharge conduction abnormalities predicted bradycardia readmission (OR 4.65). Early discharge (≤2 days) did not increase readmission risk. After adjustment, 1-year mortality was three times higher with early readmission (HR 3.03; 95% CI 1.90-4.86). Modifiable risk factors include contrast volume, paravalvular leak, and discharge conduction abnormalities.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29a6bcd6f912","type":"article","url":"https://hartvaat.nl/2026/05/21/melatonine-en-cardiovasculair-risico-nhanes-nuanceert-recent-hartfalen-signaal-v/","title":"Melatonine en cardiovasculair risico: NHANES nuanceert recent hartfalen-signaal van AHA 2025","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","aperitif-trial","biomarkers-cardiovasculair","emperor-trials","farmaco-economie","menopauze","myocardinfarct","nt-probnp","slaapapneu","vrouwen"],"journal":"Open heart","doi":"10.1136/openhrt-2026-004108","source_url":"https://doi.org/10.1136/openhrt-2026-004108","authors":["Baryalay Khan","Bruno Bezerra Lima"],"significance":5,"published":"2026-06-09","source_date":"2026-05-21","image":"https://hartvaat.nl/global/img/e721b9c72579.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"Short analysis responding to a large electronic-health-record study (presented at AHA Scientific Sessions 2025) that reported a heart failure safety signal with long-term melatonin use in adults with insomnia. The authors emphasise that observational associations between melatonin and cardiovascular outcomes are particularly vulnerable to confounding-by-indication, reverse causality and exposure misclassification — melatonin use often reflects insomnia severity, depression/anxiety, and healthcare utilisation. In a nationally representative NHANES cohort (1999-2018), recent melatonin use was not significantly associated with cardiovascular disease or heart failure after adjustment. The data do not support strong claims of cardiovascular benefit or harm. Clinical guidance: document over-the-counter use, counsel pragmatically, and prioritise evaluation and treatment of underlying sleep disorders.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2cf348a06e3b","type":"article","url":"https://hartvaat.nl/2026/05/21/eplerenon-halveert-recidief-ventriculaire-tachycardie-versus-spironolacton-bij-h/","title":"Eplerenon halveert recidief ventriculaire tachycardie versus spironolacton bij hartfalen","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","aperitif-trial","carvedilol","emperor-trials","eplerenon","mra-aldosteronantagonisten","pathfinder-trial","rechterventrikelfalen","sacubitril-valsartan","step-hfpef","supraventriculaire-tachycardie","ventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"Open heart","doi":"10.1136/openhrt-2025-003858","source_url":"https://doi.org/10.1136/openhrt-2025-003858","authors":["Imre Szakál","Ferenc Komlósi","Patrik Tóth","Bence Arnóth","Gyula Bohus","Péter Vámosi","Nándor Szegedi","Zoltán Salló","István Osztheimer","Péter Perge","Gábor Orbán","Attila Kardos","Béla Merkely","László Gellér","Klaudia Vivien Nagy"],"significance":6,"published":"2026-06-08","source_date":"2026-05-21","image":"https://hartvaat.nl/global/img/0e25c2fc9e34.webp","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/ritmestoornissen/ventriculaire-tachycardie/"],"congress":"","summary_en":"Retrospective analysis of heart failure patients with LVEF <50% hospitalised for sustained monomorphic ventricular tachycardia (VT) and receiving a mineralocorticoid receptor antagonist (MRA) at discharge. Of 292 eligible patients, 202 were matched via propensity scoring on 13 variables (median LVEF 30%, 87% male, median follow-up 32 months). All-cause mortality did not differ between eplerenone and spironolactone (HR 0.98). However, eplerenone was associated with significantly fewer VT recurrences (HR 0.42; 95% CI 0.26-0.66; Fine-Gray aHR 0.36; p<0.001). The finding favours eplerenone in HF patients with a history of monomorphic VT, albeit based on observational data.","created":"2026-07-03T10:33:01Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e43a2fb5ceb","type":"article","url":"https://hartvaat.nl/2026/05/21/bij-coronaire-vasospasmen-zonder-significante-stenose-voorspelt-verhoogd-lp-a-ge/","title":"Bij coronaire vasospasmen zonder significante stenose voorspelt verhoogd Lp(a) geen MACE","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","biomarkers-cardiovasculair","ezetimibe","fractional-flow-reserve","obesitas","ouderen","perifeer-vaatlijden","roken","stabiel-coronairlijden"],"journal":"Heart and vessels","doi":"10.1007/s00380-026-02669-0","source_url":"https://doi.org/10.1007/s00380-026-02669-0","authors":["Woo Jin Ahn","Seung-Woon Rha","Byoung Geol Choi","Se Yeon Choi","Jae Kyeong Byun","Youjin Lee","Manda Satria Chesario","Melly Susanti","Wonsang Chu","Jieun Lee","Soohyung Park","Eun Jin Park","Dong Oh Kang","Cheol Ung Choi","Chang Gyu Park","Dong Joo Oh"],"significance":5,"published":"2026-06-08","source_date":"2026-05-21","image":"https://hartvaat.nl/global/img/6e8531206aa4.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Observational study in 1,373 patients with positive intracoronary acetylcholine provocation and non-significant coronary stenosis, stratified into high Lp(a) (≥50 mg/dL) versus low Lp(a) (<50 mg/dL). 10-year MACE, MACCE and MACCE with recurrent angina were compared using inverse probability of treatment weighting and Cox regression. No significant differences emerged in MACE, MACCE or MACCE with angina between Lp(a) strata. A small increase in revascularisations with high Lp(a) (3.3% vs 0.9%) disappeared after adjustment. While Lp(a) remains an established overall cardiovascular risk factor, it adds little prognostic value in vasospastic angina without obstructive coronary disease.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ba6e3871278","type":"article","url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","title":"FIND-AF-biomarker stratificeert prognose bij HFrEF met atriale cardiomyopathie zonder atriumfibrilleren","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","dapa-hf","hfpef","nt-probnp","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag144","source_url":"https://doi.org/10.1093/eschf/xvag144","authors":["Jung Chi Hsu","Umbreen Nadeem","Khalid Kazi","Chris Hayward","Lan Mu","Wing Tak Wong","Gregory Y H Lip","Mark C Petrie","Dipak Kotecha","A John Camm","Jianhua Wu","Gary Tse","Chris P Gale","Ramesh Nadarajah"],"significance":6,"published":"2026-06-08","source_date":"2026-05-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"","summary_en":"Exploratory retrospective study in 164 patients from the ECG-HF registry (2010-2016) with heart failure with reduced ejection fraction (HFrEF) and atrial cardiomyopathy, but without atrial fibrillation at baseline. Atrial cardiomyopathy was defined per the HFA/ESC 2025 consensus on ECG and echocardiographic parameters. Stratification by the FIND-AF score showed that the composite endpoint (incident AF, ischaemic stroke, all-cause mortality) occurred in 71.9% of high-risk vs 50.8% of low-risk patients (adjusted OR 2.70; p=0.024). FIND-AF outperformed CHA2DS2-VASc for both the composite (AUC 0.74 vs 0.64) and ischaemic stroke (AUC 0.70 vs 0.58). External validation and prospective study are needed.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa52dfe455fd","type":"article","url":"https://hartvaat.nl/2026/05/22/chirurgisch-unroofing-van-myocardiale-brug-verbetert-angina-klachten-langdurig-m/","title":"Chirurgisch unroofing van myocardiale brug verbetert angina-klachten langdurig (mediaan 5 jaar follow-up)","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","bloeddrukbehandeling","coronaire-bypass","fractional-flow-reserve","hartkatheterisatie","myocardinfarct","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag373","source_url":"https://doi.org/10.1093/eurheartj/ehag373","authors":["Vedant S Pargaonkar","Ingela Schnittger","Christopher C Y Wong","Hanjay Wang","Yasuhiro Honda","Peter Fitzgerald","Michael P Fischbein","Robert Scott Mitchell","Jack H Boyd","Jennifer A Tremmel"],"significance":7,"published":"2026-06-07","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"Prospective study of 218 adults with angina in non-obstructive coronary arteries and a functionally significant LAD myocardial bridge (dobutamine-stress diastolic FFR and/or RFR ≤ 0.76) who underwent surgical unroofing. Median follow-up 5 years. Patients reported significant and clinically meaningful improvement across all Seattle Angina Questionnaire domains: physical limitation, anginal stability and frequency, treatment satisfaction, and quality of life. In a propensity-matched comparison with 65 non-surgical patients, improvement in physical limitation (27.8 vs 11.4; p=0.004) and anginal frequency (30 vs 20; p=0.01) was significantly greater after surgery. For severe angina refractory to maximal medical therapy with a confirmed functionally significant MB, surgical unroofing offers a durable long-term option.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9cd8b55e4335","type":"article","url":"https://hartvaat.nl/2026/05/22/autosomaal-dominante-alport-syndroom-meest-voorkomende-monogene-nierziekte-1-van/","title":"Autosomaal dominante Alport-syndroom: meest voorkomende monogene nierziekte (1% van de bevolking)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["huisarts","internist"],"tags":[],"journal":"Journal of the American Society of Nephrology : JASN","doi":"10.1681/ASN.0000001158","source_url":"https://doi.org/10.1681/ASN.0000001158","authors":["Judy Savige","Mary Huang"],"significance":6,"published":"2026-06-07","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ischemische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"JASN review of autosomal dominant (AD) Alport syndrome, caused by heterozygous pathogenic variants in COL4A3 or COL4A4. With ~1% population prevalence, it is the most common monogenic kidney disease — characterised by persistent glomerular haematuria, thinned glomerular basement membrane, and family history of kidney disease, without the hearing and ocular abnormalities of X-linked Alport. Penetrance is incomplete (only two-thirds of variant carriers have haematuria). Missense mutations with glycine substitutions confer proteinuria more often. Genetic testing distinguishes AD from X-linked Alport (the latter has higher kidney-failure risk). Recommended: monitoring of albuminuria and treatment with ACE inhibitors and, if needed, SGLT2 inhibitors from onset; genetic testing for all first-degree relatives regardless of haematuria status.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e38b239d8df5","type":"article","url":"https://hartvaat.nl/2026/05/22/orale-pcsk9-remmers-meta-analyse-bevestigt-krachtige-ldl-daling/","title":"Orale PCSK9-remmers: meta-analyse bevestigt krachtige LDL-daling","title_en":"Efficacy and Safety of Oral PCSK9 Inhibitors: Insights from a Meta-analysis of RCTs.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","dyslipidemie","eas-2026","enlicitide","ezetimibe","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","rosuvastatine","statines"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag273","source_url":"https://doi.org/10.1093/eurjpc/zwag273","authors":["Elena Olmastroni","Sining Xie","Federica Galimberti","Alberico L Catapano","Manuela Casula"],"significance":7,"published":"2026-06-07","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"eas-2026","summary_en":"A meta-analysis of five RCTs of three oral PCSK9 inhibitors (enlicitide, NNC0385-0434 and laroprovstat; 3,295 participants) shows a pooled LDL-C reduction of 59% versus placebo. ApoB (−50%), non-HDL cholesterol (−55%) and Lp(a) (−23%) also fell significantly, with no increase in short-term serious adverse events. The efficacy of oral PCSK9 inhibition is thus comparable to that of the injectable agents — a potential breakthrough for adherence and access.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f3be87e3f0a4","type":"article","url":"https://hartvaat.nl/2026/05/22/epicardiaal-vetweefsel-voorspelt-aritmieen-en-hartfalen-events-bij-genotype-posi/","title":"Epicardiaal vetweefsel voorspelt aritmieën en hartfalen-events bij genotype-positieve HCM","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","troponine","vrouwen"],"journal":"European journal of heart failure","doi":"10.1093/ejhf/xuag179","source_url":"https://doi.org/10.1093/ejhf/xuag179","authors":["Belend Mahmoud","Anne J Koppelaar","Michelle Michels","Moniek G P J Cox","Stephan A C Schoonvelde","Judith M A Verhagen","Ricardo P J Budde","Rudolf A de Boer","B Daan Westenbrink","Alexander Hirsch"],"significance":6,"published":"2026-06-06","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Retrospective cohort of 282 patients with genotype-positive hypertrophic cardiomyopathy, in whom epicardial adipose tissue (EAT) was quantified by cardiac MRI and patients split into high and low EAT groups by the median. High EAT was associated with greater maximal wall thickness (25.0 vs 20.8 mm), more extensive LGE (6.1% vs 1.0%), and more frequent LVOT obstruction (42.6% vs 15.6%). Over a median of 62 months, EAT was independently associated with malignant ventricular arrhythmias (HR 1.04 per mL) and HF events (HR 1.05; both p<0.001). Discriminative ability (C-statistic 0.79) exceeded even the HCM SCD risk score for arrhythmias (p=0.011). EAT warrants consideration as a novel risk-stratification parameter in HCM.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df81f21d9d81","type":"article","url":"https://hartvaat.nl/2026/05/22/m-teer-werkt-over-het-volledige-lvef-spectrum-vergroot-linkeratrium-volume-voors/","title":"M-TEER werkt over het volledige LVEF-spectrum; vergroot linkeratrium-volume voorspelt slechtere uitkomst","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag149","source_url":"https://doi.org/10.1093/eschf/xvag149","authors":["Louise Rouleau","Marina Petersen Saadi","Adrien Al Wazzan","Prayuth Rasmeehirun","Guillaume L'official","Vincent Auffret","Guillaume Leurent","Emmanuel Oger","Erwan Donal"],"significance":5,"published":"2026-06-06","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"Retrospective analysis of 93 consecutive patients with symptomatic secondary mitral regurgitation who underwent mitral transcatheter edge-to-edge repair (M-TEER) between 2018 and 2022. Composite clinical improvement (survival without HF hospitalisation, NYHA I-II, KCCQ >60) at 36 months was similar in reduced and preserved LVEF (51.8% vs 62.5%; p=0.32). Mortality was lower with preserved LVEF (9.4% vs 29.6%). Enlarged left atrial volume index (LAVI ≥60 mL/m²) was associated with higher mortality (29.4% vs 11.8%) and remained significant after adjustment. M-TEER thus delivers meaningful benefit across the LVEF spectrum, with left atrial enlargement marking advanced atrial disease and potentially supporting earlier intervention.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc9aa44567b1","type":"article","url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","title":"LGE-granulariteit op CMR voorspelt sterfte bij eindstadium hypertrofische cardiomyopathie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie"],"journal":"Circulation. Cardiovascular imaging","doi":"10.1161/CIRCIMAGING.125.019408","source_url":"https://doi.org/10.1161/CIRCIMAGING.125.019408","authors":["Julien Hudelo","Jérôme Garot","Solenn Toupin","Suzanne Duhamel","Francesca Sanguineti","Philippe Garot","Thomas Hovasse","Stéphane Champagne","Thierry Unterseeh","Mariama Akodad","Antoinette Neylon","Trecy Gonçalves","Alexandre Unger","Jeremy Florence","Jean-Guillaume Dillinger","Christophe Tribouilloy","Alexis Hermida","Valérie Bousson","Théo Pezel","Yohann Bohbot"],"significance":7,"published":"2026-06-06","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ischemische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"Retrospective multicenter cohort of 691 patients with end-stage HCM (LVEF <50%) from three French tertiary centres, followed for a median of 9 years. After 33% mortality (n=226), the LGE granularity model — combining extent (unique vs multiple), location (septal vs other) and pattern (subepicardial vs midwall) — provided independent prognostic value. Late gadolinium enhancement was associated with mortality after adjustment (HR 1.52). Each component independently predicted mortality: LGE extent (HR 2.85), septal location (HR 1.73), and midwall pattern (HR 4.15). The LGE granularity model refines risk stratification in advanced HCM.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"413a19ea1ec0","type":"article","url":"https://hartvaat.nl/2026/05/22/brede-inzet-van-oraal-semaglutide-in-de-vs-zou-jaarlijks-tot-60-000-cardiovascul/","title":"Brede inzet van oraal semaglutide in de VS zou jaarlijks tot 60.000 cardiovasculaire events kunnen voorkomen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-2","flow-trial","obesitas","ouderen","perifeer-vaatlijden","roken","select-trial","slaapapneu","soul-trial","stride-trial","vrouwen"],"journal":"Cardiovascular diabetology. Endocrinology reports","doi":"10.1186/s40842-026-00299-z","source_url":"https://doi.org/10.1186/s40842-026-00299-z","authors":["Mustafa Al-Jarshawi","Andrew Cole","Rodrigo Bagur","Hao-Yu Wang","Cheng Han Ng","Dahai Yu","Nicholas W S Chew","Mamas A Mamas"],"significance":6,"published":"2026-06-05","source_date":"2026-05-22","image":"https://hartvaat.nl/global/img/7da6a9dfc298.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/"],"congress":"","summary_en":"Population-level modeling study applying SOUL trial eligibility criteria to NHANES data of US adults with type 2 diabetes. An estimated 6.1 million Americans met eligibility for oral semaglutide. Without treatment, 847,598 major adverse cardiovascular events (MACE) were projected over 4.5 years; with treatment, 728,934 — a potential prevention of 118,664 events (14% relative reduction; NNT 55). At 50% uptake and 15.5% discontinuation (as in SOUL), this translates to roughly 59,000 MACE prevented, including 14,000 CV deaths, 41,000 non-fatal MIs, and 12,000 non-fatal strokes. The findings support oral semaglutide as a scalable cardiometabolic intervention and argue for system-level strategies to enhance access and uptake.","created":"2026-07-03T10:33:00Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c00c10a180ca","type":"article","url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","title":"PARADISE-cohort: hartfalen en COPD samen verhogen de langetermijnmortaliteit, met name HF","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag136","source_url":"https://doi.org/10.1093/eschf/xvag136","authors":["Guillaume Baudry","Lucie Ferreira","Luca Monzo","Claire Lacomblez","Emmanuel Bresso","Kevin Duarte","Charlène Duchanois","Déborah Jaeger","Tahar Chouihed","Nicolas Girerd"],"significance":6,"published":"2026-06-05","source_date":"2026-05-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"Monocentric observational study (PARADISE cohort) of 5,131 patients admitted to the emergency department for acute dyspnea between 2010 and 2019. 3,543 had a primary diagnosis of heart failure, 1,588 of COPD; in both groups ~20% had the other condition. Among primary HF patients, concomitant COPD was paradoxically associated with lower in-hospital mortality (8.5% vs 11.7%; aOR 0.74) but modestly higher long-term mortality (aHR 1.22). Among primary COPD patients, concomitant HF was not significantly associated with in-hospital mortality after adjustment but markedly increased long-term mortality (68.7% vs 48.7%; aHR 1.48). Systematic identification and optimised management of both conditions in the ED are crucial for this high-risk population.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"53a3b2465271","type":"article","url":"https://hartvaat.nl/2026/05/24/lp-a-japan-verhoogd-lp-a-blijft-risicovol-ondanks-ldl-onder-55-mg-dl/","title":"Lp(a)-JAPAN: verhoogd Lp(a) blijft risicovol ondanks LDL onder 55 mg/dl","title_en":"Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended LDL-C goals.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["anemie-ckd","diabetes-type-2","dyslipidemie","eas-2026","ezetimibe","ldl-cholesterol","lipide-aferese","lipoproteïne-a","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag446","source_url":"https://doi.org/10.1093/eurheartj/ehag446","authors":["Yu Kataoka","Kausik K Ray","Stephen J Nicholls","Aya Katasako-Yabumoto","Satoshi Kitahara","Hayato Hosoda","Kentarou Mitsui","Kota Murai","Kenichiro Sawada","Hideo Matama","Takamasa Iwai","Satoshi Honda","Masashi Fujino","Shuichi Yoneda","Kazuhiro Nakao","Kensuke Takagi","Yasuhide Asaumi","Teruo Noguchi"],"significance":7,"published":"2026-06-05","source_date":"2026-05-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"eas-2026","summary_en":"This observational study in 1,581 Japanese patients with coronary artery disease after PCI shows that elevated Lp(a) remains associated with more cardiovascular events even when LDL-C is well controlled (<55 mg/dL). At Lp(a) ≥50 mg/dL the standardised 5-year MACE risk was nearly seven times higher than at Lp(a) <30 mg/dL. The risk threshold sat around 28 mg/dL — lower than values used in Western populations. Intensive LDL lowering thus partly attenuates, but does not eliminate, Lp(a)-related risk.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c14e12923bbe","type":"article","url":"https://hartvaat.nl/2026/05/25/rca-en-hoofdstamstenosen-geven-hoogste-kans-op-plotse-hartdood-revascularisatie-/","title":"RCA- en hoofdstamstenosen geven hoogste kans op plotse hartdood — revascularisatie-strategie moduleert risico","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["ventrikelfibrilleren"],"journal":"JACC. Cardiovascular interventions","doi":"10.1016/j.jcin.2026.03.023","source_url":"https://doi.org/10.1016/j.jcin.2026.03.023","authors":["Jani Rankinen","Jussi Hernesniemi","Mikko Uimonen","Juho Tynkkynen"],"significance":7,"published":"2026-06-04","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Retrospective analysis of a Finnish registry (Tampere Heart Hospital): 22,495 patients who underwent coronary angiography between 2007 and 2018, followed to end-2022. 1,048 sudden cardiac death events were observed (median follow-up 8.1 years). Independent risk associations: right coronary artery (RCA) stenosis (HR 1.53; 95% CI 1.31-1.80) — the strongest — followed by circumflex stenosis (HR 1.34). LAD stenosis predicted sudden death only in acute coronary syndromes (HR 1.37). Effect varied by revascularization strategy: RCA stenosis weighed heaviest in PCI-treated patients; no lesion site conferred excess risk after CABG; and left main stenosis was riskiest in conservatively managed patients (HR 1.53). Anatomical location is therefore a relevant prognosticator for sudden cardiac death, modulated by the chosen treatment strategy.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7390ec49774","type":"article","url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","title":"1 op 5 oudere patiënten heeft hartfalen-opname binnen jaar na TAVR — 1-jaarsmortaliteit 44% versus 4%","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.048751","source_url":"https://doi.org/10.1161/JAHA.125.048751","authors":["Harun Kundi","Martin Leon","David J Cohen","Alexandra Popma","Yukari Kobayashi","Bjorn Redfors","Lauren S Ranard","Maria C Alu","Julia B Thompson","Jennifer von Stein","Philipp von Stein","Guido Ascione","Afek Kodesh","Juan F Granada","Jeffrey J Popma"],"significance":7,"published":"2026-06-04","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Retrospective cohort of US Medicare data: 233,309 patients ≥65 years who underwent TAVR between 2017 and 2021. In 45,502 (19.5%) a heart failure hospitalisation occurred between day 31 and day 365 post-procedure. These patients had markedly higher 1-year (43.8% vs 3.6%) and 5-year mortality (80.6% vs 41.0%). After adjustment the association remained strong (aHR 3.17; 95% CI 3.11-3.22). Strongest predictors were advanced cardiac damage stage (aSHR 1.95) and high-risk frailty (aSHR 1.65), with graded risk across stages. Early post-TAVR HF hospitalisation is a sentinel event and supports systematic frailty and cardiac damage staging before and after the procedure.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bec9b090e3c8","type":"article","url":"https://hartvaat.nl/2026/05/25/semaglutide-verlaagt-mortaliteit-cv-events-en-nierschade-in-alle-stadia-van-ckm-/","title":"Semaglutide verlaagt mortaliteit, CV-events én nierschade in alle stadia van CKM-syndroom: meta-analyse van 39.204 patiënten","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["flow-trial","select-trial","soul-trial","stride-trial"],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03215-y","source_url":"https://doi.org/10.1186/s12933-026-03215-y","authors":["Federica Marzano","Stefania Paolillo","Paola Gargiulo","Ciro Cotticelli","Mariafrancesca Di Santo","Ermanno Nardi","Giuseppe Maria Abbellito","Laura Liccardi","Fabrizio Perrone Filardi","Dario Bruzzese","Pasquale Perrone Filardi"],"significance":8,"published":"2026-06-04","source_date":"2026-05-25","image":"https://hartvaat.nl/global/img/f7f917f50a2d.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"Systematic review and meta-analysis of 8 randomised trials (39,204 patients) on semaglutide versus placebo across the full cardio-kidney-metabolic (CKM) spectrum. Semaglutide significantly reduced all-cause mortality (HR 0.84; 95% CI 0.77-0.92), cardiovascular mortality (HR 0.83), MACE (HR 0.82), non-fatal myocardial infarction (HR 0.75), worsening heart failure (HR 0.84) and adverse kidney outcomes (HR 0.83). No significant effect on non-fatal stroke. The breadth of CKM benefit — kidney, heart and mortality together — distinguishes semaglutide from many other classes and aligns with the recognition of CKM as an integrated disease entity.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leefh-opsporing-2026","type":"article","url":"https://hartvaat.nl/2026/06/04/fh-opsporing-in-nederland-zet-stabiele-lijn-voort-in-2026/","title":"FH-opsporing in Nederland zet stabiele lijn voort in 2026","title_en":"FH cascade screening in the Netherlands holds its steady course in 2026","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"Stichting LEEFH","doi":"https://www.leefh.nl/","source_url":"https://doi.org/https://www.leefh.nl/","authors":[],"significance":6,"published":"2026-06-04","source_date":"2026-06-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/cascadescreening-fh/","https://hartvaat.nl/kennis/preventie/screeningsprogramma-hart-en-vaatziekten/"],"congress":"","summary_en":"Stichting LEEFH — the Dutch National Expertise Centre for Genetic Research on Familial Cardiovascular Diseases — coordinates the Netherlands' cascade screening programme for familial hypercholesterolaemia (FH). The latest figures show detection holding the stable trajectory of recent years: roughly 806 new detections are projected for 2026, in line with the target of 800. Most arise from family screening around an index patient (projected ~507), supplemented by FH diagnoses from complex DNA testing (~299). The 2025 year-end total is projected at around 873 — above the 857 recorded in 2024 — with final figures due at the end of June as informed-consent forms are still arriving. Cascade screening remains one of the most effective ways to identify first-degree relatives of an FH patient early and prevent premature cardiovascular disease.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c9acf07cf07","type":"article","url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","title":"EAS FHSC: wereldwijd onderzoek toont grote variatie in genetische FH-diagnostiek — pleidooi voor standaardisatie","title_en":"Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag198","source_url":"https://doi.org/10.1093/eurjpc/zwag198","authors":["Joana Rita Chora","Irene Karungi","Amany Elshorbagy","Christophe A T Stevens","Antonio J Vallejo-Vaz","Kanika I Dharmayat","Marianne Abifadel","Carlos A Aguilar-Salinas","Khalid F Alhabib","Wael Almahmeed","Fahad Alnouri","Rodrigo Alonso","Khalid Al-Rasadi","Ahmad Al-Sarraf","Marcello Arca","Engy A Ashaat","Tester F Ashavaid","Maurizio Averna","Maciej Banach","Marianne Becker","Christoph J Binder","Liam R Brunham","Alberico L Catapano","Pablo Corral","Olivier S Descamps","Euridiki Drogari","Ronen Durst","Marat Ezhov","Urh Groselj","Mariko Harada-Shiba","Kirsten B Holven","G Kees Hovingh","Weerapan Khovidhunkit","Katarina Lalic","Gustavs Latkovskis","Ulrich Laufs","Evangelos Liberopoulos","Jie Lin","Winfried März","Pedro Mata","Anne Thushara Matthias","André R Miserez","Olena Mitchenko","Hapizah Mohd Nawawi","Børge G Nordestgaard","Andrie G Panayiotou","György Paragh","Zaneta Petrulioniene","Arman Postadzhiyan","Ximena Reyes","Fouzia Sadiq","Amirhossein Sahebkar","Raul D Santos","J P S Sawhney","Heribert Schunkert","Swarup A V Shah","Aleksandr B Shek","Handrean Soran","Ta-Chen Su","Tavintharan Subramaniam","Myra Tilney","Brian Tomlinson","Thanh Huong Truong","Anne Tybjærg-Hansen","Margus Viigimaa","Branislav Vohnout","Gerald F Watts","Shizuya Yamashita","Kausik K Ray","Frederick J Raal","Steve E Humphries","Tomas Freiberger","Mafalda Bourbon"],"significance":7,"published":"2026-06-04","source_date":"2026-05-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"International survey among national lead-investigators of the European Atherosclerosis Society FH-Studies Collaboration from 55 of 68 countries (81% response; Africa 2, Americas 6, Asia 20, Europe 26, Oceania 1). Referral criteria were most often the Dutch Lipid Clinic Network score (adults 72%, children 57%); Simon Broome and MEDPED were used only in high-income countries. For index patients, next-generation sequencing predominated (62%); for relatives, Sanger sequencing (71%). Copy-number variants were assessed by 65% of centres, mostly via NGS platforms. Nearly all centres screened LDLR (100%), APOB (97%), and PCSK9 (95%); pathogenicity was interpreted largely per ACMG guidelines. The authors call for global standardisation: at minimum the three FH genes, ideally also the five associated/phenocopy genes.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36c02df38dfc","type":"article","url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","title":"EAS-consensus: wereldwijde harmonisatie van lipidenklinieken","title_en":"Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","lipidenverlaging","niet-statine-therapie","plaquekarakterisatie","statines"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00123-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00123-1/fulltext","authors":["Christian Bork","Børge G. Nordestgaard","Berit Storgaard Hedegaard","Michal Vrablik","Elsie Evans","Tomas Freiberger","Zlatko Fras","David Nanchen","Fouzia Sadiq","Kausik K. Ray","Kirsten Holven","Jeanine E. Roeters van Lennep","Ulrich Laufs","Marianne Benn","Shoaib Afzal","Evangelos Liberopoulos","Katariina Öörni","Meral Kayikcioglu","Mutaz Al-Khnifsawi","Khalid Al-Rasadi","Lambert Tetteh Appiah","Makhabbat Bekbossynova","Marianne Becker","Christoph J. Binder","Máxima Méndez Castillo","Mariia Cherska","Krzysztof Chlebus","Pablo Corral","Ronen Durst","Marat Ezhov","Dan Gaita","Federica Galimberti","Daniel Gaudet","Tea Gamezardashvili","Angel Alberto García-Peña","Urh Groselj","Mariko Harada-Shiba","Sergio Emanuel Kaiser","Gustavs Latkovskis","Vincent Maher","Winfried März","Lluís Masana","Anne Thushara Matthias","Ann Mertens","Olena Mitchenko","Adam J. Nelson","Stephen J. Nicholls","Richard C. O'Brien","Belma Pojskic","György Paragh","Zaneta Petrulioniene","Arman Postadzhiyan","Frederick J. Raal","Ashraf Reda","Ximena Reyes","Željko Reiner","Stefano Romeo","Carlos A. Aguilar Salinas","Erik S. Stroes","Phivos Symeonides","Aleksandr B. Shek","Alberto Mello e Silva","Tigist Mekonnen","Myra Tilney","Lale Tokgozoglu","Alexandros D. Tselepis","Margus Viigimaa","Branislav Vohnout","Luz Clemencia Zarate-Correa","Philippe Moulin","Writing group","EAS Lipid Clinic Network Committee","EAS Executive Committee","Other national leads for the EAS Lipid Clinic Network"],"significance":8,"published":"2026-06-04","source_date":"2026-05-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Through its Lipid Clinic Network, the European Atherosclerosis Society (EAS) presents the first worldwide consensus on lipid clinics, drawing on data from 55 countries and more than 500 clinics. Lipid clinics deliver specialised diagnostics, lifestyle management and evidence-based lipid-lowering therapy to high-risk patients — including those with familial hypercholesterolaemia, markedly elevated lipoprotein(a), statin intolerance, refractory LDL cholesterol, severe hypertriglyceridaemia and other rare or complex lipid disorders — to prevent atherosclerotic cardiovascular disease and acute pancreatitis. The statement defines lipid clinics across four tiers and offers practical guidance on staffing, referral criteria, Lp(a) and genetic testing, quality monitoring and funding, highlighting the major differences between countries by income level. The authors — including Jeanine Roeters van Lennep (Erasmus MC) — call for national and international harmonisation so that patients everywhere receive equitable, high-quality lipid care.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"67f367049d91","type":"article","url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","title":"EXPLORER-CN week 78: langetermijneffect en veiligheid van mavacamten bij Chinese patiënten met obstructieve HCM","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["hypertrofische-cardiomyopathie"],"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.125.046251","source_url":"https://doi.org/10.1161/JAHA.125.046251","authors":["Zhuang Tian","Xiaoyan Li","Liwen Li","Qing Zhang","Jian'an Wang","Yunqi Shi","Daoquan Peng","Wei Ma","Ping Yang","Xiang Cheng","Wei Jin","Fang Wang","Yimeng Xie","Beth Pan","Victoria Florea","Shuyang Zhang"],"significance":7,"published":"2026-06-03","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"Open-label long-term extension of EXPLORER-CN in 79 Chinese patients with obstructive hypertrophic cardiomyopathy who completed the 30-week placebo-controlled period. Patients on mavacamten continued their dose (n=54); former placebo patients started 2.5 mg daily (n=25). Through week 78, previously achieved reductions in Valsalva and resting LVOT gradients were maintained (mean change -73.0 mm Hg and -56.3 mm Hg). NYHA class, Kansas City Cardiomyopathy Questionnaire score and cardiac biomarkers all showed numerical improvements. Mavacamten was well tolerated; LVEF <50% was rare. The Chinese data confirm long-term durability and safety of mavacamten in obstructive HCM.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44ca42c0b2a0","type":"article","url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","title":"VESALIUS-CV: Lp(a) voorspelt risico, evolocumab werkt ongeacht uitgangswaarde","title_en":"Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["eas-2026"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.080999","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.080999","authors":["Victorien Monguillon","Nicholas A Marston","Erin A Bohula","Jeong-Gun Park","Julia F Kuder","Sabina A Murphy","Gaetano M De Ferrari","Lawrence A Leiter","Jose C Nicolau","Christoph Ebenbichler","Peter Sinnaeve","Assen Goudev","Andrzej Budaj","Oleg Averkov","Lale Tokgozoglu","Ron Blankstein","Dragos Vinereanu","Robert P Giugliano","Marc S Sabatine","Michelle L O'Donoghue"],"significance":8,"published":"2026-06-03","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"eas-2026","summary_en":"In a prespecified analysis of the VESALIUS-CV trial (7,557 patients with atherosclerosis or high-risk diabetes, without prior MI or stroke), higher Lp(a) was associated with more major coronary events (HR 1.15 per 100 nmol/L), particularly myocardial infarction, but not ischaemic stroke. Evolocumab reduced relative risk to a similar degree regardless of baseline Lp(a), with a numerically greater absolute risk reduction in patients with elevated Lp(a) (NNT 28 vs 40 over five years). The findings support early PCSK9 inhibition, especially in patients with elevated Lp(a).","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"614c7e410d4f","type":"article","url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","title":"EAS-consensus: familiaire hypercholesterolemie bij kinderen en adolescenten","title_en":"Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["eas-2026","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag382","source_url":"https://doi.org/10.1093/eurheartj/ehag382","authors":["Albert Wiegman","Mafalda Bourbon","Tomas Freiberger","Samuel S Gidding","Susanne Greber-Platzer","Urh Groselj","Kirsten B Holven","Lisa C Hudgins","Steve E Humphries","Barbara A Hutten","Daiana Ibarretxe","Cristina Pederiva","Noel Peretti","Frederick J Raal","Uma Ramaswami","Veronika Sanin","Raul D Santos","Elisabeth Steinhagen-Thiessen","Gerald F Watts","Rosie Perkins","Marianne Benn","Christoph J Binder","Stefano Romeo","Jeanine E Roeters van Lennep"],"significance":9,"published":"2026-06-03","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"eas-2026","summary_en":"A new consensus statement from the European Atherosclerosis Society — led by Dutch authors (Wiegman, Amsterdam UMC; Roeters van Lennep, Erasmus MC) — urges every country to establish paediatric screening programmes, since current diagnostic criteria often miss children carrying an FH-causing variant. It presents revised diagnostic criteria and updated LDL-C goals, and stresses that lipid-lowering therapy in heterozygous FH should start before puberty — from age 6 if needed. With treatment algorithms for HeFH and HoFH and guidance on transition to adult care, the EAS aims to curb underdiagnosis and undertreatment.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"61b0a5580f6e","type":"article","url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","title":"BETAMI-DANBLOCK is representatief: bètablokker-effect ook geldig in echte Noorse infarct-populatie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag348","source_url":"https://doi.org/10.1093/eurheartj/ehag348","authors":["Anna Meta Dyrvig Kristensen","Jarle Jortveit","Therese Holmager","Dan Atar","Michael Hecht Olsen","Arnhild Bakken","Terje Steigen","Henrik Schirmer","Thor Edvardsen","Alf Inge Larsen","Jan Erik Otterstad","Eva Prescott","John Munkhaugen","Sigrun Halvorsen"],"significance":6,"published":"2026-06-02","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Comparison of participants in the BETAMI (n=2,867) and DANBLOCK (n=2,707) trials with the Norwegian nationwide myocardial infarction registry (NORMI, n=20,804) — all patients with recent MI, LVEF ≥40% and no heart failure. NORMI patients were older on average (66 vs 63 years) and had more diabetes, prior coronary disease and LVEF 40-49%. Absolute 3-year risks were higher in NORMI (mortality/MI 12.0%) than in the trials (7.7-7.8%). A transportability analysis (reweighting the trial population to NORMI characteristics) showed that the beta-blocker treatment effect remained consistent. BETAMI-DANBLOCK findings therefore generalise to the broader Norwegian — and by extension European — post-MI population.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3aa1e91b1037","type":"article","url":"https://hartvaat.nl/2026/05/25/longembolie-epidemiologie-stijgende-last-bij-vergrijzing-preventiestrategieen-bl/","title":"Longembolie-epidemiologie: stijgende last bij vergrijzing — preventiestrategieën blijven achter","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag388","source_url":"https://doi.org/10.1093/eurheartj/ehag388","authors":["Marco Zuin","Cecilia Becattini","Frederikus A Klok","Behnood Bikdeli","Stefano Barco","Ioannis Farmakis","Roman Chopard","Irene M Lang","Claudio Bilato","Elvira Grandone","Samuel Z Goldhaber","Gregory Piazza"],"significance":6,"published":"2026-06-02","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"EHJ review of acute pulmonary embolism (PE) epidemiology. As ageing populations live longer with chronic diseases associated with venous thromboembolism, PE remains a major public health challenge. Like myocardial infarction and stroke, PE is linked to established cardiovascular risk factors — age, obesity, smoking and chronic inflammatory conditions. Yet population-based primary and secondary prevention strategies remain limited. The authors call for a comprehensive public-health approach that addresses not only acute events and transient risk factors but also community-level risk assessment and long-term prevention, supported by improved clinician education and public awareness.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b80315dba60","type":"article","url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","title":"Obicetrapib verlaagt naast LDL en apoB ook lipoproteïne(a)","title_en":"Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","cetp-remmers","dyslipidemie","eas-2026","ezetimibe","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","obicetrapib","pelacarsen","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag399","source_url":"https://doi.org/10.1093/eurheartj/ehag399","authors":["Stephen J Nicholls","Adam J Nelson","Kausik K Ray","Marc Ditmarsch","Douglas Kling","Andrew Hsieh","Michael Szarek","John J Kastelein","Michael H Davidson"],"significance":8,"published":"2026-06-02","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"eas-2026","summary_en":"In a pooled analysis of trials in 2,356 high-risk patients (heterozygous FH or established ASCVD), the selective CETP inhibitor obicetrapib 10 mg daily lowered LDL-C by 37%, apoB by 21% and Lp(a) by 37% versus placebo at 12 weeks. Notably, the absolute Lp(a) reduction was similar in patients with mildly and with markedly elevated Lp(a). Obicetrapib thus offers an oral option for patients with mildly elevated Lp(a) who are unlikely to qualify for costlier RNA-targeted Lp(a) therapies.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c6aeb7d110d9","type":"article","url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","title":"PAH met renaal-diabetische overlap komt vaak voor en geeft tweemaal zo hoog mortaliteitsrisico","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["anemie-ckd","cardio-renaal-metabool","diabetes-en-hart","fidelio-dkd","figaro-dkd","soul-trial"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-327389","source_url":"https://doi.org/10.1136/heartjnl-2025-327389","authors":["Matteo Toma","Suela Vani","Giulio Savonitto","Francesca Coppi","Andrea Garascia","Alberto Giannoni","Clara Hjalmarsson","Francesco Lo Giudice","Carlo Lombardi","Claudia Raineri","Matteo Rugolotto","Laura Scelsi","Marco Metra","Luke Howard","Gianfranco Sinagra","Italo Porto","Davide Stolfo","Pietro Ameri"],"significance":6,"published":"2026-06-01","source_date":"2026-05-25","image":"https://hartvaat.nl/global/img/737cbe5a1f5d.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"Retrospective international cohort of 555 incident PAH patients (diagnosed 2001-2023). 42% (n=234) had chronic kidney disease and/or diabetes (renal-diabetic, RD): 45 DM only, 135 CKD only, 54 both. RD patients were older, had greater comorbidity burden, worse WHO functional class and higher pulmonary artery wedge pressure. At PAH diagnosis, RD patients were less often treated with endothelin receptor antagonists (61% vs 69%) and more often with single-agent therapy (55% vs 45%). Over 2.5 years of follow-up, the composite of death or PAH hospitalisation was significantly higher in RD (HR 1.45; 95% CI 1.07-1.98), as was all-cause mortality (HR 1.47). PAH with renal-diabetic overlap is common, under-treated and prognostically worse.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"017c7a91636a","type":"article","url":"https://hartvaat.nl/2026/05/25/koreaanse-studie-van-3-7-miljoen-postmenopauzale-vrouwen-hormonale-levensloop-vo/","title":"Koreaanse studie van 3,7 miljoen postmenopauzale vrouwen: hormonale levensloop voorspelt hartfalen-risico","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","menopauze","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag380","source_url":"https://doi.org/10.1093/eurheartj/ehag380","authors":["Log Young Kim","Jin-Sung Yuk","Byung Gyu Kim"],"significance":7,"published":"2026-06-01","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Nationwide Korean cohort of 3,692,157 postmenopausal women without prior heart failure or structural heart disease, followed for a median of 120 months. During follow-up, 48,640 women were hospitalised for heart failure. Prior oral contraceptive use (≥1 year; SHR 0.942) and menopausal hormone therapy (≥5 years; SHR 0.782) were associated with lower HF risk. Later menarche (≥17 years), earlier menopause (40-44 years) and shorter total reproductive period (<30 years) were associated with higher risk (all p<0.001). Among women who developed HF, OC and MHT use also reduced mortality. Conclusion: longer lifetime exposure to endogenous and exogenous oestrogens protects against HF incidence and mortality.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d66be8445375","type":"article","url":"https://hartvaat.nl/2026/05/25/diabetes-en-calcifierende-aortaklepziekte-gedeelde-immunometabole-pathways-en-th/","title":"Diabetes en calcifiërende aortaklepziekte: gedeelde immunometabole pathways en therapeutische kandidaten","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["aortainsufficiëntie","diabetes-en-hart","diabetes-type-1","diabetes-type-2"],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03219-8","source_url":"https://doi.org/10.1186/s12933-026-03219-8","authors":["Zhang Yue","Qiuchen SiTu","Jin-Hui Bian","Hong-Xiang Lu"],"significance":6,"published":"2026-06-01","source_date":"2026-05-25","image":"https://hartvaat.nl/global/img/fb173d9ccf97.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"Review of the immunometabolic mechanisms linking diabetes mellitus to accelerated calcific aortic valve disease (CAVD). Diabetes consistently increases incident aortic stenosis risk (HR 1.3-1.7), calcification burden and disease severity, independent of traditional risk factors. The authors delineate seven overlapping pathways: valvular interstitial cell phenotypic switching driven by hyperglycaemia and insulin resistance, AGE-RAGE signalling, oxidative stress, NLRP3-IL-1β inflammasome activation, endothelial dysfunction, BMP-Runx2-Wnt-Notch osteogenic reprogramming, and CKD-mineralocorticoid receptor cross-talk. Metformin, SGLT2 inhibitors, IL-1β/NLRP3 inhibitors and Lp(a)-lowering strategies are proposed candidates for clinical evaluation. The framework argues for valve-focused randomised trials in diabetic CAVD.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T13:31:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09ac8ef4bbb6","type":"article","url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","title":"KDIGO-overzicht: de nier centraal in het cardiovasculair-renaal-metabool (CKM) syndroom","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","bloeddrukbehandeling","bradycardie","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","dapagliflozine","fidelio-dkd","figaro-dkd","niet-statine-therapie","obesitas","rosuvastatine"],"journal":"Kidney international","doi":"10.1016/j.kint.2026.03.031","source_url":"https://doi.org/10.1016/j.kint.2026.03.031","authors":["Adeera Levin","Nisha Bansal","Ian H de Boer","Morgan E Grams","Michel Jadoul","Jozine M Ter Maaten","Reem A Mustafa","Peter Rossing","Michael Cheung","Jennifer King","Amy Earley","Paul E Stevens"],"significance":8,"published":"2026-05-31","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Review of KDIGO guidelines addressing the cardiovascular-kidney-metabolic (CKM) syndrome — formally recognised by the American Heart Association in 2023 as the integrated entity linking chronic kidney disease with obesity, diabetes, hypertension, dyslipidaemia, and cardiovascular disease. The review synthesises relevant KDIGO Clinical Practice Guidelines (CKD, blood pressure, diabetes, lipids), the upcoming guideline on heart failure in CKD, and Controversies Conference reports on obesity and CKD prevention. Core themes: early detection and intervention, personalised management of kidney and cardiovascular risk, and multidisciplinary care. KDIGO provides a robust framework for clinical practice and research priorities in patients at risk for or with CKM syndrome.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T13:31:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e8dae120415","type":"article","url":"https://hartvaat.nl/2026/05/25/het-spectrum-van-congestie-bij-hartfalen-pathofysiologie-en-diagnostische-strate/","title":"Het spectrum van congestie bij hartfalen: pathofysiologie en diagnostische strategieën","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","gedilateerde-cardiomyopathie","hfmref","hfpef","hfref","hypertrofische-cardiomyopathie","iaso-dcm","ijzersuppletie","laminopathie","myocardinfarct","nt-probnp","pathfinder-trial","step-hfpef","vrouwen"],"journal":"Heart failure reviews","doi":"10.1007/s10741-026-10639-x","source_url":"https://doi.org/10.1007/s10741-026-10639-x","authors":["Alberto Palazzuoli","Matteo Beltrami","Oliviana Geavlete","Gaetano Ruocco","Masatake Kobayashi","Francesca Susini","Irene Carlino","Giuseppe Schirò","Andrew P Ambrosy","Ovidiu Chioncel"],"significance":6,"published":"2026-05-31","source_date":"2026-05-25","image":"https://hartvaat.nl/global/img/5982e3e8aeca.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"Review of the complex pathophysiology and diagnosis of congestion in heart failure — the principal driver of decompensation recurrence. The authors discuss the recently proposed intra- vs extravascular congestion classification and the lack of a uniform multiparametric assessment. Clinical examination alone often underestimates congestion; a multimodal approach combining ultrasonography (lung, cardiac, IVC, abdominal), invasive haemodynamics and biomarkers is recommended. Key insight: haemodynamic congestion with elevated intracardiac pressures does not always coincide with systemic fluid retention. The review presents profile-driven approaches for early congestion detection.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d16a81e26b5","type":"article","url":"https://hartvaat.nl/2026/05/25/klassieke-lv-gls-overtreft-nieuwe-atriale-cmr-parameters-bij-voorspelling-van-lv/","title":"Klassieke LV-GLS overtreft nieuwe atriale CMR-parameters bij voorspelling van LV-remodelling na voorwand-STEMI","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["atriale-cardiomyopathie","biomarkers-cardiovasculair","bloeddrukbehandeling","cardiac-mri","gepersonaliseerde-geneeskunde","laminopathie","ouderen","ventrikelfibrilleren"],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.134587","source_url":"https://doi.org/10.1016/j.ijcard.2026.134587","authors":["B Yosofi","J M Zelis","A Raafs","K Teeuwen","C Berry","Kenneth Mangion","D C J Keulards","R Eerdekens","H C M van den Bosch","P A L Tonino","M El Farissi","S El Messaoudi","R Nijveldt","L C Otterspoor"],"significance":5,"published":"2026-05-31","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Post-hoc analysis of the EURO-ICE trial in 200 patients with anterior STEMI who underwent CMR at baseline and 3 months. LV global longitudinal strain (GLS) was the strongest functional predictor of adverse LV remodelling (OR 1.16; 95% CI 1.06-1.27; p=0.001), persisting after adjustment for clinical risk factors (OR 1.22). The association disappeared after adjustment for infarct size and microvascular obstruction, suggesting the prognostic value is largely mediated by myocardial injury burden. Left atrial strain and LACI added no predictive value. LV GLS remains the most informative functional CMR parameter and is useful when contrast cannot be given.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3b1c04e2dd8","type":"article","url":"https://hartvaat.nl/2026/05/26/adipokineprofiel-bij-acuut-hartfalen-voorspelt-natriuretische-respons-en-mortali/","title":"Adipokineprofiel bij acuut hartfalen voorspelt natriuretische respons en mortaliteit","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","ijzertekort","nt-probnp","step-hfpef","summit-trial","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag150","source_url":"https://doi.org/10.1093/eschf/xvag150","authors":["Jan Biegus","Rafał Tymków","Gracjan Iwanek","Robert Zymliński","Mateusz Guzik","Magdalena Hurkacz","Wojciech Sopyla","Piotr Gajewski","Piotr Ponikowski"],"significance":5,"published":"2026-05-30","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/"],"congress":"","summary_en":"Prospective observational study in 262 patients with acute heart failure, relating circulating adipokine profiles to the early natriuretic response (spot urine sodium 2 hours after intravenous loop diuretic). Patients with impaired response (uNa+ <90 mmol/L) had higher chemerin and FABP4 levels. An integrated adipokine score was independently associated with sodium excretion (β 3.37; 95% CI 1.51-5.23) and with 1-year mortality. FABP4 was consistently linked to both impaired natriuresis and adverse outcomes. The findings are hypothesis-generating and point to an adipo-inflammatory axis connecting diuretic response and prognosis.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"71a1dd50bdc3","type":"article","url":"https://hartvaat.nl/2026/05/26/car-t-therapie-bij-ouderen-5-8-mace-en-sterk-verhoogde-mortaliteit-cardio-oncolo/","title":"CAR-T-therapie bij ouderen: 5,8% MACE en sterk verhoogde mortaliteit — cardio-oncologie attent","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["kanker-en-hart"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag394","source_url":"https://doi.org/10.1093/eurheartj/ehag394","authors":["Raja Zaghlol","Elena Deych","Daniel A Ladin","David A Russler-Germain","Walter Schiffer","Nischit Baral","R J Waken","Bonnie Ky","Karen E Joynt Maddox","Joshua D Mitchell"],"significance":6,"published":"2026-05-30","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Retrospective cohort of 3,292 Medicare beneficiaries aged >65 who received CAR-T therapy for relapsed haematologic malignancies between 2018 and 2023. Major adverse cardiovascular events occurred in 5.8%, mainly acute heart failure (3.1%) and ischaemic (1.3%) or haemorrhagic stroke (1%). Pre-treatment atrial fibrillation (aOR 1.52), cardiomyopathy (aOR 2.49), and cerebrovascular disease (aOR 2.40) were independent predictors. MACE was associated with markedly elevated in-hospital mortality (aOR 16.9) and 1-year mortality (HR 1.91). Findings underscore the need for cardiovascular screening and monitoring in oncological immunotherapy.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T13:31:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bafc09bff146","type":"article","url":"https://hartvaat.nl/2026/05/26/ongericimab-nieuwe-pcsk9-antistof-verlaagt-ldl-fors-in-meta-analyse/","title":"Ongericimab: nieuwe PCSK9-antistof verlaagt LDL fors in meta-analyse","title_en":"Efficacy and safety of Ongericimab in patients with hypercholesterolemia: a systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","eas-2026","enlicitide","ezetimibe","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","statines"],"journal":"European journal of clinical pharmacology","doi":"10.1007/s00228-026-04081-z","source_url":"https://doi.org/10.1007/s00228-026-04081-z","authors":["Ahmed L Youseif","Ahmed F Younis","Ziad W Elmezayen","Mohamed Eldahrawy","Noha Hammad","Belal Mohamed Hamed","Amr Reda Saleh","Alaa Ashraf Mohamed","Omar Abdulrahman Saad","Aya M Ramadan","Abdelaziz A Awad"],"significance":6,"published":"2026-05-30","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/622c4897a518.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"eas-2026","summary_en":"Ongericimab, a humanised monoclonal antibody against PCSK9, reduced LDL-C by 62% to 73% depending on the regimen in a meta-analysis of five RCTs (1,421 patients with hypercholesterolaemia). Lp(a) (−45 to −50%), apoB, non-HDL cholesterol and triglycerides also fell, while the adverse-event profile was comparable to placebo. The agent widens the range of PCSK9-targeted therapies; cardiovascular outcome trials are still needed to confirm clinical benefit.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0cc70c320470","type":"article","url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","title":"ODYSSEY-OUTCOMES post-hoc: hsCRP en IL-6 zijn complementaire prognostische markers na ACS","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag317","source_url":"https://doi.org/10.1093/eurheartj/ehag317","authors":["Johan Wouter Jukema","Nicolaas J Van Neer","Michael Szarek","Christa Cobbaert","Vera A Bittner","Markus Schwertfeger","Deepak L Bhatt","Sergio Fazio","Shaun G Goodman","Robert A Harrington","Irena Stevanovic","Harvey D White","Philippe Gabriel Steg","Gregory G Schwartz"],"significance":7,"published":"2026-05-29","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Post-hoc analysis of ODYSSEY OUTCOMES (n=11,817 patients with recent acute coronary syndrome, all on optimized statin therapy). In models adjusted for each other, treatment assignment, and clinical characteristics, hsCRP independently predicted MACE (p<0.0001) while IL-6 did not; both independently predicted all-cause death. When dichotomised (hsCRP ≥2 mg/L, IL-6 ≥5 pg/ml), risks of MACE and death were elevated only when both markers were elevated. hsCRP conveys inflammatory residual-risk information beyond IL-6 — together they provide a more complete picture.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T13:31:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"010695f0e36c","type":"article","url":"https://hartvaat.nl/2026/05/26/state-of-the-art-mra-s-bij-hartfalen-en-nierziekte-over-alle-ejectiefracties/","title":"State-of-the-art: MRA's bij hartfalen en nierziekte over alle ejectiefracties","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dapa-hf","finerenon","finerenon-hartfalen-nierziekte","hfmref","hfpef","hfref","mra-aldosteronantagonisten","step-hfpef"],"journal":"Heart failure reviews","doi":"10.1007/s10741-026-10636-0","source_url":"https://doi.org/10.1007/s10741-026-10636-0","authors":["Harriette G C Van Spall","Orly Vardeny"],"significance":7,"published":"2026-05-29","source_date":"2026-05-26","image":"https://hartvaat.nl/global/img/d44fbf89ee3e.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"State-of-the-art review of clinical evidence for steroidal (spironolactone, eplerenone) and non-steroidal (finerenone) mineralocorticoid receptor antagonists in heart failure across the full ejection fraction spectrum. Evidence in HFrEF is robust; in HFmrEF and HFpEF, finerenone has recently improved outcomes. The review covers MRAs in chronic kidney disease (HF prevention and treatment) and proposes practical strategies for minimizing hyperkalaemia. Conclusion: MRAs maintain a favourable benefit-risk profile for HF prevention and treatment, including in CKD.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea5f9a667472","type":"article","url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","title":"ESC-consensusverklaring over microvasculaire obstructie en no-reflow na STEMI","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","biomarkers-cardiovasculair","bloeddrukbehandeling","endotheel","farmaco-economie","hartrevalidatie","laminopathie","microcirculatie","niet-statine-therapie","ouderen","richtlijnen-esc","secundaire-preventie","slaapapneu","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag334","source_url":"https://doi.org/10.1093/eurheartj/ehag334","authors":["Edina Cenko","Lina Badimon","Giuseppe Vadalà","Daphne Merkus","Charalambos Antoniades","Carlos Collet","Giovanni Luigi De Maria","Ana Djordjevic-Dikic","Ines Drenjancevic","Javier Escaned","José Luis Ferreiro","Ingrid Fleming","Tomasz Guzik","Olivia Manfrini","Davor Milicic","Teresa Padro","Italo Porto","Laurent Marc Riou","Nicola Ryan","Dimitris Tousoulis","Heleen M M van Beusekom","Marija Vavlukis","Gemma Vilahur","Marija Zdravkovic","Dirk J Duncker","Alfredo Ruggero Galassi","Raffaele Bugiardini"],"significance":8,"published":"2026-05-29","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/ischemie-reperfusieschade/"],"congress":"","summary_en":"Clinical consensus statement on the pathophysiology, prevention, and management of microvascular obstruction ('no-reflow') after primary PCI in STEMI. Despite timely revascularization, suboptimal myocardial reperfusion persists in up to 60% of cases, with major risk of adverse LV remodeling, heart failure and death. Pharmacological therapies (intracoronary adenosine, nitroprusside) show unclear benefit. Non-pharmacological strategies — ischemic postconditioning, supersaturated oxygen therapy, mechanical LV unloading — show promise but require large-scale RCT validation. The statement underscores the need for better risk stratification and novel microvasculature-targeted therapies.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T18:39:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06c0d7d49224","type":"article","url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","title":"ESC-consensus: vrouwenhartcentra (WHC) als nieuw zorgmodel in Europa","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag350","source_url":"https://doi.org/10.1093/eurheartj/ehag350","authors":["Julia Grapsa","Ana G Almeida","Antonia Sambola","Cristiana Vitale","Yolande Appelman","Bharati Shivalkar","Lisa J Anderson","Daniela Trabattoni","Rafael Vidal Perez","Amina Rakisheva","Marta Kaluzna-Oleksy","Sigrun Halvorsen","Sofie Gevaert","Marianna Adamo","Susanna Price","Alessia Gimelli","Bernard Cosyns","Victoria Delgado","Alaide Chieffo","Brenda Moura","Leslee Shaw","Mirvat Alasnag","Roxana Mehran","Sharon L Mulvagh","Mamas A Mamas","Martha Gulati"],"significance":8,"published":"2026-05-28","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Joint clinical consensus statement from EACVI, EAPCI, HFA and ACVC on establishing Women's Heart Centres (WHC) in Europe. WHCs are conceived as hub-and-spoke networks embedded in existing cardiovascular systems, delivering multidisciplinary, sex-sensitive care across the life course. Key domains: INOCA/MINOCA, cardio-obstetrics, cardio-oncology, autoimmune disease in women, mental health, cardiac rehabilitation. The document defines referral pathways, operational standards and core competencies; available evidence suggests improved diagnostic precision, risk factor control and patient-reported outcomes.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"acd36875baab","type":"article","url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","title":"Multimodaal AI-model verhoogt accuratesse van echo-diagnose cardiale amyloïdose","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-amyloidose"],"journal":"Circulation. Cardiovascular imaging","doi":"10.1161/CIRCIMAGING.126.019610","source_url":"https://doi.org/10.1161/CIRCIMAGING.126.019610","authors":["Jeremy A Slivnick","Sze Chi Lim","Michael Randazzo","Mathew S Maurer","Stephen Helmke","Marielle Scherrer-Crosbie","Azin Vakilpour","Karolina M Zareba","Akash Goyal","Richard Cheng","Nicole Wakamatsu","Tetsuji Kitano","Masaaki Takeuchi","Viviane Tiemi Hotta","Marcelo Luiz Campos Vieira","Pablo Elissamburu","Ricardo E Ronderos","Aldo Prado","Efstratios Koutroumpakis","Anita Deswal","Amit Pursnani","Nitasha Sarswat","Karima Addetia","Juan Cotella","Frederick L Ruberg","Matthew Frost","Marianna Fontana","Carolyn Lam Su Ping","Roberto M Lang","Federico M Asch"],"significance":7,"published":"2026-05-28","source_date":"2026-05-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"The Amyloidosis Imaging International Consortium evaluated an integrated AI model (AI-ECM) combining clinical data, laboratory biomarkers, and echocardiographic parameters with the existing TTE-only AI tool Us2.Ca. In 727 patients with cardiac amyloidosis and 316 controls, the combined model significantly outperformed Us2.Ca alone: AUC 0.94 (vs 0.89), 90% accuracy, 93% sensitivity, 85% specificity. AI-ECM also classified all cases where Us2.Ca was indeterminate in 9%. A step toward scalable AI-guided diagnostics for an underdiagnosed but treatable cause of heart failure.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"79af38564025","type":"article","url":"https://hartvaat.nl/2026/05/27/sglt2-remmers-verminderen-epicardiaal-vetweefsel-meta-analyse-van-11-studies/","title":"SGLT2-remmers verminderen epicardiaal vetweefsel: meta-analyse van 11 studies","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","empagliflozine","ezetimibe","figaro-dkd","obesitas","select-trial","sglt2-remmers"],"journal":"International journal of obesity (2005)","doi":"10.1038/s41366-026-02110-6","source_url":"https://doi.org/10.1038/s41366-026-02110-6","authors":["Shaun Khanna","Elana Kalman","Kaushik Thungathurthi","Udit Thakur","Sheran Vasanthakumar","Sohaib Virk","Aditya Bhat","Andrew Lin","Clare Arnott","Nitesh Nerlekar"],"significance":6,"published":"2026-05-28","source_date":"2026-05-27","image":"https://hartvaat.nl/global/img/a016c5ad5ee6.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"Systematic review and meta-analysis of 11 studies (284 patients) on the effect of SGLT2 inhibitors on epicardial adipose tissue (EAT). SGLT2 inhibitor therapy produced a significant reduction in EAT versus conventional antidiabetic therapy (Hedges g -1.64; 95% CI -2.10 to -1.18), consistent across thickness (echocardiography) and volume (CT/CMR) modalities. Modest reductions in BMI and systolic blood pressure were also observed. EAT reduction may contribute to the broad cardiovascular benefits of SGLT2 inhibitors.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f8989173c20","type":"article","url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","title":"EHRA-statement: pulsed field-ablatie als nieuwe standaard voor ablatie bij atriumfibrilleren","title_en":"Pulsed Field Ablation for the Interventional Treatment of Atrial Fibrillation. A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS) and the Canadian Heart Rhythm Society (CHRS).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","advent-trial","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag080","source_url":"https://doi.org/10.1093/europace/euag080","authors":["Michael Kühne","Patrick Badertscher","Jason G Andrade","Ante Anic","Julian Chun","Antonio Dello Russo","Pierre Jais","Josef Kautzner","Heiko Lehrmann","Claire Martin","Jose Merino","Damijan Miklavcic","Andrea Natale","Kars Neven","Armando Perez-Silva","Jonathan Piccini","Tobias Reichlin","Raphael Rosso","Martin Ruwald","Andrea Sarkozy","Daniel Scherr","Arian Sultan","Hiroshi Tada","Stylianos Tzeis","Atul Verma","Bradley Wilsmore","Helmut Pürerfellner"],"significance":9,"published":"2026-05-27","source_date":"2026-04-12","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"International scientific statement from EHRA, HRS, APHRS, LAHRS and CHRS on pulsed field ablation (PFA) for atrial fibrillation. Through irreversible electroporation, PFA achieves myocardial ablation while preserving surrounding structures such as nerves, vasculature and the esophagus. Randomized trials demonstrate efficacy comparable to radiofrequency and cryoballoon ablation, with clear advantages in safety and procedural efficiency. The statement summarizes biophysics, technology and clinical evidence and provides practical guidance for clinical implementation and operator training.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dadbf60ca8b9","type":"article","url":"https://hartvaat.nl/2026/04/17/glp-1-receptoragonisten-geassocieerd-met-lagere-mortaliteit-bij-hfref/","title":"GLP-1-receptoragonisten geassocieerd met lagere mortaliteit bij HFrEF","title_en":"Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-type-2","ezetimibe","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","soul-trial","summit-trial","tirzepatide"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag111","source_url":"https://doi.org/10.1093/eschf/xvag111","authors":["Joseph Kassab","Mark H Drazner","Jennifer T Thibodeau"],"significance":7,"published":"2026-05-26","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"Multicenter retrospective cohort (UT Southwestern) of 2,550 propensity-matched patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%). GLP-1 receptor agonist therapy (semaglutide, tirzepatide, or liraglutide) was associated with 32% lower 1-year all-cause mortality (7.1% vs 10.2%; OR 0.68; HR 0.54) and fewer acute decompensated heart failure hospitalizations (27.7% vs 32.8%; OR 0.79), without an increase in arrhythmic events or new ACS/stroke. Prospective randomized trials are needed before GLP-1 RAs can be recommended in HFrEF.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T13:31:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23a02700bded","type":"article","url":"https://hartvaat.nl/2026/04/10/vroege-evolocumab-na-hartinfarct-verlaagt-mace-bij-uitgestelde-randstenosen/","title":"Vroege evolocumab na hartinfarct verlaagt MACE bij uitgestelde randstenosen","title_en":"Evolocumab in patients with multivessel coronary disease after acute myocardial infarction: A target trial emulation.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["aperitif-trial","farmaco-economie","myocardinfarct","newton-cabg"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00098-5/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00098-5/fulltext","authors":["Jinying Zhou","Xiaoning Guo","Wei Gao","Yan Xia","Rende Xu","Jiatian Cao","Leilei Ma","Zhangwei Chen","Juying Qian","Chenguang Li","Junbo Ge"],"significance":7,"published":"2026-05-25","source_date":"2026-04-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"Target trial emulation in a multicenter Chinese registry (Shanghai, 2021-2022) of 1,862 patients with acute myocardial infarction and successful culprit-vessel revascularization but ≥1 deferred non-culprit intermediate lesion. Early in-hospital evolocumab initiation (n=174) was compared with standard care (n=1,688). Over 2 years, MACE occurred in 5.9% of evolocumab-treated lesions versus 11.9% in controls. The full 2-year hazard ratio was 0.72 (95% CI 0.48-1.09), but a 30-day landmark analysis showed a significant reduction (HR 0.35; 95% CI 0.16-0.74). Findings support early PCSK9 inhibition in the acute phase after AMI, including in deferred non-culprit lesions.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a178b3b1594a","type":"article","url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","title":"VERVE-102: eenmalige base-editing schakelt PCSK9 blijvend uit (fase 1)","title_en":"In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2601283","source_url":"https://doi.org/10.1056/NEJMoa2601283","authors":["Scott B Vafai","Jörg Täubel","Thomas Ashdown","Riyaz S Patel","Sadaf Diamondali","Jaimini Cegla","Handrean Soran","Bilal Bashir","Alexander Abitbol","Daniel Gaudet","Alex Lauzière","Liam R Brunham","David E Newby","Stephen J Nicholls","Russell S Scott","Jane Kerr","Jean-Claude Tardif","Catherine Lunken","Steve E Humphries","Verena Karsten","Patrick D Tyler","Xinyan Zhang","Nidal Huniti","Patrick A Flight","Chelsey L Jensen","Rick Falzone","Joseph C Biedenkapp","Troy Lister","Leslie E Stolz","Amit V Khera","Sekar Kathiresan"],"significance":9,"published":"2026-05-25","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"VERVE-102 is a base-editing therapy that permanently inactivates the hepatic PCSK9 gene with a single infusion — an adenine base-editor mRNA plus a guide RNA in a GalNAc lipid nanoparticle. In this phase 1 study of 35 patients with heterozygous familial hypercholesterolaemia or premature coronary artery disease, PCSK9 protein fell dose-dependently by 51% to 88% and LDL cholesterol by up to 62%, with a durable effect after one dose. No dose-limiting toxic effects occurred; there were mild-to-moderate infusion reactions and transient ALT elevations (and one aspiration pneumonitis in a patient with reflux). A one-time, durable LDL reduction thus comes into view as a treatment concept.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"172e763fe967","type":"article","url":"https://hartvaat.nl/2026/05/05/inotropica-bij-low-output-hartfalen-vergelijkbare-hemodynamische-effecten-in-met/","title":"Inotropica bij low-output hartfalen: vergelijkbare hemodynamische effecten in meta-analyse","title_en":"The Quantitative Haemodynamic Effect of Levosimendan, Dobutamine and Milrinone in Heart Failure Patients: a Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","hfmref","hfpef","hfref","ijzertekort"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag120","source_url":"https://doi.org/10.1093/eschf/xvag120","authors":["Vincenzo Nuzzi","Cristina Madaudo","Paolo Manca","Antonio Cannata","Giuseppe Raffa","Massimiliano Mulè","Stefano Cannata","Eluisa La Franca","Calogera Pisano","Manlio Cipriani","Roberto Lorusso"],"significance":6,"published":"2026-05-24","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/invasieve-hemodynamiek-rechts-hartkatheterisatie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Meta-analysis of 26 studies (1,888 patients) comparing the invasively measured haemodynamic effects of dobutamine, levosimendan and milrinone in low-output heart failure. All three agents improved cardiac index, PCWP, mean pulmonary and arterial pressures, and pulmonary/systemic vascular resistance, without consistent superiority of any one drug. The only significant difference concerned mean arterial pressure (p=0.05): milrinone trended toward a reduction, while dobutamine and levosimendan slightly raised it. In a sensitivity analysis, dobutamine improved cardiac index more than levosimendan in chronic HF. Findings support current practice of selecting inotropes based on individual patient characteristics.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b713bd31cb3f","type":"article","url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","title":"Intracardiale echocardiografie in de elektrofysiologie: gezamenlijk EHRA/EAPCI-statement","title_en":"Intracardiac echocardiography during invasive electrophysiological procedures. A scientific statement of the European Heart Rhythm Association of the ESC, and the European Association of Percutaneous Cardiovascular Interventions of the ESC.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","echocardiografie","ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag059","source_url":"https://doi.org/10.1093/europace/euag059","authors":["Petr Peichl","Stylianos Tzeis","Marta Skowronska","Dimitrios Asvestas","Jakub Baran","Michela Casella","Ruben Casado-Arroyo","Matevž Jan","Josef Kautzner","Jens Erik Nielsen-Kudsk","Peter Kupo","Andrej Pernat","Nandor Szegedi","Vedran Velagić"],"significance":7,"published":"2026-05-23","source_date":"2026-04-13","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"Joint scientific statement from EHRA and EAPCI on the role of intracardiac echocardiography (ICE) during invasive electrophysiological procedures. ICE provides real-time visualization of intracardiac structures and has evolved beyond transseptal puncture into an adjunct for ablation of supraventricular and ventricular arrhythmias, fluoroscopy reduction, early detection and management of periprocedural complications, identification of infective endocarditis, endomyocardial biopsy and left atrial appendage occlusion. The document serves as a practical roadmap with standardized views and considerations for optimal clinical use.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c7a9f1192c0f","type":"article","url":"https://hartvaat.nl/2026/04/24/ita-bypass-veilig-bij-patienten-met-eerdere-mediastinale-bestraling-maryland-coh/","title":"ITA-bypass veilig bij patiënten met eerdere mediastinale bestraling: Maryland-cohort van 29.206","title_en":"Safety of internal thoracic artery use in patients with prior mediastinal radiation undergoing coronary artery bypass grafting: a Maryland statewide propensity-matched analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/557?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/557?rss=1","authors":["Zhou","A. L.","Chinedozi","I. D.","Holmes","S. D.","Gammie","J. S.","Patel","D.","Akbar","A. F.","Alejo","D.","Lawton","J.","Whitman","G.","Salenger","R.","Briscoe","J. B.","Darby","Z. E.","Cameron","D.","Wang","H.","on behalf of the Maryland Cardiac Surgery Quality Initiative (MCSQI)","S Gammie","Alejo","Lawton","Whitman","Salenger","Cameron","Wang"],"significance":5,"published":"2026-05-22","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/"],"congress":"","summary_en":"Retrospective cohort from the Maryland Cardiac Surgery Quality Initiative database: 29,206 patients who underwent CABG with internal thoracic artery (ITA) grafting between July 2011 and March 2023. 294 patients (1%) had a history of mediastinal radiation. After 1:10 propensity matching, there was no significant difference in the primary composite of operative mortality and deep sternal wound infection (2% vs 3%; p=0.53) or in secondary outcomes (infectious complications, length of stay, 30-day readmission). Findings challenge the prevailing concern about ITA use in irradiated patients and argue against excluding them from arterial revascularization strategies.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"30bb6d15a20a","type":"article","url":"https://hartvaat.nl/2026/04/09/thuis-bloeddruk-time-in-target-range-hoger-percentage-in-doel-geassocieerd-met-m/","title":"Thuis-bloeddruk-time-in-target-range: hoger percentage in doel geassocieerd met minder hersenlaesies","title_en":"IoT-Based Home Blood Pressure Time in Target Range and Brain Lesions on MRI","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26519","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26519","authors":["Takashi Hisamatsu"],"significance":6,"published":"2026-05-22","source_date":"2026-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"Cohort study (n=306, mean age 56 years, 57% women) relating Internet-of-Things-based home blood pressure (measured twice daily for a year) to subclinical cerebrovascular damage on MRI (lacunar infarcts, white matter hyperintensities, microbleeds, intracranial artery stenosis). Median annual Time in Target Range was 100% in untreated participants but only 1.9% in those on antihypertensive medication — a striking signal that office-based BP control overstates real-world regulation. Each 10% higher TTR was associated with a 15% lower prevalence of brain lesions (prevalence ratio 0.85; 95% CI 0.79-0.91), with a stronger effect in untreated individuals. TTR was lower in winter than summer. Home BP TTR may be a valuable complement to office measurement for assessing cerebrovascular health.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32b1e40622df","type":"article","url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","title":"IL-6 sterker met hart- en vaatziekte geassocieerd dan LDL, Lp(a) en CRP","title_en":"Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESA.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["eas-2026","ezetimibe","hs-crp","inflammatie","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"Progress in cardiovascular diseases","doi":"10.1016/j.pcad.2026.05.005","source_url":"https://doi.org/10.1016/j.pcad.2026.05.005","authors":["James McParland","Rishi Rikhi","Harpreet S Bhatia","Alexander C Razavi","Parag Chevli","Saeid Mirzai","Jared A Spitz","Garima Sharma","Shahzeb Khan","Leandro Slipczuk","Mayank Dalakoti","Michael J Blaha","Roger S Blumenthal","Michael D Shapiro"],"significance":7,"published":"2026-05-22","source_date":"2026-05-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"eas-2026","summary_en":"In two large primary-prevention cohorts (UK Biobank and MESA), the inflammatory marker interleukin-6 (IL-6) showed the strongest association with atherosclerotic events, independent of LDL-C, Lp(a) and hsCRP. In fully adjusted models the hazard ratio for the top versus bottom quartile was 1.67 (UK Biobank) and 1.60 (MESA) for IL-6 — higher than for the other biomarkers. The authors propose IL-6 as a key driver of atherosclerosis and an attractive target for future anti-inflammatory prevention.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7deef61dbedf","type":"article","url":"https://hartvaat.nl/2026/04/29/de-secretoire-pcsk-familie-van-moleculaire-schakelaars-tot-doelwit-voor-cardiova/","title":"De secretoire PCSK-familie: van moleculaire schakelaars tot doelwit voor cardiovasculaire therapie","title_en":"The secretory PCSK family in cardiovascular disease and beyond","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["biomarkers-cardiovasculair","cardiale-amyloidose","cardiovasculaire-genetica","diabetes-type-1","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","laminopathie","lipoproteïne-a","ouderen","pcsk9-remmers","pelacarsen","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00082-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00082-1/fulltext","authors":["Nabil G. Seidah"],"significance":5,"published":"2026-05-21","source_date":"2026-04-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Review in Atherosclerosis on the proprotein convertase family (PCSK1-PCSK9), identified between 1990 and 2003. These phylogenetically ancient serine proteases activate or regulate a wide range of secretory proteins — polypeptide hormones, growth factors, receptors, adhesion molecules, metalloproteinases and cytokines — by converting inactive precursors into their active forms. The authors place PCSK9, the best-known member due to its role in LDL-receptor degradation and its therapeutic exploitation via evolocumab, alirocumab and inclisiran, in the broader family context. The article discusses overlap with cardiovascular pathology and identifies emerging therapeutic targets within the PCSK family.","created":"2026-07-03T10:32:57Z","updated":"2026-07-03T13:31:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9165edfa5014","type":"article","url":"https://hartvaat.nl/2026/05/14/bloeddrukvariabiliteit-sprint-accord-ipd-meta-even-prognostisch-als-gemiddelde-b/","title":"Bloeddrukvariabiliteit (SPRINT + ACCORD IPD-meta): even prognostisch als gemiddelde bloeddruk in hoog-risico patiënten","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","heart-failure-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag330","source_url":"https://doi.org/10.1093/eurheartj/ehag330","authors":["Wenbo Zhao","Yue Qiao","Lupei Cai","Eric L. Harshfield","Zihan Sun"],"significance":7,"published":"2026-05-15","source_date":"2026-05-14","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"heart-failure-2026","summary_en":"IPD meta-analysis of SPRINT and ACCORD (n=18,415, median 12 BP measurements over 3.6 y, 1,244 MACEs). Higher SBP variability (VIM, top vs bottom tertile) was independently associated with MACE (HR 1.15; 95% CI 1.00–1.32), with a J-shaped relationship. Prognostic value comparable to mean SBP. Argues for routine reporting of BP variability in cardiovascular risk models, not just mean BP.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T13:31:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec24f6e6082a","type":"article","url":"https://hartvaat.nl/2026/05/13/aha-scientific-statement-2026-secundaire-preventie-na-coronaire-bypassoperatie-e/","title":"AHA Scientific Statement 2026: secundaire preventie na coronaire bypassoperatie — eerste update sinds 2015","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["coronaire-bypass","coronairlijden","heart-failure-2026"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001434","source_url":"https://doi.org/10.1161/CIR.0000000000001434","authors":["Marc Ruel","Sigrid Sandner","Menaka Ponnambalam","Chase Brown","Mario Gaudino"],"significance":7,"published":"2026-05-15","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/","https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"heart-failure-2026","summary_en":"First AHA scientific statement on post-CABG secondary prevention since 2015, published in Circulation in the week after HF26. Covers lipid lowering (including PCSK9 inhibitors / inclisiran in this population), antiplatelet/anticoagulation, BP targets, diabetes and CKM management, cardiac rehabilitation, and post-discharge follow-up — separating evidence-based from consensus recommendations throughout. Reference document for the multidisciplinary CABG follow-up team.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T13:31:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc11aae1bea5","type":"article","url":"https://hartvaat.nl/2026/05/13/wereldwijde-hf-registry-fev1-is-een-onafhankelijke-prognostische-factor-pleidooi/","title":"Wereldwijde HF-registry: FEV1 is een onafhankelijke prognostische factor — pleidooi voor routine-spirometrie bij hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026","vrouwen"],"journal":"ESC Heart Failure","doi":"10.1093/eschf/xvag128","source_url":"https://doi.org/10.1093/eschf/xvag128","authors":["MyLinh Duong","Shofiqul Islam","Philip Joseph","Darryl Leong","Alex Grinvalds","Global Congestive Heart Failure Registry Investigators"],"significance":7,"published":"2026-05-15","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"heart-failure-2026","summary_en":"Global Congestive Heart Failure registry sub-study (n=3,359, 28 countries, median 3.8-y follow-up) finds FEV1 z-score ≤-2 is independently associated with all-cause mortality (HR 2.20), CV mortality (HR 2.45) and hospitalization (HR 1.40) — effect sizes comparable to other major HF prognostic factors. Even normal-range FEV1 reductions tracked with increased HF burden. Argues for routine spirometry as part of the HF workup across global populations.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9595340a3e8","type":"article","url":"https://hartvaat.nl/2026/05/13/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","title":"UK Biobank: na ischemisch CVA of TIA is het risico op hartfalen groter dan dat op een infarct","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["cerebrovasculair","heart-failure-2026"],"journal":"ESC Heart Failure","doi":"10.1093/eschf/xvag123","source_url":"https://doi.org/10.1093/eschf/xvag123","authors":["Rahul G. Muthalaly","Nitesh Nerlekar","Sean Tan","Andrew Lin","Adam J. Nelson"],"significance":7,"published":"2026-05-15","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-polikliniek-opzet/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"heart-failure-2026","summary_en":"UK Biobank cohort (n=405,406, age 40–69, 13.7-y follow-up) shows ischaemic stroke/TIA survivors face crude HR 3.6 (adjusted 1.4) for HF hospitalization. Notably, HF hospitalization risk (12.6%) exceeds subsequent MI risk (5.4%) in this group. Lower LVEF and higher LV mass on CMR among those who develop HF. Incident HF after stroke carries HR 1.8 for mortality. Argues for systematic cardiac follow-up of stroke survivors with structured HF risk assessment.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T13:31:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e62a4fd927c7","type":"article","url":"https://hartvaat.nl/2026/05/13/verisec-vericiguat-in-de-praktijk-halveert-hartfalen-decompensaties-bij-hfref-sp/","title":"VERISEC: vericiguat in de praktijk halveert hartfalen-decompensaties bij HFrEF — Spaanse 1-jaars registry van 835 patiënten","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026"],"journal":"ESC Heart Failure","doi":"10.1093/eschf/xvag138","source_url":"https://doi.org/10.1093/eschf/xvag138","authors":["Alberto Esteban-Fernández","Beatriz Calvo-Bernal","Raquel López-Vilella","Gregorio de Lara","Laia C. Belarte-Tornero","VERISEC Investigators"],"significance":8,"published":"2026-05-15","source_date":"2026-05-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"VERISEC (n=835, 41 Spanish centres) confirms vericiguat's real-world benefit in HFrEF after recent decompensation. Over 12 months on top of >90% SGLT2i / >85% RAASi / ~80% MRA / 91% beta-blocker background, NT-proBNP fell from 3,532 to 2,292 pg/mL (p<0.001), LVEF rose from 30.3% to 35.4%, NYHA class improved, and HF decompensations requiring IV diuretics halved (1.34 → 0.65 per year). 13.4% discontinued, mostly for symptomatic hypotension; higher baseline NT-proBNP predicted discontinuation.","created":"2026-07-03T10:32:56Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a53fbda0283","type":"article","url":"https://hartvaat.nl/2026/05/11/ehj-editorial-cleland-wereldwijde-hartfalenprevalentie-overschrijdt-600-miljoen-/","title":"EHJ-editorial Cleland: wereldwijde hartfalenprevalentie overschrijdt 600 miljoen — van gokken naar evidence","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026","hfmref","hfpef","nt-probnp","vrouwen"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag331","source_url":"https://doi.org/10.1093/eurheartj/ehag331","authors":["John G. F. Cleland","Mitja Lainscak","Pierpaolo Pellicori"],"significance":7,"published":"2026-05-12","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"heart-failure-2026","summary_en":"Cleland, Lainscak, Pellicori editorial (EHJ, during HF26) revises global heart failure prevalence: historical ~60M figures reflect symptomatic HF in registries, but contemporary population-based echo screening including stage A/B, HFpEF and structural/functional abnormalities consistently finds 8–12% of older adults — implying a global population >600 million. Calls for international case-definition consensus, routine NT-proBNP + echo screening in primary care, and HF prevalence in national CV registries. Frames HF as a population-health emergency rather than a sub-specialty problem.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f08989ff88d","type":"article","url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","title":"FINEARTS-HF subanalyse: virale luchtweginfecties triggeren hartfalen-verslechtering, finerenon-effect blijft behouden","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["finearts-hf","heart-failure-2026","hfmref","hfref","step-hfpef"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag384","source_url":"https://doi.org/10.1093/eurheartj/ehag384","authors":["Ragnhild Helseth","Brian L. Claggett","Ankeet Bhatt","Orly Vardeny","Henri Lu","Scott D. Solomon","FINEARTS-HF Investigators"],"significance":6,"published":"2026-05-12","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"heart-failure-2026","summary_en":"FINEARTS-HF (n=6,001) sub-analysis on viral respiratory tract infections (RTIs): RTIs were associated with subsequent worsening HF events and excess mortality, particularly in symptomatic patients. Finerenone did not modify RTI incidence, but its benefit on the primary outcome was preserved across patients with and without intercurrent RTI. Supports vaccination policy emphasis in HFmrEF/HFpEF and reassures that finerenone benefit is robust to common viral illness.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b788259e4d1","type":"article","url":"https://hartvaat.nl/2026/05/12/aha-scientific-statement-evaluatie-en-behandeling-van-het-kind-met-acuut-gedecom/","title":"AHA Scientific Statement: evaluatie en behandeling van het kind met acuut gedecompenseerd hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["heart-failure-2026"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001428","source_url":"https://doi.org/10.1161/CIR.0000000000001428","authors":["Antonio G. Cabrera","Jack F. Price","Borah J. Hong","Aamir Jeewa","Christine Tabulov"],"significance":7,"published":"2026-05-12","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"heart-failure-2026","summary_en":"AHA Scientific Statement published in Circulation during HF26 — first integrated framework for acute decompensated heart failure in children and adolescents. Driven by rising pediatric ADHF presentations with higher morbidity/mortality and resource use than adults. Covers triage, risk stratification, diagnostic workup, initial stabilization, inotrope and diuretic choice, mechanical support thresholds, transition to chronic therapy, discharge planning, and post-discharge psychosocial follow-up. Knowledge gaps explicitly named. Useful reference for tertiary paediatric cardiac centres.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T13:31:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b063624a5b9d","type":"article","url":"https://hartvaat.nl/2026/05/12/massieve-lvh-bij-pediatrische-hcm-vroeger-diagnose-vaker-sarcomere-variant-driev/","title":"Massieve LVH bij pediatrische HCM: vroeger diagnose, vaker sarcomere variant, drievoudig verhoogde sterfte","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["gedilateerde-cardiomyopathie","heart-failure-2026","hypertrofische-cardiomyopathie","iaso-dcm","laminopathie","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.078843","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.078843","authors":["Robert Przybylski","Gabrielle Norrish","Brian Claggett","Euan A. Ashley","Vinay Bhole"],"significance":7,"published":"2026-05-12","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/"],"congress":"heart-failure-2026","summary_en":"Multi-registry analysis (SHaRe + IPHCC, n=587, of which 186 had massive LVH defined as MLVWT ≥30 mm or z-score ≥+20). Massive LVH in pediatric HCM is associated with younger age at diagnosis (median 9.2 vs 13.6 years; p<0.001), higher sarcomeric variant prevalence (72% vs 61%; p=0.034), and 3.3-fold higher HCM-related mortality (95% CI 1.2–9.7; p=0.026). Supports earlier, more aggressive surveillance and intervention thresholds in this subgroup.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T13:31:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b24e16af053","type":"article","url":"https://hartvaat.nl/2026/05/11/hcmr-nhlbi-multidimensionele-risicovoorspelling-beter-dan-scd-gefocuste-richtlij/","title":"HCMR (NHLBI): multidimensionele risicovoorspelling beter dan SCD-gefocuste richtlijnen bij hypertrofische cardiomyopathie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","aficamten","biomarkers-cardiovasculair","gedilateerde-cardiomyopathie","heart-failure-2026","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","troponine","vrouwen"],"journal":"JAMA","doi":"10.1001/jama.2026.5633","source_url":"https://doi.org/10.1001/jama.2026.5633","authors":["Christopher M. Kramer","Paul Kolm","John P. DiMarco","Milind Y. Desai","HCMR Investigators"],"significance":8,"published":"2026-05-12","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"heart-failure-2026","summary_en":"HCMR (NHLBI HCM Registry) prospectively enrolled 2,750 patients with HCM at 44 expert sites across North America and Europe; all underwent contrast CMR, biomarker/genotyping bloodwork, and structured history. Median follow-up >7 years. An integrated multidimensional model (combining clinical, imaging, genetic and biomarker data via elastic-net selection) outperforms current SCD-only risk prediction, capturing patients at risk of HF events and transplant that are under-recognized today. Likely reduces both unnecessary ICDs (overtreatment) and avoidable deaths (undertreatment). Important context for HCM clinics now selecting candidates for mavacamten/aficamten therapy.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d343dd9b944","type":"article","url":"https://hartvaat.nl/2026/05/12/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pre-postc/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pre/postcapillaire PH bij HFpEF","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["heart-failure-2026","summit-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.079918","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.079918","authors":["Mardi Gomberg-Maitland","Ryan J. Tedford","David Langleben","Stephan Rosenkranz","Barry Miller"],"significance":9,"published":"2026-05-12","source_date":"2026-05-12","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/invasieve-hemodynamiek-rechts-hartkatheterisatie/","https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/"],"congress":"heart-failure-2026","summary_en":"CADENCE (n=164, multicentre, randomized, placebo-controlled phase 2) tested sotatercept (activin signalling inhibitor) in patients with combined post- and pre-capillary pulmonary hypertension (CpcPH) in HFpEF. PVR at week 24 dropped by −1.02 Wood units (95% CI −1.81 to −0.23; p=0.004) at the 0.3 mg/kg dose and −0.75 (p=0.024) at 0.7 mg/kg. Mean PAP fell by ~9 mmHg, wedge pressure by 2.5–3 mmHg, 6-min walk improved 20.3 m at the lower dose. Proof of concept for the first therapy in CpcPH-HFpEF, a high-mortality phenotype without approved treatment. Major extension of the sotatercept (WINREVAIR) platform from PAH into HFpEF-PH. (Originally presented at ACC.26 in March; full Circulation publication during HF26.)","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T13:31:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad1fe2cb3c82","type":"article","url":"https://hartvaat.nl/2026/05/10/paradise-gelijktijdig-acuut-hartfalen-plus-luchtweginfectie-verhoogt-sterfte-tij/","title":"PARADISE: gelijktijdig acuut hartfalen plus luchtweginfectie verhoogt sterfte tijdens opname, niet daarna","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026","vrouwen"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag160","source_url":"https://doi.org/10.1093/ejhf/xuag160","authors":["Stefano Coiro","Luca Monzo","Florian Boutry","Claire Lacomblez","Guillaume Baudry"],"significance":7,"published":"2026-05-11","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"PARADISE sub-analysis (French dyspnoea cohort 2010–2019, n=11,679): 37% had AHF alone, 44% respiratory infection (RI) alone, 19% both. AHF+RI together had higher in-hospital mortality than AHF alone (aOR 1.62; 95% CI 1.33–1.98; p<0.001) but not higher post-discharge mortality (aHR 0.99; p=0.9). RI alone was not associated with excess mortality. Concomitant RI in AHF is a marker for in-hospital severity, not a long-term prognostic modifier — long-term outcome is dictated by the underlying HF.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T13:31:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"771fe7e3c26e","type":"article","url":"https://hartvaat.nl/2026/05/10/hartfalen-en-infarct-verdrievoudigen-het-risico-op-kanker-vooral-hematologisch/","title":"Hartfalen en infarct verdrievoudigen het risico op kanker — vooral hematologisch","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","anticoagulatie-kwetsbare-ouderen","bisoprolol","carvedilol","emperor-trials","farmaco-economie","heart-failure-2026","hfmref","hfpef","hfref","ijzertekort","myocardinfarct","nt-probnp","step-hfpef","vrouwen"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag061","source_url":"https://doi.org/10.1093/ejhf/xuag061","authors":["Massimiliano Camilli","Nicolas Girerd","Pietro Ameri","Federico Ballacci","Antonella Lombardo"],"significance":8,"published":"2026-05-11","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"Federated cohort study (TriNetX) of 120,783 HF patients and 7,896 AMI patients propensity-matched 1:1 to controls without HF/AMI, excluding prior/concurrent cancer. New cancer diagnoses starting 6 months after index hospitalization showed strikingly elevated risk: HF HR 2.80 (95% CI 2.69–2.91); AMI HR 2.02 (95% CI 1.71–2.39); both p<0.001. The excess risk was much greater for haematologic malignancies (HF HR 6.78; AMI HR 4.45) than solid tumours. HFpEF carried slightly higher cancer incidence than HFrEF/HFmrEF (HR 1.10). Hypothesis-generating finding in 'reverse cardio-oncology' — possible mechanisms include shared inflammatory pathways and clonal haematopoiesis. Prospective confirmation needed before screening implications.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63a39abc0f31","type":"article","url":"https://hartvaat.nl/2026/05/10/porthos-nt-probnp-afkapwaarden-onbetrouwbaar-bij-obese-patienten-risico-op-gemis/","title":"PORTHOS: NT-proBNP-afkapwaarden onbetrouwbaar bij obese patiënten — risico op gemiste hartfalendiagnose","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026","nt-probnp","obesitas","summit-trial"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag154","source_url":"https://doi.org/10.1093/ejhf/xuag154","authors":["Cristina Gavina","João Pedro Ferreira","Lígia Lopes Mendes","Filipa Bernardo","Sara Gonçalves"],"significance":8,"published":"2026-05-11","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/nhg-standaard-hartfalen-2021/"],"congress":"heart-failure-2026","summary_en":"PORTHOS (Portugal, population-based, age ≥50, n=2,498) shows NT-proBNP is systematically lower in obesity — ~50 pg/mL lower per 5 kg/m² BMI increase. Obese participants with NT-proBNP <125 pg/mL had higher odds of HF symptoms (OR 1.97) and echo abnormalities (OR 3.63) than lean participants above the cut-off, despite being 9 years younger and having 4x lower NT-proBNP (59 vs 235 pg/mL). Fixed cut-offs miss HF in obesity; primary-care screening pathways need adjustment.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7197cd3ea232","type":"article","url":"https://hartvaat.nl/2026/05/10/poseidon-4-op-10-patienten-met-hartfalen-wereldwijd-heeft-inflammatoir-verhoogd-/","title":"POSEIDON: 4 op 10 patiënten met hartfalen wereldwijd heeft inflammatoir verhoogd hsCRP — basis voor anti-inflammatoire therapie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["heart-failure-2026"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag155","source_url":"https://doi.org/10.1093/ejhf/xuag155","authors":["Carolyn S. P. Lam","Johanna Contreras","Raed Darwesh","Aguinaldo F. Freitas Junior","Søren Lund Kristensen"],"significance":8,"published":"2026-05-11","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"heart-failure-2026","summary_en":"POSEIDON enrolled 18,904 individuals at 317 sites in 18 countries (2023–2025); 11,809 had HF with hsCRP available. Elevated hsCRP (≥2 mg/L) was present in ~38% of patients across HFpEF, HFmrEF and HFrEF — strikingly consistent across the EF spectrum. Patients with elevated hsCRP were more likely female with a cardio-kidney-metabolic phenotype: CKD, obesity, worse NYHA, higher NT-proBNP. Smoking, autoimmune/inflammatory disease, obesity and reduced eGFR were independent predictors. The findings define the target population for IL-6 trials (ATHENA, HERMES with ziltivekimab) also announced at HF26.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T13:31:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c654ad12a3de","type":"article","url":"https://hartvaat.nl/2026/05/09/uf-care-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-mist-primair-eindpunt-in/","title":"UF-CARE: ultrafiltratie bij type-2 cardiorenaal syndroom mist primair eindpunt in kleine Franse RCT","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","heart-failure-2026","ijzertekort","step-hfpef"],"journal":"ESC Heart Failure","doi":"10.1093/eschf/xvag133","source_url":"https://doi.org/10.1093/eschf/xvag133","authors":["Maxime Schleef","Florence Sens","Laurent Magaud","Julie Haesebaert","Carole Langlois-Jacques"],"significance":6,"published":"2026-05-11","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"heart-failure-2026","summary_en":"UF-CARE (15 French centres, n=46 randomized of 108 screened) added ultrafiltration (PD, HD or IUF) to optimized medical therapy in severe HF with refractory congestion and CKD (type-2 cardiorenal syndrome). The primary composite (all-cause death or unplanned HF hospitalization at 12 months) occurred in 63% vs 87% (p=0.144), with one technique-related death. Underpowered; the 24-point absolute difference is hypothesis-generating but not statistically significant.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5f4a3ecedea","type":"article","url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","title":"SUBCUT HF II: subcutane furosemide thuis verlaagt opnameduur met 5,5 dagen na hartfalenopname","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["furosemide","heart-failure-2026","hfref"],"journal":"Heart Failure 2026 (Late-Breaking Science)","doi":"https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html","source_url":"https://doi.org/https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html","authors":["Ross T. Campbell","Mark C. Petrie","SUBCUT HF II Investigators"],"significance":8,"published":"2026-05-11","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"SUBCUT HF II (UK, 20 NHS sites, n=170) compared at-home subcutaneous furosemide via the Lasix ONYU patch-pump (80 mg over 5h) versus continued inpatient IV furosemide in patients admitted with HF-associated edema. At-home treatment yielded +4 days alive-and-out-of-hospital at 30 days (p<0.001) and reduced index hospitalization length by 5.5 days (p<0.001), sustained at 60 days, with equivalent safety. Lasix ONYU was FDA-approved October 2025; SUBCUT HF II provides the supporting RCT evidence. Direct implications for cardiology capacity planning.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6a6ed5d8bf1","type":"article","url":"https://hartvaat.nl/2026/04/24/astma-geassocieerd-met-verhoogd-risico-op-degeneratieve-hartklepziekte-uk-bioban/","title":"Astma geassocieerd met verhoogd risico op degeneratieve hartklepziekte — UK Biobank","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-type-2","dyslipidemie","farmaco-economie","gepersonaliseerde-geneeskunde","laminopathie","menopauze","ouderen","primaire-preventie","statines","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/576?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/576?rss=1","authors":["Wang","Z.","Qian","X.","Lv","J.","Li","Z.","Yin","Z.","Wang","C.","Zhao","S.","Gao","X.","Wu","Y."],"significance":5,"published":"2026-05-11","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"A prospective cohort analysis of 483,735 UK Biobank participants (median age 56.5 years, 45.2% male) free of valvular heart disease at baseline. Cox regression adjusted for demographic, lifestyle and clinical covariates. The study assessed incidence of aortic stenosis, aortic regurgitation, mitral regurgitation and pulmonary regurgitation. Asthma was associated with higher risk across several degenerative valve disorders, with sensitivity analyses for asthma medications and duration. An under-recognised cardiovascular dimension of asthma that warrants further study.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d1ed8193d47","type":"article","url":"https://hartvaat.nl/2026/04/24/cardiovasculaire-ziekte-bij-sikkelcelziekte-ondergediagnosticeerde-drijver-van-m/","title":"Cardiovasculaire ziekte bij sikkelcelziekte: ondergediagnosticeerde drijver van mortaliteit","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","cardiogene-shock","cardiomyopathie-gerichte-therapie","cardiovasculaire-genetica","diabetes-en-hart","diabetes-type-2","echocardiografie","farmaco-economie","fractional-flow-reserve","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hartkatheterisatie","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","obesitas","ouderen","plotse-hartdood","richtlijnen-esc","secundaire-preventie","slaapapneu","ventrikelfibrilleren","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/539?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/539?rss=1","authors":["Haroun","E.","Agrawal","A.","Arockiam","A. D.","El Dahdah","J.","Kassab","J.","Nakhla","M.","Chedid El Helou","M.","Sanaka","H.","Zalaquett","Z.","Kaur","S.","Dong","T.","Hanna","R.","Griffin","B.","Wang","T. K. M."],"significance":6,"published":"2026-05-11","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"A contemporary review of cardiovascular complications in sickle cell disease: myocardial dysfunction, pulmonary hypertension, cardiac iron overload, arrhythmias, myocardial infarction, stroke and sudden death. They remain under-recognised despite their growing role in morbidity and premature mortality. Cardiac MRI with T2* mapping and ECV sequences, speckle-tracking echocardiography and invasive exercise testing reveal a distinct phenotype of restrictive cardiomyopathy with high-output heart failure. The review provides SCD-specific risk stratification and treatment algorithms.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd5cf1bfd7c7","type":"article","url":"https://hartvaat.nl/2026/04/23/aha-statement-kinderen-met-cardiomyopathie-mogen-meer-bewegen/","title":"AHA-statement: kinderen met cardiomyopathie mogen meer bewegen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aritmogene-cardiomyopathie","cardiomyopathie-gerichte-therapie","diabetes-en-hart","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","menopauze","obesitas","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001431","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001431","authors":[],"significance":8,"published":"2026-05-11","source_date":"2026-04-23","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/ritmestoornissen/brugada-syndroom/"],"congress":"","summary_en":"Decades of risk-averse guidance have left children with cardiomyopathy sedentary, with poor cardiorespiratory fitness and added cardiometabolic risk. This AHA Scientific Statement provides an evidence-based framework to actively promote physical activity in paediatric hypertrophic, dilated, restrictive and arrhythmogenic cardiomyopathy. Newer data suggest sudden cardiac death risk in selected patients is not higher with exercise than with inactivity, and physical activity may even support reverse remodelling. The statement offers a practical framework for risk stratification and personalised exercise prescription.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd9913e3a8a7","type":"article","url":"https://hartvaat.nl/2026/05/09/telesat-prior-hf-telemonitoring-na-hartfalenopname-verbonden-met-46-lagere-morta/","title":"TELESAT PRIOR-HF: telemonitoring na hartfalenopname verbonden met 46% lagere mortaliteit","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","heart-failure-2026"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag146","source_url":"https://doi.org/10.1093/ejhf/xuag146","authors":["Luca Monzo","Patrick Jourdain","Annabelle Jagu","Marie-France Seronde","Hélène Benchimol","Jean-Michel Tartière"],"significance":7,"published":"2026-05-10","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"heart-failure-2026","summary_en":"Pre-specified TELESAT-HF substudy in patients with prior HF hospitalization (~1,258 RMP, ~2,321 weighted controls from French claims data). Remote monitoring was associated with halved all-cause mortality (23.5% vs 39.6%; HR 0.54), 15% fewer HF rehospitalizations, 32% fewer ED visits, 35% fewer ICU admissions and 1.77 fewer hospital days, without higher total costs. Observational — residual confounding possible despite weighting — but a strong signal supporting structured RMP implementation in post-discharge HF care.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b1f4aac28bf","type":"article","url":"https://hartvaat.nl/2026/05/10/delta-hf-thoracale-duct-lymfedecongestie-via-elym-systeem-haalbaar-bij-acute-har/","title":"DELTA-HF: thoracale-duct lymfedecongestie via eLym-systeem haalbaar bij acute hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["heart-failure-2026","hfref","step-hfpef"],"journal":"European Journal of Heart Failure","doi":"10.1093/ejhf/xuag157","source_url":"https://doi.org/10.1093/ejhf/xuag157","authors":["Jorge Nuche","María Dolores García-Cosío Carmena","Jan Biegus","Zviad Kereselidze","Archil Chukhrukidze","George Khabeishvili"],"significance":7,"published":"2026-05-10","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"DELTA-HF (n=40, single-arm, multicenter) tested the eLym System — an endovenous axial pump creating a reduced-pressure zone at the venous angle to support lymphatic drainage via the thoracic duct — in patients with acute decompensated HF refractory to oral diuretics. Deployment was 100% successful, weight loss 3.6 kg during therapy and 6.8 kg by discharge, congestion score from 5 to 0 (sustained at 6 months), creatinine stable. 95% freedom from device/procedure SAEs; one fatal vascular complication. Encouraging proof of concept in a difficult-to-decongest population; randomized trials warranted.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26755268c6de","type":"article","url":"https://hartvaat.nl/2026/05/10/dig-rhd-digoxine-verlaagt-sterfte-en-hartfalen-bij-symptomatische-reumatische-ha/","title":"Dig-RHD: digoxine verlaagt sterfte en hartfalen bij symptomatische reumatische hartziekte","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["heart-failure-2026"],"journal":"JAMA","doi":"10.1001/jama.2026.7335","source_url":"https://doi.org/10.1001/jama.2026.7335","authors":["Ganesan Karthikeyan","Niveditha Devasenapathy","Arpita Ghosh","Prayaag Ramdas Kini","Reeta Varyani","Santhosh Satheesh"],"significance":8,"published":"2026-05-10","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"heart-failure-2026","summary_en":"Dig-RHD is the first RCT of digoxin in rheumatic heart disease. 1,769 patients across 12 Indian tertiary centers (mean age 46, 72% female, 70% AF, 90% NYHA II–IV, mostly with mixed valve lesions) were randomized to digoxin 0.125–0.25 mg/day or placebo and followed a median 2.1 years. The primary composite of all-cause death or new-onset/worsening HF occurred in 31.4% (digoxin) vs 35.5% (placebo) — HR 0.82; 95% CI 0.69–0.96. Practice-changing for the Global South where RHD remains the leading cause of HF; relevant for migrant populations with chronic rheumatic valve disease in Western settings.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38bf364941b5","type":"article","url":"https://hartvaat.nl/2026/05/09/meta-analyse-decision-digit-hf-dig-digitalisglycosiden-reduceren-verslechterende/","title":"Meta-analyse DECISION + DIGIT-HF + DIG: digitalisglycosiden reduceren verslechterende hartfalenevents over 9.013 patiënten","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","dapa-hf","heart-failure-2026","lipidenverlaging","soul-trial","statines"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag387","source_url":"https://doi.org/10.1093/eurheartj/ehag387","authors":["Ragnhild Helseth","Ryohei Ono","Brian Claggett","Yasuhiro Hamatani","Mihaly Ruppert","Akshay Desai","Scott D Solomon"],"significance":8,"published":"2026-05-10","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"heart-failure-2026","summary_en":"A study-level meta-analysis pooling DECISION, DIGIT-HF and DIG (n=9,013) shows digitalis glycosides reduce CV death or first worsening HF event (HR 0.85; 95% CI 0.80–0.90; p<0.001) and time to first worsening HF event (HR 0.75; p<0.001), with consistent benefit on top of contemporary RALES/EMPHASIS-HF/PARADIGM-HF/DAPA-HF backbones. Population-level evidence reopening the case for digitalis as an add-on in symptomatic HF(m)rEF despite four-pillar therapy.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42af12d46da0","type":"article","url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","title":"DECISION-onttrekkingssubstudie: stoppen van digoxine na lange behandeling leidt tot acute verslechtering","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulantia","aspirine","bloeddrukbehandeling","dubbele-trombocytenremming","farmaco-economie","heart-failure-2026"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag385","source_url":"https://doi.org/10.1093/eurheartj/ehag385","authors":["Peter van der Meer","Dirk J van Veldhuisen","Geert H D Voordes","Jan Tijssen","Marco Alings","M L Bouvy"],"significance":8,"published":"2026-05-10","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/nhg-standaard-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"heart-failure-2026","summary_en":"Pre-specified DECISION substudy: 587 patients on active treatment (digoxin or placebo) underwent blinded withdrawal with 6-week in-person follow-up. Pre-withdrawal event rates were similar between groups. Post-withdrawal, digoxin-withdrawn patients had a sharp increase in CV death/worsening HF events (42.8 vs 5.9 per 100 patient-years; RR 7.37; 95% CI 1.56–34.88; p=0.012), accompanied by rising heart rate, falling SBP and rising NT-proBNP. Discontinuing digoxin after long-term exposure is associated with clinical deterioration — a clinically relevant caution for deprescribing reviews.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ac8ff757b0c0","type":"article","url":"https://hartvaat.nl/2026/05/10/decision-lage-dosis-digoxine-mist-primair-eindpunt-bij-hf-m-ref-maar-suggereert-/","title":"DECISION: lage-dosis digoxine mist primair eindpunt bij HF(m)rEF, maar suggereert minder verslechterende hartfalenevents","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","carvedilol","dapa-hf","emperor-trials","heart-failure-2026"],"journal":"Nature Medicine","doi":"10.1038/s41591-026-04406-6","source_url":"https://doi.org/10.1038/s41591-026-04406-6","authors":["D. J. van Veldhuisen","M. Rienstra","A. Mosterd","M. Alings","A. A. Voors","K. Damman","Peter van der Meer"],"significance":9,"published":"2026-05-10","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"heart-failure-2026","summary_en":"DECISION (n=1,001, 43 Dutch sites, median 36.5-month follow-up) is the first major modern RCT of low-dose digoxin in contemporary HF(m)rEF on guideline-directed therapy. The primary composite of worsening HF events plus CV mortality was lower with digoxin (RR 0.81; 95% CI 0.61–1.07) but did not reach statistical significance (p=0.133). Worsening HF events trended lower (RR 0.76); CV mortality was unchanged. Drug was well tolerated. Pooled with DIGIT-HF and DIG (n=9,013), digitalis glycosides did significantly reduce the composite (HR 0.85; p<0.001), reopening the case for digitalis as a cheap, safe add-on in HF(m)rEF.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e2cd01004d0e","type":"article","url":"https://hartvaat.nl/2026/05/10/hf-revert-antisense-mirna-remmer-cdr132l-mist-primair-eindpunt-na-infarct-met-ve/","title":"HF-REVERT: antisense miRNA-remmer CDR132L mist primair eindpunt na infarct met verminderde EF","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["heart-failure-2026"],"journal":"Nature Medicine","doi":"10.1038/s41591-026-04408-4","source_url":"https://doi.org/10.1038/s41591-026-04408-4","authors":["Johann Bauersachs","Scott D. Solomon","Stefan D. Anker","Isabel Antorrena-Miranda","Rudolf A. de Boer","John J.V. McMurray","Thomas Thum"],"significance":8,"published":"2026-05-10","source_date":"2026-05-10","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"heart-failure-2026","summary_en":"HF-REVERT (n=294) is the first phase 2 randomized trial of an antisense microRNA inhibitor in cardiology. CDR132L (anti-miR-132) given as three IV doses 3–14 days post-MI did not improve the primary endpoint (% change in LVESVi at 6 months) nor any secondary endpoint over placebo. The drug was well tolerated. Pre-specified exploratory analyses suggest potential benefit in patients with marked adverse remodeling at baseline — a hypothesis-generating signal worth pursuing in chronic HF populations. Important null finding for the cardiac RNA-therapeutics pipeline.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4403c070ffcc","type":"article","url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril-valsartan verbetert inspanningshemodynamiek bij HFpEF met atriale mitralisinsufficiëntie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","heart-failure-2026","sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.126.080833","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.126.080833","authors":["Sebastiaan Dhont","Sara Moura Ferreira","Xavier Galloo","Pieter Martens","Evelyne Meekers","Wilfried Mullens","Frederik H Verbrugge"],"significance":9,"published":"2026-05-10","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"heart-failure-2026","summary_en":"PRAISE-MR is the first medical-therapy trial demonstrating exercise-hemodynamic benefit in HFpEF with atrial functional mitral regurgitation (AFMR). In 84 patients randomized to sacubitril-valsartan or standard of care, the 6-month change in exercise mPAP/CO slope improved by 0.93 mmHg/L/min with sacubitril-valsartan (95% CI 0.07–1.80; p=0.035). Peak VO2, KCCQ score, NT-proBNP, LA volume and AFMR severity all improved. The findings position ARNI as a credible disease-modifying option for HFpEF + AFMR, alongside transcatheter mitral repair as evidence emerges.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"066a0d94676a","type":"article","url":"https://hartvaat.nl/2026/04/24/bij-metabool-syndroom-zonder-diabetes-of-hypertensie-bloeddruk-en-triglyceriden-/","title":"Bij metabool syndroom zonder diabetes of hypertensie: bloeddruk en triglyceriden zijn de sleutel","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","lipidenverlaging"],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-105379","source_url":"https://doi.org/10.1136/bmjopen-2025-105379","authors":["Per Nordin","Ulf Lindblad","Kristin Ottarsdottir","Bledar Daka","Margareta Hellgren"],"significance":5,"published":"2026-05-10","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The Skaraborg cohort (Sweden) followed 2,328 individuals without diabetes or hypertension at baseline (2002-2005, follow-up to 2011). The NCEP-defined metabolic syndrome predicted cardiovascular events (HR 2.4); IDF criteria did not. Blood pressure (HR 1.77) and triglycerides (HR 2.05) were the strongest individual predictors. Combining BP ≥125/80 mmHg with triglycerides ≥1.5 mmol/L matched the full MetS for prediction (HR 2.1; sensitivity 32.5%; NNE 7.1). Lowering the triglyceride cut-off to ≥1.2 mmol/L raised sensitivity to 44.9%. Practical: pay attention to borderline blood pressure and then measure triglycerides.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T18:39:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37ec1fa37e63","type":"article","url":"https://hartvaat.nl/2026/04/24/grote-ziekenhuisvariatie-in-mcs-gebruik-bij-myocardinfarct-met-cardiogene-shock/","title":"Grote ziekenhuisvariatie in MCS-gebruik bij myocardinfarct met cardiogene shock","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","myocardinfarct"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/563?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/563?rss=1","authors":["Verma","A.","Chervu","N. L.","Kim","J. J.","Mallick","S.","Ziaeian","B.","Benharash","P."],"significance":6,"published":"2026-05-10","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"An analysis of the 2019 Nationwide Readmissions Database examined inter-hospital variation in intra-aortic balloon pump (IABP) versus percutaneous ventricular assist device (PVAD) use in adults with AMI complicated by cardiogenic shock. Large inter-hospital differences in device choice were observed, not fully explained by patient factors. Institutional characteristics (volume, academic affiliation) emerged as key determinants — underscoring the need for standardised algorithms for MCS deployment in AMI cardiogenic shock.","created":"2026-07-03T10:32:53Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e0a19e311ae","type":"article","url":"https://hartvaat.nl/2026/04/24/bayesiaanse-netwerkmeta-analyse-vergelijkt-revascularisatie-bij-stabiele-ischemi/","title":"Bayesiaanse netwerkmeta-analyse vergelijkt revascularisatie bij stabiele ischemische hartziekte","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/530?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/530?rss=1","authors":["Kawczynski","M. J.","Barili","F.","Brophy","J. M.","De Caterina","R.","Biondi Zoccai","G.","Anselmi","A.","Boden","W. E.","Parolari","A.","Heuts","S.","on behalf of the INTEGRITTY initiative","Albuquerque","Almeida","Anselmi","Almeida","Anselmi","Beurtheret","Biondi-Zoccai","Boden","Borger","Brophy","Buttiglione","Dayan","Caterina","Cuesta","Firstenberg","Garcia-Villareal","Gomes","Heuts","Kaul","Kawczynski","Mandrola","Cuartas","Misfield","Musumeci","Parolari","Quintana","Redberg","Riad","Stuart","Ronco","Uva","Tomasi","Verhoye","Zenati","Dib"],"significance":7,"published":"2026-05-10","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"A hierarchical Bayesian network meta-analysis (PROSPERO CRD42024541215) of RCTs published 2005-June 2025 compared three initial strategies for non-acute myocardial ischaemic syndromes: optimal medical therapy alone, PCI added to OMT and CABG added to OMT. The primary outcome was long-term all-cause mortality. The analysis quantifies the strength of evidence on the comparative effectiveness of revascularisation — an area where current ESC and ACC/AHA guidelines diverge — and provides a quantitative framework for decisions in stable coronary disease.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b55802246ba","type":"article","url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","title":"CRT bij volwassenen met systemische rechterventrikel: gemengde uitkomsten in internationaal cohort","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/549?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/549?rss=1","authors":["Fusco","F.","Scognamiglio","G.","Dellborg","M.","Dehghani","P.","Jameson","S. M.","Kay","W. A.","Cramer","J. W.","Vonder Muhll","I.","Krieger","E. V.","Rodriguez","F. H.","Burchill","L. J.","Nicolarsen","J.","Kay","J.","Kauling","R. M.","Shah","S.","Magalski","A.","Wong","J.","Celermajer","D. S.","Baker","D. W.","Roos-Hesselink","J. W.","Ginde","S.","Aboulhosn","J.","Kuo","M.","DeZorzi","C.","Khairy","P.","Rodriguez-Monserrate","C. P.","Kutty","S.","Wilson","W.","Lubert","A. M.","Grewal","J.","Han","F.","Cotts","T.","Pylypchuk","S.","Gupta","T.","Antonova","P.","ODonnell","C.","John","A.","Gallego","P.","van Dissel","A.","Opotowsky","A. R.","Yeung","E.","Broberg","C. S.","Sarubbi","B."],"significance":5,"published":"2026-05-09","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/bundeltakblok/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"An international retrospective study (33 centres) of 1,721 adults with a systemic right ventricle — after atrial switch for transposition of the great arteries or with congenitally corrected TGA — of whom 105 (3.5%) underwent cardiac resynchronisation therapy. With a median 4.6-year follow-up, the primary endpoint was overall and heart-failure-free survival. CRT in this unique congenital population shows heterogeneous effects depending on baseline QRS width and function; careful selection remains essential for clinical gain.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d77503e4ac37","type":"article","url":"https://hartvaat.nl/2026/04/27/genen-voor-bloeddruk-in-de-kindertijd-voorspellen-cardiometabool-risico-op-later/","title":"Genen voor bloeddruk in de kindertijd voorspellen cardiometabool risico op latere leeftijd","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["abelacimab","acuut-hartfalen","alcoholgebruik","bloeddrukbehandeling","cardiovasculaire-genetica","diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","laminopathie","menopauze","obesitas","ouderen","primaire-preventie","statines","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag313","source_url":"https://doi.org/10.1093/eurheartj/ehag313","authors":["Tian Xie","Alireza Ani","Ahmad Vaez","Ilja M Nolte","Shaoyong Su","Mami Ishikuro","Siqi Wang","Wenbo Zhang","Ana Goncalves Soares","Ehsan Motazedi","Lucinda Calas","Justiina Ronkainen","Casper-Emil T Pedersen","Xueling Lu","Sara E Stinson","Janine F Felix","Evelina Stankevic","Carol A Wang","Elisabeth Thiering","Dietmar Fernández","Beatriz Calvo-Serra","Maria G Stathopoulou","Ruby Fore","Ashish Kumar","Johanna Tuhkanen","Jose Ramon Bilbao","Jesus Ibarluzea","Aaron Isaacs","Cilius Esmann Fonvig","Fernando Rivadeneira","Morten Asp Vonsild Lund","Louise Aas Holm","Peter J van der Most","Harriëtte Riese","Akira Narita","Gen Tamiya","Claudia Flexeder","Rikstje Wiersma","Anna D Argoty-Pantoja","Rebecca Vinding","Tine Willum Hansen","Thomas Kümler","Marisa Estarlich","Mariona Bustamante","Wen Lun Yuan","Anne Boland-Augé","Jean-François Deleuze","Alexandros M Petrelis","Sheryl Rifas-Shiman","Eero Kajantie","Nora Fernandez-Jimenez","Loreto Santa-Marina","Ilja C W Arts","Jari Lahti","Timo Strandberg","Inger Kull","Anna Bergström","Marie-France Hivert","Klaus Bønnelykke","Shinichi Kuriyama","Lawrence J Beilin","Trevor A Mori","Catharina A Hartman","Niels Grarup","Carel Thijs","Katri Räikkönen","Erik Melén","Emily Oken","Sophie Visvikis-Siest","Kristine B Gützkow","Regina Grazuleviciene","Barbara Heude","Leda Chatzi","Martine Vrijheid","Marie Standl","Tanja Vrijkotte","Craig E Pennell","Albertine J Oldehinkel","Torben Hansen","Vincent W V Jaddoe","Jens-Christian Holm","Sylvain Sebert","Nicholas J Timpson","Taku Obara","Xiaoling Wang","Deborah A Lawlor","Eva Corpeleijn","Tarunveer S Ahluwalia","Harold Snieder"],"significance":7,"published":"2026-05-09","source_date":"2026-04-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The largest paediatric GWAS meta-analysis to date (28,425 children for BP, 22,565 for heart rate, ages 4-17) identified eight genome-wide significant loci for childhood blood pressure and three for heart rate — all novel in children but previously reported in adults. Childhood polygenic risk scores explained up to 1.6% of BP and 5.2% of HR variance. In the UK Biobank, higher childhood-BP PRS levels were significantly associated with adult hypertension, angina, myocardial infarction and cardiovascular mortality — supporting cardiovascular prevention strategies that begin early in life.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"34eea9995b04","type":"article","url":"https://hartvaat.nl/2026/04/25/praetorian-dft-defibrillatietest-bij-subcutane-icd-veilig-achterwege-te-laten/","title":"PRAETORIAN-DFT: defibrillatietest bij subcutane ICD veilig achterwege te laten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080638","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080638","authors":[],"significance":8,"published":"2026-05-09","source_date":"2026-04-25","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/icd-implanteerbare-defibrillator/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The multinational PRAETORIAN-DFT RCT randomised 965 subcutaneous ICD recipients across 37 centres to defibrillation testing versus no testing — using the PRAETORIAN score (based on chest X-ray) to assess implant position in the no-DFT arm. First-shock failure for spontaneous ventricular arrhythmias was non-inferior without DFT, with comparable mortality and revisions. Routine defibrillation testing can therefore be omitted in patients with a favourable PRAETORIAN score, reducing implant-related risk.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29bdaec4d4ef","type":"article","url":"https://hartvaat.nl/2026/04/24/santorini-uk-ldl-doel-onbereikt-bij-meerderheid-van-hoogrisicopatienten-na-1-jaa/","title":"SANTORINI UK: LDL-doel onbereikt bij meerderheid van hoogrisicopatiënten na 1 jaar","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["ezetimibe"],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-114031","source_url":"https://doi.org/10.1136/bmjopen-2025-114031","authors":["Derek Connolly","Ahmet Fuat","Terry McCormack","Damien Mcnally","Jonathan Garstang","John Ryan","Amelia Reed","Daniel Robinson","Alberico L Catapano","Kausik K Ray"],"significance":6,"published":"2026-05-08","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-doelwaarden-risicostratificatie/"],"congress":"","summary_en":"Secondary analysis of the SANTORINI study (663 UK patients with high/very high CV risk, 8,502 from other European countries) examined 1-year changes in lipid-lowering therapy and LDL-C goal attainment. The proportion on no LLT in the UK dropped from 20.4% to 7.1%. Monotherapy dominates in the UK (74.8% at baseline → 84.9% at 1 year), while combination therapy grew faster elsewhere (27.1% to 40.2%). Mean UK LDL-C fell from 2.5 to 2.1 mmol/L. Yet most patients still miss NICE and ESC/EAS LDL targets — room for intensification, especially via combination therapy.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2bb23b37ea39","type":"article","url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","title":"Verminderde nierfunctie verhoogt hartfalenrisico bij ouderen — ASPREE-cohort","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","anemie-ckd","anticoagulatie-kwetsbare-ouderen","aspirine","bisoprolol","chronische-nierziekte","cystatine-c","dapagliflozine","empagliflozine","hfref","ivabradine","nierfalen","primaire-preventie","sacubitril-valsartan","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/10/569?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/10/569?rss=1","authors":["Buyadaa","O.","Wolfe","R.","Tonkin","A. M.","Reid","C. M.","Zhou","Z.","Wetmore","J. B.","Fravel","M. A.","Woods","R. L.","Polkinghorne","K. R."],"significance":6,"published":"2026-05-08","source_date":"2026-04-24","image":"https://hartvaat.nl/global/img/54665943e7e6.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"A prospective cohort analysis nested in the ASPREE trial and its extension study (17,834 older adults) examined whether elevated urine albumin-creatinine ratio (UACR) or reduced eGFR predicted heart failure hospitalisation or death. Over a median 8.6-year follow-up, 354 (1.98%) had a first HF hospitalisation and 147 (0.82%) died from HF. Albuminuria (UACR ≥3.0 mg/mmol; 11.3% of the cohort) was associated with higher risk of HF events. Routine kidney screening in primary care looks valuable for cardiovascular risk stratification in older adults.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fd2453d7066","type":"article","url":"https://hartvaat.nl/2026/04/01/noac-s-onder-de-65-jaar-apixaban-heeft-het-gunstigste-baten-risicoprofiel/","title":"NOAC's onder de 65 jaar: apixaban heeft het gunstigste baten-risicoprofiel","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen","doacs","rivaroxaban"],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2026.9082","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.9082","authors":["Marie C Bradley","Andrew L Simon","Joy Kolonoski","David J Graham","Rongmei Zhang","John G Connolly"],"significance":7,"published":"2026-05-08","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A cohort study in the FDA Sentinel System of >173,000 NVAF patients aged 21-64 found that rivaroxaban was associated with higher major extracranial bleeding (HR 1.91) and gastrointestinal bleeding (HR 1.92) versus apixaban, with no difference in thromboembolic stroke. Dabigatran carried a higher thromboembolic stroke risk than both rivaroxaban and apixaban. Apixaban emerged with the most favourable benefit-harm profile — extending Medicare findings into a younger AF population.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8cd2cd225244","type":"article","url":"https://hartvaat.nl/2026/04/24/nkf-consensus-standaardiseer-urine-afname-om-albuminurie-betrouwbaar-te-meten/","title":"NKF-consensus: standaardiseer urine-afname om albuminurie betrouwbaar te meten","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag083","source_url":"https://doi.org/10.1093/ndt/gfag083","authors":["Stefan Ridderbos","Dominique van Mil","Bengt Fellström","Barbara S Gillespie","Will G Herrington","Lilio Hu","Gaetano La Manna","Maaike Mepschen","W Greg Miller","Mauro Panteghini","Michele Provenzano","Jesse C Seegmiller","Joseph A Vassalotti","Hiddo J L Heerspink","Ron T Gansevoort"],"significance":5,"published":"2026-05-07","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/albumine-creatinine-ratio/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"The US National Kidney Foundation convened a workshop (April 2025) on pre-analytical factors affecting urinary albumin and protein measurement. Heterogeneity in collection method (24-hour vs single void), timing, repeat sampling, clinical conditions causing false-positives and storage conditions all materially influence results. The consensus report offers practical recommendations to minimise biological and analytical variability — relevant for both clinical decisions and trial data.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c090be50de3d","type":"article","url":"https://hartvaat.nl/2026/05/05/verminderde-rv-vrijewandstrain-voorspelt-mcs-behoefte-bij-cardiogene-shock/","title":"Verminderde RV-vrijewandstrain voorspelt MCS-behoefte bij cardiogene shock","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiogene-shock","rechterventrikelfalen","supraventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag116","source_url":"https://doi.org/10.1093/eschf/xvag116","authors":["Chong Bin Lee","Andreas Merz","Daniel-Armando Morris","Matthias Schneider-Reigbert","Linus Haberbosch","Fabian Spinka","Caroline Büttner","Cheng-Ying Chiu","Ingo Hilgendorf","Robin Kraft","Thomas Schlabs","Athanasios Frydas"],"significance":6,"published":"2026-05-07","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"A 92-patient single-centre retrospective study found that severely impaired RV free-wall longitudinal strain (<11%) on early echocardiography predicted need for temporary mechanical circulatory support (OR 10.49) in cardiogenic shock. TAPSE and fractional area change were not predictive. Combining RV FWLS with SOFA score and LVEF achieved 78% accuracy and 95% specificity for MCS escalation. RV strain deserves a role in early risk stratification of cardiogenic shock.","created":"2026-07-03T10:32:52Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"019521d90f4a","type":"article","url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","title":"Gecombineerde mitraal- en tricuspidalis-TEER verbetert overleving bij multivalvulair lijden","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["tricuspidalisinsufficiëntie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag186","source_url":"https://doi.org/10.1093/eurheartj/ehag186","authors":["Mohammad Kassar","Fabien Praz","Muhammed Gerçek","Vera Fortmeier","Karl-Patrik Kresoja","Jennifer von Stein","Christoph Pauschinger","Wolfgang Rottbauer","Bjoern Goebel","Paolo Denti","Paul Achouh","Tienush Rassaf","Manuel Barreiro-Perez","Peter Boekstegers","Andreas Rück","Monika Zdanyte","Marianna Adamo","Flavien Vincent","Philipp Schlegel","Sebastian Rosch","Mirjam G Wild","Christian Besler","Stefan Toggweiler","Stephanie Brunner","Julia Grapsa","Tiffany Patterson","Holger Thiele","Tobias Kister","Giuseppe Tarantini","Giulia Masiero","Marco De Carlo","Alessandro Sticchi","Fabian Voss","Amin Polzin","Antonio Popolo Rubbio","Francesco Bedogni","Mathias H Konstandin","Eric Van Belle","Marco Metra","Tobias Geisler","Rodrigo Estévez-Loureiro","Amir Mahabadi","Nicole Karam","Francesco Maisano","Philipp Lauten","Mirjam Kessler","Daniel Kalbacher","Christos Iliadis","Philipp Lurz","Jörg Hausleiter","Felix Mahfoud","Stephan Windecker","Lukas Stolz","Nicolas Brugger","Volker Rudolph"],"significance":8,"published":"2026-05-07","source_date":"2026-04-24","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/vasculair/wells-score-dvt-longembolie/"],"congress":"","summary_en":"In the EuroTR registry of 3,100 patients with severe tricuspid regurgitation, 30% also had moderate mitral regurgitation — associated with higher 2-year mortality (37% vs 23%). After propensity score matching (217 pairs), concomitant mitral TEER added to tricuspid TEER produced greater TR reduction, better NYHA class and 6-minute walk distance, and significantly higher survival (87% vs 76% at 1 year; 81% vs 70% at 2 years). On multivariable analysis, moderate MR predicted death (HR 1.81) and combined M-TEER predicted survival (HR 0.46). Hypothesis-generating — a dedicated RCT is needed.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c6a3ae5279b","type":"article","url":"https://hartvaat.nl/2026/05/06/circulerend-mir-10b-5p-voorspelt-af-recidief-na-ablatie/","title":"Circulerend miR-10b-5p voorspelt AF-recidief na ablatie","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag097","source_url":"https://doi.org/10.1093/europace/euag097","authors":["Εmmanouil P Vardas","Evangelos Oikonomou","Stylianos Tzeis","Panagiotis Theofilis","Maria Gazouli","Eleni Papadogeorgaki","Konstantinos Belogiannis","Dimitrios Asvestas","Emmanouil Vavouris","Dimitrios Charitos","Dimitris Tousoulis"],"significance":5,"published":"2026-05-06","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"","summary_en":"A two-phase translational study identified circulating microRNAs associated with atrial fibrillation recurrence after catheter ablation. The discovery phase (n=29) flagged 14 miRNAs significantly linked to recurrence; in the prospective validation cohort (n=126), miR-10b-5p showed the highest discrimination (AUC=0.96). Lower miR-10b-5p expression independently predicted recurrence and substantially improved the baseline clinical model (ΔR² 63.3%). Pathway analysis linked miR-10b-5p to FOXO, p53 and circadian signalling — relevant to atrial remodelling. Multicentre validation is needed for clinical use.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9d7f27cc1c6","type":"article","url":"https://hartvaat.nl/2026/04/01/risicofactoren-voor-cardiovasculaire-events-bij-heterozygote-familiaire-hypercho/","title":"Risicofactoren voor cardiovasculaire events bij heterozygote familiaire hypercholesterolemie","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","cardiovasculaire-genetica","diabetes-type-2","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","inflammatie","laminopathie","lipoproteïne-a","menopauze","vrouwen"],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2026.120650","source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.120650","authors":["María Elena Mansilla-Rodríguez","José Luis Sánchez-Ramos","Alina Rigabert Sánchez-Junco","Jing Pang","Dick C Chan","Eva Nadiejda Gutiérrez-Cortizo","Pedro Mata","Gerald F Watts","Manuel Jesús Romero-Jiménez"],"significance":6,"published":"2026-05-06","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A systematic review and meta-analysis (21 studies, 23,613 genetically confirmed heterozygous FH patients, 3,489 cardiovascular events) showed independent associations between ASCVD and hypertension (effect size 0.41), male sex (0.33), smoking (0.32), Lp(a) (0.22), age (0.21), BMI (0.11), triglycerides (0.08) and LDL-C (0.02). Beyond intensive LDL lowering, aggressive management of classic risk factors — especially blood pressure and smoking — is essential to limit residual risk in this high-risk group.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c399314cad69","type":"article","url":"https://hartvaat.nl/2026/04/22/maternale-auto-immuunziekte-verhoogt-cardiovasculair-risico-bij-nakomelingen/","title":"Maternale auto-immuunziekte verhoogt cardiovasculair risico bij nakomelingen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["cardiovasculaire-genetica","gepersonaliseerde-geneeskunde","laminopathie","menopauze","ouderen","peripartum-cardiomyopathie","slaapapneu","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag316","source_url":"https://doi.org/10.1093/eurheartj/ehag316","authors":["Xingbo Mo","Imre Janszky","Elizabeth V Arkema","Hui Wang","Jette Möller","Yajun Liang","Krisztina D László"],"significance":7,"published":"2026-05-06","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"A Swedish population-based cohort of 1,455,645 singleton births (2001-2014, median 15.2-year follow-up) found that intrauterine exposure to maternal autoimmune disease was associated with a 19% higher risk of cardiovascular disease in offspring up to early adulthood (HR 1.19, 95% CI 1.14-1.24). Maternal effects were stronger than paternal effects, suggesting a pregnancy-specific contribution. Cousin analyses remained significant but somewhat weaker, indicating partial confounding by shared familial factors. The findings support added cardiovascular vigilance in children of mothers with autoimmune disease.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc149ed43014","type":"article","url":"https://hartvaat.nl/2026/04/19/fh-vrouwen-verliezen-mediaan-2-9-jaar-lipidenverlagende-behandeling-rond-elke-ki/","title":"FH-vrouwen verliezen mediaan 2,9 jaar lipidenverlagende behandeling rond elke kinderwens","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2026.120668","source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.120668","authors":["Marianne Klevmoen","Jeanine Roeters van Lennep","Martin Prøven Bogsrud","Elisabeth Kleivhaug Vesterbekkmo","Eva Kristine Ringdal Pedersen","Anders Hovland","Janneke W.C.M. Mulder","Hilde Kristin Brekke","Per Ole Iversen","Martina Vaclová","Michal Vrablík","Tomáš Freiberger","Kjetil Retterstøl","Kirsten B. Holven"],"significance":9,"published":"2026-05-05","source_date":"2026-04-19","image":"https://hartvaat.nl/global/img/b4a29627978f.webp","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"A Norwegian cohort within the FH-FEMINA study followed 27 women with familial hypercholesterolaemia from 36 weeks of gestation until one year postpartum or end of breastfeeding. Median pregnancy-related off-treatment time per woman was 2.9 years (range 0.8–12) across all childbirths. The pregnancy itself accounted for only 42% of off-treatment time; the pre- and post-pregnancy windows together accounted for 58%. Including untreated years in childhood and before diagnosis, lifelong off-treatment time reached a median of 66% of total lifespan. The authors — including Jeanine Roeters van Lennep (Erasmus MC) and Janneke Mulder, both active in the Dutch LEEFH cascade screening programme — call for earlier FH diagnosis in girls, prompt resumption of lipid-lowering therapy immediately after breastfeeding and between pregnancies, and urgently needed evidence on statin safety during pregnancy and lactation.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e65af50ca504","type":"article","url":"https://hartvaat.nl/2026/04/22/obesitas-en-primair-aldosteronisme-oorzaak-gevolg-of-beide/","title":"Obesitas en primair aldosteronisme: oorzaak, gevolg of beide?","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","cagrisema","lorundrostat","obesitas","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","select-trial","semaglutide","tirzepatide"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26227","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26227","authors":[],"significance":5,"published":"2026-05-05","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"A review of the bi-directional relationship between obesity and aldosterone. Obesity correlates with higher circulating aldosterone and urinary excretion in normo- and hypertensive individuals without primary aldosteronism. Mineralocorticoid receptor activation in adipocytes can expand visceral fat, while adipocytes stimulate adrenal aldosterone production via leptin, CTRP-1 and resistin. Patients with idiopathic hyperaldosteronism are more obese than those with aldosterone-producing adenomas; aldosterone falls after weight loss. Mendelian randomisation partly supports causality. Clinical implication: weight loss should be a priority in PA patients.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4a1b7deccf1","type":"article","url":"https://hartvaat.nl/2026/04/22/angptl3-remmers-verlagen-breed-lipidenspectrum-vooral-remnant-en-triglyceriden/","title":"ANGPTL3-remmers verlagen breed lipidenspectrum, vooral remnant- en triglyceriden","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["ace-remmers","cetp-remmers","dyslipidemie","ezetimibe","lipidenverlaging","obicetrapib","pcsk9-remmers-nieuwe-generatie","ras-remmers","yellow-iii"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag230","source_url":"https://doi.org/10.1093/eurjpc/zwag230","authors":["Sining Xie","Federica Galimberti","Elena Olmastroni","Alberico L Catapano","Manuela Casula"],"significance":7,"published":"2026-05-05","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"A meta-analysis of 9 RCTs (1,254 participants) showed that angiopoietin-like protein 3 (ANGPTL3) inhibition produces broad lipid lowering: triglycerides −47.1%, LDL-C −21.6%, ApoB −19.9%, non-HDL-C −31.5%, VLDL-C −40.6% and remnant cholesterol −72.7%. Lp(a) fell 11.5%. Evinacumab (monoclonal antibody) gave the largest LDL-C, ApoB and non-HDL-C reductions; siRNAs (zodasiran, solbinsiran) achieved more pronounced VLDL-C lowering. No effect on hs-CRP. ANGPTL3 inhibition is most promising for triglyceride-rich lipoproteins — a significant new pillar against residual cardiovascular risk.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1a033f5aa95d","type":"article","url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","title":"Geen sekseverschillen in werkzaamheid van hartfalenmedicatie: meta-analyse van 139 RCT's","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","empagliflozine","harttransplantatie","hfmref","hfpef","hfref","ivabradine","nt-probnp","pathfinder-trial","primaire-preventie","step-hfpef","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag311","source_url":"https://doi.org/10.1093/eurheartj/ehag311","authors":["Marte F van der Bijl","Niels T B Scholte","Julie A E van Oortmerssen","Jeanine E Roeters van Lennep","Astrid Schut","Iris C D Westendorp","Robert M A van der Boon","Jasper J Brugts","Isabella Kardys","Yolande Appelman","Hester M den Ruijter","Sanne A E Peters","Eric Boersma"],"significance":8,"published":"2026-05-05","source_date":"2026-04-28","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"A meta-analysis of 139 heart failure RCTs (292,027 patients, 28.1% women) tested whether pharmacological efficacy differs by sex. Across 78 trials reporting sex-stratified results the primary-endpoint effect was identical in women and men (delta ln[REM] 0.00; 95% CI −0.04 to 0.03), and meta-regression found no association between the proportion of women enrolled and treatment effect. Decades of female under-representation are therefore unlikely to have masked clinically meaningful sex differences — though better gender balance in HF trials remains ethically and socially essential.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebc71946dcdf","type":"article","url":"https://hartvaat.nl/2026/04/25/preoperatieve-pcsk9-remming-associeert-met-minder-postoperatieve-mace-dan-statin/","title":"Preoperatieve PCSK9-remming associeert met minder postoperatieve MACE dan statines","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["enlicitide","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2026.120760","source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.120760","authors":["Hsiang-Ling Wu","Jui-Tai Chen","Juan Pablo Cata","Yih-Giun Cherng","Ying-Hsuan Tai"],"significance":6,"published":"2026-05-04","source_date":"2026-04-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"An active-comparator cohort study (TriNetX, 35,923 propensity-matched pairs) compared perioperative PCSK9 inhibitors with statins in hyperlipidaemia patients undergoing surgery between July 2015 and June 2025. PCSK9 inhibitors were associated with lower 30-day MACE (6.4% vs 9.6%; NNT 31; RR 0.67), all-cause mortality (RR 0.45), acute kidney injury (RR 0.45) and respiratory infections (RR 0.77), as well as less delirium (RR 0.41) and transaminase rise. RCTs are needed to rule out residual confounding.","created":"2026-07-03T10:32:51Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69af20ff0033","type":"article","url":"https://hartvaat.nl/2026/04/27/routinematige-urine-natriummeting-drijft-agressievere-diurese-bij-acuut-hartfale/","title":"Routinematige urine-natriummeting drijft agressievere diurese bij acuut hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diuretica"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag119","source_url":"https://doi.org/10.1093/eschf/xvag119","authors":["Amitai Segev","Viana Copeland","David Mark Hochstein","Noam Orvieto","Elad Brav","Fernando Chernomordik","Romana Herscovici","Roy Beigel","Nathaniel M Hawkins","Elad Maor","Shlomi Matetzky"],"significance":6,"published":"2026-05-04","source_date":"2026-04-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"In a single-centre implementation study, routine urine sodium measurement was added for 160 cardiac-ICU admissions with acute heart failure from September 2021, compared with 206 historical controls. Post-implementation, patients received higher 72-hour furosemide doses (340 vs 220 mg; p<0.001) and more aggressive diuresis (aOR 4.8). Cumulative urine output was higher (6,250 vs 4,873 mL) and resolution of jugular venous distension and peripheral oedema was faster. Routine urine sodium guides faster, more aggressive decongestion in the cardiac-ICU setting.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4bce34253082","type":"article","url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","title":"Doorgaan met dezelfde DOAC na breakthrough-beroerte even goed als wisselen","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2026.9584","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.9584","authors":["Lucio D'Anna","Francesca Gabriele","Raffaele Ornello","Andrea Zini","Matteo Paolucci","Stefano Forlivesi","Ludovica Migliaccio","Maria Maddalena Viola","Angelo Cascio Rizzo","Maria Sessa","Ghil Schwarz","Rachele Tortorella","Gabriele Prandin","Soma Banerjee","Gurav Desai","Leonardo Pantoni","Francesco Mele","Giuseppe Scopelliti","Ilaria Cova","Mariarosaria Valente","Domenico Maisano","Maria Rosaria Bagnato","Giovanni Di Mauro","Francesca Bernocchi","Martina Gaia Di Donna","Barbara Casolla","Marie-Helene Mahagne","Marie-Eve Amoretti","Lucille Morgan","Laura González","Ricardo Rigual","Blanca Fuentes","Carlos Hervás","Paolo Candelaresi","Vincenzo Andreone","Antonio De Mase","Emanuele Spina","Diana Aguiar de Sousa","Mariana Almudi Souza","Alberto Fior","Miguel Serôdio","Pietro Caliandro","Aurelia Zauli","Giuseppe Reale","Ahmed Abdelalim","Sandra Ahmed","Samah Ali Ismail","Liqun Zhang","Tara Latimer","Muhammad Elboghday","Ahmed El Bassiouny","Tamer Roushdy","Hossam Shokri","Federica Ferrari","Nicola Davide Loizzo","Federico Mazzacane","Maria Guarion","Valentina Barone","Paola Forti","Giuseppe Rinaldi","Marco Rossi","Vincenzo Laterza","Giovanni Frisullo","Pier Andrea Rizzo","Aldobrando Broccolini","Marina Mannino","Valeria Terruso","Marcella Caggiula","Simona Scalise","Ana Catarina Fonseca","Bernardo Antunes","Hrvoje Budincevic","Petra Crnac","Giovanna Viticchi","Mauro Silvestrini","Lorenzo Barba","Viktoria Musienko","Piergiorgio Lochner","Benjamin Landau","Sandeep Buddha","Roumeisa Khalil","Maria Grazia Piscaglia","Elena Minguzzi","Marialuisa Zedde","Ahmed Nasreldein","Luisa Vinciguerra","Luis Costa","Ahmed ElsaidElsayed","Mona Al Banna","Laura Tudisco","Maria Giulia Mosconi","Giovanni Merlino","Federico De Santis","Simona Sacco","Matteo Foschi"],"significance":7,"published":"2026-05-04","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"A registry-based emulated target trial of 1,006 AF patients with ischaemic stroke during DOAC therapy: 463 continued the same DOAC and 543 switched. After IPTW adjustment, 90-day net clinical benefit was 4.9% with switching versus 5.1% with continuation, a difference of −0.3 percentage points (90% CI −2.7 to 2.1) — within the prespecified non-inferiority margin. Recurrent ischaemic events, intracerebral haemorrhage, all-cause mortality and vascular death did not differ. After a breakthrough stroke on DOAC, switching is not better than continuing — the upfront DOAC choice matters more.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ccfb9e6cc14","type":"article","url":"https://hartvaat.nl/2026/04/22/cardiovasculair-polygeen-risico-voorspelt-witte-stof-hyperintensiteiten-in-uk-bi/","title":"Cardiovasculair polygeen risico voorspelt witte-stof-hyperintensiteiten in UK Biobank","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","menopauze","microbioom"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26388","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26388","authors":["Yongfang Zhang"],"significance":5,"published":"2026-05-03","source_date":"2026-04-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"Analysis of 44,996 UK Biobank participants linked polygenic risk scores (PRS) for 35 diseases and traits to white matter hyperintensities (WMH) as a marker of cerebral small vessel disease. Higher PRS for cardiovascular disease, hypertension, ischaemic stroke and blood pressure were associated with greater WMH burden — strongest for total WMH. Higher WMH burden in turn prospectively predicted higher cardiovascular incidence. Multi-omics identified biomarkers jointly associated with WMH and disease-specific PRS. The findings support WMH as an integrated cardiovascular-cerebral risk trajectory.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7c95aaf286cf","type":"article","url":"https://hartvaat.nl/2026/05/06/dronedaron-na-af-ablatie-gelijke-werkzaamheid-minder-bijwerkingen-dan-amiodaron/","title":"Dronedaron na AF-ablatie: gelijke werkzaamheid, minder bijwerkingen dan amiodaron","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag095","source_url":"https://doi.org/10.1093/europace/euag095","authors":["Xuan Zhang","Rong Jiang","Yuxiao Chen","Lian Lou","Shuo Liu","Thida Sok","Jie Han","Dongchen Zhou","Biqi Zhang","Zhihang Li","Wen Shi","Zhen Dai","Xiaosheng Hu","Xiaogang Guo","Jian Yang"],"significance":7,"published":"2026-05-03","source_date":"2026-05-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"An open-label RCT randomised 280 post-AF-ablation patients to 12 weeks of dronedarone or amiodarone during the blanking period. Atrial tachyarrhythmia recurrence did not differ (23.4% vs 16.9%; p=0.184), but adverse events were far less common with dronedarone (40.9% vs 64.0%; p<0.001), driven mainly by less QTc prolongation (5.8% vs 15.4%) and hypothyroidism (8.8% vs 26.5%). Dronedarone offers comparable rhythm control with a safer profile as bridging therapy after ablation.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"843ce5ca59ad","type":"article","url":"https://hartvaat.nl/2026/04/28/viborg-screeningsprogramma-verlaagt-5-jaarssterfte-bij-67-jarigen/","title":"Viborg-screeningsprogramma verlaagt 5-jaarssterfte bij 67-jarigen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["perifeer-vaatlijden","primaire-preventie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag309","source_url":"https://doi.org/10.1093/eurheartj/ehag309","authors":["Marie Dahl","Annette Høgh","Jens Refsgaard","Mette Bredsgaard","Niels-Jørgen Moeslund","Dorthe Svenstrup","Martin Byskov Kinnerup","Anna Mejldal","Jes Sanddal Lindholt"],"significance":9,"published":"2026-05-03","source_date":"2026-04-28","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The Danish Viborg Screening Program invited all 67-year-olds for population-based screening (carotid plaque, lower-limb arterial disease, abdominal aortic aneurysm, hypertension, arrhythmia/ischaemia and diabetes). Across 5,412 invitees versus 16,236 matched controls, 5-year all-cause mortality was significantly lower (6.9% vs 8.9%; HR 0.76; number-needed-to-invite 49). Benefit was seen in both sexes and was strongest in those without prior CVD (HR 0.70); major adverse limb events also fell (HR 0.70).","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab2d99539e03","type":"article","url":"https://hartvaat.nl/2026/04/27/mexicaanse-hypertensieprevalentie-daalt-over-twee-decennia-behandelingsgaten-bli/","title":"Mexicaanse hypertensieprevalentie daalt over twee decennia, behandelingsgaten blijven","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25807","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25807","authors":[],"significance":5,"published":"2026-05-02","source_date":"2026-04-27","image":"","kennis":[],"congress":"","summary_en":"Analysis of Mexican Health and Nutrition Surveys 2000-2024 (146,904 adults ≥20 years) showed hypertension prevalence falling from 33.1% in 2000 to 26.0% in 2024, while the diagnosed share rose. Yet a substantial group remains undiagnosed or untreated. The study classifies undiagnosed hypertension into isolated systolic, isolated diastolic and systolic-diastolic phenotypes, and identifies determinants of under-treatment — relevant for public-health strategies across Latin America.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c604f242296","type":"article","url":"https://hartvaat.nl/2026/04/20/raas-blokkade-in-de-levenscyclus-van-de-nier-actuele-behandelstandaard/","title":"RAAS-blokkade in de levenscyclus van de nier — actuele behandelstandaard","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["ace-remmers","angiotensinereceptorblokkers","ras-remmers"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag090","source_url":"https://doi.org/10.1093/ndt/gfag090","authors":["Diego Moriconi","Clara Garcia-Carro","Julio Nuñez","Ricardo Correa-Rotter","Katherine Tuttle","María José Soler"],"significance":6,"published":"2026-05-02","source_date":"2026-04-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"An ERA-EDTA treatment-standard review on RAAS blockade across the kidney life cycle. ACE inhibitors, ARBs, direct renin inhibitors and mineralocorticoid receptor antagonists remain a cornerstone in proteinuric CKD and even in advanced stages, while benefit in non-proteinuric disease is limited. Non-steroidal MRAs such as finerenone add renal and cardiovascular protection in diabetes and CKD. In dialysis populations RAAS blockade may preserve residual kidney function; in kidney transplantation, early initiation may improve graft and patient survival. SGLT2 inhibitors and GLP-1 receptor agonists complement rather than replace RAAS blockade.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a3f0a435003","type":"article","url":"https://hartvaat.nl/2026/04/01/lp-a-verlaging-vergelijkbaar-tussen-alle-pcsk9-gerichte-middelen/","title":"Lp(a)-verlaging vergelijkbaar tussen alle PCSK9-gerichte middelen","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","enlicitide","lipidenverlaging","lipoproteïne-a","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen"],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.03.019","source_url":"https://doi.org/10.1016/j.jacl.2026.03.019","authors":["Martin D Mulligan","Rahul S Gandhi","Rishabh Vishwakarma","Romit Bhattacharya"],"significance":7,"published":"2026-05-02","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A systematic review and meta-analysis of 31 RCTs showed that PCSK9 inhibitors and inclisiran reduce lipoprotein(a) by a pooled 25.8% versus control (95% CI −29.5 to −22.0). Meta-regression found no significant differences between alirocumab, evolocumab and inclisiran; lerodalcibep and enlicitide produced similar ~25% reductions. For Lp(a) lowering the agent matters little — choice can be guided by dosing frequency, cost and patient preference. None of these drugs is approved purely for Lp(a) lowering yet.","created":"2026-07-03T10:32:50Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"afdfc09478a7","type":"article","url":"https://hartvaat.nl/2026/04/23/large-language-models-in-de-hypertensiezorg-kansen-en-grenzen/","title":"Large language models in de hypertensiezorg: kansen en grenzen","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.27004","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.27004","authors":["Benjamin Pariente"],"significance":4,"published":"2026-05-01","source_date":"2026-04-23","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/laboratoriumonderzoek-bij-hypertensie/","https://hartvaat.nl/kennis/nierziekte/cardiorenal-syndroom/"],"congress":"","summary_en":"A PRISMA-ScR scoping review of 33 studies (2023-2025) on large language model (LLM) applications in hypertension care. Use cases include clinical decision support, patient education, medical education, research support and administrative functions. GPT models dominate; evaluation methods are not yet standardised. Validity and clinical applicability remain under-studied. The field needs more robust study designs, clinical-outcome metrics and attention to bias and privacy.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b1b831293aa","type":"article","url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","title":"HFA-consensus: gestructureerde aanpak van recent ontstane cardiomyopathie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag115","source_url":"https://doi.org/10.1093/eschf/xvag115","authors":["Hadi Skouri","Amr Abdin","Wilfried Mullens","Chiara Bucciarelli Ducci","Randall C Starling","Peter Van der Meer","Gianluigi Savarese","Tuvia Ben Gal","Antoni Bayes-Genis","Stephane Heymans","Karin Klingel","Sanjay K Prasad","Dimitrios Farmakis","Ovidiu Chioncel","Arsen Ristic","Giuseppe Rosano","Petar Seferovic","Piotr Ponikowiski","Marco Metra","Carsten Tschöpe"],"significance":7,"published":"2026-05-01","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"The Heart Failure Association of the ESC issues a consensus statement on the evaluation and management of recent-onset non-ischaemic cardiomyopathy. The framework rests on two prognostic axes — potential for left ventricular reverse remodelling and risk of sudden cardiac death — and recognises four LVEF-trajectory categories. Diagnostics combine echocardiography, CMR, genetic testing, biomarkers and early treatment response. The management algorithm emphasises early initiation of guideline-directed medical therapy, re-assessment at 3 and 6 months, and individualised decisions on ICD, CRT, ablation and transcatheter valve repair.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ee995a145ad","type":"article","url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","title":"STOPSTORM: stereotactische bestraling reduceert refractaire VT met 80%","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ventrikelfibrilleren"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag338","source_url":"https://doi.org/10.1093/eurheartj/ehag338","authors":["L H G van der Pol","Bartłomiej Tomasik","Wiert F Hoeksema","Stefano Mandija","Marcin Miszczyk","Melanie Grehn","Jasna But Hadzic","David Calvo","Chiara Crico","Jakub Cvek","David Duncker","Felix Hohendanner","Tomasz Jadczyk","Stefan Jaschik","David Krug","Mario Levis","Gaetano Maria De Ferrari","Pieter P G Postema","Luis Schiappacasse","Jingyang Xie","Maiwand Ahmadsei","Manuel Algara","Piedad Almendros Blanco","Matteo Anselmino","Bor Antolic","Brian V Balgobind","Jacek Bednarek","Judit Boda-Heggemann","Thomas B Brunner","Corrado Carbucicchio","Francesco Cellini","Marzia Cerrato","Marian Christoph","Stefanie Corradini","Maria Del Pino Alcantara","Lukasz Dolla","Veronica Dusi","Micaela Ebert","Olgun Elicin","Niccolò Giaj-Levra","Franziska Hausmann","Colien Hazelaar","Claudia Herrera Siklody","Gerhard Hindricks","Mauro Iori","Barbara A Jereczek-Fossa","Otakar Jiravsky","Joanna Kaminska","Gunther Klautke","Lukas Knybel","Boldizsar Kovacs","Mathieu Kruska","Annika Lattermann","Tomasz Latusek","Marc D Lemoine","Evgeny Lian","Michele Magnocavallo","Felix Mehrhof","Roland Merten","Giulio Molon","Jiri Plasek","Gustavo Pozo Rodigriuez","Javier Quesada-Ocete","Robert Rademaker","Dirk Rades","Coen R N Rasch","Ardan Saguner","Mateusz Sajdok","Daniel Scherr","Ajra Secerov Ermenc","Lukas Seiss","Moritz Sinner","Jorge Solana Munoz","Rachel M A Ter Bekke","Roland Tilz","Christian Veltmann","Adrian Zaman","Nicolaus Andratschke","Katja Zeppenfeld","Slawomir Blamek","Joost J C Verhoeff","Etienne Pruvot","Oliver Blanck","M F Fast"],"significance":9,"published":"2026-05-01","source_date":"2026-04-20","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"The European STOPSTORM registry followed 193 patients (88% male, 53% non-ischaemic cardiomyopathy) treated with stereotactic arrhythmia radioablation (STAR) for refractory ventricular tachycardia. Among 107 patients with ≥6-month follow-up, median VT burden fell 80% over the six months after STAR and 72% remained free of ICD shocks. Twelve serious adverse events were adjudicated as possibly or probably treatment-related (including pericardial effusion and coronary events); 12-month overall survival was 77%.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"322118b3bafa","type":"article","url":"https://hartvaat.nl/2026/05/01/jama-cardiology-missie-en-visie/","title":"JAMA Cardiology: missie en visie","title_en":"JAMA Cardiology","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2849186","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2849186","authors":[],"significance":1,"published":"2026-05-01","source_date":"2026-05-01","image":"","kennis":[],"congress":"","summary_en":"JAMA Cardiology mission statement, positioned at the nexus of clinical investigation, actionable clinical science, and evidence-based cardiovascular medicine.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a0327444ecee","type":"article","url":"https://hartvaat.nl/2026/04/01/verhoogd-lp-a-hangt-samen-met-mitralisring-calcificatie-maar-niet-met-mitralisin/","title":"Verhoogd Lp(a) hangt samen met mitralisring-calcificatie maar niet met mitralisinsufficiëntie","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["bloeddrukbehandeling","mitralisinsufficiëntie","tricuspidalisinsufficiëntie"],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.03.022","source_url":"https://doi.org/10.1016/j.jacl.2026.03.022","authors":["Daoud Eldawud","Md Fahim","Keston Rattan","Omar Alwahadneh","Peter Khouri","Louis Salciccioli"],"significance":5,"published":"2026-04-30","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A retrospective TriNetX cohort study (>130,000 adults with Lp(a) measurements, propensity-matched into 66,292 pairs) found that elevated Lp(a) (>50 mg/dL) was independently associated with mitral annular calcification (HR 1.33) and — as positive control — with aortic stenosis (HR 1.31). No significant association was seen with mitral regurgitation, mitral stenosis or mitral valve prolapse. The findings extend Lp(a)'s role in calcific valvular disease and call for prospective studies.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5fbf299d343","type":"article","url":"https://hartvaat.nl/2026/03/30/leadless-atriaal-pacen-geeft-minder-complicaties-dan-transveneus-1-jaars-medicar/","title":"Leadless atriaal pacen geeft minder complicaties dan transveneus — 1-jaars Medicare-data","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["draadloze-pacemaker"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag072","source_url":"https://doi.org/10.1093/europace/euag072","authors":["Kent R Nilsson","Ulrika Birgersdotter-Green","Shmaila Saleem-Talib","Deepti Bettampadi","Zeyuan Yang","Jorge O Diaz","James K Gabriels","Robert D Schaller","Himanshu H Shukla","Michael Kühne","Mauro Biffi","Daniel Hofer","John Paisey","Yelena Nabutovsky","Christophe Garweg"],"significance":7,"published":"2026-04-30","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"Medicare claims compared 428 AVEIR AR leadless pacemaker recipients with 39,881 dual-chamber transvenous (DCTV) and 389 right-atrial transvenous (RATV) systems for sinus node dysfunction without AV block. At 30 days, complications were lower with AVEIR AR vs DCTV (6.7% vs 9.4%; OR 0.7) and similar to RATV; at 1 year, both overall complications (3.6% vs 8.5%; HR 0.4) and reinterventions were lower than in either transvenous cohort, with comparable mortality. Leadless atrial pacing looks attractive for selected SND patients without AV block.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"785175fa3473","type":"article","url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","title":"Triple-pill verlaagt risico op terugkerende beroerte na hersenbloeding","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aspirine","dubbele-trombocytenremming","trombocytenaggregatieremmers"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2515043","source_url":"https://doi.org/10.1056/NEJMoa2515043","authors":["Craig S Anderson","Clara K Chow","H Asita de Silva","Bimsara Senanayake","Kolawole Wahab","Rustam Al-Shahi Salman","Catharina J M Klijn","Sheila Ouriques Martins","Natalie Espinosa","Lauren Kuhles","Laurent Billot","Hisatomi Arima","Cheryl Carcel","Xia Wang","Qiang Li","Sana Shan","Mathangi Shanthakumar","Huy Thang Nguyen","Dilum Palliyaguruge","Janaka Peiris","Udaya K Ranawaka","Senaka Bandusena","Thambipillai Rajendiran","Darshana Wijegunasinghe","Harsha Gunasekera","Indunil Wijeweera","Athula Dissanayake","Ajantha Keshavaraj","Reginald O Obiako","Rufus Akinyemi","Luiz Nasi","Rodrigo Bazan","Carla Heloisa Cabral Moro","Mariana Battaglini","Viviane Zétola","Wan Chung Law","Yuen Kang Chia","Dennis Cordato","Rohan Grimley","Anuradha Dahanayaka","Sonali Liyanagamage","Nilukshi Fernando","Nihara Abdul Rasheed","Nodar Kakabadze","Maia Beridze","Mythily Aravinthan","Vithoosan Sahathevan","Devasmitha Wijesundara","Pramith Ruwanpathirana","Wan Asyraf Wan Zaidi","Tinatin Kherkheulidze","Urs Fischer","Ana Cláudia de Souza","Tsong-Hai Lee","Christopher Chen","Octavio Pontes-Neto","Thompson Robinson","Jiguang Wang","Sharon L Naismith","Michael Barnett","Carlos Delfino","Shoujiang You","Feifeng Liu","Candice Delcourt","Tom J Moullaali","Tim Wilkinson","Neil Watson","Karla Santo","Qiao Han","Mariana Almudi Souza","Wilmar M T Jolink","Anderson Berni Cristofari","Zien Zhou","Floris H Schreuder","Richard I Lindley","Manuela Armenis","Mark Woodward","Ruth Freed","Lili Song","John Chalmers","Anthony Rodgers"],"significance":10,"published":"2026-04-30","source_date":"2026-04-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"In a multinational double-blind RCT of 1670 patients with prior intracerebral haemorrhage, a once-daily low-dose triple pill (telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mg) added to standard care reduced recurrent stroke by 39% (4.6% vs 7.4%; HR 0.61) over 2.5 years, with mean systolic BP of 127 vs 138 mmHg. Major cardiovascular events were also lower (6.6% vs 9.8%). Early discontinuation for adverse events — mainly serum creatinine rises — was more common with the triple pill (13.6% vs 6.0%).","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c34de73d3938","type":"article","url":"https://hartvaat.nl/2026/03/30/adapt-cec-adaptief-ai-algoritme-voor-cardiovasculaire-event-adjudicatie-in-klini/","title":"ADAPT-CEC: adaptief AI-algoritme voor cardiovasculaire event-adjudicatie in klinische trials","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080072","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080072","authors":["Sreekanth Vemulapalli"],"significance":6,"published":"2026-04-28","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"Clinical endpoint classification (CEC) is the gold standard in CV trials but adds time and cost. ADAPT-CEC was developed on ODYSSEY OUTCOMES (MI, stroke, HF) and externally validated on EUCLID (MI, stroke, bleeding, CV death). It matches GPT-4 on F1 and offers a hybrid mode in which only the 30% of events with the lowest AI certainty go to human adjudication. Material implications for trial design: substantial time and cost savings without loss of validity.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efa1687903a2","type":"article","url":"https://hartvaat.nl/2026/04/06/aha-scientific-statement-acute-decompensatie-bij-hartfalen-in-het-kind-integraal/","title":"AHA Scientific Statement: acute decompensatie bij hartfalen in het kind — integraal managementkader","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001428","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001428","authors":[],"significance":6,"published":"2026-04-28","source_date":"2026-04-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This AHA scientific statement tackles the rising number of children with congenital or acquired heart disease presenting with acute decompensated heart failure. Compared with adults this group has higher morbidity, mortality, and healthcare utilisation, yet existing guidance is thin. The document bridges emergency medicine, paediatric cardiology, critical care, and surgery, and offers an integrated assessment, management, and discharge framework.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d7611d584e3","type":"article","url":"https://hartvaat.nl/2026/03/16/the-lancet-commentaar-vroege-atheroma-preventie-als-kosteneffectieve-route-naar-/","title":"The Lancet-commentaar: vroege atheroma-preventie als kosteneffectieve route naar gezond cardiovasculair ouder worden","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["farmaco-economie","hartrevalidatie","ouderen","perifeer-vaatlijden","primaire-preventie"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00419-8/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00419-8/fulltext","authors":["Rachael Steinhauer","Joshua Y H Xu","Roger S Blumenthal","Aaron L Troy"],"significance":6,"published":"2026-04-28","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"With annual ASCVD deaths projected to rise from 20.5 million (2025) to 35.6 million (2050), the authors make the Lancet case for earlier and longer primary prevention — aimed at slowing atheroma formation rather than intervening only once disease becomes symptomatic. The piece frames prevention as a life-course intervention and provides relevant context for conversations about early statin initiation, Lp(a) screening, and lifestyle measures.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"22f1a3d001a1","type":"article","url":"https://hartvaat.nl/2026/03/25/fontan-outcomes-network-eerste-bevindingen-uit-noord-amerikaans-register-van-1-1/","title":"Fontan Outcomes Network: eerste bevindingen uit Noord-Amerikaans register van 1.121 Fontan-patiënten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078152","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078152","authors":[],"significance":6,"published":"2026-04-27","source_date":"2026-03-25","image":"","kennis":[],"congress":"","summary_en":"The Fontan Outcomes Network is a learning health network of 38 congenital heart centres across the US and Canada. The first 1,121 participants (mean age 16.3 years; 42% female) confirm that hypoplastic left heart syndrome (38.5%) and right ventricular–dominant anatomy (54.9%) remain the dominant subtypes. The registry marks a shift: survival after Fontan palliation has improved sharply; defining the long-term trajectory is the next frontier.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca73c78bebb5","type":"article","url":"https://hartvaat.nl/2026/03/25/lvad-ondersteuning-activeert-microvasculair-herstel-in-het-falende-hart-mechanis/","title":"LVAD-ondersteuning activeert microvasculair herstel in het falende hart: mechanisme ontrafeld","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["harttransplantatie","laminopathie","microcirculatie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078996","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078996","authors":["Shuang Li"],"significance":6,"published":"2026-04-27","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/insulineresistentie-mechanisme/"],"congress":"","summary_en":"Single-nucleus RNA sequencing on myocardial tissue from HF patients before and after LVAD, complemented by a murine model with lineage tracing, identified the cell populations driving microvascular repair deep enough that some patients avoid transplantation after LVAD removal. A mechanistic study that surfaces concrete targets for HF reversal — and helps explain why some LVAD patients recover without needing a transplant.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c729c406ac41","type":"article","url":"https://hartvaat.nl/2026/03/28/echofocus-chd-ai-model-detecteert-20-aangeboren-hartafwijkingen-op-standaard-ech/","title":"EchoFocus-CHD: AI-model detecteert 20 aangeboren hartafwijkingen op standaard echocardiografie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079781","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079781","authors":["Platon Lukyanenko"],"significance":7,"published":"2026-04-27","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"EchoFocus-CHD is a multi-task AI model that automatically detects 12 critical and 8 non-critical congenital heart lesions on standard echocardiography. On an external cohort the model matched expert interpretation — with the promise of extending scarce paediatric echo expertise beyond academic centres. A concrete example of where AI-assisted imaging can rapidly deliver clinical value in primary care and smaller hospitals.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32da6952def0","type":"article","url":"https://hartvaat.nl/2026/03/31/mr-proadm-voorspelt-mortaliteit-en-hf-events-bij-attr-cardiale-amyloidose/","title":"MR-proADM voorspelt mortaliteit en HF-events bij ATTR cardiale amyloïdose","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","cardiale-amyloidose","nt-probnp","troponine"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077833","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077833","authors":["Belén Peiró"],"significance":7,"published":"2026-04-26","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/"],"congress":"","summary_en":"In 337 ATTR-CM patients from Spain, 12 circulating biomarkers were benchmarked for predicting mortality and HF events, with validation in two independent cohorts. Mid-regional pro-adrenomedullin (MR-proADM) emerged as a robust complement to NT-proBNP and high-sensitivity troponin for risk stratification — increasingly relevant as ATTR cardiomyopathy is diagnosed earlier and new therapies improve prognosis.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e896ebaf3c24","type":"article","url":"https://hartvaat.nl/2026/04/01/zwangerschap-als-stresstest-consensus-over-langetermijn-cardiovasculair-risico-b/","title":"Zwangerschap als stresstest: consensus over langetermijn-cardiovasculair risico bij adverse pregnancy outcomes","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845161","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2845161","authors":[],"significance":7,"published":"2026-04-26","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Adverse pregnancy outcomes — hypertensive disorders, gestational diabetes, preterm birth, SGA — complicate nearly one in five pregnancies and are associated with both short- and long-term maternal CV risk. This review consolidates the growing consensus that pregnancy is a natural stress test and the postpartum period an opportunistic window for targeted CV risk screening and lifestyle counselling. It argues for formally embedding pregnancy history into cardiovascular risk assessment.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2140beb7f6ab","type":"article","url":"https://hartvaat.nl/2026/03/26/aha-scientific-statement-niet-optimale-omgevingstemperatuur-als-cardiovasculaire/","title":"AHA Scientific Statement: niet-optimale omgevingstemperatuur als cardiovasculaire risicofactor","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","farmaco-economie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001419","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001419","authors":["Kate Hanneman"],"significance":7,"published":"2026-04-26","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This AHA scientific statement consolidates the evidence that ambient heat and cold drive cardiovascular events: MI, stroke, heart failure decompensation, arrhythmias, and sudden death. Mechanisms include autonomic and neurohormonal activation, endothelial dysfunction, inflammation, haemoconcentration, and impaired thermoregulation. With rising global temperatures and extreme-event frequency, contextual risk assessment — geography, housing, occupation — becomes a serious component of prevention.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"820b2a46271d","type":"article","url":"https://hartvaat.nl/2026/03/18/systematische-review-welke-factoren-voorspellen-langetermijnrisico-op-beroerte-n/","title":"Systematische review: welke factoren voorspellen langetermijnrisico op beroerte na TIA of kleine beroerte?","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078763","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078763","authors":["Faizan Khan"],"significance":7,"published":"2026-04-25","source_date":"2026-03-18","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/","https://hartvaat.nl/kennis/vasculair/ischemische-beroerte-tia/"],"congress":"","summary_en":"This systematic review and meta-analysis of 28 cohort studies (n≈86,000) identifies factors predicting long-term stroke risk after TIA or minor stroke. Pooled hazard ratios and population attribution fractions were estimated. The findings reinforce that TIA carries sustained risk over many years and provide practical targets for secondary prevention focused on vascular risk factors.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"673ad27ee028","type":"article","url":"https://hartvaat.nl/2026/03/30/crt-zonder-atriale-lead-tweeledig-crt-dx-systeem-non-inferieur-aan-klassieke-dri/","title":"CRT zonder atriale lead: tweeledig CRT-DX-systeem non-inferieur aan klassieke drie-leads CRT-D","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079859","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079859","authors":["Mauro Biffi"],"significance":8,"published":"2026-04-25","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"In this Italian multicenter RCT (n=636), a two-lead CRT-DX system with atrial sensing via a floating dipole on the RV lead was non-inferior to standard three-lead CRT-D on the 1-year composite of mortality, cardiovascular hospitalisation, and lead-related complications. For CRT-D candidates without sinus node dysfunction, the simplification is clinically appealing: fewer leads, fewer complications.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"127a9652b7bd","type":"article","url":"https://hartvaat.nl/2026/03/29/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pulmonale/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pulmonale hypertensie bij HFpEF","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","precision-trial","pulmonale-hypertensie","soul-trial","summit-trial"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079918","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079918","authors":["Mardi Gomberg"],"significance":9,"published":"2026-04-25","source_date":"2026-03-29","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/invasieve-hemodynamiek-rechts-hartkatheterisatie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"In this phase 2, placebo-controlled trial (n=164), sotatercept lowered pulmonary vascular resistance at week 24 in patients with combined post- and pre-capillary pulmonary hypertension associated with HFpEF. The median placebo-adjusted decline was largest in the 0.3 mg/kg arm. Until now no proven therapy existed for this CpcPH–HFpEF population, which involves remodeling in both the heart and pulmonary vasculature.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"30e92c5391b6","type":"article","url":"https://hartvaat.nl/2026/04/01/aric-ckm-syndroom-stadiering-voorspelt-hartfalen-risico-bij-ouderen-ook-met-subk/","title":"ARIC: CKM-syndroom stadiëring voorspelt hartfalen-risico bij ouderen — ook met subklinisch echoprofiel","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["cardio-renaal-metabool"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077894","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077894","authors":[],"significance":8,"published":"2026-04-24","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"In 5,646 older ARIC participants (66–90), CKM syndrome staging using the AHA framework showed a clear gradient: higher stages tracked with greater echocardiographic remodelling and significantly increased incident heart failure over follow-up. The results validate the CKM framework as a clinically useful risk model in older adults — the very group where HF prevention yields the highest absolute benefit.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dff27a9d5401","type":"article","url":"https://hartvaat.nl/2026/04/01/conduction-system-pacing-versus-biventriculaire-pacing-twee-trials-vergelijken-b/","title":"Conduction System Pacing versus biventriculaire pacing: twee trials vergelijken beide CRT-strategieën","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","linkerbundeltakpacing"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845804","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2845804","authors":[],"significance":9,"published":"2026-04-24","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/ritmestoornissen/pacemaker-indicaties-typen/"],"congress":"","summary_en":"Two new RCTs compare conduction system pacing (chiefly left bundle-branch area pacing) with conventional biventricular pacing in heart failure patients with LBBB. Earlier observational data suggested superior electrical resynchronisation and larger LVEF gains with CSP, fuelling rapid clinical adoption. These trials finally test whether the physiologically attractive approach actually outperforms BiVP on hard endpoints.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3eb9f70510f2","type":"article","url":"https://hartvaat.nl/2026/03/31/aha-scientific-statement-2026-nieuwe-voedingsleidraad-voor-cardiovasculaire-gezo/","title":"AHA Scientific Statement 2026: nieuwe voedingsleidraad voor cardiovasculaire gezondheid","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["farmaco-economie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001435","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001435","authors":[],"significance":9,"published":"2026-04-24","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This AHA scientific statement updates food-based guidance for cardiovascular health with seven practical pillars: energy balance, abundant vegetables and fruit, mostly whole grains, healthy protein sources, unsaturated over saturated fats, less ultra-processed food, and less sodium and added sugar. It deliberately emphasises dietary pattern over isolated nutrients — relevant simultaneously for prevention, CKM syndrome, and oncology.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"475b2d300a37","type":"article","url":"https://hartvaat.nl/2026/03/28/minoca-oorzaken-bij-vrouwen-en-mannen-in-beeld-gebracht-met-oct-en-cmr/","title":"MINOCA-oorzaken bij vrouwen én mannen in beeld gebracht met OCT en CMR","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080234","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080234","authors":[],"significance":7,"published":"2026-04-23","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/coronairlijden/minoca/"],"congress":"","summary_en":"This international prospective diagnostic study (28 US/Canada/UK sites) used multi-vessel optical coherence tomography during angiography and cardiac MRI within one week to map MINOCA mechanisms. After a women-only opening phase, men were added. The analysis identifies which patients are most likely to show abnormal imaging findings and highlights sex differences in MINOCA mechanisms — relevant for the diagnostic work-up where imaging is now recommended.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2973d16b182d","type":"article","url":"https://hartvaat.nl/2026/04/01/franse-multicentertrial-lage-dosis-rivaroxaban-verlaagt-linkerventrikeltrombus-n/","title":"Franse multicentertrial: lage dosis rivaroxaban verlaagt linkerventrikeltrombus na anterior STEMI","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aperitif-trial"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845590","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2845590","authors":[],"significance":8,"published":"2026-04-23","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/vasculair/claudicatio-intermittens/"],"congress":"","summary_en":"This French multicenter randomized trial assessed whether adding low-dose rivaroxaban to dual antiplatelet therapy reduces left ventricular thrombus incidence at one month in anterior STEMI patients. The strategy targets a persistent problem: subclinical LV thrombus soon after anterior MI with silent embolic implications. The results support targeted thromboprophylaxis in this high-risk subgroup without disproportionate bleeding.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad7c4ea303b7","type":"article","url":"https://hartvaat.nl/2026/03/30/essence-timi-73b-apoc3-remmer-olezarsen-reduceert-niet-verkalkte-coronairplaque-/","title":"Essence-TIMI 73b: APOC3-remmer olezarsen reduceert niet-verkalkte coronairplaque bij hypertriglyceridemie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["ezetimibe","lipidenverlaging","niet-statine-therapie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080012","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080012","authors":[],"significance":9,"published":"2026-04-23","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This CCTA sub-study of Essence-TIMI 73b showed that olezarsen — an APOC3 antisense oligonucleotide — lowered triglycerides by ~60% and remnant cholesterol by ~70%, with neutral LDL-C and ~15% apoB reduction. Over 12 months in patients with moderate hypertriglyceridemia and non-calcified coronary plaque, olezarsen produced a placebo-adjusted reduction in non-calcified plaque volume. It provides some of the first imaging evidence that triglyceride-directed therapy favorably modifies coronary atherosclerosis.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0150a9616c2b","type":"article","url":"https://hartvaat.nl/2026/03/19/memantine-remt-premature-atriumcontracties-in-fase-2-trial-nieuw-aangrijpingspun/","title":"Memantine remt premature atriumcontracties in fase 2-trial — nieuw aangrijpingspunt voor atriale aritmie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aperitif-trial"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.079023","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.079023","authors":["Yunli Shen"],"significance":8,"published":"2026-04-22","source_date":"2026-03-19","image":"","kennis":[],"congress":"","summary_en":"In this phase 2 double-blind randomized trial, memantine — an NMDA-receptor antagonist — suppressed premature atrial contractions in symptomatic adults with ≥1,000 PACs per 24 h. The result opens a genuinely new pharmacological route for atrial arrhythmia, grounded in the recently identified cardiac glutamatergic system. If PAC reduction translates into downstream AF and stroke benefit, it could reshape atrial arrhythmia treatment.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a0ecfbe47af","type":"article","url":"https://hartvaat.nl/2026/03/30/heparin-stemi-prehospitale-heparine-vergroot-vroege-doorstroming-bij-stemi-zonde/","title":"HEPARIN-STEMI: prehospitale heparine vergroot vroege doorstroming bij STEMI zonder meer bloedingen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["anticoagulantia","stemi"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079839","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079839","authors":["Misa Fister"],"significance":9,"published":"2026-04-22","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-acs-2023/"],"congress":"","summary_en":"This single-center RCT in 593 STEMI patients found that unfractionated heparin (70–100 IU/kg) given at first medical contact — prior to PCI-center arrival — significantly improved TIMI 2–3 flow in the infarct-related artery at initial angiography compared with standard UFH at PCI. BARC 3–5 bleeding was similar. The trial supports prehospital heparin as a simple, low-cost reperfusion strategy ahead of primary PCI.","created":"2026-07-03T10:32:47Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f92f641c36c","type":"article","url":"https://hartvaat.nl/2026/03/13/2026-acc-aha-richtlijn-dyslipidemie-lagere-doelen-meer-rol-voor-non-hdl-lp-a-en-/","title":"2026 ACC/AHA-richtlijn dyslipidemie: lagere doelen, meer rol voor non-HDL, Lp(a) en apoB","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","statines"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001423","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001423","authors":[],"significance":10,"published":"2026-04-22","source_date":"2026-03-13","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"The 2026 ACC/AHA dyslipidemia guideline retires the 2018 cholesterol document and broadens scope to hypertriglyceridemia and elevated lipoprotein(a). Non-HDL-C and apoB gain ground as secondary targets, LDL goals tighten for high-risk groups, and Lp(a) gets formal standing in risk assessment. Clinicians should anticipate broader lipid panels and more frequent escalation to PCSK9 inhibitors and emerging Lp(a)-lowering therapies.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"71696dfee65f","type":"article","url":"https://hartvaat.nl/2026/03/25/ehj-review-wearables-in-de-cardiovasculaire-praktijk-hoe-ver-zijn-we/","title":"EHJ-review: wearables in de cardiovasculaire praktijk — hoe ver zijn we?","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["digitale-gezondheid","hartrevalidatie","holter","lichaamsbeweging"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag189","source_url":"https://doi.org/10.1093/eurheartj/ehag189","authors":["Andrew M Hughes","Daniel J Taylor","Paul D Morris","Evan L Brittain"],"significance":6,"published":"2026-04-21","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/"],"congress":"","summary_en":"This EHJ review maps the current landscape of wearables (smartwatches and activity trackers) in cardiovascular care, from lifestyle coaching to continuous monitoring of heart failure and arrhythmias. It highlights the main barriers — variability in device methodology and validation, EHR incompatibility, and lack of standardised clinical workflows — and discusses AI-assisted interpretation. It offers practical guidance for clinicians integrating wearable data into routine practice.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c4b40a91899","type":"article","url":"https://hartvaat.nl/2026/03/23/clorotic-subanalyse-acute-egfr-daling-door-thiaziden-bij-acuut-hf-is-geen-progno/","title":"CLOROTIC-subanalyse: acute eGFR-daling door thiaziden bij acuut HF is geen prognostisch alarm","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag070","source_url":"https://doi.org/10.1093/ndt/gfag070","authors":["Wendy McCallum","Hocine Tighiouart","Marcelle Tuttle","Tatsufumi Oka","Tavleen Kaur","Jesús Casado","Jose Luís Morales-Rull","Francesc Formiga","Luís Manzano","Jeffrey M Testani","Mark J Sarnak","Joan Carles Trullás"],"significance":6,"published":"2026-04-21","source_date":"2026-03-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diuretica-bij-ckd/"],"congress":"","summary_en":"In this CLOROTIC sub-analysis (n=225), adding thiazide to loop diuretics in acute decompensated heart failure caused median eGFR declines of 9.7% at day 2 and 14.4% at day 4 (vs ~0% in placebo). However, these acute eGFR declines were not associated with increased mortality or the composite of death or HF hospitalisation at 3-month follow-up. The data support continuing combination diuresis when clinical decongestion is progressing, even with visible eGFR dips.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c3487e7fc6a","type":"article","url":"https://hartvaat.nl/2026/03/24/myocardiale-brug-praktische-gids-voor-diagnose-en-behandeling-in-het-ccta-tijdpe/","title":"Myocardiale brug: praktische gids voor diagnose en behandeling in het CCTA-tijdperk","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1038","source_url":"https://doi.org/10.1093/eurheartj/ehaf1038","authors":["Beatriz Castillo Rodriguez","Renzo Laborante","Affan Rizwan","Muzamil Khawaja","Stefano Elia","Noah Newman","Rehma Siddiqui","Daniel Berman","Giuseppe Patti","Hartzell V Schaff","Domenico D'Amario","Chayakrit Krittanawong"],"significance":6,"published":"2026-04-21","source_date":"2026-03-24","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/"],"congress":"","summary_en":"Myocardial bridging is the most common congenital coronary anomaly, usually benign but increasingly detected by coronary CT angiography and implicated in ischaemia with non-obstructive coronary arteries (INOCA). This EHJ review provides an evidence-based guide to diagnosis (CCTA, invasive angiography with IVUS/OCT) and management, addressing unresolved controversies around symptomatic treatment. A practical reference as imaging-led incidental findings rise.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb3d42585b53","type":"article","url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","title":"Tien jaar real-world sacubitril/valsartan: mortaliteitsreductie bevestigd, maar slechts 15–25% haalt doeldosis","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","sacubitril-valsartan","soul-trial"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag095","source_url":"https://doi.org/10.1093/eschf/xvag095","authors":["Gianluigi Savarese","Christian Basile","Alexandre Mebazaa","Antoni Bayes-Genis","Seok Min Kang","Byung-Su Yoo","Carlos Eid","Biykem Bozkurt","Javed Butler"],"significance":6,"published":"2026-04-20","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/ace-remmers-bij-hartfalen/"],"congress":"","summary_en":"This systematic review of 30 real-world studies confirms sacubitril/valsartan in HFrEF is associated with 10–16% lower cardiovascular mortality, 10–38% fewer HF hospitalisations and 10–25% lower all-cause mortality, along with cardiac reverse remodelling and reduced mitral regurgitation. Hypotension remained the most common adverse event (up to 17.6%). Only 15–25% of patients reach target dose — the true bottleneck is titration discipline rather than drug efficacy.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a436b17e4866","type":"article","url":"https://hartvaat.nl/2026/03/25/mendeliaanse-randomisatie-lp-a-verhoogt-coronarialijden-onafhankelijk-van-ldl-c-/","title":"Mendeliaanse randomisatie: Lp(a) verhoogt coronarialijden onafhankelijk van LDL-C, maar niet het diabetesrisico","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","figaro-dkd","lipide-aferese","lipidenverlaging","lipoproteïne-a","pelacarsen","soul-trial"],"journal":"JACC. Advances","doi":"10.1016/j.jacadv.2026.102697","source_url":"https://doi.org/10.1016/j.jacadv.2026.102697","authors":["Moa P Lee","Sarah H Koenigsberg","Mohammad Y Anwar","Laura M Raffield","Zhaotong Lin","Anna F Ballou","John N Booth","Thibaut Davy-Mendez","Helina Kassahun","Shia T Kent","J Antonio G López","Keri L Monda","Kari E North","Rina Yarosh","Christie M Ballantyne","Misa Graff","Christy L Avery"],"significance":7,"published":"2026-04-20","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"A phenome-wide Mendelian randomisation study in the UK Biobank (n=425,677) identified coronary artery disease (OR 1.36) and HbA1c (β 0.099) as the only direct, causal effects of Lp(a) exposure — independent of LDL-C. Very low Lp(a) was not linked to diabetes, addressing earlier safety concerns about Lp(a)-lowering therapies. Ancestry-specific risk thresholds were identified (86 nmol/L European, 93 nmol/L African). The findings support targeted Lp(a) testing and strengthen the mechanistic case for RNA-based Lp(a) lowering.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58d0e9d385aa","type":"article","url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","title":"ATHENA-register: pulsed field ablatie voor atriumfibrilleren ook effectief bij hartfalen, vooral paroxismaal","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag049","source_url":"https://doi.org/10.1093/europace/euag049","authors":["Marco Schiavone","Francesco Solimene","Antonio Dello Russo","Stefano Bianchi","Saverio Iacopino","Maurizio Malacrida","Antonio Rossillo","Sakis Themistoclakis","Matteo Bertini","Ilaria Meynet","Massimo Moltrasio","Vincenzo Schillaci","Michela Casella","Antonio Bisignani","Jacopo Colella","Maurizio Russo","Mario Volpicelli","Stefano Bandino","Gianluca Zingarini","Gianfranco Mitacchione","Matteo Casula","Gaetano Fassini","Roberto Rordorf","Valerio De Sanctis","Antonio De Simone","Giovanni Rovaris","Giulio Zucchelli","Claudio Tondo"],"significance":7,"published":"2026-04-20","source_date":"2026-03-17","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"In the ATHENA registry (n=1224), 79.9% of patients were free from atrial arrhythmias at 1 year after pentaspline pulsed-field ablation. The HF subgroup (n=176) had lower freedom (73.3% vs 81.0%, HR 1.5), driven by paroxysmal-AF patients (68.6% vs 82.2%). No difference was observed in patients with persistent AF. PFA appears safe and effective in heart failure, supporting broader use in this population.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"76b64c1e8034","type":"article","url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","title":"Gestandaardiseerd stappenplan voor tricuspidalisinsufficiëntie: van verwijzing tot expertcentrum","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["tricuspidalisinsufficiëntie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag214","source_url":"https://doi.org/10.1093/eurheartj/ehag214","authors":["Julien Dreyfus","Fabien Praz","Rebecca Hahn","Davide Margonato","Denisa Muraru","David Messika-Zeitoun","Marianna Adamo","Eustachio Agricola","Erwan Donal","Mirjam Wild","Haran Burri","Marco Metra","Augustin Coisne","Karl-Patrik Kresoja","Julia Grapsa","Jeroen Bax","Marta Sitges","Bernard Prendergast","Francesco Maisano","Joao Cavalcante","Nina Ajmone Marsan"],"significance":7,"published":"2026-04-19","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"This EHJ review proposes a standardised stepwise work-up for patients with tricuspid regurgitation, aligned with the 2025 ESC/EACTS Valvular Heart Disease guidelines. It covers clinical assessment, multimodality imaging (echocardiography, CT, CMR) and invasive haemodynamics, and emphasises multidisciplinary collaboration between imagers, heart failure specialists, interventional cardiologists, electrophysiologists and surgeons. As transcatheter TR therapies expand, the framework aims to improve timely referral and consistent management.","created":"2026-07-03T10:32:46Z","updated":"2026-07-03T13:31:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82f5da260636","type":"article","url":"https://hartvaat.nl/2026/03/20/hokuriku-plus-genetische-diagnose-bij-familiaire-hypercholesterolemie-verlaagt-m/","title":"Hokuriku-Plus: genetische diagnose bij familiaire hypercholesterolemie verlaagt MACE-risico onafhankelijk van LDL-C","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipoproteïne-a"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-25-1189","source_url":"https://doi.org/10.1253/circj.CJ-25-1189","authors":["Hayato Tada","Yasuaki Takeji","Chiaki Goten","Hirofumi Okada","Shohei Yoshida","Masaya Shimojima","Akihiro Nomura","Mika Mori","Shin-Ichiro Takashima","Takeshi Kato","Soichiro Usui","Kenji Sakata","Kenshi Hayashi","Noboru Fujino","Katsuhiko Nagase","Masa-Aki Kawashiri","Masayuki Takamura"],"significance":7,"published":"2026-04-19","source_date":"2026-03-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"In the Japanese Hokuriku-Plus registry (n=386 heterozygous FH), 52% of patients underwent genetic testing. These patients achieved lower LDL-C (102 vs 130 mg/dL) and had 34% lower MACE risk (HR 0.66) even after adjusting for LDL-C over 3.9-year median follow-up. The results suggest genetic confirmation itself drives better adherence and treatment intensity, arguing for broader FH genetic testing in clinical practice.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fedbba6624ee","type":"article","url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","title":"LINEAR-trial: lattice-tip-katheter verslaat standaard irrigatie bij CTI-ablatie voor typische atriumflutter","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag046","source_url":"https://doi.org/10.1093/europace/euag046","authors":["Stylianos Tzeis","Dimitrios Asvestas","Vasileios Sousonis","Emmanouil Vavouris","Paschalis Karakasis","Dimitrios Charitos","Stavros Karanikas","Konstantinos Pamporis","Panos Vardas","Konstantinos Vlachos"],"significance":7,"published":"2026-04-19","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"In the randomised LINEAR trial (n=102), the lattice-tip dual-energy catheter achieved bidirectional CTI block in 94.1% of patients versus 68.6% with the standard 3.5-mm irrigated catheter (P=0.002). First-pass block was 90.2% vs 60.8%, with dramatically shorter ablation time (41 vs 245 seconds) and fewer lesions (8.3 vs 13.4). No procedural complications occurred. Lattice-tip technology shows clear technical superiority for CTI ablation; longer-term clinical outcomes are still needed.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0b1a14d8894","type":"article","url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","title":"FINE-HEART: vrouwen met cardiovasculair-renaal-metabool syndroom worden systematisch onderbehandeld","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","cardio-renaal-metabool","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","farmaco-economie","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","gepersonaliseerde-geneeskunde","kanker-en-hart","menopauze","microbioom","obesitas","ouderen","ramipril","richtlijnen-esc","slaapapneu","soul-trial","voeding-hart"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag162","source_url":"https://doi.org/10.1093/eurheartj/ehag162","authors":["Maria A Pabon","John W Ostrominski","Xiaowen Wang","Brian L Claggett","Kevin B Lo","Gerasimos Filippatos","Akshay S Desai","Pardeep S Jhund","Alaisdair Henderson","Carolyn S P Lam","Michele Senni","Sanjiv Shah","Adriaan A Voors","Faiez Zannad","Cândida Fonseca","Eva Goncalvesova","Tzvetana Katova","Savina Nodari","Clara Inés Saldarriaga","Kavita Sharma","Orly Vardeny","Shelley Zieroth","Sorel Goland","Peter Rossing","Stefan D Anker","Bertram Pitt","Rajiv Agarwal","Lucas Hofmeister","Meike Brinker","Andrea Scalise","Katharina Mueller","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":8,"published":"2026-04-18","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This prespecified pooled analysis of FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF (n=18,991) found women with cardiovascular-kidney-metabolic syndrome were older, had more Stage 4 CKM disease, and received fewer guideline-recommended therapies (aspirin, statins, RAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists) than men. Rates of HF hospitalisation or CV death were similar across sexes, but women had 17% lower all-cause mortality. Finerenone was equally effective in both sexes. The results highlight a persistent treatment gap that deserves clinical attention.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T18:39:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ed12d028ba9","type":"article","url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","title":"Lp(a) verhoogt risico op veneuze trombo-embolie bij premenopauzale vrouwen en hormoon-gebruiksters","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["aperitif-trial","dubbele-trombocytenremming","ezetimibe","lipoproteïne-a","menopauze","trombocytenaggregatieremmers","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag252","source_url":"https://doi.org/10.1093/eurheartj/ehag252","authors":["Daniel Ezzat","Diana M Lopez","Brian L Claggett","Linke Li","Niekbachsh Mohammadnia","Art Schuermans","Jan Hemeryck","Annie Chang","Samantha Murillo","Michelle L O'Donoghue","Behnood Bikdeli","Zhi Yu","Pradeep Natarajan","Aniruddh P Patel","Maria A Pabon","Michael C Honigberg"],"significance":8,"published":"2026-04-18","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"In the UK Biobank (≈373,000 participants), Lp(a) ≥ 125 nmol/L was associated with incident venous thromboembolism in premenopausal women (aHR 1.32) and in postmenopausal women on menopausal hormone therapy (aHR 1.48), but not in postmenopausal women without hormones or in men. Oral contraceptive use did not modify the relationship in premenopausal women. The findings suggest sex-hormone status modifies Lp(a)-related VTE risk and support considering Lp(a) before starting hormone therapy.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"963f7d3500a0","type":"article","url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","title":"Meta-analyse: GLP-1-agonisten voorkomen hartfalen in type 2 diabetes, sterkste effect met semaglutide","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["bisoprolol","diabetes-type-2","empagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag091","source_url":"https://doi.org/10.1093/eschf/xvag091","authors":["Keerthenan Raveendra","Tobin Joseph","Jing Kang","Ben Hurdus","Uther Cutting","Mohammad Haris","Tanina Younsi","Amaan Aslam","Mark Petrie","Marco Metra","Ramzi A Ajjan","Jianhua Wu","Chris P Gale","Ramesh Nadarajah"],"significance":8,"published":"2026-04-18","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis of 12 placebo-controlled trials (n=95,023) found GLP-1 receptor agonists reduced heart failure events by 12% (NNT 238), and by 19% (NNT 167) in patients without baseline HF. Semaglutide specifically reduced HF events by 16% overall and by 31% in those without prior HF (NNT 80). Absolute benefits are modest but clinically relevant given the widespread use of GLP-1 therapy in type 2 diabetes and obesity management.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6b7df5a86126","type":"article","url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","title":"CONFIDENCE-analyse: acute eGFR-daling bij empagliflozin + finerenone is reversibel en geen reden om te stoppen","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["dapagliflozine","emperor-trials","fidelio-dkd","fidelity","figaro-dkd"],"journal":"Journal of the American Society of Nephrology : JASN","doi":"10.1681/ASN.0000001071","source_url":"https://doi.org/10.1681/ASN.0000001071","authors":["Rajiv Agarwal","Ricardo Correa-Rotter","Sankar D Navaneethan","Kei Fukami","Hiddo J L Heerspink","Johannes F E Mann","Janet B McGill","Amy K Mottl","Masaomi Nangaku","Julio Rosenstock","Peter Rossing","Muthiah Vaduganathan","Charlie Scott","Li Li","Carolina Aldworth","Jennifer B Green","Matthew R Weir"],"significance":8,"published":"2026-04-17","source_date":"2026-03-29","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/metformine-en-nierfunctie/"],"congress":"","summary_en":"This prespecified CONFIDENCE analysis (n=790 with T2D, CKD and albuminuria) found the greatest acute day-14 eGFR decline with combination therapy (-6.6 mL/min) vs finerenone alone (-2.1) or empagliflozin alone (-4.8), but declines were reversible. Finerenone's additive UACR-lowering effect was non-haemodynamic, while empagliflozin's effect was partly eGFR-mediated. The results reinforce that initial eGFR dips should not trigger discontinuation and support combination therapy in diabetic CKD.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46ae7fd030b7","type":"article","url":"https://hartvaat.nl/2026/03/29/uk-biobank-hogere-intensiteit-van-beweging-belangrijker-dan-totale-tijd-voor-car/","title":"UK Biobank: hogere intensiteit van beweging belangrijker dan totale tijd voor cardiovasculair risico","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","diabetes-type-2","farmaco-economie","fidelity","obesitas","ouderen","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag168","source_url":"https://doi.org/10.1093/eurheartj/ehag168","authors":["Jiehua Wei","Minxue Shen","Shenxin Li","Yi Xiao","Dan Luo","Gerson Ferrari","Dong Hoon Lee","Leandro F M Rezende","Jason M R Gill","Matthew N Ahmadi","Emmanuel Stamatakis","Xiang Chen"],"significance":8,"published":"2026-04-17","source_date":"2026-03-29","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"Using wrist-accelerometer data from 96,408 UK Biobank participants, a higher share of vigorous activity (%VPA) showed a non-linear inverse association with MACE, atrial fibrillation, type 2 diabetes, CKD, dementia and all-cause mortality — independent of total activity volume. Participants exceeding 4% VPA had 29–61% lower risk of these outcomes. The study suggests exercise intensity deserves more weight in prevention counselling, alongside the traditional focus on weekly duration.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce2c31c8a18e","type":"article","url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","title":"VESALIUS-CV-subgroep JAMA: evolocumab beschermt ook diabeten zonder vastgestelde atherosclerose","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["clear-outcomes","diabetes-en-hart","ezetimibe","rosuvastatine","soul-trial"],"journal":"JAMA","doi":"10.1001/jama.2026.3277","source_url":"https://doi.org/10.1001/jama.2026.3277","authors":["Nicholas A Marston","Erin A Bohula","Ajay K Bhatia","Gaetano M De Ferrari","Lawrence A Leiter","Jose C Nicolau","Jeong-Gun Park","Sabina A Murphy","Emileigh Walsh","Lyrica Liu","Subodh Verma","Naveed Sattar","Stephen J Nicholls","Jose Lopez-Sendon","Ioanna Gouni-Berthold","Lale Tokgozoglu","Ron Blankstein","Marcoli Cyrille","Gabriel Paiva da Silva Lima","Robert P Giugliano","Marc S Sabatine"],"significance":9,"published":"2026-04-17","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"This prespecified VESALIUS-CV subgroup (n=3655 diabetics with LDL-C ≥ 90 mg/dL and no established atherosclerosis) found that evolocumab on top of optimised statin therapy significantly reduced first MACE over a median 4.8 years of follow-up. The JAMA-published analysis pushes PCSK9 inhibition further upstream in high-risk diabetics without prior arterial disease, calcium score ≥ 100, or stenosis ≥ 50%. It strengthens the case for earlier intensive LDL-C lowering in primary prevention for diabetic patients.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"33a542cdf34c","type":"article","url":"https://hartvaat.nl/2026/03/05/nationaal-cardiologisch-netwerk-als-nieuwe-zorgstandaard-in-polen/","title":"Nationaal cardiologisch netwerk als nieuwe zorgstandaard in Polen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["bradycardie","diabetes-en-hart","laminopathie","ouderen","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1123","source_url":"https://doi.org/10.1093/eurheartj/ehaf1123","authors":["Robert Gil","Konrad Korbiński","Marek Gierlotka"],"significance":3,"published":"2026-04-12","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"This article presents Poland's national cardiology network as a new model for cardiovascular care delivery. The authors describe how coordinated network care can improve outcomes for cardiac patients.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b879216c18a6","type":"article","url":"https://hartvaat.nl/2026/03/03/prasugrel-vs-clopidogrel-invloed-van-patientkenmerken-op-trombocytenremming-bij-/","title":"Prasugrel vs. clopidogrel: invloed van patiëntkenmerken op trombocytenremming bij acute beroerte","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["dubbele-trombocytenremming","trombocytenaggregatieremmers"],"journal":"Journal of atherosclerosis and thrombosis","doi":"10.5551/jat.66056","source_url":"https://doi.org/10.5551/jat.66056","authors":["Shigeru Fujimoto","Yasuyuki Iguchi","Hiroshi Yamagami","Masatoshi Koga","Ryo Itabashi","Yusuke Yakushiji","Kazuma Kowata","Naoto Kimura","Yuka Terasawa","Takahiro Shimizu","Yuichi Miyazaki","Koichi Oki","Osamu Masuo","Hideki Matsuoka","Shuji Arakawa","Toshihiro Ueda","Ryota Tanaka","Wataru Hashimoto","Satoru Abe","Go Kato","Taketoshi Furugori","Kazumi Kimura"],"significance":4,"published":"2026-04-12","source_date":"2026-03-03","image":"","kennis":[],"congress":"","summary_en":"In a post-hoc analysis of the ACUTE-PRAS trial, this study examined whether the antiplatelet effects of prasugrel and clopidogrel differ by patient characteristics in acute atherothrombotic stroke or TIA. The results identify subgroups at higher risk of high on-treatment platelet reactivity under clopidogrel.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"892e87dff836","type":"article","url":"https://hartvaat.nl/2026/03/05/trem-1-remming-vermindert-in-stent-neoatherosclerose-in-diermodel/","title":"TREM-1-remming vermindert in-stent neoatherosclerose in diermodel","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00067-5/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00067-5/fulltext","authors":["Mengting Jiang","Yingqian Zhang","Xiaohang Yuan","Yuxing Chen","Yan Han","Xietian Pan","Xi Zhang","Haoyi Ye","Wei Wang","Wei Tong","Lei Gao"],"significance":4,"published":"2026-04-12","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"In-stent neoatherosclerosis contributes to late stent thrombosis and restenosis. This study investigated pharmacological TREM-1 inhibition with nangibotide (LR12) in a rabbit model and found favourable effects on neoatherosclerosis development via macrophage polarisation modulation, identifying a potential therapeutic target.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c50c53773dcd","type":"article","url":"https://hartvaat.nl/2026/03/05/nlr-trajecten-versus-absolute-waarden-als-prognostische-marker-bij-acuut-hartfal/","title":"NLR-trajecten versus absolute waarden als prognostische marker bij acuut hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag071","source_url":"https://doi.org/10.1093/eschf/xvag071","authors":["Akinori Higaki"],"significance":4,"published":"2026-04-11","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/high-sensitivity-troponine/"],"congress":"","summary_en":"The neutrophil-to-lymphocyte ratio (NLR) is a simple inflammatory marker in heart failure. This ESC Heart Failure commentary discusses whether NLR trajectories over time have better prognostic value than a single absolute measurement in acute heart failure.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"773c5fe467f5","type":"article","url":"https://hartvaat.nl/2026/02/13/leadless-pacemaker-implantatie-ter-hoogte-van-de-bundel-van-bachmann/","title":"Leadless pacemaker-implantatie ter hoogte van de bundel van Bachmann","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["draadloze-pacemaker"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag027","source_url":"https://doi.org/10.1093/europace/euag027","authors":["Ashraf Alzahrani","Leena Makhdum","Mohammed Mhanna","Peter Farjo","Paari Dominic","Steven Bailin"],"significance":4,"published":"2026-04-11","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/pacemaker-indicaties-typen/"],"congress":"","summary_en":"This Europace study describes initial results of implanting a leadless pacemaker at the Bachmann's bundle region, an alternative stimulation site that may provide more physiological atrial activation. The data are presented as proof of concept.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e744f518196f","type":"article","url":"https://hartvaat.nl/2026/02/03/ultrakorte-radiofrequentieablatie-voor-vena-cava-superior-isolatie/","title":"Ultrakorte radiofrequentieablatie voor vena cava superior-isolatie","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","katheterablatie","pulmonaalvenenisolatie","stabiel-coronairlijden","supraventriculaire-tachycardie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag026","source_url":"https://doi.org/10.1093/europace/euag026","authors":["Masaki Honda","Masateru Takigawa","Iwanari Kawamura","Tasuku Yamamoto","Miho Negishi","Ryo Tateishi","Kentaro Goto","Takuro Nishimura","Kazuya Yamao","Susumu Tao","Takehiro Iwanaga","Sayaka Suzuki","Iichiroh Onishi","Shinsuke Miyazaki","Tetsuo Sasano"],"significance":4,"published":"2026-04-11","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This study investigates the feasibility of very high-power, ultra-short radiofrequency energy for superior vena cava isolation as a source of atrial fibrillation. Translational validation was performed in a porcine model and clinical cohorts, suggesting the technique may improve procedural safety and efficiency.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62ee49bdde87","type":"article","url":"https://hartvaat.nl/2026/02/27/smoothened-signalering-bevordert-nierfibrose-via-autofagieremming/","title":"Smoothened-signalering bevordert nierfibrose via autofagieremming","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00140-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00140-7/fulltext","authors":["Xiaonan Wang","Ye Liang","Jiemei Li","Xiaoxu Wang","Weijie Zhong","Yabing Xiong","Wenting Ye","Canzhen Liu","Xian Ling","Jinhua Miao","Weiwei Shen","Shan Zhou","Ping Meng","Youhua Liu","Fan Fan Hou","Xiaolong Li","Lili Zhou"],"significance":4,"published":"2026-04-10","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/progressie-nierziekte-mechanisme/"],"congress":"","summary_en":"Research in Kidney International shows that enhanced Smoothened receptor signalling promotes renal fibrosis by inhibiting autophagy in fibroblasts. This mechanistic insight into the Hedgehog signalling pathway contributes to understanding progressive kidney disease.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3cfd42378278","type":"article","url":"https://hartvaat.nl/2026/02/27/pdgf-b-uit-tubulusepitheel-drijft-nierfibrose-aan/","title":"PDGF-B uit tubulusepitheel drijft nierfibrose aan","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00141-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00141-9/fulltext","authors":["Barbara Mara Klinkhammer","Eva Miriam Buhl","Tim Caspers","Sidrah Maryam","Dickson W.L. Wong","Michael Goedertier","David Laurin Hölscher","Roman David Buelow","Rafael Kramann","Sikander Hayat","Jürgen Floege","Peter Boor"],"significance":4,"published":"2026-04-10","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/progressie-nierziekte-mechanisme/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This Kidney International study demonstrates that tubular epithelial cell-derived PDGF-B creates fibrogenic niches and plays a crucial role in renal fibrosis. This epithelial-mesenchymal communication mechanism offers a potential therapeutic target for chronic kidney disease.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23c27ca6c62e","type":"article","url":"https://hartvaat.nl/2026/03/05/ongelijke-toegang-tot-cardiovasculaire-zorg-in-europa/","title":"Ongelijke toegang tot cardiovasculaire zorg in Europa","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","obesitas","ouderen","richtlijnen-esc"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1106","source_url":"https://doi.org/10.1093/eurheartj/ehaf1106","authors":["Raffaele Bugiardini","Olivia Manfrini","Edina Cenko"],"significance":4,"published":"2026-04-10","source_date":"2026-03-05","image":"","kennis":[],"congress":"","summary_en":"This European Heart Journal article highlights inequalities in access to cardiovascular care across Europe. The authors analyse regional differences in treatment outcomes and advocate for policies promoting equitable access to evidence-based cardiovascular care.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32c2fd7d1ff3","type":"article","url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","title":"IVUS-segmentatiemethoden vergeleken in de PACMAN-AMI-trial","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-25-0590","source_url":"https://doi.org/10.1253/circj.CJ-25-0590","authors":["Nathan Angelo Lecaros Yap","Christos V Bourantas","Sylvain Losdat","Nathaniel Yu Jian Ng","Jonas Häner","Ibrahim Halil Tanboga","Tatsuhiko Otsuka","Yasushi Ueki","Andreas Baumbach","Anthony Mathur","Ryota Kakizaki","Ernest Spitzer","Jouke Dijkstra","Thomas Engstrøm","David Spirk","Irene Lang","Konstantinos C Koskinas","Lorenz Räber"],"significance":4,"published":"2026-04-09","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This post-hoc analysis of the PACMAN-AMI trial compared two IVUS segmentation methods — conventional 1-mm segmentation versus end-diastolic segmentation — for atherosclerosis measurement accuracy in clinical trials.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a77222751fa","type":"article","url":"https://hartvaat.nl/2026/02/26/cardiologen-onderschatten-omgevingsrisicofactoren/","title":"Cardiologen onderschatten omgevingsrisicofactoren","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["aficamten","biomarkers-cardiovasculair","cardiogene-shock","hypertrofische-cardiomyopathie","inflammatie","laminopathie","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1096","source_url":"https://doi.org/10.1093/eurheartj/ehaf1096","authors":["Rocco A Montone","Thomas Münzel","Thomas F Luscher"],"significance":4,"published":"2026-04-09","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This European Heart Journal article identifies barriers preventing cardiologists from incorporating environmental risk factors such as air pollution and noise exposure into cardiovascular risk assessment. The authors advocate for greater awareness of these growing risk factors.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b26abecb09a1","type":"article","url":"https://hartvaat.nl/2026/03/02/micro-en-nanoplastics-nieuw-perspectief-voor-cardiovasculaire-preventie/","title":"Micro- en nanoplastics: nieuw perspectief voor cardiovasculaire preventie","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["inflammatie","microcirculatie","secundaire-preventie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077882","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077882","authors":[],"significance":4,"published":"2026-04-09","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This Circulation perspective discusses the emerging concern about micro- and nanoplastics as potential cardiovascular risk factors. The article outlines possible pathophysiological mechanisms and calls for further research into these ubiquitous environmental contaminants in relation to cardiovascular disease.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b9bfa661721f","type":"article","url":"https://hartvaat.nl/2025/01/01/kwaliteit-van-hartfalenzorg-bij-aziatische-patienten-in-de-vs/","title":"Kwaliteit van hartfalenzorg bij Aziatische patiënten in de VS","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725101526?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725101526?dgcid=rss_sd_all","authors":["Xiaoning Huang","Mark D. Huffman","Namratha R. Kandula","Lucia C. Petito","Anubha Agarwal","Clyde W. Yancy","Gregg C. Fonarow","Pardeep S. Jhund","Matthew T. Mefford","Kristi L. Reynolds"],"significance":4,"published":"2026-04-08","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This JACC study examined the quality of heart failure care among Asian patients in the United States and identified disparities in treatment and outcomes. While US-specific, the findings underscore the broader message that ethnic background influences heart failure care quality.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f4979c87e64","type":"article","url":"https://hartvaat.nl/2025/01/01/voedingskwaliteit-en-plantaardige-voeding-centraal-voor-cardiovasculaire-gezondh/","title":"Voedingskwaliteit en plantaardige voeding centraal voor cardiovasculaire gezondheid","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","diabetes-en-hart","ezetimibe","farmaco-economie","ijzertekort","microbioom","obesitas","ouderen","perifeer-vaatlijden","roken","voeding-hart","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726003013?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726003013?dgcid=rss_sd_all","authors":["Eric J. Brandt","Katherine W. Bauer"],"significance":4,"published":"2026-04-08","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This JACC editorial emphasises that overall dietary quality and plant-based foods, rather than individual macronutrients, are the key determinants of cardiovascular health. It contextualises recent nutrition research and advocates for a shift from macronutrient-focused thinking to dietary pattern approaches.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f62ad608ec2","type":"article","url":"https://hartvaat.nl/2026/03/03/cardiovasculaire-mortaliteit-bij-chronische-nierziekte-en-dialyse-een-tweestappe/","title":"Cardiovasculaire mortaliteit bij chronische nierziekte en dialyse: een tweestappenmodel","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","chronische-nierziekte","ouderen","secundaire-preventie","vrouwen"],"journal":"Journal of atherosclerosis and thrombosis","doi":"10.5551/jat.RV22048","source_url":"https://doi.org/10.5551/jat.RV22048","authors":["Tetsuo Shoji","Christoph Wanner"],"significance":5,"published":"2026-04-08","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Dialysis patients face a 10- to 30-fold elevated risk of cardiovascular mortality compared to the general population. This narrative review proposes a two-step model — first the occurrence of a cardiovascular event, then the inability to recover — identifying intervention targets for prevention in CKD.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a3160eebd323","type":"article","url":"https://hartvaat.nl/2026/03/06/sociaaleconomische-status-en-cardiovasculaire-ziekte-wereldwijde-meta-analyse/","title":"Sociaaleconomische status en cardiovasculaire ziekte: wereldwijde meta-analyse","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-2","farmaco-economie","fractional-flow-reserve","gepersonaliseerde-geneeskunde","hartrevalidatie","laminopathie","lichaamsbeweging","menopauze","microbioom","obesitas","ouderen","primaire-preventie","richtlijnen-esc","secundaire-preventie","slaapapneu","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00063-8/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00063-8/fulltext","authors":["Sepehr Golriz Khatami","Rieke Baumkötter","Julia Petersen","Vincent ten Cate","Philipp S. Wild"],"significance":5,"published":"2026-04-08","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This systematic review and meta-analysis examined the association between socioeconomic status and cardiovascular disease using global data. The strength and direction of the association varied with countries' development level, underscoring the context-dependent role of socioeconomic factors in cardiovascular risk.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09e2bdbd963b","type":"article","url":"https://hartvaat.nl/2026/03/03/evolocumab-naast-empagliflozine-verandert-ldl-subdeeltjes-bij-type-2-diabetes/","title":"Evolocumab naast empagliflozine verandert LDL-subdeeltjes bij type 2 diabetes","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","diabetes-en-hart","diabetes-type-2","empagliflozine","emperor-trials","ezetimibe","figaro-dkd","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","soul-trial","statines"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00052-3/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00052-3/fulltext","authors":["Isabella Bonilha","Marcos Yukio Yoshinaga","Adriano Britto Chaves-Filho","Érica Ivana Lázaro Gomes","Rosangela Silva Santos","Ikaro Breder","Jessica Breder","Sayuri Miyamoto","Wilson Nadruz","Anatol Kontush","Andrei C. Sposito"],"significance":5,"published":"2026-04-08","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"In a pre-specified analysis of a randomised trial, the addition of the PCSK9 inhibitor evolocumab to empagliflozin in type 2 diabetes was found to alter LDL subparticle composition and the lipidome beyond standard LDL-cholesterol reduction, potentially contributing to the cardiovascular benefits of this combination therapy.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62abd6309e34","type":"article","url":"https://hartvaat.nl/2026/03/05/ai-echocardiografie-door-niet-specialisten-kosteneffectiviteitsanalyse-uit-singa/","title":"AI-echocardiografie door niet-specialisten: kosteneffectiviteitsanalyse uit Singapore","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["echocardiografie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag069","source_url":"https://doi.org/10.1093/eschf/xvag069","authors":["Aprajita Kaushik","Sameera Senanayake","Sanjeewa Kularatna","Khung-Keong Yeo","Nicholas Graves","Carolyn S P Lam","Huang Weiting","Chanchal Chandramouli","Jasper Tromp"],"significance":5,"published":"2026-04-08","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"AI-assisted point-of-care echocardiography can shift left ventricular ejection fraction assessment from specialist sonographers to non-specialist healthcare providers. This cost-minimisation analysis from Singapore shows that AI-POC devices can reduce diagnostic costs in heart failure without compromising accuracy.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"092a3d81e566","type":"article","url":"https://hartvaat.nl/2026/03/03/darmmicrobioom-bevordert-atriumfibrilleren-bij-chronische-nierziekte-via-nlrp3-i/","title":"Darmmicrobioom bevordert atriumfibrilleren bij chronische nierziekte via NLRP3-inflammasoom","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["anemie-ckd","atriale-cardiomyopathie","cardiorenal-behandelstrategie","chronische-nierziekte","gedilateerde-cardiomyopathie","inflammatie","laminopathie","microbioom"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag037","source_url":"https://doi.org/10.1093/europace/euag037","authors":["Xuejie Han","Hui Yu","Qianhui Gao","Xiaoyu Wang","Linwei Zhang","Qian Zhao","Luyang Yu","Yun Zhang","Manshu Sui","Yue Li"],"significance":5,"published":"2026-04-07","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Chronic kidney disease increases the risk of atrial fibrillation, but the underlying mechanism is incompletely understood. In a rat model, this study demonstrates that gut microbiome dysbiosis promotes CKD-associated AF via NLRP3 inflammasome activation, opening potential therapeutic avenues at the nephrology-cardiology interface.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1533b8cb3fb2","type":"article","url":"https://hartvaat.nl/2026/03/02/stand-van-zaken-palliatieve-zorg-bij-hartfalen/","title":"Stand van zaken: palliatieve zorg bij hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag067","source_url":"https://doi.org/10.1093/eschf/xvag067","authors":["C Gross","A Gupta","R Burgess","L Ziegler","E De Graaf","T Jaarsma","K K Witte","S Straw"],"significance":5,"published":"2026-04-07","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"Heart failure patients often have a high symptom burden and limited life expectancy, yet palliative care remains poorly integrated. This ESC Heart Failure review describes the current state of palliative care research in heart failure and identifies knowledge gaps for future investigation.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6bbb4a573bf4","type":"article","url":"https://hartvaat.nl/2026/03/01/non-hdl-hdl-ratio-als-voorspeller-van-cardiovasculaire-ziekte-bij-ckm-syndroom/","title":"Non-HDL/HDL-ratio als voorspeller van cardiovasculaire ziekte bij CKM-syndroom","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["cardio-renaal-metabool","cardiorenal-behandelstrategie","diabetes-en-hart","dyslipidemie","ezetimibe","hdl-cholesterol","lipidenverlaging","niet-statine-therapie","obesitas","select-trial","statines"],"journal":"Journal of clinical hypertension (Greenwich, Conn.)","doi":"10.1111/jch.70221","source_url":"https://doi.org/10.1111/jch.70221","authors":["Yu Huang","Yanwen Gao","Jiming Shao","Ke Wang","Yexiang Ma","Long Ai","Jing Yu"],"significance":5,"published":"2026-04-07","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"The American Heart Association introduced the cardiovascular-renal-metabolic (CKM) syndrome as a new concept. This prospective cohort study evaluated the non-HDL/HDL cholesterol ratio as a predictor of cardiovascular events in CKM stages 0-3, finding it a promising, readily available lipid marker for risk stratification.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1fb55dc5e91","type":"article","url":"https://hartvaat.nl/2026/02/28/epic-hiv-trial-pcsk9-remming-ter-cardiovasculaire-preventie-bij-hiv-patienten/","title":"EPIC-HIV trial: PCSK9-remming ter cardiovasculaire preventie bij hiv-patiënten","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"American heart journal","doi":"10.1016/j.ahj.2026.107400","source_url":"https://doi.org/10.1016/j.ahj.2026.107400","authors":["Matthew S Durstenfeld","Marta Levkova-Clark","Danny Li Ms","Veronica Schaffer","Shady Abohashem","Yifei Ma","Kosuke Kawai","Michael T Lu","Irini Sereti","Steven G Deeks","Ahmed Tawakol","Priscilla Y Hsue"],"significance":5,"published":"2026-04-06","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"People living with HIV face elevated cardiovascular risk. Following positive results with statins, the EPIC-HIV trial investigates whether PCSK9 inhibition can further reduce cardiovascular risk in HIV patients. This American Heart Journal article describes the trial design and baseline characteristics.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5cc194999636","type":"article","url":"https://hartvaat.nl/2026/02/26/ai-clustering-identificeert-functionele-risicofenotypen-bij-hartfalen/","title":"AI-clustering identificeert functionele risicofenotypen bij hartfalen","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["kunstmatige-intelligentie","vrouwen"],"journal":"Open heart","doi":"10.1136/openhrt-2025-003530","source_url":"https://doi.org/10.1136/openhrt-2025-003530","authors":["Xunhan Qiu","Jun Ma","Li Xu","Meng Jiang","Jun Pu"],"significance":5,"published":"2026-04-06","source_date":"2026-02-26","image":"https://hartvaat.nl/global/img/2d2cb7186baf.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Using unsupervised AI clustering on 15 multimodal clinical variables in 505 heart failure patients, this study identified distinct functional risk phenotypes. The clusters predicted cardiorespiratory fitness and clinical outcomes, potentially aiding early risk stratification.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f84b2126aa95","type":"article","url":"https://hartvaat.nl/2026/02/26/fluoroscopieminimalisatie-bij-svt-ablatie-door-vrouwelijke-elektrofysiologen/","title":"Fluoroscopieminimalisatie bij SVT-ablatie door vrouwelijke elektrofysiologen","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aritmogene-cardiomyopathie","bloeddrukbehandeling","bradycardie","cardiale-resynchronisatie","elektrocardiografie","gedilateerde-cardiomyopathie","hfpef","hfref","holter","hypertrofische-cardiomyopathie","laminopathie","pulsed-field-ablatie-atriumfibrilleren","slaapapneu","supraventriculaire-tachycardie","ventriculaire-tachycardie","ventrikelfibrilleren","vericiguat"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag030","source_url":"https://doi.org/10.1093/europace/euag030","authors":["Sara Poggi","Marzia Giaccardi","Laura Cipolletta","Ana Jordan","Cheryl Teres","Laura Vitali Serdoz","Veronica Buia","Chiara Ghiglieno","Ilaria Meynet","Laura Valverde Soria","Martina Nesti","Silvia Garibaldi","Michela Casella","Raquel Adelino","Assunta Iuliano","Federica Torri","Alessia Agresta","Rosa Caruso","Federica Troisi","Valentina De Regibus","Valentina Mangiafico","Teresa Strisciuglio"],"significance":5,"published":"2026-04-06","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/ecg-ritmestoornissen-herkenning/","https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/"],"congress":"","summary_en":"The STOOP registry assessed radiation exposure of female electrophysiologists of reproductive age during catheter ablation of supraventricular tachycardia. Using a fluoroscopy minimisation strategy across 12 European centres, estimated annual occupational exposure remained well within safe limits.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d66f77d8ab1e","type":"article","url":"https://hartvaat.nl/2026/02/03/klinische-impact-van-veiligheidswaarschuwingen-voor-implanteerbare-pacemakers-en/","title":"Klinische impact van veiligheidswaarschuwingen voor implanteerbare pacemakers en defibrillatoren","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["icd-implantatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag031","source_url":"https://doi.org/10.1093/europace/euag031","authors":["Yijun Ren","Alessandra Baruffini","Sofia Biolo","Rita Corti","Jens Cosedis Nielsen","Alan G Fraser","Enrico G Caiani"],"significance":5,"published":"2026-04-05","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"Field safety notices for implantable cardiac devices are issued regularly, but their clinical impact is not always clear. This Europace study analyses the real-world effect of these notices on patient safety and clinical decision-making for pacemakers and ICDs.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c3eab5cac51","type":"article","url":"https://hartvaat.nl/2026/03/04/veroudering-immuundysfunctie-en-nierfibrose-kip-of-ei/","title":"Veroudering, immuundysfunctie en nierfibrose: kip of ei?","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00950-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00950-0/fulltext","authors":["David P. Baird","David A. Ferenbach"],"significance":5,"published":"2026-04-05","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/progressie-nierziekte-mechanisme/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"Ageing is a major risk factor for chronic kidney disease, with renal fibrosis as a central feature. This review examines the interplay between immune system ageing, epithelial senescence, and fibrotic changes in the kidney, seeking therapeutic targets for age-related CKD.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72c14c79b53a","type":"article","url":"https://hartvaat.nl/2026/03/04/winterhypertensie-koude-als-cardiovasculaire-risicofactor/","title":"Winterhypertensie: koude als cardiovasculaire risicofactor","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","bradycardie","inflammatie","menopauze","slaapapneu"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26518","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26518","authors":["Kazuomi Kario"],"significance":5,"published":"2026-04-05","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Cardiovascular events increase globally during winter, partly due to cold-induced hypertension. This Japanese review describes how low ambient temperatures amplify morning blood pressure surges and increase cardiovascular risk, and discusses preventive strategies including home insulation and seasonally adjusted antihypertensive therapy.","created":"2026-07-03T10:32:42Z","updated":"2026-07-03T18:39:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2e9059b8a96","type":"article","url":"https://hartvaat.nl/2026/02/27/gerichte-immunotherapie-bij-nierziekten-b-cel-targeting-en-car-t/","title":"Gerichte immunotherapie bij nierziekten: B-cel-targeting en CAR-T","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00145-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00145-6/fulltext","authors":["Johanna T. Kurzhagen","William Laqua","Georg Schett","Ricardo Grieshaber-Bouyer","Hamid Rabb","Sanjeev Noel","Mario Schiffer"],"significance":5,"published":"2026-04-04","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This Kidney International review discusses emerging targeted immunotherapies for kidney disease, including CAR-T cell therapy and T-cell engagers directed against B cells. Initial results in treatment-resistant lupus nephritis are promising and may extend to other autoimmune kidney diseases.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc5516299a94","type":"article","url":"https://hartvaat.nl/2026/02/26/ai-model-voorspelt-nachtelijke-hypertensie-bij-chronische-nierziekte/","title":"AI-model voorspelt nachtelijke hypertensie bij chronische nierziekte","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","kunstmatige-intelligentie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26706","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26706","authors":["Xiaoyu Cai"],"significance":5,"published":"2026-04-04","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"Researchers developed a diffusion model that predicts nocturnal hypertension in chronic kidney disease patients, potentially enabling more selective use of costly 24-hour blood pressure monitoring. The model was validated in an external cohort of over 1,200 patients.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"200f1478b7a7","type":"article","url":"https://hartvaat.nl/2026/03/06/editoriaal-langetermijnresultaten-van-aficamten-bij-obstructieve-hcm/","title":"Editoriaal: langetermijnresultaten van aficamten bij obstructieve HCM","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag059","source_url":"https://doi.org/10.1093/eurheartj/ehag059","authors":["Luis R Lopes"],"significance":5,"published":"2026-04-04","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This European Heart Journal editorial places the long-term results of aficamten in the context of the growing arsenal of myosin inhibitors for obstructive hypertrophic cardiomyopathy, discussing the clinical implications.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5b5fc140a71","type":"article","url":"https://hartvaat.nl/2026/03/05/microrna-s-in-de-celkern-sturen-hartmetabolisme-bij-hfpef/","title":"MicroRNA's in de celkern sturen hartmetabolisme bij HFpEF","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["laminopathie","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf841","source_url":"https://doi.org/10.1093/eurheartj/ehaf841","authors":["Donato Santovito","Christian Weber"],"significance":5,"published":"2026-04-03","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This European Heart Journal editorial discusses the discovery that nuclear microRNAs, acting via the Argonaute protein, regulate cardiac metabolism in heart failure with preserved ejection fraction. These findings open a new perspective on HFpEF pathophysiology.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8ef9677269cc","type":"article","url":"https://hartvaat.nl/2026/03/05/coronairverkalkingen-en-myocardiale-flowreserve-na-harttransplantatie/","title":"Coronairverkalkingen en myocardiale flowreserve na harttransplantatie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","hartkatheterisatie","harttransplantatie","myocardinfarct","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag163","source_url":"https://doi.org/10.1093/eurheartj/ehag163","authors":["Catherine X Wright","James N Kiage","Ioannis Kyriakoulis","Ibolya Csecs","Ahmed Ibrahim Ahmed","Guangyu Tong","Yukang Zeng","Yi-Hwa Liu","Lavanya Bellumkonda","Damianos G Kokkinidis","Albert J Sinusas","Edward J Miller","Attila Feher"],"significance":5,"published":"2026-04-03","source_date":"2026-03-05","image":"","kennis":[],"congress":"","summary_en":"This longitudinal European Heart Journal study examined the relationship between coronary artery calcification and myocardial flow reserve in heart transplant recipients. The findings are relevant for follow-up and risk stratification in this vulnerable patient population.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26c7d0164f1b","type":"article","url":"https://hartvaat.nl/2026/03/05/nucleair-ago2-verergert-hfpef-via-myocardiale-ketogenese/","title":"Nucleair AGO2 verergert HFpEF via myocardiale ketogenese","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag067","source_url":"https://doi.org/10.1093/eurheartj/ehag067","authors":["Kunying Jin","Yuyan Tang","Jiabing Zhan","Yufei Zhou","Rong Xie","Guo Hu","Yatong Qin","Jianpei Wen","Zheng Wen","Yanru Zhao","Jiahui Fan","Hengzhi Du","Feng Wang","Suzhen Tang","Shaowen Yang","Yusong R Guo","Dawei Jiang","Junfang Wu","Qian Liu","Xiang Cheng","Huaping Li","Chen Chen"],"significance":5,"published":"2026-04-03","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Research in the European Heart Journal reveals that nuclear argonaute-2 (AGO2), a core component of the microRNA machinery, exacerbates heart failure with preserved ejection fraction by stimulating myocardial ketogenesis. This mechanistic study identifies a novel therapeutic target for diet-related HFpEF.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18818e711e0b","type":"article","url":"https://hartvaat.nl/2026/03/05/cardio-oncologie-een-snel-veranderend-vakgebied/","title":"Cardio-oncologie: een snel veranderend vakgebied","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["atleten","kanker-en-hart","ouderen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag137","source_url":"https://doi.org/10.1093/eurheartj/ehag137","authors":["Filippo Crea"],"significance":5,"published":"2026-04-02","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This European Heart Journal editorial by Filippo Crea reviews recent trials and risk scores in cardio-oncology, a rapidly evolving field driven by increasing attention to the cardiovascular side effects of cancer therapies.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"917b496394e6","type":"article","url":"https://hartvaat.nl/2026/02/28/onbeantwoorde-vragen-over-lipoproteine-a-en-atherosclerose/","title":"Onbeantwoorde vragen over lipoproteïne(a) en atherosclerose","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["atherosclerose","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","statines"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-26-0036","source_url":"https://doi.org/10.1253/circj.CJ-26-0036","authors":["Hayato Tada","Masayuki Takamura"],"significance":5,"published":"2026-04-02","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This review discusses unresolved questions regarding the relationship between lipoprotein(a) and atherosclerotic cardiovascular risk. Despite growing evidence for Lp(a) as an independent risk factor, questions remain about therapeutic thresholds and the efficacy of targeted treatment.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"254b18c18b93","type":"article","url":"https://hartvaat.nl/2026/02/24/adamts-7-vaccin-beschermt-nieren-en-vaten-bij-chronische-nierziekte/","title":"ADAMTS-7-vaccin beschermt nieren en vaten bij chronische nierziekte","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"Circulation research","doi":"10.1161/CIRCRESAHA.125.327881","source_url":"https://doi.org/10.1161/CIRCRESAHA.125.327881","authors":["Shiyu Yang","Zihan Ma","Rongbo Dai","Qingfeng Xu","Wu Hao","Liao Tan","Zijie Liu","Jiazi Zhang","Fang Yu","Yi Fu","Wei Kong"],"significance":5,"published":"2026-04-02","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/cardiorenal-syndroom/"],"congress":"","summary_en":"Researchers report in Circulation Research that a vaccine targeting ADAMTS-7 provides both renal and vascular protection in a chronic kidney disease model. This innovative vaccination approach opens new avenues for treating cardiorenal syndrome.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7af70252e5e","type":"article","url":"https://hartvaat.nl/2026/02/24/parodontale-behandeling-remt-progressie-van-atherosclerose/","title":"Parodontale behandeling remt progressie van atherosclerose","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["atherosclerose"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf525","source_url":"https://doi.org/10.1093/eurheartj/ehaf525","authors":["Marta Czesnikiewicz-Guzik","Tomasz J Guzik"],"significance":5,"published":"2026-04-01","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This European Heart Journal study investigates the link between oral health and atherosclerosis. Periodontal therapy may slow atherosclerosis progression, suggesting a role for chronic oral inflammation in the pathogenesis of vascular disease.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee6fc1d267a4","type":"article","url":"https://hartvaat.nl/2026/02/24/kwaliteitscriteria-voor-ai-implementatie-in-de-cardiologie-bijgewerkt/","title":"Kwaliteitscriteria voor AI-implementatie in de cardiologie bijgewerkt","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["farmaco-economie","kunstmatige-intelligentie","ouderen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag121","source_url":"https://doi.org/10.1093/eurheartj/ehag121","authors":["Evangelos K Oikonomou","Folkert W Asselbergs","Panos E Vardas"],"significance":5,"published":"2026-04-01","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This European Heart Journal article presents updated quality criteria for implementing artificial intelligence in clinical cardiology practice. The authors emphasise the need for standardised evaluation before broad deployment of AI tools in patient care.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d533e5d015e","type":"article","url":"https://hartvaat.nl/2026/02/23/ehj-editoriaal-hartfalen-en-cardiomyopathieen/","title":"EHJ-editoriaal: hartfalen en cardiomyopathieën","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","harttransplantatie","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag109","source_url":"https://doi.org/10.1093/eurheartj/ehag109","authors":["Filippo Crea"],"significance":5,"published":"2026-04-01","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"In this European Heart Journal editorial, Filippo Crea reviews the current epidemiology and management of heart failure and cardiomyopathies, providing an overview of recent developments in this rapidly evolving field.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cac05e810d86","type":"article","url":"https://hartvaat.nl/2026/04/01/kosteneffectiviteit-van-cascadescreening-voor-familiaire-hypercholesterolemie-ti/","title":"Kosteneffectiviteit van cascadescreening voor familiaire hypercholesterolemie (tijdelijk verwijderd)","title_en":"TEMPORARY REMOVAL: Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of novel treatment","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["dyslipidemie","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","primaire-preventie","statines","vrouwen"],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2025.120416","source_url":"https://doi.org/10.1016/j.atherosclerosis.2025.120416","authors":["Jing Lou","Kok Joon Chong","Sharon Li Ting Pek","Yasmin Bylstra","Chester Lee Drum","Weng Khong Lim","Yi Wang","Khung Keong Yeo","Subramaniam Tavintharan","Hwee-Lin Wee"],"significance":4,"published":"2026-04-01","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/","https://hartvaat.nl/kennis/lipiden/cascadescreening-fh/"],"congress":"","summary_en":"This article on cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolaemia has been temporarily removed by the publisher pending replacement or reinstatement.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"27a9f3799e51","type":"article","url":"https://hartvaat.nl/2026/03/02/senescente-p16-cellen-verergeren-hartremodellering-na-ischemie-via-cytotoxische-/","title":"Senescente P16+ cellen verergeren hartremodellering na ischemie via cytotoxische lymfocyten","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ouderen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077172","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077172","authors":["Lei Yan"],"significance":5,"published":"2026-03-31","source_date":"2026-03-02","image":"","kennis":[],"congress":"","summary_en":"This Circulation study shows that P16-positive senescent cells recruit cytotoxic lymphocytes via CCL8 after myocardial infarction, driving adverse cardiac remodelling. Senolytic therapy showed beneficial effects in a mouse model, identifying a potential therapeutic target.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a969e807cb8","type":"article","url":"https://hartvaat.nl/2026/03/02/extracellulaire-vesikels-medieren-adipocyt-cardiomyocytcommunicatie-bij-diabetis/","title":"Extracellulaire vesikels mediëren adipocyt-cardiomyocytcommunicatie bij diabetisch ischemisch hartfalen","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","myocardinfarct","obesitas","perifeer-vaatlijden","richtlijnen-esc","select-trial","soul-trial","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076372","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076372","authors":["Zhen Zhang"],"significance":5,"published":"2026-03-31","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This Circulation study demonstrates that small extracellular vesicles bearing surface adiponectin play a crucial role in adipocyte-cardiomyocyte communication in diabetic ischaemic heart failure. The findings partly explain why diabetes patients have worse prognosis after myocardial infarction.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b62727ce9aa0","type":"article","url":"https://hartvaat.nl/2026/02/28/clopidogrel-versus-aspirine-bij-coronairlijden-kanttekeningen-bij-meta-analyse/","title":"Clopidogrel versus aspirine bij coronairlijden: kanttekeningen bij meta-analyse","title_en":"","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulantia","aspirine","bisoprolol","clear-outcomes","statines","trombocytenaggregatieremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02643-1/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02643-1/fulltext","authors":["Agostino Colli","Giovanni Casazza","Christian Gluud"],"significance":5,"published":"2026-03-31","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This Lancet correspondence raises methodological concerns about a recent meta-analysis by Valgimigli et al. comparing clopidogrel versus aspirin for secondary prevention in coronary artery disease. The authors point out limitations that nuance the conclusion of clopidogrel superiority.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8fff077cd386","type":"article","url":"https://hartvaat.nl/2026/03/31/titine-cardiomyopathie-meestal-dcm-of-linksdominante-acm-met-blijvend-ritmestoor/","title":"Titine-cardiomyopathie: meestal DCM of linksdominante ACM, met blijvend ritmestoornisrisico","title_en":"Genotype-phenotype correlations in patients with pathogenic/likely pathogenic titin variants from the Swiss Arrhythmogenic Cardiomyopathy Registry","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aficamten","aritmogene-cardiomyopathie","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","inflammatoire-cardiomyopathie","laminopathie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003750?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003750?rss=1","authors":["Scha&#x0308;tti","N. A.","Fokstuen","S.","Medeiros-Domingo","A.","Maccio","U.","Na&#x0308;gele","M. P.","Mikulicic","F.","Flammer","A. J.","Sazgary","L.","Manka","R.","Wilzeck","V. C.","Tanner","F.","Grebmer","C.","Vischer","A. S.","Odening","K. E.","Rieder","M.","Ruschitzka","F.","Brunckhorst","C.","Duru","F.","Saguner","A. M.","Bonetti","N. R."],"significance":5,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"Truncating variants in the titin gene (TTNtv) are associated with cardiomyopathy, mainly dilated cardiomyopathy (DCM); arrhythmogenic phenotypes are scarcely studied. In this Swiss study (46 cardiomyopathy patients with a pathogenic/likely-pathogenic TTNtv; 63% male, median age 47), at baseline 89% met DCM criteria and 17% the revised Padua criteria for arrhythmogenic cardiomyopathy (ACM) — exclusively the left-dominant type, never the ARVC type. Most variants were in the A-band (74%). Under optimal medical therapy, left and right ventricular function improved, yet ventricular arrhythmias in the primary-prevention group still increased over time. Late gadolinium enhancement was usually in the basal septum and was not associated with more arrhythmias; high-grade AV block, unlike in sarcoidosis, did not occur. TTN cardiomyopathy thus presents as DCM or left-dominant ACM, with a persistently high arrhythmia risk despite favourable remodelling.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f081708e0e26","type":"article","url":"https://hartvaat.nl/2026/03/31/gespecialiseerde-hartklepklinieken-leiden-tot-betere-richtlijnconforme-zorg/","title":"Gespecialiseerde hartklepklinieken leiden tot betere richtlijnconforme zorg","title_en":"Specialised heart valve clinics result in greater adherence to guideline-directed care: a comparative study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003608?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003608?rss=1","authors":["Montarello","N.","Page","C.","Bennett","S.","Androshchuk","V.","Saeed","S.","Grigoryan","K.","Demetrescu","C.","Zhou","C.","Rajani","R."],"significance":5,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/","https://hartvaat.nl/kennis/vasculair/claudicatio-intermittens/"],"congress":"","summary_en":"International guidelines emphasise the role of heart valve centres and specialist heart valve clinics (SHVC) in optimal care for valve disease. In this comparative study, 134 patients with valve disease seen outside an SHVC were compared with 173 SHVC attendees against international guidelines. Outside the SHVC, the relationship between symptoms and valve disease was more often undocumented (31.5% vs 5.7%), exercise testing was used far less (3.4% vs 32%) and surgical referral was lower (3.4% vs 26.8%); no patient with prior valve surgery received endocarditis-prevention advice outside the SHVC (vs 100% within). Overall, management was discordant in 38% of native-valve and 84% of prior-surgery patients outside the SHVC, versus 3-4% within. Almost 5% of valve patients are thus still seen outside a specialist clinic and receive suboptimal care.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90c59b79f92c","type":"article","url":"https://hartvaat.nl/2026/03/31/volwassenen-met-een-ventrikelseptumdefect-hebben-drie-keer-hogere-sterfte-zweeds/","title":"Volwassenen met een ventrikelseptumdefect hebben drie keer hogere sterfte (Zweeds register)","title_en":"Mortality in patients with ventricular septal defect in Sweden: a national register study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004098?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004098?rss=1","authors":["Lundberg","P.","Fedchenko","M.","Giang","K. W.","Eckerstro&#x0308;m","F.","Eriksson","P.","Dellborg","M.","Mandalenakis","Z."],"significance":6,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/"],"congress":"","summary_en":"Ventricular septal defect (VSD) is the most common congenital heart defect, but much about long-term prognosis is unclear. In this Swedish register study, 22,855 VSD patients (born 1970-2017) were compared with ten matched controls without congenital heart disease per patient; patients with complex congenital disease were excluded. Mortality was elevated versus controls: hazard ratio 6.8 at ages 0-17 and 3.1 above age 18. Even in isolated, non-syndromic VSD, mortality remained elevated regardless of whether the defect had been repaired in childhood. Mortality was highest in cohorts with syndromes and associated valvular lesions. Adults with VSD thus have more than threefold higher mortality than controls — arguing for continued cardiology follow-up, even after repair.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"566f3ff83d73","type":"article","url":"https://hartvaat.nl/2026/03/31/stemi-uitgestelde-primaire-pci-gaat-gepaard-met-hogere-sterfte-dan-trombolyse-ie/","title":"STEMI: uitgestelde primaire PCI gaat gepaard met hogere sterfte dan trombolyse (Iers register)","title_en":"Outcomes according to timely or delayed primary PCI or fibrinolysis in a national registry of STEMI patients","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["stemi"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003886?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003886?rss=1","authors":["Laffan","J.","Gao","H.","Street","A.","Coughlan","J.","Armstrong","R.","Maree","A.","Blake","G.","Kearney","P.","Crowley","J.","Kiernan","T. J.","McCreery","C.","Aleong","G.","Peace","A.","Kennedy","M.","Byrne","R. A."],"significance":7,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-acs-2023/"],"congress":"","summary_en":"Time to reperfusion partly determines long-term outcome in ST-elevation myocardial infarction (STEMI). Timely primary PCI is the preferred strategy; fibrinolysis is recommended when timely PCI is not feasible but may be underused. In this nationwide Irish STEMI registry (4,156 patients, 2013-2018), 4.9% received fibrinolysis, 25.8% delayed primary PCI (>120 min after diagnosis) and 69.3% timely primary PCI (<120 min). Over three years' follow-up, delayed primary PCI was associated with higher mortality than fibrinolysis (adjusted HR 1.36), whereas timely PCI gave comparable mortality to fibrinolysis (HR 1.10; not significant). A sizeable proportion of STEMI patients thus still receive delayed PCI — a strategy that fares worse than fibrinolysis. The findings underscore the importance of timely reperfusion and of fibrinolysis when timely PCI is not possible.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2c89ac7abcef","type":"article","url":"https://hartvaat.nl/2026/03/31/tofacitinib-bij-cardiale-sarcoidose-veelbelovend-als-corticosteroidsparende-beha/","title":"Tofacitinib bij cardiale sarcoïdose: veelbelovend als corticosteroïdsparende behandeling","title_en":"Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiale-sarcoidose","trombocytenaggregatieremmers"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003659?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003659?rss=1","authors":["Frischknecht","L.","Stu&#x0308;ssi-Helbling","M.","Tian","Y.","Mallone","A.","Farokhnia","A.","Buechel","R.","Kolios","A. G.","Nilsson","J."],"significance":5,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/"],"congress":"","summary_en":"Cardiac sarcoidosis (CS) is difficult to treat, especially in patients who fail immunosuppressants and second-line TNF inhibitors; these refractory cases often lead to serious complications. This study treated eight patients with (probable) refractory CS with the JAK inhibitor tofacitinib (University Hospital Zurich, 2020-2024), tracking inflammation with 18F-FDG PET/CT, ejection fraction, corticosteroid use and blood neopterin. Seven of eight patients (87.5%) achieved inactive or remitting disease, with decreased myocardial uptake; ejection fraction stabilised or improved and the mean daily prednisone dose fell from 5.94 to 2.5 mg. Tofacitinib thus shows promising results in treatment-refractory cardiac sarcoidosis, though larger prospective studies are needed to confirm efficacy and safety.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c20caad9af55","type":"article","url":"https://hartvaat.nl/2026/03/31/era-s-abcde-raamwerk-voor-preventie-van-nierziekten/","title":"ERA's ABCDE-raamwerk voor preventie van nierziekten","title_en":"ERA's ABCDE Framework for Kidney Disease Prevention: Turning the WHO Kidney Health Resolution into action.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["cardiorenal-behandelstrategie"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfaf198","source_url":"https://doi.org/10.1093/ndt/gfaf198","authors":["Roser Torra","Dimitrios S Goumenos","Mustafa Arici","Alberto Ortiz","Adamczak Marcin","Kathrin Eller","Ana Carina Ferreira","Giuseppe Grandaliano","Kitty Jager","Jennifer Lees","Vassilios Liakopoulos","Roberto Minutolo","Siren Sezer","Federico Torres","Laura Azzolini","Monica Fontana"],"significance":6,"published":"2026-03-31","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This ERA ABCDE Framework translated the WHO kidney health resolution into practical action steps for kidney disease prevention, providing a structured approach for implementing global nephrology policy.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8ccbafb405be","type":"article","url":"https://hartvaat.nl/2025/01/01/acc-braunwald-lecture-2025-cardiovasculaire-wetenschap-en-maatschappij/","title":"ACC Braunwald Lecture 2025: cardiovasculaire wetenschap en maatschappij","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["microbioom"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000732?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000732?dgcid=rss_sd_all","authors":["Jessica A. Regan","Melissa H. Laitner","Victor J. Dzau"],"significance":5,"published":"2026-03-30","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"The 2025 ACC Braunwald Lecture, published in JACC, outlines a future vision at the intersection of cardiovascular science, medicine, and society. It highlights how technological innovation, population health, and health equity will shape cardiology in the coming years.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c58bf228d605","type":"article","url":"https://hartvaat.nl/2025/01/01/coronaire-atherosclerose-bij-levertransplantatiepatienten-vergeleken-met-algemen/","title":"Coronaire atherosclerose bij levertransplantatiepatiënten vergeleken met algemene bevolking","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","atherosclerose","biomarkers-cardiovasculair","coronaire-ct-angiografie","fractional-flow-reserve","hartkatheterisatie","harttransplantatie","ouderen","perifeer-vaatlijden","stabiel-coronairlijden"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972600207X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972600207X?dgcid=rss_sd_all","authors":["Andreas Dehlbæk Knudsen","Jørgen Tobias Kühl","Nicolai Aagaard Schultz","Gerda Elisabeth Villadsen","Julie Høgh","Nicoline Arentoft","Moisés Alberto Suarez-Zdunek","Ask Bock","Annette Dam Fialla","Jesper Bach Hansen"],"significance":5,"published":"2026-03-30","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Using protocolised CT angiography in a nationwide Danish cohort, this JACC study compared coronary atherosclerosis between liver transplant recipients and population controls. The findings are relevant for cardiovascular risk stratification in transplant patients.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1493763ce243","type":"article","url":"https://hartvaat.nl/2025/01/01/noodprotocollen-voor-plotse-hartstilstand-bij-jonge-sporters-moeten-worden-aange/","title":"Noodprotocollen voor plotse hartstilstand bij jonge sporters moeten worden aangescherpt","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726003293?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726003293?dgcid=rss_sd_all","authors":["Bradley J. Petek","Jonathan A. Drezner"],"significance":5,"published":"2026-03-30","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/ritmestoornissen/plotse-hartstilstand-plotse-hartdood/"],"congress":"","summary_en":"This JACC perspective addresses preparedness for sudden cardiac arrest in young athletes, advocating for improved emergency protocols. The authors stress that current guidelines are insufficient and that AED availability, training, and response plans at sports venues urgently need enhancement.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"328f227302d1","type":"article","url":"https://hartvaat.nl/2026/03/30/leaf-liraglutide-voor-ablatie-verbetert-af-vrije-overleving/","title":"LEAF: liraglutide vóór ablatie verbetert AF-vrije overleving","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["liraglutide","obesitas"],"journal":"JACC. Clinical electrophysiology","doi":"10.1016/j.jacep.2026.03.026","source_url":"https://doi.org/10.1016/j.jacep.2026.03.026","authors":["Jeffrey J Goldberger","Raul D Mitrani","Joel Fishman","Ghaith Zaatari","Maureen Lowery","Carmen Baez-Garcia","Valeria Aguilar","Catherine Blandon","Barry E Hurwitz","Alex H Velasquez","Litsa K Lambrakos","Damini Dey","Yalda Zarnegarnia","Gianluca Iacobellis"],"significance":7,"published":"2026-03-30","source_date":"2026-03-30","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"In this randomized study, 59 overweight or obese patients with (mostly persistent) atrial fibrillation received three months of risk-factor modification with or without liraglutide before catheter ablation. The primary endpoint — reduction of left-atrial epicardial adipose tissue — did not differ significantly between groups. Nonetheless, one-year freedom from AF/atrial flutter was higher with liraglutide (81% vs 54%; p=0.007). The authors suggest pleiotropic GLP-1 effects may offer a novel target for AF treatment, to be confirmed in larger trials.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e82e6522afb","type":"article","url":"https://hartvaat.nl/2025/01/01/betere-diagnostiek-als-sleutel-tot-vooruitgang-na-acuut-myocardinfarct/","title":"Betere diagnostiek als sleutel tot vooruitgang na acuut myocardinfarct","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["myocardinfarct"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001488?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726001488?dgcid=rss_sd_all","authors":["Jason H. Wasfy"],"significance":5,"published":"2026-03-29","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/endocarditis/"],"congress":"","summary_en":"This JACC perspective argues that the next leap in improving outcomes after acute myocardial infarction lies not in treatment but in diagnostics. More accurate and faster diagnosis could fundamentally improve the care trajectory and prevent unnecessary delays.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26b73d8a7b7f","type":"article","url":"https://hartvaat.nl/2025/01/01/luchtvervuiling-en-hypertensierisico-ernst-van-de-ziekte-doet-ertoe/","title":"Luchtvervuiling en hypertensierisico: ernst van de ziekte doet ertoe","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002305?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002305?dgcid=rss_sd_all","authors":["Yi Zheng","Ruijun Xu","Hong Sun","Yuanhui Liu","Wenhao Xia","Yuewei Liu"],"significance":5,"published":"2026-03-29","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/"],"congress":"","summary_en":"This JACC study re-examines the association between air pollution and hypertension, highlighting that the effect of air pollution on blood pressure varies with disease severity. The findings carry implications for prevention policy and cardiovascular risk stratification.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1176c2305d7","type":"article","url":"https://hartvaat.nl/2026/03/03/wereldwijde-toename-atriumfibrilleren-treft-steeds-vaker-jongere-volwassenen/","title":"Wereldwijde toename atriumfibrilleren treft steeds vaker jongere volwassenen","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","ouderen","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag036","source_url":"https://doi.org/10.1093/europace/euag036","authors":["Siyuan Tan","Zixi Zhang","Qiuzhen Lin","Tao Tu","Jiayi Zhu","Gaoming Zeng","Fanqi Li","Kangrong Li","Yongguo Dai","Jiabao Zhou","Cancan Wang","Chan Liu","Yichao Xiao","Qiming Liu"],"significance":6,"published":"2026-03-29","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"Analysis of Global Burden of Disease 2023 data reveals a rising global incidence of atrial fibrillation and atrial flutter, notably among younger and middle-aged adults, particularly in low- and middle-income countries. Six modifiable risk factors were identified as contributing to AF-related mortality.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cf6aa03860e4","type":"article","url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","title":"CHAMPION-AF: WATCHMAN FLX non-inferieur aan NOAC's en superieur in bloedingsreductie bij atriumfibrilleren","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["abelacimab","acc-2026","linkerhartoorsluiting"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2517213&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2517213&rss=currentIssue","authors":["Shephal K. Doshi","Saibal Kar","Devi G. Nair","Thomas Waggoner","Himanshu Agarwal","Mehran Moussavian","Amir Kashani","Saumil Oza","Leon Feldman","Ashish Sadhu","David DeLurgio","Oluseun Alli","Jens Erik Nielsen-Kudsk","Masanori Yamamoto","Mohamad Alkhouli","A. John Camm","Megan Coylewright","C. Michael Gibson","Christopher B. Granger","Mahmut Edip Gurol"],"significance":10,"published":"2026-03-29","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"acc-2026","summary_en":"In CHAMPION-AF, 3,000 patients with non-valvular AF were randomized to WATCHMAN FLX LAA closure or NOAC therapy. At 36 months, the device was noninferior for the primary efficacy endpoint (stroke, CV death, systemic embolism: 5.7% vs 4.8%; P<0.001 for noninferiority) and superior for non-procedural bleeding (45% reduction: 10.9% vs 19.0%; P<0.001). This contrasts with the negative CLOSURE-AF trial and establishes WATCHMAN FLX as the first LAA closure device to demonstrate noninferiority vs NOACs as first-line therapy.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"65155ad0cd18","type":"article","url":"https://hartvaat.nl/2026/03/28/hi-peitho-katheter-gestuurde-trombolyse-halveert-ernstige-uitkomsten-bij-interme/","title":"HI-PEITHO: katheter-gestuurde trombolyse halveert ernstige uitkomsten bij intermediair-hoog-risico longembolie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acc-2026","longarts","seh-arts"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2516567&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2516567&rss=currentIssue","authors":["Kenneth Rosenfield Frederikus"],"significance":10,"published":"2026-03-29","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-bloeding/"],"congress":"acc-2026","summary_en":"In the HI-PEITHO trial, 544 patients with acute intermediate-high-risk PE were randomized to ultrasound-facilitated catheter-directed fibrinolysis (EKOS) vs anticoagulation alone. The primary composite endpoint (PE-related death, cardiorespiratory decompensation, or recurrent PE within 7 days) occurred in 3.7% vs 10.3% — a 61% relative risk reduction (RR 0.4; P=0.005). No intracranial bleeding in either group. First positive hard-outcome trial for catheter-directed intervention in intermediate-risk PE.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84196ac73806","type":"article","url":"https://hartvaat.nl/2026/03/02/therapietrouw-aan-lipidenverlagende-medicatie-na-pci-in-nederland/","title":"Therapietrouw aan lipidenverlagende medicatie na PCI in Nederland","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":["dyslipidemie","farmaco-economie","lipidenverlaging","niet-statine-therapie","obesitas","statines"],"journal":"Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","doi":"10.1007/s12471-026-02028-8","source_url":"https://doi.org/10.1007/s12471-026-02028-8","authors":["Marijke J C Timmermans","M Patrick Witvliet","Judith A van Erkelens","Jan Reitsma","Pieter W Kamphuisen","Cyril Camaro","Peter W Danse","E Karin Arkenbout"],"significance":6,"published":"2026-03-28","source_date":"2026-03-02","image":"https://hartvaat.nl/global/img/686cc0e10ae7.webp","kennis":["https://hartvaat.nl/kennis/farmacologie/polypil-cardiovasculair/"],"congress":"","summary_en":"This Dutch retrospective cohort study used Vektis claims data to assess adherence to lipid-lowering medication in the first year after percutaneous coronary intervention. Despite proven benefits of post-PCI statin therapy, real-world adherence remained disappointing, highlighting concrete opportunities for quality improvement.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dee021ce7186","type":"article","url":"https://hartvaat.nl/2026/02/03/ryr2-mutaties-als-oorzaak-van-onverklaarde-plotse-hartdood-bij-jongeren/","title":"RYR2-mutaties als oorzaak van onverklaarde plotse hartdood bij jongeren","title_en":"","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf303","source_url":"https://doi.org/10.1093/europace/euaf303","authors":["Lucilla Giammarino","Raquel Neves","David J Tester","Sahej Bains","Vanessa Karlinski Vizentin","J Martijn Bos","John R Giudicessi","Michael J Ackerman"],"significance":6,"published":"2026-03-28","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/brugada-syndroom/","https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"Calcium release channel deficiency syndrome (CRCDS), caused by loss-of-function RYR2 variants, can lead to ventricular fibrillation without exercise test abnormalities. This study assessed the prevalence of potentially CRCDS-causing variants in idiopathic ventricular fibrillation and unexplained sudden death in young individuals, underscoring the importance of genetic screening.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5996da70a20","type":"article","url":"https://hartvaat.nl/2026/03/04/big-data-benadering-voor-aldosteron-renineratio-bij-primair-hyperaldosteronisme/","title":"Big data-benadering voor aldosteron-renineratio bij primair hyperaldosteronisme","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","ras-remmers"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26435","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26435","authors":[],"significance":6,"published":"2026-03-28","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"Using administrative healthcare data from Alberta, Canada, researchers developed a five-component definition of primary hyperaldosteronism independent of the aldosterone-renin ratio (ARR). By circumventing selection bias, the study re-evaluated the sensitivity of ARR thresholds, offering insights for identifying surgically treatable forms of secondary hypertension.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2492b2e72d07","type":"article","url":"https://hartvaat.nl/2026/03/28/coronaire-autoregulatie-samenspel-van-epicardiale-en-microvasculaire-weerstand/","title":"Coronaire autoregulatie: samenspel van epicardiale en microvasculaire weerstand","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","microcirculatie","microvasculaire-angina","percutane-coronaire-interventie","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag145","source_url":"https://doi.org/10.1093/eurheartj/ehag145","authors":["Thabo Mahendiran","Sara Corradetti","Divaka Perera","Nico H J Pijls","Bernard De Bruyne"],"significance":6,"published":"2026-03-28","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/","https://hartvaat.nl/kennis/coronairlijden/myocardperfusiescintigrafie/"],"congress":"","summary_en":"This EHJ review examines coronary autoregulation: the coronary circulation's ability to keep flow stable despite fluctuating perfusion pressure, with microvascular resistance as the main control. New techniques such as continuous intracoronary thermodilution allow simultaneous measurement of absolute coronary flow and epicardial and microvascular resistance. The authors present an integrative model from rest to maximal hyperaemia and stress that understanding this interplay is essential for correctly interpreting coronary physiological assessments in epicardial coronary disease.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62668f462417","type":"article","url":"https://hartvaat.nl/2026/03/28/kardinal-tonlamarsen-verlaagt-angiotensinogeen-maar-laat-geen-significant-bloedd/","title":"KARDINAL: tonlamarsen verlaagt angiotensinogeen maar laat geen significant bloeddrukeffect zien","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acc-2026","angiotensinereceptorblokkers","bloeddrukbehandeling","ras-remmers","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"https://www.jacc.org/doi/10.1016/j.jacc.2026.03.001","source_url":"https://doi.org/https://www.jacc.org/doi/10.1016/j.jacc.2026.03.001","authors":["Luke Laffin, Ashish Sarraju, Markus P. Schlaich et al."],"significance":7,"published":"2026-03-28","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"acc-2026","summary_en":"In the KARDINAL phase 2 trial, 206 patients with uncontrolled hypertension (despite 2-5 antihypertensives) received monthly injections of tonlamarsen, an antisense oligonucleotide targeting angiotensinogen. At 20 weeks, angiotensinogen levels dropped significantly (-67% vs -23% with placebo). Systolic BP dropped 6.7 mmHg in both groups with no significant between-group difference. The unexpectedly long-lasting effect of a single dose complicated interpretation. Simultaneously published in JACC.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f76be3653ed9","type":"article","url":"https://hartvaat.nl/2026/03/28/vesalius-cv-evolocumab-verlaagt-risico-op-eerste-cardiovasculair-event-met-31-bi/","title":"VESALIUS-CV: evolocumab verlaagt risico op eerste cardiovasculair event met 31% bij patiënten zonder significant atherosclerose","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["acc-2026","biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-2","ezetimibe","farmaco-economie","figaro-dkd","obesitas","ouderen","perifeer-vaatlijden","soul-trial"],"journal":"JAMA","doi":"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4521","source_url":"https://doi.org/https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4521","authors":["Nicholas Marston, Erin Ann Bohula, Ajay Bhatia et al."],"significance":9,"published":"2026-03-28","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"acc-2026","summary_en":"In a subgroup analysis of VESALIUS-CV, 3,655 patients with diabetes but no known significant atherosclerosis were followed for a median of 4.8 years. Evolocumab reduced 3-P MACE by 31% (HR 0.69; P=0.009) and 4-P MACE by 31% (HR 0.69; P=0.001). The effect appeared after 1 year and grew to ~40% reduction thereafter. CV death was reduced by 32% and all-cause mortality by 24%. This supports the use of PCSK9 inhibitors for primary prevention in high-risk diabetes patients.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2d96fd7d589","type":"article","url":"https://hartvaat.nl/2026/03/28/ez-pave-ldl-streefwaarde-55-mg-dl-superieur-aan-70-mg-dl-bij-patienten-met-ather/","title":"Ez-PAVE: LDL-streefwaarde <55 mg/dL superieur aan <70 mg/dL bij patiënten met atherosclerotisch vaatlijden","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["acc-2026","dyslipidemie","ezetimibe","ldl-cholesterol","statines"],"journal":"The New England Journal of Medicine","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2600757","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2600757","authors":["Byeong-Keuk Kim, Yong-Joon Lee, Seung-Jun Lee et al."],"significance":10,"published":"2026-03-28","source_date":"2026-03-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"acc-2026","summary_en":"In the Ez-PAVE trial, the first randomized head-to-head comparison of LDL-C targets, 3,048 patients with ASCVD were shown to have a 33% lower risk of cardiovascular events with a target of <55 mg/dL vs <70 mg/dL (HR 0.67; P=0.002). At 3 years, the primary composite endpoint occurred in 6.6% vs 9.7%. Safety profiles were similar. This is the first randomized evidence that the lower target in the 2026 ACC/AHA dyslipidemia guideline is superior.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a085873511e1","type":"article","url":"https://hartvaat.nl/2026/03/04/prevalentie-en-behandelpatronen-van-therapieresistente-hypertensie-in-de-vs/","title":"Prevalentie en behandelpatronen van therapieresistente hypertensie in de VS","title_en":"","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","precision-trial","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25659","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25659","authors":[],"significance":6,"published":"2026-03-27","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/"],"congress":"","summary_en":"Using NHANES data (2003-2020), this study analysed the prevalence of apparent treatment-resistant hypertension in the United States. Despite stricter blood pressure targets, a substantial proportion of patients remain inadequately treated, with many not receiving optimal diuretic regimens.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62f6c0959b12","type":"article","url":"https://hartvaat.nl/2026/03/03/kdigo-versnelt-richtlijnontwikkeling-voor-nierziekten/","title":"KDIGO versnelt richtlijnontwikkeling voor nierziekten","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","farmaco-economie","fidelio-dkd","richtlijnen-esc"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00012-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00012-8/fulltext","authors":["Morgan E. Grams","Michel Jadoul"],"significance":6,"published":"2026-03-27","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"KDIGO has published 17 kidney disease guidelines, but traditional full-revision cycles take years and lag behind rapidly evolving therapies such as SGLT2 inhibitors and finerenone. This article describes KDIGO's transition to modular, faster guideline updates to accelerate evidence translation into cardiometabolic clinical practice.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df5a08bb393b","type":"article","url":"https://hartvaat.nl/2026/02/27/deep-endotypering-onthult-heterogeniteit-van-nierschade-bij-diabetes-type-2/","title":"Deep endotypering onthult heterogeniteit van nierschade bij diabetes type 2","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00143-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00143-2/fulltext","authors":["Loreto Gesualdo","Matthias Kretzler","Paola Pontrelli"],"significance":6,"published":"2026-03-27","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Kidney damage in type 2 diabetes is highly heterogeneous and poorly captured by traditional markers such as albuminuria and eGFR. This Kidney International review discusses how deep endotyping — integrating clinical trajectory analysis, renal histopathology, and molecular profiling — can identify subgroups with distinct pathophysiology, enabling more targeted therapy selection.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eeae357f0846","type":"article","url":"https://hartvaat.nl/2026/03/27/nt-probnp-afkapwaarden-voor-hartfalentrials-optimaliseren-swedehf/","title":"NT-proBNP-afkapwaarden voor hartfalentrials optimaliseren (SwedeHF)","title_en":"Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","bloeddrukbehandeling","dapa-hf","harttransplantatie","hfmref","hfpef","hfref","nt-probnp","sacubitril-valsartan","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag089","source_url":"https://doi.org/10.1093/eschf/xvag089","authors":["Megan Schroeder","Lars H Lund","Christoph Gerlinger","Yvonne Mei Fong Lim","Stefan Koudstaal","Ulf Dahlström","Gianluigi Savarese"],"significance":6,"published":"2026-03-27","source_date":"2026-03-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"NT-proBNP is widely used as an enrolment criterion in heart-failure trials, but cut-offs vary widely. Using the Swedish Heart Failure Registry (SwedeHF, 43,750 patients), the investigators applied prior-trial cut-offs (200–5,000 pg/mL) and computed the 1-year incidence of cardiovascular death or heart-failure hospitalisation across subgroups (ejection fraction, care setting, AF, CKD, obesity). Higher cut-offs increased event enrichment but excluded more patients (more screening failures). In HFrEF outpatients, 1-year incidence rose from 22.0% (no cut-off) to 26.2% at ≥1,200 pg/mL, at the cost of 26% screening failure. The authors advise tailoring cut-offs to trial aims while accounting for obesity and CKD.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8593f42fe5d","type":"article","url":"https://hartvaat.nl/2026/03/06/metabool-cardiovasculair-risico-nieuwe-mechanismen-en-therapiekansen/","title":"Metabool cardiovasculair risico: nieuwe mechanismen en therapiekansen","title_en":"","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","dyslipidemie","endotheel","ezetimibe","familiaire-hypercholesterolemie","farmaco-economie","figaro-dkd","gepersonaliseerde-geneeskunde","glp1-agonisten","hdl-cholesterol","inflammatie","lipidenverlaging","lipoproteïne-a","menopauze","microbioom","niet-statine-therapie","obesitas","ouderen","roken","semaglutide","slaapapneu","tirzepatide","voeding-hart"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag116","source_url":"https://doi.org/10.1093/eurheartj/ehag116","authors":["Paul C Evans","Gemma Vilahur","Petra Kleinbongard","Elena Osto","Carol Ann Remme","Rosalinda Madonna","Dunja Aksentijevic","Harald Sourij","Sean M Davidson","Donato Santovito","Jürgen Gindlhuber","Christian Weber","Wolfgang A Linke","Esther Lutgens","Luc Bertrand","Dana Dawson","Magnus Bäck","G Danilo Norata","Johann Wojta","Cinzia Perrino"],"significance":6,"published":"2026-03-26","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This European Heart Journal review examines how metabolic disorders — obesity, type 2 diabetes, and dyslipidaemia — drive cardiovascular risk through newly identified mechanisms. The authors highlight unexpected cardiovascular benefits from metabolic drug classes including GLP-1 receptor agonists and SGLT2 inhibitors, and discuss emerging therapeutic opportunities at the intersection of metabolic and cardiovascular disease.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d282b086a59","type":"article","url":"https://hartvaat.nl/2026/03/06/veroudering-en-myocarddisfunctie-het-hart-jong-houden/","title":"Veroudering en myocarddisfunctie: het hart jong houden","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag095","source_url":"https://doi.org/10.1093/eurheartj/ehag095","authors":["Ramzi A Ajjan","Robert T R Huckstepp","Naveed Akbar","Johann Bauersachs","Jesher Ching Wai Lok","Juel Choppy-Madeleine","Gary Christopher","Mayank Dalakoti","Emily Dawson-Plincke","John Dodds","Georgina M Ellison-Hughes","Costanza Emanueli","Christopher H George","Anushka Goyal","Victoria Higginbotham","Lorenz Holzner","Venkateswarlu Kanamarlapudi","Paolo Madeddu","Claudio Mauro","Fiona Lewis-McDougall","Andrew J Murray","Renita Peter Damien Genetus","Emma Short","Mark A Sussman","Adriana A S Tavares","Samuel Thompson","Morya Wadodkar","Stuart R G Calimport","Barry L Bentley"],"significance":6,"published":"2026-03-26","source_date":"2026-03-06","image":"","kennis":[],"congress":"","summary_en":"This European Heart Journal review provides a comprehensive overview of ageing-related myocardial dysfunction. The authors discuss how cellular senescence affects cardiac pump function and explore therapeutic strategies to slow this process.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"203c01b2db0c","type":"article","url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","title":"Barrières bij implementatie van lipidenverlagende therapie in de praktijk","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","lipidenverlaging","niet-statine-therapie"],"journal":"Circulation. Population health and outcomes","doi":"10.1161/CIRCOUTCOMES.125.012330","source_url":"https://doi.org/10.1161/CIRCOUTCOMES.125.012330","authors":["Christopher S Marnell","Wolfgang Koenig","Vera Bittner","Karol E Watson","Paul Muntner","Børge G Nordestgaard","Lijing L Yan","Mariette Verbakel","Robert S Rosenson"],"significance":6,"published":"2026-03-26","source_date":"2026-03-02","image":"","kennis":[],"congress":"","summary_en":"Despite proven efficacy of lipid-lowering therapies, their implementation in daily clinical practice remains suboptimal. This Circulation article analyses barriers — from adherence to financial accessibility — and discusses strategies to close the gap between guidelines and practice.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"473de645136c","type":"article","url":"https://hartvaat.nl/2026/03/26/hoge-cardiometabole-last-bij-bilaterale-macronodulaire-bijnierziekte-met-primair/","title":"Hoge cardiometabole last bij bilaterale macronodulaire bijnierziekte met primair aldosteronisme","title_en":"Cardiometabolic Burden in Bilateral Macronodular Adrenal Disease With Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","aldosteronsynthaseremmers","baxdrostat","bloeddrukbehandeling","cardio-renaal-metabool","diabetes-en-hart","hypertrofische-cardiomyopathie","lorundrostat","obesitas","resistente-hypertensie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25507","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25507","authors":["Annalisa Panarelli"],"significance":5,"published":"2026-03-26","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Bilateral macronodular adrenocortical disease is often linked to autonomous cortisol secretion but can also present with primary aldosteronism (PA). In this international retrospective cohort (249 patients from 41 centres in 12 countries; median age 55, 62% male), hypertension had been present for a median of 9.9 years at PA diagnosis. Of those tested, 52% had cortisol cosecretion and 47% isolated PA. At baseline, 56% had metabolic comorbidity and 16% had at least one prior major cardiovascular event (MACE); patients with MACE were older, more often male and had longer-standing hypertension. Bilateral macronodular adrenal disease with PA thus carries a substantial cardiometabolic and cardiovascular burden, driven partly by the often long duration of hypertension and frequent cortisol cosecretion.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f2c66dbe15d9","type":"article","url":"https://hartvaat.nl/2026/03/26/kunstmatige-intelligentie-in-de-cardiovasculaire-geneeskunde-focus-op-hypertensi/","title":"Kunstmatige intelligentie in de cardiovasculaire geneeskunde: focus op hypertensie","title_en":"Artificial Intelligence in Cardiovascular Medicine: Focus on Hypertension","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","endotheel","farmaco-economie","gepersonaliseerde-geneeskunde","laminopathie","menopauze","obesitas","precision-trial","slaapapneu","thuisbloeddrukmeting","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26094","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26094","authors":["Fahimeh Varzideh"],"significance":6,"published":"2026-03-26","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/sotalol-bij-af/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"Hypertension remains the most prevalent modifiable risk factor worldwide, while blood-pressure control stays persistently suboptimal — partly because care models rely on episodic measurements and population-based algorithms. This systematic review maps how artificial intelligence (AI) can support the entire hypertension care continuum: risk prediction, phenotyping, blood-pressure measurement, wearable-based monitoring, trial analysis, population health, detection of secondary hypertension, behavioural and adherence interventions, and multi-omics-driven precision medicine. The authors stress the methodological prerequisites for clinically meaningful AI — robust ground-truth standards, external and temporal validation, interpretability, workflow integration and equity-aware design — and discuss cuffless BP measurement, natural language processing and decision support, with the ethical and regulatory challenges. AI could shift hypertension care from reactive and threshold-based to predictive, personalised and patient-centred, provided it is carefully validated and implemented.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55bac470c9a9","type":"article","url":"https://hartvaat.nl/2026/03/26/reverse-cardio-oncologie-obesitas-en-veroudering-als-aanjagers-van-borstkanker/","title":"Reverse cardio-oncologie: obesitas en veroudering als aanjagers van borstkanker","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["kanker-en-hart","obesitas","select-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag144","source_url":"https://doi.org/10.1093/eurheartj/ehag144","authors":["Federico Carbone","Alessandro Scuricini","Mara Cabri","Luca Liberale","Fabrizio Montecucco","Victoria Catalán","Valter D Longo","Gema Frühbeck"],"significance":6,"published":"2026-03-26","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This EHJ review introduces 'reverse cardio-oncology': how cardiometabolic dysfunction — such as obesity — influences breast-cancer risk and biology through shared mechanisms (chronic inflammation, hormonal dysregulation, cellular senescence), even without overt cardiovascular disease. Refined obesity phenotypes (metabolically healthy/unhealthy, sarcopenic obesity) stratify risk better than BMI. Senescent adipose tissue is a key driver of the tumour microenvironment. Cardiometabolic therapies (GLP-1 agonists, SGLT2 inhibitors) and senolytics may offer shared targets for cardiovascular and oncologic prevention.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"08997551b10a","type":"article","url":"https://hartvaat.nl/2026/03/26/acc-verklaring-2026-gen-editing-als-therapie-bij-hart-en-vaatziekten/","title":"ACC-verklaring 2026: gen-editing als therapie bij hart- en vaatziekten","title_en":"Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["pcsk9-remmers-nieuwe-generatie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726055609?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726055609?dgcid=rss_sd_all","authors":["Amrut V. Ambardekar","Ami Bhatt","Menno Hoekstra","Melissa A. Kelly","Kiran Musunuru","Pradeep Natarajan"],"significance":8,"published":"2026-03-26","source_date":"2026-03-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"In this scientific statement the American College of Cardiology charts the rise of gene and base editing as a therapeutic strategy in cardiovascular disease. It places the rapid advances — such as permanently switching off PCSK9 — in a broader context and discusses the technology, the potential targets and the clinical, safety, regulatory and ethical questions that accompany these one-time, durable interventions. The international author panel includes Dutch researcher Menno Hoekstra (Leiden University).","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40eb60688ed4","type":"article","url":"https://hartvaat.nl/2026/03/18/closure-af-sluiting-van-het-linker-hartoor-niet-non-inferieur-aan-medicamenteuze/","title":"CLOSURE-AF: sluiting van het linker hartoor niet non-inferieur aan medicamenteuze therapie bij atriumfibrilleren","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acc-2026","linkerhartoorsluiting"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2513310&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2513310&rss=currentIssue","authors":["Ulf Landmesser Carsten Skurk Paulus Kirchhof Thorsten Lewalter Johannes Hartung Andi Rroku Burkert Pieske Johannes Brachmann Ibrahim Akin Claudius Jacobshagen Benjamin Meder Andreas Zeiher Stefan"],"significance":9,"published":"2026-03-26","source_date":"2026-03-18","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"acc-2026","summary_en":"In the CLOSURE-AF trial, 912 patients with atrial fibrillation at high risk for both stroke and bleeding were randomized to catheter-based left atrial appendage closure or physician-directed best medical care. After a median follow-up of 3 years, LAA closure was not noninferior to medical therapy for the composite endpoint of stroke, systemic embolism, major bleeding, or cardiovascular death (16.8 vs 13.3 events per 100 patient-years; P=0.44 for noninferiority). Serious adverse events occurred in 82.5% of the device group versus 77.4% of the medical-therapy group. These results provide critical context for the CHAMPION-AF trial results to be presented at ACC.26.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"08cd789f6caa","type":"article","url":"https://hartvaat.nl/2026/03/02/diploide-cardiomyocyten-geassocieerd-met-hartregeneratie/","title":"Diploide cardiomyocyten geassocieerd met hartregeneratie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","cardiale-amyloidose","harttransplantatie","laminopathie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.071679","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.071679","authors":["Wenbin Fu"],"significance":6,"published":"2026-03-25","source_date":"2026-03-02","image":"","kennis":[],"congress":"","summary_en":"Research in Circulation demonstrates that the presence of mononuclear diploid cardiomyocytes is associated with the capacity for cardiac regeneration. These findings offer new insights into the cellular basis of myocardial repair and may pave the way for regenerative therapies after myocardial infarction.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc11ee06d4d9","type":"article","url":"https://hartvaat.nl/2026/03/02/pam-vt-2-littekenverloop-na-vt-ablatie-beoordeeld-met-seriele-cardiale-mri/","title":"PAM-VT 2: littekenverloop na VT-ablatie beoordeeld met seriële cardiale MRI","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074748","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074748","authors":["Ivo Roca"],"significance":6,"published":"2026-03-25","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"The PAM-VT 2 study used serial late gadolinium enhancement cardiac MRI to assess the long-term evolution of scar and ablation lesions after ventricular tachycardia ablation. The prospective study provides insight into how substrate and ablation lesions change over time, relevant for predicting recurrences.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"103b4b6d78f6","type":"article","url":"https://hartvaat.nl/2025/01/01/aficamten-en-de-toekomst-van-obstructieve-hcm-behandeling/","title":"Aficamten en de toekomst van obstructieve HCM-behandeling","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103343?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103343?dgcid=rss_sd_all","authors":["Sara Saberi"],"significance":6,"published":"2026-03-25","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This JACC editorial outlines how aficamten may fundamentally change the treatment of obstructive hypertrophic cardiomyopathy. It places recent trial results in the context of the evolving therapeutic landscape, including the relationship to mavacamten and surgical myectomy.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ac117a0acaf","type":"article","url":"https://hartvaat.nl/2026/03/25/aortacoarctatie-voorspelt-langetermijnmorbiditeit-na-de-arteriele-switchoperatie/","title":"Aortacoarctatie voorspelt langetermijnmorbiditeit na de arteriële-switchoperatie (EPOCH-ASO)","title_en":"Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortacoarctatie"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/437?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/437?rss=1","authors":["Ruperti-Repilado","F. J.","Ladron","R.","Lopez-Ayala","P.","Gabra","B.","Gonzalez-Fernandez","V.","Engele","L. J.","Manso","B.","Bouma","B. J.","Gabriel","H.","Schwitz","F.","Possner","M.","Schwerzmann","M.","Rueda","J.","Buendia-Fuentes","F.","Bouchardy","J.","Ladouceur","M.","Dos-Subira","L.","Greutmann","M.","Tobler","D.","Gallego","P."],"significance":5,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"After the arterial switch operation (ASO) for transposition of the great arteries, later interventions and complications are common. Whether aortic coarctation (CoA) plays an independent role was unclear. In this international multicentre study (502 adults from the EPOCH-ASO registry, median age 25.5 years), time to first right ventricular outflow tract (RVOT)-related intervention was the primary outcome. Aortic coarctation emerged as the strongest independent predictor of an RVOT intervention. The findings help identify patients after arterial switch at increased risk of later interventions and to follow them more closely.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"61aba5d9bd3a","type":"article","url":"https://hartvaat.nl/2026/03/25/geleidelijk-afbouwen-van-rilonacept-bij-recidiverende-pericarditis-voorkomt-vake/","title":"Geleidelijk afbouwen van rilonacept bij recidiverende pericarditis voorkomt vaker een recidief dan abrupt stoppen","title_en":"Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/454?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/454?rss=1","authors":["Saraswati","U.","Bhalla","J. S.","Tereshchenko","L. G.","Heine","M.","Syed","A. B.","Wang","T. K. M.","Cremer","P. C.","Abbate","A.","Imazio","M.","Klein","A. L."],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/","https://hartvaat.nl/kennis/vasculair/claudicatio-intermittens/"],"congress":"","summary_en":"Rilonacept, an interleukin-1α/β inhibitor, prevents recurrence in recurrent pericarditis (RP), but stopping after 18 months carries a higher recurrence risk. In this retrospective cohort (Cleveland Clinic; 53 patients with refractory RP, median treatment 24 months), abrupt discontinuation was compared with a slow taper (from weekly to fortnightly, monthly, then cessation). Recurrence occurred more often after abrupt stopping (82%) than after tapering (37%). Colchicine after stopping rilonacept delayed a flare by an average of 60.7 weeks. Most patients (80%) resumed rilonacept after a recurrence, and long-term therapy was well tolerated. A gradual taper of rilonacept thus appears associated with a lower recurrence risk than abrupt discontinuation — though larger studies are needed for a standardised tapering protocol.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41ba713e763d","type":"article","url":"https://hartvaat.nl/2026/03/25/kinderen-van-een-hypertensieve-zwangerschap-hebben-later-vaker-hoge-bloeddruk-en/","title":"Kinderen van een hypertensieve zwangerschap hebben later vaker hoge bloeddruk en hart- en vaatziekten","title_en":"Heritability and Cardiovascular Disease in Adult Offspring of Hypertensive Disorder of Pregnancy: A Systematic Review and Meta-Analysis","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","nt-probnp","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25834","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25834","authors":["Ansu Mari Saji"],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/"],"congress":"","summary_en":"This systematic review and meta-analysis examined the heritability of hypertensive disorders of pregnancy (HDP) and their association with cardiovascular disease in adult offspring. Fifteen studies (266,244 participants, offspring aged 19-55) were pooled. Adults exposed in utero to HDP had higher systolic (+3.40 mmHg) and diastolic blood pressure (+2.19 mmHg) and more hypertension (OR 1.50). Female offspring had 72% higher odds of developing HDP themselves (OR 1.72) and 90% higher odds of preeclampsia (OR 1.90). Exposure to HDP and severe preeclampsia was also associated with more premature acute coronary syndrome and higher stroke risk. HDP heritability is thus high, and exposure is associated with hypertension, acute coronary syndrome and stroke in offspring — arguing for lifestyle advice, monitoring and prevention.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"815455df5d25","type":"article","url":"https://hartvaat.nl/2026/03/25/glp-1-agonisten-en-sglt2-remmers-in-de-praktijk-bescherming-van-hart-en-nieren-v/","title":"GLP-1-agonisten en SGLT2-remmers in de praktijk: bescherming van hart en nieren voorbij diabetes","title_en":"Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","empagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/422?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/422?rss=1","authors":["Dalpiaz","H.","Masi","S.","Piludu","S.","Agnoletti","D.","Piani","F.","Fiorini","G.","Borghi","C."],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/"],"congress":"","summary_en":"The obesity epidemic has heightened the impact of cardiometabolic risk factors on cardiovascular and kidney disease. GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), originally developed for type 2 diabetes, reduce cardiovascular and renal risk in randomised trials. SGLT2is are the first class proven to improve prognosis in heart failure with preserved ejection fraction (HFpEF), and evidence is accumulating that GLP-1RAs may also help there. Notably, the benefits are independent of diabetes status and baseline renal function. This practice-oriented review discusses how to use these drugs in everyday care for patients at high cardiovascular and renal risk, in line with evolving guidelines.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a327e943dffa","type":"article","url":"https://hartvaat.nl/2026/03/25/sekseverschillen-in-hartremodellering-bij-primair-aldosteronisme-vrouwen-hebben-/","title":"Sekseverschillen in hartremodellering bij primair aldosteronisme: vrouwen hebben een ongunstiger fenotype","title_en":"Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26213","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26213","authors":[],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Sex differences influence cardiovascular risk assessment, but their role in aldosterone-mediated cardiac remodelling in primary aldosteronism (PA) was incompletely understood. In this retrospective study (547 PA patients: 249 men, 298 women), clinical and echocardiographic data were collected at baseline and after one year of aldosterone-targeted therapy. At baseline, men had a higher left ventricular mass index (LVMI), but women more often had LV hypertrophy and worse diastolic function (higher E/e' and left atrial volume index). Plasma aldosterone concentration was associated with LVMI in both sexes. After one year, LVMI reduction was comparable between sexes, but diastolic function improved less in women. Despite lower LVMI, women with PA thus have a more adverse cardiac phenotype that recovers less well after treatment.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"01335be7a0bb","type":"article","url":"https://hartvaat.nl/2026/03/25/vrouwen-krijgen-een-type-a-aortadissectie-bij-een-kleinere-aortadiameter-door-hu/","title":"Vrouwen krijgen een type A-aortadissectie bij een kleinere aortadiameter — door hun kleinere lichaamsbouw","title_en":"Sex differences in ascending aortic diameter at the time of acute type A aortic dissection","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortadissectie","aortainsufficiëntie","perifeer-vaatlijden"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/462?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/462?rss=1","authors":["Wagner","C. M.","Marway","P. S.","Ferrel","M. N.","Campello Jorge","C. A.","Fukuhara","S.","Hawkins","R. B.","Deeb","G. M.","Patel","H. J.","Ailawadi","G.","Yang","B.","Burris","N. S.","Hamilton","B. C. S."],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Guideline size criteria for prophylactic ascending aortic aneurysm repair do not account for sex, although women may experience acute type A aortic dissection (ATAAD) at smaller diameters. In this single-centre retrospective study (413 patients with ATAAD, 35% female), aortic diameter at dissection was smaller in women, who were also older (65 vs 58 years). Female sex was associated with dissection at a smaller absolute diameter, but this association disappeared when accounting for women's smaller body size (diameter indexed to height or body surface area). Guidelines that account for sex or body size could thus reduce preventable complications in women.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f95a596d93f4","type":"article","url":"https://hartvaat.nl/2026/03/25/waarom-de-sterfte-na-een-hartinfarct-daalde-15-jaar-nationale-data-uit-engeland-/","title":"Waarom de sterfte na een hartinfarct daalde: 15 jaar nationale data uit Engeland en Wales","title_en":"Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","myocardinfarct","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/446?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/446?rss=1","authors":["Ayayo","S. A.","Martin","G. P.","Zghebi","S.","Taxiarchi","V. P.","Rashid","M.","Kontopantelis","E.","Mamas","M. A."],"significance":7,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/metformine-cardiovasculair/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"One-year mortality after acute myocardial infarction (AMI) has declined over time, but the reasons were unclear. In this analysis of 852,914 AMI patients in England and Wales (2005-2019), decomposition analysis examined which factors contributed to the trend. One-year mortality fell from 22.8% to 14.2% — an absolute reduction of 8.6 percentage points. About 68% of this decline was explained by measured factors, the greatest contributor being increased use of evidence-based pharmacological therapy. The remainder stayed unexplained. The findings show that broader use of proven medications has been the main driver of improved post-infarction survival — an important pointer for clinical strategy and policy.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"861594a86ebd","type":"article","url":"https://hartvaat.nl/2026/03/25/vier-klinische-fenotypes-bij-coronairlijden-met-sterk-verschillend-risico-op-nie/","title":"Vier klinische fenotypes bij coronairlijden met sterk verschillend risico op nieuwe events (SWEDEHEART + UCC-SMART)","title_en":"Identifying clinical phenotype clusters in patients with coronary artery disease","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","diabetes-en-hart","fractional-flow-reserve","gepersonaliseerde-geneeskunde","hartrevalidatie","inflammatie","laminopathie","obesitas","ouderen","primaire-preventie","supraventriculaire-tachycardie","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/431?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/431?rss=1","authors":["Holtrop","J.","Lim","C.-E.","Uijl","A.","Ueda","P.","Jernberg","T.","van der Meer","M. G.","van der Harst","P.","Kraaijeveld","A. O.","Balder","J.-W.","Hageman","S. H. J.","Visseren","F. L. J.","Dorresteijn","J. A. N.","on behalf of the UCC-SMART study group","on behalf of the UCC-SMART studygroup","Bongers","van Giele","Vandersteen","Cramer","van der Meer","van der Harst","Nathoe","de Borst","Teraa","Bots","van Smeden","Emmelot-Vonk","de Jong","Lely","Mokhles","Ruigrok","Verhaar","Dorresteijn","Visseren"],"significance":7,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Guideline recommendations for secondary prevention in coronary artery disease (CAD) are largely one-size-fits-all, while clinically identifiable phenotypes needing specific approaches may exist. Using unsupervised machine learning (latent class analysis), four phenotypes were identified in the Swedish SWEDEHEART registry (88,894 patients) and validated in the Dutch UCC-SMART cohort (Utrecht, 5,506 patients): cluster 1 (38%) younger men with higher BMI, blood pressure and CRP; cluster 2 (21%) smokers with few traditional risk factors; cluster 3 (30%) older patients with few comorbidities; and cluster 4 (11%) patients with multimorbidity. Compared with cluster 1, cluster 4 had the highest risk of a recurrent event (myocardial infarction, stroke or cardiovascular death; HR 4.38), followed by cluster 3 (HR 1.78); cluster 2 did not differ. These four reproducible phenotypes may help target CAD care more precisely.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26a287bcd400","type":"article","url":"https://hartvaat.nl/2026/03/25/hoe-bouw-je-il-1-remmers-af-bij-recidiverende-pericarditis-strategieen-voor-afbo/","title":"Hoe bouw je IL-1-remmers af bij recidiverende pericarditis? Strategieën voor afbouw en staken","title_en":"Strategies for optimising tapering and withdrawal of interleukin-1 blockers in recurrent pericarditis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["colchicine","ezetimibe","pericarditis"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/413?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/413?rss=1","authors":["Lazaros","G.","Tsioufis","C."],"significance":5,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Interleukin-1 (IL-1) blockers radically changed the treatment of glucocorticoid-dependent, colchicine-resistant (GD-CR) recurrent pericarditis about fifteen years ago. This group comprises roughly 5-10% of patients with recurrent pericarditis, in whom disease can persist beyond three years and earlier options (glucocorticoids, colchicine, NSAIDs, conventional immunosuppressants) fell short. This review discusses strategies for tapering and withdrawing IL-1 blockers (such as anakinra and rilonacept) in a controlled way to prevent recurrence on discontinuation. The authors address timing, tapering speed and accompanying therapy, aiming to limit the duration of IL-1 blockade without flaring the disease — practical guidance for a difficult-to-treat condition.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c03a3cc43007","type":"article","url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","title":"Inspanningsecho identificeert HCM-patiënten die baat hebben bij mavacamten","title_en":"Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","hypertrofische-cardiomyopathie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag087","source_url":"https://doi.org/10.1093/eschf/xvag087","authors":["Jonas Erzeel","Sebastiaan Dhont","Marnicq van Es","Duhan Ulgar","Philippe Bertrand","Wilfried Mullens","Pieter Martens"],"significance":7,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"Left ventricular outflow tract obstruction (LVOTO) drives symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Some patients show treatment-qualifying obstruction only during exercise echocardiography. In this single-centre retrospective cohort (56 symptomatic oHCM patients on mavacamten), 42.9% qualified exclusively during exercise echo. These patients did not have milder disease: functional limitation and exercise capacity were similar to those qualifying at rest or with Valsalva. By 24 weeks, both groups similarly achieved a non-obstructive gradient (<30 mmHg) and NYHA improvement. Exercise echocardiography thus identifies a substantial group of treatable oHCM patients missed by resting assessment.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db4fe9e46bbe","type":"article","url":"https://hartvaat.nl/2026/03/25/bmi-en-prognose-bij-acuut-hartfalen-verschillen-per-fenotype-en-geslacht/","title":"BMI en prognose bij acuut hartfalen verschillen per fenotype en geslacht","title_en":"Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","nt-probnp","step-hfpef","summit-trial","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag050","source_url":"https://doi.org/10.1093/eschf/xvag050","authors":["Yoonsun Won","Mi-Seung Shin","Eunji Kim","Wook-Jin Chung","Eung Ju Kim","Seong Woo Han","Seong-Mi Park","Hyung-Seop Kim","Ju-Hee Lee","Hyo-Suk Ahn","Hyun-Jai Cho","Seok-Jae Hwang","Jin-Ok Jeong","Dong Heon Yang","Junho Hyun","Jin Oh Choi","Byung-Su Yoo","Seok-Min Kang","Dong-Ju Choi"],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"Whether the prognostic value of BMI differs by heart-failure phenotype and sex was examined in the Korean HF III registry (5,271 patients hospitalised for acute heart failure). The primary outcome was 2-year all-cause mortality or heart transplantation. In HFrEF, lower BMI was consistently associated with worse outcomes in both men and women (in women with HFrEF higher BMI was favourable, HR 0.66). In HFpEF, BMI was prognostic only in women (lower BMI borderline unfavourable, HR 1.56), not in men. The findings underscore the importance of sex- and phenotype-specific interpretation of BMI in risk assessment.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a14a70c8c5bb","type":"article","url":"https://hartvaat.nl/2026/03/25/cardiale-betrokkenheid-bij-parasitaire-infecties/","title":"Cardiale betrokkenheid bij parasitaire infecties","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bradycardie","covid-hart","endocarditis","pericarditis"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag173","source_url":"https://doi.org/10.1093/eurheartj/ehag173","authors":["Maria Carmo Pereira Nunes","Johannes Blum","Teresa Cristina Abreu Ferrari"],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/"],"congress":"","summary_en":"Parasitic infections are an underrecognised but important cause of cardiovascular disease, especially in endemic regions and — through migration and travel — increasingly beyond them. Cardiac involvement arises from direct invasion or, more often, immune-mediated inflammation, affecting myocardium and pericardium: acute myocarditis, dilated or restrictive cardiomyopathy, pericardial effusion, tamponade, constrictive pericarditis or cystic lesions. This EHJ review advises considering a parasitic cause in unexplained myocardial or pericardial disease — particularly with relevant exposure, immunosuppression, fever or eosinophilia — and offers practical diagnostic and management guidance.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19da168dc8b4","type":"article","url":"https://hartvaat.nl/2026/03/25/hart-en-vaatziekten-in-china-epidemiologische-evolutie-19902021/","title":"Hart- en vaatziekten in China: epidemiologische evolutie 1990–2021","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1121","source_url":"https://doi.org/10.1093/eurheartj/ehaf1121","authors":["Yue Qi","Jiangtao Li","Zixuan Yang","Jing Liu","Dong Zhao"],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This EHJ review analyses the epidemiological transition of cardiovascular disease in China from 1990 to 2021, for total CVD and the subtypes ischaemic heart disease (IHD), ischaemic stroke and haemorrhagic stroke. It quantifies the underlying drivers and shows that the fall in haemorrhagic-stroke mortality was mainly due to primary prevention, whereas declining IHD and ischaemic-stroke mortality stemmed largely from better medical care (fewer fatal events). The findings inform future prevention strategies.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5bdabedbde92","type":"article","url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","title":"Palliatieve zorg in de cardiologie: een state-of-the-art overzicht","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","delirium-cardiologie","ouderen","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag219","source_url":"https://doi.org/10.1093/eurheartj/ehag219","authors":["Endrit Cekaj","Frederik Sand","David H V Vogel","Peter M Spieth","Benedikt Schrage","Aitor Uribarri","Frederic De Roeck","Jordi Riera","Federico Pappalardo","Norman Mangner","Guido Tavazzi","Tom Verbelen","Christian Jung","Andreas Schäfer","Dirk Westermann","Sebastian Zimmer","Malte Kelm","Stephan Baldus","Christian Hagl","Martin Neukirchen","Farhad Bakhtiary","Georg Nickenig","Steffen T Simon","Holger Thiele","Claudia Bausewein","Lukas Radbruch","Alexandra Philipsen","Enzo Lüsebrink"],"significance":7,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/reanimatie-besluitvorming/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"Thanks to better treatment, more people live longer with advanced cardiovascular disease, often with a high symptom burden and complex decisions. This EHJ review summarises how palliative care — symptom management, communication, shared decision-making, advance care planning and psychosocial/spiritual support — improves quality of life and reduces low-value, high-intensity end-of-life care. It covers disease-specific aspects (heart failure, valvular disease, pulmonary hypertension, arrhythmias, congenital heart disease), ethical and legal issues such as device deactivation, and offers a practical algorithm for integrating palliative care into cardiology practice.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb14bba9dfb1","type":"article","url":"https://hartvaat.nl/2025/01/01/medicamenteuze-therapie-bij-niet-obstructieve-hcm-nieuwe-perspectieven/","title":"Medicamenteuze therapie bij niet-obstructieve HCM: nieuwe perspectieven","title_en":"Drug Therapy in Nonobstructive Hypertrophic Cardiomyopathy: Out of the Darkness Into the Light","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","answer-hf","bloeddrukbehandeling","bradycardie","cardiale-resynchronisatie","cardiomyopathie-gerichte-therapie","cardiorenal-behandelstrategie","diabetes-en-hart","farmaco-economie","gedilateerde-cardiomyopathie","hartrevalidatie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct","niet-statine-therapie","obesitas","ouderen","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104361?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104361?dgcid=rss_sd_all","authors":["Martin S. Maron"],"significance":6,"published":"2026-03-24","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This JACC editorial discussed the therapeutic advances in nonobstructive hypertrophic cardiomyopathy, a subgroup previously lacking targeted treatment options, evaluating the potential of cardiac myosin inhibitors beyond obstruction relief.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"369de070f1ea","type":"article","url":"https://hartvaat.nl/2025/01/01/troponine-i-t-ratio-bij-myocardschade-nieuwe-inzichten-uit-bekende-biomarkers/","title":"Troponine I/T-ratio bij myocardschade: nieuwe inzichten uit bekende biomarkers","title_en":"High-Sensitivity Troponin I-to-High-Sensitivity Troponin T Ratio in Myocardial Injury: Old Dogs, New Tricks","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["troponine"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002238?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002238?dgcid=rss_sd_all","authors":["L. Kristin Newby"],"significance":6,"published":"2026-03-24","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"This JACC commentary discussed the clinical value of the high-sensitivity troponin I-to-T ratio in myocardial injury, exploring whether the differential release pattern can help distinguish ischemic from non-ischemic causes.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f758f6c5cfa0","type":"article","url":"https://hartvaat.nl/2025/01/01/innovatie-in-longemboliebehandeling-loopt-de-praktijk-voor-op-het-bewijs/","title":"Innovatie in longemboliebehandeling: loopt de praktijk voor op het bewijs?","title_en":"Innovation and Evidence in Pulmonary Embolism Management: Putting the Cart Before the Horse","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["farmaco-economie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002378?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002378?dgcid=rss_sd_all","authors":["Aaron W. Aday","Alexander E. Sullivan"],"significance":6,"published":"2026-03-24","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC editorial criticized the rapid clinical adoption of interventional techniques for pulmonary embolism (catheter-directed therapy, mechanical thrombectomy) without sufficient randomized evidence, advocating for evidence before widespread implementation.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ffb5a74340f1","type":"article","url":"https://hartvaat.nl/2026/03/24/triglyceride-glucose-index-voorspelt-sterfte-bij-kritiek-zieke-patienten-met-ckm/","title":"Triglyceride-glucose-index voorspelt sterfte bij kritiek zieke patiënten met CKM-syndroom stadium 4","title_en":"Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["cardio-renaal-metabool","diabetes-en-hart","hypertriglyceridemie","obesitas"],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-025-03061-4","source_url":"https://doi.org/10.1186/s12933-025-03061-4","authors":["Xueshi Yin","Shuaixian Han","Zhiming Zheng","Long Tang","Jianping Liu","Yongheng Zhang"],"significance":6,"published":"2026-03-24","source_date":"2026-03-24","image":"https://hartvaat.nl/global/img/66aa05cd5d78.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/stijve-arterieen-arteriosclerose/"],"congress":"","summary_en":"The triglyceride-glucose (TyG) index is a surrogate marker of insulin resistance. In early stages of cardiovascular-kidney-metabolic (CKM) syndrome a higher TyG index is linked to more events, but its value in critically ill patients with CKM stage 4 was unclear. In this retrospective study from the MIMIC-IV database (3,125 ICU patients with CKM-4), 1-year mortality was 34%. Each standard-deviation higher TyG index was associated with 23% higher mortality (HR 1.23), and the highest tertile had 30% higher risk than the lowest (HR 1.30), with a linear relationship. The TyG index may serve as a simple marker for risk stratification in this group, though prospective studies must confirm its clinical value.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a85f73f66eea","type":"article","url":"https://hartvaat.nl/2026/03/24/cascadescreening-op-verhoogd-lp-a-via-kinderen-opbrengst-in-de-praktijk-amsterda/","title":"Cascadescreening op verhoogd Lp(a) via kinderen: opbrengst in de praktijk (Amsterdam UMC)","title_en":"Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","plaquekarakterisatie","primaire-preventie","statines","vrouwen"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag161","source_url":"https://doi.org/10.1093/eurjpc/zwag161","authors":["Sibbeliene E van den Bosch","Lotte M de Boer","Felicia P T de Graaff","Michael W T Tanck","Willemijn E Corpeleijn","Albert Wiegman","Barbara A Hutten"],"significance":7,"published":"2026-03-24","source_date":"2026-03-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/cascadescreening-fh/"],"congress":"","summary_en":"Cascade screening can identify people with elevated lipoprotein(a) [Lp(a)], a causal cardiovascular risk factor. This retrospective study from the Amsterdam University Medical Centers paediatric lipid clinic (1989–2023) examined whether asymptomatic children as index cases can identify relatives with elevated Lp(a). Of 1,931 children (732 index cases, 1,199 relatives), 25% had elevated Lp(a) (≥30 mg/dL or ≥75 nmol/L). The number needed to screen to find one case was 3.7 (systematic) to 4.1 (opportunistic), and similar in the FH subgroup. Screening through children as index cases is thus effective; Lp(a) should be part of cardiovascular risk assessment, especially in familial hypercholesterolaemia.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dae724686550","type":"article","url":"https://hartvaat.nl/2026/03/16/coronaire-calciumscore-blijft-bruikbaar-bij-verhoogd-lp-a-multicohort-studie-met/","title":"Coronaire calciumscore blijft bruikbaar bij verhoogd Lp(a): multicohort-studie met 11.000 deelnemers","title_en":"Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["acc-2026","calciumscore","dyslipidemie","lipoproteïne-a","plaquekarakterisatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2026.02.5067","source_url":"https://doi.org/10.1016/j.jacc.2026.02.5067","authors":["Bhatia Harpreet S","Fan Yihang","Dharmavaram Gourisree","Razavi Alexander C","Tsai Michael Y","Ramsis Mattheus","Mahmud Ehtisham","Wilkinson Michael","Taub Pam","Nasir Khurram","Blaha Michael J","Wong Nathan D"],"significance":8,"published":"2026-03-24","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"acc-2026","summary_en":"This multicohort study demonstrated that coronary artery calcium scoring remains a useful ASCVD risk assessment tool in individuals with elevated lipoprotein(a). CAC provides incremental risk stratification even when Lp(a) is elevated, supporting its use in Lp(a)-enriched populations.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"13dda6d13571","type":"article","url":"https://hartvaat.nl/2026/03/13/nieuwe-acc-aha-richtlijn-dyslipidemie-2026-lagere-ldl-streefwaarden-en-lp-a-meti/","title":"Nieuwe ACC/AHA-richtlijn dyslipidemie 2026: lagere LDL-streefwaarden en Lp(a)-meting aanbevolen","title_en":"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acc-2026","bempedoïnezuur","dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.11.016","source_url":"https://doi.org/10.1016/j.jacc.2025.11.016","authors":["Blumenthal Roger S","Morris Pamela B","Gaudino Mario","Johnson Heather M","Anderson Timothy S","Bittner Vera A","Blankstein Ron","Brewer LaPrincess C","Cho Leslie","de Ferranti Sarah D","Gianos Eugenia","Gluckman Ty J","Gradney Kristen F","Isiadinso Ijeoma","Lloyd-Jones Donald M","Marrs Joel C","Martin Seth S","McLain Kellie H","Mehta Laxmi S","Mora Samia","Mulugeta Wudeneh M","Natarajan Pradeep","Navar Ann Marie","Orringer Carl E","Polonsky Tamar S","Reynolds Harmony R","Saseen Joseph J","Shapiro Michael D","Soffer Daniel E","Tynes Sheila A","Villavaso Chloé D","Virani Salim S","Wilkins John T"],"significance":10,"published":"2026-03-24","source_date":"2026-03-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"acc-2026","summary_en":"The 2026 ACC/AHA dyslipidemia guideline introduces a universal LDL-cholesterol target of <100 mg/dL for primary prevention and <55 mg/dL for very-high-risk secondary prevention. The guideline endorses earlier initiation of lipid-lowering therapy, Lp(a) measurement, and expanded indications for PCSK9 inhibitors and inclisiran.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06288944be8c","type":"article","url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","title":"Systemische inflammatie en recidief na een AF-gerelateerd herseninfarct","title_en":"Systemic Inflammation and Recurrence After Atrial Fibrillation-Related Stroke: An Individual Participant Data Meta-Analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["cerebrovasculair","hs-crp","inflammatie"],"journal":"Neurology","doi":"10.1212/WNL.0000000000214701","source_url":"https://doi.org/10.1212/WNL.0000000000214701","authors":["John J McCabe","Katie Harris","Sarah Gorey","Cathal Walsh","Markus Arnold","Gian Marco De Marchis","Pablo Hervella","Ramon Iglesias-Rey","Christina Jern","Mira Katan","Linxin Li","Nobukazu Miyamoto","Joan Montaner","Francisco Purroy","Peter M Rothwell","Tara M Stanne","Cathie L M Sudlow","Yuji Ueno","Mikel Vicente-Pascual","Will N Whiteley","Mark Woodward","Peter J Kelly"],"significance":8,"published":"2026-03-24","source_date":"2026-03-24","image":"","kennis":[],"congress":"","summary_en":"This individual participant data meta-analysis showed that systemic inflammatory markers (IL-6 and hsCRP) predict recurrent vascular events after AF-related stroke, irrespective of AF status. The findings support including AF patients in future trials of anti-inflammatory therapy for secondary stroke prevention.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"603adc2ee388","type":"article","url":"https://hartvaat.nl/2025/01/01/vroege-heropnames-na-chirurgische-aortaklepvervanging-beinvloeden-trial-eindpunt/","title":"Vroege heropnames na chirurgische aortaklepvervanging beïnvloeden trial-eindpunten","title_en":"Surgical Aortic Valve Replacement: Early Rehospitalizations and Their Implication for Trial Endpoints","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002159?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002159?dgcid=rss_sd_all","authors":["Zara Dietze","Mateo Marin-Cuartas","Milan Milojevic","Patrick O. Myers","Volkmar Falk","Michael A. Borger"],"significance":6,"published":"2026-03-23","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/hartgeruisen-herkenning/","https://hartvaat.nl/kennis/kleplijden/chirurgische-klepvervanging/"],"congress":"","summary_en":"This JACC study analyzed early rehospitalizations after surgical aortic valve replacement and their implications for trial endpoint design, providing data relevant to the interpretation of TAVR-versus-surgery comparisons.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c479088728ae","type":"article","url":"https://hartvaat.nl/2025/01/01/ai-analyse-van-ecg-als-digitale-biomarker-voor-hartfalen/","title":"AI-analyse van ECG als digitale biomarker voor hartfalen","title_en":"The Emerging Role of ECG-AI as a Digital Risk Biomarker for Incident Heart Failure","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ai-ecg","kunstmatige-intelligentie","nt-probnp"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103446?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103446?dgcid=rss_sd_all","authors":["Evangelos K. Oikonomou"],"significance":6,"published":"2026-03-23","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This JACC editorial discussed the emerging role of AI-interpreted ECGs as a digital biomarker for predicting incident heart failure, evaluating the clinical potential of machine learning applied to routine cardiac diagnostics.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T18:39:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0fa895cc2e7f","type":"article","url":"https://hartvaat.nl/2025/01/01/wat-betekent-verbetering-bij-hypertrofische-cardiomyopathie/","title":"Wat betekent 'verbetering' bij hypertrofische cardiomyopathie?","title_en":"What Does Improvement Mean?: Interpreting Progress and Evidence in Hypertrophic Cardiomyopathy","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002093?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002093?dgcid=rss_sd_all","authors":["Harlan M. Krumholz"],"significance":6,"published":"2026-03-23","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC editorial by Harlan Krumholz discussed how to interpret evidence of treatment benefit and clinical progress in hypertrophic cardiomyopathy, addressing the challenges of evaluating novel cardiac myosin inhibitors.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5cd71b00f0ca","type":"article","url":"https://hartvaat.nl/2026/03/23/transapicale-tavi-met-de-j-valve-bij-ernstige-aortaklepinsufficientie-vergelijkb/","title":"Transapicale TAVI met de J-Valve bij ernstige aortaklepinsufficiëntie: vergelijkbaar met chirurgie","title_en":"Comparing TA-TAVR and SAVR in severe aortic regurgitation: outcomes and valve haemodynamics","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortainsufficiëntie","aortastenose","tavi"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003969?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003969?rss=1","authors":["He","Z.","Cai","D.","Li","M.","Feng","Z.","Liang","C.","Ma","R.","Jian","Z.","Xiao","Y."],"significance":6,"published":"2026-03-23","source_date":"2026-03-23","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"Transcatheter aortic valve replacement (TAVR) is already recommended for some high-risk patients with aortic regurgitation (AR), but evidence versus surgical replacement (SAVR) is limited. In this retrospective single-centre study (369 patients with severe AR; 256 transapical TAVR with the J-Valve system, 113 SAVR), 76 matched pairs were compared after propensity score matching. There were no differences in mortality, stroke, heart-failure rehospitalisation, pacemaker implantation or paravalvular leakage at 30 days or 2 years. The TAVR group had superior valve haemodynamics, while reduction in left ventricular dimensions was greater after SAVR; ejection-fraction improvement was comparable. Transapical TAVR with the J-Valve is thus an effective treatment for severe AR with outcomes comparable to surgery, especially in high-risk patients.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T13:31:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b8b141e2d52","type":"article","url":"https://hartvaat.nl/2026/03/23/bloeddrukbeloop-vanaf-jongvolwassenheid-voorspelt-leververvetting-op-middelbare-/","title":"Bloeddrukbeloop vanaf jongvolwassenheid voorspelt leververvetting op middelbare leeftijd (CARDIA)","title_en":"Blood Pressure Trajectories in Young Adulthood and Midlife Steatotic Liver Disease","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26319","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26319","authors":["Yun Chen"],"significance":6,"published":"2026-03-23","source_date":"2026-03-23","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"High blood pressure is a risk factor for steatotic liver disease (SLD), but whether BP trajectories from young adulthood relate to midlife SLD was unclear. In the US CARDIA cohort (2,817 participants enrolled aged 18-30 in 1985-1986), BP was measured up to eight times over 25 years, with SLD assessed by CT at year 25. Compared with a low-stable diastolic BP trajectory, all other trajectories had higher SLD prevalence, with adjusted relative risks up to 2.02 for the 'elevated-increasing' trajectory; the same held for systolic BP. Those who developed hypertension had a 1.6- to 1.8-fold higher SLD risk, and a faster rate of BP increase carried the highest risk. Long-term BP trajectory in young adulthood is thus independently associated with later-life fatty liver.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"668b6daaf45c","type":"article","url":"https://hartvaat.nl/2026/03/23/residuele-linker-atriale-v-golf-voorspelt-de-uitkomst-van-mitralisklep-edge-to-e/","title":"Residuele linker-atriale v-golf voorspelt de uitkomst van mitralisklep-edge-to-edge-reparatie","title_en":"Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag086","source_url":"https://doi.org/10.1093/eschf/xvag086","authors":["Michael Paulus","Jonas Rösch","Franziska Grewe","Moritz Haus","Valeska Bienert","Michael Wester","Christian Schach","Andreas Luchner","Christoph Birner","Bernhard Unsöld","Lars S Maier","Kurt Debl","Christine Meindl"],"significance":7,"published":"2026-03-23","source_date":"2026-03-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"Intraprocedural assessment of residual mitral regurgitation (MR) is crucial in transcatheter edge-to-edge mitral repair (M-TEER) but difficult with ambiguous echo findings. In this prospective study (299 patients, 63% secondary MR), left-atrial mean pressure and v-wave pressure (LAvP) were measured before and after implantation. LAvP fell from 30.5 to 23.2 mmHg. High residual LAvP after implantation strongly predicted death or heart-failure hospitalisation over two years, independent of echocardiographic MR grade (HR per 10 mmHg ~1.3). Residual LAvP below 25 mmHg was associated with favourable outcome, even with residual MR grade I–II. LAvP measurement thus adds prognostic information and may support intraprocedural decision-making.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"66b19b63acd3","type":"article","url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","title":"TRIPLACE-register: paravalvulaire lekkage na transkatheter-tricuspidalisklepvervanging","title_en":"Incidence, Clinical Implications, and Predictors of Paravalvular Leak Following Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JACC. Cardiovascular interventions","doi":"10.1016/j.jcin.2026.01.281","source_url":"https://doi.org/10.1016/j.jcin.2026.01.281","authors":["Andrea Scotti","Azeem Latib","Annalisa Filtz","Matteo Sturla","Firas Zahr","Robert Boone","Susheel Kodali","Didier Tchétché","Ole De Backer","Augustin Coisne","Sebastian Ludwig","Santiago A Garcia","Lukas Stolz","Rodrigo Estevez Loureiro","Matti Adam","Federico De Marco","Edwin C Ho","Anson Cheung","Matteo Biroli","Alexandru Patrascu","Sami Alnasser","Scott Chadderdon","Davorka Lulic","Joanna Bartkowiak","Julio Echarte-Morales","Horst Sievert","Timothy Byrne","Francesco Maisano","Christian Frerker","Nicolas Dumonteil","Omar A Oliva","Tanja K Rudolph","Felix Rudolph","Raviteja Guddeti","Beka Bakhtadze","Amar Krishnaswamy","Samir R Kapadia","Juan Del Portillo","Josep Rodés-Cabau","Niklas Schofer","Ignacio Cruz-Gonzalez","Juan Granada","Jörg Hausleiter","Rebecca T Hahn","Thomas Modine","Neil Fam","Rishi Puri"],"significance":7,"published":"2026-03-23","source_date":"2026-03-23","image":"","kennis":[],"congress":"","summary_en":"The international TRIPLACE registry examined the incidence and prognostic impact of paravalvular leak (PVL) after transcatheter tricuspid valve replacement (TTVR) in 394 patients. Moderate-to-severe PVL occurred in 6.1% and was associated with markedly higher 1-year mortality (39.7% vs ~11%; adjusted HR 2.6) and worse functional class. Larger right-atrial volume, device malposition and type IV valve morphology were independent predictors. The findings have implications for future TTVR device design and procedural optimisation.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d16e45dd83aa","type":"article","url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","title":"FATE-register: mislukte transkatheter-tricuspidalisreparatie (T-TEER)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JACC. Cardiovascular interventions","doi":"10.1016/j.jcin.2026.01.285","source_url":"https://doi.org/10.1016/j.jcin.2026.01.285","authors":["Federico De Marco","Gianmaria Calamita","Valentina Ardizzone","Mirjam Gauri Winkel","Mohammad Kassar","Fabien Praz","Nicolas M Van Mieghem","Joris F W Ooms","Muhammed Gerçek","Felix Rudolph","Marianna Adamo","Augustin Coisne","Jérémie Arlanda","Philipp Lurz","Rodrigo Estévez-Loureiro","Neil P Fam","Joachim Schofer","Christina Brinkmann","Marina Urena","Gregory Ducrocq","Jan-Malte Sinning","Tobias Geisler","Alessia Azzano","Elvis Brscic","Antonella Millin","Azeem Latib","Maurizio Taramasso","Antonio Popolo Rubbio","Francesco Bedogni","Stephanie Brunner","Stefan Toggweiler","Martin J Swaans","Leo Timmers","Francesco Giannini","Alfonso Ielasi","Omar Oliva","Nicolas Dumonteil","Didier Tchetchè","Dabit Arzamendi","Giulia Maisero","Giuseppe Tarantini","Gabriele Crimi","Italo Porto","Fausto Castriota","Luca Ferri","Matteo Montorfano","Alessandro Sticchi","Maria Lopez-Laporte","David Messika-Zeitoun","Marino Labinaz","Peter Lüdike","Horst Sievert","Giulia Antonelli","Fabio Fazzari","Cristina Ferrari","Antonio Mangieri"],"significance":7,"published":"2026-03-23","source_date":"2026-03-23","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The international FATE registry examined device-related failures of transcatheter edge-to-edge tricuspid valve repair (T-TEER). Across 2,278 procedures at 31 centres, 123 failures occurred (5.4%; mostly single-leaflet device attachment, 75%), often recognised early and with severe residual regurgitation in 73%. Reintervention (in 46%) achieved greater tricuspid-regurgitation reduction and more favourable right-atrial remodelling than medical therapy, but the composite of death or heart-failure rehospitalisation remained high (38%) and did not differ between strategies. Higher TRI-SCORE, acute kidney injury and greater residual regurgitation predicted adverse outcomes.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6aaf4cfbf575","type":"article","url":"https://hartvaat.nl/2026/03/04/genetisch-bevestigde-familiaire-hypercholesterolemie-in-de-vs-prevalentie-en-ond/","title":"Genetisch bevestigde familiaire hypercholesterolemie in de VS: prevalentie en onderbehandeling","title_en":"Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cardiovasculaire-genetica","dyslipidemie","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2026.0006","source_url":"https://doi.org/10.1001/jamacardio.2026.0006","authors":["Catherine Spinks","Margaret Sunitha Selvaraj","Christopher Robinson","Gina M Peloso","Courtney Gwynne","Sarah Urbut","Buu Truong","Kaavya Paruchuri","Whitney Hornsby","Pradeep Natarajan"],"significance":7,"published":"2026-03-22","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This All of Us cohort study revealed that genetically confirmed familial hypercholesterolemia remains massively underdiagnosed and undertreated in the US, with only a minority receiving appropriate lipid-lowering therapy.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T13:31:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7730289d309","type":"article","url":"https://hartvaat.nl/2026/03/03/beeldvorming-bij-atriale-cardiomyopathie-esc-scientific-statement/","title":"Beeldvorming bij atriale cardiomyopathie: ESC scientific statement","title_en":"Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["aritmogene-cardiomyopathie","atriale-cardiomyopathie","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","laminopathie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag068","source_url":"https://doi.org/10.1093/eschf/xvag068","authors":["Massimiliano Camilli","Emilia D'Elia","Jean Sebastien Hulot","Massimi Iacoviello","Nicolò Sisti","Otilia Tica","Mariya Tokmakova","Jef Van den Eynde","Jerremy Weerts","Rosita Zakeri","Antoni Bayes Genis","Wojciech Kosmala"],"significance":7,"published":"2026-03-22","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This scientific statement addressed the role of imaging techniques in monitoring atrial cardiomyopathy and atrial failure, a condition increasingly recognized as a distinct entity predisposing to AF and stroke.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58e020425250","type":"article","url":"https://hartvaat.nl/2026/03/04/leeftijd-en-geslacht-beinvloeden-verband-tussen-ambulante-bloeddruk-en-cardiovas/","title":"Leeftijd en geslacht beïnvloeden verband tussen ambulante bloeddruk en cardiovasculaire sterfte","title_en":"Interplay of Age and Sex With Clinic and Ambulatory Blood Pressure and Mortality","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","gedilateerde-cardiomyopathie","obesitas","ouderen","slaapapneu"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26084","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26084","authors":["Michael Böhm"],"significance":7,"published":"2026-03-22","source_date":"2026-03-04","image":"","kennis":[],"congress":"","summary_en":"This analysis from the Spanish ABPM registry explored the interplay between age, sex, clinic and ambulatory blood pressure values, and cardiovascular mortality, providing insights into sex-specific blood pressure targets.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1e7d1b35901","type":"article","url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","title":"Debat: preventieve PCI bij kwetsbare plaques als standaardbehandeling?","title_en":"Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["percutane-coronaire-interventie","perifeer-vaatlijden","secundaire-preventie","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag103","source_url":"https://doi.org/10.1093/eurheartj/ehag103","authors":["Duk-Woo Park","William E Boden","Raffaele De Caterina","Emanuele Gallinoro","Jung-Min Ahn","C Noel Bairey Merz","Juan Carlos Kaski","Do-Yoon Kang","Sanjay Kaul","Mario Marzilli","Carl J Pepine","Seung-Jung Park","Emanuele Barbato"],"significance":7,"published":"2026-03-21","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/"],"congress":"","summary_en":"This EHJ debate discussed whether preventive PCI of non-flow-limiting vulnerable plaques should become the default strategy added to optimal medical therapy, weighing the PREVENT trial evidence against long-term uncertainties.","created":"2026-07-03T10:32:37Z","updated":"2026-07-03T13:31:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29114687de07","type":"article","url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","title":"Laminopathieën: natuurlijk beloop en voorspelmodel voor hartfalen","title_en":"Laminopathies: natural history and risk prediction of heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","harttransplantatie","hfref","hypertrofische-cardiomyopathie","laminopathie","nt-probnp","pathfinder-trial","step-hfpef","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag104","source_url":"https://doi.org/10.1093/eurheartj/ehag104","authors":["Philippe Charron","Julie Proukhnitzky","Rabah Ben Yaou","Pascale Richard","Mohamed Dembélé","Mario Urtis","Thomas Gossios","Saurabh Kumar","Konstantinos Savvatis","Tanya Stojkovic","Frédéric Anselme","Philippe Maury","Estelle Gandjbakhch","Raphaël Martins","Frédéric Sacher","Jean-Noel Trochu","Stéphanie Rouanet","Julie Lejeune","Ghassan Moubarak","Abdallah Fayssoil","Eloi Marijon","Pascal Laforêt","Anthony Béhin","Sarah Leonard-Louis","Guilhem Sole","Fabien Labombarda","Corinne Metay","Susana Quijano-Roy","Ivana Dabaj","Didier Klug","Gilbert Habib","Marie-Christine Vantyghem","Philippe Chevalier","Emmanuelle Salort-Campana","Jean-Marc Sellal","Xavier Waintraub","Katja Zeppenfeld","Ahmad S Amin","Daria R Kramarenko","Yigal M Pinto","Andrew Landstrom","Alessandra Serio","Cathy Chikhaoui","Nicolas Combes","Christine Barnerias","Henri-Marc Bécane","Eric Bieth","Franck Boccara","Damien Bonnet","Françoise Bouhour","Anne-Claire Brehin","Pascal Cintas","François Roubille","Nicolas Lamblin","Pascal de Groote","Pierre-Francois Winum","Nicolas Piriou","Patricia Réant","Annachiara De Sandre-Giovannoli","Marion Masingue","Isabelle Desguerre","Julien Durigneux","Andoni Echaniz-Laguna","Romain Eschalier","Ana Ferreiro","Mélanie Fradin","Bénédicte Gaborit","Arnaud Gay","Albert Hagège","Arnaud Isapof","Isabelle Jeru","Emmanuelle Lagrue","Vincent Laugel","Arnaud Lazarus","France Leturcq","Armelle Magot","Véronique Manel","Sandra Mercier","Christophe Meune","Maud Michaud","Marie-Christine Minot-Myhié","Aleksandra Nadaj-Pakleza","Yann Péréon","Florence Petit","Julien Praline","Anne Rollin","Catherine Sarret","Frederic Taithe","Céline Tard","Vincent Tiffreau","Laurent Fauchier","Camille Vatier","Ulrike Walther-Louvier","Benjamin Schurr","Pierre Bobin","Mohamed El Hachmi","Clarisse Billon","Bertrand Fontaine","Corinne Vigouroux","Neal K Lakdawala","Eloisa Arbustini","Perry Elliott","Gisèle Bonne","Karim Wahbi"],"significance":7,"published":"2026-03-21","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This large EHJ study of 470 patients with LMNA gene variants characterized the risk of severe heart failure in laminopathies and developed a prediction model to guide surveillance and early intervention in this high-risk genetic cardiomyopathy.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f1449bb02ce2","type":"article","url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","title":"Aficamten veilig en effectief bij langdurige behandeling van obstructieve HCM","title_en":"Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","mavacamten"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1085","source_url":"https://doi.org/10.1093/eurheartj/ehaf1085","authors":["Albree Tower-Rader","Ahmad Masri","Michael E Nassif","Theodore P Abraham","Roberto Barriales-Villa","Lubna Choudhury","Robert M Cooper","Perry M Elliott","Martin S Maron","Iacopo Olivotto","Artur Oreziak","Anjali Tiku Owens","Scott D Solomon","Stephen B Heitner","Daniel L Jacoby","Stuart Kupfer","Xueli Liu","Fady I Malik","Chiara Melloni","Tyrell J Simkins","Jenny Wei","Sara Saberi"],"significance":7,"published":"2026-03-21","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"The FOREST-HCM long-term study confirmed that sustained treatment with aficamten, a selective cardiac myosin inhibitor, is safe and effective for reducing LVOT obstruction and improving symptoms in hypertrophic cardiomyopathy.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c6fea75e950","type":"article","url":"https://hartvaat.nl/2026/03/05/doac-of-vka-bij-kwetsbare-ouderen-met-atriumfibrilleren/","title":"DOAC of VKA bij kwetsbare ouderen met atriumfibrilleren?","title_en":"Direct-acting oral anticoagulant or vitamin K antagonist for the frail elderly patient with atrial fibrillation: does one size fit all?","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen","doacs","rivaroxaban","warfarine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf984","source_url":"https://doi.org/10.1093/eurheartj/ehaf984","authors":["William A E Parker","Robert F Storey"],"significance":7,"published":"2026-03-20","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"This EHJ editorial discussed the choice between DOACs and vitamin K antagonists for frail elderly AF patients, reviewing the emerging evidence supporting safe transition to NOACs even in the most vulnerable anticoagulation population.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6acec489e45","type":"article","url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","title":"Semaglutide bij perifeer arterieel vaatlijden en diabetes: STRIDE-trial","title_en":"Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","cagrisema","diabetes-en-hart","diabetes-type-1","ezetimibe","figaro-dkd","flow-trial","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","perifeer-vaatlijden","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial","summit-trial","tirzepatide"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag129","source_url":"https://doi.org/10.1093/eurheartj/ehag129","authors":["Joakim Nordanstig","Ecenur Guder Arslan","Andrei-Mircea Catarig","Kim Houlind","Bernhard Ludvik","Neda Rasouli","Harald Sourij","Sebastian Thomas","Subodh Verma","Marc P Bonaca"],"significance":7,"published":"2026-03-20","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This EHJ article presented STRIDE trial subanalyses of semaglutide in patients with peripheral artery disease and diabetes stratified by baseline disease severity and age, informing the use of GLP-1 agonists in the PAD population.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae84a9e7b414","type":"article","url":"https://hartvaat.nl/2026/03/07/aldosteronsynthaseremming-bij-resistente-hypertensie-beloften-en-onzekerheden/","title":"Aldosteronsynthaseremming bij resistente hypertensie: beloften en onzekerheden","title_en":"Aldosterone synthase inhibition in resistant hypertension: promises and unknowns","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aldosteronsynthaseremmers","aprocitentan","bax24-trial","baxdrostat","bloeddrukbehandeling","eplerenon","lorundrostat","precision-trial","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00253-9/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00253-9/fulltext","authors":["Felix Mahfoud","Lucas Lauder"],"significance":7,"published":"2026-03-20","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This Lancet commentary discussed the promises and unknowns of aldosterone synthase inhibition for resistant hypertension, evaluating the therapeutic potential and remaining questions for this novel drug class.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af897d7f3e4f","type":"article","url":"https://hartvaat.nl/2026/03/20/bloeddrukverlaging-corrigeert-de-gestoorde-maternale-hemodynamiek-bij-pre-eclamp/","title":"Bloeddrukverlaging corrigeert de gestoorde maternale hemodynamiek bij pre-eclampsie niet","title_en":"Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","laminopathie","peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26126","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26126","authors":["Julia Binder"],"significance":6,"published":"2026-03-20","source_date":"2026-03-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"Hypertensive disorders of pregnancy (HDP) involve cardiovascular impairment reflected in an abnormal maternal haemodynamic profile, yet treatment targets blood pressure, not that profile. In this multicentre prospective case-control study (238 women: 69 gestational hypertension, 63 preeclampsia, 106 controls), haemodynamic parameters (cardiac output, stroke volume, systemic vascular resistance, inotropy) were measured before and after α-methyldopa and postnatally, complemented by a preeclamptic rat model. In gestational hypertension, treatment improved cardiac output and lowered vascular resistance, but in preeclampsia no significant haemodynamic changes occurred: vascular resistance remained elevated and stroke volume reduced up to one year postpartum. The rat model showed the same. Blood-pressure lowering thus does not correct the cardiovascular impairment in preeclampsia — novel strategies are needed for maternal heart health after HDP.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7dfa609c5a16","type":"article","url":"https://hartvaat.nl/2026/03/20/ongunstige-zwangerschapsuitkomsten-en-het-latere-cardiovasculaire-risico-nurses-/","title":"Ongunstige zwangerschapsuitkomsten en het latere cardiovasculaire risico (Nurses' Health Study II)","title_en":"Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["diabetes-type-2","ezetimibe","menopauze","obesitas","ouderen","peripartum-cardiomyopathie","slaapapneu","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25916","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25916","authors":["Tiange Liu"],"significance":6,"published":"2026-03-20","source_date":"2026-03-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"How multiple types of adverse pregnancy outcomes (APOs) across reproductive life jointly affect long-term cardiovascular risk is little studied. In 59,154 parous women from the Nurses' Health Study II, lifetime history of gestational diabetes, gestational hypertension, preeclampsia, preterm delivery and low birth weight was self-reported and linked to cardiovascular events. Each APO was associated with higher cardiovascular risk, but after accounting for co-occurrence of multiple APOs, only gestational hypertension (HR 1.62) and preeclampsia (HR 1.31) retained independent associations. Later development of hypertension, diabetes and hypercholesterolaemia explained much (58%) of the association. Adding APOs to established risk factors improved prediction only modestly. APOs — especially gestational hypertension and preeclampsia — thus flag higher future risk, largely via subsequent risk factors.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c06d9484e16f","type":"article","url":"https://hartvaat.nl/2026/03/20/evolution-hf-cee-ba-real-world-dapagliflozin-bij-hfref-in-centraal-en-oost-europ/","title":"EVOLUTION-HF CEE-BA: real-world dapagliflozin bij HFrEF in Centraal- en Oost-Europa","title_en":"Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study)","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag085","source_url":"https://doi.org/10.1093/eschf/xvag085","authors":["Przemysław Leszek","Zoltan Csanádi","Ivan Gruev","Tiina Uuetoa","Diana Žaliaduonytė","Davor Miličić","Kārlis Trušinskis","Jūratė Baukienė","Alexandru Mihai Isvoranu","Ovidiu Chioncel"],"significance":6,"published":"2026-03-20","source_date":"2026-03-20","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"SGLT2 inhibitors are one of the four pillars of heart failure with reduced ejection fraction (HFrEF) treatment. After dapagliflozin's 2020 approval, real-world data are relevant for clinicians and payers. EVOLUTION-HF CEE-BA is an observational, longitudinal study across 102 centres in nine Central/Eastern European and Baltic countries that characterised the population started on dapagliflozin for HFrEF in routine practice (1,131 patients; ischaemic aetiology in 52%). All treatment decisions were at the provider's discretion per local practice. The study thus maps the use and course of dapagliflozin for HFrEF in Central/Eastern European practice.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ed3a5d21584","type":"article","url":"https://hartvaat.nl/2026/03/04/beoordeling-van-niet-culprit-coronairlaesies-bij-stemi/","title":"Beoordeling van niet-culprit coronairlaesies bij STEMI","title_en":"Assessing Nonculprit Coronary-Artery Lesions in STEMI","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMe2517834&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMe2517834&rss=currentIssue","authors":[],"significance":7,"published":"2026-03-19","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This NEJM editorial discussed strategies for assessing nonculprit coronary artery lesions in STEMI, reviewing the evidence for immediate versus staged complete revascularization.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38a6354b1327","type":"article","url":"https://hartvaat.nl/2026/03/04/finerenon-bij-diabetische-nierziekte-en-type-1-diabetes-een-editoriaal/","title":"Finerenon bij diabetische nierziekte en type 1 diabetes: een editoriaal","title_en":"Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer?","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","diabetes-en-hart","diabetes-type-1","fidelio-dkd","figaro-dkd","finerenon-hartfalen-nierziekte","vrouwen"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMe2600575&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMe2600575&rss=currentIssue","authors":["Aleksandra Kukla"],"significance":7,"published":"2026-03-19","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This NEJM editorial discussed the implications of finerenone for diabetic kidney disease in type 1 diabetes, evaluating whether the cardiorenal benefit extends beyond the type 2 diabetes population.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9bbd9491d2cb","type":"article","url":"https://hartvaat.nl/2026/03/02/aorta-en-iliacale-calcificaties-voorspellen-dissectie-aneurysmaruptuur-en-perife/","title":"Aorta- en iliacale calcificaties voorspellen dissectie, aneurysmaruptuur en perifeer vaatlijden","title_en":"Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["aorta-aneurysma","aortacoarctatie","aortadissectie","aortainsufficiëntie","aortastenose","perifeer-vaatlijden"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076240","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076240","authors":["Cecilie Skov Petersen"],"significance":7,"published":"2026-03-19","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"This prospective cohort study showed that aortic and iliac calcifications on CT predict aortic dissection, aneurysm rupture, and peripheral vascular events, establishing vascular calcification as a marker for acute aortic complications.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"689fa66d1a42","type":"article","url":"https://hartvaat.nl/2026/03/19/angiotensinogeen-als-nieuw-aangrijppunt-bij-hypertensie-opkomst-van-rna-medicijn/","title":"Angiotensinogeen als nieuw aangrijppunt bij hypertensie: opkomst van RNA-medicijnen (zilebesiran, tonlamarsen)","title_en":"Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ace-remmers","angiotensinereceptorblokkers","bloeddrukbehandeling","ras-remmers"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26091","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26091","authors":["Mehmet Kanbay"],"significance":5,"published":"2026-03-19","source_date":"2026-03-19","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"Hypertension is the leading modifiable risk factor for cardiovascular disease. Angiotensinogen (AGT) is a central component of the renin-angiotensin-aldosterone system (RAAS) but was long viewed as a passive substrate rather than an active target — unlike ACE and the angiotensin II receptor. This review describes the molecular biology and regulation of AGT, genetic variants (such as M235T and −6G>A) and its role in salt-sensitive hypertension, obesity-related inflammation and 'RAAS escape'. Especially relevant are the new RNA-based agents that inhibit AGT: the small interfering RNA zilebesiran and the antisense oligonucleotide tonlamarsen, which show prolonged blood-pressure reduction with a favourable safety profile in trials. AGT thus emerges as a promising upstream target and biomarker — with potential for long-acting treatment of (resistant) hypertension and better adherence.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"add663de3c0f","type":"article","url":"https://hartvaat.nl/2026/03/19/welke-ijzermarker-voorspelt-de-prognose-bij-nieuw-hartfalen-lage-transferrinesat/","title":"Welke ijzermarker voorspelt de prognose bij nieuw hartfalen? Lage transferrinesaturatie wijst op meer events","title_en":"Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","hfpef","hfref","ijzertekort","nt-probnp","step-hfpef","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003898?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003898?rss=1","authors":["Johansson","J. S. M.","Henrysson","J.","Basic","C.","Cleland","J. G. F.","Fu","M.","Ljungman","C."],"significance":6,"published":"2026-03-19","source_date":"2026-03-19","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/ecg-linkerventrikelhypertrofie/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"Iron deficiency is common in heart failure (HF) and is defined in guidelines by ferritin and transferrin saturation (TSAT), not soluble transferrin receptor (sTfR) or its ratios. In this study (325 patients hospitalised with new-onset HFrEF, Sahlgrenska, 2016-2020), the prognostic value of these iron markers was examined; 52% had iron deficiency by current criteria. In the prespecified analysis, markers were not significantly associated with the composite endpoint (HF rehospitalisation or death), although each standard-deviation higher TSAT was associated with 56% less HF rehospitalisation, as were higher iron/sTfR and TSAT/sTfR ratios. In a sensitivity analysis excluding extreme values, higher TSAT was associated with 47% fewer events. Lower TSAT thus predicts more events in new-onset HF; the sTfR ratios offer no clear advantage over TSAT alone.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daca8e6fd55a","type":"article","url":"https://hartvaat.nl/2026/03/19/ai-heartage-een-biologische-hartleeftijd-uit-de-polsgolf-voorspelt-hartfalen-en-/","title":"AI-HeartAge: een 'biologische hartleeftijd' uit de polsgolf voorspelt hartfalen en hart- en vaatziekten","title_en":"Development and Validation of the AI-HeartAge Model in Framingham and UK Biobank","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","nt-probnp","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26209","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26209","authors":[],"significance":6,"published":"2026-03-19","source_date":"2026-03-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"The shape of the arterial pressure waveform reflects left ventricle-aorta interaction and could estimate 'biological heart age'. The AI-HeartAge model (AI-HA) averages two neural networks that predict mitral-annulus tissue Doppler velocities from an uncalibrated arterial tonometry or photoplethysmography waveform. It was developed in the Framingham Heart Study (6,916 participants) and validated in a Framingham holdout set and the UK Biobank (67,986 participants). After adjusting for PREVENT risk factors, higher AI-HA was associated with incident heart failure (HR 2.09 in Framingham, 1.23 in UK Biobank) and cardiovascular disease (HR 1.52 and 1.22), with improved reclassification. AI-HeartAge is thus a novel, accessible measure of left ventricular function and heart-failure risk in community populations.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T13:31:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f7136bbc108","type":"article","url":"https://hartvaat.nl/2025/12/25/levensbedreigende-myocardischemie-en-maligne-aritmieen-na-pulsed-field-ablatie-v/","title":"Levensbedreigende myocardischemie en maligne aritmieën na pulsed field ablatie van AF","title_en":"Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After Pulsed Field Ablation of Atrial Fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","advent-trial","hfpef","hypertrofische-cardiomyopathie","laminopathie","ouderen","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren","slaapapneu","ventrikelfibrilleren"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983","authors":[],"significance":7,"published":"2026-03-18","source_date":"2025-12-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/flecainide-en-propafenon/"],"congress":"","summary_en":"This Circulation report documented life-threatening delayed myocardial ischemia and malignant arrhythmias occurring after pulsed field ablation for AF, raising important safety concerns about this rapidly adopted new technology.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"48ba39613fc4","type":"article","url":"https://hartvaat.nl/2025/01/01/maple-hcm-is-aficamten-een-keerpunt-bij-obstructieve-hcm/","title":"MAPLE-HCM: is aficamten een keerpunt bij obstructieve HCM?","title_en":"Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","mavacamten"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103598?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103598?dgcid=rss_sd_all","authors":["Bettina Heidecker","Iacopo Olivotto"],"significance":7,"published":"2026-03-18","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This JACC editorial discussed the MAPLE-HCM results and whether aficamten represents a turning point in the treatment of obstructive hypertrophic cardiomyopathy, comparing the potential of next-generation cardiac myosin inhibitors with established therapies.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e01f8ad7d2b","type":"article","url":"https://hartvaat.nl/2025/01/01/bisoprolol-versus-verapamil-bij-niet-obstructieve-hcm-gerandomiseerde-crossover-/","title":"Bisoprolol versus verapamil bij niet-obstructieve HCM: gerandomiseerde crossover-trial","title_en":"Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bisoprolol"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103331?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103331?dgcid=rss_sd_all","authors":["Louise Bjerregaard","Anne M. Dybro","Lotte Saaby","Steen Hvitfeldt Poulsen","Torsten Bloch Rasmussen","Morten Steen Kvistholm Jensen"],"significance":7,"published":"2026-03-18","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This randomized triple-crossover trial compared bisoprolol with verapamil in patients with nonobstructive hypertrophic cardiomyopathy, providing the first head-to-head comparison of beta-blocker versus calcium channel blocker therapy in this population.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3121df968ff","type":"article","url":"https://hartvaat.nl/2026/03/18/st-elevatie-bij-acute-pericarditis-wijst-op-myocardiale-betrokkenheid/","title":"ST-elevatie bij acute pericarditis wijst op myocardiale betrokkenheid","title_en":"ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","endocarditis","hartkatheterisatie","myocardinfarct","myocarditis","slaapapneu","stemi"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004019?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004019?rss=1","authors":["Ceriani","E.","Berra","S.","Agozzino","F.","Ceriani","M.","Ghisolfi","L.","Moda","F.","Rubuano","F.","Sicignano","L. L.","Gerardino","L.","Trotta","L.","Pancrazi","M.","De Carlini","C. C.","Maestroni","S.","Cumetti","D.","Carrozzo","L.","Casarin","F.","Collini","V.","Imazio","M.","Brucato","A."],"significance":6,"published":"2026-03-18","source_date":"2026-03-18","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/","https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/"],"congress":"","summary_en":"The pericardium is considered electrically inert, yet diffuse ST-elevation is an ECG marker of acute pericarditis. The investigators hypothesised that ST-elevation reflects myocardial involvement. In this longitudinal multicentre study (351 pericarditis patients, 70 with myopericarditis defined by troponin elevation and/or MRI), 34.5% had ST-elevation; these patients were younger, more often male, with higher CRP and fewer pericardial effusions. Myocardial involvement occurred in 19.9% and more often with ST-elevation (26.4% vs 16.5%); ST-elevation predicted myocardial involvement (OR 1.82). Myopericarditis patients more often had transient systolic dysfunction, a lower remission rate (18.5% vs 31.2%) and slightly more hospitalisations, with comparable recurrence rates and treatment. ST-elevation in acute pericarditis thus indicates myocardial involvement — consistent with the pericardium being electrically inert.","created":"2026-07-03T10:32:22Z","updated":"2026-07-03T13:31:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"769683a83cf8","type":"article","url":"https://hartvaat.nl/2025/01/01/coact-trial-langetermijnlessen-over-coronairangiografie-na-reanimatie/","title":"COACT-trial: langetermijnlessen over coronairangiografie na reanimatie","title_en":"Long-Term Lessons From the COACT Trial: Coronary Angiography After Out-of-Hospital Cardiac Arrest Revisited","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aperitif-trial","colcot-trial","iaso-dcm","select-trial","stabiel-coronairlijden"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972600224X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972600224X?dgcid=rss_sd_all","authors":["Anne Freund","Christian Spaulding"],"significance":7,"published":"2026-03-17","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"This JACC commentary revisited the COACT trial on coronary angiography after out-of-hospital cardiac arrest, discussing long-term lessons for clinical practice regarding the timing of invasive evaluation.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef74665abd52","type":"article","url":"https://hartvaat.nl/2025/01/01/ai-voorspelt-hartfalen-op-basis-van-12-afleidingen-ecg-in-grote-cohortanalyse/","title":"AI voorspelt hartfalen op basis van 12-afleidingen-ECG in grote cohortanalyse","title_en":"Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ventrikelfibrilleren","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972510079X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972510079X?dgcid=rss_sd_all","authors":["Akshay S. Desai","Ambarish Pandey","Rohit Suratekar","Faraz S. Ahmad","Heather M. Alger","Ausath G. Anto","Suhana Nujum G","Francisco Lopez-Jimenez","Jae K. Oh","Shahir Asfahan"],"significance":7,"published":"2026-03-17","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC study used AI-based 12-lead ECG analysis from pooled cohort data to predict heart failure development, demonstrating the potential of machine learning for early detection of subclinical cardiac dysfunction.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da98c2198b03","type":"article","url":"https://hartvaat.nl/2025/01/01/eheart-trial-real-time-hartteam-verbetert-besluitvorming-bij-complexe-coronaire-/","title":"EHEART-trial: real-time hartteam verbetert besluitvorming bij complexe coronaire revascularisatie","title_en":"Real-Time Heart Team for Revascularization in Complex Coronary Artery Disease: The EHEART Randomized Trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","farmaco-economie","hartkatheterisatie","hartrevalidatie","harttransplantatie","hfpef","iaso-dcm","ivabradine","myocardinfarct","newton-cabg","ouderen","secundaire-preventie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000707?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000707?dgcid=rss_sd_all","authors":["Shen Lin","Xiaoting Su","Hanping Ma","Kefei Dou","Lei Song","Hanjun Zhao","Jie Qian","Sheng Liu","Fei Xu","Xianqiang Wang"],"significance":7,"published":"2026-03-17","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"","summary_en":"The EHEART randomized trial investigated whether real-time heart team consultation improves revascularization strategy selection in patients with complex coronary artery disease, testing the value of multidisciplinary decision-making.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad328d98d4dd","type":"article","url":"https://hartvaat.nl/2026/03/17/veel-vrouwen-met-hypertensie-en-een-doorgemaakte-zwangerschapshypertensie-blijke/","title":"Veel vrouwen met hypertensie en een doorgemaakte zwangerschapshypertensie blijken primair aldosteronisme te hebben","title_en":"Hypertensive Disorders of Pregnancy and Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26718","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26718","authors":["Stéfanie Parisien"],"significance":6,"published":"2026-03-17","source_date":"2026-03-17","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Hypertensive disorders of pregnancy (HDP) affect up to 15% of pregnancies, and primary aldosteronism (PA) occurs in up to 25% of people with hypertension. In this prospective study, adults meeting guideline criteria for PA screening were tested; women with prior HDP completed an additional questionnaire. Of 330 hypertensive parous women (mean age 62), 25% had an HDP history; these women were younger at hypertension diagnosis (38.8 vs 47.9 years). A positive PA test was equally common with and without HDP (26.5% vs 32%). Of 63 HDP women with follow-up, 23.8% tested positive for PA; PA-positive women had more hypertensive pregnancies and fetal complications. More than a quarter of women with hypertension and at least one PA risk factor thus have PA, regardless of HDP history — in women with HDP, PA may be a treatable contributor to their elevated cardiovascular risk.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b40520710481","type":"article","url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","title":"Langetermijneffecten van sacubitril/valsartan bij HFrEF: Italiaanse real-world studie","title_en":"Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","bloeddrukbehandeling","carvedilol","dubbele-trombocytenremming","farmaco-economie","lipidenverlaging","nt-probnp","primaire-preventie","sacubitril-valsartan","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag082","source_url":"https://doi.org/10.1093/eschf/xvag082","authors":["Giuseppe Dattilo","Roberto Licordari","Egidio Imbalzano","Antonio Cannata","Piergiuseppe Agostoni","Alberto Aimo","Francesca Barillà","Erberto Carluccio","Michele Ciccarelli","Gianluca Di Bella","Frank L Dini","Michele Emdin","Francesco Loria","Massimo Mapelli","Enrica Mariano","Francesco Paolo Niglio","Alberto Palazzuoli","Gianpaolo Palmieri","Simona Pavoncelli","Elisabetta Salvioni","Gianluigi Savarese","Michele Correale"],"significance":7,"published":"2026-03-17","source_date":"2026-03-17","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/diagnostiek/speckle-tracking-strain/"],"congress":"","summary_en":"The long-term real-world effects of sacubitril/valsartan (S/V) and the impact of dose reduction or discontinuation are less well defined. In this multicentre retrospective study (592 outpatient HFrEF patients, mean LVEF 32%), after S/V initiation NT-proBNP, quality of life (KCCQ), LVEF and global longitudinal strain improved significantly and durably. Over a median follow-up of 3.7 years, 38% had a major adverse cardiovascular event (MACE). S/V discontinuation (HR 1.52) and adverse change in GLS or KCCQ were independently associated with MACE; dose reduction and discontinuation identified higher-risk patients. S/V thus produced sustained improvement in remodelling and quality of life, while stopping or dose-reducing was a risk signal.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adf364a18ccd","type":"article","url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","title":"ANSWER-HF: sacubitril/valsartan versus enalapril bij Chagas-HF — primaire resultaten","title_en":"Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.053","source_url":"https://doi.org/10.1016/j.jacc.2025.10.053","authors":["Vagner Madrini","Paulo Vinicius Ramos Souza","Fabio Fernandes","Barbara Maria Ianni","Alan Silva Martins","Georgina Jadán Luzuriaga","Keila Cardoso Barbosa Fonseca","Orlando do Nascimento Ribeiro","Allecineia Bispo da Cruz","Rosimeiri Oliveira","Talita Leopoldino Antunes","Fernanda Gallinaro Pessoa","Lucas Petri Damiani","Laura Sbeghen Quaglio","Vinicius Machado Correia","Murillo Oliveira Antunes","Charles Mady","Patrícia O Guimarães","Caio A M Tavares","Bruno Biselli","Cesar José Gruppi","Wilson Mathias","David Costa de Souza Le Bihan","Edimar Alcides Bocchi","Renato D Lopes","Felix José Alvarez Ramires"],"significance":7,"published":"2026-03-17","source_date":"2026-03-17","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"The ANSWER-HF primary results confirmed that sacubitril-valsartan reduces NT-proBNP more than enalapril in Chagas cardiomyopathy, the first ARNI evidence specific to this Latin American heart failure etiology.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6284a8d78570","type":"article","url":"https://hartvaat.nl/2025/01/01/sotatercept-bij-pah-centrale-hematologische-en-perifere-werkingsmechanismen/","title":"Sotatercept bij PAH: centrale, hematologische en perifere werkingsmechanismen","title_en":"Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["anemie-ckd","bloeddrukbehandeling"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726056330?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726056330?dgcid=rss_sd_all","authors":["Yogesh N.V. Reddy","Robert P. Frantz","William R. Miranda","Tomonari Harada","Sho Kazui","Barry A. Borlaug"],"significance":7,"published":"2026-03-16","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/"],"congress":"","summary_en":"This JACC article explored the central, hematologic, and peripheral mechanisms underlying the benefit of sotatercept in pulmonary arterial hypertension, including activin receptor signaling, erythropoiesis modulation, and vascular remodeling reversal.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8d7c482fedd5","type":"article","url":"https://hartvaat.nl/2025/01/01/strive-trial-neutraal-resultaat-herformuleert-uitdaging-microvasculaire-obstruct/","title":"STRIVE-trial: neutraal resultaat herformuleert uitdaging microvasculaire obstructie","title_en":"The STRIVE Trial: A Neutral Result That Reframes the Challenge of Microvascular Obstruction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","microcirculatie","soul-trial","summit-trial"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001257?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726001257?dgcid=rss_sd_all","authors":["Ke Pan","Sunzhang He","Xiao Yuan","Yan He"],"significance":7,"published":"2026-03-16","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC editorial discussed the neutral STRIVE trial result for microvascular obstruction treatment after acute MI, reframing the challenge and discussing future directions for this persistent complication.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a82f5d8da56","type":"article","url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","title":"Varenicline vermindert ventriculaire ectopie na myocardinfarct","title_en":"Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["myocardinfarct"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002330?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002330?dgcid=rss_sd_all","authors":["Yunli Shen","Xiaogang Guo","Chunyu Zeng","Dao Wen Wang","Wei Han","Xiang Cheng","Xinyang Hu","Duanyang Xie","Yi Liu","Dandan Liang"],"significance":7,"published":"2026-03-16","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This phase 2 study investigated varenicline (a nicotinic receptor partial agonist) for reducing ventricular ectopy after myocardial infarction, exploring a novel anti-arrhythmic mechanism through nicotinic receptor modulation.","created":"2026-07-03T10:32:35Z","updated":"2026-07-03T13:31:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8ba07031fdd","type":"article","url":"https://hartvaat.nl/2026/03/16/eenvoudige-risicofactoren-voorspellen-hart-en-vaatziekten-beter-dan-een-complexe/","title":"Eenvoudige risicofactoren voorspellen hart- en vaatziekten beter dan een complexe comorbiditeitsindex","title_en":"Comorbidity indices in observational studies on cardiovascular risk","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","inflammatie","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003999?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003999?rss=1","authors":["Zethelius","B.","Talba&#x0308;ck","M.","Ljung","R."],"significance":5,"published":"2026-03-16","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Which comorbidity measure best predicts cardiovascular events? In this large Swedish register study (4,454,895 people born 1936-1975), the predictive value of age-and-sex, the Nordic Multimorbidity Index (NMI), a set of five classic cardiovascular risk factors (CV-IV) and the number of filled prescriptions was compared for coronary heart disease, myocardial infarction, heart failure and stroke. In 40-64-year-olds, age-and-sex alone predicted better than any index alone. Combined with age and sex, the simple five-risk-factor set (CV-IV) gave the highest predictive value, especially for heart failure (AUROC 0.78), followed by the number of prescriptions. Simple indicators based on a few well-established risk factors thus outperform a complex index such as the NMI; the number of filled prescriptions can serve as a practical proxy for comorbidity.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e1304fbae30","type":"article","url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","title":"Natrium-HF-subanalyse: natriuretische peptiden lopen achter op de klinische ontstuwing bij hartfalen","title_en":"Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag075","source_url":"https://doi.org/10.1093/eschf/xvag075","authors":["Jolie Bruno","Aziz Daghmouri","Malha Sadoune","Romane Lafontaine","Alexis Nguyen","Christopher Edwards","Beth Davison","Gad Cotter","Koji Takagi","Christos Varounis","Priyanka Morishetty","Feriel Azibani","Elisabeth Masson","Camille Chenevier-Gobeaux","Alexandre Mebazaa","Benjamin Deniau"],"significance":6,"published":"2026-03-16","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"Natriuretic peptides (NPs) guide heart-failure diagnosis and treatment, but their short-term dynamics under sacubitril/valsartan (S/V) and during acute volume changes are incompletely characterised. In this sub-analysis of the Natrium-HF study, 229 ambulatory HFrEF patients started S/V; at three visits (before start and after 2 and 3 months) they underwent a standardised 9-hour protocol of volume infusion followed by diuretics. S/V initiation lowered BNP by 8% and NT-proBNP by 35%. During the acute protocol, however, both BNP and NT-proBNP rose significantly with identical trajectories before and after S/V — and kept rising despite marked natriuresis and clinical improvement after diuretics. BNP and NT-proBNP thus convey comparable information, but their short-term dynamics lag behind clinical decongestion; very-short-interval serial measurements likely add little in the early phase of acute heart failure.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40a7fdbf9e4c","type":"article","url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","title":"Vroege linkerventrikel-reverse-remodellering na mitralisklep-edge-to-edge-reparatie (EXPAND)","title_en":"Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag081","source_url":"https://doi.org/10.1093/eschf/xvag081","authors":["Mirjam Keßler","Gilbert H L Tang","Sébastien Deferm","Rodrigo Estevez-Loureiro","Wolfgang Rottbauer","Federico M Asch","Jose L Zamorano","Janani Aiyer","Rong Huang","Evelio Rodriguez","Saibal Kar","Francesco Maisano","Ralph Stephan von Bardeleben"],"significance":7,"published":"2026-03-16","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"Left ventricular reverse remodeling (LVRR) is a key goal of heart-failure therapy. In the combined EXPAND and EXPAND G4 cohorts (2,205 patients after mitral transcatheter edge-to-edge repair, M-TEER), early (30-day) LVRR was examined, defined as a >10% reduction in LV dimension or volume. In secondary MR, 64% showed early LVRR; at one year these patients had fewer deaths or heart-failure hospitalisations (24.7% vs 35.9%), despite similar MR reduction and symptom improvement. In primary MR, LVRR occurred in 73% with broadly similar outcomes — except in dilated ventricles, where early LVRR was associated with lower mortality. Early LVRR after M-TEER, especially in secondary MR, is thus associated with better outcomes.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T13:31:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12c1bb1e4f5b","type":"article","url":"https://hartvaat.nl/2026/03/16/cdpp3-bij-acuut-hartfalen-geen-prognostische-waarde-strong-hf-en-cortahf/","title":"cDPP3 bij acuut hartfalen: geen prognostische waarde (STRONG-HF en CORTAHF)","title_en":"cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag076","source_url":"https://doi.org/10.1093/eschf/xvag076","authors":["J Bruno","C Edwards","K Takagi","F Azibani","B Davison","G Cotter","K Bourgeois","O Hartmann","A P Ambrosy","A Mebazaa","A Picod"],"significance":6,"published":"2026-03-16","source_date":"2026-03-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"Circulating dipeptidyl peptidase 3 (cDPP3) is implicated in circulatory failure and predicts poor outcomes in shock, but its role in acute heart failure (AHF) was unknown. In an analysis of two prospective AHF trials (STRONG-HF and CORTAHF), 23% in STRONG-HF had elevated cDPP3 (≥40 ng/mL); these patients were younger, more often female and Black, with lower NT-proBNP. Baseline elevated cDPP3 was not associated with 180-day outcomes, and changes in cDPP3 did not track NT-proBNP reduction. MRA use was associated with elevated cDPP3. cDPP3 thus identified a distinct clinical phenotype but had no prognostic value and no relationship with congestion relief in AHF.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T13:31:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b446a3592f7","type":"article","url":"https://hartvaat.nl/2026/03/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-cholesterol-in-fase-2-studie/","title":"Orale PCSK9-remmer enlicitide verlaagt LDL-cholesterol in fase 2-studie","title_en":"Oral PCSK9 inhibitor enlicitide lowers LDL cholesterol levels in phase 2 trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cetp-remmers","dyslipidemie","enlicitide","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","statines"],"journal":"Nature cardiovascular research","doi":"10.1038/s44161-026-00794-7","source_url":"https://doi.org/10.1038/s44161-026-00794-7","authors":["Xiulin Koehler"],"significance":8,"published":"2026-03-15","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"This phase 2 trial of enlicitide, an oral PCSK9 inhibitor, showed significant LDL cholesterol reduction. As the first oral PCSK9 inhibitor in clinical development, enlicitide could dramatically expand access to advanced lipid-lowering therapy.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T13:31:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"742638d05092","type":"article","url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","title":"KDIGO-consensusconferentie: uitdagingen bij gecombineerd hartfalen en nierziekte","title_en":"Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","cardiorenal-behandelstrategie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00884-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00884-1/fulltext","authors":["Carolyn S.P. Lam","Biykem Bozkurt","David Z.I. Cherney","Justin A. Ezekowitz","Meg J. Jardine","Sadiya S. Khan","Magdalena Madero","Mark J. Sarnak","Jozine M. ter Maaten","Michael Cheung","Jennifer M. King","Morgan E. Grams","Michel Jadoul","Nisha Bansal","Conference Participants"],"significance":8,"published":"2026-03-15","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This KDIGO consensus conference summary addressed the intersection of heart failure and chronic kidney disease, reviewing advances in cardiorenal understanding and the challenges of managing patients with both conditions, including the role of SGLT2 inhibitors and finerenone.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5b6fbdd67ab","type":"article","url":"https://hartvaat.nl/2026/03/04/aspirine-na-pci-bij-acuut-coronair-syndroom/","title":"Aspirine na PCI bij acuut coronair syndroom","title_en":"Aspirin after PCI in Acute Coronary Syndromes","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","aspirine","percutane-coronaire-interventie"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMc2518964&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMc2518964&rss=currentIssue","authors":[],"significance":8,"published":"2026-03-15","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This NEJM article evaluated the role of aspirin after PCI in acute coronary syndromes in light of contemporary de-escalation evidence from TWILIGHT, T-PASS, and STOPDAPT trials, addressing the shifting paradigm toward aspirin-free antiplatelet strategies.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T13:31:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f2d639545bb6","type":"article","url":"https://hartvaat.nl/2026/03/04/bloeddrukdoelen-bij-de-behandeling-van-hypertensie/","title":"Bloeddrukdoelen bij de behandeling van hypertensie","title_en":"Blood-Pressure Targets in Hypertension Management","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie","diabetes-en-hart","farmaco-economie","hypertrofische-cardiomyopathie","obesitas","ouderen","vrouwen"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMclde2505268&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMclde2505268&rss=currentIssue","authors":[],"significance":8,"published":"2026-03-14","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/sotalol-bij-af/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This NEJM article discussed optimal blood pressure targets in hypertension management, reviewing the evidence from SPRINT, STEP, and ESPRIT that supports lower targets while addressing the clinical challenges of implementing aggressive blood pressure control.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e77126c7400","type":"article","url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","title":"Nieuwe medicamenteuze therapieën voor hypertensie","title_en":"New drug therapies for hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["baxdrostat","bloeddrukbehandeling","lorundrostat","ras-remmers","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02064-1/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02064-1/fulltext","authors":["Michel Azizi","Katherine R Tuttle","Jenifer M Brown","Daniel L Piskorz","Kazuomi Kario","Bryan Williams"],"significance":8,"published":"2026-03-14","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/"],"congress":"","summary_en":"This Lancet review described new drug therapies for hypertension targeting novel physiological pathways including aldosterone synthase inhibition, endothelin antagonism, and RNA interference-based angiotensinogen silencing, addressing the unmet need for patients with resistant blood pressure.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce328350273d","type":"article","url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","title":"Aficamten bij obstructieve HCM: multidomeinanalyse van MAPLE-HCM","title_en":"Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","cardio-renaal-metabool","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct","summit-trial","ventrikelfibrilleren","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725100685?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725100685?dgcid=rss_sd_all","authors":["Andrew Wang","Pablo Garcia-Pavia","Ahmad Masri","Bela Merkely","Michael E. Nassif","Maria Luisa Peña-Peña","Roberto Barriales-Villa","Ozlem Bilen","Melissa Burroughs","Brian L. Claggett"],"significance":8,"published":"2026-03-14","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This multidomain patient-level analysis of the MAPLE-HCM trial evaluated aficamten across multiple outcome domains in obstructive hypertrophic cardiomyopathy, providing comprehensive evidence on the clinical benefit of cardiac myosin inhibition.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2a9c27a9056a","type":"article","url":"https://hartvaat.nl/2026/03/14/inte-africa-2-community-based-versus-facilitair-beheer-hiv-dm-htn/","title":"INTE-AFRICA 2: community-based versus facilitair beheer HIV/DM/HTN","title_en":"Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02641-8","source_url":"https://doi.org/10.1016/S0140-6736(25)02641-8","authors":["Francis X Kasujja","Faith Aikaeli","Anupam Garrib","Erik van Widenfelt","Ivan Namakoola","Sokoine Kivuyo","James A Prior","Josephine Birungi","Faith Moyo","Duolao Wang","Stavia Turyahabwe","Gerald Mutungi","Mina Nakawuka Ssali","Omary Said Ubuguyu","Stephen Watiti","Said Aboud","Marie Claire Van Hout","Geoff Gill","Nelson K Sewankambo","Peter G Smith","Sayoki Mfinanga","Kaushik Ramaiya","Moffat J Nyirenda","Shabbar Jaffar"],"significance":5,"published":"2026-03-14","source_date":"2026-03-14","image":"","kennis":[],"congress":"","summary_en":"The INTE-COMM cluster-randomised trial compared integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in Tanzania and Uganda. The results inform optimal care delivery models in sub-Saharan Africa.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c23260ad66e9","type":"article","url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","title":"Antistolling alleen of met plaatjesremming bij coronairlijden: meta-analyse","title_en":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Trials","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001361?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726001361?dgcid=rss_sd_all","authors":["Giuseppe Gargiulo","Raffaele Piccolo","Duk-Woo Park","Gi-Byoung Nam","Yasuo Okumura","Martine Gilard","Gilles Lemesle","Guillaume Cayla","Jung-Sun Kim","Giovanni Esposito"],"significance":8,"published":"2026-03-13","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This JACC meta-analysis of randomized trials examined whether anticoagulation alone is as effective as anticoagulation combined with antiplatelet therapy in patients with coronary artery disease, addressing the optimal antithrombotic strategy in patients requiring both treatments.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7c23350691c","type":"article","url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","title":"Aficamten versus metoprolol: betere levenskwaliteit bij obstructieve HCM","title_en":"Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bisoprolol","bloeddrukbehandeling","hypertrofische-cardiomyopathie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725100703?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725100703?dgcid=rss_sd_all","authors":["Michael E. Nassif","Pablo Garcia-Pavia","Ahmad Masri","Bela Merkely","Maria Luisa Peña-Peña","Roberto Barriales-Villa","Ozlem Bilen","Melissa Burroughs","Brian L. Claggett","Juan Pablo Costabel"],"significance":8,"published":"2026-03-13","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This MAPLE-HCM trial analysis compared patient-reported health status outcomes between aficamten and metoprolol in patients with obstructive hypertrophic cardiomyopathy, providing head-to-head evidence on quality-of-life endpoints for cardiac myosin inhibitors versus beta-blockers.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d211dfbea16","type":"article","url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","title":"Intravasculaire beeldvorming superieur aan angiografie bij complexe PCI: 5-jaarsresultaten","title_en":"Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001476?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726001476?dgcid=rss_sd_all","authors":["Joo Myung Lee","Onyou Kim","Young Bin Song","Jong-Young Lee","Seung-Jae Lee","Sang Yeub Lee","Sang Min Kim","Kyeong Ho Yun","Jae Young Cho","Chan Joon Kim"],"significance":8,"published":"2026-03-13","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"Five-year outcomes from a randomized trial comparing intravascular imaging-guided versus angiography-guided complex PCI demonstrated sustained superiority of imaging guidance for reducing target vessel failure, confirming the long-term benefit of IVUS/OCT in complex coronary interventions.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c382e6c37dc","type":"article","url":"https://hartvaat.nl/2026/03/13/tubulaire-nierschade-hangt-samen-met-natriumretentie-en-diureticarespons-bij-acu/","title":"Tubulaire nierschade hangt samen met natriumretentie en diureticarespons bij acuut hartfalen","title_en":"Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","hfpef","hfref","nt-probnp"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag079","source_url":"https://doi.org/10.1093/eschf/xvag079","authors":["Yu Horiuchi","Stephen Duff","Dirk J van Veldhuisen","Michelle M Estrella","Michael G Shlipak","Yoshimitsu Takaoka","Patrick T Murray","Joachim H Ix","Nicholas Wettersten"],"significance":6,"published":"2026-03-13","source_date":"2026-03-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/","https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"Strong sodium retention ('sodium avidity') in acute heart failure (AHF) predicts worse outcomes, but whether kidney tubule injury contributes was unclear. In 339 participants of the ROSE-AHF trial (AHF with kidney dysfunction), urinary injury markers KIM-1, NAG and NGAL were measured at enrolment. Higher KIM-1 and NAG were associated with lower urinary sodium concentration and lower fractional sodium excretion (FeNa); higher KIM-1 was also associated with lower total 72-hour sodium output. None of the markers was associated with urine output. Tubular kidney injury in AHF is thus associated with greater sodium avidity, and KIM-1 with impaired diuretic responsiveness — a possible explanation for diuretic resistance in the cardiorenal syndrome.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ba9fe90441b","type":"article","url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","title":"Finerenon effectief bij type 1 diabetes met chronische nierziekte","title_en":"Finerenone in Type 1 Diabetes and Chronic Kidney Disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","menopauze","soul-trial","vrouwen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2512854","source_url":"https://doi.org/10.1056/NEJMoa2512854","authors":["Hiddo J L Heerspink","Andreas L Birkenfeld","David Z I Cherney","Helen M Colhoun","Per-Henrik Groop","Linong Ji","Niels Jongs","Chantal Mathieu","Richard E Pratley","Sylvia E Rosas","Peter Rossing","Jay S Skyler","Katherine R Tuttle","Robert Lawatscheck","Meike Brinker","Markus F Scheerer","Julie Russell","Patrick Schloemer","Janet B McGill"],"significance":9,"published":"2026-03-12","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This NEJM phase 3 trial demonstrated that finerenone improved kidney outcomes in patients with type 1 diabetes and chronic kidney disease, extending the benefit of nonsteroidal mineralocorticoid receptor antagonism beyond the type 2 diabetes population. The results address a previously unmet therapeutic need in type 1 diabetes nephropathy.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4dfd0d97df2e","type":"article","url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","title":"Lancet-seminar: atriumfibrilleren in 2026","title_en":"Atrial fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen","pulsed-field-ablatie-atriumfibrilleren"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02166-X/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02166-X/fulltext","authors":["Deirdre A Lane","Jason G Andrade","Elena Arbelo","Giuseppe Boriani","Jeroen M Hendriks","So-Ryoung Lee","Gregory Y H Lip","Jonathan Mant","Melissa E Middeldorp"],"significance":9,"published":"2026-03-12","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"This comprehensive Lancet Seminar provides a state-of-the-art overview of atrial fibrillation, covering its rising global prevalence of 37.6 million affected individuals, the impact of wearable device-based detection, contemporary management strategies including early rhythm control and pulsed field ablation, and integrated AF care pathways.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19c18b0f3594","type":"article","url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","title":"Baxdrostat verlaagt bloeddruk significant bij resistente hypertensie","title_en":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aldosteronsynthaseremmers","ambulante-bloeddrukmeting","aprocitentan","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","precision-trial","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02549-8/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02549-8/fulltext","authors":["Michel Azizi","Jenifer M Brown","Jamie P Dwyer","John M Flack","Erica S W Jones","Raisa Kurlyandskaya","Hongjian Li","Filip Birve","Aina S Lihn","Shira Perl","Markus P Schlaich","Hirotaka Shibata","Ji-Guang Wang","Bryan Williams","Bax24 investigators"],"significance":9,"published":"2026-03-12","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The phase 3 Bax24 trial demonstrated that baxdrostat, an aldosterone synthase inhibitor, significantly reduced 24-hour ambulatory systolic blood pressure compared with placebo in patients with resistant hypertension. The results advance aldosterone synthase inhibition as a promising new drug class for treatment-resistant blood pressure.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3344f9c5cc6b","type":"article","url":"https://hartvaat.nl/2026/03/12/betere-cardiovasculaire-gezondheid-life-s-simple-7-hangt-samen-met-minder-leverv/","title":"Betere cardiovasculaire gezondheid (Life's Simple 7) hangt samen met minder leververvetting","title_en":"Association of Life's Simple 7 with metabolic-associated steatotic liver disease and non-invasive fibrosis markers","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["obesitas"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003982?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003982?rss=1","authors":["Hofer","H.","Wernly","S.","Semmler","G.","Flamm","M.","Vo&#x0308;lkerer","A.","Singhartinger","F.","Jung","C.","Erkens","R.","Ausserwinkler","M.","Aigner","E.","Datz","C.","Wernly","B."],"significance":5,"published":"2026-03-12","source_date":"2026-03-12","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about a third of the global population, but good screening tools are lacking. The American Heart Association's Life's Simple 7 (LS7) — seven modifiable lifestyle factors (smoking, BMI, blood pressure, cholesterol, fasting glucose, physical activity and diet) — overlaps with MASLD criteria. In this study (3,204 participants in a colonoscopy screening programme in Salzburg), MASLD was assessed by ultrasound and liver fibrosis by non-invasive markers. MASLD prevalence was 82% with a poor LS7, 47% with intermediate and 16% with an ideal score. A higher LS7 was significantly associated with lower risk of MASLD (RR 0.80) and liver fibrosis. Better cardiovascular health is thus strongly associated with less fatty liver — though this partly reflects the shared metabolic components.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T13:31:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc034c039490","type":"article","url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","title":"Off-label onderdosering edoxaban bij AF en systemische embolieën","title_en":"Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["anticoagulatie-kwetsbare-ouderen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-326646","source_url":"https://doi.org/10.1136/heartjnl-2025-326646","authors":["Min Soo Cho","Do-Yoon Kang","Jung-Bok Lee","Yong-Seog Oh","Chang Hoon Lee","Eue-Keun Choi","Ji Hyun Lee","Chang Hee Kwon","Gyung-Min Park","Hyung Oh Choi","Kyoung-Ha Park","Kyoung-Min Park","Jongmin Hwang","Ki-Dong Yoo","Young Rak Cho","Ji-Hyun Kim","Ki Won Hwang","Eun Sun Jin","Osung Kwon","Ki-Hun Kim","Duk-Woo Park","Gi-Byoung Nam"],"significance":6,"published":"2026-03-12","source_date":"2026-03-12","image":"","kennis":[],"congress":"","summary_en":"This study documented the adverse consequences of off-label edoxaban underdosing in AF patients, showing increased thrombotic risk without meaningful bleeding reduction, reinforcing adherence to approved dosing criteria.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"059ababd53b1","type":"article","url":"https://hartvaat.nl/2025/01/01/nieuwe-acc-aha-richtlijn-2025-voor-volwassenen-met-aangeboren-hartafwijkingen/","title":"Nieuwe ACC/AHA-richtlijn 2025 voor volwassenen met aangeboren hartafwijkingen","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725077630?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725077630?dgcid=rss_sd_all","authors":["Michelle Gurvitz","Eric V. Krieger","Stephanie Fuller","Leslie L. Davis","Michelle M. Kittleson","Jamil A. Aboulhosn","Elisa A. Bradley","Jonathan Buber","Curt J. Daniels","Konstantinos Dimopoulos"],"significance":9,"published":"2026-03-11","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"The 2025 ACC/AHA/HRS/ISACHD/SCAI guideline provides comprehensive updated recommendations for the management of adults with congenital heart disease, addressing arrhythmia management, pregnancy, surgical and catheter-based interventions, and long-term follow-up in this growing patient population.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"10fd4a7349ad","type":"article","url":"https://hartvaat.nl/2026/02/10/lipoproteine-a-bij-familiaire-hypercholesterolemie-een-dubbel-risico/","title":"Lipoproteïne(a) bij familiaire hypercholesterolemie: een dubbel risico","title_en":"Lipoprotein(a) in familial hypercholesterolemia.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"Current opinion in lipidology","doi":"10.1097/MOL.0000000000001032","source_url":"https://doi.org/10.1097/MOL.0000000000001032","authors":["Ali K Jaafar","Steeve Bourane","Gilles C Lambert","Kevin Chemello"],"significance":5,"published":"2026-03-11","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This review discusses lipoprotein(a) metabolism and associated cardiovascular risk specifically in familial hypercholesterolaemia. The combination of elevated LDL-C and elevated Lp(a) represents perhaps the most detrimental lipid profile for cardiovascular health.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dab803622417","type":"article","url":"https://hartvaat.nl/2026/02/10/rna-interferentie-bij-lipidestoornissen-de-toekomst-van-cholesterolverlaging/","title":"RNA-interferentie bij lipidestoornissen: de toekomst van cholesterolverlaging?","title_en":"RNA interference for lipid disorders: is this the future?","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","pelacarsen","statines"],"journal":"Current opinion in lipidology","doi":"10.1097/MOL.0000000000001033","source_url":"https://doi.org/10.1097/MOL.0000000000001033","authors":["Miguel Nassif","Renata Turrini Jacob Fazoli","Giuliano Generoso"],"significance":5,"published":"2026-03-11","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/"],"congress":"","summary_en":"This review discusses the current state of RNA interference therapies for lipid disorders. Inclisiran achieves sustained 50% LDL-C reduction, with emerging siRNA agents targeting Lp(a), triglycerides, and other lipid-regulating proteins.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7150383bcf46","type":"article","url":"https://hartvaat.nl/2026/03/11/behandeling-van-primair-aldosteronisme-chirurgie-of-mra-met-zoutbeperking-als-ho/","title":"Behandeling van primair aldosteronisme: chirurgie of MRA, met zoutbeperking als hoeksteen","title_en":"Treatment of Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","spironolacton"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26238","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26238","authors":["Stéfanie Parisien"],"significance":6,"published":"2026-03-11","source_date":"2026-03-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"Primary aldosteronism (PA) is a common cause of hypertension, in which renin-independent aldosterone production drives inappropriate mineralocorticoid receptor activation, sodium retention, volume expansion and potassium wasting, with adverse cardiorenal outcomes. Treatment is tailored to patient preference and whether PA is lateralising. For lateralising PA, surgical adrenalectomy (and, less often, minimally invasive adrenal or adrenal-artery ablation) is highly effective for blood pressure and cardiovascular risk. Most patients, however, are treated medically, with a steroidal mineralocorticoid receptor antagonist (MRA) as the cornerstone and epithelial sodium channel inhibitors as alternatives. Dietary sodium restriction is strongly encouraged, as it reduces the substrate of PA pathophysiology and enhances blood-pressure lowering, especially combined with an MRA. Medical therapy is intensified to, in order, normalise blood pressure with the fewest agents, normalise potassium, and raise renin as a marker of adequate aldosterone blockade.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T13:31:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6958d31f12ae","type":"article","url":"https://hartvaat.nl/2026/02/16/polygene-risicoscores-bij-familiaire-hypercholesterolemie-nuttig-of-niet/","title":"Polygene risicoscores bij familiaire hypercholesterolemie: nuttig of niet?","title_en":"Polygenic risk scores in familial hypercholesterolemia. Do they have a role?","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipoproteïne-a","niet-statine-therapie","polygene-risicoscore","statines","vrouwen"],"journal":"Current opinion in lipidology","doi":"10.1097/MOL.0000000000001029","source_url":"https://doi.org/10.1097/MOL.0000000000001029","authors":["Martine Paquette","Simon-Pierre Guay","Alexis Baass"],"significance":5,"published":"2026-03-10","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This review evaluates the role of polygenic risk scores in familial hypercholesterolaemia management. A high Lp(a) PRS explains the phenotype in approximately one-fifth of variant-negative FH patients, with implications for risk stratification and therapy decisions.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"480303d72ded","type":"article","url":"https://hartvaat.nl/2026/02/28/familiaire-hypercholesterolemie-in-belgie-7-jaar-ervaring/","title":"Familiaire hypercholesterolemie in België: 7 jaar ervaring","title_en":"Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","statines"],"journal":"Acta clinica Belgica","doi":"10.1080/17843286.2026.2638804","source_url":"https://doi.org/10.1080/17843286.2026.2638804","authors":["Amber Vanhulle","Dilara Yurdaer","Lynn van Calster","Anne-Marie Willems","Veronique Moerman","Johan De Sutter"],"significance":4,"published":"2026-03-10","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"A Belgian single-centre study describes the clinical characteristics and lipid management of 189 patients with familial hypercholesterolaemia over seven years. The study highlights persistent undertreatment and analyses treatment response in genetically confirmed carriers.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b87321c8325","type":"article","url":"https://hartvaat.nl/2026/02/26/lp-a-geassocieerd-met-microvasculaire-disfunctie-bij-niet-obstructief-coronairli/","title":"Lp(a) geassocieerd met microvasculaire disfunctie bij niet-obstructief coronairlijden","title_en":"Association of Coronary Microvascular Dysfunction with Lipoprotein (a) levels in Patients with Non-Obstructive Coronary Artery Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","aficamten","biomarkers-cardiovasculair","dyslipidemie","ezetimibe","hdl-cholesterol","hypertrofische-cardiomyopathie","inflammatie","laminopathie","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","microcirculatie","microvasculaire-angina","myocardinfarct","ouderen","pelacarsen","plaquekarakterisatie","slaapapneu"],"journal":"The American journal of cardiology","doi":"10.1016/j.amjcard.2026.02.038","source_url":"https://doi.org/10.1016/j.amjcard.2026.02.038","authors":["Eleni Adamopoulou","Kyriakos Dimitriadis","Athanasios Sakalidis","Konstantinos Kyriakoulis","Alexandros Koulouriotis","Nikolaos Pyrpyris","Konstantinos Aznaouridis","Philippos Orfanos","Pagona Lagiou","Konstantinos Tsioufis"],"significance":6,"published":"2026-03-10","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This study investigated the association between lipoprotein(a) levels and coronary microvascular dysfunction in patients with non-obstructive coronary artery disease, exploring Lp(a) as a driver of microvascular pathology.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"856a0bc449f3","type":"article","url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","title":"Machine learning voorspelt 30-daagse sterfte na een dotterbehandeling (Australisch register)","title_en":"Risk prediction modelling of 30-day all-cause mortality following percutaneous coronary intervention in an Australian population: leveraging machine learning","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ai-ecg","biomarkers-cardiovasculair","fractional-flow-reserve","gepersonaliseerde-geneeskunde","kunstmatige-intelligentie","ouderen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003619?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003619?rss=1","authors":["Chowdhury","M. R. K.","Dinh","D. T.","Brennan","A.","Reid","C. M.","Nanayakkara","S.","Lefkovits","J.","Chew","D. P.","Karim","M. N.","Moni","M. A.","Islam","M. S.","Billah","B.","Stub","D."],"significance":6,"published":"2026-03-10","source_date":"2026-03-10","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"Preprocedural estimation of 30-day mortality after percutaneous coronary intervention (PCI) aids decision-making and hospital benchmarking. In this Australian study (93,055 consecutive PCI procedures from the Victorian Cardiac Outcomes Registry), seven machine-learning algorithms were compared. The Extreme Gradient Boosting (XGB) model performed best, with good discrimination (AUC 85.5%). The five leading predictors were left ventricular ejection fraction, acute coronary syndrome, kidney function (eGFR), age and complex lesions; followed by cardiogenic shock, BMI and resuscitated out-of-hospital cardiac arrest, among others. A preprocedural-data-based model can thus estimate individual risk and support care and resource use around PCI — external validation in other populations is still needed.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T13:31:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f8814ec0e83d","type":"article","url":"https://hartvaat.nl/2026/02/26/niet-statine-therapie-welk-middel-voor-welke-patient/","title":"Niet-statine therapie: welk middel voor welke patiënt?","title_en":"Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["clear-outcomes","dyslipidemie","ezetimibe","lipidenverlaging","niet-statine-therapie","pcsk9-remmers-nieuwe-generatie","rosuvastatine","statines"],"journal":"Current atherosclerosis reports","doi":"10.1007/s11883-026-01390-7","source_url":"https://doi.org/10.1007/s11883-026-01390-7","authors":["Julius L Katzmann","Ulrich Laufs"],"significance":7,"published":"2026-03-09","source_date":"2026-02-26","image":"https://hartvaat.nl/global/img/35ed22042ef3.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/"],"congress":"","summary_en":"This review discussed how to optimally sequence available and emerging non-statin lipid-lowering therapies (ezetimibe, PCSK9 inhibitors, inclisiran, bempedoic acid) for patients not at LDL goal on statins.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04b3720249bf","type":"article","url":"https://hartvaat.nl/2026/02/27/lp-a-en-atherosclerotisch-vaatlijden-een-niet-lineair-verband/","title":"Lp(a) en atherosclerotisch vaatlijden: een niet-lineair verband","title_en":"Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["atherosclerose","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","luchtvervuiling","niet-statine-therapie","pelacarsen","plaquekarakterisatie","statines","vrouwen"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-25-0847","source_url":"https://doi.org/10.1253/circj.CJ-25-0847","authors":["Hsin-Yin Hsu","Hsien-Yu Fan","Ming-Chieh Tsai","Chih-Jun Lai","Lee-Ching Hwang","Kuo-Liong Chien"],"significance":7,"published":"2026-03-09","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This analysis of over 350,000 UK Biobank participants showed that the association between Lp(a) and atherosclerotic cardiovascular disease is nonlinear, with risk accelerating at higher levels — a finding with implications for treatment thresholds.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4763c6f39c92","type":"article","url":"https://hartvaat.nl/2026/02/27/prognose-takotsubo-syndroom-versus-hartfalen-op-de-lange-termijn/","title":"Prognose takotsubo-syndroom versus hartfalen op de lange termijn","title_en":"Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","nt-probnp","takotsubo"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag065","source_url":"https://doi.org/10.1093/eschf/xvag065","authors":["Enrico Tartaglia","Muath Alobaida","Tommaso Bucci","Michele Rossi","Amir Askarinejad","Ho Man Lam","Mert Kaskal","Andrea Galeazzo Rigutini","Giuseppe Boriani","Gregory Y H Lip"],"significance":5,"published":"2026-03-09","source_date":"2026-02-27","image":"","kennis":[],"congress":"","summary_en":"An observational study compared three-year outcomes between patients with Takotsubo syndrome and heart failure using a global research network. The findings inform the long-term prognosis and follow-up requirements for Takotsubo patients.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a1da41759eb","type":"article","url":"https://hartvaat.nl/2026/03/09/stress-verhoogt-de-bloeddruk-na-de-bevalling-vooral-bij-vrouwen-die-een-zwangers/","title":"Stress verhoogt de bloeddruk na de bevalling vooral bij vrouwen die een zwangerschapscomplicatie hadden","title_en":"Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","stress-psychosociaal","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25991","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25991","authors":[],"significance":6,"published":"2026-03-09","source_date":"2026-03-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"Adverse pregnancy outcomes (APOs) increase the risk of chronic hypertension. The prospective nuMoM2b-HHS study examined whether trajectories of perceived stress during and after pregnancy were associated with blood pressure and incident hypertension 2-7 years after delivery, and whether an APO modified this. Using the Perceived Stress Scale (first and third trimester and 2-7 years postpartum), three stress trajectories emerged: low, moderate and high. After adjustment, there was no overall association between stress trajectory and blood pressure or hypertension. However, there was a significant interaction with APO: a higher stress trajectory was associated with higher blood pressure only in women who had had an APO (β ≈ 2 mmHg), not in women without an APO. Elevated stress may thus contribute to higher blood pressure, specifically in women who experienced an adverse pregnancy outcome.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bccfe1128c9f","type":"article","url":"https://hartvaat.nl/2026/03/09/sarcomere-versus-niet-sarcomere-hypertrofische-cardiomyopathie-een-verschillend-/","title":"Sarcomere versus niet-sarcomere hypertrofische cardiomyopathie: een verschillend ziektebeloop","title_en":"Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["hypertrofische-cardiomyopathie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076036","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076036","authors":[],"significance":8,"published":"2026-03-09","source_date":"2026-03-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/"],"congress":"","summary_en":"Sarcomere variants are a major cause of hypertrophic cardiomyopathy (HCM) and are associated with worse prognosis. In this longitudinal multicentre study from the SHaRe registry (6,120 genotyped HCM patients, 50% sarcomeric, median follow-up 5.3 years), the influence of genetic classification and comorbidities on disease trajectory, event timing and causes of death was examined. Sarcomeric HCM was diagnosed at a younger age (median 38.1 vs 54.3 years) and more often in women. Using time-varying models, the study maps the sequence of cardiovascular events to better inform prognosis and treatment in sarcomeric versus nonsarcomeric HCM.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46cc3b60f2b2","type":"article","url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","title":"Semaglutide stimuleert anti-inflammatoire stamcelflux vanuit beenmerg","title_en":"Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["cagrisema","canagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","select-trial","semaglutide","tirzepatide"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf690","source_url":"https://doi.org/10.1093/eurheartj/ehaf690","authors":["Brady Park","Fallon Dennis","Arianna Z He","Aishwarya Krishnaraj","Ehab Bakbak","Cole J Dennis","Yi Pan","Elizabeth Misner","Veena Thayanithy","Bhavaani Lambotharan","Vaasudevan Lambotharan","Aruna Lambotharan","C David Mazer","Adrian Quan","Hwee Teoh","David A Hess","Subodh Verma"],"significance":6,"published":"2026-03-09","source_date":"2026-03-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This translational study showed that semaglutide mobilizes anti-inflammatory and pro-regenerative progenitor cells from the bone marrow, providing a novel mechanistic explanation for the cardiovascular benefit of GLP-1 receptor agonists.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1d98806a2264","type":"article","url":"https://hartvaat.nl/2026/02/27/obicetrapib-veelbelovende-cetp-remmer-voor-hoogrisicopatienten/","title":"Obicetrapib: veelbelovende CETP-remmer voor hoogrisicopatiënten","title_en":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","bempedoïnezuur","bloeddrukbehandeling","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","lipide-aferese","lipidenverlaging","liraglutide","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","statines","trombocytenaggregatieremmers"],"journal":"Vascular diseases (Paris, France)","doi":"10.1016/j.vasdi.2026.02.004","source_url":"https://doi.org/10.1016/j.vasdi.2026.02.004","authors":["Abdul Mueez Alam Kayani","Muhammad Faiq Umar","Daniel Navarro-Martinez","Alan Garcia","Muhammad Affan Rashid","Ricky E Lemus-Zamora"],"significance":5,"published":"2026-03-08","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated the lipid-modifying efficacy and safety of obicetrapib, a CETP inhibitor, in high-risk cardiovascular patients. The agent optimises lipid profiles by blocking cholesterol ester transfer between HDL and apoB-containing lipoproteins.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cfb75e6855fe","type":"article","url":"https://hartvaat.nl/2026/02/25/glp-1-agonisten-en-gezonde-leefstijl-samen-sterker-tegen-hart-en-vaatziekten/","title":"GLP-1-agonisten én gezonde leefstijl: samen sterker tegen hart- en vaatziekten","title_en":"Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"The lancet. Diabetes & endocrinology","doi":"10.1016/S2213-8587(25)00395-X","source_url":"https://doi.org/10.1016/S2213-8587(25)00395-X","authors":["Xuan-Mai T Nguyen","Yanping Li","Sébastien Czernichow","Nathalie Rassy","Serena C Houghton","Bing Lu","Yuk-Lam Ho","Brian R Charest","Dong D Wang","David R Gagnon","John Michael Gaziano","Walter C Willett","Peter W F Wilson","Kelly Cho","Frank B Hu"],"significance":9,"published":"2026-03-08","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This prospective cohort study in Lancet Diabetes & Endocrinology examined the combined effects of GLP-1 receptor agonists and eight healthy lifestyle factors on cardiovascular outcomes. The findings demonstrate additive benefit, with the combination of pharmacotherapy and healthy lifestyle conferring the greatest cardiovascular risk reduction.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fe698b5a0cb8","type":"article","url":"https://hartvaat.nl/2026/02/27/nieuwe-aldosteronsynthase-remmers-bij-hypertensie-bayesiaanse-meta-analyse/","title":"Nieuwe aldosteronsynthase-remmers bij hypertensie: Bayesiaanse meta-analyse","title_en":"Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","lorundrostat","ras-remmers","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"JACC. Advances","doi":"10.1016/j.jacadv.2026.102621","source_url":"https://doi.org/10.1016/j.jacadv.2026.102621","authors":["Flavia Queiroga","Beatriz Araújo","André Rivera","Leo Consoli","Aditi Ujjawal","Ensieh Sadat Mansouri","Maria Antonia Costa Cruz Akabane","Nelson I Barrera","Ana Beatriz Valverde Ramos","Asad Iqbal","Marcelo Braga","Anna K Krawisz","Paula Dibo","Deepak L Bhatt"],"significance":7,"published":"2026-03-08","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This Bayesian meta-analysis evaluated second-generation aldosterone synthase inhibitors (baxdrostat, lorundrostat) for hypertension, confirming their blood pressure-lowering efficacy and characterizing the dose-response relationship.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5128ad33f56c","type":"article","url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","title":"SGLT2-remmers bij ernstig verminderde nierfunctie: data uit CREDENCE","title_en":"SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","empagliflozine","sglt2-remmers"],"journal":"Journal of cardiac failure","doi":"10.1016/j.cardfail.2026.01.020","source_url":"https://doi.org/10.1016/j.cardfail.2026.01.020","authors":["Safia Chatur","Robert A Fletcher","Emily Yeung","Amanda Siriwardana","Lauren Heath","Muthiah Vaduganathan","Clare Arnott","Sunil V Badve","Sradha Kotwal","Min Jun","Meg Jardine","Carol Pollock","Hiddo Jl Heerspink","Vlado Perkovic","Brendon L Neuen"],"significance":8,"published":"2026-03-07","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This post-hoc CREDENCE analysis showed that SGLT2 inhibition remains safe and effective when eGFR declines below 20 mL/min, supporting continuation of therapy in patients with severely reduced kidney function rather than discontinuation at an arbitrary eGFR threshold.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b534471b25b4","type":"article","url":"https://hartvaat.nl/2026/02/27/finerenon-plus-sglt2-remmer-additief-cardiorenal-voordeel-bij-diabetische-nierzi/","title":"Finerenon plus SGLT2-remmer: additief cardiorenal voordeel bij diabetische nierziekte","title_en":"Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","ramipril","sglt2-remmers"],"journal":"The American journal of cardiology","doi":"10.1016/j.amjcard.2026.02.035","source_url":"https://doi.org/10.1016/j.amjcard.2026.02.035","authors":["Ibrahim Mortada","Aaron Lee","Ayushi Sahu","Cullins Nwaogu","Valerie Quach","Shareef Mansour","Khaled Chatila","Thomas Blackwell","Hani Jneid"],"significance":6,"published":"2026-03-07","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This real-world propensity-matched study showed that combining finerenone with SGLT2 inhibitors provides additive cardiorenal benefits in diabetic CKD compared with SGLT2 inhibitor monotherapy, supporting dual neurohormonal and metabolic protection.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90f6ac61b44b","type":"article","url":"https://hartvaat.nl/2026/02/27/van-vitamine-k-antagonist-naar-doac-bij-kwetsbare-ouderen-met-af/","title":"Van vitamine K-antagonist naar DOAC bij kwetsbare ouderen met AF","title_en":"Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","doacs","rivaroxaban","rosuvastatine","trombocytenaggregatieremmers","warfarine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf999","source_url":"https://doi.org/10.1093/eurheartj/ehaf999","authors":["So-Ryoung Lee","Young-Hae Go","Eue-Keun Choi","Hee-Won Rha","Min-Ha Jeong","JungMin Choi","Kyung-Yeon Lee","Hyo-Jeong Ahn","Soonil Kwon","Bongseong Kim","Myoung-Jin Jang","Kyung-Do Han","Seil Oh","Gregory Y H Lip"],"significance":9,"published":"2026-03-07","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This Korean nationwide study showed that switching from well-managed warfarin to DOACs in frail elderly patients with atrial fibrillation was associated with similar or improved outcomes. The real-world evidence supports transitioning to DOACs even in the oldest and most vulnerable AF population.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6e421b04828","type":"article","url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","title":"Bax24: baxdrostat en ambulante bloeddruk bij resistente hypertensie","title_en":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","ambulante-bloeddrukmeting","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02549-8","source_url":"https://doi.org/10.1016/S0140-6736(25)02549-8","authors":["Michel Azizi","Jenifer M Brown","Jamie P Dwyer","John M Flack","Erica S W Jones","Raisa Kurlyandskaya","Hongjian Li","Filip Birve","Aina S Lihn","Shira Perl","Markus P Schlaich","Hirotaka Shibata","Ji-Guang Wang","Bryan Williams"],"significance":8,"published":"2026-03-07","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"The Bax24 phase 3 trial confirmed that baxdrostat significantly reduces ambulatory blood pressure in patients with resistant hypertension. The results replicate the earlier phase 2 findings and advance aldosterone synthase inhibition toward clinical implementation.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"980ba3228c53","type":"article","url":"https://hartvaat.nl/2026/02/27/bloeddruk-time-in-target-range-voorspelt-sterfte-bij-hypertensie/","title":"Bloeddruk 'time in target range' voorspelt sterfte bij hypertensie","title_en":"Association Between 24-Hour Systolic Blood Pressure Time in Target Range and Mortality","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","bloeddrukbehandeling"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26112","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26112","authors":["Lucas Lauder"],"significance":7,"published":"2026-03-06","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"This study showed that 24-hour systolic blood pressure time-in-target-range predicts mortality better than single measurements, supporting continuous assessment of blood pressure control quality using ambulatory monitoring.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7e0271809a5","type":"article","url":"https://hartvaat.nl/2026/02/03/lichamelijke-activiteit-en-risico-op-complicaties-bij-atriumfibrilleren/","title":"Lichamelijke activiteit en risico op complicaties bij atriumfibrilleren","title_en":"Physical activity and risk of adverse events in atrial fibrillation: evidence from European and Asian cohorts.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atleten","bradycardie","farmaco-economie","hartrevalidatie","inflammatie","obesitas","ouderen","slaapapneu"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag032","source_url":"https://doi.org/10.1093/europace/euag032","authors":["Michele Rossi","Tommaso Bucci","Enrico Tartaglia","Amir Askarinejad","Steven Ho Man Lam","Andrea Galeazzo Rigutini","Claudio Ferri","Giuseppe Boriani","Hung-Fat Tse","Tze-Fan Chao","Gregory Y H Lip"],"significance":7,"published":"2026-03-06","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This post-hoc analysis of European and Asian-Pacific AF registries showed that physical activity levels are associated with different clinical characteristics and outcomes in AF patients, supporting exercise recommendations across diverse populations.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7af7e3d9f306","type":"article","url":"https://hartvaat.nl/2026/02/28/hartfalen-bij-ouderen-van-epidemiologie-tot-behandeling/","title":"Hartfalen bij ouderen: van epidemiologie tot behandeling","title_en":"Heart failure in the elderly: epidemiology, mechanisms, and management.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","alcoholgebruik","bisoprolol","bloeddrukbehandeling","laminopathie","myocardinfarct","nt-probnp","pathfinder-trial","primaire-preventie","step-hfpef","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag110","source_url":"https://doi.org/10.1093/eurheartj/ehag110","authors":["Rudolf A de Boer","Mahmoud Abdellatif","Johann Bauersachs","Veronique L Roger"],"significance":9,"published":"2026-03-06","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This European Heart Journal review describes the epidemiology, pathophysiology, and management of heart failure in the elderly, highlighting that the lifetime risk exceeds 25% after age 70. The article addresses the challenges of polypharmacy, frailty, and comorbidity that complicate guideline-directed therapy in older patients.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"388a10c21b59","type":"article","url":"https://hartvaat.nl/2026/03/06/kouno-tori-antitrombine-verlengt-de-zwangerschap-niet-bij-vroege-ernstige-pre-ec/","title":"KOUNO-TORI: antitrombine verlengt de zwangerschap niet bij vroege ernstige pre-eclampsie en geeft meer bloedingen","title_en":"Randomized Study of Antithrombin in Early-Onset Preeclampsia: KOUNO-TORI Study","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["abelacimab","dubbele-trombocytenremming","trombocytenaggregatieremmers","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25431","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25431","authors":["Jun Takeda"],"significance":5,"published":"2026-03-06","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"In preeclampsia, prolonging pregnancy reduces fetal risks. This randomised, double-blind, placebo-controlled study (KOUNO-TORI; 61 institutions) tested whether recombinant human antithrombin-gamma prolongs pregnancy in women with early-onset severe preeclampsia (24-32 weeks, antithrombin activity ≤100%). Pregnancy was prolonged by 13 days in the placebo group (n=92) and 16.9 days in the antithrombin group (n=90) — not a significant difference (p=0.07). The antithrombin group had more haemorrhage-related adverse events (+19.0%) and more anaemia (+16.8%). Antithrombin thus does not significantly prolong pregnancy in early-onset severe preeclampsia and appears to increase bleeding risk.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cab545ade8bb","type":"article","url":"https://hartvaat.nl/2026/03/06/promise-minimal-risk-score-identificeert-veilig-laagrisicopatienten-met-stabiele/","title":"PROMISE Minimal Risk Score identificeert veilig laagrisicopatiënten met stabiele pijn op de borst","title_en":"Retrospective analysis of the performance of the PROMISE minimal risk tool for patients presenting with recent onset stable chest pain","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["ouderen","primaire-preventie","stabiel-coronairlijden"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003837?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003837?rss=1","authors":["Tuffs","C.","Khullar","N.","Levy","T.","Kodoth","V.","Swallow","R.","OKane","P.","Din","J.","Kwok","C. S.","Curzen","N.","Hinton","J."],"significance":5,"published":"2026-03-06","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/coronairlijden/myocardperfusiescintigrafie/"],"congress":"","summary_en":"The PROMISE Minimal Risk Score (PMRS) can identify patients with recent-onset stable chest pain who can be safely reassured and discharged without further testing, but is little used. In this retrospective real-world analysis (3,983 stable chest-pain referrals, median age 64), 10.9% were at minimal risk (PMRS >0.46). In that group, only 0.7% had obstructive coronary disease on CT coronary angiography, and over a median 306-day follow-up there were no myocardial infarctions or deaths. A PMRS above 0.46 is thus associated with a very low likelihood of significant coronary disease and of infarction or death. Applying the PMRS could spare low-risk patients further testing and use healthcare resources more efficiently.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e09f804c5a3b","type":"article","url":"https://hartvaat.nl/2026/03/06/cardiale-sarcoidose-een-onderhoudsdosis-corticosteroiden-van-5-10-mg-dag-geeft-d/","title":"Cardiale sarcoïdose: een onderhoudsdosis corticosteroïden van 5-10 mg/dag geeft de beste prognose","title_en":"Prognostic impact of corticosteroid maintenance dose and re-escalation in patients with cardiac sarcoidosis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiale-sarcoidose"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004048?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e004048?rss=1","authors":["Nishimura","T.","Ishibashi","K.","Kanaoka","K.","Nakajima","K.","Ikee","T.","Syako","D.","Nakamura","T.","Oka","S.","Wakamiya","A.","Ueda","N.","Kamakura","T.","Wada","M.","Inoue","Y.","Miyamoto","K.","Aiba","T.","Kusano","K."],"significance":6,"published":"2026-03-06","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/vasculair/claudicatio-intermittens/"],"congress":"","summary_en":"Japanese guidelines recommend a corticosteroid maintenance dose of 5-10 mg/day for cardiac sarcoidosis (CS), but the optimal dose was unclear. In this multicentre retrospective cohort from a Japanese national CS registry (352 patients on oral corticosteroids), patients were grouped by maintenance dose: low (<5 mg/day), recommended (5-10 mg/day) and high (>10 mg/day). Over a median 5.1-year follow-up, 11% died. The recommended dose gave the best survival; the high dose did significantly worse (mortality 8% with the recommended dose vs 25% low and 17% high). Dose re-escalation was needed in 19%, associated with mortality in the high- and low-dose groups. Achieving and maintaining the recommended 5-10 mg/day maintenance dose is thus important for prognosis in cardiac sarcoidosis.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T13:31:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f166aff70f0a","type":"article","url":"https://hartvaat.nl/2026/03/06/kwetsbaarheid-bepaalt-de-optimale-bloeddrukstreefwaarde-beter-dan-leeftijd-sprin/","title":"Kwetsbaarheid bepaalt de optimale bloeddrukstreefwaarde beter dan leeftijd (SPRINT + ACCORD)","title_en":"Frailty Index Offers Greater Discrimination Than Age for Optimal Blood Pressure Targets: A Pooled Analysis of Two Randomized Trials","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","farmaco-economie","ouderen","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26397","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26397","authors":["Yizhen Lyu"],"significance":7,"published":"2026-03-06","source_date":"2026-03-06","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Hypertension guidelines advocate individualised blood-pressure management, often based on age — but chronological age alone may be insufficient. The frailty index, a multidimensional measure of biological ageing, may guide this better. The investigators pooled participant data from SPRINT and ACCORD (19,230 patients; 68% frail by a 31-item frailty index >0.21) and calculated time within different systolic BP ranges (time in target range, TTR). A J-shaped relationship between average systolic BP and cardiovascular events separated more clearly by frailty than by age. In frail patients, more time in the 110-140 mmHg range was associated with fewer events, whereas in non-frail patients more time below 130 mmHg was favourable. Age discriminated poorly. The frailty index thus more accurately predicts the optimal BP target than chronological age, though age remains more practical in resource-limited settings.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T18:39:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f4c6c74a5232","type":"article","url":"https://hartvaat.nl/2025/01/01/mechanische-trombectomie-bij-longembolie-trends-uit-het-pert-register-2016-2024/","title":"Mechanische trombectomie bij longembolie: trends uit het PERT-register 2016-2024","title_en":"Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024)","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106281?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106281?dgcid=rss_sd_all","authors":["Joseph M. Kim","Steven R. Horbal","Christian Mewaldt","Abhinay Ramachandran","Robert W. Yeh","Eric A. Secemsky","Brett J. Carroll"],"significance":8,"published":"2026-03-05","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/ischemische-beroerte-tia/","https://hartvaat.nl/kennis/ritmestoornissen/adenosine-bij-svt/"],"congress":"","summary_en":"This PERT Consortium registry analysis described trends and practice patterns of mechanical thrombectomy and catheter-directed thrombolysis in acute pulmonary embolism, providing real-world data on the adoption and outcomes of interventional PE therapies.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"33b61d9d46bc","type":"article","url":"https://hartvaat.nl/2026/02/27/albuminurie-geassocieerd-met-verhoogd-risico-op-abdominaal-aorta-aneurysma/","title":"Albuminurie geassocieerd met verhoogd risico op abdominaal aorta-aneurysma","title_en":"Association of albuminuria and changes in albuminuria with the risk of abdominal aortic aneurysm","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["aorta-aneurysma","perifeer-vaatlijden"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00058-4/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00058-4/fulltext","authors":["Shigeru Tanaka","Alessandro Bosi","Toshiaki Nakano","Rebecka Hultgren","Kunihiro Matsushita","Juan Jesus Carrero","Anne-Laure Faucon"],"significance":5,"published":"2026-03-05","source_date":"2026-02-27","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that albuminuria — an early, modifiable marker of vascular damage — is independently associated with increased risk of abdominal aortic aneurysm, offering potential new opportunities for risk stratification beyond eGFR alone.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"009b7502a6ee","type":"article","url":"https://hartvaat.nl/2025/12/11/angiotensine-ii-meten-bij-screening-op-primair-hyperaldosteronisme/","title":"Angiotensine II meten bij screening op primair hyperaldosteronisme","title_en":"Time to Measure Angiotensin II When Screening for Primary Aldosteronism in the Evaluation of Secondary Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["ace-remmers","bloeddrukbehandeling","lorundrostat","ras-remmers","resistente-hypertensie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25990","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25990","authors":["James Brian Byrd"],"significance":7,"published":"2026-03-05","source_date":"2025-12-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This Hypertension article advocated for measuring angiotensin II as a valuable addition to aldosterone-renin ratio screening for primary aldosteronism, potentially improving diagnostic accuracy for secondary hypertension evaluation.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"60cf9fd49d3f","type":"article","url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","title":"Directe versus uitgestelde non-culprit PCI bij MI: gerandomiseerde trial","title_en":"Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["percutane-coronaire-interventie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2512918","source_url":"https://doi.org/10.1056/NEJMoa2512918","authors":["Robin Nijveldt","Michael Maeng","Casper W H Beijnink","Jan J Piek","Rasha K Al-Lamee","Luís Raposo","Sergio Bravo Baptista","Javier Escaned","Justin Davies","Igor Klem","Bahram Yosofi","Robert-Jan M van Geuns","Christian A Frederiksen","Lars Jakobsen","Abdelilah El Barzouhi","Dirk J van der Heijden","Mustafa Ilhan","Saman Rasoul","Stijn Brinckman","Colette Saraber","Daniel A Jones","Steffen E Petersen","Tomaž Podlesnikar","Matjaž Bunc","Marcel A M Beijk","Lieuwe H Piers","Johannes B van Rees","Henry Seligman","Graham Cole","Juan F Iglesias","Sophie Degrauwe","Arnoud W J van 't Hof","Erik Lipsic","Gabija Pundziute-do Prado","Pairoj Chattranukulchai","José F Rodríguez-Palomares","Johannes Rigger","Martijn Meuwissen","Lennaert Kleijn","Bruno Pereira","Lorenzo Monti","René J van der Schaaf","Juan Sanchis","Guido Belli","Jan G P Tijssen","Troels Thim","Niels van Royen"],"significance":7,"published":"2026-03-05","source_date":"2026-03-05","image":"","kennis":[],"congress":"","summary_en":"This NEJM trial compared immediate with deferred nonculprit-lesion PCI in STEMI, addressing the optimal timing of complete revascularization in the acute MI setting with contemporary evidence.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9310db10f07c","type":"article","url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","title":"EMPATHY: hartfalentherapie bij patiënten met gevorderde kanker en palliatieve zorg","title_en":"Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","pathfinder-trial","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf705","source_url":"https://doi.org/10.1093/eurheartj/ehaf705","authors":["Markus S Anker","Amir A Mahabadi","Matthias Totzeck","Mitra Tewes","Muhammad Shahzeb Khan","Raluca I Mincu","Ulrike B Hendgen-Cotta","Lars Michel","Baicy Mathew","Ophelia Drescher","Martin Schuler","Ulrich Keller","Kathrin Rieger","Johann Ahn","Lars Bullinger","Dominik P Modest","Corinna Denecke","Lucie Kretzler","Luisa V Ramer","Danara Krug","Ulf Landmesser","Lorenz H Lehmann","Norbert Frey","Sven Bercker","Ulrich Laufs","Michael Böhm","Felix Mahfoud","Bela Merkely","Monika Diek","Javed Butler","Anja Veiser","Tim Heise","Martin Hellmich","Marius Placzek","Tim Friede","Stefan D Anker","Tienush Rassaf"],"significance":6,"published":"2026-03-05","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"The EMPATICC trial examined heart failure therapy in patients with advanced cancer receiving palliative care, showing that optimizing HF treatment improves symptoms and function even in the end-of-life setting.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f06534789ee","type":"article","url":"https://hartvaat.nl/2026/02/06/glp-1-receptoragonisten-en-nieruitkomsten-focus-op-albuminurie/","title":"GLP-1-receptoragonisten en nieruitkomsten: focus op albuminurie","title_en":"Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","cystatine-c","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","tirzepatide"],"journal":"Journal of personalized medicine","doi":"10.3390/jpm16020097","source_url":"https://doi.org/10.3390/jpm16020097","authors":["Ana Checa-Ros","Owahabanun Joshua Okojie","Jacob Gabriel Wassouf","Aida Yedean","Wei-Chung Hsueh","Patryk Hebda","Esther Rodriguez Llobell","Greta Bianca Muhmenthaler","Martin Duc-Duy Tran","Luis D'Marco"],"significance":6,"published":"2026-03-04","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/"],"congress":"","summary_en":"This review assessed the renoprotective effects of GLP-1 receptor agonists with specific focus on albuminuria reduction, positioning these agents as important kidney-protective therapies alongside SGLT2 inhibitors in the personalized medicine era.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b7b8b025291","type":"article","url":"https://hartvaat.nl/2026/02/17/albuminurie-of-proteinurie-bij-glomerulaire-ziekte-en-ckd-wat-te-gebruiken/","title":"Albuminurie of proteïnurie bij glomerulaire ziekte en CKD: wat te gebruiken?","title_en":"Albuminuria or proteinuria in glomerular disease and CKD - which one to use?","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["chronische-nierziekte","cystatine-c","flow-trial"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag020","source_url":"https://doi.org/10.1093/ndt/gfag020","authors":["Vanja Ivković","Andreas Kronbichler","Chee Kay Cheung","Jonathan Barratt","Annette Bruchfeld","Jürgen Floege","Augusto Vaglio"],"significance":6,"published":"2026-03-04","source_date":"2026-02-17","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This NDT discussion addressed the clinical question of whether albuminuria or proteinuria is the preferred measurement in glomerular disease and CKD, informing the standardization of kidney disease monitoring.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c5e9ba34879","type":"article","url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","title":"IJzertekort bij chronische nierziekte en hartfalen: expertperspectieven","title_en":"Expert Perspectives on Managing Iron Deficiency in People with CKD and/or HF.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","anemie-ckd","bisoprolol","bradycardie","cardiale-resynchronisatie","chronische-nierziekte","hartkatheterisatie","holter","inflammatie","ivabradine","laminopathie","myocardinfarct","nt-probnp","ouderen","pathfinder-trial","vrouwen"],"journal":"Journal of clinical medicine","doi":"10.3390/jcm15041676","source_url":"https://doi.org/10.3390/jcm15041676","authors":["Sunil Bhandari","John G F Cleland","Fozia Z Ahmed","Fraser J Graham","Matt Hall","Paul R Kalra","Philip A Kalra","Kate I Stevens","David C Wheeler","Simon G Williams","Dora I A Pereira","Marco Soscia","Harry Lewis","Imogen Taylor"],"significance":5,"published":"2026-03-04","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-ckd/"],"congress":"","summary_en":"An international expert panel provides practical recommendations for diagnosing and managing iron deficiency in patients with chronic kidney disease and/or heart failure. The review addresses diagnostic uncertainties and identifies patients most likely to benefit from iron therapy.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93bb843cedb1","type":"article","url":"https://hartvaat.nl/2026/02/03/linkerbundeltakpacing-versus-rechterventrikel-pacing-na-tavi/","title":"Linkerbundeltakpacing versus rechterventrikel pacing na TAVI","title_en":"Left bundle branch area pacing vs. right ventricular pacing in post-transcatheter aortic valve implantation patients: a retrospective propensity-matched analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","linkerbundeltakpacing","tavi"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf322","source_url":"https://doi.org/10.1093/europace/euaf322","authors":["Zarko Calovic","Raffaele Salerno","Marco Gamardella","Alessandro Fuga","Alessia Vuturo","Antonio Boccellino","Davide Morciano","Antonio Izzo","Michele Morosato","Gabriele Negro","Roberto Rondine","Luigi Giannelli","Vincenzo Maiolo","Marco Ballarotto","Mario Baldi","Cristiano Ciaccio","Nedy Brambilla","Mauro Agnifili","Luca Testa","Francesco Bedogni","Luigi Anastasia","Giuseppe Ciconte","Carlo Pappone"],"significance":7,"published":"2026-03-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This Europace study compared left bundle branch area pacing with conventional RV pacing in patients requiring permanent pacing after TAVI, evaluating whether physiological pacing strategies improve outcomes in this specific population.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T13:31:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"badd3a2627c3","type":"article","url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","title":"VARIPURE-studie: pulsed field ablatie in de dagelijkse AF-praktijk","title_en":"Workflow and sedation choice with the PFA variable-loop circular catheter in real-world AF procedures: insights from the prospective multi-centre VARIPURE clinical study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","advent-trial","hfpef","hfref","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren","varipure"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag025","source_url":"https://doi.org/10.1093/europace/euag025","authors":["Philipp Sommer","Mads B Kronborg","Frédéric Sebag","Christian Sohns","Tom De Potter","Francis Bessière","Pedro Adragão","Carlo Pappone","Daniel Scherr","Mattias Duytschaever","Alexandre Almorad"],"significance":7,"published":"2026-03-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"The VARIPURE study described real-world workflow and sedation practices with the variable-loop circular PFA catheter for AF ablation, providing practical implementation data for this emerging technology.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7772c36b283a","type":"article","url":"https://hartvaat.nl/2026/02/11/ai-gestuurde-ecg-lokalisatie-verbetert-ablatie-bij-instabiele-ventriculaire-tach/","title":"AI-gestuurde ECG-lokalisatie verbetert ablatie bij instabiele ventriculaire tachycardie","title_en":"Artificial Intelligence ECG Localization Facilitates Focused Activation Mapping and Improves Outcomes in Hemodynamically Unstable Ventricular Tachycardia.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","ai-ecg","bradycardie","pulsed-field-ablatie-atriumfibrilleren","supraventriculaire-tachycardie","ventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag024","source_url":"https://doi.org/10.1093/europace/euag024","authors":["Gordon Ho","Kevin Sung","Frederick T Han","Jonathan C Hsu","Kurt Hoffmayer","Farshad S Raissi","Anne-Sophie Lacharite-Roberge","Gregory K Feld","David E Krummen"],"significance":7,"published":"2026-03-03","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/","https://hartvaat.nl/kennis/ritmestoornissen/ecg-ritmestoornissen-herkenning/"],"congress":"","summary_en":"This Europace study demonstrated that AI-based ECG localization of ventricular tachycardia origin facilitates focused activation mapping, improving procedural efficiency and outcomes for VT ablation.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T13:31:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b9172992af5d","type":"article","url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","title":"Voorspelmodellen voor hartfalen bij patiënten met instabiele angina pectoris","title_en":"Development and validation of diagnostic and prognostic models for heart failure in unstable angina patients","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","bisoprolol","hartkatheterisatie","hartrevalidatie","hfpef","hfref","laminopathie","myocardinfarct","nt-probnp","ouderen","pathfinder-trial","step-hfpef","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003468?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003468?rss=1","authors":["Zhang","L.","Peng","L.","Liu","Z.","Chen","J.","Peng","K.","Wu","M.","Zhou","X.","Jiang","M."],"significance":5,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"To detect heart failure (HF) early in patients with unstable angina (UA), the investigators developed diagnostic and prognostic models. From 12,857 acute coronary syndrome patients, 7,092 UA patients were analysed (split into training and validation cohorts). LASSO regression identified three key factors: left ventricular diameter, NT-proBNP and ischaemic cardiomyopathy. The diagnostic model (for a first HF hospitalisation) had excellent discrimination (AUC 0.94 in both training and validation cohorts). The prognostic models (for HF rehospitalisation at 1, 2 and 6 months) had AUCs of 0.75-0.79. These models can quickly identify high-risk unstable-angina patients and enable targeted, timely care.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4337b13237ef","type":"article","url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","title":"C-MIC II: hartfunctie, inspanningscapaciteit en kwaliteit van leven zijn verwante maar aparte domeinen","title_en":"Association between functional status and cardiac function in chronic heart failure: insights from the C-MIC II Trial","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","empagliflozine","hfmref","hfpef","nt-probnp","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag102","source_url":"https://doi.org/10.1093/eschf/xvag102","authors":["Marat Fudim","Tamara Kovacevic-Preradovic","Marija Zdravkovic","Sasko Jovev","Nermir Granov","Tanja Popov","Igor Rudez","Petar Vukovic","Velibor Ristic","Annette Holtdirk","Muhammad Shahzeb Khan","Faouzi Kallel","Miodrag Peric","Javed Butler","Stefan D Anker","Dragana Kosevic","J Eduardo Rame"],"significance":5,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"In heart failure, the relationship between changes in cardiac function, exercise capacity and patient-reported health is incompletely defined — relevant to endpoint selection in trials. In this post-hoc analysis of the randomised C-MIC II trial (65 ambulatory patients with non-ischaemic dilated cardiomyopathy, NYHA III-IV, LVEF 25-35%), the six-month associations between the KCCQ questionnaire, 6-minute walk distance (6MWD), left ventricular ejection fraction (LVEF) and peak oxygen uptake (peak VO2) were examined. Changes in KCCQ and 6MWD correlated strongly with each other (r=0.63) but only modestly with LVEF (both r=0.39) and not significantly with peak VO2. LVEF correlated more closely with peak VO2 (r=0.41, rising to 0.56 at six months). Cardiac function, exercise capacity and perceived health are thus related but distinct domains — supporting multidimensional assessment in heart-failure trials.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41fae41b4abb","type":"article","url":"https://hartvaat.nl/2026/03/03/ai-echotool-voor-hfpef-hoge-specificiteit-lage-sensitiviteit-bij-invasieve-valid/","title":"AI-echotool voor HFpEF: hoge specificiteit, lage sensitiviteit bij invasieve validatie","title_en":"Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag052","source_url":"https://doi.org/10.1093/eschf/xvag052","authors":["Ryan Sachar","Maria Latz","Tess Allan","John E Blair","Gene Kim","Jonathan Grinstein","Gary Woodward","Roberto Lang","Mark N Belkin"],"significance":6,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/invasieve-hemodynamiek-rechts-hartkatheterisatie/"],"congress":"","summary_en":"An FDA-approved AI tool detects heart failure with preserved ejection fraction (HFpEF) from echocardiographic images (apical 4-chamber), without other clinical data. In this external validation (47 patients with unexplained dyspnoea who underwent both echo and right heart catheterisation), the tool was compared with the invasive standard (wedge pressure ≥15 mmHg at rest or ≥25 mmHg with exercise). The AI had high specificity (88%) and positive predictive value (86%) but low sensitivity (30%); using the PCWP/cardiac-output slope, specificity and PPV reached 100%. AI-positive patients had higher filling pressures and pulmonary resistance. Among patients with indeterminate H2FPEF scores, the AI identified 80% of invasively confirmed HFpEF. The tool is thus best for identifying patients with clearly abnormal haemodynamics, not for ruling out HFpEF.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29e8baec8fac","type":"article","url":"https://hartvaat.nl/2026/03/03/plasma-eiwitprofielen-onthullen-gedeelde-en-fenotype-specifieke-routes-bij-hartf/","title":"Plasma-eiwitprofielen onthullen gedeelde en fenotype-specifieke routes bij hartfalen (UK Biobank)","title_en":"Plasma protein profiles in different heart failure phenotypes","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","hfmref","hfpef","hfref","ijzersuppletie","laminopathie","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag098","source_url":"https://doi.org/10.1093/eschf/xvag098","authors":["Lars Lind","Mario Delgado-Velandia"],"significance":7,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"Heart failure (HF) is often preceded by myocardial infarction (MI) or atrial fibrillation (AF). In 50,765 UK Biobank participants with 2,922 plasma proteins measured, the investigators examined whether protein profiles of incident HF with preceding MI, with preceding AF, or with neither are similar. Sixty proteins were associated with HF across all three groups; thirteen related to left ventricular ejection fraction and seven to the diastolic E/A ratio. ADM was the strongest predictor in the MI and AF groups, while LRRN1 was protective in all groups. A further 110 proteins were uniquely associated with HF without preceding MI or AF. Enriched pathways (interleukin-10 signalling, death receptors, TNF receptor binding) point to a shared pathophysiological profile independent of prior MI or AF.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a638446cdd2","type":"article","url":"https://hartvaat.nl/2026/03/03/spierstofwisseling-bij-hfpef-verminderde-oxidatieve-capaciteit-los-van-ijzergebr/","title":"Spierstofwisseling bij HFpEF: verminderde oxidatieve capaciteit los van ijzergebrek (31P-MRS)","title_en":"Quantifying skeletal muscle energy metabolism during exercise in heart failure with preserved ejection fraction using in vivo 31P magnetic resonance spectroscopy","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hfmref","hfpef","hfref","step-hfpef","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf035","source_url":"https://doi.org/10.1093/eschf/xvaf035","authors":["Jerremy Weerts","Suzanne N Voorrips","Jeroen A L Jeneson","Arantxa Barandiarán Aizpurua","Julian Mevenkamp","Anita J Sibeijn-Kuiper","Remco J Renken","Blanche L M Schroen","Christian Knackstedt","Alfons J H M Houben","Peter Van der Meer","Vera B Schrauwen-Hinderling","B Daan Westenbrink","Vanessa P M van Empel"],"significance":6,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"Patients with heart failure and preserved ejection fraction (HFpEF) have markedly reduced exercise capacity with poorly understood, multifactorial causes. In this Dutch two-site study (58 HFpEF patients, 16 controls), in-vivo 31phosphorus MR spectroscopy measured mitochondrial oxidative muscle metabolism via phosphocreatine recovery after isometric or dynamic exercise. Phosphocreatine recovery halftime after isometric exercise was prolonged in HFpEF patients (27 vs 24 seconds), indicating reduced skeletal-muscle oxidative capacity. This held regardless of iron deficiency, whereas higher hs-CRP was associated with slower recovery. Exercise intolerance in HFpEF thus arises partly from intrinsically impaired muscle energetics, not iron deficiency alone.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"674a0dc56f40","type":"article","url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","title":"Expertopinie: hiërarchische eindpunten op basis van verslechterend hartfalen, voorbij de ziekenhuisopname","title_en":"Worsening heart failure-based hierarchical endpoints beyond HF hospitalization: expert opinion paper","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag107","source_url":"https://doi.org/10.1093/eschf/xvag107","authors":["Agustín Fernández-Cisnal","Gema Miñana","Rafael de la Espriella","Enrique Santas","Joan Carles Trullas","Jan Biegus","Harriette Van Spall","Julio Núñez"],"significance":5,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The classic composite of cardiovascular death or first heart-failure hospitalisation aligns increasingly poorly with modern HF care: better survival and ambulatory pathways mean much worsening HF is treated outside hospital and patients may have recurrent episodes. Time-to-first-hospitalisation alone therefore misses clinically relevant morbidity. In this expert opinion, the authors propose a standardised, adjudicated definition of worsening-HF events extended to ambulatory settings, and recommend hierarchical endpoints that prioritise all-cause death, measure morbidity via all (first and recurrent) events, and incorporate validated patient-reported outcomes. This better reflects total disease burden and improves statistical power and interpretability across evolving care models.","created":"2026-07-03T10:32:19Z","updated":"2026-07-03T18:39:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68cc928cf6b4","type":"article","url":"https://hartvaat.nl/2026/03/03/yolt-101-base-editing-schakelt-pcsk9-uit-bij-heterozygote-fh-fase-1/","title":"YOLT-101: base-editing schakelt PCSK9 uit bij heterozygote FH (fase 1)","title_en":"In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie-screening","pcsk9-remmers"],"journal":"Nature medicine","doi":"10.1038/s41591-026-04254-4","source_url":"https://doi.org/10.1038/s41591-026-04254-4","authors":["Ping Wan","Siyuan Tang","Dongni Lin","Yuming Lu","Mei Long","Ling Xiao","Yanhong Jiang","Jiaoyang Liao","Xiaoying Ma","Ying Liu","Wensu Yu","Michael Ott","Zi Jun Wang","Yuxuan Wu","Taihua Yang","Qiang Xia"],"significance":8,"published":"2026-03-03","source_date":"2026-03-03","image":"https://hartvaat.nl/global/img/85198a3494d0.webp","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"YOLT-101 is an in vivo gene therapy that uses adenine base editing — delivered via GalNAc-modified lipid nanoparticles — to inactivate PCSK9 for durable LDL lowering. In this ongoing phase 1 trial, six adults with heterozygous familial hypercholesterolaemia and uncontrolled LDL received a single ascending dose (0.2–0.6 mg/kg). No grade ≥3 adverse events occurred; transient infusion reactions and liver-enzyme elevations were most common. A single infusion produced dose-dependent, durable reductions: at the highest dose (0.6 mg/kg) PCSK9 and LDL cholesterol fell by 74.4% and 52.3% respectively at 24 weeks. Alongside VERVE-102, this is a second base-editing programme pursuing one-time, durable PCSK9 knockdown.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b9158f39ec03","type":"article","url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","title":"4-eiwitmodel voor cardiogene shock prognose: DanGer substudie","title_en":"Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","cardiogene-shock"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag010","source_url":"https://doi.org/10.1093/eschf/xvag010","authors":["Danilo Obradovic","Lisa Schulz","Goran Loncar","Norman Mangner","Axel Linke","Uwe Zeymer","Steffen Desch","Janine Pöss","Anne Freund","Hans-Josef Feistritzer","Petra Büttner","Holger Thiele"],"significance":5,"published":"2026-03-03","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"A DanGer Shock substudy evaluated the cardiogenic shock 4-protein biomarker-based risk score in infarct-related cardiogenic shock. The biomarker panel improves risk stratification for mechanical circulatory support decisions.","created":"2026-07-03T10:32:13Z","updated":"2026-07-03T13:31:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2cf4a12a235b","type":"article","url":"https://hartvaat.nl/2026/02/03/voedingsstatus-voorspelt-ventriculaire-ritmestoornissen-bij-gevorderd-hartfalen/","title":"Voedingsstatus voorspelt ventriculaire ritmestoornissen bij gevorderd hartfalen","title_en":"Controlling Nutritional Status score as a predictor of ventricular arrhythmias in patients with advanced heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","diabetes-en-hart","fractional-flow-reserve","hartrevalidatie","harttransplantatie","ijzertekort","laminopathie","myocardinfarct","nierfalen","nt-probnp","ouderen","pathfinder-trial","rechterventrikelfalen","step-hfpef","summit-trial","supraventriculaire-tachycardie","ventrikelfibrilleren","voeding-hart"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag037","source_url":"https://doi.org/10.1093/eschf/xvag037","authors":["Yuma Ono","Hidekazu Kondo","Taisuke Harada","Kunio Yufu","Hiroki Sato","Kazuki Mitarai","Keisuke Yonezu","Katsunori Tawara","Akira Fukui","Hidefumi Akioka","Yasushi Teshima","Naohiko Takahashi"],"significance":5,"published":"2026-03-02","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This study demonstrated that the Controlling Nutritional Status score predicts ventricular arrhythmias in patients with advanced heart failure receiving cardiac resynchronisation therapy. Malnutrition appears to be an independent risk factor for life-threatening arrhythmias.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"427ab262d377","type":"article","url":"https://hartvaat.nl/2026/02/25/lvad-versus-harttransplantatie-bij-hartfalen-finse-kosten-en-uitkomsten/","title":"LVAD versus harttransplantatie bij hartfalen: Finse kosten en uitkomsten","title_en":"Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","harttransplantatie","hfref","lvad"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag063","source_url":"https://doi.org/10.1093/eschf/xvag063","authors":["Riina Kandolin","Sami Pakarinen","Paavo Koivistoinen","Saara Tiainen","Jan Kiss","Deirdre Blissett","Markku Pentikäinen"],"significance":5,"published":"2026-03-02","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A Finnish real-world study compared clinical outcomes and healthcare costs between advanced heart failure patients receiving LVAD therapy versus heart transplantation. The European cost-effectiveness data inform decision-making in advanced heart failure management.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb321256a2c5","type":"article","url":"https://hartvaat.nl/2026/02/26/cardiogene-shock-bij-myocardinfarct-resultaten-van-het-shock-pol-register/","title":"Cardiogene shock bij myocardinfarct: resultaten van het Shock-POL-register","title_en":"Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","myocardinfarct"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag066","source_url":"https://doi.org/10.1093/eschf/xvag066","authors":["Maciej T Wybraniec","Artur Sufryd","Małgorzata Cichoń","Tomasz Tokarek","Dominika Dykla","Aleksander Zeliaś","Katarzyna Holcman","Sylwia Szczepara","Robert Kowalik","Anna Fojt","Agnieszka Kapłon-Cieślicka","Mikołaj Błaziak","Mateusz Sokolski","Michał Tkaczyszyn","Wiktor Kuliczkowski","Paweł Gąsior","Paweł Pawlus","Wojciech Wojakowski","Beata Morawiec","Damian Kawecki","Andrzej Kułach","Grzegorz Smolka","Adam Janas","Katarzyna Mizia-Stec","Krystian Wita"],"significance":5,"published":"2026-03-02","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiogene-shock/"],"congress":"","summary_en":"The Shock-POL registry documented current management patterns, mortality rates, and risk factors in patients with cardiogenic shock complicating acute myocardial infarction across nine Polish cardiology centres.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03ac59d3bba7","type":"article","url":"https://hartvaat.nl/2025/01/01/de-troponine-i-t-ratio-bij-myocardschade-een-multicohort-synthese/","title":"De troponine I/T-ratio bij myocardschade: een multicohort-synthese","title_en":"The cTnI/cTnT Ratio in Myocardial Injury: A Multicohort and Experimental Synthesis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","gepersonaliseerde-geneeskunde","myocardinfarct","troponine"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106591?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106591?dgcid=rss_sd_all","authors":["Tobias Zimmermann","Luca Koechlin","Joan Walter","Dorien M. Kimenai","Anda Bularga","Giulia Milan","Antonio Sileo","Deborah Fusco","Xiya Mu","Fabian J. Brunner"],"significance":8,"published":"2026-03-02","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This multicohort study investigated the ratio of cardiac troponin I to troponin T as a diagnostic tool in myocardial injury, exploring whether this ratio can differentiate between ischemic and non-ischemic causes of myocardial damage.","created":"2026-07-03T10:32:30Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8af4dbfaa553","type":"article","url":"https://hartvaat.nl/2025/01/01/ultra-lage-dosis-combinatiepil-als-startbehandeling-voor-hypertensie/","title":"Ultra-lage dosis combinatiepil als startbehandeling voor hypertensie","title_en":"Small But Mighty: Blood Pressure Control Through Ultra-Low-Dose Single-Pill Antihypertensive Medication as Initial Therapy","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aprocitentan","bloeddrukbehandeling","lorundrostat","renale-denervatie","resistente-hypertensie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106578?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106578?dgcid=rss_sd_all","authors":["Alexander R. Zheutlin","Daichi Shimbo","Adam P. Bress"],"significance":8,"published":"2026-03-02","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This JACC study explored ultra-low-dose single-pill antihypertensive combinations as initial therapy for hypertension. The approach aims to overcome treatment inertia by starting with minimally dosed multi-drug combinations that maximize efficacy while minimizing side effects.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T18:39:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa75bbf70007","type":"article","url":"https://hartvaat.nl/2026/02/27/macrofaagbelasting-in-carotisplaque-voorspelt-cardiovasculaire-events-na-endarte/","title":"Macrofaagbelasting in carotisplaque voorspelt cardiovasculaire events na endarterectomie","title_en":"Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["atherosclerose","biomarkers-cardiovasculair","carotisstenose","inflammatie","secundaire-preventie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag117","source_url":"https://doi.org/10.1093/eurheartj/ehag117","authors":["Koen H M Prange","Gemma Bel-Bordes","Marie A C Depuydt","Panos Barlampas","Moritz J Reif","Max L B Grönloh","Rosalie W M Kempkes","Guillermo R Griffith","Cindy van Roomen","Yayuan Zhu","Andreas Edsfeldt","Jiangming Sun","Maaike J M de Jong","Barend M Mol","Bram Slütter","Ilze Bot","Annette E Neele","Dominique P V de Kleijn","Gert J de Borst","Jeffrey Kroon","Anouk Wezel","Harm J Smeets","Erik S G Stroes","Jaap D van Buul","Pieter Goossens","Johan Kuiper","Isabel Goncalves","Gerard Pasterkamp","Michal Mokry","Menno P J de Winther"],"significance":9,"published":"2026-03-02","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/"],"congress":"","summary_en":"This European Heart Journal study demonstrated that carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers independently predict secondary major adverse cardiovascular events beyond traditional risk factors. The findings link plaque inflammation at the cellular level to recurrent cardiovascular risk.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fafa07295772","type":"article","url":"https://hartvaat.nl/2026/03/02/is-depressie-een-onafhankelijke-risicofactor-voor-sterfte-bij-hart-en-vaatziekte/","title":"Is depressie een onafhankelijke risicofactor voor sterfte bij hart- en vaatziekten? Mogelijk niet (NHANES)","title_en":"Depression may not be an independent risk factor for mortality in patients with cardiovascular disease: data from NHANES 2011-2018","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003754?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003754?rss=1","authors":["Nguyen","B. T.","Li","Y.-C.","Dang","H. N.","Nguyen","H. T.","Thai","N. T. H.","Nguyen","D. T.","Nguyen","Q. T.","Nguyen","D. T. K.","Le","H. T. N.","Nguyen","V. N. B.","Tran","A. V."],"significance":5,"published":"2026-03-02","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Depression is common in cardiovascular disease (CVD) and has long been regarded as an independent risk factor for higher mortality, although this association may be confounded by symptom overlap and residual confounding. In this secondary analysis of 2,064 adults with CVD (NHANES 2011-2018, linked to mortality data), depression was defined using the PHQ-9 (cut-off ≥10). Over a median 4.67-year follow-up, 403 deaths were recorded. In a basic adjusted Cox model, depression was associated with higher all-cause (HR 1.33) and non-cardiovascular mortality (HR 1.46). After rigorous adjustment with propensity score matching and inverse probability weighting, however, these associations were no longer significant. After thorough adjustment for confounders and comorbidity, depression may thus not be an independent risk factor for mortality in patients with cardiovascular disease.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7bc5059d489a","type":"article","url":"https://hartvaat.nl/2026/03/02/vrouwen-na-coronaire-bypasschirurgie-hoger-ziekenhuisrisico-en-minder-grafts-maa/","title":"Vrouwen na coronaire bypasschirurgie: hoger ziekenhuisrisico en minder grafts, maar vergelijkbare langetermijnoverleving","title_en":"Worse risk profile, number of grafts and hospital death but acceptable late survival in females undergoing coronary surgery: a 20-year propensity matched analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-bypass"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003894?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003894?rss=1","authors":["Dixon","L. K.","Di Tommaso","E.","Gemelli","M.","Bruno","D. V.","Ascione","R."],"significance":6,"published":"2026-03-02","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This study examined sex differences in isolated coronary artery bypass grafting (CABG) over 20 years (2001-2021) at a single centre, with 1:1 propensity score matching (2,573 women vs 2,573 men). Women were older and more often had class III-IV angina, hypertension and diabetes. After matching, women received fewer left internal mammary artery (LIMA) grafts (84% vs 88%) and fewer total grafts (median 2 vs 3), had higher in-hospital mortality (2.2% vs 1.3%; OR 1.74) and longer hospital stays. Twenty-year survival, however, was similar. Off-pump CABG lowered in-hospital mortality in women (1.6% off-pump vs 3.0% on-pump). Women thus have higher perioperative risk and receive fewer (arterial) grafts, while long-term survival is equal — arguing for a female-tailored perioperative approach.","created":"2026-07-03T10:32:23Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2bcdf5e67f31","type":"article","url":"https://hartvaat.nl/2026/03/02/staken-van-ras-remmers-na-acute-egfr-daling-hangt-samen-met-meer-nierfalen-en-st/","title":"Staken van RAS-remmers na acute eGFR-daling hangt samen met meer nierfalen en sterfte","title_en":"Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":["ace-remmers","ezetimibe","ramipril","ras-remmers"],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2026.3680","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.3680","authors":["Elaine Ku","Navdeep Tangri","Ranveer Brar","Charles E McCulloch","Mark J Sarnak"],"significance":7,"published":"2026-03-02","source_date":"2026-03-02","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/metformine-en-nierfunctie/"],"congress":"","summary_en":"Renin-angiotensin system inhibitors (RASIs) are frequently discontinued when an acute decline in eGFR occurs after initiation. In this Canadian target-trial-emulation cohort (4,233 patients with a >15% eGFR decline within 90 days), discontinuation — versus continuation — carried a higher risk of death (HR 1.23) and end-stage kidney disease (HR 1.74); differences in cardiovascular events and acute kidney injury were not significant. The authors argue for caution before stopping and for strategies that support continued RASI use.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c558c4c56905","type":"article","url":"https://hartvaat.nl/2026/02/26/intensieve-bloeddrukbehandeling-en-cognitieve-functie-een-gerandomiseerde-klinis/","title":"Intensieve bloeddrukbehandeling en cognitieve functie: een gerandomiseerde klinische trial","title_en":"Intensive BP Control and Cognitive Function: A Randomized Clinical Trial","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","figaro-dkd","soul-trial","summit-trial"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26572","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26572","authors":["Bin Wang"],"significance":7,"published":"2026-03-01","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/"],"congress":"","summary_en":"This randomized trial investigated whether intensive blood pressure control preserves cognitive function in an East Asian population, addressing the uncertainty about aggressive BP targets and brain health in this demographic.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c899c186aba2","type":"article","url":"https://hartvaat.nl/2025/01/01/luchtvervuiling-verhoogt-sterfte-door-hypertensie-case-crossover-studie-bij-2-1-/","title":"Luchtvervuiling verhoogt sterfte door hypertensie: case-crossover studie bij 2,1 miljoen sterfgevallen","title_en":"Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications: A Case Crossover Study of 2.1 Million Deaths in China","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","hypertrofische-cardiomyopathie","obesitas","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000586?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000586?dgcid=rss_sd_all","authors":["Xiaowei Xue","Zifang Zhou","Huihuan Luo","Ya Gao","Haidong Kan","Jianping Li","Renjie Chen"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This large Chinese case-crossover study demonstrated that short-term exposure to air pollution significantly increases mortality from hypertension and its multiorgan complications, establishing a direct link between environmental pollutants and hypertensive crisis outcomes.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"143a1d7edc3d","type":"article","url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","title":"APERITIF-trial: laaggedoseerd rivaroxaban voorkomt linkerventrikeltrombose na voorwandinfarct","title_en":"Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["aperitif-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2026.0026","source_url":"https://doi.org/10.1001/jamacardio.2026.0026","authors":["Etienne Puymirat","Gilles Soulat","Benoit Lattuca","Claire Bouleti","Nicolas Delarche","François Roubille","Yves Cottin","Didier Bression","Nicolas Combaret","Edouard Gerbaud","Thibaut Lhermusier","Loic Biere","Olivier Dubreuil","Elie Mousseaux","Philippe Gabriel Steg","Guillaume Cayla","Gilles Lemesle","Johanne Silvain","Jean-Guillaume Dillinger","Jean-Louis Georges","Grégory Ducrocq","Thibaud Genet","Jean-François Morelle","Gilles Montalescot","Laurence Berard","Alexandra Rousseau","Maxime Soen","Tabassome Simon","Nicolas Danchin"],"significance":7,"published":"2026-03-01","source_date":"2026-02-25","image":"","kennis":[],"congress":"","summary_en":"The APERITIF randomized trial investigated whether adding low-dose rivaroxaban to dual antiplatelet therapy prevents left ventricular thrombus formation after anterior acute myocardial infarction.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4c9746cc10b3","type":"article","url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","title":"Intensieve bloeddrukcontrole en cognitieve functie: gerandomiseerde trial","title_en":"Intensive BP Control and Cognitive Function: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.26572","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.26572","authors":["Bin Wang","Ying Sun","Yan Li","Liyong Wu","Yue Peng","Shitian Li","Jinzhuo Ge","Liping Zhang","Lingshan Zhao","Jiangling Liu","Shuhong Su","Bin Zhang","Yaqin Liu","Xiaowen Ma","Zhaokai Zuo","Haibo Zhang","Yang Wang","Jiamin Liu","Jing Li"],"significance":7,"published":"2026-03-01","source_date":"2026-04-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that intensive blood pressure control protects cognitive function in an East Asian hypertensive population, extending the SPRINT MIND findings to this demographic group.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7cf2c368682","type":"article","url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","title":"Lage-dosis TEL/AML/CHTD combinatietablet versus standaard TEL: fase III","title_en":"Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25810","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25810","authors":["Jeong Cheon Ahn","Cheol Whan Lee","Jong-Hwa Ahn","Kyung Hee Lim","Il Suk Sohn","Ki-Chul Sung","Kye Hun Kim","Jang-Ho Bae","Seung Pyo Hong","Won-Young Jang","Sang-Ho Jo","Seung Hwan Han","Ji Bak Kim","Chan Joo Lee","Ju-Hee Lee","Namkyun Kim","Eun Joo Cho","Jung-Hoon Sung","Hyo-Suk Ahn","Seok-Yeon Kim","Jinho Shin","Suk Min Seo","Soon Jun Hong","Weon Kim","Chang-Gyu Park"],"significance":7,"published":"2026-03-01","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/","https://hartvaat.nl/kennis/farmacologie/polypil-cardiovasculair/"],"congress":"","summary_en":"This phase III RCT confirmed the superior blood pressure-lowering efficacy of a low-dose triple combination (telmisartan/amlodipine/chlorthalidone) versus standard-dose telmisartan monotherapy for hypertension treatment.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"15c31ab052bb","type":"article","url":"https://hartvaat.nl/2026/04/01/mhealth-interventie-verbetert-hypertensiezorg-bij-hoogrisicopatienten/","title":"mHealth-interventie verbetert hypertensiezorg bij hoogrisicopatiënten","title_en":"mHealth Intervention to Improve Hypertension Care in High-Risk Patients.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","digitale-gezondheid"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.26148","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.26148","authors":["Kamakshi Lakshminarayan","Thomas A Murray","Scott Lunos","Teresa McCarthy","Susan A Everson-Rose","Valerie Overton","Paul E Drawz","Christopher Streib","Boonsub Sakboonyarat","Hilary Hatch","Judith H Hibbard","Russell V Luepker","John Connett","Sarah M Westberg"],"significance":6,"published":"2026-03-01","source_date":"2026-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study confirmed that a pharmacist-led mobile health technology care model improves blood pressure control in high-risk patients, supporting the integration of mHealth and interprofessional collaboration for hypertension management.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T18:39:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5dc206cd949","type":"article","url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","title":"Abelacimab versus rivaroxaban bij ouderen met AF: subanalyse","title_en":"Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["abelacimab","anticoagulatie-kwetsbare-ouderen","esc-2026"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.5418","source_url":"https://doi.org/10.1001/jamacardio.2025.5418","authors":["Samer Al Said","Siddharth M Patel","Robert P Giugliano","David A Morrow","Erica L Goodrich","Sabina A Murphy","Bruce Hug","Sanobar Parkar","Shih-Ann Chen","Shaun G Goodman","Boyoung Joung","Robert G Kiss","Wojciech Wojakowski","Jeffrey I Weitz","Dan Bloomfield","Marc S Sabatine","Christian T Ruff"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"esc-2026","summary_en":"This AZALEA-TIMI 71 subanalysis confirmed that abelacimab provides less bleeding than rivaroxaban in older AF patients, the population at highest bleeding risk with conventional anticoagulants.","created":"2026-07-03T10:32:13Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84140eb4c85b","type":"article","url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","title":"Ambulante arteriële stijfheidsindex: eindpuntgebaseerde drempelwaarde","title_en":"End Point-Based Threshold for the Ambulatory Arterial Stiffness Index.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["perifeer-vaatlijden"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25442","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25442","authors":["Yi-Bang Cheng","De-Wei An","Dong-Yan Zhang","Yu-Ling Yu","Jesus D Melgarejo","José Boggia","Dries S Martens","Tine W Hansen","Kei Asayama","Takayoshi Ohkubo","Katarzyna Stolarz-Skrzypek","Qi-Fang Huang","Sofia Malyutina","Edoardo Casiglia","Lars Lind","Gladys E Maestre","Ji-Guang Wang","Masahiro Kikuya","Kalina Kawecka-Jaszcz","Eamon Dolan","Edgardo Sandoya","Marek Rajzer","Tim S Nawrot","Krzysztof Narkiewicz","Wen-Yi Yang","Peter Verhamme","Jan Filipovský","Auxiliadora Graciani","José R Banegas","Yan Li","Jan A Staessen"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"An individual-participant meta-analysis of 14 population studies derived an endpoint-based risk threshold for the ambulatory arterial stiffness index. The prognostic biomarker may complement blood pressure-based cardiovascular risk stratification.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebfe1824fd1e","type":"article","url":"https://hartvaat.nl/2025/01/01/2025-richtlijn-voor-aangeboren-hartafwijkingen-bij-volwassenen-vergeleken-met-de/","title":"2025-richtlijn voor aangeboren hartafwijkingen bij volwassenen vergeleken met de 2020-richtlijn kleplijden","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline Recommendations for the Treatment of Adult Congenital Heart Disease and Comparison With the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000549?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000549?dgcid=rss_sd_all","authors":["Patrick T. O’Gara"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"This comparison of the 2025 with the 2018 ACC/AHA congenital heart disease guidelines highlighted key changes in recommendations, including updated surgical timing, expanded catheter intervention indications, and improved pregnancy counseling.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e1caf50db0d","type":"article","url":"https://hartvaat.nl/2025/01/01/de-2025-richtlijn-voor-aangeboren-hartafwijkingen-bij-volwassenen-vanuit-early-c/","title":"De 2025-richtlijn voor aangeboren hartafwijkingen bij volwassenen vanuit early-career perspectief","title_en":"2025 Adults With Congenital Heart Disease Guideline From the Early-Career Perspective","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105858?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105858?dgcid=rss_sd_all","authors":["Lidija B. McGrath","Katherine Salciccioli","Adam Small","Jill M. Steiner"],"significance":5,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This early-career perspective on the 2025 ACHD guideline discussed how the next generation of cardiologists can implement contemporary recommendations for adults with congenital heart disease in their training and clinical practice.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1cbcdd19fae0","type":"article","url":"https://hartvaat.nl/2025/01/01/richtlijn-volwassenen-met-aangeboren-hartafwijkingen-2025-in-een-oogopslag/","title":"Richtlijn volwassenen met aangeboren hartafwijkingen 2025 in één oogopslag","title_en":"2025 Adults With Congenital Heart Disease Guideline-at-a-Glance","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725101691?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725101691?dgcid=rss_sd_all","authors":["Chayakrit Krittanawong","Mykela M. Moore","Morgane Cibotti-Sun"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This guideline-at-a-glance provided a concise visual summary of the 2025 ACHD guidelines, distilling key recommendations for clinical practice in a rapid-reference format.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"949c11cc63ef","type":"article","url":"https://hartvaat.nl/2025/01/01/richtlijn-acute-longembolie-2026-in-een-oogopslag/","title":"Richtlijn acute longembolie 2026 in één oogopslag","title_en":"2026 Acute Pulmonary Embolism Guideline-at-a-Glance","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104798?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104798?dgcid=rss_sd_all","authors":["David M. Dudzinski","Morgane Cibotti-Sun","Mykela M. Moore"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/wells-score-dvt-longembolie/"],"congress":"","summary_en":"This JACC guideline-at-a-glance provides a concise visual summary of the 2026 acute pulmonary embolism guideline, distilling the key recommendations into an accessible reference format for rapid clinical decision-making.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d69fe36e30c8","type":"article","url":"https://hartvaat.nl/2025/01/01/de-2025-richtlijn-voor-volwassenen-met-aangeboren-hartafwijkingen-aanpassen-aan-/","title":"De 2025-richtlijn voor volwassenen met aangeboren hartafwijkingen aanpassen aan lage-inkomenslanden","title_en":"Adapting the 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for Management of Adults With Congenital Heart Disease to Low Resource Settings","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105950?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105950?dgcid=rss_sd_all","authors":["Babar S. Hasan","Raman Krishna Kumar"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/claudicatio-intermittens/"],"congress":"","summary_en":"This analysis discussed how the 2025 ACC/AHA guideline for adults with congenital heart disease can be adapted to diverse healthcare settings, addressing implementation challenges in different resource environments.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"43cf4b45a82a","type":"article","url":"https://hartvaat.nl/2025/01/01/aangeboren-hartafwijkingen-bij-volwassenen-nieuwe-richtlijnen-kennishiaten-en-ka/","title":"Aangeboren hartafwijkingen bij volwassenen: nieuwe richtlijnen, kennishiaten en kansen","title_en":"Adult Congenital Heart Disease: New Guidelines, Remaining Gaps, and Continual Opportunities","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001312?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726001312?dgcid=rss_sd_all","authors":["Anne Marie Valente"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC editorial discussed the new ACC/AHA guideline for adults with congenital heart disease, identifying remaining evidence gaps and opportunities for improving care in this growing patient population.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b274093021c","type":"article","url":"https://hartvaat.nl/2025/01/01/atriale-mechanische-contractie-voorspelt-cerebrovasculair-risico-bij-transthyret/","title":"Atriale mechanische contractie voorspelt cerebrovasculair risico bij transthyretine-amyloïdcardiomyopathie en sinusritme","title_en":"Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["aficamten","aritmogene-cardiomyopathie","atriale-cardiomyopathie","cardiale-amyloidose","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","ouderen","supraventriculaire-tachycardie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105640?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105640?dgcid=rss_sd_all","authors":["Aldostefano Porcari","Beatrice Dal Passo","Lucia Venneri","Alberto Aimo","Zehra Irem Sezer","Francesco Bandera","Yousuf Razvi","Awais Sheikh","Josephine Mansell","Muhammad Umaid Rauf"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that atrial mechanical contraction assessed by imaging predicts cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy, suggesting a functional marker for stroke risk stratification in ATTR-CM.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efc241860081","type":"article","url":"https://hartvaat.nl/2025/01/01/voorbij-de-ventrikels-cardiomyopathiegenen-en-het-risico-op-atriumfibrilleren/","title":"Voorbij de ventrikels: cardiomyopathiegenen en het risico op atriumfibrilleren","title_en":"Beyond the Ventricles: Cardiomyopathy Genes and Atrial Fibrillation Risk","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aortainsufficiëntie","aritmogene-cardiomyopathie","atriale-cardiomyopathie","bradycardie","cardiomyopathie-gerichte-therapie","congenitale-hartafwijking","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","ouderen","slaapapneu","ventrikelfibrilleren"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000689?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000689?dgcid=rss_sd_all","authors":["Aniruddh P. Patel","Elizabeth Silver","Si-Die Demeester"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This JACC commentary discussed the growing evidence that gene mutations traditionally associated with ventricular cardiomyopathies also independently increase the risk of atrial fibrillation, blurring the distinction between ventricular and atrial genetic disease.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6cc166668fdf","type":"article","url":"https://hartvaat.nl/2025/01/01/cardiale-screening-bij-104-369-jongeren-opbrengst-interventies-en-incidentie-van/","title":"Cardiale screening bij 104.369 jongeren: opbrengst, interventies en incidentie van plotse hartdood","title_en":"Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103574?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103574?dgcid=rss_sd_all","authors":["Hamish MacLachlan","Raghav Bhatia","Hariharan Raju","Greg Mellor","Emmanouil Androulakis","Joyee Basu","Elijah R. Behr","Navin Chandra","Nikhil Chatrath","Harshil Dhutia"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/ritmestoornissen/plotse-hartstilstand-plotse-hartdood/"],"congress":"","summary_en":"This large-scale screening study of over 104,000 young individuals for conditions associated with sudden cardiac death evaluated the diagnostic yield, interventions triggered, and subsequent incidence of sudden cardiac arrest, informing the ongoing debate about population-level cardiac screening.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T13:25:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"092ff6c79ef3","type":"article","url":"https://hartvaat.nl/2025/01/01/cardiale-screening-bij-jongeren-tijd-voor-actie/","title":"Cardiale screening bij jongeren: tijd voor actie?","title_en":"Cardiac Screening in the Young: Time to Sound the Battle CRY?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105809?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105809?dgcid=rss_sd_all","authors":["Aaron Baggish"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This JACC commentary discussed the implications of the CRY cardiac screening study in young individuals, debating the value and limitations of population-level cardiac screening programs for sudden cardiac death prevention.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04b9ec27c512","type":"article","url":"https://hartvaat.nl/2025/01/01/cardiomyopathie-genvarianten-en-polygene-risicoscores-bij-atriumfibrilleren-bewi/","title":"Cardiomyopathie-genvarianten en polygene risicoscores bij atriumfibrilleren: bewijs voor een atriaal-eerst fenotype","title_en":"Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["atriale-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104282?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104282?dgcid=rss_sd_all","authors":["Guilherme L. da Rocha","James Feiner","Julieta Lazarte","Keona Pang","Yanran Li","Ann Le","Alice Man","Nazia Pathan","Richard P. Whitlock","Emilie P. Belley-Côté"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This study explored the role of cardiomyopathy-associated gene variants and polygenic risk scores in the development of atrial fibrillation, providing evidence for an atrial-first phenotype in genetic cardiomyopathy.","created":"2026-07-03T10:25:48Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e4709c9abe1","type":"article","url":"https://hartvaat.nl/2025/01/01/esc-0-1-uur-versus-0-2-of-0-3-uur-hoog-sensitief-troponine-algoritmen-bij-verden/","title":"ESC 0/1-uur versus 0/2- of 0/3-uur hoog-sensitief troponine-algoritmen bij verdenking acuut coronair syndroom","title_en":"Comparison of the European Society of Cardiology 0/1-Hour and High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome 0/2-or-0/3-Hour Algorithms for Rapid Myocardial Infarction Diagnosis: A Prospective Multicenter Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["esc-2026","troponine"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105883?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105883?dgcid=rss_sd_all","authors":["Jonas Glaeser","Pedro Lopez-Ayala","Caroline Kellner","Jasper Boeddinghaus","Thomas Nestelberger","Luca Koechlin","Nils.A. Sörensen","Paul M. Haller","Paolo Bima","Luca Crisanti"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/diagnostiek/high-sensitivity-troponine/"],"congress":"esc-2026","summary_en":"This prospective multicenter study compared the diagnostic accuracy of the ESC 0/1-hour high-sensitivity troponin algorithm with standard evaluation for patients presenting with suspected acute coronary syndromes, assessing real-world performance of the rapid rule-out/rule-in protocol.","created":"2026-07-03T10:25:48Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c2822195e0e6","type":"article","url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","title":"Effect van Baduanjin op bloeddruk bij hoog-normaal bloeddruk: gerandomiseerde trial","title_en":"Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972600077X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972600077X?dgcid=rss_sd_all","authors":["Boxuan Pu","Lihua Zhang","Ying Sun","Yanwu Yu","Lei Yan","Yan Li","Jiamin Liu","Xin Zheng","Haibo Zhang","Yue Peng"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This multicenter randomized trial evaluated Baduanjin, a traditional Chinese exercise form, for blood pressure reduction in individuals with high-normal blood pressure, testing a culturally appropriate lifestyle intervention for hypertension prevention.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"928456cf30a3","type":"article","url":"https://hartvaat.nl/2025/01/01/van-overleving-naar-rentmeesterschap-hypergespecialiseerde-cardiovasculaire-zorg/","title":"Van overleving naar rentmeesterschap: hypergespecialiseerde cardiovasculaire zorg op schaal leveren","title_en":"From Survival to Stewardship: Delivering Hyperspecialized Cardiovascular Care at Scale","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","obesitas","slaapapneu"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000793?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000793?dgcid=rss_sd_all","authors":["Harlan M. Krumholz"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC perspective addressed the challenges of delivering hyperspecialized cardiovascular care at scale, discussing strategies for maintaining quality while expanding access to advanced treatments.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cebc1a996b8d","type":"article","url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","title":"Hartfalenpreventie: bewijsgeneratie, trialontwerp en regulatoire trajecten","title_en":"Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105603?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105603?dgcid=rss_sd_all","authors":["Javed Butler","Muhammad Shahzeb Khan","João Pedro Ferreira","Nicolas Girerd","Martha Gulati","Anuradha Lala","Mark C. Petrie","Norman Stockbridge","Muthiah Vaduganathan","Faiez Zannad"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC review discussed the current landscape of heart failure prevention, addressing evidence generation, clinical trial design challenges, and regulatory pathways for therapies aimed at preventing rather than treating established heart failure.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cdad464239f6","type":"article","url":"https://hartvaat.nl/2025/01/01/hoge-dosis-griepvaccinatie-bij-atherosclerotisch-vaatlijden-flunity-hd-analyse/","title":"Hoge-dosis griepvaccinatie bij atherosclerotisch vaatlijden: FLUNITY-HD-analyse","title_en":"High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD)","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972510661X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972510661X?dgcid=rss_sd_all","authors":["Manan Pareek","Niklas Dyrby Johansen","Daniel Modin","Jacobo Pardo-Seco","Carmen Rodriguez-Tenreiro-Sánchez","Matthew M. Loiacono","Rebecca C. Harris","Marine Dufournet","Robertus van Aalst","Ayman Chit"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This multinational pooled analysis of the DANFLU-2 and GALFLU trials evaluated the effect of high-dose versus standard-dose influenza vaccination on cardiovascular outcomes in patients with atherosclerotic cardiovascular disease, addressing whether enhanced immunogenicity translates to better cardiovascular protection.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"372ef763bb7e","type":"article","url":"https://hartvaat.nl/2025/01/01/impact-van-vroege-uitgestelde-of-onderbroken-behandeling-bij-kinderen-met-famili/","title":"Impact van vroege, uitgestelde of onderbroken behandeling bij kinderen met familiaire hypercholesterolemie","title_en":"Impact of Early, Delayed, or Interrupted Treatment in Children With Familial Hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","statines","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725102477?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725102477?dgcid=rss_sd_all","authors":["Yun-Lin Huang","Sarah D. de Ferranti","Jacob Hartz","Yiyi Zhang","Natalia Ruiz-Negrón","Dhruv S. Kazi","Amit V. Khera","Jessica G. Woo","Elaine M. Urbina","David R. Jacobs"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"This study examined the long-term cardiovascular effects of early, delayed, or interrupted lipid-lowering treatment in children with familial hypercholesterolemia, providing evidence for the importance of early and continuous treatment initiation.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"acba12679ef9","type":"article","url":"https://hartvaat.nl/2025/01/01/langdurige-blootstelling-aan-bosbranden-pm2-5-en-cardiovasculaire-ziekenhuisopna/","title":"Langdurige blootstelling aan bosbranden-PM2.5 en cardiovasculaire ziekenhuisopnames bij ouderen in de VS","title_en":"Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM<sub>2.5</sub> on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-type-2","farmaco-economie","gepersonaliseerde-geneeskunde","luchtvervuiling","obesitas","slaapapneu","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106608?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106608?dgcid=rss_sd_all","authors":["Siqi Zhang","Yongfei Wang","Jing Wei","Tarik Benmarhnia","Yang Liu","Harlan M. Krumholz","Yuan Lu","Kai Chen"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This population-based cohort study examined the cardiovascular impact of long-term cumulative exposure to wildfire smoke PM2.5 on hospital admissions, addressing the growing health threat of climate-related air pollution.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1638aac365d","type":"article","url":"https://hartvaat.nl/2025/01/01/stijging-van-serum-transthyretine-na-tafamidis-voorspelt-betere-overleving-bij-a/","title":"Stijging van serum-transthyretine na tafamidis voorspelt betere overleving bij ATTR-cardiomyopathie","title_en":"Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000574?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000574?dgcid=rss_sd_all","authors":["Bilal Ansari","Nelson I. Barrera","Dimitrios Bampatsias","Sergio Teruya","Alfonsina Mirabal-Santos","Stephen Helmke","Karan Wats","Yevgeniy Brailovsky","Mathew S. Maurer"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that an increase in serum transthyretin after starting tafamidis is associated with improved survival in ATTR cardiomyopathy, establishing a potential on-treatment biomarker for monitoring therapeutic response.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fff2e716e0ee","type":"article","url":"https://hartvaat.nl/2025/01/01/langetermijn-cardiovasculaire-en-niet-cardiovasculaire-mortaliteit-na-acuut-coro/","title":"Langetermijn cardiovasculaire en niet-cardiovasculaire mortaliteit na acuut coronair syndroom","title_en":"Long-Term Cardiovascular and Noncardiovascular Mortality After Acute Coronary Syndrome: A Nationwide Competing-Risks Analysis of 1.56 Million Patients","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","biomarkers-cardiovasculair","myocardinfarct","ouderen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105974?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105974?dgcid=rss_sd_all","authors":["Jing Yang","Peng Yin","Mingxuan Li","Yuanchao Gao","Dingcheng Xiang","Maigeng Zhou","Yong Huo"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/ecg-bij-acs/"],"congress":"","summary_en":"This nationwide competing-risks analysis of 1.56 million patients characterized long-term cardiovascular and non-cardiovascular mortality trajectories after acute coronary syndrome, revealing the shifting causes of death over time.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3cae859db2ba","type":"article","url":"https://hartvaat.nl/2025/01/01/menopauzale-status-en-docetaxel-geinduceerde-vasculaire-disfunctie-bij-borstkank/","title":"Menopauzale status en docetaxel-geïnduceerde vasculaire disfunctie bij borstkankerpatiënten","title_en":"Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725101629?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725101629?dgcid=rss_sd_all","authors":["Piotr Szczepaniak","Tomasz P. Mikolajczyk","Ewelina Jozefczuk","Diana Hodorowicz-Zaniewska","Joanna Streb","Jakub Jurczyk","Ryszard Nosalski","Mateusz Siedlinski","Paulina Sajdak","Karolina Brzuszkiewicz"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study investigated the association between menopausal status and docetaxel-induced vascular dysfunction in breast cancer patients, exploring hormonal vulnerability as a modifier of chemotherapy-related cardiovascular toxicity.","created":"2026-07-03T10:25:47Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f3861a19158","type":"article","url":"https://hartvaat.nl/2025/01/01/mitralisklepherstel-bij-degeneratief-mr-met-matige-tricuspidalisinsufficientie-2/","title":"Mitralisklepherstel bij degeneratief MR met matige tricuspidalisinsufficiëntie: 2-jaarsuitkomsten","title_en":"Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory–Adjudicated Cohort","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["mitralisinsufficiëntie","tricuspidalisinsufficiëntie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105986?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105986?dgcid=rss_sd_all","authors":["Michael W.A. Chu","Samantha Raymond","Annetine C. Gelijns","Alan J. Moskowitz","Michael A. Borger","Michael Mack","Judy Hung","Pierre Voisine","James S. Gammie","Markus Krane"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"Two-year outcomes from a multicenter echocardiographic core lab-assessed cohort evaluated mitral valve repair for degenerative mitral regurgitation in the presence of moderate or less tricuspid regurgitation, informing surgical decision-making for concomitant valve disease.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ded5decfd90d","type":"article","url":"https://hartvaat.nl/2025/01/01/niet-lineair-verband-en-optimale-drempelwaarden-voor-mondiale-pm2-5-blootstellin/","title":"Niet-lineair verband en optimale drempelwaarden voor mondiale PM2.5-blootstelling en cardiovasculaire mortaliteit","title_en":"Nonlinear Association Evidence and Optimal Alert Thresholds for Global Short-Term PM<sub>2.5</sub> Exposure and Cardiovascular Mortality Risk","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bloeddrukbehandeling","luchtvervuiling","slaapapneu"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104750?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104750?dgcid=rss_sd_all","authors":["Chenlu Yang","Lijun Bai","Shaowei Wu"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This analysis characterized the nonlinear association between short-term PM2.5 exposure and cardiovascular mortality across global datasets, establishing optimal alert thresholds for public health interventions.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d71a9cbc8041","type":"article","url":"https://hartvaat.nl/2025/01/01/fijnstofpieken-en-cardiovasculaire-sterfte-beleidsprioriteiten-voor-luchtkwalite/","title":"Fijnstofpieken en cardiovasculaire sterfte: beleidsprioriteiten voor luchtkwaliteitswaarschuwingen","title_en":"PM<sub>2.5</sub> Spikes and Cardiovascular Mortality: Policy Priorities for Air Quality Alerts","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","farmaco-economie","inflammatie","luchtvervuiling","menopauze","obesitas","ouderen","roken","secundaire-preventie","slaapapneu","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104105?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104105?dgcid=rss_sd_all","authors":["María Neira"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This commentary discussed the relationship between acute PM2.5 air pollution spikes and cardiovascular mortality, emphasizing the need for improved air quality alert systems to protect vulnerable populations during pollution events.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ab83a8dd33e","type":"article","url":"https://hartvaat.nl/2025/01/01/polygeen-risico-gestuurde-detectie-en-behandeling-van-subklinische-coronaire-ath/","title":"Polygeen risico-gestuurde detectie en behandeling van subklinische coronaire atherosclerose (PROACT)","title_en":"Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105639?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105639?dgcid=rss_sd_all","authors":["Roukoz Abou-Karam","Min Seo Kim","So Mi Jemma Cho","Fouad Bitar","Shoshana Gady","Fangzhou Cheng","Abigail Grace Thompson","Elizabeth W. Karlson","Pradeep Natarajan","Patrick T. Ellinor"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/coronairlijden/nitraten-bij-angina/"],"congress":"","summary_en":"The PROACT clinical trial results demonstrated the use of polygenic risk scores for detecting and treating subclinical coronary atherosclerosis, exploring genetics-guided prevention before clinical events occur.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80275daa36f7","type":"article","url":"https://hartvaat.nl/2025/01/01/cholesterolmanagement-bij-vrouwen-heroverwogen-van-risicoschatting-naar-levensla/","title":"Cholesterolmanagement bij vrouwen heroverwogen: van risicoschatting naar levenslange gezondheid","title_en":"Rethinking Cholesterol Management in Women: From Short-Term Risk Estimation to Lifecourse Cardiovascular Health","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","hdl-cholesterol","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","statines"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000525?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000525?dgcid=rss_sd_all","authors":["Michael C. Honigberg"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This JACC perspective advocated rethinking cholesterol management in women by shifting from short-term risk estimation to a lifecourse approach that accounts for pregnancy-related lipid changes, menopause, and sex-specific risk trajectories.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bd72eac0d03f","type":"article","url":"https://hartvaat.nl/2025/01/01/risico-op-atherosclerotische-hart-en-vaatziekten-bij-familiaire-restanthyperlipi/","title":"Risico op atherosclerotische hart- en vaatziekten bij familiaire restanthyperlipidemie en FH","title_en":"Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia","category":"algemeen","category_label":"Algemeen","professions":["apotheker","huisarts","internist"],"tags":["cardiovasculaire-genetica","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S073510972600135X?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S073510972600135X?dgcid=rss_sd_all","authors":["Takahito Doi","Shoaib Afzal","Børge G. Nordestgaard"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This study compared the risk of atherosclerotic cardiovascular disease in familial remnant hyperlipidemia (dysbetalipoproteinemia) with familial hypercholesterolemia, characterizing the cardiovascular impact of remnant lipoprotein elevation.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8bf2405d3189","type":"article","url":"https://hartvaat.nl/2025/01/01/serum-transthyretine-voor-en-na-tafamidisstart-als-uitkomstvoorspeller-bij-attr-/","title":"Serum-transthyretine vóór en na tafamidisstart als uitkomstvoorspeller bij ATTR-cardiomyopathie","title_en":"Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["cardiale-amyloidose","cardiomyopathie-gerichte-therapie","laminopathie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000690?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000690?dgcid=rss_sd_all","authors":["Vincenzo Castiglione","Alberto Aimo","Maria Franzini","Angela Castiglione","Gianpaolo Palmieri","Olena Chubuchna","Veronica Musetti","Concetta Prontera","Silvia Masotti","Alberto Cipriani"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study examined the prognostic value of serum transthyretin levels before and after tafamidis initiation in patients with ATTR cardiomyopathy, exploring whether transthyretin dynamics can guide treatment monitoring.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"91346f87ffb8","type":"article","url":"https://hartvaat.nl/2025/01/01/sekseverschillen-bij-gedilateerde-cardiomyopathie-kennishiaten-en-toekomstige-ri/","title":"Sekseverschillen bij gedilateerde cardiomyopathie: kennishiaten en toekomstige richtingen","title_en":"Sex Differences in Dilated Cardiomyopathy: Evidence Gaps and Future Directions","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","alcoholgebruik","anemie-ckd","aortainsufficiëntie","aritmogene-cardiomyopathie","atriale-cardiomyopathie","bradycardie","cardiomyopathie-gerichte-therapie","diabetes-en-hart","gedilateerde-cardiomyopathie","harttransplantatie","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","obesitas","ouderen","richtlijnen-esc","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725098110?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725098110?dgcid=rss_sd_all","authors":["Sophie L.V.M. Stroeks","Shanelle Oko-Osi","Arianna Arasu","Jane E. Hirst","Upasana (Paz) Tayal"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This review summarized sex differences in dilated cardiomyopathy, including differences in etiology, clinical presentation, response to therapy, and prognosis, identifying knowledge gaps that require targeted research.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db3edec87391","type":"article","url":"https://hartvaat.nl/2025/01/01/geslacht-doet-ertoe-cardiovasculaire-opleiding-optimaliseren-voor-vrouwenhartgez/","title":"Geslacht doet ertoe: cardiovasculaire opleiding optimaliseren voor vrouwenhartgezondheid","title_en":"Sex Matters: Optimizing Cardiovascular Education and Training to Improve Women’s (and Men’s) Heart Health","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","diabetes-en-hart","farmaco-economie","gepersonaliseerde-geneeskunde","hartrevalidatie","lichaamsbeweging","menopauze","obesitas","ouderen","richtlijnen-esc","secundaire-preventie","slaapapneu","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000513?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000513?dgcid=rss_sd_all","authors":["Celina M. Yong","Erica S. Spatz","Sharonne N. Hayes"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This JACC article discussed the importance of incorporating sex-specific considerations into cardiovascular education and training, arguing that improved gender awareness in medical training translates to better heart health outcomes for both women and men.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97c201eb683a","type":"article","url":"https://hartvaat.nl/2025/01/01/kortdurende-blootstelling-aan-fijnstof-en-cardiovasculaire-sterfte-mondiale-anal/","title":"Kortdurende blootstelling aan fijnstof en cardiovasculaire sterfte: mondiale analyse voor waarschuwingsdrempels","title_en":"Short-Term PM<sub>2.5</sub> Exposure and Cardiovascular Mortality: A Global Exposure-Response Analysis to Inform Alert Thresholds","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","diabetes-en-hart","diabetes-type-2","farmaco-economie","fractional-flow-reserve","gepersonaliseerde-geneeskunde","hartrevalidatie","inflammatie","laminopathie","luchtvervuiling","obesitas","ouderen","secundaire-preventie","slaapapneu","supraventriculaire-tachycardie","ventrikelfibrilleren","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725105895?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725105895?dgcid=rss_sd_all","authors":["Yongkang Yang","Jianyu Deng","Peng Zhou","Pengfei Li","Tianjia Guan","Tao Xue","Tong Zhu"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This global analysis characterized the exposure-response relationship between short-term PM2.5 exposure and cardiovascular mortality across different regions, providing data to inform air quality standards for cardiovascular protection.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e7185dc2f8e","type":"article","url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","title":"Sirolimus-eluerende bioresorbeerbare stents versus everolimus-eluerende stents (IRONMAN II)","title_en":"Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II)","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725104920?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725104920?dgcid=rss_sd_all","authors":["Runlin Gao","Lei Song","Guosheng Fu","Changdong Guan","Yang Li","Shaobin Jia","Yong He","Jiyan Chen","Feng Qi","Mengyue Yu"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This randomized trial compared sirolimus-eluting iron bioresorbable scaffolds with everolimus-eluting permanent stents for PCI, evaluating the next generation of bioresorbable technology after the setbacks with earlier polymer-based scaffolds.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da9bfcf60a3e","type":"article","url":"https://hartvaat.nl/2025/01/01/zesjaarsuitkomsten-van-transkatheter-versus-chirurgische-aortaklepvervanging-bij/","title":"Zesjaarsuitkomsten van transkatheter versus chirurgische aortaklepvervanging bij laagrisicopatiënten","title_en":"Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726054239?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726054239?dgcid=rss_sd_all","authors":["John K. Forrest","Steven J. Yakubov","G. Michael Deeb","Michael J. Reardon","Paul Sorajja","Timothy Byrne","Merick Kirshner","Tanvir Bajwa","John Crouch","Joseph Coselli"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/chirurgische-klepvervanging/"],"congress":"","summary_en":"Six-year outcomes from the comparison of transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis demonstrated sustained comparable results, providing long-term reassurance about TAVR durability in this population.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f347a299aa77","type":"article","url":"https://hartvaat.nl/2025/01/01/vertrouwen-nodig-om-de-risico-behandelparadox-bij-ckd-te-bestrijden/","title":"Vertrouwen nodig om de risico-behandelparadox bij CKD te bestrijden","title_en":"Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte","fidelio-dkd","figaro-dkd","flow-trial","ijzertekort"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103392?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103392?dgcid=rss_sd_all","authors":["Daniel Edmonston"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This JACC commentary discussed the risk-treatment paradox in chronic kidney disease, where patients at highest cardiovascular risk are least likely to receive evidence-based therapies including SGLT2 inhibitors and statins.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"befa4d2fb037","type":"article","url":"https://hartvaat.nl/2025/01/01/de-toekomst-van-zorg-voor-volwassenen-met-aangeboren-hartafwijkingen-in-de-vs/","title":"De toekomst van zorg voor volwassenen met aangeboren hartafwijkingen in de VS","title_en":"The Future of Adult Congenital Heart Care in the United States: Are We Keeping Up With the Pace of Progress?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106566?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106566?dgcid=rss_sd_all","authors":["Curt J. Daniels","Ariane Marelli","Jeannette P. Lin"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This perspective assessed whether US healthcare infrastructure is keeping pace with advances in adult congenital heart disease care, identifying gaps in specialist workforce, transition services, and long-term follow-up capacity.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"faa1a6600839","type":"article","url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","title":"Timing van cardiovasculaire en renale voordelen van finerenon bij hartfalen en CKD met diabetes","title_en":"Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","biomarkers-cardiovasculair","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","diabetes-en-hart","diabetes-type-1","diabetes-type-2","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","flow-trial","ijzertekort","myocardinfarct","ouderen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725100715?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725100715?dgcid=rss_sd_all","authors":["John W. Ostrominski","Brendon L. Neuen","Brian L. Claggett","Gerasimos Filippatos","Akshay S. Desai","Pardeep S. Jhund","Alasdair Henderson","Carolyn S.P. Lam","Michele Senni","Sanjiv J. Shah"],"significance":8,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This JACC analysis examined the time course of cardiovascular and kidney benefits with finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes, characterizing how quickly the cardiorenal protection emerges after treatment initiation.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc0aa8cf2da7","type":"article","url":"https://hartvaat.nl/2025/01/01/de-cardiovasculaire-professie-in-het-tijdperk-van-ai/","title":"De cardiovasculaire professie in het tijdperk van AI","title_en":"Tip of the Spear: The Cardiovascular Profession in the Age of AI","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","obesitas","ouderen","richtlijnen-esc"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726002925?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726002925?dgcid=rss_sd_all","authors":["Haider Warraich"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This JACC commentary discussed how artificial intelligence is transforming the cardiovascular profession, addressing the practical impact on clinical workflows, training requirements, and professional identity.","created":"2026-07-03T10:25:45Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a223016ba731","type":"article","url":"https://hartvaat.nl/2025/01/01/vasculaire-disfunctie-in-de-cardio-oncologie-hormoonstatus-chemotherapie-en-risi/","title":"Vasculaire disfunctie in de cardio-oncologie: hormoonstatus, chemotherapie en risico","title_en":"Vascular Dysfunction in Cardio-Oncology: Hormone Status, Chemotherapy, and Risk","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["kanker-en-hart"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103562?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103562?dgcid=rss_sd_all","authors":["Julia Bertazzo","Caitlin F. Bell"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This JACC review examined vascular dysfunction in cardio-oncology, focusing on how hormonal status and chemotherapy agents contribute to cardiovascular risk in cancer patients and survivors.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba41698c0bcc","type":"article","url":"https://hartvaat.nl/2025/01/01/wat-is-veranderd-sinds-de-eerste-richtlijn-voor-volwassenen-met-aangeboren-harta/","title":"Wat is veranderd sinds de eerste richtlijn voor volwassenen met aangeboren hartafwijkingen?","title_en":"What Has Changed Since the First ACC/AHA Guidelines for the Management of Adult Congenital Heart Disease in 2008?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725106554?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725106554?dgcid=rss_sd_all","authors":["Carole A. Warnes","Anne Marie Valente"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This review outlined the key changes in ACC/AHA guidelines for adults with congenital heart disease since the first edition, highlighting evolving recommendations in surgical timing, catheter interventions, and pregnancy management.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dcd400c26714","type":"article","url":"https://hartvaat.nl/2025/01/01/wanneer-zorg-autonoom-wordt-ai-en-de-toekomst-van-de-cardiovasculaire-geneeskund/","title":"Wanneer zorg autonoom wordt: AI en de toekomst van de cardiovasculaire geneeskunde","title_en":"When Care Becomes Autonomous: AI and the Future of Cardiovascular Medicine","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726003001?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726003001?dgcid=rss_sd_all","authors":["Harlan M. Krumholz"],"significance":6,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/reanimatie-besluitvorming/"],"congress":"","summary_en":"This JACC perspective explored the emergence of autonomous AI systems in cardiovascular medicine and their implications for clinical decision-making, patient safety, and the future role of cardiovascular physicians.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"642b23d5bca4","type":"article","url":"https://hartvaat.nl/2025/01/01/cardiovasculaire-gezondheid-van-vrouwen-van-inclusie-naar-onderzoeksontwerp/","title":"Cardiovasculaire gezondheid van vrouwen: van inclusie naar onderzoeksontwerp","title_en":"Women’s Cardiovascular Health: From Inclusion to Design","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","diabetes-en-hart","farmaco-economie","hartrevalidatie","obesitas","ouderen","richtlijnen-esc","slaapapneu","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000537?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000537?dgcid=rss_sd_all","authors":["Harlan M. Krumholz"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This JACC article discussed the need to move beyond merely including women in cardiovascular trials to designing studies that specifically address sex-specific mechanisms, outcomes, and therapeutic responses in women's cardiovascular health.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84f89f134db6","type":"article","url":"https://hartvaat.nl/2026/03/01/bruine-tumor-van-de-patella-bij-een-langdurig-hemodialysepatient/","title":"Bruine tumor van de patella bij een langdurig hemodialysepatiënt","title_en":"Brown tumor of the patella in a long-term hemodialysis patient","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00852-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00852-X/fulltext","authors":["Alon Bnaya","Daniela Gomez","Omar Abu Libdeh","Nour Elayan","Thaer Barakat","Linda Shavit"],"significance":2,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"A case of brown tumour of the patella in a 38-year-old woman on long-term haemodialysis since age 12, illustrating a rare complication of secondary hyperparathyroidism in chronic dialysis patients.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f8c247824983","type":"article","url":"https://hartvaat.nl/2026/03/01/causale-claims-vereisen-gedefinieerde-interventies-kanttekening-bij-ckd-mbd-anal/","title":"Causale claims vereisen gedefinieerde interventies: kanttekening bij CKD-MBD-analyse","title_en":"Causal claims require defined interventions: a note on the EQUAL chronic kidney disease–mineral and bone disorder analysis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","cardio-renaal-metabool","chronische-nierziekte","fidelio-dkd","fidelity","figaro-dkd","flow-trial","ijzertekort","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01021-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01021-X/fulltext","authors":["Pierre Letourneau"],"significance":3,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This commentary discusses the methodological requirements for causal claims in the EQUAL CKD-mineral and bone disorder analysis, emphasising the need for clearly defined interventions in causal inference frameworks.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f38eccde3cdc","type":"article","url":"https://hartvaat.nl/2026/03/01/uitdagingen-bij-het-bepalen-van-de-werkelijke-incidentie-van-eindstadium-nierzie/","title":"Uitdagingen bij het bepalen van de werkelijke incidentie van eindstadium nierziekte bij ouderen","title_en":"Challenges in revealing the true incidence of end-stage kidney disease in the elderly population","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01003-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01003-8/fulltext","authors":["Boris Bikbov"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/ckd-stadia-g1-g5/"],"congress":"","summary_en":"This commentary raises two methodological considerations that could substantially impact estimates of the true incidence of end-stage kidney disease in elderly patients with eGFR below 15 mL/min.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed6529b744fb","type":"article","url":"https://hartvaat.nl/2026/03/01/adpkd-samen-met-primaire-hyperoxalurie-type-3/","title":"ADPKD samen met primaire hyperoxalurie type 3","title_en":"Coexistence of autosomal dominant polycystic kidney disease and primary hyperoxaluria type 3","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00738-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00738-0/fulltext","authors":["Alexandra Corceovei","Arnaud Devresse","Sandy Van Nieuwenhove","Linda Cherchali","Nathalie Demoulin","Karin Dahan","Valentine Gillion"],"significance":3,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A case of the rare coexistence of autosomal dominant polycystic kidney disease and primary hyperoxaluria type 3 in a 29-year-old woman with recurrent nephrolithiasis, identified through genetic testing.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03d1eb50cdf6","type":"article","url":"https://hartvaat.nl/2026/03/01/histoplasma-capsulatum-een-zeldzame-oorzaak-van-interstitiele-nefritis/","title":"Histoplasma capsulatum: een zeldzame oorzaak van interstitiële nefritis","title_en":"Histoplasma capsulatum: a rare cause of interstitial nephritis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00674-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00674-X/fulltext","authors":["Osvaldo Mariano Viana Neto","Elizabeth De Francesco Daher","Mariana Salomão Braga","Lauro Vieira Perdigão Neto","Luis Arthur Brasil Gadelha Farias","Geraldo Bezerra da Silva Júnior","Juliana Reis Machado","Marlene Antônia dos Reis"],"significance":3,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"A case report of Histoplasma capsulatum as a rare cause of interstitial nephritis in a 46-year-old Brazilian man, presenting with rising creatinine in the context of known interstitial lung disease.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2fbbcd8b01f8","type":"article","url":"https://hartvaat.nl/2026/03/01/tijd-voor-een-vijfde-pijler-bij-lichamelijk-onderzoek-van-kinderen-aan-dialyse/","title":"Tijd voor een vijfde pijler bij lichamelijk onderzoek van kinderen aan dialyse?","title_en":"Is it time to add a fifth pillar to the physical examination in pediatric dialysis?","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00991-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00991-3/fulltext","authors":["Mohamed Nassiri","Fernando Parra-Londoño","Víctor López-Baez","Pedro Arango-Sancho","Yolanda Calzada-Baños","Cristina Aguilar","Álvaro Madrid-Aris","Claudio Ronco","Gregorio Romero-González"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This commentary discusses whether it is time to add a fifth pillar to the physical examination in paediatric dialysis, emphasising the high cardiovascular burden and the need for early, personalised preventive strategies targeting fluid overload and hypertension.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04dc51e51dcd","type":"article","url":"https://hartvaat.nl/2026/03/01/niergezonheid-voor-iedereen-zorg-voor-mensen-bescherming-van-de-planeet/","title":"Niergezonheid voor iedereen: zorg voor mensen, bescherming van de planeet","title_en":"Kidney health for all: caring for people, protecting the planet","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01030-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01030-0/fulltext","authors":["Raymond Vanholder","Dina Abdellatif","Augusto Cesar Soares Dos Santos","Ricardo Correa-Rotter","Natarajan Gopalakrishnan","Bill Wang","Stefanos Roumeliotis","Alessandro Balducci","Ágnes Haris","Manjusha Yadla","Li-Li Hsiao"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This World Kidney Day editorial calls for reshaping kidney care from the current unsustainable model focused on late-stage disease toward early detection, prevention, and environmentally conscious treatment approaches.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e77e78abf99","type":"article","url":"https://hartvaat.nl/2026/03/01/monoklonaal-versus-monotypisch-bewustwording-van-terminologie-bij-mgrs/","title":"Monoklonaal versus monotypisch: bewustwording van terminologie bij MGRS","title_en":"Monoclonal versus monotypic: promoting awareness of terminology and clinical take-aways","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01000-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01000-2/fulltext","authors":["Sijie Zheng","David J. Iberri","Susan Ziolkowski"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This commentary highlights the importance of distinguishing monoclonal from monotypic immunoglobulin deposits in proliferative glomerulonephritis, with implications for the classification and management of monoclonal gammopathy of renal significance.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ea6132f5135","type":"article","url":"https://hartvaat.nl/2026/03/01/optimalisatie-van-caart-voor-wisselende-antilichaamlandschappen/","title":"Optimalisatie van CAART voor wisselende antilichaamlandschappen","title_en":"Optimizing CAART for evolving antibody landscapes","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["pelacarsen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01002-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01002-6/fulltext","authors":["Man Sun","Dan Zang","Jun Chen"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This commentary discusses the preclinical validation of chimeric autoantibody receptor T cells targeting the PLA2 receptor in membranous nephropathy, with considerations for adapting this precision immunotherapy approach to evolving antibody profiles.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"608a8ff91e16","type":"article","url":"https://hartvaat.nl/2026/03/01/pathologische-diagnostiek-met-moleculaire-monitoring-bij-nierxenotransplantatie/","title":"Pathologische diagnostiek met moleculaire monitoring bij nierxenotransplantatie","title_en":"Pathologic diagnosis incorporating molecular monitoring highlights new pathophysiological mechanisms in kidney xenotransplantation","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01040-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01040-3/fulltext","authors":["Hisashi Sahara","Akira Shimizu"],"significance":6,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/cardiorenal-syndroom/"],"congress":"","summary_en":"This study used pathologic diagnosis incorporating molecular monitoring to highlight new pathophysiological mechanisms in kidney xenotransplantation, advancing the understanding of long-term graft changes in this emerging field.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b9cbcc03d17","type":"article","url":"https://hartvaat.nl/2026/03/01/rna-methylering-bij-acuut-nierletsel-nieuwe-therapeutische-mogelijkheden/","title":"RNA-methylering bij acuut nierletsel: nieuwe therapeutische mogelijkheden","title_en":"RNA methylation in acute kidney injury: opening up new therapeutic avenues","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01029-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01029-4/fulltext","authors":["Volker H. Haase"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This commentary discusses how epithelial methyltransferase-like 1 promotes mitochondrial dysfunction and tubular injury in acute kidney injury through RNA guanosine methylation, identifying a new epigenetic regulatory axis as a potential therapeutic target.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40672040194a","type":"article","url":"https://hartvaat.nl/2026/03/01/tsc2-pkd1-contigue-gendeletiesyndroom/","title":"TSC2/PKD1 contigue gendeletiesyndroom","title_en":"TSC2/PKD1 contiguous gene deletion syndrome","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00739-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00739-2/fulltext","authors":["Jean Bertrand","Ysaline Zizi","Dana Dumitriu","Valentine Gillion","Yves Sznajer","Eric Olinger","Nathalie Demoulin"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"A case of the rare TSC2/PKD1 contiguous gene deletion syndrome presenting with hypertension and polycystic kidneys in a 16-year-old, combining features of tuberous sclerosis complex and autosomal dominant polycystic kidney disease.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0af91094fab6","type":"article","url":"https://hartvaat.nl/2026/03/01/slappe-verlamming-en-tetanie-na-chemotherapie-een-diagnostische-uitdaging/","title":"Slappe verlamming en tetanie na chemotherapie: een diagnostische uitdaging","title_en":"The Case | Flaccid paralysis and tetany after chemotherapy: a diagnostic challenge","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00742-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00742-2/fulltext","authors":["Carolin Herzog","Peter R. Mertens","Florian G. Scurt"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"A diagnostic challenge case of a 75-year-old woman with cervical carcinoma who developed flaccid paralysis and tetany after chemotherapy, illustrating complex electrolyte disturbances requiring systematic evaluation.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd8c2a2e966f","type":"article","url":"https://hartvaat.nl/2026/03/01/onverklaarde-transplantaatdisfunctie-bij-een-zeldzame-metabole-stoornis/","title":"Onverklaarde transplantaatdisfunctie bij een zeldzame metabole stoornis","title_en":"The Case | Unexplained post-transplant graft dysfunction in a rare metabolic disorder","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["harttransplantatie","niertransplantatie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00669-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00669-6/fulltext","authors":["George Terinte-Balcan","Juliette Leon","Michael Padden","Aude Servais","Marion Rabant","Dany Anglicheau","Jean Paul Duong Van Huyen","Pierre Isnard"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/"],"congress":"","summary_en":"A case report of unexplained post-transplant graft dysfunction in a patient with lysinuric protein intolerance, a rare multisystem disorder caused by defective cationic amino acid transport.","created":"2026-07-03T10:25:15Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a58db4b545dd","type":"article","url":"https://hartvaat.nl/2026/03/01/auteurs-reageren-pravastatine-bij-autosomaal-dominante-polycysteuze-nierziekte/","title":"Auteurs reageren: pravastatine bij autosomaal dominante polycysteuze nierziekte","title_en":"The authors reply","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["anemie-ckd"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01011-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01011-7/fulltext","authors":["Berenice Y. Gitomer","Anna Ostrow","Michel Chonchol"],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"The authors respond to comments on their randomised study of pravastatin for kidney disease outcomes in adults with early-stage autosomal dominant polycystic kidney disease, addressing methodological considerations and clinical implications.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dccdebd55afb","type":"article","url":"https://hartvaat.nl/2026/03/01/in-dit-nummer-xeno-transplantatie-en-moleculaire-respons-bij-orgaantransplantati/","title":"In dit nummer: xeno-transplantatie en moleculaire respons bij orgaantransplantatie","title_en":"in this issue","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["harttransplantatie","niertransplantatie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01041-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01041-5/fulltext","authors":[],"significance":5,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This editorial overview highlights key articles in the issue, including transcript analysis of porcine xenografts in non-human primates revealing progressive replacement of pig endothelial transcripts with host-derived endothelial markers over two years of xenograft survival.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8f4209f3d6a3","type":"article","url":"https://hartvaat.nl/2026/03/01/journal-club-ivaleptische-nefropathie-bij-complement-gemedieerde-trombotische-mi/","title":"Journal Club: ivaleptische nefropathie bij complement-gemedieerde trombotische microangiopathie","title_en":"journal club","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["complementremmers","iga-nefropathie","immunoadsorptie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01043-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01043-9/fulltext","authors":[],"significance":6,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This Journal Club discussed the clinical implications of the VALIANT trial results from the New England Journal of Medicine, addressing contemporary treatment approaches in nephrology.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0000d7c644d","type":"article","url":"https://hartvaat.nl/2026/12/31/annexine-a1-verergert-activatie-van-eilandjessterrecellen-via-triglyceridenafbra/","title":"Annexine A1 verergert activatie van eilandjessterrecellen via triglyceridenafbraak","title_en":"Annexin A1 exacerbates islet stellate cell activation by regulating triglyceride catabolism via the PPARα/ACOX1/CYP4a pathway.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["ezetimibe","lipide-aferese"],"journal":"Islets","doi":"10.1080/19382014.2026.2633793","source_url":"https://doi.org/10.1080/19382014.2026.2633793","authors":["Qing Li","Yan Zhang","Tianpei Yu","Li Shi","Qinqin Qiu","Ben Wang","Yiquan Sang","Rui Li","Qian Lv","Jie Wang","Xuekui Liu","Houfa Geng","Peter M Jones","Jun Liang","Wei Xu"],"significance":2,"published":"2026-03-01","source_date":"2026-12-31","image":"","kennis":[],"congress":"","summary_en":"This study demonstrates that annexin A1 exacerbates islet stellate cell activation by regulating triglyceride catabolism via the PPARalpha/ACOX1/CYP4a pathway, contributing to islet fibrosis and diabetes progression.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a82a321dbca5","type":"article","url":"https://hartvaat.nl/2026/12/31/mechanismen-van-hypertensie-tot-hart-en-hersenvaatziekten-een-uitgebreid-overzic/","title":"Mechanismen van hypertensie tot hart- en hersenvaatziekten: een uitgebreid overzicht","title_en":"Mechanisms linking hypertension to cardiovascular and cerebrovascular diseases and their clinical implications: A comprehensive review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","aprocitentan","bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","diabetes-en-hart","endotheel","endothelineantagonisten","obesitas","ras-remmers","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","vrouwen","zwangerschap-hart"],"journal":"Clinical and experimental hypertension (New York, N.Y. : 1993)","doi":"10.1080/10641963.2026.2631606","source_url":"https://doi.org/10.1080/10641963.2026.2631606","authors":["Guangya Li","Jing Jing Zhang","Xiaojie Mou","Xin Zhuo","Weikai Li","Shenghao Zhang","Shuang Qi","Xiubin Li"],"significance":4,"published":"2026-03-01","source_date":"2026-12-31","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This comprehensive review summarises how hypertension interacts with obesity, metabolic syndrome, sleep apnoea, and pregnancy to drive coronary heart disease and stroke, discussing blood pressure targets and pharmacotherapy across diverse populations.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f745ea9314b0","type":"article","url":"https://hartvaat.nl/2026/03/01/bij-niervervanging-bescherm-het-hart/","title":"Bij niervervanging: bescherm het hart","title_en":"When replacing the kidney, protect the heart","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","cardiorenal-behandelstrategie","dialyse","harttransplantatie","nierfalen","niertransplantatie","nt-probnp","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01005-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01005-1/fulltext","authors":["Gregorio Romero-González","Jordi Soler-Majoral","Marina Urrutia-Jou","Rafael de la Espriella","Nestor Rodriguez-Chitiva","Maribel Troya","Maria Fernanda Slon-Roblero","J. Emilio Sánchez Álvarez"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This Kidney International editorial emphasized that heart protection must be considered when choosing kidney replacement therapy, highlighting the cardiovascular implications of dialysis modality selection.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc95bbe86731","type":"article","url":"https://hartvaat.nl/2026/03/01/gepersonaliseerde-gfr-percentielen-een-nieuw-instrument-voor-ckd-detectie/","title":"Gepersonaliseerde GFR-percentielen: een nieuw instrument voor CKD-detectie","title_en":"Percentiles of estimating glomerular filtration rate: a new personalized tool for detection of chronic kidney disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte","cystatine-c"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01014-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01014-2/fulltext","authors":["Pierre Delanaye","Christophe Mariat"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This editorial discussed age- and sex-specific eGFR percentiles as a new personalized approach to CKD detection, addressing limitations of the fixed 60 mL/min threshold that may miss early kidney disease in younger patients.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"358f2e8ac568","type":"article","url":"https://hartvaat.nl/2026/03/01/pravastatine-bij-volwassenen-met-adpkd-potentiele-subgroepvoordelen/","title":"Pravastatine bij volwassenen met ADPKD: potentiële subgroepvoordelen","title_en":"Reassessing pravastatin in adult autosomal dominant polycystic kidney disease and potential subgroup benefits","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01009-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01009-9/fulltext","authors":["Youyi Lu","Zhitao Teng","Zimin Meng"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This commentary reassessed the evidence for pravastatin in autosomal dominant polycystic kidney disease, discussing potential subgroup benefits and the need for further study of statin effects on cyst growth and kidney function.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"53a45a8d30bf","type":"article","url":"https://hartvaat.nl/2026/03/01/complementremmers-winnen-terrein-bij-de-behandeling-van-iga-nefropathie/","title":"Complementremmers winnen terrein bij de behandeling van IgA-nefropathie","title_en":"The expanding role of complement inhibitors in the treatment of IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["cardiorenal-behandelstrategie","complementremmers","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01025-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01025-7/fulltext","authors":["Fernando Caravaca-Fontán","Manuel Praga"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This editorial discussed complement inhibition as an emerging therapeutic approach for IgA nephropathy, reviewing promising phase 2 results of targeted complement therapies for this common glomerular disease.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"856c2029df40","type":"article","url":"https://hartvaat.nl/2026/12/01/cardiometabole-index-en-sarcopenie-voorspellen-sterfte-bij-chronische-nierziekte/","title":"Cardiometabole index en sarcopenie voorspellen sterfte bij chronische nierziekte","title_en":"Cardiometabolic index (CMI) and sarcopenia as predictors of all-cause and cardiovascular mortality in chronic kidney disease: a NHANES-based cohort study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","biomarkers-cardiovasculair","chronische-nierziekte","diabetes-en-hart","obesitas"],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2624299","source_url":"https://doi.org/10.1080/0886022X.2026.2624299","authors":["Zixuan Zhang","Yue Xing","Fan Zhang","Xianwen Zhang","Yifei Zhong"],"significance":3,"published":"2026-03-01","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"A NHANES-based cohort study demonstrated that the cardiometabolic index and sarcopenia independently predict all-cause and cardiovascular mortality in CKD patients, with the highest risk when both conditions coexist.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T13:24:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c9b09a28a89","type":"article","url":"https://hartvaat.nl/2026/12/31/tijdgebonden-eten-verlaagt-bloeddruk-bij-kinderen-een-clustergerandomiseerde-tri/","title":"Tijdgebonden eten verlaagt bloeddruk bij kinderen: een clustergerandomiseerde trial","title_en":"Effects of time-restricted eating on blood pressure in children: A cluster randomized controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["primaire-preventie","vrouwen"],"journal":"Clinical and experimental hypertension (New York, N.Y. : 1993)","doi":"10.1080/10641963.2026.2635384","source_url":"https://doi.org/10.1080/10641963.2026.2635384","authors":["Xiaofei Wu","Jingkun Miao","Zhilian Peng","Xizhou An","Qin Liu","Lanling Chen","Xiaohua Liang"],"significance":4,"published":"2026-03-01","source_date":"2026-12-31","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"A 12-month cluster-randomised trial evaluated the safety and efficacy of a 12-hour time-restricted eating window for reducing blood pressure in children and adolescents, providing evidence for non-pharmacological interventions in paediatric hypertension.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T13:24:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a45b08894c21","type":"article","url":"https://hartvaat.nl/2026/06/01/hypertensie-wijzigt-de-relatie-tussen-lp-a-en-mortaliteit-bij-acuut-gedecompense/","title":"Hypertensie wijzigt de relatie tussen Lp(a) en mortaliteit bij acuut gedecompenseerd hartfalen","title_en":"Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","bloeddrukbehandeling","dyslipidemie","ezetimibe","hypertrofische-cardiomyopathie","ijzertekort","laminopathie","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","myocardinfarct","nt-probnp","pelacarsen","sacubitril-valsartan","vrouwen"],"journal":"International journal of cardiology. Cardiovascular risk and prevention","doi":"10.1016/j.ijcrp.2026.200594","source_url":"https://doi.org/10.1016/j.ijcrp.2026.200594","authors":["Ashen L Vidanage","Tianyu Xu","Zihao Chen","Zhongping Yu","Chang Chen","Shilan Chen","Wengen Zhu","Jiangui He","Yugang Dong","Chen Liu","Jingjing Zhao","Fang-Fei Wei"],"significance":4,"published":"2026-03-01","source_date":"2026-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This study demonstrates that hypertension modifies the prognostic value of lipoprotein(a) in patients with acute decompensated heart failure, with the Lp(a)-mortality association differing by blood pressure status.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"52681e6b9939","type":"article","url":"https://hartvaat.nl/2026/06/01/pcsk9-remmers-bij-perifeer-vaatlijden-meta-analyse-toont-vaatfunctie-en-lipidevo/","title":"PCSK9-remmers bij perifeer vaatlijden: meta-analyse toont vaatfunctie- en lipidevoordelen","title_en":"Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","enlicitide","ezetimibe","figaro-dkd","inclisiran","lipidenverlaging","lipoproteïne-a","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","perifeer-vaatlijden","statines"],"journal":"International journal of cardiology. Cardiovascular risk and prevention","doi":"10.1016/j.ijcrp.2026.200590","source_url":"https://doi.org/10.1016/j.ijcrp.2026.200590","authors":["Khadeeja Ali Hamzah","Yousif Hameed Kurmasha","Mohamed Fouad Abdrabo","Mohamed F Srour","Ali Saad Al-Shammari","Mohammed Hamed Ibrahium Badi","Mohammedsadeq A Shweliya","Nihar Jena","Yasar Sattar"],"significance":4,"published":"2026-03-01","source_date":"2026-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated the effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes specifically in patients with peripheral artery disease who fail to reach targets on statin therapy alone.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1db7cac7255f","type":"article","url":"https://hartvaat.nl/2026/12/01/ezetimibe-als-monotherapie-voor-primaire-preventie-bij-75-plussers/","title":"Ezetimibe als monotherapie voor primaire preventie bij 75-plussers","title_en":"Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","ouderen","primaire-preventie","statines","vrouwen"],"journal":"Annals of medicine","doi":"10.1080/07853890.2026.2634484","source_url":"https://doi.org/10.1080/07853890.2026.2634484","authors":["Alpo Vuorio","Petri T Kovanen","Timo Strandberg"],"significance":5,"published":"2026-03-01","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The EWTOPIA 75 study demonstrated that ezetimibe monotherapy reduces atherosclerotic cardiovascular disease events in adults aged 75 and older without prior coronary artery disease. The evidence, now incorporated into the 2025 ESC/EAS guidelines, supports cholesterol absorption inhibition as an effective primary prevention strategy in the elderly.","created":"2026-07-03T10:24:06Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b9866fe6f53","type":"article","url":"https://hartvaat.nl/2026/03/01/lager-ldl-c-verlaagt-risico-op-recidief-cardiovasculaire-events-bij-cva-patiente/","title":"Lager LDL-C verlaagt risico op recidief cardiovasculaire events bij CVA-patiënten","title_en":"Lower LDL-C, lower risk of recurrent cardiovascular events in stroke survivors.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["ezetimibe","hdl-cholesterol","lipide-aferese","ouderen","roken","secundaire-preventie","slaapapneu"],"journal":"The American journal of nursing","doi":"10.1097/AJN.0000000000000261d","source_url":"https://doi.org/10.1097/AJN.0000000000000261d","authors":["Karen Rosenberg"],"significance":3,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This brief report confirms that stroke survivors benefit from more aggressive LDL-cholesterol lowering, with lower LDL-C levels associated with fewer recurrent cardiovascular events.","created":"2026-07-03T10:24:06Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c8fcf99bf3e","type":"article","url":"https://hartvaat.nl/2026/03/01/lichaamsbeweging-beinvloedt-de-relatie-tussen-crp-triglyceriden-en-coronaire-ath/","title":"Lichaamsbeweging beïnvloedt de relatie tussen CRP, triglyceriden en coronaire atherosclerose","title_en":"Physical Activity Modifies the Association between C-Reactive Protein - Triglyceride - Glucose Index (CTI) and Dyslipidemia: Evidence from a 10-Year Chinese Cohort.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["acuut-coronair-syndroom","diabetes-en-hart","dyslipidemie","ezetimibe","hs-crp","inflammatie","ldl-cholesterol","lipidenverlaging"],"journal":"Journal of sports science & medicine","doi":"10.52082/jssm.2026.112","source_url":"https://doi.org/10.52082/jssm.2026.112","authors":["Yang Wang","Zixuan Luo","Zihan Zhou","Xiaoquan Zhang"],"significance":4,"published":"2026-03-01","source_date":"2026-03-01","image":"https://hartvaat.nl/global/img/de5cad639e89.webp","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A 10-year Chinese cohort study demonstrated that regular physical activity significantly modifies the association between the CRP-triglyceride-glucose index and dyslipidaemia, emphasising the importance of an active lifestyle alongside lipid-lowering medication.","created":"2026-07-03T10:24:06Z","updated":"2026-07-03T20:09:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7e46824bf107","type":"article","url":"https://hartvaat.nl/2026/02/27/verhoogd-lp-a-en-diabetes-verergeren-samen-de-prognose-bij-coronairlijden/","title":"Verhoogd Lp(a) en diabetes verergeren samen de prognose bij coronairlijden","title_en":"Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","plaquekarakterisatie","soul-trial"],"journal":"Diabetes, obesity & metabolism","doi":"10.1111/dom.70603","source_url":"https://doi.org/10.1111/dom.70603","authors":["Xiaozhao Lu","Ziyao Yuan","Xiaoyu Lin","Zuxian Huang","Ziwei Zhou","Haozhang Huang","Yingying Li","Shaozhao Zhang","Ziwen Hui","Yihang Ling","Wei Guo","Shiqun Chen","Jiyan Chen","Jin Liu","Xiaodong Zhuang","Yong Liu"],"significance":5,"published":"2026-02-27","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Analysis of over 65,000 patients with coronary artery disease demonstrated that the combination of elevated lipoprotein(a) and diabetes mellitus is associated with significantly worse survival than either risk factor alone. The findings support combined Lp(a) and metabolic risk assessment in daily clinical practice.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73c67bf1b24d","type":"article","url":"https://hartvaat.nl/2026/02/26/ai-clustering-onthult-drie-functionele-risicoprofielen-bij-hartfalen/","title":"AI-clustering onthult drie functionele risicoprofielen bij hartfalen","title_en":"Artificial intelligence-based clustering to identify functional risk phenotypes in heart failure","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003530?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003530?rss=1","authors":["Qiu","X.","Ma","J.","Xu","L.","Jiang","M.","Pu","J."],"significance":5,"published":"2026-02-26","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Patients with heart failure (HF) often have undetected declines in cardiorespiratory fitness (CRF), increasing the risk of poor outcomes, but tools for early CRF risk stratification are lacking. In this study, unsupervised AI clustering on 15 multimodal variables (metabolic, inflammatory and body-composition measures) in 505 HF patients sought phenotypes, with external validation in 201 patients. Three phenotypes emerged: 'balanced', 'inflammatory-sarcopenic' and 'metabolically dysregulated'. Both non-balanced phenotypes had clearly higher odds of impaired CRF (peak oxygen uptake ≤20 mL/kg/min). The best predictive models reached an AUC of about 0.75. Combining multimodal data with AI clustering thus yields an interpretable model for early functional risk stratification — a basis for more targeted rehabilitation in heart failure.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64f43672e89d","type":"article","url":"https://hartvaat.nl/2026/02/26/cascadescreening-bij-hypertrofische-cardiomyopathie-genotype-positieve-familiele/","title":"Cascadescreening bij hypertrofische cardiomyopathie: genotype-positieve familieleden houden een verhoogd risico","title_en":"Characterising the phenotype and outcomes of cascade-tested relatives of probands with hypertrophic cardiomyopathy","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiovasculaire-genetica","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","iaso-dcm","laminopathie","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003557?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003557?rss=1","authors":["Chaudhry","W. R.","McWilliam","C.","Berg","J.","Choy","A.-M."],"significance":5,"published":"2026-02-26","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"In hypertrophic cardiomyopathy (HCM) due to a pathogenic sarcomere variant, cascade screening of relatives is recommended, but outcomes in such relatives are little studied. In this retrospective cohort (64 families, 280 patients, NHS Tayside, 2010-2018), the occurrence of a major adverse cardiac event (MACE) was examined. Asymmetrical septal hypertrophy meeting diagnostic criteria occurred in 35.4% of cascade-tested individuals. The adjusted septal thickness of genotype-positive relatives (13.9 mm) lay between that of probands (22.1 mm) and genotype-negative relatives (12.3 mm). Cardiac event risk was also intermediate: lower than probands but higher than genotype-negative relatives. Genotype-positive cascade-tested relatives thus retain a degree of complication risk, justifying their identification and follow-up.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0237351507d7","type":"article","url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","title":"Hiv-infectie hangt onafhankelijk samen met meer en kwetsbaardere halsslagaderplaques","title_en":"HIV infection is independently associated with carotid plaque burden and echogenic characteristics","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003853?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003853?rss=1","authors":["Li","X.","Liu","L.","Chen","J.","Cao","J.","Wang","Z.","Qi","T.","Sun","J.","Yang","J.","Xu","S.","Song","W.","Shao","Y.","Chen","Y.","Tang","Y.","Wang","J.","Wang","L.","Huang","J.","Wang","K.","Sun","M.","Jin","Y.","Zeng","Z.","Zhao","Z.","Zhang","R.","Ding","Y.","Shen","Y."],"significance":5,"published":"2026-02-26","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"People with HIV are at increased cardiovascular risk, but data from Asian populations are limited. In this cross-sectional study (Shanghai; 1,390 people with HIV and 1,390 age- and sex-matched people without HIV, aged ≥40), carotid ultrasonography assessed plaque presence and characteristics. Plaques were more common in people with HIV (45.3% vs 37.5%), as were echo-lucent (vulnerable) plaques (21.1% vs 18.0%); they also more often had three or more plaques and greater maximum plaque thickness. After adjustment for age, sex and dyslipidaemia, HIV remained independently associated with plaques (aOR 1.45) and echo-lucent plaques (aOR 1.24), strongest in men and younger participants. HIV infection is thus associated with accelerated atherosclerosis beyond traditional risk factors — supporting routine cardiovascular risk assessment and early prevention in people with HIV.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"34c03a844fff","type":"article","url":"https://hartvaat.nl/2026/02/26/niergezondheid-en-bloeddruk-op-schoolleeftijd-na-zeer-vroeggeboorte/","title":"Niergezondheid en bloeddruk op schoolleeftijd na zeer vroeggeboorte","title_en":"Kidney health and blood pressure after very preterm birth: a cohort study at school age.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Pediatric nephrology (Berlin, Germany)","doi":"10.1007/s00467-026-07190-0","source_url":"https://doi.org/10.1007/s00467-026-07190-0","authors":["Juliette Delbreil","Valérie Leroy","Simon Lorrain","Marine Trigolet","Francesco Bonsante","Silvia Iacobelli"],"significance":3,"published":"2026-02-26","source_date":"2026-02-26","image":"https://hartvaat.nl/global/img/e4281fe6c659.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"A cohort study of school-age children born very preterm (under 32 weeks) identified subtle kidney function and blood pressure abnormalities that may precede clinically apparent kidney disease in later life, with perinatal and nutritional factors contributing.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ebab1bdd161","type":"article","url":"https://hartvaat.nl/2026/02/26/weer-een-stap-vooruit-in-de-verlaging-van-ernstige-hypertriglyceridemie/","title":"Weer een stap vooruit in de verlaging van ernstige hypertriglyceridemie","title_en":"Another brick in the wall of severe hypertriglyceridaemia lowering.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","cardiorenal-behandelstrategie","cystatine-c","diabetes-en-hart","dyslipidemie","ezetimibe","farmaco-economie","hypertriglyceridemie","hypertrofische-cardiomyopathie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","liraglutide","niet-statine-therapie","obesitas","pcsk9-remmers","pelacarsen","plaquekarakterisatie","rosuvastatine","sacubitril-valsartan","select-trial","slaapapneu","soul-trial","statines","tirzepatide","tricuspidalisinsufficiëntie","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag124","source_url":"https://doi.org/10.1093/eurheartj/ehag124","authors":["Daniela Pedicino","Rocco Vergallo"],"significance":7,"published":"2026-02-26","source_date":"2026-02-26","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/"],"congress":"","summary_en":"This European Heart Journal editorial commented on advances in treating severe hypertriglyceridemia, discussing the growing pipeline of APOC3- and ANGPTL3-targeted therapies for this difficult lipid disorder.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3351651f5b3","type":"article","url":"https://hartvaat.nl/2026/02/25/langetermijnincidentie-van-atriumfibrilleren-en-het-risico-op-beroerte-20-jaar-f/","title":"Langetermijnincidentie van atriumfibrilleren en het risico op beroerte: 20 jaar follow-up (INTERGENE)","title_en":"Long-term incidence of atrial fibrillation and cardiovascular outcomes in men and women with sinus rhythm: a 20-year follow-up of the INTERGENE population-based cohort","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["atriale-cardiomyopathie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003944?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003944?rss=1","authors":["Viktorisson","A.","Khatib","I. A.","Bashir","M.","Nyberg","F.","Lissner","L.","Thelle","D. S."],"significance":6,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Estimates of long-term atrial fibrillation (AF) incidence in people with sinus rhythm are limited. In the Swedish population-based INTERGENE study, 2,967 AF-free participants (mean age 50.7, 53% female) were followed for over 20 years. During 53,447 person-years, 12.0% developed AF (incidence 6.66 per 1,000 person-years). At 20 years, cumulative AF incidence (accounting for competing death) was 2.1% in those younger than 45 at baseline, 13.3% at 45-65 and 29.5% above 65; men had higher incidence in all age groups. Incident AF was associated with ischaemic stroke (HR 1.80) and overall cardiovascular disease (HR 2.07). AF is thus a common long-term outcome, especially in older adults and men, associated with increased stroke and cardiovascular risk — arguing for age- and sex-specific risk stratification and early AF detection.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e6ba8170501","type":"article","url":"https://hartvaat.nl/2026/02/25/voorspelling-cardiovasculaire-ziektelast-bij-vrouwen-in-de-vs-tot-2050/","title":"Voorspelling cardiovasculaire ziektelast bij vrouwen in de VS tot 2050","title_en":"Forecasting the Burden of Cardiovascular Disease and Stroke in Women in the United States Through 2050: A Scientific Statement From the American Heart Association","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","diabetes-type-2","farmaco-economie","gepersonaliseerde-geneeskunde","obesitas","ouderen","perifeer-vaatlijden","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001406","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001406","authors":[],"significance":8,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This AHA scientific statement provided forecasts for cardiovascular disease and stroke prevalence in women through 2050, highlighting projected increases driven by aging, obesity, and diabetes, and informing prevention strategies targeting women's cardiovascular health.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7c8f671bc159","type":"article","url":"https://hartvaat.nl/2026/02/25/alcoholgebruik-en-het-ontstaan-van-atriumfibrilleren-dosis-risico-en-dogma-herov/","title":"Alcoholgebruik en het ontstaan van atriumfibrilleren: dosis, risico en dogma heroverwogen","title_en":"Alcohol Consumption and Incident Atrial Fibrillation: Rethinking Dose, Risk, and Dogma.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["alcoholgebruik"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag029","source_url":"https://doi.org/10.1093/europace/euag029","authors":["Marco Zuin","Matteo Bertini","Giuseppe Boriani"],"significance":6,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This Europace overview reconsidered the relationship between alcohol consumption and AF risk, challenging some traditional assumptions about safe consumption levels and arguing for a more nuanced understanding of dose-response.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2b9f05a6a6f","type":"article","url":"https://hartvaat.nl/2026/02/25/de-mondiale-ziektelast-van-chronische-nierziekte-elke-20-seconden-een-sterfgeval/","title":"De mondiale ziektelast van chronische nierziekte: elke 20 seconden een sterfgeval","title_en":"The updated global burden of chronic kidney disease: one death every 20 seconds.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag040","source_url":"https://doi.org/10.1093/ndt/gfag040","authors":["Alberto Ortiz","Jennifer S Lees","Roser Torra","Vianda S Stel","Anneke Kramer","Patrick B Mark"],"significance":6,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This Global Burden of Disease update projected that CKD mortality will increase by more than 50% in the coming decades, with one death every 20 seconds globally, underscoring the urgency of kidney disease prevention.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c6827eb6864","type":"article","url":"https://hartvaat.nl/2026/02/25/obesitas-en-hypertensie-bij-kindercardiologiepatienten-voor-en-na-covid-19-lockd/","title":"Obesitas en hypertensie bij kindercardiologiepatiënten voor en na COVID-19-lockdown","title_en":"The prevalence of obesity and hypertension in paediatric cardiology patients before and after COVID-19 lockdown measures.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["obesitas"],"journal":"European journal of pediatrics","doi":"10.1007/s00431-026-06816-7","source_url":"https://doi.org/10.1007/s00431-026-06816-7","authors":["Jemima Ball","Jasmine Hulme Kenny","Charalampos Kotidis"],"significance":3,"published":"2026-02-25","source_date":"2026-02-25","image":"https://hartvaat.nl/global/img/92a920b1a396.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"A retrospective audit at the East Midlands Congenital Heart Centre found increased prevalence of obesity and hypertension in paediatric cardiology patients after COVID-19 lockdown measures, with these comorbidities often under-recognised and undertreated.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d731c20f3b8f","type":"article","url":"https://hartvaat.nl/2026/02/25/hemodynamische-en-bloedviscositeitsprofielen-van-culprit-versus-non-culprit-coro/","title":"Hemodynamische en bloedviscositeitsprofielen van culprit- versus non-culprit-coronairvaten","title_en":"Haemodynamic and Blood Viscosity Profiles of Culprit vs. Non-Culprit Coronary Vessels: Insights from NIRS-IVUS and CFD Analysis","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["bloeddrukbehandeling","dyslipidemie","percutane-coronaire-interventie","plaquekarakterisatie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00056-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00056-0/fulltext","authors":["Eric K.W. Poon","Daisuke Shishikura","Jeremy D. Silver","Lucas Hatzikostas","Philip Macanovic","Jouke Dijkstra","Patrick W. Serruys","Hideaki Morita","Peter Barlis"],"significance":5,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":[],"congress":"","summary_en":"Using combined NIRS-IVUS imaging and computational fluid dynamics, this study compared haemodynamic and blood viscosity profiles between culprit and non-culprit coronary vessels, providing new insights into plaque vulnerability mechanisms.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d51166f93759","type":"article","url":"https://hartvaat.nl/2026/02/25/klotho-in-het-distale-nefron-reguleert-calciumreabsorptie-maar-niet-fosfaathomeo/","title":"Klotho in het distale nefron reguleert calciumreabsorptie maar niet fosfaathomeostase","title_en":"Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00142-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00142-0/fulltext","authors":["Laurent Bourqui","Adisa Trnjanin","Klaudia Kopper","Dominique Loffing-Cueni","Zsuzsa Radvanyi","Artyom Karpovich","Tara Rahimi","Rui Santos","Agnieszka Wengi","Johanne Pastor","Orson W. Moe","Johannes Loffing","Ganesh Pathare"],"significance":4,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This study demonstrates that Klotho in the kidney distal convolution regulates urinary Klotho excretion and calcium reabsorption but does not directly participate in phosphate homeostasis, refining understanding of Klotho biology.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29c40ff764c1","type":"article","url":"https://hartvaat.nl/2026/02/25/onvervulde-zorgbehoefte-bij-hypertensie-en-diabetes-in-sub-sahara-afrika/","title":"Onvervulde zorgbehoefte bij hypertensie en diabetes in Sub-Sahara Afrika","title_en":"Assessing the burden and inequality in the unmet need for hypertension and type 2 diabetes care using a care cascade framework in Tanzania, Lesotho, and South Africa.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","diabetes-en-hart","ezetimibe","zwangerschap-hart"],"journal":"Primary health care research & development","doi":"10.1017/S1463423626100978","source_url":"https://doi.org/10.1017/S1463423626100978","authors":["Denis Okova","Akim Tafadzwa Lukwa","Robinson Oyando","Folahanmi Tomiwa Akinsolu","Abodunrin Olunike","Plaxcedes Chiwire","Charles Hongoro"],"significance":3,"published":"2026-02-25","source_date":"2026-02-25","image":"https://hartvaat.nl/global/img/5181c53adb01.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"Using a care cascade framework, this study assessed the prevalence and inequality in unmet care needs for hypertension and diabetes in Tanzania, Lesotho, and South Africa, mapping access gaps in regions with rapidly rising non-communicable disease burden.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3b8aea702800","type":"article","url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","title":"Uitkomsten van hartfalen naar ejectiefractie: het ESC HF III Register","title_en":"Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfmref","hfpef","hfref","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1074","source_url":"https://doi.org/10.1093/eurheartj/ehaf1074","authors":["Lars H Lund","Aldo P Maggioni","Maria G Crespo-Leiro","Cecile Laroche","Israel Gotsman","Belma Pojskic","Eleonora B Vataman","Lucica Grigorica","Hamayak Sisakian","Duska Glavas","Dulce A Brito","Stefan Anker","Ovidiu Chioncel","Gerasimos Filippatos","Mitja Lainscak","Theresa A McDonagh","Alexandre Mebazaa","Massimo Piepoli","Frank Ruschitzka","Gianluigi Savarese","Petar M Seferović","Marco Metra","Giuseppe Rosano"],"significance":8,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"The ESC Heart Failure III Registry followed 10,162 patients across 41 countries with HFrEF, HFmrEF, and HFpEF, providing contemporary real-world data on in-hospital and 1-year outcomes across the heart failure spectrum in routine clinical practice.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d940ba7003a0","type":"article","url":"https://hartvaat.nl/2026/02/25/foxo1-als-schakel-tussen-hemodynamiek-inflammatie-en-metabolisme-in-atherosclero/","title":"FOXO1 als schakel tussen hemodynamiek, inflammatie en metabolisme in atherosclerose","title_en":"FOXO1 Integrates Endothelial Hemodynamic, Inflammatory, and Metabolic Pathways in Atherosclerosis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["endotheel"],"journal":"Circulation research","doi":"10.1161/CIRCRESAHA.125.327592","source_url":"https://doi.org/10.1161/CIRCRESAHA.125.327592","authors":["Hanqiang Deng","Xing Zhang","Yewei Wang","Divyesh Joshi","George Tellides","Martin A Schwartz"],"significance":7,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This basic science study revealed how the transcription factor FOXO1 integrates hemodynamic, inflammatory, and metabolic pathways in endothelial cells to protect against atherosclerosis, identifying a master regulator of vascular health.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68acb181994e","type":"article","url":"https://hartvaat.nl/2026/02/25/pyelonefritis-verlaagt-serumcholesterol-en-remt-atherosclerose-ondanks-systemisc/","title":"Pyelonefritis verlaagt serumcholesterol en remt atherosclerose ondanks systemische inflammatie","title_en":"Pyelonephritis decreases serum cholesterol and mitigates atherosclerosis severity despite systemic inflammation.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["cetp-remmers","dyslipidemie","ezetimibe","iga-nefropathie","ldl-cholesterol","lipoproteïne-a","pcsk9-remmers","pelacarsen"],"journal":"American journal of physiology. Heart and circulatory physiology","doi":"10.1152/ajpheart.00914.2025","source_url":"https://doi.org/10.1152/ajpheart.00914.2025","authors":["Lena Possenriede","Georg W Sendtner","Peyman Falahat","Uta Scheidt","Julia Miranda","Jessica Schmitz","Jan Hinrich Bräsen","Sibylle von Vietinghoff"],"significance":3,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"In LDL receptor-deficient mice, pyelonephritis paradoxically lowered serum cholesterol and reduced atherosclerosis despite systemic inflammation, through hepatic PCSK9 downregulation — providing unexpected insights into infection-lipid metabolism interactions.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a3b76dbba676","type":"article","url":"https://hartvaat.nl/2026/02/25/behandeling-van-familiaire-hypercholesterolemie-bij-kinderen-3-jaar-lipigen-regi/","title":"Behandeling van familiaire hypercholesterolemie bij kinderen: 3 jaar LIPIGEN-register","title_en":"Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00057-2/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00057-2/fulltext","authors":["Federica Galimberti","Maria Elena Capra","Elena Olmastroni","Davide Braghiroli","Giuseppe Banderali","Francesco Baratta","Giacomo Biasucci","Marta Biolo","Paola Sabrina Buonuomo","Angelo Baldassare Cefalù","Francesco Cipollone","Nadia Citroni","Sergio D'Addato","Simonetta Genovesi","Ornella Guardamagna","Lorenzo Iughetti","Giuseppe Mandraffino","Ilenia Minicocci","Giuliana Germana Mombelli","Tiziana Montalcini","Fabio Nascimbeni","Angelina Passaro","Matteo Pirro","Elisabetta Rinaldi","Francesco Sbrana","Roberto Scicali","Patrizia Suppressa","Pablo Josè Werba","Maria Grazia Zenti","Marcello Arca","Maurizio Averna","Patrizia Tarugi","Sebastiano Calandra","Alberico Luigi Catapano","Cristina Pederiva","Manuela Casula","the LIPIGEN Paediatric Group"],"significance":5,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"Data from the Italian LIPIGEN registry describe the timing, pharmacological approach, and early outcomes of lipid-lowering therapy initiation in children with familial hypercholesterolaemia. Early identification and treatment are crucial for reducing lifetime cardiovascular risk.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b74cad2f3392","type":"article","url":"https://hartvaat.nl/2026/02/24/cardiale-sarcoidose-als-eerste-uiting-van-sarcoidose-verloopt-ernstiger/","title":"Cardiale sarcoïdose als eerste uiting van sarcoïdose verloopt ernstiger","title_en":"Diagnostic delay and phenotypic differences in cardiac sarcoidosis: a descriptive study of diagnostic and follow-up clinical data","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiale-sarcoidose"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003934?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003934?rss=1","authors":["Kullberg","S.","Faxen","J.","Cagan","J.","Torabzadeh","H.","Eklund","A.","Smed-So&#x0308;rensen","A.","Darlington","P.","Eldhagen","P.","Rossides","M."],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/"],"congress":"","summary_en":"Worse prognosis in cardiac sarcoidosis (CS) is likely linked to diagnostic delay and to cardiac first presentation ('de novo'). In this retrospective study (95 CS patients, 2003-2024), the median time from first symptoms to diagnosis was 9 months. Patients with diagnostic delay more often received a CRT defibrillator. Time to diagnosis did not differ between de novo CS (n=49) and patients with prior extracardiac sarcoidosis (n=46), but de novo patients more often had severe symptoms at onset. At a median 46 months, de novo patients more often had reduced ejection fraction and an ICD than those with prior extracardiac sarcoidosis — despite more immunosuppressive therapy. Disease thus runs a more severe course when cardiac sarcoidosis is the first manifestation, and may not be adequately altered by immunosuppression.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63d7d5048a09","type":"article","url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","title":"Systemische embolieën bij AF: IPD mega-meta-analyse van 71.683 patiënten","title_en":"Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.075275","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.075275","authors":["Samer Al Said","Eugene Braunwald","Michael G Palazzolo","Giorgio E M Melloni","Bram J Geller","Christian T Ruff","Elliott M Antman","Anthony P Carnicelli","John W Eikelboom","Christopher B Granger","Manesh R Patel","Lars Wallentin","Robert P Giugliano"],"significance":7,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This individual patient data meta-analysis of over 71,000 AF patients characterized systemic embolic events, showing that NOACs effectively prevent both stroke and non-cerebral embolism compared with warfarin.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8f345956932","type":"article","url":"https://hartvaat.nl/2026/02/24/van-biobank-naar-voorspelling-polygenetische-risicoscores-voor-perifeer-vaatlijd/","title":"Van biobank naar voorspelling: polygenetische risicoscores voor perifeer vaatlijden","title_en":"From biobank to prediction: polygenic risk scores for peripheral artery disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","gepersonaliseerde-geneeskunde","polygene-risicoscore","primaire-preventie","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1042","source_url":"https://doi.org/10.1093/eurheartj/ehaf1042","authors":["Eri Fukaya","Nicholas J Leeper"],"significance":7,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/vasculair/perifeer-arterieel-vaatlijden/"],"congress":"","summary_en":"This European Heart Journal article explored the use of polygenic risk scores for predicting peripheral artery disease, testing whether genetic risk stratification can improve identification of individuals at risk for this common vascular condition.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cd26a9d5282e","type":"article","url":"https://hartvaat.nl/2026/02/24/perinatale-hiv-blootstelling-en-hiv-ernst-geassocieerd-met-bloeddruk-bij-jongere/","title":"Perinatale HIV-blootstelling en HIV-ernst geassocieerd met bloeddruk bij jongeren","title_en":"Association of Perinatal HIV Exposure and HIV Disease Severity With BP in Youth","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24937","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24937","authors":[],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This study compared blood pressure between youth with and without perinatally acquired HIV infection and evaluated whether HIV disease severity influences blood pressure. The findings inform cardiovascular risk monitoring in the growing population of young people living with HIV.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b632e9ffcd6f","type":"article","url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","title":"Invloed van coronaire ziekte patronen op klinische uitkomsten: pullback pressure gradient meta-analyse","title_en":"Impact of Coronary Artery Disease Patterns Assessed with Pullback Pressure Gradient on Clinical Outcomes: Meta-analysis","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00054-7/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00054-7/fulltext","authors":["Adrian Bednarek","Patrick W. Serruys","Tsung-Ying Tsai","Karolina Gumiężna","Shigetaka Kageyama","Nozomi Kotoku","Scot Garg","Yoshinobu Onuma","Mariusz Tomaniak"],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A meta-analysis assessed the prognostic impact of the pullback pressure gradient index for quantitatively characterising focal versus diffuse coronary artery disease patterns. The physiological assessment adds prognostic value to standard coronary evaluation.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"92be22775b03","type":"article","url":"https://hartvaat.nl/2026/02/24/ondervoeding-en-cachexie-bij-opgenomen-patienten-met-acute-cardiale-aandoeningen/","title":"Ondervoeding en cachexie bij opgenomen patiënten met acute cardiale aandoeningen","title_en":"Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","cardiogene-shock","hartkatheterisatie","laminopathie","menopauze","myocardinfarct","obesitas","ouderen","slaapapneu","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001405","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001405","authors":[],"significance":8,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This AHA scientific statement addressed malnutrition and cachexia in patients with acute cardiovascular conditions beyond heart failure, covering assessment, management, and the impact of nutritional status on clinical outcomes across the spectrum of acute cardiac disease.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d39175f3bdc","type":"article","url":"https://hartvaat.nl/2026/02/24/uitkomstgericht-cardiovasculair-risicoframework-nodig-na-dwarslaesie/","title":"Uitkomstgericht cardiovasculair risicoframework nodig na dwarslaesie","title_en":"Outcome-Based Cardiovascular Risk Framework is Required After Spinal Cord Injury","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","aficamten","aortainsufficiëntie","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","cardiomyopathie-gerichte-therapie","diabetes-en-hart","diabetes-type-2","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","inflammatie","laminopathie","menopauze","microbioom","obesitas","ouderen","perifeer-vaatlijden","richtlijnen-esc","slaapapneu","supraventriculaire-tachycardie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26543","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26543","authors":["Armin Khavandegar"],"significance":6,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This article highlighted the need for an outcome-based cardiovascular risk framework after spinal cord injury, where blood pressure instability and autonomic dysfunction create unique cardiovascular challenges.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16dd2b509ccc","type":"article","url":"https://hartvaat.nl/2026/02/24/polygene-risicoscores-en-hla-klasse-ii-als-biomarkers-voor-corticosteroidrespons/","title":"Polygene risicoscores en HLA klasse II als biomarkers voor corticosteroïdrespons bij nefrotisch syndroom","title_en":"Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["polygene-risicoscore"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00134-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00134-1/fulltext","authors":["Tiffany Tu","Alejandro Ochoa","Amika Sood","Ashley Dabrik","Megan Chryst-Stangl","Brandon Lane","Guanghong Wu","Frank Donovan","Ursula Harper","Settara Chandrasekharappa","Christopher Esezobor","Adaobi Solarin","David Hooper","Christine Sethna","Sandra Amaral","Mahmoud Kallash","Michelle Rheault","Priya Verghese","Vikas Dharnidharka","Eloise Salmon","Patricia Weng","Tarak Srivastava","Michael E. Seifert","Cozumel Pruette","David Selewski","Keisha Gibson","Tracy Hunley","Asiri Abeyagunawardena","Shenal Thalgahagoda","Arvind Bagga","Aditi Sinha","Nicholas Webb","Larry Greenbaum","Ali Gharavi","Krzysztof Kiryluk","Matthias Kretzler","Lisa Guay-Woodford","Simone Sanna-Cherchi","Agnieszka Bierzynska","Ania Koziell","Gavin Welsh","Moin Saleem","Charles Rotimi","Eileen Chambers","Cliburn Chan","CureGN Consortium","PNRC Glomerular Disease Group","CIBMTR/NMDP Consortium","Annette Jackson","Adebowale Adeyemo","Rasheed Gbadegesin"],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This study identified polygenic risk scores and HLA class II variants as biomarkers for predicting corticosteroid response in childhood nephrotic syndrome, potentially enabling treatment stratification at initial presentation.","created":"2026-07-03T10:25:16Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef1cea3fd727","type":"article","url":"https://hartvaat.nl/2026/02/24/s100a8-a9-versnelt-cox-1-herstel-in-bloedplaatjes-en-beperkt-aspirinerespons/","title":"S100A8/A9 versnelt COX-1-herstel in bloedplaatjes en beperkt aspirinerespons","title_en":"Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["aspirine","inflammatie"],"journal":"Blood advances","doi":"10.1182/bloodadvances.2025017653","source_url":"https://doi.org/10.1182/bloodadvances.2025017653","authors":["Rossella Liani","Paola Giustina Simeone","Margherita Alfonsetti","Stefano Lattanzio","Alessia Ricci","Maurizio Frezza","Sonia Ciotti","Myriam Luongo","Francesco Cipollone","Fabio Pulcinelli","Francesca Santilli"],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/polypil-cardiovasculair/","https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/"],"congress":"","summary_en":"This study reveals that circulating S100A8/A9 accelerates platelet COX-1 recovery via the MRP4 transporter, shortening the duration of aspirin-mediated thromboxane suppression. The thromboinflammatory mechanism has implications for individualising cardiovascular prevention.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be59876910c4","type":"article","url":"https://hartvaat.nl/2026/02/24/cystatine-c-bij-chronische-nierziekte-betere-diagnostiek-en-patientuitkomsten/","title":"Cystatine C bij chronische nierziekte: betere diagnostiek en patiëntuitkomsten","title_en":"Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte","cystatine-c","flow-trial"],"journal":"Postgraduate medicine","doi":"10.1080/00325481.2026.2634426","source_url":"https://doi.org/10.1080/00325481.2026.2634426","authors":["Shrujal Patel","Mayank Dhalani","Meghana Reddy","Namita Ruhela","Rohit Jain","Gurwant Kaur"],"significance":4,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This review discusses the diagnostic advantages of cystatin C over creatinine for estimating GFR in chronic kidney disease, particularly in elderly patients, those with muscle disease, and across racial and ethnic diversity.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"679f8678ce45","type":"article","url":"https://hartvaat.nl/2026/02/24/effecten-van-micro-en-nanoplastics-op-de-nieren/","title":"Effecten van micro- en nanoplastics op de nieren","title_en":"Effects of Microplastics and Nanoplastics on the Kidneys.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag034","source_url":"https://doi.org/10.1093/ndt/gfag034","authors":["Lucie Augey","Jessica Berdougo-Tritz","Aicha Mbarek","Michel Jadoul","Ziad Massy","Gilbert Deray","Sophie Liabeuf"],"significance":4,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This review describes the nephrotoxic effects of micro- and nanoplastics, which can enter the bloodstream and reach the kidneys. The findings raise concerns about renal consequences of chronic environmental plastic exposure.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"662807b17865","type":"article","url":"https://hartvaat.nl/2026/02/24/mfsd2a-is-essentieel-voor-de-epidermale-homeostase/","title":"Mfsd2a is essentieel voor de epidermale homeostase","title_en":"Mfsd2a is important for maintaining epidermal homeostasis.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":[],"journal":"Proceedings of the National Academy of Sciences of the United States of America","doi":"10.1073/pnas.2531159123","source_url":"https://doi.org/10.1073/pnas.2531159123","authors":["Bernice H Wong","Kunal Mishra","Cheen Fei Chin","Dwight L A Galam","Bryan C Tan","Mei Ding","Federico Torta","Jacques Behmoaras","Alvin W C Chua","David L Silver"],"significance":3,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This study demonstrates that the lipid transporter Mfsd2a plays a crucial role in maintaining epidermal barrier function by facilitating linoleate uptake for acylceramide synthesis, with implications for skin diseases.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"849833b0aa73","type":"article","url":"https://hartvaat.nl/2026/02/24/aortacoarctatie-met-zeldzame-congenitale-afwijkingen-casuistiek/","title":"Aortacoarctatie met zeldzame congenitale afwijkingen: casuïstiek","title_en":"Rebuttal: aortic coarctation and concomitant anomalies - left circumflex fistula, persistent left SVC and ventricular diverticulum.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["aortacoarctatie","congenitale-hartafwijking"],"journal":"BMJ case reports","doi":"10.1136/bcr-2025-265520","source_url":"https://doi.org/10.1136/bcr-2025-265520","authors":["Abrar Alameri","Ahmed Sherif"],"significance":2,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"A case report of an adolescent with aortic coarctation accompanied by rare congenital anomalies including a left circumflex coronary fistula, persistent left superior vena cava, and ventricular diverticulum.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"446b5d579aaa","type":"article","url":"https://hartvaat.nl/2026/02/24/systemische-effecten-van-metabole-acidose/","title":"Systemische effecten van metabole acidose","title_en":"Systemic effects of metabolic acidosis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["metabole-acidose"],"journal":"Clinical nephrology","doi":"10.5414/CN111953","source_url":"https://doi.org/10.5414/CN111953","authors":["Raymond Chen","Caitlin Kumala","Lynh Vu","Biff F Palmer"],"significance":4,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This literature review synthesises the systemic effects of metabolic acidosis on cardiovascular, vascular, pulmonary, and renal systems, with particular clinical implications for patients with chronic kidney disease.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2c7de1f2aa19","type":"article","url":"https://hartvaat.nl/2026/02/24/de-overgang-naar-de-menopauze-tien-klinische-vragen-beantwoord/","title":"De overgang naar de menopauze: tien klinische vragen beantwoord","title_en":"[Menopausal transition].","category":"algemeen","category_label":"Algemeen","professions":["huisarts","internist"],"tags":["bradycardie","vrouwen"],"journal":"Nederlands tijdschrift voor geneeskunde","doi":"https://pubmed.ncbi.nlm.nih.gov/41718673/","source_url":"https://doi.org/https://pubmed.ncbi.nlm.nih.gov/41718673/","authors":["C A H Ineke Janssen","Anneloes A L Smits"],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"https://hartvaat.nl/global/img/0ef5024189ff.webp","kennis":[],"congress":"","summary_en":"This educational article in the Nederlands Tijdschrift voor Geneeskunde answers ten common clinical questions about the menopausal transition, covering aetiology, symptoms, laboratory evaluation, sexuality, contraception, and the risks and benefits of hormonal and non-hormonal treatments.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb10fc259655","type":"article","url":"https://hartvaat.nl/2026/02/24/glp-1-agonisten-versus-dpp-4-remmers-en-sglt2-remmers-bij-hartfalenrisico/","title":"GLP-1-agonisten versus DPP-4-remmers en SGLT2-remmers bij hartfalenrisico","title_en":"Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","empagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075157","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075157","authors":["Yang Xu"],"significance":8,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This target trial emulation using Swedish population data compared GLP-1 receptor agonists with DPP-4 inhibitors and SGLT2 inhibitors for heart failure hospitalization risk in type 2 diabetes, providing real-world comparative effectiveness data for cardiometabolic drug selection.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ebd2aa9a228","type":"article","url":"https://hartvaat.nl/2026/02/24/af-geinduceerde-ernstige-lv-disfunctie-na-mitralisklepprocedure-bij-adolescent/","title":"AF-geïnduceerde ernstige LV-disfunctie na mitralisklepprocedure bij adolescent","title_en":"Atrial fibrillation-induced severe left ventricular dysfunction postmitral valve replacement in an adolescent with rheumatic mitral regurgitation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aritmogene-cardiomyopathie","hfmref","hfpef","hfref","mitralisinsufficiëntie"],"journal":"BMJ case reports","doi":"10.1136/bcr-2025-267313","source_url":"https://doi.org/10.1136/bcr-2025-267313","authors":["Raghuraj Chawla","Yash Shrivastava","Anish Gupta","Bhanu Duggal"],"significance":2,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/"],"congress":"","summary_en":"A case report of an adolescent with rheumatic heart disease who developed severe left ventricular dysfunction (LVEF 14%) four months after mechanical mitral valve replacement due to atrial fibrillation with rapid ventricular response.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6f2ac43935cc","type":"article","url":"https://hartvaat.nl/2026/02/24/uitgebreid-cta-bereik-detecteert-vroegtijdig-thrombus-in-het-linker-atrium-bij-a/","title":"Uitgebreid CTA-bereik detecteert vroegtijdig thrombus in het linker atrium bij acute CVA","title_en":"Extended CTA scan range for early detection of left atrial and left atrial appendage thrombus and other filling defects in acute ischemic stroke.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of neurology","doi":"10.1007/s00415-026-13692-6","source_url":"https://doi.org/10.1007/s00415-026-13692-6","authors":["Juan Marta-Enguita","Sara Biain","Diego Ayuso","Sergio Vasquez-Ferreccio","Cristina Del Bosque","Patricia de la Riva","Noemí Diez","Felix Gonzalez","Ana de Arce","Jon Equiza","Gorka Arenaza","Virginia Gomez-Usabiaga","Maite Martinez-Zabaleta"],"significance":5,"published":"2026-02-24","source_date":"2026-02-24","image":"https://hartvaat.nl/global/img/629f64045fcb.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"By extending CT angiography scan range to include the left atrium and appendage during acute stroke imaging, this study detected filling defects in 13% of patients. These patients had more severe strokes and higher mortality, suggesting therapeutic implications for early detection.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36cb132446e2","type":"article","url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","title":"Colchicine bij chronische inflammatoire cardiomyopathie: de CMP-MYTHiC-trial","title_en":"Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["aficamten","bradycardie","cardiomyopathie-gerichte-therapie","colchicine","colcot-trial","ezetimibe","gedilateerde-cardiomyopathie","hs-crp","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","inflammatie","inflammatoire-cardiomyopathie","laminopathie","microbioom","pericarditis"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag058","source_url":"https://doi.org/10.1093/eschf/xvag058","authors":["Enrico Ammirati","Iside Cartella","Michele Ciabatti","Giada Colombo","Marco Masetti","Maurizio Pieroni","Guglielmo Gallone","Giovanni Peretto","Luciano Potena","Roberto Scacciavillani","Claudia Raineri","Adriano Caputo","Patrizia Pedrotti","Paola Sormani","Nicolina Conti","Marco Merlo","Massimo Imazio","Arianna Pani","Mirko L Ciliberti","Piero Gentile","Gianluca Pontone","Andrea Villatore","Enrica Pezzullo","Matteo Palazzini","Michela Casella","Maria Grazia Valsecchi","Francesco Burzotta","Veronica Carmina","Andrea Garascia","Antonio F Scarale","Davide P Bernasconi","Francesco S Loffredo","Maria Lucia Narducci"],"significance":6,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This article described the rationale and design of the CMP-MYTHiC trial testing colchicine in chronic inflammatory cardiomyopathy, exploring anti-inflammatory therapy for a condition characterized by persistent myocardial inflammation and arrhythmia risk.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T13:24:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72d009877881","type":"article","url":"https://hartvaat.nl/2026/02/24/cochrane-review-interventies-om-deelname-aan-hartrevalidatie-te-bevorderen/","title":"Cochrane-review: interventies om deelname aan hartrevalidatie te bevorderen","title_en":"Interventions to promote patient utilisation of cardiac rehabilitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"The Cochrane database of systematic reviews","doi":"10.1002/14651858.CD007131.pub5","source_url":"https://doi.org/10.1002/14651858.CD007131.pub5","authors":["Linda Long","Cho Zin Lin","Philippa Davies","Valerie Wells","Sherry L Grace","Rod S Taylor"],"significance":7,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":[],"congress":"","summary_en":"This updated Cochrane review of 47 trials evaluated interventions to promote cardiac rehabilitation utilization, finding that motivational approaches, early appointment scheduling, and automatic referral increase participation rates.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T13:24:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e6ee2a164d4","type":"article","url":"https://hartvaat.nl/2026/02/24/renale-denervatie-verbetert-leververvetting-bij-hypertensieve-patienten-met-meta/","title":"Renale denervatie verbetert leververvetting bij hypertensieve patiënten met metabool syndroom","title_en":"Renal Denervation Improves Hepatic Steatosis in Hypertensive Patients With Metabolic Syndrome","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","diuretica","dubbele-trombocytenremming","fidelity","figaro-dkd","perifeer-vaatlijden","radiance-htn","renale-denervatie","resistente-hypertensie-aldosteronremmers","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26601","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26601","authors":["Mert Tokcan"],"significance":7,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study showed that renal denervation improves hepatic steatosis in hypertensive patients with metabolic syndrome, demonstrating that sympathetic nervous system modulation has metabolic benefits beyond blood pressure reduction.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9201eeef2b26","type":"article","url":"https://hartvaat.nl/2026/02/24/multidisciplinaire-cardiometabole-kliniek-ldl-c-verlaging-in-de-dagelijkse-prakt/","title":"Multidisciplinaire cardiometabole kliniek: LDL-C-verlaging in de dagelijkse praktijk","title_en":"Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obesitas","ouderen","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","statines","vrouwen"],"journal":"Internal medicine journal","doi":"10.1111/imj.70334","source_url":"https://doi.org/10.1111/imj.70334","authors":["Ying Yi Wendy Yap","Nick S R Lan","Girish Dwivedi","Bu B Yeap","P Gerry Fegan","Krishnamurthy Chikkaveerappa"],"significance":4,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"Real-world data from the first 200 patients at a new multidisciplinary cardiometabolic clinic demonstrate effective LDL-cholesterol lowering with PCSK9 inhibitors in patients with FH and cardiovascular disease who fail to reach targets on statins alone.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"721436c37114","type":"article","url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","title":"YELLOW-III: intracoronaire beeldvorming en genexpressie na maximale lipideverlaging met evolocumab","title_en":"Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["abelacimab","biomarkers-cardiovasculair","ezetimibe","intracoronaire-beeldvorming","pcsk9-remmers-nieuwe-generatie","pelacarsen","plaquekarakterisatie","yellow-iii"],"journal":"JACC. Cardiovascular imaging","doi":"10.1016/j.jcmg.2025.12.013","source_url":"https://doi.org/10.1016/j.jcmg.2025.12.013","authors":["Annapoorna S Kini","Yuliya Vengrenyuk","JiaJia Liu","Keisuke Yasumura","Pruthvi C Revaiah","Aishwaria Mandava","Hardik Shah","Joseph M Sweeny","Sahil Khera","Vishal Kapur","Parasuram Melarcode-Krishnamoorthy","Amit Hooda","Shingo Minatoguchi","Nimisha Baruah","Derek A Pineda","Vivian Chen","Ethan Ellis","Aana Hahn","Prakash Krishnan","Usman Baber","Pedro R Moreno","Roxana Mehran","Robert Sebra","Eric Boerwinkle","Xiaobo Zhou","Jagat Narula","Samin K Sharma"],"significance":7,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/"],"congress":"","summary_en":"The YELLOW-III study used intracoronary imaging and transcriptomic analysis to characterize the effects of evolocumab on coronary plaque composition at the molecular level, providing the deepest mechanistic insight into PCSK9 inhibitor-mediated plaque stabilization.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"980a40a8ed13","type":"article","url":"https://hartvaat.nl/2026/02/24/lp-a-spiegels-bij-kinderen-met-hypercholesterolemie-impact-op-ldl-c-interpretati/","title":"Lp(a)-spiegels bij kinderen met hypercholesterolemie: impact op LDL-C-interpretatie","title_en":"Lipoprotein(a) levels in children with hypercholesterolemia.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag126","source_url":"https://doi.org/10.1093/eurjpc/zwag126","authors":["Matej Mlinaric","Barbara Cugalj Kern","Ana Drole Torkar","Jaka Sikonja","Jan Kafol","Robert Sket","Tine Tesovnik","Jernej Kovac","Tadej Battelino","Urh Groselj"],"significance":6,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"This study showed that lipoprotein(a) contributes substantially to measured LDL cholesterol in children with hypercholesterolemia, complicating the interpretation of lipid panels and potentially leading to overestimation of true LDL levels.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5385afd8676b","type":"article","url":"https://hartvaat.nl/2026/02/24/lipide-aferese-verlaagt-lp-a-met-60-75-systematische-review-en-meta-analyse/","title":"Lipide-aferese verlaagt Lp(a) met 60-75%: systematische review en meta-analyse","title_en":"The impact of lipid apheresis on changes of lipoprotein(a): a systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","statines"],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag089","source_url":"https://doi.org/10.1093/eurjpc/zwag089","authors":["Bahman Razi","Masoud Eslami","Saeed Aslani","Shahab Alizadeh","Alireza Hatami","Wael Almahmeed","Salim S Virani","Amirhossein Sahebkar"],"significance":6,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This meta-analysis evaluated the impact of lipid apheresis on lipoprotein(a) levels, quantifying the Lp(a) reduction achieved with this established extracorporeal therapy while awaiting pharmacological Lp(a)-lowering agents.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f490e3d86a1","type":"article","url":"https://hartvaat.nl/2026/02/23/invasieve-coronaire-functietest-bij-anoca-verandert-de-behandeling-bij-driekwart/","title":"Invasieve coronaire functietest bij ANOCA verandert de behandeling bij driekwart van de patiënten","title_en":"Impact of invasive coronary function testing on management of ANOCA patients and secondary care resource utilisation: a multicentre retrospective study in the UK","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003910?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003910?rss=1","authors":["Abramik","J.","Withers","H.","Murphy","D.","Rodrigues","J. C.","Khavandi","A.","Thompson","D.","Felekos","I.","Carson","K.","Mariathas","M."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/angina-bij-normale-coronairen/","https://hartvaat.nl/kennis/coronairlijden/minoca/"],"congress":"","summary_en":"Invasive coronary function testing (CFT) is indicated in refractory angina with non-obstructed coronary arteries (ANOCA), but patient selection, safety and place in the pathway remain unclear. In this retrospective multicentre study (159 patients, two UK centres), patients were tested for microvascular dysfunction (CMD) and coronary vasospasm (vasospastic angina, VSA). An ANOCA endotype was found in 63.5%: 23.8% isolated CMD, 52.4% isolated VSA and 23.8% mixed. Intraprocedural complications were rare (3.1%). CFT led to a change in medication in 77.3%. Rehospitalisation for chest pain occurred in 21.7% (CFT-positive) versus 13.7% (CFT-negative); VSA was associated with more and earlier rehospitalisations (OR 2.64). CFT is thus safe and guides treatment, but rehospitalisation for chest pain is frequent — arguing for early follow-up and medication optimisation.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"54eeef19d09e","type":"article","url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","title":"Aspirinestop bij LVAD met VKA: veiligheidsanalyse","title_en":"Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aspirine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf745","source_url":"https://doi.org/10.1093/eurheartj/ehaf745","authors":["Jean M Connors","Finn Gustafsson","Nir Uriel","Francis D Pagani","Ulrich P Jorde","Jason N Katz","Ivan Netuka","Daniel Zimpfer","Hassan Nemeh","John M Ransom","Richa Agarwal","Mirnela Byku","Michael M Givertz","Shelley Hall","Manreet K Kanwar","Rebecca Cogswell","Farooq H Sheikh","Anita Phancao","Ashwin Ravichandran","Jennifer Conway","Eric Adler","Eugene S Chung","Jonathan Grinstein","Nicholas Dirckx","Nourdine Chakouri","Mandeep R Mehra"],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"This study showed that withdrawing aspirin in LVAD patients on vitamin K antagonists is safe with fewer bleeding events, supporting simplification of the antithrombotic regimen in mechanically supported patients.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d148e27cf524","type":"article","url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","title":"Colchicine en spironolacton bij acuut MI: voordeel-risico analyse","title_en":"Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-326218","source_url":"https://doi.org/10.1136/heartjnl-2025-326218","authors":["Marc-André d'Entremont","Sanjit S Jolly","Faisal Alharthi","Binita Shah","David Austin","Quilong Yi","Robert F Storey","Matthias Bossard","Jan Cornel","Jeroen Jaspers Focks","Sasko Kedev","Valon Asani","Goran Stankovic","Michael Tsang","Nicholas Valettas","Jessica Tyrwhitt","Jackie Betz","Shun Fu Lee","Rajibul Mian","Johanne Silvain","Farzin Beygui","Andrew Czarnecki","Payam Dehghani","Warren Cantor","Shahar Lavi","James C Spratt","Emilie P Belley-Côté","John W Eikelboom"],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This prespecified generalized pairwise comparison analysis of CLEAR SYNERGY assessed the combined benefit-risk of colchicine and spironolactone after MI, providing a more nuanced evaluation than conventional composite endpoints.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cd8b5966f7cb","type":"article","url":"https://hartvaat.nl/2026/02/23/het-jaar-in-de-cardiovasculaire-geneeskunde-2025-top-10-publicaties-ischemische-/","title":"Het jaar in de cardiovasculaire geneeskunde 2025: top 10 publicaties ischemische hartziekten","title_en":"The year in cardiovascular medicine 2025: the top 10 papers in ischaemic heart disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","farmaco-economie","fractional-flow-reserve","gepersonaliseerde-geneeskunde","myocardinfarct","ouderen","richtlijnen-esc","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag028","source_url":"https://doi.org/10.1093/eurheartj/ehag028","authors":["Diana A Gorog","Ranil de Silva","William E Boden"],"significance":8,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This European Heart Journal annual review highlighted the top 10 papers of 2025 in ischemic heart disease, providing an expert-curated summary of the most impactful developments in coronary artery disease research.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"27f268879b6f","type":"article","url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","title":"Immunoadsorptie bij gedilateerde cardiomyopathie: de IASO-DCM-trial","title_en":"Immunoadsorption in dilated cardiomyopathy: the IASO-DCM trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aperitif-trial","aritmogene-cardiomyopathie","cardiomyopathie-gerichte-therapie","dapa-hf","gedilateerde-cardiomyopathie","harttransplantatie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","inflammatoire-cardiomyopathie","laminopathie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1055","source_url":"https://doi.org/10.1093/eurheartj/ehaf1055","authors":["Stephan B Felix","Michael Böhm","Rüdiger C Braun-Dullaeus","Alida L P Caforio","Erland Erdmann","Ulrich Grabmaier","Stefan Groß","Karin Klingel","Fabian Knebel","Kristin Lehnert","Amir A Mahabadi","Veselin Mitrovic","Matthias Nauck","Georg Nickening","Michel Noutsias","Anja Sandek","Heinz-Peter Schultheiss","Christian Schulze","Heribert Schunkert","Petar M Seferovic","Karl Stangl","Alexander Staudt","Carsten Tschöpe","Rolf Wachter","Danilo Wegner","Karl Werdan","Finn Waagstein","Åke Hjalmarson","Marcus Dörr"],"significance":8,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/dilaterende-cardiomyopathie/"],"congress":"","summary_en":"The IASO-DCM trial investigated immunoadsorption as a treatment for dilated cardiomyopathy with cardiac autoantibodies, exploring a novel immunomodulatory approach to this form of heart failure.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e60169ed7a5","type":"article","url":"https://hartvaat.nl/2026/02/23/ai-adoptie-in-de-cardiologie-regulering-op-een-mondiaal-kruispunt/","title":"AI-adoptie in de cardiologie: regulering op een mondiaal kruispunt","title_en":"AI adoption in cardiology: regulation at a global crossroad","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","ai-ecg","biomarkers-cardiovasculair","farmaco-economie","gepersonaliseerde-geneeskunde","kunstmatige-intelligentie","laminopathie","ouderen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/295?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/295?rss=1","authors":["Leeson","P.","Rahimi","K."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":[],"congress":"","summary_en":"This commentary discussed the global regulatory landscape for AI adoption in cardiology, highlighting the crossroads between enabling innovation and ensuring patient safety across different regulatory frameworks.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bff3c453c1cc","type":"article","url":"https://hartvaat.nl/2026/02/23/cysteuze-massa-bij-een-jonge-vrouw-met-atriumseptumdefect/","title":"Cysteuze massa bij een jonge vrouw met atriumseptumdefect","title_en":"Abnormal echocardiographic finding: what is the cystic mass in a young woman with secundum atrial septal defect","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["gedilateerde-cardiomyopathie"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/350?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/350?rss=1","authors":["Li","Y.","Ren","D.","Sun","D."],"significance":3,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":[],"congress":"","summary_en":"A diagnostic case of a woman in her thirties with an unexpected cystic mass identified on echocardiography in the setting of a secundum atrial septal defect, illustrating the differential diagnosis of intracardiac cystic lesions.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8d55e0b4b683","type":"article","url":"https://hartvaat.nl/2026/02/23/objectief-gemeten-lichaamsbeweging-en-levenskwaliteit-bij-hypertrofische-cardiom/","title":"Objectief gemeten lichaamsbeweging en levenskwaliteit bij hypertrofische cardiomyopathie","title_en":"Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","aficamten","aritmogene-cardiomyopathie","bradycardie","cardiale-resynchronisatie","cardiogene-shock","cardiomyopathie-gerichte-therapie","diabetes-en-hart","gedilateerde-cardiomyopathie","hartrevalidatie","harttransplantatie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","inflammatie","laminopathie","lichaamsbeweging","mavacamten","microbioom","myocardinfarct","obesitas","ouderen","peripartum-cardiomyopathie","slaapapneu","summit-trial","takotsubo","ventrikelfibrilleren","vrouwen"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/333?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/333?rss=1","authors":["Schoonvelde","S. A. C.","Zwetsloot","P.-P.","Hirsch","A.","Schinkel","A. F. L.","Knackstedt","C.","Germans","T.","van Slegtenhorst","M. A.","Verhagen","J. M. A.","de Boer","R. A.","Michels","M."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/ritmestoornissen/lang-qt-syndroom/"],"congress":"","summary_en":"This study used accelerometry to objectively measure physical activity in HCM patients, showing that reduced activity levels are associated with worse quality of life and challenging the assumption that exercise restriction improves safety.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80699b694335","type":"article","url":"https://hartvaat.nl/2026/02/23/biologische-versus-mechanische-prothesen-bij-aortaklepvervanging-op-middelbare-l/","title":"Biologische versus mechanische prothesen bij aortaklepvervanging op middelbare leeftijd","title_en":"Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortainsufficiëntie","klepprothese","perifeer-vaatlijden"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/341?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/341?rss=1","authors":["Chang","C.-J.","Chi","N.-H.","Wu","C.-H.","Huang","L.-Y.","Lin","F.-J."],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":["https://hartvaat.nl/kennis/kleplijden/klepprothese-mechanisch-biologisch/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This population-based study compared biological and mechanical prostheses for aortic valve replacement in middle-aged patients, addressing the lack of guideline consensus on prosthesis selection in this age group.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d5ceafd4ee7","type":"article","url":"https://hartvaat.nl/2026/02/23/correctie-ai-evaluatie-en-monitoring-in-de-gezondheidszorg-aha/","title":"Correctie: AI-evaluatie en monitoring in de gezondheidszorg (AHA)","title_en":"Correction to: Pragmatic Approaches to the Evaluation and Monitoring of Artificial Intelligence in Health Care: A Science Advisory From the American Heart Association","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001418","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001418","authors":[],"significance":1,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"Correction to the AHA Science Advisory on pragmatic approaches to evaluating and monitoring artificial intelligence in healthcare.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e702a8b81c12","type":"article","url":"https://hartvaat.nl/2026/02/23/elektrocardiografische-beeldvorming-technische-ontwikkelingen-en-toekomst/","title":"Elektrocardiografische beeldvorming: technische ontwikkelingen en toekomst","title_en":"Electrocardiographic imaging: technical developments and future applications for non-invasive electroanatomical study of the human heart","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/307?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/307?rss=1","authors":["Kadambadi","N.","Webber","M.","Captur","G."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":[],"congress":"","summary_en":"This review described electrocardiographic imaging (ECGI) as a non-invasive technique combining patient-specific cardiac anatomy with body-surface potentials, discussing current technical developments and future clinical applications.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"007112650d39","type":"article","url":"https://hartvaat.nl/2026/02/23/brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten-huang-fogacci/","title":"Brief over intensieve lichaamsbeweging en coronaire uitkomsten (Huang & Fogacci)","title_en":"Letter by Huang and Fogacci Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075723","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075723","authors":["Jian Huang"],"significance":2,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"Huang and Fogacci submit a letter regarding the article on high-volume physical activity and clinical coronary artery disease outcomes from the Cooper Center Longitudinal Study.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2bb318d44fd0","type":"article","url":"https://hartvaat.nl/2026/02/23/brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten-xie-et-al/","title":"Brief over intensieve lichaamsbeweging en coronaire uitkomsten (Xie et al.)","title_en":"Letter by Xie et al Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075503","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075503","authors":["Juan Xie"],"significance":2,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-coronaire-calcium-score/"],"congress":"","summary_en":"Xie et al. submit a letter regarding the article on high-volume physical activity and clinical coronary artery disease outcomes from the Cooper Center Longitudinal Study.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"860820bc17c4","type":"article","url":"https://hartvaat.nl/2026/02/23/reactie-op-brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten/","title":"Reactie op brief over intensieve lichaamsbeweging en coronaire uitkomsten","title_en":"Response by Berry et al to Letter Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077402","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077402","authors":[],"significance":2,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-coronaire-calcium-score/"],"congress":"","summary_en":"Berry et al. respond to correspondence regarding their article on high-volume physical activity and clinical coronary artery disease outcomes from the Cooper Center Longitudinal Study.","created":"2026-07-03T10:25:17Z","updated":"2026-07-03T13:24:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b2bc4d91943","type":"article","url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","title":"Semaglutide vermindert infectierisico bij diabetes en chronische nierziekte","title_en":"Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["anemie-ckd","cagrisema","canagliflozine","chronische-nierziekte","credence-trial","cystatine-c","diabetes-en-hart","ezetimibe","fidelio-dkd","figaro-dkd","flow-trial","glp1-semaglutide-cardiovasculair","select-trial","semaglutide","soul-trial","stride-trial"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag036","source_url":"https://doi.org/10.1093/ndt/gfag036","authors":["Brian Rayner","Kenneth W Mahaffey","Johannes F E Mann","Richard E Pratley","Peter Rossing","Nicolas Belmar","Heidrun Bosch-Traberg","Ole Kleist Jeppesen","Minh Chau Tran","Gil Chernin","Katherine R Tuttle"],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This FLOW trial analysis showed that semaglutide reduces the risk of COVID-19 and other infections in patients with type 2 diabetes and CKD, demonstrating an unexpected anti-infectious benefit of GLP-1 receptor agonism.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ab2e754035f","type":"article","url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","title":"Van internationale richtlijnen naar nationale implementatie bij cardio-renaal-metabole ziekten","title_en":"From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","diabetes-en-hart","diabetes-type-2","fidelio-dkd","figaro-dkd","ijzertekort","obesitas","richtlijnen-esc","select-trial","soul-trial","vrouwen"],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03098-z","source_url":"https://doi.org/10.1186/s12933-026-03098-z","authors":["Christoph Wanner","Francesco Cosentino","Katharine Barnard-Kelly","Tadej Battelino","Matthias Blüher","Helena N Boll","Frank C Brosius","Luca Busetto","Antonio Ceriello","James R Gavin","Francesco Giorgino","Jennifer Green","Linong Ji","Monika Kellerer","Sue Koob","Nebojsa Lalic","Nikolaus Marx","Prashant Nedungadi","Christopher G Parkin","Helena W Rodbard","Lars Rydén","Banshi Saboo","Wayne Huey-Herng Sheu","Eberhard Standl","Frank Tacke","Pinar Topsever","Oliver Schnell"],"significance":5,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/f844d2771686.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This perspective article from a multidisciplinary guideline workshop discusses translating international guidelines for cardio-kidney-metabolic diseases into national clinical practice. Key barriers include linguistic adaptation, limited clinician communication, and siloed reimbursement processes.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T13:24:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a0b72049e47b","type":"article","url":"https://hartvaat.nl/2026/02/23/telehealth-verbetert-zelfzorg-bij-kwetsbare-hartfalenpatienten/","title":"Telehealth verbetert zelfzorg bij kwetsbare hartfalenpatiënten","title_en":"How and Why Telehealth Interventions Improve Self-Care Among Vulnerable Groups of Patients With Heart Failure: Scoping Review and Rapid Realist Synthesis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","digitale-gezondheid"],"journal":"JMIR human factors","doi":"10.2196/78859","source_url":"https://doi.org/10.2196/78859","authors":["Saleema Allana","Colleen Norris","Armish Hussain","Nada Alaidarous","Raza Muhammad Haider","Alexander M Clark"],"significance":3,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/1257cfbb5ea5.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A scoping review and rapid realist synthesis examined how and why telehealth interventions improve self-care among vulnerable groups of heart failure patients in Canada, identifying key mechanisms of benefit.","created":"2026-07-03T10:25:09Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"318dffb383fe","type":"article","url":"https://hartvaat.nl/2026/02/23/polygene-en-monogene-bijdragen-aan-tachycardie-geassocieerde-cardiomyopathie/","title":"Polygene en monogene bijdragen aan tachycardie-geassocieerde cardiomyopathie","title_en":"Polygenic and Monogenic Contributions to Tachycardia-Associated Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["alcoholgebruik","aritmogene-cardiomyopathie","atriale-cardiomyopathie","cardiomyopathie-gerichte-therapie","cardiovasculaire-genetica","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","ouderen","supraventriculaire-tachycardie","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076235","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076235","authors":["Sina Safabakhsh"],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"This Circulation study analyzed the polygenic and monogenic genetic contributions to tachycardia-associated cardiomyopathy, revealing shared and distinct genetic pathways underlying this reversible form of heart failure.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c21abe63f3c9","type":"article","url":"https://hartvaat.nl/2026/02/23/remming-van-vetzuuroxidatie-bij-hartfalen-met-behouden-ejectiefractie/","title":"Remming van vetzuuroxidatie bij hartfalen met behouden ejectiefractie","title_en":"Inhibiting Fatty Acid Oxidation With a Mitotrope in Heart Failure With Preserved Ejection Fraction","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","dapa-hf","empagliflozine","emperor-trials","hfmref","hfpef","hfref","nt-probnp","step-hfpef","ventrikelfibrilleren"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078151","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078151","authors":[],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This Circulation article explored the role of a mitotrope (fatty acid oxidation inhibitor) in treating HFpEF, investigating a novel metabolic mechanism targeting cardiac energy substrate utilization.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"623b98a4f31e","type":"article","url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-myocardinfarct-winratio-analyse-uit-de-cle/","title":"Colchicine en spironolacton bij acuut myocardinfarct: winratio-analyse uit de CLEAR-trial","title_en":"Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["colchicine","colcot-trial"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/326?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/326?rss=1","authors":["dEntremont","M.-A.","Jolly","S. S.","Alharthi","F.","Shah","B.","Austin","D.","Yi","Q.","Storey","R. F.","Bossard","M.","Cornel","J.","Jaspers Focks","J.","Kedev","S.","Asani","V.","Stankovic","G.","Tsang","M.","Valettas","N.","Tyrwhitt","J.","Betz","J.","Lee","S. F.","Mian","R.","Silvain","J.","Beygui","F.","Czarnecki","A.","Dehghani","P.","Cantor","W.","Lavi","S.","Spratt","J. C.","Belley-Cote","E. P.","Eikelboom","J. W."],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This prespecified CLEAR SYNERGY analysis used generalized pairwise comparisons to assess the benefit-risk of colchicine and spironolactone after acute MI, finding net clinical benefit for colchicine but not for routine spironolactone.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c59170ca3e5","type":"article","url":"https://hartvaat.nl/2026/02/23/luchtvervuiling-en-multimorbiditeit-verhogen-het-risico-op-atriumfibrilleren/","title":"Luchtvervuiling en multimorbiditeit verhogen het risico op atriumfibrilleren","title_en":"Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","laminopathie","slaapapneu"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/318?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/318?rss=1","authors":["Zhang","J.","Chen","G.","Wei","S.","Li","W.","Lip","G. Y. H.","Lin","H."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This UK Biobank study of 480,000 participants showed that air pollution exposure interacts with multimorbidity to increase AF risk, demonstrating synergistic effects between environmental and clinical risk factors.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7478da863b08","type":"article","url":"https://hartvaat.nl/2026/02/23/regulering-van-ai-in-de-cardiologie-door-de-fda-een-scoping-review/","title":"Regulering van AI in de cardiologie door de FDA: een scoping review","title_en":"Is the FDA regulation of cardiology AI devices supporting cardiovascular innovation: a scoping review","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/6/300?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/6/300?rss=1","authors":["Hussain","A.","Guni","A.","Gandhewar","R.","Warner-Levy","J.","Davidson","A.","Shah","K.","Darzi","A.","Ashrafian","H."],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/e8315535d29a.webp","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"This scoping review of FDA-approved AI/ML devices in cardiology analyzed trends in clinical applications and regulatory pathways, assessing whether the approval framework adequately supports cardiovascular innovation.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21fc60154329","type":"article","url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","title":"Nierbescherming na harttransplantatie: risicoreductie en therapeutische mogelijkheden","title_en":"Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","harttransplantatie","hfpef","ijzertekort","niertransplantatie","ventrikelfibrilleren"],"journal":"Circulation. Heart failure","doi":"10.1161/CIRCHEARTFAILURE.125.013747","source_url":"https://doi.org/10.1161/CIRCHEARTFAILURE.125.013747","authors":["Ersilia M DeFilippis","Richard K Cheng","Elena M Donald","Shannon M Dunlay","Lorraine S Evangelista","Forum Kamdar","Prateeti Khazanie","Selma F Mohammed","Ana Rossi","Harriette G C Van Spall","Aradhana Verma","Khadijah Breathett"],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This Circulation Heart Failure review addressed strategies for mitigating kidney dysfunction after heart transplantation, covering recipient risk factors, perioperative management, and therapeutic approaches to preserve renal function.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"afbcfd7aa350","type":"article","url":"https://hartvaat.nl/2026/02/23/diabetes-verhoogt-het-risico-op-hartfalen-bij-myocarditis/","title":"Diabetes verhoogt het risico op hartfalen bij myocarditis","title_en":"Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","alcoholgebruik","anemie-ckd","bradycardie","chronische-nierziekte","diabetes-en-hart","diabetes-type-1","diabetes-type-2","endocarditis","figaro-dkd","ijzertekort","immunoadsorptie","laminopathie","microbioom","myocardinfarct","slaapapneu","soul-trial"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag064","source_url":"https://doi.org/10.1093/eschf/xvag064","authors":["Rayane El-Khoury","Shadi Mahmoud","Soha Dargham","Ziyad Mahfoud","Amin Jayyousi","Jassim Al Suwaidi","Charbel Abi Khalil"],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"This US nationwide database analysis showed that diabetes significantly increases the risk of heart failure in patients hospitalized with myocarditis, highlighting the adverse interaction between metabolic disease and myocardial inflammation.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d781e0ea95e","type":"article","url":"https://hartvaat.nl/2026/02/23/verhoogd-activine-a-bij-peripartum-cardiomyopathie-en-tijdens-lv-herstel/","title":"Verhoogd Activine-A bij peripartum cardiomyopathie en tijdens LV-herstel","title_en":"Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiomyopathie-gerichte-therapie","peripartum-cardiomyopathie","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag062","source_url":"https://doi.org/10.1093/eschf/xvag062","authors":["Thomas Gausepohl","Tobias Jonathan Pfeffer","Tobias König","Dominik Berliner","Martina Kasten","Jason Roh","Denise Hilfiker-Kleiner","Johann Bauersachs","Melanie Ricke-Hoch"],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-zwangerschap/"],"congress":"","summary_en":"This German PPCM registry study found elevated serum levels of Activin-A, a senescence-associated factor, in patients with acute peripartum cardiomyopathy, identifying a potential biomarker for this pregnancy-associated heart failure.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T13:24:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c83ab4923a5","type":"article","url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","title":"PATHFINDER-trial: betere naleving van hartfalenrichtlijnen in de huisartsenpraktijk","title_en":"Primary care Adherence To Heart failure guidelines in post-Discharge, Evaluation & Routine management (PATHFINDER): a randomised controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["esc-2026","pathfinder-trial"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag061","source_url":"https://doi.org/10.1093/eschf/xvag061","authors":["Liying Dai","Tashi Dorje","Jan Gootjes","Amit Shah","Lawrence Dembo","Graham S Hillis","Angela Jacques","Hui Jun Chih","James Rankin","John J Atherton","Suzanne Robinson","Christopher M Reid","Andrew Maiorana"],"significance":6,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"esc-2026","summary_en":"The PATHFINDER trial tested a combined intervention of inpatient education, a discharge plan with cardiac rehabilitation referral, and primary care support for heart failure, evaluating implementation strategies for guideline adherence.","created":"2026-07-03T10:25:00Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4d836aa9593","type":"article","url":"https://hartvaat.nl/2026/02/23/hartfalen-app-verbetert-ziektekennis-bij-patienten-een-gerandomiseerde-pilotstud/","title":"Hartfalen-app verbetert ziektekennis bij patiënten: een gerandomiseerde pilotstudie","title_en":"Impact of the Cardio-Meds Mobile App on Heart Failure Knowledge and Medication Adherence: Pilot Randomized Controlled Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bisoprolol","carvedilol","farmaco-economie","hfpef","hfref","pathfinder-trial","step-hfpef","vrouwen"],"journal":"JMIR cardio","doi":"10.2196/83022","source_url":"https://doi.org/10.2196/83022","authors":["Victor Buswell","Emmanuelle Massie","Elena Tessitore","Lisa Simioni","Guillaume Guebey","Hamdi Hagberg","Aurélie Schneider-Paccot","Samaksha Pant","Katherine Blondon","Liliane Gschwind","Frederic Ehrler","Philippe Meyer"],"significance":3,"published":"2026-02-23","source_date":"2026-02-23","image":"https://hartvaat.nl/global/img/70a41f630660.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"A pilot randomised trial of the Cardio-Meds mobile app showed significant improvement in heart failure knowledge after 30 days of use. The app scored high on usability, though no effect on medication adherence was detected in this small study.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a72f98d10d1d","type":"article","url":"https://hartvaat.nl/2026/02/23/arni-verbetert-kwaliteit-van-leven-en-vermindert-ziekenhuisopnames-bij-hartfalen/","title":"ARNI verbetert kwaliteit van leven en vermindert ziekenhuisopnames bij hartfalen","title_en":"Association between angiotensin receptor-neprilysin inhibitor use and clinical outcomes in patients with heart failure: a 1-year prospective cohort study from Jordan.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","nt-probnp","sacubitril-valsartan"],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-111865","source_url":"https://doi.org/10.1136/bmjopen-2025-111865","authors":["Rama S Odeh","Mariam Abdel Jalil","Mohammad Ali Qudah","Hanna K Al-Makhamreh","Akram Saleh","Oriana Awwad"],"significance":5,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/hartfalen/arb-bij-hartfalen/"],"congress":"","summary_en":"A prospective cohort study from Jordan demonstrated that angiotensin receptor-neprilysin inhibitor treatment improved quality of life, ejection fraction, and reduced hospitalisations in heart failure patients compared to ACE inhibitors or ARBs.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"237a7ac174ac","type":"article","url":"https://hartvaat.nl/2026/02/23/lichamelijke-activiteit-op-het-werk-en-bloeddruk-sekseverschillen-en-de-rol-van-/","title":"Lichamelijke activiteit op het werk en bloeddruk: sekseverschillen en de rol van vrije tijd","title_en":"Occupational Physical Activity and Blood Pressure: The Role of Leisure Time Physical Activity and Sex Differences.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"Journal of Korean medical science","doi":"10.3346/jkms.2026.41.e94","source_url":"https://doi.org/10.3346/jkms.2026.41.e94","authors":["Soo-Hyeon Kim","Seunghyeon Cho","Hyeonjun Kim","Won-Ju Park"],"significance":4,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":[],"congress":"","summary_en":"A Korean study revealed sex-specific associations between occupational physical activity and blood pressure, moderated by leisure-time physical activity. The findings support sex-specific approaches in occupational blood pressure management.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5d004c7bf5bd","type":"article","url":"https://hartvaat.nl/2026/02/23/analytische-validatie-van-een-directe-lp-a-cholesterolbepaling/","title":"Analytische validatie van een directe Lp(a)-cholesterolbepaling","title_en":"Analytical Validation of Direct Lipoprotein(a)-Cholesterol Assay.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Journal of lipid research","doi":"10.1016/j.jlr.2026.101008","source_url":"https://doi.org/10.1016/j.jlr.2026.101008","authors":["Santica M Marcovina","Spenser Smith","Lizhu Lin","Sotirios Tsimikas"],"significance":4,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Analytical validation of a direct immunocapture ELISA for measuring lipoprotein(a)-cholesterol in human plasma, demonstrating excellent linearity, precision, and specificity. Accurate Lp(a)-C measurement is essential for correct lipid panel interpretation.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fda2318eee76","type":"article","url":"https://hartvaat.nl/2026/02/23/lp-a-en-ai-ccta-onthullen-onzichtbaar-restrisico-voorbij-de-calciumscore/","title":"Lp(a) en AI-CCTA onthullen 'onzichtbaar' restrisico voorbij de calciumscore","title_en":"Beyond CACS: Can Lp(a) and AI-CCTA Unmask \"Invisible\" Residual Cardiovascular Risk?","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["calciumscore","coronaire-ct-angiografie","laminopathie","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"European heart journal. Cardiovascular Imaging","doi":"10.1093/ehjci/jeag051","source_url":"https://doi.org/10.1093/ehjci/jeag051","authors":["Christiaan J M Vrints","Emeline M Van Craenenbroeck"],"significance":7,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This editorial discussed how Lp(a) measurement combined with AI-driven coronary CT angiography can unmask residual cardiovascular risk invisible to traditional calcium scoring, advancing precision risk assessment.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f144c1e62e4","type":"article","url":"https://hartvaat.nl/2026/02/23/pcsk9-remmers-bij-cardiaal-syndroom-x-nieuw-perspectief-op-microvasculaire-angin/","title":"PCSK9-remmers bij cardiaal syndroom X: nieuw perspectief op microvasculaire angina","title_en":"The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","enlicitide","ezetimibe","laminopathie","microvasculaire-angina","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","ras-remmers"],"journal":"Microvascular research","doi":"10.1016/j.mvr.2026.104925","source_url":"https://doi.org/10.1016/j.mvr.2026.104925","authors":["Sherouk Hussein Sweilam","Hayder M Al-Kuraishy","Aya M Mustafa","Shaimaa M Hassan","Reem Alsharari","Gaber El-Saber Batiha"],"significance":3,"published":"2026-02-23","source_date":"2026-02-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This review discusses the potential role of PCSK9 inhibitors in cardiac syndrome X (microvascular angina), highlighting their effects beyond lipid lowering on endothelial dysfunction, oxidative stress, and inflammation — mechanisms central to microvascular angina pathophysiology.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c0c4c39fb8a0","type":"article","url":"https://hartvaat.nl/2026/02/22/bloeddrukcontrole-bij-hypertensie-in-gezondheidscentra-in-shenzhen/","title":"Bloeddrukcontrole bij hypertensie in gezondheidscentra in Shenzhen","title_en":"Blood pressure control rates among hypertensive patients managed in community health centres in Shenzhen, China: a megacity population-based observational study.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["bloeddrukbehandeling"],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-105830","source_url":"https://doi.org/10.1136/bmjopen-2025-105830","authors":["Jinyu He","Ning Zhang","Liangyu Kang","Wenxin Yan","Huatang Zeng","Liqun Wu","Zhenzhen Zhu","Min Liu","Wannian Liang"],"significance":4,"published":"2026-02-22","source_date":"2026-02-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A population-based observational study examined factors influencing blood pressure control rates among hypertensive patients managed in community health centres in the megacity of Shenzhen, China.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"51e6b3c23b43","type":"article","url":"https://hartvaat.nl/2026/02/22/liposomaal-bupivacaine-peng-blok-tegen-diepveneuze-trombose-bij-heupfracturen/","title":"Liposomaal bupivacaïne PENG-blok tegen diepveneuze trombose bij heupfracturen","title_en":"Effect of preoperative liposomal bupivacaine single-injection pericapsular nerve group (PENG) block on lower extremity deep vein thrombosis in elderly patients with hip fractures: a randomised controlled, double-blind, prospective clinical study protocol.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":[],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-111579","source_url":"https://doi.org/10.1136/bmjopen-2025-111579","authors":["Haobin Peng","Jiajun Wen","Manli Chen","Ying Jiang","Jianxin Ou","Xianping Wu"],"significance":4,"published":"2026-02-22","source_date":"2026-02-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A study protocol describes a randomised trial of preoperative liposomal bupivacaine pericapsular nerve group block to reduce deep vein thrombosis in elderly hip fracture patients, addressing the role of pain-induced immobilisation and inflammation.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b32477b986c0","type":"article","url":"https://hartvaat.nl/2026/02/22/kosteneffectiviteit-van-sglt2-remmers-en-glp-1-agonisten-bij-hoog-cardiovasculai/","title":"Kosteneffectiviteit van SGLT2-remmers en GLP-1-agonisten bij hoog cardiovasculair risico in Canada","title_en":"Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.","category":"preventie","category_label":"Preventie","professions":["apotheker","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","farmaco-economie","fidelity","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","semaglutide","sglt2-remmers","tirzepatide"],"journal":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","doi":"10.1503/cmaj.250591","source_url":"https://doi.org/10.1503/cmaj.250591","authors":["Ethan S McNally","Pedro Marques","Elite Possik","Ankur Pandya","Michael A Tsoukas","Thomas A Mavrakanas","Kaberi Dasgupta","Nisha Gupta","Abhinav Sharma","W Alton Russell"],"significance":6,"published":"2026-02-22","source_date":"2026-02-22","image":"https://hartvaat.nl/global/img/b42970cebaad.webp","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This Canadian simulation study compared the cost-effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes with high cardiovascular risk, informing formulary and reimbursement decisions for cardiometabolic therapy.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ec09fc9978a","type":"article","url":"https://hartvaat.nl/2026/02/22/genetische-voorspelling-van-lp-a-spiegels-in-diverse-populaties/","title":"Genetische voorspelling van Lp(a)-spiegels in diverse populaties","title_en":"Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["dyslipidemie","laminopathie","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"medRxiv : the preprint server for health sciences","doi":"10.64898/2026.02.20.26346738","source_url":"https://doi.org/10.64898/2026.02.20.26346738","authors":["Michael G Levin","Margaret Sunitha Selvaraj","Ha My T Vy","Renae Judy","Michael C Honigberg","Archna Bajaj","Girish Nadkarni","Ron Do","Pradeep Natarajan","Joshua C Denny","Po-Ru Loh"],"significance":2,"published":"2026-02-22","source_date":"2026-02-22","image":"https://hartvaat.nl/global/img/bf9768fb7dcb.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This study developed an improved genetic prediction model for lipoprotein(a) levels that works across diverse ethnic populations, potentially addressing the clinical measurement gap where fewer than 1% of US patients have Lp(a) tested.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b0ee7468de69","type":"article","url":"https://hartvaat.nl/2026/02/21/erratum-sapien-3-versus-myval-bij-tavi-compare-tavi-1/","title":"Erratum: SAPIEN 3 versus Myval bij TAVI (COMPARE-TAVI 1)","title_en":"Department of Error","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00315-6/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00315-6/fulltext","authors":[],"significance":1,"published":"2026-02-21","source_date":"2026-02-21","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"Erratum for the COMPARE-TAVI 1 trial article by Terkelsen et al. comparing SAPIEN 3 and Myval transcatheter heart valves for TAVI.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80b546cb4307","type":"article","url":"https://hartvaat.nl/2026/02/21/barrieres-en-facilitatoren-voor-mhealth-programma-diabetes-en-hypertensie-in-gha/","title":"Barrières en facilitatoren voor mHealth-programma diabetes en hypertensie in Ghana","title_en":"Barriers and Facilitators to the implementation and scale-up of a mHealth integrated care program for diabetes and hypertension in Ghana: a qualitative study of the Akoma Pa program.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"BMC health services research","doi":"10.1186/s12913-026-14175-0","source_url":"https://doi.org/10.1186/s12913-026-14175-0","authors":["Luise Struss","Paulina Afia Gyinae Wilberforce","Daniel Opoku","Daniel Boateng","Kofi Akohene Mensah","Anthony Kwaku Edusei","Cornelia Henschke","Wilm Quentin","Verena Struckmann"],"significance":3,"published":"2026-02-21","source_date":"2026-02-21","image":"https://hartvaat.nl/global/img/2d5740d20cf5.webp","kennis":[],"congress":"","summary_en":"Through in-depth interviews with 30 implementers and healthcare providers, this qualitative study identified barriers and facilitators to scaling the Akoma Pa mHealth-integrated care programme for diabetes and hypertension in Ghana.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31c45307d19e","type":"article","url":"https://hartvaat.nl/2026/02/21/driedimensionale-echocardiografie-bij-kleplijden-klinische-implicaties/","title":"Driedimensionale echocardiografie bij kleplijden: klinische implicaties","title_en":"Three-dimensional echocardiography for valvular heart disease: clinical implications.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["echocardiografie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1127","source_url":"https://doi.org/10.1093/eurheartj/ehaf1127","authors":["Nadeen N Faza","Victora Delgado","Alain Berrebi","William A Zoghbi","Stephen H Little"],"significance":7,"published":"2026-02-21","source_date":"2026-02-21","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/hartgeruisen-herkenning/","https://hartvaat.nl/kennis/kleplijden/kleplijden-en-zwangerschap/"],"congress":"","summary_en":"This European Heart Journal review described the clinical implications of three-dimensional echocardiography for valvular heart disease assessment, covering its role in surgical planning, transcatheter interventions, and monitoring.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2113bfcb908","type":"article","url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","title":"Aspirine, lipoproteïne(a) en aortaklepstenose: de MESA-studie","title_en":"Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag018","source_url":"https://doi.org/10.1093/eurheartj/ehag018","authors":["Alexander C Razavi","Harpreet S Bhatia","Natalie Marrero","Omar Dzaye","Wendy S Post","Khurram Nasir","Michael Tsai","Viola Vaccarino","Ramachandran S Vasan","George Thanassoulis","Sotirios Tsimikas","Laurence S Sperling","Matthew J Budoff","Roger S Blumenthal","Michael J Blaha","Seamus P Whelton"],"significance":7,"published":"2026-02-21","source_date":"2026-02-21","image":"","kennis":[],"congress":"","summary_en":"This MESA study examined the relationship between aspirin use, lipoprotein(a) levels, and calcific aortic valve disease, exploring whether aspirin modifies the Lp(a)-driven pathway to aortic stenosis.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9cd4f9c76a7","type":"article","url":"https://hartvaat.nl/2026/02/21/pelacarsen-vermindert-de-behoefte-aan-lipoproteine-a-aferese-lp-a-frontiers-aphe/","title":"Pelacarsen vermindert de behoefte aan lipoproteïne(a)-aferese: Lp(a)FRONTIERS APHERESIS","title_en":"Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","soul-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag073","source_url":"https://doi.org/10.1093/eurheartj/ehag073","authors":["Klaus G Parhofer","Ulrich Julius","Anna Laura Herzog","Thilo Krüger","Julia Weinmann-Menke","Gunnar H Heine","Hui Cao","Jessica Schorr","Philippe Ferber","Jing Wang","Enrico Cristante","Björn Müller-Edenborn","Anja Vogt","Volker Schettler","Elisabeth Steinhagen-Thiessen"],"significance":8,"published":"2026-02-21","source_date":"2026-02-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"The Lp(a)FRONTIERS APHERESIS trial investigated whether pelacarsen can reduce the need for lipoprotein apheresis in patients with elevated Lp(a) and established cardiovascular disease. The study addresses a critical question about the potential of pharmacological Lp(a) lowering to replace this burdensome procedure.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4bde4dee978f","type":"article","url":"https://hartvaat.nl/2026/02/20/kosteneffectiviteit-van-mavacamten-bij-obstructieve-hcm-gezondheidswinst-maar-ee/","title":"Kosteneffectiviteit van mavacamten bij obstructieve HCM: gezondheidswinst, maar een hoge prijs","title_en":"Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","biomarkers-cardiovasculair","cardiomyopathie-gerichte-therapie","emperor-trials","farmaco-economie","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","mavacamten","myocardinfarct","summit-trial"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003914?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003914?rss=1","authors":["Qian","J.","Zhang","J.","Jiang","Q.","Wu","T."],"significance":5,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/revalidatie-na-hartinfarct/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The phase III EXPLORER-HCM trial showed that the cardiac myosin inhibitor mavacamten improves symptoms and function in obstructive hypertrophic cardiomyopathy (HCM). This study used a Markov model to assess the cost-effectiveness of mavacamten plus a beta-blocker or calcium-channel blocker versus placebo plus the same agents, from the Chinese healthcare perspective. Compared with placebo, mavacamten yielded 2.1 additional quality-adjusted life years (QALYs) and 3.15 additional life years, at an incremental cost-effectiveness ratio (ICER) of about US$50,587 per QALY. Drug price was the key driver. Mavacamten thus provides substantial health benefit, but the ICER exceeds the common willingness-to-pay threshold — underscoring the importance of pricing in reimbursing this new, expensive agent.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73c10eb16e67","type":"article","url":"https://hartvaat.nl/2026/02/20/virtuele-afdeling-met-thuismonitoring-is-veilig-voor-patienten-die-wachten-op-sp/","title":"Virtuele afdeling met thuismonitoring is veilig voor patiënten die wachten op spoed-bypasschirurgie","title_en":"Feasibility, safety and outcomes of a virtual ward with remote monitoring for patients awaiting urgent coronary artery bypass graft surgery","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003568?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003568?rss=1","authors":["Kirupananthavel","A.","Woldman","S.","Jones","D. A.","Ferguson","G.","Knight","C.","Ozkor","M.","Edmondson","S.","Archbold","A.","Radley","J.","Niblock","C.","Johnson","A.","Theisinger","J.","Rossi","A.","AlJaaly","E.","Kelshiker","M.","Peters","N. S.","Lall","K.","Das","D.","Yates","M. T."],"significance":5,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/"],"congress":"","summary_en":"Waiting times for urgent coronary artery bypass grafting (CABG) are rising in the UK, with long preoperative admissions occupying beds and burdening patients. A 'virtual ward' with home monitoring could let clinically stable patients go home safely earlier. In this prospective multicentre study (128 patients, three UK cardiac centres), patients were discharged home with daily symptom reporting via a digital platform and structured review. No preoperative major adverse cardiac events occurred (0%) and 30-day mortality was 0%; resternotomy occurred in 2.3%, comparable to national rates. Median time from discharge to surgery was 10 days, with an estimated saving of 1,152 inpatient bed-days. Patients were positive (95% felt safe at home). A virtual ward with home monitoring is thus safe and feasible for selected patients awaiting urgent CABG, with major gains in bed capacity.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"54032b35ed1c","type":"article","url":"https://hartvaat.nl/2026/02/20/geintegreerd-machine-learningmodel-voorspelt-cardiovasculair-risico-beter-dan-de/","title":"Geïntegreerd machine-learningmodel voorspelt cardiovasculair risico beter dan de Framingham-score (UK Biobank)","title_en":"Enhanced cardiovascular disease risk prediction using integrated machine learning models: a study from the UK Biobank cohort","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","cardiovasculaire-genetica","diabetes-en-hart","diabetes-type-2","farmaco-economie","gepersonaliseerde-geneeskunde","kunstmatige-intelligentie","laminopathie","menopauze","ouderen","polygene-risicoscore","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003827?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003827?rss=1","authors":["Yang","Q.","Lu","Y.","Jiang","X.","Hu","H.","Lu","X.","Guo","C."],"significance":6,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"Classical risk scores such as Framingham and SCORE sometimes fall short due to their limited variable set. In this study, machine learning was used to develop a comprehensive cardiovascular risk model from the UK Biobank (240,644 participants), combining genetic scores, clinical parameters and lifestyle factors, with separate models for overall cardiovascular risk, cerebrovascular and thrombotic disease. The integrated model (clinical + lifestyle + genetic) performed best, with an AUC of 0.85 — an improvement of 0.12 over the Framingham score. Models based on clinical, lifestyle or genetic data alone performed worse. Key predictors were age, systolic blood pressure, cystatin C and waist circumference. Combining clinical, lifestyle and genetic data thus substantially improves cardiovascular risk prediction — though validation in diverse populations is still needed.","created":"2026-07-03T10:32:24Z","updated":"2026-07-03T13:31:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9c7539600ec","type":"article","url":"https://hartvaat.nl/2026/02/20/darmmicrobiota-en-geschatte-glomerulaire-filtratiesnelheid-in-twee-zweedse-cohor/","title":"Darmmicrobiota en geschatte glomerulaire filtratiesnelheid in twee Zweedse cohorten","title_en":"Association between the gut microbiota and estimated glomerular filtration rate in two Swedish population-based cohorts","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["chronische-nierziekte","cystatine-c","microbioom","semaglutide","tirzepatide"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00129-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00129-8/fulltext","authors":["Yi-Ting Lin","Tiscar Graells","Sergi Sayols-Baixeras","Koen F. Dekkers","Tessa Schillemans","Gabriel Baldanzi","Jonas Wuopio","Nynne Nielsen","Aron C. Eklund","Jacob B. Holm","H. Bjørn Nielsen","Göran Bergström","J. Gustav Smith","Andrei Malinovschi","Gunnar Engström","Marju Orho-Melander","Tove Fall","Johan Ärnlöv"],"significance":5,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This study quantified links between gut microbiota composition and estimated GFR in two population-based Swedish cohorts, providing evidence for gut-kidney interactions even in community-dwelling adults with largely preserved kidney function.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2201ddadf356","type":"article","url":"https://hartvaat.nl/2026/02/20/hev-gericht-antilichaam-medicijnconjugaat-bevordert-langdurige-acceptatie-van-ha/","title":"HEV-gericht antilichaam-medicijnconjugaat bevordert langdurige acceptatie van harttransplantaat","title_en":"HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["harttransplantatie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076423","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076423","authors":["Yanjia Che"],"significance":5,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":[],"congress":"","summary_en":"This study developed an HEV-targeted antibody-drug conjugate that promotes long-term cardiac allograft acceptance by modulating naive T-cell trafficking through lymph node high endothelial venules. The approach represents a novel immunomodulatory strategy for transplantation.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5c70b4f1efc","type":"article","url":"https://hartvaat.nl/2026/02/20/in-memoriam-claudio-ponticelli-1936-2026/","title":"In memoriam: Claudio Ponticelli (1936-2026)","title_en":"Memories of Claudio Ponticelli","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00135-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00135-3/fulltext","authors":["Gabriella Moroni","Richard Glassock","Alessia Fornoni"],"significance":1,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":[],"congress":"","summary_en":"In memoriam for Claudio Ponticelli (1936-2026), a world-renowned nephrologist who passed away on January 1, 2026, at age 89. He was esteemed for his humanistic character and patient-centred contributions to nephrology.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14dbec3c1982","type":"article","url":"https://hartvaat.nl/2026/02/20/milt-norepinefrine-2-adrenerge-as-verergert-sepsis-geassocieerd-acuut-nierletsel/","title":"Milt-norepinefrine-β2-adrenerge as verergert sepsis-geassocieerd acuut nierletsel","title_en":"The splenic norepinephrine–β2-adrenergic receptor axis aggravates sepsis-associated acute kidney injury via neutrophil-mediated immunosuppression","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00132-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00132-8/fulltext","authors":["Shuai Ma","Xiaoqian Hu","Bo Deng","Yaqi Wan","Wenchang Meng","Zhihao Wu","Juan Liu","Xuezhu Li","Lingyun Shao","Xuguang Yang","Feng Ding","Yuli Lin"],"significance":4,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":[],"congress":"","summary_en":"This study uncovers a neural mechanism whereby the splenic norepinephrine-beta2-adrenergic receptor axis aggravates sepsis-associated acute kidney injury through neutrophil-mediated immunosuppression.","created":"2026-07-03T10:25:18Z","updated":"2026-07-03T13:24:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da891f9cfd7b","type":"article","url":"https://hartvaat.nl/2026/02/20/longdan-xiegan-formule-als-aanvullende-therapie-bij-hypertensie-systematische-re/","title":"Longdan Xiegan-formule als aanvullende therapie bij hypertensie: systematische review","title_en":"Longdan Xiegan formula as adjuvant therapy for hypertension: A systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","huisarts"],"tags":[],"journal":"Medicine","doi":"10.1097/MD.0000000000047736","source_url":"https://doi.org/10.1097/MD.0000000000047736","authors":["Shengye Lu","Xueyan Lv","Jun Zuo"],"significance":2,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated the efficacy of Longdan Xiegan decoction, a traditional Chinese medicine formula, as adjunctive therapy for hypertension.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12d2dbbf65c2","type":"article","url":"https://hartvaat.nl/2026/02/20/rol-van-appelzuurenzym-1-bij-ferroptose-en-zenuwschade-bij-hypertensieve-muizen-/","title":"Rol van appelzuurenzym-1 bij ferroptose en zenuwschade bij hypertensieve muizen na loodblootstelling","title_en":"[The role of malic enzyme 1 regulating ferroptosis on nerve impairment of hypertensive mice following lead exposure].","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["anemie-ckd","bloeddrukbehandeling","diuretica","ezetimibe","renale-denervatie","semaglutide","tirzepatide"],"journal":"Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases","doi":"10.3760/cma.j.cn121094-20241029-00494","source_url":"https://doi.org/10.3760/cma.j.cn121094-20241029-00494","authors":["J N Li","Z Y Zhang","Y J Wang","Y T Zhang","W X Wang","Y S Zhang"],"significance":2,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":[],"congress":"","summary_en":"This animal study explored the role of hippocampal ferroptosis mediated by malic enzyme 1 in nerve impairment caused by lead exposure in hypertensive mice.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"faf92de1439c","type":"article","url":"https://hartvaat.nl/2026/02/20/intensief-bewegen-verlaagt-het-risico-op-veneuze-trombo-embolie-mendeliaanse-ran/","title":"Intensief bewegen verlaagt het risico op veneuze trombo-embolie: Mendeliaanse randomisatie","title_en":"The impact of different intensities of physical activity on the risk of venous thromboembolism: A Mendelian randomization study.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["veneuze-trombose"],"journal":"Medicine","doi":"10.1097/MD.0000000000047589","source_url":"https://doi.org/10.1097/MD.0000000000047589","authors":["Yongjin Xie","Jintuo Zhou","Yanting Zhu","Yingling Xie"],"significance":3,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A Mendelian randomisation study using genetic data from the UK Biobank and FinnGen demonstrated that vigorous physical activity is causally associated with a 27% lower risk of venous thromboembolism.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"20c036fbd407","type":"article","url":"https://hartvaat.nl/2026/02/20/hartslagvariabiliteit-modereert-het-verband-tussen-angst-en-sympathische-zenuwac/","title":"Hartslagvariabiliteit modereert het verband tussen angst en sympathische zenuwactiviteit","title_en":"Heart Rate Variability Moderates the Association Between Trait Anxiety and Sympathetic Nerve Activity in Humans","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","renale-denervatie","stress-psychosociaal","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26014","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26014","authors":[],"significance":7,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study investigated whether heart rate variability moderates the association between trait anxiety and sympathetic nerve activity, exploring the neurophysiological mechanism linking chronic anxiety to hypertension development.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T13:24:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb4125785b16","type":"article","url":"https://hartvaat.nl/2026/02/20/lage-dosis-drievoudige-combinatiepil-versus-standaard-telmisartan-bij-hypertensi/","title":"Lage dosis drievoudige combinatiepil versus standaard telmisartan bij hypertensie","title_en":"Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25810","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25810","authors":["Jeong Cheon Ahn"],"significance":7,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/calciumantagonisten-hypertensie/","https://hartvaat.nl/kennis/preventie/hartrevalidatie-programma/"],"congress":"","summary_en":"This phase III RCT compared a low-dose triple single-pill combination (telmisartan/amlodipine/chlorthalidone) with standard-dose telmisartan monotherapy, showing superior blood pressure reduction with the combination approach.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T13:24:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"48b437319ae9","type":"article","url":"https://hartvaat.nl/2026/02/20/proteomische-risicoscore-voorspelt-het-ontstaan-van-hypertensie/","title":"Proteomische risicoscore voorspelt het ontstaan van hypertensie","title_en":"Proteomic Risk Score for Prediction of Incident Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["abelacimab","baxdrostat","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","dyslipidemie","fidelity","figaro-dkd","gepersonaliseerde-geneeskunde","lipidenverlaging","lorundrostat","primaire-preventie","ras-remmers","renale-denervatie","resistente-hypertensie-aldosteronremmers","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26321","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26321","authors":["Minkwan Kim"],"significance":7,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study developed a proteomic risk score from UK Biobank data that predicts incident hypertension better than traditional risk factors, advancing precision medicine approaches to blood pressure management.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f434d95c81c","type":"article","url":"https://hartvaat.nl/2026/02/20/mhealth-interventie-verbetert-hypertensiezorg-bij-hoogrisicopatienten/","title":"mHealth-interventie verbetert hypertensiezorg bij hoogrisicopatiënten","title_en":"mHealth Intervention to Improve Hypertension Care in High-Risk Patients","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["acuut-hartfalen","bloeddrukbehandeling","digitale-gezondheid","farmaco-economie","holter","summit-trial","thuisbloeddrukmeting","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26148","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26148","authors":["Kamakshi Lakshminarayan"],"significance":7,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The mGlide trial showed that a pharmacist-led, mobile health technology-facilitated care model improves blood pressure control in diverse patients with uncontrolled hypertension, demonstrating the effectiveness of technology-enabled interprofessional care.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f80441ee26f2","type":"article","url":"https://hartvaat.nl/2026/02/20/risicofactoren-voor-pulmonale-hypertensie-bij-linkszijdig-hartlijden/","title":"Risicofactoren voor pulmonale hypertensie bij linkszijdig hartlijden","title_en":"The risk factors associated with pulmonary hypertension in patients with left heart diseases.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hypertrofische-cardiomyopathie","laminopathie","pulmonaalvenenisolatie","pulmonale-hypertensie"],"journal":"Medicine","doi":"10.1097/MD.0000000000047799","source_url":"https://doi.org/10.1097/MD.0000000000047799","authors":["Kaina Wang","Jin Fan","Ling Mei"],"significance":3,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"In 411 elderly male patients with left heart disease, atrial fibrillation, left atrial dilatation, and reduced left ventricular ejection fraction were identified as independent predictors of pulmonary hypertension.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a8e76e2b31f1","type":"article","url":"https://hartvaat.nl/2026/02/20/hypertensie-bij-45-plussers-in-china-prevalentie-bewustzijn-en-behandeling/","title":"Hypertensie bij 45-plussers in China: prevalentie, bewustzijn en behandeling","title_en":"Prevalence and management of hypertension among adults aged 45 and older in mainland China: Insights from the 2020 CHARLS survey.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Medicine","doi":"10.1097/MD.0000000000047704","source_url":"https://doi.org/10.1097/MD.0000000000047704","authors":["Aiai Zhu","Yanna Le","Lei Zhang","Zhiwei Leng","Changfeng Hu","Chengjian Cao","Luoxian Yang"],"significance":3,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"A CHARLS survey of nearly 20,000 Chinese adults aged 45 and older found a hypertension prevalence of 38%. While 79% used antihypertensives, fewer than half received education on complication prevention, highlighting the need for improved primary care health literacy.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T18:38:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bfb9dd0db327","type":"article","url":"https://hartvaat.nl/2026/02/20/biomarkers-voor-atherosclerotische-events-bij-reumatoide-artritis-lp-a-als-voors/","title":"Biomarkers voor atherosclerotische events bij reumatoïde artritis: Lp(a) als voorspeller","title_en":"Biomarkers for Atherosclerotic Cardiovascular Events in Rheumatoid Arthritis: Towards Validation of a Biomarker-Enhanced Risk Model.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["atherosclerose","biomarkers-cardiovasculair","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"medRxiv : the preprint server for health sciences","doi":"10.64898/2026.02.18.26346592","source_url":"https://doi.org/10.64898/2026.02.18.26346592","authors":["Daniel H Solomon","Leah Santacroce","Jon T Giles","Pamela Rist","Brendan M Everett","Katherine P Liao","Misti Paudel","Nancy A Shadick","Michael Weinblatt","Joan M Bathon","Olga Demler"],"significance":2,"published":"2026-02-20","source_date":"2026-02-20","image":"https://hartvaat.nl/global/img/bf9768fb7dcb.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This study validates a biomarker-enhanced risk model incorporating lipoprotein(a), osteoprotegerin, and troponin T for improved cardiovascular risk stratification in rheumatoid arthritis patients, outperforming traditional risk scores.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"229b39243b6b","type":"article","url":"https://hartvaat.nl/2026/02/20/secundaire-preventie-na-myocardinfarct-in-saudi-arabie-het-4s-register/","title":"Secundaire preventie na myocardinfarct in Saudi-Arabië: het 4S-register","title_en":"Saudi Secondary Prevention Survey Study in Patients with Prior Acute Myocardial Infarction (4S Registry): Study Design and Pilot Phase Results.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of cardiovascular development and disease","doi":"10.3390/jcdd13020100","source_url":"https://doi.org/10.3390/jcdd13020100","authors":["Rakan K Alhabib","Naji Kholaif","Mohammed Mahmoud","Abdulrahman Alnwiji","Fayez Al Zubair","Hassan Almir","Ahmad Saad Alzoman","Abdulmalik Abdullah Alqahtani","Rasha Alsharkawy","Zahra Mohammed Albahar","Khalid F Alhabib"],"significance":3,"published":"2026-02-20","source_date":"2026-02-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"The 4S registry evaluated adherence to guideline-recommended secondary prevention strategies after acute myocardial infarction in Saudi Arabia. Risk factors including Lp(a) were inadequately controlled, reflecting the global challenge of optimal secondary prevention.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7464f64565ba","type":"article","url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","title":"PARTNER 3: TAVR versus chirurgie bij laagrisico — zevenjaarsresultaten NEJM","title_en":"Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2509766","source_url":"https://doi.org/10.1056/NEJMoa2509766","authors":["Martin B Leon","Michael J Mack","Philippe Pibarot","Rebecca T Hahn","Vinod H Thourani","S H Kodali","Philippe Généreux","Samir R Kapadia","David J Cohen","Stuart J Pocock","Yiran Zhang","Molly Szerlip","Julien Ternacle","S Chris Malaisrie","Howard C Herrmann","Wilson Y Szeto","Mark J Russo","Vasilis Babaliaros","Tamim Nazif","John G Webb","Raj R Makkar"],"significance":9,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":[],"congress":"","summary_en":"The 7-year PARTNER 3 results confirmed comparable outcomes between TAVR and surgical aortic valve replacement in low-risk patients, with maintained valve durability and no excess structural deterioration. These are the longest-term data supporting TAVR across the full surgical risk spectrum.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6cc977400731","type":"article","url":"https://hartvaat.nl/2026/02/19/2026-aha-acc-richtlijn-voor-evaluatie-en-behandeling-van-acute-longembolie/","title":"2026 AHA/ACC-richtlijn voor evaluatie en behandeling van acute longembolie","title_en":"2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001415","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001415","authors":[],"significance":9,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The 2026 AHA/ACC multisociety guideline provides comprehensive, de novo recommendations for the evaluation and management of acute pulmonary embolism in adults, covering risk stratification, anticoagulation, thrombolysis, catheter-directed therapy, and long-term follow-up.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"857b08c6da0f","type":"article","url":"https://hartvaat.nl/2026/02/19/kanker-en-coronaire-atherosclerotische-plaquebelasting-inzichten-uit-de-bravado-/","title":"Kanker en coronaire atherosclerotische plaquebelasting: inzichten uit de BRAVADO-studie","title_en":"Association of Cancer on Coronary Atherosclerotic Burden and Plaque Rupture: Insights from the BRAVADO Study","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","atherosclerose","biomarkers-cardiovasculair","inflammatie","ouderen","perifeer-vaatlijden","plaquekarakterisatie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00049-3/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00049-3/fulltext","authors":["Vinicius Bocchino Seleme","Isabela Bispo Santos da Silva Costa","Bruna Pileggi","Carlos Eduardo de Barros Branco","Stephanie Itala Rizk","Maria Antonieta Albanez Albuquerque de Medeiros Lopes","Diego Carter Campanha Borges","Rodrigo Noronha Campos","Fabio Sandoli de Brito","Josiane Mara Abdalla Sanches","Roger Renault Godinho","Rodrigo Barbosa Esper","Bruno Faillace","Dalton Bertolim Precoma","Marcelo Harada Ribeiro","Juliane Dantas Seabra-Garcez","Amanda Fonseca Nunes Ferreira","Roberto Kalil Filho","Alexandre Abizaid","Ludhmila Abrahao Hajjar","Carlos M. Campos"],"significance":5,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/psychosociale-risicofactoren-hart/"],"congress":"","summary_en":"The BRAVADO study investigated the specific impact of cancer on coronary atherosclerotic plaque burden and lesion complexity in patients presenting with acute coronary syndrome. The findings advance understanding of cardio-oncology interactions.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cd1de7239f04","type":"article","url":"https://hartvaat.nl/2026/02/19/mettl3-interventie-onderdrukt-pathogene-th17-differentiatie-en-herstelt-nierscha/","title":"METTL3-interventie onderdrukt pathogene Th17-differentiatie en herstelt nierschade bij lupusnefritis","title_en":"METTL3-targeted intervention on nuclear factors RORA/RORγt suppressing pathogenic T helper 17 cell differentiation and restores kidney damage in lupus nephritis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00133-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00133-X/fulltext","authors":["Xinhang Xia","Chunhao Long","Wenwen Chen","Xuyang Yao","Binbing Xu","Huilin Teng","Yanli Fang","Qihui Xu","Cong Zhang","Mingli Chen","Zhangyi Xie","Xinya Tong","Aqiong Chen","Feifei Hu","Xiangyang Xue","Huidi Zhang","Gangqiang Guo"],"significance":4,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This study reveals that METTL3-mediated m6A modification of nuclear factors RORA/RORgammat suppresses pathogenic Th17 cell differentiation and restores kidney damage in lupus nephritis, identifying a new epigenetic regulatory mechanism.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa5e6592f016","type":"article","url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","title":"Geleidingsstoornissen na transkatheter aortaklepimplantatie","title_en":"Conduction disturbances after transcatheter aortic valve implantation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aortainsufficiëntie","aortastenose","bradycardie","hartkatheterisatie","perifeer-vaatlijden","supraventriculaire-tachycardie","tavi","ventrikelfibrilleren"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag093","source_url":"https://doi.org/10.1093/eurheartj/ehag093","authors":["Annette Maznyczka","Thomas Pilgrim","François Philippon","Josep Rodés-Cabau","Ole De Backer"],"significance":8,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"This European Heart Journal review addressed conduction disturbances after TAVI, covering the predictors of permanent pacemaker implantation, the impact on long-term outcomes, and strategies for minimizing conduction complications during transcatheter valve procedures.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7a467ccf4245","type":"article","url":"https://hartvaat.nl/2026/02/19/creatinine-cystatine-c-of-beide-voor-gfr-schatting-bij-niertransplantatiepatient/","title":"Creatinine, cystatine C of beide voor GFR-schatting bij niertransplantatiepatiënten?","title_en":"Creatinine, cystatin C or both to estimate glomerular filtration rate in kidney transplant recipients?","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["chronische-nierziekte","cystatine-c"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag037","source_url":"https://doi.org/10.1093/ndt/gfag037","authors":["Pierre Delanaye","Marco van Londen","Emmanuelle Vidal-Petiot","Ingrid Masson","Nicolas Maillard","Antoine Bouquegneau","Laurent Weekers","Martin H de Borst","Stephan J L Bakker","Hans Pottel","Martin Flamant","Christophe Mariat"],"significance":5,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/egfr-berekening-interpretatie/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This multicentre study compared creatinine-based, cystatin C-based, and combined GFR estimation equations in kidney transplant recipients. The findings inform the clinical choice of biomarkers for post-transplant renal function monitoring.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8cee399f7c5b","type":"article","url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","title":"Delirium in de cardiovasculaire geneeskunde","title_en":"Delirium in cardiovascular medicine.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","delirium-cardiologie","ouderen","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag088","source_url":"https://doi.org/10.1093/eurheartj/ehag088","authors":["Endrit Cekaj","David H V Vogel","Peter M Spieth","Benedikt Schrage","Aitor Uribarri","Frederic De Roeck","Jordi Riera","Federico Pappalardo","Norman Mangner","Guido Tavazzi","Tom Verbelen","Carsten Skurk","Christian Jung","Andreas Schäfer","Dirk Westermann","Sebastian Zimmer","Frederik Sand","Malte Kelm","Stefan Baldus","Christian Hagl","Farhad Bakhtiary","Georg Nickenig","Alain Combes","Holger Thiele","Alexandra Philipsen","Enzo Lüsebrink"],"significance":7,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This European Heart Journal review addressed delirium in cardiovascular medicine, covering its prevalence, pathophysiology, and management in patients undergoing cardiac procedures and intensive care.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5764820a805","type":"article","url":"https://hartvaat.nl/2026/02/19/competenties-na-certificering-en-cardiovasculaire-zorgverlening/","title":"Competenties na certificering en cardiovasculaire zorgverlening","title_en":"Post-certification competencies and cardiovascular care delivery.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["hartrevalidatie","ouderen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1037","source_url":"https://doi.org/10.1093/eurheartj/ehaf1037","authors":["Chris Plummer","Ronen Beeri","Franz Weidinger","Cecilia Linde","Thomas F Luescher","Theresa McDonagh","Susanna Price","Felix C Tanner","Mark Westwood","Lampros Michalis"],"significance":6,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This European Heart Journal article discussed post-certification competencies in cardiovascular care delivery, addressing how subspecialization within cardiology can be structured to maintain quality across the expanding scope of the field.","created":"2026-07-03T10:25:10Z","updated":"2026-07-03T13:24:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ade4d705dc6","type":"article","url":"https://hartvaat.nl/2026/02/19/secundaire-preventie-na-ischemisch-cva-overzicht-uit-het-nejm/","title":"Secundaire preventie na ischemisch CVA: overzicht uit het NEJM","title_en":"Secondary Prevention after Ischemic Stroke.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMcp2415601","source_url":"https://doi.org/10.1056/NEJMcp2415601","authors":["Karen L Furie","Peter J Kelly"],"significance":8,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":[],"congress":"","summary_en":"This NEJM review provided a comprehensive update on secondary prevention after ischemic stroke, covering modifiable risk factors, mechanism-specific therapies, and contemporary evidence on anticoagulation, antiplatelet therapy, and lipid lowering for recurrent stroke prevention.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb72851a8e6e","type":"article","url":"https://hartvaat.nl/2026/02/19/cardiovasculair-renaal-metabool-samenspel-bij-patienten-met-atriumfibrilleren/","title":"Cardiovasculair-renaal-metabool samenspel bij patiënten met atriumfibrilleren","title_en":"Cardiovascular-Kidney-Metabolic Interplay in Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulants.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","obesitas","richtlijnen-esc","voeding-hart"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag028","source_url":"https://doi.org/10.1093/europace/euag028","authors":["Yi-Hsin Chan","Yi-Wei Kao","Wen-Han Cheng","Shao-Wei Chen","Chung-Lieh Hung","Giulio Francesco Romiti","Gregory Y H Lip","Tze-Fan Chao"],"significance":7,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This comprehensive review examined the cardiovascular-kidney-metabolic interplay in AF patients on DOACs, exploring how CKM syndrome affects anticoagulation efficacy, safety, and dosing decisions.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f202fadafac3","type":"article","url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","title":"Evolocumab en doorgankelijkheid van veneuze bypasses na CABG: NEWTON-CABG CardioLink-5","title_en":"Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["coronaire-bypass","evolocumab","newton-cabg","pcsk9-remmers-nieuwe-generatie"],"journal":"Diabetes, obesity & metabolism","doi":"10.1111/dom.70590","source_url":"https://doi.org/10.1111/dom.70590","authors":["Hwee Teoh","Subodh Verma","G B John Mancini","Adrian Quan","Michael Szarek","Randi Elituv","Meena Verma","Elizabeth Misner","Aishwarya Krishnaraj","Peter Jüni","Michael J Koren","Stephen J Nicholls","Deepak L Bhatt","C David Mazer","Lawrence A Leiter"],"significance":5,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"The NEWTON-CABG CardioLink-5 trial evaluated whether adding evolocumab to statin therapy improves saphenous vein graft patency after coronary artery bypass surgery, with separate analysis for patients with and without diabetes.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7260f88c15c9","type":"article","url":"https://hartvaat.nl/2026/02/19/enkelvoudige-onverzadigde-vetzuren-in-vetweefsel-en-het-risico-op-perifeer-vaatl/","title":"Enkelvoudige onverzadigde vetzuren in vetweefsel en het risico op perifeer vaatlijden","title_en":"Monounsaturated Fatty Acids in Adipose Tissue and the Risk of Peripheral Artery Disease: A Danish Case-Cohort study","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00051-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00051-1/fulltext","authors":["Jonas Pedersen","Alberte Sjælland","Frederik Kistrup Gerth Kramme","Jytte Halkjær","Anja Olsen","Christina C. Dahm","Kirsten B. Holven","Erik Berg Schmidt","Stine Krogh Venø","Christian Bork"],"significance":5,"published":"2026-02-19","source_date":"2026-02-19","image":"","kennis":[],"congress":"","summary_en":"A Danish case-cohort study examined the association between individual monounsaturated fatty acids in adipose tissue and the risk of peripheral artery disease. The findings nuance dietary recommendations on replacing saturated fats with MUFAs.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af84be5ef0bd","type":"article","url":"https://hartvaat.nl/2026/02/18/angiotensine-1-7-activeert-pomc-neuronen-in-de-nucleus-arcuatus/","title":"Angiotensine-(1-7) activeert POMC-neuronen in de nucleus arcuatus","title_en":"Angiotensin-(1–7) Activates Proopiomelanocortin Neurons in the Arcuate Nucleus","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["ras-remmers"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26262","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26262","authors":[],"significance":4,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/hypertensie/pathofysiologie-hypertensie/"],"congress":"","summary_en":"This study demonstrates that angiotensin-(1-7) activates proopiomelanocortin neurons in the arcuate nucleus, revealing a central mechanism underlying the cardiometabolic protective effects of this peptide in obesity and hypertension.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80ba59983d9f","type":"article","url":"https://hartvaat.nl/2026/02/18/betablokkers-na-een-myocardinfarct/","title":"Bètablokkers na een myocardinfarct","title_en":"Beta-Blockers after Myocardial Infarction","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":["betablokkers","myocardinfarct"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMc2518019&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMc2518019&rss=currentIssue","authors":[],"significance":9,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This NEJM review article synthesizes the current evidence on beta-blocker use after myocardial infarction, reflecting the paradigm shift from routine long-term therapy to an evidence-based approach where beta-blockers are no longer mandatory when ejection fraction is preserved.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"34b9bbed5cb9","type":"article","url":"https://hartvaat.nl/2026/02/18/verstoring-van-de-cystine-1-myristoyl-elektrostatische-schakelaar-veroorzaakt-po/","title":"Verstoring van de cystine-1 myristoyl-elektrostatische schakelaar veroorzaakt polycysteuze nierziekte","title_en":"Disruption of the human cystin-1 myristoyl-electrostatic switch causes polycystic kidney disease that phenocopies autosomal recessive polycystic kidney disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00131-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00131-6/fulltext","authors":["Chaozhe Yang","Naoe Harafuji","Jacob A. Watts","Binli Tao","Claire Moran","Jenna Clements","Kalyn Price","Anthony Laucevicius","Natalie Burrill","Juliana Gebb","Shelly Soni","Edward Oliver","Jill J. Savla","Lori Christ","Julie Moldenhauer","Erum A. Hartung","Ryne Didier","Avni Santani","Richard N. Sandford","Lisa Selkirk","Jessica A. Radley","Kathy Mann","Ingrid Simonicova","Rudolfo Karl","Arsila Palliyulla Kariat Ashraf","Dagmar Wachten","Landon Wilson","Zsuzsanna Bebok","Ljubica Caldovic","Lisa M. Guay-Woodford"],"significance":4,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":[],"congress":"","summary_en":"This study demonstrates that disruption of the myristoyl-electrostatic switch of human cystin-1 causes polycystic kidney disease phenocopying autosomal recessive PKD, providing mechanistic insight into ciliopathy-related cystogenesis.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8ce8c6812cb","type":"article","url":"https://hartvaat.nl/2026/02/18/gentherapie-voor-nefropathische-cystinose/","title":"Gentherapie voor nefropathische cystinose","title_en":"Gene Therapy for Nephropathic Cystinosis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMe2600177&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMe2600177&rss=currentIssue","authors":["Olivier Devuyst"],"significance":8,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":[],"congress":"","summary_en":"This NEJM article discussed gene therapy as a treatment option for nephropathic cystinosis, a rare lysosomal storage disorder affecting kidney function, exploring the potential for curative genetic intervention.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e20292a21681","type":"article","url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","title":"Groene dialyse: duurzame zorg, groei en innovatie (KDIGO-conferentie)","title_en":"Green Dialysis: Environmentally Sustainable Care, Growth, and Innovation: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00079-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00079-7/fulltext","authors":["Katherine A. Barraclough","Nathan Berman-Parks","Vivekanand Jha","Giorgina B. Piccoli","Caroline Stigant","Benjamin Talbot","Faissal Tarrass","Michael Cheung","Jennifer M. King","Morgan E. Grams","Michel Jadoul","Jennifer E. Flythe","Conference Participants"],"significance":6,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":[],"congress":"","summary_en":"This KDIGO Conference addressed the environmental sustainability of dialysis therapies, proposing green dialysis practices to reduce the substantial carbon footprint, water consumption, and waste of kidney replacement therapy.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cbcfb78d52db","type":"article","url":"https://hartvaat.nl/2026/02/18/osilodrostat-bij-bilaterale-bijnieroverproductie-van-cortisol-bij-primair-aldost/","title":"Osilodrostat bij bilaterale bijnieroverproductie van cortisol bij primair aldosteronisme","title_en":"More on Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","lorundrostat","mra-aldosteronantagonisten","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","spironolacton"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMc2518967&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMc2518967&rss=currentIssue","authors":[],"significance":4,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":[],"congress":"","summary_en":"This correspondence provides additional considerations regarding the use of osilodrostat for bilateral adrenal hypercortisolism in the context of primary aldosteronism.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b548c42e3b13","type":"article","url":"https://hartvaat.nl/2026/02/18/nox4-gemedieerde-metabole-herprogrammering-bij-zoutgevoelige-hypertensie/","title":"Nox4-gemedieerde metabole herprogrammering bij zoutgevoelige hypertensie","title_en":"Renox Reloaded: How Metabolic Reprogramming by the NADPH Oxidase Nox4 Promotes Salt-Sensitive Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26461","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26461","authors":["Matthias Barton"],"significance":5,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/"],"congress":"","summary_en":"This review discusses how the NADPH oxidase Nox4 promotes salt-sensitive hypertension through metabolic reprogramming, identifying new mechanistic pathways in the pathogenesis of salt-dependent blood pressure elevation.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4461b7f160ab","type":"article","url":"https://hartvaat.nl/2026/02/18/retractie-abstract-over-ruimtelijk-temporele-dynamiek-van-diabetesprevalentie/","title":"Retractie: abstract over ruimtelijk-temporele dynamiek van diabetesprevalentie","title_en":"Retraction of: Abstract FR512: Spatio-Temporal Dynamics of Diabetes Prevalence: Structural and Environmental Drivers of Chronic Disease Burdens","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["anemie-ckd","diabetes-en-hart","dyslipidemie","ezetimibe","tirzepatide"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000261","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000261","authors":["Suresh Neupane"],"significance":1,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":[],"congress":"","summary_en":"Retraction of an abstract on spatio-temporal dynamics of diabetes prevalence and structural and environmental drivers of chronic disease burden.","created":"2026-07-03T10:25:20Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"785495960d1b","type":"article","url":"https://hartvaat.nl/2026/02/18/telomeerherstel-via-gentherapie-bij-cardiorenaal-syndroom-type-4/","title":"Telomeerherstel via gentherapie bij cardiorenaal syndroom type 4","title_en":"Telomere recapping via gene therapy as a beneficial strategy for cardio-renal syndrome type 4","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00130-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00130-4/fulltext","authors":["Danshu Xie","Chenguang Wang","Xin Wan","Longyu Wang","Yinlong Zhao","Jianan Pan","Yushu Zhao","Jiaying Ji","Jiaolun Li","Yangyang Liu","Feng Ding","Alex C.Y. Chang","Wei Ding"],"significance":4,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study investigated telomere recapping via gene therapy as a beneficial strategy for cardiorenal syndrome type 4, where heart failure is driven by chronic kidney disease. The approach addresses the shortened telomere lengths observed in advanced CKD patients.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc03dd4eadf1","type":"article","url":"https://hartvaat.nl/2026/02/18/trends-in-het-gebruik-van-zoutvervangingsmiddelen-in-de-vs-2003-2020/","title":"Trends in het gebruik van zoutvervangingsmiddelen in de VS (2003-2020)","title_en":"Trends in Salt Substitute Use Among Adults in the United States from 2003 to 2020","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26196","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26196","authors":["Yinying Wei"],"significance":5,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This analysis documents trends in salt substitute use among US adults from 2003 to 2020, relevant to population-level blood pressure management and cardiovascular prevention strategies.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ec4b507360f","type":"article","url":"https://hartvaat.nl/2026/02/18/ongecontroleerde-hypertensie-bij-jongvolwassenen-in-de-verenigde-staten/","title":"Ongecontroleerde hypertensie bij jongvolwassenen in de Verenigde Staten","title_en":"Uncontrolled Hypertension in Young Adults: A Real-World Analysis of 89,130 Adults in the United States","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","thuisbloeddrukmeting","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26081","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26081","authors":["Shahrin Islam"],"significance":6,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This real-world analysis of 89,130 US adults documented uncontrolled hypertension in young adults, highlighting the growing public health problem of inadequate blood pressure management in the younger population.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37345cc796a3","type":"article","url":"https://hartvaat.nl/2026/02/18/gezondheidsgeletterdheid-en-kwaliteit-van-leven-na-een-acuut-coronair-syndroom/","title":"Gezondheidsgeletterdheid en kwaliteit van leven na een acuut coronair syndroom","title_en":"Health Literacy and Quality of Life after Acute Coronary Syndrome: The Mediating Role of Self-Care in Palestine","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","gedilateerde-cardiomyopathie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00037-7/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00037-7/fulltext","authors":["Kefah Jehad Zaben","Amani Anwar Khalil"],"significance":5,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This study investigated the mediating role of self-care behaviours in the relationship between health literacy and quality of life among Palestinian patients with acute coronary syndrome. Patient education and self-management are particularly important in resource-limited healthcare settings.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca13358dbe0c","type":"article","url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","title":"DanGer Shock: sekseverschillen in Impella-gebruik bij cardiogene shock","title_en":"Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bradycardie","cardiogene-shock"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.019","source_url":"https://doi.org/10.1016/j.jacc.2025.09.019","authors":["Norman Mangner","Rasmus Paulin Beske","Christian Hassager","Lisette Okkels Jensen","Hans Eiskjær","Axel Linke","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Peter Clemmensen","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Nikos Werner","Thomas Engstrøm","Lene Holmvang","Jacob Thomsen Lønborg","Nanna Louise Junker Udesen","Henrik Schmidt","Anders Junker","Christian Juhl Terkelsen","Benedikt Schrage","Felix J Woitek","Jacob Eifer Møller"],"significance":5,"published":"2026-02-17","source_date":"2026-02-17","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"A prespecified DanGer Shock subanalysis examined sex differences in microaxial flow pump use and outcomes in infarct-related cardiogenic shock. Women experienced comparable survival benefit despite more technical challenges with device implantation.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"02720b14ec16","type":"article","url":"https://hartvaat.nl/2026/02/17/lactylering-van-bcat2-k377-draagt-bij-aan-ernstige-pre-eclampsie/","title":"Lactylering van BCAT2-K377 draagt bij aan ernstige pre-eclampsie","title_en":"Lactylation of BCAT2-K377 Contributes to the Progression of Severe Preeclampsia","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25378","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25378","authors":["Yangxue Yin"],"significance":4,"published":"2026-02-17","source_date":"2026-02-17","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/"],"congress":"","summary_en":"This study reveals that hypoxia-induced lactylation of BCAT2 at K377 is a novel mechanism contributing to severe preeclampsia progression, linking metabolic reprogramming under placental hypoxia to trophoblast dysfunction.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5623a2187dc7","type":"article","url":"https://hartvaat.nl/2026/02/17/ngal-veroorzaakt-cardiale-remodeling-bij-ratten-met-chronische-nierziekte/","title":"NGAL veroorzaakt cardiale remodeling bij ratten met chronische nierziekte","title_en":"Neutrophil Gelatinase–Associated Lipocalin Drives Cardiac Remodeling in Rats With Chronic Kidney Disease","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","atriale-cardiomyopathie","cardiorenal-behandelstrategie","chronische-nierziekte"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25658","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25658","authors":["Matthieu Soulié"],"significance":5,"published":"2026-02-17","source_date":"2026-02-17","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study demonstrates that neutrophil gelatinase-associated lipocalin drives cardiac remodelling and inflammation in rats with chronic kidney disease, providing mechanistic insight into the cardiorenal syndrome and identifying NGAL as a potential therapeutic target.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7a9c7daa9230","type":"article","url":"https://hartvaat.nl/2026/02/16/smart2-risicomodel-onderschat-het-recidiefrisico-bij-kwetsbare-groepen-leids-haa/","title":"SMART2-risicomodel onderschat het recidiefrisico bij kwetsbare groepen (Leids-Haagse validatie)","title_en":"External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroups","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["primaire-preventie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003882?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003882?rss=1","authors":["van Egeraat","J. W. A.","van Geloven","N.","Hageman","S. H. J.","Bonten","T. N.","Cahn","W.","Vos","R. C.","Kist","J.","Mairuhu","A.","van Os","H."],"significance":7,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"The SMART2 model predicts recurrent atherosclerotic event (ASCVD) risk in patients with established cardiovascular disease, but does not account for psychiatric disorders, socioeconomic deprivation or ethnicity. In this external validation using records from the Leiden-The Hague region (15,528 patients aged 40-80 with established ASCVD, median follow-up 6 years), overall discrimination was moderate (AUC 0.63) and overall calibration good (OE ratio 0.96). However, the model underestimated risk in patients with low socioeconomic status (OE 1.09) and in non-Western patients (OE 1.16), most strongly in those combining multiple vulnerabilities (low SES, non-Western ethnicity and psychiatric history; OE 1.19-1.29). The SMART2 model is thus well-calibrated in the general population but underestimates risk in vulnerable subgroups — who may need intensified monitoring. Clinicians should weigh social, ethnic and psychiatric factors when interpreting the risk estimate.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c4b5379b897","type":"article","url":"https://hartvaat.nl/2026/02/16/landelijk-aki-alarmsysteem-effecten-op-zorg-en-patientuitkomsten/","title":"Landelijk AKI-alarmsysteem: effecten op zorg en patiëntuitkomsten","title_en":"A population-based, regression discontinuity analysis examined the effects of nationwide alerting for acute kidney injury on health care and patient outcomes","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00091-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00091-8/fulltext","authors":["Min Xie","Pascal Geldsetzer","Tom Blakeman","Matthew James","Tim Scale","Zhi Tan","Simon Sawhney"],"significance":6,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":[],"congress":"","summary_en":"This population-based regression discontinuity analysis examined the effects of nationwide electronic alerting for acute kidney injury, contributing to the evidence on whether automated AKI alerts improve clinical outcomes at scale.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c4361b7e8257","type":"article","url":"https://hartvaat.nl/2026/02/16/fibrilline-1-is-een-nieuw-ligand-van-de-egf-receptor-dat-mesangiumcellen-activee/","title":"Fibrilline-1 is een nieuw ligand van de EGF-receptor dat mesangiumcellen activeert","title_en":"Fibrillin-1 is a novel ligand of the epidermal growth factor receptor promoting mesangial cell activation and glomerulosclerosis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00090-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00090-6/fulltext","authors":["Meizhi He","Liuyan Xiao","Zhao Liu","Wenjian Min","Jiongcheng Chen","Xue Hong","Peng Yang","Haiyan Fu","Li Li","Youhua Liu"],"significance":4,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":[],"congress":"","summary_en":"This study reveals that fibrillin-1 is a novel ligand of the epidermal growth factor receptor that promotes mesangial cell activation and glomerulosclerosis, identifying a new mechanism connecting podocyte damage to mesangial pathology.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23fd0c7f63f1","type":"article","url":"https://hartvaat.nl/2026/02/16/nieuwe-plasma-eiwitbiomarkers-en-risico-op-veneuze-trombo-embolie/","title":"Nieuwe plasma-eiwitbiomarkers en risico op veneuze trombo-embolie","title_en":"Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","trombocytenaggregatieremmers","trombose","veneuze-trombose"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074493","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074493","authors":["Weihong Tang"],"significance":7,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This Circulation study used large-scale, high-throughput proteomics to identify novel plasma protein markers associated with venous thromboembolism risk, advancing the molecular understanding of VTE pathogenesis.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df535bec433f","type":"article","url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","title":"Aanvullende farmacologische strategieën voor restrisicoreductie na revascularisatie","title_en":"Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["atherosclerose","atorvastatine","bempedoïnezuur","biomarkers-cardiovasculair","bloeddrukbehandeling","cetp-remmers","clear-outcomes","diabetes-en-hart","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","ldl-cholesterol","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","ouderen","pcsk9-remmers","pelacarsen","perifeer-vaatlijden","plaquekarakterisatie","statines"],"journal":"EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology","doi":"10.4244/EIJ-D-25-00598","source_url":"https://doi.org/10.4244/EIJ-D-25-00598","authors":["Asahi Oshima","Patrick W Serruys","Scot Garg","J William McEvoy","David A Wood","Torsten Doenst","David P Taggart","John D Puskas","Ajmal Shajahan","Faisal Sharif","Kotaro Miyashita","Akihiro Tobe","Tsung-Ying Tsai","Pruthvi C Revaiah","Fidelma Dunne","Roxana Mehran","Matthew J Budoff","John J Kastelein","Eric S G Stroes","Ramzi Khamis","Wolfgang Koenig","Yoshinobu Onuma"],"significance":6,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This EuroIntervention review discussed adjunctive pharmacological strategies for reducing residual cardiovascular risk after coronary revascularization, covering anti-inflammatory, lipid-lowering, and antithrombotic approaches beyond standard therapy.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9666f57e0025","type":"article","url":"https://hartvaat.nl/2026/02/16/vroege-versus-late-antistolling-na-ischemisch-cva-met-atriumfibrilleren-meta-ana/","title":"Vroege versus late antistolling na ischemisch CVA met atriumfibrilleren: meta-analyse","title_en":"Early versus late anticoagulation treatment after acute ischemic stroke with atrial fibrillation: a meta-analysis of randomized controlled trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen"],"journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","doi":"10.1007/s10072-025-08789-1","source_url":"https://doi.org/10.1007/s10072-025-08789-1","authors":["Mariana Letícia de Bastos Maximiano","Ocilio Ribeiro Gonçalves","Filipe Virgilio Ribeiro","Mariana Lee Han","Altair Pereira de Melo Neto","João Vitor Andrade Fernandes","Marianna Leite","Anderson Matheus Pereira da Silva","Ahmet Günkan"],"significance":6,"published":"2026-02-16","source_date":"2026-02-16","image":"https://hartvaat.nl/global/img/8cd10807f88e.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"This meta-analysis of randomized trials compared early versus late anticoagulation initiation after acute ischemic stroke in AF patients, providing the pooled evidence to guide the timing of DOAC start after cerebrovascular events.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3b69dd77029d","type":"article","url":"https://hartvaat.nl/2026/02/16/sluiting-van-het-linker-hartoor-versus-doac-s-na-longembolie/","title":"Sluiting van het linker hartoor versus DOAC's na longembolie","title_en":"Left atrial appendage closure versus direct oral anticoagulants after pulmonary vein isolation for atrial fibrillation: protocol for a multicentre, prospective, randomised, non-inferiority trial (PROMOTE study).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen","doacs"],"journal":"BMJ open","doi":"10.1136/bmjopen-2025-103632","source_url":"https://doi.org/10.1136/bmjopen-2025-103632","authors":["Lan Shen","Lisheng Jiang","Ziyong Hao","Huimin Chu","Xinhua Wang","Zhongping Ning","Junfeng Zhang","Bin Yang","Yawei Xu","Renyuan Fang","Lingcong Kong","Xiaogang Zhang","Qing He","Zongqi Zhang","Tiantian Zhang","Cen Du","Yizhang Wu","Dongdong Zhao","Hengye Huang","Wenyan Ma","Zhao Liang","Xin Pan","Cheng Wang","Yutong Miao","Linghong Shen","Ben He"],"significance":5,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"The PROMOTE study protocol describes a multicentre randomised non-inferiority trial comparing left atrial appendage closure with direct oral anticoagulants after pulmonary vein isolation for atrial fibrillation. The trial addresses the unresolved question of optimal stroke prevention post-ablation.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb2eef99954c","type":"article","url":"https://hartvaat.nl/2026/02/16/trends-in-gebruik-van-directe-orale-anticoagulantia-een-case-controlstudie/","title":"Trends in gebruik van directe orale anticoagulantia: een case-controlstudie","title_en":"Overview of direct oral anticoagulation trends in the Bronx: case control study of patient and systemic factors in medication non-adherence.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","doacs","rivaroxaban","trombocytenaggregatieremmers","warfarine"],"journal":"Open heart","doi":"10.1136/openhrt-2025-003536","source_url":"https://doi.org/10.1136/openhrt-2025-003536","authors":["Sujoy Khasnavis","Jee-Young Moon","Ephraim Leiderman"],"significance":4,"published":"2026-02-16","source_date":"2026-02-16","image":"https://hartvaat.nl/global/img/c2482a08f6c8.webp","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"A case-control study in the Bronx examined patient and systemic factors contributing to non-adherence with direct oral anticoagulants, providing insights into the persistent challenge of medication non-adherence despite the clinical advantages of DOACs.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"128ce7fcbff9","type":"article","url":"https://hartvaat.nl/2026/02/16/apolipoproteine-c3-verergert-vaatverkalking-via-ferroptose-bij-chronisch-nierfal/","title":"Apolipoproteïne C3 verergert vaatverkalking via ferroptose bij chronisch nierfalen","title_en":"Apolipoprotein C3 exacerbates vascular calcification by promoting ferroptosis via the TLR2/AMPK pathway in vascular smooth muscle cells.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["cetp-remmers","ezetimibe","pcsk9-remmers","yellow-iii"],"journal":"Redox biology","doi":"10.1016/j.redox.2026.104088","source_url":"https://doi.org/10.1016/j.redox.2026.104088","authors":["Zihao Zhou","Jinxuan Chen","Huan Wang","Yufei Han","Changyun Liu","Qiang Shen","Zhao Dong","Kaikai Lu","Chao Zhai","Yitong Xu","Lianxin Zhang","Lei He","Yuan Fang","Ling Zhang","Yuhui Wang","Xunde Xian","Lin Yao","Erdan Dong","Wei Huang"],"significance":3,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This translational study demonstrates that apolipoprotein C3 promotes vascular calcification by inducing ferroptosis in vascular smooth muscle cells via the TLR2/AMPK pathway. ApoC3 knockdown reduced calcification in human renal arteries ex vivo, identifying a potential therapeutic target.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T13:24:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0f73e86d47a","type":"article","url":"https://hartvaat.nl/2026/02/15/hormonale-menopauzetherapie-bij-cardiovasculaire-en-metabole-ziekten-russische-d/","title":"Hormonale menopauzetherapie bij cardiovasculaire en metabole ziekten: Russische Delphi-consensus","title_en":"[Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists].","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["acuut-hartfalen","aficamten","cardio-renaal-metabool","clear-outcomes","diabetes-en-hart","ezetimibe","farmaco-economie","fidelity","hypertrofische-cardiomyopathie","laminopathie","menopauze","microbioom","myocardinfarct","obesitas","ouderen","summit-trial","vrouwen"],"journal":"Terapevticheskii arkhiv","doi":"10.26442/00403660.2026.01.203470","source_url":"https://doi.org/10.26442/00403660.2026.01.203470","authors":["G T Sukhikh","V N Serov","E V Shlyakhto","I I Dedov","G P Arutyunov","O N Tkacheva","A A Smetnik","I A Suchkov","I I Baranov","M V Shestakova","G A Mel'nichenko","O V Vasyukova","E V Sheremetyeva","E N Andreeva","E A Shestakova","Y A Orlova","S V Villevalde","O B Irtyuga","I V Sergienko","I S Yavelov","N A Koziolova","E I Ermakova","E N Dudinskaya"],"significance":3,"published":"2026-02-15","source_date":"2026-02-15","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"An interdisciplinary Russian Delphi consensus provides recommendations for menopausal hormone therapy in women with cardiovascular and metabolic comorbidities, addressing the oestrogen deficiency that increases cardiovascular risk.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f498c063055","type":"article","url":"https://hartvaat.nl/2026/02/15/risicofactoren-voor-een-slechte-jaarprognose-na-acute-decompensatie-van-hartfale/","title":"Risicofactoren voor een slechte jaarprognose na acute decompensatie van hartfalen","title_en":"[Risk factors for poor annual prognosis in patients after acute decompensation of heart failure].","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair"],"journal":"Terapevticheskii arkhiv","doi":"10.26442/00403660.2026.01.203520","source_url":"https://doi.org/10.26442/00403660.2026.01.203520","authors":["O A Lozhkina","E A Shmidt","A G Neeshpapa","V N Karetnikova","D P Golubovskaya","O L Barbarash"],"significance":3,"published":"2026-02-15","source_date":"2026-02-15","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"This study identified risk factors for poor one-year prognosis after hospitalisation for acute decompensated heart failure, addressing the high 25% rehospitalisation rate within three months of discharge.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ffb91a47c73","type":"article","url":"https://hartvaat.nl/2026/02/15/kenmerken-en-vijfjaarsuitkomsten-bij-patienten-met-cll-en-atriumfibrilleren/","title":"Kenmerken en vijfjaarsuitkomsten bij patiënten met CLL en atriumfibrilleren","title_en":"[Characteristics and 5-year outcomes in patients with chronic lymphocytic leukemia receiving ibrutinib (a real-world study)].","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["laminopathie"],"journal":"Terapevticheskii arkhiv","doi":"10.26442/00403660.2026.01.203492","source_url":"https://doi.org/10.26442/00403660.2026.01.203492","authors":["U P Ergasheva","E P Panchenko","C G Chernyshenko","E A Dmitrieva","M I Kislova","Y A Fedotkina","E B Yarovaya","E V Rimashevskaya","V V Ptushkin","E A Nikitin"],"significance":3,"published":"2026-02-15","source_date":"2026-02-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/"],"congress":"","summary_en":"A real-world study evaluated cardiovascular complications, particularly new-onset atrial fibrillation, in chronic lymphocytic leukaemia patients receiving ibrutinib over 5-year follow-up.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"503324fe8f9a","type":"article","url":"https://hartvaat.nl/2026/02/14/bijwerkingen-toegeschreven-aan-statines-in-bijsluiters-meta-analyse-van-rct-s/","title":"Bijwerkingen toegeschreven aan statines in bijsluiters: meta-analyse van RCT's","title_en":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["primaire-preventie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01578-8","source_url":"https://doi.org/10.1016/S0140-6736(25)01578-8","authors":[],"significance":7,"published":"2026-02-14","source_date":"2026-02-14","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This Lancet meta-analysis compared statin adverse effects listed on product labels with actual incidence rates in double-blind trials, finding that many attributed side effects occur at similar rates with placebo, supporting a significant nocebo contribution.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"668ed14066b5","type":"article","url":"https://hartvaat.nl/2026/02/14/tricorder-ai-stethoscoop-voor-triple-cv-ziektedetectie/","title":"TRICORDER: AI-stethoscoop voor triple CV-ziektedetectie","title_en":"Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02156-7","source_url":"https://doi.org/10.1016/S0140-6736(25)02156-7","authors":["Mihir A Kelshiker","Patrik Bächtiger","Camille F Petri","Saloni Nakhare","Josephine Mansell","Karanjot Chhatwal","Abdullah Alrumayh","Jahed Zaman","Moulesh Shah","Holly Young","Helena Roy","Melanie T Almonte","Céire Costelloe","Yasmin Razak","Azeem Majeed","James P Howard","Carys Barton","Daniel B Kramer","Carla M Plymen","Nicholas S Peters"],"significance":7,"published":"2026-02-14","source_date":"2026-02-14","image":"","kennis":[],"congress":"","summary_en":"The TRICORDER trial demonstrated that an AI-enabled stethoscope can simultaneously detect heart failure, valvular heart disease, and atrial fibrillation during routine clinical encounters, validating a scalable screening technology for multiple cardiovascular conditions.","created":"2026-07-03T10:32:12Z","updated":"2026-07-03T13:31:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"292bfceb9e06","type":"article","url":"https://hartvaat.nl/2026/02/14/snelheid-van-lipidedoelbereik-en-langetermijnuitkomsten-na-acuut-coronair-syndro/","title":"Snelheid van lipidedoelbereik en langetermijnuitkomsten na acuut coronair syndroom","title_en":"[Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy].","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["acuut-coronair-syndroom","dyslipidemie","ezetimibe","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"Terapevticheskii arkhiv","doi":"10.26442/00403660.2025.12.203499","source_url":"https://doi.org/10.26442/00403660.2025.12.203499","authors":["A A Nekrasov","E S Timoshchenko","S G Erofeeva","T A Nekrasova","F N Muradova","E S Kuzyakina"],"significance":4,"published":"2026-02-14","source_date":"2026-02-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A Russian study evaluated the effect of early versus delayed initiation of alirocumab on the time to achieve lipid targets and 18-month outcomes after acute coronary syndrome, demonstrating the importance of early treatment initiation.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"435361697846","type":"article","url":"https://hartvaat.nl/2026/02/13/aldosteron-en-de-mineralocorticoidreceptor-bij-atriumfibrilleren/","title":"Aldosteron en de mineralocorticoïdreceptor bij atriumfibrilleren","title_en":"Aldosterone and the Mineralocorticoid Receptor in Atrial Fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","finerenon","laminopathie","mra-aldosteronantagonisten","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26187","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26187","authors":["Argen Mamazhakypov"],"significance":7,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"This review examined the role of aldosterone and the mineralocorticoid receptor in atrial fibrillation pathophysiology, discussing how aldosterone-driven atrial remodeling contributes to AF initiation and maintenance.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c713169b927e","type":"article","url":"https://hartvaat.nl/2026/02/13/bcma-gerichte-t-cel-engagertherapie-bij-refractaire-hla-sensitisatie/","title":"BCMA-gerichte T-cel-engagertherapie bij refractaire HLA-sensitisatie","title_en":"B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00092-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00092-X/fulltext","authors":["Juliette Leon","Olivier Aubert","Magali Devriese","Florence Alameda","Soëli Charbonnier","Jacques Fourgeaud","Tifanie Blein","Thu Ngan Nguyen","Antoine Troger","Stéphanie Chhun","Marie Roelens","Cédric Usureau","Camille Gons","Camille Roger","Carole Burger","Marie-Bénédicte Le Stang","Camille Cotteret","Marc-Olivier Timsit","Simon Fillatreau","Marion Rabant","Jean-Luc Taupin","Alexis Talbot","Felipe Suarez","Dany Anglicheau","Julien Zuber"],"significance":6,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":[],"congress":"","summary_en":"This study tested B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for refractory anti-HLA antibodies in transplant candidates, exploring novel immunotherapy to overcome sensitization barriers.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"52b9ef150cf9","type":"article","url":"https://hartvaat.nl/2026/02/13/verhoogde-wiggendruk-bij-groep-1-pulmonale-hypertensie/","title":"Verhoogde wiggendruk bij groep 1 pulmonale hypertensie","title_en":"Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["anemie-ckd","bloeddrukbehandeling","pulmonale-hypertensie","renale-denervatie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077606","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077606","authors":[],"significance":7,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/vasculair/chronisch-trombo-embolische-ph/"],"congress":"","summary_en":"This Circulation study examined elevated pulmonary artery wedge pressure in patients with group 1 pulmonary hypertension, exploring the clinical significance and management implications of this hemodynamic overlap between pre- and post-capillary disease.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b3b4cad40fc","type":"article","url":"https://hartvaat.nl/2026/02/13/nieuwe-medicamenteuze-therapieen-bij-primair-aldosteronisme/","title":"Nieuwe medicamenteuze therapieën bij primair aldosteronisme","title_en":"Emerging Medical Therapies for Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","bloeddrukbehandeling","cardiorenal-behandelstrategie","eplerenon","lorundrostat","mra-aldosteronantagonisten","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","sacubitril-valsartan","spironolacton"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26229","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.126.26229","authors":["Peeradon Vibhatavata"],"significance":7,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This review discussed emerging medical therapies for primary aldosteronism beyond traditional MRAs, including aldosterone synthase inhibitors and other novel agents targeting upstream aldosterone production.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2746ea559c7e","type":"article","url":"https://hartvaat.nl/2026/02/13/endotheliale-prolylhydroxylase-3-vermindert-maladaptieve-inflammatie-bij-nierher/","title":"Endotheliale prolylhydroxylase 3 vermindert maladaptieve inflammatie bij nierherstel na ischemie","title_en":"Endothelial prolyl hydroxylase 3 mitigates maladaptive inflammation to promote post-ischemic kidney repair","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00089-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00089-X/fulltext","authors":["Rajni Sharma","Ratnakar Tiwari","Yalu Zhou","James O'Sullivan","Hiroshi Maekawa","Gabriella S. Borkowski","Haris Bukaric","Si Young An","Edward B. Thorp","Navdeep S. Chandel","Susan E. Quaggin","Pinelopi P. Kapitsinou"],"significance":4,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This study demonstrates that endothelial prolyl hydroxylase 3 mitigates maladaptive inflammation to promote post-ischaemic kidney repair, linking dysregulated oxygen sensing in endothelial cells to CKD progression after acute kidney injury.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"781862e27a4c","type":"article","url":"https://hartvaat.nl/2026/02/13/genetisch-bepaalde-afkomst-en-morfologische-en-moleculaire-kenmerken-van-carotis/","title":"Genetisch bepaalde afkomst en morfologische en moleculaire kenmerken van carotisplaques","title_en":"Genetically determined ancestry associates with morphological and molecular carotid plaque features","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00046-8/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00046-8/fulltext","authors":["Nima Fahim","Tim R. Sakkers","Floor B.H. van der Zalm","Joost Hoekstra","Dominique P.V. de Kleijn","Michal Mokry","Jose Verdezoto Mosquera","Gerard Pasterkamp","Hester M. den Ruijter","Clint L. Miller","Jessica van Setten","Sander W. van der Laan"],"significance":5,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"This study examined how genetically determined ancestry associates with morphological and molecular features of carotid atherosclerotic plaques. Genome-informed ancestry offers a more accurate framework for studying ethnic disparities in cardiovascular disease burden.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb66d8fe16a7","type":"article","url":"https://hartvaat.nl/2026/02/13/nierbeschermende-medicatie-tijdens-borstvoeding/","title":"Nierbeschermende medicatie tijdens borstvoeding","title_en":"Use of kidney-preserving medications in breastfeeding","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00081-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00081-5/fulltext","authors":["Paula Parnizari","Jonathan S. Zipursky","Michelle A. Hladunewich"],"significance":6,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This Kidney International review addressed the safety of kidney-preserving medications during breastfeeding, providing practical guidance for CKD women on which cardiovascular and renal therapies are compatible with lactation.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"67f0af90e1a0","type":"article","url":"https://hartvaat.nl/2026/02/13/ccr8-expressie-op-regulatoire-t-cellen-beschermt-tegen-myocardinfarctschade/","title":"CCR8-expressie op regulatoire T-cellen beschermt tegen myocardinfarctschade","title_en":"CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction–Induced Tissue Damage","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["laminopathie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076426","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076426","authors":["Nana Li"],"significance":6,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":[],"congress":"","summary_en":"This study mapped the developmental trajectory of regulatory T cells after MI using single-cell RNA sequencing, showing that CCR8-positive Tregs accumulate in the heart and play a vital role in limiting post-infarction inflammation.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f117980e13dc","type":"article","url":"https://hartvaat.nl/2026/02/13/mydgf-beschermt-de-endotheelfunctie-bij-hypertensie/","title":"MYDGF beschermt de endotheelfunctie bij hypertensie","title_en":"MYDGF Governs Endothelial Homeostasis in Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25816","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25816","authors":["Min Liu"],"significance":7,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"This basic science study demonstrated that MYDGF (myeloid-derived growth factor) is essential for maintaining endothelial homeostasis in hypertension, revealing a novel molecular pathway linking immune cell-derived factors to vascular protection.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T13:24:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e6d62d64a20","type":"article","url":"https://hartvaat.nl/2026/02/13/verdeling-van-lp-a-spiegels-en-klinische-associaties-in-een-libanese-populatie/","title":"Verdeling van Lp(a)-spiegels en klinische associaties in een Libanese populatie","title_en":"Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","laminopathie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pcsk9-remmers","pelacarsen","plaquekarakterisatie","ras-remmers","statines","vrouwen"],"journal":"Journal of clinical medicine","doi":"10.3390/jcm15041461","source_url":"https://doi.org/10.3390/jcm15041461","authors":["Alaaeddine El Ghazawi","Mahmoud Hammad","Zyad Saifi","Sarah Omran","Samir Alam","Marwan M Refaat"],"significance":3,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/screeningsprogramma-hart-en-vaatziekten/"],"congress":"","summary_en":"This retrospective study mapped lipoprotein(a) distribution in a Lebanese adult population and confirmed the association with atherosclerotic cardiovascular disease, highlighting that Lp(a) is measured in fewer than 20-30% of patients.","created":"2026-07-03T10:24:57Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb8b239ce18d","type":"article","url":"https://hartvaat.nl/2026/02/12/ct-coronairangiografie-bij-nstemi-uitstekende-diagnostische-nauwkeurigheid-maar-/","title":"CT-coronairangiografie bij NSTEMI: uitstekende diagnostische nauwkeurigheid, maar nog geen duidelijke winst in uitkomsten","title_en":"CT coronary angiography guided treatment versus routine invasive coronary angiography in patients with non-ST elevation myocardial infarction: a systematic review and meta-analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-ct-angiografie","hartkatheterisatie","iaso-dcm"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003919?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003919?rss=1","authors":["Lee","R. H. K.","Kam","M. H. M.","Chatchalermwit","P.","Weston","C.","Oon","G. R.","Moosa","B.","Gray","A. J.","Kelham","M.","Jones","D. A.","Wang","K.-L.","Henriksen","P. A."],"significance":6,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-angiografie/"],"congress":"","summary_en":"In non-ST-elevation myocardial infarction (NSTEMI), invasive coronary angiography (ICA) is recommended but not always feasible in time and unnecessary in patients without obstructive disease. CT coronary angiography (CTCA) may be a non-invasive alternative for lower-risk patients. This systematic review and meta-analysis (8 studies — 3 randomised trials and 5 observational cohorts, ~2,700 patients) compared a CTCA-first strategy with standard care (ICA-first). In the randomised trials, CTCA-first did not significantly reduce ICA use (RR 0.82), and outcomes were mixed (one trial no difference in death/MI, another fewer events at 1 year). Pooled diagnostic accuracy was high (sensitivity 96%, specificity 80%). CTCA thus shows excellent diagnostic accuracy and may limit complications, but so far yields no consistent reduction in ICA use or events — larger trials are needed.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"471d12444f94","type":"article","url":"https://hartvaat.nl/2026/02/12/stress-perfusie-mri-bepaalt-het-risico-na-een-niet-conclusieve-inspanningstest-b/","title":"Stress-perfusie-MRI bepaalt het risico na een niet-conclusieve inspanningstest bij verdenking coronairlijden","title_en":"Prognostic utility of stress perfusion cardiac magnetic resonance in patients with known or suspected coronary artery disease and inconclusive exercise stress testing","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003623?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003623?rss=1","authors":["Tanvisut","N.","Kaolawanich","Y."],"significance":6,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"Exercise stress testing (EST) is widely used for risk stratification in coronary artery disease (CAD) but yields inconclusive results in up to 20%. Stress perfusion CMR is an accurate alternative, but data after inconclusive EST were limited. In this study (414 patients with known or suspected CAD and inconclusive EST referred for stress CMR, 2009-2022), major adverse cardiovascular events (MACE) were examined. Over a median 6.9-year follow-up, 7.7% had a MACE. Patients with inducible ischaemia on CMR had a much higher annual MACE rate (2.8 vs 0.8 per 100 patient-years). Inducible ischaemia was an independent predictor of MACE (HR 4.03), alongside atrial fibrillation and resting systolic blood pressure. Stress perfusion CMR thus provides valuable prognostic information and effectively stratifies risk in patients with an inconclusive exercise test.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T13:31:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87159ce5594e","type":"article","url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","title":"AF-therapie bij patiënten met drug-eluting stents","title_en":"Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["farmaco-economie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2512091","source_url":"https://doi.org/10.1056/NEJMoa2512091","authors":["Seung-Jun Lee","Hee Tae Yu","Yong-Joon Lee","Sang-Hyup Lee","Jung Ho Heo","Sung Gyun Ahn","Sanghoon Shin","Joon-Hyung Doh","Ae-Young Her","Byung-Ryul Cho","Gwang-Sil Kim","Taek-Geun Kwon","Sang-Wook Lim","Jaemin Shim","Ji-Yong Jang","Kyounghoon Lee","Yun-Hyeong Cho","Cheol Ung Choi","Sang-Rok Lee","Hyung-Bok Park","Han Cheol Lee","Seunghwan Kim","Kyeong Ho Yun","Jong-Hwa Ahn","Byoung-Kwon Lee","Deok-Kyu Cho","Song-Yi Kim","Ung Kim","Tae Soo Kang","Seong Huan Choi","Won-Ho Kim","Jin Bae Lee","Moo-Yong Rhee","Jin-Bae Kim","Sang-Ho Jo","Dae Woo Hyun","Daehoon Kim","Tae-Hoon Kim","Sung-Jin Hong","Jae-Sun Uhm","Dong-Ho Shin","Chul-Min Ahn","Byeong-Keuk Kim","Boyoung Joung","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Hui-Nam Pak","Jung-Sun Kim"],"significance":6,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":[],"congress":"","summary_en":"This NEJM study examined the optimal antithrombotic regimen for AF patients with drug-eluting stents, providing randomized evidence supporting NOAC with P2Y12 inhibitor without aspirin for the contemporary DES era.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45a51a2a88c5","type":"article","url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","title":"GDMT na functioneel complete revascularisatie: prognostische impact","title_en":"Prognostic impact of guideline-directed medical therapy after functionally complete revascularisation in patients with obstructive coronary artery diseases.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-325670","source_url":"https://doi.org/10.1136/heartjnl-2025-325670","authors":["Yingyang Geng","Changdong Guan","Yao Jiang","WeiXian Yang","Bo Yu","Guosheng Fu","Jun Pu","Xinkai Qu","Qi Zhang","Yanyan Zhao","Lilei Yu","Yunfei Huang","Shengxian Tu","Shubin Qiao","Lei Song"],"significance":6,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/"],"congress":"","summary_en":"This analysis showed that optimal guideline-directed medical therapy further improves prognosis after functionally complete revascularization, demonstrating that PCI and pharmacotherapy provide complementary rather than competing benefit.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c2013875f4e","type":"article","url":"https://hartvaat.nl/2026/02/12/multi-lijns-assemblage-brengt-ruimtelijke-orde-in-menselijke-nierorganoiden/","title":"Multi-lijns assemblage brengt ruimtelijke orde in menselijke nierorganoïden","title_en":"Multilineage assembly brings spatial order to human kidney organoids","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01013-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01013-0/fulltext","authors":["Chao Zhang","Meng Liu","Yun Xia"],"significance":4,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":[],"congress":"","summary_en":"This review discusses how multilineage assembly approaches bring spatial organisation to human kidney organoids, representing a critical advance toward generating functional kidney models with physiological architecture.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c79f9ffb70fb","type":"article","url":"https://hartvaat.nl/2026/02/12/niet-langer-vergeten-lymfevaten-in-het-afstotende-transplantaat/","title":"Niet langer vergeten: lymfevaten in het afstotende transplantaat","title_en":"Neglected no longer: lymphatic vessels in the rejecting allograft","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00074-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00074-8/fulltext","authors":["Griffith B. Perkins","Maarten Naesens"],"significance":4,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":[],"congress":"","summary_en":"This article highlights the previously neglected role of lymphatic vessels in kidney allograft rejection. As transplant pathologies become more complex, understanding lymphatic contributions may improve long-term graft outcomes.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd35c0976702","type":"article","url":"https://hartvaat.nl/2026/02/12/fenotype-eerst-een-datagestuurde-benadering-van-genetische-penetrantie/","title":"Fenotype eerst: een datagestuurde benadering van genetische penetrantie","title_en":"Phenotype first: a data-driven approach to genetic penetrance","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00072-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00072-4/fulltext","authors":["Jan Halbritter","Eric Olinger"],"significance":4,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/cardiorenal-syndroom/","https://hartvaat.nl/kennis/nierziekte/albumine-creatinine-ratio/"],"congress":"","summary_en":"This commentary discusses a phenotype-first, data-driven approach to assessing genetic penetrance in nephrology, addressing the growing challenge of interpreting genetic variants in the era of massively parallel sequencing.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6371899d5c6","type":"article","url":"https://hartvaat.nl/2026/02/12/aanhoudende-monocytactivatie-door-geoxideerd-ldl-en-vrij-cholesterol/","title":"Aanhoudende monocytactivatie door geoxideerd LDL en vrij cholesterol","title_en":"Sustained monocyte activation by persistent challenges with either oxLDL or free cholesterol and underlying mechanisms.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","inflammatie","ldl-cholesterol","lipide-aferese","pelacarsen","statines"],"journal":"ImmunoHorizons","doi":"10.1093/immhor/vlag005","source_url":"https://doi.org/10.1093/immhor/vlag005","authors":["Yajun Wu","Shuo Geng","Grace Atkinson","Blake Caldwell","Jing Wang","Liwu Li"],"significance":3,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This study demonstrates that prolonged exposure to oxidised LDL or free cholesterol reprogrammes monocytes into a sustained activated state, describing the underlying epigenetic and metabolic mechanisms in chronic atherosclerotic inflammation.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84d44cb4b661","type":"article","url":"https://hartvaat.nl/2026/02/12/bcr-abl-tyrosinekinaseremmers-en-het-risico-op-pulmonale-arteriele-hypertensie/","title":"BCR-ABL-tyrosinekinaseremmers en het risico op pulmonale arteriële hypertensie","title_en":"Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","bloeddrukbehandeling","pcsk9-remmers","pulmonale-hypertensie","ras-remmers"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077764","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077764","authors":["Clément Jambon"],"significance":7,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/pulmonale-hypertensie/"],"congress":"","summary_en":"This Circulation study quantified the risk of pulmonary arterial hypertension with second- and third-generation BCR-ABL tyrosine kinase inhibitors used for chronic myeloid leukemia, using French national health database data to characterize this serious drug side effect.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"13a507e0b9af","type":"article","url":"https://hartvaat.nl/2026/02/12/obesitas-en-de-ernst-ervan-voorspellen-negen-cardiovasculaire-aandoeningen/","title":"Obesitas en de ernst ervan voorspellen negen cardiovasculaire aandoeningen","title_en":"Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["obesitas","ouderen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075327","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075327","authors":[],"significance":7,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/ldl-doelwaarden-risicostratificatie/"],"congress":"","summary_en":"This prospective cross-cohort analysis showed that not only obesity but particularly its severity is strongly predictive of multiple cardiovascular outcomes, with a graded relationship across the full BMI spectrum.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e794725bdf0a","type":"article","url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","title":"FFR-geleide nierslagaderstenting bij atherosclerotische renovasculaire hypertensie","title_en":"Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["aperitif-trial","biomarkers-cardiovasculair","bloeddrukbehandeling","chronische-nierziekte","cystatine-c","endotheel","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","figaro-dkd","flow-trial","fractional-flow-reserve","lipidenverlaging","perifeer-vaatlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf746","source_url":"https://doi.org/10.1093/eurheartj/ehaf746","authors":["Yuxi Li","Jingang Zheng","Chengzhi Lu","Fangfang Fan","Zhihao Liu","Shengcong Liu","Tieci Yi","Long Zhang","Haoyu Weng","Beining Wang","Xu Liu","Hui Zhou","Dengfeng Ma","Zhi Jia","Li Xiang","Renqiang Yang","Dongmei Shi","Hui Chen","Li Xu","Cun Liu","Kazuomi Kario","Yan Zhang","Jianping Li"],"significance":6,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"The FAIR trial tested FFR-guided renal artery stenting versus medical therapy in atherosclerotic renovascular hypertension, reviving the concept of physiologically guided intervention for this common secondary hypertension cause.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55e28b72232f","type":"article","url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","title":"ANDAMAN: aspirinedosering na ACS met verdenking aspirineresistentie","title_en":"Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["aspirine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf680","source_url":"https://doi.org/10.1093/eurheartj/ehaf680","authors":["Jean-Guillaume Dillinger","Théo Pezel","Laure Batias","Denis Angoulvant","Marc Goralski","Emile Ferrari","Guillaume Cayla","Johanne Silvain","Martine Gilard","Gilles Lemesle","Géraud Souteyrand","Pascal Lim","François Roubille","Jean-Louis Georges","Claire Bal Dit Sollier","Thibaut Petroni","Olivier Morel","Nicolas Delarche","Meier Elbaz","Etienne Puymirat","Solenn Toupin","Gilles Montalescot","Ludovic Drouet","Eric Vicaut","Patrick Henry"],"significance":6,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"The ANDAMAN trial tested higher aspirin dosing in ACS patients with suspected aspirin resistance, evaluating whether dose escalation overcomes inadequate platelet inhibition in diabetes and high-risk patients.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab427213af6a","type":"article","url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","title":"REBOOT: bètablokkers na MI — sekseverschillen","title_en":"Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf673","source_url":"https://doi.org/10.1093/eurheartj/ehaf673","authors":["Xavier Rossello","Alberto Dominguez-Rodriguez","Roberto Latini","Pedro L Sánchez","Sergio Raposeiras-Roubín","Manuel Anguita","José A Barrabés","Giulietta Grigis","Ruth Owen","Stuart Pocock","Sandra Gómez-Talavera","Ines García-Lunar","Noemí Escalera","Carlos Nicolás Pérez-García","Stefania Angela Di Fusco","Gonzalo Pizarro","María López Benito","Giulia Pongetti","Luis M Rincón-Díaz","Irene Buera","José Rozado","María Jesús García","Oscar Prada-Delgado","Deborah Cosmi","Valentín Fuster","Borja Ibanez"],"significance":5,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"A prespecified sex-specific subgroup analysis of the REBOOT trial examined whether the neutral effect of beta-blockers after MI without reduced LVEF applies equally to women and men. No sex difference was found, generalising the result to both sexes.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abe327c4d14d","type":"article","url":"https://hartvaat.nl/2026/02/11/gepersonaliseerde-leefstijlinterventie-verbetert-af-ablatie-uitkomsten/","title":"Gepersonaliseerde leefstijlinterventie verbetert AF-ablatie-uitkomsten","title_en":"Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf689","source_url":"https://doi.org/10.1093/eurheartj/ehaf689","authors":["Jasper Vermeer","Tineke Vinck-de Greef","Maarten van den Broek","Bianca de Louw","Gijs van Steenbergen","Dennis van Veghel","Lukas Dekker"],"significance":7,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This randomized trial confirmed that integrated personalized lifestyle interventions (weight management, fitness, sleep optimization, alcohol reduction) significantly improve catheter ablation outcomes for atrial fibrillation.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09e4a54803d8","type":"article","url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","title":"VICTOR: vericiguat en mortaliteit bij HFrEF — definitieve analyse","title_en":"Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf655","source_url":"https://doi.org/10.1093/eurheartj/ehaf655","authors":["Javed Butler","Francesco Fioretti","Ciaran J McMullan","Kevin J Anstrom","Irina Barash","Marc P Bonaca","Maria Borentain","Stefano Corda","Pedro P Teixeira","Justin A Ezekowitz","Davis Gates","Carolyn S P Lam","Eldrin F Lewis","JoAnn Lindenfeld","Robert J Mentz","Christopher M O'Connor","Piotr Ponikowski","Yogesh N V Reddy","Giuseppe M C Rosano","Clara Saldarriaga","Michele Senni","James Udelson","Alessia Urbinati","Vanja Vlajnic","Adriaan A Voors","Aiwen Xing","Mahesh J Patel","Faiez Zannad"],"significance":8,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"The VICTOR trial analysis confirmed that vericiguat reduces mortality in patients with HFrEF and recent decompensation. The mortality benefit adds to the heart failure event reduction shown in VICTORIA, strengthening vericiguat's position in guideline-directed therapy.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"903cf545599e","type":"article","url":"https://hartvaat.nl/2026/02/11/drosophila-model-voor-de-ziekte-van-dent-type-1-onthult-pathogeen-mechanisme/","title":"Drosophila-model voor de ziekte van Dent type 1 onthult pathogeen mechanisme","title_en":"A Drosophila model for Dent’s disease type 1 revealed impaired endoplasmic reticulum export of Cubilin as pathogenic mechanism","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00087-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00087-6/fulltext","authors":["Salómon Christer","Zvonimir Marelja","Indira Dibra","Hannah Hauschild","Marine Berquez","Hetvi Gandhi","Yung-Hsin Shih","Svenja Keller","Martin Helmstädter","Christoph Schell","Olivier Devuyst","Matias Simons"],"significance":3,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This Drosophila model for Dent disease type 1 revealed that impaired endoplasmic reticulum export of Cubilin is the pathogenic mechanism underlying the endolysosomal disorder caused by CLCN5 mutations.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"17bfd197b54c","type":"article","url":"https://hartvaat.nl/2026/02/11/bloeddruk-voor-zwangerschap-en-ivf-uitkomsten/","title":"Bloeddruk vóór zwangerschap en IVF-uitkomsten","title_en":"Association Between Prepregnancy Blood Pressure and Reproductive Outcomes of In Vitro Fertilization","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25872","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25872","authors":["Yuan Fang"],"significance":5,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This study investigated whether the 2017/2025 ACC/AHA hypertension classification (threshold 130/80 mmHg) has implications for reproductive outcomes in women undergoing in vitro fertilisation. Prepregnancy blood pressure may influence IVF success rates.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ff9b4b50d3de","type":"article","url":"https://hartvaat.nl/2026/02/11/criteria-voor-beoordeling-van-nieuwe-cardiovasculaire-risicomodellen-aha/","title":"Criteria voor beoordeling van nieuwe cardiovasculaire risicomodellen (AHA)","title_en":"Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001401","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001401","authors":[],"significance":8,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This AHA scientific statement described criteria for assessing the predictive and clinical utility of novel cardiovascular risk models, biomarkers, and tools, providing a methodological framework for evaluating new risk assessment technologies.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"15796056048f","type":"article","url":"https://hartvaat.nl/2026/02/11/dna-methyleringsmarkers-voor-zwangerschapshypertensie-via-machine-learning/","title":"DNA-methyleringsmarkers voor zwangerschapshypertensie via machine learning","title_en":"DNA Methylation Markers for Pregnancy Hypertension via Machine Learning Methods","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["gepersonaliseerde-geneeskunde","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25388","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25388","authors":["Jueming Lei"],"significance":5,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This study developed a prediction model for hypertensive disorders of pregnancy by integrating DNA methylation biomarkers and clinical factors using machine learning. First-trimester epigenetic screening may enable early identification of at-risk pregnancies.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b0ab2aafb20b","type":"article","url":"https://hartvaat.nl/2026/02/11/factoren-bij-discordante-bloeddrukmeting-bij-zeer-oude-volwassenen-aric-studie/","title":"Factoren bij discordante bloeddrukmeting bij zeer oude volwassenen (ARIC-studie)","title_en":"Factors Associated With Discordant Blood Pressure Measures among Very Old Adults: Results From the Atherosclerosis Risk in Communities (ARIC) Study","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26377","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26377","authors":["Fredrick Larbi Kwapong"],"significance":6,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This ARIC study identified factors associated with discordant home versus office blood pressure measurements in very old adults, informing the interpretation of home monitoring in the oldest patient populations.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b896c90411a","type":"article","url":"https://hartvaat.nl/2026/02/11/hybride-car-s-macrofaagsignalering-herbedraden-voor-gerichte-niertherapie/","title":"Hybride CAR's: macrofaagsignalering herbedraden voor gerichte niertherapie","title_en":"Hybrid CARs: rewiring macrophage signaling for targeted therapy in acute and chronic kidney inflammation","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00070-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00070-0/fulltext","authors":["Yi Tian Ting","Joshua D. Ooi"],"significance":4,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This article discusses the development of hybrid chimeric antigen receptors that rewire macrophage signalling for targeted therapy in acute and chronic kidney inflammation, extending CAR technology beyond oncology.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"526124fc678d","type":"article","url":"https://hartvaat.nl/2026/02/11/macrofaag-prmt9-verbetert-uitkomsten-na-acuut-myocardinfarct-via-stat1-degradati/","title":"Macrofaag-PRMT9 verbetert uitkomsten na acuut myocardinfarct via STAT1-degradatie","title_en":"Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","myocardinfarct","ouderen","pcsk9-remmers"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076101","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076101","authors":["Xuemei Bai"],"significance":6,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This study showed that macrophage PRMT9 promotes degradation of inflammatory mediators through symmetric dimethylation, ameliorating acute MI by modulating the deleterious M1 macrophage response.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c2e2b1c63cb","type":"article","url":"https://hartvaat.nl/2026/02/11/proteogenomische-ontleding-van-nierziekte-en-cardiovasculair-renaal-metabool-syn/","title":"Proteogenomische ontleding van nierziekte en cardiovasculair-renaal-metabool syndroom","title_en":"Proteogenomic dissection of kidney disease and cardiovascular-kidney-metabolic syndrome","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardio-renaal-metabool","niet-statine-therapie","ras-remmers","statines"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00071-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00071-2/fulltext","authors":["Haikuo Li"],"significance":5,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This review discusses how modern proteogenomic techniques provide new insights into the pathophysiology of kidney disease and the cardiovascular-kidney-metabolic syndrome. The integrated approach advances understanding of the cardiorenal connections first described by Richard Bright in 1836.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"794fdf201007","type":"article","url":"https://hartvaat.nl/2026/02/10/welke-hartfalenpatienten-ontwikkelen-ernstige-mitralisinsufficientie-voorspellen/","title":"Welke hartfalenpatiënten ontwikkelen ernstige mitralisinsufficiëntie? Voorspellende factoren","title_en":"Factors associated with the development of severe mitral regurgitation in patients with heart failure","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","dapa-hf","hfmref","hfpef","hfref","myocardinfarct","nt-probnp","pathfinder-trial","step-hfpef","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003920?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003920?rss=1","authors":["Ahmed","F.","Youngson","E.","Sasikumar","A.","Ezekowitz","J. A.","Fine","N.","McAlister","F. A.","Howlett","J. G.","Miller","R. J. H."],"significance":6,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitralistenose/","https://hartvaat.nl/kennis/cardiometabool/obstructief-slaapapneu-en-hart/"],"congress":"","summary_en":"Patients with heart failure (HF) and severe mitral regurgitation (MR) have poor outcomes; early recognition could enable timely intervention. In this study, 7,391 HF patients with at least two echocardiograms (≥6 months apart) were analysed to find factors associated with progression to severe MR. Over a median 1.4 years, 4.8% developed severe MR. Besides baseline MR severity, atrial fibrillation (aOR 1.52), ischaemic heart disease (aOR 1.44), hypertension (aOR 1.35) and larger left ventricular end-diastolic dimension (aOR 1.36 per cm) were associated with more progression. Beta-blocker use was associated with less progression (aOR 0.74). These factors can help identify HF patients needing closer echocardiographic follow-up and timely access to interventions.","created":"2026-07-03T10:32:25Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b895c4a4e3e3","type":"article","url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","title":"Stressor-geassocieerd AF: incidentie, risicofactoren en uitkomsten","title_en":"Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.076421","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.076421","authors":["Julian S Haimovich","Shinwan Kany","Yuchiao Chang","Leila H Borowsky","David D McManus","Steven J Atlas","Daniel E Singer","Steven A Lubitz","Patrick T Ellinor","Shaan Khurshid"],"significance":5,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":[],"congress":"","summary_en":"Analysis of the VITAL-AF trial documented the incidence, risk factors, and outcomes of stressor-associated atrial fibrillation — AF diagnosed in the setting of acute illness, surgery, or sepsis. The prognosis and management implications differ from spontaneous AF.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a063a2b4ffe","type":"article","url":"https://hartvaat.nl/2026/02/10/2025-acc-attr-cm-evaluatie-en-management-beknopte-klinische-richtlijn/","title":"2025 ACC: ATTR-CM evaluatie en management — beknopte klinische richtlijn","title_en":"Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.004","source_url":"https://doi.org/10.1016/j.jacc.2025.09.004","authors":["Michelle M Kittleson","Amrut V Ambardekar","Richard K Cheng","Jan M Griffin","Mathew S Maurer","Jose Nativi-Nicolau","Frederick L Ruberg"],"significance":8,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This 2025 ACC clinical guidance for transthyretin amyloid cardiomyopathy provides structured recommendations for diagnosis, risk stratification, and treatment including tafamidis. The document addresses the growing recognition and improved detection of this previously underdiagnosed condition.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f352a57a64ad","type":"article","url":"https://hartvaat.nl/2026/02/10/resistente-hypertensie-is-geen-essentiele-hypertensie-het-is-vooral-aldosteronis/","title":"Resistente hypertensie is geen essentiële hypertensie — het is vooral aldosteronisme","title_en":"Resistant Hypertension Is Not Essential: It Is Primarily Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aldosteronsynthaseremmers","aprocitentan","baxdrostat","lorundrostat","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26401","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26401","authors":[],"significance":7,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This opinion piece argued that most cases of resistant hypertension are primarily driven by aldosteronism, challenging the conventional paradigm and advocating for systematic aldosterone assessment before labeling hypertension as treatment-resistant.","created":"2026-07-03T10:25:49Z","updated":"2026-07-03T18:38:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd09f60de21c","type":"article","url":"https://hartvaat.nl/2026/02/10/klonale-hematopoese-en-cardiovasculaire-implicaties-aha-statement/","title":"Klonale hematopoëse en cardiovasculaire implicaties (AHA-statement)","title_en":"Clonal Hematopoiesis and Its Cardiovascular Implications: A Scientific Statement From the American Heart Association","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001404","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001404","authors":[],"significance":8,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This AHA scientific statement reviewed the emerging evidence on clonal hematopoiesis and its cardiovascular implications, describing how somatic mutations in hematopoietic stem cells drive inflammation and increase cardiovascular risk independent of traditional risk factors.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a46ceb2f3d6","type":"article","url":"https://hartvaat.nl/2026/02/10/spontaan-myocardinfarct-na-linkerhoofdstamrevascularisatie-de-excel-trial/","title":"Spontaan myocardinfarct na linkerhoofdstamrevascularisatie: de EXCEL-trial","title_en":"Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","anemie-ckd","aperitif-trial","bloeddrukbehandeling","colcot-trial","kanker-en-hart","myocardinfarct","ouderen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075875","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075875","authors":[],"significance":8,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"This EXCEL analysis compared rates and prognostic implications of spontaneous MI after PCI versus CABG for left main disease, providing granular data on the long-term ischemic risk profile of each revascularization strategy.","created":"2026-07-03T10:25:23Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"892acd582431","type":"article","url":"https://hartvaat.nl/2026/02/10/risico-op-nier-en-urotheelkanker-bij-sglt2-remmers-versus-glp-1-receptoragoniste/","title":"Risico op nier- en urotheelkanker bij SGLT2-remmers versus GLP-1-receptoragonisten","title_en":"Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-type-2","figaro-dkd","flow-trial","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag028","source_url":"https://doi.org/10.1093/ndt/gfag028","authors":["Chien-Wei Huang","Edward Chia-Cheng Lai","Vin-Cent Wu","Miyuki Hsing-Chun Hsieh","Chia-Jung Li","Renin Chang","Jin-Shuen Chen","Yau-Sheng Tsai","Junne-Ming Sung"],"significance":6,"published":"2026-02-10","source_date":"2026-02-10","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This target trial emulation compared renal and urothelial cancer risks between SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes, addressing an important safety question for these widely prescribed cardiometabolic agents.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f4b31ec2e5cf","type":"article","url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","title":"OCCUPI: OCT-geleide stentoptimalisatie bij complexe coronairlaesies","title_en":"Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf884","source_url":"https://doi.org/10.1093/eurheartj/ehaf884","authors":["Seung-Jun Lee","Seung-Jae Lee","Sung-Jin Hong","Deok-Kyu Cho","Jin Won Kim","Sang Min Kim","Seung-Ho Hur","Jung Ho Heo","Ji-Yong Jang","Jin Sin Koh","Hoyoun Won","Jun-Won Lee","Soon Jun Hong","Dong-Kie Kim","Jeong Cheon Choe","Jin Bae Lee","Tae-Hyun Yang","Jung-Hee Lee","Young Joon Hong","Jong-Hwa Ahn","Sang-Hyup Lee","Yong-Joon Lee","Chul-Min Ahn","Jung-Sun Kim","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Jong-Young Lee","Byeong-Keuk Kim"],"significance":7,"published":"2026-02-09","source_date":"2026-02-09","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"The OCCUPI trial evaluated OCT-guided stent optimization for complex coronary lesions, assessing the incidence, determinants, and clinical impact of achieving optimal stent expansion under intravascular imaging guidance.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d364a4b3ffe","type":"article","url":"https://hartvaat.nl/2026/02/09/coronaire-atherosclerose-bij-kankerpatienten-en-overlevenden-aha-statement/","title":"Coronaire atherosclerose bij kankerpatiënten en -overlevenden (AHA-statement)","title_en":"Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","lipide-aferese"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001391","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001391","authors":["Lili Zhang"],"significance":8,"published":"2026-02-09","source_date":"2026-02-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This AHA scientific statement addressed the emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors, overlapping pathophysiology, and the cardiovascular toxicity of cancer therapies.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d05850aeb90","type":"article","url":"https://hartvaat.nl/2026/02/09/podocyt-endotheline-1-en-endotheelcel-eta-receptoren-essentieel-bij-fsgs/","title":"Podocyt-endotheline-1 en endotheelcel-ETA-receptoren essentieel bij FSGS","title_en":"Podocyte-derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["aprocitentan","endotheel","endothelineantagonisten"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00077-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00077-3/fulltext","authors":["Liping Yu","Ubong S. Ekperikpe","Hunter W. Korsmo","Serena Zhao","Zhengzi Yi","Jonathan Haydak","Sean Lefferts","Kristin Meliambro","Kirk N. Campbell","Evren U. Azeloglu","Donald E. Kohan","Phillip J. McCown","Abhijit S. Naik","Edgar A. Otto","Börje Haraldsson","Weijia Zhang","Ilse S. Daehn"],"significance":4,"published":"2026-02-09","source_date":"2026-02-09","image":"","kennis":[],"congress":"","summary_en":"This study demonstrates that podocyte-derived endothelin-1 and glomerular endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis, establishing a podocyte-endothelial crosstalk mechanism.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"070badfdfd37","type":"article","url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","title":"Communicatie tussen nier en hart via extracellulaire vesikels","title_en":"Kidney-Heart Crosstalk: The Extracellular Vesicles Connection.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte","ijzertekort"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag022","source_url":"https://doi.org/10.1093/ndt/gfag022","authors":["Carmine Zoccali","José Manuel Valdivielso","Liffert Vogt","Evangelia Ntounousi","Fotini Iatridi","Nejc Piko","Beatriz Fernández-Fernández","Alberto Ortiz","Shanmugakumar Chinnappa","Patrick B Mark","Mehmet Kanbay","Francesca Mallamaci","Andrzej Wiecek","Benedetta Bussolati","Roel Bijkerk"],"significance":5,"published":"2026-02-09","source_date":"2026-02-09","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This review discusses the role of extracellular vesicles in kidney-heart crosstalk during chronic kidney disease. Altered EV abundance and molecular cargo in CKD transport pathological signals between organs, amplifying cardiovascular vulnerability.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5858b7ffcf19","type":"article","url":"https://hartvaat.nl/2026/02/07/lipoproteine-a-en-cardiovasculaire-ziekte-van-genetische-risicofactor-naar-thera/","title":"Lipoproteïne(a) en cardiovasculaire ziekte: van genetische risicofactor naar therapeutisch doelwit","title_en":"Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["biomarkers-cardiovasculair","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","inflammatie","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen"],"journal":"Cells","doi":"10.3390/cells15040315","source_url":"https://doi.org/10.3390/cells15040315","authors":["Hyeong Rok Yun","Manish Kumar Singh","Sunhee Han","Jyotsna S Ranbhise","Joohun Ha","Sung Soo Kim","Insug Kang"],"significance":3,"published":"2026-02-07","source_date":"2026-02-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A comprehensive review of lipoprotein(a) as a cardiovascular risk factor, covering its causal link to atherosclerosis and aortic valve stenosis, and emerging phase III therapies including pelacarsen, olpasiran, and lepodisiran.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"263603b606fc","type":"article","url":"https://hartvaat.nl/2026/02/06/jonge-patienten-met-een-hartinfarct-meer-leefstijl-en-psychosociale-risicofactor/","title":"Jonge patiënten met een hartinfarct: meer leefstijl- en psychosociale risicofactoren","title_en":"Risk factors, clinical profile, angiographic characteristics and reperfusion therapy in young patients (<=45 years) with acute ST-elevation myocardial infarction compared to older patients: a tertiary centre in South India","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","alcoholgebruik","aperitif-trial","diabetes-en-hart","laminopathie","myocardinfarct","ouderen","roken","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003937?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003937?rss=1","authors":["Das","M.","Ramamoorthy","L.","Ahamed","A. S.","HT","L.","Baby","P.","Jacob","J.","Pan","S.","Singha","P.","CV","K.","Ravi","R. K."],"significance":5,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"Myocardial infarction is rising among young people, including in India. This cross-sectional study at a South Indian hospital compared 65 young (≤45 years) and 195 older patients (>45 years) with a first ST-elevation myocardial infarction (STEMI). Young patients were more often male and more often had high alcohol consumption, a family history of premature cardiovascular disease, shorter sleep duration and higher anxiety scores. Older patients more often had hypertension and diabetes. In multivariable analysis, longer sleep duration was associated with older age and a higher anxiety score with younger age. Young STEMI patients thus show a greater burden of modifiable lifestyle and psychosocial risk factors — arguing for age-specific prevention.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1b6841c0c82","type":"article","url":"https://hartvaat.nl/2026/02/06/nierfunctiebeloop-bij-nieuw-ontstaan-hfref-voorspelt-de-uitkomst/","title":"Nierfunctiebeloop bij nieuw ontstaan HFrEF voorspelt de uitkomst","title_en":"Renal function trajectories in 'de novo' heart failure with reduced ejection fraction: impact on outcomes","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","bloeddrukbehandeling","chronische-nierziekte","cystatine-c","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","ijzertekort","nierfalen","nt-probnp","sacubitril-valsartan","step-hfpef","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003193?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003193?rss=1","authors":["Otero Garcia","O.","Donoso Trenado","V.","de la Fuente-Lopez","P.","Lopez Vilella","R.","Adarraga-Gomez","J.","Yebra Pimentel-Brea","C.","Gallego-Latorre","G.","Gomez-Otero","M. I.","Bouzas Cruz","N.","Garcia-Vega","D.","Almenar Bonet","L.","Gonzalez Juanatey","J. R."],"significance":5,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Heart failure (HF) often coexists with chronic kidney disease (CKD), affecting prognosis. This prospective cohort followed renal function in patients hospitalised with new-onset heart failure with reduced ejection fraction (de novo HFrEF) at two university hospitals. Of 306 patients analysed, 24.6% had an eGFR <45 mL/min/1.73 m² at discharge. Higher eGFR at discharge was associated with better outcomes. During follow-up, 79.1% had an eGFR ≥45; patients with stable or improved renal function had lower mortality and fewer readmissions. Factors associated with improvement or stabilisation included less prior CKD, hypertension, younger age, higher eGFR at discharge and greater use of quadruple HF therapy. Routine renal function assessment in de novo HFrEF is thus important to personalise treatment.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5209295d151","type":"article","url":"https://hartvaat.nl/2026/02/06/apolipoproteine-d-een-nieuw-ligand-voor-cd36-is-essentieel-voor-de-bloed-hersenb/","title":"Apolipoproteïne D, een nieuw ligand voor CD36, is essentieel voor de bloed-hersenbarrière","title_en":"Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077356","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077356","authors":[],"significance":6,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":[],"congress":"","summary_en":"This study identified apolipoprotein D as a novel ligand for CD36 essential for blood-brain barrier integrity, revealing a new mechanism at the interface between lipid metabolism and cerebrovascular health.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b73d1daea517","type":"article","url":"https://hartvaat.nl/2026/02/06/verbreding-van-screening-op-primair-aldosteronisme-consensus-tussen-richtlijnen/","title":"Verbreding van screening op primair aldosteronisme: consensus tussen richtlijnen","title_en":"Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["figaro-dkd","primaire-preventie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26228","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26228","authors":["Lily Owei"],"significance":7,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This Hypertension article advocated for broadening primary aldosteronism screening, noting that fewer than 2% of eligible patients are currently screened despite evidence that early detection and targeted therapy improve cardiovascular outcomes.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"847fdd6189e6","type":"article","url":"https://hartvaat.nl/2026/02/06/genoom-en-transcriptoomanalyses-identificeren-kandidaatgenen-bij-bicuspide-aorta/","title":"Genoom- en transcriptoomanalyses identificeren kandidaatgenen bij bicuspide aortaklep","title_en":"Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074752","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074752","authors":["Sébastien Thériault"],"significance":6,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/thoracaal-aorta-aneurysma/"],"congress":"","summary_en":"This genome and transcriptome-wide study identified multiple candidate genes and significant polygenic contributions to bicuspid aortic valve, advancing the genetic understanding of this common congenital heart defect.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"77bce0554d8a","type":"article","url":"https://hartvaat.nl/2026/02/06/insulineresistentie-compromitteert-pentosefosfaatroute-en-lvad-gemedieerd-herste/","title":"Insulineresistentie compromitteert pentosefosfaatroute en LVAD-gemedieerd herstel bij obese hartfalenpatiënten","title_en":"Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device–Mediated Myocardial Recovery in Obese Patients with Heart Failure","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","carvedilol","empagliflozine","hfmref","hfpef","hfref","ijzersuppletie","ijzertekort","ivabradine","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.072850","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.072850","authors":["Tuo Pan"],"significance":6,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that insulin resistance compromises the pentose phosphate pathway and impairs LVAD-mediated cardiac recovery, explaining why diabetic patients have worse myocardial recovery during mechanical support.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ac10c293570c","type":"article","url":"https://hartvaat.nl/2026/02/06/natuurlijk-beloop-van-histologisch-bewezen-acute-eosinofiele-myocarditis/","title":"Natuurlijk beloop van histologisch bewezen acute eosinofiele myocarditis","title_en":"Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074797","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074797","authors":["Enrico Ammirati"],"significance":7,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This Circulation study characterized the natural history of histologically proven acute eosinophilic myocarditis, providing the first large registry data on clinical presentation, treatment, and outcomes of this rare but severe form of myocardial inflammation.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c4ab11d217d","type":"article","url":"https://hartvaat.nl/2026/02/06/sirt1-ncor2-corepressor-moduleert-trofoblast-macrofaaginteracties-bij-pre-eclamp/","title":"SIRT1-NCOR2-corepressor moduleert trofoblast-macrofaaginteracties bij pre-eclampsie","title_en":"SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26144","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26144","authors":["Zhenzhen Liu"],"significance":4,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":[],"congress":"","summary_en":"This study investigated how the SIRT1-NCOR2 corepressor complex modulates trophoblast-macrophage interactions at the maternal-fetal interface in preeclampsia, linking low SIRT1 levels to abnormal Rarres2-Cmklr1 signalling.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4d0a773aa50","type":"article","url":"https://hartvaat.nl/2026/02/06/trpm7-deficientie-beschermt-tegen-myocardiale-ischemie-reperfusieschade/","title":"TRPM7-deficiëntie beschermt tegen myocardiale ischemie-reperfusieschade","title_en":"TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","hypertrofische-cardiomyopathie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074791","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074791","authors":["Xin Li"],"significance":6,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/"],"congress":"","summary_en":"This study showed that TRPM7 channel deficiency protects against myocardial ischemia-reperfusion injury by regulating intracellular zinc homeostasis, identifying a potential therapeutic target for reducing reperfusion damage.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc81df341309","type":"article","url":"https://hartvaat.nl/2026/02/06/aldh2-rs671-variant-versterkt-plaatjesactivatie-en-arteriele-trombose/","title":"ALDH2 rs671-variant versterkt plaatjesactivatie en arteriële trombose","title_en":"The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074318","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074318","authors":["Song Sun"],"significance":6,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":[],"congress":"","summary_en":"This study showed that the ALDH2 rs671 variant, present in 30-50% of East Asians, enhances platelet activation and arterial thrombosis, explaining the increased MI risk in carriers of this common genetic polymorphism.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be8f30607f71","type":"article","url":"https://hartvaat.nl/2026/02/06/onvoldoende-eiwit-en-energie-inname-bij-subklinische-congestie-bij-hartfalen/","title":"Onvoldoende eiwit- en energie-inname bij subklinische congestie bij hartfalen","title_en":"Use of a Structured Interview to Assess the Association of Inadequate Energy and Protein Intake with Subclinical Congestion in Heart Failure Patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","vrouwen"],"journal":"Journal of visualized experiments : JoVE","doi":"10.3791/69496","source_url":"https://doi.org/10.3791/69496","authors":["Tania Alexa Godinez-Flores","Lilia Castillo-Martínez","Gerardo Payro-Ramírez","Clemente Barron-Magdaleno","José Rubén García-Sánchez"],"significance":3,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study used structured interviews to assess whether subclinical congestion is associated with inadequate energy and protein intake in heart failure patients, addressing a gap in nutritional assessment methodology.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"77581300f867","type":"article","url":"https://hartvaat.nl/2026/02/06/voorbij-lipidenverlaging-pcsk9-remming-vermindert-ook-inflammatie-en-verbetert-h/","title":"Voorbij lipidenverlaging: PCSK9-remming vermindert ook inflammatie en verbetert HDL-functie","title_en":"Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","dyslipidemie","enlicitide","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen"],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.02.003","source_url":"https://doi.org/10.1016/j.jacl.2026.02.003","authors":["Maximilian Seidel","Felix S Seibert","Adrian Doevelaar","Benjamin Rohn","Sebastian Bertram","Jonas F Kolodziej","Nikolaos Pagonas","Johannes Korth","Nina Babel","Timm H Westhoff"],"significance":5,"published":"2026-02-06","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"Beyond LDL-C lowering, this real-world study demonstrated that PCSK9 inhibition reduces vascular and systemic inflammation and improves HDL antioxidant function. The pleiotropic effects include Lp(a) reduction and decreased inflammatory markers.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ccb21df940b4","type":"article","url":"https://hartvaat.nl/2026/02/05/de-erfelijke-basis-van-coronairlijden-nejm-overzicht/","title":"De erfelijke basis van coronairlijden (NEJM-overzicht)","title_en":"The Inherited Basis of Coronary Artery Disease","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["stabiel-coronairlijden"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMra2405153","source_url":"https://doi.org/10.1056/NEJMra2405153","authors":["Heribert Schunkert","Pradeep Natarajan","Nilesh J Samani"],"significance":8,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This NEJM review summarises how genetic research has reshaped the understanding, treatment, prevention and risk prediction of coronary artery disease. Monogenic causes occur in roughly 1 in 250 people and usually produce markedly elevated lipid levels. At the population level, hundreds of common small-effect variants together have even greater influence; combined into a polygenic risk score (PRS), risk in the top 5% is 3–5 times the average. The PRS can multiply the absolute risk from clinical scores. Questions about clinical value, cost-effectiveness and implementation remain.","created":"2026-07-03T10:32:17Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee3fbc3a835b","type":"article","url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","title":"Orale PCSK9-remmer enlicitide verlaagt LDL met 57% (placebogecontroleerde trial)","title_en":"A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["clear-outcomes","enlicitide","ezetimibe","figaro-dkd","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","soul-trial","statines"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2511002","source_url":"https://doi.org/10.1056/NEJMoa2511002","authors":["Ann Marie Navar","Elina Mikhailova","Alberico L Catapano","Puja Banka","Dirk J Blom","Alberto Cadena","Susan Kourpanidis","Norman E Lepor","Kazuhisa Tsukamoto","Geraldine Mendizabal","Julio Nunez","Wenjuan Zhang","Pengfei Zhu","Min Zhuo","Christie M Ballantyne"],"significance":9,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Enlicitide decanoate, an oral PCSK9 inhibitor, was tested in this multinational double-blind, placebo-controlled trial in 2,909 adults with established atherosclerotic cardiovascular disease (LDL ≥55 mg/dL) or at risk of a first event (LDL ≥70 mg/dL). Participants received daily enlicitide 20 mg or placebo (2:1) for 52 weeks. At week 24, LDL cholesterol fell by a mean of 57.1% with enlicitide versus +3.0% with placebo — a difference of almost 56 percentage points. Oral PCSK9 inhibition thus approaches the efficacy of the injectable agents, with potential to greatly improve access and adherence.","created":"2026-07-03T10:32:16Z","updated":"2026-07-03T13:31:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8363d5ecbb5","type":"article","url":"https://hartvaat.nl/2026/02/05/angiopoetine-2-remming-en-tie2-reactivatie-bij-chronische-nierziekte/","title":"Angiopoëtine-2-remming en TIE2-reactivatie bij chronische nierziekte","title_en":"Angiopoietin-2 inhibition and TIE2 reactivation in chronic kidney disease: the next step forward","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","bloeddrukbehandeling","canagliflozine","chronische-nierziekte","dapagliflozine","empagliflozine"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00067-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00067-0/fulltext","authors":["Fan-Chi Chang","Shuei-Liong Lin"],"significance":5,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This article discusses angiopoietin-2 inhibition and TIE2 receptor reactivation as therapeutic strategies to address microvascular rarefaction in chronic kidney disease, targeting the endothelial plasticity that underlies CKD progression.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f31fde520ca","type":"article","url":"https://hartvaat.nl/2026/02/05/postprandiale-hypotensie-en-valrisico-bij-oudere-hypertensieve-patienten-ambrosi/","title":"Postprandiale hypotensie en valrisico bij oudere hypertensieve patiënten (AMBROSIA)","title_en":"Association Between Postprandial Hypotension Determined by Ambulatory Blood Pressure Monitoring and Falls Among Older Adults With Hypertension Who Are Taking Antihypertensive Medication: Results From the AMBROSIA Study","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","menopauze","renale-denervatie","sacubitril-valsartan","slaapapneu","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25518","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25518","authors":["Keisuke Narita"],"significance":6,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This AMBROSIA study showed that postprandial hypotension detected by ambulatory monitoring is associated with falls in older adults taking antihypertensive medication, identifying a modifiable risk factor for fall prevention.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a0750d230d07","type":"article","url":"https://hartvaat.nl/2026/02/05/concordante-en-discordante-transcriptomische-kenmerken-van-tweelingplacenta-s-bi/","title":"Concordante en discordante transcriptomische kenmerken van tweelingplacenta's bij pre-eclampsie","title_en":"Concordant and Discordant Transcriptomic Signatures of Twin Placentas in the Setting of Preeclampsia","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25854","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25854","authors":[],"significance":4,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"RNA sequencing of individual twin placentas revealed both concordant and discordant transcriptomic signatures in preeclampsia, suggesting that the molecular pathogenesis may differ between monochorionic and dichorionic twin gestations.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1a6693569bb","type":"article","url":"https://hartvaat.nl/2026/02/05/efimosfermine-alfa-bij-mash-met-f2-f3-fibrose-fase-2-resultaten/","title":"Efimosfermine alfa bij MASH met F2/F3-fibrose: fase 2-resultaten","title_en":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","category":"algemeen","category_label":"Algemeen","professions":["apotheker","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02276-7/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02276-7/fulltext","authors":["Mazen Noureddin","Kris V Kowdley","Tatjana Odrljin","Gerard Bain","Jeff Zhao","Brenda Jeglinski","Margaret James Koziel","Rohit Loomba"],"significance":8,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":[],"congress":"","summary_en":"This phase 2 trial of efimosfermin alfa (FGF21 analogue) showed favorable tolerability in patients with MASH and F2/F3 fibrosis. The results support further development of metabolic therapies targeting the liver-cardiovascular axis.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7938bacf328f","type":"article","url":"https://hartvaat.nl/2026/02/05/eenmaal-per-maand-efimosfermine-bij-niet-cirrotische-mash/","title":"Eenmaal per maand efimosfermine bij niet-cirrotische MASH","title_en":"Once-monthly efimosfermin for non-cirrhotic MASH","category":"algemeen","category_label":"Algemeen","professions":["internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02431-6/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02431-6/fulltext","authors":["Luca Valenti","Giulia Periti"],"significance":7,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"This Lancet article discussed once-monthly efimosfermin for non-cirrhotic MASH, addressing the growing intersection between metabolic liver disease and cardiovascular risk through a novel FGF21-based therapeutic approach.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1158ae397e4","type":"article","url":"https://hartvaat.nl/2026/02/05/geslachtsspecifieke-bloeddruk-en-hersenvasculaire-kenmerken-bij-laag-renine-hype/","title":"Geslachtsspecifieke bloeddruk en hersenvasculaire kenmerken bij laag-renine hypertensie","title_en":"Sex-Specific Blood Pressure and Brain Microvascular Traits in a Model of Low-Renin Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25795","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25795","authors":[],"significance":4,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study examined sex-specific blood pressure and brain microvascular traits in a low-renin hypertension model produced by brain renin-angiotensin system activation, addressing an understudied form of hypertension.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cac8736be839","type":"article","url":"https://hartvaat.nl/2026/02/05/circmfn2-reguleert-igf2bp3-pdk4-bij-pulmonale-hypertensie/","title":"circMFN2 reguleert IGF2BP3-PDK4 bij pulmonale hypertensie","title_en":"circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25460","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25460","authors":[],"significance":4,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study identified circMFN2 as a circular RNA significantly downregulated in pulmonary hypertension that ameliorates disease through regulation of the IGF2BP3-PDK4 axis, offering a potential therapeutic target.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87b7b2a9ee98","type":"article","url":"https://hartvaat.nl/2026/02/05/tenecteplase-bij-basilarisocclusie-tot-24-uur-veelbelovende-lancet-data/","title":"Tenecteplase bij basilarisocclusie tot 24 uur: veelbelovende Lancet-data","title_en":"Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00139-X/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00139-X/fulltext","authors":["Georgios Tsivgoulis","Lina Palaiodimou","Guillaume Turc"],"significance":9,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This Lancet publication addresses basilar artery occlusion, the most severe presentation of large-vessel ischemic stroke, with new randomized and observational evidence supporting intravenous tenecteplase therapy within an extended 24-hour treatment window.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16fbbc19102d","type":"article","url":"https://hartvaat.nl/2026/02/05/tenecteplase-versus-standaardbehandeling-bij-basilaris-occlusie-in-the-lancet/","title":"Tenecteplase versus standaardbehandeling bij basilaris-occlusie in The Lancet","title_en":"Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02633-9/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02633-9/fulltext","authors":["Yunyun Xiong","Fana Alemseged","Zhixin Cao","Lee H Schwamm","Si Zhang","Mark W Parsons","Marc Fisher","Yahui Hao","Aoming Jin","Jinfeng Yin","Yong Jiang","Fengyuan Che","Lihua Wang","Li Zhou","Hongguo Dai","Yutie Zhao","Chunmiao Duan","Shuangzhe Wu","Ganghua Feng","Lixia Zong","Wanxing Ye","Ziran Wang","Ziqi Xu","Hao Wang","Manjun Hao","Yujie Ma","Xia Meng","Hao Li","Zixiao Li","Yilong Wang","Liping Liu","Xingquan Zhao","Bruce C V Campbell","Yongjun Wang","TRACE-5 investigators"],"significance":9,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/ischemische-beroerte-tia/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"The TRACE-5 trial demonstrated that intravenous tenecteplase within 24 hours improved functional outcomes in Chinese patients with ischemic stroke due to basilar artery occlusion. The results support thrombolysis as an effective treatment for this devastating posterior circulation stroke subtype.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"602910270521","type":"article","url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","title":"Driejaarsuitkomsten van linker hartoorsluiting met of zonder ablatie: RECORD-studie","title_en":"Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag022","source_url":"https://doi.org/10.1093/europace/euag022","authors":["Tingting Zhang","Xueni He","Guotao Fu","Haitao Liu","Fu Yi","Jianzheng Liu","Ping Wang","Zhengquan Chen","Xianxian Zhao","Huimin Chu","Zhongbao Ruan","Xiaofei Jiang","Chengxing Shen","Yansong Guo","Zulu Wang","Ming Bai","Yiqiang Yuan","Haixiong Wang","Chenyang Jiang","Shijun Li","Scot Garg","Osama Soliman","Patrick W Serruys","Chao Gao","Ling Tao"],"significance":7,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"The RECORD study provided three-year outcomes of LAA occlusion with or without concurrent AF ablation in a large Chinese cohort, showing that the combination may provide additive rhythm and stroke prevention benefits.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"74d7315c9300","type":"article","url":"https://hartvaat.nl/2026/02/04/200-joule-als-startenergie-voor-elektrische-cardioversie-bij-atriumfibrilleren-w/","title":"200 joule als startenergie voor elektrische cardioversie bij atriumfibrilleren werkt goed en veilig","title_en":"200 J-first, fixed-escalation biphasic electrical cardioversion for atrial fibrillation >48 hours in the emergency department: a single-centre retrospective observational study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["farmaco-economie","ouderen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003875?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003875?rss=1","authors":["Nozewski","J.","Siudak","Z.","Backus","B. E.","Exadaktylos","A."],"significance":5,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"In electrical cardioversion (ECV) of atrial fibrillation (AF) lasting more than 48 hours, up to 360 joules is permitted; the CHESS trial found higher success with a fixed 360J start. In this retrospective single-centre study (374 elective ECVs in the emergency department, 2019-2021), a fixed escalating sequence of 200→300→360 J was used with a standardised technique (hand-held paddles, firm pressure, anterolateral placement under deep sedation). Sinus rhythm was restored in 97.3%; the first 200 J shock succeeded in 88.0%. Only 44 and 15 patients needed 300 J and 360 J respectively. There were two minor adverse events (0.5%) and none serious. A 200J-first protocol with standardised technique thus gives high first-shock and excellent cumulative success in long-standing AF, without routine pharmacological adjuncts.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90183076a84d","type":"article","url":"https://hartvaat.nl/2026/02/04/pulsed-field-ablatie-bereikt-vaker-complete-achterwandisolatie-dan-radiofrequent/","title":"Pulsed-field-ablatie bereikt vaker complete achterwandisolatie dan radiofrequente ablatie bij persisterend atriumfibrilleren","title_en":"Clinical outcomes of pulsed field versus radiofrequency ablation, incorporating posterior wall isolation, in persistent atrial fibrillation","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["advent-trial","pulmonaalvenenisolatie","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren","varipure"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003798?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003798?rss=1","authors":["Ahmed","O.","Li","A.","Zazai","I.","Bajpai","A.","Zuberi","Z.","Norman","M.","Leung","L.","Specterman","M. J.","Sohal","M.","Behr","E. R.","Saba","M.","Kaba","R. A."],"significance":6,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"Persistent atrial fibrillation (AF) remains difficult to treat with catheter ablation. The left atrial posterior wall is a potentially important substrate, but adjunctive posterior wall isolation (PWI) with thermal ablation did not improve outcomes in trials — possibly due to technical limitations. Pulsed-field ablation (PFA) is a non-thermal technique that selectively targets myocardium and may make PWI safer and more consistent. In this real-world cohort (200 patients, 100 PFA and 100 RFA, with combined pulmonary vein and posterior wall isolation), PFA achieved near-universal complete PWI (99% vs 65%), with shorter procedure and left-atrial dwell times. Major non-vascular complications were rare (1.5%) and similar. At 12 months, freedom from recurrent atrial tachyarrhythmia was higher with PFA (70% vs 54%). PFA thus appears to achieve complete posterior wall isolation more often and fewer recurrences than RFA — randomised studies should confirm the role of PWI with PFA.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T18:39:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba49c9cee76d","type":"article","url":"https://hartvaat.nl/2026/02/04/bacteriele-extracellulaire-vesikels-reguleren-bloeddruk-via-microbiota-gastheer-/","title":"Bacteriële extracellulaire vesikels reguleren bloeddruk via microbiota-gastheer-communicatie","title_en":"Bacterial Extracellular Vesicles Mediate Microbiota-Host Communication to Regulate Blood Pressure in Male Rats","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["microbioom"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25962","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25962","authors":["Huanan Shi"],"significance":4,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/alfa-blokkers-hypertensie/"],"congress":"","summary_en":"This study demonstrates that bacterial extracellular vesicles from the gut microbiota reach the circulation and modulate blood pressure in spontaneously hypertensive stroke-prone rats, revealing a novel microbiota-host communication pathway in hypertension.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39717cb07e96","type":"article","url":"https://hartvaat.nl/2026/02/04/c-type-natriuretisch-peptide-beschermt-vasculaire-en-cardiale-functie-bij-sepsis/","title":"C-type natriuretisch peptide beschermt vasculaire en cardiale functie bij sepsis","title_en":"C-Type Natriuretic Peptide Preserves Vascular and Cardiac Function in Sepsis","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25938","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25938","authors":[],"significance":5,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This study demonstrates that C-type natriuretic peptide preserves vascular and cardiac function during sepsis. The findings suggest CNP supplementation as a potential therapeutic strategy for sepsis-associated cardiovascular dysfunction.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"75820b987c66","type":"article","url":"https://hartvaat.nl/2026/02/04/determinanten-van-placentaire-versus-maternale-pre-eclampsie/","title":"Determinanten van placentaire versus maternale pre-eclampsie","title_en":"Determinants of Placental Versus Maternal Preeclampsia","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26236","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26236","authors":["Omonigho Aisagbonhi"],"significance":5,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":[],"congress":"","summary_en":"This study evaluated clinical classification systems for distinguishing placental from maternal preeclampsia based on placental pathological features. The findings inform subtype-specific approaches to preeclampsia management and prevention.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4c3106b7fb0d","type":"article","url":"https://hartvaat.nl/2026/02/04/endotheliaal-lrrc8c-reguleert-vasculaire-reactiviteit-en-bloeddruk/","title":"Endotheliaal LRRC8C reguleert vasculaire reactiviteit en bloeddruk","title_en":"Endothelial LRRC8C Associates With LRRC8A and LRRC8B to Regulate Vascular Reactivity and Blood Pressure","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["endotheel"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25889","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25889","authors":["Qiujun Yu"],"significance":4,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":[],"congress":"","summary_en":"This study identifies LRRC8C as a partner subunit of the mechanoresponsive endothelial LRRC8 complex, working with LRRC8A and LRRC8B to regulate vascular reactivity and blood pressure through endothelial mechanosensing.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a32c4a0c324d","type":"article","url":"https://hartvaat.nl/2026/02/04/verlies-van-ror2-tyrosinekinase-veroorzaakt-endotheeldisfunctie-bij-pah/","title":"Verlies van ROR2-tyrosinekinase veroorzaakt endotheeldisfunctie bij PAH","title_en":"Loss of ROR2 Tyrosine Kinase Receptor Is Associated With Endothelial Dysfunction in PAH via Inappropriate Integrin β1 Activation","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["endotheel"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25881","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25881","authors":["Ankita Mitra"],"significance":5,"published":"2026-02-04","source_date":"2026-02-04","image":"","kennis":[],"congress":"","summary_en":"This study reveals that loss of the ROR2 tyrosine kinase receptor causes endothelial dysfunction in pulmonary arterial hypertension through inappropriate integrin beta1 activation, identifying a novel Wnt signalling pathway in PAH pathogenesis.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"76fde89a81e5","type":"article","url":"https://hartvaat.nl/2026/02/03/neuromusculaire-elektrostimulatie-bij-ernstig-hartfalen-functionele-verbetering/","title":"Neuromusculaire elektrostimulatie bij ernstig hartfalen: functionele verbetering","title_en":"Improved performance after neuromuscular electrical stimulation in hospitalized patients with severe heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf042","source_url":"https://doi.org/10.1093/eschf/xvaf042","authors":["Theresa Maria Betz","Hannes Kinitz","Isabel Kristen","Silke Günter","Mai Knarr","Ute Eck","Michael Preusch","Jasmin Penelope Soethoff","Matthias Karck","Norbert Frey","Hugo Albert Katus","Birgit Friedmann-Bette"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"A randomised trial demonstrated that neuromuscular electrical stimulation improves functional performance in hospitalised patients with severe heart failure who cannot mobilise. The intervention offers a safe alternative for maintaining muscle function during prolonged bedrest.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32eccc06eb02","type":"article","url":"https://hartvaat.nl/2026/02/03/adaptieve-bloeddrukgemoduleerde-atriale-pacing-bij-hypertensief-hfpef-eerste-rct/","title":"Adaptieve bloeddrukgemoduleerde atriale pacing bij hypertensief HFpEF: eerste RCT","title_en":"Adaptive blood pressure-modulated atrial pacing in hypertensive HFpEF patients: a randomized, first-in-human study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","cardiale-resynchronisatie","hfpef","hfref","step-hfpef","summit-trial","supraventriculaire-tachycardie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf020","source_url":"https://doi.org/10.1093/eschf/xvaf020","authors":["Michael H Burnam","Santosh Kumar Sinha","Mukesh Jitendra Jha","Sanjay Kumar Sharma","Amitesh Nagarwal","Rohit Chopra","Eli S Gang"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This first-in-human randomized trial of adaptive blood pressure-modulated atrial pacing in hypertensive HFpEF tested an innovative device concept that links pacemaker rate response to real-time blood pressure feedback.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db1b2fb970fc","type":"article","url":"https://hartvaat.nl/2026/02/03/mortaliteit-en-hospitalisaties-bij-hfpef-versus-hfref-vergelijkende-analyse/","title":"Mortaliteit en hospitalisaties bij HFpEF versus HFrEF: vergelijkende analyse","title_en":"Mortality and heart failure hospitalizations in heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag026","source_url":"https://doi.org/10.1093/eschf/xvag026","authors":["Krzysztof Irlik","Julia Piaśnik","Mirela Hendel","Urszula Faron","Gregory Y H Lip","Katarzyna Nabrdalik","Konstantinos Prokopidis"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This comparative analysis showed that mortality in HFpEF is approaching that of HFrEF in the modern era, establishing that preserved ejection fraction heart failure is not a mild condition but a serious prognostic entity.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ba73b1604bd","type":"article","url":"https://hartvaat.nl/2026/02/03/vochtbeperking-versus-liberale-inname-bij-hartfalen-meta-analyse-van-rct-s/","title":"Vochtbeperking versus liberale inname bij hartfalen: meta-analyse van RCT's","title_en":"Fluid restriction vs liberal intake in patients with heart failure: a meta-analysis of randomized trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf004","source_url":"https://doi.org/10.1093/eschf/xvaf004","authors":["Agata Bielecka-Dabrowa","Maciej Banach","Danisha Kumar","Vikash Jaiswal"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis found that fluid restriction in heart failure does not consistently improve outcomes compared with liberal intake, challenging the traditional practice of routine fluid limitation.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efa2da5b342b","type":"article","url":"https://hartvaat.nl/2026/02/03/levosimendan-infusies-en-klinisch-beloop-bij-hartfalen-levo-d-resultaten/","title":"Levosimendan-infusies en klinisch beloop bij hartfalen: LEVO-D resultaten","title_en":"The possible impact of levosimendan infusions on clinical course of heart failure: the results of the LEIA-HF study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag021","source_url":"https://doi.org/10.1093/eschf/xvag021","authors":["Ewelina Kazimierczyk","Remigiusz Kazimierczyk","Anna M Imiela","Dominika Południewska","Ewelina Rogalska","Anna Szyszkowska","Klaudia Mickiewicz","Franciszek Kukliński","Teresa Fernandez-Moreno","Marek Gierlotka","Ewa Straburzyńska-Migaj","Jadwiga M Nessler","Agnieszka Pawlak","Mariusz Gąsior","Jacek Kubica","Miłosz Jaguszewski","Jarosław D Kasprzak","Agata Bielecka-Dąbrowa","Wojciech Wojakowski","Przemysław Leszek","Łukasz Szarpak","Agnieszka Tycińska"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The LEIA-HF study of repeated levosimendan infusions in ambulatory heart failure showed improved quality of life and functional capacity, supporting intermittent inotropic support for selected advanced HF patients.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e292135d7adb","type":"article","url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","title":"ICE bij AF-ablatie: veiligheid en effectiviteit — meta-analyse","title_en":"Safety and efficacy of intracardiac echocardiography in atrial fibrillation ablation: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag002","source_url":"https://doi.org/10.1093/europace/euag002","authors":["Paschalis Karakasis","Stylianos Tzeis","Konstantinos Pamporis","Konstantinos Vlachos","Konstantinos C Siontis","Antonios P Antoniadis","Karim Benali","Panagiotis Theofilis","Dimitrios Tsiachris","Julian K R Chun","Pierre Jaïs","Nikolaos Fragakis"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed the safety and efficacy of intracardiac echocardiography during AF ablation, supporting ICE as the emerging standard imaging modality for procedural guidance.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9643378216b","type":"article","url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","title":"DARE-AF: dapagliflozine vermindert vroeg AF-recidief na ablatie","title_en":"Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.077447","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.077447","authors":["Chao Jiang","Zixu Zhao","Zejun Yang","Yiping Wang","Yang Xu","Hui Xu","Hang Guo","Chi Wang","Liu He","Shijun Xia","Xiangyi Kong","Wenli Dai","Junmeng Zhang","Song Zuo","Xiaoxia Liu","Xueyuan Guo","Nian Liu","Songnan Li","Ning Zhou","Chenxi Jiang","Ribo Tang","Caihua Sang","Paul C Zei","Deyong Long","Xin Du","Jianzeng Dong","Laurent Macle","Changsheng Ma"],"significance":8,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The DARE-AF trial demonstrated that dapagliflozin reduces early AF recurrence after catheter ablation. The finding suggests that SGLT2 inhibitors may have antiarrhythmic properties that complement ablation therapy.","created":"2026-07-03T10:32:10Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"151f5170fce2","type":"article","url":"https://hartvaat.nl/2026/02/03/cumulatieve-blootstelling-aan-cardiometabole-index-en-risico-op-hartfalen/","title":"Cumulatieve blootstelling aan cardiometabole index en risico op hartfalen","title_en":"Association between cumulative exposure to cardiometabolic index and risk of heart failure: a prospective cohort study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf040","source_url":"https://doi.org/10.1093/eschf/xvaf040","authors":["Peng Fu","Huancong Zheng","Weiqiang Wu","Zegui Huang","Kuangyi Wu","Yuxian Wang","Zhen He","Zefeng Cai","Guanlin Chen","Hong Zheng","Bo Zhang","Shouling Wu","Youren Chen"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"A large prospective cohort study from the Kailuan Study examined the association between cumulative exposure to the cardiometabolic index and incident heart failure risk. Higher cumulative CMI exposure was associated with increased heart failure incidence.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a41e5cdfb268","type":"article","url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","title":"Kenmerken van asymptomatische patiënten met hartfalen en verminderde ejectiefractie","title_en":"Baseline characteristics in the TransitionCHF study: asymptomatic patients with heart failure and reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","dapa-hf","empagliflozine","hfmref","hfpef","hfref","pathfinder-trial","primaire-preventie","step-hfpef","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag012","source_url":"https://doi.org/10.1093/eschf/xvag012","authors":["Irina Müller-Kozarez","Anja Sandek","Frank Edelmann","Christoph Gertler","Marius Placzek","Tim Friede","Manuela Licka","Andreas Rieth","Heribert Schunkert","Ibrahim Akin","Natalie Arnold","Stefan Störk","Anna Feuerstein","Christoph Herrmann-Lingen","Gerd Hasenfuß","Rolf Wachter"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"The TransitionCHF study describes baseline characteristics of patients with asymptomatic systolic left ventricular dysfunction, a population underrepresented in heart failure research. Understanding progression to symptomatic heart failure in this group addresses an important knowledge gap.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"538954f88e53","type":"article","url":"https://hartvaat.nl/2026/02/03/plotse-hartstilstand-tijdens-duursporten-tien-jaar-parijse-registerdata/","title":"Plotse hartstilstand tijdens duursporten: tien jaar Parijse registerdata","title_en":"Characteristics of sudden cardiac arrest during endurance racing: a decade of the Paris registry.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf313","source_url":"https://doi.org/10.1093/europace/euaf313","authors":["Richard Chocron","Thomas Laurenceau","Pierre Cezard","Marion Chabrol","Soline Mignot","Ugo Meli","Camille Langlois","Peter J Schwartz","Stefan Kääb","Bernard I Levy","Frankie Beganton","Wulfran Bougouin","Alain Cariou","Frédéric Adnet","Florence Dumas","Thomas Loeb","Anne-Laure Feral-Piersens","Matthieu Heidet","Daniel Jost","Jean-Philippe Empana","Xavier Jouven"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"This decade-long Paris registry analysis characterized sudden cardiac arrest during endurance racing, documenting the incidence, causes, and survival rates of this rare but devastating complication of competitive endurance sports.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T13:24:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b75696f1d8e","type":"article","url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","title":"Coronaire vaatspasmen bij overlevenden van hartstilstand","title_en":"Coronary artery spasm in cardiac arrest survivors.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","hartkatheterisatie","hypertrofische-cardiomyopathie","stabiel-coronairlijden","ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag020","source_url":"https://doi.org/10.1093/europace/euag020","authors":["Dorte Stavnem","Priya Bhardwaj","Reza Jabbari","Thomas Engstrøm","Lia Evi Bang","Colin Berry","Juan-Carlos Kaski","Jacob Tfelt-Hansen","Bo Gregers Winkel"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/plotse-hartstilstand-plotse-hartdood/","https://hartvaat.nl/kennis/ritmestoornissen/brugada-syndroom/"],"congress":"","summary_en":"This Europace review addressed coronary artery spasm as a cause of cardiac arrest, covering the pathophysiology, diagnostic workup with provocation testing, and management strategies for this potentially lethal but treatable condition.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T13:24:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c514cd0445bd","type":"article","url":"https://hartvaat.nl/2026/02/03/intracardiale-elektrogrammen-bij-perforatie-tijdens-linkerbundeltakpacing/","title":"Intracardiale elektrogrammen bij perforatie tijdens linkerbundeltakpacing","title_en":"Distinct intracardiac electrogram waveforms with perforation during left bundle branch area pacing implantation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["bradycardie","cardiogene-shock","elektrocardiografie","holter","hypertrofische-cardiomyopathie","icd-implantatie","laminopathie","linkerbundeltakpacing","supraventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag010","source_url":"https://doi.org/10.1093/europace/euag010","authors":["Heli Tolppanen","Valerian Valiton","Samuel Stempfel","Haran Burri"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This study systematically analysed unipolar intracardiac electrogram waveforms during perforation events in left bundle branch area pacing. The findings help operators recognise perforation patterns and improve procedural safety.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"83f72105a704","type":"article","url":"https://hartvaat.nl/2026/02/03/gecombineerde-pulsed-field-ablatie-en-linker-atriumoorsluiting-haalbaarheid-en-u/","title":"Gecombineerde pulsed field-ablatie en linker-atriumoorsluiting: haalbaarheid en uitkomsten","title_en":"Feasibility, procedural efficiency, and early imaging outcomes of concomitant pulsed field ablation and left atrial appendage closure: a prospective single-centre study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag017","source_url":"https://doi.org/10.1093/europace/euag017","authors":["Brandon Doty","Mohamed Mraiyan","Ganesh Nair","Momin Khan","Kirollos Gabrah","Devi G Nair"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/abc-pad-af/"],"congress":"","summary_en":"This study demonstrated the feasibility and early outcomes of combined pulsed field ablation with LAA closure in a single procedure, offering a one-stop approach for AF rhythm control and stroke prevention.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"88e251f3b0a9","type":"article","url":"https://hartvaat.nl/2026/02/03/langetermijnwaarde-van-inspanningstesten-bij-hypertrofische-cardiomyopathie/","title":"Langetermijnwaarde van inspanningstesten bij hypertrofische cardiomyopathie","title_en":"Long-term prognostic value of cardiopulmonary exercise testing in patients with hypertrophic cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag013","source_url":"https://doi.org/10.1093/eschf/xvag013","authors":["Leopoldo Ordine","Grazia Canciello","Salvatore Di Napoli","Roberto Polizzi","Daniela Pacella","Raffaella Lombardi","Giovanni Esposito","Maria-Angela Losi"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This study investigated the long-term prognostic value of cardiopulmonary exercise testing in patients with hypertrophic cardiomyopathy. CPET parameters predicted major adverse cardiac events independently of baseline symptoms over extended follow-up.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T13:24:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b26895090055","type":"article","url":"https://hartvaat.nl/2026/02/03/metformine-remt-proliferatie-van-fibro-adipogene-stamcellen-uit-falende-harten/","title":"Metformine remt proliferatie van fibro-adipogene stamcellen uit falende harten","title_en":"Metformin inhibits proliferation of residing fibroadipogenic progenitor cells from failing human hearts.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfref"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag001","source_url":"https://doi.org/10.1093/eschf/xvag001","authors":["Anders Hostrup Larsen","Lin Lin","Andreas Buch Møller","Jean Farup","Lars Poulsen Tolbod","Tine Billeskov","Jonas Brorson","Elias Immanuel Ordell Sundelin","Steen Jakobsen","Helene Nørrelund","Hendrik Johannes Harms","Nils Henrik Hansson","Steen Bønløkke Pedersen","Lars Christian Gormsen","Yonglun Luo","Frank Vincenzo de Paoli","Jørgen Frøkiær","Henrik Wiggers","Niels Jessen"],"significance":4,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This study investigated myocardial metformin distribution in vivo and its effects on fibroadipogenic progenitor cells from failing human hearts, revealing that metformin inhibits their proliferation — a potential mechanism for its beneficial effects in HFrEF.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e48f1cff0c6","type":"article","url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","title":"Aanbesteding van cardiale implanteerbare devices in Europa: waarde of kosten?","title_en":"Public procurement of cardiac implantable electronic devices across Europe: are we purchasing value or cost-effectiveness?","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["icd-implantatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf323","source_url":"https://doi.org/10.1093/europace/euaf323","authors":["Lucía Osoro","Elena Arbelo","Nikola Kozhuharov","Runa Landen","Martin Martinek","Christophe Leclerq","Laurent Fauchier","Jean-Claude De Haro","Serge Boveda","Philipp Sommer","Michiel Rienstra","Piotr Symanski","Michal Farkowski","Anastasia Egorova","Francisco Moscoso Costa","Diana Tint","Stefan Simovic","Krasimir Dzhinsov","Francisco Leyva","Giuseppe Boriani","Josep Figueras","Zenichi Ihara","Jose Luis Merino","Haran Burri","Helmut Pürerfellner","Rubén Casado-Arroyo"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"A survey across 22 European countries examined how procurement of cardiac implantable electronic devices is implemented, exploring clinical, economic, and structural factors that influence tendering processes under the shared EU legal framework.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T13:24:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"57ad65934218","type":"article","url":"https://hartvaat.nl/2026/02/03/rechterhart-hemodynamiek-voor-risicostratificatie-bij-pulmonale-arteriele-hypert/","title":"Rechterhart-hemodynamiek voor risicostratificatie bij pulmonale arteriële hypertensie","title_en":"Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","harttransplantatie","pulmonale-hypertensie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf012","source_url":"https://doi.org/10.1093/eschf/xvaf012","authors":["Laura Scelsi","Roberto Badagliacca","Michele D'Alto","Mauro Acquaro","Pietro Ameri","Paola Argiento","Natale Daniele Brunetti","Gavino Casu","Nadia Cedrone","Paola Confalonieri","Marco Corda","Michele Correale","Carlo D'Agostino","Elisabetta De Tommasi","Domenico Filomena","Giuseppe Galgano","Alessandra Greco","Massimo Grimaldi","Carlo Lombardi","Rosalinda Madonna","Giovanna Manzi","Valentina Mercurio","Alexandra Mihai","Massimiliano Mulè","Giuseppe Paciocco","Silvia Papa","Tommaso Recchioni","Antonella Romaniello","Emanuele Romeo","Davide Stolfo","Annalisa Turco","Marco Vatrano","Patrizio Vitulo","Carmine Dario Vizza","Stefano Ghio"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This study evaluated the added prognostic value of invasive right heart haemodynamic parameters at follow-up in patients with pulmonary arterial hypertension stratified by the non-invasive ESC/ERS risk model. Haemodynamic assessment refined risk prediction beyond non-invasive parameters alone.","created":"2026-07-03T10:25:12Z","updated":"2026-07-03T18:38:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41d31315d0ed","type":"article","url":"https://hartvaat.nl/2026/02/03/effect-van-mavacamten-op-risicoscores-voor-plotse-hartdood-bij-hypertrofische-ca/","title":"Effect van mavacamten op risicoscores voor plotse hartdood bij hypertrofische cardiomyopathie","title_en":"Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","aficamten","biomarkers-cardiovasculair","cardiomyopathie-gerichte-therapie","hypertrofische-cardiomyopathie","inflammatie","laminopathie","mavacamten","menopauze","obesitas"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag003","source_url":"https://doi.org/10.1093/eschf/xvag003","authors":["Paolo Usai","Eve Cariou","Erwan Donal","Damien Eyharts","Nicolas Cohen","Claire Lucas","Adrien Al Wazzan","Miloud Cherbi","Romain Itier","Pauline Fournier","Gilbert Habib","Olivier Lairez"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This study showed that mavacamten not only reduces LVOT obstruction but also improves sudden cardiac death risk scores in obstructive HCM, suggesting potential antiarrhythmic benefits beyond hemodynamic improvement.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df113526cd67","type":"article","url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","title":"Upgrade van draadloze pacemaker: van enkelvoudig naar tweekamersysteem","title_en":"Upgrading expandable leadless pacemakers from single- to dual-chamber.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["draadloze-pacemaker","pacemaker","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag023","source_url":"https://doi.org/10.1093/europace/euag023","authors":["Maria Grazia Bongiorni","Rahul Doshi","James E Ip","Derek V Exner","Vivek Y Reddy","Pascal Defaye","Robert Canby","Morio Shoda","Gerhard Hindricks","Mayer Rashtian","Petr Neuzil","Rajesh Banker","Stephanie M Delgado","Leonard Ganz","Chris Hubbard","Anuradha Bulusu","Reinoud E Knops"],"significance":7,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/pacemaker-indicaties-typen/"],"congress":"","summary_en":"This prospective multicenter study evaluated the safety and feasibility of upgrading expandable leadless pacemakers from single- to dual-chamber systems, demonstrating the practical viability of staged leadless pacing implantation.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"143c9e76321a","type":"article","url":"https://hartvaat.nl/2026/02/03/kortste-af-cycluslengte-in-de-longvenen-identificeert-pvi-responders/","title":"Kortste AF-cycluslengte in de longvenen identificeert PVI-responders","title_en":"Shortest pulmonary vein atrial fibrillation cycle length identifies pulmonary vein isolation responders beyond clinical atrial fibrillation pattern: the FARS-AF II study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["katheterablatie","pulmonaalvenenisolatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag033","source_url":"https://doi.org/10.1093/europace/euag033","authors":["Lorenzo Marcon","Marco Bergonti","Francesco Spera","Johan Saenen","Wim Huybrechts","Hielko Miljoen","Olivier Van Leuven","Lien Vandaele","Anouk Wittock","Hein Heidbuchel","Andrea Sarkozy"],"significance":7,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The FARS-AF II study demonstrated that AF cycle length measured in the pulmonary veins can predict which patients will respond to pulmonary vein isolation, advancing personalized patient selection for AF ablation.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2bd5de8b01e","type":"article","url":"https://hartvaat.nl/2026/02/03/semaglutide-als-aanvulling-op-katheterablatie-bij-obesitas-gerelateerd-atriumfib/","title":"Semaglutide als aanvulling op katheterablatie bij obesitas-gerelateerd atriumfibrilleren","title_en":"Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["cagrisema","ezetimibe","flow-trial","glp1-agonisten","glp1-semaglutide-cardiovasculair","obesitas","pulsed-field-ablatie-atriumfibrilleren","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euag018","source_url":"https://doi.org/10.1093/europace/euag018","authors":["Giuseppe Ciconte","Raffaele Salerno","Alessandro Fuga","Alessia Vuturo","Antonio Boccellino","Gabriele Negro","Roberto Rondine","Marco Ballarotto","Cristiano Ciaccio","Antonio Izzo","Davide Antonio Morciano","Arianna Garbelli","Luigi Giannelli","Vincenzo Maiolo","Zarko Calovic","Luigi Anastasia","Carlo Pappone"],"significance":7,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/"],"congress":"","summary_en":"This study evaluated semaglutide as adjunctive therapy to catheter ablation in obese patients with paroxysmal AF, testing whether GLP-1 receptor agonist-mediated weight loss improves ablation outcomes in obesity-related arrhythmia.","created":"2026-07-03T10:25:03Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"89b3bba7636a","type":"article","url":"https://hartvaat.nl/2026/02/03/atriumfibrilleren-bij-kankerpatienten-de-esc-richtlijn-2025-in-de-praktijk/","title":"Atriumfibrilleren bij kankerpatiënten: de ESC-richtlijn 2025 in de praktijk","title_en":"Contemporary management of atrial fibrillation in patients with cancer-the 2025 European Heart Rhythm Association survey.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["richtlijnen-esc"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf325","source_url":"https://doi.org/10.1093/europace/euaf325","authors":["Michal M Farkowski","Sebastian Szmit","Giuseppe Boriani","Sergio Castrejon","Michael Fradley","Avirup Guha","Josè L Merino","Giacomo Mugnai","Geraldine A Lee","Alexander R Lyon","Diego Penela","Laura Perrotta","Teresa Lopez-Fernandez","Julian K R Chun"],"significance":7,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This 2025 EHRA position paper addressed the contemporary management of AF in patients with cancer, providing practical guidance for the complex decisions around anticoagulation, rate/rhythm control, and drug interactions in this dual-disease population.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c05332cf5036","type":"article","url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","title":"Vroeg starten met MRA na acuut hartfalen of myocardinfarct: meta-analyse","title_en":"Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","farmaco-economie","laminopathie","mra-aldosteronantagonisten","myocardinfarct","pathfinder-trial","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag018","source_url":"https://doi.org/10.1093/eschf/xvag018","authors":["Renzo Laborante","Donato Antonio Paglianiti","Stefano Elia","Giuseppe Patti","Nicolas Girerd","Gianluigi Savarese","Domenico D'Amario"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/mineralocorticoid-antagonisten-farmacologie/"],"congress":"","summary_en":"This meta-analysis evaluated early initiation of MRA after acute decompensated heart failure, showing that in-hospital MRA start is safe and may improve short-term outcomes, supporting proactive neurohormonal blockade.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56afcfa7f7be","type":"article","url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","title":"Intraveneus ijzer bij hartfalen met ijzertekort: meta-analyse met trial-sequentiële analyse","title_en":"Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["iaso-dcm","ijzersuppletie","pathfinder-trial"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvaf018","source_url":"https://doi.org/10.1093/eschf/xvaf018","authors":["Mushood Ahmed","Eeshal Zulfiqar","Tallal Mushtaq Hashmi","Rohma Zia","Hadiah Ashraf","Muhammad Abdullah Naveed","Raheel Ahmed","Jamal S Rana","Faizan Ahmed","Stephen J Greene","Marat Fudim","Robert J Mentz","Gregg C Fonarow"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arb-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This meta-analysis of randomized trials confirmed that intravenous ferric carboxymaltose in heart failure with iron deficiency reduces hospitalizations and improves functional outcomes, consolidating the IV iron evidence base.","created":"2026-07-03T10:25:01Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d557dbc99792","type":"article","url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","title":"Bio-impedantie voor vochtstatusbepaling en prognose bij chronisch hartfalen","title_en":"Bioimpedance-derived compartmental fluid status and prognosis in chronic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","klepprothese","nt-probnp","vrouwen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag002","source_url":"https://doi.org/10.1093/eschf/xvag002","authors":["Jorge Montiel","Alicia Lucas","Pablo Peiró","Gonzalo Núñez","Miguel Lorenzo","Andrea Gasull","Gema Miñana","Anna Mollar","Enrique Santas","José Luis Górriz","Juan Sanchis","Julio Núñez","Rafael de la Espriella"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/vochtstatus-bewaking-hartfalen/"],"congress":"","summary_en":"This study showed that bioimpedance-derived compartmental fluid status provides prognostic information in chronic heart failure, supporting non-invasive fluid assessment technology for monitoring congestion.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"88c716874153","type":"article","url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","title":"Geslachtsverschillen bij patiënten met gevorderd hartfalen","title_en":"Sex differences in patients with advanced heart failure: an analysis of the HELP-HF registry.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bisoprolol","step-hfpef"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag004","source_url":"https://doi.org/10.1093/eschf/xvag004","authors":["Mauro Riccardi","Chiara Tedino","Mauro Chiarito","Davide Stolfo","Luca Baldetti","Daniela Tomasoni","Riccardo Maria Inciardi","Marianna Adamo","Alessandro Villaschi","Ferdinando Loiacono","Marta Maccallini","Gaia Gasparini","Stefano Contessi","Daniele Cocianni","Maria Perotto","Giuseppe Barone","Marco Merlo","Alberto Maria Cappelletti","Gianfranco Sinagra","Daniela Pini","Marco Metra","Matteo Pagnesi","Carlo Mario Lombardi"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":[],"congress":"","summary_en":"This HELP-HF registry analysis revealed important sex differences in advanced heart failure, showing that women are referred later and less likely to receive advanced therapies including mechanical support and transplantation.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ade77a30f12f","type":"article","url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","title":"Semaglutide versus tirzepatide bij patiënten met obesitas en HFpEF","title_en":"Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["cagrisema","dapa-hf","flow-trial","glp1-semaglutide-cardiovasculair","hfpef","hfref","obesitas","select-trial","semaglutide","step-hfpef","summit-trial","tirzepatide"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag042","source_url":"https://doi.org/10.1093/eschf/xvag042","authors":["Luca Monzo","Gianluigi Savarese","Kevin Duarte","Guillaume Baudry","Mark C Petrie","Nicolas Girerd"],"significance":6,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"This federated research network analysis provided the first direct comparison of semaglutide versus tirzepatide in patients with obesity and HFpEF, comparing real-world outcomes of these two leading incretin therapies.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T13:24:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ce3e53a58bb","type":"article","url":"https://hartvaat.nl/2026/02/03/statine-intolerantie-bij-kinderen-met-familiaire-hypercholesterolemie-15-jaar-kl/","title":"Statine-intolerantie bij kinderen met familiaire hypercholesterolemie: 15 jaar klinische ervaring","title_en":"Statin-associated symptoms and Statin Intolerance in Children with Familial Hypercholesterolemia: Insights from 15 Years of Clinical Practice","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["anemie-ckd","atorvastatine","clear-outcomes","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","niet-statine-therapie","rosuvastatine","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00025-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00025-0/fulltext","authors":["Sibbeliene E. van den Bosch","Fianna C. Kowsoleea","Willemijn E. Corpeleijn","Sophie A. Huisman","Astra I.E. Kowsoleea","Albert Wiegman","Barbara A. Hutten"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"An analysis of 15 years of clinical practice assessed the incidence of statin-associated symptoms and statin intolerance in children with heterozygous familial hypercholesterolaemia. The study provides reassuring tolerability data for first-line lipid-lowering therapy in paediatric FH.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5cc2083de00","type":"article","url":"https://hartvaat.nl/2026/02/02/machine-learning-nomogram-voorspelt-vroeg-transplantaatfalen-na-harttransplantat/","title":"Machine-learning-nomogram voorspelt vroeg transplantaatfalen na harttransplantatie (UNOS + Chinese validatie)","title_en":"Bridging machine learning and clinical practice: a multicentre nomogram for 90-day graft failure risk stratification in heart transplantation","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["harttransplantatie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003790?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003790?rss=1","authors":["Yim","W. Y.","Li","Y.","Hou","J.","Chen","Y.","Xiong","T.","Li","C.","Lai","J.","Peng","Y.","Geng","B.","Wu","Y.","Tong","F.","Wang","Y.","Dong","N."],"significance":5,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/coronairlijden/nitraten-bij-angina/"],"congress":"","summary_en":"Early graft failure within 90 days is the leading cause of death after heart transplantation, but existing risk scores poorly capture complex donor-recipient interactions. Using explainable machine learning, a clinically applicable nomogram was developed from the US UNOS registry (25,200 transplants) out of 32 variables. The final model used eight predictors: recipient prior cardiac surgery, age, bilirubin and BMI; donor age, sex and BMI; and cold ischaemia time. The nomogram had fair discrimination (AUC 0.67); the high-risk group had 2.4-fold higher risk of graft failure. External validation in a Chinese cohort (563 patients) confirmed performance (AUC 0.67). This ML nomogram using routinely available data can support donor-recipient matching and post-transplant care in heart transplantation.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T13:31:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d565bcd1a593","type":"article","url":"https://hartvaat.nl/2026/02/02/jamac-studie-slechte-5-jaarsprognose-bij-mitralisstenose-door-mitralisringverkal/","title":"JAMAC-studie: slechte 5-jaarsprognose bij mitralisstenose door mitralisringverkalking","title_en":"Mitral Annular Calcification-Related Mitral Stenosis: 5-Year Outcomes and Prognostic Determinants in the JAMAC Study","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog"],"tags":["mitralisstenose"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.12.004","source_url":"https://doi.org/10.1016/j.jacc.2025.12.004","authors":["Nahoko Kato","Takatomo Watanabe","Takuma Ishihara","Nobuyuki Kagiyama","Maika Shimizu","Yukio Abe","Yoshiki Matsumura","Tetsuari Onishi","Yasushi Ichikawa","Koki Nakanishi","Yasuki Nakada","Nozomi Fukuda","Chisato Izumi","Shinichi Kurashima","Yoshihiro Seo","Shohei Kikuchi","Nozomi Watanabe","Keiko Nagatomo","Yuki Izumi","Ayumi Nakabo","Masao Daimon","Hiroyuki Watanabe","Hiroyuki Okura"],"significance":7,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"Mitral stenosis from mitral annular calcification (MAC) occurs mainly in older patients and is associated with increased mortality, but reliable long-term data were lacking. The retrospective, multicentre JAMAC study (264 patients from 11 Japanese centres, median age 78, 73% female) examined 5-year outcomes: 76% had calcific and 24% rheumatic mitral stenosis. Median mitral valve area (MVA) was 1.40 cm² and mean transmitral gradient 6.1 mmHg. Five-year survival was only 57%, with more non-cardiac (24%) than cardiac (16%) death; calcific stenosis had higher mortality than rheumatic. Anterior and severe posterior MAC, and MVA <1.5 cm², predicted mortality; on multivariable analysis MVA remained independently associated with death (adjusted HR 1.56), alongside age and chronic kidney disease. The prognosis of MAC-related mitral stenosis is thus poor, driven mainly by non-cardiac mortality.","created":"2026-07-03T10:32:20Z","updated":"2026-07-03T13:31:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"27246a5b2480","type":"article","url":"https://hartvaat.nl/2026/02/02/medische-kosten-en-productiviteitsverlies-door-atriumfibrilleren-in-de-vs/","title":"Medische kosten en productiviteitsverlies door atriumfibrilleren in de VS","title_en":"Medical Costs and Productivity Losses of Atrial Fibrillation Among US Privately Insured Employees.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["farmaco-economie"],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2025.59227","source_url":"https://doi.org/10.1001/jamanetworkopen.2025.59227","authors":["Han Zhang","Jun Soo Lee","Sein Kim","Ashutosh Kumar","Yu Wang","Omoye Imoisili","Feijun Luo","Utibe R Essien"],"significance":5,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/"],"congress":"","summary_en":"This cross-sectional study estimated the medical costs and productivity losses associated with atrial fibrillation among privately insured US employees. The full economic impact, particularly productivity losses in working-age adults, has been underexplored.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d82be24c802","type":"article","url":"https://hartvaat.nl/2026/02/02/sglt2-remmers-en-cardiorenale-uitkomsten-bij-diabetes-type-2-met-levercirrose/","title":"SGLT2-remmers en cardiorenale uitkomsten bij diabetes type 2 met levercirrose","title_en":"SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","figaro-dkd","obesitas","semaglutide","sglt2-remmers"],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2025.60429","source_url":"https://doi.org/10.1001/jamanetworkopen.2025.60429","authors":["Mu-Chi Chung","Tung-Min Yu","Laing-You Wu","Ming-Ju Wu","Jeng-Jer Shieh","Chi-Jung Chung"],"significance":6,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study evaluated SGLT2 inhibitor use and cardiorenal outcomes in patients with both type 2 diabetes and liver cirrhosis, providing safety and efficacy data for this high-risk and typically excluded population.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T13:24:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26eb359b8456","type":"article","url":"https://hartvaat.nl/2026/02/02/gezamenlijke-besluitvorming-bij-percutane-linker-atriumoorsluiting/","title":"Gezamenlijke besluitvorming bij percutane linker-atriumoorsluiting","title_en":"Shared Decision-Making and Patient Decision Aids for Percutaneous Left Atrial Appendage Occlusion.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA network open","doi":"10.1001/jamanetworkopen.2025.56937","source_url":"https://doi.org/10.1001/jamanetworkopen.2025.56937","authors":["Joshua B Rager","Chien-Yu Huang","Sarah Zimmerman","Sanket S Dhruva","James V Freeman","Daniel D Matlock","Karl Minges","Amneet Sandhu","Erica S Spatz","Paul Varosy","Tanner J Caverly"],"significance":6,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"This study examined the current state of shared decision-making and patient decision aids for percutaneous LAA occlusion, addressing the CMS requirement for SDM documentation before this structural heart procedure.","created":"2026-07-03T10:25:13Z","updated":"2026-07-03T13:24:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"275a8c8c3dad","type":"article","url":"https://hartvaat.nl/2026/02/02/apob-apoa-i-ratio-voor-diagnostiek-en-ernst-van-coronairlijden-bij-statinegebrui/","title":"ApoB/ApoA-I-ratio voor diagnostiek en ernst van coronairlijden bij statinegebruikers","title_en":"Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","dyslipidemie","familiaire-hypercholesterolemie-screening","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","plaquekarakterisatie"],"journal":"Medicina (Kaunas, Lithuania)","doi":"10.3390/medicina62020297","source_url":"https://doi.org/10.3390/medicina62020297","authors":["Raul-Alexandru Jigoranu","Ovidiu Mitu","Alexandru Florinel Oancea","Radu-Stefan Miftode","Ana Maria Buburuz","Amin Bazyani","Radu-Sebastian Gavril","Theodor-Constantin Stamate","Cristina Andreea Adam","Ionela-Larisa Miftode","Antoniu Octavian Petris","Irina-Iuliana Costache Enache","Florin Mitu"],"significance":3,"published":"2026-02-02","source_date":"2026-02-02","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"In an Eastern European cohort of statin-treated patients, the ApoB/ApoA-I ratio outperformed traditional lipid parameters for assessing the severity of coronary artery disease, supporting apolipoprotein measurements including Lp(a) for refined risk assessment.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d21249a1862a","type":"article","url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","title":"LDL-cholesterol en neoatherosclerose na STEMI: secundaire analyse","title_en":"Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI: A Secondary Analysis of the CONNECT Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["cetp-remmers","dyslipidemie","ezetimibe","hdl-cholesterol","ldl-cholesterol","lipide-aferese","lipidenverlaging","statines"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.4723","source_url":"https://doi.org/10.1001/jamacardio.2025.4723","authors":["Jonas Dominik Häner","Ryota Kakizaki","Masanori Taniwaki","Yohei Ohno","Kazuyuki Yahagi","Yoshiharu Higuchi","George C M Siontis","Kenji Ando","Stefan Stortecky","Nobuaki Suzuki","Naoki Watanabe","Jonas Lanz","Yasushi Ueki","Tatsuhiko Otsuka","Flavio Giuseppe Biccirè","Masami Sakurada","Konstantinos C Koskinas","Sylvain Losdat","Lorenz Räber"],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This CONNECT secondary analysis confirmed that achieving lower LDL cholesterol levels reduces neoatherosclerosis formation within drug-eluting stents after STEMI, demonstrating that intensive lipid lowering protects against late stent failure.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4981a63dd76c","type":"article","url":"https://hartvaat.nl/2026/02/01/cox-2-remming-en-bloeddrukrespons-graad-van-remming-is-bepalend/","title":"COX-2-remming en bloeddrukrespons: graad van remming is bepalend","title_en":"Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.25516","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.25516","authors":["Katherine N Theken","Soumita Ghosh","Carsten Skarke","Susanne Fries","Nicholas F Lahens","Dimitra Sarantopoulou","Gregory R Grant","Garret A FitzGerald","Tilo Grosser"],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This study showed that the degree of COX-2 inhibition modulates blood pressure response, with more selective COX-2 inhibitors causing greater blood pressure elevation, informing NSAID selection in hypertensive patients.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9ad5679bc692","type":"article","url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","title":"Aprocitentan bij CKD en resistente hypertensie","title_en":"Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["anemie-ckd","aprocitentan","chronische-nierziekte","figaro-dkd","flow-trial","ijzertekort","precision-trial","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25563","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25563","authors":["Patrick Rossignol","Martine Clozel","Roland F Dreier","John M Flack","Bruno Flamion","Johannes Mann","Krzysztof Narkiewicz","Mouna Sassi-Sayadi","Ji-Guang Wang","Michael A Weber","Markus P Schlaich"],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This study showed that aprocitentan effectively lowers blood pressure in patients with CKD and resistant hypertension, extending the endothelin antagonist approach to the renally impaired population where resistant blood pressure is most prevalent.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9282f8b5b8e7","type":"article","url":"https://hartvaat.nl/2026/02/01/antihypertensieve-behandeling-na-acuut-ischemisch-cva-continueren-of-niet/","title":"Antihypertensieve behandeling na acuut ischemisch CVA: continueren of niet?","title_en":"Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not?","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25575","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25575","authors":["Chongke Zhong","Ming Wang","Dacheng Liu","Yufei Wei","Mengxing Wang","Yanbo Peng","Jing Chen","Yuesong Pan","Tan Xu","Yilong Wang","Jiang He","Yongjun Wang","Yonghong Zhang","Liping Liu","Xuewei Xie"],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This review summarized the evidence on antihypertensive management after acute ischemic stroke, addressing whether existing medications should be continued, modified, or temporarily withheld in the acute phase.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e864d66094f5","type":"article","url":"https://hartvaat.nl/2026/02/01/dapagliflozine-bij-cv-risico-met-zonder-diabetes-cardiorenale-effecten/","title":"Dapagliflozine bij CV-risico met/zonder diabetes: cardiorenale effecten","title_en":"Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["dapa-hf","dapagliflozine","diabetes-type-2","fidelio-dkd","figaro-dkd","soul-trial"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25955","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25955","authors":["Vikas S Sridhar","Luxcia Kugathasan","Yuliya Lytvyn","Yangqing Deng","Hongyan Liu","Leif Erik Lovblom","Josephine Tse","Massimo Nardone","John S Floras","Tosin Osuntokun","Tomoyuki Tobushi","Ruthabella C Y Lam","Brian Lam","Jasper Stevens","Dylan Burger","Daan J Touw","Hiddo J L Heerspink","Julie A Lovshin","Bruce A Perkins","David Z I Cherney"],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This study demonstrated that dapagliflozin improves vascular stiffness and cardiorenal markers in patients at cardiovascular risk regardless of diabetes status, providing mechanistic support for the universal cardiorenal protective effects of SGLT2 inhibitors.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de3884c92492","type":"article","url":"https://hartvaat.nl/2026/02/01/cagrisema-verlaagt-bloeddruk-bij-overgewicht-obesitas-redefine-1/","title":"CagriSema verlaagt bloeddruk bij overgewicht/obesitas: REDEFINE 1","title_en":"CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["cagrisema"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.26055","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.26055","authors":["Subodh Verma","Morten Böttcher","Paul Brown","Dror Dicker","Domenica Rubino","Paolo Sbraccia","Arya M Sharma","Lærke Smedegaard","Rasmus Sørrig","W Timothy Garvey"],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"The REDEFINE 1 analysis showed that CagriSema (cagrilintide plus semaglutide) significantly reduces blood pressure in adults with overweight or obesity, with the antihypertensive effect adding to the metabolic and weight-loss benefits.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"279fe2c20401","type":"article","url":"https://hartvaat.nl/2026/02/01/postpartum-diureticabehandeling-bij-hypertensieve-zwangerschapsstoornissen/","title":"Postpartum diureticabehandeling bij hypertensieve zwangerschapsstoornissen","title_en":"Effects of Immediate Postpartum Diuretic Treatment on Postpartum Blood Pressure Among Individuals With Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24263","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24263","authors":["Susan K Keen","Koura Sall","Agnes Koczo","Yisi Wang","Rebekah S Miller","Matthew F Muldoon","Alisse K Hauspurg","Malamo E Countouris"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated immediate postpartum diuretic treatment for blood pressure control in hypertensive disorders of pregnancy. Early diuretic intervention improved postpartum blood pressure outcomes.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62126eac3974","type":"article","url":"https://hartvaat.nl/2026/02/01/kanttekeningen-bij-statistische-analyse-van-nhanes-data-en-orale-microbioomstudi/","title":"Kanttekeningen bij statistische analyse van NHANES-data en orale microbioomstudie","title_en":"Considerations on statistical analysis of NHANES data in oral microbiome diversity and mortality study","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01527-8/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01527-8/fulltext","authors":["Yang Shen","Weijie Hu"],"significance":3,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This correspondence raises statistical considerations regarding the analysis of NHANES data in the study by Mondal et al. on oral microbiome alpha diversity and mortality.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c9bba9a9430e","type":"article","url":"https://hartvaat.nl/2026/02/01/is-er-een-nieuwe-keerzijde-van-persisterende-chylomicronemie/","title":"Is er een nieuwe keerzijde van persisterende chylomicronemie?","title_en":"Is there a new dark side of persistent chylomicronemia?","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01524-2/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01524-2/fulltext","authors":["Philippe Moulin"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/"],"congress":"","summary_en":"This commentary accompanies evidence suggesting that persistent severe hypertriglyceridaemia in familial and multifactorial chylomicronaemia syndromes may contribute to glomerular nephropathy, representing a previously unrecognised clinical complication.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aaf4c00b9bcc","type":"article","url":"https://hartvaat.nl/2026/02/01/reactie-op-kanttekeningen-bij-statistiek-van-orale-microbioomdiversiteit-en-mort/","title":"Reactie op kanttekeningen bij statistiek van orale microbioomdiversiteit en mortaliteit","title_en":"Reply to: “Considerations on statistical analysis of NHANES data in oral microbiome diversity and mortality study”","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["microbioom","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01528-X/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01528-X/fulltext","authors":["Rajib Mondal","Yuichiro Yano"],"significance":3,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"The authors reply to methodological comments regarding the statistical analysis of NHANES data in their study on oral microbiome alpha diversity and all-cause and cardiovascular mortality in US adults.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"898c4fd1e35a","type":"article","url":"https://hartvaat.nl/2026/02/01/klonale-hematopoese-en-incident-hartfalen/","title":"Klonale hematopoëse en incident hartfalen","title_en":"Clonal Hematopoiesis and Incident Heart Failure","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["ijzersuppletie"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841165","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2841165","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This cohort study investigated the association between specific clonal hematopoiesis (CHIP) driver gene subtypes and incident heart failure, exploring a novel genetic pathway linking somatic mutations in hematopoietic stem cells to cardiac disease.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64bcffc2fc01","type":"article","url":"https://hartvaat.nl/2026/02/01/klonale-hematopoese-kans-om-de-hartfalenepidemie-aan-te-pakken/","title":"Klonale hematopoëse: kans om de hartfalenepidemie aan te pakken","title_en":"Clonal Hematopoiesis—An Opportunity to Confront the Heart Failure Epidemic","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841166","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2841166","authors":[],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This commentary discussed clonal hematopoiesis of indeterminate potential (CHIP) as an opportunity to address the heart failure epidemic, exploring how somatic mutations in blood cells drive cardiovascular inflammation.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b461df800c59","type":"article","url":"https://hartvaat.nl/2026/02/01/coronaire-reperfusie-bij-stemi-patienten-die-overplaatsing-vereisen/","title":"Coronaire reperfusie bij STEMI-patiënten die overplaatsing vereisen","title_en":"Coronary Reperfusion in Patients With ST-Elevation MI Requiring Transfer","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["stemi"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843428","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843428","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This Viewpoint evaluated the evolution of STEMI reperfusion guidelines and strategies for patients requiring interhospital transfer, addressing the evidence for timely primary PCI versus pharmacoinvasive approaches in transfer settings.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39b5888be4e8","type":"article","url":"https://hartvaat.nl/2026/02/01/detectie-van-transthyretine-cardiale-amyloidose-met-kunstmatige-intelligentie/","title":"Detectie van transthyretine cardiale amyloïdose met kunstmatige intelligentie","title_en":"Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["cardiale-amyloidose"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841169","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2841169","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This study developed and evaluated an AI-augmented screening program for detecting transthyretin cardiac amyloidosis, demonstrating that machine learning applied to routine clinical data can identify patients with this increasingly recognized but underdiagnosed condition.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd878cc5ccee","type":"article","url":"https://hartvaat.nl/2026/02/01/correctie-naam-van-niet-auteur-in-surtavi-trial/","title":"Correctie: naam van niet-auteur in SURTAVI-trial","title_en":"Error in Nonauthor Collaborator’s Name","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2842752","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2842752","authors":[],"significance":1,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"Correction to a non-author collaborator name in the SURTAVI trial publication on self-expanding transcatheter versus surgical aortic valve replacement in intermediate-risk patients.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00316be161fb","type":"article","url":"https://hartvaat.nl/2026/02/01/inspanningssyncope-bij-een-tienermeisje/","title":"Inspanningssyncope bij een tienermeisje","title_en":"Exertional Syncope in a Female Teenage Student","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["bradycardie","syncope"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843432","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843432","authors":[],"significance":3,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"A diagnostic challenge case of a previously healthy teenage girl presenting with chest tightness and exertional syncope, with ECG showing ST-elevation and elevated troponin T.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bde07f6e4915","type":"article","url":"https://hartvaat.nl/2026/02/01/richtlijnnaleving-bij-myocardinfarctbehandeling-ingezonden-brief/","title":"Richtlijnnaleving bij myocardinfarctbehandeling — ingezonden brief","title_en":"Guideline Adherence in Myocardial Infarction Treatment","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["myocardinfarct","ouderen","stemi"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843039","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843039","authors":[],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This letter to the editor discusses the importance of timely primary PCI or pharmacoinvasive therapy for STEMI management, emphasising that reperfusion timing remains the most critical determinant of survival.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dec24d526b40","type":"article","url":"https://hartvaat.nl/2026/02/01/richtlijnnaleving-bij-myocardinfarctbehandeling-reactie/","title":"Richtlijnnaleving bij myocardinfarctbehandeling — reactie","title_en":"Guideline Adherence in Myocardial Infarction Treatment—Reply","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["hypertrofische-cardiomyopathie","myocardinfarct"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843038","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843038","authors":[],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The authors reply to correspondence regarding challenges in achieving timely reperfusion in STEMI patients and the role of guideline adherence in myocardial infarction treatment.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e43ce3091d9","type":"article","url":"https://hartvaat.nl/2026/02/01/implementatie-intelligentie-met-ai-prospectieve-evaluaties-nodig/","title":"Implementatie-intelligentie met AI: prospectieve evaluaties nodig","title_en":"Implementation Intelligence With AI—Prospective Evaluations Needed","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841170","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2841170","authors":[],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This editorial discusses the role of AI in improving detection of amyloid transthyretin cardiomyopathy and emphasises the critical need for prospective evaluations before clinical implementation of AI-based screening tools.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"197db0704ca8","type":"article","url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neo-atherosclerose-na-stemi/","title":"LDL-cholesterol en neo-atherosclerose na STEMI","title_en":"Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["cetp-remmers","ezetimibe","hdl-cholesterol","ldl-cholesterol","lipidenverlaging","statines"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843037","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843037","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This secondary analysis of the CONNECT trial evaluated whether achieving guideline-endorsed LDL cholesterol levels after drug-eluting stent implantation for STEMI reduces neoatherosclerosis development within the stented segment.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e9e89fe3e40","type":"article","url":"https://hartvaat.nl/2026/02/01/myocarddisfunctie-bij-primaire-mitralisinsufficientie/","title":"Myocarddisfunctie bij primaire mitralisinsufficiëntie","title_en":"Myocardial Dysfunction in Primary Mitral Regurgitation","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aficamten","biomarkers-cardiovasculair","gedilateerde-cardiomyopathie","mitralisinsufficiëntie","myocardinfarct"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843036","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843036","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tricuspidalisregurgitatie/"],"congress":"","summary_en":"This narrative review discussed myocardial dysfunction in primary mitral regurgitation, exploring an approach that incorporates additional imaging and biomarker parameters beyond ejection fraction to guide the timing of surgical intervention.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"052a88b25567","type":"article","url":"https://hartvaat.nl/2026/02/01/uitkomsten-na-wisseling-van-cardiale-troponine-assays-bij-acs/","title":"Uitkomsten na wisseling van cardiale troponine-assays bij ACS","title_en":"Outcomes After Switching Cardiac Troponin Assays in ACS","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","aperitif-trial","iaso-dcm","trombocytenaggregatieremmers","troponine"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843040","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843040","authors":[],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"This interrupted time-series analysis evaluated the clinical implications of switching high-sensitivity cardiac troponin assays, showing that assay changes affect diagnostic rates and patient management in acute care.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d41683fe2135","type":"article","url":"https://hartvaat.nl/2026/02/01/shr-1918-bij-homozygote-familiaire-hypercholesterolemie/","title":"SHR-1918 bij homozygote familiaire hypercholesterolemie","title_en":"SHR-1918 for Homozygous Familial Hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843433","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843433","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This nonrandomized study of SHR-1918, a fully human ANGPTL3 antibody, showed significant LDL cholesterol reduction in homozygous familial hypercholesterolemia, adding another ANGPTL3 inhibitor to the pipeline for this severe genetic disorder.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee818856a410","type":"article","url":"https://hartvaat.nl/2026/02/01/semaglutide-en-ziekenhuisopnames-bij-obesitas-met-hart-en-vaatziekten/","title":"Semaglutide en ziekenhuisopnames bij obesitas met hart- en vaatziekten","title_en":"Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["flow-trial","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843245","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843245","authors":[],"significance":8,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This SELECT prespecified analysis showed that semaglutide reduces total hospital admissions and length of stay in patients with obesity and established cardiovascular disease, demonstrating healthcare utilization benefits beyond cardiovascular event reduction.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39516119ada7","type":"article","url":"https://hartvaat.nl/2026/02/01/sociale-determinanten-van-gezondheid-en-uitkomsten-bij-hypertrofische-cardiomyop/","title":"Sociale determinanten van gezondheid en uitkomsten bij hypertrofische cardiomyopathie","title_en":"Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","alcoholgebruik","cardiomyopathie-gerichte-therapie","diabetes-en-hart","gedilateerde-cardiomyopathie","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","menopauze","vrouwen"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843430","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843430","authors":[],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This study examined the association between area-based social determinants of health and clinical outcomes in hypertrophic cardiomyopathy, highlighting socioeconomic disparities in this genetic cardiac condition.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8dfbc25dfbd8","type":"article","url":"https://hartvaat.nl/2026/02/01/dertigjaars-cardiovasculair-risico-bij-vrouwen-naar-lipoproteine-a-drempelwaarde/","title":"Dertigjaars cardiovasculair risico bij vrouwen naar lipoproteïne(a)-drempelwaarden","title_en":"Thirty-Year Risk of Cardiovascular Disease Among Women According to Thresholds of Lipoprotein(a)","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","diabetes-type-2","dyslipidemie","ezetimibe","hdl-cholesterol","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","menopauze","pelacarsen","statines","vrouwen"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843429","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843429","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-doelwaarden-risicostratificatie/"],"congress":"","summary_en":"This cohort study examined Lp(a) levels as 30-year predictors of cardiovascular risk in women, showing that clinically relevant thresholds identify women at substantially elevated long-term cardiovascular risk who may benefit from emerging Lp(a)-lowering therapies.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4608b3c9ff1b","type":"article","url":"https://hartvaat.nl/2026/02/01/betablokkers-na-myocardinfarct-bij-behouden-ejectiefractie-meta-analyse/","title":"Bètablokkers na myocardinfarct bij behouden ejectiefractie: meta-analyse","title_en":"β-Blockers After Myocardial Infarction in Patients With Preserved Ejection Fraction","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","farmaco-economie","kanker-en-hart","laminopathie","myocardinfarct","ouderen"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843431","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843431","authors":[],"significance":8,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis of four randomized trials confirmed that beta-blockers after MI in patients with preserved ejection fraction do not improve cardiovascular outcomes. The consolidated evidence definitively supports discontinuation in this population.","created":"2026-07-03T10:25:26Z","updated":"2026-07-03T18:38:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90b832e2cc67","type":"article","url":"https://hartvaat.nl/2026/02/01/renale-denervatie-bij-resistente-hypertensie-het-tel-aviv-register/","title":"Renale denervatie bij resistente hypertensie: het Tel Aviv-register","title_en":"Clinical Outcomes of Renal Denervation for Resistant Hypertension: The Tel Aviv Renal Denervation Prospective Registry.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"The Israel Medical Association journal : IMAJ","doi":"https://pubmed.ncbi.nlm.nih.gov/41736604/","source_url":"https://doi.org/https://pubmed.ncbi.nlm.nih.gov/41736604/","authors":["Netanel Golan","Ophir Freund","Yael Horwitz","Yaron Arbel"],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"https://hartvaat.nl/global/img/0ef5024189ff.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"A prospective registry from Tel Aviv reports clinical outcomes of renal denervation in patients with apparent treatment-resistant hypertension, providing real-world evidence for this interventional approach.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daf86bf00507","type":"article","url":"https://hartvaat.nl/2026/02/01/factor-xi-xia-remmers-bij-atriumfibrilleren-dosisrespons-werkzaamheid-en-veiligh/","title":"Factor XI/XIa-remmers bij atriumfibrilleren: dosisrespons, werkzaamheid en veiligheid","title_en":"Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["abelacimab","apixaban","atriale-cardiomyopathie","bloeddrukbehandeling","edoxaban","esc-2026","rivaroxaban"],"journal":"Clinical cardiology","doi":"10.1002/clc.70263","source_url":"https://doi.org/10.1002/clc.70263","authors":["Muhammad Aqib Faizan","Tooba Rehman","Mrunalini Dandamudi","Jaivardhan A Menon","Victoria Zecchin Ferrara","Zeyad Kholeif","Alina Tanvir","Fatima Saeed","Jibran Ikram","Moiuz Chaudhri","Carlos Espiche","Main Muhammad Salman Aslam","Zainab Humayun","Ahmad Mustafa Khalid","Saad Ahmad Waqas","Raheel Ahmad","Luis Cerna"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"esc-2026","summary_en":"A systematic review and meta-analysis with trial sequential validation evaluated the dose-response efficacy and safety of factor XI/XIa inhibitors compared to direct oral anticoagulants in atrial fibrillation. These emerging agents may reduce bleeding complications while providing adequate stroke prevention.","created":"2026-07-03T10:25:14Z","updated":"2026-08-10T11:07:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0eaf20038682","type":"article","url":"https://hartvaat.nl/2026/02/01/sacubitril-valsartan-bij-secundaire-mitralisinsufficientie-en-reverse-remodeling/","title":"Sacubitril-valsartan bij secundaire mitralisinsufficiëntie en reverse remodeling","title_en":"Effect of Sacubitril-Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","answer-hf","cardiorenal-behandelstrategie","hfpef","hfref","mitralisinsufficiëntie","sacubitril-valsartan"],"journal":"Echocardiography (Mount Kisco, N.Y.)","doi":"10.1111/echo.70413","source_url":"https://doi.org/10.1111/echo.70413","authors":["Mohammed Ali Mohammed Hammad","Ismael Elbarky","Reda Biomy","Wael Anwar Elshahat Hassib","Khaled Abouelmagd","Mohamed Kamal Ibrahim Salama"],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"A 2D and 3D echocardiographic study evaluated the effect of sacubitril-valsartan on secondary mitral regurgitation and left ventricular reverse remodelling in patients with HFrEF.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T18:38:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6a25c42da1e5","type":"article","url":"https://hartvaat.nl/2026/02/01/nierbeschermende-effecten-van-statines-bij-ckd-patienten-in-hong-kong/","title":"Nierbeschermende effecten van statines bij CKD-patiënten in Hong Kong","title_en":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["acuut-hartfalen","anemie-ckd","chronische-nierziekte","clear-outcomes","credence-trial","fidelio-dkd","figaro-dkd","flow-trial","niertransplantatie"],"journal":"EClinicalMedicine","doi":"10.1016/j.eclinm.2026.103798","source_url":"https://doi.org/10.1016/j.eclinm.2026.103798","authors":["Zoey Cho Ting Wong","Franco Wing Tak Cheng","Ivy Lynn Mak","Emily Tsui Yee Tse","Sydney Chi Wai Tang","Ian Chi Kei Wong","Eric Yuk Fai Wan"],"significance":6,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This target trial emulation evaluated the renoprotective effects of statins in CKD patients in Hong Kong, providing real-world evidence for lipid-lowering therapy's role in slowing kidney disease progression.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1dd033313227","type":"article","url":"https://hartvaat.nl/2026/02/01/innovatieve-wereldwijde-modellen-voor-ckd-zorg-casestudies-en-strategieen/","title":"Innovatieve wereldwijde modellen voor CKD-zorg: casestudies en strategieën","title_en":"Transformative global models for CKD care: case studies and strategies.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte","cystatine-c","fidelio-dkd","figaro-dkd","flow-trial","ijzertekort","nierfalen","niertransplantatie"],"journal":"Clinical kidney journal","doi":"10.1093/ckj/sfag011","source_url":"https://doi.org/10.1093/ckj/sfag011","authors":["James O Burton","Andrew H Frankel","Katherine Kwon","María Marqués","Gengru Jiang","Jiguang Wang","Kieran McCafferty"],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This article presents international case studies and strategies for transformative CKD care models, addressing the need for early diagnosis and intervention in the 10% of adults worldwide affected by chronic kidney disease.","created":"2026-07-03T10:25:14Z","updated":"2026-07-03T13:24:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64714d8eec4a","type":"article","url":"https://hartvaat.nl/2026/02/01/therapeutische-innovaties-in-de-secundaire-preventie-van-cardiovasculair-risico/","title":"Therapeutische innovaties in de secundaire preventie van cardiovasculair risico","title_en":"[Therapeutic innovations in secondary prevention of cardiovascular risk].","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","aspirine","bempedoïnezuur","biomarkers-cardiovasculair","cardiorenal-behandelstrategie","cetp-remmers","clear-outcomes","colchicine","diabetes-en-hart","diabetes-type-2","dyslipidemie","enlicitide","ezetimibe","farmaco-economie","figaro-dkd","gepersonaliseerde-geneeskunde","glp1-agonisten","hartrevalidatie","hdl-cholesterol","inflammatie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","menopauze","microbioom","niet-statine-therapie","obesitas","ouderen","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","plaquekarakterisatie","ramipril","richtlijnen-esc","roken","secundaire-preventie","slaapapneu","statines","trombocytenaggregatieremmers","voeding-hart"],"journal":"La Revue du praticien","doi":"https://pubmed.ncbi.nlm.nih.gov/41732931/","source_url":"https://doi.org/https://pubmed.ncbi.nlm.nih.gov/41732931/","authors":["Franck Boccara"],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"https://hartvaat.nl/global/img/0ef5024189ff.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This review discusses therapeutic innovations in secondary cardiovascular prevention including PCSK9 inhibitors, inclisiran, bempedoic acid, Lp(a)-targeting RNA therapies, individualised antithrombotic strategies, and low-dose colchicine as anti-inflammatory therapy.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c9fed8c7517","type":"article","url":"https://hartvaat.nl/2026/02/01/preventie-van-atherosclerotische-hart-en-vaatziekten-bij-jonge-mannelijke-anabol/","title":"Preventie van atherosclerotische hart- en vaatziekten bij jonge mannelijke anabolengebruikers","title_en":"Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","aspirine","atherosclerose","atleten","bloeddrukbehandeling","cetp-remmers","clear-outcomes","diabetes-en-hart","dyslipidemie","ezetimibe","hartkatheterisatie","hartrevalidatie","ldl-cholesterol","lipidenverlaging","menopauze","myocardinfarct","perifeer-vaatlijden","primaire-preventie","secundaire-preventie","statines","trombocytenaggregatieremmers","vrouwen"],"journal":"Clinical cardiology","doi":"10.1002/clc.70257","source_url":"https://doi.org/10.1002/clc.70257","authors":["Peter Bond","Diederik L Smit","Tijs Verdegaal","Willem de Ronde"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This review examines the mechanisms by which supraphysiological androgen exposure accelerates atherosclerosis in young men, including adverse effects on lipoproteins, blood pressure, and vascular function. Screening strategies and preventive measures are discussed for this underrecognised risk population.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db0d1a08aefd","type":"article","url":"https://hartvaat.nl/2026/02/01/gedeeld-gennetwerk-verklaart-de-wisselwerking-tussen-atriumfibrilleren-en-hartfa/","title":"Gedeeld gennetwerk verklaart de wisselwerking tussen atriumfibrilleren en hartfalen","title_en":"A reduced TBX5-dependent gene regulatory network links atrial fibrillation and heart failure.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","atriale-cardiomyopathie","hfpef","hfref","laminopathie","ventrikelfibrilleren"],"journal":"Nature cardiovascular research","doi":"10.1038/s44161-025-00775-2","source_url":"https://doi.org/10.1038/s44161-025-00775-2","authors":["Sonja Lazarevic","Carlos Perez-Cervantes","Zhezhen Wang","Kaitlyn M Shen","Margaret Gadek","Junhua Xiao","Naoko Yamaguchi","Johnathon M Hall","Yildiz Koca","Douglas J Chapski","Manuel Rosa-Garrido","Marcello Rubino","Rangarajan D Nadadur","Timothy A McKinsey","Thomas M Vondriska","Alexander J Ruthenburg","Sebastian Pott","David S Park","Ivan P Moskowitz"],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"https://hartvaat.nl/global/img/65747e238e62.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"This Nature Cardiovascular Research study revealed that atrial fibrillation and heart failure share a common TBX5-dependent gene regulatory network, providing molecular evidence for the bidirectional relationship between these two conditions.","created":"2026-07-03T10:25:00Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3c355356bf6","type":"article","url":"https://hartvaat.nl/2026/02/01/praktische-overwegingen-bij-vericiguat-voor-oudere-patienten-met-hartfalen/","title":"Praktische overwegingen bij vericiguat voor oudere patiënten met hartfalen","title_en":"Practical considerations for the use of vericiguat in older patients with heart failure and reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","bisoprolol","bradycardie","empagliflozine","hfmref","hfpef","hfref","ivabradine","laminopathie","vericiguat","vrouwen"],"journal":"European journal of clinical investigation","doi":"10.1111/eci.70173","source_url":"https://doi.org/10.1111/eci.70173","authors":["Francesco Castelletti","Elena Bianco","Giulia Fabro","Eleonora Nicolini","Francesco Dentali","Luca Liberale","Flavio Tangianu","Aldo Bonaventura"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"A practice-oriented review discusses the use of vericiguat, an oral soluble guanylate cyclase stimulator, specifically in older patients with heart failure and reduced ejection fraction. The article addresses dosing, drug interactions, and positioning alongside established pillar therapies.","created":"2026-07-03T10:24:59Z","updated":"2026-07-03T18:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"53f10d180b51","type":"article","url":"https://hartvaat.nl/2026/02/01/de-verborgen-nierschade-bij-chylomicronemiesyndromen/","title":"De verborgen nierschade bij chylomicronemiesyndromen","title_en":"The hidden burden of kidney damage in chylomicronemia syndromes","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":["alcoholgebruik","cardiale-amyloidose","diabetes-en-hart","dyslipidemie","ezetimibe","hypertriglyceridemie","hypertrofische-cardiomyopathie","laminopathie","ldl-cholesterol","lipidenverlaging","microbioom","niet-statine-therapie","obesitas","select-trial","tricuspidalisinsufficiëntie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01519-9/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01519-9/fulltext","authors":["Laura D'Erasmo","Daniele Tramontano","Alessia Di Costanzo","Simone Bini","Marzia Pasquali","Daniela Commodari","Ina Arizaj","Valeria Pecce","Bruna Cerbelli","Ilenia Minicocci","Miriam Larouche","Diane Brisson","Loreto Gesualdo","Daniel Gaudet","Marcello Arca"],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hypertriglyceridemie/"],"congress":"","summary_en":"This review discusses the nephrotoxic effects of sustained severe hypertriglyceridaemia in monogenic and polygenic chylomicronaemia syndromes. The kidney damage burden in these conditions may be underrecognised in clinical practice.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af141f74e73d","type":"article","url":"https://hartvaat.nl/2026/01/31/wereldwijde-ziektelast-van-chronische-nierziekte-bij-kinderen-en-adolescenten/","title":"Wereldwijde ziektelast van chronische nierziekte bij kinderen en adolescenten","title_en":"Global, Regional, and National Burden of CKD in Children and Adolescents.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","primaire-preventie","vrouwen"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag018","source_url":"https://doi.org/10.1093/ndt/gfag018","authors":["Xiaocui Zhang","Jiale Shao","Mengqi Wang","Xiu Li","Qianwen Yang","Qing Zhang","Fang Deng"],"significance":5,"published":"2026-01-31","source_date":"2026-01-31","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"Using Global Burden of Disease 2021 data, this study mapped the incidence, prevalence, mortality, and disability-adjusted life years of chronic kidney disease in children and adolescents aged 0-19 years worldwide. Low-middle-income regions showed the fastest increases, with a strong inverse correlation between sociodemographic index and mortality.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2cafee788524","type":"article","url":"https://hartvaat.nl/2026/01/30/lager-opleidingsniveau-hangt-samen-met-meer-halsslagaderplaques-los-van-risicofa/","title":"Lager opleidingsniveau hangt samen met meer halsslagaderplaques, los van risicofactoren (ACE 1950)","title_en":"Association between socioeconomic variables and carotid plaque in middle-aged adults: data from the Akershus Cardiac Examination (ACE) 1950 Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bradycardie","laminopathie","obesitas","ouderen","slaapapneu"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003865?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003865?rss=1","authors":["Bratholm","A. O.","Ihle-Hansen","H.","Vigen","T.","Lyngbakken","M. N.","Omland","T.","Rosjo","H.","Ariansen","I.","Berge","T.","Tveit","A.","Ronningen","P. S."],"significance":5,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"Low socioeconomic status (SES) is linked to higher cardiovascular risk, but its association with carotid atherosclerosis in the general population is less studied. In this cross-sectional analysis of the Norwegian Akershus Cardiac Examination 1950 Study (3,673 participants, mean age 63.9), individual SES was defined by educational attainment and area-level SES by urban/rural residence and municipal median income; carotid ultrasound yielded a plaque score. An elevated plaque score occurred in 23.3% of the highly educated, 28.2% of the secondary-educated and 31.4% of the primary-educated. After adjustment for risk factors, lower-educated women and men retained 22% and 12% more atherosclerotic burden respectively. Area-level SES showed no association. Lower educational attainment is thus associated, independent of classical risk factors, with more carotid atherosclerosis.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8ec426ff8f45","type":"article","url":"https://hartvaat.nl/2026/01/30/kosteneffectiviteit-van-een-dual-energy-lattice-tip-katheter-sphere-9-versus-rad/","title":"Kosteneffectiviteit van een dual-energy lattice-tip-katheter (Sphere-9) versus radiofrequente ablatie bij persisterend AF","title_en":"Economic evaluation of a novel dual-energy, large focal lattice-tip catheter versus conventional contact-force sensing radiofrequency catheter for persistent atrial fibrillation ablation, from the English NHS perspective","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["farmaco-economie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003770?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003770?rss=1","authors":["Mellor","G.","Reddy","V.","Kanagaratnam","P.","Iskandar","R.","Ismyrloglou","E.","Mburu","W.","Souter","M.","Anter","E."],"significance":5,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"Persistent atrial fibrillation (AF) carries a large clinical and economic burden and gives worse ablation outcomes than paroxysmal AF. The Sphere-9 is a novel dual-energy large-focal lattice-tip catheter also capable of high-density mapping. This study evaluated, using patient data from the randomised SPHERE Per-AF trial, the cost-effectiveness of the Sphere-9 versus conventional radiofrequency (RF) ablation from the English NHS perspective, with a decision tree and Markov model over a lifetime horizon. Lattice-tip ablation was 'dominant': lower cost (£15,433 vs £20,861 per patient) and greater health benefit (8.26 vs 8.20 QALYs). The result remained robust across all sensitivity analyses. The Sphere-9 catheter is thus a cost-saving option for persistent AF compared with conventional RF ablation.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T13:31:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1142dcda9b1","type":"article","url":"https://hartvaat.nl/2026/01/30/off-label-lage-dosis-bloedplaatjesremmers-bij-coronairlijden-minder-infarcten-en/","title":"Off-label lage dosis bloedplaatjesremmers bij coronairlijden: minder infarcten en bloedingen (vooral Aziatische data)","title_en":"Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["bloeddrukbehandeling"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003839?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003839?rss=1","authors":["Zheng","L.","Ren","Z.","Shi","Y.","Zou","J.","Hao","C.","Li","Y.","Sun","L.","Wang","D.","Liu","H.","Liang","S.","Zhu","B.","Li","C."],"significance":5,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"This meta-analysis compared off-label low-dose with standard-dose antiplatelet agents in coronary heart disease (CHD), focusing on the gap around low- versus standard-dose ticagrelor and prasugrel. Twenty-two randomised trials (7,486 patients, 92% Asian; 64% exclusively acute coronary syndrome) were included, all using dual antiplatelet therapy (aspirin plus a low or standard dose P2Y12 inhibitor). Compared with standard dose, low dose reduced the risk of myocardial infarction (RR 0.75) and minimal bleeding (RR 0.64), with comparable other ischaemic and bleeding risks. Versus standard-dose clopidogrel, low dose reduced infarction but increased bleeding; versus standard-dose prasugrel/ticagrelor, ischaemic risks were similar with less bleeding. Low dose thus appears an effective secondary-prevention strategy, though the evidence rests mainly on Asian patients — in whom the ischaemia-bleeding balance differs from Europeans.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T13:31:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"004ec3e59a0b","type":"article","url":"https://hartvaat.nl/2026/01/30/dapk2-reguleert-pkm2-fosforylering-bij-verstoorde-stroming-geinduceerde-atherosc/","title":"DAPK2 reguleert PKM2-fosforylering bij verstoorde-stroming-geïnduceerde atherosclerose","title_en":"DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075951","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075951","authors":["Shuai Guo"],"significance":6,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":[],"congress":"","summary_en":"This basic science study revealed that DAPK2 regulates PKM2 phosphorylation to facilitate disturbed flow-induced atherosclerosis, identifying a new molecular pathway linking hemodynamic stress to plaque formation.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd711e32b25a","type":"article","url":"https://hartvaat.nl/2026/01/30/galectine-1-is-een-marker-maar-geen-mediator-van-hfpef/","title":"Galectine-1 is een marker maar geen mediator van HFpEF","title_en":"Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26006","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26006","authors":[],"significance":6,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":[],"congress":"","summary_en":"This study showed that galectin-1 is a biomarker but not a mediator of HFpEF, distinguishing association from causation and cautioning against therapeutic targeting of this immune-related protein.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78c4c38b1ef3","type":"article","url":"https://hartvaat.nl/2026/01/30/retractie-proteasoom-afhankelijke-degradatie-van-gtp-cyclohydrolase-i-bij-diabet/","title":"Retractie: proteasoom-afhankelijke degradatie van GTP-cyclohydrolase I bij diabetes","title_en":"Retraction of: Proteasome-Dependent Degradation of Guanosine 5’-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["ezetimibe","ras-remmers","sglt2-remmers","tirzepatide"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001420","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001420","authors":["Jian Xu"],"significance":1,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"Retraction notice for an article on proteasome-dependent degradation of GTP cyclohydrolase I causing tetrahydrobiopterin deficiency in diabetes mellitus.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e00a94fd26dc","type":"article","url":"https://hartvaat.nl/2026/01/30/systemische-embolische-events-bij-boezemfibrilleren-een-meta-analyse-op-patientn/","title":"Systemische embolische events bij boezemfibrilleren: een meta-analyse op patiëntniveau","title_en":"Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["myocardinfarct"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075275","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075275","authors":["Samer Al Said"],"significance":8,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"This individual patient data meta-analysis characterized the incidence, risk factors, and outcomes of systemic embolic events in AF, demonstrating that DOACs effectively prevent both stroke and non-cerebral embolism compared with warfarin.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4cf3de2e853d","type":"article","url":"https://hartvaat.nl/2026/01/30/familiaire-hypercholesterolemie-gemaskeerd-door-een-pcsk9-verlies-van-functievar/","title":"Familiaire hypercholesterolemie gemaskeerd door een PCSK9-verlies-van-functievariant","title_en":"Familial hypercholesterolemia concealed by a protein-truncating variant of PCSK9.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["cardiovasculaire-genetica","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","laminopathie","ldl-cholesterol","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","vrouwen"],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.01.020","source_url":"https://doi.org/10.1016/j.jacl.2026.01.020","authors":["Hayato Tada","Atsushi Furukawa","Masayuki Takamura"],"significance":5,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"A remarkable case report describes familial hypercholesterolaemia that was concealed by a co-existing PCSK9 loss-of-function variant, artificially lowering LDL-cholesterol. The case underscores the importance of genetic diagnostics when FH is suspected, even with apparently normal lipid levels.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabf6057afe2","type":"article","url":"https://hartvaat.nl/2026/01/29/obesitasparadox-bij-het-takotsubosyndroom-ondergewicht-geeft-de-hoogste-sterfte-/","title":"Obesitasparadox bij het takotsubosyndroom: ondergewicht geeft de hoogste sterfte (InterTAK)","title_en":"Body weight and mortality in Takotsubo syndrome: insights from the International Takotsubo (InterTAK) Registry","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["obesitas"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003851?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003851?rss=1","authors":["Sta&#x0308;hli","B.","Schweiger","V.","Cammann","V. L.","Schindler","M.","Szawan","K. A.","Niederseer","D.","Wu&#x0308;rdinger","M.","Scho&#x0308;nberger","A.","Scho&#x0308;nberger","M.","Koleva","I.","Mercier","J. C.","Petkova","V.","Steigmeier","M.","Citro","R.","Bossone","E.","Lu&#x0308;scher","T. F.","Templin-Ghadri","J.-R.","Di Vece","D.","Templin","C.","On behalf of the InterTAK Collaborators"],"significance":5,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"The so-called obesity paradox has been described in various cardiac conditions, but data in Takotsubo syndrome (TTS) were lacking. In the international InterTAK registry (2,707 patients with TTS, 2011-2021), patients were stratified by BMI. One-year mortality was 11.3% in underweight, 6.9% in normal weight, 5.5% in overweight, 4.9% in obese and 9.3% in very obese patients — a U-shaped curve. Being overweight or obese was associated with lower 1-year mortality (HR 0.70), also after adjustment (HR 0.67). An obesity paradox thus exists in Takotsubo syndrome, with the highest mortality in underweight and the lowest in (moderate) obesity — demonstrated for the first time in this patient group.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T13:31:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"49f1d62cad52","type":"article","url":"https://hartvaat.nl/2026/01/29/lineaire-ablatie-van-de-voorwand-van-het-linkeratrium-vermindert-af-recidieven-b/","title":"Lineaire ablatie van de voorwand van het linkeratrium vermindert AF-recidieven bij aorta-inkapseling","title_en":"Left atrial anterior wall ablation reduces the recurrence of atrial fibrillation in patients with aortic encroachment","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003816?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003816?rss=1","authors":["Zhang","R.","Che","Q.-J.","Yao","P.-C.","Chen","M.","Wang","Q.-S.","Sun","J.","Li","W.","Zhang","P.-P.","Liu","B.","Li","Y.-G."],"significance":5,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"Mechanical compression from the ascending aorta on the left atrial anterior wall (LAAW) can cause low-voltage areas (LVAs) that raise the risk of recurrent atrial fibrillation (AF) after catheter ablation. This retrospective study (267 patients with both aortic encroachment and LAAW low-voltage areas, first ablation 2019-2023) examined different ablation strategies. Without LAAW ablation, patients with aortic encroachment had higher AF recurrence risk (aHR 2.29). Patients receiving LAAW ablation of complex fractionated electrograms (CFAE) had higher recurrence than those with linear LAAW ablation. Linear LAAW ablation was a strong independent predictor of fewer recurrences (HR 0.13). When LAAW low-voltage areas are present, linear ablation of the atrial anterior wall thus appears a highly effective strategy to reduce post-ablation AF recurrence.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T13:31:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95b3e6154d6a","type":"article","url":"https://hartvaat.nl/2026/01/29/tavi-versus-afwachtend-beleid-bij-ernstige-aortastenose-groot-en-blijvend-overle/","title":"TAVI versus afwachtend beleid bij ernstige aortastenose: groot en blijvend overlevingsvoordeel","title_en":"Multidisciplinary team-guided management of severe aortic stenosis: 5-year outcomes following TAVI versus conservative treatment","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortastenose"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003872?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003872?rss=1","authors":["Manning","J.","Koizia","L. J.","Dani","M.","Malik","I.","Di Giovannantonio","M.","Harris","B. H. L.","Fertleman","M. B."],"significance":6,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"Multidisciplinary team (MDT) meetings guide treatment decisions in aortic stenosis (AS), especially for borderline or high-risk patients. This retrospective study followed all patients with severe AS discussed at a UK MDT between 2014 and 2016 (178 TAVI, 195 conservative). TAVI patients were younger (81.3 vs 83.5 years) and less frail. Survival at 1, 2 and 5 years was much higher with TAVI (87.6%, 74.7%, 44.9%) than with conservative management (60.8%, 44.2%, 12.1%); median survival was 53 versus 20 months. On multivariable analysis, TAVI was independently associated with lower mortality (HR 0.38). TAVI thus provided a substantial and durable survival advantage over conservative treatment — underscoring the poor prognosis of untreated severe AS and arguing for systematic follow-up of conservatively managed patients too.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T13:31:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00fd93f97c53","type":"article","url":"https://hartvaat.nl/2026/01/29/verminderde-pompfunctie-na-een-hartinfarct-hoge-symptoomlast-en-slechtere-secund/","title":"Verminderde pompfunctie na een hartinfarct: hoge symptoomlast en slechtere secundaire preventie (SWEDEHEART)","title_en":"Symptom burden and secondary prevention in patients with left ventricular systolic dysfunction after acute myocardial infarction: a nationwide register-based study in Sweden","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","vrouwen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003506?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003506?rss=1","authors":["Hamilton","E.","Jernberg","T.","Alfredsson","J.","Christersson","C.","Erlinge","D.","Lindmark","K.","Omerovic","E.","Desta","L.","Reitan","C."],"significance":6,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"Contemporary data on patients with left ventricular dysfunction after myocardial infarction (MI) are scarce. In this nationwide Swedish study (49,564 patients from the SWEDEHEART registry, first MI, 2011-2018, no prior heart failure), patients were stratified by degree of LV dysfunction. Compared with normal ejection fraction (≥50%), patients with severely reduced EF (<30%) far more often had dyspnoea (32.3% vs 5.6%; OR 7.45), were more often readmitted (48.1% vs 31.2%) and on sick leave (26.6% vs 9.5%); chest pain and quality of life did not differ. Patients with EF <30% less often took part in education programmes, physiotherapy and regular physical activity. Reduced pump function after infarction is thus associated with a high symptom burden and poorer uptake of secondary prevention — an important focus for aftercare.","created":"2026-07-03T10:32:26Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35c0e10c54e4","type":"article","url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","title":"Olezarsen bij ernstige hypertriglyceridemie en pancreatitisrisico","title_en":"Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","hypertriglyceridemie","ldl-cholesterol","select-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2512761","source_url":"https://doi.org/10.1056/NEJMoa2512761","authors":["Nicholas A Marston","Brian A Bergmark","Veronica J Alexander","Thomas A Prohaska","Yu Mi Kang","Filipe A Moura","Andre Zimerman","Elaine Waldman","Julia Weinland","Sabina A Murphy","Erica L Goodrich","Shuanglu Zhang","Shuting Xia","Dan Li","Anne C Goldberg","Assen Goudev","Lina Badimon","Robert Gabor Kiss","Michal Vrablik","Daniel Gaudet","Philippe Moulin","Erik S G Stroes","Maciej Banach","Hofit Cohen","Dirk Blom","Min-Ji Charng","Børge G Nordestgaard","Stephen J Nicholls","Sotirios Tsimikas","Robert P Giugliano","Marc S Sabatine"],"significance":8,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hypertriglyceridemie/","https://hartvaat.nl/kennis/lipiden/fibraten-bij-hypertriglyceridemie/"],"congress":"","summary_en":"This trial evaluated olezarsen specifically in patients with severe hypertriglyceridemia and pancreatitis risk, demonstrating dramatic triglyceride reduction and pancreatitis prevention. The APOC3-targeted antisense therapy offers a definitive solution for this dangerous metabolic condition.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1098124cf714","type":"article","url":"https://hartvaat.nl/2026/01/29/abnormale-pro-inflammatoire-immuuncelresponsen-voorafgaand-aan-hypertensieve-zwa/","title":"Abnormale pro-inflammatoire immuuncelresponsen voorafgaand aan hypertensieve zwangerschapsaandoeningen","title_en":"Abnormal Proinflammatory Immune Cell Responses Precede Clinical Onset of Hypertensive Disorders of Pregnancy","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25680","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25680","authors":["Ayman Rezk"],"significance":5,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This study demonstrates that abnormal proinflammatory immune cell responses are present before the clinical onset of hypertensive disorders of pregnancy, particularly among Black women. The findings support early immune profiling for risk prediction.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b007e1ce6287","type":"article","url":"https://hartvaat.nl/2026/01/29/ijzeroverbelasting-geinduceerde-ferroptose-veroorzaakt-placentadisfunctie-bij-pr/","title":"IJzeroverbelasting-geïnduceerde ferroptose veroorzaakt placentadisfunctie bij pre-eclampsie","title_en":"Iron Overload-Induced Ferroptosis Drives Placental Dysfunction in Preeclampsia","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["zwangerschap-hart"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26344","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26344","authors":["Yike Yang"],"significance":5,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":[],"congress":"","summary_en":"Using clinical data, mouse models, and placental organoids, this study demonstrates that iron overload induces ferroptosis leading to placental dysfunction in preeclampsia. The findings identify iron chelation as a potential therapeutic strategy.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d87c4061d27","type":"article","url":"https://hartvaat.nl/2026/01/29/trainingsbelasting-gemeten-met-wearables-en-coronaire-atherosclerose-bij-middelb/","title":"Trainingsbelasting gemeten met wearables en coronaire atherosclerose bij middelbare leeftijd","title_en":"Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","atleten","diabetes-en-hart","farmaco-economie","hartkatheterisatie","hartrevalidatie","holter","lichaamsbeweging","obesitas","ouderen","select-trial","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077117","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077117","authors":["Rik Pauwels"],"significance":7,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This study used wearable device-derived training load data to investigate the relationship between exercise volume and coronary atherosclerosis in middle-aged and older athletes, addressing the paradox of increased coronary plaque in endurance athletes.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9f887cb6d7d","type":"article","url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","title":"NLA-consensusupdate familiaire hypercholesterolemie: screening, diagnostiek en behandeling","title_en":"Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"Journal of clinical lipidology","doi":"10.1016/j.jacl.2026.01.011","source_url":"https://doi.org/10.1016/j.jacl.2026.01.011","authors":["Zahid Ahmad","Anandita Agarwala","Marina Cuchel","P Barton Duell","Robert A Hegele","Lisa Hudgins","Allison Jamison","Dinesh Kalra","Amit Khera","Joshua W Knowles","Iftikhar J Kullo","Ana Morales","Mark A Rothstein","Joseph J Saseen","Daniel E Soffer","Bruce A Warden","William S Weintraub","Lauren Williams","Anne C Goldberg"],"significance":6,"published":"2026-01-29","source_date":"2026-01-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This NLA expert consensus update on familial hypercholesterolemia provided revised guidance on FH screening, diagnosis, and treatment including cascade testing, pediatric management, and the expanding role of PCSK9 inhibitors and inclisiran.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9dda376705bf","type":"article","url":"https://hartvaat.nl/2026/01/28/risicocommunicatie-instrument-in-de-huisartsenpraktijk-verlaagt-bloeddruk-en-cho/","title":"Risicocommunicatie-instrument in de huisartsenpraktijk verlaagt bloeddruk en cholesterol (Deense RCT)","title_en":"Danish evaluation of Your Heart Forecast: a cluster randomised controlled trial aimed at improving modifiable risk factors of CVD","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003812?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003812?rss=1","authors":["Stjernholm","K.","Andersen","H. S.","Jensen","A. E.","Nielsen","J. B."],"significance":5,"published":"2026-01-28","source_date":"2026-01-28","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/metabool-syndroom/"],"congress":"","summary_en":"Can a tool that visualises cardiovascular risk, combined with education, improve risk factors? In this cluster-randomised trial across 17 Danish general practices (255 hypertensive patients aged 35-75 without cardiovascular disease), the intervention group received the risk-communication tool 'Your Heart Forecast' at the annual blood-pressure consultation plus a monthly lifestyle email for twelve months; the control group received usual care. In the most poorly controlled patients, blood pressure fell in both groups but more in the intervention group; intervention patients with moderately raised blood pressure also improved significantly. The cholesterol ratio (TC/HDL) fell only in intervention patients with the highest baseline values. A risk-communication tool plus education thus lowered blood pressure and cholesterol ratio in patients with dysregulated values, compared with usual care.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ea23a470715","type":"article","url":"https://hartvaat.nl/2026/01/28/hypertensie-bij-dialysepatienten-de-kloof-tussen-bewijs-en-praktijk/","title":"Hypertensie bij dialysepatiënten: de kloof tussen bewijs en praktijk","title_en":"Hypertension in Patients With End-Stage Kidney Disease Requiring Dialysis: Bridging the Divide Between Evidence and Practice","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","anemie-ckd","bloeddrukbehandeling","chronische-nierziekte","renale-denervatie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24344","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24344","authors":["Laura Mayeda"],"significance":6,"published":"2026-01-28","source_date":"2026-01-28","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This review addressed hypertension management in dialysis patients, highlighting the distinct pathophysiology (volume overload, sympathetic activation, arterial stiffness) and evidence gaps that make blood pressure control challenging in end-stage kidney disease.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"567875b666b1","type":"article","url":"https://hartvaat.nl/2026/01/28/kdigo-2026-richtlijn-anemie-bij-chronische-nierziekte-europees-commentaar/","title":"KDIGO 2026-richtlijn anemie bij chronische nierziekte: Europees commentaar","title_en":"KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","ijzertekort"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag014","source_url":"https://doi.org/10.1093/ndt/gfag014","authors":["Lucia Del Vecchio","Aleix Cases","Michele F Eisenga","Jolanta Małyszko","Jonathan Barratt","Davide Bolignano"],"significance":6,"published":"2026-01-28","source_date":"2026-01-28","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This ERA commentary on the KDIGO 2026 anemia in CKD guideline discussed the substantial updates including new recommendations for intravenous iron, HIF-prolyl hydroxylase inhibitors, and ESA targets in the contemporary treatment landscape.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c887ac18ecc4","type":"article","url":"https://hartvaat.nl/2026/01/27/minimaal-invasieve-mitralisklepchirurgie-sneller-herstel-even-veilig-als-de-conv/","title":"Minimaal-invasieve mitralisklepchirurgie: sneller herstel, even veilig als de conventionele operatie","title_en":"Minimally invasive versus conventional mitral valve surgery: a systematic review and meta-analysis of randomised clinical trials","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003612?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003612?rss=1","authors":["Spadini","F. A.","Lira","K. B.","Delvaux","R. S.","Kopittke","L.","Anschau","F.","Ceron","R. O.","Rode","J.","Rey","R. A. W.","Almeida","A. S."],"significance":6,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/hartgeruisen-herkenning/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-bloeding/"],"congress":"","summary_en":"Whether minimally invasive mitral valve surgery (MIMVS) offers advantages over the conventional approach (CMVS) was controversial. This systematic review and meta-analysis of randomised trials (8 RCTs, 9 studies, 1,248 patients: 686 CMVS, 562 MIMVS) compared short-term outcomes. MIMVS did not differ in mortality or acute kidney injury, with a trend toward fewer wound infections and shorter ICU stay. MIMVS did reduce reoperations for bleeding (RR 0.24) and hospital stay (mean 1.8 days shorter). Operative time was longer but without clinical impact; stroke, infarction, ventilation time and transfusions were comparable. Certainty of evidence was mostly moderate to high. MIMVS thus enhances postoperative recovery — shorter stay, fewer reoperations for bleeding — with safety comparable to conventional surgery.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T13:31:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"332f963955d8","type":"article","url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","title":"ORBITA-2: leeftijd en PCI-effectiviteit bij stabiel coronairlijden","title_en":"Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.086","source_url":"https://doi.org/10.1016/j.jacc.2025.10.086","authors":["Florentina A Simader","Christopher A Rajkumar","Michael J Foley","Fiyyaz Ahmed-Jushuf","Shayna Chotai","Kayla Chiew","Zahra Naderi","John R Davies","Thomas R Keeble","Peter D O'Kane","Peter Haworth","Sukhjinder S Nijjer","James P Howard","Graham Cole","Frank E Harrell","Darrel P Francis","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":6,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This ORBITA-2 subanalysis confirmed that the placebo-controlled benefit of PCI is consistent across age groups in stable angina, supporting revascularization regardless of patient age when ischemia is objectively demonstrated.","created":"2026-07-03T10:32:09Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8f2350c1b519","type":"article","url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","title":"Prognostische implicaties van universele definities van periprocedureel MI","title_en":"Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.077174","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.077174","authors":["Sergio Leonardi","Antonio Landi","Andrea Zito","Mattia Branca","Enrico Frigoli","Giuseppe Ando'","Carlo Briguori","Paolo Calabro","Andrea Gagnor","Roberto Garbo","Dik Heg","Ugo Limbruno","Andrea Milzi","Elmir Omerovic","Filippo Russo","Manel Sabaté","Andrea Santarelli","Gennaro Sardella","Paolo Tosi","Arnoud W J Van't Hof","Pascal Vranckx","Marco Valgimigli"],"significance":5,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":[],"congress":"","summary_en":"This study compared the prognostic implications of successive universal definitions of periprocedural myocardial infarction in patients with acute coronary syndrome. Not all definition iterations carry equal prognostic significance, informing interpretation of trial endpoints.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"53fcf1f0d492","type":"article","url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","title":"NEO-MINOR: potente P2Y12-monotherapie versus DAPT na PCI bij STEMI","title_en":"Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.058","source_url":"https://doi.org/10.1016/j.jacc.2025.10.058","authors":["Caio A M Tavares","Patricia O Guimarães","Marcelo Franken","José Mariani Junior","Stefano Lemos","Breno O Almeida","Eduardo B Martins","Estêvão L Figueiredo","Aloísio M da Rocha","Alexandre A Soares","Marcos A Marino","Bruno Paolino","Mayler Olombrada Santos","Paulo R A Caramori","Rodrigo M Joaquim","Edgard F Quintella","André F Antonangelo","Alberto G T Fonseca","Marcos S Silveira","Milena R da Fonseca","Frederico Monfardini","Silvia R L Assis","Leonardo R Costa","José C Nicolau","Andrei C Sposito","Renato D Lopes","Yoshinobu Onuma","Marco Valgimigli","Dominick J Angiolillo","Patrick W J C Serruys","Otavio Berwanger","Raul D Santos","Fernando Bacal","Pedro A Lemos"],"significance":8,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The NEO-MINDSET substudy showed that potent P2Y12 inhibitor monotherapy after very early aspirin withdrawal is noninferior to DAPT after PCI in STEMI patients, with fewer bleeding events. The result extends the de-escalation strategy to the acute STEMI population.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ffafa16f4205","type":"article","url":"https://hartvaat.nl/2026/01/27/vroege-versus-late-gestageerde-pci-na-subintimale-re-entry-bij-cto/","title":"Vroege versus late gestageerde PCI na subintimale re-entry bij CTO","title_en":"Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.1598","source_url":"https://doi.org/10.1016/j.jacc.2025.09.1598","authors":["Lorenzo Azzalini","Kathleen Kearney","Adam C Salisbury","Nancy Stone","Kensey L Gosch","Philip G Jones","John A Spertus","Ashish Pershad","William Nicholson","William Lombardi","R Michael Wyman","Rhian Davies","J Aaron Grantham","Taishi Hirai"],"significance":5,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"A randomised trial compared early versus late staged PCI after subintimal tracking and re-entry for chronic total occlusions. The timing of the staged procedure did not significantly influence outcomes, providing flexibility in procedural planning.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a04c7bd5792","type":"article","url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","title":"DECAF: cafeïnehoudende koffie en AF — gerandomiseerde trial","title_en":"Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.21056","source_url":"https://doi.org/10.1001/jama.2025.21056","authors":["Christopher X Wong","Christopher C Cheung","Gabrielle Montenegro","Hannah H Oo","Isabella J Peña","Janet J Tang","Samuel J Tu","Grace Wall","Thomas A Dewland","Joshua D Moss","Edward P Gerstenfeld","Zian H Tseng","Henry H Hsia","Randall J Lee","Jeffrey E Olgin","Vasanth Vedantham","Melvin M Scheinman","Catherine Lee","Prashanthan Sanders","Gregory M Marcus"],"significance":7,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":[],"congress":"","summary_en":"The DECAF randomized trial showed that caffeinated coffee consumption does not increase AF risk compared with abstinence, debunking the widely held belief that caffeine triggers atrial fibrillation.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ec0e0a8a010","type":"article","url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","title":"Intracoronair lage-dosis rtPA bij primaire PCI voor STEMI: RCT","title_en":"Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.008","source_url":"https://doi.org/10.1016/j.jacc.2025.10.008","authors":["Shamir R Mehta","Natalia Pinilla-Echeverri","Denise Tiong","Tanya Kovalova","Tej Sheth","Madhu K Natarajan","Matthew Sibbald","James L Velianou","Robert Welsh","Bryan Har","Sanjit S Jolly","Nicholas Valettas","J D Schwalm","Michael Tsang","Rutaba Khatun","Rajibul Mian","Jennifer Cunningham","Eric Ly","Tara McCready","Kevin R Bainey"],"significance":6,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This randomized trial showed that intracoronary low-dose rtPA as an adjunct to primary PCI for STEMI improves microvascular perfusion, testing clot-dissolving therapy to address the residual microvascular obstruction problem.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"808b118f620d","type":"article","url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","title":"REC-CAGEFREE: DCB versus stenting bij de novo CAD — driejaarsdata","title_en":"Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.027","source_url":"https://doi.org/10.1016/j.jacc.2025.10.027","authors":["Ling Tao","Xingqiang He","Guidong Shen","Mingxing Wu","Yuquan He","Likun Ma","Feng Yang","Zheng Ji","Hua Wang","Yanqing Wu","Zhenfei Fang","Hong Jiang","Shangyu Wen","Yuanzhe Jin","Hui Chen","Lin Zhong","Sigan Hu","Yi Liu","Fei Li","Jingyu Zhou","Fan Ouyang","Zhihui Zhang","Bin Zhu","Ruining Zhang","Guotao Fu","Jianzheng Liu","Zhiwei Jiang","Duolao Wang","Davide Capodanno","Scot Garg","Yoshinobu Onuma","Patrick W Serruys","Chao Gao"],"significance":6,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":[],"congress":"","summary_en":"Three-year REC-CAGEFREE data confirmed that drug-coated balloon angioplasty offers a durable stent-free alternative for selected de novo coronary lesions, supporting the leave-nothing-behind approach for long-term outcomes.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd2c23bd2cb9","type":"article","url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","title":"PCI van natief coronairvat versus veneuze graft na eerdere CABG: RCT","title_en":"PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-bypass"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.1577","source_url":"https://doi.org/10.1016/j.jacc.2025.09.1577","authors":["Ruben W de Winter","Roel Hoek","Simon J Walsh","Colm G Hanratty","Ralf W Sprengers","Jos W R Twisk","Iris Vegting","Stefan P Schumacher","Michiel J Bom","Niels J Verouden","José P Henriques","Adriaan Wilgenhof","Michele M Viscusi","Koen Teeuwen","Maksymilian P Opolski","Rafał Wolny","Pierfrancesco Agostoni","Jan-Peter van Kuijk","Bas E Schölzel","Adriaan O Kraaijeveld","Robert-Jan M van Geuns","Maurits T Dirksen","Antonius A C M Heestermans","Jo Dens","Johan Bennett","Steven E F Haine","Ronak Delewi","Alexander Nap","James C Spratt","Paul Knaapen"],"significance":7,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This multicenter randomized trial compared PCI of the native coronary artery versus the saphenous vein graft in patients with prior CABG and graft failure, providing the first randomized evidence to guide the target vessel for intervention after bypass surgery.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ed16c6325d8","type":"article","url":"https://hartvaat.nl/2026/01/27/colchicine-bij-acs-meta-analyse-van-alle-rct-s/","title":"Colchicine bij ACS: meta-analyse van alle RCT's","title_en":"Colchicine in acute coronary syndromes: a systematic review and meta-analysis of randomised controlled trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["colchicine"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-325826","source_url":"https://doi.org/10.1136/heartjnl-2025-325826","authors":["Ramon Huntermann","Juan Peres de Oliveira","Lucas M Barbosa","Ivo Queiroz","Douglas Nunes Cavalcante","Caroline de Oliveira Fischer Bacca"],"significance":8,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This updated meta-analysis of all colchicine trials in acute coronary syndromes confirmed significant MACE reduction with an acceptable safety profile. The anti-inflammatory concept in ACS is now supported by robust pooled evidence.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7568f029c2e","type":"article","url":"https://hartvaat.nl/2026/01/27/aldosteronsynthase-remmers-bij-ongecontroleerde-en-resistente-hypertensie-bij-ck/","title":"Aldosteronsynthase-remmers bij ongecontroleerde en resistente hypertensie bij CKD","title_en":"Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","lorundrostat","ras-remmers","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag013","source_url":"https://doi.org/10.1093/ndt/gfag013","authors":["Marieta P Theodorakopoulou","Fotini Iatridi","Manfred Hecking","Pantelis Sarafidis"],"significance":6,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This NDT review assessed aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD, evaluating the bench-to-bedside translation of this new drug class for the renally impaired hypertensive population.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"697bdc2e1421","type":"article","url":"https://hartvaat.nl/2026/01/27/lp-a-verstoort-de-ldl-cholesterolberekening-welke-formule-is-het-meest-betrouwba/","title":"Lp(a) verstoort de LDL-cholesterolberekening: welke formule is het meest betrouwbaar?","title_en":"Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Diseases (Basel, Switzerland)","doi":"10.3390/diseases14020041","source_url":"https://doi.org/10.3390/diseases14020041","authors":["Olga I Afanasieva","Alexandra V Tyurina","Elena A Klesareva","Marat V Ezhov","Sergei N Pokrovsky"],"significance":3,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This study demonstrates that lipoprotein(a) cholesterol contributes to overestimation of \"true\" LDL-C in standard calculations. Correction for Lp(a)-cholesterol significantly improves lipid profile accuracy in patients with elevated Lp(a).","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12c6abf3ba13","type":"article","url":"https://hartvaat.nl/2026/01/26/impact-van-britse-zoutreductiedoelen-2024-op-cardiovasculaire-uitkomsten-modelle/","title":"Impact van Britse zoutreductiedoelen 2024 op cardiovasculaire uitkomsten: modelleerstudie","title_en":"Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["farmaco-economie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25159","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25159","authors":["Lauren Bandy"],"significance":6,"published":"2026-01-26","source_date":"2026-01-26","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This modeling study estimated the potential cardiovascular health impact of the 2024 UK salt reduction targets, projecting significant prevention of hypertension, stroke, and heart disease through industry-led reformulation.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1530c755e83","type":"article","url":"https://hartvaat.nl/2026/01/26/zoutreductie-in-het-franse-stokbrood-heeft-duizenden-levens-gered/","title":"Zoutreductie in het Franse stokbrood heeft duizenden levens gered","title_en":"From French Gastronomy to Cardiovascular Health: Cutting Salt in the Baguette Has Saved Thousands of Lives in France","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25977","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25977","authors":["Clémence Grave"],"significance":6,"published":"2026-01-26","source_date":"2026-01-26","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This perspective described how reducing salt content in the French baguette — a staple consumed daily by millions — has prevented thousands of cardiovascular deaths, demonstrating the population-level impact of industry-level sodium reduction.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e64dcabc9f3","type":"article","url":"https://hartvaat.nl/2026/01/26/isolinderalacton-remt-nlrp3-inflammasoomactivatie-bij-atherosclerose/","title":"Isolinderalacton remt NLRP3-inflammasoomactivatie bij atherosclerose","title_en":"Isolinderalactone alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation and inflammatory response in macrophages","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["atherosclerose","inflammatie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00014-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00014-6/fulltext","authors":["Jingjing Shao","Haowen Xu","Fangmin Ning","Leiyu Xu","Weifeng Li","Yong Xu","Zhe Wang","Haiyi Chen","Binglu Shi","Ying Kong","Aleksandr V. Samorodov","Wan Gan","Yi Wang"],"significance":3,"published":"2026-01-26","source_date":"2026-01-26","image":"","kennis":["https://hartvaat.nl/kennis/preventie/psychosociale-risicofactoren-hart/"],"congress":"","summary_en":"This study shows that isolinderalactone, a sesquiterpene compound from Lindera aggregata, alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation and the inflammatory response in macrophages.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f17cb9889784","type":"article","url":"https://hartvaat.nl/2026/01/26/zittende-zoutbelastingstest-voor-lateralisatie-van-primair-aldosteronisme/","title":"Zittende zoutbelastingstest voor lateralisatie van primair aldosteronisme","title_en":"Seated Saline Suppression Test for Lateralizing Primary Aldosteronism","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26008","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26008","authors":[],"significance":6,"published":"2026-01-26","source_date":"2026-01-26","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This blinded clinical trial evaluated a seated saline suppression test for lateralizing primary aldosteronism, testing a simplified confirmatory approach for identifying surgical candidates in PA management.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1228ab6d543e","type":"article","url":"https://hartvaat.nl/2026/01/24/oproep-tot-actie-europese-trials-nodig-tegen-tsunami-van-nierfalen/","title":"Oproep tot actie: Europese trials nodig tegen tsunami van nierfalen","title_en":"Randomised controlled trials in Europe: a call to action to protect national health care systems from the upcoming tsunami of kidney failure.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag007","source_url":"https://doi.org/10.1093/ndt/gfag007","authors":["Alberto Ortiz","Mustafa Arici","Dimitrios S Goumenos","Marcin Adamczak","Kathrin Eller","Ana Carina Ferreira","Giuseppe Grandaliano","Kitty J Jager","Jennifer S Lees","Vassilios Liakopoulos","Roberto Minutolo","Siren Sezer","Laura Azzolini","Monica Fontana","Federico Torres","Roser Torra"],"significance":5,"published":"2026-01-24","source_date":"2026-01-24","image":"","kennis":[],"congress":"","summary_en":"This call to action highlights that kidney diseases are among the fastest-growing global health burdens, with CKD projected to become the third leading cause of death by 2050. Despite this, no EMA-approved treatment exists for AKI and no drug prevents the need for kidney replacement therapy, necessitating a European randomised trial network.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc5c7c9e70e7","type":"article","url":"https://hartvaat.nl/2026/01/23/multidisciplinair-cardiogene-shockteam-verbetert-de-1-jaarsoverleving-bij-infarc/","title":"Multidisciplinair cardiogene-shockteam verbetert de 1-jaarsoverleving bij infarct-gerelateerde shock","title_en":"Advanced Cardiogenic-shock Team versus standard care in cardiogenic shock: a single centre service evaluation project","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","myocardinfarct"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003794?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003794?rss=1","authors":["Chandra Mohan","N.","Govier","M.","Johnson","T. W.","Felekos","I.","Richards","G.","Strange","J.","Dastidar","A.","Sidik","N.","Dorman","S.","Joshi","N.","Gurney","S.","Bourdeaux","C.","Grant","A.","Oglesby","K.","McInerney-Baker","G.","Yaya","S.","Keeble","T.","Pareek","N.","Rees","P.","Curzen","N.","Mariathas","M."],"significance":6,"published":"2026-01-23","source_date":"2026-01-23","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"Cardiogenic shock after myocardial infarction (AMI) carries high mortality; structured multidisciplinary care is little studied. In this service evaluation at a UK tertiary cardiac centre (ACT-SHOCK), 82 patients with AMI-related cardiogenic shock needing emergent PCI were identified using protocolised physiological criteria and managed by an Advanced Cardiogenic-Shock Team (interventional cardiologists, intensivists, anaesthetists and cardiac physiologists). They were compared with 83 historical controls from the prior year (standard care). Shock-team management was associated with lower 1-year mortality (HR 0.53); 30-day mortality was also lower but not significant. At 24 hours, fewer patients were in the most severe shock stages (SCAI D/E). Protocolised shock recognition with activation of a multidisciplinary team was thus associated with earlier detection and better 1-year survival — a basis for further multicentre study.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"75800eade1a7","type":"article","url":"https://hartvaat.nl/2026/01/23/etnische-verschillen-in-aortadiameters-indiase-versus-nederlandse-patienten-amst/","title":"Etnische verschillen in aortadiameters: Indiase versus Nederlandse patiënten (Amsterdam UMC)","title_en":"Ethnic variation in thoracic aortic dimensions in the general population: a comparison between Indian and Dutch populations","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003808?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003808?rss=1","authors":["Bacour","N.","Idhrees","M.","Samraj","J.","Grewal","S.","Velayudhan","B.","Busra Celik","N.","Zafar","M.","Elefteriades","J. A.","Grewal","N."],"significance":6,"published":"2026-01-23","source_date":"2026-01-23","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Guidelines use absolute diameter thresholds for aortic surgery, largely based on Western cohorts. This retrospective study compared aortic diameters of Indian (SIMS Hospital) and Dutch patients (Amsterdam UMC) who underwent CT in 2022 (3,692 patients: 2,000 Indian, 1,692 Dutch) at five anatomical locations. Indian patients had a larger aortic root (33.9 vs 31.5 mm), but Dutch patients had significantly larger diameters of the ascending aorta (33.1 vs 30.5 mm), aortic arch, descending aorta and abdominal aorta. These differences persisted after adjustment for age, sex, height and comorbidity. There is thus substantial ethnic-geographic variation in aortic diameters — raising questions about applying current (Western) surgical thresholds to Indian patients and arguing for individualised, indexed risk assessment.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T13:31:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36e020b14540","type":"article","url":"https://hartvaat.nl/2026/01/23/cellulaire-senescentie-als-therapeutisch-doelwit-bij-diabetische-nierziekte/","title":"Cellulaire senescentie als therapeutisch doelwit bij diabetische nierziekte","title_en":"Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","diabetes-en-hart","diabetische-nefropathie","fidelio-dkd","figaro-dkd","ijzertekort","soul-trial"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00054-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00054-2/fulltext","authors":["Helly A. Patel","Jiaxuan Wang","Caroline J. Zinn","Maya Learmonth","Xiaohui Bian","Diana Jurk","Lilach O. Lerman","Joy Wolfram","LaTonya J. Hickson"],"significance":5,"published":"2026-01-23","source_date":"2026-01-23","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This review discusses the potential of regenerative cell-based therapies and senotherapeutic approaches targeting cellular senescence in diabetic kidney disease. Addressing senescence-driven chronic inflammation may overcome treatment resistance in patients who progress despite optimal therapy.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d866f766add","type":"article","url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","title":"Antitrombotische therapie na succesvolle AF-ablatie: gerandomiseerde trial","title_en":"Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","trombose"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2509688","source_url":"https://doi.org/10.1056/NEJMoa2509688","authors":["Atul Verma","David H Birnie","Chenyang Jiang","Hein Heidbüchel","Gerhard Hindricks","Paulus Kirchhof","Jeff S Healey","Yunhe Wang","Nikolaos Dagres","Marc W Deyell","Prashanthan Sanders","Rajeev K Pathak","Pieter Koopman","Dieter Nuyens","Paul Novak","Guy Amit","Charles Dussault","Bhavanesh Makanjee","F Russell Quinn","Umjeet Jolly","Leon Iden","Malte Kuniss","Mukul Sharma","Andrew Ha","Vidal Essebag","Jean Champagne","Michael D Hill","Eric E Smith","George A Wells"],"significance":8,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This randomized trial investigated the optimal antithrombotic regimen after successful catheter ablation for atrial fibrillation, addressing whether successful ablation eliminates the need for long-term oral anticoagulation.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb77c8d48448","type":"article","url":"https://hartvaat.nl/2026/01/22/verschil-tussen-klinische-en-ambulante-bloeddruk-en-valrisico-bij-ouderen/","title":"Verschil tussen klinische en ambulante bloeddruk en valrisico bij ouderen","title_en":"Association of Clinic Blood Pressure and Out-of-Clinic Blood Pressure Difference With Falls Among Older Adults With Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bisoprolol","bloeddrukbehandeling","dubbele-trombocytenremming","perifeer-vaatlijden","sacubitril-valsartan"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25783","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25783","authors":["Daichi Shimbo"],"significance":6,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study showed that the difference between clinic and out-of-office blood pressure is not associated with increased falls in older hypertensive adults, addressing a common barrier to antihypertensive treatment intensification.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5aae528f381b","type":"article","url":"https://hartvaat.nl/2026/01/22/nieuw-ratmodel-voor-chronisch-trombo-embolische-pulmonale-hypertensie/","title":"Nieuw ratmodel voor chronisch trombo-embolische pulmonale hypertensie","title_en":"Development and Characterization of a Novel Chronic Thromboembolic Pulmonary Hypertension Rat Model: Identifying Sell-Podxl as Potential Regulators","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["pulmonale-hypertensie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25589","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25589","authors":["Jixiang Liu"],"significance":4,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":[],"congress":"","summary_en":"This study developed a novel chronic thromboembolic pulmonary hypertension rat model using gelatin sponge combined with SU5416 and identified Sell-Podxl as potential regulators of the dual-compartment pulmonary vascular remodelling.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf11d028863c","type":"article","url":"https://hartvaat.nl/2026/01/22/werkzaamheid-en-veiligheid-van-finerenon-bij-primair-aldosteronisme/","title":"Werkzaamheid en veiligheid van finerenon bij primair aldosteronisme","title_en":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048","authors":["Ping Li"],"significance":6,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This multicenter study provided the first prospective evidence on finerenone efficacy and safety in primary aldosteronism, testing the nonsteroidal MRA in the condition where aldosterone excess is the primary pathology.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3b2b1ac124c","type":"article","url":"https://hartvaat.nl/2026/01/22/finerenon-verbetert-albuminurie-via-mr-trpc-signalering-bij-diabetische-nierziek/","title":"Finerenon verbetert albuminurie via MR-TRPC-signalering bij diabetische nierziekte","title_en":"Finerenone Improves Albuminuria via MR-TRPC Signaling in Diabetic Kidney Disease","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","diabetes-en-hart","dyslipidemie","fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","tirzepatide"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25739","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25739","authors":["Tsukasa Iwakura"],"significance":5,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This study reveals that finerenone improves albuminuria in diabetic kidney disease through the mineralocorticoid receptor-TRPC signalling pathway, protecting podocytes by limiting excessive calcium influx via TRPC5 channels.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14a6416f9a26","type":"article","url":"https://hartvaat.nl/2026/01/22/heat-shock-eiwitten-70-als-modificatoren-van-endotheelfunctie-bij-de-ziekte-van-/","title":"Heat shock-eiwitten 70 als modificatoren van endotheelfunctie bij de ziekte van Fabry","title_en":"Heat shock protein 70s are modifiers of endothelial function in Fabry disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00013-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00013-X/fulltext","authors":["Rakesh Verma","Audrey Cleuren","Vania Hinkovska-Galcheva","Ilka Decker","Robert Kelly","David Ginsburg","James A. Shayman"],"significance":5,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/cardiorenal-syndroom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This research identifies heat shock protein 70 family members as disease modifiers of endothelial function in Fabry disease, helping explain the variable clinical phenotypes observed among patients with identical GLA gene mutations.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f44a9b706a29","type":"article","url":"https://hartvaat.nl/2026/01/22/microbiele-metaboliet-4eps-remt-at1r-en-verlaagt-bloeddruk-en-aorta-aneurysmavor/","title":"Microbiële metaboliet 4EPS remt AT1R en verlaagt bloeddruk en aorta-aneurysmavorming","title_en":"Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25364","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25364","authors":[],"significance":5,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study demonstrates that the gut microbial metabolite 4-ethylphenylsulfate directly inhibits the angiotensin II type 1 receptor, reducing blood pressure and aortic aneurysm formation. The finding reveals a novel microbiome-cardiovascular signalling axis.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cdb78b50b48c","type":"article","url":"https://hartvaat.nl/2026/01/22/nachtelijke-hypertensie-en-prognose-bij-zeer-oude-patienten/","title":"Nachtelijke hypertensie en prognose bij zeer oude patiënten","title_en":"Nocturnal Hypertension and Prognosis in Patients of Very Advanced Age","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","nt-probnp"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25199","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25199","authors":["Takeshi Fujiwara"],"significance":6,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"This study confirmed that nocturnal blood pressure predicts outcomes even in very advanced age, establishing the clinical significance of ambulatory monitoring in the oldest patient populations.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21d1dcf90390","type":"article","url":"https://hartvaat.nl/2026/01/22/primaire-hyperoxalurie-van-trials-naar-real-world-data-en-pijplijntherapieen/","title":"Primaire hyperoxalurie: van trials naar real-world data en pijplijntherapieën","title_en":"Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00053-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00053-0/fulltext","authors":["Justine Bacchetta","Cécile Acquaviva-Bourdain","Nadia Abid","Anne Laure Sellier Leclerc","Arnaud Molin","Sandrine Lemoine"],"significance":5,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":[],"congress":"","summary_en":"This review summarises the evolving landscape of primary hyperoxaluria treatment, from clinical trials to real-world data and pipeline therapies. siRNA-based hepatic enzyme silencing has revolutionised management of these rare disorders of glyoxylate metabolism.","created":"2026-07-03T10:25:30Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"86f81f93a77f","type":"article","url":"https://hartvaat.nl/2026/01/22/medicatiebeheer-van-ras-remmers-en-sglt2-remmers-bij-chronische-nierziekte/","title":"Medicatiebeheer van RAS-remmers en SGLT2-remmers bij chronische nierziekte","title_en":"Drug stewardship for RAS-inhibitors and SGLT2-inhibitors in chronic kidney disease: stay on, restart.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","huisarts","internist"],"tags":["anemie-ckd","canagliflozine","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","dapagliflozine","empagliflozine","fidelio-dkd","flow-trial","ijzertekort","ras-remmers","sglt2-remmers"],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag008","source_url":"https://doi.org/10.1093/ndt/gfag008","authors":["Pim Bouwmans","Catherine M Clase","Juan-Jesus Carrero"],"significance":6,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This NDT article emphasized that RAS inhibitors and SGLT2 inhibitors should not be discontinued in CKD patients, showing that drug stewardship programs focusing on continuation and restart of these cornerstone therapies improve outcomes.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb8ca2f71eca","type":"article","url":"https://hartvaat.nl/2026/01/21/genetische-test-bij-cardiomyopathie-huidige-britse-criteria-missen-een-op-de-zev/","title":"Genetische test bij cardiomyopathie: huidige Britse criteria missen één op de zeven dragers","title_en":"Genetic testing in cardiomyopathies: do we need to redefine the UK national testing criteria?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003838?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003838?rss=1","authors":["Madu","A. C.","Dimarco","A. D.","Hardy-Wallace","A.","Ganapathy","A.","Savage","H. O.","Dungu","J. N."],"significance":5,"published":"2026-01-21","source_date":"2026-01-21","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/ritmestoornissen/arvc-aritmogene-rechterventrikeldysplasie/"],"congress":"","summary_en":"In inherited heart muscle diseases such as dilated (DCM) and hypertrophic cardiomyopathy (HCM), genetic testing can reveal a pathogenic variant, with implications for the patient and relatives. The UK criteria (NGTD) are strict, while the ESC recommends wider testing. In this retrospective analysis (257 patients with DCM or HCM, Essex clinic, 2023-2025), diagnostic yield was 19.9% in DCM and 17.4% in HCM. Of gene-positive patients, 14.8% (DCM) and 14.3% (HCM) did not meet current UK testing criteria — mainly due to age cut-offs. All gene-positive DCM patients falling outside the criteria had myocardial fibrosis. One in seven cardiomyopathy patients with a pathogenic variant would thus be missed under current UK criteria — each with on average four first-degree relatives who would benefit from predictive testing. The authors argue for the wider ESC approach without strict age cut-offs.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b11e0976c86","type":"article","url":"https://hartvaat.nl/2026/01/21/patientgerapporteerde-uitkomsten-verbeteren-voorspelling-van-mortaliteit-bij-dia/","title":"Patiëntgerapporteerde uitkomsten verbeteren voorspelling van mortaliteit bij dialysepatiënten","title_en":"A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["acuut-hartfalen","dialyse"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00677-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00677-5/fulltext","authors":["Jet Milders","Roemer J. Janse","Willem Jan W. Bos","Fergus J. Caskey","Claudia Torino","Antonio Vilasi","Maciej Szymczak","Christiane Drechsler","Christoph Wanner","Maria Pippias","Kitty J. Jager","Nicholas C. Chesnaye","Marie Evans","Friedo W. Dekker","Merel van Diepen","EQUAL study investigators"],"significance":5,"published":"2026-01-21","source_date":"2026-01-21","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that patient-reported outcomes such as pain and fatigue improve the prediction of mortality in incident dialysis patients beyond traditional clinical predictors, supporting holistic assessment at dialysis initiation.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7ee342c3309","type":"article","url":"https://hartvaat.nl/2026/01/21/niertransplantatie-bij-ouderen-indicaties-timing-en-orgaankwaliteit/","title":"Niertransplantatie bij ouderen: indicaties, timing en orgaankwaliteit","title_en":"Eligibility, timing, and organ quality: indications and outcomes of kidney transplantation in older patients","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["niertransplantatie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00052-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00052-9/fulltext","authors":["Constantin Kupsch","Sarah Tsou","Friederike Martin","Rosalie Wolff von Gudenberg","Stefan Fichtner-Feigl","Reza Abdi","Stefan G. Tullius"],"significance":5,"published":"2026-01-21","source_date":"2026-01-21","image":"","kennis":[],"congress":"","summary_en":"This review details kidney transplantation indications, timing, and organ quality considerations for older patients. As the most rapidly growing transplant candidate population, data-driven approaches are needed to optimise recipient selection and outcomes.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1d3516ee2b05","type":"article","url":"https://hartvaat.nl/2026/01/21/body-roundness-index-en-mortaliteit-bij-hemodialysepatienten/","title":"Body Roundness Index en mortaliteit bij hemodialysepatiënten","title_en":"Association between body roundness index and all-cause and cardiovascular disease mortality in maintenance hemodialysis patients: evidence from a prospective cohort study in Southern China.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","doi":"10.1093/ndt/gfag006","source_url":"https://doi.org/10.1093/ndt/gfag006","authors":["Yu Wang","Liheng Zhu","Yaya Yang","Ziyang You","Zhiqiang Peng","Shenglin Yang","Yongxin Lu","Yanhong Zhao","Yaozhong Kong","Qijun Wan","Yumin Li","Sheng Huang","Yan Liu","Aiqun Liu","Fanna Liu","Min Liang"],"significance":5,"published":"2026-01-21","source_date":"2026-01-21","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A prospective cohort study from Southern China investigated the association between the Body Roundness Index and all-cause and cardiovascular mortality in maintenance haemodialysis patients. The anthropometric index, which predicts body fat and visceral adipose tissue, was associated with mortality outcomes in this population.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2edcfa4dc271","type":"article","url":"https://hartvaat.nl/2026/01/21/hart-en-vaatziektestatistieken-2026-wereldwijde-cijfers-van-de-aha/","title":"Hart- en vaatziektestatistieken 2026: wereldwijde cijfers van de AHA","title_en":"2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","harttransplantatie","myocardinfarct","vrouwen"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001412","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001412","authors":[],"significance":8,"published":"2026-01-21","source_date":"2026-01-21","image":"","kennis":[],"congress":"","summary_en":"The 2026 AHA Heart Disease and Stroke Statistics report provides comprehensive global data on cardiovascular disease burden, trends, risk factors, and outcomes, serving as the definitive annual reference for cardiovascular epidemiology.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T18:38:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb783c77ec62","type":"article","url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","title":"SGLT2-remmers en nieruitkomsten naar GFR en albuminurie: mega-meta-analyse","title_en":"SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","chronische-nierziekte","cystatine-c","dapagliflozine","empagliflozine","sglt2-remmers"],"journal":"JAMA","doi":"10.1001/jama.2025.20834","source_url":"https://doi.org/10.1001/jama.2025.20834","authors":["Brendon L Neuen","Robert A Fletcher","Stefan D Anker","Deepak L Bhatt","Javed Butler","David Z I Cherney","Kieran F Docherty","Silvio E Inzucchi","Meg J Jardine","Kenneth W Mahaffey","Finnian R McCausland","Darren K McGuire","John J V McMurray","Bruce Neal","Milton Packer","Siddharth M Patel","Vlado Perkovic","Marc S Sabatine","Rebecca J Sardell","Scott D Solomon","Muthiah Vaduganathan","Christoph Wanner","David C Wheeler","Faiez Zannad","Richard Haynes","Natalie Staplin","William G Herrington","Hiddo J L Heerspink"],"significance":9,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This JAMA meta-analysis confirmed that SGLT2 inhibitors improve kidney outcomes across the entire spectrum of glomerular filtration rate and albuminuria. The universal renoprotective effect supports SGLT2 inhibitor use in virtually all patients with or at risk for chronic kidney disease.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f76224fc2ce6","type":"article","url":"https://hartvaat.nl/2026/01/20/es-bempedacs-triple-versus-duale-lipidenbehandeling-na-acs/","title":"ES-BempedACS: triple versus duale lipidenbehandeling na ACS","title_en":"Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["niet-statine-therapie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.075388","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.075388","authors":["Sergio Raposeiras-Roubín","Emad Abu Assi","César Jiménez Méndez","Ester Mínguez de la Guía","José Ángel Pérez Rivera","Marta Marcos Mangas","Ana Ayesta","Aitor Uribarri","Pablo Jorge Pérez","Pablo José Antúnez Muinos","Clara Bonanad Lozano","Anna Carrasquer","Ana Viana-Tejedor","Pablo Domínguez Erquicia","Alberto Villar Ruiz","Macarena López Vázquez","Lara Aguilar Iglesias","Alberto Alén Andrémar","Maria Vidal Burdeus","Marta Maria Martin Cabeza","María Cristina González Cambeiro","Daznia Bompart","Juan Carlos Gómez Polo","Marina Teresa García García","Ana Merino Merino","José Rozado","José Antonio Panera de la Mano","Francisco Salmerón Martínez","Ester Sánchez Corral","Isabel Santos Sánchez","Ángel Víctor Hernández-Martos","Andrés Antelo Abejón","Andrés Iñiguez Romo","Miguel Corbi-Pascual","Albert Ariza-Solé"],"significance":8,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The ES-BempedACS trial showed that triple lipid-lowering therapy (statin + ezetimibe + bempedoic acid) achieves lower LDL levels faster than dual therapy after ACS. The early intensive approach may reduce residual cardiovascular risk in the vulnerable post-ACS period.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ff4ea4b3d23","type":"article","url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","title":"AF-screening naar genetisch risico: LOOP subanalyse","title_en":"Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.024","source_url":"https://doi.org/10.1016/j.jacc.2025.09.024","authors":["Oliver B Vad","Søren Z Diederichsen","Lucas Y Xing","Christian Paludan-Müller","Laia M Monfort","Gustav Ahlberg","Laura Andreasen","Ketil J Haugan","Claus Graff","Søren Højberg","Derk Krieger","Axel Brandes","Lars Køber","Jesper H Svendsen"],"significance":6,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":[],"congress":"","summary_en":"This LOOP subanalysis showed that higher genetic risk scores for AF increase the yield of systematic arrhythmia screening, supporting a genetics-enriched approach to targeted AF detection programs.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9c199be1667","type":"article","url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","title":"Voorspelling van individuele corticosteroïdrespons bij IgA-nefropathie (TESTING-trial)","title_en":"A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["iaso-dcm"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00005-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00005-0/fulltext","authors":["Mark Canney","Sana Shan","Lee Er","Laurent Billot","Jialin Han","Muh Geot Wong","Helen Monaghan","Michelle Hladunewich","Lai Seong Hooi","Vivek Jha","Jicheng Lv","Vlado Perkovic","Hong Zhang","Daniel C. Cattran","Sean J. Barbour","TESTING trial steering committee"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":[],"congress":"","summary_en":"A secondary analysis of the TESTING trial developed a prediction model for individual patient response to corticosteroid treatment in IgA nephropathy, enabling more targeted use of immunosuppression while minimising adverse effects.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b8a0d024d93","type":"article","url":"https://hartvaat.nl/2026/01/20/milieustressoren-en-cardiovasculaire-gezondheid-gezamenlijk-statement-esc-acc-ah/","title":"Milieustressoren en cardiovasculaire gezondheid: gezamenlijk statement ESC, ACC, AHA en WHF","title_en":"Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A Statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","obesitas","ouderen","richtlijnen-esc","slaapapneu"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.079034","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.079034","authors":["Thomas Münzel"],"significance":8,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This AHA statement described how environmental stressors — air pollution, extreme temperatures, noise, and climate change — contribute to cardiovascular disease globally. The document provided a framework for integrating environmental health into cardiovascular prevention strategies.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa7664238ce6","type":"article","url":"https://hartvaat.nl/2026/01/20/multi-omics-onthult-pathogene-rol-van-iga-7-cellen-bij-iga-nefropathie/","title":"Multi-omics onthult pathogene rol van IgA+β7+ cellen bij IgA-nefropathie","title_en":"Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["complementremmers","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00010-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00010-4/fulltext","authors":["Xingzi Liu","Lan Wang","Miaomiao Lin","Niya Jia","Guanyi Liu","Jiawen Peng","Jingyu Wang","Tong Xie","Shaoqing Dang","Jingyi Wu","Xujie Zhou","Lijun Liu","Sufang Shi","Jicheng Lv","Jonathan Barratt","Yuemiao Zhang","Hong Zhang"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":[],"congress":"","summary_en":"Multi-omics analyses revealed the pathogenic role of terminal ileum-derived IgA-positive beta7-positive cells in IgA nephropathy, identifying the mucosal origin of the galactose-deficient IgA1 producing plasma cells central to disease pathogenesis.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"002c33b6a02b","type":"article","url":"https://hartvaat.nl/2026/01/20/het-onbekende-uit-ckdu-halen-optimale-benaderingen-voor-epidemische-nierziekte/","title":"Het 'onbekende' uit CKDu halen: optimale benaderingen voor epidemische nierziekte","title_en":"Taking the “unknown” out of CKDu—optimizing approaches to uncover the cause(s) of epidemic-level kidney disease in low- and middle-income settings: a report from the ISN’s International Consortium of CKDu Collaborators (ISN i3C)","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00011-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00011-6/fulltext","authors":["Ben Caplin","Shuchi Anand","Marvin González-Quiroz","Magdalena Madero","Marie Michael","Sumit Mohan","Anna Strasma","Sundararaman Swaminathan","Sushrut Waikar","Eranga Wijewickrama","ISN i3C Working Group"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":[],"congress":"","summary_en":"An ISN i3C report discusses optimised approaches to uncover the causes of chronic kidney disease of undetermined aetiology, which remains a major mortality cause in low- and middle-income settings despite two decades of research.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5ed2f99b6af","type":"article","url":"https://hartvaat.nl/2026/01/20/uremie-en-bijschildklierhormoon-hebben-verschillende-effecten-op-boteiwit-en-gen/","title":"Uremie en bijschildklierhormoon hebben verschillende effecten op boteiwit en genexpressie","title_en":"Uremia and parathyroid hormone have distinct effects on bone protein and gene expression","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","flow-trial","ijzertekort","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00006-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00006-2/fulltext","authors":["Carolina S. Wagner","Rosilene M. Elias","Thomas L. Nickolas","Aline Martin","Marta Martinez-Calle","Ivone B. Oliveira","Ana C. Coelho","Luciene M. dos Reis","Vanda Jorgetti","Valentin David","Rosa M.A. Moysés"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This study demonstrates that uraemia and parathyroid hormone exert distinct effects on bone protein and gene expression in CKD-associated osteoporosis. The findings have implications for treatment strategies beyond PTH management alone.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95cb8809f6be","type":"article","url":"https://hartvaat.nl/2026/01/19/bloeddrukdoelen-en-niergezondheid-risico-op-nierziekte-door-ras-remmers/","title":"Bloeddrukdoelen en niergezondheid: risico op nierziekte door RAS-remmers","title_en":"Balancing Blood Pressure Targets and Kidney Health: The Potential Risk of Kidney Disease Due to Concentric Arterial and Arteriolar Hypertrophy From Renin-Angiotensin-Aldosterone Inhibitors","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","huisarts","internist"],"tags":["abelacimab","ace-remmers","aldosteronsynthaseremmers","anemie-ckd","baxdrostat","bloeddrukbehandeling","bradycardie","canagliflozine","cardio-renaal-metabool","endotheel","ezetimibe","figaro-dkd","lorundrostat","perifeer-vaatlijden","ramipril","ras-remmers","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","roken","sacubitril-valsartan","slaapapneu"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26125","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26125","authors":["Lucas Ferreira"],"significance":5,"published":"2026-01-19","source_date":"2026-01-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This perspective discusses the potential risk of kidney disease from concentric arterial and arteriolar hypertrophy caused by renin-angiotensin-aldosterone system inhibitors during intensive blood pressure treatment, highlighting the need to balance blood pressure targets with kidney health.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5dd0cfc81be","type":"article","url":"https://hartvaat.nl/2026/01/19/genotype-fenotypekenmerken-bij-fan1-gerelateerde-karyomegale-tubulointerstitiele/","title":"Genotype-fenotypekenmerken bij FAN1-gerelateerde karyomegale tubulointerstitiële nefropathie","title_en":"Genotype-phenotype characteristics and disease progression of FAN1-related karyomegalic tubulointerstitial nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00007-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00007-4/fulltext","authors":["Michelle Clince","Elhussein A.E. Elhassan","Kendrah O. Kidd","Emily Malamud","Susan M. McAnallen","Arbab Danial","Byung Ha Chung","Myungshin Kim","John A. Sayer","Intisar Al Alawi","Jelle Bernards","Mouna Jerbi","Rym Goucha","Lamia Ben Jemaa","Imen Rejeb","Chirag Patel","Andrew J. Mallett","C. John Sperati","Koen de Boeck","Maximilian Müller","Thomas Stehlé","Nisrine Bennani Guebessi","Thomas Robert","Bela Ivanyi","Ildiko Csaszar","Shirlee Shril","Sijie Zheng","Gerry George Mathew","Merve Guzel Dirim","Ahmet Burak Dirim","Laurent Mesnard","Lorraine Gueguen","Franz Schafer","Carsten Bergmann","Daniel P. Gale","Jan Halbritter","Kathleen J. Claes","Bertrand Knebelmann","Martina Živná","Stanislav Kmoch","Stanislas Faguer","Friedhelm Hildebrandt","Anthony J. Bleyer","Peter J. Conlon"],"significance":4,"published":"2026-01-19","source_date":"2026-01-19","image":"","kennis":[],"congress":"","summary_en":"A collaborative cross-sectional study characterised genotype-phenotype correlations in FAN1-related karyomegalic tubulointerstitial nephropathy, a rare condition poorly characterised in terms of kidney and patient survival.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9dbd8d4e5107","type":"article","url":"https://hartvaat.nl/2026/01/19/neurale-upregulatie-van-sglt2-map17-pdzk1-complex-in-nieren-bij-hartfalen/","title":"Neurale upregulatie van SGLT2-MAP17-PDZK1-complex in nieren bij hartfalen","title_en":"Neural Upregulation of SGLT2-MAP17-PDZK1 Complex in Kidneys of Rats With Heart Failure","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26077","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26077","authors":[],"significance":5,"published":"2026-01-19","source_date":"2026-01-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This study reveals neural upregulation of the SGLT2-MAP17-PDZK1 scaffolding protein complex in kidneys during heart failure, providing molecular insight into the relationship between renal sympathetic activation and SGLT2 expression that may explain the efficacy of SGLT2 inhibitors in heart failure.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0303c9ecbe96","type":"article","url":"https://hartvaat.nl/2026/01/19/parasympathische-zenuwen-in-het-nierbekken-reguleren-de-bloeddruk/","title":"Parasympathische zenuwen in het nierbekken reguleren de bloeddruk","title_en":"Parasympathetic nerves in the kidney pelvis contribute to blood pressure regulation","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00008-6/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00008-6/fulltext","authors":["Jin Zhao","Linlin Hu","Changwei Guo","Ran Ran","Mingrui Xu","Hui Lu","Qi Xie","Zhaoyou Meng","Sen Lin","Chenhao Zhao","Qingwu Yang","Xiaofeng Cheng"],"significance":5,"published":"2026-01-19","source_date":"2026-01-19","image":"","kennis":[],"congress":"","summary_en":"This research demonstrates that parasympathetic nerves in the kidney pelvis contribute to blood pressure regulation, providing functional evidence for the long-debated existence of renal parasympathetic innervation and its role in cardiovascular homeostasis.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4fa5558cd2c8","type":"article","url":"https://hartvaat.nl/2026/01/19/sglt2-remming-behoudt-antibacteriele-respons-van-de-nier-door-complement-c1q-ver/","title":"SGLT2-remming behoudt antibacteriële respons van de nier door complement C1q-verlaging","title_en":"Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["canagliflozine","sglt2-remmers"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00009-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00009-8/fulltext","authors":["Georg W. Sendtner","Julia Miranda","Pia Naumann","Maximilian Weiss","Pelin Güls","Ernst Molitor","Uta Scheidt","Axel Schmidt","Kerstin U. Ludwig","Annika Hilger","Ulrich Dobrindt","Thomas Mayrhofer","Christian Kurts","Florian Wagenlehner","Olga Shevshuk","Sibylle von Vietinghoff"],"significance":5,"published":"2026-01-19","source_date":"2026-01-19","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This study reveals that SGLT2 inhibition maintains the kidney's antibacterial defence by decreasing complement C1q, explaining why glycosuria from SGLT2 inhibitors does not increase urinary tract infection rates despite promoting bacterial growth conditions.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c4b5edae45fd","type":"article","url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","title":"Abluminus DES+ versus EES bij diabetes en coronairlijden","title_en":"Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["figaro-dkd","select-trial","soul-trial"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02157-9","source_url":"https://doi.org/10.1016/S0140-6736(25)02157-9","authors":["Alexandre Abizaid","Roxana Mehran","Angelo Oliva","Daniel Chamié","Rodolfo Staico","Fazila Malik","Maarten Vink","Arief Kurniadi","Davide Cao","Piera Capranzano","Benjamin Faurie","Philippe Garot","David Hildick-Smith","Alfonso Ielasi","Nikolaus Löffelhardt","Sasko Kedev","Darren Mylotte","Krzysztof Milewski","Valeria Paradies","Thomas Schmitz","Koen Teeuwen","Luca Testa","Ralph Toelg","François Vochelet","Birgit Vogel","Joanna Wykrzykowska","Samantha Sartori","Antonio Colombo","Shigeru Saito","Marie-Claude Morice"],"significance":5,"published":"2026-01-17","source_date":"2026-01-17","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The ABILITY Diabetes Global trial compared the Abluminus DES+ sirolimus-eluting stent with the XIENCE everolimus-eluting stent in patients with diabetes undergoing PCI. Both stent platforms demonstrated comparable efficacy and safety outcomes in this high-risk population.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb00229badff","type":"article","url":"https://hartvaat.nl/2026/01/16/aortaklepsclerose-ongeveer-een-op-de-zeven-gaat-binnen-vier-jaar-over-in-aortast/","title":"Aortaklepsclerose: ongeveer één op de zeven gaat binnen vier jaar over in aortastenose","title_en":"Prognostic implications of aortic valve sclerosis in the development of aortic stenosis: a systematic review and meta-analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","aortacoarctatie","aortainsufficiëntie","aortastenose","atherosclerose"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003859?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003859?rss=1","authors":["Myasoedova","V. A.","Valerio","V.","Massaiu","I.","Bertolini","F.","Rusconi","V.","Marenzi","G.","Poggio","P."],"significance":5,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"Fibrocalcific aortic valve sclerosis (AVSc) is the earliest form of aortic stenosis (AS) and is increasingly seen as a marker of systemic vascular damage and cardiovascular risk. Reported progression to AS varies widely. This systematic review and meta-analysis (8 studies, 12,388 patients for progression to any AS; 9 studies, 19,486 for severe AS) mapped the natural history. Over a median four-year follow-up, 14.1% of AVSc patients progressed to any form of AS and 2.0% to severe AS. Heterogeneity was high and meta-regression found no significant predictors. About one in seven patients with aortic valve sclerosis thus develops aortic stenosis within four years, and 2% a severe form — underscoring the importance of structured echocardiographic surveillance and of AVSc as a risk marker.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2745726683a7","type":"article","url":"https://hartvaat.nl/2026/01/16/nt-probnp-voorspelt-sterfte-na-een-stemi-onafhankelijk-van-de-ejectiefractie/","title":"NT-proBNP voorspelt sterfte na een STEMI, onafhankelijk van de ejectiefractie","title_en":"Prognostic value of N-terminal pro-B-type natriuretic peptide and C reactive protein testing in patients with acute ST-segment elevation myocardial infarction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003845?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003845?rss=1","authors":["Dregoesc","I. M.","Cramariuc","D.","Wilsgaard","T.","Istrate","M.","Buiga","V. S.","Ichim","S.","Ober","C.","Manole","S.","Sharashova","E.","Stylidis","M.","Hung","J.","Iancu","A. C.","Bleie","O.","Steigen","T."],"significance":5,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"Biomarkers can improve risk stratification after ST-elevation myocardial infarction (STEMI), beyond ejection fraction (LVEF). This prospective study (566 patients with reperfused STEMI, 2020-2023) examined the relationship between NT-proBNP, CRP and mortality. After a median follow-up of 39 months, mortality was 13.4%. NT-proBNP was associated with mortality regardless of LVEF (HR ~2.3 per standard deviation), whereas CRP was predictive only at LVEF <50% (HR 1.55). NT-proBNP remained associated with mortality after adjustment for age, sex, diabetes, troponin, TIMI flow and reduced LVEF. In patients with preserved ejection fraction, routine NT-proBNP testing clearly improved risk stratification over LVEF alone (AUC 0.75 vs 0.59). NT-proBNP is thus a valuable, independent prognostic marker after STEMI.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f4b90ac6ac6","type":"article","url":"https://hartvaat.nl/2026/01/16/seismocardiografie-spoort-ernstige-aortastenose-op-met-een-eenvoudige-sensor/","title":"Seismocardiografie spoort ernstige aortastenose op met een eenvoudige sensor","title_en":"Severe aortic stenosis detection using seismocardiography","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["aortastenose"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003563?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003563?rss=1","authors":["Pyka&#x0308;ri","J.","Elnaggar","I.","Kaisti","M.","Airola","A.","Koivisto","T.","Vasankari","T.","Savontaus","M."],"significance":5,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"Patients with severe aortic stenosis (AS) are at high mortality risk, but timely recognition is difficult and valve replacement lags. This study developed and validated a non-invasive algorithm detecting severe AS with seismocardiography (SCG): a sensor with a single-lead ECG and a three-dimensional accelerometer measuring the vibrations of cardiac activity. The model was trained and validated in 115 subjects and then tested in an independent, blinded cohort of 99 (50 AS patients, 49 age- and sex-matched controls). The algorithm correctly classified 89 of 99, with sensitivity 92%, specificity 88% and AUC 0.96. This SCG-based technique could thus be a low-cost, accessible tool to detect severe aortic stenosis.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d7519527093","type":"article","url":"https://hartvaat.nl/2026/01/16/sekseverschillen-na-tavi-vrouwen-lagere-sterfte-bij-intermediair-risico-maar-mee/","title":"Sekseverschillen na TAVI: vrouwen lagere sterfte bij intermediair risico, maar meer bloedingen","title_en":"Sex-based differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis of randomised trials","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortainsufficiëntie","aortastenose","perifeer-vaatlijden"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003642?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003642?rss=1","authors":["Ferraz-Costa","G. N.","Almeida","M. d. J.","Delgado Silva","J.","Goncalves","L."],"significance":6,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"In surgical aortic valve replacement, female sex has historically been associated with worse outcomes, but for transcatheter aortic valve implantation (TAVI) the evidence is unclear — even as women are more often referred for TAVI. This systematic review and meta-analysis of randomised trials (14 RCTs, 15,225 participants) compared outcomes between women and men. There was no overall difference in all-cause mortality (OR 0.83), but a protective effect for women among intermediate-risk patients (OR 0.64). Women had a higher risk of major bleeding (OR 1.35). Cardiovascular mortality, stroke/TIA and pacemaker implantation did not differ. Female sex was thus associated with lower mortality in intermediate-risk TAVI but more bleeding — warranting further study of anatomical and procedural sex differences.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T13:31:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1123c9702e8d","type":"article","url":"https://hartvaat.nl/2026/01/16/statinegebruik-in-de-zwangerschap-en-congenitale-afwijkingen-noors-cohort/","title":"Statinegebruik in de zwangerschap en congenitale afwijkingen: Noors cohort","title_en":"Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":["congenitale-hartafwijking"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf592","source_url":"https://doi.org/10.1093/eurheartj/ehaf592","authors":["Jacob J Christensen","Kirsten B Holven","Martin P Bogsrud","Kjetil Retterstøl","Jeanine E Roeters van Lennep","Trond M Michelsen","Marit B Veierød","Hedvig Nordeng"],"significance":7,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This Norwegian nationwide study examined the risk of congenital malformations with statin use during pregnancy, providing population-level safety data relevant to the evolving guidance on lipid-lowering therapy in women of childbearing age.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cae5a75412bd","type":"article","url":"https://hartvaat.nl/2026/01/16/non-hdl-c-doelen-halen-in-de-eerste-en-tweede-lijn-een-da-vinci-deelanalyse/","title":"Non-HDL-C doelen halen in de eerste en tweede lijn: een DA VINCI-deelanalyse","title_en":"Attainment of Non-High-Density Lipoprotein Cholesterol Targets in Secondary and Primary Care: A secondary-analysis of the DA VINCI study","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","ezetimibe","niet-statine-therapie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00010-9/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00010-9/fulltext","authors":["Aksaan Arif","Irene Karungi","Christophe A.T. Stevens","Amany Elshorbagy","Kausik K. Ray","the DA VINCI study group"],"significance":5,"published":"2026-01-16","source_date":"2026-01-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A secondary analysis of the European DA VINCI study assessed non-HDL-cholesterol goal attainment in primary and secondary care. Non-HDL-C provides prognostic information beyond LDL-C alone, particularly when LDL-C appears well controlled.","created":"2026-07-03T10:24:55Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58f556c8e45a","type":"article","url":"https://hartvaat.nl/2026/01/15/populatiegebaseerde-egfr-verdelingen-voor-vroege-identificatie-van-chronische-ni/","title":"Populatiegebaseerde eGFR-verdelingen voor vroege identificatie van chronische nierziekte","title_en":"Population-based estimated Glomerular Filtration Rate distributions and associated health outcomes provide opportunities for early identification of and primary prevention of chronic kidney disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte","cystatine-c","flow-trial","primaire-preventie","statines","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00989-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00989-5/fulltext","authors":["Yuanhang Yang","Antoine Creon","Andrew S. Levey","Anne-Laure Faucon","Aurora Caldinelli","Marie Evans","Arvid Sjölander","Alberto Ortiz","Edouard L. Fu","Juan Jesus Carrero"],"significance":5,"published":"2026-01-15","source_date":"2026-01-15","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/wat-is-chronische-nierziekte/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This study explored population-based eGFR distributions and associated health outcomes to identify opportunities for early CKD detection and primary prevention. Comparison with age-matched population norms may help identify at-risk individuals through opportunistic screening.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da9960e88fb8","type":"article","url":"https://hartvaat.nl/2026/01/15/sociaaleconomische-barrieres-bij-het-aanpakken-van-obesitas-aha-statement/","title":"Sociaaleconomische barrières bij het aanpakken van obesitas: AHA-statement","title_en":"Socioeconomic and Structural Barriers to Addressing Obesity in Communities: A Scientific Statement From the American Heart Association","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001395","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001395","authors":[],"significance":8,"published":"2026-01-15","source_date":"2026-01-15","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This AHA scientific statement addressed the socioeconomic and structural barriers to obesity prevention and treatment in communities, highlighting how poverty, food insecurity, and built environment disproportionately affect cardiovascular health in disadvantaged populations.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82a6cf6a1ef7","type":"article","url":"https://hartvaat.nl/2026/01/14/glp-1-receptoragonisten-en-de-volgende-generatie-incretinegebaseerde-middelen/","title":"GLP-1-receptoragonisten en de volgende generatie incretinegebaseerde middelen","title_en":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","semaglutide","tirzepatide"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02105-1/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02105-1/fulltext","authors":["Michael A Nauck","Katherine R Tuttle","Matthias H Tschöp","Matthias Blüher"],"significance":9,"published":"2026-01-14","source_date":"2026-01-14","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This comprehensive Lancet review describes how GLP-1 receptor agonists, originally developed for type 2 diabetes, have expanded into cardiovascular prevention, obesity treatment, heart failure with preserved ejection fraction, and chronic kidney disease. The review covers next-generation agents including dual and triple incretin agonists.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95888688e6ba","type":"article","url":"https://hartvaat.nl/2026/01/14/polygene-risicoscore-voorspelt-langetermijn-bloeddrukcontrole-en-therapieresiste/","title":"Polygene risicoscore voorspelt langetermijn bloeddrukcontrole en therapieresistente hypertensie","title_en":"Blood Pressure Polygenic Score Predicts Long-Term Blood Pressure Control and Treatment-Resistant Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","bloeddrukbehandeling","cardiovasculaire-genetica","figaro-dkd","gepersonaliseerde-geneeskunde","hypertrofische-cardiomyopathie","laminopathie","obesitas","polygene-risicoscore","ras-remmers","renale-denervatie","resistente-hypertensie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26399","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26399","authors":["So Mi Jemma Cho"],"significance":6,"published":"2026-01-14","source_date":"2026-01-14","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/"],"congress":"","summary_en":"This study showed that a blood pressure polygenic score independently predicts long-term blood pressure control and treatment-resistant hypertension, advancing genetics-guided blood pressure management.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd0156c1e130","type":"article","url":"https://hartvaat.nl/2026/01/14/geslachtsspecifieke-bloeddrukdrempels-bij-volwassenen-van-middelbare-leeftijd/","title":"Geslachtsspecifieke bloeddrukdrempels bij volwassenen van middelbare leeftijd","title_en":"Sex-Specific Blood Pressure Thresholds in Middle-Aged Adults","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","bradycardie","diabetes-en-hart","ezetimibe","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","obesitas","ouderen","perifeer-vaatlijden","slaapapneu","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25490","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25490","authors":["Katie Williams"],"significance":6,"published":"2026-01-14","source_date":"2026-01-14","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This study investigated sex-specific blood pressure thresholds for cardiovascular risk in middle-aged adults, finding that women develop cardiovascular risk at lower blood pressure levels than men.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T18:38:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eca7b993b33b","type":"article","url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","title":"Enlicitide: orale PCSK9-remmer bij heterozygote FH — fase 3","title_en":"Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["enlicitide","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"JAMA","doi":"10.1001/jama.2025.20620","source_url":"https://doi.org/10.1001/jama.2025.20620","authors":["Christie M Ballantyne","Laura Gellis","Jean-Claude Tardif","Puja Banka","Ann Marie Navar","Emil Andreas Asprusten","Russell Scott","Erik S G Stroes","Samar Froman","Geraldine Mendizabal","Fan Wang","Alberico L Catapano"],"significance":9,"published":"2026-01-13","source_date":"2026-01-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This phase 3 trial demonstrated that enlicitide, an oral PCSK9 inhibitor, significantly reduced LDL cholesterol in adults with heterozygous familial hypercholesterolemia. An oral daily tablet offers a practical alternative to injectable PCSK9-lowering therapies for patients with genetic hypercholesterolemia.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06aad04b611b","type":"article","url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","title":"Effectiviteit en veiligheid van zeer laag bereikt LDL na ischemisch CVA","title_en":"Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","farmaco-economie","ldl-cholesterol","lipide-aferese","lipidenverlaging","perifeer-vaatlijden","rosuvastatine","soul-trial","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.077549","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.077549","authors":["Victorien Monguillon","Peter J Kelly","Michelle L O'Donoghue","Jeong-Gun Park","Erin A Bohula","Jeffrey L Saver","Dan Atar","Anthony C Keech","Peter S Sever","Huei Wang","Gabriel Paiva da Silva Lima","Marc S Sabatine","Robert P Giugliano"],"significance":7,"published":"2026-01-13","source_date":"2026-01-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This analysis confirmed the safety and cardiovascular benefit of achieving very low LDL cholesterol levels (<30 mg/dL) in patients after ischemic stroke, with no increase in hemorrhagic stroke or other adverse events at the lowest LDL levels.","created":"2026-07-03T10:32:07Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5e61f6383e0","type":"article","url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","title":"Risicofactoren en plaquevolume op coronaire CT-angiografie: lessen uit het ADVANCE-register","title_en":"The association of risk factors on coronary computed tomography angiography derived atherosclerotic plaque volume - Lessons from the ADVANCE registry","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","coronaire-ct-angiografie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01413-3/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01413-3/fulltext","authors":["Alexander Haenel","Ruurt A. Jukema","John K. Khoo","Fionn Coughlan","Philipp Blanke","Aaisha Ferkh","Timothy Fairbairn","Nicholas Ng","Lynne M. Koweek","Pamela Douglas","Mark Rabbat","Gianluca Pontone","Kavitha M. Chinnaiyan","Bernard De Bruyne","Jeroen Bax","Tetsuya Amano","Koen Nieman","Campbell Rogers","Hironori Kitabata","Niels PR. Sand","Tomohiro Kawasaki","Sarah Mullen","Whitney Huey","Hitoshi Matsuo","Manesh Patel","Bjarne L. Nørgaard","Jonathon A. Leipsic","Georgios Tzimas","The ADVANCE investigators"],"significance":5,"published":"2026-01-13","source_date":"2026-01-13","image":"","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"Cross-sectional analysis of the ADVANCE registry using AI-based quantitative plaque assessment found that cardiovascular risk factors are only modestly associated with total coronary plaque volume on CT angiography. The findings suggest additional determinants of plaque burden beyond traditional risk factors.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a84f0bbbcbb","type":"article","url":"https://hartvaat.nl/2026/01/12/werkzaamheid-en-veiligheid-van-lage-doses-spironolacton-bij-primair-aldosteronis/","title":"Werkzaamheid en veiligheid van lage doses spironolacton bij primair aldosteronisme","title_en":"Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","lorundrostat","mra-aldosteronantagonisten","spironolacton"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24881","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24881","authors":["Elisa Sconfienza"],"significance":6,"published":"2026-01-12","source_date":"2026-01-12","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This retrospective study evaluated the efficacy and safety of low-dose spironolactone in primary aldosteronism, showing that reduced doses may achieve adequate blood pressure and potassium control with fewer side effects.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"599dfb5783f4","type":"article","url":"https://hartvaat.nl/2026/01/12/late-menopauze-vermindert-aortastijfheid-in-de-postmenopauzale-periode/","title":"Late menopauze vermindert aortastijfheid in de postmenopauzale periode","title_en":"Late-Onset Menopause Attenuates Aortic Stiffness in the Postmenopausal Period","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["menopauze","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26346","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26346","authors":["Sanna Darvish"],"significance":5,"published":"2026-01-12","source_date":"2026-01-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study demonstrates that late-onset menopause attenuates aortic stiffness in postmenopausal women. The vascular protection may partly explain the lower cardiovascular risk associated with later menopause age.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae2c61b3f17f","type":"article","url":"https://hartvaat.nl/2026/01/12/lipide-inhoud-in-verkalkte-plaques-kenmerken-en-respons-op-lage-ldl-c/","title":"Lipide-inhoud in verkalkte plaques: kenmerken en respons op lage LDL-C","title_en":"Lipidic contents within calcified plaques: Characteristics and response to LDL-C<55 mg/dL on multi-modality imaging","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","plaquekarakterisatie","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01398-X/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01398-X/fulltext","authors":["Kentaro Mitsui","Yu Kataoka","Stephen J. Nicholls","Eri Kiyoshige","Kunihiro Nishimura","Rishi Puri","Kota Murai","Kenichiro Sawada","Hideo Matama","Takamasa Iwai","Satoshi Honda","Masashi Fujino","Kazuhiro Nakao","Kensuke Takagi","Shuichi Yoneda","Fumiyuki Otsuka","Kensaku Nishihira","Itaru Takamisawa","Yasuhide Asaumi","Kenichi Tsujita","Teruo Noguchi"],"significance":5,"published":"2026-01-12","source_date":"2026-01-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/"],"congress":"","summary_en":"This multimodality imaging study evaluated lipidic contents within calcified coronary plaques and their response to LDL-C lowering below 55 mg/dL. The findings challenge the traditional view of calcified plaques as entirely quiescent atheroma.","created":"2026-07-03T10:25:33Z","updated":"2026-07-03T13:24:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f04c5af1657","type":"article","url":"https://hartvaat.nl/2026/01/11/zeventien-jaar-voor-verandering-doorbreken-de-2025-esc-eas-dyslipidemierichtlijn/","title":"Zeventien jaar voor verandering: doorbreken de 2025 ESC/EAS-dyslipidemierichtlijnen de cyclus?","title_en":"Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","statines"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00002-X/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00002-X/fulltext","authors":["Kausik K. Ray","Florian Kronenberg"],"significance":7,"published":"2026-01-11","source_date":"2026-01-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/"],"congress":"","summary_en":"This commentary on the 2025 ESC/EAS dyslipidemia guideline update discussed the modernized recommendations for risk assessment and lipid-lowering therapy, including expanded indications for non-statin treatments and lower LDL targets.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8c7205047cc","type":"article","url":"https://hartvaat.nl/2026/01/09/hartfalendiagnostiek-na-corona-bijna-niemand-kreeg-de-echo-binnen-de-aanbevolen-/","title":"Hartfalendiagnostiek na corona: bijna niemand kreeg de echo binnen de aanbevolen termijn","title_en":"Post-COVID-19 era heart failure diagnosis and outcomes: adherence to NICE Guidelines","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","nt-probnp","step-hfpef"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003785?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003785?rss=1","authors":["Razzaq","U. B.","Docherty","K. F.","Al Ajmi","A.","Alebraheem","A.","Burns","R.","Davie","A. P.","Gan","J.","Hogg","K. J.","Jackson","C. E.","Mathioudaki","E.","Pasupulate","R.","Piya","S.","Ritchie","L.","Simpson","J.","Steel","L. C.","Wei","H. N.","McMurray","J. J.","Petrie","M. C.","Campbell","R. T."],"significance":5,"published":"2026-01-09","source_date":"2026-01-09","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The UK NICE guideline recommends prioritising suspected heart failure (HF) by natriuretic peptide (NP) level: an echocardiogram within two weeks for markedly elevated NP. This retrospective audit (899 referrals to an HF diagnostic pathway across seven West of Scotland hospitals, early 2022) assessed adherence in the post-COVID era. Of patients, 29% had an NT-proBNP >2000 ng/L and 71% 400-2000 ng/L. Only 8% in both groups received the echo within the recommended timeframe. HF was diagnosed in 28% (42% in the high and 22% in the lower NP group). One-year mortality was 12%, higher in the NT-proBNP >2000 ng/L group (21% vs 9%). A high NP level thus identifies a high-risk group, but few received a timely echo — the authors argue for the same urgency as suspected cancer.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"92d5f10fca64","type":"article","url":"https://hartvaat.nl/2026/01/09/endocarditis-van-de-natieve-klep-verschuift-naar-ouderen-chirurgie-blijft-levens/","title":"Endocarditis van de natieve klep verschuift naar ouderen — chirurgie blijft levens redden (Korea, 18 jaar)","title_en":"Changing epidemiology and outcomes of native valve infective endocarditis: a nationwide study, 2006-2023","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bradycardie","endocarditis","slaapapneu"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003764?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003764?rss=1","authors":["Kim","D. Y.","Kim","M.-J.","Lee","J.","Kim","K. A.","Jung","H. O.","Yoon","J. S.","Jeon","D. S."],"significance":6,"published":"2026-01-09","source_date":"2026-01-09","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/pulmonale-hypertensie/","https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/"],"congress":"","summary_en":"The epidemiology of native-valve infective endocarditis (IE) is shifting toward older patients with substantial comorbidity. In this 18-year nationwide Korean cohort (18,402 adults with native-valve IE, 2006-2023), incidence fell in those <45 but rose in those ≥65. In-hospital mortality was 25.5% and 5-year mortality exceeded 50%. Older age, dialysis, cancer and major complications predicted mortality. Valve surgery, performed in 29.1%, was consistently associated with lower short- and long-term mortality across all age groups, with no age-by-treatment interaction; both early (≤7 days) and late surgery improved survival. Relapse was also less frequent after surgery. Despite declining use, surgery's survival benefit was preserved across the age spectrum — supporting operative consideration even in selected older patients.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4f15f31f80c","type":"article","url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","title":"Littekenweefsel voorspelt plotse hartdood na een infarct grotendeels buiten de ejectiefractie om","title_en":"Replacement fibrosis, left ventricular ejection fraction and sudden cardiac death in patients after myocardial infarction: a mediation analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfmref","hfpef","hfref","laminopathie","myocardinfarct","ouderen","plotse-hartdood","ventrikelfibrilleren"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003799?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003799?rss=1","authors":["Zhou","P.","Aisikaier","K.","Dong","Z.","Ma","X.","Tang","Y.","Wei","Z.","Jia","X.","Chen","X.","Liu","Y.","Xu","W.","Sa","F.","Yang","S.-J.","Wang","J.","Zhao","F.","Lu","M.","Zhao","X.","Chen","X.","Zhao","S."],"significance":6,"published":"2026-01-09","source_date":"2026-01-09","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/","https://hartvaat.nl/kennis/ritmestoornissen/arvc-aritmogene-rechterventrikeldysplasie/"],"congress":"","summary_en":"Selection for an implantable defibrillator (ICD) after myocardial infarction relies mainly on reduced ejection fraction (LVEF), which may not capture the full risk of sudden cardiac death (SCD). In this retrospective study (917 post-infarction patients, cardiac MRI, median follow-up 63 months), the extent to which LVEF explains the link between replacement fibrosis (measured by late gadolinium enhancement, LGE) and SCD was examined. Over follow-up, 65 patients (7.1%) had an SCD event. More LGE was associated with lower LVEF, and both LGE and LVEF independently predicted SCD. In a mediation analysis, however, LVEF explained only 19.7% of LGE's effect on SCD — 40.4% in patients with LVEF >35%, while there was no mediation in those with LVEF ≤35%. Scar tissue thus predicts sudden cardiac death largely independent of ejection fraction; LVEF alone is an inadequate risk measure, whether above or below 35%.","created":"2026-07-03T10:32:27Z","updated":"2026-07-03T18:39:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6bc37029b39f","type":"article","url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","title":"Evolocumab bij patiënten zonder eerder MI of CVA: FOURIER subanalyse","title_en":"Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["yellow-iii"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2514428","source_url":"https://doi.org/10.1056/NEJMoa2514428","authors":["Erin A Bohula","Nicholas A Marston","Ajay K Bhatia","Gaetano M De Ferrari","Lawrence A Leiter","Jose C Nicolau","Jeong-Gun Park","Julia F Kuder","Sabina A Murphy","Emileigh Walsh","Huei Wang","Vladimir Blaha","Andrzej Budaj","Jan H Cornel","Assen Goudev","Robert Gabor Kiss","Alberto J Lorenzatti","Alexander Parkhomenko","Marcoli Cyrille","Gabriel Paiva da Silva Lima","E Magnus Ohman","Robert P Giugliano","Marc S Sabatine"],"significance":7,"published":"2026-01-08","source_date":"2026-01-08","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/"],"congress":"","summary_en":"This FOURIER subanalysis showed that evolocumab effectively reduces cardiovascular events in patients with atherosclerotic disease who have never had an MI or stroke, extending the PCSK9 inhibitor benefit to the broader secondary prevention population.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7875fcf27771","type":"article","url":"https://hartvaat.nl/2026/01/08/atriale-strain-overtreft-ventriculaire-strain-bij-detectie-van-hypertensieve-hfp/","title":"Atriale strain overtreft ventriculaire strain bij detectie van hypertensieve HFpEF","title_en":"Atrial Strain Outperforms Ventricular Strain for Detecting Hypertensive HFpEF Using CMR Feature Tracking","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25985","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25985","authors":["Zhen Wang"],"significance":6,"published":"2026-01-08","source_date":"2026-01-08","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"This study showed that atrial strain measured by CMR feature tracking outperforms ventricular strain for detecting hypertensive HFpEF, advancing imaging-based diagnosis of the atrial component of heart failure.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"acdc1e725fd2","type":"article","url":"https://hartvaat.nl/2026/01/08/eindpuntgebaseerde-drempel-voor-de-ambulante-arteriele-stijfheidsindex/","title":"Eindpuntgebaseerde drempel voor de ambulante arteriële stijfheidsindex","title_en":"End Point–Based Threshold for the Ambulatory Arterial Stiffness Index","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["perifeer-vaatlijden"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25442","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25442","authors":[],"significance":6,"published":"2026-01-08","source_date":"2026-01-08","image":"","kennis":[],"congress":"","summary_en":"This individual participant data meta-analysis established an endpoint-based threshold for the ambulatory arterial stiffness index (AASI), providing a clinically actionable cutoff for this vascular biomarker.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c382d1a0162d","type":"article","url":"https://hartvaat.nl/2026/01/08/urokinase-bevordert-intratubulair-c3a-maar-niet-enac-gedreven-hypertensie-bij-do/","title":"Urokinase bevordert intratubulair C3a maar niet ENaC-gedreven hypertensie bij DOCA/zout-nierletsel","title_en":"Urokinase Promotes Redundantly Intratubular C3a-Formation But Not ENaC-Driven Hypertension in DOCA/Salt Kidney Injury","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["abelacimab","cystatine-c","ezetimibe"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25050","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25050","authors":["Marie Lykke Bach"],"significance":5,"published":"2026-01-08","source_date":"2026-01-08","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study examined whether urokinase-type plasminogen activator contributes to intratubular complement C3a formation and ENaC-driven hypertension in a chronic DOCA/salt kidney injury model. Urokinase promoted C3a formation redundantly but did not drive hypertension.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"caebbdf00864","type":"article","url":"https://hartvaat.nl/2026/01/07/machine-learningmodel-schat-het-cardiovasculaire-risico-van-niet-cardiale-chirur/","title":"Machine-learningmodel schat het cardiovasculaire risico van niet-cardiale chirurgie nauwkeurig in","title_en":"Machine learning-based cardiovascular risk calculator for non-cardiac surgery","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["ai-ecg","biomarkers-cardiovasculair","farmaco-economie","gepersonaliseerde-geneeskunde","kunstmatige-intelligentie","laminopathie","ouderen"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003565?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003565?rss=1","authors":["Al Khatib","N.","Chehab","A.","Tamim","H.","Dakik","H. A.","Tajeddine","R."],"significance":6,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Each year, 4% of the global population undergoes non-cardiac surgery, and 30% of them have at least one cardiovascular risk factor. This study developed an interpretable machine-learning model to predict cardiovascular risk up to 30 days after non-cardiac surgery in patients older than 50, using the US NSQIP dataset (497,011 patients). The composite endpoint (death, myocardial infarction, cardiac arrest or stroke within 30 days) occurred in 1.44%. Of the algorithms tested, LightGBM performed best, with excellent discrimination (AUROC 0.90). The model used just six elements: type of surgery, ASA class, blood urea nitrogen (BUN), sepsis, emergent surgery and mechanical ventilation. A simple, explainable model using routine data can thus reliably estimate perioperative cardiovascular risk.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df152ce39605","type":"article","url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","title":"Hartfalentherapie staken na EF-herstel door AF-ritmecontrole","title_en":"Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf563","source_url":"https://doi.org/10.1093/eurheartj/ehaf563","authors":["Louise Segan","Peter M Kistler","Shane Nanayakkara","Andrew Taylor","James Hare","Benedict Costello","David Chieng","Rose Crowley","Jeremy William","Hariharan Sugumar","Kenneth Cho","Aleksandr Voskoboinik","Liang-Han Ling","Ziporah Nderitu","Sonia Azzopardi","Annie Curtin","Manuja Premaratne","Alex J McLellan","Justin Mariani","Joseph B Morton","Geoffrey Lee","Stephen Joseph","Christopher Reid","David M Kaye","Jonathan M Kalman","Sandeep Prabhu"],"significance":6,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":[],"congress":"","summary_en":"This study explored whether heart failure therapy can be safely withdrawn after ejection fraction normalization following successful AF rhythm control, addressing the clinical question of medication discontinuation in AF-mediated cardiomyopathy.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4814ac10ed6","type":"article","url":"https://hartvaat.nl/2026/01/07/afferente-niersenuwen-veroorzaken-sympathische-overactivatie-en-hypertensief-har/","title":"Afferente niersenuwen veroorzaken sympathische overactivatie en hypertensief hartfalen","title_en":"Afferent Renal Nerves Drive Sympathoexcitation and Hypertensive Heart Failure","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","cardio-renaal-metabool","empagliflozine","endotheel","hfref","ivabradine","nt-probnp","renale-denervatie","sacubitril-valsartan","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25247","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25247","authors":["Shota Ikeda"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study investigated how afferent renal nerves drive sympathoexcitation and contribute to hypertensive heart failure through the hypothalamic paraventricular nucleus. The findings support renal denervation strategies targeting afferent signalling pathways.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"85ff58ac9d5b","type":"article","url":"https://hartvaat.nl/2026/01/07/cxcr6-t-cellen-veroorzaken-immuuncheckpointremmer-myocarditis/","title":"CXCR6+ T-cellen veroorzaken immuuncheckpointremmer-myocarditis","title_en":"CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["inflammatie","inflammatoire-cardiomyopathie","myocarditis"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076976","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076976","authors":[],"significance":8,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/"],"congress":"","summary_en":"This study identified CXCR6+ T cells as key drivers of immune checkpoint inhibitor-associated myocarditis, particularly with combination ICI therapy including anti-LAG-3 agents. The mechanistic insight may guide future prevention and treatment strategies for this serious complication.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f38409e3a0b9","type":"article","url":"https://hartvaat.nl/2026/01/07/circulerend-malat1-bij-pre-eclampsie-en-cardiometabool-risico/","title":"Circulerend MALAT1 bij pre-eclampsie en cardiometabool risico","title_en":"Circulating MALAT1 in Preeclampsia and Association With Cardiometabolic Risk","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26379","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26379","authors":["Tove Lekva"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study investigated the long noncoding RNA MALAT1 as a circulating biomarker in preeclampsia and its association with cardiometabolic risk. MALAT1 expression changes may link pregnancy-related hypertensive disorders to long-term cardiovascular disease risk.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8adfd502f2a7","type":"article","url":"https://hartvaat.nl/2026/01/07/klinische-proteomics-in-de-cardiovasculaire-geneeskunde-huidige-stand-en-toekoms/","title":"Klinische proteomics in de cardiovasculaire geneeskunde: huidige stand en toekomst","title_en":"Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","cardiovasculaire-genetica","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","laminopathie","menopauze","microbioom","ouderen","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00003-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00003-1/fulltext","authors":["Bhawana Singh","Oleg A. Karpov","Manuel Mayr"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This review discusses the current capabilities and limitations of commercial high-throughput proteomics platforms such as Olink and SomaLogic for cardiovascular research. While widely applied in biobank studies, data quality issues remain underappreciated and must be addressed for clinical translation.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44ddc1a2f6c9","type":"article","url":"https://hartvaat.nl/2026/01/07/serpinb1-beschermt-tegen-hypoxie-geinduceerde-pulmonale-hypertensie-via-macrofaa/","title":"SerpinB1 beschermt tegen hypoxie-geïnduceerde pulmonale hypertensie via macrofaag-PASMC-crosstalk","title_en":"Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["bloeddrukbehandeling","pulmonale-hypertensie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25832","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25832","authors":["Jiajin Hao"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":[],"congress":"","summary_en":"This study demonstrates that SerpinB1 protects against hypoxia-induced pulmonary hypertension by blunting the inflammatory phenotype of perivascular macrophages, thereby reducing their pathological crosstalk with pulmonary artery smooth muscle cells.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f8af63967021","type":"article","url":"https://hartvaat.nl/2026/01/07/weekendstrijder-bewegingspatroon-en-mortaliteit-bij-hypertensie-uk-biobank/","title":"Weekendstrijder-bewegingspatroon en mortaliteit bij hypertensie (UK Biobank)","title_en":"Weekend Warrior Physical Activity Pattern and Mortality in Patients With Hypertension: A Prospective Cohort Study From UK Biobank","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25444","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25444","authors":["Ronghui Zhu"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A UK Biobank study investigated whether the \"weekend warrior\" physical activity pattern provides comparable mortality benefits to regularly distributed exercise in patients with hypertension. Both active patterns were associated with reduced mortality and stroke risk.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e2800b108624","type":"article","url":"https://hartvaat.nl/2026/01/07/gedragsveranderingstheorie-bij-implementatie-van-thuisbloeddrukmeting/","title":"Gedragsveranderingstheorie bij implementatie van thuisbloeddrukmeting","title_en":"Applying behavior change theory to intervention design: promoting clinic-level implementation of self-measured blood pressure monitoring in safety net primary care settings.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["bloeddrukbehandeling","thuisbloeddrukmeting"],"journal":"Translational behavioral medicine","doi":"10.1093/tbm/ibaf094","source_url":"https://doi.org/10.1093/tbm/ibaf094","authors":["Lina Tieu","Elaine C Khoong","Nilpa D Shah","Melissa M Gosdin","Sophia J Wang","Anjana Sharma","Nooshin Abtahi","Rachel J Stern","Crystal Zhou","Urmimala Sarkar","Courtney R Lyles"],"significance":3,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/"],"congress":"","summary_en":"This study applied behaviour change theory to design an implementation intervention for integrating self-measured blood pressure monitoring into primary care settings serving underserved communities.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4ab18e63b88","type":"article","url":"https://hartvaat.nl/2026/01/06/machine-learning-algoritme-mi3-helpt-een-infarct-uitsluiten-bij-een-onduidelijke/","title":"Machine-learning-algoritme MI3 helpt een infarct uitsluiten bij een onduidelijke troponinewaarde","title_en":"Diagnostic performance of the Myocardial-Ischaemic-Injury index machine-learning algorithm in patients with an initial indeterminate troponin","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["myocardinfarct","troponine"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003767?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003767?rss=1","authors":["Snavely","A. C.","Hunter","C. J.","Jackson","L.","Stopyra","J. P.","Ashburn","N. P.","Supples","M. W.","Christenson","R.","Miller","C. D.","Mahler","S. A."],"significance":5,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/vasculair/d-dimeer-interpretatie/"],"congress":"","summary_en":"Ruling out myocardial infarction in patients with an initially indeterminate (detectable to mildly elevated) troponin is difficult. The Myocardial-Ischaemic-Injury Index (MI3) is a machine-learning algorithm to diagnose infarction. This secondary analysis (207 patients with suspected acute coronary syndrome and an initial troponin of 0.006-1.0 ng/mL, four US hospitals) tested the algorithm, which classifies patients into low, intermediate and high risk based on initial and 3-hour high-sensitivity troponin. Infarction within 30 days occurred in 43.5%. The AUC of MI3 was 0.88. The low-risk group (35%) had 8.3% infarctions (sensitivity 93%, negative likelihood ratio 0.12), whereas the high-risk group had 100% with infarction (specificity 100%). In patients with an indeterminate troponin, the MI3 algorithm thus had high accuracy and specificity for 30-day infarction.","created":"2026-07-03T10:32:29Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb1e4aecca24","type":"article","url":"https://hartvaat.nl/2026/01/06/biomarkers-onderscheiden-type-2-hartinfarct-nog-onvoldoende-van-type-1/","title":"Biomarkers onderscheiden type 2-hartinfarct nog onvoldoende van type 1","title_en":"Utility of biomarkers in patients with a type 2 myocardial infarction: a systematic review","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","diabetes-type-2","myocardinfarct","nt-probnp","troponine"],"journal":"Open Heart","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e003867?rss=1","source_url":"https://doi.org/http://openheart.bmj.com/cgi/content/short/13/1/e003867?rss=1","authors":["Gouda","P.","Lalani","S.","Newby","K.","Lopes","R.","Jones","S."],"significance":5,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/"],"congress":"","summary_en":"Distinguishing type 1 myocardial infarction (T1MI, from plaque rupture) from type 2 (T2MI, from supply-demand mismatch) is often difficult on clinical grounds. This systematic review examined whether biomarkers can help discriminate and prognosticate. Thirty-one studies (16,111 patients with T2MI) were included, of which 97% had moderate to high risk of bias. Traditional cardiac biomarkers (troponin, CK, BNP) discriminated T2MI from T1MI moderately (AUC 0.61-0.71); adding them to clinical variables improved this slightly (AUC 0.71-0.82). Non-traditional, metabolic and proteomic markers showed widely varying accuracy (AUC 0.50-0.77). Prognostic value was inconsistent. The role of biomarkers in diagnosing and prognosticating type 2 myocardial infarction thus remains unclear — better studies and a sharper definition of T2MI are needed.","created":"2026-07-03T10:32:28Z","updated":"2026-07-03T13:31:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4cef83f5632","type":"article","url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","title":"Sacubitril/valsartan versus enalapril bij Chagas-hartfalen","title_en":"Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"JAMA","doi":"10.1001/jama.2025.19808","source_url":"https://doi.org/10.1001/jama.2025.19808","authors":["Renato D Lopes","Edimar Alcides Bocchi","Luis Eduardo Echeverría","Caroline Demacq","Pedro Gabriel Melo de Barros E Silva","Lilian Mazza Barbosa","Lucas Damiani","Sarfaraz Sayyed","Liandra A F Yoshida","Remo Holanda M Furtado","Carlos A Morillo","Ruben Kevorkian","Felix Ramires","M Cecilia Bahit","Antonio Magaña","Adolfo Chávez-Mendoza","Adegil Henrique Miguel da Silva","Aguinaldo Coelho da Silva","Aguinaldo F Freitas","Alfredo Alejandro Romano","Anne Parneix","Armando Segura","Cesar Cassio Broilo França","Cristian Edgardo Botta","Edileide de Barros","Eduardo Roque Perna","Eleonora Montenegro","Franklin Roberto Quiroz Diaz","Gilson Soares Feitosa-Filho","Graciela Viviana Severini","Israel Molina","Jacqueline Dos Santos Sampaio Miranda","Jorgelina Sala","José Francisco Kerr Saraiva","Justo Carbajales","Lilia Nigro Maia","Luiz Carlos Santana Passos","Marcus Vinicius Simões","Maria da Consolação V Moreira","Maria Carmo P Nunes","Mauro Esteves Hernandes","Miguel Hominal","Raquel Saa Zarandon","Ricardo Leon de la Fuente","Roque Aras","Silméia Garcia Zanati Bazan","Telêmaco Luiz da Silva","Vagner Madrini","Wilson Alves de Oliveira","Wladmir Faustino Saporito","Claudio Gimpelewicz","John J V McMurray"],"significance":7,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This multicenter trial compared sacubitril-valsartan with enalapril for heart failure due to Chagas disease, the first randomized evidence for ARNI therapy in this tropical cardiomyopathy unique to Latin America.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9ca9fba7f99d","type":"article","url":"https://hartvaat.nl/2026/01/06/levoecmo-levosimendan-bij-ecmo-weaning-bij-cardiogene-shock/","title":"LEVOECMO: levosimendan bij ECMO-weaning bij cardiogene shock","title_en":"Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["iaso-dcm"],"journal":"JAMA","doi":"10.1001/jama.2025.19843","source_url":"https://doi.org/10.1001/jama.2025.19843","authors":["Alain Combes","Ouriel Saura","Nicolas Nesseler","Said Lebbah","Bertrand Rozec","Bruno Levy","Jean-Luc Fellahi","Antoine Beurton","Simon Meslin","Philippe Gaudard","Adrien Bouglé","André Vincentelli","Romain Sonneville","Guillaume Lebreton","David Lévy","Alexandre Ouattara","Florence Tubach"],"significance":7,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The LEVOECMO trial investigated whether levosimendan facilitates ECMO weaning in patients with severe cardiogenic shock, testing this inotropic agent as a bridge strategy to device separation.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"708858c95e63","type":"article","url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","title":"CAVIAR: alirocumab bij cardiale allograft vasculopathie na harttransplantatie","title_en":"Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["alirocumab"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.077603","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.077603","authors":["William F Fearon","Kosei Terada","Kuniaki Takahashi","Anette Skoda","Helen I Luikart","Cynthia A Lamendola","Frederik M Zimmermann","Takehiro Hashikata","Kan Saito","Akihiro Yoshida","Brandon Varr","Joshua W Knowles","Christopher Woo","Yasuhiro Honda","Jeffrey Teuteberg","Kiran K Khush"],"significance":7,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":[],"congress":"","summary_en":"The CAVIAR trial investigated alirocumab for preventing cardiac allograft vasculopathy after heart transplantation, exploring PCSK9 inhibition as a strategy to reduce the progressive coronary disease that limits graft survival.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f666f057be7","type":"article","url":"https://hartvaat.nl/2026/01/06/gofresh-dash-boodschappen-en-bloeddrukeffect-rct/","title":"GoFresh: DASH-boodschappen en bloeddrukeffect — RCT","title_en":"DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.21112","source_url":"https://doi.org/10.1001/jama.2025.21112","authors":["Stephen P Juraschek","Hannah Col","Kayla Ferro","Ruth-Alma N Turkson-Ocran","Jennifer L Cluett","Roger B Davis","Kristen M Kraemer","Kathy McManus","Kenneth J Mukamal","Emily L Aidoo","Fredrick Larbi Kwapong","Marian Budu","Dhrumil Patil","Sarah Nartey","Jacqueline Michetti","Sofia Allison","Manfred Mate-Kole","Jingyi Cao","Benjamin Grobman","Reva Seager","Anika L Hines","Edgar R Miller","Deidra C Crews","Stephanie L Fitzpatrick"],"significance":6,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":[],"congress":"","summary_en":"The GoFresh randomized trial showed that home delivery of DASH-patterned groceries improves dietary quality and lowers blood pressure in Black adults, demonstrating that removing food access barriers translates to measurable health benefit.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d23d489dcd05","type":"article","url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","title":"ESPRIT: intensieve bloeddrukcontrole bij fragiele patiënten — post-hoc analyse","title_en":"Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.092","source_url":"https://doi.org/10.1016/j.jacc.2025.08.092","authors":["Shitian Li","Yue Peng","Yan Li","Ying Sun","Xiaofang Yan","Liping Zhang","Jiangling Liu","Lingshan Zhao","Jieyun Liu","Jun Qian","Na Zhai","Lei Dong","Jiahui Ruan","Ping Zhang","Xiqing Wei","Yong Liu","Qiaojuan Ma","Weijun Huang","Qiang Zhang","Chun An","Jiamin Liu","Li Sheng","Haibo Zhang","Jing Li"],"significance":7,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This ESPRIT post-hoc analysis showed that intensive blood pressure control reduces cardiovascular events even in frail patients, with moderate frailty not attenuating the treatment benefit. Only the most severely frail may not benefit.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b20680d5af51","type":"article","url":"https://hartvaat.nl/2026/01/06/remming-van-annexine-a2-bevordert-mitofagie-en-vermindert-hartschade-na-infarct/","title":"Remming van annexine A2 bevordert mitofagie en vermindert hartschade na infarct","title_en":"Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["myocardinfarct"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077780","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077780","authors":[],"significance":6,"published":"2026-01-06","source_date":"2026-01-06","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that inhibition of annexin A2 enhances mitophagy in cardiomyocytes and alleviates cardiac injury after myocardial infarction, identifying a new molecular target for cardioprotection.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78fc9df1790c","type":"article","url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","title":"Magnesium en uitkomsten bij HFrEF: GALACTIC-HF subanalyse","title_en":"Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf706","source_url":"https://doi.org/10.1093/eurheartj/ehaf706","authors":["Misato Chimura","Kieran F Docherty","Pardeep S Jhund","Mingming Yang","Ryohei Ono","Alasdair D Henderson","Marco Metra","Genzhou Liu","Punag H Divanji","Stephen B Heitner","Stuart Kupfer","Fady I Malik","G Michael Felker","Scott D Solomon","John R Teerlink","John J V McMurray"],"significance":5,"published":"2026-01-05","source_date":"2026-01-05","image":"","kennis":[],"congress":"","summary_en":"A GALACTIC-HF subanalysis evaluated the prognostic significance of serum magnesium in patients with HFrEF. Higher magnesium levels were associated with better outcomes, suggesting that magnesium monitoring and optimisation may have clinical value.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f75fd595ae0","type":"article","url":"https://hartvaat.nl/2026/01/05/klinisch-spectrum-van-parvovirus-b19-geassocieerde-acute-myocarditis-bij-kindere/","title":"Klinisch spectrum van parvovirus B19-geassocieerde acute myocarditis bij kinderen","title_en":"Clinical Spectrum of Children With Parvovirus B19–Associated Acute Myocarditis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075943","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075943","authors":["Enrico Ammirati"],"significance":7,"published":"2026-01-05","source_date":"2026-01-05","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/kleppathologie-reumatische-origine/","https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/"],"congress":"","summary_en":"This Circulation study characterized the clinical spectrum of parvovirus B19-associated acute myocarditis in children, describing the presentation, diagnosis, and outcomes of this viral cardiac complication in the pediatric population.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae7149789e42","type":"article","url":"https://hartvaat.nl/2026/01/05/samenstelling-en-classificatie-van-coronaire-atherosclerotische-plaques-bij-hype/","title":"Samenstelling en classificatie van coronaire atherosclerotische plaques bij hypercholesterolemische varkens","title_en":"Coronary atherosclerotic plaque composition and classification in hypercholesterolemic pigs","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","atherosclerose","cardiovasculaire-genetica","diabetes-type-1","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","laminopathie","ldl-cholesterol","pcsk9-remmers","plaquekarakterisatie","stabiel-coronairlijden","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00001-8/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00001-8/fulltext","authors":["Mingqiao Li","Di Tian","Patrice Delafontaine","Sergiy Sukhanov"],"significance":4,"published":"2026-01-05","source_date":"2026-01-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"This study characterised and classified coronary atherosclerotic plaque composition and progression in Rapacz pigs with familial hypercholesterolaemia, establishing a standardised classification system for this widely used preclinical atherosclerosis model.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f564e7f6d57c","type":"article","url":"https://hartvaat.nl/2026/01/05/grsf1-beschermt-tegen-hartfalen-door-bcaa-homeostase-te-handhaven/","title":"GRSF1 beschermt tegen hartfalen door BCAA-homeostase te handhaven","title_en":"GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074700","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074700","authors":["Hu Wang"],"significance":6,"published":"2026-01-05","source_date":"2026-01-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This basic science study showed that GRSF1 protects against heart failure by maintaining branched-chain amino acid homeostasis, revealing a novel metabolic regulatory mechanism in cardiac disease.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"27d57b66f035","type":"article","url":"https://hartvaat.nl/2026/01/05/myocardherstel-bij-mechanische-ondersteuning-hangt-samen-met-alternatieve-splici/","title":"Myocardherstel bij mechanische ondersteuning hangt samen met alternatieve splicing van CAMK2D","title_en":"Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["laminopathie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075789","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075789","authors":[],"significance":6,"published":"2026-01-05","source_date":"2026-01-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This study showed that myocardial recovery with LVAD support is linked to specific alternative splicing and subcellular localization changes, providing molecular insights into the mechanisms of cardiac reverse remodeling.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5fa3ae5ad03f","type":"article","url":"https://hartvaat.nl/2026/01/02/albuminurie-en-cardiovasculair-risico-gemiste-kans-in-de-2025-esc-eas-dyslipidem/","title":"Albuminurie en cardiovasculair risico: gemiste kans in de 2025 ESC/EAS-dyslipidemierichtlijnen","title_en":"Albuminuria and cardiovascular risk: A missed opportunity in the 2025 focused update of the ESC/EAS dyslipidaemia guidelines","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","diabetes-type-2","ezetimibe","menopauze","richtlijnen-esc","voeding-hart"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01531-X/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01531-X/fulltext","authors":["Carlos Guijarro","Alberto Ortiz"],"significance":5,"published":"2026-01-02","source_date":"2026-01-02","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/"],"congress":"","summary_en":"The Spanish Societies of Nephrology and Arteriosclerosis welcome the 2025 ESC/EAS dyslipidaemia guidelines update but identify albuminuria as an insufficiently incorporated cardiovascular risk enhancer. The commentary advocates for broader integration of kidney markers in lipid management.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d95c1e3ef33","type":"article","url":"https://hartvaat.nl/2026/01/01/insulineresistentie-en-bloeddrukcontrole-op-cognitieve-uitkomsten/","title":"Insulineresistentie en bloeddrukcontrole op cognitieve uitkomsten","title_en":"Insulin Resistance and Blood Pressure Control on Cognitive Outcomes.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["semaglutide","tirzepatide"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.24666","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24666","authors":["Chenyu Fan","Xuan Wang","Liyuan Tao","Yundan Liao","Ling Jin","Quanyou Shi","Hu Wang","Yidan Shi","Tianqi Chang","Yuzhou Xue","Jiaxing Wang","Weihua Yue","Yuesong Pan","Zixiao Li","Yongjun Wang","Ming Xu"],"significance":5,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":[],"congress":"","summary_en":"A SPRINT post-hoc analysis examined whether insulin resistance modifies the cognitive benefits of intensive blood pressure treatment. Intensive therapy provided cognitive benefit regardless of insulin resistance status, supported by metabolomic pathway analysis.","created":"2026-07-03T10:32:06Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"50b2f864fac7","type":"article","url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","title":"Consistentie van bloeddrukrespons op kaliumverrijkt zout: SSaSS subanalyse","title_en":"Consistency of Blood Pressure Response to Potassium-Enriched Salt in the China Salt Substitute Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.24723","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24723","authors":["Katrina Kissock","Bruce Neal","Yifang Yuan","Johan Sundström","Helena Jonsson","Anthony Rodgers","Nelson Wang","Liping Huang","Yangfeng Wu"],"significance":6,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":[],"congress":"","summary_en":"This SSaSS subanalysis confirmed a consistent blood pressure-lowering response to potassium-enriched salt across all demographic and clinical subgroups, supporting universal applicability of the salt substitution strategy.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6aea4769270d","type":"article","url":"https://hartvaat.nl/2026/01/01/haptoglobinefenotype-en-cv-risico-accord-bloeddruk-rct/","title":"Haptoglobinefenotype en CV-risico: ACCORD bloeddruk-RCT","title_en":"Haptoglobin Phenotype and Cardiovascular Risk: The ACCORD Blood Pressure RCT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25021","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25021","authors":["Samantha K Lavallée","Allie S Carew","Rachel A Warren","John L Sapp","Andrew P Levy","Pantelis Andreou","Christine R Herman","Eric B Rimm","Leah E Cahill"],"significance":5,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"An ACCORD blood pressure trial analysis investigated haptoglobin phenotype as a modifier of cardiovascular outcomes with intensive versus standard blood pressure treatment in type 2 diabetes. Specific phenotypes may influence treatment response, potentially explaining conflicting trial results.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"98126e6b24ee","type":"article","url":"https://hartvaat.nl/2026/01/01/renale-histologie-bij-maligne-hypertensie-systematische-review/","title":"Renale histologie bij maligne hypertensie: systematische review","title_en":"Renal Histology Findings in Malignant Hypertension, a Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25069","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25069","authors":["Valentin Maisons","Ferhat Demir","Alexandre Fillon","Paul Delalande","Theodora Bejan-Angoulvant","Sebastien Rubin","Romain Boulestreau","Aurélien Lorthioir","Bénédicte Sautenet","Dominique Guerrot","Menno Pruijm","Liffert Vogt","Jean-Michel Halimi"],"significance":5,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/"],"congress":"","summary_en":"A systematic review documented the renal histological findings in malignant hypertension. Thrombotic microangiopathy and arteriolar fibrinoid necrosis are the characteristic lesions, providing pathological context for this hypertensive emergency.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1894c4dc5a2b","type":"article","url":"https://hartvaat.nl/2026/01/01/effect-van-finerenon-op-de-nierfunctie-bij-diabetische-nefropathie-type-2/","title":"Effect van finerenon op de nierfunctie bij diabetische nefropathie type 2","title_en":"Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","huisarts","internist"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","canagliflozine","cardiorenal-behandelstrategie","chronische-nierziekte","diabetes-en-hart","diabetes-type-2","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","perifeer-vaatlijden","ras-remmers","sacubitril-valsartan","soul-trial"],"journal":"Frontiers in endocrinology","doi":"10.3389/fendo.2026.1753126","source_url":"https://doi.org/10.3389/fendo.2026.1753126","authors":["Xu-Ying Liu","Ya-Min Zhao","Ya-Guang Zhang","Yi Liu","Bo-Ya Wang","Zhen-Zhen Hao","Man-Hui Hu"],"significance":4,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/f9ed94fb64aa.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"A retrospective cohort study evaluated finerenone added to ACE inhibitor or ARB therapy in type 2 diabetic nephropathy. Finerenone slowed renal function decline and reduced albuminuria with a favourable safety profile.","created":"2026-07-03T10:25:50Z","updated":"2026-07-03T13:25:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c0bdae55cccf","type":"article","url":"https://hartvaat.nl/2026/01/01/3-hydroxystearinezuur-bevordert-cholesterolefflux-en-vermindert-atherosclerose-v/","title":"3-Hydroxystearinezuur bevordert cholesterolefflux en vermindert atherosclerose via ALKBH5/PAX-8/ABCA1","title_en":"3-Hydroxystearic acid promotes cholesterol efflux and attenuates atherosclerosis via the ALKBH5/PAX-8/ABCA1 pathway.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["bempedoïnezuur","ezetimibe","ldl-cholesterol","pcsk9-remmers","statines"],"journal":"Frontiers in immunology","doi":"10.3389/fimmu.2026.1750021","source_url":"https://doi.org/10.3389/fimmu.2026.1750021","authors":["Qin-Yi Zhou","Wang Liu","Zhen-Wang Zhao","Duo Gong","Xiao-Feng Ma","Chao-Ke Tang"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/4ec87a4aea17.webp","kennis":["https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"This study demonstrates that 3-hydroxystearic acid promotes cholesterol efflux and attenuates atherosclerosis through the ALKBH5/PAX-8/ABCA1 signalling pathway, reducing macrophage foam cell formation.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ffc78234021","type":"article","url":"https://hartvaat.nl/2026/01/01/matig-gewichtsverlies-verbetert-hartslagvariabiliteit-bij-obese-patienten-met-ho/","title":"Matig gewichtsverlies verbetert hartslagvariabiliteit bij obese patiënten met hoog cardiovasculair risico","title_en":"A tertiary care study on the effectiveness of moderate weight loss on heart rate variability frequency-domain components in obese patients at high cardiovascular risk.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bradycardie","diabetes-en-hart","diabetes-type-2","ezetimibe","harttransplantatie","microbioom","myocardinfarct","obesitas","ouderen","perifeer-vaatlijden","select-trial","slaapapneu","summit-trial","voeding-hart","vrouwen"],"journal":"Einstein (Sao Paulo, Brazil)","doi":"10.31744/einstein_journal/2026AO1470","source_url":"https://doi.org/10.31744/einstein_journal/2026AO1470","authors":["Priscila Moreira","Cristiane Kovacs Amaral","Dalmo Antônio Ribeiro Moreira","Maria do Carmo Franco"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":[],"congress":"","summary_en":"A tertiary care study evaluated the impact of a structured nutritional intervention on weight loss, heart rate variability, and biochemical parameters in obese patients at high cardiovascular risk.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6904e5512bda","type":"article","url":"https://hartvaat.nl/2026/01/01/west-nijlvirus-meningo-encefalitis-bij-een-patient-op-ixekizumab-en-prednison/","title":"West-Nijlvirus-meningo-encefalitis bij een patiënt op ixekizumab en prednison","title_en":"Case Report: First case of West Nile virus meningoencephalitis in Southwest Michigan in a patient on ixekizumab and prednisone.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Frontiers in medicine","doi":"10.3389/fmed.2026.1744404","source_url":"https://doi.org/10.3389/fmed.2026.1744404","authors":["Henry Zou","Sara Elzalabany","Ingrid Kenyon","Matthew Kelly"],"significance":2,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/58557d5c3461.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"A case report of the first documented West Nile virus meningoencephalitis in Southwest Michigan, occurring in a patient immunocompromised by ixekizumab and prednisone therapy.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e969ea285c88","type":"article","url":"https://hartvaat.nl/2026/01/01/effect-van-sglt2-remmers-op-atriumfibrilleren-bij-diabetes-met-gedilateerde-card/","title":"Effect van SGLT2-remmers op atriumfibrilleren bij diabetes met gedilateerde cardiomyopathie","title_en":"Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["atriale-cardiomyopathie","canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","empagliflozine","fidelio-dkd","figaro-dkd","gedilateerde-cardiomyopathie","laminopathie","obesitas","sglt2-remmers","soul-trial","supraventriculaire-tachycardie"],"journal":"Cardiovascular therapeutics","doi":"10.1155/cdr/5113761","source_url":"https://doi.org/10.1155/cdr/5113761","authors":["Jie Wang","Shanshan Qi","Siyuan Chen","Hang Yu"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"A cohort study evaluated the effect of SGLT2 inhibitors on atrial fibrillation incidence in patients with type 2 diabetes and dilated cardiomyopathy, a population at particularly high risk for arrhythmias.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"391dd3eed394","type":"article","url":"https://hartvaat.nl/2026/01/01/werving-van-zwarte-mannen-met-beroerte-voor-een-gerandomiseerde-klinische-trial/","title":"Werving van zwarte mannen met beroerte voor een gerandomiseerde klinische trial","title_en":"Engaging and Recruiting Black Men With Stroke or TIA in a Randomized Clinical Trial Conducted: Addressing Research Barriers and Developing Solutions for Successful Engagement.","category":"preventie","category_label":"Preventie","professions":["huisarts"],"tags":[],"journal":"American journal of men's health","doi":"10.1177/15579883261424111","source_url":"https://doi.org/10.1177/15579883261424111","authors":["Martha Sajatovic","Carolyn H Still","Beth Lute","Jacqueline Krehel-Montgomery","Jessica Surdam","Edna Fuentes-Casiano","Jacquelyn Whitlow","Carla Conroy","Michaela Broadnax","Shirley Moore","Sophia Sundararajan"],"significance":2,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"This report describes the implementation of a clinical trial testing a behavioural approach to reduce stroke risk factors in Black men with stroke or TIA, addressing macro-, mediator-, and micro-level barriers to research participation.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d858e0ece9b7","type":"article","url":"https://hartvaat.nl/2026/01/01/factoren-geassocieerd-met-anemie-bij-chronische-nierziekte-in-brazilie/","title":"Factoren geassocieerd met anemie bij chronische nierziekte in Brazilië","title_en":"Factors associated with anemia in chronic kidney disease in the Brazilian population: national health survey.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","nierfalen"],"journal":"Frontiers in nutrition","doi":"10.3389/fnut.2026.1714573","source_url":"https://doi.org/10.3389/fnut.2026.1714573","authors":["Letícia Cristina Machado de Sousa","Nathalia Rabello Silva","Bianca Uliana Picolo","Marcus Vinícius de Pádua Netto","Luciana Saraiva da Silva"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/071993c7d6da.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This study identified factors associated with anaemia in chronic kidney disease in the Brazilian population based on national health survey data, addressing limited evidence in this demographic.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"829168ec973c","type":"article","url":"https://hartvaat.nl/2026/01/01/rivaroxaban-discontinueringspercentages-bij-niet-valvulair-af-in-de-italiaanse-p/","title":"Rivaroxaban-discontinueringspercentages bij niet-valvulair AF in de Italiaanse praktijk","title_en":"Rivaroxaban treatment discontinuation rates in patients with nonvalvular atrial fibrillation in Italian clinical practice: RITMUS-AF.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["rivaroxaban"],"journal":"PloS one","doi":"10.1371/journal.pone.0341633","source_url":"https://doi.org/10.1371/journal.pone.0341633","authors":["Carmine Pizzi","Leopoldo Pagliani","Luca Dalle Carbonare","Piergiuseppe Agostoni","Egidio Imbalzano","Gennaro Galasso","Gianni Casella","Nicolò Dasseni","Leonardo De Luca","Italo Porto","Biagio Sassone","Davide Tosarello","Pareen Vora","Claudia Erminero","Giovanni Battista Forleo","Paolo Fusco","Ciro Mauro","Francesco Milone","Gian Piero Perna"],"significance":4,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/1eafc516f825.webp","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"The RITMUS-AF prospective study documented rivaroxaban discontinuation rates in Italian clinical practice among patients with non-valvular atrial fibrillation. Approximately 20% of patients discontinue DOAC therapy within the first year.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9c252f77b12","type":"article","url":"https://hartvaat.nl/2026/01/01/rosuvastatine-beschermt-tegen-oxldl-geinduceerde-endotheelstress-en-atherosclero/","title":"Rosuvastatine beschermt tegen oxLDL-geïnduceerde endotheelstress en atherosclerose via NF-κB","title_en":"Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["atherosclerose","atorvastatine","clear-outcomes","endotheel","ezetimibe","lipidenverlaging","niet-statine-therapie","rosuvastatine","statines"],"journal":"PloS one","doi":"10.1371/journal.pone.0339967","source_url":"https://doi.org/10.1371/journal.pone.0339967","authors":["Yichen Wu","Jiaqi Ke","Jiaxin Lv","Chaowei Cao","Chunxian Zhou","Lili Wu","Qiyang Zhou"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/95799f1d119f.webp","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/"],"congress":"","summary_en":"This study demonstrates that rosuvastatin protects endothelial cells against oxidised LDL-induced oxidative stress and attenuates atherosclerotic plaque formation in ApoE knockout mice through the NF-kappaB signalling pathway.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"875406113927","type":"article","url":"https://hartvaat.nl/2026/01/01/sophocarpine-beschermt-tegen-pulmonale-hypertensie-in-preklinische-modellen/","title":"Sophocarpine beschermt tegen pulmonale hypertensie in preklinische modellen","title_en":"Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["pulmonale-hypertensie"],"journal":"Mediators of inflammation","doi":"10.1155/mi/5524066","source_url":"https://doi.org/10.1155/mi/5524066","authors":["Feng Xie","Jie Feng","Kai Li","Yi Chen","Leilei Han","Yanqing Wu"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study describes the protective role of sophocarpine, a plant alkaloid from Lindera aggregata, against pulmonary hypertension in preclinical models, identifying a potential novel therapeutic agent.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8aa8446cfcbd","type":"article","url":"https://hartvaat.nl/2026/01/01/metabole-score-voor-visceraal-vet-en-risico-op-perifeer-arterieel-vaatlijden-bij/","title":"Metabole score voor visceraal vet en risico op perifeer arterieel vaatlijden bij hypertensie","title_en":"The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: a prospective cohort study.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["diabetes-en-hart","obesitas","perifeer-vaatlijden","voeding-hart"],"journal":"Frontiers in endocrinology","doi":"10.3389/fendo.2026.1764481","source_url":"https://doi.org/10.3389/fendo.2026.1764481","authors":["Shiping Li","Congcong Yan","Meihui Wu","Tao Wang","Lingjuan Zhu","Chao Yu","Weifang Zhang","Wei Zhou","Huihui Bao","Xiaoshu Cheng"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/f9ed94fb64aa.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A prospective cohort study demonstrated that the Metabolic Score for Visceral Fat is associated with increased risk of peripheral artery disease in hypertensive patients, supporting this novel adiposity metric as a cardiovascular risk marker.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:25:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"86ec9340e4e2","type":"article","url":"https://hartvaat.nl/2026/01/01/transcriptomische-onderdrukking-van-immuun-en-ecm-stabiliteit-in-skeletspier-bij/","title":"Transcriptomische onderdrukking van immuun- en ECM-stabiliteit in skeletspier bij CKD","title_en":"Transcriptomic suppression of immune and ECM stability in skeletal muscle of patients with chronic kidney disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","flow-trial","ijzertekort"],"journal":"PloS one","doi":"10.1371/journal.pone.0328947","source_url":"https://doi.org/10.1371/journal.pone.0328947","authors":["Luke A Baker","Nicholas Eastley","Robert U Ashford","Matthew Denniff","Matthew Graham-Brown","Emma L Watson"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/89ab4ac5475e.webp","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study investigated the molecular mechanisms of sarcopenia in chronic kidney disease through skeletal muscle transcriptome analysis, finding suppression of immune and extracellular matrix stability genes.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9bdb274b5af0","type":"article","url":"https://hartvaat.nl/2026/01/01/iatrogene-letsels-en-trombotische-complicaties-bij-spoed-endovasculaire-interven/","title":"Iatrogene letsels en trombotische complicaties bij spoed-endovasculaire interventies","title_en":"[Iatrogenic injuries and thrombotic complications following emergency endovascular interventions].","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["perifeer-vaatlijden","secundaire-preventie"],"journal":"Khirurgiia","doi":"10.17116/hirurgia2026021100","source_url":"https://doi.org/10.17116/hirurgia2026021100","authors":["B S Sukovatykh","N V Bolomatov","D V Sidorov","M B Sukovatykh","A Yu Grigorian","S V Gunov"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This review analyses national and international literature on iatrogenic injuries and arterial thrombotic complications following emergency percutaneous coronary and carotid interventions.","created":"2026-07-03T10:25:36Z","updated":"2026-07-03T13:24:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ac8328c94f9","type":"article","url":"https://hartvaat.nl/2026/01/01/jackson-pratt-drains-verminderen-pericardeffusie-en-atriumfibrilleren-na-cabg/","title":"Jackson-Pratt-drains verminderen pericardeffusie en atriumfibrilleren na CABG","title_en":"Efficacy of Jackson-Pratt Mediastinal Drains in Reducing Pericardial Effusion and Atrial Fibrillation After Coronary Artery Bypass Grafting: A Retrospective Cohort Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Brazilian journal of cardiovascular surgery","doi":"10.21470/1678-9741-2025-0277","source_url":"https://doi.org/10.21470/1678-9741-2025-0277","authors":["Mehmet Ali Yuruk","Ahmet Coşkun Özdemir"],"significance":4,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"A retrospective cohort study evaluated whether Jackson-Pratt mediastinal drains offer advantages over standard chest tubes in reducing pericardial effusion, pleural effusion, and atrial fibrillation after coronary artery bypass grafting.","created":"2026-07-03T10:25:08Z","updated":"2026-07-03T13:24:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3888dcb98fd7","type":"article","url":"https://hartvaat.nl/2026/01/01/matig-alcoholgebruik-gezond-of-riskant-een-kritisch-perspectief/","title":"Matig alcoholgebruik: gezond of riskant? Een kritisch perspectief","title_en":"[Moderate alcohol consumption - healthy or risky? A critical perspective on existing research and WHO guidelines].","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["alcoholgebruik","primaire-preventie"],"journal":"Praxis","doi":"10.23785/PRAXIS.2026.01.002","source_url":"https://doi.org/10.23785/PRAXIS.2026.01.002","authors":["Joseph Osterwalder"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/"],"congress":"","summary_en":"This critical perspective reviews the controversial evidence on moderate alcohol consumption and health, noting that newer data challenge older studies suggesting cardiovascular benefits. The WHO 2023 position that no safe level exists is itself debated.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78a2cb333d06","type":"article","url":"https://hartvaat.nl/2026/01/01/diabetes-obesitas-en-de-metabole-drijfveren-van-perifeer-arterieel-vaatlijden/","title":"Diabetes, obesitas en de metabole drijfveren van perifeer arterieel vaatlijden","title_en":"Diabetes, Obesity, and the Metabolic Drivers of Peripheral Artery Disease: Lessons from Recent Forecasts.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["cardio-renaal-metabool","diabetes-en-hart","diabetes-type-1","figaro-dkd","metabole-acidose","microbioom","obesitas","perifeer-vaatlijden","select-trial","soul-trial","tirzepatide"],"journal":"Vascular health and risk management","doi":"10.2147/VHRM.S576743","source_url":"https://doi.org/10.2147/VHRM.S576743","authors":["Edward Jude","Hongyan Wang"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/446852548547.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"This review examines how diabetes and obesity contribute to peripheral artery disease through metabolic pathways, discussing new treatment perspectives and preventive strategies as PAD prevalence is projected to rise dramatically by 2050.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d5535227d903","type":"article","url":"https://hartvaat.nl/2026/01/01/lp-a-geoxideerde-fosfolipiden-en-apob100-bij-acuut-ischemisch-herseninfarct/","title":"Lp(a), geoxideerde fosfolipiden en apoB100 bij acuut ischemisch herseninfarct","title_en":"Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Advances in lipoprotein(a) research","doi":"10.70401/alr.2026.0005","source_url":"https://doi.org/10.70401/alr.2026.0005","authors":["Yihao Li","Emmie Then","Salwa Rahman","Nelsa Matienzo","Anastasiya Matveyenko","Marianna Pavlyha","Farid Khasiyev","Randolph S Marshall","Joshua Willey","Jose Gutierrez","Gissette Reyes-Soffer"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"This study examined the relationships between lipoprotein(a), oxidised phospholipids, and apolipoprotein B100 in acute ischaemic stroke, suggesting differential contributions of these markers to stroke subtypes with implications for targeted prevention.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa59f009e404","type":"article","url":"https://hartvaat.nl/2026/01/01/dyslipidemie-bij-diabetes-een-complex-landschap-voor-betere-cardiovasculaire-uit/","title":"Dyslipidemie bij diabetes: een complex landschap voor betere cardiovasculaire uitkomsten","title_en":"Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","figaro-dkd","lipidenverlaging","niet-statine-therapie","obesitas","pcsk9-remmers","soul-trial"],"journal":"Clinical medicine insights. Endocrinology and diabetes","doi":"10.1177/11795514261422310","source_url":"https://doi.org/10.1177/11795514261422310","authors":["Roshaida Abdul Wahab","Wan Aizad Wan Mahmood"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This review discusses the complex interplay of dyslipidaemia and diabetes, with emphasis on PCSK9 inhibitors, ezetimibe, and bempedoic acid as add-on therapies for patients who fail to reach lipid targets despite statin treatment.","created":"2026-07-03T10:24:58Z","updated":"2026-07-03T13:24:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58d12ca92ca4","type":"article","url":"https://hartvaat.nl/2026/01/01/overgewicht-en-de-tyg-index-als-voorspellers-van-sterfte-bij-diabetes-type-2/","title":"Overgewicht en de TyG-index als voorspellers van sterfte bij diabetes type 2","title_en":"Individual and joint effects of overweight/obesity and the triglyceride-glucose index on mortality risk in type 2 diabetic patients: a retrospective cohort study in China.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","obesitas","soul-trial","vrouwen"],"journal":"Frontiers in endocrinology","doi":"10.3389/fendo.2026.1652682","source_url":"https://doi.org/10.3389/fendo.2026.1652682","authors":["Anthony Diwon","Yuxin Chen","Yang Chen","Xinlv Zhang","Hui Wang","Ziyi Wang","Guomiao Zhang","Qichao Sheng","Huiqin Mei","Yixi Xu","Qingyang Mao","Chao Zheng","Xiaoyu Zhang","Guangyun Mao"],"significance":4,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/f9ed94fb64aa.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"A Chinese retrospective cohort study found that overweight and a higher triglyceride-glucose index were paradoxically associated with lower mortality in type 2 diabetes patients, particularly those over 60 years. The obesity paradox in diabetes requires further causal investigation.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"802666cb5c72","type":"article","url":"https://hartvaat.nl/2026/01/01/lipoproteine-a-gecombineerd-met-catlet-score-voorspelt-events-na-spoed-pci/","title":"Lipoproteïne(a) gecombineerd met CatLet-score voorspelt events na spoed-PCI","title_en":"Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"PloS one","doi":"10.1371/journal.pone.0342704","source_url":"https://doi.org/10.1371/journal.pone.0342704","authors":["Mengru Wang","Fudong Hu","Rongyan Jiang","Sheng Tu"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/ada509cb622d.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/stijve-arterieen-arteriosclerose/"],"congress":"","summary_en":"In 307 acute MI patients after emergency PCI, the combination of lipoprotein(a) and the CatLet angiographic score was a significantly better predictor of cardiovascular events than either marker alone, achieving an AUC of 0.86 with 88% sensitivity.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d437a71664d","type":"article","url":"https://hartvaat.nl/2026/01/01/apolipoproteine-e-genpolymorfismen-en-het-risico-op-coronairlijden/","title":"Apolipoproteïne E-genpolymorfismen en het risico op coronairlijden","title_en":"Association of apolipoprotein E gene polymorphisms with risk of coronary artery disease in a Han Chinese population at middle and high altitude in China.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","cardiovasculaire-genetica","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","menopauze","pcsk9-remmers","pelacarsen","statines","vrouwen"],"journal":"Frontiers in endocrinology","doi":"10.3389/fendo.2026.1765770","source_url":"https://doi.org/10.3389/fendo.2026.1765770","authors":["Fanrong Zeng","Xinyi Zhang","Meng Zhang","Hongli Liu","Yuan Li","Fan Ye","Xuejiao Chen","Fangyi Zhu","Lihong Zhai"],"significance":4,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/950d82e1061b.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A case-control study in Han Chinese populations at middle and high altitudes investigated the association between apolipoprotein E gene polymorphisms and coronary artery disease risk, with focus on lipid regulation and altitude-specific effects.","created":"2026-07-03T10:24:06Z","updated":"2026-07-03T13:24:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a3b5e07b8444","type":"article","url":"https://hartvaat.nl/2025/12/30/ire1-bemiddelt-hypertensie-en-vasculaire-remodeling/","title":"IRE1α bemiddelt hypertensie en vasculaire remodeling","title_en":"Inositol Requiring Enzyme 1α Mediates Hypertension and Vascular Remodeling","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["endotheel","renale-denervatie","resistente-hypertensie"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26400","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26400","authors":["Keiichi Torimoto"],"significance":5,"published":"2025-12-30","source_date":"2025-12-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This preclinical study demonstrated that inhibition of the endoplasmic reticulum stress effector inositol requiring enzyme 1a mitigates angiotensin II-induced hypertension and vascular remodelling. The findings identify a potential therapeutic target in the unfolded protein response pathway.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68d5d6bcdd0d","type":"article","url":"https://hartvaat.nl/2025/12/30/overgang-van-aki-naar-ckd-rol-van-niermacrofagen-en-neutrofielen/","title":"Overgang van AKI naar CKD: rol van niermacrofagen en neutrofielen","title_en":"Key drivers and potential therapeutic targets in the AKI-to-CKD transition: roles of kidney-resident macrophages and neutrophils","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","ijzertekort"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01028-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01028-2/fulltext","authors":["Kensei Taguchi","Kei Fukami"],"significance":5,"published":"2025-12-30","source_date":"2025-12-30","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/anemie-bij-ckd/"],"congress":"","summary_en":"This review discusses the key drivers of the AKI-to-CKD transition, focusing on kidney-resident macrophages and neutrophils as potential therapeutic targets. Understanding innate immune mechanisms in maladaptive repair may identify new interventions to prevent CKD progression.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2179d56e197","type":"article","url":"https://hartvaat.nl/2025/12/30/transcriptanalyse-van-langdurige-varken-naar-primaat-nierxenograften/","title":"Transcriptanalyse van langdurige varken-naar-primaat nierxenograften","title_en":"Mechanistic insights from transcript analysis of long-term pig to non-human primate kidney xenografts","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01008-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01008-7/fulltext","authors":["Ivy A. Rosales","Alessia Giarraputo","Claire Trivin-Avillach","Ahmad Karadagi","Christina Laguerre","Toru Goto","Jeremy Marcin","Nicole Brousaides","Tatsuo Kawai","Robert B. Colvin"],"significance":5,"published":"2025-12-30","source_date":"2025-12-30","image":"","kennis":[],"congress":"","summary_en":"Transcript analysis of long-term porcine kidney xenografts in non-human primates achieving up to two years of survival revealed distinct molecular mechanisms compared with allografts. The insights inform the development of xenotransplantation for future organ shortage solutions.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fb5ecdc2ede","type":"article","url":"https://hartvaat.nl/2025/12/29/effect-van-cilostazol-op-de-prognose-van-perifeer-arterieel-vaatlijden-bij-diabe/","title":"Effect van cilostazol op de prognose van perifeer arterieel vaatlijden bij diabetes in Korea","title_en":"Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["credence-trial","fidelio-dkd","soul-trial"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01532-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01532-1/fulltext","authors":["Shinje Moon","Sangmo Hong","Kyungdo Han","Cheol-Young Park"],"significance":5,"published":"2025-12-29","source_date":"2025-12-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A Korean nationwide population-based study analysed the long-term prognostic effects of cilostazol in patients with diabetes and lower extremity peripheral arterial disease. The findings inform the use of this PDE3 inhibitor beyond symptomatic walking distance improvement.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ede7eb60a31","type":"article","url":"https://hartvaat.nl/2025/12/29/gemodificeerde-regulatoire-t-lymfocyten-bevorderen-herstel-van-het-geinfarceerde/","title":"Gemodificeerde regulatoire T-lymfocyten bevorderen herstel van het geïnfarceerde hart","title_en":"Engineered Regulatory T Lymphocytes Promote Infarcted Heart Repair","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["harttransplantatie","laminopathie","myocardinfarct"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076321","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076321","authors":["Min Zhang"],"significance":7,"published":"2025-12-29","source_date":"2025-12-29","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that engineered regulatory T lymphocytes can promote repair of infarcted myocardium by resolving inflammation and reducing fibrosis, advancing cell-based immunomodulation as a regenerative cardiac therapy approach.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f829cc231b6","type":"article","url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","title":"Functionele en morfologische karakterisering van coronaire atherosclerose","title_en":"Functional and morphological characterization of coronary atherosclerosis","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["atherosclerose"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01530-8/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01530-8/fulltext","authors":["Koshiro Sakai","Toshiro Shinke","Ziad Ali","Takuya Mizukami","Hitoshi Matsuo","Hirohiko Ando","Tetsuya Amano","Thomas Engstrøm","Jeroen Sonck","Adriaan Wilgenhof","Divaka Perera","Masafumi Nakayama","William F. Fearon","Brian Ko","Javier Escaned","Daniel Munhoz","Frederic Bouisset","Kazumasa Ikeda","Taito Arai","Ethan Korngold","Evald Høj Christiansen","Colin Berry","Bernard De Bruyne","Nils P. Johnson","Carlos Collet"],"significance":5,"published":"2025-12-29","source_date":"2025-12-29","image":"","kennis":[],"congress":"","summary_en":"This study provides functional and morphological characterisation of coronary atherosclerosis using the novel Pullback Pressure Gradient metric to classify disease into focal or diffuse patterns. The physiological assessment complements anatomical imaging for treatment planning.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5acebd5a3fe9","type":"article","url":"https://hartvaat.nl/2025/12/29/monocyt-hdl-ratio-en-risico-op-beroerte-myocardinfarct-en-mortaliteit/","title":"Monocyt-HDL-ratio en risico op beroerte, myocardinfarct en mortaliteit","title_en":"Monocyte to high-density lipoprotein ratio and risk of incident stroke, myocardial infarction, and mortality: A large prospective cohort study","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["hdl-cholesterol"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01529-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01529-1/fulltext","authors":["Zijie Wang","Xiao Hu","Jianshang Wen","Yanfang Xie","Mengqiu Zhang","Chuanqin Fang","Yanghua Tian","Qi Li"],"significance":6,"published":"2025-12-29","source_date":"2025-12-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This meta-analysis evaluated the monocyte-to-HDL cholesterol ratio as a predictor of stroke, MI, and mortality, establishing this easily calculated inflammatory index as a cardiovascular risk marker.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"281ddb320d93","type":"article","url":"https://hartvaat.nl/2025/12/26/pth-suppressieprofielen-na-orale-calciumbelasting-bij-niertransplantatiepatiente/","title":"PTH-suppressieprofielen na orale calciumbelasting bij niertransplantatiepatiënten","title_en":"Parathyroid hormone suppression profiles following oral calcium challenge in kidney transplant recipients","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["niertransplantatie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01010-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01010-5/fulltext","authors":["Jordan Desenclos","Caroline Halimi","Emmanuelle Vidal-Petiot","Justina Motiejunaite","Eric Daugas","Tiphaine Robert-Mercier","Anne Boutten","Marie-Noëlle Peraldi","Corinne Antoine","François Vrtovsnik","Christine Randoux","Guillaume Hanouna","Quentin Raimbourg","Martin Flamant","Nahid Tabibzadeh"],"significance":5,"published":"2025-12-26","source_date":"2025-12-26","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This study characterised parathyroid hormone suppression profiles after oral calcium challenge in kidney transplant recipients with post-transplant hyperparathyroidism. The calcium-mediated PTH suppression patterns were associated with PTH control in the first year post-transplant.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a56265f43af9","type":"article","url":"https://hartvaat.nl/2025/12/26/systematische-identificatie-van-familiaire-hypercholesterolemie-geactualiseerde-/","title":"Systematische identificatie van familiaire hypercholesterolemie: geactualiseerde review","title_en":"Systematic identification of familial hypercholesterolaemia: An updated systematic review and meta-analysis","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01523-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01523-0/fulltext","authors":["Diandra Daley","Aya Ayoub","Ralph K. Akyea","Veline L'Esperance","Luisa Silva","Anthony S. Wierzbicki","Helen Williams","Nadeem Qureshi","Mariam Molokhia"],"significance":5,"published":"2025-12-26","source_date":"2025-12-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/cascadescreening-fh/"],"congress":"","summary_en":"An updated systematic review evaluated electronic health record-based strategies for systematic identification of familial hypercholesterolaemia. Despite effective treatments, FH remains substantially underdiagnosed, and EHR-based case-finding shows promise for improving detection rates.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1f93c2cafe0","type":"article","url":"https://hartvaat.nl/2025/12/24/infectiepreventie-bij-nieuwe-complementremmers-ingekapselde-micro-organismen/","title":"Infectiepreventie bij nieuwe complementremmers: ingekapselde micro-organismen","title_en":"Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["complementremmers","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01024-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01024-5/fulltext","authors":["Ayman Al Jurdi","Camille N. Kotton","Richard Lafayette"],"significance":5,"published":"2025-12-24","source_date":"2025-12-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This review addresses infection prevention strategies for patients receiving novel complement inhibitors approved for aHUS, IgA nephropathy, and C3 glomerulopathy. The risk of encapsulated organism infections requires systematic vaccination and monitoring protocols.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ee7a6bf6be3","type":"article","url":"https://hartvaat.nl/2025/12/24/genomische-ontdekking-bij-nefrotisch-syndroom-mefv-varianten-als-risicofactor-vo/","title":"Genomische ontdekking bij nefrotisch syndroom: MEFV-varianten als risicofactor voor FSGS","title_en":"Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["cardiovasculaire-genetica","cystatine-c","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01023-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01023-3/fulltext","authors":["Janewit Wongboonsin","Kristen M. Gibson","Juntao Ke","Zachary T. Sentell","Juliana E. Arcila-Galvis","Satoshi Koyama","Anya Greenberg","Kaylia M. Reynolds","Giovanni Montini","Riccardo Magistroni","Adele Mitrotti","Loreto Gesualdo","Alessandro Pezzuto","Licia Peruzzi","Yasar Caliskan","Ana C. Onuchic-Whitford","Srichan Bunlungsup","Michelle McNulty","Rasheed Gbadegesin","Moin A. Saleem","Martin R. Pollak","Friedhelm Hildebrandt","Pradeep Natarajan","Dongwon Lee","Sagar U. Nigwekar","John A. Sayer","Simone Sanna-Cherchi","Matthew G. Sampson"],"significance":5,"published":"2025-12-24","source_date":"2025-12-24","image":"","kennis":[],"congress":"","summary_en":"A genomic discovery study in the Mass General Brigham Biobank identified monoallelic MEFV variants as a novel risk factor for focal segmental glomerulosclerosis. The finding links inflammatory pathway genetics to nephrotic syndrome susceptibility.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba25c8c26a4c","type":"article","url":"https://hartvaat.nl/2025/12/24/risicovoorspellingsmodellen-voor-ouderen-met-chronische-nierziekte/","title":"Risicovoorspellingsmodellen voor ouderen met chronische nierziekte","title_en":"Utilizing risk prediction models for older patients with chronic kidney disease","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01015-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01015-4/fulltext","authors":["Amanda Siriwardana","Navdeep Tangri","Brendon L. Neuen","Meg J. Jardine","Celine Foote","Martin Gallagher"],"significance":5,"published":"2025-12-24","source_date":"2025-12-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This review discusses the use of risk prediction models for older patients with chronic kidney disease. The slower progression rate and high competing mortality risk in elderly patients require tailored tools for shared decision-making about kidney replacement therapy.","created":"2026-07-03T10:25:38Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd7da5e30405","type":"article","url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","title":"TOP: liberaal versus restrictief transfusiebeleid bij hoogrisico hartchirurgie","title_en":"Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.20841","source_url":"https://doi.org/10.1001/jama.2025.20841","authors":["Panos Kougias","Sherene E Sharath","Min Zhan","Jeffrey L Carson","L Erin Norman","Zhibao Mi","Rupsi Pal","Hasan Dosluoglu","J Gregory Modrall","George A Sarosi","Peter Nelson","Shipra Arya","Alexandra Scrymgeour","Jade Ollison","Lawrence A Calais","Vijay Nambi","L Parker Gregg","Shuaib M Abdullah","Shirling Tsai","Natasha Becker","Justin C Choi","Louisa Chiu","Salvatore Scali","Neal R Barshes","Samir Awad","Mohammed Moursi","Matthew C Koopmann","Mitchell Sally","Daniel Ihnat","Archana Ramaswamy","Warren Gasper","Edith Tzeng","Mark A Wilson","Gale Tang","Grant Huang","Kousick Biswas"],"significance":7,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/vaatchirurgie-perioperatief-cardiologisch-beleid/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"The TOP trial compared liberal with restrictive postoperative transfusion strategies in patients with high cardiac risk, informing the optimal hemoglobin threshold for transfusion in the most vulnerable surgical population.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d3c913f563c","type":"article","url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","title":"Korte anticoagulatie versus DAPT na LAA-occlusie: devicetrombosepreventie","title_en":"Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen","dubbele-trombocytenremming","rivaroxaban"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.077469","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.077469","authors":["Josep Rodés-Cabau","Luis Nombela-Franco","Ignacio Cruz-Gonzalez","Benjamin Hibbert","Xavier Freixa","Jean-Bernard Masson","Réda Ibrahim","Rodrigo Estevez-Loureiro","Xavier Millan","Malek Kass","Jean-Michel Paradis","Jean Champagne","Pablo Salinas","Ana Laffond","Omar Abdel-Razek","Marino Labinaz","Pedro Cepas-Guillen","Dabit Arzamendi","Pablo Vidal-Cales","Marco Pavesi","Mélanie Côté","Gilles O'Hara","Erwan Salaun"],"significance":6,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":[],"congress":"","summary_en":"This trial compared short-term anticoagulation with DAPT for preventing device thrombosis after LAA closure, providing the first randomized comparison of antithrombotic strategies in the early post-LAAC period.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf3cddbc97ed","type":"article","url":"https://hartvaat.nl/2025/12/23/kwetsbaarheid-genetische-gevoeligheid-en-risico-op-abdominaal-aorta-aneurysma/","title":"Kwetsbaarheid, genetische gevoeligheid en risico op abdominaal aorta-aneurysma","title_en":"Frailty, genetic susceptibility, and the risk of abdominal aortic aneurysm: Evidence from the UK Biobank cohort study","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["aorta-aneurysma"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01521-7/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01521-7/fulltext","authors":["Yiyang Tang","Mukamengjiang Juaiti","Xinyi Zhou","Baohua Peng","Zhenzhen Da","Ziwei Ou","Wenchao Lin","Mengqiu Zhang","Zaixin Yu","Lihuang Zha","Benhui Liang"],"significance":5,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This UK Biobank study demonstrated that frailty is independently associated with increased risk of abdominal aortic aneurysm, even after accounting for genetic susceptibility. The interaction between frailty and genetic risk informs screening strategies.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d46f694cd44","type":"article","url":"https://hartvaat.nl/2025/12/23/plasma-proteomische-biomarkers-voor-risico-en-therapeutische-doelen-bij-abdomina/","title":"Plasma-proteomische biomarkers voor risico en therapeutische doelen bij abdominaal aorta-aneurysma","title_en":"Identifying plasma proteomic biomarkers for risk prediction and therapeutic targets of abdominal aortic aneurysm: Prospective cohort and Mendelian randomization analyses","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["aorta-aneurysma","lipoproteïne-a-therapeutisch-doel"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01522-9/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01522-9/fulltext","authors":["Yanjun Zhang","Yu Huang","Xiaoqin Gan","Ziliang Ye","Yuanyuan Zhang","Sisi Yang","Hao Xiang","Yiwei Zhang","Yiting Wu","Xianhui Qin"],"significance":5,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":[],"congress":"","summary_en":"Using prospective cohort data and Mendelian randomisation, this study identified plasma proteomic biomarkers associated with abdominal aortic aneurysm risk. The findings provide potential targets for AAA risk prediction and pharmacological intervention.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cba874f8530f","type":"article","url":"https://hartvaat.nl/2025/12/23/meta-organismaal-tryptofaanmetabolisme-als-therapeutisch-doelwit-bij-ckd-mbd/","title":"Meta-organismaal tryptofaanmetabolisme als therapeutisch doelwit bij CKD-MBD","title_en":"Meta-organismal tryptophan metabolism: an appealing therapeutic target in CKD-MBD","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","ijzertekort","microbioom"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01019-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01019-1/fulltext","authors":["Guillaume Fernandes","Stéphane Burtey","Ward Zadora","Bjorn Meijers","Dieter Smout","Laura Labriola","Pieter Evenepoel"],"significance":5,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This review discusses meta-organismal tryptophan metabolism — the interplay between host and gut microbiome — as a promising therapeutic target for CKD-mineral and bone disorder. The approach represents a paradigm shift from the traditional PTH-calcium-phosphate-centric framework.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9cb73c022f34","type":"article","url":"https://hartvaat.nl/2025/12/23/sglt2-remming-verbetert-leeftijdsafhankelijke-microvasculaire-rarefactie-van-de-/","title":"SGLT2-remming verbetert leeftijdsafhankelijke microvasculaire rarefactie van de nier","title_en":"Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["canagliflozine","empagliflozine","perifeer-vaatlijden","sglt2-remmers"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01020-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01020-8/fulltext","authors":["Anastasia Paulmann","Matthew D. Cox","Tom Boewer","Hannah M. Somers","Heath Fuqua","Ryan P. Seaman","Joel H. Graber","Anchal Mahajan","Cory P. Johnson","Laura L. Beverly-Staggs","Sonia Sandhi","Heiko Schenk","Hermann Haller"],"significance":5,"published":"2025-12-23","source_date":"2025-12-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/"],"congress":"","summary_en":"This research demonstrates that SGLT2 inhibition improves age-dependent microvascular rarefaction in the kidney. The findings suggest a novel mechanism by which SGLT2 inhibitors may protect against age-related decline in kidney function and vascular structure.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c9b42056781","type":"article","url":"https://hartvaat.nl/2025/12/22/sefaxersen-bij-iga-nefropathie-fase-2-trial-van-complementfactor-b-remming/","title":"Sefaxersen bij IgA-nefropathie: fase 2-trial van complementfactor B-remming","title_en":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["abelacimab","complementremmers","iaso-dcm","iga-nefropathie","ijzersuppletie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01007-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01007-5/fulltext","authors":["Sean J. Barbour","Michelle A. Hladunewich","Michael L. McCaleb","Richard Robson","Terrance D. Barrett","Lixuan Yin","Ashley Frazer-Abel","Jay P. Garg","Richard Geary","Eugene Schneider","Gary T. Brice"],"significance":6,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This phase 2 trial of sefaxersen, an RNA therapeutic targeting complement factor B, showed efficacy in IgA nephropathy, advancing complement-targeted therapy for this common glomerular disease.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae6af30bcc92","type":"article","url":"https://hartvaat.nl/2025/12/22/complementactivatie-drijft-compartiment-specifieke-immuunrespons-bij-c3-glomerul/","title":"Complementactivatie drijft compartiment-specifieke immuunrespons bij C3-glomerulopathie","title_en":"Complement activation drives a compartmentalized innate immune response in C3 glomerulopathy contributing to the disease phenotype","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["cystatine-c","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01012-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01012-9/fulltext","authors":["Marie-Sophie Meuleman","Aurélien de Reyniès","Céline Mayinga","Stéphanie Ngo","Nathalie Rioux-Leclercq","Agathe Vermorel","Jérome Olagne","Diane Giovannini","Arnaud Francois","Anne Croué","Gaëtane Planchard","David Buob","Yahsou Delmas","Marie Courbebaisse","Béatrice Parfait","David Lebeaux","Gérard Friedlander","Marina Avramescu","Benoit Brilland","Hugoline Boulay","Manon Martins","Lubka Roumenina","Véronique Frémeaux-Bacchi","Jean-Paul Duong Van Huyen","Sophie Chauvet"],"significance":6,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This study characterized how complement activation drives compartmentalized innate immune responses in C3 glomerulopathy, advancing the understanding of complement-mediated kidney disease pathophysiology.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e82ad11d1e06","type":"article","url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","title":"Evinacumab bij kinderen van 5-17 jaar met homozygote familiaire hypercholesterolemie","title_en":"Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipoproteïne-a","statines","vrouwen","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01525-4/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01525-4/fulltext","authors":["Robert S. Rosenson","Eliot A. Brinton","Daniel Gaudet","Frederick J. Raal","Carissa Baker-Smith","Patrick M. Moriarty","Susanne Greber-Platzer","Jean Bergeron","Brian W. McCrindle","Alpana Waldron","Shazia Ali","Richard T. George","Robert Pordy","Xue-Qiao Zhao","Albert Wiegman"],"significance":5,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/"],"congress":"","summary_en":"This study assessed the long-term efficacy and safety of evinacumab, an anti-ANGPTL3 antibody, in children and adolescents aged 5-17 years with homozygous familial hypercholesterolaemia. The findings support early advanced lipid-lowering therapy in this severe paediatric condition.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ef3c0352625","type":"article","url":"https://hartvaat.nl/2025/12/22/therapeutische-herprogrammering-van-myeloide-cellen-via-sirp-vesikels-bij-acuut-/","title":"Therapeutische herprogrammering van myeloïde cellen via SIRPα-vesikels bij acuut nierletsel","title_en":"Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01022-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01022-1/fulltext","authors":["Dong-U Shin","Min Kyoung Jo","Minjeong Kwon","Yewon Jeong","Bogyeong Cho","Seong A Kim","Ga-Eun Choi","Seohyun Kim","Seok Ho Song","Hyemin Joo","Hyun Jung Kim","Jung Pyo Lee","Jeonghwan Lee","In-San Kim","Gi-Hoon Nam"],"significance":5,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This research describes therapeutic reprogramming of circulating myeloid cells using SIRPa extracellular vesicles as a novel treatment strategy for acute kidney injury. The approach targets the CD47 immune checkpoint to modulate inflammatory cell infiltration.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6cdb30a3d21a","type":"article","url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","title":"TAVI plus FFR-geleide PCI: gecombineerde benadering onderzocht","title_en":"TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)02100-7","source_url":"https://doi.org/10.1016/S0140-6736(24)02100-7","authors":["Elvin Kedhi","Renicus S Hermanides","Jan-Henk E Dambrink","Sandeep K Singh","Jurriën M Ten Berg","DirkJan van Ginkel","Martin Hudec","Giovanni Amoroso","Ignacio J Amat-Santos","Martin Andreas","Rui Campante Teles","Guillaume Bonnet","Eric Van Belle","Lenard Conradi","Leen van Garsse","Wojtek Wojakowski","Vassilis Voudris","Jerzy Sacha","Pavel Cervinka","Erik Lipsic","Samer Somi","Luis Nombela-Franco","Sonja Postma","Kerstin Piayda","Giuseppe De Luca","Evelien Kolkman","Krzysztof P Malinowski","Thomas Modine"],"significance":6,"published":"2025-12-21","source_date":"2025-12-21","image":"","kennis":[],"congress":"","summary_en":"This study evaluated combined TAVI plus FFR-guided PCI for patients with severe aortic stenosis and concomitant coronary disease, testing whether addressing both conditions simultaneously improves outcomes.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da1d9d869107","type":"article","url":"https://hartvaat.nl/2025/12/20/orforglipron-bij-obesitas-nejm-definitieve-fase-3-resultaten/","title":"Orforglipron bij obesitas: NEJM definitieve fase 3 resultaten","title_en":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["credence-trial","ezetimibe","glp1-semaglutide-cardiovasculair","obesitas","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02165-8","source_url":"https://doi.org/10.1016/S0140-6736(25)02165-8","authors":["Deborah B Horn","Donna H Ryan","Sanja Giljanovic Kis","Breno Alves","Yiming Mu","Sin Gon Kim","Jens Aberle","Stephen C Bain","Sheryl Allen","Elizabeth Sarker","Qiwei Wu","Adam Stefanski","Irina Jouravskaya"],"significance":10,"published":"2025-12-20","source_date":"2025-12-20","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The ATTAIN-2 trial demonstrated that orforglipron, an oral GLP-1 receptor agonist, achieved approximately 15% weight loss in adults with obesity and type 2 diabetes. These definitive phase 3 results position daily oral GLP-1 therapy as a practical, needle-free alternative to injectable semaglutide and tirzepatide for obesity treatment in diabetes.","created":"2026-07-03T10:32:14Z","updated":"2026-07-03T13:31:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"51d855798fd2","type":"article","url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","title":"Tirzepatide versus dulaglutide en CV-uitkomsten bij type 2 diabetes","title_en":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2505928","source_url":"https://doi.org/10.1056/NEJMoa2505928","authors":["Stephen J Nicholls","Imre Pavo","Deepak L Bhatt","John B Buse","Stefano Del Prato","Steven E Kahn","A Michael Lincoff","Darren K McGuire","Debra Miller","Michael A Nauck","Hiroshi Nishiyama","Steven E Nissen","Naveed Sattar","Govinda Weerakkody","Russell J Wiese","Bernard Zinman","Sophia Zoungas","Jan Basile","Melanie J Davies","Francesco Giorgino","Monika Kellerer","Linong Ji","Tamas Varkonyi","Venu Menon","Jonathan C Broder","Alan Herschtal","David D'Alessio"],"significance":7,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This NEJM trial compared tirzepatide with dulaglutide head-to-head on cardiovascular outcomes in type 2 diabetes, providing the first direct comparison of dual versus single incretin agonism for cardiovascular protection.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"629b5cefc7d0","type":"article","url":"https://hartvaat.nl/2025/12/18/2025-acc-aha-richtlijn-voor-behandeling-van-volwassenen-met-aangeboren-hartafwij/","title":"2025 ACC/AHA-richtlijn voor behandeling van volwassenen met aangeboren hartafwijkingen","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001402","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001402","authors":["Michelle Gurvitz"],"significance":9,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":[],"congress":"","summary_en":"The 2025 ACC/AHA/HRS/ISACHD/SCAI guideline for adults with congenital heart disease (Circulation edition) provides comprehensive, updated recommendations covering surgical indications, electrophysiology management, pregnancy counseling, and lifelong follow-up for this growing patient population.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"097ea21fdfd6","type":"article","url":"https://hartvaat.nl/2025/12/18/endotheliale-transcriptiefactor-eb-beschermt-tegen-doxorubicine-cardiotoxiciteit/","title":"Endotheliale transcriptiefactor EB beschermt tegen doxorubicine-cardiotoxiciteit","title_en":"Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["kanker-en-hart"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.071774","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.124.071774","authors":["Wa Du"],"significance":6,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/hart-en-kanker-cardio-oncologie/","https://hartvaat.nl/kennis/cardiometabool/insulineresistentie-mechanisme/"],"congress":"","summary_en":"This basic science study showed that endothelial transcription factor EB protects against doxorubicin-induced endothelial toxicity and cardiac dysfunction, identifying a potential therapeutic target for cardio-oncology.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7a3353960d55","type":"article","url":"https://hartvaat.nl/2025/12/18/improve-dice-veiligheid-en-werkzaamheid-van-ninerafaxstat-bij-cardiometabole-syn/","title":"IMPROVE-DiCE: veiligheid en werkzaamheid van ninerafaxstat bij cardiometabole syndromen","title_en":"IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074041","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074041","authors":[],"significance":8,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The IMPROVE-DiCE phase 2a trial evaluated ninerafaxstat, a novel agent designed to improve diabetic cardiac energetics, in patients with diabetic cardiomyopathy. The study explores a new therapeutic mechanism targeting myocardial metabolism.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39c677e6bffa","type":"article","url":"https://hartvaat.nl/2025/12/18/gedeeltelijk-succesvolle-bijniervenesampling-bij-subtypering-van-primair-aldoste/","title":"Gedeeltelijk succesvolle bijniervenesampling bij subtypering van primair aldosteronisme","title_en":"Partially Successful Adrenal Vein Sampling With and Without Cross-Sectional Imaging in Primary Aldosteronism Subtyping","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26149","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26149","authors":["Peeradon Vibhatavata"],"significance":6,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":[],"congress":"","summary_en":"This study addressed the clinical interpretation of partially successful adrenal vein sampling in primary aldosteronism, providing guidance when only one adrenal vein is successfully cannulated.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc654a6760d0","type":"article","url":"https://hartvaat.nl/2025/12/18/bradycardie-bij-topsporters-prevalentie-mechanismen-en-risico-s/","title":"Bradycardie bij topsporters: prevalentie, mechanismen en risico's","title_en":"Bradycardia in Athletes: Prevalence, Mechanisms, and Risks","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["bradycardie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076170","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076170","authors":[],"significance":7,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/","https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"This study from the Pro@Heart cohort characterized bradycardia in endurance athletes using comprehensive imaging and monitoring, exploring the genetic and physiological mechanisms of sinus node remodeling and distinguishing benign athletic adaptation from pathological conduction disease.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"858ef673a8a1","type":"article","url":"https://hartvaat.nl/2025/12/18/trim31-in-macrofagen-remt-atherosclerotische-plaquevorming-via-lox-1-afbraak/","title":"TRIM31 in macrofagen remt atherosclerotische plaquevorming via LOX-1-afbraak","title_en":"Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["atherosclerose","ezetimibe","pcsk9-remmers","pelacarsen","plaquekarakterisatie"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076514","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076514","authors":["Jie Zhang"],"significance":5,"published":"2025-12-18","source_date":"2025-12-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This Circulation study reveals that the macrophage-specific E3 ubiquitin ligase TRIM31 protects against atherosclerosis by targeting LOX-1 for proteasomal degradation. TRIM31 deficiency increases oxidised LDL uptake and foam cell formation, identifying a potential therapeutic target.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3bd2c0df166","type":"article","url":"https://hartvaat.nl/2025/12/17/geintegreerde-mirnomics-en-lipidomics-bij-muizen-met-veranderd-lipoproteinemetab/","title":"Geïntegreerde miRNomics en lipidomics bij muizen met veranderd lipoproteïnemetabolisme","title_en":"Integrated high-throughput miRNomics and lipidomics in mice with altered lipoprotein metabolism","category":"cholesterol","category_label":"Cholesterol","professions":[],"tags":["dyslipidemie","ezetimibe","laminopathie","ldl-cholesterol","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","plaquekarakterisatie","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01520-5/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01520-5/fulltext","authors":["Stefano Manzini","Alice Colombo","Elsa Franchi","Giada Poletti","Marco Busnelli","Giulia Chiesa"],"significance":3,"published":"2025-12-17","source_date":"2025-12-17","image":"","kennis":[],"congress":"","summary_en":"This study explored a novel integrative approach combining miRNomic and lipidomic data from mice with specific lipid traits to increase understanding of the mutual interplay between microRNAs and lipid metabolism.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"304072b052ef","type":"article","url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","title":"Geoxideerde fosfolipiden, Lp(a) en CV-uitkomsten na ACS","title_en":"Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["lipide-aferese"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.073855","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.073855","authors":["Sotirios Tsimikas","Michael Szarek","Christa M Cobbaert","Fred Romijn","J Wouter Jukema","Deepak L Bhatt","Vera A Bittner","Rafael Diaz","Sergio Fazio","Genevieve Garon","Chong Yuan","Xiao-Min Gong","Shaun G Goodman","Harvey D White","Joseph L Witztum","P Gabriel Steg","Gregory G Schwartz"],"significance":6,"published":"2025-12-16","source_date":"2025-12-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This analysis showed that oxidized phospholipids on apolipoprotein B and Lp(a) are synergistic risk factors for cardiovascular events after ACS, supporting combined measurement for comprehensive residual risk assessment.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec0716af04d3","type":"article","url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","title":"DANISH langetermijn: ICD bij niet-ischemische HFrEF — uitgebreide follow-up","title_en":"Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.089","source_url":"https://doi.org/10.1016/j.jacc.2025.08.089","authors":["Jawad H Butt","Seiko N Doi","Jens J Thune","Jens C Nielsen","Lars Videbæk","Adelina Yafasova","Niels E Bruun","Christian Torp-Pedersen","Hans Eiskjær","Kenneth Egstrup","Axel Brandes","Christian Hassager","Jesper H Svendsen","Dan Høfsten","Steen Pehrson","Lars Køber"],"significance":8,"published":"2025-12-16","source_date":"2025-12-16","image":"","kennis":[],"congress":"","summary_en":"Extended DANISH follow-up confirmed that ICDs in nonischemic HFrEF do not provide significant long-term survival benefit, even with over a decade of follow-up. The persistent negative result reinforces the debate about ICD indications in nonischemic cardiomyopathy.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31eca5c396c1","type":"article","url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","title":"VICTOR: vericiguat en totale hartfalengebeurtenissen bij stabiel HFrEF","title_en":"Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.051","source_url":"https://doi.org/10.1016/j.jacc.2025.08.051","authors":["Faiez Zannad","Yogesh N V Reddy","Irina Barash","Kevin J Anstrom","Marc P Bonaca","Maria Borentain","Stefano Corda","Pedro P Teixeira","Justin A Ezekowitz","Davis Gates","Carolyn S P Lam","Eldrin F Lewis","JoAnn Lindenfeld","Ciaran J McMullan","Robert J Mentz","Christopher M O'Connor","Piotr Ponikowski","Giuseppe M C Rosano","Clara Saldarriaga","Michele Senni","James Udelson","Alessia Urbinati","Vanja Vlajnic","Adriaan A Voors","Aiwen Xing","Mahesh J Patel","Javed Butler"],"significance":6,"published":"2025-12-16","source_date":"2025-12-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This VICTOR analysis showed that vericiguat reduces total (including recurrent) heart failure events in compensated outpatient HFrEF, demonstrating the cumulative benefit of sGC stimulation in stable heart failure.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c65a1c712a07","type":"article","url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","title":"Farmacologische behandeling van HFrEF: geactualiseerde systematische review","title_en":"Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["hfpef","hfref","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.054","source_url":"https://doi.org/10.1016/j.jacc.2025.08.054","authors":["Bart J van Essen","Daan C H Ceelen","Wouter Ouwerkerk","Tiew-Hwa K Teng","Ganash N Tharshana","Fook Ming Hew","Javed Butler","Faiez Zannad","Carolyn S Lam","Justin Ezekowitz","Adriaan A Voors","Jasper Tromp"],"significance":7,"published":"2025-12-16","source_date":"2025-12-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"This updated systematic review and network meta-analysis of pharmacological HFrEF treatment confirmed that the four-pillar combination (SGLT2i + ARNI + beta-blocker + MRA) provides the optimal mortality and hospitalization reduction, with quantified contributions from each drug class.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4bfc0b8b0a89","type":"article","url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","title":"Hypokaliëmie en AF gedetecteerd door implanteerbare loop recorders","title_en":"Hypokalaemia and atrial fibrillation detected by implanted loop recorders.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf623","source_url":"https://doi.org/10.1093/eurheartj/ehaf623","authors":["August Krebs Hessellund","Emilie Katrine Kongebro","Ketil Jørgen Haugan","Claus Graff","Daniel Camillo Spona","Jonas Alexander Baadsgaard","Lucas Yixi Xing","Søren Højberg","Derk Krieger","Axel Brandes","Lars Køber","Ruth Frikke-Schmidt","Jesper Hastrup Svendsen","Søren Zöga Diederichsen"],"significance":5,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/holter-monitoring-bij-af/"],"congress":"","summary_en":"Analysis of the LOOP study investigated the association between plasma potassium levels and daily AF episodes detected by implantable loop recorders. Lower potassium values were associated with greater AF burden, reinforcing the importance of electrolyte management.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"257632a56859","type":"article","url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","title":"Circadiaanse patronen van AF en ziekteprogressie via implanted loop recorders","title_en":"Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf386","source_url":"https://doi.org/10.1093/eurheartj/ehaf386","authors":["Daniel Camillo Spona","Ketil Jørgen Haugan","Claus Graff","Søren Højberg","Derk Krieger","Axel Brandes","Lars Køber","Morten S Olesen","Jesper Hastrup Svendsen","Søren Zöga Diederichsen"],"significance":5,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/holter-monitoring-bij-af/"],"congress":"","summary_en":"A post-hoc analysis of the LOOP study revealed distinct circadian patterns of atrial fibrillation episodes detected by implantable loop recorders. Nocturnal episodes predominated and were associated with faster AF progression, informing monitoring and treatment strategies.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ae28105c8a0","type":"article","url":"https://hartvaat.nl/2025/12/15/aldh1a1-reguleert-pd-l1-transcriptie-combinatietherapie-bij-adpkd/","title":"ALDH1A1 reguleert PD-L1-transcriptie: combinatietherapie bij ADPKD","title_en":"Aldehyde dehydrogenase 1 A1 regulates the transcription of PD-L1 and its targeting with disulfiram together with PD-L1 immunotherapy synergistically delays cyst growth in ADPKD","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00988-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00988-3/fulltext","authors":["Alice Shasha Cheng","Linda Xiaoyan Li","Julie Xia Zhou","Peter C. Harris","James P. Calvet","Xiaogang Li"],"significance":5,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This study demonstrates that aldehyde dehydrogenase 1A1 regulates PD-L1 transcription in autosomal dominant polycystic kidney disease. Combination therapy with disulfiram and PD-L1 immunotherapy synergistically delayed cyst growth, offering a novel therapeutic approach.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T13:25:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"057fd38d57c6","type":"article","url":"https://hartvaat.nl/2025/12/15/geslachtsspecifieke-exosoom-inhoud-onthult-nieuwe-mechanismen-van-zoutgevoelige-/","title":"Geslachtsspecifieke exosoom-inhoud onthult nieuwe mechanismen van zoutgevoelige hypertensie","title_en":"Sex-Specific Exosome Cargo Reveals Potential New Mechanisms of Salt-Sensitive Hypertension","category":"hypertensie","category_label":"Hypertensie","professions":[],"tags":["bloeddrukbehandeling","endotheel","ezetimibe","ras-remmers","renale-denervatie","semaglutide","tirzepatide","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25949","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25949","authors":["Vahideh Tarhriz"],"significance":4,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/"],"congress":"","summary_en":"This study identified sex-specific differences in circulating bacterial extracellular vesicle-derived microRNA and protein cargo in hypertensive rats, revealing potential new mechanisms underlying sex differences in salt-sensitive hypertension.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8357bd524186","type":"article","url":"https://hartvaat.nl/2025/12/15/enkelvoudige-pil-combinatietherapie-bij-hypertensie-aha-wetenschappelijk-stateme/","title":"Enkelvoudige-pil combinatietherapie bij hypertensie: AHA-wetenschappelijk statement","title_en":"Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","cardio-renaal-metabool","ras-remmers","renale-denervatie","sacubitril-valsartan","slaapapneu","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000258","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000258","authors":[],"significance":7,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This AHA scientific statement on single-pill combination therapy for hypertension reviewed the evidence supporting fixed-dose combinations as the preferred approach for improving blood pressure control at the population level.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c58f3def2278","type":"article","url":"https://hartvaat.nl/2025/12/15/m7g-methyltransferase-mettl1-bevordert-acuut-nierletsel-via-mitochondriale-disfu/","title":"m7G-methyltransferase METTL1 bevordert acuut nierletsel via mitochondriale disfunctie","title_en":"The m7G methyltransferase METTL1 promotes acute kidney inflammation by disrupting mitochondrial function","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00990-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00990-1/fulltext","authors":["Shuai-shuai Xie","Yu-hang Dong","Jian Gao","Wei Li","Long Xu","Jia-nan Wang","Ju-tao Yu","Chao Hou","Chao Li","Ying-ying Gao","Ze-hui Dong","Wen-xian Ma","Rui Hou","Shuai Sun","Ming-lu Ji","Ruo-bing He","Xiao-guo Suo","Wei-jian Ni","Jia-gen Wen","Juan Jin","Qin Yang","Hong Cai","Xiao-ming Meng"],"significance":5,"published":"2025-12-15","source_date":"2025-12-15","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This research reveals that the m7G methyltransferase METTL1 promotes acute kidney inflammation by disrupting mitochondrial function. The findings identify a new RNA modification-mediated pathway in acute kidney injury pathogenesis.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21cdbf76716a","type":"article","url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","title":"Complete Revascularisation Evaluation: meta-analyse van individuele patiëntdata","title_en":"Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)02170-1","source_url":"https://doi.org/10.1016/S0140-6736(25)02170-1","authors":["Shamir R Mehta","Denise T W Tiong","Felix Böhm","Chinthanie Ramasundarahettige","Simone Biscaglia","Gianluca Campo","Stefan James","Pieter C Smits","Daniele Giacoppo","Gerry P McCann","Amerjeet Banning","Dan Eik Høfsten","Gianni Casella","Faith R Kirabo","Helen Nguyen","David A Wood","John A Cairns","Thomas Engstrøm"],"significance":9,"published":"2025-12-13","source_date":"2025-12-13","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This individual patient data meta-analysis from the Complete Revascularisation Trialists provided definitive evidence that complete revascularization reduces cardiovascular death and MI compared with culprit-only PCI in patients with acute MI and multivessel disease. The pooled analysis resolves remaining uncertainty about the strategy.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3221113f30ad","type":"article","url":"https://hartvaat.nl/2025/12/11/ticagrelor-plus-aspirine-versus-aspirine-na-cabg-voor-acs-gerandomiseerde-trial/","title":"Ticagrelor plus aspirine versus aspirine na CABG voor ACS: gerandomiseerde trial","title_en":"Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2508026","source_url":"https://doi.org/10.1056/NEJMoa2508026","authors":["Anders Jeppsson","Stefan James","Christian H Moller","Carl Johan Malm","Magnus Dalén","Farkas Vanky","Ivy Susanne Modrau","Karl Andersen","Vesa Anttila","Gennady V Atroshchenko","Mikael Barbu","Mats Dreifaldt","Ali Imad El-Akkawi","Örjan Friberg","Tomas Gudbjartsson","Jarmo Gunn","Rune Haaverstad","Jari Halonen","Emma C Hansson","Jonas Holm","Annastiina Husso","Tatu Juvonen","Øyvind Jakobsen","Lena Jideus","Emilia Johannesson","Anna Jonsson Holmdahl","Kristjan Jonsson","Solveig Moss Kolseth","Lytfi Krasniqi","Tuomas Mäkelä","Ari Mennander","Lars-Erik Mohagen Krogstad","Sulman Rafiq","Peter Raivio","Lars Riber","Aminah Tahir","Carl Thorsen","Theis Tønnessen","Alexander Wahba","Igor Zindovic","Aldina Pivodic","Susanne J Nielsen","David Erlinge","Joakim Alfredsson","Ulrik Sartipy"],"significance":7,"published":"2025-12-11","source_date":"2025-12-11","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"This NEJM trial investigated whether adding ticagrelor to aspirin after CABG for ACS improves outcomes compared with aspirin alone, addressing the optimal antiplatelet strategy in the post-surgical setting.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18c7b1f7e736","type":"article","url":"https://hartvaat.nl/2025/12/11/pulmonale-hemodynamiek-op-hoogte-bij-hfpef/","title":"Pulmonale hemodynamiek op hoogte bij HFpEF","title_en":"Pulmonary haemodynamics and right heart function during exercise at high versus low altitude in patients with pulmonary vascular disease: a randomised crossover trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325605","source_url":"https://doi.org/10.1136/heartjnl-2024-325605","authors":["Julian Müller","Laura Mayer","Simon Raphael Schneider","Meret Bauer","Michael Furian","Konrad E Bloch","Esther I Schwarz","Mona Lichtblau","Ulrich Silvia"],"significance":5,"published":"2025-12-11","source_date":"2025-12-11","image":"","kennis":[],"congress":"","summary_en":"A randomised crossover trial investigated pulmonary haemodynamics and right heart function during exercise at high versus low altitude in patients with pulmonary vascular disease. Altitude exposure worsened haemodynamic responses, informing travel advice for these patients.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68b1d638dc33","type":"article","url":"https://hartvaat.nl/2025/12/11/klinische-fenotypen-bij-hypertensie-datagestuurde-risicostratificatie/","title":"Klinische fenotypen bij hypertensie: datagestuurde risicostratificatie","title_en":"Clinical Phenotypes in Hypertension: A Data-Driven Approach to Risk Stratification","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","dyslipidemie","gepersonaliseerde-geneeskunde","kunstmatige-intelligentie","primaire-preventie","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25187","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25187","authors":["Elisa Rauseo"],"significance":6,"published":"2025-12-11","source_date":"2025-12-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/hypertensie/witte-jas-hypertensie/"],"congress":"","summary_en":"This study used unsupervised machine learning to identify distinct clinical phenotypes within hypertension, showing that data-driven subtyping improves cardiovascular risk stratification beyond traditional blood pressure thresholds.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"413a326d2d15","type":"article","url":"https://hartvaat.nl/2025/12/11/manchetloze-bloeddrukmeting-aha-wetenschappelijk-statement/","title":"Manchetloze bloeddrukmeting: AHA-wetenschappelijk statement","title_en":"Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000254","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYP.0000000000000254","authors":[],"significance":7,"published":"2025-12-11","source_date":"2025-12-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This AHA scientific statement evaluated cuffless blood pressure measurement devices, addressing the potential and limitations of continuous, non-invasive BP monitoring technologies as alternatives to conventional cuff-based measurement.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T13:25:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a121dc1a92f3","type":"article","url":"https://hartvaat.nl/2025/12/10/invloed-van-leeftijd-geslacht-en-ras-op-testinterpretatie-bij-primair-aldosteron/","title":"Invloed van leeftijd, geslacht en ras op testinterpretatie bij primair aldosteronisme","title_en":"Impact of Age, Sex, and Race on Primary Aldosteronism Test Interpretations","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","bloeddrukbehandeling","figaro-dkd","lorundrostat","ras-remmers","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","soul-trial","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25855","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25855","authors":[],"significance":6,"published":"2025-12-10","source_date":"2025-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"This study addressed how age, sex, and race affect the interpretation of primary aldosteronism tests, essential for avoiding misdiagnosis as screening expands to all hypertensive patients under new guidelines.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c78088db2f3","type":"article","url":"https://hartvaat.nl/2025/12/10/nox4-en-metabole-stress-in-nieren-bij-zoutgevoelige-hypertensie/","title":"NOX4 en metabole stress in nieren bij zoutgevoelige hypertensie","title_en":"NADPH Oxidase 4 and Metabolic Stress in Dahl Salt-Sensitive Rat Kidneys","category":"hypertensie","category_label":"Hypertensie","professions":[],"tags":["endotheel"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25718","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25718","authors":["Satoshi Shimada"],"significance":4,"published":"2025-12-10","source_date":"2025-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This study investigated the role of NOX4-derived reactive oxygen species in shaping renal metabolic and vascular responses to high-salt intake in Dahl salt-sensitive rats, linking oxidative stress to metabolic reprogramming in salt-sensitive hypertension.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T18:38:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e2ce8989976e","type":"article","url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","title":"Nieuw bifasisch PFA-systeem versus thermale ablatie bij paroxysmaal AF","title_en":"Pulsed Field Ablation Using a Novel Biphasic Catheter vs Thermal Ablation for Paroxysmal Atrial Fibrillation: InsightPFA Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.09.1593","source_url":"https://doi.org/10.1016/j.jacc.2025.09.1593","authors":["Weidong Lin","Huimin Chu","Chuangshi Wang","Dong Chang","Xiaomeng Yin","Yuegang Wang","Chenyang Jiang","Yizhou Xu","Qiwei Liao","Jian Yang","Wenqing Zhu","Songnan Li","Weidong Gao","Yanbo Chen","Yibo Yu","Qiang Li","Hongtao Liao","Hai Deng","Wei Wei","Sijia Pu","Zhuli Guo","Dong Xu","Wei Li","Feifan Ouyang","Yumei Xue"],"significance":7,"published":"2025-12-09","source_date":"2025-12-09","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared a novel biphasic nanosecond pulsed field ablation system with thermal ablation for paroxysmal AF, finding that the next-generation PFA technology is noninferior with a favorable safety profile.","created":"2026-07-03T10:32:04Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c86e637dde6","type":"article","url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","title":"ASPREE: cardiale stress en bloeddrukmanagement bij ouderen","title_en":"Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","nt-probnp"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.076263","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.076263","authors":["Anping Cai","Antoni Bayes-Genis","Joanne Ryan","Yingqing Feng","James L Januzzi","Andrew M Tonkin","Jiazhen Zheng","Mark R Nelson","Johannes T Neumann","Robyn L Woods","Cammie Tran","Aletta E Schutte","Ambarish Pandey","Lin Yee Chen","Lin Liu","Junguo Zhang","John J McNeil","Lawrence Beilin","Hung-Fat Tes","Gianfranco Parati","Zhen Zhou"],"significance":6,"published":"2025-12-09","source_date":"2025-12-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This ASPREE post-hoc analysis examined the relationship between cardiac stress biomarkers and blood pressure management in older adults, showing that subclinical cardiac injury influences the benefit-risk balance of antihypertensive therapy.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T18:39:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4119499b360","type":"article","url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","title":"Gepersonaliseerde versus standaard DAPT-duur na PCI: gerandomiseerde trial","title_en":"Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.040","source_url":"https://doi.org/10.1016/j.jacc.2025.08.040","authors":["Raffaele Piccolo","Paolo Calabrò","Greta Carrara","Fiorenzo Simonetti","Attilio Varricchio","Tiziana Attisano","Giovanni Napolitano","Ciro De Simone","Gerardo Carpinella","Eugenio Stabile","Plinio Cirillo","Luigi Di Serafino","Gianluca Caiazzo","Tullio Tesorio","Marco Boccalatte","Bernardino Tuccillo","Marisa Avvedimento","Attilio Leone","Gennaro Galasso","Arturo Cesaro","Rocco Perrotta","Tullio Niglio","Domenico Simone Castiello","Maddalena Immobile Molaro","Luca Bardi","Alessandra Spinelli","Stefano Cristiano","Michele Bellino","Sergio Leonardi","Simone Biscaglia","Francesco Costa","Salvatore Cassese","Eugene McFadden","Dik Heg","Giulio G Stefanini","Anna Franzone","Davide Capodanno","Giovanni Esposito"],"significance":7,"published":"2025-12-09","source_date":"2025-12-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This trial compared personalized (risk-stratified) with standard DAPT duration after PCI, showing that a tailored approach based on individual bleeding and ischemic risk optimizes the benefit-harm balance of antiplatelet therapy.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f319a404dd0b","type":"article","url":"https://hartvaat.nl/2025/12/09/tweemaal-daags-clopidogrel-versus-ticagrelor-voor-korttermijn-mace-na-pci/","title":"Tweemaal daags clopidogrel versus ticagrelor voor korttermijn MACE na PCI","title_en":"Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.041","source_url":"https://doi.org/10.1016/j.jacc.2025.08.041","authors":["Abdul Hakeem","Jehangir Ali Shah","Rajesh Kumar","Asim Ali","Ahsan Ali Lakho","Hamayal Zeeshan","Muhammad Inam Uddin","Kamran Khan","Bashir Solangi","Mukesh Kumar","Mahesh Kumar","Romana Awan","Haroon Ishaq","Faiza Farooq","Ejaz Ul Haq","Abdul Hameed","Waheed A Lehri","Shakir Zada","Asif Ali","Ahsan Raza","Sobia Masood","Ahmadullah Humza","Musa Karim"],"significance":6,"published":"2025-12-09","source_date":"2025-12-09","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/rivaroxaban/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"This trial tested twice-daily clopidogrel as an alternative to ticagrelor after primary PCI for STEMI, evaluating an accelerated dosing strategy to achieve faster platelet inhibition with a widely available agent.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6b06d75bf80","type":"article","url":"https://hartvaat.nl/2025/12/08/bijdrage-van-genetische-varianten-aan-nefrolithiase/","title":"Bijdrage van genetische varianten aan nefrolithiase","title_en":"Contribution of genetic variants to nephrolithiasis","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00943-3/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00943-3/fulltext","authors":["Tilman B. Drueke","Krzysztof Kiryluk","Robert J. Unwin"],"significance":6,"published":"2025-12-08","source_date":"2025-12-08","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This review discussed the genetic contribution to nephrolithiasis, highlighting that kidney stones have cardiovascular implications through shared metabolic pathways with hypertension and CKD.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T13:25:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"464259268c1e","type":"article","url":"https://hartvaat.nl/2025/12/05/hypoxie-responsieve-trna-fragmenten-als-regulatoren-van-rna-autofagie-en-nierbes/","title":"Hypoxie-responsieve tRNA-fragmenten als regulatoren van RNA-autofagie en nierbescherming","title_en":"Small but mighty: hypoxia-responsive tRNA-derived small RNA as a novel regulator of RNA autophagy and kidney protection","category":"chronische nierziekte","category_label":"Nierziekte","professions":[],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00942-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00942-1/fulltext","authors":["Divya Bhatia","Mary E. Choi"],"significance":5,"published":"2025-12-05","source_date":"2025-12-05","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This study identifies hypoxia-responsive tRNA-derived small RNA fragments as novel regulators of RNA autophagy in kidney cells. The findings reveal a new mechanism of kidney protection through selective RNA recycling during cellular stress.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abe5c318169d","type":"article","url":"https://hartvaat.nl/2025/12/05/hyperactivatie-van-yap-in-podocyten-verstoort-de-rust-van-glomerulaire-cellen/","title":"Hyperactivatie van YAP in podocyten verstoort de rust van glomerulaire cellen","title_en":"When YAP is hyperactivated in podocytes, it persistently “yaps,” disrupting the quiescence of neighboring glomerular cells","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00934-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00934-2/fulltext","authors":["Olivia Lenoir","Pierre-Louis Tharaux"],"significance":5,"published":"2025-12-05","source_date":"2025-12-05","image":"","kennis":[],"congress":"","summary_en":"This research demonstrates that hyperactivation of YAP in podocytes disrupts the quiescence of neighbouring glomerular cells, contributing to the pathogenesis of focal segmental glomerulosclerosis and crescentic glomerulonephritis.","created":"2026-07-03T10:25:41Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef2254d4a279","type":"article","url":"https://hartvaat.nl/2025/12/03/galectine-1-herprogrammeert-macrofagen-en-moduleert-t-celimmuniteit-bij-atherosc/","title":"Galectine-1 herprogrammeert macrofagen en moduleert T-celimmuniteit bij atherosclerose","title_en":"Galectin-1 induces macrophage immunometabolic reprogramming, modulates T cell immunity and attenuates atherosclerotic plaque formation","category":"cholesterol","category_label":"Cholesterol","professions":[],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01506-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01506-0/fulltext","authors":["Ya Li","Julian Leberzammer","Xavier Blanchet","Rundan Duan","Michael Lacy","Vasiliki Triantafyllidou","Veit Eckardt","Eva Briem","Anna Simone Jung","Rui Su","Joel Guerra","Yvonne Jansen","Michael Hristov","Wolfgang Enard","Jürgen Bernhagen","Christian Weber","Dorothee Atzler","Alexander Bartelt","Yvonne Döring","Donato Santovito","Herbert Kaltner","Anna-Kristin Ludwig","Philipp von Hundelshausen"],"significance":4,"published":"2025-12-03","source_date":"2025-12-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/atherosclerose-pathofysiologie/"],"congress":"","summary_en":"This study demonstrates that galectin-1 induces macrophage immunometabolic reprogramming and modulates T-cell immunity to attenuate atherosclerotic plaque formation, providing mechanistic insight into its anti-atherogenic properties.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c2219b45ae2a","type":"article","url":"https://hartvaat.nl/2025/12/03/risicoverfijning-in-het-tijdperk-van-een-cac-score-van-nul-de-meerwaarde-van-fit/","title":"Risicoverfijning in het tijdperk van een CAC-score van nul: de meerwaarde van fitheid","title_en":"Refining risk in the power of zero era: The added value of cardiorespiratory fitness","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","calciumscore"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01505-9/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01505-9/fulltext","authors":["Ahmed Ibrahim Ahmed","Mouaz H. Al-Mallah"],"significance":4,"published":"2025-12-03","source_date":"2025-12-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This commentary discusses the added value of cardiorespiratory fitness for cardiovascular risk refinement in patients with a zero coronary artery calcium score, shifting focus from static imaging to functional capacity assessment.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64dcc6c3061c","type":"article","url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","title":"Discordantie creatinine- versus cystatine C-eGFR en klinische uitkomsten: meta-analyse","title_en":"Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["cystatine-c"],"journal":"JAMA","doi":"10.1001/jama.2025.17578","source_url":"https://doi.org/10.1001/jama.2025.17578","authors":["Michelle M Estrella","Shoshana H Ballew","Yingying Sang","Morgan E Grams","Josef Coresh","Aditya Surapaneni","Natalia Alencar de Pinho","Johan Ärnlöv","Hermann Brenner","Juan-Jesus Carrero","Teresa K Chen","Debbie L Cohen","Mary Cushman","Ron T Gansevoort","Shih-Jen Hwang","Lesley A Inker","Joachim H Ix","Keiko Kabasawa","Tsuneo Konta","Jennifer S Lees","Kevan R Polkinghorne","Michael G Shlipak","Robin W M Vernooij","David C Wheeler","Ashok Kumar Yadav","Andrew S Levey","Kai-Uwe Eckardt"],"significance":6,"published":"2025-12-02","source_date":"2025-12-02","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This meta-analysis showed that discordance between creatinine- and cystatin C-based eGFR predicts worse clinical outcomes, supporting the combined use of both markers for more accurate kidney function and risk assessment.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5ef60baae8e4","type":"article","url":"https://hartvaat.nl/2025/12/02/geindividualiseerd-perioperatief-bloeddrukmanagement-bij-grote-buikchirurgie/","title":"Geïndividualiseerd perioperatief bloeddrukmanagement bij grote buikchirurgie","title_en":"Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.17235","source_url":"https://doi.org/10.1001/jama.2025.17235","authors":["Bernd Saugel","Agnes S Meidert","Frank M Brunkhorst","Robert Bischoff","Joseph Esser","Minca Mattis","Pauline Naue","Katharina Vogel","Alina Bergholz","Moritz Flick","Alina Kröker","Dominik X Müller","Kristen K Thomsen","Christina Vokuhl","Mirja Wegge","Sebastian Bratke","Martin Graeßner","Bettina Jungwirth","Sebastian Schmid","Carla D Grundmann","Jan M Wischermann","Patrick Kellner","Moritz Steinhaus","Linda Grüßer","Sina M Coldewey","Kai Zacharowski","Patrick Meybohm","Marit Habicher","Alexander Zarbock","Amelie Zitzmann","Svenja Letz","Claudia Neumann","Jan Larmann","Thomas Renné","Linda Krause","Eik Vettorazzi","Antonia Zapf","Annemarie Carlstedt","Daniel I Sessler","Karim Kouz"],"significance":6,"published":"2025-12-02","source_date":"2025-12-02","image":"","kennis":[],"congress":"","summary_en":"This IMPACT randomized trial of individualized versus standard perioperative blood pressure management showed that personalized hemodynamic targets reduce organ injury during major abdominal surgery.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2397aa20c6e0","type":"article","url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","title":"ARTESIA: majeure bloedingen met apixaban versus aspirine — subanalyse","title_en":"Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.4151","source_url":"https://doi.org/10.1001/jamacardio.2025.4151","authors":["Deborah M Siegal","Christian Sticherling","Jeff S Healey","William F McIntyre","Lene S Christensen","Ratika Parkash","Thomas Vanassche","David Conen","Michael Gold","Christopher B Granger","Jens Cosedis Nielsen","Marc Carrier","Daniel M Wojdyla","Julia W Erath","Lena Rivard","Valentina Kutyifa","David J Wright","Renato D Lopes"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"This ARTESIA subanalysis detailed the major bleeding events with apixaban versus aspirin in subclinical AF, characterizing the bleeding types and clinical consequences that inform the anticoagulation risk-benefit discussion.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"891c0f0976b9","type":"article","url":"https://hartvaat.nl/2025/12/01/comorbiditeitsbelasting-en-uitkomsten-van-ablatie-versus-medicatie-bij-af/","title":"Comorbiditeitsbelasting en uitkomsten van ablatie versus medicatie bij AF","title_en":"Association between comorbidity burden and outcomes of catheter ablation vs. medical therapy for atrial fibrillation: insights from the CABANA trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf292","source_url":"https://doi.org/10.1093/europace/euaf292","authors":["Yang Chen","Eva Soler-Espejo","Manlin Zhao","Wenhui Li","Hongyu Liu","Ying Gue","Garry McDowell","Douglas L Packer","Gregory Y H Lip"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This analysis showed that catheter ablation maintains its benefit over medical therapy for AF regardless of comorbidity burden, supporting ablation as a treatment option even in patients with significant multimorbidity.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1c14323be15","type":"article","url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","title":"ARREST-AF: agressieve risicofactorreductie en ablatie-uitkomsten","title_en":"Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.4007","source_url":"https://doi.org/10.1001/jamacardio.2025.4007","authors":["Rajeev K Pathak","Adrian D Elliott","Dennis H Lau","Melissa E Middeldorp","Dominik Linz","John L Fitzgerald","Aashray Gupta","Jonathan P Ariyaratnam","Varun Malik","Jean Jacques Noubiap","Walter P Abhayaratna","Jonathan M Kalman","Prashanthan Sanders"],"significance":7,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/wolff-parkinson-white/"],"congress":"","summary_en":"The ARREST-AF study confirmed that aggressive risk factor reduction (weight loss, fitness improvement, sleep apnea treatment) significantly improves catheter ablation outcomes in AF patients, establishing upstream therapy as an essential adjunct to ablation.","created":"2026-07-03T10:32:03Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"532ffe416c2a","type":"article","url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","title":"ICE versus TEE bij AF-ablatie: gerandomiseerde trial","title_en":"Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.3687","source_url":"https://doi.org/10.1001/jamacardio.2025.3687","authors":["Xiaofeng Hu","Weifeng Jiang","Xinhua Wang","Ping Ye","Xiangting Li","Ying Wang","Qidong Zheng","Yanzhe Wang","Lihua Leng","Zengtang Zhang","Bing Han","Yu Zhang","Mu Qin","Xu Liu","Xumin Hou"],"significance":7,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that intracardiac echocardiography (ICE) is noninferior to transesophageal echocardiography for pre-procedural thrombus screening during AF ablation, avoiding the need for sedation or general anesthesia for TEE.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d417639eb2b1","type":"article","url":"https://hartvaat.nl/2025/12/01/lawt-geleide-pvi-bij-persisterend-af-gepersonaliseerde-benadering/","title":"LAWT-geleide PVI bij persisterend AF: gepersonaliseerde benadering","title_en":"Personalized pulmonary vein isolation guided by left atrial wall thickness for persistent atrial fibrillation ablation: the PeAF-by-LAWT randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf163","source_url":"https://doi.org/10.1093/europace/euaf163","authors":["Giulio Falasconi","Diego Penela","David Soto-Iglesias","Alessia Chiara Latini","Federico Landra","Emanuele Curti","Pietro Francia","Andrea Saglietto","Dario Turturiello","Daniel Viveros","Aldo Bellido","Jose Alderete","Fatima Zaraket","Paula Franco-Ocaña","Stefano Valcher","Francesco Amata","Chiara Valeriano","Carlo Gigante","Lucio Teresi","Bruno Tonello","Roberta Mea","Lautaro Sánchez-Mollá","Carmine De Lucia","Marina Huguet","Óscar Cámara","José-Tomás Ortiz-Pérez","Julio Martí-Almor","Antonio Berruezo"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"The PeAF-by-LAWT trial evaluated personalised pulmonary vein isolation guided by left atrial wall thickness mapping for persistent AF. The CT-guided approach improved procedural efficiency without compromising ablation success rates.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad4585612d9c","type":"article","url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","title":"Economische ziektelast van hartfalen in Europa: systematische review","title_en":"Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.70017","source_url":"https://doi.org/10.1002/ehf2.70017","authors":["Josep Darbà","Meritxell Ascanio","Antonio Rodríguez","Sarah J Charman","Nduka C Okwose","Renae J Stefanetti","Amy Groenewegen","Annamaria Del Franco","Maria Tafelmeier","Andrej Preveden","Amy S Fuller","Fatima Bano","David R Sinclair","Duncan Edwards","Anne P Nelissen","Petros N Malitas","Aikaterini Zisaki","Zoran Bosnić","Petar Vračar","Alessandra Fornaro","Fausto Barlocco","Dimitris Fotiadis","Prithwish Banerjee","Guy A MacGowan","Oscar Fernandez","José Luis Zamorano","Marta Jimenez-Blanco Bravo","Lars S Maier","Iacopo Olivotto","Massimo Milli","Frans H Rutten","Jonathan Mant","Lazar Velicki","Petar M Seferovic","Nenad Filipovic","Djordje G Jakovljevic"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"A systematic review documented the economic burden of heart failure across European healthcare systems. Costs are substantial and rising, primarily driven by hospitalisations, with prevention and ambulatory care representing more cost-effective strategies.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42a6f88f9341","type":"article","url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","title":"Intensieve bloeddrukcontrole en cerebrale small vessel disease markers","title_en":"Effect of Intensive Systolic Blood Pressure Control on Markers of Cerebral Small Vessel Disease by Age.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25202","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25202","authors":["Jeremy J Pruzin","Wai-Ying Wendy Yau","Adam P Bress","Hediyeh Bardaran","Jasmeer P Chhatwal","Pierre N Tariot","William C Cushman","Aditi Gupta","Clinton B Wright","Jeff Williamson","David M Reboussin","Nicholas M Pajewski","Ilya M Nasrallah","Kyle C Kern"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that intensive blood pressure control reduces markers of cerebral small vessel disease, with the effect present across age groups, supporting aggressive blood pressure management for brain health preservation.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"972c9d4beb6c","type":"article","url":"https://hartvaat.nl/2025/12/01/hoog-versus-laag-natrium-oxybaat-en-bloeddruk-bij-narcolepsie/","title":"Hoog versus laag natrium-oxybaat en bloeddruk bij narcolepsie","title_en":"Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25730","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25730","authors":["William B White","Richard J Kovacs","Jessica K Alexander","Christine Baranak","Deborah A Nichols","Douglas S Fuller","Jing Dai","Marisa Whalen","Akinyemi Ajayi","Barbara Hutchinson","Yves Dauvilliers","Virend K Somers"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/mineralocorticoid-antagonisten-farmacologie/"],"congress":"","summary_en":"This study compared the blood pressure effects of high- versus low-sodium oxybate in patients with narcolepsy and elevated blood pressure. The sodium load significantly influenced blood pressure, which is clinically relevant for patients with comorbid hypertension.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aba380a95fbb","type":"article","url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","title":"Istaroxime bij HF-gerelateerde cardiogene shock: hemodynamische effecten","title_en":"Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","hfpef","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15448","source_url":"https://doi.org/10.1002/ehf2.15448","authors":["Matteo Pagnesi","Gad Cotter","Beth Davison","Daniel Burkhoff","Alexander Mebazaa","Jan Biegus","Ovidiu Chioncel","Christopher Edwards","Koji Takagi","Gerasimos Filippatos","Agnieszka Tycińska","Maria Novosadova","Gaurav Gulati","Marianela Barros","Maria Luz Diaz","Carlos Guardia","Robert Zymliński","Piotr Gajewski","Piotr Ponikowski","Phillip Simmons","Steven Simonson","Marco Metra"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/cardiogene-shock/"],"congress":"","summary_en":"This SEISMiC substudy evaluated the hemodynamic effects of istaroxime in heart failure-related cardiogenic shock (SCAI stage B), showing improved cardiac contractility and diastolic function with this novel luso-inotropic agent.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0578f7e66216","type":"article","url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","title":"SCAI-shockklassen en prognose bij AMI-cardiogene shock: DanGer substudie","title_en":"Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15446","source_url":"https://doi.org/10.1002/ehf2.15446","authors":["Janine Pöss","Jacob Jentzer","Steffen Desch","Hans-Josef Feistritzer","Anne Freund","Michelle Roßberg","Christian Jung","Taoufik Ouarrak","Steffen Schneider","Ibrahim Akin","Tienush Rassaf","Tharusan Thevathasan","Uwe Zeymer","Holger Thiele"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"This DanGer Shock substudy showed that SCAI shock classification modifies the treatment effect of Impella CP, with the device providing the greatest survival benefit in patients with the most severe hemodynamic compromise.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T13:31:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8d9988eb018","type":"article","url":"https://hartvaat.nl/2025/12/01/tijd-in-streefwaarde-van-bloeddruk-en-acute-nierschade-bij-hypertensie/","title":"Tijd-in-streefwaarde van bloeddruk en acute nierschade bij hypertensie","title_en":"Systolic Blood Pressure Time in Target Range and Acute Kidney Injury in Patients With Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","bradycardie","perifeer-vaatlijden","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25511","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25511","authors":["Wei-Hua Chen","Cheng Yang","Yi-Tian Chen","Zi-Jin Li","Kai Guan","Jian-Jun Li","Rong-Chong Huang"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"A SPRINT post-hoc analysis examined the association between systolic blood pressure time in target range and acute kidney injury risk. Greater time in the target range was associated with kidney protection, supporting TTR as a quality metric for blood pressure management.","created":"2026-07-03T10:32:02Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2955a9d83fa1","type":"article","url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","title":"Intensieve bloeddrukverlaging bij ongediagnosticeerde HFpEF met hoog risico","title_en":"Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hfpef","step-hfpef","summit-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15435","source_url":"https://doi.org/10.1002/ehf2.15435","authors":["Xinru Liu","Zhiyan Wang","Chang Hua","Yanfang Wu","Yangyang Tang","Yuling Xiong","Jingwei Liu","Jiaqi Zhang","Qiang Lv","Chao Jiang","Jianzeng Dong","Xin Du"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that intensive blood pressure lowering benefits patients with undiagnosed HFpEF, suggesting that screening for subclinical preserved ejection fraction heart failure can identify those who benefit most from aggressive treatment.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ae0e26a220c","type":"article","url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","title":"Gelijktijdige griep- en RSV-vaccinatie bij hoogrisico hartfalenpatiënten","title_en":"Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15432","source_url":"https://doi.org/10.1002/ehf2.15432","authors":["Jan Biegus","Leszek Szenborn","Michał Tkaczyszyn","Robert Zymlinski","Gad Cotter","Michał Zakliczynski","Krzysztof Reczuch","Mateusz Guzik","Szymon Urban","Marta Rosiek-Biegus","Berenika Jankowiak","Gracjan Iwanek","Marta Wleklik","Marat Fudim","Piotr Ponikowski"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"A prospective randomised study evaluated simultaneous influenza and RSV vaccination in high-risk heart failure patients. The co-vaccination strategy was safe and effective, potentially improving vaccine uptake in this vulnerable population.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc8cfdc8afe4","type":"article","url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","title":"Geografische variatie in HFrEF: patiëntkenmerken en behandeling","title_en":"Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15416","source_url":"https://doi.org/10.1002/ehf2.15416","authors":["Cynthia M Westerhout","Wendimagegn Alemayehu","Alain Cohen-Solal","Carolyn S P Lam","Justin A Ezekowitz","Stefano Corda","Ciaran J McMullan","Christopher M O'Connor","Paul W Armstrong"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"Analysis of the VICTORIA trial documented geographic variation in HFrEF patient characteristics, guideline-directed therapy implementation, and clinical outcomes across world regions. Substantial regional differences in GDMT use highlight the need for targeted implementation strategies.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6aee26632197","type":"article","url":"https://hartvaat.nl/2025/12/01/supar-en-uitkomsten-bij-hfpef-topcat-subanalyse/","title":"suPAR en uitkomsten bij HFpEF: TOPCAT subanalyse","title_en":"Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15423","source_url":"https://doi.org/10.1002/ehf2.15423","authors":["Christina G Hutten","Annika Tekumulla","Anis Ismail","Alexi Vasbinder","Theresa Farhat","Pennelope Kunkle","Sascha N Goonewardena","Ahmed Abdel-Latif","Bertram Pitt","Salim S Hayek"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"A TOPCAT ancillary study evaluated soluble urokinase plasminogen activator receptor as a biomarker in HFpEF. Elevated suPAR levels predicted adverse outcomes independently of NT-proBNP, supporting its role as an inflammatory prognostic marker.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f33da3ced546","type":"article","url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","title":"Dapagliflozine na MI naar EF: cardiometabole uitkomsten","title_en":"Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","emperor-trials"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15420","source_url":"https://doi.org/10.1002/ehf2.15420","authors":["David Erlinge","Stefan James","John Deanfield","Niclas Eriksson","Mark de Belder","Monér Alchay","David Austin","Daniel A Jones","Annica Ravn-Fischer","Sofia Sederholm Lawesson","Nikunj Shah","Julian W Strange","Karolina Szummer","Wilhelm Ridderstråle","Ehsan Parvaresh Rizi","Anna Maria Langkilde","Peter A Johansson","Darren K McGuire","Jonas Oldgren","Robert F Storey"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"Analysis of DAPA-MI assessed dapagliflozin after acute MI stratified by baseline ejection fraction. The cardiometabolic benefit was more pronounced at lower EF values, consistent with the established heart failure indication for SGLT2 inhibitors.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"494a5767b391","type":"article","url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","title":"Empagliflozine na MI met en zonder diabetes en CKD: EMPACT-MI subanalyse","title_en":"Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte","dapagliflozine","empagliflozine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15393","source_url":"https://doi.org/10.1002/ehf2.15393","authors":["Francesco Fioretti","Javed Butler","Jacob A Udell","W Schuyler Jones","Mark C Petrie","Josephine Harrington","Michaela Mattheus","Johann Bauersachs","Antoni Bayes-Genis","Shaun G Goodman","Tomasz Gasior","James L Januzzi","Renato D Lopes","Piotr Ponikowski","Xavier Rossello","Morten Schou","Peter van der Meer","Dragos Vinereanu","Shelley Zieroth","Martina Brueckmann","Mikhail Sumin","Deepak L Bhatt","Adrian F Hernandez","Stefan D Anker"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":[],"congress":"","summary_en":"An EMPACT-MI subanalysis examined empagliflozin after acute myocardial infarction stratified by diabetes and chronic kidney disease status. The heart failure benefit was concentrated in higher-risk subgroups, refining the potential indication for post-MI SGLT2 inhibition.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63529231be27","type":"article","url":"https://hartvaat.nl/2025/12/01/re-perfuse-relaxinereceptoragonist-en-renale-perfusie-bij-hfref-fase-1b/","title":"Re-PERFUSE: relaxinereceptoragonist en renale perfusie bij HFrEF — fase 1b","title_en":"Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["renale-denervatie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15412","source_url":"https://doi.org/10.1002/ehf2.15412","authors":["Marcin Ufnal","Macarena P Quintana-Hayashi","Kathleen Connolly","Daniel Pettersen","Zsolt Cselényi","Aurelija Jucaite","Magnus Schou","Andrea Varrone","Melanie Chan","Lars H Lund"],"significance":6,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The Re-PERFUSE phase 1b study of AZD3427, a novel relaxin receptor agonist, showed improved renal perfusion in HFrEF, exploring a new mechanism for addressing the cardiorenal syndrome.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31bb83f588e5","type":"article","url":"https://hartvaat.nl/2025/12/01/hartrevalidatie-en-kwaliteit-van-leven-bij-hfpef-meta-analyse/","title":"Hartrevalidatie en kwaliteit van leven bij HFpEF: meta-analyse","title_en":"Cardiac rehabilitation and health-related quality of life in preserved ejection fraction heart failure: A meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15404","source_url":"https://doi.org/10.1002/ehf2.15404","authors":["Chenyao Ding","Yawen Gao","Rod S Taylor"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A meta-analysis confirmed that exercise-based cardiac rehabilitation improves health-related quality of life in patients with HFpEF. Exercise remains a cornerstone of HFpEF management with consistent benefits across outcome domains.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5c311437847","type":"article","url":"https://hartvaat.nl/2025/12/01/hfpef-fenotypen-in-device-en-chirurgische-trials-karakterisatie/","title":"HFpEF-fenotypen in device- en chirurgische trials: karakterisatie","title_en":"Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15401","source_url":"https://doi.org/10.1002/ehf2.15401","authors":["Kurdo Araz","Francesco Fioretti","Sara Ladak","Mohammed Obaidan","Javed Butler","Aamir Hameed"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"A systematic review characterised HFpEF phenotypes enrolled in medical device and surgical trials. The heterogeneity of HFpEF requires phenotype-specific treatment strategies, with devices targeting specific pathophysiological mechanisms.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a6f1afe8427a","type":"article","url":"https://hartvaat.nl/2025/11/28/sekseverschillen-in-mortaliteit-en-hospitalisatie-bij-hartfalenpatienten/","title":"Sekseverschillen in mortaliteit en hospitalisatie bij hartfalenpatiënten","title_en":"Sex differences in mortality and hospitalisation in heart failure patients: sex differences in heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","delirium-cardiologie","harttransplantatie","hfpef","hfref","nierfalen","plotse-hartdood","step-hfpef"],"journal":"Cardiovascular journal of Africa","doi":"10.5830/CVJA-2025-083","source_url":"https://doi.org/10.5830/CVJA-2025-083","authors":["Ahmet Genç","Gülsüm Meral Yılmaz Öztekin"],"significance":3,"published":"2025-11-28","source_date":"2025-11-28","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This study examined clinical and demographic characteristics and mortality differences between male and female patients hospitalised with heart failure with reduced ejection fraction in a South African setting.","created":"2026-07-03T10:25:37Z","updated":"2026-07-03T18:38:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1bbac8fce1cd","type":"article","url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","title":"Vroege aspirinestop na PCI bij laagrisico acuut MI","title_en":"Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2508808","source_url":"https://doi.org/10.1056/NEJMoa2508808","authors":["Giuseppe Tarantini","Benjamin Honton","Valeria Paradies","Gilles Lemesle","Gregoire Range","Matthieu Godin","Lionel Mangin","Thomas Cuisset","Juan M Ruiz-Nodar","Salvatore Brugaletta","Thibault Lhermusier","Christophe Piot","Fabien De Poli","Jean-Christophe Macia","Pascal Motreff","Maribel Madera-Cambero","Farzin Beygui","Philippe Riccini","Sylvain Ranc","Jacopo A Oreglia","Beatriz Vaquerizo","Yann Poezevara","David Bouchez","Pieter C Smits","Guillaume Cayla"],"significance":7,"published":"2025-11-27","source_date":"2025-11-27","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This trial specifically studied early aspirin discontinuation in low-risk acute MI patients after PCI, showing the strategy is safe and cost-effective, extending the de-escalation approach to the broadest AMI population.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c66c6c39d07","type":"article","url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","title":"Vroege aspirinestop na PCI bij ACS: gerandomiseerde trial","title_en":"Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2507980","source_url":"https://doi.org/10.1056/NEJMoa2507980","authors":["Patricia O Guimarães","Marcelo Franken","Caio A M Tavares","Murillo O Antunes","Fabio S Silveira","Pedro B Andrade","Ricardo R Bergo","Rodrigo M Joaquim","João E Tinoco de Paula","Bruno R Nascimento","Fabio G Pitta","José A Arruda","Renato G Serpa","Louis N Ohe","Fernanda M Mangione","Remo H M Furtado","Esmeralci Ferreira","Fernanda B A Sampaio","Charlene T do Nascimento","Luiz O O Genelhu","Cristiano G Bezerra","Rogério Sarmento-Leite","Lilia N Maia","Flavio R A Oliveira","Marco V Wainstein","Frederico T C Dall'Orto","Frederico Monfardini","Silvia R L Assis","José C Nicolau","Andrei C Sposito","Renato D Lopes","Yoshinobu Onuma","Marco Valgimigli","Dominick J Angiolillo","Patrick W J C Serruys","Otavio Berwanger","Fernando Bacal","Pedro A Lemos"],"significance":7,"published":"2025-11-27","source_date":"2025-11-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This randomized trial confirmed that early aspirin withdrawal after PCI in ACS is safe with significantly less bleeding, providing the latest and largest evidence for the P2Y12 monotherapy de-escalation strategy.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d521dc17a6a","type":"article","url":"https://hartvaat.nl/2025/11/26/lipideveranderingen-bij-vrouwen-met-fh-tijdens-de-menopauzale-transitie/","title":"Lipideveranderingen bij vrouwen met FH tijdens de menopauzale transitie","title_en":"Lipid changes in females with familial hypercholesterolemia during the menopausal transition period","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","menopauze","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01485-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01485-6/fulltext","authors":["Gia V. Da Roza","Lubomira Cermakova","Jeanine Roeters van Lennep","Kirsten B. Holven","Iulia Iatan","Liam R. Brunham"],"significance":5,"published":"2025-11-26","source_date":"2025-11-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"This study investigated lipid profile changes in women with familial hypercholesterolaemia during the menopausal transition. The findings inform lipid-lowering therapy adjustments during this critical period of hormonal and metabolic change.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6bdb1e67bb7b","type":"article","url":"https://hartvaat.nl/2025/11/25/frequente-pvc-s-en-risico-op-af-hf-cva-en-sterfte/","title":"Frequente PVC's en risico op AF, HF, CVA en sterfte","title_en":"Frequent premature ventricular complexes and risk of atrial fibrillation, heart failure, stroke and mortality: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["slaapapneu"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-326174","source_url":"https://doi.org/10.1136/heartjnl-2025-326174","authors":["Mustafa Eray Kiliç","Mehmet Emin Arayici","Resit Yigit Yilancioglu","Oguzhan Ekrem Turan","Emin Evren Ozcan","Mehmet Birhan Yilmaz"],"significance":6,"published":"2025-11-25","source_date":"2025-11-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"This study documented the increased risks of AF, heart failure, stroke, and mortality associated with frequent premature ventricular complexes, establishing high PVC burden as a clinically significant arrhythmia marker.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c146c2c08b1","type":"article","url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","title":"ABC-AF risicoscores voor gepersonaliseerde AF-behandeling","title_en":"Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.076725","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.076725","authors":["Jonas Oldgren","Ziad Hijazi","Håkan Arheden","Anna Björkenheim","Viveka Frykman","Magnus Janzon","Annica Ravn-Fischer","Henrik Renlund","Anders Själander","Torbjörn Åkerfeldt","Lars Wallentin"],"significance":6,"published":"2025-11-25","source_date":"2025-11-25","image":"","kennis":[],"congress":"","summary_en":"This study validated biomarker-based ABC-AF risk scores for personalized treatment decisions in AF, showing that prospective application of these scores improves clinical outcomes compared with standard care.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f682915a435d","type":"article","url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","title":"Amphilimus versus zotarolimus-eluting stent bij diabetes en coronairlijden","title_en":"Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-325773","source_url":"https://doi.org/10.1136/heartjnl-2025-325773","authors":["Pablo Salinas","Rafael Romaguera","Josep Gómez-Lara","Salvatore Brugaletta","Antonio Gómez-Menchero","Pedro Martín","Miguel Romero","Sergio García-Blas","Marcelo Jiménez","Victor A Jiménez","Pascual Bordes","Jeremías Bayón","Neus Salvatella","Mar Alameda","Dae Hyun-Lee","Ramiro Trillo-Nouche","María López-Benito","Araceli Frutos","José Moreu","Bruno García Del Blanco","Mohsen Mohandes","Francisco Bosa Ojeda","Felipe Hernández Hernández","Eduardo Pinar-Bermúdez","Pilar Jiménez-Quevedo","Xavier Rosselló","Stuart Pocock","Manel Sabaté","Joan Antoni Gómez-Hospital","Josep Comin-Colet","Nieves Gonzalo","Antonio Fernández Ortiz"],"significance":5,"published":"2025-11-25","source_date":"2025-11-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The SUGAR trial compared amphilimus-eluting and zotarolimus-eluting stents in patients with diabetes mellitus undergoing PCI over extended follow-up. Both stent platforms demonstrated comparable target lesion failure rates in this high-risk population.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80706ad15622","type":"article","url":"https://hartvaat.nl/2025/11/20/kaliumverhoging-bij-hoogrisicopatienten-voor-ventriculaire-aritmieen-rct/","title":"Kaliumverhoging bij hoogrisicopatiënten voor ventriculaire aritmieën: RCT","title_en":"Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["cardiale-resynchronisatie","supraventriculaire-tachycardie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2509542","source_url":"https://doi.org/10.1056/NEJMoa2509542","authors":["Christian Jøns","Chaoqun Zheng","Ulrik C G Winsløw","Elisabeth M Danielsen","Tharsika Sakthivel","Emil A Frandsen","Hillah Saffi","Sadjedeh S Vakilzadeh-Hashemi","Ketil J Haugan","Niels E Bruun","Kasper K Iversen","Helle S Bosselmann","Niels Risum","Henning Bundgaard"],"significance":7,"published":"2025-11-20","source_date":"2025-11-20","image":"","kennis":[],"congress":"","summary_en":"This randomized trial investigated whether potassium supplementation targeting higher serum levels reduces ventricular arrhythmias in high-risk cardiovascular patients, testing the electrophysiological benefit of correcting even mild hypokalemia.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ab591104654","type":"article","url":"https://hartvaat.nl/2025/11/20/afbouw-van-antihypertensieve-behandeling-bij-verpleeghuisbewoners-rct/","title":"Afbouw van antihypertensieve behandeling bij verpleeghuisbewoners: RCT","title_en":"Reduction of Antihypertensive Treatment in Nursing Home Residents.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2508157","source_url":"https://doi.org/10.1056/NEJMoa2508157","authors":["Athanase Benetos","Sylvie Gautier","Anne Freminet","Alice Metz","Carlos Labat","Ioannis Georgiopoulos","François Bertin-Hugault","Jean-Baptiste Beuscart","Olivier Hanon","Patrick Karcher","Patrick Manckoundia","Jean-Luc Novella","Abdourahmane Diallo","Eric Vicaut","Patrick Rossignol"],"significance":7,"published":"2025-11-20","source_date":"2025-11-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This randomized trial showed that careful reduction of antihypertensive medications in nursing home residents is safe, with blood pressure remaining adequately controlled in the majority. The result supports deprescribing in the most frail elderly population.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4051dab272d3","type":"article","url":"https://hartvaat.nl/2025/11/20/primair-aldosteronisme-kleine-molecuulantagonisten-van-gemuteerde-kcnj5-kaliumka/","title":"Primair aldosteronisme: kleine molecuulantagonisten van gemuteerde KCNJ5-kaliumkanalen","title_en":"Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","internist"],"tags":["lorundrostat","mra-aldosteronantagonisten","spironolacton"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25360","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25360","authors":["Sanas Mir"],"significance":5,"published":"2025-11-20","source_date":"2025-11-20","image":"","kennis":[],"congress":"","summary_en":"This study identified small molecule compounds that specifically antagonise mutant KCNJ5 potassium channels responsible for aldosterone overproduction in a subset of aldosterone-producing adenomas. The findings represent a step toward targeted pharmacotherapy for primary aldosteronism.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4dbc0754934d","type":"article","url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","title":"Sekseverschillen in semaglutide-effect bij PAD: STRIDE-subanalyse","title_en":"Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.046","source_url":"https://doi.org/10.1016/j.jacc.2025.08.046","authors":["Subodh Verma","Andrei-Mircea Catarig","Kim Houlind","Bernhard Ludvik","Joakim Nordanstig","Neda Rasouli","Harald Sourij","Sebastian Thomas","Sidse K Nørgaard","Marc P Bonaca"],"significance":5,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"A STRIDE trial subanalysis examined sex differences in the effectiveness of semaglutide for peripheral artery disease with type 2 diabetes. The functional and quality-of-life benefits were comparable between men and women.","created":"2026-07-03T10:32:00Z","updated":"2026-07-03T13:30:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"07fbdcdb2046","type":"article","url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","title":"CV-effecten en verdraagbaarheid van GLP-1-agonisten: meta-analyse","title_en":"Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","farmaco-economie","fidelity","figaro-dkd","gepersonaliseerde-geneeskunde","glp1-agonisten","glp1-semaglutide-cardiovasculair","laminopathie","lipidenverlaging","liraglutide","obesitas","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.027","source_url":"https://doi.org/10.1016/j.jacc.2025.08.027","authors":["Mattia Galli","Stefano Benenati","Claudio Laudani","Beatrice Simeone","Gianmarco Sarto","Luis Ortega-Paz","Erica Rocco","Marco Bernardi","Luigi Spadafora","Domenico D'Amario","Ernesto Greco","Giacomo Frati","Massimo Federici","Roxana Mehran","Filippo Crea","Dominick J Angiolillo","Sebastiano Sciarretta"],"significance":7,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This comprehensive meta-analysis of 9 GLP-1 receptor agonist trials summarized all cardiovascular effects and tolerability data, confirming the class-wide benefit on MACE, heart failure, and kidney outcomes with a defined side effect profile.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"532db5ca7913","type":"article","url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","title":"DAPA ACT HF-TIMI 68: dapagliflozine bij gehospitaliseerd hartfalen — NEJM","title_en":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["dapa-hf","dapagliflozine","empagliflozine","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.076575","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.076575","authors":["David D Berg","Siddharth M Patel","Paul M Haller","Abby L Cange","Michael G Palazzolo","Andrea Bellavia","Julia F Kuder","Akshay S Desai","Silvio E Inzucchi","John J V McMurray","Eileen O'Meara","Subodh Verma","Jan Bělohlávek","Jarosław Drożdż","Béla Merkely","Modele O Ogunniyi","Tomáš Drasnar","Joseph L Izzo","Balazs Sarman","John E McGinty","Krishnan Ramanathan","Angel J Mulkay","Andrzej Przybylski","Christian T Ruff","Michelle L O'Donoghue","Sabina A Murphy","Marc S Sabatine","Stephen D Wiviott"],"significance":9,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The DAPA ACT HF-TIMI 68 trial showed that dapagliflozin initiated during heart failure hospitalization was safe and reduced heart failure events. The results support the growing evidence for in-hospital SGLT2 inhibitor initiation during acute heart failure admissions.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f884f76d1067","type":"article","url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","title":"Adipositas-gerelateerde antropometrie en uitkomsten bij HFmrEF/HFpEF","title_en":"Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.012","source_url":"https://doi.org/10.1016/j.jacc.2025.08.012","authors":["John W Ostrominski","Mats C Højbjerg Lassen","Jawad H Butt","Brian L Claggett","Inder S Anand","Akshay S Desai","Pardeep S Jhund","Carolyn S P Lam","Marc A Pfeffer","Bertram Pitt","Faiez Zannad","Michael R Zile","Milton Packer","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":5,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":[],"congress":"","summary_en":"A participant-level pooled analysis of five HFmrEF/HFpEF trials examined the prognostic value of different adiposity measures. Central adiposity measures were stronger predictors of adverse outcomes than BMI alone, supporting waist-based assessment in heart failure.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1c900ddb732","type":"article","url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","title":"2025 ACC Scientific Statement: obesitasmanagement bij hartfalen","title_en":"2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.008","source_url":"https://doi.org/10.1016/j.jacc.2025.05.008","authors":["Michelle M Kittleson","Emelia J Benjamin","Vanessa Blumer","Josephine Harrington","James L Januzzi","John J V McMurray","Amanda R Vest"],"significance":8,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"This ACC scientific statement provided a structured framework for obesity management in adults with heart failure, integrating evidence on GLP-1 receptor agonists, tirzepatide, and bariatric surgery as disease-modifying interventions for the obesity-heart failure phenotype.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5aa9b979fe25","type":"article","url":"https://hartvaat.nl/2025/11/18/monocyten-hun-verdiende-erkenning-geven-cd47-sirp-herkadert-allograaftstoting/","title":"Monocyten hun verdiende erkenning geven: CD47-SIRPα herkadert allograaftstoting","title_en":"Giving monocytes their due: how CD47–SIRP-α reframes allograft rejection","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00877-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00877-4/fulltext","authors":["Lennie Messager","Baptiste Lamarthée"],"significance":5,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":[],"congress":"","summary_en":"This commentary discusses how the CD47-SIRPa axis reframes the understanding of monocyte-mediated allograft rejection. Despite decades of innovation targeting adaptive immunity, long-term graft survival has stagnated, highlighting the overlooked role of innate immune mechanisms in transplant rejection.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ff1a5195ce9","type":"article","url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","title":"Nierfunctietrajecten vóór en na hospitalisatie voor HFrEF","title_en":"Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf457","source_url":"https://doi.org/10.1093/eurheartj/ehaf457","authors":["Masatake Kobayashi","Antoni Bayes-Genis","Kevin Duarte","John J V McMurray","João Pedro Ferreira","Stuart J Pocock","Dirk J Van Veldhuisen","Josep Lupón","Bertram Pitt","Faiez Zannad","Nicolas Girerd"],"significance":5,"published":"2025-11-14","source_date":"2025-11-14","image":"","kennis":[],"congress":"","summary_en":"Using individual patient data from clinical trials and a real-world cohort, this study characterised kidney function trajectories before and after heart failure hospitalisation in HFrEF. Distinct trajectory patterns carried different prognostic implications, informing personalised nephrological management.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4038b265a032","type":"article","url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","title":"Bètablokkers na MI bij patiënten zonder hartfalen: definitieve trial","title_en":"Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bisoprolol","carvedilol"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2505985","source_url":"https://doi.org/10.1056/NEJMoa2505985","authors":["John Munkhaugen","Anna Meta D Kristensen","Sigrun Halvorsen","Therese Holmager","Michael Hecht Olsen","Arnhild Bakken","Thomas S G Sehested","Vidar Ruddox","Michael Mæng","Kjell Vikenes","Svend E Jensen","Terje Steigen","Jess Lambrechtsen","Jarle Jortveit","Ann Bovin","Henrik Schirmer","Morten Krogh Christiansen","Rune Wiseth","Dennis Mikkelsen","Alf Inge Larsen","Camilla Lyngby Kjærgaard","Kristoffer Andresen","Ida Gustafsson","Vegard Tuseth","Mogens Lytken Larsen","Peter Stefan Deeg","Karsten Veien","Ellen Bøhmer","Hans Erik Bøtker","Anja Otrebska Brattrud","Jens Brønnum-Schou","Alf-Åge Reistad Pettersen","Lia Evi Bang","Erik Øie","Thomas Engstrøm","Eva Bostad Borg","Kjeld Kristensen","Ståle Haugset Nymo","Gunnar Gislason","Nils Tore Vethe","Jawdat Abdul Majid Abdulla","Toril Dammen","Mette Rauhe Mouridsen","Bjørn Bendz","Mette Lykke Norgaard Bertelsen","Jens Dahlgaard Hove","Louise Schierbeck","Martin Snoer","Cedric Davidsen","Gro Egholm","Kristian Korsgaard Thomsen","Ghassan Jadou","Monica Poenaru","Nikolaj Thure Krarup","Morten Böttcher","Peter Bisgaard Stæhr","Ann-Dorthe Zwisler","Thor Edvardsen","Christian Torp-Pedersen","Jan Erik Otterstad","Theis Lange","Morten W Fagerland","Dan Atar","Eva Prescott"],"significance":9,"published":"2025-11-13","source_date":"2025-11-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This additional definitive trial confirmed that beta-blockers after MI in patients without heart failure do not reduce cardiovascular events or mortality. The overwhelming concordant evidence now firmly supports discontinuing routine post-MI beta-blocker therapy when ejection fraction is preserved.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e9586726cd2","type":"article","url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","title":"Bètablokkers na MI zonder gereduceerde EF: definitieve meta-analyse","title_en":"Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2504735","source_url":"https://doi.org/10.1056/NEJMoa2504735","authors":["Borja Ibanez","Roberto Latini","Xavier Rossello","Alberto Dominguez-Rodriguez","Felipe Fernández-Vazquez","Valentina Pelizzoni","Pedro L Sánchez","Manuel Anguita","José A Barrabés","Sergio Raposeiras-Roubín","Stuart Pocock","Noemí Escalera","Lidia Staszewsky","Carlos Nicolás Pérez-García","Pablo Díez-Villanueva","Jose-Angel Pérez-Rivera","Oscar Prada-Delgado","Ruth Owen","Gonzalo Pizarro","Onofre Caldes","Sandra Gómez-Talavera","José Tuñón","Matteo Bianco","Jesus Zarauza","Alfredo Vetrano","Ana Campos","Susana Martínez-Huertas","Héctor Bueno","Miguel Puentes","Giulietta Grigis","Juan L Bonilla-Palomas","Elvira Marco","José R González-Juanatey","Roi Bangueses","Carlos González-Juanatey","Ana García-Álvarez","Juan Ruiz-García","Anna Carrasquer","Juan C García-Rubira","Domingo Pascual-Figal","Carlos Tomás-Querol","J Alberto San Román","Pasquale Baratta","Jaume Agüero","Roberto Martín-Reyes","Furio Colivicchi","Rosario Ortas-Nadal","Pablo Bazal","Alberto Cordero","Antonio Fernández-Ortiz","Pierangelo Basso","Eva González","Fabrizio Poletti","Giulia Bugani","Marzia Debiasio","Deborah Cosmi","Alessandro Navazio","Javier Bermejo","Giovanni Tortorella","Marco Marini","Javier Botas","José M de la Torre-Hernández","Filippo Ottani","Valentín Fuster"],"significance":9,"published":"2025-11-13","source_date":"2025-11-13","image":"","kennis":[],"congress":"","summary_en":"This definitive meta-analysis confirmed that beta-blockers after myocardial infarction without reduced ejection fraction provide no cardiovascular benefit. Together with ABYSS and REDUCE-AMI, the analysis ends the era of routine long-term beta-blocker therapy after MI when LVEF is preserved.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6b583d3d4a2","type":"article","url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","title":"Risicostratificatie met hoog-sensitief troponine op de SEH: veiligheidsanalyse","title_en":"Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["troponine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.059","source_url":"https://doi.org/10.1016/j.jacc.2025.08.059","authors":["Ziwen Li","Dimitrios Doudesis","Anda Bularga","Ryan Wereski","Caelan Taggart","Matthew T H Lowry","Andrew R Chapman","Chris Tuck","Amy V Ferry","Alasdair Gray","David E Newby","Atul Anand","Kuan Ken Lee","Nicholas L Mills"],"significance":6,"published":"2025-11-11","source_date":"2025-11-11","image":"","kennis":[],"congress":"","summary_en":"This study confirmed that risk stratification using high-sensitivity troponin in the emergency department safely identifies patients who can be discharged early, reducing unnecessary hospitalization for suspected ACS.","created":"2026-07-03T10:31:59Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f68028980dfa","type":"article","url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","title":"FFR-geleide complete versus culprit-only revascularisatie bij NSTEMI","title_en":"Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.16189","source_url":"https://doi.org/10.1001/jama.2025.16189","authors":["Tobias F S Pustjens","Leo Veenstra","Cyril Camaro","Alexander W Ruiters","Árpad Lux","Zoltán Ruzsa","Zsolt Piroth","Mustafa Ilhan","Jindrich Vainer","Ben Gho","Patty J C Winkler","Mera Stein","Ralph A L J Theunissen","Petr Kala","Jawed Polad","Balázs Berta","Andrea Gabrio","Niels van Royen","Arnoud W J van 't Hof","Saman Rasoul"],"significance":7,"published":"2025-11-11","source_date":"2025-11-11","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This randomized trial showed that FFR-guided complete revascularization in NSTEMI reduces unnecessary stenting while maintaining comparable clinical outcomes to culprit-only PCI, extending physiologically guided intervention to the NSTEMI setting.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e9a72b40c6a3","type":"article","url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","title":"CT-angiografie of standaardzorg na PCI van de linker hoofdstam","title_en":"Computed Tomography Angiography or Standard Care After Left Main PCI?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-ct-angiografie","perifeer-vaatlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.060","source_url":"https://doi.org/10.1016/j.jacc.2025.07.060","authors":["Fabrizio D'Ascenzo","Enrico Cerrato","Ovidio De Filippo","Luca Gaido","Alfonso Franzè","Mario Iannaccone","Wojciech Wańha","Andrea Santarelli","Vincenzo Guiducci","Umberto Barbero","Carlos Fernandez Pereira","Marco Gatti","Matteo Tebaldi","Massimo Giammaria","Giacomo Boccuzzi","Wojciech Wojakowski","Gianluca di Pietro","Roberto Placido","Sebastiano Gili","Alessandro Depaoli","Giuseppe Biondi Zoccai","Francesco Tomassini","Francesco Bruno","Daniela Zugna","Riccardo Faletti","Simone Biscaglia","Serena Caglioni","Ferdinando Varbella","Gaetano Maria de Ferrari","Gianluca Campo"],"significance":6,"published":"2025-11-11","source_date":"2025-11-11","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This study evaluated routine CT angiography surveillance after left main PCI, testing whether imaging follow-up can detect stent failure early and improve long-term outcomes.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb335b865e4d","type":"article","url":"https://hartvaat.nl/2025/11/10/hoog-gedoseerd-griepvaccin-vermindert-cardiovasculaire-events-bij-ouderen/","title":"Hoog gedoseerd griepvaccin vermindert cardiovasculaire events bij ouderen","title_en":"High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["ouderen","select-trial"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077801","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077801","authors":["Niklas Dyrby Johansen"],"significance":8,"published":"2025-11-10","source_date":"2025-11-10","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This FLUNITY-HD pooled analysis of over 466,000 older adults demonstrated that high-dose influenza vaccine provides superior cardiovascular protection compared with standard-dose vaccine. The data support preferential use of high-dose formulations in elderly patients with cardiovascular disease.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b0caa7f960e","type":"article","url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","title":"HOST-REDUCE: DAPT na PCI naar bloedingsrisico","title_en":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01571-5","source_url":"https://doi.org/10.1016/S0140-6736(25)01571-5","authors":["Jeehoon Kang","Kyung Woo Park","Jung-Kyu Han","Doyeon Hwang","Han-Mo Yang","Sungjoon Park","Hyo-Suk Ahn","Kyung-Kuk Hwang","Byung Gyu Kim","Jin-Ok Jeong","Jong-Hwa Ahn","Jay Young Rhew","Hanbit Park","Tae Soo Kang","Jin-Sin Koh","Kyung-Taek Park","Duk Won Bang","Choong-Won Goh","Hyuck-Jun Yoon","Sang-Ho Jo","Ji Yong Jang","Young Jin Choi","Sang Rok Lee","Young-Hyo Lim","Hyo-Soo Kim"],"significance":7,"published":"2025-11-08","source_date":"2025-11-08","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The HOST-BR trial investigated optimal DAPT duration after PCI stratified by bleeding risk, demonstrating that risk-stratified antiplatelet duration optimizes the balance between ischemic protection and bleeding prevention.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7c0e29b1958a","type":"article","url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","title":"CRRF-PeAF: cryoballon versus RF-ablatie bij persisterend AF","title_en":"Cryoballoon vs radiofrequency ablation in persistent atrial fibrillation: the CRRF-PeAF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf451","source_url":"https://doi.org/10.1093/eurheartj/ehaf451","authors":["Koji Miyamoto","Koshiro Kanaoka","Kenji Yodogawa","Yuhi Fujimoto","Hiroshi Fukunaga","So Asano","Takahiko Nagase","Muryo Terasawa","Takahiro Kusume","Yasuyuki Takada","Ken Takarada","Yuichiro Sagawa","Takatoshi Shigeta","Junichi Ooka","Masahiro Ishikura","Masue Yoh","Hiroki Takahashi","Yuko Inoue","Satoshi Nagase","Takeshi Aiba","Naoya Kataoka","Masahiko Takagi","Shintaro Yamagami","Suguru Nishiuchi","Yasuhiro Sasaki","Atsushi Kobori","Yasuteru Yamauchi","Yoshinao Yazaki","Kazuhiro Satomi","Junichi Nitta","Shingo Mizuno","Masato Murakami","Keiichi Ashikaga","Jun Kishihara","Hidehira Fukaya","Yu-Ki Iwasaki","Wataru Shimizu","Kengo Kusano"],"significance":7,"published":"2025-11-07","source_date":"2025-11-07","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"The CRRF-PeAF trial compared cryoballoon with radiofrequency ablation specifically for persistent AF, providing prospective data on the relative efficacy and safety of these two energy sources in the more challenging persistent arrhythmia phenotype.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"812dd8d2a99d","type":"article","url":"https://hartvaat.nl/2025/11/06/orforglipron-voor-obesitasbehandeling-nejm-fase-3/","title":"Orforglipron voor obesitasbehandeling: NEJM fase 3","title_en":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["obesitas","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2511774","source_url":"https://doi.org/10.1056/NEJMoa2511774","authors":["Sean Wharton","Louis J Aronne","Adam Stefanski","Nasreen F Alfaris","Andreea Ciudin","Koutaro Yokote","Bruno Halpern","Alpana P Shukla","Chunmei Zhou","Lisa Macpherson","Sheryl E Allen","Nadia N Ahmad","Suzanne R Klise"],"significance":10,"published":"2025-11-06","source_date":"2025-11-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/"],"congress":"","summary_en":"This phase 3 trial demonstrated that orforglipron, an oral small-molecule GLP-1 receptor agonist, produced dose-dependent weight loss of up to 15% in adults with obesity, comparable to subcutaneous semaglutide. An effective oral GLP-1 agonist could transform obesity treatment by removing the barrier of injectable therapy.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4cefd9e4af8e","type":"article","url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","title":"Risicobeoordeling voor bloeddrukmanagement: begeleidend document","title_en":"Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.08.001","source_url":"https://doi.org/10.1016/j.jacc.2025.08.001","authors":["Sadiya S Khan","Donald M Lloyd-Jones","Marwah Abdalla","Natalie A Bello","Ciantel A Blyler","Jocelyn Carter","Yvonne Commodore-Mensah","Keith C Ferdinand","Heather M Johnson","Daniel Jones","Amit Khera","Paul Muntner","Stacey Schott","Daichi Shimbo","Sidney C Smith","Sandra J Taler","Eugene Yang"],"significance":6,"published":"2025-11-04","source_date":"2025-11-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This companion document to the 2025 hypertension guideline detailed the use of cardiovascular risk assessment for guiding blood pressure treatment decisions in primary prevention.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"33deb512e3d1","type":"article","url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-op-een-blik/","title":"2025 AHA/ACC hypertensierichtlijn op een blik","title_en":"2025 High Blood Pressure Guideline-at-a-Glance.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.010","source_url":"https://doi.org/10.1016/j.jacc.2025.07.010","authors":["Martha Gulati","Mykela M Moore","Morgane Cibotti-Sun"],"significance":6,"published":"2025-11-04","source_date":"2025-11-04","image":"","kennis":[],"congress":"","summary_en":"This guideline-at-a-glance provided a concise visual summary of the 2025 AHA/ACC hypertension guidelines, distilling the key recommendations including the new 130/80 mmHg definition.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d423f6e3e3e","type":"article","url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","title":"2025 AHA/ACC hypertensierichtlijn: Circulation-editie","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.007","source_url":"https://doi.org/10.1016/j.jacc.2025.05.007","authors":["Daniel W Jones","Keith C Ferdinand","Sandra J Taler","Heather M Johnson","Daichi Shimbo","Marwah Abdalla","M Martine Altieri","Nisha Bansal","Natalie A Bello","Adam P Bress","Jocelyn Carter","Jordana B Cohen","Karen J Collins","Yvonne Commodore-Mensah","Leslie L Davis","Brent Egan","Sadiya S Khan","Donald M Lloyd-Jones","Bernadette Mazurek Melnyk","Eva A Mistry","Modele O Ogunniyi","Stacey L Schott","Sidney C Smith","Amy W Talbot","Wanpen Vongpatanasin","Karol E Watson","Paul K Whelton","Jeff D Williamson"],"significance":8,"published":"2025-11-04","source_date":"2025-11-04","image":"","kennis":[],"congress":"","summary_en":"Simultaneous Circulation edition of the 2025 AHA/ACC hypertension guideline with updated definitions (130/80 mmHg), combination therapy emphasis, and home blood pressure monitoring recommendations.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1a2878ee000d","type":"article","url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","title":"Pneumokokkenvaccinatie en CV-eventpreventie: IPD meta-analyse","title_en":"Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.3043","source_url":"https://doi.org/10.1001/jamacardio.2025.3043","authors":["Alexis Hure","Roseanne Peel","Catherine D'Este","Walter P Abhayaratna","Andrew Tonkin","Ingrid Hopper","Amanda G Thrift","Christopher Levi","Jonathan Sturm","David Durrheim","Joseph Hung","Tom Briffa","Derek P Chew","Shu Ren","Mark McEvoy","Philip Hansbro","David Newby","Stuart Szwec","Simon Chiu","John Attia"],"significance":6,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This individual patient data meta-analysis explored whether pneumococcal vaccination prevents cardiovascular events, finding suggestive but not definitive evidence for a cardioprotective effect of respiratory infection prevention.","created":"2026-07-03T10:31:58Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"313a2f50410e","type":"article","url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","title":"Abelacimab bij AF naar nierfunctie: veiligheidssubanalyse","title_en":"Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","anemie-ckd","chronische-nierziekte","flow-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.3393","source_url":"https://doi.org/10.1001/jamacardio.2025.3393","authors":["Siddharth M Patel","Robert P Giugliano","David A Morrow","Erica L Goodrich","Sabina A Murphy","Bruce Hug","Sanobar Parkar","Shih-Ann Chen","Shaun G Goodman","Boyoung Joung","Robert G Kiss","Wojciech Wojakowski","Jeffrey I Weitz","Dan Bloomfield","Marc S Sabatine","Christian T Ruff"],"significance":6,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This AZALEA-TIMI 71 subanalysis confirmed that abelacimab maintains its favorable safety profile across different levels of kidney function in AF, supporting FXI inhibition as a safer anticoagulation option in CKD.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19b4d6b32612","type":"article","url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","title":"SBP en Impella-geassocieerde overleving bij cardiogene shock","title_en":"Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","hypertrofische-cardiomyopathie","obesitas"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.3337","source_url":"https://doi.org/10.1001/jamacardio.2025.3337","authors":["Astrid Duus Mikkelsen","Rasmus Paulin Beske","Lisette Okkels Jensen","Hans Eiskjær","Norman Mangner","Amin Polzin","Christian Schulze","Carsten Skurk","Peter Nordbeck","Benedikt Schrage","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Thomas Engstrøm","Lene Holmvang","Martin Frydland","Anders Bo Junker","Henrik Schmidt","Nanna Louise Junker Udesen","Kristian Wachtell","Christian Juhl Terkelsen","Axel Linke","Jesper Kjærgaard","Jacob Eifer Møller","Christian Hassager"],"significance":5,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"A post-hoc analysis of the DanGer Shock trial investigated systolic blood pressure as a modifier of Impella microaxial flow pump survival benefit in infarct-related cardiogenic shock. Higher systolic blood pressure at randomisation was associated with greater survival benefit from mechanical support.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be705e37ded4","type":"article","url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","title":"Fysiologisch geleide complete revascularisatie bij ouderen met MI: driejaarsdata","title_en":"Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["perifeer-vaatlijden"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.3099","source_url":"https://doi.org/10.1001/jamacardio.2025.3099","authors":["Simone Biscaglia","Andrea Erriquez","Vincenzo Guiducci","Javier Escaned","Raul Moreno","Valerio Lanzilotti","Andrea Santarelli","Enrico Cerrato","Giorgio Sacchetta","Alberto Menozzi","Ignacio Amat-Santos","José Luis Díez Gil","Marco Ruozzi","Marco Barbierato","Luca Fileti","Andrea Picchi","Rita Pavasini","Paolo Cimaglia","Iginio Colaiori","Gianni Casella","Mila Menozzi","Caterina Cavazza","Giorgio Caretta","Roberto Scarsini","Gianpiero D'Amico","Giuseppe Vadalà","Gerlando Pilato","Elisabetta Moscarella","Matteo Tebaldi","Gianluca Campo"],"significance":7,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":[],"congress":"","summary_en":"Three-year results confirmed the durable benefit of physiology-guided (FFR/iFR) complete revascularization in older MI patients, providing the longest follow-up data for this approach in the elderly population.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b8cee7b5b91","type":"article","url":"https://hartvaat.nl/2025/11/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-rct-s/","title":"Magnesiumsuppletie en bloeddruk: meta-analyse van RCT's","title_en":"Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25129","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25129","authors":["Zoe Argeros","Xiaoye Xu","Buna Bhandari","Katie Harris","Rhian M Touyz","Aletta E Schutte"],"significance":6,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This meta-analysis confirmed that magnesium supplementation modestly but significantly lowers blood pressure, with the greatest effect in patients with hypertension, supporting magnesium as a nutritional adjunct to pharmacotherapy.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cdb7da5c23f4","type":"article","url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","title":"Bloeddrukzelfmanagement en vasculaire remodelling na hypertensieve zwangerschap","title_en":"Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","perifeer-vaatlijden","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.24854","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24854","authors":["Jamie Kitt","Luca Biasiolli","Samuel Krasner","Paul A Bateman","Hannah R Cutler","Logan C Barr","Annabelle Frost","Katherine L Tucker","Katie Suriano","Yvonne Kenworthy","Winok Lapidaire","Miriam Lacharie","Rebecca Mills","Cristian Roman","Lucy Mackillop","Christina Y L Aye","Alexandra E Cairns","Basky Thilaganathan","Lucy C Chappell","Adam J Lewandowski","Richard J McManus","Paul Leeson"],"significance":5,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"The POP-HT trial demonstrated that blood pressure self-management after hypertensive pregnancy leads to improved vascular remodelling during the first postpartum year. Early intervention with structured self-monitoring provided long-term vascular protection beyond the blood pressure-lowering effect alone.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T18:39:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e594a1cfc3fa","type":"article","url":"https://hartvaat.nl/2025/11/01/causaal-verband-tussen-mitochondriale-genen-en-carotisplaques-multi-omics-mr-stu/","title":"Causaal verband tussen mitochondriale genen en carotisplaques: multi-omics MR-studie","title_en":"Exploring the causal biological association between mitochondrial genes and carotid plaques: A multiomics Mendelian randomization study","category":"cholesterol","category_label":"Cholesterol","professions":[],"tags":[],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01468-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01468-6/fulltext","authors":["Zhuyuan Yu","Xiangyuan Meng","Ziyu Zong","Qi Song","Yingchao Huo","Hao Chen"],"significance":4,"published":"2025-11-01","source_date":"2025-11-01","image":"","kennis":[],"congress":"","summary_en":"A multi-omics integrated Mendelian randomisation analysis investigated the causal relationship between mitochondrial gene expression and the pathogenesis of carotid atherosclerotic plaques.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"433e6c0b91ca","type":"article","url":"https://hartvaat.nl/2025/10/31/vrouwen-met-persisterend-af-pvi-alleen-is-onvoldoende/","title":"Vrouwen met persisterend AF: PVI alleen is onvoldoende","title_en":"Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf281","source_url":"https://doi.org/10.1093/europace/euaf281","authors":["Isabel Deisenhofer","Julien Seitz","Marie-Sophie Nguyen-Tu","Sabine Lotteau","Clément Bars","Jean-Paul Albenque","Sonia Busch","Edouard Gitenay","Stavros Mountantonakis","Antoine Roux","Jérôme Horvilleur","Babe Bakouboula","Saumil Oza","Selim Abbey","Guillaume Theodore","Antoine Lepillier","Yves Guyomar","Francis Bessière","Jaap Jan Smit","Anil Rajendra","Daniel H Cooper","Haroon Rashid","Tom De Potter","Christian De Chillou","Seth Goldbarg","Atul Verma","Gustavo Morales","Paola Milpied","John D Hummel","Jérôme Kalifa"],"significance":6,"published":"2025-10-31","source_date":"2025-10-31","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study showed that women with persistent AF benefit more from personalized extended ablation beyond PVI than from PVI alone, identifying a sex-specific ablation strategy that addresses the different AF substrate in women.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d5b995d3e5b1","type":"article","url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","title":"PFA versus thermale ablatie: periprocedurale en middellangetermijneffecten","title_en":"Peri-procedure and Mid-Long Term Effects of Pulsed Field Ablation vs. Thermal Ablation (Cryo- or Radiofrequency) on Autonomic Nervous System Function in Atrial Fibrillation: A Systematic and Quantitative Pooled-Analysis with Potential Implications for Patient Selection (The PULSE-COLD-HEAT-ANS Collaboration).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["pulsed-field-ablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf242","source_url":"https://doi.org/10.1093/europace/euaf242","authors":["Sebastian Graeger","Sanjiv M Narayan","Christian Meyer","Dominik Linz","Andreas Rillig","Maura M Zylla","Ramin Ebrahimi","Firat Duru","Laura Perrotta","Kars Neven","Christian-Hendrik Heeger","Martin H Ruwald","Piotr Futyma","Bart A Mulder","Gozal Mirzayeva","Márcio Galindo Kiuchi","Martin Martinek","Helmut Pürerfellner","Serge Boveda","Yuehui Yin","Gang Yang","Hailei Liu","Minglong Chen","Boris Schmidt","Julian K R Chun","Mu Qin","Xumin Hou","Xu Liu","Jingquan Zhong","Shaojie Chen"],"significance":6,"published":"2025-10-31","source_date":"2025-10-31","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This comparative analysis of PFA versus thermal ablation for AF documented differences in periprocedural autonomic effects and medium-term outcomes, characterizing the distinct tissue interactions of pulsed field energy.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de22680aacee","type":"article","url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","title":"Herhaalde in-situ ablatie versus uitgebreide ablatie bij recidief persisterend AF","title_en":"Repeat in situ ablation vs. extensive ablation for recurrent persistent atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf232","source_url":"https://doi.org/10.1093/europace/euaf232","authors":["Mu Qin","Shi-Yi Wang","Zi-Liang Song","Feng Zhang","Nan-Nan Chen","Yu Zhang","Yang Liu","Wei-Feng Jiang","Shao-Hui Wu","Xu-Min Hou","Xu Liu"],"significance":5,"published":"2025-10-31","source_date":"2025-10-31","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"A randomised trial compared repeat in-situ pulmonary vein re-isolation with extensive extra-pulmonary vein ablation for recurrent persistent atrial fibrillation. The results inform redo ablation strategy selection in this challenging patient population.","created":"2026-07-03T10:31:57Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c52592c94019","type":"article","url":"https://hartvaat.nl/2025/10/29/cannabis-en-cardiovasculair-risico-systematische-review-en-meta-analyse/","title":"Cannabis en cardiovasculair risico: systematische review en meta-analyse","title_en":"Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","roken","slaapapneu"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325429","source_url":"https://doi.org/10.1136/heartjnl-2024-325429","authors":["Wilhelm Storck","Meyer Elbaz","Cécile Vindis","Amélia Déguilhem","Maryse Lapeyre-Mestre","Emilie Jouanjus"],"significance":6,"published":"2025-10-29","source_date":"2025-10-29","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This meta-analysis documented the cardiovascular risks of cannabis use, showing associations with acute coronary syndrome, arrhythmia, and stroke, informing clinical counseling for this increasingly prevalent substance.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2dc7b258584c","type":"article","url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","title":"PREVENT-vergelijkingen voor intensieve versus standaard bloeddrukcontrole","title_en":"Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.037","source_url":"https://doi.org/10.1016/j.jacc.2025.07.037","authors":["Catherine G Derington","Ransmond O Berchie","Tom Greene","Joshua A Jacobs","Andrew E Moran","Yizhe Xu","Keisuke Narita","Alexander R Zheutlin","Jordana B Cohen","Daichi Shimbo","Adam P Bress"],"significance":5,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This SPRINT secondary analysis applied the PREVENT risk equations to quantify the benefit of intensive versus standard blood pressure control across risk levels. Intensive therapy provided greater absolute risk reduction in patients with higher baseline cardiovascular risk.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2f755492e39","type":"article","url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","title":"STEP 6-jaarsresultaten: intensieve bloeddrukcontrole bij ouderen — langetermijn","title_en":"Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.045","source_url":"https://doi.org/10.1016/j.jacc.2025.06.045","authors":["Qirui Song","Xinyi Peng","Jingjing Bai","Ruixue Yang","Qianhui Ling","Sifei Chen","Yufei Ji","Xilan Dong","Xiaoqi Wang","Shouling Wu","Tzung-Dau Wang","Xiaoxu Yu","Hualing Liu","Jie Ren","Xiaoyang Zhou","Rong Chen","Li Yang","Jinfeng Yang","Gang Tian","Hongwei Zhang","Dechao Zhao","Fang Chen","Dongfeng Li","Jing Yu","Juyan Zhang","Zhao Yang","Weili Zhang","Jun Cai"],"significance":8,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/"],"congress":"","summary_en":"Six-year STEP follow-up confirmed the durable benefit of intensive blood pressure control (SBP <130 mmHg) in older patients with hypertension. The sustained cardiovascular advantage supports long-term commitment to lower blood pressure targets in the elderly.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3c6e842fb2ec","type":"article","url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","title":"ESPRIT: bescheiden effecten van intensieve bloeddrukverlaging op kwaliteit van leven","title_en":"Modest Effects of Intensive Blood Pressure-Lowering on Quality of Life in Patients at High Cardiovascular Risk: The ESPRIT Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.010","source_url":"https://doi.org/10.1016/j.jacc.2025.06.010","authors":["Xinghe Huang","Haibo Zhang","Yan Li","Jinzhuo Ge","Ying Sun","Liping Zhang","Lingshan Zhao","Jiangling Liu","Chengbo Zhang","Jie Du","Yanfang Li","Hailin Zhang","Feng Hao","Qiuli Wang","Wei Xu","Jiamin Liu","Jing Li"],"significance":6,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This ESPRIT analysis confirmed that intensive blood pressure lowering does not significantly impair quality of life compared with standard treatment, addressing concerns that aggressive targets may reduce patient well-being.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce230fe49e16","type":"article","url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","title":"ESPRIT: intensieve bloeddrukverlaging en retinale microvasculatuur","title_en":"Effect of Intensive Blood Pressure Lowering Treatment on Retinal Microvasculature: Secondary Analysis From ESPRIT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","microcirculatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.020","source_url":"https://doi.org/10.1016/j.jacc.2025.05.020","authors":["Bin Wang","Danli Shi","Zhibao Zhang","Liping Zhang","Ying Sun","Jiangling Liu","Xiaofang Yan","Jiajie Jing","Jingkuo Li","Jinxiao Song","Yinchu Li","Guixin Li","Li Zhang","Zhimin Wang","Jian Chen","Wanting Zhang","Shuhui Cai","Suhui Han","Tianwei Luan","Shaowei Yi","Shuhong Su","Jie Du","Xianli Kou","Juan Liu","Xing Dai","Nan Li","Jing Zhu","Chunyan Tang","Shaobo Liu","He Su","Yaqin Liu","Yu Mao","Xiaohui Yang","Mingguang He","Qing Zhang","Jing Li"],"significance":5,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":[],"congress":"","summary_en":"An ESPRIT secondary analysis demonstrated that intensive blood pressure lowering improves retinal microvasculature compared to standard treatment. Retinal vessels serve as a window into systemic microvascular health and treatment response.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3169e3a2326","type":"article","url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","title":"RSV-vaccin vermindert CV-hospitalisaties bij ouderen","title_en":"Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.15405","source_url":"https://doi.org/10.1001/jama.2025.15405","authors":["Mats C Højbjerg Lassen","Niklas Dyrby Johansen","Sine H Christensen","Negar Aliabadi","Kristoffer G Skaarup","Daniel Modin","Brian L Claggett","Carsten S Larsen","Lykke Larsen","Lothar Wiese","Michael Dalager-Pedersen","Matias G Lindholm","Anne Marie R Jensen","Maria Dons","Katrine F Bernholm","Filip S Davidovski","Lisa S Duus","Camilla I Ottosen","Anne B Nielsen","Julie H Borchsenius","Caroline Espersen","Güldas Köse","Frederik H Fussing","Manan Pareek","Lars Køber","Scott D Solomon","Jens Ulrik Stæhr Jensen","Cyril Jean-Marie Martel","Bradford D Gessner","Claudia Schwarz","Elisa Gonzalez","Mette Skovdal","Lawrence H Moulton","Pingping Zhang","Elizabeth Begier","Tor Biering-Sørensen"],"significance":7,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This study demonstrated that a bivalent RSV vaccine reduces cardiovascular hospitalizations in older adults, establishing vaccination against respiratory pathogens as a cardiovascular prevention strategy beyond influenza.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"74b55580be28","type":"article","url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","title":"ESPRIT: intensieve bloeddrukcontrole en CVA-preventie","title_en":"Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.055","source_url":"https://doi.org/10.1016/j.jacc.2025.07.055","authors":["Jingkuo Li","Lubi Lei","Yan Li","Haibo Zhang","Xiaofang Yan","Ying Sun","Dejian He","Laijing Du","Jian Hu","Liwei Qi","Xinli Yu","Guoquan Xiu","Yunhong Jiao","Lijie Yu","Weifeng Zhou","Ling Feng","Zheng Guan","Aijun Liu","Qun Luo","Manman Niu","Hongmei Tian","Jiamin Liu","Jing Li"],"significance":8,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This ESPRIT subanalysis showed that intensive blood pressure control significantly reduces stroke risk, with the greatest benefit in patients with the highest baseline blood pressure. The data support aggressive targets specifically for stroke prevention.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"605518115c6b","type":"article","url":"https://hartvaat.nl/2025/10/28/prince-remote-ischemische-preconditionering-en-myocardletsel-bij-niet-cardiale-c/","title":"PRINCE: remote ischemische preconditionering en myocardletsel bij niet-cardiale chirurgie","title_en":"Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.075254","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.075254","authors":["Massimiliano Greco","Gaetano Lombardi","Claudia Brusasco","Marina Pieri","Agostino Roasio","Fabrizio Monaco","Levan Berikashvili","Alessandro Belletti","Francesco Meroi","Stefano Fresilli","Aituar Kabibulatov","Giuseppe Giardina","Andrea Russo","Federico Mattia Oliva","Sergey Efremov","Rosalba Lembo","Lini Wang","Simone Vietri","Elena Momesso","Filippo D'Amico","Kristina Kadantseva","Rosa Labanca","Pavel Ryzhkov","Marilena Marmiere","Valerii Subbotin","Alessandro Pruna","Nerlep Rana","Francesca Livi","Hugo Mantilla-Gutierrez","Fabio Guarracino","Lorenzo Schiavoni","Ivan Šitum","Marco Micali","Stefano Bosso","Anastasia Smirnova","Giuseppe Fresta","Andrey Cherednichenko","Luigi Beretta","Giacomo Monti","Lian Kah Ti","Pasquale Sansone","Francesco Corradi","Maurizio Cecconi","Andrey Yavorovskiy","Chong Lei","Aidos Konkayev","Tiziana Bove","Valery Likhvantsev","Alberto Zangrillo","Giovanni Landoni","Rinaldo Bellomo","Remo Daniel Covello","Stefano Turi"],"significance":6,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":[],"congress":"","summary_en":"The PRINCE trial tested whether remote ischemic preconditioning reduces myocardial injury after non-cardiac surgery, exploring a simple limb-cuff-based cardioprotective strategy for the perioperative setting.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3160e7f67456","type":"article","url":"https://hartvaat.nl/2025/10/28/directe-of-uitgestelde-pci-van-niet-culprit-laesie-bij-myocardinfarct/","title":"Directe of uitgestelde PCI van niet-culprit laesie bij myocardinfarct","title_en":"Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["myocardinfarct","nstemi","percutane-coronaire-interventie","stemi"],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2512918&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2512918&rss=currentIssue","authors":["Robin Nijveldt Michael Maeng Casper"],"significance":9,"published":"2025-10-28","source_date":"2025-10-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This NEJM study examined the optimal timing of nonculprit lesion PCI in patients with myocardial infarction and multivessel disease, comparing immediate complete revascularization during the index procedure with a deferred staged approach.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"11663723dc1d","type":"article","url":"https://hartvaat.nl/2025/10/27/rol-van-stressresponsief-nr4a2-bij-aldosteron-producerende-celclustervorming/","title":"Rol van stressresponsief NR4A2 bij aldosteron-producerende celclustervorming","title_en":"Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["aldosteronsynthaseremmers","lorundrostat"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24825","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24825","authors":["Norifusa Iwahashi"],"significance":5,"published":"2025-10-27","source_date":"2025-10-27","image":"","kennis":[],"congress":"","summary_en":"This study identified the stress-responsive transcription factor NR4A2 as a key driver of aldosterone-producing cell cluster formation in the adrenal cortex. The findings advance understanding of primary aldosteronism pathogenesis and age-related aldosterone dysregulation.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"502f1b0c4b9f","type":"article","url":"https://hartvaat.nl/2025/10/27/transkatheter-versus-chirurgische-aortaklepvervanging-bij-laagrisicopatienten-na/","title":"Transkatheter versus chirurgische aortaklepvervanging bij laagrisicopatiënten na 7 jaar","title_en":"Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"NEJM","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2509766&rss=currentIssue","source_url":"https://doi.org/https://www.nejm.org/doi/full/10.1056/NEJMoa2509766&rss=currentIssue","authors":[],"significance":10,"published":"2025-10-27","source_date":"2025-10-27","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/chirurgische-klepvervanging/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"The 7-year follow-up of TAVR versus surgery in low-risk aortic stenosis patients showed durable outcomes for transcatheter intervention, with mortality and stroke rates remaining comparable to surgical aortic valve replacement. These long-term data support TAVR as a viable option across the full surgical risk spectrum.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d16922f99a51","type":"article","url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","title":"Sotatercept bij PAH binnen het eerste jaar na diagnose: STELLAR subanalyse","title_en":"Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2508170","source_url":"https://doi.org/10.1056/NEJMoa2508170","authors":["Vallerie V McLaughlin","Marius M Hoeper","David B Badesch","H Ardeschir Ghofrani","J Simon R Gibbs","Mardi Gomberg-Maitland","Ioana R Preston","Rogerio Souza","Aaron B Waxman","Grzegorz Kopeć","Gisela Meyer","Karen M Olsson","Wei Fu","Yaru Shi","Barry Miller","Samuel S Kim","Harald S Mackenzie","Michela Brambatti","Mahesh J Patel","Joerg Koglin","Alexandra G Cornell","Marc Humbert"],"significance":7,"published":"2025-10-23","source_date":"2025-10-23","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This analysis showed that sotatercept is particularly effective when initiated early in pulmonary arterial hypertension (within the first year after diagnosis), supporting a paradigm of early, aggressive combination therapy in PAH.","created":"2026-07-03T10:31:56Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b04caf5f05ae","type":"article","url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","title":"Aspirine bij chronisch coronairsyndroom plus OAC: wel of niet?","title_en":"Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","anemie-ckd","aspirine","cardiale-resynchronisatie","stabiel-coronairlijden"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2507532","source_url":"https://doi.org/10.1056/NEJMoa2507532","authors":["Gilles Lemesle","Romain Didier","Philippe Gabriel Steg","Tabassome Simon","Gilles Montalescot","Nicolas Danchin","Christophe Bauters","Didier Blanchard","Claire Bouleti","Denis Angoulvant","Stéphane Andrieu","Gérald Vanzetto","Mathieu Kerneis","Véronique Decalf","Etienne Puymirat","Dominique Mottier","Abdourahmane Diallo","Eric Vicaut","Martine Gilard","Guillaume Cayla"],"significance":7,"published":"2025-10-23","source_date":"2025-10-23","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This NEJM study examined whether adding aspirin to oral anticoagulation benefits patients with chronic coronary syndrome, finding that OAC monotherapy is sufficient without additional antiplatelet therapy in stable disease.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9cae50e71348","type":"article","url":"https://hartvaat.nl/2025/10/22/lagere-cardiorespiratoire-fitheid-en-atherosclerose-ondanks-cac-score-nul-scapis/","title":"Lagere cardiorespiratoire fitheid en atherosclerose ondanks CAC-score nul (SCAPIS)","title_en":"Lower cardiorespiratory fitness is associated with coronary artery atherosclerosis in individuals with a zero CAC score – cross-sectional results from SCAPIS","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["calciumscore"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01448-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01448-0/fulltext","authors":["Frida Griffin","Jonatan Fridolfsson","Daniel Arvidsson","Elin Ekblom-Bak","Örjan Ekblom","Göran Bergström","Mats Börjesson"],"significance":5,"published":"2025-10-22","source_date":"2025-10-22","image":"","kennis":[],"congress":"","summary_en":"This SCAPIS cross-sectional study found that lower estimated cardiorespiratory fitness is associated with coronary atherosclerosis even in individuals with a zero coronary artery calcium score. Adding fitness to conventional risk models improved atherosclerosis risk prediction.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e0c4772bd1c","type":"article","url":"https://hartvaat.nl/2025/10/21/amalfi-remote-screening-voor-asymptomatisch-af-gerandomiseerde-trial/","title":"AMALFI: remote screening voor asymptomatisch AF — gerandomiseerde trial","title_en":"Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"JAMA","doi":"10.1001/jama.2025.15440","source_url":"https://doi.org/10.1001/jama.2025.15440","authors":["Rohan Wijesurendra","Guilherme Pessoa-Amorim","Georgina Buck","Charlie Harper","Richard Bulbulia","Alison Offer","Nicholas R Jones","Christine A'Court","Rijo Kurien","Karen Taylor","Barbara Casadei","Louise Bowman"],"significance":7,"published":"2025-10-21","source_date":"2025-10-21","image":"","kennis":[],"congress":"","summary_en":"The AMALFI trial evaluated remote AF screening using wearable devices in the general population, providing data on the feasibility, detection yield, and downstream clinical impact of technology-enabled arrhythmia screening.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4ee5c059809","type":"article","url":"https://hartvaat.nl/2025/10/20/dynamische-controle-van-na-cl-cotransporter-door-wnk1-kinase-bifasische-respons-/","title":"Dynamische controle van Na-Cl-cotransporter door WNK1-kinase: bifasische respons op kalium","title_en":"Dynamic control of Na-Cl cotransporter by kidney-specific with-no-lysine 1 kinase: a biphasic response to K+ via condensate signaling","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00826-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00826-9/fulltext","authors":["Maria Chavez-Canales","Gerardo Gamba"],"significance":5,"published":"2025-10-20","source_date":"2025-10-20","image":"","kennis":[],"congress":"","summary_en":"This research describes the dynamic control of the Na-Cl cotransporter by kidney-specific WNK1 kinase through a biphasic potassium signalling mechanism involving condensate formation. The findings explain how dietary potassium influences blood pressure via renal sodium handling.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6dcd3b0bf6ea","type":"article","url":"https://hartvaat.nl/2025/10/20/gwas-verplaatst-endotheline-naar-vasculaire-gladde-spiercellen-en-bloeddrukregul/","title":"GWAS verplaatst endotheline naar vasculaire gladde spiercellen en bloeddrukregulatie","title_en":"GWAS moves endothelin directly to vascular smooth muscle and blood pressure regulation","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["endothelineantagonisten"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00785-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00785-9/fulltext","authors":["Friedrich C. Luft"],"significance":5,"published":"2025-10-20","source_date":"2025-10-20","image":"","kennis":[],"congress":"","summary_en":"This commentary discusses how genome-wide association studies have directly linked endothelin signalling in vascular smooth muscle cells to blood pressure regulation. GWAS findings illuminate mechanisms beyond classical Mendelian genetics in hypertension research.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a6c1a176b7ee","type":"article","url":"https://hartvaat.nl/2025/10/17/peptidedeformylase-reguleert-aldosteronproductie-via-calbindine-1/","title":"Peptidedeformylase reguleert aldosteronproductie via calbindine 1","title_en":"Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["aldosteronsynthaseremmers","baxdrostat"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.124.24395","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.124.24395","authors":["Mansi Luo"],"significance":4,"published":"2025-10-17","source_date":"2025-10-17","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This study demonstrates that peptide deformylase, essential for maturation of mitochondrially encoded proteins, regulates aldosterone production through calbindin 1 in aldosterone-producing adenomas, advancing understanding of primary aldosteronism pathogenesis.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b363fbb05e76","type":"article","url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","title":"ALONE-AF: langetermijn anticoagulatieonthouding na AF-ablatie — RCT","title_en":"Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.14679","source_url":"https://doi.org/10.1001/jama.2025.14679","authors":["Daehoon Kim","Jaemin Shim","Eue-Keun Choi","Il-Young Oh","Jun Kim","Young Soo Lee","Junbeom Park","Jum-Suk Ko","Kyoung-Min Park","Jung-Hoon Sung","Hyung Wook Park","Hyung-Seob Park","Jong-Youn Kim","Ki-Woon Kang","Dongmin Kim","Jin-Kyu Park","Dae-Hyeok Kim","Jin-Bae Kim","Hee Tae Yu","Tae-Hoon Kim","Jae-Sun Uhm","Hui-Nam Pak","Boyoung Joung"],"significance":8,"published":"2025-10-14","source_date":"2025-10-14","image":"","kennis":[],"congress":"","summary_en":"The ALONE-AF trial investigated whether anticoagulation can be safely discontinued after successful catheter ablation for atrial fibrillation. The study addresses one of the most consequential unresolved questions in AF management.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5fe49df5d51e","type":"article","url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","title":"FFR versus angiografie voor PCI-begeleiding: IPD meta-analyse","title_en":"Fractional flow reserve vs angiography to guide percutaneous coronary intervention: an individual patient data meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf504","source_url":"https://doi.org/10.1093/eurheartj/ehaf504","authors":["Fabio Mangiacapra","Luca Paolucci","Bernard De Bruyne","Gilles Rioufol","Joo-Yong Hahn","Shao-Liang Chen","Bon-Kwon Koo","Pim A L Tonino","Marcel van 't Veer","Pascal Motreff","Denis Angoulvant","Joo Myung Lee","Doyeon Hwang","Seokhun Yang","Nico H J Pijls","Emanuele Barbato"],"significance":7,"published":"2025-10-14","source_date":"2025-10-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This individual patient data meta-analysis of FFR-guided versus angiography-guided PCI confirmed that FFR guidance reduces unnecessary stent implantation without compromising clinical outcomes, providing the most definitive evidence for physiologically guided intervention.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"439fa39e39f4","type":"article","url":"https://hartvaat.nl/2025/10/14/heparine-bij-eerste-medisch-contact-versus-voor-primaire-pci-bij-stemi/","title":"Heparine bij eerste medisch contact versus vóór primaire PCI bij STEMI","title_en":"Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["anticoagulantia"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf481","source_url":"https://doi.org/10.1093/eurheartj/ehaf481","authors":["Jing Chen","Changwu Xu","Liqiang Qiu","Bin Li","Wei Yao","Hui Wu","Longcai Hu","Guang Xu","Dongmei Zhu","Zhengzai Li","Xiaolin Wu","Chuang Xiao","Bo Liu","Xiuzhen Shen","Zhaowu Deng","Chaogui Zhuo","Huajun Su","Keping Yang","Youen Zhang","Meichun Zhang","Chang Li","Xuexiang Lv","Lifeng Hong","Fan Guo","Xingan Wu","Hao Xu","Mingjian Li","Liqun He","Wenjun Wu","Yuhua Lei","Dongsheng Li","Huoping Li","Shaoze Chen","Hong Bao","Xuguang Xiong","Bo Liu","Guokang Yang","Jinke Chen","Xiao Lan","Qibin Zheng","Guanglong Yang","Mingxi Zhang","Jian Yang","Hong Jiang"],"significance":6,"published":"2025-10-14","source_date":"2025-10-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-acs-2023/"],"congress":"","summary_en":"This study evaluated whether early heparin administration at first medical contact improves STEMI outcomes compared with administration immediately before PCI, informing the timing of antithrombotic therapy in acute MI care pathways.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8599d88c11b3","type":"article","url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","title":"Baxdrostat bij ongecontroleerde en resistente hypertensie: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","aldosteronsynthaseremmers","aprocitentan","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","mra-aldosteronantagonisten","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2507109","source_url":"https://doi.org/10.1056/NEJMoa2507109","authors":["John M Flack","Michel Azizi","Jenifer M Brown","Jamie P Dwyer","Jakub Fronczek","Erika S W Jones","Daniel S Olsson","Shira Perl","Hirotaka Shibata","Ji-Guang Wang","Ulrica Wilderäng","Janet Wittes","Bryan Williams"],"significance":8,"published":"2025-10-09","source_date":"2025-10-09","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/"],"congress":"","summary_en":"This study confirmed the efficacy and safety of baxdrostat in patients with both uncontrolled and resistant hypertension. The aldosterone synthase inhibitor demonstrated consistent blood pressure reduction across these challenging treatment populations.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc5944528dde","type":"article","url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","title":"Vroege substraatablatie versus antiaritmica bij VT: gerandomiseerde trial","title_en":"Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["iaso-dcm"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf236","source_url":"https://doi.org/10.1093/europace/euaf236","authors":["Pekka Raatikainen","Heikki Mäkynen","Juha Hartikainen","Mats Jensen Urstad","Leena Konkola","Niels C F Sandgaard","Peter Lukac","Arne Johannessen","Anders Jönsson","Peter Schuster","Carina Blomström-Lundqvist","Jussi Kuutti","Piia Lavikainen","Hannu Parikka"],"significance":7,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The MANTRA-VT trial showed that early substrate-based catheter ablation reduces ventricular tachyarrhythmia recurrence compared with antiarrhythmic drugs in patients with prior MI, supporting proactive ablation over escalated pharmacotherapy.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dbb7aa795ddf","type":"article","url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","title":"Atriale cardiomyopathie bij recent gediagnosticeerd AF: prevalentie en ernst","title_en":"Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["aritmogene-cardiomyopathie","atriale-cardiomyopathie","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","laminopathie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf256","source_url":"https://doi.org/10.1093/europace/euaf256","authors":["Andreas Goette","Marc D Lemoine","Katrin Borof","Ulrich Schotten","Günter Breithardt","A John Camm","Harry J G M Crijns","Lars Eckardt","Andreas Metzner","Stephan Willems","Antonia Zapf","Renate B Schnabel","Larissa Fabritz","Paulus Kirchhof"],"significance":6,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study documented the prevalence of atrial cardiomyopathy in patients with recently diagnosed AF, showing that atrial fibrosis and dysfunction are established at the time of AF diagnosis in many patients.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18f57529b40b","type":"article","url":"https://hartvaat.nl/2025/10/07/cti-blok-na-pfa-versus-rf-cryo-ablatie-gerandomiseerde-vergelijking/","title":"CTI-blok na PFA versus RF/cryo-ablatie: gerandomiseerde vergelijking","title_en":"Acute durability of cavotricuspid isthmus block after pulsed electric field ablation: randomized comparison of two pentaspline catheter configurations (SECTION trial).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf234","source_url":"https://doi.org/10.1093/europace/euaf234","authors":["Predrag Stojadinović","Dan Wichterle","Alan Bulava","Jiří Plášek","Štěpán Havránek","Petr Peichl","Nicoletta Ventrella","Josef Marek","Eva Borišincová","Petr Štiavnický","Jana Hašková","Robert Čihák","Josef Kautzner"],"significance":5,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":[],"congress":"","summary_en":"The SECTION trial randomised patients to two pentaspline catheter configurations for cavotricuspid isthmus ablation using pulsed electric field energy. The study assessed acute block durability and haemolysis with different PEF delivery approaches.","created":"2026-07-03T10:31:55Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7324c3d17c16","type":"article","url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","title":"Nieuwe inspanningsherstelpatronen als maat voor cardiale prestatie","title_en":"Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.073585","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.073585","authors":["Joseph Campain","Catharine Griskowitz","Chloe Newlands","Brian L Claggett","Ian J Kulac","Shaina McGinnis","Ilya Giverts","Fabely Moreno","Alexandra Minasian","Cheshta Prasad","Lillian Rupert","Isabela Landsteiner","Nick Iskenderian","Caroline J Coats","Matthew M Y Lee","Martin S Maron","Anjali T Owens","Daniel L Jacoby","Stephen B Heitner","Stuart Kupfer","Fady I Malik","Amy Wohltman","Rajeev Malhotra","Gregory D Lewis"],"significance":5,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":[],"congress":"","summary_en":"A SEQUOIA-HCM substudy characterised novel post-exercise oxygen uptake recovery patterns as measures of cardiac performance. These recovery metrics provide additional diagnostic and prognostic information beyond conventional cardiopulmonary exercise parameters.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b00376946fd4","type":"article","url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","title":"Obicetrapib en MACE bij hoogrisicopatiënten: gepoolde analyse","title_en":"Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","obicetrapib"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.056","source_url":"https://doi.org/10.1016/j.jacc.2025.07.056","authors":["Stephen J Nicholls","Adam J Nelson","Kausik K Ray","Christie M Ballantyne","Marc Ditmarsch","Douglas Kling","Andrew Hsieh","Michael Szarek","John J Kastelein","Michael H Davidson"],"significance":8,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This pooled analysis suggested that obicetrapib may reduce MACE in high-risk patients, providing the first signal of clinical cardiovascular benefit from a CETP inhibitor after decades of setbacks with earlier agents in this class.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"20ade728d6eb","type":"article","url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","title":"HELP-MI: Helicobacter pylori-screening na acuut MI — cluster-RCT","title_en":"Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.15047","source_url":"https://doi.org/10.1001/jama.2025.15047","authors":["Robin Hofmann","Stefan James","Martin O Sundqvist","Jonatan Wärme","Oskar Angerås","Joakim Alfredsson","David Erlinge","Gabriel Arefalk","Göran Arstad","Simon Blomberg","Ole Fröbert","Kristina Hambraeus","Per M Hellström","Jörg Lauermann","Matthias Lidin","Lars Lindhagen","Georgios Mourtzinis","Carolina Schoede","Erik Thunström","Birgitta Voldberg","Henrik Wagner","Ollie Östlund","Tomas Jernberg","Magnus Bäck"],"significance":7,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":[],"congress":"","summary_en":"The HELP-MI trial showed that routine H. pylori screening and eradication after MI may reduce gastrointestinal bleeding in patients on dual antiplatelet therapy, exploring an interesting preventive strategy for a common antiplatelet complication.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T13:30:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87b8dcb23201","type":"article","url":"https://hartvaat.nl/2025/10/07/laa-occlusie-bij-terminale-nierziekte-ipd-meta-analyse/","title":"LAA-occlusie bij terminale nierziekte: IPD meta-analyse","title_en":"Left atrial appendage occlusion in patients with end-stage renal disease: an individual patient-level meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf198","source_url":"https://doi.org/10.1093/europace/euaf198","authors":["Juan F Rodriguez-Riascos","Hema S Vemulapalli","Ibrahim Akin","Luis A Areiza","Domenico G Della Rocca","Ingo Eitel","Thomas Fink","Simonetta Genovesi","Joelle Kefer","David Zweiker","Poojan Prajapati","Komandoor Srivathsan"],"significance":6,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":[],"congress":"","summary_en":"This individual patient data meta-analysis evaluated LAA occlusion in patients with end-stage renal disease and AF, showing feasibility and potential effectiveness in this high-risk population with limited anticoagulation options.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f44d693fce6d","type":"article","url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","title":"Relatie tussen obesitas en CKD: conclusies van een KDIGO-conferentie","title_en":"The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","category":"chronische nierziekte","category_label":"Nierziekte","professions":["huisarts","internist"],"tags":["chronische-nierziekte"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00774-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00774-4/fulltext","authors":["Susan L. Furth","Helen M. Colhoun","Mehmet Kanbay","Aleksandra Kukla","Lee-Ling Lim","Helen L. MacLaughlin","Sankar D. Navaneethan","Rukshana Shroff","Peter Stenvinkel","Michael Cheung","Jennifer M. King","Morgan E. Grams","Michel Jadoul","Peter Rossing","Conference Participants"],"significance":7,"published":"2025-10-07","source_date":"2025-10-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This KDIGO conference addressed the complex relationship between obesity and CKD, providing consensus conclusions on the direct and indirect mechanisms linking excess adiposity to kidney disease progression and cardiovascular risk.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8a8ba4e10fe","type":"article","url":"https://hartvaat.nl/2025/10/02/thuisgebaseerde-hypertensiezorg-in-ruraal-zuid-afrika-gerandomiseerde-trial/","title":"Thuisgebaseerde hypertensiezorg in ruraal Zuid-Afrika: gerandomiseerde trial","title_en":"Home-Based Care for Hypertension in Rural South Africa.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","summit-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2509958","source_url":"https://doi.org/10.1056/NEJMoa2509958","authors":["Mark J Siedner","Nombulelo Magula","Lusanda Mazibuko","Nsika Sithole","Alison Castle","Siyabonga Nxumalo","Thabang Manyaapelo","Shafika Abrahams-Gessel","Dickman Gareta","Joanna Orne-Gliemann","Kathy Baisley","Max Bachmann","Thomas A Gaziano"],"significance":6,"published":"2025-10-02","source_date":"2025-10-02","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This NEJM randomized trial of home-based hypertension care in rural South Africa showed significant blood pressure improvement, demonstrating a scalable community-based model for underserved regions.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb5bdd6dbfe3","type":"article","url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","title":"Olezarsen bij matige hypertriglyceridemie: CV-uitkomstpotentieel","title_en":"Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","hypertriglyceridemie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obicetrapib","pelacarsen","statines","yellow-iii"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2507227","source_url":"https://doi.org/10.1056/NEJMoa2507227","authors":["Brian A Bergmark","Nicholas A Marston","Thomas A Prohaska","Veronica J Alexander","Andre Zimerman","Filipe A Moura","Yu Mi Kang","Julia Weinland","Sabina A Murphy","Erica L Goodrich","Shuanglu Zhang","Dan Li","Maciej Banach","Erik Stroes","Michael T Lu","Sotirios Tsimikas","Robert P Giugliano","Marc S Sabatine"],"significance":7,"published":"2025-10-02","source_date":"2025-10-02","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/fibraten-bij-hypertriglyceridemie/"],"congress":"","summary_en":"This study of olezarsen targeting APOC3 in moderate hypertriglyceridemia demonstrated significant triglyceride reduction, addressing the unmet need for effective triglyceride-lowering therapy in the broader cardiovascular risk population.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7f37fb465b7","type":"article","url":"https://hartvaat.nl/2025/10/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-klinische-uitkomsten/","title":"Gepersonaliseerde versnelde pacing bij HFpEF: klinische uitkomsten","title_en":"Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.2827","source_url":"https://doi.org/10.1001/jamacardio.2025.2827","authors":["Margaret Infeld","Jamie Cyr","Alexandra E Novelli","Rebecca Rawlings","Kramer Wahlberg","Timothy B Plante","Jeanne du Fay de Lavallaz","Nicole Habel","Daniel L Lustgarten","Markus Meyer"],"significance":6,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This study reported clinical outcomes of personalized accelerated pacing in HFpEF patients with pacemakers, exploring whether optimized heart rate response during activity improves functional capacity.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d6a23a709f59","type":"article","url":"https://hartvaat.nl/2025/10/01/langetermijneffect-van-cacao-extract-op-incident-hypertensie/","title":"Langetermijneffect van cacao-extract op incident hypertensie","title_en":"Long-Term Effect of Cocoa Extract Supplementation on Incident Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25209","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25209","authors":["Rikuta Hamaya","Sidong Li","Jessica Lau","Matthew Allison","Bernhard Haring","Aladdin H Shadyab","Nudy Matthew","Lisa Warsinger Martin","Pamela M Rist","JoAnn E Manson","Howard D Sesso"],"significance":5,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":[],"congress":"","summary_en":"The COSMOS trial examined whether long-term cocoa extract supplementation reduces incident hypertension. The effect was modest and not statistically significant, indicating that cocoa flavanols do not function as an effective antihypertensive intervention.","created":"2026-07-03T10:31:54Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"807583a37ec1","type":"article","url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","title":"2025 AHA/ACC hypertensierichtlijn: JACC-editie","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYP.0000000000000249","source_url":"https://doi.org/10.1161/HYP.0000000000000249","authors":["Daniel W Jones","Keith C Ferdinand","Sandra J Taler","Heather M Johnson","Daichi Shimbo","Marwah Abdalla","M Martine Altieri","Nisha Bansal","Natalie A Bello","Adam P Bress","Jocelyn Carter","Jordana B Cohen","Karen J Collins","Yvonne Commodore-Mensah","Leslie L Davis","Brent Egan","Sadiya S Khan","Donald M Lloyd-Jones","Bernadette Mazurek Melnyk","Eva A Mistry","Modele O Ogunniyi","Stacey L Schott","Sidney C Smith","Amy W Talbot","Wanpen Vongpatanasin","Karol E Watson","Paul K Whelton","Jeff D Williamson"],"significance":10,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"The 2025 AHA/ACC hypertension guideline (Hypertension edition) redefines high blood pressure at 130/80 mmHg, endorses combination therapy as first-line treatment, and prioritizes out-of-office blood pressure measurement. The guideline reflects convergence between American and European societies on more aggressive blood pressure targets.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63690aa20b95","type":"article","url":"https://hartvaat.nl/2025/10/01/piek-vo2-en-prognose-bij-hartfalen-meta-analyse/","title":"Piek-VO2 en prognose bij hartfalen: meta-analyse","title_en":"Prognostic impact of peak oxygen consumption in heart failure: A systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15391","source_url":"https://doi.org/10.1002/ehf2.15391","authors":["Konstantinos Prokopidis","Krzysztof Irlik","Julia Piaśnik","Zuzanna Michalska","Mirela Hendel","Katarzyna Nabrdalik","Gregory Y H Lip"],"significance":5,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"A meta-analysis confirmed the strong prognostic value of peak oxygen consumption in heart failure. Exercise capacity remains one of the most powerful predictors of survival across heart failure phenotypes.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"30d6ec50cd41","type":"article","url":"https://hartvaat.nl/2025/10/01/intra-abdominale-druk-en-pocus-voor-decongestiebegeleiding-bij-hf/","title":"Intra-abdominale druk en POCUS voor decongestiebegeleiding bij HF","title_en":"The role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15380","source_url":"https://doi.org/10.1002/ehf2.15380","authors":["C Josa-Laorden","A Campos-Saenz de Santamaría","S Crespo-Aznarez","J Pérez-Silvestre","E Montero-Hernandez","P Llacer-Iborra","J Torres-Macho","M Méndez-Bailon","J L Morales-Rull","P Salamanca-Bautista","N Fernández-Villa","I Torres-Courchoud","M A Vázquez-Ronda","R Martínez-Gutiérrez","P Serrano-Irigoyen","N García-Lorente","J C Trullas","M Cobo-Marcos","M J Pinilla","M Sánchez-Marteles","J Rubio-Gracia"],"significance":5,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":[],"congress":"","summary_en":"The ABDOPOCUS-HF trial evaluated intra-abdominal pressure measurement combined with point-of-care ultrasound to guide decongestive therapy in acute heart failure. The multimodal monitoring approach offers real-time assessment of fluid status during diuretic treatment.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b224be8076e5","type":"article","url":"https://hartvaat.nl/2025/10/01/ambulante-iv-diurese-bij-chronisch-hf-decongest-inzichten/","title":"Ambulante IV-diurese bij chronisch HF: DECONGEST-inzichten","title_en":"Efficacy of ambulatory intravenous diuresis for chronic heart failure patients: Insights from the DEA-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15358","source_url":"https://doi.org/10.1002/ehf2.15358","authors":["Amit Gruber","Aharon Ronnie Abbo","Ina Volis","Doron Aronson","Nicolas Girerd","Søren Lund Kristensen","Robert Zukermann","Natalia Alberkant","Elena Sitnitsky","Anton Kruger","Polina Khasis","Evgeny Bravo","Boaz Elad","Ludmila Helmer Levin","Oren Caspi"],"significance":5,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The DEA-HF trial assessed ambulatory high-dose intravenous diuresis as a strategy for chronic heart failure patients with refractory congestion. The approach reduced hospitalisations and represents a practical outpatient alternative to inpatient decongestion.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b945bc733652","type":"article","url":"https://hartvaat.nl/2025/10/01/dapagliflozine-als-toevoeging-aan-iv-lisdiureticum-bij-acuut-hf-congestieverlich/","title":"Dapagliflozine als toevoeging aan IV-lisdiureticum bij acuut HF: congestieverlichting","title_en":"Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["answer-hf","canagliflozine","dapa-hf","dapagliflozine","empagliflozine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15356","source_url":"https://doi.org/10.1002/ehf2.15356","authors":["Daniela Mocan","Maria Puschita","Diana Lungeanu","Adina Pop-Moldovan","Luminita Pilat","Dan Darabantiu","Radu Jipa","Radu Ioan Lala"],"significance":6,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/diuretica-farmacologie/"],"congress":"","summary_en":"This study showed that adding dapagliflozin to IV loop diuretics in acute heart failure accelerates pulmonary congestion relief, supporting early SGLT2 inhibitor initiation as an adjunctive decongestion strategy.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a4215c9c71a","type":"article","url":"https://hartvaat.nl/2025/10/01/heart-camp-connect-beweegadherentie-bij-hfpef-patienten/","title":"HEART Camp Connect: beweegadherentie bij HFpEF-patiënten","title_en":"HEART Camp Connect-Promoting adherence to exercise in adults with heart failure with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15341","source_url":"https://doi.org/10.1002/ehf2.15341","authors":["Windy W Alonso","Sara E Bills","Scott W Lundgren","Steven J Keteyian","Joseph Norman","Alfred L Fisher","Cheng Zheng","Kevin A Kupzyk","Fernando A Wilson","Tiffany J Dudley","Bunny J Pozehl"],"significance":5,"published":"2025-10-01","source_date":"2025-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The HEART Camp Connect trial evaluated a virtual coaching programme to promote exercise adherence in adults with HFpEF. The theory-informed intervention improved long-term physical activity participation and quality of life.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63c066889532","type":"article","url":"https://hartvaat.nl/2025/09/30/granzyme-k-zet-het-complementsysteem-in-beweging/","title":"Granzyme K zet het complementsysteem in beweging","title_en":"Granzyme K sets complement in motion","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00752-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00752-5/fulltext","authors":["Felix Poppelaars","Mohamed R. Daha"],"significance":5,"published":"2025-09-30","source_date":"2025-09-30","image":"","kennis":[],"congress":"","summary_en":"This commentary discusses how granzyme K initiates complement activation in kidney disease. The complement system, comprising nearly 50 proteins, functions as a surveillance mechanism in circulation and tissues, with emerging therapeutic implications for nephrology.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12b94743ffa9","type":"article","url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","title":"VICTOR: vericiguat bij chronisch HFrEF — dubbelblinde fase 3b trial","title_en":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["step-hfpef"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01665-4","source_url":"https://doi.org/10.1016/S0140-6736(25)01665-4","authors":["Javed Butler","Ciaran J McMullan","Kevin J Anstrom","Irina Barash","Marc P Bonaca","Maria Borentain","Stefano Corda","Justin A Ezekowitz","G Michael Felker","Davis Gates","Carolyn S P Lam","Eldrin F Lewis","JoAnn Lindenfeld","Robert J Mentz","Christopher M O'Connor","Piotr Ponikowski","Yogesh N V Reddy","Giuseppe M C Rosano","Clara Saldarriaga","Michele Senni","Lilin She","Pedro Pinto Teixeira","James Udelson","Alessia Urbinati","Vanja Vlajnic","Adriaan A Voors","Aiwen Xing","Mahesh J Patel","Faiez Zannad"],"significance":7,"published":"2025-09-27","source_date":"2025-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"The VICTOR trial investigated vericiguat in a broader HFrEF population, confirming its value as an additional therapeutic pillar for heart failure treatment on top of established quadruple therapy.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"588e8f9b1719","type":"article","url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","title":"Vericiguat over het risicospectrum bij HFrEF","title_en":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01682-4","source_url":"https://doi.org/10.1016/S0140-6736(25)01682-4","authors":["Faiez Zannad","Christopher M O'Connor","Javed Butler","Ciaran J McMullan","Kevin J Anstrom","Irina Barash","Marc P Bonaca","Maria Borentain","Stefano Corda","Davis Gates","Justin A Ezekowitz","Adrian F Hernandez","Carolyn S P Lam","Eldrin F Lewis","JoAnn Lindenfeld","Robert J Mentz","Piotr Ponikowski","Yogesh N V Reddy","Giuseppe M C Rosano","Clara Saldarriaga","Michele Senni","Pedro P Teixeira","James Udelson","Alessia Urbinati","Vanja Vlajnic","Adriaan A Voors","Aiwen Xing","Mahesh J Patel","Paul W Armstrong"],"significance":6,"published":"2025-09-27","source_date":"2025-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This individual patient data analysis confirmed that vericiguat is consistently effective across the full risk spectrum of HFrEF, with the greatest absolute benefit in the highest-risk patients with recent hospitalization.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23ec27b0ec8d","type":"article","url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","title":"Digitoxine bij HFrEF: gerandomiseerde trial — NEJM","title_en":"Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["dapa-hf","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2415471","source_url":"https://doi.org/10.1056/NEJMoa2415471","authors":["Udo Bavendiek","Anika Großhennig","Johannes Schwab","Dominik Berliner","Andreas Rieth","Lars S Maier","Thomas Gaspar","Nele Henrike Thomas","Xiaofei Liu","Sven Schallhorn","Eleonora Angelini","Samira Soltani","Fabian Rathje","Mircea-Andrei Sandu","Welf Geller","Rainer Hambrecht","Marija Zdravkovic","Sebastian Philipp","Dragana Kosevic","Georg Nickenig","Daniel Scheiber","Sebastian Winkler","Peter Moritz Becher","Philipp Lurz","Martin Hülsmann","Sören Wiesner","Christoph Schröder","Barbara Neuhaus","Anika Seltmann","Heiko von der Leyen","Christian Veltmann","Stefan Störk","Michael Böhm","Armin Koch","Johann Bauersachs"],"significance":9,"published":"2025-09-25","source_date":"2025-09-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This NEJM trial showed that digitoxin reduced heart failure hospitalization in patients with HFrEF receiving contemporary guideline-directed medical therapy. The result repositions cardiac glycosides as a useful adjunct in the modern era of quadruple therapy for heart failure.","created":"2026-07-03T10:31:53Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd7fc160558a","type":"article","url":"https://hartvaat.nl/2025/09/25/cardiale-cachexie-en-uitkomsten-bij-hartfalen-meta-analyse/","title":"Cardiale cachexie en uitkomsten bij hartfalen: meta-analyse","title_en":"Association between cardiac cachexia and adverse outcomes in patients with heart failure: a meta-analysis of cohort studies.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiale-amyloidose","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325431","source_url":"https://doi.org/10.1136/heartjnl-2024-325431","authors":["Bing Liu","Xinyue Wu","Yuxin Wang","Xinhua Hu"],"significance":5,"published":"2025-09-25","source_date":"2025-09-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A meta-analysis confirmed that cardiac cachexia in heart failure is associated with significantly higher mortality. This wasting syndrome requires targeted nutritional and exercise interventions as part of comprehensive heart failure management.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a116389fa39","type":"article","url":"https://hartvaat.nl/2025/09/23/intensief-versus-conventioneel-intraoperatief-bloeddrukmanagement-en-cv-events-n/","title":"Intensief versus conventioneel intraoperatief bloeddrukmanagement en CV-events na chirurgie","title_en":"Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.07.027","source_url":"https://doi.org/10.1016/j.jacc.2025.07.027","authors":["Bingcheng Zhao","Jiaqiang Zhang","Yishan Xie","Zhuoxi Wu","Gaofeng Guo","Shaohui Lei","Jiaming Liu","Huamin Liu","Jian Liu","Weifeng Liu","Cai Li","Yangyang Lian","Yuting Tan","Dongxin Wang","Hong Li","Daniel I Sessler","Kexuan Liu"],"significance":6,"published":"2025-09-23","source_date":"2025-09-23","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that intensive intraoperative blood pressure management reduces postoperative cardiovascular events after major abdominal surgery, supporting proactive hemodynamic control during non-cardiac operations.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a05361938dc7","type":"article","url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","title":"PCI versus CABG en gezondheidsstatus bij stabiel coronairlijden","title_en":"Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.073591","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.073591","authors":["Chetan P Huded","John A Spertus","Philip G Jones","Sean M O'Brien","Daniel B Mark","Sripal Bangalore","Gregg W Stone","David O Williams","Harvey D White","William E Boden","Harmony R Reynolds","Judith S Hochman","David J Maron"],"significance":6,"published":"2025-09-23","source_date":"2025-09-23","image":"","kennis":[],"congress":"","summary_en":"This ISCHEMIA health status analysis compared patient-reported outcomes after PCI versus CABG, showing that CABG provides more initial improvement but PCI achieves comparable long-term symptom benefit.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb3f02b4f806","type":"article","url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","title":"NEWTON-CABG: evolocumab en veneuze graftpatency na CABG","title_en":"Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["newton-cabg"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01633-2","source_url":"https://doi.org/10.1016/S0140-6736(25)01633-2","authors":["Subodh Verma","Lawrence A Leiter","Hwee Teoh","G B John Mancini","Adrian Quan","Randi Elituv","Meena Verma","Elizabeth Misner","Michael Szarek","Kevin E Thorpe","Tarit Saha","Richard P Whitlock","Bobby Yanagawa","Béla Merkely","Peter Jüni","Michael J Koren","Stephen J Nicholls","Deepak L Bhatt","C David Mazer"],"significance":8,"published":"2025-09-20","source_date":"2025-09-20","image":"","kennis":[],"congress":"","summary_en":"The NEWTON-CABG trial showed that evolocumab improved saphenous vein graft patency after CABG through intensive LDL cholesterol lowering. The finding establishes aggressive lipid therapy as a graft-protective strategy after coronary bypass surgery.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"11009b1a646d","type":"article","url":"https://hartvaat.nl/2025/09/18/orforglipron-bij-vroeg-type-2-diabetes-nejm-fase-3/","title":"Orforglipron bij vroeg type 2 diabetes: NEJM fase 3","title_en":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["orforglipron","select-trial","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2505669","source_url":"https://doi.org/10.1056/NEJMoa2505669","authors":["Julio Rosenstock","Stanley Hsia","Luis Nevarez Ruiz","Sarah Eyde","David Cox","Wen-Shuo Wu","Rong Liu","Jianghao Li","Laura Fernández Landó","Max Denning","Lisa Ludwig","Yanyun Chen"],"significance":9,"published":"2025-09-18","source_date":"2025-09-18","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This phase 3 NEJM trial demonstrated that orforglipron, an oral GLP-1 receptor agonist, significantly improved HbA1c and body weight in patients with early type 2 diabetes. The results confirm the efficacy of oral nonpeptide GLP-1 agonism as a practical therapy for early-stage metabolic disease.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0580f9d1c86d","type":"article","url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","title":"ISCHEMIA: anginatrajecten na invasieve versus conservatieve strategie","title_en":"Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["perifeer-vaatlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.044","source_url":"https://doi.org/10.1016/j.jacc.2025.06.044","authors":["Nobuhiro Ikemura","Philip G Jones","Zhuxuan Fu","Paul S Chan","Charles F Sherrod","Suzanne V Arnold","David J Cohen","Daniel B Mark","David J Maron","Judith S Hochman","John A Spertus"],"significance":7,"published":"2025-09-16","source_date":"2025-09-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/nstemi-en-instabiele-angina/"],"congress":"","summary_en":"This ISCHEMIA long-term analysis documented individual angina trajectories, showing that invasively treated patients have less angina burden over time but the advantage narrows compared with conservative management.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6558894ecbc","type":"article","url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","title":"Risicobeoordeling voor bloeddrukmanagement bij primaire preventie","title_en":"Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001355","source_url":"https://doi.org/10.1161/CIR.0000000000001355","authors":["Sadiya S Khan","Marwah Abdalla","Natalie A Bello","Ciantel A Blyler","Jocelyn Carter","Yvonne Commodore-Mensah","Keith C Ferdinand","Heather M Johnson","Daniel Jones","Amit Khera","Paul Muntner","Stacey Schott","Daichi Shimbo","Sidney C Smith","Sandra J Taler","Eugene Yang","Donald M Lloyd-Jones"],"significance":7,"published":"2025-09-16","source_date":"2025-09-16","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This document described the use of cardiovascular risk assessment to guide blood pressure management decisions in primary prevention, providing a framework for risk-based rather than threshold-based treatment initiation.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"373ff88332a6","type":"article","url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","title":"2025 AHA/ACC hypertensierichtlijn: preventie, detectie en management","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001356","source_url":"https://doi.org/10.1161/CIR.0000000000001356","authors":["Daniel W Jones","Keith C Ferdinand","Sandra J Taler","Heather M Johnson","Daichi Shimbo","Marwah Abdalla","M Martine Altieri","Nisha Bansal","Natalie A Bello","Adam P Bress","Jocelyn Carter","Jordana B Cohen","Karen J Collins","Yvonne Commodore-Mensah","Leslie L Davis","Brent Egan","Sadiya S Khan","Donald M Lloyd-Jones","Bernadette Mazurek Melnyk","Eva A Mistry","Modele O Ogunniyi","Stacey L Schott","Sidney C Smith","Amy W Talbot","Wanpen Vongpatanasin","Karol E Watson","Paul K Whelton","Jeff D Williamson"],"significance":10,"published":"2025-09-16","source_date":"2025-09-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"The 2025 AHA/ACC hypertension guideline lowered the definition of hypertension to 130/80 mmHg, converging with the 2024 ESC guidelines. The document emphasizes home blood pressure monitoring, initial combination therapy, and integrates GLP-1 receptor agonists as blood pressure-lowering agents in patients with obesity and hypertension.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"168eb3671d08","type":"article","url":"https://hartvaat.nl/2025/09/16/causale-inferentie-via-regressiediscontinuiteit-lessen-uit-de-gordelroosvaccinat/","title":"Causale inferentie via regressiediscontinuïteit: lessen uit de gordelroosvaccinatie","title_en":"Causal inference using regression discontinuity analysis: what can the nephrologist learn from herpes zoster vaccination?","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00692-1/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00692-1/fulltext","authors":["Craig Peter Coorey","Lin Zhu","Germaine Wong"],"significance":4,"published":"2025-09-16","source_date":"2025-09-16","image":"","kennis":[],"congress":"","summary_en":"This article explains how regression discontinuity analysis provides a quasi-experimental alternative to randomised trials for establishing causal relationships, using herpes zoster vaccination studies as an illustrative example for nephrologists.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cfb1c78803d6","type":"article","url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","title":"Bètablokkers na MI met milde EF-verlaging: IPD meta-analyse","title_en":"β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01592-2","source_url":"https://doi.org/10.1016/S0140-6736(25)01592-2","authors":["Xavier Rossello","Eva Irene Bossano Prescott","Anna Meta Dyrvig Kristensen","Roberto Latini","Valentin Fuster","Morten Wang Fagerland","Stuart J Pocock","Sigrun Halvorsen","Alberto Dominguez-Rodriguez","Therese Lucia Friis Holmager","Pedro Luis Sanchez","Arnhild Bakken","Sergio Raposeiras-Roubin","Svend Eggert Jensen","Takeshi Kimura","Filippo Ottani","Jess Lambrechtsen","Manuel Anguita","Neiko Ozasa","Dan Atar","Borja Ibanez","John Munkhaugen"],"significance":8,"published":"2025-09-13","source_date":"2025-09-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This individual patient data meta-analysis examined beta-blockers after MI with mildly reduced ejection fraction (40-49%), a gray zone between preserved and reduced EF. The data suggest a modest benefit in this subgroup, informing the nuanced decision about beta-blocker continuation.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e26ea529ed4b","type":"article","url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","title":"Multidomein revalidatie bij ouderen na MI: gerandomiseerde trial — NEJM","title_en":"Multidomain Rehabilitation for Older Patients with Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2502799","source_url":"https://doi.org/10.1056/NEJMoa2502799","authors":["Elisabetta Tonet","Andrea Raisi","Silvia Zagnoni","Giorgio Chiaranda","Giovanni Pasanisi","Daniela Aschieri","Paola Emanuela D'Intino","Rita Pavasini","Paolo Cimaglia","Roberta Campana","Francesco Vitali","Tommaso Piva","Gianni Casella","Serena Caglioni","Valentina Zerbini","Giulia Bugani","Marta Cocco","Erica Menegatti","Martina De Raffele","Simona Mandini","Donato Martella","Nicola Pesenti","Gianni Mazzoni","Simone Biscaglia","Stefano Volpato","Giovanni Grazzi","Gianluca Campo"],"significance":8,"published":"2025-09-11","source_date":"2025-09-11","image":"","kennis":[],"congress":"","summary_en":"This NEJM trial evaluated multidomain rehabilitation (physical, cognitive, nutritional, psychosocial) in older patients after MI. The comprehensive approach improved functional outcomes, supporting holistic rehabilitation for elderly cardiac patients.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb6ae8ecfe53","type":"article","url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","title":"IVUS-geleide PCI versus CABG: langetermijnuitkomsten","title_en":"Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325107","source_url":"https://doi.org/10.1136/heartjnl-2024-325107","authors":["Jinho Lee","Jung-Min Ahn","Hoyun Kim","Yeonwoo Choi","Sangyong Jo","Do-Yoon Kang","Min-Ju Kim","Seung Ho Hur","Hun-Jun Park","Damras Tresukosol","Woong Chol Kang","Hyuck Moon Kwon","Seung-Woon Rha","Do-Sun Lim","Myung-Ho Jeong","Bong-Ki Lee","He Huang","Young-Hyo Lim","Jang Ho Bae","Byung Ok Kim","Tiong Kiam Ong","Sung Gyun Ahn","Cheol-Hyun Chung","Duk-Woo Park","Seung-Jung Park"],"significance":7,"published":"2025-09-11","source_date":"2025-09-11","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"This long-term comparison showed that IVUS-guided PCI narrows the outcome gap with CABG, suggesting that optimized percutaneous intervention may approach surgical results when intravascular imaging guidance is consistently used.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80cce10a60a2","type":"article","url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","title":"Pathogene cardiomyopathie-genvarianten en prognose bij AF","title_en":"Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cardiovasculaire-genetica","gepersonaliseerde-geneeskunde","laminopathie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.052","source_url":"https://doi.org/10.1016/j.jacc.2025.06.052","authors":["Sean J Jurgens","Giorgio E M Melloni","Shinwan Kany","Larissa Fabritz","Joel T Rämö","Andreas Goette","Frederick K Kamanu","David D Berg","Christina Magnussen","Seung Hoan Choi","Marc P Bonaca","Robert P Giugliano","Benjamin M Scirica","Stephen D Wiviott","Deepak L Bhatt","Philippe Gabriel Steg","Itamar Raz","Eugene Braunwald","James P Pirruccello","Marc S Sabatine","Nicholas A Marston","Paulus Kirchhof","Patrick T Ellinor","Christian T Ruff"],"significance":6,"published":"2025-09-09","source_date":"2025-09-09","image":"","kennis":[],"congress":"","summary_en":"This study of 18,000 AF patients showed that pathogenic cardiomyopathy gene variants are present in a significant proportion and associated with worse prognosis, supporting genetic testing in the AF population for risk stratification.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"934924e6ffa5","type":"article","url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","title":"SUMMIT: tirzepatide-effect bij HFpEF met en zonder diabetes","title_en":"Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diabetes-type-2","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.058","source_url":"https://doi.org/10.1016/j.jacc.2025.06.058","authors":["Milton Packer","Michael R Zile","Christopher M Kramer","Joseph M DiMaria","Seth J Baum","Sheldon E Litwin","Masahiro Murakami","Chunmei Zhou","Yang Ou","Lisette Koeneman","Barry A Borlaug"],"significance":6,"published":"2025-09-09","source_date":"2025-09-09","image":"","kennis":[],"congress":"","summary_en":"This SUMMIT analysis confirmed that tirzepatide's benefit in HFpEF is consistent regardless of type 2 diabetes status, showing that the dual incretin agonist works through obesity-related mechanisms independent of glycemic effects.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23d4a253b20a","type":"article","url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","title":"Voordeel-nadeel afwegingen van intensieve bloeddrukcontrole","title_en":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01391-1","source_url":"https://doi.org/10.1016/S0140-6736(25)01391-1","authors":["Xiaofan Guo","Guozhe Sun","Yu Xu","Shiyu Zhou","Qirui Song","Yan Li","Nanxiang Ouyang","Guangxiao Li","Zhongde Cheng","Ning Ye","Jun Wang","Ying Zhou","Hongmei Yang","Chuning Shi","Chang Wang","Songyue Liu","Wensheng Zhu","Andrew E Moran","Guang Ning","Yufang Bi","Weiqing Wang","Jun Cai","Jing Li","Yingxian Sun"],"significance":6,"published":"2025-09-06","source_date":"2025-09-06","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This comprehensive analysis of intensive versus standard blood pressure control showed that for most patients, the cardiovascular benefits of intensive treatment outweigh the harms, supporting aggressive targets as the default strategy.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ebf47b9b7f2","type":"article","url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","title":"Directe versus gestageerde complete revascularisatie tijdens index-opname bij STEMI","title_en":"Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01529-6","source_url":"https://doi.org/10.1016/S0140-6736(25)01529-6","authors":["Min Chul Kim","Joon Ho Ahn","Dae Young Hyun","Yongwhan Lim","Kyung Hoon Cho","Seung Hun Lee","Seongho Park","Seok Oh","Doo Sun Sim","Young Joon Hong","Ju Han Kim","Myung Ho Jeong","Jang Hyun Cho","Sang-Rok Lee","Dong Oh Kang","Jin-Yong Hwang","Young Jin Youn","Jung-Hee Lee","Young-Hoon Jeong","Jong-Hwa Ahn","Dong-Bin Kim","Eun Ho Choo","Chan Joon Kim","Weon Kim","Jay Young Rhew","Jong-Il Park","Sang-Yong Yoo","Youngkeun Ahn"],"significance":7,"published":"2025-09-06","source_date":"2025-09-06","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This randomized trial comparing immediate with staged complete revascularization during the index admission for STEMI showed that both timing approaches produce similar outcomes, supporting either strategy based on clinical circumstances.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c351f1f82587","type":"article","url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","title":"PANDA II: griepvaccinatie bij acuut hartfalen — multicenter RCT","title_en":"Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01485-0","source_url":"https://doi.org/10.1016/S0140-6736(25)01485-0","authors":["Craig S Anderson","Chang Hua","Zhiyan Wang","Chi Wang","Chao Jiang","Rong Liu","Rong Han","Qiang Li","Sana Shan","Laurent Billot","C Raina Macintyre","Anushka Patel","Hongjia Zhang","Changsheng Ma","Jianzeng Dong","Xin Du"],"significance":6,"published":"2025-09-06","source_date":"2025-09-06","image":"","kennis":[],"congress":"","summary_en":"The PANDA II trial tested influenza vaccination in patients hospitalized for acute heart failure, addressing whether vaccination during an HF admission provides cardiovascular protection through respiratory infection prevention.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"146beca4cb49","type":"article","url":"https://hartvaat.nl/2025/09/02/coronaire-flow-capaciteits-geleide-revascularisatie-versus-standaardzorg-rct/","title":"Coronaire flow-capaciteits-geleide revascularisatie versus standaardzorg: RCT","title_en":"Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf356","source_url":"https://doi.org/10.1093/eurheartj/ehaf356","authors":["K Lance Gould","Nils P Johnson","Amanda E Roby","Richard Kirkeeide","Mary Haynie","Tung Nguyen","Linh Bui","Monica B Patel","Danai Kitkungvan","Patricia Mendoza","Dejian Lai","Ruosha Li","Stefano Sdringola","David McPherson","Jagat Narula"],"significance":7,"published":"2025-09-02","source_date":"2025-09-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"The CENTURY randomized trial tested a comprehensive strategy integrating coronary flow capacity-guided revascularization with intensive lifestyle modification against usual care for chronic coronary disease, exploring a physiologically optimized management approach.","created":"2026-07-03T10:31:51Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cd1a3332200d","type":"article","url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","title":"AF en ICD bij niet-ischemische HFrEF: impliciaties voor devicetherapie","title_en":"Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","hfref"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf200","source_url":"https://doi.org/10.1093/europace/euaf200","authors":["Seiko N Doi","Adelina Yafasova","Jens Jakob Thune","Jens C Nielsen","Niels E Bruun","Lars Videbæk","Hans Eiskjær","Christian Hassager","Jesper H Svendsen","Dan E Høfsten","Steen Pehrson","Lars Køber","Jawad H Butt"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"Analysis of the DANISH trial examined the impact of atrial fibrillation on ICD outcomes in non-ischaemic heart failure with reduced ejection fraction. AF influenced the ICD indication and the risk of inappropriate shocks, informing device therapy decisions.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e57a638134c6","type":"article","url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","title":"Sedatie versus narcose bij AF-catheterablatie: meta-analyse","title_en":"Sedation vs. general anaesthesia in patients with atrial fibrillation undergoing catheter ablation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf156","source_url":"https://doi.org/10.1093/europace/euaf156","authors":["Beatriz Araújo","André Rivera","Vanessa de Oliveira Tapioca","Lucas M Barbosa","Lucas Caetano","Samuel Navarro Abreu","Sanghamitra Mohanty","Caique M P Ternes","Frans Serpa","Kamala P Tamirisa","André d'Avila","Andrea Natale"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"A meta-analysis compared sedation with general anaesthesia for catheter ablation of atrial fibrillation. General anaesthesia was associated with better outcomes due to more stable catheter positioning, though sedation may be preferable in selected patients.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7712af0aee5c","type":"article","url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","title":"Nierfunctie en effectiviteit van LVA-ablatie na PVI bij AF","title_en":"Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf205","source_url":"https://doi.org/10.1093/europace/euaf205","authors":["Yasuhiro Matsuda","Masaharu Masuda","Toshiaki Mano","Takuya Tsujimura","Hiroyuki Uematsu","Hirotaka Ooka","Satoshi Kudo","Mizuki Ochi","Shin Okamoto","Takayuki Ishihara","Kiyonori Nanto","Yosuke Hata","Sho Nakao","Masaya Kusuda","Wataru Ariyasu","Akihiro Sunaga","Nobuaki Tanaka","Tetsuya Watanabe","Hitoshi Minamiguchi","Yasuyuki Egami","Takafumi Oka","Tomoko Minamisaka","Takashi Kanda","Masato Okada","Masato Kawasaki","Koji Tanaka","Nobuhiko Makino","Hirota Kida","Shungo Hikoso","Tomoharu Dohi","Koichi Inoue","Yohei Sotomi","Yasushi Sakata"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":[],"congress":"","summary_en":"A SUPPRESS-AF substudy investigated whether renal function modifies the efficacy of low-voltage area ablation after pulmonary vein isolation. Kidney function did not significantly influence the benefit of substrate-based ablation.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7f426d3f737","type":"article","url":"https://hartvaat.nl/2025/09/01/la-low-voltage-prevalentie-en-voorspellers-bij-paroxysmaal-versus-niet-paroxysma/","title":"LA low-voltage prevalentie en voorspellers bij paroxysmaal versus niet-paroxysmaal AF","title_en":"Prevalence and multiple predictors of left atrial low voltage in paroxysmal and non-paroxysmal atrial fibrillation patients undergoing ablation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["laminopathie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf206","source_url":"https://doi.org/10.1093/europace/euaf206","authors":["Carlo-Agostino Oliva","Matteo Morello","Jordana Kron","Kenneth A Ellenbogen","Michele Golino","Roberto De Ponti"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"A meta-analysis documented the prevalence and predictors of left atrial low-voltage areas in patients undergoing AF ablation. Atrial fibrosis increases with AF duration and predicts ablation outcome, supporting voltage-guided strategies for patient selection.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c82d54409d75","type":"article","url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","title":"Kosteneffectiviteit van apixaban versus aspirine bij hoogrisico subclinisch AF","title_en":"Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["aspirine"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf195","source_url":"https://doi.org/10.1093/europace/euaf195","authors":["Andre Lamy","Roopinder K Sandhu","Wesley Tong","William F McIntyre","Renato D Lopes","Christopher B Granger","David J Wright","Jens C Nielsen","Valentina Kutyifa","Julia W Erath","Marco Alings","David H Birnie","Dan Atar","Stefan H Hohnloser","Cecilia Linde","Josef Kautzner","Juan Benezet-Mazuecos","A John Camm","Christian Sticherling","Michael R Gold","Charlotte E Larroudé","Jeff S Healey"],"significance":6,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"This cost-effectiveness analysis showed that apixaban is cost-effective compared with aspirin for thromboembolic prevention in high-risk patients with subclinical AF, supporting anticoagulation in device-detected arrhythmia.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e58a06d7b96d","type":"article","url":"https://hartvaat.nl/2025/09/01/csp-sync-geleidingssysteempacing-versus-biventriculaire-pacing-voor-crt-rct/","title":"CSP-SYNC: geleidingssysteempacing versus biventriculaire pacing voor CRT — RCT","title_en":"Conduction system pacing vs. biventricular pacing for cardiac resynchronization: the CSP-SYNC randomized single centre study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","linkerbundeltakpacing"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf192","source_url":"https://doi.org/10.1093/europace/euaf192","authors":["David Žižek","Tadej Žlahtič","Miha Mrak","Maja Ivanovski","Jernej Štublar","Dinko Zavrl Džananović","Jakob Peterlin","Marta Cvijić","Anja Zupan Mežnar"],"significance":8,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":[],"congress":"","summary_en":"The CSP-SYNC trial comparing conduction system pacing (His bundle or left bundle branch area) with biventricular pacing for CRT showed that conduction system pacing is noninferior and potentially superior. The results support physiologic pacing as a viable CRT alternative.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06a3ceab8e10","type":"article","url":"https://hartvaat.nl/2025/09/01/systematische-af-screening-met-gedetailleerde-fenotypering-en-risicopredictie/","title":"Systematische AF-screening met gedetailleerde fenotypering en risicopredictie","title_en":"Systematic, randomized atrial fibrillation screening using detailed phenotyping with a risk prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: the CONSIDERING-AF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf190","source_url":"https://doi.org/10.1093/europace/euaf190","authors":["Emelie Rakai","Farzaneh Etminani","Ninia Younan","Anton Andersson","Maria Andersson","Torbjörn Vik","Stefan Kunkel","Anna Sundin","Johan Holm","Angelo Modica","Helena M Linge","Purvee Parikh","Manish Wadhwa","Johan Engdahl","Emma Sandgren"],"significance":6,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This study showed that systematic AF screening using detailed phenotyping with risk prediction models improves the detection yield of previously undiagnosed atrial fibrillation.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"611c35e3bea3","type":"article","url":"https://hartvaat.nl/2025/09/01/pvi-met-of-zonder-empirische-svc-isolatie-bij-af-ablatie/","title":"PVI met of zonder empirische SVC-isolatie bij AF-ablatie","title_en":"Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["pulmonaalvenenisolatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf175","source_url":"https://doi.org/10.1093/europace/euaf175","authors":["Wenzhi Shen","Yuzhen Zhang","Weichun Qian","Chengzong Li","Cheng Wang","Wei Li","Jian Li","Juan Chen","Youquan Wei","Yu Liu","Yingming Zhao","Wei Xu"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The ESVCI-AF trial assessed whether adding empirical superior vena cava isolation to pulmonary vein isolation improves outcomes in paroxysmal AF ablation. Routine SVC isolation provided no incremental benefit in unselected patients.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d49dd3169150","type":"article","url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","title":"EAST-AFNET 4: diabetes, obesitas en vroege ritmecontrole bij AF","title_en":"Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","obesitas","select-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.2374","source_url":"https://doi.org/10.1001/jamacardio.2025.2374","authors":["Andreas Metzner","Stephan Willems","Katrin Borof","Guenther Breithardt","A John Camm","Harry J G M Crijns","Lars Eckardt","Larissa Fabritz","Nele Gessler","Andreas Goette","Bruno Reissmann","Renate B Schnabel","Ulrich Schotten","Antonia Zapf","Andreas Rillig","Paulus Kirchhof"],"significance":6,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":[],"congress":"","summary_en":"This EAST-AFNET 4 subanalysis confirmed that the benefit of early rhythm control in AF is consistent in patients with and without diabetes and obesity, supporting universal early rhythm management.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bcf205bdd280","type":"article","url":"https://hartvaat.nl/2025/09/01/medicatietrouw-bij-hypertensie-cluster-gerandomiseerde-trial/","title":"Medicatietrouw bij hypertensie: cluster-gerandomiseerde trial","title_en":"Medication Adherence in Hypertension: A Cluster Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling","summit-trial","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.2155","source_url":"https://doi.org/10.1001/jamacardio.2025.2155","authors":["Saul Blecker","Devin M Mann","Tiffany R Martinez","Hayley M Belli","Yunan Zhao","Aamina Ahmed","Cassidy Fitchett","Christina Wong","Harris R Bearnot","Corrine I Voils","Antoinette M Schoenthaler"],"significance":6,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This cluster-randomized trial showed that an intervention targeting medication non-adherence in hypertension significantly improves both adherence and blood pressure control.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4fb9104a5a01","type":"article","url":"https://hartvaat.nl/2025/09/01/preoperatief-cv-risico-en-raas-remmergebruik-postoperatieve-uitkomsten/","title":"Preoperatief CV-risico en RAAS-remmergebruik: postoperatieve uitkomsten","title_en":"Preoperative Cardiovascular Risk and Postoperative Outcomes by Renin-Angiotensin System Inhibitor Use: A Secondary Analysis of a Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.1920","source_url":"https://doi.org/10.1001/jamacardio.2025.1920","authors":["Justine Tang","Romain Pirracchio","Bernard Cholley","Alexandre Joosten","Julien Birckener","Jeremy Falcone","Hélène Charbonneau","Amélie Delaporte","David Chen","Etienne Gayat","Matthieu Legrand"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"A post-hoc analysis of the STOP-or-NOT trial examined whether preoperative cardiovascular risk stratification influences outcomes when continuing versus discontinuing renin-angiotensin system inhibitors before major surgery. Continuing RAS inhibitors was safe across all risk levels.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa8ceca76251","type":"article","url":"https://hartvaat.nl/2025/09/01/veranderde-bloeddrukrefexen-bij-vrouwen-met-endometriose/","title":"Veranderde bloeddrukrefexen bij vrouwen met endometriose","title_en":"Altered Blood Pressure Reflexes in Women With Endometriosis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25089","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25089","authors":["Auni C Williams","Lacy M Alexander"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This study documented altered baroreflex function in women with endometriosis, showing exaggerated blood pressure responses during sympathoexcitatory stimuli. The autonomic dysregulation may partially explain the elevated cardiovascular risk observed in endometriosis.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b07cf93a190b","type":"article","url":"https://hartvaat.nl/2025/09/01/systolische-bloeddrukamplificatie-ipd-meta-analyse/","title":"Systolische bloeddrukamplificatie: IPD meta-analyse","title_en":"Systolic BP Amplification: Systematic Review and Individual Participant Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24483","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24483","authors":["Dean S Picone","Tan V Bui","Martin G Schultz","Petr Otahal","Alun D Hughes","J Andrew Black","Berend E Westerhof","Chen-Huan Chen","Fuyou Liang","Giacomo Pucci","Hao-Min Cheng","Heath Adams","Ji-Guang Wang","Nathan B Dwyer","Philip Roberts-Thomson","Remi Goupil","Sarang Paleri","Scott W Eaves","Xiaoqing Peng","James E Sharman"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"An individual participant data meta-analysis examined systolic blood pressure amplification — the pressure difference between brachial and aortic measurements. Greater amplification was associated with lower cardiovascular risk, underscoring the importance of central blood pressure assessment.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d8342e3111b","type":"article","url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","title":"Bloeddrukverlagende effectiviteit van antihypertensiva en combinaties: uitgebreide meta-analyse","title_en":"Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["abelacimab","bloeddrukbehandeling","farmaco-economie","fidelity","ras-remmers","vrouwen"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00991-2","source_url":"https://doi.org/10.1016/S0140-6736(25)00991-2","authors":["Nelson Wang","Abdul Salam","Rashmi Pant","Amit Kumar","Rupasvi Dhurjati","Faraidoon Haghdoost","Kota Vidyasagar","Prachi Kaistha","Hariprasad Esam","Sonali R Gnanenthiran","Raju Kanukula","Paul K Whelton","Brent Egan","Aletta E Schutte","Kazem Rahimi","Otavio Berwanger","Anthony Rodgers"],"significance":8,"published":"2025-08-30","source_date":"2025-08-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/"],"congress":"","summary_en":"This comprehensive meta-analysis quantified the blood pressure-lowering efficacy of all antihypertensive drug classes and their combinations, providing an evidence-based reference for estimating expected blood pressure reduction with different regimens.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"66b129b6eeb5","type":"article","url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","title":"FLAVOUR langetermijn: FFR versus IVUS voor PCI-begeleiding","title_en":"Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.042","source_url":"https://doi.org/10.1016/j.jacc.2025.06.042","authors":["Seokhun Yang","Xinyang Hu","Jinlong Zhang","Jun Jiang","Joo-Yong Hahn","Joon-Hyung Doh","Bong-Ki Lee","Weon Kim","Jinyu Huang","Fan Jiang","Hao Zhou","Peng Chen","Lijiang Tang","Wenbing Jiang","Hao Chen","Xiaomin Chen","Wenming He","Sung Gyun Ahn","Seung-Jea Tahk","Ung Kim","Doyeon Hwang","Jeehoon Kang","You-Jeong Ki","Eun-Seok Shin","Chang-Wook Nam","Jian'an Wang","Bon-Kwon Koo"],"significance":7,"published":"2025-08-26","source_date":"2025-08-26","image":"","kennis":[],"congress":"","summary_en":"Long-term FLAVOUR results confirmed that FFR-guided PCI produces comparable outcomes to IVUS-guided PCI over extended follow-up, supporting both physiological and anatomical approaches as equivalent guidance strategies.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"baaf4f20f1db","type":"article","url":"https://hartvaat.nl/2025/08/26/hepa-luchtzuivering-en-bloeddruk-pragmatische-cross-over-trial/","title":"HEPA-luchtzuivering en bloeddruk: pragmatische cross-over trial","title_en":"Effect of HEPA Filtration Air Purifiers on Blood Pressure: A Pragmatic Randomized Crossover Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.06.037","source_url":"https://doi.org/10.1016/j.jacc.2025.06.037","authors":["Doug Brugge","Misha Eliasziw","Mohan Thanikachalam","Vedaant Kuchhal","Chermaine Morson","Teresa Vazquez-Dodero","Amy Mertl","Pratham Tallam","Sangita Kunwar","Linda Sprague Martinez","Humza Shamoon Rashid","Kiran Singh-Smith","Hunter Gates","Sharly Palma","Warren Goldstein-Gelb","Shir Lerman Ginzburg","Scott Oakley Hersey","Francesca Majluf","Wig Zamore"],"significance":5,"published":"2025-08-26","source_date":"2025-08-26","image":"","kennis":[],"congress":"","summary_en":"A pragmatic crossover trial tested whether HEPA air purifiers reduce blood pressure in adults living near highways. The blood pressure-lowering effect was limited, tempering expectations for air quality interventions as a hypertension management strategy.","created":"2026-07-03T10:31:49Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"663bfb714ab7","type":"article","url":"https://hartvaat.nl/2025/08/26/minder-zitten-of-meer-staan-effect-op-bloeddruk-en-glucose/","title":"Minder zitten of meer staan: effect op bloeddruk en glucose","title_en":"Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.073385","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.073385","authors":["Sheri J Hartman","Andrea Z LaCroix","Dorothy D Sears","Loki Natarajan","Rong W Zablocki","Ruohui Chen","Jeffrey S Patterson","Lindsay Dillon","James F Sallis","Simon Schenk","David W Dunstan","Neville Owen","Dori E Rosenberg"],"significance":5,"published":"2025-08-26","source_date":"2025-08-26","image":"","kennis":[],"congress":"","summary_en":"A three-arm randomised trial in sedentary postmenopausal women compared reducing sitting time versus increasing sit-to-stand transitions for cardiovascular and metabolic health. Both sedentary behaviour modification strategies produced modest but significant improvements in blood pressure and glucose regulation.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"746e78273dd4","type":"article","url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","title":"OCT versus angiografie bij PCI van verkalkte laesies: driejaarsdata","title_en":"Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf331","source_url":"https://doi.org/10.1093/eurheartj/ehaf331","authors":["Ziad A Ali","Doosup Shin","Rajesh Vijayvergiya","Atit A Gawalkar","Richard A Shlofmitz","Fernando Alfonso","Giuseppe Calligaris","Paolo Canova","Koshiro Sakai","Matthew J Price","David Leistner","Francesco Prati","Gary Mintz","Mitsuaki Matsumura","Robert J McGreevy","Robert W McNutt","Hong Nie","Jana Buccola","Ulf Landmesser","Akiko Maehara","Gregg W Stone"],"significance":6,"published":"2025-08-21","source_date":"2025-08-21","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"Three-year ILUMIEN IV data showed that the procedural advantage of OCT-guided PCI in calcified lesions now translates to improved clinical outcomes, establishing imaging guidance as particularly valuable for calcified coronary disease.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c66545d3637","type":"article","url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","title":"PREVENT: langetermijn follow-up van preventieve PCI bij kwetsbare plaques","title_en":"Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["primaire-preventie","secundaire-preventie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf273","source_url":"https://doi.org/10.1093/eurheartj/ehaf273","authors":["Min Chul Kim","Seung-Jung Park","Duk-Woo Park","Jung-Min Ahn","Do-Yoon Kang","Won-Jang Kim","Chang-Wook Nam","Jin-Ok Jeong","In-Ho Chae","Hiroki Shiomi","Hsien-Li Kao","Joo-Yong Hahn","Sung-Ho Her","Bong-Ki Lee","Tae Hoon Ahn","Kiyuk Chang","Jei Keon Chae","David Smyth","Gary S Mintz","Gregg W Stone","Youngkeun Ahn"],"significance":8,"published":"2025-08-21","source_date":"2025-08-21","image":"","kennis":[],"congress":"","summary_en":"Long-term PREVENT data confirmed the benefit of preventive PCI for vulnerable plaques identified by IVUS/OCT in diabetic patients. The paradigm of treating non-flow-limiting high-risk lesions continues to gain evidence.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97034847b9ab","type":"article","url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","title":"Paclitaxel-gecoate ballon bij multilayer in-stent restenose: AGENT IDE subgroep","title_en":"Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.062","source_url":"https://doi.org/10.1016/j.jacc.2025.05.062","authors":["Ajay J Kirtane","Richard Shlofmitz","Jeffrey Moses","William Bachinsky","Suhail Dohad","Steven Rudick","Robert Stoler","Brian K Jefferson","William Nicholson","John Altman","Cinthia Bateman","Amar Krishnaswamy","J Aaron Grantham","Francis J Zidar","Jennifer A Tremmel","Cindy Grines","Mustafa I Ahmed","Azeem Latib","Behnam Tehrani","J Dawn Abbott","Wayne Batchelor","Rafael Cavalcante","Robert W Yeh"],"significance":5,"published":"2025-08-19","source_date":"2025-08-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"An AGENT IDE subgroup analysis evaluated the paclitaxel-coated balloon for treating coronary in-stent restenosis with multiple stent layers. The drug-coated balloon was effective in these complex restenosis patterns, offering a stent-free alternative.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4730c0415a17","type":"article","url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","title":"MASTER DAPT: recurrente events analyse van verkorte versus standaard DAPT","title_en":"Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patients.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.010","source_url":"https://doi.org/10.1016/j.jacc.2025.05.010","authors":["Dario Bongiovanni","Antonio Landi","Enrico Frigoli","Dik Heg","Konstantina Chalkou","Jozef Bartunek","Laurent Delorme","Willem Dewilde","David Hildick-Smith","Gregor Leibundgut","Sergio Leonardi","Maciej Lesiak","Petr Kala","Sasko Kedev","Marco Roffi","Goran Stankovic","Pim A L Tonino","Vasil Velchev","Pascal Vranckx","Stephan Windecker","Pieter C Smits","Marco Valgimigli"],"significance":6,"published":"2025-08-19","source_date":"2025-08-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This MASTER DAPT recurrent events analysis confirmed that abbreviated DAPT reduces the total bleeding burden without increasing total ischemic events in high-bleeding-risk PCI patients.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f70f1a583813","type":"article","url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","title":"ACHIEVE: spironolacton bij dialysepatiënten — internationale RCT","title_en":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01198-5","source_url":"https://doi.org/10.1016/S0140-6736(25)01198-5","authors":["Michael Walsh","David Collister","Martin Gallagher","Patrick B Mark","Janak R de Zoysa","Jessica Tyrwhitt","Karthik Tennankore","Gilmar Reis","Denis Xavier","Wen J Liu","Li Zuo","Amanda Y Wang","Camilo Félix","Laura Sola","Mustafa Arici","Russell Villanueva","Vivekanand Jha","Dalton Précoma","Christian G Rabbat","Sheik Sulthan Alavudeen","Atiya R Faruqui","Mavel López-Flecher","Lonnie Pyne","Ron Wald","Fei Yuan","Kumar Balasubramanian","Shun Fu Lee","Alena Kuptsova","Courtney Christou","P J Devereaux"],"significance":7,"published":"2025-08-16","source_date":"2025-08-16","image":"","kennis":[],"congress":"","summary_en":"The ACHIEVE trial established the safety and potential cardiovascular benefit of spironolactone in patients on maintenance dialysis, a population where MRA use has traditionally been avoided due to hyperkalemia concerns.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"262f725f1d71","type":"article","url":"https://hartvaat.nl/2025/08/14/cagrisema-gecombineerd-cagrilintide-en-semaglutide-bij-overgewicht-nejm/","title":"CagriSema: gecombineerd cagrilintide en semaglutide bij overgewicht — NEJM","title_en":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cagrisema","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2502081","source_url":"https://doi.org/10.1056/NEJMoa2502081","authors":["W Timothy Garvey","Matthias Blüher","Cynthia Karenina Osorto Contreras","Melanie J Davies","Eva Winning Lehmann","Kirsi H Pietiläinen","Domenica Rubino","Paolo Sbraccia","Thomas Wadden","Niels Zeuthen","John P H Wilding"],"significance":10,"published":"2025-08-14","source_date":"2025-08-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"This pivotal trial of CagriSema (cagrilintide plus semaglutide) in adults with overweight or obesity demonstrated up to 25% body weight reduction, substantially exceeding semaglutide monotherapy. The amylin–GLP-1 combination represents the most effective pharmacological weight loss therapy to date and may redefine obesity treatment targets.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d27e1cec3436","type":"article","url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","title":"Hartfalen: mondiale economische ziektelast","title_en":"Heart failure: assessment of the global economic burden.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf323","source_url":"https://doi.org/10.1093/eurheartj/ehaf323","authors":["Mohammad Darvish","Abdul Shakoor","Lida Feyz","Jeroen Schaap","Nicolas M van Mieghem","Rudolf A de Boer","Jasper J Brugts","Robert M A van der Boon"],"significance":6,"published":"2025-08-14","source_date":"2025-08-14","image":"","kennis":[],"congress":"","summary_en":"This comprehensive analysis documented the global economic burden of heart failure, showing annual costs in the hundreds of billions, driven primarily by hospitalization and demonstrating the economic case for effective HF prevention.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e58c37c43eba","type":"article","url":"https://hartvaat.nl/2025/08/14/plaque-remodeling-als-surrogaat-voor-ernstige-cardiale-events/","title":"Plaque-remodeling als surrogaat voor ernstige cardiale events","title_en":"Plaque remodelling as a surrogate for major adverse cardiac events","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["atherosclerose","plaquekarakterisatie","secundaire-preventie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01379-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01379-6/fulltext","authors":["G.B. John Mancini"],"significance":4,"published":"2025-08-14","source_date":"2025-08-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This commentary discusses plaque remodelling as a surrogate endpoint for major adverse cardiac events in the context of intensive lipid-lowering therapy. The use of imaging-based plaque assessment as a trial endpoint has evolved since the classic FATS trial.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b84027512b8d","type":"article","url":"https://hartvaat.nl/2025/08/14/kanttekening-bij-coronaire-plaquefenotypeveranderingen-onder-lipidenverlagende-t/","title":"Kanttekening bij coronaire plaquefenotypeveranderingen onder lipidenverlagende therapie","title_en":"Regarding “Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events”: a compelling hypothesis warranting cautious interpretation","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","bloeddrukbehandeling","dyslipidemie","ezetimibe","hartkatheterisatie","lipidenverlaging","niet-statine-therapie","obesitas","plaquekarakterisatie","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01380-2/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01380-2/fulltext","authors":["Artur Dziewierz","Beata Bobrowska","Renata Rajtar-Salwa"],"significance":4,"published":"2025-08-14","source_date":"2025-08-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"This commentary provides a cautious interpretation of the systematic review by Patti et al. on lipid-lowering therapy-induced coronary plaque phenotype changes and their relationship with cardiovascular events. The hypothesis is compelling but requires careful methodological scrutiny.","created":"2026-07-03T10:25:43Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"07494417b130","type":"article","url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","title":"COMBINE AF: overstap naar nieuwer anticoagulans versus warfarine bij ouderen","title_en":"Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["abelacimab","anticoagulatie-kwetsbare-ouderen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.060","source_url":"https://doi.org/10.1016/j.jacc.2025.05.060","authors":["Andre M Nicolau","Robert P Giugliano","Andre Zimerman","Jonathan Afilalo","Baris Gencer","Jan Steffel","Michael G Palazzolo","John W Eikelboom","Christopher B Granger","Manesh R Patel","Renato D Lopes","Bernard J Gersh","Belal Suleiman","Joris R de Groot","Mauricio I Scanavacca","Christian T Ruff","Elliott M Antman","Eugene Braunwald","Lars Wallentin"],"significance":6,"published":"2025-08-12","source_date":"2025-08-12","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This COMBINE-AF analysis showed that switching from warfarin to a NOAC in older AF patients is associated with improved outcomes compared with remaining on warfarin, supporting anticoagulant modernization even in the elderly.","created":"2026-07-03T10:31:48Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"99b2c0dc20cf","type":"article","url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","title":"Catheterablatie versus rate control bij persisterend AF en ouder hartfalen","title_en":"Catheter ablation versus medical rate control for persistent atrial fibrillation in older heart failure patients with reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324668","source_url":"https://doi.org/10.1136/heartjnl-2024-324668","authors":["Ziliang Song","Shi-Yi Wang","Zheng Qidong","Nannan Chen","Yu Zhang","Weifeng Jiang","Shao Hui Wu","Kai Xu","Yang Liu","Xu Liu","Xumin Hou","Mu Qin"],"significance":7,"published":"2025-08-12","source_date":"2025-08-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This randomized trial compared catheter ablation with medical rate control in older patients with persistent AF and HFrEF, showing that ablation improves left ventricular function and reduces heart failure events even in elderly patients.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af9317ea00e7","type":"article","url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","title":"ABPM, ESC-streefwaarden en CV-uitkomsten: IPD meta-analyse","title_en":"Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf220","source_url":"https://doi.org/10.1093/eurheartj/ehaf220","authors":["Dong-Yan Zhang","De-Wei An","Yu-Ling Yu","Jesus D Melgarejo","José Boggia","Dries S Martens","Tine W Hansen","Kei Asayama","Takayoshi Ohkubo","Katarzyna Stolarz-Skrzypek","Sofia Malyutina","Edoardo Casiglia","Lars Lind","Gladys E Maestre","Ji-Guang Wang","Yutaka Imai","Kalina Kawecka-Jaszcz","Edgardo Sandoya","Marek Rajzer","Tim S Nawrot","Eoin O'Brien","Wen-Yi Yang","Jan Filipovský","Auxiliadora Graciani","José R Banegas","Yan Li","Jan A Staessen"],"significance":7,"published":"2025-08-08","source_date":"2025-08-08","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This individual patient data meta-analysis examined the relationship between ambulatory blood pressure values and the new ESC guideline targets, showing that time below target on 24-hour monitoring predicts cardiovascular outcomes more accurately than office measurements.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44d4e64e8773","type":"article","url":"https://hartvaat.nl/2025/08/05/sglt2-remmer-met-en-zonder-mra-bij-hartfalen-gecombineerde-analyse/","title":"SGLT2-remmer met en zonder MRA bij hartfalen: gecombineerde analyse","title_en":"Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","fidelity","hfref","sglt2-remmers","vericiguat"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.033","source_url":"https://doi.org/10.1016/j.jacc.2025.05.033","authors":["João Pedro Ferreira","Francisco Vasques-Nóvoa","Francisca Saraiva","Ana C Oliveira","Jorge Almeida","Ana Beatriz Batista","Arsénio Barbosa","Ana Filipa Ferreira","Cátia Costa","Silvia O Diaz","Diogo Santos-Ferreira","Fernando Friões","Cândida Goncalves","João Tiago Guimarães","Marta Leite","Pedro Marques","Joana Mascarenhas","Maria Inês Matos","Catarina Pereira","Pedro Rodrigues","Abhinav Sharma","Gualter Silva","Inês Pereira-Sousa","Carla Sousa","Faiez Zannad","Joana Pimenta","Ricardo Fontes-Carvalho","Adelino Leite-Moreira"],"significance":7,"published":"2025-08-05","source_date":"2025-08-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This analysis showed that combining SGLT2 inhibitors with aldosterone antagonists in HFpEF provides additive cardiovascular benefit beyond either drug class alone, supporting the emerging four-pillar approach for preserved ejection fraction heart failure.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"65f82f438e1f","type":"article","url":"https://hartvaat.nl/2025/08/05/lorundrostat-bij-ongecontroleerde-en-therapieresistente-hypertensie-fase-3-resul/","title":"Lorundrostat bij ongecontroleerde en therapieresistente hypertensie: fase 3 resultaten","title_en":"Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","aprocitentan","baxdrostat","bloeddrukbehandeling","lorundrostat","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"JAMA","doi":"10.1001/jama.2025.9413","source_url":"https://doi.org/10.1001/jama.2025.9413","authors":["Manish Saxena","Luke Laffin","Claudio Borghi","Beatriz Fernandez Fernandez","Jalal K Ghali","Branko Kopjar","Krishna Polu","Simon D Roger","B T Slingsby","Frank Strutz","Liffert Vogt","Matthew R Weir","David Rodman"],"significance":8,"published":"2025-08-05","source_date":"2025-08-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/"],"congress":"","summary_en":"Phase 3 results of lorundrostat confirmed significant blood pressure reduction in both uncontrolled and treatment-resistant hypertension. The aldosterone synthase inhibitor class is now supported by multiple positive phase 3 trials.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab36a704410f","type":"article","url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","title":"Abelacimab versus rivaroxaban bij AF op antiplaatjestherapie: subanalyse","title_en":"Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["abelacimab","aperitif-trial","rivaroxaban"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.074037","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.074037","authors":["Samer Al Said","Siddharth M Patel","Robert P Giugliano","David A Morrow","Erica L Goodrich","Sabina A Murphy","Bruce Hug","Sanobar Parkar","Shih-Ann Chen","Shaun G Goodman","Boyoung Joung","Robert G Kiss","Wojciech Wojakowski","Jeffrey I Weitz","Dan Bloomfield","Marc S Sabatine","Christian T Ruff"],"significance":7,"published":"2025-08-05","source_date":"2025-08-05","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This AZALEA-TIMI 71 subanalysis confirmed that abelacimab causes less bleeding than rivaroxaban even in AF patients on concurrent antiplatelet therapy, the highest-bleeding-risk scenario for anticoagulation.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3cacffff942","type":"article","url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","title":"LBBAP versus RV-pacing: tweejaarsresultaten bij pacemakergeïndiceerde patiënten","title_en":"Two-year outcomes of left bundle branch area pacing versus traditional right ventricular pacing in middle-aged adults: a registry-based trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["linkerbundeltakpacing"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf181","source_url":"https://doi.org/10.1093/europace/euaf181","authors":["Matteo Bertini","Luca Canovi","Francesco Vitali","Lina Marcantoni","Gianni Pastore","Mario Volpicelli","Orlando Munciguerra","Mauro Biffi","Matteo Ziacchi","Luca Rossi","Valeria Carinci","Paolo Sirugo","Paolo Pastori","Jacopo Francesco Imberti","Pier Luigi Pellegrino","Erminia Guerriero","Biagio Sassone","Enrico Bertagnin","Giuseppe Coppola","Michele Malagù","Cristina Balla","Giorgia Azzolini","Gloria Zuccari","Francesco Zanon","Giuseppe Boriani","Marco Zuin"],"significance":7,"published":"2025-08-04","source_date":"2025-08-04","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"Two-year data showed that left bundle branch area pacing is superior to conventional right ventricular pacing for preserving LV function and preventing heart failure in patients requiring frequent ventricular pacing.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e7047dad3d9","type":"article","url":"https://hartvaat.nl/2025/08/04/pvi-met-versus-zonder-lineaire-ablatie-bij-persisterend-af-gerandomiseerde-trial/","title":"PVI met versus zonder lineaire ablatie bij persisterend AF: gerandomiseerde trial","title_en":"Circumferential pulmonary vein isolation with adjunctive linear ablation vs. circumferential pulmonary vein isolation alone for long-standing persistent atrial fibrillation: a randomized pilot study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf176","source_url":"https://doi.org/10.1093/europace/euaf176","authors":["Yeqian Zhu","Yan Dong","Qiushi Chen","Li Jiang","Yuan He","Nishant Yadav","Kejiang Cao","Fengxiang Zhang"],"significance":6,"published":"2025-08-04","source_date":"2025-08-04","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized trial showed that adding linear ablation to circumferential PVI provides better outcomes for persistent AF, an exception to the prevailing neutral evidence for adjunctive ablation beyond PVI.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fe723db1ba2b","type":"article","url":"https://hartvaat.nl/2025/08/04/zeer-hoog-vermogen-70w-rf-ablatie-met-flexibele-tip-voor-pvi-bij-af/","title":"Zeer hoog vermogen (70W) RF-ablatie met flexibele tip voor PVI bij AF","title_en":"Very high-power short-duration using 70W and a flexible tip ablation catheter for pulmonary vein isolation: the POWER PULSE randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf105","source_url":"https://doi.org/10.1093/europace/euaf105","authors":["Miruna A Popa","Hannah Krafft","Fabian Bahlke","Florian Englert","Sarah Lengauer","Marta Telishevska","Nico Erhard","Madeleine Tydecks","Martin Hadamitzky","Felix Bourier","Tilko Reents","Elisabeth Klupp","Carsten Lennerz","Gabriele Hessling","Isabel Deisenhofer","Marc Kottmaier"],"significance":5,"published":"2025-08-04","source_date":"2025-08-04","image":"","kennis":[],"congress":"","summary_en":"The POWER PULSE trial evaluated very high-power short-duration radiofrequency ablation at 70W with a flexible-tip catheter for pulmonary vein isolation in paroxysmal AF. The technique achieved rapid and effective PVI with an acceptable safety profile.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a130a4f758ff","type":"article","url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","title":"FINEARTS-HF: finerenon naar frailteit bij hartfalen","title_en":"Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","finearts-hf","finerenon-hartfalen-nierziekte","hfmref","hfpef","hfref"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.1775","source_url":"https://doi.org/10.1001/jamacardio.2025.1775","authors":["Jawad H Butt","Pardeep S Jhund","Alasdair D Henderson","Brian L Claggett","Chern-En Chiang","Gerard C M Linssen","Clara I Saldarriaga","Jose F K Saraiva","Naoki Sato","Morten Schou","Dirk von Lewinski","James Lay-Flurrie","Andrea Scalise","Katja Rohwedder","Akshay S Desai","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This FINEARTS-HF analysis confirmed that finerenone provides consistent heart failure benefit regardless of frailty status, supporting MRA therapy even in the most vulnerable HFpEF patients.","created":"2026-07-03T10:31:47Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"54ad6d89ee3c","type":"article","url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","title":"Cellulaire adhesiemoleculen en uitkomsten bij chronisch HF: DAPA-HF analyse","title_en":"Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.1592","source_url":"https://doi.org/10.1001/jamacardio.2025.1592","authors":["Kirsty McDowell","Paul Welsh","Kieran F Docherty","David A Morrow","Pardeep S Jhund","Rudolf A De Boer","Eileen O'Meara","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Felipe A Martinez","Piotr Ponikowski","Ann Hammarstedt","Anna Maria Langkilde","Scott D Solomon","Naveed Sattar","Marc S Sabatine","John J V McMurray"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"Analysis of the DAPA-HF biomarker substudy demonstrated that elevated vascular and intracellular adhesion molecules predict adverse outcomes in chronic heart failure. Dapagliflozin reduced these inflammatory markers, providing mechanistic insight into SGLT2 inhibitor cardioprotection.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"17380bfdebca","type":"article","url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","title":"REDUCE-AMI: bètablokker-interruptie en bloeddruk/hartfrequentie-effecten na MI","title_en":"Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["betablokkers","bisoprolol","bloeddrukbehandeling"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf170","source_url":"https://doi.org/10.1093/eurheartj/ehaf170","authors":["Niki Procopi","Michel Zeitouni","Mathieu Kerneis","Guillaume Cayla","Emile Ferrari","Grégoire Range","Etienne Puymirat","Nicolas Delarche","Paul Guedeney","Farzin Beygui","Laurent Desprets","Jean-Louis Georges","Thomas Bochaton","François Schiele","Grégory Ducrocq","Marie Hauguel-Moreau","Raphaelle Dumaine","Michel S Slama","Laurent Payot","Mohamad El Kasty","Karim Aacha","Abdourahmane Diallo","Xavier Girerd","Eric Vicaut","Johanne Silvain","Gilles Montalescot"],"significance":6,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"This ABYSS subanalysis showed that beta-blocker interruption after MI leads to modest increases in blood pressure and heart rate that remain clinically acceptable, providing hemodynamic reassurance for the discontinuation strategy.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e55983eab3d","type":"article","url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","title":"Biodegradeerbare versus duurzame polymeer EES: langetermijn neoatherosclerose","title_en":"Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae589","source_url":"https://doi.org/10.1093/eurheartj/ehae589","authors":["Masanori Taniwaki","Jonas Dominik Häner","Ryota Kakizaki","Yohei Ohno","Kazuyuki Yahagi","Yoshiharu Higuchi","George C M Siontis","Kenji Ando","Stefan Stortecky","Nobuaki Suzuki","Laura Morf","Naoki Watanabe","Jonas Lanz","Yasushi Ueki","Tatsuhiko Otsuka","Flavio Giuseppe Biccirè","Masami Sakurada","Sylvain Losdat","Lorenz Räber"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":[],"congress":"","summary_en":"The CONNECT trial compared neoatherosclerosis development in biodegradable versus durable polymer everolimus-eluting stents 3 years after primary PCI for STEMI. Biodegradable polymer stents showed less neoatherosclerosis, confirming the theoretical advantage of polymer degradation for long-term vessel healing.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c6e3a7f9868","type":"article","url":"https://hartvaat.nl/2025/08/01/voordeel-en-risico-van-intensieve-bloeddrukcontrole-naar-cv-risico/","title":"Voordeel en risico van intensieve bloeddrukcontrole naar CV-risico","title_en":"Benefit and Harm of Intensive Blood Pressure Control by Cardiovascular Risk.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","obesitas","slaapapneu","voeding-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.25162","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25162","authors":["Xilan Dong","Qianhui Ling","Xueyan Zhao","Qirui Song","Jun Cai"],"significance":7,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This analysis examined the balance between benefit and harm of intensive blood pressure treatment across cardiovascular risk profiles, confirming that higher-risk patients derive the greatest net benefit from aggressive targets.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7559d6ed9943","type":"article","url":"https://hartvaat.nl/2025/08/01/ctrh-als-biomarker-voor-medicijneffectiviteit-real-world-bewijs/","title":"CTRH als biomarker voor medicijneffectiviteit: real-world bewijs","title_en":"CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","troponine"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24523","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24523","authors":["Farzin Khosrow-Khavar","Reinhold Kreutz","Antonios Douros"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"This systematic review assessed the methodological quality of observational studies linking cancer treatment-related hypertension with survival outcomes. The findings support further investigation of CTRH as a potential biomarker of anticancer drug efficacy.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b42eda65771","type":"article","url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","title":"Sympathische overactiviteit bij resistente hypertensie: meta-analyse","title_en":"Sympathetic Overactivation in the Resistant Hypertensive Phenotype: A Meta-Analysis of Published Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["aprocitentan","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.125.24749","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24749","authors":["Guido Grassi","Fosca Quarti-Trevano","Cesare Cuspidi","Elias Sanidas","Giuseppe Mancia","Costas Thomopoulos"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/"],"congress":"","summary_en":"A meta-analysis confirmed that sympathetic overactivation is a core pathophysiological mechanism in resistant hypertension. These findings support sympatholytic therapies such as renal denervation and baroreflex activation as targeted treatment options.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"853a69fb6a67","type":"article","url":"https://hartvaat.nl/2025/08/01/lipideparameters-en-prognose-bij-hartfalen-meta-analyse/","title":"Lipideparameters en prognose bij hartfalen: meta-analyse","title_en":"Prognostic value of lipid parameters among patients with heart failure: A systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","nt-probnp","statines"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15315","source_url":"https://doi.org/10.1002/ehf2.15315","authors":["Ahmed Sayed","Hesham Afify","Malak Munir","Ibrahim ElGarhy","Omar Shazly","Mohamed ElRefaei","Saeed Ahmed","Ahmed Mazen Amin","Omar Chikh Amine","Islam Y Elgendy"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"A meta-analysis evaluated the prognostic significance of lipid parameters in heart failure. The cholesterol paradox — lower cholesterol associated with worse prognosis in heart failure — was confirmed, requiring nuanced interpretation of lipid values in this context.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4f6379dc9067","type":"article","url":"https://hartvaat.nl/2025/08/01/nt-probnp-veranderingen-en-klinische-uitkomsten-bij-pediatrisch-hartfalen/","title":"NT-proBNP-veranderingen en klinische uitkomsten bij pediatrisch hartfalen","title_en":"Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15326","source_url":"https://doi.org/10.1002/ehf2.15326","authors":["Robert Shaddy","Jianjian Gong","Tania Garito","Susan Solar-Yohay","Sijia Zhang","Margaret F Prescott","Damien Bonnet","Paul F Kantor","Michael Burch","Chad Mao","Antoinette Cilliers","Charles Canter","Yuk Law","Giorgia Grutter","Jou Kou Wang","Aamir Jeewa","Joseph Rossano"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"Analysis of the PANORAMA-HF trial demonstrated that declining NT-proBNP levels correlate with improved clinical outcomes in paediatric heart failure. Serial biomarker monitoring informs treatment response assessment in this underserved population.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f84a48f3d4c1","type":"article","url":"https://hartvaat.nl/2025/08/01/linkeratriale-strain-en-prognose-bij-acuut-en-chronisch-hartfalen-meta-analyse/","title":"Linkeratriale strain en prognose bij acuut en chronisch hartfalen: meta-analyse","title_en":"Prognostic value of left atrial strain in acute and chronic heart failure: A meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15302","source_url":"https://doi.org/10.1002/ehf2.15302","authors":["Maria Concetta Pastore","Mariangela Vigna","Andrea Saglietto","Maria Alma Iuliano","Giulia Elena Mandoli","Andrea Stefanini","Chiara Carrucola","Laura Fusini","Luna Cavigli","Flavio D'ascenzi","Marta Focardi","Serafina Valente","Matteo Cameli"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/echocardiografie-bij-hartfalen/"],"congress":"","summary_en":"A meta-analysis confirmed the prognostic value of peak atrial longitudinal strain in both acute and chronic heart failure. Left atrial strain provides incremental prognostic information beyond conventional echocardiographic parameters across heart failure phenotypes.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dbe1c924e885","type":"article","url":"https://hartvaat.nl/2025/08/01/tricuspidalisinsufficientie-en-hartfalenuitkomsten-meta-analyse/","title":"Tricuspidalisinsufficiëntie en hartfalenuitkomsten: meta-analyse","title_en":"Association between tricuspid regurgitation and heart failure outcomes: A meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","tricuspidalisinsufficiëntie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15303","source_url":"https://doi.org/10.1002/ehf2.15303","authors":["Zongle Sun","Yan Luo","Xiaoli Wang","Tianying Chang","Mengmeng Chang","Yingzi Cui","Jiajuan Guo"],"significance":6,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that tricuspid regurgitation severity independently predicts worse outcomes in heart failure, supporting aggressive evaluation and treatment of TR as a prognostically significant comorbidity.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T18:39:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da3343d4e35d","type":"article","url":"https://hartvaat.nl/2025/08/01/opnameduur-en-eerdere-hf-opnames-bij-frailteit-en-hartfalen-systematische-review/","title":"Opnameduur en eerdere HF-opnames bij frailteit en hartfalen: systematische review","title_en":"Length of stay and prior heart failure admission in frailty and heart failure: A systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15300","source_url":"https://doi.org/10.1002/ehf2.15300","authors":["Konstantinos Prokopidis","Amy Nortcliffe","Chukwuma Okoye","Massimo Venturelli","Gregory Y H Lip","Masoud Isanejad"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A systematic review and meta-analysis documented the relationship between frailty, hospital length of stay, and prior heart failure admissions. Frail patients had significantly longer hospitalisations and more readmissions, underscoring the need for targeted transitional care.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"086f091f749b","type":"article","url":"https://hartvaat.nl/2025/08/01/vroege-diuretische-respons-en-uitkomstvoorspelling-bij-ambulant-verslechterend-h/","title":"Vroege diuretische respons en uitkomstvoorspelling bij ambulant verslechterend HF","title_en":"Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15275","source_url":"https://doi.org/10.1002/ehf2.15275","authors":["M Cobo Marcos","R de la Espriella","I Zegri-Reiriz","P Llacer","J Rubio Gracia","J Comín-Colet","J L Morales-Rull","P Diez-Villanueva","J de Juan Bagudá","S Jiménez-Marrero","C Ortiz Cortés","M A Restrepo-Córdoba","J M García-Pinilla","E Barrios","S Del Prado Díaz","J Núñez"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":[],"congress":"","summary_en":"A post-hoc analysis of the SALT-HF trial compared early natriuresis and diuresis as predictors of 30-day outcomes in ambulatory worsening heart failure. Natriuresis proved a superior early marker of therapeutic response to decongestive therapy.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a400cef86e7","type":"article","url":"https://hartvaat.nl/2025/08/01/inspanningsmodaliteiten-en-fysieke-functie-bij-hfpef-meta-analyse/","title":"Inspanningsmodaliteiten en fysieke functie bij HFpEF: meta-analyse","title_en":"Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15256","source_url":"https://doi.org/10.1002/ehf2.15256","authors":["Jiang-Ying Li","Lu Chen","Qiu-Chen Wang","Jian Zhu","Zhen-Qing Ren","Li-Chun Wang"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A network meta-analysis compared exercise modalities for physical function and quality of life in heart failure. Combined aerobic and resistance training provided the greatest benefits, while yoga showed particular promise for left ventricular function improvement.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2a7555c3c61f","type":"article","url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","title":"SUMMIT: BMI, centrale adipositas en gewichtsverlies beïnvloeden tirzepatide-effect bij HFpEF","title_en":"Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas","select-trial","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.04.059","source_url":"https://doi.org/10.1016/j.jacc.2025.04.059","authors":["Barry A Borlaug","Michael R Zile","Christopher M Kramer","Wenyu Ye","Yang Ou","Karla Hurt","Masahiro Murakami","Milton Packer"],"significance":6,"published":"2025-07-29","source_date":"2025-07-29","image":"","kennis":[],"congress":"","summary_en":"This SUMMIT analysis confirmed that tirzepatide benefits HFpEF patients consistently regardless of BMI, central adiposity measures, or degree of weight loss achieved, supporting the drug across the obesity spectrum.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e9461997d32","type":"article","url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","title":"ASCOT-Legacy: atorvastatine verlaagt CV-events over 20 jaar","title_en":"Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["statines"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325104","source_url":"https://doi.org/10.1136/heartjnl-2024-325104","authors":["Peter S Sever","Somayeh Rostamian","William Whiteley","Cono Ariti","Thomas Godec","Ajay Gupta","Judith Mackay","Andrew Whitehouse","Neil R Poulter"],"significance":8,"published":"2025-07-28","source_date":"2025-07-28","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"The ASCOT-Legacy 20-year follow-up showed that cardiovascular benefits of atorvastatin remain measurable two decades after the original trial, demonstrating one of the longest legacy effects of statin therapy ever documented.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"655a21adef71","type":"article","url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","title":"Routine invasieve strategie en herinfarctrisico bij fragiele ouderen met NSTE-ACS","title_en":"Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ouderen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325254","source_url":"https://doi.org/10.1136/heartjnl-2024-325254","authors":["Juan Sanchis","Hector Bueno","David Martí Sánchez","Manuel Martinez-Selles","Pablo Díez Villanueva","Jose A Barrabes","Francisco Marín","Adolfo Villa","Marcelo Sanmartin Fernandez","Cinta Llibre","Alessandro Sionis","Jaime Elizaga","Fernando Alfonso","Eduardo Nuñez","Julio Núñez","Vijay Kunadian","Albert Ariza-Solé"],"significance":7,"published":"2025-07-28","source_date":"2025-07-28","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that routine invasive management reduces reinfarction risk in frail older adults with NSTE-ACS, demonstrating that frailty should not be a reason to withhold evidence-based invasive treatment.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3188bd075534","type":"article","url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","title":"VICTORION-INITIATE: inclisiran monotherapie bij patiënten zonder ASCVD","title_en":"Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.04.049","source_url":"https://doi.org/10.1016/j.jacc.2025.04.049","authors":["Pam R Taub","Alexis Gutierrez","Donavon Wewers","Elias Garcia Cantu","Hui Cao","Catrin Deck","Anastasia Lesogor","Denise Ott","Jorge Mena-Madrazo","Xiao Zang","R Scott Wright"],"significance":7,"published":"2025-07-22","source_date":"2025-07-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The VICTORION-Mono trial demonstrated that inclisiran monotherapy (without statins) effectively lowers LDL cholesterol in patients without established ASCVD, expanding the potential role of twice-yearly siRNA therapy to primary prevention.","created":"2026-07-03T10:31:45Z","updated":"2026-07-03T13:30:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab8ef7b2b12b","type":"article","url":"https://hartvaat.nl/2025/07/22/cooperative-pfa-driearmige-gerandomiseerde-trial-van-pfa-versus-rf-versus-cryo/","title":"COOPERATIVE-PFA: driearmige gerandomiseerde trial van PFA versus RF versus cryo","title_en":"COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.074427","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.074427","authors":["Veronika Sochorová","Veronika Kunštátová","Pavel Osmančík","František Duška","Dalibor Heřman","Petr Waldauf","Lukáš Povišer","Jakub Karch","Lucie Znojilová","Věra Filipcová","Jana Hozmanová","Jana Veselá","Marek Hozman"],"significance":8,"published":"2025-07-22","source_date":"2025-07-22","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"The COOPERATIVE-PFA three-arm randomized trial directly compared pulsed field ablation, radiofrequency ablation, and cryoablation for atrial fibrillation, providing the first head-to-head-to-head comparison of all three energy sources for pulmonary vein isolation.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78aca071d76a","type":"article","url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","title":"Antitrombotische middelen bij ACS bij vrouwen: seksegecorrigeerde behandeling","title_en":"Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf352","source_url":"https://doi.org/10.1093/eurheartj/ehaf352","authors":["Valeria Paradies","Giulia Masiero","Andrea Rubboli","Heleen M M Van Beusekom","Francesco Costa","Piera Capranzano","Sophie Degrauwe","Diana A Gorog","Claudia Moreira Jorge","Gill Louise Buchanan","Mirvat Alasnag","Daniela Trabattoni","Chiara Fraccaro","Dirk Sibbing","Dariusz Dudek","Gemma Vilahur","Alaide Chieffo","Roxana Mehran","Davide Capodanno","Emanuele Barbato","Jolanta M Siller-Matula"],"significance":6,"published":"2025-07-21","source_date":"2025-07-21","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"This review documented that women with ACS receive less antithrombotic therapy and are underrepresented in clinical trials, highlighting persistent sex-based disparities in acute coronary care and evidence generation.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7569d4f3b92","type":"article","url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","title":"OCT-gebaseerde post-PCI fysiologiebeoordeling voorspelt klinische uitkomsten","title_en":"Impact of Optical Coherence Tomography-Based Post-PCI Physiology Assessment to Predict Clinical Outcomes: An ILUMIEN-IV Substudy.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.019","source_url":"https://doi.org/10.1016/j.jacc.2025.05.019","authors":["Thomas W Johnson","Brian A Bergmark","Kevin Croce","Dario Pellegrini","Akiko Maehara","Tommaso Gori","Natalia Pinilla-Echeverri","Jason Wollmuth","Nieves Gonzalo","Hsien-Li Kao","Giulio Guagliumi","Kanitha Phalakornkule","Divine Ediebah","JoAnna McNutt","Wei-Che Chiu","Jorn Op den Buijs","Jana Buccola","Ulf Landmesser","Ziad Ali","Gregg W Stone","Allen Jeremias"],"significance":6,"published":"2025-07-15","source_date":"2025-07-15","image":"","kennis":[],"congress":"","summary_en":"This study showed that OCT-based virtual flow reserve assessment after PCI predicts clinical outcomes, combining anatomical and physiological evaluation in a single imaging modality for post-procedure optimization.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cabcfc78e503","type":"article","url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","title":"SORT OUT XI: biomatrix versus duale-therapie sirolimus-eluting stent bij PCI","title_en":"Biolimus-Eluting Biomatrix Stent vs a Dual-Therapy Sirolimus-Eluting Stent in PCI: The SORT OUT XI Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.012","source_url":"https://doi.org/10.1016/j.jacc.2025.05.012","authors":["Ashkan Eftekhari","Lisette Okkels Jensen","Karsten Veien","Bent Raungaard","Jeppe Grøndahl Rasmussen","Michael Mæng","Christian Juhl Terkelsen","Julia Ellert-Gregersen","Nicolaj Brejnholt Støttrup","Jens Flensted Lassen","Henrik Steen Hansen","Troels Thim","Rebekka Vibjerg Jensen","Roni Nielsen","Svend Eggert Jensen","Steen Dalby Kristensen","Mikkel Hougaard","Anders Junker","Martin Kirk Christensen","Jens Aarøe","Trine Frøslev","Lars Jakobsen","Evald Høj Christiansen"],"significance":6,"published":"2025-07-15","source_date":"2025-07-15","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The SORT OUT XI trial confirmed comparable efficacy and safety between two contemporary DES platforms (biolimus-eluting BioMatrix vs dual-therapy sirolimus-eluting stent), demonstrating therapeutic equivalence in modern stent technology.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3703e659bb28","type":"article","url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","title":"Complete versus culprit-only revascularisatie bij STEMI: tienjaarsresultaten","title_en":"10-Year Outcome of Complete or Infarct Artery-Only Revascularization in STEMI With Multivessel Disease: The DANAMI-3-PRIMULTI Study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.05.013","source_url":"https://doi.org/10.1016/j.jacc.2025.05.013","authors":["Jasmine M Marquard","Rasmus P Beske","Henning Kelbæk","Lene Holmvang","Frants Pedersen","Peter Clemmensen","Ole De Backer","Bent Raungaard","Ashkan Eftekhari","Utsho Islam","Lars Køber","Hans-Henrik Tilsted","Charlotte Glinge","Reza Jabbari","Thomas Scheike","Dan E Høfsten","Jacob T Lønborg","Thomas Engstrøm"],"significance":8,"published":"2025-07-15","source_date":"2025-07-15","image":"","kennis":[],"congress":"","summary_en":"Ten-year DANAMI-3-PRIMULTI results confirmed the durable benefit of complete revascularization over culprit-only PCI in patients with STEMI and multivessel disease. The survival advantage persisted over a decade of follow-up.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c601cb72de6d","type":"article","url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","title":"Hartfrequentieverlagende middelen en uitkomsten bij hypertensie/CVD: meta-analyse","title_en":"Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","fidelity","ivabradine","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf291","source_url":"https://doi.org/10.1093/eurheartj/ehaf291","authors":["Elias Sanidas","Michael Böhm","Ilektra Oikonomopoulou","Penelope Dinopoulou","Dimitris Papadopoulos","Helena Michalopoulou","Konstantinos Tsioufis","Giuseppe Mancia","Costas Thomopoulos"],"significance":6,"published":"2025-07-14","source_date":"2025-07-14","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis evaluated heart rate-lowering drugs in hypertension and cardiovascular disease, finding that the cardiovascular benefit of beta-blockers is partly but not entirely mediated through heart rate reduction.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dae0a13b1bfb","type":"article","url":"https://hartvaat.nl/2025/07/14/depressietrajecten-bij-hfpef-impact-op-uitkomsten/","title":"Depressietrajecten bij HFpEF: impact op uitkomsten","title_en":"Influence of depression trajectories in heart failure patients with preserved ejection fractions: a secondary analysis of adverse outcomes in the TOPCAT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324505","source_url":"https://doi.org/10.1136/heartjnl-2024-324505","authors":["Fuwei Xing","Min Gao","Yuzhong Wu","Weihao Liang","Jingzhou Jiang","Yu-Gang Dong","Yi Li","Bin Dong","Chen Liu"],"significance":5,"published":"2025-07-14","source_date":"2025-07-14","image":"","kennis":[],"congress":"","summary_en":"Analysis of TOPCAT data documented the impact of depression trajectories on outcomes in HFpEF. Persistent depression was associated with significantly worse prognosis, supporting integrated mental health screening and care in heart failure management.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b9f275c8b60d","type":"article","url":"https://hartvaat.nl/2025/07/12/amycretine-fase-2-subcutaan-toegediend-bij-obesitas/","title":"Amycretine fase 2: subcutaan toegediend bij obesitas","title_en":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["cagrisema","semaglutide","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01185-7","source_url":"https://doi.org/10.1016/S0140-6736(25)01185-7","authors":["Kirsten Dahl","Søren Toubro","Sohan Dey","Ruben Duque do Vale","Anne Flint","Agnes Gasiorek","Arne Heydorn","Ania M Jastreboff","Cassandra Key","Signe Beck Petersen","Andreas Vegge","Kasper Adelborg"],"significance":8,"published":"2025-07-12","source_date":"2025-07-12","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/"],"congress":"","summary_en":"Phase 2 results of subcutaneous amycretin confirmed dose-dependent weight loss and metabolic improvement. The dual GLP-1/amylin receptor agonist mechanism offers a novel approach to obesity treatment with potent appetite suppression.","created":"2026-07-03T10:31:44Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a99a79159a6","type":"article","url":"https://hartvaat.nl/2025/07/12/amycretine-eerste-glp-1-amyline-agonist-fase-1-veiligheid-en-farmacologie/","title":"Amycretine: eerste GLP-1/amyline-agonist — fase 1 veiligheid en farmacologie","title_en":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)01176-6","source_url":"https://doi.org/10.1016/S0140-6736(25)01176-6","authors":["Agnes Gasiorek","Arne Heydorn","Sanaz Gabery","Julie B Hjerpsted","Katrine Kirkeby","Thomas Kruse","Signe B Petersen","Søren Toubro","Andreas Vegge","Cassandra Key"],"significance":9,"published":"2025-07-12","source_date":"2025-07-12","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/"],"congress":"","summary_en":"This first-in-human phase 1 trial of amycretin, a unimolecular dual GLP-1 and amylin receptor agonist, demonstrated up to 10% weight loss in 12 weeks with potent appetite suppression. The single-molecule dual agonist approach offers manufacturing and dosing advantages over combination products like CagriSema.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9be01b83f691","type":"article","url":"https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/","title":"Coronaire plaquefenotypeveranderingen bij lipidenverlagende therapie en cardiovasculaire events","title_en":"Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","atherosclerose","coronaire-ct-angiografie","dyslipidemie","ezetimibe","farmaco-economie","inflammatie","lipide-aferese","lipidenverlaging","lipoproteïne-a","niet-statine-therapie","obesitas","percutane-coronaire-interventie","plaquekarakterisatie","secundaire-preventie","select-trial","stabiel-coronairlijden","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext","authors":["Giuseppe Patti","Leonardo Grisafi","Danila Azzolina","Luca Cumitini","Domenico D'Amario","Marco Mennuni"],"significance":5,"published":"2025-07-09","source_date":"2025-07-09","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"This systematic review and meta-regression quantified the relationship between lipid-lowering therapy-induced coronary plaque phenotype changes on OCT and major adverse cardiovascular events. Plaque stabilisation correlated with reduced event rates across therapeutic classes.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a3b18e513f7","type":"article","url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","title":"Amulet versus Watchman FLX: driejaarsresultaten LAA-sluiting","title_en":"3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.535","source_url":"https://doi.org/10.1016/j.jacc.2025.03.535","authors":["Roberto Galea","Federico De Marco","Adel Aminian","Nicolas Meneveau","Konstantina Chalkou","Frederic Anselme","Christoph Gräni","Anna Franzone","Pascal Vranckx","Urs Fischer","Marco Valgimigli","Lorenz Räber"],"significance":6,"published":"2025-07-08","source_date":"2025-07-08","image":"","kennis":[],"congress":"","summary_en":"Three-year results confirmed comparable long-term effectiveness of Amulet and Watchman FLX devices for LAA closure in AF, providing the longest-term head-to-head comparison of these leading technologies.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8bd727e4da1","type":"article","url":"https://hartvaat.nl/2025/07/08/catheterablatie-versus-leefstijlmodificatie-plus-antiaritmica-bij-af-gerandomise/","title":"Catheterablatie versus leefstijlmodificatie plus antiaritmica bij AF: gerandomiseerde trial","title_en":"Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.04.042","source_url":"https://doi.org/10.1016/j.jacc.2025.04.042","authors":["Pavel Osmancik","Tomas Roubicek","Stepan Havranek","Jan Chovancik","Veronika Bulkova","Dalibor Herman","Martin Matoulek","Vladimir Tuka","Ivan Ranic","Jana Hozmanova","Marek Hozman","Lucie Znojilova","Adam Latinak","Jan Pidhorodecky","Milan Dusik","Jan Simek","Otakar Jiravsky","Bogna Jiravska-Godula","Frantisek Lehar","Michal Cernosek","Zuzana Hejdukova","Hana Zelinkova","Jiri Jarkovsky","Klara Benesova"],"significance":8,"published":"2025-07-08","source_date":"2025-07-08","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The PRAGUE-25 trial compared catheter ablation with lifestyle modification plus antiarrhythmic drugs in AF patients with obesity. The results inform the choice between invasive and comprehensive conservative management strategies for atrial fibrillation.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec6cec351f06","type":"article","url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","title":"Colchicine voor secundaire CV-preventie: meta-analyse van alle trials","title_en":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf210","source_url":"https://doi.org/10.1093/eurheartj/ehaf210","authors":["Marc-André d'Entremont","Michiel H F Poorthuis","Aernoud T L Fiolet","Pierre Amarenco","Kevin Emery Boczar","Ian Buysschaert","Noel C Chan","Jan H Cornel","Jalina Jannink","Shirley Jansen","Sasko Kedev","Anthony C Keech","Jamie Layland","Nathan Mewton","Gilles Montalescot","Domingo A Pascual-Figal","Alfredo E Rodriguez","Binita Shah","Martin Teraa","Aimee van Zelm","Yongjun Wang","Arend Mosterd","Peter Kelly","John Eikelboom","Sanjit S Jolly"],"significance":9,"published":"2025-07-07","source_date":"2025-07-07","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This meta-analysis of all colchicine trials in secondary cardiovascular prevention confirmed a 20-30% reduction in MACE with an acceptable safety profile. The pooled evidence from COLCOT, LoDoCo2, and CLEAR SYNERGY consolidates colchicine as a cost-effective anti-inflammatory strategy for atherosclerotic disease.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4d8149c4e8f3","type":"article","url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","title":"Colchicine voor secundaire vasculaire preventie: meta-analyse van lange trials","title_en":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["colchicine","colcot-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf174","source_url":"https://doi.org/10.1093/eurheartj/ehaf174","authors":["Michelle Samuel","Colin Berry","Marie-Pierre Dubé","Wolfgang Koenig","José López-Sendón","Aldo Pietro Maggioni","Fausto J Pinto","François Roubille","Jean-Claude Tardif"],"significance":8,"published":"2025-07-07","source_date":"2025-07-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"This meta-analysis of long-term colchicine trials confirmed that colchicine significantly reduces recurrent vascular events in secondary prevention. After COLCOT, LoDoCo2, and CLEAR SYNERGY, the pooled long-term data consolidate colchicine as a cost-effective anti-inflammatory strategy.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eee7c287d21d","type":"article","url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","title":"Optimale timing van anticoagulatie na ischemisch CVA en AF: collaboratief project","title_en":"Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","anticoagulantia","rivaroxaban"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00439-8","source_url":"https://doi.org/10.1016/S0140-6736(25)00439-8","authors":["Hakim-Moulay Dehbi","Urs Fischer","Signild Åsberg","Truman J Milling","Stefanie Abend","Norin Ahmed","Mattia Branca","Lisa A Davis","Stefan T Engelter","Nick Freemantle","Thomas Gattringer","Tatevik Ghukasyan Lakic","Ziad Hijazi","Martin James","Masatoshi Koga","Patrick Lawrence","Robin Lemmens","Gregory Y H Lip","Susan Massingham","Philip S Nash","Amalia Ndoutoumou","Bo Norrving","Georgia Salanti","Nikola Sprigg","Götz Thomalla","Tishok Vanniyasingam","Per Wester","Steven J Warach","Jonas Oldgren","Jesse Dawson","David J Werring"],"significance":7,"published":"2025-07-05","source_date":"2025-07-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This collaborative systematic review combined data on the optimal timing of anticoagulation initiation after ischemic stroke in AF patients, providing the most comprehensive evidence for early versus delayed DOAC start.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb28cfa05d95","type":"article","url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","title":"Obicetrapib bij hoog CV-risico: veiligheid en effectiviteit — fase 3","title_en":"Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","obicetrapib"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2415820","source_url":"https://doi.org/10.1056/NEJMoa2415820","authors":["Stephen J Nicholls","Adam J Nelson","Marc Ditmarsch","John J P Kastelein","Christie M Ballantyne","Kausik K Ray","Ann Marie Navar","Steven E Nissen","Mariko Harada-Shiba","Danielle L Curcio","Annie Neild","Douglas Kling","Andrew Hsieh","Julie Butters","Brian A Ference","Ulrich Laufs","Maciej Banach","Roxana Mehran","Alberico L Catapano","Yong Huo","Michael Szarek","Violeta Balinskaite","Michael H Davidson"],"significance":8,"published":"2025-07-03","source_date":"2025-07-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"Phase 3 data confirmed that obicetrapib, a highly selective CETP inhibitor, significantly lowers LDL cholesterol with an acceptable safety profile in patients at high cardiovascular risk. The results position obicetrapib as the first CETP inhibitor with genuine clinical promise.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"779b1236fafb","type":"article","url":"https://hartvaat.nl/2025/07/01/geleidingssysteempacing-versus-biventriculaire-pacing-bij-av-blok-vergelijkende-/","title":"Geleidingssysteempacing versus biventriculaire pacing bij AV-blok: vergelijkende analyse","title_en":"A comparative analysis of conduction system pacing and biventricular pacing in patients undergoing atrioventricular node ablation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerbundeltakpacing"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf106","source_url":"https://doi.org/10.1093/europace/euaf106","authors":["Akash Mavilakandy","Ahmed M Abdelrazik","Khaled Abouelmagd","Ivelin Koev","Ravi Chotalia","Sachin Sudhakaran","Abdulmalik Idris Koya","Ibrahim Antoun","Hany Eldeeb","Hisham Ahamed","Harshil Dhutia","Riyaz Somani","G Andre Ng","Mokhtar Ibrahim"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":[],"congress":"","summary_en":"This comparative analysis showed that conduction system pacing (His bundle or LBBP) achieves comparable outcomes to biventricular pacing for patients undergoing AV node ablation for AF, supporting physiological pacing alternatives.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b357b2d67da","type":"article","url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","title":"DanGer Shock: hemodynamische effecten van Impella bij STEMI en cardiogene shock","title_en":"Effect of Microaxial Flow Pump on Hemodynamics in STEMI-Related Cardiogenic Shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.04.062","source_url":"https://doi.org/10.1016/j.jacc.2025.04.062","authors":["Jacob Eifer Møller","Rasmus Paulin Beske","Lisette Okkels Jensen","Hans Eiskjær","Norman Mangner","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Benedikt Schrage","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Nikos Werner","Lene Holmvang","Jesper Kjærgaard","Thomas Engstøm","Nanna Louise Junker Udesen","Henrik Schmidt","Anders Junker","Kristian Wachtell","Christian Juhl Terkelsen","Steffen Christensen","Axel Linke","Daniel Burkhoff","Christian Hassager"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This hemodynamic DanGer Shock analysis detailed the direct effects of the Impella microaxial flow pump on cardiac output, ventricular unloading, and coronary perfusion in STEMI-related cardiogenic shock.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1fe86433eca","type":"article","url":"https://hartvaat.nl/2025/07/01/ventriculaire-aritmieen-na-lvad-implantatie-meta-analyse/","title":"Ventriculaire aritmieën na LVAD-implantatie: meta-analyse","title_en":"Ventricular arrhythmias following left ventricular assist device implantation: a systematic review and meta-analysis of incidence and clinical impact.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf129","source_url":"https://doi.org/10.1093/europace/euaf129","authors":["Miloud Cherbi","Paul Gautier","Frederic Sacher","Raphael Martins","Sebastien Knecht","Philippe Maury","Clément Delmas"],"significance":5,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":[],"congress":"","summary_en":"A meta-analysis documented the incidence and clinical impact of ventricular arrhythmias following left ventricular assist device implantation. Arrhythmias were frequent and associated with worse outcomes, supporting proactive monitoring and consideration of prophylactic strategies.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b129d52918f","type":"article","url":"https://hartvaat.nl/2025/07/01/kardia-2-zilebesiran-als-toevoeging-bij-ongecontroleerde-hypertensie-rct/","title":"KARDIA-2: zilebesiran als toevoeging bij ongecontroleerde hypertensie — RCT","title_en":"Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2025.6681","source_url":"https://doi.org/10.1001/jama.2025.6681","authors":["Akshay S Desai","Adam D Karns","Jolita Badariene","Ahmad Aswad","Joel M Neutel","Farhana Kazi","Wansu Park","Daniel Stiglitz","Nune Makarova","Andrea Havasi","Dion H Zappe","Manish Saxena"],"significance":9,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The KARDIA-2 trial showed that zilebesiran, an siRNA targeting hepatic angiotensinogen, significantly reduced blood pressure when added to existing antihypertensive therapy in patients with inadequately controlled hypertension. The twice-yearly injectable represents a novel approach to treatment-resistant blood pressure.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06f0c864798f","type":"article","url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","title":"FINEARTS-HF: finerenon bij hartfalen met verbeterde ejectiefractie","title_en":"Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["finearts-hf","hfmref","hfpef","hfref"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.1101","source_url":"https://doi.org/10.1001/jamacardio.2025.1101","authors":["Maria A Pabon","Orly Vardeny","Muthiah Vaduganathan","Akshay S Desai","Brian L Claggett","Ian J Kulac","Pardeep S Jhund","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Clara I Saldarriaga","Mark C Petrie","Béla Merkely","Maria Borentain","Katharina Mueller","Prabhakar Viswanathan","Flaviana Amarante","Alanna Morris","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This FINEARTS-HF subanalysis showed that finerenone is effective in patients with heart failure and improved (recovered) ejection fraction, protecting against recurrence of heart failure events even after LVEF has normalized.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84746e1d4ac3","type":"article","url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","title":"CALCIFIED: OCT versus angiografie bij PCI van verkalkte laesies","title_en":"OCT vs Angiography for Guidance of Percutaneous Coronary Intervention of Calcified Lesions: The CALIPSO Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0741","source_url":"https://doi.org/10.1001/jamacardio.2025.0741","authors":["Nicolas Amabile","Gregoire Rangé","Quentin Landolff","Erwan Bressollette","Nicolas Meneveau","Benoit Lattuca","Sebastien Levesque","Ziad Boueri","Julien Adjedj","Frederic Casassus","Ayoub Belfekih","Aurelie Veugeois","Géraud Souteyrand","Benjamin Honton"],"significance":7,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The CALIPSO randomized trial showed that OCT-guided PCI improves procedural results in heavily calcified coronary lesions compared with angiographic guidance, establishing intravascular imaging as particularly valuable for complex calcified plaque management.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19f11cf57f7a","type":"article","url":"https://hartvaat.nl/2025/07/01/touch-seh-educatie-en-mhealth-voor-hypertensie-gerandomiseerde-trial/","title":"TOUCH: SEH-educatie en mHealth voor hypertensie — gerandomiseerde trial","title_en":"Emergency Department-Based Education and mHealth Empowerment Intervention for Hypertension: The TOUCHED Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0675","source_url":"https://doi.org/10.1001/jamacardio.2025.0675","authors":["Heather Prendergast","Spyros Kitsiou","Renee Petzel Gimbar","Sally Freels","Anissa Sanders","Martha Daviglus","Pavitra Kotini-Shah","Barry Carter","Marina Del Rios","Sara Heinert","Shaveta Khosla"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The TOUCHED randomized trial showed that emergency department-based education combined with mHealth intervention improves blood pressure control, turning the ED visit into a cardiovascular prevention opportunity.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"596b722ff7f8","type":"article","url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","title":"Bestaande CV-data benutten voor hypertensiedetectie en -behandeling: VITAL-trial","title_en":"Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0871","source_url":"https://doi.org/10.1001/jamacardio.2025.0871","authors":["Adam N Berman","Michael K Hidrue","Curtis Ginder","Linnea Shirkey","Japneet Kwatra","Anna C O'Kelly","Sean P Murphy","Jennifer M Searl Como","Danielle Daly","Yee-Ping Sun","William T Curry","Marcela G Del Carmen","Ron Blankstein","John A Dodson","David A Morrow","Benjamin M Scirica","Niteesh K Choudhry","James L Januzzi","Jason H Wasfy"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This study showed that leveraging existing cardiovascular data from electronic health records combined with trained healthcare workers can significantly improve hypertension detection and treatment.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21b178bbadea","type":"article","url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","title":"FINEARTS-HF: modus van overlijden bij HFmrEF/HFpEF","title_en":"Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["finearts-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0860","source_url":"https://doi.org/10.1001/jamacardio.2025.0860","authors":["Akshay S Desai","Pardeep S Jhund","Muthiah Vaduganathan","Brian L Claggett","Jonathan W Cunningham","Maria A Pabon","Carolyn S P Lam","Michele Senni","Sanjiv Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Flaviana Amarante","James Lay-Flurrie","Markus F Scheerer","Andrea Lage","John J V McMurray","Scott D Solomon"],"significance":5,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":[],"congress":"","summary_en":"Analysis of FINEARTS-HF characterised the mode of death in patients with HFmrEF and HFpEF. Non-cardiovascular death predominated, emphasising the importance of comorbidity management alongside heart failure-specific therapy in these populations.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3a2e314d9267","type":"article","url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","title":"FINEARTS-HF: finerenon en atriumfibrilleren bij hartfalen","title_en":"Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","finearts-hf","finerenon-hartfalen-nierziekte","hfmref","hfpef","hfref","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0848","source_url":"https://doi.org/10.1001/jamacardio.2025.0848","authors":["Shingo Matsumoto","Alasdair D Henderson","Pardeep S Jhund","Johann Bauersachs","Ovidiu Chioncel","Brian L Claggett","Josep Comin-Colet","Akshay S Desai","Gerasimos Filippatos","Carolyn S P Lam","Bertram Pitt","Markus Florian Scheerer","James Lay-Flurrie","Flaviana Amarante","Meike Brinker","Morten Schou","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Shelley Zieroth","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/mineralocorticoid-antagonisten-farmacologie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This FINEARTS-HF subanalysis showed that finerenone reduces new-onset AF in HFmrEF/HFpEF, adding arrhythmia prevention to the benefits of nonsteroidal MRA therapy in this population.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d62cff1c231","type":"article","url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","title":"Centrale adipositas bijna universeel bij HFpEF: fenotypering","title_en":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf057","source_url":"https://doi.org/10.1093/eurheartj/ehaf057","authors":["Alexander Peikert","Muthiah Vaduganathan","Brian L Claggett","Ian J Kulac","Sheldon Litwin","Michael Zile","Akshay S Desai","Pardeep S Jhund","Jawad H Butt","Carolyn S P Lam","Felipe Martinez","Dirk J Van Veldhuisen","Faiez Zannad","Jean Rouleau","Martin Lefkowitz","John J V McMurray","Scott D Solomon","Milton Packer"],"significance":6,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":[],"congress":"","summary_en":"This PARAGON-HF analysis showed that central adiposity is nearly universal in HFpEF regardless of BMI category, reinforcing the concept that visceral fat — not just body weight — is central to the obesity-HFpEF phenotype.","created":"2026-07-03T10:31:42Z","updated":"2026-07-03T13:30:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4f2e8db585c","type":"article","url":"https://hartvaat.nl/2025/07/01/cardiale-structuur-en-functie-bij-hypertensieve-zwangerschapsstoornissen-systema/","title":"Cardiale structuur en functie bij hypertensieve zwangerschapsstoornissen: systematische review","title_en":"Cardiac Structure, Function and Mechanics in Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atriale-cardiomyopathie","bloeddrukbehandeling","hypertrofische-cardiomyopathie","laminopathie","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24472","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24472","authors":["Jamie J Edwards","Veronica Giorgione","Megan Griffiths","Claire Compton","Evelyn Greenhough","Elliot Smith","Eliane Cunliffe","Navazh Jalaludeen","Thomas Yates","Claire Meek","Joseph Cheriyan","Anna Marciniak","Baskaran Thilaganathan","Rajan Sharma","Jamie M O'Driscoll"],"significance":5,"published":"2025-07-01","source_date":"2025-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A comprehensive meta-analysis documented cardiac structural and functional changes in hypertensive disorders of pregnancy using conventional and advanced echocardiography. The cardiac remodelling observed represents an early marker for long-term cardiovascular risk in affected women.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"956a1d5e289a","type":"article","url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","title":"Inclisiran bij adolescenten met homozygote FH: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.073233","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.073233","authors":["Albert Wiegman","Amy L Peterson","Robert A Hegele","Eric Bruckert","Anja Schweizer","Anastasia Lesogor","Yibo Wang","Joep Defesche"],"significance":7,"published":"2025-06-24","source_date":"2025-06-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This study showed that inclisiran effectively and safely lowers LDL cholesterol in adolescents with homozygous FH, supporting early RNA interference-based lipid-lowering therapy in the youngest patients with severe genetic dyslipidemia.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b3b418286f5","type":"article","url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","title":"AZALEA-TIMI 71: langwerkende factor XI-remmer en periprocedurale bloedingen","title_en":"Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","apixaban","edoxaban","rivaroxaban"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.04.018","source_url":"https://doi.org/10.1016/j.jacc.2025.04.018","authors":["Siddharth M Patel","Robert P Giugliano","David A Morrow","Sanobar Parkar","Hannah Shapiro","Bruce Hug","Julia F Kuder","Erica L Goodrich","Shih-Ann Chen","Shaun G Goodman","Boyoung Joung","Robert G Kiss","Wojciech Wojakowski","Jeffrey I Weitz","Sabina A Murphy","Stephen D Wiviott","Daniel Bloomfield","Marc S Sabatine","Christian T Ruff"],"significance":7,"published":"2025-06-17","source_date":"2025-06-17","image":"","kennis":[],"congress":"","summary_en":"This AZALEA-TIMI 71 analysis showed that abelacimab (long-acting factor XI inhibitor) reduces periprocedural bleeding compared with rivaroxaban, demonstrating the safety advantage of factor XI inhibition around invasive procedures.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b15774c302c0","type":"article","url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","title":"Spironolacton versus amiloride bij resistente hypertensie: gerandomiseerde trial","title_en":"Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"JAMA","doi":"10.1001/jama.2025.5129","source_url":"https://doi.org/10.1001/jama.2025.5129","authors":["Chan Joo Lee","Sang-Hyun Ihm","Dong-Ho Shin","Jin-Ok Jeong","Ju Han Kim","Kyeong-Hyeon Chun","JiWung Ryu","Hae-Young Lee","Seonghoon Choi","Eun Mi Lee","Jung Hyun Choi","Kwang-Il Kim","Jinho Shin","Wook Bum Pyun","Dae-Hee Kim","Sungha Park","Bryan Williams"],"significance":8,"published":"2025-06-17","source_date":"2025-06-17","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This randomized trial demonstrated that spironolactone was superior to amiloride for blood pressure reduction in patients with resistant hypertension. The result confirmed spironolactone as the preferred fourth-line agent and defined the comparative effectiveness of potassium-sparing diuretics.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d45600a3aa6","type":"article","url":"https://hartvaat.nl/2025/06/17/bedmed-timing-van-antihypertensieve-medicatie-en-cv-events-jama-definitieve-tria/","title":"BedMed: timing van antihypertensieve medicatie en CV-events — JAMA definitieve trial","title_en":"Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"JAMA","doi":"10.1001/jama.2025.4390","source_url":"https://doi.org/10.1001/jama.2025.4390","authors":["Scott R Garrison","Jeffrey A Bakal","Michael R Kolber","Christina S Korownyk","Lee A Green","Jessica E M Kirkwood","Finlay A McAlister","Raj S Padwal","Richard Lewanczuk","Michael D Hill","Alexander G Singer","Alan Katz","Michael D Kelmer","Armine Gayayan","Farah N Campbell","Ana Vucenovic","Nathan R Archibald","Jack M S Yeung","Erik R E Youngson","Kimberlyn McGrail","Braden G O'Neill","Michelle Greiver","Donna P Manca","Roni Y Kraut","Ting Wang","Braden J Manns","Dee A Mangin","Cathy MacLean","James McCormack","Sabrina T Wong","Colleen Norris","G Michael Allan"],"significance":9,"published":"2025-06-17","source_date":"2025-06-17","image":"","kennis":[],"congress":"","summary_en":"The BedMed trial definitively confirmed that the timing of antihypertensive medication (morning versus evening) has no effect on cardiovascular outcomes or death. Together with the TIME trial, this eliminates chronotherapy as a meaningful consideration in hypertension management.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"430b8bf7d5fd","type":"article","url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","title":"IRONMAN: leeftijdgestratificeerde effecten van IV-ijzer bij HF","title_en":"Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324908","source_url":"https://doi.org/10.1136/heartjnl-2024-324908","authors":["Shirley Sze","Iain Squire","Paul R Kalra","John G Cleland","Mark C Petrie","Philip A Kalra","Fozia Ahmed","Prithwish Banerjee","Christopher J Boos","Callum Chapman","Peter James Cowburn","Lana Dixon","Simon Duckett","Rebecca Lane","Paul Foley","Ninian N Lang","Kristopher Lyons","Robin Ray","Rebekah Schiff","Elizabeth A Thomson","Michele Robertson","Ian Ford"],"significance":6,"published":"2025-06-13","source_date":"2025-06-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This IRONMAN subanalysis confirmed that the benefit of intravenous iron in heart failure is consistent across age groups, including elderly patients who may have higher baseline iron deficiency rates.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"54103f8229a7","type":"article","url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","title":"Frailteit en intensieve bloeddrukcontrole bij diabetes","title_en":"The Impact of frailty on the effectiveness of intensive blood pressure control for patients with type 2 diabetes: a secondary analysis of a randomised controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","diabetes-en-hart","ouderen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324360","source_url":"https://doi.org/10.1136/heartjnl-2024-324360","authors":["Li Wenjie","Zhiyan Wang","Mingxiao Li","Chao Jiang","Chang Hua","Yangyang Tang","Hao Zhang","Xinru Liu","Shiyue Zheng","Hang Guo","Manlin Zhao","Yu Feng Wang","Mingyang Gao","Qiang Lv","Jianzeng Dong","Chang-Sheng Ma","Xin Du"],"significance":6,"published":"2025-06-13","source_date":"2025-06-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This analysis showed that moderately frail patients with type 2 diabetes still benefit from intensive blood pressure control, while the benefit may be attenuated in the most severely frail, guiding treatment intensity by frailty status.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cec01503c5a8","type":"article","url":"https://hartvaat.nl/2025/06/13/griepvaccinatie-en-cardiovasculaire-bescherming-inflammatie-heroverwogen-bij-isc/","title":"Griepvaccinatie en cardiovasculaire bescherming: inflammatie heroverwogen bij ischemische hartziekte","title_en":"The flu shot and cardiovascular Protection: Rethinking inflammation in ischemic heart disease","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bradycardie","covid-hart","inflammatie","slaapapneu"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01303-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01303-6/fulltext","authors":["Ole Fröbert","Ida B. Pedersen","Astrid J. Hjelholt","Christian Erikstrup","Sara Cajander"],"significance":5,"published":"2025-06-13","source_date":"2025-06-13","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This review examines the evidence supporting influenza vaccination as a cardiovascular preventive strategy. Observational studies and randomised trials consistently demonstrate reduced cardiovascular event rates among vaccinated individuals, with the greatest benefit seen after myocardial infarction.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e21ce53862c6","type":"article","url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","title":"FAIR-HF2: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — definitieve RCT","title_en":"Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["hfpef","hfref","ijzersuppletie","ijzertekort"],"journal":"JAMA","doi":"10.1001/jama.2025.3833","source_url":"https://doi.org/10.1001/jama.2025.3833","authors":["Stefan D Anker","Tim Friede","Javed Butler","Khawaja M Talha","Marius Placzek","Monika Diek","Anna Nosko","Adriane Stas","Stefan Kluge","Dominik Jarczak","Geraldine deHeer","Meike Rybczynski","Antoni Bayés-Genís","Michael Böhm","Andrew J S Coats","Frank Edelmann","Gerasimos Filippatos","Gerd Hasenfuß","Wilhelm Haverkamp","Mitja Lainscak","Ulf Landmesser","Iain C Macdougall","Bela Merkely","Burkert M Pieske","Fausto J Pinto","Tienush Rassaf","Jennifer K Visser-Rogers","Giuseppe Rosano","Maurizio Volterrani","Stephan von Haehling","Markus S Anker","Wolfram Doehner","Hüseyin Ince","Friedrich Koehler","Gianluigi Savarese","Muhammad Shahzeb Khan","Ursula Rauch-Kröhnert","Tommaso Gori","Teresa Trenkwalder","Ibrahim Akin","Christina Paitazoglou","Iwona Kobielusz-Gembala","Luca Kuthi","Norbert Frey","Manuela Licka","Stefan Kääb","Karl-Ludwig Laugwitz","Piotr Ponikowski","Mahir Karakas"],"significance":10,"published":"2025-06-10","source_date":"2025-06-10","image":"","kennis":[],"congress":"","summary_en":"The FAIR-HF2 trial confirmed that intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency significantly reduced the composite of cardiovascular death and heart failure hospitalization. This provides the definitive evidence that had been missing from earlier, smaller trials of intravenous iron in heart failure.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"738a99681825","type":"article","url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","title":"TRILUMINATE tweejaarsresultaten: transcatheter TR-repair duurzaam effectief","title_en":"Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.074536","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.074536","authors":["Saibal Kar","Raj R Makkar","Brian K Whisenant","Nadira Hamid","Hursh Naik","Peter Tadros","Matthew J Price","Gagan Singh","Jonathan G Schwartz","Samir Kapadia","Oluseun Alli","Samuel Horr","Puvi Seshiah","Wayne Batchelor","Brandon M Jones","Mustafa I Ahmed","Raymond Benza","Ulrich Jorde","Vinod H Thourani","Andrew A Ghobrial","Gilbert H L Tang","Phillip M Trusty","Dina Huang","Rebecca T Hahn","David H Adams","Paul Sorajja"],"significance":7,"published":"2025-06-10","source_date":"2025-06-10","image":"","kennis":[],"congress":"","summary_en":"Two-year TRILUMINATE results confirmed durable effectiveness of transcatheter edge-to-edge repair for severe tricuspid regurgitation, with sustained TR reduction and maintained symptom improvement beyond the initial follow-up.","created":"2026-07-03T10:31:41Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5fa5619a7211","type":"article","url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","title":"SOUL: oraal semaglutide CV-voordeel naar SGLT2i-gebruik","title_en":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.074545","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.074545","authors":["Nikolaus Marx","John E Deanfield","Johannes F E Mann","Rosario Arechavaleta","Stephen C Bain","Harpreet S Bajaj","Katrine Bayer Tanggaard","Andreas L Birkenfeld","John B Buse","Zaklina Davicevic-Elez","Cyrus Desouza","Scott S Emerson","Mads D M Engelmann","G Kees Hovingh","Silvio E Inzucchi","Pardeep S Jhund","Sharon L Mulvagh","Rodica Pop-Busui","Neil R Poulter","Søren Rasmussen","Shih-Te Tu","Darren K McGuire"],"significance":7,"published":"2025-06-10","source_date":"2025-06-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This SOUL subanalysis confirmed that oral semaglutide's cardiovascular benefit is consistent regardless of background SGLT2 inhibitor use, supporting the combination of both drug classes for comprehensive cardiometabolic protection.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8aea632a34f","type":"article","url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","title":"2025 ACC/AHA ACS-richtlijn: JACC-editie","title_en":"2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.009","source_url":"https://doi.org/10.1016/j.jacc.2024.11.009","authors":["Sunil V Rao","Michelle L O'Donoghue","Marc Ruel","Tanveer Rab","Jaqueline E Tamis-Holland","John H Alexander","Usman Baber","Heather Baker","Mauricio G Cohen","Mercedes Cruz-Ruiz","Leslie L Davis","James A de Lemos","Tracy A DeWald","Islam Y Elgendy","Dmitriy N Feldman","Abhinav Goyal","Ijeoma Isiadinso","Venu Menon","David A Morrow","Debabrata Mukherjee","Elke Platz","Susan B Promes","Sigrid Sandner","Yader Sandoval","Rachel Schunder","Binita Shah","Jason P Stopyra","Amy W Talbot","Pam R Taub","Marlene S Williams"],"significance":10,"published":"2025-06-10","source_date":"2025-06-10","image":"","kennis":[],"congress":"","summary_en":"The 2025 ACC/AHA ACS guideline (JACC edition) provides updated recommendations for acute coronary syndromes incorporating evidence from ABYSS, REDUCE-AMI, COMPLETE, and other contemporary trials, endorsing DAPT de-escalation, optional beta-blockers after MI with preserved EF, and troponin-guided management pathways.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fecbd1653b18","type":"article","url":"https://hartvaat.nl/2025/06/09/remote-ischemische-preconditionering-en-nierschade-na-coronairangiografie/","title":"Remote ischemische preconditionering en nierschade na coronairangiografie","title_en":"Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf135","source_url":"https://doi.org/10.1093/eurheartj/ehaf135","authors":["Ping Jia","Gang Zhao","Yuli Huang","Zhouping Zou","Qi Zeng","Weize Chen","Ting Ren","Yang Li","Xiaoyan Wang","Tingting Kang","Zhihe Liu","Mengqing Ma","Jiwei Yu","Qiong Wu","Bing Deng","Xiaoxiang Yan","Xin Wan","Xin Chen","Changchun Cao","Junbo Ge","Xiaoqiang Ding"],"significance":5,"published":"2025-06-09","source_date":"2025-06-09","image":"","kennis":[],"congress":"","summary_en":"A multicentre randomised trial evaluated whether delayed remote ischaemic preconditioning prevents contrast-associated acute kidney injury after coronary angiography. The intervention provided no significant benefit over standard care.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d65f11aa4aa4","type":"article","url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","title":"TiNO-stents versus DES bij ACS: IPD meta-analyse","title_en":"Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf098","source_url":"https://doi.org/10.1093/eurheartj/ehaf098","authors":["Thabo Mahendiran","Frederic Bouisset","Pim Tonino","Nico H J Pijls","Jussi Sia","Kari Kervinen","Fernando Rivero-Crespo","Peter Jüni","Bruno Roza da Costa","Carlos Collet","Takuya Mizukami","Pasi Karjalainen","Bernard De Bruyne"],"significance":5,"published":"2025-06-09","source_date":"2025-06-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"An individual patient data meta-analysis compared titanium-nitride-oxide-coated stents with drug-eluting stents in acute coronary syndromes over 5 years. TiNO stents showed comparable outcomes, offering an alternative when prolonged dual antiplatelet therapy is contraindicated.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"565ef1c3df7a","type":"article","url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","title":"AF-ablatie timing naar AF-duur: impact op aritmierecidief","title_en":"Impact of catheter ablation timing according to duration of atrial fibrillation history on arrhythmia recurrences and clinical outcomes: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf110","source_url":"https://doi.org/10.1093/europace/euaf110","authors":["Paschalis Karakasis","Stylianos Tzeis","Konstantinos Pamporis","Art Schuermans","Panagiotis Theofilis","Nikias Milaras","Dimitrios Tsiachris","Michael Efremidis","Antonios P Antoniadis","Nikolaos Fragakis"],"significance":6,"published":"2025-06-03","source_date":"2025-06-03","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that earlier catheter ablation (shorter duration of AF history) is associated with fewer arrhythmia recurrences, reinforcing the time-sensitive nature of rhythm control intervention.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4f928893489","type":"article","url":"https://hartvaat.nl/2025/06/03/pursuit-orale-pcsk9-remmer-voor-hypercholesterolemie-gerandomiseerde-trial/","title":"PURSUIT: orale PCSK9-remmer voor hypercholesterolemie — gerandomiseerde trial","title_en":"An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["clear-outcomes","dyslipidemie","enlicitide","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","figaro-dkd","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","ramipril","rosuvastatine","select-trial","soul-trial","statines","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.499","source_url":"https://doi.org/10.1016/j.jacc.2025.03.499","authors":["Michael J Koren","Rick B Vega","Nikhil Agrawal","Yuejia Xu","April M Barbour","Hongtao Yu","Emelie Wallerstedt","Debra Carter","Jessica Middlemiss","Lee Twaddle","Michael C McCarthy","Jaya B Rosenmeier"],"significance":9,"published":"2025-06-03","source_date":"2025-06-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"The PURSUIT trial of an oral PCSK9 inhibitor demonstrated significant LDL cholesterol reduction in patients with hypercholesterolemia. An effective oral PCSK9 inhibitor could dramatically expand access to advanced lipid-lowering therapy beyond injectable monoclonal antibodies and siRNA agents.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7a1ef26ba7cf","type":"article","url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","title":"Multipoint pacing vermindert HF-hospitalisaties en sterfte bij CRT-non-responders","title_en":"Multipoint pacing is associated with reduction of heart failure hospitalizations or death in patients who do not respond to cardiac resynchronization therapy: results of the MORE-CRT MPP randomized trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf070","source_url":"https://doi.org/10.1093/europace/euaf070","authors":["Christophe Leclercq","Haran Burri","Leonardo Calò","Christopher Aldo Rinaldi","Johannes Sperzel","Bernard Thibault","Tim Betts","Pascal Defaye","Andreas Hain","Olivier Piot","Kwangdeok Lee","Wenjiao Lin","Annalisa Pollastrelli","Andrea Grammatico","Giuseppe Boriani"],"significance":6,"published":"2025-06-03","source_date":"2025-06-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"This study confirmed that multipoint pacing reduces heart failure hospitalization and death in CRT non-responders, establishing MPP as a rescue strategy for patients who fail to improve with conventional biventricular stimulation.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2d2c5f6a8eb","type":"article","url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","title":"OCEANIC-AF: asundexian naar eerder OAC-gebruik","title_en":"Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0277","source_url":"https://doi.org/10.1001/jamacardio.2025.0277","authors":["John H Alexander","Elizabeth J Lydon","Jonathan P Piccini","Thomas Viethen","Jonas Oldgren","Shaun G Goodman","Jan Steffel","Andrea M Russo","Isabelle C van Gelder","Keith C Ferdinand","Renato D Lopes","Hardi Mundl","Bela Benczur","Juan José Gómez-Doblas","Michael Glikson","Assen Goudev","Erik L Grove","Sigrun Halvorsen","Tuomas Kiviniemi","Anne-Céline Martin","Roopinder K Sandhu","Dragos Vinereanu","Frank W Rockhold","Valeria Caso","Rosa Coppolecchia","Manesh R Patel"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":[],"congress":"","summary_en":"A prespecified subgroup analysis of OCEANIC-AF assessed asundexian efficacy by prior oral anticoagulant experience. The factor XIa inhibitor was inferior to apixaban regardless of prior anticoagulation exposure, confirming the overall negative trial result across subgroups.","created":"2026-07-03T10:31:40Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"346f1a26a951","type":"article","url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","title":"HuMAIN-HFpEF: nieuwe metabole accelerator bij obesitas-HFpEF — RCT","title_en":"Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["step-hfpef","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0103","source_url":"https://doi.org/10.1001/jamacardio.2025.0103","authors":["Ambarish Pandey","Gregory D Lewis","Barry A Borlaug","Sanjiv J Shah","Andrew J Sauer","Sheldon Litwin","Kavita Sharma","Diane K Jorkasky","Elizabeth A Tarka","Shaharyar M Khan","Dalane W Kitzman"],"significance":7,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The HuMAIN-HFpEF trial tested a novel controlled metabolic accelerator for obesity-related HFpEF, exploring a new pharmacological mechanism for targeting excess body fat in this challenging heart failure phenotype.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f2e9c6056314","type":"article","url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","title":"FFR-geleide PCI versus CABG bij diffuus coronairlijden","title_en":"FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0095","source_url":"https://doi.org/10.1001/jamacardio.2025.0095","authors":["Kuniaki Takahashi","Hisao Otsuki","Frederik M Zimmermann","Victoria Y Ding","Thomas Engstrøm","Hans Gustav Hørsted Thyregod","Branko Beleslin","Svetozar Putnik","Luke Tapp","Thomas Barker","Simon Redwood","Christopher Young","G Jan-Willem Bech","Gerard J F Hoohenkerk","Bernard De Bruyne","Nico H J Pijls","William F Fearon"],"significance":6,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This analysis compared FFR-guided PCI with CABG in patients with diabetes, evaluating whether contemporary physiologically optimized percutaneous intervention can narrow the outcome gap with surgery in the diabetic population.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1a8ff23a4565","type":"article","url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","title":"FINEARTS-HF: finerenon en PREDICT-HFpEF risicoscore","title_en":"Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["finearts-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0025","source_url":"https://doi.org/10.1001/jamacardio.2025.0025","authors":["Kirsty McDowell","Kieran F Docherty","Ross T Campbell","Alasdair D Henderson","Pardeep S Jhund","Brian L Claggett","Akshay S Desai","James Lay-Flurrie","Lucas Hofmeister","Andrea Scalise","Carolyn S P Lam","Mark C Petrie","Morten Schou","Michele Senni","Sanjiv J Shah","Jacob A Udell","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":[],"congress":"","summary_en":"A FINEARTS-HF secondary analysis validated the PREDICT-HFpEF risk model and evaluated finerenone efficacy across the risk spectrum. Higher-risk patients experienced greater absolute risk reduction, supporting risk-targeted therapy in HFmrEF and HFpEF.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87095e456412","type":"article","url":"https://hartvaat.nl/2025/06/01/bloeddrukcontrole-en-arteriele-stijfheidsmechanismen-in-sprint/","title":"Bloeddrukcontrole en arteriële stijfheidsmechanismen in SPRINT","title_en":"Effects of Blood Pressure Control on Arterial Stiffness Mechanisms in SPRINT: A Randomized Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24816","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24816","authors":["Ryan Pewowaruk","Byron C Jaeger","Timothy M Hughes","Bharathi Upadhya","Dalane W Kitzman","Mark A Supiano","Adam D Gepner"],"significance":6,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This SPRINT analysis showed that intensive blood pressure control improves the structural components of arterial stiffness over time, demonstrating direct vascular remodeling benefit from aggressive blood pressure management.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"326336e6ea4b","type":"article","url":"https://hartvaat.nl/2025/06/01/seksegerelateerde-pathofysiologie-voor-hfpef-symptomen/","title":"Seksegerelateerde pathofysiologie vóór HFpEF-symptomen","title_en":"Sex-related pathophysiological mechanisms may be present before symptoms of HFpEF develop.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15228","source_url":"https://doi.org/10.1002/ehf2.15228","authors":["B Wong","J D Dodd","J Gallagher","B Dyer","C Ryan","K McDonald","M Ledwidge"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/"],"congress":"","summary_en":"Analysis of the PARABLE trial documented sex-related pathophysiological differences in pre-HFpEF. Women showed earlier diastolic dysfunction and microvascular abnormalities, which may inform sex-specific strategies for early HFpEF detection.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f8636a54c77f","type":"article","url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","title":"STRONG-HF: socio-economische status beïnvloedt GDMT-effect niet","title_en":"Socio-economic status and the effect of guideline-directed medical therapy in the STRONG-HF study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15156","source_url":"https://doi.org/10.1002/ehf2.15156","authors":["Albertino Damasceno","Hadiza Saidu","Gad Cotter","Beth Davison","Christopher Edwards","Jelena Celutkiene","Marianna Adamo","Mattia Arrigo","Marianela Barros","Jan Biegus","Kamilė Čerlinskaitė-Bajorė","Ovidiu Chioncel","Alain Cohen-Solal","Benjamin Deniau","Rafael Diaz","Gerasimos Filippatos","Etienne Gayat","Antoine Kimmoun","Carolyn S P Lam","Marco Metra","Maria Novosadova","Matteo Pagnesi","Peter S Pang","Piotr Ponikowski","Jozine M Ter Maaten","Daniela Tomasoni","Adriaan A Voors","Koji Takagi","Alexandre Mebazaa","Karen Sliwa"],"significance":6,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":[],"congress":"","summary_en":"This STRONG-HF analysis showed that the benefit of intensive guideline-directed medical therapy up-titration after acute HF is independent of socioeconomic status, supporting equitable implementation across income levels.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d735e5d096d5","type":"article","url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","title":"Trainingseffect op diastolische functie bij HFpEF","title_en":"Training-induced change of diastolic function in heart failure with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15225","source_url":"https://doi.org/10.1002/ehf2.15225","authors":["Andreas B Gevaert","Ephraim B Winzer","Stephan Mueller","Stephanie De Schutter","Paul J Beckers","Jennifer Hommel","Axel Linke","Ulrik Wisløff","Volker Adams","Burkert Pieske","Martin Halle","Emeline M Van Craenenbroeck","Caroline M Van De Heyning"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/","https://hartvaat.nl/kennis/hartfalen/echocardiografie-bij-hartfalen/"],"congress":"","summary_en":"A substudy of the OptimEx-Clin trial investigated whether exercise training improves diastolic function during exercise in HFpEF patients. Training improved the E/e’ ratio and diastolic filling, providing mechanistic insight into the exercise capacity benefit in HFpEF.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"707a845722f4","type":"article","url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","title":"Steroïdstoot bij acuut hartfalen: kwaliteit van leven — CORTAHF inzichten","title_en":"Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","ivabradine","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15235","source_url":"https://doi.org/10.1002/ehf2.15235","authors":["Matteo Pagnesi","Gad Cotter","Beth A Davison","Yonathan Freund","Adriaan A Voors","Christopher Edwards","Maria Novosadova","Koji Takagi","Hamlet Hayrapetyan","Andranik Mshetsyan","Mayranush Drambyan","Alain Cohen-Solal","Jozine M Ter Maaten","Jan Biegus","Piotr Ponikowski","Gerasimos Filippatos","Ovidiu Chioncel","Malha Sadoune","Tabassome Simon","Douglas L Mann","Alexandre Mebazaa","Marco Metra"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"A CORTAHF post-hoc analysis examined the effect of a 7-day prednisone course on quality of life in acute heart failure. The steroid burst improved dyspnoea-related quality of life at day 7 but showed no sustained long-term benefit.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5c0f90ba931","type":"article","url":"https://hartvaat.nl/2025/06/01/rv-disfunctie-voorspelt-langetermijnherstel-bij-de-novo-hfref-prolong-ii/","title":"RV-disfunctie voorspelt langetermijnherstel bij de novo HFrEF: PROLONG-II","title_en":"Right ventricular dysfunction for prediction of long-term recovery in de novo HFrEF : a PROLONG-II substudy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15236","source_url":"https://doi.org/10.1002/ehf2.15236","authors":["Aiste Monika Jakstaite","Johanna Mueller-Leisse","Henrike A K Hillmann","Stephan Hohmann","Jörg Eiringhaus","Udo Bavendiek","Tibor Kempf","Christian Veltmann","Johann Bauersachs","David Duncker","D Berliner"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The PROLONG-II substudy demonstrated that right ventricular dysfunction predicts long-term left ventricular recovery in patients with newly diagnosed heart failure with reduced ejection fraction. Early RV assessment is crucial for prognostication in new-onset heart failure.","created":"2026-07-03T10:31:39Z","updated":"2026-07-03T13:30:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94a9a074fafb","type":"article","url":"https://hartvaat.nl/2025/06/01/dapagliflozine-bij-acuut-gedecompenseerd-hartfalen-en-nierfunctie-rct/","title":"Dapagliflozine bij acuut gedecompenseerd hartfalen en nierfunctie: RCT","title_en":"Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","canagliflozine","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfpef","hfref","sglt2-remmers","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15212","source_url":"https://doi.org/10.1002/ehf2.15212","authors":["Shodai Kawanami","Yasuyuki Egami","Masaru Abe","Mizuki Osuga","Hiroaki Nohara","Kohei Ukita","Akito Kawamura","Koji Yasumoto","Naotaka Okamoto","Yasuharu Matsunaga-Lee","Masamichi Yano","Masami Nishino"],"significance":6,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial confirmed that dapagliflozin does not worsen renal function when added for acute decompensated heart failure, providing safety data for early SGLT2 inhibitor initiation during AHF hospitalization.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"15754544732b","type":"article","url":"https://hartvaat.nl/2025/06/01/egfr-en-incident-hartfalen-bij-intensieve-bloeddrukbehandeling/","title":"eGFR en incident hartfalen bij intensieve bloeddrukbehandeling","title_en":"Association of baseline eGFR and incident heart failure on patients receiving intensive blood pressure treatment.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hfmref","hfpef","hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15232","source_url":"https://doi.org/10.1002/ehf2.15232","authors":["Li Haonan","He Qiaorui","Zhu Wenqing","Zhang Yanjun","Pingcuo Wangjia","Yu Shikai","Deji Zhuoga","Zhang Yi","Zhao Yifan"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"A post-hoc analysis of SPRINT examined the relationship between baseline eGFR and incident heart failure during intensive blood pressure treatment. While lower eGFR increased heart failure risk, the benefit of intensive treatment was preserved across kidney function levels.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T18:39:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e51b5af0651d","type":"article","url":"https://hartvaat.nl/2025/06/01/cardiale-myosinebindend-eiwit-c-en-troponine-i-tijdens-inspanningstraining-bij-h/","title":"Cardiale myosinebindend eiwit C en troponine I tijdens inspanningstraining bij HF","title_en":"Cardiac myosin binding protein C correlate with cardiac troponin I during an exercise training program in patients with HFrEF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","biomarkers-cardiovasculair","immunoadsorptie","mavacamten","myocardinfarct","troponine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15222","source_url":"https://doi.org/10.1002/ehf2.15222","authors":["E Riveland","A Ushakova","T Valborgland","T Karlsen","H Dalen","E Prescott","T Omland","A Linke","M Halle","M Marber","Ø Ellingsen","A I Larsen"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study compared cardiac myosin binding protein C with troponin I as biomarkers for myocardial effects of exercise training in chronic heart failure. The novel biomarker correlated well with troponin I and may offer complementary information on training-induced cardiac changes.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a5260d53aa1","type":"article","url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","title":"Nierfunctie en dapagliflozine-effect op gezondheidsstatus: DEFINE-HF","title_en":"Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15184","source_url":"https://doi.org/10.1002/ehf2.15184","authors":["Andrew P Ambrosy","Andrew J Sauer","Shachi Patel","Sheryl L Windsor","Barry A Borlaug","Mansoor Husain","Silvio E Inzucchi","Dalane W Kitzman","Darren K McGuire","Sanjiv J Shah","Kavita Sharma","Guillermo Umpierrez","Mikhail N Kosiborod"],"significance":5,"published":"2025-06-01","source_date":"2025-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"A pooled analysis of DEFINE-HF and PRESERVED-HF examined whether baseline kidney function modifies the health status benefits of dapagliflozin in heart failure. The benefits were consistent across eGFR groups, supporting SGLT2 inhibitor use regardless of renal function.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e4c7d6c9b4d","type":"article","url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","title":"SOUL: oraal semaglutide en CV-uitkomsten bij hoogrisico type 2 diabetes — NEJM","title_en":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","glp1-semaglutide-cardiovasculair","select-trial","semaglutide","soul-trial","stride-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2501006","source_url":"https://doi.org/10.1056/NEJMoa2501006","authors":["Darren K McGuire","Nikolaus Marx","Sharon L Mulvagh","John E Deanfield","Silvio E Inzucchi","Rodica Pop-Busui","Johannes F E Mann","Scott S Emerson","Neil R Poulter","Mads D M Engelmann","Maria Sejersten Ripa","G Kees Hovingh","Kirstine Brown-Frandsen","Stephen C Bain","Matthew A Cavender","Mette Gislum","Jens-Peter David","John B Buse"],"significance":10,"published":"2025-05-29","source_date":"2025-05-29","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The SOUL trial demonstrated that oral semaglutide significantly reduced major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk. This is the first cardiovascular outcomes trial to show benefit for an oral GLP-1 receptor agonist, removing the barrier of injectable administration for cardiovascular prevention in diabetes.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93253baad7ca","type":"article","url":"https://hartvaat.nl/2025/05/27/vutrisiran-bij-attr-cm-impact-van-hartfalenernst-op-effectiviteit/","title":"Vutrisiran bij ATTR-CM: impact van hartfalenernst op effectiviteit","title_en":"Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.477","source_url":"https://doi.org/10.1016/j.jacc.2025.03.477","authors":["Mathew S Maurer","Ronald M Witteles","Pablo Garcia-Pavia","Farooq H Sheikh","Caroline Morbach","Daniel Rodriguez Duque","Emre Aldinc","Satish A Eraly","Julian D Gillmore"],"significance":6,"published":"2025-05-27","source_date":"2025-05-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This analysis showed that vutrisiran's cardiovascular benefit in ATTR cardiomyopathy is consistent regardless of heart failure severity, supporting RNA interference-based TTR silencing across the disease spectrum.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8624210460e","type":"article","url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","title":"Intensieve LDL-verlaging met evolocumab bij auto-immuunziekten: RCT","title_en":"Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["ezetimibe"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072756","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072756","authors":["Andre Zimerman","Ana Laura F Kunzler","Brittany N Weber","Xinhui Ran","Sabina A Murphy","Huei Wang","Narimon Honarpour","Anthony C Keech","Peter S Sever","Marc S Sabatine","Robert P Giugliano"],"significance":6,"published":"2025-05-20","source_date":"2025-05-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This FOURIER analysis showed that intensive LDL lowering with evolocumab provides consistent cardiovascular event reduction in patients with autoimmune or inflammatory diseases, a population with heightened baseline inflammatory risk.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2f0bb62e9d65","type":"article","url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","title":"ANGPTL3-antilichaam bij suboptimaal gecontroleerde hyperlipidemie: fase 2","title_en":"Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ace-remmers","ezetimibe","familiaire-hypercholesterolemie","lipidenverlaging"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.008","source_url":"https://doi.org/10.1016/j.jacc.2025.03.008","authors":["Xiaojie Xie","Xiaoxia Shi","Yuming Zhang","Shuhong Su","Chenyan Jiang","Liu Miao","Junkui Wang","Daoquan Peng","Lingchun Lv","Xiaohong Chai","Suxin Luo","Yang Zheng","Shan Huang","Dan Zhu","Shangshang Liao","Meng Ren","Xiaohong Gao","Haibo Yang","Hao Zhou","Yuquan He","Yajun Han","Jiahong Xu","Lin Zhang","Laijing Du","Zhuhua Yao","Jianlong Sheng","Xiaoping Peng","Xiaowen Chen","Juxiang Li","Jie Mi","Qiang Lu","Hongju Wang","Zheng Shen","Zhilin Zhao","Feng Gao","Chao Lv","Min Zhu","Ying Zhu","Jian'an Wang"],"significance":7,"published":"2025-05-20","source_date":"2025-05-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This phase 2 trial of an ANGPTL3 antibody showed significant LDL and triglyceride lowering in patients with suboptimally controlled hyperlipidemia, expanding the ANGPTL3 inhibition approach to a broader dyslipidemia population.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a2b37e48cf2","type":"article","url":"https://hartvaat.nl/2025/05/20/solbinsiran-angptl3-remming-van-preklinisch-tot-eerste-humane-studies/","title":"Solbinsiran: ANGPTL3-remming van preklinisch tot eerste humane studies","title_en":"Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["ace-remmers","ras-remmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.005","source_url":"https://doi.org/10.1016/j.jacc.2025.03.005","authors":["Kausik K Ray","Helle Linnebjerg","Laura F Michael","Xi Shen","Xiaosu Ma","Shufen Lim","Eugene Y Zhen","Henryk Dudek","Marc Abrams","Utsav Saxena","Anton Turanov","Stephen J Nicholls","Giacomo Ruotolo"],"significance":5,"published":"2025-05-20","source_date":"2025-05-20","image":"","kennis":[],"congress":"","summary_en":"Translational studies documented the development of solbinsiran, an siRNA targeting ANGPTL3, from preclinical models to first-in-human application. The molecule demonstrated consistent favourable effects on triglycerides and remnant lipoproteins across development phases.","created":"2026-07-03T10:31:38Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14b2afc84f94","type":"article","url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","title":"Plozasiran en lipoproteïne-deeltjesgrootte bij hypertriglyceridemie","title_en":"Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pcsk9-remmers","pelacarsen","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.496","source_url":"https://doi.org/10.1016/j.jacc.2025.03.496","authors":["Christie M Ballantyne","Daniel Gaudet","Robert S Rosenson","Robert A Hegele","Rong Zhou","Stacey Melquist","Jennifer Hellawell","Nicholas J Leeper"],"significance":6,"published":"2025-05-20","source_date":"2025-05-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This analysis showed that plozasiran not only reduces triglycerides but favorably remodels the lipoprotein particle profile, shifting from small dense LDL to larger, less atherogenic particles through APOC3 suppression.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32610ec35394","type":"article","url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","title":"TANDEM: obicetrapib plus ezetimibe voor LDL-verlaging — Lancet fase 3","title_en":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","ezetimibe","lipidenverlaging","obicetrapib","pcsk9-remmers"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00721-4","source_url":"https://doi.org/10.1016/S0140-6736(25)00721-4","authors":["Ashish Sarraju","Danielle Brennan","Kierstyn Hayden","Amanda Stronczek","Anne C Goldberg","Erin D Michos","Darren K McGuire","Denise Mason","Grace Tercek","Stephen J Nicholls","Douglas Kling","Annie L Neild","John Kastelein","Michael Davidson","Marc Ditmarsch","Steven E Nissen"],"significance":9,"published":"2025-05-17","source_date":"2025-05-17","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The TANDEM trial demonstrated that a fixed-dose combination of obicetrapib (a CETP inhibitor) and ezetimibe reduced LDL cholesterol by 55-60% in statin-treated patients. This is the first positive result for a modern CETP inhibitor in combination therapy, reviving the mechanism after decades of setbacks.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f2bd92743ad","type":"article","url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","title":"Empagliflozine, erytropoëse en ijzermobilisatie bij hartfalen","title_en":"Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","canagliflozine","dapagliflozine","empagliflozine","emperor-trials","hfpef","hfref","ijzersuppletie","sglt2-remmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.503","source_url":"https://doi.org/10.1016/j.jacc.2025.03.503","authors":["João Pedro Ferreira","Stefan D Anker","Javed Butler","Gerasimos Filippatos","James L Januzzi","Elke Schueler","Marina Panova-Noeva","Kristiane Wetzel","Juergen Prochaska","Stuart J Pocock","Naveed Sattar","Mikhail Sumin","Faiez Zannad","Milton Packer"],"significance":6,"published":"2025-05-13","source_date":"2025-05-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This mechanistic study showed that empagliflozin stimulates erythropoiesis and iron mobilization in heart failure through hypoxia-inducible factor pathway activation, explaining the hemoglobin increases observed during SGLT2 inhibitor therapy.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b388086d9175","type":"article","url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","title":"ORBITA-2: dobutamine-stress-echo voorspelt PCI-effectiviteit","title_en":"Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["stress-echocardiografie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.02.034","source_url":"https://doi.org/10.1016/j.jacc.2025.02.034","authors":["Fiyyaz Ahmed-Jushuf","Michael J Foley","Christopher A Rajkumar","Shayna Chotai","Florentina A Simader","Danqi Wang","Krzysztof Macierzanka","Joban Sehmi","Gajen Kanaganayagam","Guy Lloyd","Niall Keenan","Nina Bual","John R Davies","Thomas R Keeble","Peter D O'Kane","Peter Haworth","Helen Routledge","Tushar Kotecha","Rupert Williams","Jehangir Din","Sukhjinder S Nijjer","Nick Curzen","Manas Sinha","Neil Ruparelia","Reto Gamma","James C Spratt","Graham D Cole","Frank E Harrell","James P Howard","Darrel P Francis","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":7,"published":"2025-05-13","source_date":"2025-05-13","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/"],"congress":"","summary_en":"This ORBITA-2 subanalysis showed that ischemia on dobutamine stress echocardiography predicts the placebo-controlled efficacy of PCI in stable angina, supporting objective functional testing for patient selection before revascularization.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f302bd504a9","type":"article","url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","title":"SUMMIT: tirzepatide en CKD-interactie bij HFpEF met obesitas","title_en":"Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["anemie-ckd","chronische-nierziekte","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.009","source_url":"https://doi.org/10.1016/j.jacc.2025.03.009","authors":["Milton Packer","Michael R Zile","Christopher M Kramer","Masahiro Murakami","Yang Ou","Barry A Borlaug"],"significance":6,"published":"2025-05-13","source_date":"2025-05-13","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that CKD does not attenuate the benefit of tirzepatide in HFpEF with obesity, supporting the dual incretin agonist across the cardiorenal comorbidity spectrum.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b0315e31efd","type":"article","url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","title":"Lorundrostat bij ongecontroleerde hypertensie: fase 3 — NEJM","title_en":"Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","bloeddrukbehandeling","lorundrostat","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2501440","source_url":"https://doi.org/10.1056/NEJMoa2501440","authors":["Luke J Laffin","Branko Kopjar","Carrie Melgaard","Kathy Wolski","Jessica Ibbitson","Shivani Bhikam","Matthew R Weir","Elizabeth O Ofili","Reena Mehra","James M Luther","Debbie L Cohen","Ashish Sarraju","Michael J Wilkinson","John M Flack","David Rodman","Steven E Nissen"],"significance":10,"published":"2025-05-08","source_date":"2025-05-08","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/"],"congress":"","summary_en":"This phase 3 trial demonstrated that lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced blood pressure in patients with uncontrolled hypertension on existing therapy. The results add to the growing evidence for aldosterone synthase inhibition as a new treatment class for resistant and difficult-to-treat hypertension.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e0a0f6e0b9b6","type":"article","url":"https://hartvaat.nl/2025/05/07/aanvullende-substraatmodificatie-bij-persisterend-af-met-low-voltage-gebieden/","title":"Aanvullende substraatmodificatie bij persisterend AF met low-voltage gebieden","title_en":"Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","hfpef","hfref","ouderen","supraventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf095","source_url":"https://doi.org/10.1093/europace/euaf095","authors":["Hengzhi Zhang","Ning Chen","Qiuheng Bian","Mingchuan Yuan","Gang Yang","Youmei Shen","Hongwu Chen","Weizhu Ju","Mingfang Li","Kai Gu","Nan Wu","Hailei Liu","Minglong Chen"],"significance":6,"published":"2025-05-07","source_date":"2025-05-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"This study investigated which patients with persistent AF and left atrial low-voltage areas benefit from additional substrate modification beyond PVI, identifying subgroups where targeted ablation adds value.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16a095e9312a","type":"article","url":"https://hartvaat.nl/2025/05/07/hoog-vermogen-korte-duur-rf-ablatie-versus-cryoballon-bij-paroxysmaal-af-rct/","title":"Hoog-vermogen korte duur RF-ablatie versus cryoballon bij paroxysmaal AF: RCT","title_en":"HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf066","source_url":"https://doi.org/10.1093/europace/euaf066","authors":["Arian Sultan","Sven Kreutzer","Jonas Wörmann","Jakob Lüker","Jana Ackmann","Jan-Hendrik Schipper","Jan van den Bruck","Karlo Filipovic","Cornelia Scheurlen","Kerstin Rosenberger","Daniel Steven"],"significance":6,"published":"2025-05-07","source_date":"2025-05-07","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared high-power short-duration RF ablation with cryoballoon ablation for paroxysmal AF, confirming equivalent efficacy and safety between these two established energy delivery approaches.","created":"2026-07-03T10:31:37Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0415c6dbdf1d","type":"article","url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","title":"Solbinsiran: langwerkend siRNA tegen ANGPTL3 — duurzaamheid en effectiviteit","title_en":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00507-0","source_url":"https://doi.org/10.1016/S0140-6736(25)00507-0","authors":["Kausik K Ray","Ena Oru","Robert S Rosenson","Jeremiah Jones","Xiaosu Ma","Jennie Walgren","Axel Haupt","Subodh Verma","Daniel Gaudet","Stephen J Nicholls","Giacomo Ruotolo"],"significance":7,"published":"2025-05-03","source_date":"2025-05-03","image":"","kennis":[],"congress":"","summary_en":"Phase 2 data on solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, showed durable and effective reduction of triglycerides and LDL cholesterol in mixed dyslipidemia, advancing a new RNA-based approach for comprehensive lipid management.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2f3af45014d7","type":"article","url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","title":"Semaglutide en loopafstand bij perifeer vaatlijden en diabetes","title_en":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["anemie-ckd","aortainsufficiëntie","bloeddrukbehandeling","bradycardie","cagrisema","canagliflozine","chronische-nierziekte","diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","figaro-dkd","flow-trial","gedilateerde-cardiomyopathie","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","microbioom","obesitas","orforglipron","perifeer-vaatlijden","sacubitril-valsartan","select-trial","semaglutide","slaapapneu","soul-trial","stride-trial","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00509-4","source_url":"https://doi.org/10.1016/S0140-6736(25)00509-4","authors":["Marc P Bonaca","Andrei-Mircea Catarig","Kim Houlind","Bernhard Ludvik","Joakim Nordanstig","Chethana Kalmady Ramesh","Neda Rasouli","Harald Sourij","Alex Videmark","Subodh Verma"],"significance":6,"published":"2025-05-03","source_date":"2025-05-03","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/"],"congress":"","summary_en":"The STRIDE trial investigated whether semaglutide improves walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, testing GLP-1 receptor agonism for PAD-specific functional outcomes.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e01949f659fb","type":"article","url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","title":"Paclitaxel-gecoate ballonnen versus DES bij kleine vaten: IPD meta-analyse","title_en":"Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf002","source_url":"https://doi.org/10.1093/eurheartj/ehaf002","authors":["Simone Fezzi","Daniele Giacoppo","Gregor Fahrni","Azeem Latib","Fernando Alfonso","Antonio Colombo","Felix Mahfoud","Bruno Scheller","Raban Jeger","Bernardo Cortese"],"significance":6,"published":"2025-05-02","source_date":"2025-05-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"This individual patient data meta-analysis compared paclitaxel-coated balloons with drug-eluting stents for small coronary artery disease, confirming DCB noninferiority and supporting the leave-nothing-behind approach in small vessels.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c95360b426f6","type":"article","url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","title":"Determinanten van medicatietrouw na ACS: secundaire analyse","title_en":"Determinants of medication adherence in patients with acute coronary syndrome: a secondary analysis of a randomised clinical trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325144","source_url":"https://doi.org/10.1136/heartjnl-2024-325144","authors":["Richard Kha","Haeri Min","Simone Marschner","Shehane Mahendran","Aravinda Thiagalingam","Rohan Poulter","Julie Redfern","David Brieger","Peter L Thompson","Graham S Hillis","Nicholas Collins","Pratap Shetty","Michele McGrady","Christian Hamilton-Craig","Nadarajah Kangaharan","John Atherton","Andrew Maiorana","Harry Klimis","Craig Juergens","Clara K Chow"],"significance":5,"published":"2025-05-02","source_date":"2025-05-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/secundaire-preventie-na-acs/"],"congress":"","summary_en":"A secondary analysis identified key determinants of medication adherence following acute coronary syndrome. Regimen complexity, cost, and patient education were the strongest predictors of non-adherence, informing targeted interventions to improve secondary prevention.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b5f47d93641","type":"article","url":"https://hartvaat.nl/2025/05/01/apothekerverwijzingen-voor-statine-start-twee-cluster-rct-s/","title":"Apothekerverwijzingen voor statine-start: twee cluster-RCT's","title_en":"Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2025.0244","source_url":"https://doi.org/10.1001/jamacardio.2025.0244","authors":["Alexander C Fanaroff","Qian Huang","Kayla Clark","Laurie A Norton","Wendell E Kellum","Dwight Eichelberger","John C Wood","Zachary Bricker","Andrea G Dooley Wood","Greta Kemmer","Jennifer I Smith","Srinath Adusumalli","Mary E Putt","Kevin G Volpp"],"significance":6,"published":"2025-05-01","source_date":"2025-05-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"","summary_en":"These two cluster-randomized trials showed that encouraging pharmacist referrals for statin initiation significantly increases evidence-based therapy use, positioning community pharmacies as an access point for cardiovascular prevention.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7c75ecfe2a8c","type":"article","url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","title":"Aspirine versus clopidogrel na coronaire stenting naar bloedingsrisico en complexiteit","title_en":"Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["trombocytenaggregatieremmers"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4030","source_url":"https://doi.org/10.1001/jamacardio.2024.4030","authors":["Jeehoon Kang","Jaewook Chung","Kyung Woo Park","Jang-Whan Bae","Huijin Lee","Doyeon Hwang","Han-Mo Yang","Kyoo-Rok Han","Keon-Woong Moon","Ung Kim","Moo-Yong Rhee","Doo-Il Kim","Song-Yi Kim","Sung-Yun Lee","Seung Uk Lee","Sang-Wook Kim","Seok Yeon Kim","Jung-Kyu Han","Eun-Seok Shin","Bon-Kwon Koo","Hyo-Soo Kim"],"significance":7,"published":"2025-05-01","source_date":"2025-05-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This analysis compared aspirin with clopidogrel monotherapy after coronary stenting stratified by bleeding risk and procedural complexity, finding that clopidogrel consistently outperforms aspirin across all risk categories.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d47b04511a0d","type":"article","url":"https://hartvaat.nl/2025/04/29/vroege-iabp-bij-hartfalen-gerelateerde-cardiogene-shock-gerandomiseerde-trial/","title":"Vroege IABP bij hartfalen-gerelateerde cardiogene shock: gerandomiseerde trial","title_en":"Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiogene-shock","iaso-dcm","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.03.003","source_url":"https://doi.org/10.1016/j.jacc.2025.03.003","authors":["Nuccia Morici","Alice Sacco","Simone Frea","Matteo Rota","Luca Villanova","Carol Gravinese","Carlotta Sorini Dini","Nicoletta D'Ettore","Giulia Maj","Giulia De Lio","Luciano Potena","Serafina Valente","Mario Sabatino","Giovanna Viola","Laura Garatti","Giovanni Amedeo Tavecchia","Letizia Bertoldi","Fabrizio Oliva","Navin K Kapur","Guido Tavazzi","Gaetano Maria De Ferrari","Federico Pappalardo"],"significance":7,"published":"2025-04-29","source_date":"2025-04-29","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiogene-shock/"],"congress":"","summary_en":"This randomized trial showed that early IABP support in heart failure-related cardiogenic shock improves hemodynamics and may facilitate successful bridging to heart replacement therapies, providing evidence for IABP use outside the acute MI setting.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebaa5b848812","type":"article","url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","title":"FFR-geleide PCI versus CABG: langetermijn uitkomsten vergelijking","title_en":"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00505-7","source_url":"https://doi.org/10.1016/S0140-6736(25)00505-7","authors":["William F Fearon","Frederik M Zimmermann","Victoria Y Ding","Kuniaki Takahashi","Zsolt Piroth","Albert H M van Straten","Laszlo Szekely","Giedrius Davidavičius","Gintaras Kalinauskas","Samer Mansour","Rajesh Kharbanda","Nikolaos Östlund-Papadogeorgos","Adel Aminian","Keith G Oldroyd","Nawwar Al-Attar","Nikola Jagic","Jan-Henk E Dambrink","Petr Kala","Oskar Angerås","Philip MacCarthy","Olaf Wendler","Filip Casselman","Nils Witt","Kreton Mavromatis","Steven E S Miner","Jaydeep Sarma","Thomas Engstrøm","Evald H Christiansen","Pim A L Tonino","Michael J Reardon","Hisao Otsuki","Yuhei Kobayashi","Mark A Hlatky","Kenneth W Mahaffey","Manisha Desai","Y Joseph Woo","Alan C Yeung","Nico H J Pijls","Bernard De Bruyne"],"significance":7,"published":"2025-04-26","source_date":"2025-04-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"","summary_en":"This analysis compared long-term outcomes of FFR-guided PCI with CABG, informing the revascularization strategy decision based on contemporary physiologically guided percutaneous intervention results.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"749b9f4b86e8","type":"article","url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","title":"Angiografie-afgeleide FFR versus IVUS bij PCI: gerandomiseerde trial","title_en":"Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00504-5","source_url":"https://doi.org/10.1016/S0140-6736(25)00504-5","authors":["Xinyang Hu","Jinlong Zhang","Seokhun Yang","Jun Jiang","Xiaoping Peng","Dongsheng Lu","Yibin Pan","Lijun Guo","Jilin Li","Wenming He","Hao Zhou","Jun Pu","Jinyu Huang","Fan Jiang","Qiang Liu","Daqing Song","Liang Lu","Zhenfeng Cheng","Bin Yang","Jianliang Ma","Peng Chen","Shiqiang Li","Zhaohui Meng","Lijiang Tang","Yongzhen Fan","Eun-Seok Shin","Shengxian Tu","Chang-Wook Nam","William F Fearon","Bon-Kwon Koo","Jian'an Wang"],"significance":7,"published":"2025-04-26","source_date":"2025-04-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/"],"congress":"","summary_en":"This randomized trial showed that angiography-derived FFR (QFR/vFFR) is noninferior to IVUS for guiding PCI decisions, validating the wire-free computational approach as an alternative to intravascular imaging guidance.","created":"2026-07-03T10:31:36Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2311517390c5","type":"article","url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","title":"Thoracentese bij acuut hartfalen: gerandomiseerde trial","title_en":"A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.073521","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.073521","authors":["Signe Glargaard","Jakob Hartvig Thomsen","Christian Tuxen","Matias Greve Lindholm","Christian Axel Bang","Morten Schou","Kasper Iversen","Rasmus Vedby Rasmussen","Brian Bridal Løgstrup","Søren Vraa","Nis Stride","Ekim Seven","Anders Barasa","Marlene Tofterup","Dan Eik Høfsten","Kasper Rossing","Lars Køber","Finn Gustafsson","Jens Jakob Thune"],"significance":7,"published":"2025-04-22","source_date":"2025-04-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This randomized trial showed that therapeutic thoracentesis in acute heart failure with pleural effusion improves dyspnea and respiratory function, supporting targeted drainage as an adjunct to standard decongestive therapy.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7efd99f652cd","type":"article","url":"https://hartvaat.nl/2025/04/22/anemie-beinvloedt-ijzerhomeostase-en-empagliflozine-respons-bij-hf/","title":"Anemie beïnvloedt ijzerhomeostase en empagliflozine-respons bij HF","title_en":"Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","anemie-ckd","bisoprolol","bloeddrukbehandeling","canagliflozine","carvedilol","complementremmers","cystatine-c","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","ezetimibe","hfmref","hfpef","hfref","ijzersuppletie","statines","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae917","source_url":"https://doi.org/10.1093/eurheartj/ehae917","authors":["Christiane E Angermann","Susanne Sehner","Louisa M S Gerhardt","Carlos G Santos-Gallego","Juan Antonio Requena-Ibanez","Tanja Zeller","Christoph Maack","Javier Sanz","Stefan Frantz","Georg Ertl","Juan J Badimon"],"significance":5,"published":"2025-04-22","source_date":"2025-04-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"Analysis from the EMPATROPISM-FE trial showed that anaemia disrupts iron homeostasis in heart failure and modifies the response to empagliflozin. Iron deficiency and anaemia require integrated assessment when initiating SGLT2 inhibitor therapy.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8cf4e3e7acd9","type":"article","url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","title":"PFA versus cryoballon bij paroxysmaal AF: gerandomiseerde trial","title_en":"Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["advent-trial","cryoablatie","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2502280","source_url":"https://doi.org/10.1056/NEJMoa2502280","authors":["Tobias Reichlin","Thomas Kueffer","Patrick Badertscher","Peter Jüni","Sven Knecht","Gregor Thalmann","Nikola Kozhuharov","Philipp Krisai","Corinne Jufer","Jens Maurhofer","Dik Heg","Tiago V Pereira","Felix Mahfoud","Helge Servatius","Hildegard Tanner","Michael Kühne","Laurent Roten","Christian Sticherling"],"significance":8,"published":"2025-04-17","source_date":"2025-04-17","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"This randomized trial showed that pulsed field ablation was noninferior to cryoballoon ablation for pulmonary vein isolation in paroxysmal atrial fibrillation, with comparable efficacy and safety. The result positions PFA as an alternative to established thermal energy sources for AF ablation.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d98bfb381ea5","type":"article","url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","title":"Clopidogrel versus aspirine monotherapie bij hoog risico op recidief-CVA","title_en":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00449-0","source_url":"https://doi.org/10.1016/S0140-6736(25)00449-0","authors":["Ki Hong Choi","Yong Hwan Park","Jong-Young Lee","Jin-Ok Jeong","Chan Joon Kim","Kyeong Ho Yun","Han Cheol Lee","Kiyuk Chang","Mahn-Won Park","Jang-Whan Bae","Joon-Hyung Doh","Byung Ryul Cho","Hee-Yeol Kim","Weon Kim","Ung Kim","Seung-Woon Rha","Young Joon Hong","Hyun-Jong Lee","Sung Gyun Ahn","Doo-Il Kim","Jang Hyun Cho","Sung Ho Her","Doo Soo Jeon","Seung Hwan Han","Jin-Bae Lee","Cheol Whan Lee","Danbee Kang","Joo Myung Lee","Taek Kyu Park","Jeong Hoon Yang","Soo-Youn Lee","Seung-Hyuk Choi","Hyeon-Cheol Gwon","Young Bin Song","Joo-Yong Hahn"],"significance":6,"published":"2025-04-12","source_date":"2025-04-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This study compared clopidogrel with aspirin as long-term antiplatelet monotherapy in patients at high risk of recurrent cardiovascular events, contributing to the growing evidence for clopidogrel as the preferred single agent after PCI.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T13:30:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae1d55caff72","type":"article","url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","title":"Orbitale atherectomie versus ballonangioplastie vóór DES bij ernstig verkalkte laesies","title_en":"Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00450-7","source_url":"https://doi.org/10.1016/S0140-6736(25)00450-7","authors":["Ajay J Kirtane","Philippe Généreux","Bruce Lewis","Richard A Shlofmitz","Suhail Dohad","Jithendra Choudary","Thom Dahle","Andres M Pineda","Kendrick Shunk","Akiko Maehara","Alexandra Popma","Bjorn Redfors","Ziad A Ali","Mitchell Krucoff","Ehrin Armstrong","David E Kandzari","William O'Neill","Carlye Kraemer","Krista M Stiefel","Denise E Jones","Jeff Chambers","Gregg W Stone"],"significance":6,"published":"2025-04-12","source_date":"2025-04-12","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This randomized trial compared orbital atherectomy with balloon angioplasty for calcium modification before DES implantation in severely calcified coronary lesions, testing whether advanced plaque preparation improves PCI outcomes.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a426c46925d7","type":"article","url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","title":"Dapagliflozine bij patiënten die TAVI ondergaan: gerandomiseerde trial — NEJM","title_en":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","dapagliflozine","emperor-trials"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2500366","source_url":"https://doi.org/10.1056/NEJMoa2500366","authors":["Sergio Raposeiras-Roubin","Ignacio J Amat-Santos","Xavier Rossello","Rocío González Ferreiro","Inmaculada González Bermúdez","Diego Lopez Otero","Luis Nombela-Franco","Livia Gheorghe","Jose L Diez","Carlos Baladrón Zorita","José A Baz","Antonio J Muñoz García","Victoria Vilalta","Soledad Ojeda-Pineda","José M de la Torre Hernández","Juan G Cordoba Soriano","Ander Regueiro","Pascual Bordes Siscar","Jorge Salgado Fernández","Bruno Garcia Del Blanco","Roberto Martín-Reyes","Rafael Romaguera","César Moris","Sergio García Blas","Juan A Franco-Peláez","Ignacio Cruz-González","Dabit Arzamendi","Nieves Romero Rodríguez","Felipe Díez-Del Hoyo","Santiago Camacho Freire","Francisco Bosa Ojeda","Juan C Astorga Burgo","Eduardo Molina Navarro","Juan Caballero Borrego","Valeriano Ruiz Quevedo","Ángel Sánchez-Recalde","Vicente Peral Disdier","Eduardo Alegría-Barrero","Javier Torres-Llergo","Gisela Feltes","José A Fernández Díaz","Carlos Cuellas","Gustavo Jiménez Britez","Juan Sánchez-Rubio Lezcano","Cristina Barreiro-Pardal","Iván Núñez-Gil","Emad Abu-Assi","Andrés Iñiguez-Romo","Valentín Fuster","Borja Ibáñez"],"significance":8,"published":"2025-04-10","source_date":"2025-04-10","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This NEJM trial evaluated dapagliflozin in patients undergoing TAVI, exploring whether SGLT2 inhibition provides additional cardiac protection in this high-risk valvular heart disease population.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7b3a3528869","type":"article","url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","title":"EMPERIAL: empagliflozine bij resistente hypertensie en HFpEF","title_en":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["aprocitentan","bloeddrukbehandeling","dapa-hf","empagliflozine","emperor-trials","lorundrostat","step-hfpef","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae938","source_url":"https://doi.org/10.1093/eurheartj/ehae938","authors":["Michael Böhm","Javed Butler","Andrew Coats","Lucas Lauder","Felix Mahfoud","Gerasimos Filippatos","João Pedro Ferreira","Stuart J Pocock","Martina Brueckmann","Sibylle J Hauske","Elke Schueler","Christoph Wanner","Subodh Verma","Faiez Zannad","Milton Packer","Stefan D Anker"],"significance":7,"published":"2025-04-07","source_date":"2025-04-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This EMPEROR-Preserved subanalysis showed that empagliflozin improves blood pressure in patients with resistant hypertension and HFpEF, providing additional hemodynamic benefit in this difficult-to-treat overlap population.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31ee930b0eeb","type":"article","url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","title":"SGLT2-remmers voorkomen nieuw-ontstane diabetes bij CV- en nierziekte","title_en":"Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["canagliflozine","empagliflozine","sglt2-remmers","soul-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae780","source_url":"https://doi.org/10.1093/eurheartj/ehae780","authors":["John W Ostrominski","Mats C Højbjerg Lassen","Brian L Claggett","Zi Michael Miao","Silvio E Inzucchi","Kieran F Docherty","Akshay S Desai","Pardeep S Jhund","Lars Køber","Piotr Ponikowski","Marc S Sabatine","Carolyn S P Lam","Felipe A Martinez","Rudolf A de Boer","Adrian F Hernandez","Sanjiv J Shah","Magnus Petersson","Anna Maria Langkilde","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":7,"published":"2025-04-07","source_date":"2025-04-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This analysis showed that SGLT2 inhibitors reduce the risk of new-onset diabetes in patients with cardiovascular or kidney disease, adding a metabolic prevention benefit to their established cardiorenal protection.","created":"2026-07-03T10:31:35Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82f0cdbf0346","type":"article","url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","title":"LAA-sluiting na AF-ablatie: gerandomiseerde trial — NEJM","title_en":"Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2408308","source_url":"https://doi.org/10.1056/NEJMoa2408308","authors":["Oussama M Wazni","Walid I Saliba","Devi G Nair","Eloi Marijon","Boris Schmidt","Troy Hounshell","Henning Ebelt","Carsten Skurk","Saumil Oza","Chinmay Patel","Arvindh Kanagasundram","Ashish Sadhu","Sri Sundaram","Jose Osorio","George Mark","Madhukar Gupta","David B DeLurgio","Jeffrey Olson","Jens Erik Nielsen-Kudsk","Lucas V A Boersma","Jeff S Healey","Karen P Phillips","Federico M Asch","Katherine Wolski","Kristine Roy","Thomas Christen","Brad S Sutton","Kenneth M Stein","Vivek Y Reddy"],"significance":9,"published":"2025-04-03","source_date":"2025-04-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/transesofageale-echo-bij-af/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"This NEJM trial investigated whether left atrial appendage closure combined with catheter ablation for atrial fibrillation can reduce stroke risk and enable anticoagulation cessation. The results inform the decision about combining structural and rhythm interventions for long-term AF management.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca983c5d179d","type":"article","url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","title":"ISCHEMIA: invasief versus conservatief bij chronische totale occlusie","title_en":"Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.01.029","source_url":"https://doi.org/10.1016/j.jacc.2025.01.029","authors":["Sripal Bangalore","G B John Mancini","Jonathan Leipsic","Mathew J Budoff","Yifan Xu","Rebecca Anthopolos","Emmanouil S Brilakis","Aeshita Dwivedi","John A Spertus","Phil G Jones","Yoon Joo Cho","Daniel B Mark","Cameron J Hague","James K Min","Harmony R Reynolds","Ahmed Elghamaz","Rajesh Goplan Nair","Kreton Mavromatis","Gilbert Gosselin","Subhash Banerjee","Hristo Pejkov","Steven Lindsay","J Aaron Grantham","David O Williams","Gregg W Stone","Sean M O'Brien","Judith S Hochman","David J Maron"],"significance":7,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/kleplijden/aortaregurgitatie/"],"congress":"","summary_en":"This ISCHEMIA subanalysis in patients with chronic total occlusions showed no benefit of invasive management over conservative treatment, consistent with the overall trial findings and dedicated CTO trials.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7da7ed3bf543","type":"article","url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","title":"GDMT en uitkomsten in ISCHEMIA-trial","title_en":"Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.01.028","source_url":"https://doi.org/10.1016/j.jacc.2025.01.028","authors":["David J Maron","Jonathan D Newman","Rebecca Anthopolos","Ying Lu","Susanna Stevens","William E Boden","Kreton Mavromatis","Jason Linefsky","Rajesh G Nair","Olga Bockeria","Gilbert Gosselin","Gian P Perna","Elena Demchenko","David Foo","Michael D Shapiro","Mary Ann Champagne","Christie Ballantyne","Peter McCullough","Jose Luis Lopez-Sendon","Frank Rockhold","Frank Harrell","Yves Rosenberg","Gregg W Stone","Sripal Bangalore","Harmony R Reynolds","John A Spertus","Judith S Hochman"],"significance":7,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"This ISCHEMIA analysis showed that better adherence to guideline-directed medical therapy improves outcomes regardless of revascularization strategy, reinforcing that optimal pharmacotherapy is the foundation of stable coronary disease management.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cf8ece01e4b8","type":"article","url":"https://hartvaat.nl/2025/04/01/behandelstrategieen-voor-bloeddrukcontrole-in-tanzania-en-lesotho-rct/","title":"Behandelstrategieën voor bloeddrukcontrole in Tanzania en Lesotho: RCT","title_en":"Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.5124","source_url":"https://doi.org/10.1001/jamacardio.2024.5124","authors":["Herry Mapesi","Martin Rohacek","Fiona Vanobberghen","Ravi Gupta","Herieth Ismael Wilson","Blaise Lukau","Alain Amstutz","Aza Lyimo","Josephine Muhairwe","Elizabeth Senkoro","Theonestina Byakuzana","Jacqueline Nkouabi","Geofrey Mbunda","Jamali Siru","Ayesha Tarr","Elsie Ramapepe","Madavida Mphunyane","Johanna Oehri","Valeriya Nemtsova","Xiaohan Yan","Moniek Bresser","Tracy Renée Glass","Daniel Henry Paris","Günther Fink","Winfrid Gingo","Niklaus Daniel Labhardt","Thilo Burkard","Maja Weisser"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This randomized trial compared hypertension treatment strategies in Tanzania and Lesotho, showing that structured protocol-driven care significantly improves blood pressure control in sub-Saharan Africa.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5cda297717f","type":"article","url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","title":"Symptomatisch versus asymptomatisch AF en klinische uitkomsten: meta-analyse","title_en":"Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae694","source_url":"https://doi.org/10.1093/eurheartj/ehae694","authors":["Paschalis Karakasis","Konstantinos Pamporis","Konstantinos C Siontis","Panagiotis Theofilis","Athanasios Samaras","Dimitrios Patoulias","Panagiotis Stachteas","Efstratios Karagiannidis","George Stavropoulos","Apostolos Tzikas","George Kassimis","George Giannakoulas","Theodoros Karamitsos","Demosthenes G Katritsis","Nikolaos Fragakis"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ecg-herkenning-af/"],"congress":"","summary_en":"This meta-analysis showed that symptomatic and asymptomatic AF have comparable clinical outcomes, supporting the paradigm that treatment decisions should be based on thromboembolic risk rather than symptom status alone.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef2da6bffe31","type":"article","url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","title":"2025 ACC/AHA ACS-richtlijn: management van acuut coronair syndroom","title_en":"2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-coronair-syndroom"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001309","source_url":"https://doi.org/10.1161/CIR.0000000000001309","authors":["Sunil V Rao","Michelle L O'Donoghue","Marc Ruel","Tanveer Rab","Jaqueline E Tamis-Holland","John H Alexander","Usman Baber","Heather Baker","Mauricio G Cohen","Mercedes Cruz-Ruiz","Leslie L Davis","James A de Lemos","Tracy A DeWald","Islam Y Elgendy","Dmitriy N Feldman","Abhinav Goyal","Ijeoma Isiadinso","Venu Menon","David A Morrow","Debabrata Mukherjee","Elke Platz","Susan B Promes","Sigrid Sandner","Yader Sandoval","Rachel Schunder","Binita Shah","Jason P Stopyra","Amy W Talbot","Pam R Taub","Marlene S Williams"],"significance":10,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"The 2025 ACC/AHA ACS guideline integrates contemporary evidence on DAPT de-escalation, routine complete revascularization, troponin-based diagnosis, and post-MI therapy. Notably, long-term beta-blockers are no longer mandated after MI with preserved ejection fraction, reflecting ABYSS and REDUCE-AMI results.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd51a08fed40","type":"article","url":"https://hartvaat.nl/2025/04/01/aldosteronsynthaseremmers-bij-hypertensie-meta-analyse-van-rct-s/","title":"Aldosteronsynthaseremmers bij hypertensie: meta-analyse van RCT's","title_en":"Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","mra-aldosteronantagonisten","ras-remmers","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23962","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23962","authors":["Luigi Marzano","Matteo Merlo","Nicola Martinelli","Francesca Pizzolo","Simonetta Friso"],"significance":8,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis of all randomized trials with aldosterone synthase inhibitors (baxdrostat, lorundrostat) confirmed significant blood pressure reduction in patients with hypertension. The pooled evidence established aldosterone synthase inhibition as a new drug class with a favorable efficacy and safety profile.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d349c509e9ca","type":"article","url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","title":"Hypotensieve episodes op 24-uurs ABPM en cognitieve functie: SPRINT inzichten","title_en":"Hypotensive Episodes on 24-Hour Ambulatory Blood Pressure and Cognitive Function: Insights From the SPRINT Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24222","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24222","authors":["Wenxin Zhang","Susan Redline","Anand Viswanathan","Simon B Ascher","Darshana Hari","Stephen P Juraschek","Christophe Tzourio","Paul E Drawz","Lewis A Lipsitz","Murray A Mittleman","Yuan Ma"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT analysis showed that hypotensive episodes detected on 24-hour ambulatory monitoring are not associated with cognitive impairment, providing reassurance about brain safety during intensive blood pressure treatment.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"98d2d5cab002","type":"article","url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","title":"Aprocitentan bij zwarte patiënten met hypertensie","title_en":"Aprocitentan for Blood Pressure Reduction in Black Patients.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","aprocitentan","bloeddrukbehandeling","endotheel","endothelineantagonisten","precision-trial","renale-denervatie","vrouwen","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24142","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24142","authors":["John M Flack","Markus P Schlaich","Michael A Weber","Mouna Sassi-Sayadi","Krzysztof Narkiewicz","Martine Clozel","Roland F Dreier","Nabil S Andrawis","Parisa Danaietash","Nashwa Gabra","David Scott","Ji-Guang Wang","Keith C Ferdinand"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This subanalysis confirmed that aprocitentan effectively lowers blood pressure in Black hypertensive patients, extending the endothelin antagonist evidence to a population with disproportionate hypertension burden.","created":"2026-07-03T10:31:34Z","updated":"2026-07-03T18:39:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e04fa4b6b423","type":"article","url":"https://hartvaat.nl/2025/04/01/ultrafiltratie-bij-cardiorenaal-syndroom-systematische-review/","title":"Ultrafiltratie bij cardiorenaal syndroom: systematische review","title_en":"Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","cardio-renaal-metabool","cardiorenal-behandelstrategie","fidelity","hypertrofische-cardiomyopathie","ijzertekort","laminopathie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15125","source_url":"https://doi.org/10.1002/ehf2.15125","authors":["Borja Guerrero Cervera","Raquel López-Vilella","Víctor Donoso Trenado","María Peris-Fernández","Paula Carmona","Amparo Soldevila","Sergi Tormo","Ramón Devesa","María Jesús Montero Hernández","Luis Martínez Dolz","Julio Hernández Jaras","Pilar Sánchez-Pérez","Luis Almenar-Bonet"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"A systematic review compared ultrafiltration with conventional diuretic therapy in cardiorenal syndrome. Ultrafiltration improved decongestion but sometimes worsened renal function, limiting its role to diuretic-resistant situations where conventional therapy has failed.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2ef7b9a4a5a","type":"article","url":"https://hartvaat.nl/2025/04/01/clip-hfpef-cilostazol-bij-hfpef-gerandomiseerde-trial/","title":"CLIP-HFpEF: cilostazol bij HFpEF — gerandomiseerde trial","title_en":"Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15162","source_url":"https://doi.org/10.1002/ehf2.15162","authors":["Norman Aiad","Jeanne du Fay de Lavallaz","Michael J Zhang","Thanat Chaikijurajai","Bo Ye","Prabhjot S Nijjar","Julie A Lahiri","Cindy M Martin","Tamas Alexy","Markus Meyer"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"The CLIP-HFpEF trial evaluated cilostazol, an oral PDE-3 inhibitor, in patients with heart failure with preserved ejection fraction. The drug did not significantly improve exercise capacity or health status, indicating that PDE-3 inhibition is not an effective therapeutic strategy for HFpEF.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a8c433da5934","type":"article","url":"https://hartvaat.nl/2025/04/01/sacubitril-valsartan-na-acuut-mi-meta-analyse-van-in-hospital-initiatie/","title":"Sacubitril/valsartan na acuut MI: meta-analyse van in-hospital initiatie","title_en":"The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15082","source_url":"https://doi.org/10.1002/ehf2.15082","authors":["Gianluca Di Pietro","Riccardo Improta","Paolo Severino","Andrea D'Amato","Lucia Ilaria Birtolo","Ovidio De Filippo","Antonio Lattanzio","Raffaele De Cristofaro","Giacchino Galardo","Fabrizio D'Ascenzo","Roberto Badagliacca","Gennaro Sardella","Maurizio Volterrani","Francesco Fedele","Carmine Dario Vizza","Massimo Mancone"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated in-hospital sacubitril-valsartan initiation after acute MI, showing that early ARNI therapy is safe with favorable effects on cardiac biomarkers and remodeling.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56c494174ca0","type":"article","url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","title":"Vericiguat-voordeel geprojecteerd op PARADIGM-HF en DAPA-HF populaties","title_en":"Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15134","source_url":"https://doi.org/10.1002/ehf2.15134","authors":["Veraprapas Kittipibul","Robert J Mentz","Rebecca Young","Javed Butler","Justin A Ezekowitz","Carolyn S P Lam","Piotr Ponikowski","Adriaan Voors","Stefano Corda","Ciaran McMullan","Christopher M O'Connor","Kevin J Anstrom","Paul W Armstrong"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This analysis projected the potential benefit of vericiguat onto simulated PARADIGM-HF and DAPA-HF populations. The estimated additional benefit over existing guideline-directed therapy supports vericiguat as a fifth pillar in the treatment of severe heart failure.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebf2932e8108","type":"article","url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","title":"Socio-economische ongelijkheid en hartfalenuitkomsten: systematische review","title_en":"Socio-economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14986","source_url":"https://doi.org/10.1002/ehf2.14986","authors":["Abdul Shakoor","Willemijn A van Maarschalkerwaart","Jeroen Schaap","Rudolf A de Boer","Nicolas M van Mieghem","Eric H Boersma","Loek van Heerebeek","Jasper J Brugts","Robert M A van der Boon"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review documented the impact of socioeconomic inequalities on heart failure morbidity and mortality. Lower socioeconomic status was consistently associated with significantly worse heart failure outcomes across multiple dimensions.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8bd8a475392b","type":"article","url":"https://hartvaat.nl/2025/04/01/cardiale-akoestische-biomarkers-bij-hartfalenmonitoring-systematische-review/","title":"Cardiale akoestische biomarkers bij hartfalenmonitoring: systematische review","title_en":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15075","source_url":"https://doi.org/10.1002/ehf2.15075","authors":["Javed Butler","Malcolm Brown","Philippe Prokocimer","Ashley C Humphries","Sophie Pope","Olivia Wright","Jun Su","Osama Elnawasany","Bogdan Muresan"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"A systematic review evaluated the role of cardiac acoustic biomarkers — including digital auscultation and remote monitoring — in heart failure management. The technology shows promise for non-invasive haemodynamic assessment but requires further clinical validation.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c0a7c69312d","type":"article","url":"https://hartvaat.nl/2025/04/01/sotagliflozine-duale-sglt1-sglt2-remmer-bij-hartfalen-meta-analyse/","title":"Sotagliflozine (duale SGLT1/SGLT2-remmer) bij hartfalen: meta-analyse","title_en":"Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15036","source_url":"https://doi.org/10.1002/ehf2.15036","authors":["Maria Anna Bantounou","Panagiotis Sardellis","Josip Plascevic","Ribeya Awaes-Mahmood","Justyna Kaczmarek","Daniel Black Boada","Rosa Thuemmler","Sam Philip"],"significance":7,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events and hospitalizations in heart failure patients with type 2 diabetes, supporting the dual transporter inhibition approach.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"02dee4ac4acd","type":"article","url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","title":"Ambulante behandeling van gedecompenseerd hartfalen: meta-analyse","title_en":"Outpatient treatment of decompensated heart failure: A systematic review and study level meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14841","source_url":"https://doi.org/10.1002/ehf2.14841","authors":["Jameela Bahar","Amna Rahman","Grace W Y Wong","Rajiv Sankaranarayanan","Fozia Z Ahmed","Rebecca Taylor","Ahmet Fuat","Iain Squire","John G F Cleland","Gregory Y H Lip","James H P Gamble","Sundas Masudi","Prince Josiah S Joseph","Kenneth Y K Wong"],"significance":6,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated outpatient treatment of decompensated heart failure as an alternative to hospitalization, showing that selected patients can be safely managed with intravenous diuretics in ambulatory settings.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d83077f37e8f","type":"article","url":"https://hartvaat.nl/2025/04/01/copd-en-slechtere-uitkomsten-bij-hfpef-meta-analyse/","title":"COPD en slechtere uitkomsten bij HFpEF: meta-analyse","title_en":"Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14958","source_url":"https://doi.org/10.1002/ehf2.14958","authors":["Shuo Xu","Zhenbang Gu","Wengen Zhu","Shenghui Feng"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":[],"congress":"","summary_en":"A meta-analysis confirmed that COPD as a comorbidity significantly worsens outcomes in patients with heart failure with preserved ejection fraction. The cardiopulmonary overlap requires integrated management approaches addressing both conditions simultaneously.","created":"2026-07-03T10:31:33Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"91930a13aae8","type":"article","url":"https://hartvaat.nl/2025/04/01/icd-deactivatie-aan-het-levenseinde-de-moeilijke-discussie/","title":"ICD-deactivatie aan het levenseinde: de moeilijke discussie","title_en":"The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14831","source_url":"https://doi.org/10.1002/ehf2.14831","authors":["Siobhan C Murray","Claire McNamara","Anna V Chatzi"],"significance":5,"published":"2025-04-01","source_date":"2025-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This systematic review explored the ethical and practical aspects of implantable cardioverter defibrillator deactivation at end of life. Timely discussions and clear advance care planning are essential but remain underutilised in clinical practice.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73f0065f5d9a","type":"article","url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","title":"ATHENA post-hoc: dronedaron als effectieve vroege ritmecontrole","title_en":"Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf080","source_url":"https://doi.org/10.1093/europace/euaf080","authors":["Paulus Kirchhof","A John Camm","Harry J G M Crijns","Jonathan P Piccini","Christian Torp-Pedersen","David S McKindley","Mattias Wieloch","Stefan H Hohnloser"],"significance":6,"published":"2025-03-28","source_date":"2025-03-28","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This ATHENA post-hoc analysis using EAST-AFNET 4 criteria confirmed that dronedarone provides effective early rhythm control in AF, showing cardiovascular benefit when applied to contemporary rhythm management paradigms.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0421cb010d8","type":"article","url":"https://hartvaat.nl/2025/03/28/geinhaleerde-flecainide-voor-cardioversie-van-recent-onset-af-lancet/","title":"Geïnhaleerde flecaïnide voor cardioversie van recent-onset AF: Lancet","title_en":"Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["roken"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf064","source_url":"https://doi.org/10.1093/europace/euaf064","authors":["Michiel Rienstra","Anderson C Woite-Silva","Aaf Kuijper","Sabine Eijsbouts","Karin Kraaier","Tomas Janota","Clara Van Ofwegen","Ype Tuininga","Erik Badings","Jose Luis Merino","Jeremy N Ruskin","A John Camm","Peter R Kowey","Christopher Dufton","Jean Maupas","Dawn Parsell","Luiz Belardinelli"],"significance":9,"published":"2025-03-28","source_date":"2025-03-28","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/abc-pad-af/"],"congress":"","summary_en":"The RESTORE-1 trial demonstrated that inhaled flecainide rapidly and effectively cardioverted recent-onset symptomatic atrial fibrillation in an outpatient setting. The needle-free, self-administered formulation offers a patient-controlled 'pill-in-the-pocket' alternative with faster onset than oral antiarrhythmic drugs.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a5fd28144f2","type":"article","url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","title":"Intensieve bloeddrukcontrole bij type 2 diabetes — NEJM","title_en":"Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","select-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2412006","source_url":"https://doi.org/10.1056/NEJMoa2412006","authors":["Yufang Bi","Mian Li","Yan Liu","Tingzhi Li","Jieli Lu","Peng Duan","Fengmei Xu","Qijuan Dong","Ailiang Wang","Tiange Wang","Ruizhi Zheng","Yuhong Chen","Min Xu","Xiaohu Wang","Xinhuan Zhang","Yanbo Niu","Zhiqiang Kang","Chunru Lu","Jing Wang","Xinwen Qiu","An Wang","Shujing Wu","Jingya Niu","Jingya Wang","Zhiyun Zhao","Huanfeng Pan","Xiaohua Yang","Xiaohong Niu","Shuguang Pang","Xiaoliang Zhang","Yuancheng Dai","Qin Wan","Shihong Chen","Qidong Zheng","Shaoping Dai","Juan Deng","Leshan Liu","Guixia Wang","Huiqi Zhu","Weidong Tang","Haixia Liu","Zhenfang Guo","Guang Ning","Jiang He","Yu Xu","Weiqing Wang"],"significance":10,"published":"2025-03-27","source_date":"2025-03-27","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This large randomized trial showed that intensive blood pressure control (systolic <120 mmHg) significantly reduced cardiovascular events compared with standard treatment (<140 mmHg) in patients with type 2 diabetes and elevated cardiovascular risk. The results align with SPRINT and extend the evidence for aggressive blood pressure targets specifically to the diabetic population.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f78495a4df5a","type":"article","url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","title":"RATE-AF: kosteneffectiviteit van digoxine versus bètablokkers bij permanent AF","title_en":"Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["bisoprolol"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324761","source_url":"https://doi.org/10.1136/heartjnl-2024-324761","authors":["Zainab Abdali","Karina V Bunting","Samir Mehta","John Camm","Kazem Rahimi","Mary Stanbury","Sandra Haynes","Dipak Kotecha","Sue Jowett"],"significance":7,"published":"2025-03-26","source_date":"2025-03-26","image":"","kennis":[],"congress":"","summary_en":"This RATE-AF cost-effectiveness analysis showed that digoxin is more cost-effective than beta-blockers for rate control in permanent AF, driven by fewer adverse events and comparable quality of life at lower cost.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cbe198b412ab","type":"article","url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","title":"Antitrombotische therapie bij AF na ACS/PCI: AUGUSTUS gecombineerde inzichten","title_en":"Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.125","source_url":"https://doi.org/10.1016/j.jacc.2024.10.125","authors":["Manasi Tannu","Renato D Lopes","Daniel M Wojdyla","Shaun G Goodman","Ronald Aronson","Roxana Mehran","Christopher B Granger","Stephan Windecker","John H Alexander","W Schuyler Jones"],"significance":7,"published":"2025-03-25","source_date":"2025-03-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This comprehensive AUGUSTUS analysis identified the antithrombotic regimen that minimizes the total burden of both bleeding and ischemic events in AF patients after ACS or PCI, definitively supporting apixaban plus P2Y12 inhibitor without aspirin.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"89c788eb3df2","type":"article","url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","title":"Anticoagulatie en antiplaatjestherapie bij AF en stabiel coronairlijden: meta-analyse","title_en":"Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","rivaroxaban","stabiel-coronairlijden","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.12.030","source_url":"https://doi.org/10.1016/j.jacc.2024.12.030","authors":["Sina Rashedi","Mohammad Keykhaei","Alyssa Sato","Philippe Gabriel Steg","Gregory Piazza","John W Eikelboom","Renato D Lopes","Marc P Bonaca","Satoshi Yasuda","Hisao Ogawa","Satoshi Shizuta","Takeshi Kimura","Yasuo Okumura","Felicita Andreotti","Laurent Bertoletti","Gregg W Stone","Roxana Mehran","David J Cohen","Gregory Y H Lip","Behnood Bikdeli"],"significance":7,"published":"2025-03-25","source_date":"2025-03-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis confirmed that oral anticoagulant monotherapy without antiplatelet therapy is the preferred long-term strategy for AF patients with stable coronary disease, with no ischemic cost from dropping the antiplatelet agent.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d11bdcd9112a","type":"article","url":"https://hartvaat.nl/2025/03/25/leeftijds-en-sekseverschillen-in-effectiviteit-van-diabetesbehandeling-netwerk-m/","title":"Leeftijds- en sekseverschillen in effectiviteit van diabetesbehandeling: netwerk-meta-analyse","title_en":"Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","figaro-dkd","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","select-trial","semaglutide","sglt2-remmers","soul-trial","tirzepatide"],"journal":"JAMA","doi":"10.1001/jama.2024.27402","source_url":"https://doi.org/10.1001/jama.2024.27402","authors":["Peter Hanlon","Elaine Butterly","Lili Wei","Heather Wightman","Saleh Ali M Almazam","Khalid Alsallumi","Jamie Crowther","Ryan McChrystal","Heidi Rennison","Katherine Hughes","Jim Lewsey","Robert Lindsay","Stuart McGurnaghan","John Petrie","Laurie A Tomlinson","Sarah Wild","Amanda Adler","Naveed Sattar","David M Phillippo","Sofia Dias","Nicky J Welton","David A McAllister"],"significance":6,"published":"2025-03-25","source_date":"2025-03-25","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/"],"congress":"","summary_en":"This network meta-analysis showed that the efficacy of SGLT2 inhibitors and GLP-1 agonists for type 2 diabetes treatment is consistent across age and sex subgroups, supporting equitable prescribing.","created":"2026-07-03T10:31:32Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8d514a73e070","type":"article","url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","title":"AMULET IDE vijfjaarsresultaten: LAA-occlusie met Amulet","title_en":"5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.101","source_url":"https://doi.org/10.1016/j.jacc.2024.10.101","authors":["Dhanunjaya Lakkireddy","Christopher R Ellis","David Thaler","Vijendra Swarup","Alok Gambhir","James Hermiller","Jens Erik Nielsen-Kudsk","Stephen Worthley","Devi Nair","Boris Schmidt","Rodney Horton","Nigel Gupta","Jordan A Anderson","Hong Zhao","Mohamad Alkhouli","Stephan Windecker"],"significance":7,"published":"2025-03-25","source_date":"2025-03-25","image":"","kennis":[],"congress":"","summary_en":"Five-year results from the Amulet IDE trial confirmed the long-term durability and effectiveness of the Amplatzer Amulet LAA occluder for stroke prevention in AF, providing the longest follow-up data for this device.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1def28e5f4a","type":"article","url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","title":"FLOW: semaglutide CV-voordelen naar CKD-ernst bij diabetes","title_en":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","diabetes-en-hart","fidelio-dkd","flow-trial","ijzertekort","select-trial","soul-trial","stride-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae613","source_url":"https://doi.org/10.1093/eurheartj/ehae613","authors":["Kenneth W Mahaffey","Katherine R Tuttle","Mustafa Arici","Florian M M Baeres","George Bakris","David M Charytan","David Z I Cherney","Gil Chernin","Ricardo Correa-Rotter","Janusz Gumprecht","Thomas Idorn","Giuseppe Pugliese","Ida Kirstine Bull Rasmussen","Søren Rasmussen","Peter Rossing","Ekaterina Sokareva","Johannes F E Mann","Vlado Perkovic","Richard Pratley"],"significance":7,"published":"2025-03-24","source_date":"2025-03-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/"],"congress":"","summary_en":"This FLOW subanalysis confirmed that semaglutide's cardiovascular benefit is consistent across CKD severity stages in type 2 diabetes, with the greatest absolute benefit in patients with more advanced kidney disease.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a4739606f69","type":"article","url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","title":"Natriumzirconiumcyclosilicaat voor spironolacton-optitratie na HF: gerandomiseerde trial","title_en":"Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.014","source_url":"https://doi.org/10.1016/j.jacc.2024.11.014","authors":["Mikhail N Kosiborod","David Z I Cherney","Akshay S Desai","Jeffrey M Testani","Subodh Verma","Khaja Chinnakondepalli","David Dolling","Shachi Patel","Magnus Dahl","James M Eudicone","Lovisa Friberg","Mario Ouwens","Murillo O Antunes","Kim A Connelly","Vagner Madrini","Luca Kuthi","Anuradha Lala","Miguel Lorenzo","Patrícia O Guimarães","Marta Cobo Marcos","Béla Merkely","Julio Nuñez","Iain Squire","Jan Václavík","Jerzy Wranicz","Mark C Petrie"],"significance":7,"published":"2025-03-18","source_date":"2025-03-18","image":"","kennis":[],"congress":"","summary_en":"This randomized trial demonstrated that sodium zirconium cyclosilicate enables spironolactone optimization in HFrEF patients with hyperkalemia, providing an alternative potassium binder to facilitate guideline-directed MRA therapy.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5b7bd281b16","type":"article","url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","title":"DOAC's versus geen anticoagulatie na intracraniële bloeding bij AF: meta-analyse","title_en":"Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","doacs","rivaroxaban"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(25)00333-2","source_url":"https://doi.org/10.1016/S0140-6736(25)00333-2","authors":["Roland Veltkamp","Eleni Korompoki","Kirsten H Harvey","Emily R Harvey","Cornelia Fießler","Uwe Malzahn","Viktoria Rücker","Joan Montaner","Valeria Caso","Igor Sibon","Peter Ringleb","Omid Halse","Klemens Hügen","Sabine Ullmann","Carolin Schuhmann","Gabriele Putz Todd","Kirsten Haas","Elena Palà","Stéphanie Debette","Morgane Lachaize","Tim D'Aoust","Christian Enzinger","Stefan Ropele","Simon Fandler-Höfler","Melanie Haidegger","Yanzhong Wang","Hatem A Wafa","Virginia Cancelloni","Maria Giulia Mosconi","Gregory Y H Lip","Deirdre A Lane","Walter E Haefeli","Kathrin I Foerster","Viktoria S Wurmbach","Peter Brønnum Nielsen","Karim Hajjar","Patrick Müller","Sven Poli","Jan Purrucker","Mona Laible","Lucio D'Anna","Yolanda Silva","Reyes de Torres Chacon","Patricia Martínez-Sánchez","Marion Boulanger","Bo Norrving","Guillaume Paré","Rolf Wachter","George Ntaios","Charles D A Wolfe","Peter U Heuschmann"],"significance":7,"published":"2025-03-15","source_date":"2025-03-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This meta-analysis showed that restarting DOACs after intracerebral hemorrhage in AF patients is associated with fewer ischemic events and lower mortality without significantly increased recurrent ICH, supporting cautious anticoagulation resumption.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c3edfa43394","type":"article","url":"https://hartvaat.nl/2025/03/13/minoca-pathologische-bevindingen-bij-invasieve-beoordeling-meta-analyse/","title":"MINOCA: pathologische bevindingen bij invasieve beoordeling — meta-analyse","title_en":"Pathological findings at invasive assessment in MINOCA: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming","perifeer-vaatlijden"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324565","source_url":"https://doi.org/10.1136/heartjnl-2024-324565","authors":["Damiano Fedele","Daniele Cavallo","Francesca Bodega","Nicole Suma","Lisa Canton","Mariachiara Ciarlantini","Khrystyna Ryabenko","Sara Amicone","Virginia Marinelli","Claudio Asta","Giuseppe Pastore","Marcello Casuso Alvarez","Rebecca Belà","Angelo Sansonetti","Francesco Angeli","Matteo Armillotta","Alberto Foà","Luca Bergamaschi","Pasquale Paolisso","Marta Belmonte","Paola Rucci","Emanuele Barbato","Carmine Pizzi"],"significance":6,"published":"2025-03-13","source_date":"2025-03-13","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"This systematic review documented the pathological mechanisms of MINOCA identified through invasive assessment (OCT, IVUS, provocation testing), showing heterogeneous etiologies including plaque disruption, coronary spasm, and microvascular dysfunction.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"796364211b2c","type":"article","url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","title":"SUMMIT: tirzepatide en klinisch traject bij HFpEF met obesitas — langetermijn","title_en":"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["summit-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072679","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072679","authors":["Michael R Zile","Barry A Borlaug","Christopher M Kramer","Seth J Baum","Sheldon E Litwin","Venu Menon","Yang Ou","Govinda J Weerakkody","Karla C Hurt","Chisom Kanu","Masahiro Murakami","Milton Packer"],"significance":7,"published":"2025-03-11","source_date":"2025-03-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"Long-term SUMMIT analysis showed that tirzepatide durably improves the clinical trajectory of patients with HFpEF and obesity, with sustained benefits on symptoms, function, and body composition beyond the initial treatment period.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0181745e4e76","type":"article","url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","title":"TAVR bij systolisch hartfalen en matige aortastenose — NEJM","title_en":"Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.070","source_url":"https://doi.org/10.1016/j.jacc.2024.10.070","authors":["Nicolas M Van Mieghem","Sammy Elmariah","Ernest Spitzer","Philippe Pibarot","Tamim M Nazif","Jeroen J Bax","Rebecca T Hahn","Alexandra Popma","Ori Ben-Yehuda","Faouzi Kallel","Björn Redfors","Michael L Chuang","Maria C Alu","Wietze Lindeboom","Dhaval Kolte","Firas E Zahr","Susheel K Kodali","Justin A Strote","Renicus S Hermanides","David J Cohen","Jan G P Tijssen","Martin B Leon"],"significance":9,"published":"2025-03-11","source_date":"2025-03-11","image":"","kennis":[],"congress":"","summary_en":"The TAVR UNLOAD trial explored TAVR in patients with HFrEF and moderate (not severe) aortic stenosis. The results inform the growing debate about the role of valve intervention in patients where hemodynamic afterload reduction may benefit ventricular recovery even below conventional severity thresholds for aortic stenosis.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5457affe4e0d","type":"article","url":"https://hartvaat.nl/2025/03/05/biventriculair-versus-rv-pacing-bij-patienten-met-verwachte-frequente-pacing/","title":"Biventriculair versus RV-pacing bij patiënten met verwachte frequente pacing","title_en":"Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf029","source_url":"https://doi.org/10.1093/europace/euaf029","authors":["Reinhard C Funck","Hans-Helge Müller","Maurizio Lunati","Luc De Roy","Norbert Klein","Eckhard Meisel","Goran Milasinovic","Mark D Carlson","Michael Wittenberg","Gerhard Hindricks","Jean-Jacques Blanc"],"significance":7,"published":"2025-03-05","source_date":"2025-03-05","image":"","kennis":[],"congress":"","summary_en":"This study compared biventricular with right ventricular pacing in patients expected to require frequent ventricular pacing, showing that biventricular pacing prevents pacing-induced LV dysfunction and improves clinical outcomes.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f2276ee9490c","type":"article","url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","title":"AF-last in klinische praktijk, onderzoek en technologie: consensus document","title_en":"Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf019","source_url":"https://doi.org/10.1093/europace/euaf019","authors":["Wolfram Doehner","Giuseppe Boriani","Tatjana Potpara","Carina Blomstrom-Lundqvist","Rod Passman","Luciano A Sposato","Dobromir Dobrev","Ben Freedman","Isabelle C Van Gelder","Taya V Glotzer","Jeff S Healey","Theodore Karapanayiotides","Gregory Y H Lip","Jose Luis Merino","George Ntaios","Renate B Schnabel","Jesper H Svendsen","Emma Svennberg","Rolf Wachter","Karl Georg Haeusler","A John Camm"],"significance":6,"published":"2025-03-05","source_date":"2025-03-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"This clinical consensus statement defined AF burden as a standardized metric for assessing treatment effectiveness, establishing measurement standards and clinical thresholds for arrhythmia monitoring.","created":"2026-07-03T10:31:31Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e14bbdb452c","type":"article","url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","title":"Stapsgewijze provisionale versus systematische dualstent bij ware linker hoofdstam bifurcatie","title_en":"Stepwise Provisional Versus Systematic Dual-Stent Strategies for Treatment of True Left Main Coronary Bifurcation Lesions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071153","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071153","authors":["Sandeep Arunothayaraj","Mohaned Egred","Adrian P Banning","Philippe Brunel","Miroslaw Ferenc","Thomas Hovasse","Adrian Wlodarczak","Manuel Pan","Thomas Schmitz","Marc Silvestri","Andreis Erglis","Evgeny Kretov","Jens Flensted Lassen","Alaide Chieffo","Thierry Lefèvre","Francesco Burzotta","James Cockburn","Olivier Darremont","Goran Stankovic","Marie-Claude Morice","Yves Louvard","David Hildick-Smith"],"significance":7,"published":"2025-03-04","source_date":"2025-03-04","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized trial compared provisional with systematic dual-stent strategies for true left main bifurcation lesions in the EBC MAIN study, finding comparable long-term outcomes between approaches.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6fccfdd2bbfc","type":"article","url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","title":"Aspirine en hemocompatibiliteit na LVAD bij atherosclerotisch vaatlijden","title_en":"Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["anticoagulantia","aspirine","trombocytenaggregatieremmers"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4849","source_url":"https://doi.org/10.1001/jamacardio.2024.4849","authors":["Finn Gustafsson","Nir Uriel","Ivan Netuka","Jason N Katz","Francis D Pagani","Jean M Connors","Ulrich P Jorde","Daniel Zimpfer","Yuriy Pya","Jennifer Conway","Anelechi Anyanwu","Anna Mara Scandroglio","Nasir Sulemanjee","Pavan Atluri","Mary Keebler","Craig H Selzman","Jeffrey D Alexis","Christopher Hayward","John Henderson","Nicholas Dirckx","Carlo Gazzola","Mandeep R Mehra"],"significance":6,"published":"2025-03-01","source_date":"2025-03-01","image":"","kennis":[],"congress":"","summary_en":"This ARIES-HM3 secondary analysis examined aspirin's role in LVAD patients with atherosclerotic vascular disease, characterizing the hemocompatibility trade-off of antiplatelet therapy in mechanically supported patients.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a83c3577cfd2","type":"article","url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","title":"Kaliumnitraat bij HFpEF: gerandomiseerde trial","title_en":"Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4417","source_url":"https://doi.org/10.1001/jamacardio.2024.4417","authors":["Payman Zamani","Sanjiv J Shah","Jordana B Cohen","Manyun Zhao","Wei Yang","Jessica L Afable","Maria Caturla","Hannah Maynard","Bianca Pourmussa","Cassandra Demastus","Ipsita Mohanty","Michelle Menon Miyake","Srinath Adusumalli","Kenneth B Margulies","Stuart B Prenner","David C Poole","Neil Wilson","Ravinder Reddy","Raymond R Townsend","Harry Ischiropoulos","Thomas P Cappola","Julio A Chirinos"],"significance":6,"published":"2025-03-01","source_date":"2025-03-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial of potassium nitrate in HFpEF tested whether inorganic nitrate supplementation improves exercise tolerance through enhanced nitric oxide availability, exploring a dietary approach to the NO-deficiency hypothesis.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"079959d38d44","type":"article","url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","title":"Frailteit en antihypertensieve behandeling bij ouderen: meta-analyse","title_en":"Impact of Frailty on Antihypertensive Treatment in Older Adults.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","anemie-ckd","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","fidelity","ouderen","statines","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24214","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24214","authors":["Linan Chen","Shoujiang You","Nicole Ee","Kenneth Rockwood","David D Ward","Mark Woodward","Tao Liu","Yijie Gao","Jeff D Williamson","Craig S Anderson","Katie Harris","Xiaoying Chen","Ruth Peters"],"significance":7,"published":"2025-03-01","source_date":"2025-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This meta-analysis found that moderately frail older adults still benefit from antihypertensive treatment, while severely frail patients may not. The results support continued blood pressure treatment in most elderly patients but caution against aggressive targets in the most frail.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c4476b4329b","type":"article","url":"https://hartvaat.nl/2025/03/01/tijd-in-streefwaarde-voor-bloeddruk-en-gezondheidsuitkomsten-systematische-revie/","title":"Tijd-in-streefwaarde voor bloeddruk en gezondheidsuitkomsten: systematische review","title_en":"Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.24013","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24013","authors":["Huairong Wang","Jialu Song","Zhike Liu","Huan Yu","Kun Wang","Xueying Qin","Yiqun Wu"],"significance":6,"published":"2025-03-01","source_date":"2025-03-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review established blood pressure time-in-target-range as a clinically meaningful metric associated with better cardiovascular outcomes, shifting the focus from single BP measurements to sustained control quality.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a589d1c8a7f9","type":"article","url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","title":"Ambulante HF-verslechtering bij ATTR-CM: ATTR-ACT subanalyse","title_en":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","aritmogene-cardiomyopathie","atleten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","ouderen","slaapapneu","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.097","source_url":"https://doi.org/10.1016/j.jacc.2024.10.097","authors":["Marianna Fontana","Mathew S Maurer","Julian D Gillmore","Shaun Bender","Patrick Y Jay","Scott D Solomon"],"significance":5,"published":"2025-02-25","source_date":"2025-02-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"A post-hoc analysis of the APOLLO-B trial investigated outpatient worsening heart failure in transthyretin amyloidosis cardiomyopathy. Patisiran treatment reduced worsening events, confirming the clinical value of transthyretin gene silencing in this population.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd353ce63100","type":"article","url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","title":"Systolische bloeddruk en polsdruk bij hartfalen: gepoolde IPD analyse","title_en":"Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.007","source_url":"https://doi.org/10.1016/j.jacc.2024.11.007","authors":["Henri Lu","Toru Kondo","Brian L Claggett","Muthiah Vaduganathan","Brendon L Neuen","Iris E Beldhuis","Pardeep S Jhund","Finnian R Mc Causland","Inder S Anand","Marc A Pfeffer","Bertram Pitt","Faiez Zannad","Michael R Zile","John J V McMurray","Scott D Solomon","Akshay S Desai"],"significance":7,"published":"2025-02-25","source_date":"2025-02-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This pooled analysis of four heart failure trials showed that lower systolic blood pressure and pulse pressure are associated with worse outcomes in HFmrEF/HFpEF, informing the blood pressure management balance in this population.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47598b5b62d3","type":"article","url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","title":"Ambulante hartfalenverslechtering bij ATTR-cardiomyopathie: ATTR-ACT analyse","title_en":"Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aritmogene-cardiomyopathie","atleten","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","ouderen","pathfinder-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.015","source_url":"https://doi.org/10.1016/j.jacc.2024.11.015","authors":["Marianna Fontana","Mathew S Maurer","Julian D Gillmore","Shaun Bender","Emre Aldinc","Satish A Eraly","Patrick Y Jay","Scott D Solomon"],"significance":5,"published":"2025-02-25","source_date":"2025-02-25","image":"","kennis":[],"congress":"","summary_en":"Analysis of the HELIOS-B trial documented patterns of outpatient worsening heart failure in patients with transthyretin amyloidosis cardiomyopathy. Worsening events were frequent and prognostically significant, supporting early treatment with RNA interference therapy vutrisiran.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"83928d112853","type":"article","url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","title":"SUMMIT: tirzepatide vermindert LV-massa en paracardiaal vetweefsel bij HFpEF","title_en":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.001","source_url":"https://doi.org/10.1016/j.jacc.2024.11.001","authors":["Christopher M Kramer","Barry A Borlaug","Michael R Zile","Dustin Ruff","Joseph M DiMaria","Venu Menon","Yang Ou","Angela M Zarante","Karla C Hurt","Masahiro Murakami","Milton Packer"],"significance":7,"published":"2025-02-25","source_date":"2025-02-25","image":"","kennis":[],"congress":"","summary_en":"The SUMMIT CMR substudy showed that tirzepatide significantly reduces LV mass and paracardiac adipose tissue in obesity-related HFpEF, providing imaging evidence that dual incretin agonism reverses the adverse cardiac remodeling of the obesity-HFpEF phenotype.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78bed94bea06","type":"article","url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","title":"VANISH2: catheterablatie versus antiaritmica bij ventriculaire tachycardie — NEJM","title_en":"Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["ventriculaire-tachycardie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2409501","source_url":"https://doi.org/10.1056/NEJMoa2409501","authors":["John L Sapp","Anthony S L Tang","Ratika Parkash","William G Stevenson","Jeff S Healey","Lorne J Gula","Girish M Nair","Vidal Essebag","Lena Rivard","Jean-Francois Roux","Pablo B Nery","Jean-Francois Sarrazin","Guy Amit","Jean-Marc Raymond","Marc Deyell","Chris Lane","Frederic Sacher","Christian de Chillou","Vikas Kuriachan","Amir AbdelWahab","Isabelle Nault","Katia Dyrda","Stephen Wilton","Umjeet Jolly","Arvindh Kanagasundram","George A Wells"],"significance":9,"published":"2025-02-20","source_date":"2025-02-20","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The VANISH2 trial confirmed that catheter ablation was superior to escalation of antiarrhythmic drug therapy for recurrent ventricular tachycardia in patients with ischemic cardiomyopathy, significantly reducing VT recurrence and ICD shocks. The results strengthen the position of early ablation in VT management.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25ec350df77d","type":"article","url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","title":"Impella bij ouderen met cardiogene shock: is het veilig?","title_en":"Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous?","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.003","source_url":"https://doi.org/10.1016/j.jacc.2024.11.003","authors":["Anika Klein","Rasmus P Beske","Christian Hassager","Lisette O Jensen","Hans Eiskjær","Norman Mangner","Axel Linke","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Peter Clemmensen","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Nikos Werner","Thomas Engstøm","Lene Holmvang","Anders Junker","Henrik Schmidt","Christian J Terkelsen","Jacob E Møller"],"significance":7,"published":"2025-02-18","source_date":"2025-02-18","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This DanGer Shock subanalysis showed that Impella CP provides consistent survival benefit regardless of age in cardiogenic shock, supporting mechanical circulatory support even in older patients with MI-related shock.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c2223601a42","type":"article","url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","title":"Lage-dosis sirolimus BDP-stent versus tweede-generatie DES: non-inferioriteit","title_en":"Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.074","source_url":"https://doi.org/10.1016/j.jacc.2024.10.074","authors":["Robert W Yeh","Olivier F Bertrand","Ehtisham Mahmud","Emanuele Barbato","Batla Falah","Melek Ozgu Issever","Björn Redfors","Alexandra Popma","Michael Curtis","Niels van Royen","Jean-Francois Tanguay","Luc Janssens","William N Newman","Koen Teeuwen","James W Choi","Maurits T Dirksen","Akiko Maehara","Martin B Leon"],"significance":6,"published":"2025-02-18","source_date":"2025-02-18","image":"","kennis":[],"congress":"","summary_en":"This randomized trial confirmed that a novel low-dose sirolimus biodegradable polymer stent is noninferior to conventional second-generation DES, advancing stent technology toward safer, lower-drug platforms.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9f3e838e00b","type":"article","url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","title":"CLEAR SYNERGY: colchicine bij acuut MI — NEJM","title_en":"Colchicine in Acute Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["colchicine"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2405922","source_url":"https://doi.org/10.1056/NEJMoa2405922","authors":["Sanjit S Jolly","Marc-André d'Entremont","Shun Fu Lee","Rajibul Mian","Jessica Tyrwhitt","Sasko Kedev","Gilles Montalescot","Jan H Cornel","Goran Stanković","Raul Moreno","Robert F Storey","Timothy D Henry","Shamir R Mehta","Matthias Bossard","Petr Kala","Jamie Layland","Biljana Zafirovska","P J Devereaux","John Eikelboom","John A Cairns","Binita Shah","Tej Sheth","Sanjib K Sharma","Wadea Tarhuni","David Conen","Sarah Tawadros","Shahar Lavi","Salim Yusuf"],"significance":10,"published":"2025-02-13","source_date":"2025-02-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"The CLEAR SYNERGY trial demonstrated that colchicine initiated within days of acute MI reduced major cardiovascular events by 33% compared with placebo over a median of 3 years. This is the third major positive trial of colchicine in atherosclerotic disease, after COLCOT and LoDoCo2, consolidating anti-inflammatory therapy as a pillar of secondary prevention.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78eb8fdf04c3","type":"article","url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","title":"Routine spironolacton na acuut MI: gerandomiseerde trial — NEJM","title_en":"Routine Spironolactone in Acute Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2405923","source_url":"https://doi.org/10.1056/NEJMoa2405923","authors":["Sanjit S Jolly","Marc-André d'Entremont","Bertram Pitt","Shun Fu Lee","Rajibul Mian","Jessica Tyrwhitt","Sasko Kedev","Gilles Montalescot","Jan H Cornel","Goran Stanković","Raul Moreno","Robert F Storey","Timothy D Henry","Shamir R Mehta","Matthias Bossard","Petr Kala","Ravinay Bhindi","Biljana Zafirovska","P J Devereaux","John Eikelboom","John A Cairns","Madhu K Natarajan","J D Schwalm","Sanjib K Sharma","Wadea Tarhuni","David Conen","Sarah Tawadros","Shahar Lavi","Valon Asani","Dragan Topic","Warren J Cantor","Olivier F Bertrand","Ali Pourdjabbar","Salim Yusuf"],"significance":8,"published":"2025-02-13","source_date":"2025-02-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This NEJM trial showed that routine spironolactone after acute MI in patients without heart failure or reduced ejection fraction did not significantly reduce the primary composite endpoint. The result limits MRA use after MI to those with established HF or reduced LVEF.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18433580df10","type":"article","url":"https://hartvaat.nl/2025/02/13/cabozantinib-bij-gevorderde-neuro-endocriene-tumoren-fase-3/","title":"Cabozantinib bij gevorderde neuro-endocriene tumoren: fase 3","title_en":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2403991","source_url":"https://doi.org/10.1056/NEJMoa2403991","authors":["Jennifer A Chan","Susan Geyer","Tyler Zemla","Michael V Knopp","Spencer Behr","Sydney Pulsipher","Fang-Shu Ou","Amylou C Dueck","Jared Acoba","Ardaman Shergill","Edward M Wolin","Thorvardur R Halfdanarson","Bhavana Konda","Nikolaos A Trikalinos","Bernard Tawfik","Nitya Raj","Shagufta Shaheen","Namrata Vijayvergia","Arvind Dasari","Jonathan R Strosberg","Elise C Kohn","Matthew H Kulke","Eileen M O'Reilly","Jeffrey A Meyerhardt"],"significance":5,"published":"2025-02-13","source_date":"2025-02-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"A phase 3 trial evaluated cabozantinib in patients with advanced neuroendocrine tumours, including phaeochromocytoma and paraganglioma. The multikinase inhibitor improved progression-free survival, with relevance to cardiovascular practice through secondary hypertension management.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56ff6f142825","type":"article","url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","title":"Langetermijn evolocumab bij ouderen: effectiviteit en veiligheid","title_en":"Long-Term Lipid Lowering With Evolocumab in Older Individuals.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.019","source_url":"https://doi.org/10.1016/j.jacc.2024.11.019","authors":["Samer Al Said","Michelle L O'Donoghue","Xinhui Ran","Sabina A Murphy","Dan Atar","Anthony Keech","Jose H Flores-Arredondo","Bei Wang","Marc S Sabatine","Robert P Giugliano"],"significance":6,"published":"2025-02-11","source_date":"2025-02-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This analysis confirmed that long-term evolocumab therapy in older individuals is equally effective and safe as in younger patients, providing age-specific reassurance for PCSK9 inhibitor use in the elderly.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eace9e93b43e","type":"article","url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","title":"Look AHEAD: intensieve leefstijlinterventie, cardiale biomarkers en CV-uitkomsten bij diabetes","title_en":"Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-1","nt-probnp","primaire-preventie","soul-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.004","source_url":"https://doi.org/10.1016/j.jacc.2024.11.004","authors":["Kershaw V Patel","Zainali Chunawala","Subodh Verma","Matthew W Segar","Katelyn R Garcia","Chiadi E Ndumele","Thomas J Wang","James L Januzzi","Antoni Bayes-Genis","Javed Butler","Carolyn S P Lam","Christie M Ballantyne","James A de Lemos","Alain G Bertoni","Mark Espeland","Ambarish Pandey"],"significance":7,"published":"2025-02-11","source_date":"2025-02-11","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"The Look AHEAD cardiac biomarker analysis showed that intensive lifestyle intervention in diabetes improves troponin and NT-proBNP levels, providing biomarker evidence that weight loss and exercise produce measurable cardiac benefit.","created":"2026-07-03T10:31:29Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a4e28b184a2","type":"article","url":"https://hartvaat.nl/2025/02/05/smartphone-ppg-voor-af-detectie-en-management-verbeterde-screening/","title":"Smartphone-PPG voor AF-detectie en -management: verbeterde screening","title_en":"Improving atrial fibrillation or flutter detection and management by smartphone-based photoplethysmography rhythm monitoring following cardiac surgery: a pragmatic randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf015","source_url":"https://doi.org/10.1093/europace/euaf015","authors":["Henri Gruwez","Nicolas De Melio","Paulien Vermunicht","Leen Van Langenhoven","Lien Desteghe","Marie Lamberigts","Dieter Nuyens","Hugo Van Herendael","Inez Rodrigus","Christiaan Van Kerrebroeck","Pieter Vandervoort","Hein Heidbuchel","Laurent Pison","Filip Rega","Peter Haemers"],"significance":6,"published":"2025-02-05","source_date":"2025-02-05","image":"","kennis":[],"congress":"","summary_en":"This study showed that smartphone-based photoplethysmography effectively detects AF and improves arrhythmia management, demonstrating the potential of consumer-grade technology for post-cardiac surgery rhythm monitoring.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f737e6de474c","type":"article","url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","title":"PVI met geoptimaliseerde lineaire ablatie versus PVI alleen bij persisterend AF","title_en":"Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.24438","source_url":"https://doi.org/10.1001/jama.2024.24438","authors":["Caihua Sang","Qiang Liu","Yiwei Lai","Shijun Xia","Ruhong Jiang","Songnan Li","Qi Guo","Qifan Li","Mingyang Gao","Xueyuan Guo","Lihong Huang","Nian Liu","Chenxi Jiang","Song Zuo","Xiaoxia Liu","Mengmeng Li","Weili Ge","Shangming Song","Lianghua Chen","Shuanglun Xie","Jiangang Zou","Ke Chen","Xiangfei Liu","Hesheng Hu","Xinhua Wang","Jinlin Zhang","Zhaojun Wang","Chi Wang","Liu He","Chao Jiang","Ribo Tang","Ning Zhou","Yunlong Wang","Deyong Long","Xin Du","Chenyang Jiang","Laurent Macle","Jianzeng Dong","Changsheng Ma"],"significance":7,"published":"2025-02-04","source_date":"2025-02-04","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This randomized trial showed that PVI with optimized linear ablation does not significantly improve outcomes over PVI alone for persistent AF, adding to the evidence that additional lesion sets beyond pulmonary vein isolation have limited benefit.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4d9d3f481ecc","type":"article","url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","title":"Klinische risicopredictie, CT-coronairangiografie en CV-events bij nieuwe angina","title_en":"Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","calciumscore","coronaire-ct-angiografie","hartkatheterisatie","inflammatie","perifeer-vaatlijden","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae742","source_url":"https://doi.org/10.1093/eurheartj/ehae742","authors":["Laust Dupont Rasmussen","Samuel Emil Schmidt","Juhani Knuuti","Christiaan Vrints","Morten Bøttcher","Borek Foldyna","Michelle C Williams","David E Newby","Pamela S Douglas","Simon Winther"],"significance":6,"published":"2025-02-03","source_date":"2025-02-03","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This study showed that coronary CT angiography adds prognostic value beyond clinical risk prediction in patients with new-onset chest pain, supporting CCTA as a first-line investigation for stable angina evaluation.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee79430f2baa","type":"article","url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","title":"Alternatieve LDL-verlagingsstrategie versus hoge-dosis statine bij ASCVD: meta-analyse","title_en":"Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","figaro-dkd","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","statines"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3911","source_url":"https://doi.org/10.1001/jamacardio.2024.3911","authors":["Yong-Joon Lee","Bum-Kee Hong","Kyeong Ho Yun","Woong Chol Kang","Soon Jun Hong","Sang-Hyup Lee","Seung-Jun Lee","Sung-Jin Hong","Chul-Min Ahn","Jung-Sun Kim","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Yangsoo Jang","Myeong-Ki Hong"],"significance":7,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This meta-analysis showed that alternative LDL-lowering strategies (moderate statin plus ezetimibe or PCSK9 inhibitor) achieve comparable cardiovascular outcomes to high-intensity statin monotherapy in ASCVD patients, supporting personalized lipid-lowering approaches.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f2c5fa4f762","type":"article","url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","title":"FINEARTS-HF: geschatte langetermijnvoordelen van finerenon bij hartfalen","title_en":"Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","finearts-hf","hfmref","hfpef","hfref","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3782","source_url":"https://doi.org/10.1001/jamacardio.2024.3782","authors":["Muthiah Vaduganathan","Brian L Claggett","Akshay S Desai","Pardeep S Jhund","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Maria Borentian","James Lay-Flurrie","Prabhakar Viswanathan","Friederike U Behmenburg","John J V McMurray","Scott D Solomon"],"significance":6,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This prespecified analysis estimated that finerenone would provide 100+ additional days alive and out of hospital over 5 years in HFpEF, quantifying the lifetime benefit of nonsteroidal MRA therapy in this growing population.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2a1c00aa2445","type":"article","url":"https://hartvaat.nl/2025/02/01/digitale-interventie-voor-dash-dieet-en-bloeddrukverlaging-bij-vs-volwassenen/","title":"Digitale interventie voor DASH-dieet en bloeddrukverlaging bij VS-volwassenen","title_en":"Effects of a Digital Intervention to Improve DASH and Blood Pressure Among US Adults.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23887","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23887","authors":["Hailey N Miller","Sandy Askew","Miriam B Berger","Melissa C Kay","Anushka Palipana","Elizabeth Trefney","Loneke T Blackman Carr","Cherie Barnes","Crystal C Tyson","Laura P Svetkey","Ryan Shaw","Dori M Steinberg","Qing Yang","Gary G Bennett"],"significance":6,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that a digital intervention improves DASH diet adherence and blood pressure in US adults with hypertension, showing that technology-delivered nutritional coaching is an effective non-pharmacological treatment.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69f0d8413d74","type":"article","url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","title":"Transveneuze frenische zenuwstimulatie bij centraal slaapapneu en hartfalen","title_en":"Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","carvedilol","empagliflozine","hfpef","hfref","slaapapneu","vericiguat"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15074","source_url":"https://doi.org/10.1002/ehf2.15074","authors":["William T Abraham","Olaf Oldenburg","Mitja Lainscak","Rami Khayat","Jerryll Asin","Piotr Ponikowski","Robin Germany","Scott McKane","Maria Rosa Costanzo"],"significance":6,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This win ratio analysis of phrenic nerve stimulation for central sleep apnea in heart failure showed improved apnea severity and clinical outcomes, supporting neuromodulation as a treatment for this common HF comorbidity.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"878c59768707","type":"article","url":"https://hartvaat.nl/2025/02/01/diureticaresistentie-bij-acuut-hartfalen-prevalentie-en-kenmerken/","title":"Diureticaresistentie bij acuut hartfalen: prevalentie en kenmerken","title_en":"Prevalence and characteristics of upfront diuretic resistance in acute heart failure: The P-Value-AHF study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15069","source_url":"https://doi.org/10.1002/ehf2.15069","authors":["Julia Baumberger","Sabine Dinges","Eleonora Lupi","Thomas Wolters","Melina Stüssi-Helbling","Pietro E Cippà","Antonio Bellasi","Lars C Huber","Mattia Arrigo"],"significance":5,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The P-Value-AHF substudy documented the prevalence and characteristics of upfront diuretic resistance in acute heart failure. Resistance was common and associated with worse outcomes, supporting early identification and escalation to combination diuretic therapy.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1409629b331b","type":"article","url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","title":"Finerenon en LVH bij CKD en diabetes","title_en":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["anemie-ckd","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","diabetes-en-hart","diabetische-nefropathie","fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","flow-trial","ijzertekort"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14962","source_url":"https://doi.org/10.1002/ehf2.14962","authors":["Gerasimos Filippatos","Stefan D Anker","George L Bakris","Peter Rossing","Luis M Ruilope","Andrew J S Coats","Stephan von Haehling","Piotr Ponikowski","Giuseppe M C Rosano","Meike Brinker","Alfredo E Farjat","Luke Roberts","Bertram Pitt"],"significance":6,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This study showed that finerenone reduces left ventricular hypertrophy in patients with CKD and type 2 diabetes, demonstrating a direct cardiac structural benefit of nonsteroidal MRA therapy beyond cardiorenal event reduction.","created":"2026-07-03T10:31:28Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"469d7afe6552","type":"article","url":"https://hartvaat.nl/2025/02/01/iv-ijzer-bij-hartfalen-en-ijzerdeficientie-geactualiseerde-meta-analyse-van-rct-/","title":"IV-ijzer bij hartfalen en ijzerdeficiëntie: geactualiseerde meta-analyse van RCT's","title_en":"Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["ijzersuppletie","ivabradine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14905","source_url":"https://doi.org/10.1002/ehf2.14905","authors":["Mushood Ahmed","Aimen Shafiq","Hira Javaid","Priyansha Singh","Haania Shahbaz","Muhammad Talha Maniya","Hritvik Jain","Najwa Shakir","Huzaifa Ahmad Cheema","Adeel Ahmad","Wajeeh Ur Rehman","Gabriel Yeap","Abdulqadir J Nashwan","Abdul Mannan Khan Minhas","Raheel Ahmed","Marat Fudim","Gregg C Fonarow"],"significance":8,"published":"2025-02-01","source_date":"2025-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This updated meta-analysis of all randomized trials confirmed that intravenous iron in heart failure with iron deficiency significantly reduces heart failure hospitalization without increasing adverse events. The comprehensive evidence supports IV iron as a standard of care in iron-deficient heart failure.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3b7cd20e613","type":"article","url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","title":"SUMMIT: tirzepatide bij HFpEF met obesitas — NEJM","title_en":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["glp1-semaglutide-cardiovasculair","obesitas","select-trial","semaglutide","step-hfpef","summit-trial","tirzepatide"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2410027","source_url":"https://doi.org/10.1056/NEJMoa2410027","authors":["Milton Packer","Michael R Zile","Christopher M Kramer","Seth J Baum","Sheldon E Litwin","Venu Menon","Junbo Ge","Govinda J Weerakkody","Yang Ou","Mathijs C Bunck","Karla C Hurt","Masahiro Murakami","Barry A Borlaug"],"significance":10,"published":"2025-01-30","source_date":"2025-01-30","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The SUMMIT trial showed that tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduced heart failure hospitalization and cardiovascular death in patients with HFpEF and obesity, with substantial improvements in symptoms, quality of life, and body weight. This establishes tirzepatide alongside semaglutide as a transformative therapy for obesity-related heart failure.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7e6755f187d8","type":"article","url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","title":"OAC continueren versus onderbreken tijdens TAVI: gerandomiseerde trial — NEJM","title_en":"Continuation versus Interruption of Oral Anticoagulation during TAVI.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2407794","source_url":"https://doi.org/10.1056/NEJMoa2407794","authors":["Dirk Jan van Ginkel","Willem L Bor","Hugo M Aarts","Christophe Dubois","Ole De Backer","Maxim J P Rooijakkers","Liesbeth Rosseel","Leo Veenstra","Frank van der Kley","Kees H van Bergeijk","Nicolas M Van Mieghem","Pierfrancesco Agostoni","Michiel Voskuil","Carl E Schotborgh","Alexander J J IJsselmuiden","Jan A S Van Der Heyden","Renicus S Hermanides","Emanuele Barbato","Darren Mylotte","Enrico Fabris","Peter Frambach","Karl Dujardin","Bert Ferdinande","Joyce Peper","Benno J W M Rensing","Leo Timmers","Martin J Swaans","Jorn Brouwer","Vincent J Nijenhuis","Daniel C Overduin","Tom Adriaenssens","Yusuke Kobari","Pieter A Vriesendorp","Jose M Montero-Cabezas","Hicham El Jattari","Jonathan Halim","Ben J L Van den Branden","Remigio Leonora","Marc Vanderheyden","Michael Lauterbach","Joanna J Wykrzykowska","Arnoud W J van 't Hof","Niels van Royen","Jan G P Tijssen","Ronak Delewi","Jurriën M Ten Berg"],"significance":8,"published":"2025-01-30","source_date":"2025-01-30","image":"","kennis":[],"congress":"","summary_en":"This NEJM trial showed that continuation of oral anticoagulation during TAVI was noninferior to interruption for the composite of bleeding and thromboembolic events. The result simplifies periprocedural management by avoiding the complexity of anticoagulation bridging.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"434f28964449","type":"article","url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","title":"Lp(a) en LDL-cholesterol: onafhankelijke CV-risicopaden","title_en":"Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","hdl-cholesterol","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069556","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069556","authors":["Harpreet S Bhatia","Simon Wandel","Peter Willeit","Anastasia Lesogor","Keith Bailey","Paul M Ridker","Paul Nestel","John Simes","Andrew Tonkin","Gregory G Schwartz","Helen Colhoun","Christoph Wanner","Sotirios Tsimikas"],"significance":7,"published":"2025-01-28","source_date":"2025-01-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This participant-level analysis confirmed that Lp(a) and LDL cholesterol represent independent cardiovascular risk pathways, supporting the concept that both must be addressed for comprehensive atherosclerotic risk reduction.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e0ed559715be","type":"article","url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","title":"SCOT-HEART: CT-coronairangiografie bij stabiele thoracale pijn — tienjaarsresultaten","title_en":"Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["coronaire-ct-angiografie","stabiel-coronairlijden"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)02679-5","source_url":"https://doi.org/10.1016/S0140-6736(24)02679-5","authors":["Michelle C Williams","Ryan Wereski","Christopher Tuck","Philip D Adamson","Anoop S V Shah","Edwin J R van Beek","Giles Roditi","Colin Berry","Nicholas Boon","Marcus Flather","Steff Lewis","John Norrie","Adam D Timmis","Nicholas L Mills","Marc R Dweck","David E Newby"],"significance":8,"published":"2025-01-25","source_date":"2025-01-25","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/diagnostiek/cardiale-ct-angiografie/"],"congress":"","summary_en":"The 10-year SCOT-HEART follow-up confirmed that coronary CT angiography-guided management of stable chest pain provides sustained cardiovascular benefit, with persistent reductions in MI. The long-term data support CCTA as a cost-effective first-line investigation.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6c872092ec7c","type":"article","url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","title":"Abelacimab versus rivaroxaban bij AF — NEJM","title_en":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","aperitif-trial","rivaroxaban"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2406674","source_url":"https://doi.org/10.1056/NEJMoa2406674","authors":["Christian T Ruff","Siddharth M Patel","Robert P Giugliano","David A Morrow","Bruce Hug","Julia F Kuder","Erica L Goodrich","Shih-Ann Chen","Shaun G Goodman","Boyoung Joung","Robert G Kiss","Jindrich Spinar","Wojciech Wojakowski","Jeffrey I Weitz","Sabina A Murphy","Stephen D Wiviott","Sanobar Parkar","Daniel Bloomfield","Marc S Sabatine"],"significance":10,"published":"2025-01-23","source_date":"2025-01-23","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/rivaroxaban/"],"congress":"","summary_en":"This trial demonstrated that abelacimab, a factor XI-targeting monoclonal antibody, significantly reduced major bleeding compared with rivaroxaban while maintaining comparable efficacy in stroke prevention in patients with atrial fibrillation. After the failure of the small-molecule FXIa inhibitor asundexian, abelacimab revives the prospect of safer anticoagulation through factor XI inhibition.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fee74d1906ba","type":"article","url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","title":"FINEARTS-HF: initiële eGFR-dip met finerenon bij HFpEF is veilig","title_en":"Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["finearts-hf","hfmref","hfpef","hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.11.020","source_url":"https://doi.org/10.1016/j.jacc.2024.11.020","authors":["Shingo Matsumoto","Pardeep S Jhund","Alasdair D Henderson","Johann Bauersachs","Brian L Claggett","Akshay S Desai","Meike Brinker","Patrick Schloemer","Prabhakar Viswanathan","Jon W Mares","Andrea Scalise","Carolyn S P Lam","Gerard C M Linssen","Jose Francisco Kerr Saraiva","Michele Senni","Richard Troughton","Jacob A Udell","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This FINEARTS-HF analysis confirmed that the initial eGFR decline with finerenone is predictable, manageable, and not associated with adverse kidney or clinical outcomes, supporting continued therapy despite creatinine changes.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a491b14d6f5a","type":"article","url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en obesitas bij HFmrEF/HFpEF","title_en":"Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["finearts-hf","obesitas","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.111","source_url":"https://doi.org/10.1016/j.jacc.2024.10.111","authors":["Jawad H Butt","Alasdair D Henderson","Pardeep S Jhund","Brian L Claggett","Akshay S Desai","James Lay-Flurrie","Prabhakar Viswanathan","Andrea Lage","Markus F Scheerer","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Johann Bauersachs","Cândida Fonseca","Mikhail N Kosiborod","Gerard C M Linssen","Mark C Petrie","Morten Schou","Subodh Verma","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This FINEARTS-HF analysis showed that finerenone provides consistent heart failure benefit regardless of obesity status, relevant given the proposed role of adipocyte-derived aldosterone in the obesity-HFpEF phenotype.","created":"2026-07-03T10:31:27Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e76b126c623f","type":"article","url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","title":"Muvalaplin: orale Lp(a)-verlaging — NEJM gerandomiseerde trial","title_en":"Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["soul-trial"],"journal":"JAMA","doi":"10.1001/jama.2024.24017","source_url":"https://doi.org/10.1001/jama.2024.24017","authors":["Stephen J Nicholls","Wei Ni","Grace M Rhodes","Steven E Nissen","Ann Marie Navar","Laura F Michael","Axel Haupt","John H Krege"],"significance":10,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":[],"congress":"","summary_en":"This randomized trial demonstrated that muvalaplin, the first oral lipoprotein(a) inhibitor, produced dose-dependent Lp(a) reductions of up to 85% with an acceptable safety profile. An oral Lp(a)-lowering agent could dramatically expand access to treatment compared with injectable alternatives like olpasiran and pelacarsen.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"302510beae46","type":"article","url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en KCCQ bij HFmrEF/HFpEF","title_en":"Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["finearts-hf"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.09.023","source_url":"https://doi.org/10.1016/j.jacc.2024.09.023","authors":["Mingming Yang","Alasdair D Henderson","Atefeh Talebi","John J Atherton","Chern-En Chiang","Vijay Chopra","Josep Comin-Colet","Mikhail N Kosiborod","Jose F Kerr Saraiva","Brian L Claggett","Akshay S Desai","Peter Kolkhof","Prabhakar Viswanathan","Andrea Lage","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Katja Rohwedder","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Pardeep S Jhund","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":[],"congress":"","summary_en":"This prespecified FINEARTS-HF analysis showed that finerenone significantly improves KCCQ health status scores in HFmrEF/HFpEF, demonstrating patient-centered symptom benefit alongside the clinical event reduction.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf0fa95df305","type":"article","url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon en nieruitkomsten bij HFpEF","title_en":"Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["finearts-hf","finerenon-hartfalen-nierziekte","hfpef","hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.091","source_url":"https://doi.org/10.1016/j.jacc.2024.10.091","authors":["Finnian R Mc Causland","Muthiah Vaduganathan","Brian L Claggett","Ian J Kulac","Akshay S Desai","Pardeep S Jhund","Alasdair D Henderson","Meike Brinker","Robert Perkins","Markus F Scheerer","Patrick Schloemer","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","John J V McMurray","Scott D Solomon"],"significance":6,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":[],"congress":"","summary_en":"This FINEARTS-HF kidney analysis showed that finerenone causes a predictable, reversible initial eGFR decline in HFpEF without compromising long-term kidney outcomes, providing reassurance about renal safety.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0b059981f06","type":"article","url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","title":"EVOLVED: vroege interventie bij asymptomatische ernstige aortastenose met myocardfibrose","title_en":"Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.22730","source_url":"https://doi.org/10.1001/jama.2024.22730","authors":["Krithika Loganath","Neil J Craig","Russell J Everett","Rong Bing","Vasiliki Tsampasian","Patrycja Molek","Simona Botezatu","Saadia Aslam","Steff Lewis","Catriona Graham","Audrey C White","Tom MacGillivray","Christopher E Tuck","Phillip Rayson","Denise Cranley","Sian Irvine","Ruth Armstrong","Lynsey Milne","Calvin W L Chin","Graham S Hillis","Timothy Fairbairn","John P Greenwood","Richard Steeds","Stephen J Leslie","Chim C Lang","Chiara Bucciarelli-Ducci","Nikhil V Joshi","Vijay Kunadian","Vassilios S Vassiliou","Jason N Dungu","Sandeep S Hothi","Nicholas Boon","Sanjay K Prasad","Niall G Keenan","Dana Dawson","Thomas A Treibel","Mani Motwani","Christopher A Miller","Nicholas L Mills","Ronak Rajani","David P Ripley","Gerry P McCann","Bernard Prendergast","Anvesha Singh","David E Newby","Marc R Dweck"],"significance":9,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":[],"congress":"","summary_en":"The EVOLVED trial demonstrated that early aortic valve intervention guided by myocardial fibrosis on cardiac MRI reduced all-cause death and unplanned heart failure hospitalization in patients with asymptomatic severe aortic stenosis. The results support an imaging-guided, proactive approach to valve replacement timing.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32ab4f3a53b3","type":"article","url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","title":"FFR en iFR als voorspellers van placebo-gecontroleerd PCI-effect","title_en":"Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072281","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072281","authors":["Michael J Foley","Christopher A Rajkumar","Fiyyaz Ahmed-Jushuf","Florentina Simader","Shayna Chotai","Henry Seligman","Krzysztof Macierzanka","John R Davies","Thomas R Keeble","Peter O'Kane","Peter Haworth","Helen Routledge","Tushar Kotecha","Gerald Clesham","Rupert Williams","Jehangir Din","Sukhjinder S Nijjer","Nick Curzen","Manas Sinha","Ricardo Petraco","James Spratt","Sayan Sen","Graham D Cole","Frank E Harrell","James P Howard","Darrel P Francis","Matthew J Shun-Shin","Rasha Al-Lamee"],"significance":7,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":[],"congress":"","summary_en":"This analysis from ORBITA-2 showed that lower FFR and iFR values predict greater placebo-controlled symptom improvement from PCI, supporting the use of physiological assessment to select patients most likely to benefit from revascularization.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09e8cb114416","type":"article","url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","title":"FINEARTS-HF: finerenon bij recent verslechterend hartfalen","title_en":"Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","finearts-hf","hfmref","hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.09.004","source_url":"https://doi.org/10.1016/j.jacc.2024.09.004","authors":["Akshay S Desai","Muthiah Vaduganathan","Brian L Claggett","Ian J Kulac","Pardeep S Jhund","Jonathan Cunningham","Maria Borentain","James Lay-Flurrie","Prabhakar Viswanathan","Katja Rohwedder","Flaviana Amarante","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Mikhail Kosiborod","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2025-01-21","source_date":"2025-01-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"This FINEARTS-HF subanalysis confirmed that finerenone is effective in patients with recent worsening heart failure events, supporting its use in the higher-acuity HFpEF population at greatest risk of recurrence.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d11261bf3fe","type":"article","url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","title":"Tri.Fr: transcatheter edge-to-edge repair bij geïsoleerde ernstige TR — RCT","title_en":"Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The Tri.Fr Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip"],"journal":"JAMA","doi":"10.1001/jama.2024.21189","source_url":"https://doi.org/10.1001/jama.2024.21189","authors":["Erwan Donal","Julien Dreyfus","Guillaume Leurent","Augustin Coisne","Pierre-Yves Leroux","Anne Ganivet","Catherine Sportouch","Yoan Lavie-Badie","Patrice Guerin","Frédéric Rouleau","Christelle Diakov","Jan van der Heyden","Stéphane Lafitte","Jean-François Obadia","Mohammed Nejjari","Nicole Karam","Anne Bernard","Antoinette Neylon","Romain Pierrard","Didier Tchetche","Said Ghostine","Gregory Ducrocq","Thiziri Si Moussi","Antoine Jeu","Marcel Peltier","Bernard Cosyns","Yvan Le Dolley","Gilbert Habib","Vincent Auffret","Florent Le Ven","François Picard","Nicolas Piriou","Thierry Laperche","Elena Galli","Sabina Istratoaie","Jerome Jouan","Guillaume Bonnet","Pascal de Groote","Amedeo Anselmi","Jean-Noel Trochu","Emmanuel Oger"],"significance":8,"published":"2025-01-14","source_date":"2025-01-14","image":"","kennis":[],"congress":"","summary_en":"The Tri.Fr trial showed that transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation significantly improved functional capacity and quality of life compared with optimal medical therapy alone. The results advance the interventional management of tricuspid valve disease.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26a94785c5ce","type":"article","url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","title":"FINEARTS-HF: finerenon met en zonder SGLT2-remmer bij HFpEF","title_en":"Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["fidelity","finearts-hf","hfref"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072055","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072055","authors":["Muthiah Vaduganathan","Brian L Claggett","Ian J Kulac","Zi Michael Miao","Akshay S Desai","Pardeep S Jhund","Alasdair D Henderson","Meike Brinker","James Lay-Flurrie","Prabhakar Viswanathan","Markus Florian Scheerer","Andrea Lage","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2025-01-14","source_date":"2025-01-14","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that finerenone provides consistent heart failure benefit regardless of concurrent SGLT2 inhibitor use, confirming additive cardiorenal protection when combining nonsteroidal MRA with SGLT2 inhibition.","created":"2026-07-03T10:31:26Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4f0e8d214e2","type":"article","url":"https://hartvaat.nl/2025/01/13/nt-probnp-en-af-risico-systematische-review-en-meta-analyse/","title":"NT-proBNP en AF-risico: systematische review en meta-analyse","title_en":"Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["abelacimab","biomarkers-cardiovasculair","nt-probnp"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324685","source_url":"https://doi.org/10.1136/heartjnl-2024-324685","authors":["Wanyue Wang","Tao Zhou","Jinyue Li","Chenxi Yuan","Chenyang Li","Shufeng Chen","Chong Shen","Dongfeng Gu","Xiangfeng Lu","Fangchao Liu"],"significance":6,"published":"2025-01-13","source_date":"2025-01-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This meta-analysis confirmed the strong association between NT-proBNP levels and AF risk, supporting natriuretic peptide measurement as a pre-screening tool for targeted arrhythmia surveillance.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca0f7ab8540a","type":"article","url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","title":"Transcatheter klepvervanging bij ernstige tricuspidalisinsufficiëntie — NEJM","title_en":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2401918","source_url":"https://doi.org/10.1056/NEJMoa2401918","authors":["Rebecca T Hahn","Raj Makkar","Vinod H Thourani","Moody Makar","Rahul P Sharma","Christiane Haeffele","Charles J Davidson","Akhil Narang","Brian O'Neill","James Lee","Pradeep Yadav","Firas Zahr","Scott Chadderdon","Mackram Eleid","Sorin Pislaru","Robert Smith","Molly Szerlip","Brian Whisenant","Nishant K Sekaran","Santiago Garcia","Terri Stewart-Dehner","Holger Thiele","Robert Kipperman","Konstantinos Koulogiannis","D Scott Lim","Dale Fowler","Samir Kapadia","Serge C Harb","Paul A Grayburn","Anna Sannino","Michael J Mack","Martin B Leon","Philipp Lurz","Susheel K Kodali"],"significance":9,"published":"2025-01-09","source_date":"2025-01-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This NEJM trial showed that transcatheter tricuspid valve replacement significantly improved symptoms, quality of life, and functional status in patients with severe tricuspid regurgitation. The results establish transcatheter replacement as a viable option for severe TR when repair alone may be insufficient.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"51fae501946d","type":"article","url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","title":"Plozasiran bij persisterende chylomicronemie en pancreatitisrisico — NEJM","title_en":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2409368","source_url":"https://doi.org/10.1056/NEJMoa2409368","authors":["Gerald F Watts","Robert S Rosenson","Robert A Hegele","Ira J Goldberg","Antonio Gallo","Ann Mertens","Alexis Baass","Rong Zhou","Ma'an Muhsin","Jennifer Hellawell","Nicholas J Leeper","Daniel Gaudet"],"significance":9,"published":"2025-01-09","source_date":"2025-01-09","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/"],"congress":"","summary_en":"This NEJM trial demonstrated that plozasiran, an siRNA targeting APOC3, dramatically reduced triglycerides and prevented pancreatitis episodes in patients with persistent chylomicronemia from both genetic and multifactorial causes. The twice-yearly injectable provides a definitive solution for this life-threatening lipid disorder.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dcfc43fceefc","type":"article","url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","title":"Optimale strategie voor complete revascularisatie bij STEMI met meervatslijden: meta-analyse","title_en":"Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ouderen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.09.1231","source_url":"https://doi.org/10.1016/j.jacc.2024.09.1231","authors":["Hiroki A Ueyama","Keitaro Akita","Yuko Kiyohara","Hisato Takagi","Alexandros Briasoulis","Jose Wiley","Sripal Bangalore","Roxana Mehran","Gregg W Stone","Toshiki Kuno","Deepak L Bhatt"],"significance":7,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This meta-analysis compared different complete revascularization strategies in STEMI with multivessel disease, finding that immediate complete PCI during the index procedure is noninferior to staged approaches.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a4654676763","type":"article","url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","title":"Urinair wijnzuur als biomarker voor wijnconsumptie en CV-risico: PREDIMED","title_en":"Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae804","source_url":"https://doi.org/10.1093/eurheartj/ehae804","authors":["Inés Domínguez-López","Rosa M Lamuela-Raventós","Cristina Razquin","Camila Arancibia-Riveros","Polina Galkina","Jordi Salas-Salvadó","Ángel M Alonso-Gómez","Montserrat Fitó","Miquel Fiol","José Lapetra","Enrique Gómez-Gracia","José V Sorlí","Miguel Ruiz-Canela","Olga Castañer","Liming Liang","Lluis Serra-Majem","Frank B Hu","Emilio Ros","Miguel Ángel Martínez-González","Ramon Estruch"],"significance":5,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/"],"congress":"","summary_en":"A PREDIMED case-cohort analysis demonstrated that urinary tartaric acid is a reliable objective biomarker of wine consumption and is associated with cardiovascular risk. Objective measurement of alcohol intake improves the quality of nutritional epidemiological research.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c55ba85a997d","type":"article","url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","title":"EuroHeart: definities van klinische studie-eindpunten voor CVD","title_en":"Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae724","source_url":"https://doi.org/10.1093/eurheartj/ehae724","authors":["Chris Wilkinson","Asad Bhatty","Gorav Batra","Suleman Aktaa","Adam B Smith","Jeremy Dwight","Marcin Ruciński","Sam Chappell","Joakim Alfredsson","David Erlinge","Jorge Ferreira","Ingibjörg J Guðmundsdóttir","Þórdís Jóna Hrafnkelsdóttir","Inga Jóna Ingimarsdóttir","Alar Irs","András Jánosi","Zoltán Járai","Manuel Oliveira-Santos","Bogdan A Popescu","Peter Vasko","Dragos Vinereanu","Jonathan Yap","Raffaele Bugiardini","Edina Cenko","Ramesh Nadarajah","Matthew R Sydes","Stefan James","Aldo P Maggioni","Lars Wallentin","Barbara Casadei","Chris P Gale"],"significance":5,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":[],"congress":"","summary_en":"The EuroHeart project standardised definitions for clinical study outcome measures in cardiovascular disease across registries and trials. Uniform endpoint definitions are essential for producing comparable results across European cardiovascular research.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"71db0ceb5e1d","type":"article","url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","title":"DCB voor zijtak bij provisionale stenting: gerandomiseerde trial","title_en":"Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.067","source_url":"https://doi.org/10.1016/j.jacc.2024.08.067","authors":["Xiaofei Gao","Nailiang Tian","Jing Kan","Ping Li","Mian Wang","Imad Sheiban","Filippo Figini","Jianping Deng","Xiang Chen","Teguh Santoso","Eun-Seok Shin","Muhammad Munawar","Shangyu Wen","Zhengzhong Wang","Shaoping Nie","Yue Li","Tan Xu","Bin Wang","Fei Ye","Junjie Zhang","Xiling Shou","Shao-Liang Chen"],"significance":6,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":[],"congress":"","summary_en":"This multicenter RCT evaluated drug-coated balloon treatment of the compromised side branch during provisional coronary stenting, testing a leave-nothing-behind approach for bifurcation lesion management.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"86e7c83257f3","type":"article","url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon effectief over het hele EF-spectrum bij HFmrEF/HFpEF","title_en":"Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["finearts-hf","finerenon-hartfalen-nierziekte"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072011","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072011","authors":["Kieran F Docherty","Alasdair D Henderson","Pardeep S Jhund","Brian L Claggett","Akshay S Desai","Katharina Mueller","Prabhakar Viswanathan","Andrea Scalise","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":8,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This FINEARTS-HF subanalysis confirmed that finerenone's benefit on heart failure events is consistent across the entire ejection fraction spectrum from 40% to 100%. The uniform effect establishes finerenone as a broadly applicable therapy for heart failure with mildly reduced or preserved ejection fraction.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3cc0a7a1e76a","type":"article","url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","title":"PVI met versus zonder posteriore wand-isolatie bij persisterend AF: RCT","title_en":"Radiofrequency catheter ablation of persistent atrial fibrillation by pulmonary vein isolation with or without left atrial posterior wall isolation: long-term outcomes of the CAPLA trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae580","source_url":"https://doi.org/10.1093/eurheartj/ehae580","authors":["Jeremy William","David Chieng","Annie G Curtin","Hariharan Sugumar","Liang Han Ling","Louise Segan","Rose Crowley","Anoushka Iyer","Sandeep Prabhu","Aleksandr Voskoboinik","Joseph B Morton","Geoffrey Lee","Alex J McLellan","Rajeev K Pathak","Laurence Sterns","Matthew Ginks","Christopher M Reid","Prashanthan Sanders","Jonathan M Kalman","Peter M Kistler"],"significance":6,"published":"2025-01-07","source_date":"2025-01-07","image":"","kennis":[],"congress":"","summary_en":"This randomized trial confirmed that adding posterior wall isolation to PVI during persistent AF ablation does not significantly improve freedom from arrhythmia, consistent with multiple prior studies.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea19e0408741","type":"article","url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","title":"OCEANIC-AF: asundexian versus apixaban bij AF — NEJM","title_en":"Asundexian versus Apixaban in Patients with Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2407105","source_url":"https://doi.org/10.1056/NEJMoa2407105","authors":["Jonathan P Piccini","Manesh R Patel","Jan Steffel","Keith Ferdinand","Isabelle C Van Gelder","Andrea M Russo","Chang-Sheng Ma","Shaun G Goodman","Jonas Oldgren","Christopher Hammett","Renato D Lopes","Masaharu Akao","Raffaele De Caterina","Paulus Kirchhof","Diana A Gorog","Martin Hemels","Michiel Rienstra","W Schuyler Jones","Josephine Harrington","Gregory Y H Lip","Stephen J Ellis","Frank W Rockhold","Christoph Neumann","John H Alexander","Thomas Viethen","James Hung","Rosa Coppolecchia","Hardi Mundl","Valeria Caso"],"significance":10,"published":"2025-01-02","source_date":"2025-01-02","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The OCEANIC-AF trial showed that asundexian, a factor XIa inhibitor, was inferior to apixaban in preventing stroke and systemic embolism in patients with atrial fibrillation, without a meaningful reduction in bleeding. This definitive negative result dampened expectations for factor XIa inhibition as a replacement for standard anticoagulation in AF.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a17f27173f6","type":"article","url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","title":"FINEARTS-HF: finerenon gelijk effectief bij vrouwen en mannen met HFpEF","title_en":"Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["finearts-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4613","source_url":"https://doi.org/10.1001/jamacardio.2024.4613","authors":["Misato Chimura","Xiaowen Wang","Pardeep S Jhund","Alasdair D Henderson","Brian L Claggett","Akshay S Desai","Cândida Fonseca","Eva Goncalvesova","Tzvetana Katova","Katharina Mueller","Andrea Glasauer","Katja Rohwedder","Prabhakar Viswanathan","Savina Nodari","Carolyn S P Lam","Clara Inés Saldarriaga","Michele Senni","Kavita Sharma","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Orly Vardeny","Muthiah Vaduganathan","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This FINEARTS-HF sex-stratified analysis confirmed that finerenone provides equal heart failure benefit in women and men with HFmrEF/HFpEF, supporting sex-neutral prescribing of the nonsteroidal MRA.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68bb6976af50","type":"article","url":"https://hartvaat.nl/2025/01/01/gedeeltelijke-cardiale-denervatie-voorkomt-af-na-cabg-rct/","title":"Gedeeltelijke cardiale denervatie voorkomt AF na CABG: RCT","title_en":"Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["newton-cabg"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4639","source_url":"https://doi.org/10.1001/jamacardio.2024.4639","authors":["Ziang Yang","Xieraili Tiemuerniyazi","Fei Xu","Yang Wang","Yang Sun","Peng Yan","Liangxin Tian","Chao Han","Yan Zhang","Shiwei Pan","Zhan Hu","Xi Li","Wei Zhao","Wei Feng"],"significance":7,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that partial cardiac denervation (autonomic ganglionated plexus ablation) during CABG significantly reduces postoperative AF, adding a simple surgical technique to the AF prevention armamentarium.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f6bbf93a528","type":"article","url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","title":"NUDGE-FLU subanalyse: griepvaccinatie-nudges bij MI — langetermijn","title_en":"Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4648","source_url":"https://doi.org/10.1001/jamacardio.2024.4648","authors":["Ankeet S Bhatt","Niklas Dyrby Johansen","Muthiah Vaduganathan","Daniel Modin","Manan Pareek","Safia Chatur","Brian L Claggett","Kira Hyldekær Janstrup","Carsten Schade Larsen","Lykke Larsen","Lothar Wiese","Michael Dalager-Pedersen","Erica L Dueger","Sandrine Samson","Matthew M Loiacono","Rebecca C Harris","Lars Køber","Scott D Solomon","Cyril Jean-Marie Martel","Pradeesh Sivapalan","Jens Ulrik Stæhr Jensen","Tor Biering-Sørensen"],"significance":5,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"Long-term analysis of three NUDGE-FLU nationwide trials confirmed that electronically delivered behavioural nudges sustainably increase influenza vaccination rates among post-myocardial infarction patients. The intervention is scalable and cost-effective for this high-risk population.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba52b43a474d","type":"article","url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon, kalium en klinische uitkomsten bij HFpEF","title_en":"Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["finearts-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4539","source_url":"https://doi.org/10.1001/jamacardio.2024.4539","authors":["Orly Vardeny","Muthiah Vaduganathan","Brian L Claggett","Akshay S Desai","Pardeep S Jhund","Carolyn S P Lam","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Bertram Pitt","Shingo Matsumoto","Béla Merkely","Shelley Zieroth","Mehmet Birhan Yilmaz","James Lay-Flurrie","Prabhakar Viswanathan","Andrea Horvat-Broecker","Andrea Scalise","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This analysis of finerenone-associated potassium changes in HFpEF showed that hyperkalemia occurs but is manageable with monitoring, providing practical safety data for MRA use in the preserved ejection fraction population.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"83452ca8d80f","type":"article","url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","title":"KCCQ-interpretatie bij hartfalen: patiënt-ankering","title_en":"Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4470","source_url":"https://doi.org/10.1001/jamacardio.2024.4470","authors":["Mohammad Abdel Jawad","Philip G Jones","Suzanne V Arnold","David J Cohen","Charles F Sherrod","Mirza S Khan","Nobuhiro Ikemura","Paul S Chan","John A Spertus"],"significance":5,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"A patient-level meta-analysis across 11 heart failure trials established anchor-based thresholds for interpreting mean KCCQ treatment effects. These patient-anchored benchmarks help translate population-level trial results into clinically meaningful individual benefit.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d848cb6af60a","type":"article","url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","title":"DanGer Shock: hemodynamische en metabole effecten van Impella bij cardiogene shock","title_en":"Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.4197","source_url":"https://doi.org/10.1001/jamacardio.2024.4197","authors":["Nanna Louise Junker Udesen","Rasmus Paulin Beske","Christian Hassager","Lisette Okkels Jensen","Hans Eiskjær","Norman Mangner","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Peter Clemmensen","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Nikos Werner","Martin Frydland","Lene Holmvang","Jesper Kjærgaard","Thomas Engstøm","Henrik Schmidt","Anders Junker","Christian Juhl Terkelsen","Steffen Christensen","Axel Linke","Jacob Eifer Møller"],"significance":7,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This DanGer Shock hemodynamic substudy detailed the cardiac output improvement and metabolic normalization achieved with Impella CP, characterizing the mechanism by which microaxial flow pump support improves survival in cardiogenic shock.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adda037d0d7d","type":"article","url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","title":"FFR versus iFR bij coronaire revascularisatie: vijfjaars follow-up","title_en":"Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio: A 5-Year Follow-Up of the DEFINE FLAIR Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3314","source_url":"https://doi.org/10.1001/jamacardio.2024.3314","authors":["Javier Escaned","Alejandro Travieso","Hakim-Moulay Dehbi","Sukhjinder S Nijjer","Sayan Sen","Ricardo Petraco","Manesh Patel","Patrick W Serruys","Justin Davies"],"significance":7,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"Five-year follow-up confirmed that FFR-guided and iFR-guided coronary revascularization produce identical long-term outcomes, providing the most robust evidence for the interchangeability of these physiological assessment tools.","created":"2026-07-03T10:31:24Z","updated":"2026-07-03T13:30:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b2bbf3c6cd2","type":"article","url":"https://hartvaat.nl/2025/01/01/reproduceerbaarheid-en-behandeleffect-op-kantoor-versus-ambulante-bloeddrukrelat/","title":"Reproduceerbaarheid en behandeleffect op kantoor- versus ambulante bloeddrukrelatie","title_en":"Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23549","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23549","authors":["Giuseppe Mancia","Rita Facchetti","Fosca Quarti-Trevano","Guido Grassi"],"significance":5,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"Using data from the ELSA and PHYLLIS trials, this study examined the reproducibility of the office-to-ambulatory blood pressure relationship and its stability during antihypertensive treatment. The findings inform optimal blood pressure measurement strategies for therapy monitoring.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5fbbc5cc4486","type":"article","url":"https://hartvaat.nl/2025/01/01/poise-3-substudie-perioperatieve-hypotensievermijding-en-orgaanschade/","title":"POISE-3 substudie: perioperatieve hypotensievermijding en orgaanschade","title_en":"A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","slaapapneu"],"journal":"Kidney international","doi":"10.1016/j.kint.2024.10.007","source_url":"https://doi.org/10.1016/j.kint.2024.10.007","authors":[],"significance":6,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This POISE-3 substudy showed that a perioperative hypotension-avoidance strategy reduces kidney injury and myocardial damage, informing hemodynamic management during non-cardiac surgery.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"188d81f00d9e","type":"article","url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","title":"Dialysaat-kalium 3.0 mmol/L met natriumzirconiumcyclosilicaat bij dialyse","title_en":"Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["internist"],"tags":[],"journal":"Kidney international","doi":"10.1016/j.kint.2024.10.010","source_url":"https://doi.org/10.1016/j.kint.2024.10.010","authors":["David M Charytan","Wolfgang C Winkelmayer","Christopher B Granger","John P Middleton","Charles A Herzog","Glenn M Chertow","James M Eudicone","Jeremy D Whitson","James A Tumlin"],"significance":5,"published":"2025-01-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This trial compared a higher dialysate potassium concentration (3.0 mmol/L) combined with oral sodium zirconium cyclosilicate versus standard low-potassium dialysate in haemodialysis patients with hyperkalaemia. The novel strategy safely reduced interdialytic hyperkalaemia and cardiac arrhythmias.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c1c2eed2487","type":"article","url":"https://hartvaat.nl/2025/01/01/nieuwe-therapeutische-mogelijkheden-voor-cholesterolverlaging-een-expertreview/","title":"Nieuwe therapeutische mogelijkheden voor cholesterolverlaging: een expertreview","title_en":"An expert narrative review on the mechanisms and therapeutic potential of gut microbiota-derived metabolites in multi-organ crosstalk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","clear-outcomes","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","hdl-cholesterol","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pelacarsen","statines"],"journal":"Frontiers in endocrinology","doi":"10.3389/fendo.2025.1706353","source_url":"https://doi.org/10.3389/fendo.2025.1706353","authors":["Yushu Zhang","Xuebin Cao","Shihong Xiong","Wenqi Zhen","Yang Yang","Na Gong"],"significance":4,"published":"2025-01-01","source_date":"2025-01-01","image":"https://hartvaat.nl/global/img/f9ed94fb64aa.webp","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"This expert narrative review discusses gut microbiota-derived metabolites — short-chain fatty acids, tryptophan derivatives, and uraemic toxins — and their role in multi-organ crosstalk along the gut-kidney-heart-brain-endocrine axis.","created":"2026-07-03T10:24:06Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abae313a6745","type":"article","url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","title":"Gerichte patiënteneducatie vermindert ongeplande CV-events bij AF","title_en":"Effect of targeted education of patients with atrial fibrillation on unplanned cardiovascular outcomes: results of the multicentre randomized AF-EduCare trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["hartrevalidatie","ouderen","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae211","source_url":"https://doi.org/10.1093/europace/euae211","authors":["Lien Desteghe","Michiel Delesie","Lieselotte Knaepen","Rana Önder","Johan Verbeeck","Paul Dendale","Thomas Phlips","Peter Haemers","Johan Saenen","Joris Ector","Johan Vijgen","Hein Heidbuchel"],"significance":6,"published":"2024-12-26","source_date":"2024-12-26","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that targeted patient education about AF improves understanding and reduces unplanned cardiovascular events, supporting structured educational programs as part of integrated AF care.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5d343d30ded","type":"article","url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","title":"DanGer Shock: Impella en nieruitkomsten bij cardiogene shock","title_en":"Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardiogene-shock"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.072370","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.072370","authors":["Elric Zweck","Christian Hassager","Rasmus P Beske","Lisette O Jensen","Hans Eiskjær","Norman Mangner","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Peter Clemmensen","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Malte Kelm","Thomas Engstrøm","Lene Holmvang","Anders Junker","Henrik Schmidt","Christian J Terkelsen","Axel Linke","Ralf Westenfeld","Jacob E Møller"],"significance":7,"published":"2024-12-17","source_date":"2024-12-17","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This DanGer Shock secondary analysis showed that Impella CP support may improve renal outcomes in infarct-related cardiogenic shock, suggesting that mechanical circulatory support provides renal hemodynamic benefits in addition to cardiac support.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e60dbdabe67d","type":"article","url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","title":"Ablatiestrategie bij AF-recidief na duurzame PVI","title_en":"Ablation Strategies for Repeat Procedures in Atrial Fibrillation Recurrences Despite Durable Pulmonary Vein Isolation: The Prospective Randomized ASTRO AF Multicenter Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069993","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069993","authors":["Boris Schmidt","Stefano Bordignon","Andreas Metzner","Philipp Sommer","Daniel Steven","Tilmann Dahme","Matthias Busch","Roland Richard Tilz","David Schaack","Andreas Rillig","Christian Sohns","Arian Sultan","Karolina Weinmann-Emhardt","Astrid Hummel","Julia Vogler","Thomas Fink","Jakob Lueker","Alexander Pott","Christian Heeger","K R Julian Chun"],"significance":6,"published":"2024-12-17","source_date":"2024-12-17","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/pathofysiologie-af/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study characterized ablation strategies for AF recurrence despite confirmed durable pulmonary vein isolation, showing that non-PV triggers and atrial substrate modification are necessary for these challenging cases.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e312f4435ece","type":"article","url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","title":"ApoA-I infusie na MI naar Lp(a)-niveau: AEGIS-II subanalyse","title_en":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae614","source_url":"https://doi.org/10.1093/eurheartj/ehae614","authors":["C Michael Gibson","Danielle Duffy","Maria Cecilia Bahit","Gerald Chi","Harvey White","Serge Korjian","John H Alexander","A Michael Lincoff","Mark Heise","Bronwyn A Kingwell","Jose C Nicolau","Renato D Lopes","Jan H Cornel","Basil S Lewis","Dragos Vinereanu","Shaun G Goodman","Christoph Bode","Ph Gabriel Steg","Peter Libby","Frank M Sacks","Kevin R Bainey","Paul M Ridker","Kenneth W Mahaffey","Philip Aylward","Stephen J Nicholls","Stuart J Pocock","Roxana Mehran","Robert A Harrington"],"significance":5,"published":"2024-12-16","source_date":"2024-12-16","image":"","kennis":[],"congress":"","summary_en":"An AEGIS-II subanalysis investigated whether the efficacy of apolipoprotein A-I infusion after acute MI varies by baseline LDL-cholesterol level. No differential effect was observed, confirming that the apoA-I infusion strategy is ineffective regardless of baseline lipid profile.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e243aaa06b3","type":"article","url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","title":"GP IIb/IIIa-remmers bij acuut MI en microvasculaire obstructie: meta-analyse","title_en":"Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","ezetimibe","farmaco-economie","microcirculatie","microvasculaire-angina","myocardinfarct","obesitas","ouderen","ras-remmers"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae587","source_url":"https://doi.org/10.1093/eurheartj/ehae587","authors":["Ingo Eitel","Roza Saraei","Dominik Jurczyk","Andreas Fach","Rainer Hambrecht","Harm Wienbergen","Christian Frerker","Tobias Schmidt","Abdelhakim Allali","Alexander Joost","Christoph Marquetand","Thomas Kurz","Philip Haaf","Gregor Fahrni","Christian Mueller","Steffen Desch","Holger Thiele","Thomas Stiermaier"],"significance":5,"published":"2024-12-16","source_date":"2024-12-16","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"The REVERSE-FLOW trial randomised patients with acute myocardial infarction and angiographic microvascular obstruction to GP IIb/IIIa inhibitors versus standard care. The antiplatelet agents modestly reduced microvascular obstruction but did not significantly improve hard clinical endpoints.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35272b3f0585","type":"article","url":"https://hartvaat.nl/2024/12/16/scoff-nuchter-versus-niet-nuchter-voor-hartkatheterisatie-rct/","title":"SCOFF: nuchter versus niet-nuchter vóór hartkatheterisatie — RCT","title_en":"Fasting vs. no fasting prior to catheterization laboratory procedures: the SCOFF trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae573","source_url":"https://doi.org/10.1093/eurheartj/ehae573","authors":["David Ferreira","Jack Hardy","William Meere","Lloyd Butel-Simoes","Shanathan Sritharan","Max Ray","Matthew French","Michael McGee","Simon O'Connor","Nicholas Whitehead","Stuart Turner","Paul Healey","Allan Davies","Gwilym Morris","Nicholas Jackson","Malcolm Barlow","Tom Ford","Sarah Leask","Christopher Oldmeadow","John Attia","Aaron Sverdlov","Nicholas Collins","Andrew Boyle","Bradley Wilsmore"],"significance":7,"published":"2024-12-16","source_date":"2024-12-16","image":"","kennis":[],"congress":"","summary_en":"The SCOFF trial showed that not fasting before catheterization laboratory procedures with conscious sedation is as safe as the traditional 6-hour fasting requirement, simplifying pre-procedural preparation for cardiac catheterization.","created":"2026-07-03T10:31:23Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b95df1d950f0","type":"article","url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","title":"Biomarkervoorspelling van sinusritme bij AF: EAST-AFNET 4 biomoleculaire analyse","title_en":"Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae611","source_url":"https://doi.org/10.1093/eurheartj/ehae611","authors":["Larissa Fabritz","Christoph Al-Taie","Katrin Borof","Günter Breithardt","A John Camm","Harry J G M Crijns","Victor Roth Cardoso","Winnie Chua","Silke van Elferen","Lars Eckardt","Georgios Gkoutos","Andreas Goette","Eduard Guasch","Stéphane Hatem","Andreas Metzner","Lluís Mont","Vaishnavi Ameya Murukutla","Julius Obergassel","Andreas Rillig","Moritz F Sinner","Renate B Schnabel","Ulrich Schotten","Laura C Sommerfeld","Ursula-Henrike Wienhues-Thelen","Antonia Zapf","Tanja Zeller","Paulus Kirchhof"],"significance":6,"published":"2024-12-16","source_date":"2024-12-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"This EAST-AFNET 4 biomolecular study identified circulating biomarkers that predict sinus rhythm maintenance after early rhythm control in AF, advancing precision medicine approaches to rhythm management.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"549e38107350","type":"article","url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","title":"Aspirine versus clopidogrel na PCI: eenjaars follow-up van RCT","title_en":"Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine","trombocytenaggregatieremmers"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae617","source_url":"https://doi.org/10.1093/eurheartj/ehae617","authors":["Hirotoshi Watanabe","Masahiro Natsuaki","Takeshi Morimoto","Ko Yamamoto","Yuki Obayashi","Ryusuke Nishikawa","Tomoya Kimura","Kenji Ando","Takenori Domei","Satoru Suwa","Manabu Ogita","Tsuyoshi Isawa","Hiroyuki Takenaka","Takashi Yamamoto","Tetsuya Ishikawa","Itaru Hisauchi","Kohei Wakabayashi","Yuko Onishi","Kiyoshi Hibi","Kazuya Kawai","Ruka Yoshida","Hiroshi Suzuki","Gaku Nakazawa","Takanori Kusuyama","Itsuro Morishima","Koh Ono","Takeshi Kimura"],"significance":7,"published":"2024-12-16","source_date":"2024-12-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"One-year STOPDAPT-3 data confirmed clopidogrel monotherapy superiority over aspirin after PCI, consistent with HOST-EXAM and other trials, reinforcing clopidogrel as the preferred long-term single antiplatelet agent.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d7be4bb98be","type":"article","url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","title":"PCI bij patiënten die TAVI ondergaan: gerandomiseerde trial — NEJM","title_en":"PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2401513","source_url":"https://doi.org/10.1056/NEJMoa2401513","authors":["Jacob Lønborg","Reza Jabbari","Muhammad Sabbah","Karsten T Veien","Matti Niemelä","Phillip Freeman","Rickard Linder","Dan Ioanes","Christian J Terkelsen","Olli A Kajander","Sasha Koul","Mikko Savontaus","Pasi Karjalainen","Andrejs Erglis","Mikko Minkkinen","Rikke Sørensen","Hans-Henrik Tilsted","Lene Holmvang","Gintautas Bieliauskas","Julia Ellert","Jarkko Piuhola","Ashkan Eftekhari","Oskar Angerås","Andreas Rück","Evald H Christiansen","Troels Jørgensen","Burcu T Özbek","Charlotte Glinge","Lars Søndergaard","Ole De Backer","Thomas Engstrøm"],"significance":9,"published":"2024-12-12","source_date":"2024-12-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/spontane-coronaire-arterie-dissectie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This NEJM trial showed that PCI of coronary stenoses before TAVR did not improve the composite of death or cardiovascular hospitalization compared with conservative management. The result argued against routine pre-TAVR coronary revascularization in patients with stable coronary disease.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"22318fd53b65","type":"article","url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","title":"Ernstige bloeding en mortaliteit na revascularisatie van linker hoofdstam","title_en":"Major Bleeding and Mortality After Revascularization of Left Main Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","ouderen","perifeer-vaatlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.07.065","source_url":"https://doi.org/10.1016/j.jacc.2024.07.065","authors":["Gennaro Giustino","Joseph F Sabik","Patrick W Serruys","John D Puskas","Dimitri Karmpaliotis","David E Kandzari","Marie-Claude Morice","Michael Ragosta","Zixuan Zhang","Ovidiu Dressler","Bjorn Redfors","Ori Ben-Yehuda","Samin K Sharma","Arie Pieter Kappetein","Gregg W Stone"],"significance":6,"published":"2024-12-10","source_date":"2024-12-10","image":"","kennis":[],"congress":"","summary_en":"This analysis documented the incidence and prognostic impact of major bleeding after left main revascularization, showing that bleeding complications significantly increase mortality for both PCI and CABG approaches.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5c7ff4425d5","type":"article","url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","title":"Cognitieve disfunctie bij HFpEF: klinische correlaten en prognostische impact","title_en":"Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["primaire-preventie","stress-psychosociaal","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.070553","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.070553","authors":["Li Shen","Pooja Dewan","João Pedro Ferreira","Jonathan W Cunningham","Pardeep S Jhund","Inder S Anand","Alvin Chandra","Lu-May Chiang","Brian Claggett","Akshay S Desai","Jianjian Gong","Carolyn S P Lam","Martin P Lefkowitz","Aldo P Maggioni","Felipe Martinez","Milton Packer","Margaret M Redfield","Jean L Rouleau","Dirk J van Veldhuisen","Faiez Zannad","Michael R Zile","Scott D Solomon","John J V McMurray"],"significance":5,"published":"2024-12-10","source_date":"2024-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/"],"congress":"","summary_en":"Analysis of the PARAGON-HF substudy documented the prevalence and prognostic impact of cognitive dysfunction in patients with HFpEF. Cognitive impairment was common and independently associated with worse outcomes, highlighting the need for screening and integrated multidisciplinary care.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T13:30:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90ffa1d8b615","type":"article","url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","title":"RELIEVE-HF: interatriale shunt bij hartfalen — negatieve gerandomiseerde trial","title_en":"Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","dapa-hf","finearts-hf","hfmref","hfpef","hfref","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.070870","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.070870","authors":["Gregg W Stone","JoAnn Lindenfeld","Josep Rodés-Cabau","Stefan D Anker","Michael R Zile","Saibal Kar","Richard Holcomb","Michael P Pfeiffer","Antoni Bayes-Genis","Jeroen J Bax","Alan J Bank","Maria Rosa Costanzo","Stefan Verheye","Ariel Roguin","Gerasimos Filippatos","Julio Núñez","Elizabeth C Lee","Michal Laufer-Perl","Gil Moravsky","Sheldon E Litwin","Edgard Prihadi","Hemal Gada","Eugene S Chung","Matthew J Price","Vinay Thohan","Dimitry Schewel","Sachin Kumar","Stephan Kische","Kevin S Shah","Daniel J Donovan","Yiran Zhang","Neal L Eigler","William T Abraham"],"significance":7,"published":"2024-12-10","source_date":"2024-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The RELIEVE-HF trial definitively showed that the interatrial shunt device does not improve clinical outcomes in heart failure, ending the therapeutic pursuit of creating a controlled left-to-right atrial shunt for heart failure management.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14e1d64dd511","type":"article","url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","title":"Hospitalisatie bij symptomatische HF met matige tot ernstige functionele MR","title_en":"Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.027","source_url":"https://doi.org/10.1016/j.jacc.2024.08.027","authors":["Piotr Ponikowski","Tim Friede","Ralph Stephan von Bardeleben","Javed Butler","Muhammad Shahzeb Khan","Monika Diek","Jutta Heinrich","Martin Geyer","Marius Placzek","Roberto Ferrari","William T Abraham","Ottavio Alfieri","Angelo Auricchio","Antoni Bayes-Genis","John G F Cleland","Gerasimos Filippatos","Finn Gustafsson","Wilhelm Haverkamp","Malte Kelm","Karl-Heinz Kuck","Ulf Landmesser","Aldo P Maggioni","Marco Metra","Vlasis Ninios","Mark C Petrie","Tienush Rassaf","Frank Ruschitzka","Ulrich Schäfer","P Christian Schulze","Konstantinos Spargias","Alec Vahanian","Jose Luis Zamorano","Andreas Zeiher","Mahir Karakas","Friedrich Koehler","Mitja Lainscak","Alper Öner","Nikolaos Mezilis","Efstratios K Theofilogiannakos","Ilias Ninios","Michael Chrissoheris","Panagiota Kourkoveli","Konstantinos Papadopoulos","Grzegorz Smolka","Wojciech Wojakowski","Krzysztof Reczuch","Fausto J Pinto","Łukasz Wiewiórka","Witold Streb","Marianna Adamo","Evelyn Santiago-Vacas","Tobias Friedrich Ruf","Michael Gross","Joern Tongers","Gerd Hasenfuß","Wolfgang Schillinger","Stefan D Anker"],"significance":5,"published":"2024-12-10","source_date":"2024-12-10","image":"","kennis":[],"congress":"","summary_en":"An analysis of RESHAPE-HF2 assessed the impact of MitraClip on hospitalisation rates in patients with symptomatic heart failure and moderate to severe functional mitral regurgitation. The findings support early intervention in patients with recurrent heart failure hospitalisations.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d791944735a2","type":"article","url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","title":"Lage-dosis triple combinatiepil versus placebo bij initiële hypertensiebehandeling","title_en":"Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling","fidelity","lorundrostat","precision-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.025","source_url":"https://doi.org/10.1016/j.jacc.2024.08.025","authors":["Anthony Rodgers","Abdul Salam","Aletta E Schutte","William C Cushman","H Asita de Silva","Gian Luca Di Tanna","Diederick Grobbee","Krzysztof Narkiewicz","Dike B Ojji","Neil R Poulter","Markus P Schlaich","Suzanne Oparil","Wilko Spiering","Bryan Williams","Jackson T Wright","Alexis Gutierez","Aliu Sanni","Poopalan Lakshman","Deirdre McMullen","Gotabhaya Ranasinghe","Chris Gianacas","Mathangi Shanthakumar","Xiaoqiu Liu","Nelson Wang","Paul Whelton"],"significance":7,"published":"2024-12-10","source_date":"2024-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This randomized trial confirmed that a low-dose triple combination pill is significantly more effective than placebo for initial hypertension treatment, validating the ultra-low-dose multi-drug approach as a first-line strategy.","created":"2026-07-03T10:31:22Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a2c4ac950d1","type":"article","url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","title":"Anticoagulatie bij device-gedetecteerd AF met/zonder vaatlijden: NOAH+ARTESIA gecombineerd","title_en":"Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","anticoagulantia"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae596","source_url":"https://doi.org/10.1093/eurheartj/ehae596","authors":["Renate B Schnabel","Juan Benezet-Mazuecos","Nina Becher","William F McIntyre","Alexander Fierenz","Shun Fu Lee","Andreas Goette","Dan Atar","Emanuele Bertaglia","Alexander P Benz","Gregory Chlouverakis","David H Birnie","Wolfgang Dichtl","Carina Blomstrom-Lundqvist","A John Camm","Julia W Erath","Emmanuel Simantirakis","Valentina Kutyifa","Gregory Y H Lip","Philippe Mabo","Eloi Marijon","Lena Rivard","Ulrich Schotten","Marco Alings","Susanne Sehner","Tobias Toennis","Cecilia Linde","Panos Vardas","Christopher B Granger","Antonia Zapf","Renato D Lopes","Jeff S Healey","Paulus Kirchhof"],"significance":7,"published":"2024-12-07","source_date":"2024-12-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This combined NOAH-ARTESIA analysis examined whether concomitant vascular disease modifies the benefit of anticoagulation for device-detected subclinical AF, informing risk-stratified treatment decisions in this growing patient population.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db658d0f85aa","type":"article","url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","title":"Edoxaban bij AF en stabiel coronairlijden: antitrombotische monotherapie","title_en":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","bloeddrukbehandeling","stabiel-coronairlijden"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2407362","source_url":"https://doi.org/10.1056/NEJMoa2407362","authors":["Min Soo Cho","Do-Yoon Kang","Jung-Min Ahn","Sung-Cheol Yun","Yong-Seog Oh","Chang Hoon Lee","Eue-Keun Choi","Ji Hyun Lee","Chang Hee Kwon","Gyung-Min Park","Hyung Oh Choi","Kyoung-Ha Park","Kyoung-Min Park","Jongmin Hwang","Ki-Dong Yoo","Young-Rak Cho","Ji Hyun Kim","Ki Won Hwang","Eun-Sun Jin","Osung Kwon","Ki-Hun Kim","Seung-Jung Park","Duk-Woo Park","Gi-Byoung Nam"],"significance":6,"published":"2024-12-05","source_date":"2024-12-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This NEJM trial provided randomized evidence that edoxaban monotherapy is appropriate for AF patients with stable coronary artery disease, supporting the transition from combined antithrombotic therapy to anticoagulant alone.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a581cf0210c","type":"article","url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","title":"Inflammatie, cholesterol, Lp(a) en 30-jaars CV-uitkomsten bij vrouwen","title_en":"Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","hs-crp","inflammatie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","plaquekarakterisatie","statines","vrouwen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2405182","source_url":"https://doi.org/10.1056/NEJMoa2405182","authors":["Paul M Ridker","M Vinayaga Moorthy","Nancy R Cook","Nader Rifai","I-Min Lee","Julie E Buring"],"significance":7,"published":"2024-12-05","source_date":"2024-12-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This 30-year follow-up study in women demonstrated that hsCRP, LDL cholesterol, and Lp(a) independently predict cardiovascular events over three decades, establishing that these biomarkers provide meaningful long-term risk prediction well beyond the standard 10-year horizon.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a05d143b780e","type":"article","url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","title":"CT-gestuurde atriale wanddiktemapping bij cryoballon PVI","title_en":"Using computed tomography atrial myocardial thickness maps in cryoballoon pulmonary vein isolation: the UTMOST AF II randomized clinical trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie","gedilateerde-cardiomyopathie","pulmonaalvenenisolatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae292","source_url":"https://doi.org/10.1093/europace/euae292","authors":["Daehoon Kim","Oh-Seok Kwon","Taehyun Hwang","Hanjin Park","Hee Tae Yu","Tae-Hoon Kim","Jae-Sun Uhm","Boyoung Joung","Moon-Hyoung Lee","Hui-Nam Pak"],"significance":5,"published":"2024-12-03","source_date":"2024-12-03","image":"","kennis":[],"congress":"","summary_en":"The UTMOST AF II trial evaluated CT-based left atrial wall thickness mapping to guide personalised cryoballoon pulmonary vein isolation for paroxysmal AF. The thickness-guided approach did not demonstrate superiority over empirical ablation duration.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c430b31a5c6","type":"article","url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","title":"PFA versus cryoballon voor AF-ablatie: multielectrode vergelijking","title_en":"Multielectrode catheter-based pulsed electric field vs. cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae293","source_url":"https://doi.org/10.1093/europace/euae293","authors":["Giampaolo Vetta","Domenico Giovanni Della Rocca","Antonio Parlavecchio","Michele Magnocavallo","Antonio Sorgente","Luigi Pannone","Alvise Del Monte","Alexandre Almorad","Juan Sieira","Lorenzo Marcon","Ioannis Doundoulakis","Sanghamitra Mohanty","Charles Audiat","Kazutaka Nakasone","Gezim Bala","Erwin Ströker","Stéphane Combes","Ingrid Overeinder","Stefano Bianchi","Pietro Palmisano","Pietro Rossi","Serge Boveda","Marc La Meir","Andrea Natale","Andrea Sarkozy","Carlo de Asmundis","Gian-Battista Chierchia"],"significance":7,"published":"2024-12-03","source_date":"2024-12-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"This systematic review compared multielectrode pulsed field ablation with cryoballoon for AF treatment, finding that PFA is noninferior with comparable efficacy and potentially fewer extracardiac complications.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84c8c8d637a2","type":"article","url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","title":"NT-proBNP en ECG screening bij 75-jarigen voor AF-detectie: RCT","title_en":"Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["nt-probnp","primaire-preventie","supraventriculaire-tachycardie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071176","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071176","authors":["Katrin Kemp Gudmundsdottir","Emma Svennberg","Leif Friberg","Tove Hygrell","Viveka Frykman","Faris Al-Khalili","Ziad Hijazi","Mårten Rosenqvist","Johan Engdahl"],"significance":7,"published":"2024-12-03","source_date":"2024-12-03","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This randomized trial of systematic NT-proBNP and ECG screening for AF in 75-year-olds showed increased AF detection, though the impact on downstream clinical outcomes requires longer follow-up to establish the value of population-level screening.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4f41db6e8e7","type":"article","url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","title":"Restrictief versus liberaal transfusiebeleid bij type 1 versus type 2 MI: REALITY subanalyse","title_en":"Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071208","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071208","authors":["Andrew P DeFilippis","J Dawn Abbott","Brandon M Herbert","Marnie H Bertolet","Bernard R Chaitman","Harvey D White","Andrew M Goldsweig","Tamar S Polonsky","Rajesh Gupta","Caroline Alsweiler","Johanne Silvain","Pedro G M de Barros E Silva","Graham S Hillis","Benoit Daneault","Meechai Tessalee","Mark A Menegus","Sunil V Rao","Renato D Lopes","Paul C Hébert","John H Alexander","Maria M Brooks","Jeffrey L Carson","Shaun G Goodman"],"significance":6,"published":"2024-12-03","source_date":"2024-12-03","image":"","kennis":[],"congress":"","summary_en":"This REALITY prespecified analysis confirmed that restrictive transfusion is safe in both type 1 and type 2 MI patients, showing that MI subtype does not modify the transfusion strategy decision.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2beb97c24a84","type":"article","url":"https://hartvaat.nl/2024/12/01/polygene-risicoscore-en-chloortalidone-respons/","title":"Polygene risicoscore en chloortalidone-respons","title_en":"Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["polygene-risicoscore"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3649","source_url":"https://doi.org/10.1001/jamacardio.2024.3649","authors":["Nicole D Armstrong","Vinodh Srinivasasainagendra","Amit Patki","Alana C Jones","Vibhu Parcha","Akhil Pampana","Ulrich Broeckel","Leslie A Lange","Pankaj Arora","Nita A Limdi","Hemant K Tiwari","Marguerite R Irvin"],"significance":5,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"This GenHAT/ALLHAT ancillary study investigated whether a polygenic risk score for systolic blood pressure predicts response to chlorthalidone treatment. The genetic score had limited predictive value for individual antihypertensive treatment response.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c33b3da784f9","type":"article","url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","title":"Korte DAPT na DES bij ACS: IPD meta-analyse bevestigt veiligheid","title_en":"Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3216","source_url":"https://doi.org/10.1001/jamacardio.2024.3216","authors":["Pedro E P Carvalho","Douglas M Gewehr","Bruno R Nascimento","Lara Melo","Giullia Burkhardt","André Rivera","Marcelo A P Braga","Patricia O Guimarães","Roxana Mehran","Stephan Windecker","Marco Valgimigli","Dominick J Angiolillo","Deepak L Bhatt","Yader Sandoval","Shao-Liang Chen","Gregg W Stone","Renato D Lopes"],"significance":7,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that short-term DAPT (1-3 months) after drug-eluting stenting in ACS patients is safe with fewer bleeding events, providing the strongest patient-level evidence for abbreviated antiplatelet therapy.","created":"2026-07-03T10:31:21Z","updated":"2026-07-03T13:30:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ae0e174b4e4","type":"article","url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","title":"Splanchnische zenuwablatie bij HFpEF: endovasculaire benadering","title_en":"Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","hfref","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2612","source_url":"https://doi.org/10.1001/jamacardio.2024.2612","authors":["Marat Fudim","Barry A Borlaug","Rajeev C Mohan","Matthew J Price","Peter Fail","Parag Goyal","Scott L Hummel","Teona Zirakashvili","Tamaz Shaburishvili","Ravi B Patel","Vivek Y Reddy","Christopher D Nielsen","Stanley J Chetcuti","Devraj Sukul","Rajiv Gulati","Luke Kim","Keith Benzuly","Sumeet S Mitter","Liviu Klein","Nir Uriel","Ralph S Augostini","John E Blair","Krishna Rocha-Singh","Daniel Burkhoff","Manesh R Patel","Sami I Somo","Sheldon E Litwin","Sanjiv J Shah"],"significance":7,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"This study of endovascular greater splanchnic nerve ablation in HFpEF showed reduced exertional pulmonary capillary wedge pressure, exploring a novel neuromodulation approach targeting the splanchnic circulation to improve hemodynamics in heart failure.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"77c294586a2a","type":"article","url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","title":"LDL-verlaging en lesie-niveau effecten na acuut MI","title_en":"Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["dyslipidemie","ezetimibe","inflammatie","ldl-cholesterol","lipide-aferese","lipidenverlaging"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.3200","source_url":"https://doi.org/10.1001/jamacardio.2024.3200","authors":["Flavio G Biccirè","Ryota Kakizaki","Konstantinos C Koskinas","Yasushi Ueki","Jonas Häner","Hiroki Shibutani","Jacob Lønborg","Ernest Spitzer","Juan F Iglesias","Tatsuhiko Otsuka","George C M Siontis","Stefan Stortecky","Christoph Kaiser","Maria Ambühl","Laura Morf","Anna S Ondracek","Robert-Jan van Geuns","David Spirk","Joost Daemen","François Mach","Stephan Windecker","Thomas Engstrøm","Irene Lang","Sylvain Losdat","Lorenz Räber"],"significance":6,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"This post-hoc analysis examined the lesion-level effects of LDL cholesterol lowering after MI, showing that lower achieved LDL is associated with greater plaque regression in individual coronary lesions.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"54c9cae95f24","type":"article","url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","title":"COLICA: colchicine bij acuut gedecompenseerd hartfalen","title_en":"Colchicine in acutely decompensated heart failure: the COLICA trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["colchicine","colcot-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae538","source_url":"https://doi.org/10.1093/eurheartj/ehae538","authors":["Domingo Pascual-Figal","Julio Núñez","Maria T Pérez-Martínez","José Ramón González-Juanatey","Mikel Taibo-Urquia","Pau Llàcer-Iborra","Juan Delgado","Sandra Villar","Sonia Mirabet","Alberto Aimo","Alejandro Riquelme-Pérez","Manuel Anguita-Sánchez","Manuel Martínez-Sellés","Jose A Noguera-Velasco","Borja Ibáñez","Antoni Bayés-Genís"],"significance":7,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The COLICA trial explored colchicine in acutely decompensated heart failure, testing whether anti-inflammatory therapy can improve decongestion and outcomes in this inflammatory-activated condition.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"519d8b256dd3","type":"article","url":"https://hartvaat.nl/2024/12/01/nt-probnp-voorspelt-nieuw-ontstaan-af-bij-hfpef/","title":"NT-proBNP voorspelt nieuw-ontstaan AF bij HFpEF","title_en":"Predictive value of NT pro BNP for new-onset atrial fibrillation in heart failure and preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14951","source_url":"https://doi.org/10.1002/ehf2.14951","authors":["Xiao Liu","Sixu Chen","Hong Pan","Zenghui Zhang","Yue Wang","Yuan Jiang","Maoxiong Wu","Zhiteng Chen","Ayiguli Abudukeremu","Zhengyu Cao","Qingyuan Gao","Minghai Zhang","Wengen Zhu","Yangxin Chen","Yuling Zhang","Jingfeng Wang"],"significance":5,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"A TOPCAT substudy demonstrated that NT-proBNP is a strong predictor of new-onset atrial fibrillation in patients with heart failure with preserved ejection fraction. The biomarker could improve selection of HFpEF patients for targeted AF screening programmes.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef57025d229d","type":"article","url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","title":"Hartfrequentiereactiviteit en inspanningstolerantie bij hartfalen","title_en":"Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfref","ivabradine","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15000","source_url":"https://doi.org/10.1002/ehf2.15000","authors":["Fang-Fei Wei","Beatrice Mariottoni","De-Wei An","Pierpaolo Pellicori","Yu-Ling Yu","Job A J Verdonschot","Chen Liu","Fozia Z Ahmed","Johannes Petutschnigg","Patrick Rossignol","Stephane Heymans","Joe Cuthbert","Nicolas Girerd","Yan Li","Andrew L Clark","Tim S Nawrot","João Pedro Ferreira","Faiez Zannad","John G F Cleland","Jan A Staessen"],"significance":5,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"Analysis of the HOMAGE trial examined heart rate reactivity and recovery during the incremental shuttle walk test in patients prone to heart failure. Chronotropic incompetence predicted worse exercise endurance and was not modified by spironolactone treatment.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e3341d20bc3","type":"article","url":"https://hartvaat.nl/2024/12/01/mortaliteitsvoorspelling-bij-hfpef-systematische-review-en-meta-analyse/","title":"Mortaliteitsvoorspelling bij HFpEF: systematische review en meta-analyse","title_en":"Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.15008","source_url":"https://doi.org/10.1002/ehf2.15008","authors":["Chuanhe Wang","Lin Guan","Su Han","Fei Tong","Ying Li","Zhichao Li","Hao Sun","Zhijun Sun"],"significance":5,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis identified the strongest mortality predictors in HFpEF — age, NT-proBNP, renal function, and functional status — and developed the HF-DANAS risk score. Integrated prognostic models are needed for better risk stratification in this growing patient population.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ace64176465b","type":"article","url":"https://hartvaat.nl/2024/12/01/dynamische-optimalisatie-bij-crt-systematische-review-en-netwerk-meta-analyse/","title":"Dynamische optimalisatie bij CRT: systematische review en netwerk-meta-analyse","title_en":"Emergent role of dynamic optimization in cardiac resynchronization therapy: Systematic review and network meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","cardiale-resynchronisatie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14957","source_url":"https://doi.org/10.1002/ehf2.14957","authors":["Előd-János Zsigmond","Richárd Masszi","Réka Ehrenberger","Caner Turan","Péter Fehérvári","Noémi Gede","Péter Hegyi","Zsolt Molnár","Domonkos Trásy","Gábor Zoltán Duray"],"significance":5,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":[],"congress":"","summary_en":"A systematic review and network meta-analysis investigated optimisation strategies for cardiac resynchronisation therapy. Dynamic algorithms that continuously adapt device settings to changing haemodynamics showed promise for improving CRT response rates compared with empirical or static programming.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37695d7688ed","type":"article","url":"https://hartvaat.nl/2024/12/01/sglt2-remming-en-cardiale-reverse-remodelling-bij-hartfalen-systematische-review/","title":"SGLT2-remming en cardiale reverse remodelling bij hartfalen: systematische review","title_en":"Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","empagliflozine","vericiguat"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14993","source_url":"https://doi.org/10.1002/ehf2.14993","authors":["Patrick Savage","Chris Watson","Jaimie Coburn","Brian Cox","Michael Shahmohammadi","David Grieve","Lana Dixon"],"significance":6,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/"],"congress":"","summary_en":"This meta-analysis confirmed that SGLT2 inhibitors promote reverse cardiac remodeling in heart failure, with measurable improvements in LV volumes, mass, and ejection fraction that explain the clinical outcomes benefit.","created":"2026-07-03T10:31:20Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4baf2e0450dd","type":"article","url":"https://hartvaat.nl/2024/12/01/sekseverschillen-in-effect-van-sglt2-remmers-en-glp-1-agonisten-meta-analyse/","title":"Sekseverschillen in effect van SGLT2-remmers en GLP-1-agonisten: meta-analyse","title_en":"Effect of sex on sodium-glucose co-transporter-2 antagonists and glucagon-like peptide-1 agonists in heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","sglt2-remmers","soul-trial","tirzepatide"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14979","source_url":"https://doi.org/10.1002/ehf2.14979","authors":["Mevin A Philip","Carolyn M Webb","Turja Chakraborty","Peter Collins"],"significance":7,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This meta-analysis found that both SGLT2 inhibitors and GLP-1 receptor agonists provide comparable cardiovascular benefit in men and women with heart failure, supporting equal treatment across sexes for these newer cardioprotective drug classes.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e1fa9bb19a2","type":"article","url":"https://hartvaat.nl/2024/12/01/science-ii-mesenchymale-stamcellen-bij-niet-ischemisch-hartfalen-negatieve-trial/","title":"SCIENCE II: mesenchymale stamcellen bij niet-ischemisch hartfalen — negatieve trial","title_en":"Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14925","source_url":"https://doi.org/10.1002/ehf2.14925","authors":["Abbas Ali Qayyum","Sabina Frljak","Morten Juhl","Gregor Poglajen","Gregor Zemljičl","Andraz Cerar","Thomas Litman","Annette Ekblond","Mandana Haack-Sørensen","Lisbeth Drozd Højgaard","Jens Kastrup","Bojan Vrtovec"],"significance":6,"published":"2024-12-01","source_date":"2024-12-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"The SCIENCE II pilot study showed that allogeneic mesenchymal stromal cells in non-ischemic heart failure do not improve clinical outcomes, adding to the negative evidence for stem cell therapy in cardiomyopathy.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1819777baae","type":"article","url":"https://hartvaat.nl/2024/11/26/panorama-hf-sacubitril-valsartan-bij-pediatrisch-hartfalen-nejm/","title":"PANORAMA-HF: sacubitril/valsartan bij pediatrisch hartfalen — NEJM","title_en":"Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","sacubitril-valsartan","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066605","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066605","authors":["Robert Shaddy","Michael Burch","Paul F Kantor","Susan Solar-Yohay","Tania Garito","Sijia Zhang","Michele Kocun","Chad Mao","Antoinette Cilliers","Xu Wang","Charles Canter","Joseph Rossano","Gonzalo Wallis","Jondavid Menteer","Linda Daou","Jacek Kusa","Kursat Tokel","Daniel Dilber","Zhuoming Xu","Tingting Xiao","Nancy Halnon","Kevin P Daly","Matthew J Bock","Warren Zuckerman","Tajinder P Singh","Manisha Chakrabarti","Aviva Levitas","Michele Senni","Giorgia Grutter","Gi Beom Kim","Jinyoung Song","Hyoung Doo Lee","Ching Kit Chen","Joan Sanchez-de-Toledo","Yuk Law","Suthep Wanitkun","Yanqin Cui","Rui Anjos","Timur Mese","Damien Bonnet"],"significance":7,"published":"2024-11-26","source_date":"2024-11-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"The PANORAMA-HF trial showed that sacubitril-valsartan did not significantly improve the primary composite endpoint in pediatric heart failure, highlighting the challenges of translating adult HF therapies to the pediatric population.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ff4bafc9be5c","type":"article","url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","title":"AEGIS-II subanalyse: apoA-I infusie en ischemische eventlast na MI","title_en":"ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.001","source_url":"https://doi.org/10.1016/j.jacc.2024.08.001","authors":["C Michael Gibson","Gerald Chi","Danielle Duffy","M Cecilia Bahit","Harvey White","Serge Korjian","John H Alexander","A Michael Lincoff","Gaya Anschuetz","Ihab G Girgis","Jose C Nicolau","Renato D Lopes","Jan H Cornel","Kevin R Bainey","Peter Libby","Frank M Sacks","Paul M Ridker","Shaun G Goodman","Kenneth W Mahaffey","Stephen J Nicholls","Stuart J Pocock","Roxana Mehran","Robert A Harrington"],"significance":5,"published":"2024-11-26","source_date":"2024-11-26","image":"","kennis":[],"congress":"","summary_en":"A prespecified analysis of AEGIS-II examined the effect of apolipoprotein A-I infusion on total ischaemic event burden after acute myocardial infarction. No benefit was observed, definitively establishing the failure of the HDL infusion strategy in this setting.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2ddfa4644c0","type":"article","url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","title":"ARTESIA subanalyse: CVA-risico naar frequentie en duur van subclinisch AF","title_en":"Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069903","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069903","authors":["William F McIntyre","Alexander P Benz","Jeff S Healey","Stuart J Connolly","Mu Yang","Shun Fu Lee","Thalia S Field","Marco Alings","J Benezet-Mazuecos","Giuseppe Boriani","J Cosedis Nielsen","Michael R Gold","Francesco Pergolini","Taya V Glotzer","Christopher B Granger","Renato D Lopes"],"significance":7,"published":"2024-11-26","source_date":"2024-11-26","image":"","kennis":[],"congress":"","summary_en":"This ARTESIA subanalysis showed that the stroke risk and benefit of apixaban increase with higher frequency and longer duration of subclinical AF episodes, supporting dose-response-based anticoagulation decisions for device-detected arrhythmia.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"71fcc6d53cbe","type":"article","url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","title":"GLP-1-agonisten alleen en met SGLT2-remmers: CV, renale en veiligheidsuitkomsten","title_en":"Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071689","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071689","authors":["Brendon L Neuen","Robert A Fletcher","Lauren Heath","Adam Perkovic","Muthiah Vaduganathan","Sunil V Badve","Katherine R Tuttle","Richard Pratley","Hertzel C Gerstein","Vlado Perkovic","Hiddo J L Heerspink"],"significance":8,"published":"2024-11-26","source_date":"2024-11-26","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/glp1-agonisten-cardiovasculair/"],"congress":"","summary_en":"This comprehensive meta-analysis confirmed that GLP-1 receptor agonists and SGLT2 inhibitors provide complementary cardiovascular and kidney protection in patients with type 2 diabetes. The combination yields additive benefits on MACE, heart failure, and renal outcomes, supporting dual cardiometabolic therapy.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c931dae95130","type":"article","url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","title":"Screening op niet-gediagnosticeerd AF voor CVA-preventie: gerandomiseerde trial","title_en":"Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.019","source_url":"https://doi.org/10.1016/j.jacc.2024.08.019","authors":["Renato D Lopes","Steven J Atlas","Alan S Go","Steven A Lubitz","David D McManus","Rowena J Dolor","Ranee Chatterjee","Michael B Rothberg","David R Rushlow","Lori A Crosson","Ronald S Aronson","Michael Patlakh","Dianne Gallup","Donna J Mills","Emily C O'Brien","Daniel E Singer"],"significance":8,"published":"2024-11-19","source_date":"2024-11-19","image":"","kennis":[],"congress":"","summary_en":"This randomized trial of AF screening versus usual care demonstrated that screening detects more undiagnosed AF and increases anticoagulation initiation, though the impact on stroke incidence was not statistically significant. Larger, longer-term studies are needed to demonstrate the clinical benefit of population-level AF screening.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a259adc9e253","type":"article","url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","title":"AFLOAT: flecaïnide voorkomt AF na PFO-sluiting — RCT","title_en":"Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071186","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071186","authors":["Marie Hauguel-Moreau","Paul Guedeney","Claire Dauphin","Vincent Auffret","Jean-Michel Clerc","Eloi Marijon","Meyer Elbaz","Philippe Aldebert","Farzin Beygui","Wissam Abi Khalil","Antoine Da Costa","Jean-Christophe Macia","Simon Elhadad","Guillaume Cayla","Xavier Iriart","Mikael Laredo","Thomas Rolland","Yassine Temmar","Maria Elisabeta Gheorghiu","Delphine Brugier","Johanne Silvain","Nadjib Hammoudi","Guillaume Duthoit","Abdourahmane Diallo","Eric Vicaut","Gilles Montalescot"],"significance":7,"published":"2024-11-19","source_date":"2024-11-19","image":"","kennis":[],"congress":"","summary_en":"The AFLOAT trial showed that flecainide significantly prevents atrial arrhythmias after PFO closure, establishing prophylactic antiarrhythmic therapy as an effective strategy for this common post-procedural complication.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"002bbb858232","type":"article","url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","title":"Plotse hartdood na MI: IPD analyse van gepoolde cohorten","title_en":"Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae326","source_url":"https://doi.org/10.1093/eurheartj/ehae326","authors":["Niels Peek","Gerhard Hindricks","Artur Akbarov","Jan G P Tijssen","David A Jenkins","Zoher Kapacee","Le Mai Parkes","Rob J van der Geest","Enrico Longato","Daniel Sprague","Youssef Taleb","Marcus Ong","Christopher A Miller","Alireza Sepehri Shamloo","Christine Albert","Petra Barthel","Serge Boveda","Frieder Braunschweig","Jens Brock Johansen","Nancy Cook","Christian de Chillou","Petra Elders","Jonas Faxén","Tim Friede","Laura Fusini","Chris P Gale","Jiri Jarkovsky","Xavier Jouven","Juhani Junttila","Josef Kautzner","Antti Kiviniemi","Valentina Kutyifa","Christophe Leclercq","Daniel C Lee","Jill Leigh","Radosław Lenarczyk","Francisco Leyva","Michael Maeng","Andrea Manca","Eloi Marijon","Ursula Marschall","Jose Luis Merino","Lluis Mont","Jens Cosedis Nielsen","Thomas Olsen","Julie Pester","Gianluca Pontone","Ivo Roca","Georg Schmidt","Peter J Schwartz","Christian Sticherling","Mahmoud Suleiman","Milos Taborsky","Hanno L Tan","Jacob Tfelt-Hansen","Holger Thiele","Gordon F Tomaselli","Tom Verstraelen","Manickavasagar Vinayagamoorthy","Kevin Kris Warnakula Olesen","Arthur Wilde","Rik Willems","Katherine C Wu","Markus Zabel","Glen P Martin","Nikolaos Dagres"],"significance":7,"published":"2024-11-14","source_date":"2024-11-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This individual participant data analysis identified risk factors for sudden cardiac death after MI in the modern GDMT era, finding that the risk has decreased but remains significant and is not captured by ejection fraction alone.","created":"2026-07-03T10:31:19Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f520e8219c49","type":"article","url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","title":"MATTERHORN: transcatheter repair versus chirurgie bij secundaire MR — NEJM","title_en":"Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2408739","source_url":"https://doi.org/10.1056/NEJMoa2408739","authors":["Stephan Baldus","Torsten Doenst","Roman Pfister","Jan Gummert","Mirjam Kessler","Peter Boekstegers","Edith Lubos","Jörg Schröder","Holger Thiele","Thomas Walther","Malte Kelm","Jörg Hausleiter","Ingo Eitel","Ulrich Fischer-Rasokat","Alexander Bufe","Alexander Schmeisser","Hüseyin Ince","Philipp Lurz","Ralph Stephan von Bardeleben","Christian Hagl","Thilo Noack","Sebastian Reith","Harald Beucher","Hermann Reichenspurner","Wolfgang Rottbauer","P Christian Schulze","Wiebke Müller","Julia Frank","Martin Hellmich","Thorsten Wahlers","Volker Rudolph"],"significance":9,"published":"2024-11-14","source_date":"2024-11-14","image":"","kennis":[],"congress":"","summary_en":"The MATTERHORN trial demonstrated that transcatheter edge-to-edge mitral valve repair was noninferior to surgical mitral valve intervention for reducing mitral regurgitation severity in patients with heart failure and secondary MR, with fewer perioperative complications. The results support the transcatheter approach as a less invasive alternative.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T13:30:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"567650b6d452","type":"article","url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","title":"RESHAPE-HF2: transcatheter kleprepair bij HF met matige tot ernstige MR — NEJM","title_en":"Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2314328","source_url":"https://doi.org/10.1056/NEJMoa2314328","authors":["Stefan D Anker","Tim Friede","Ralph-Stephan von Bardeleben","Javed Butler","Muhammad-Shahzeb Khan","Monika Diek","Jutta Heinrich","Martin Geyer","Marius Placzek","Roberto Ferrari","William T Abraham","Ottavio Alfieri","Angelo Auricchio","Antoni Bayes-Genis","John G F Cleland","Gerasimos Filippatos","Finn Gustafsson","Wilhelm Haverkamp","Malte Kelm","Karl-Heinz Kuck","Ulf Landmesser","Aldo P Maggioni","Marco Metra","Vlasis Ninios","Mark C Petrie","Tienush Rassaf","Frank Ruschitzka","Ulrich Schäfer","P Christian Schulze","Konstantinos Spargias","Alec Vahanian","Jose Luis Zamorano","Andreas Zeiher","Mahir Karakas","Friedrich Koehler","Mitja Lainscak","Alper Öner","Nikolaos Mezilis","Efstratios K Theofilogiannakos","Ilias Ninios","Michael Chrissoheris","Panagiota Kourkoveli","Konstantinos Papadopoulos","Grzegorz Smolka","Wojciech Wojakowski","Krzysztof Reczuch","Fausto J Pinto","Łukasz Wiewiórka","Zbigniew Kalarus","Marianna Adamo","Evelyn Santiago-Vacas","Tobias F Ruf","Michael Gross","Joern Tongers","Gerd Hasenfuss","Wolfgang Schillinger","Piotr Ponikowski"],"significance":9,"published":"2024-11-14","source_date":"2024-11-14","image":"","kennis":[],"congress":"","summary_en":"The RESHAPE-HF2 trial showed that transcatheter mitral valve repair improved outcomes in patients with heart failure and moderate-to-severe secondary mitral regurgitation, adding to the COAPT evidence for device therapy in functional MR. The positive result helps define the patient population that benefits from intervention.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1756af800fa0","type":"article","url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","title":"ILUMIEN IV: OCT-predictoren van klinische uitkomsten na stentimplantatie","title_en":"Optical coherence tomography predictors of clinical outcomes after stent implantation: the ILUMIEN IV trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae521","source_url":"https://doi.org/10.1093/eurheartj/ehae521","authors":["Ulf Landmesser","Ziad A Ali","Akiko Maehara","Mitsuaki Matsumura","Richard A Shlofmitz","Giulio Guagliumi","Matthew J Price","Jonathan M Hill","Takashi Akasaka","Francesco Prati","Hiram G Bezerra","William Wijns","David Leistner","Paolo Canova","Fernando Alfonso","Franco Fabbiocchi","Giuseppe Calligaris","Rohit M Oemrawsingh","Stephan Achenbach","Carlo Trani","Balbir Singh","Robert J McGreevy","Robert W McNutt","Shih-Wa Ying","Jana Buccola","Gregg W Stone"],"significance":6,"published":"2024-11-14","source_date":"2024-11-14","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This ILUMIEN IV analysis identified OCT-derived parameters (minimum stent area, dissection, malapposition) that predict clinical outcomes after PCI, informing the criteria for procedural optimization with intravascular imaging.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87abcbe3a810","type":"article","url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","title":"Recaticimab als toevoeging aan statines: fase 3 REMAIN-2","title_en":"Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","lipidenverlaging","niet-statine-therapie","soul-trial","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.09.012","source_url":"https://doi.org/10.1016/j.jacc.2024.09.012","authors":["Yihong Sun","Qiang Lv","Yuhan Guo","Zhifang Wang","Rongjie Huang","Xiaohong Gao","Yajun Han","Zhuhua Yao","Mingqi Zheng","Suxin Luo","Yue Li","Xiang Gu","Yumin Zhang","Junkui Wang","Lang Hong","Xueping Ma","Guohai Su","Jianlong Sheng","Chunlin Lai","Aidong Shen","Mian Wang","WeiHua Zhang","Shaorong Wu","Zeqi Zheng","Juxiang Li","Tingyan Zhong","Ying Wang","Liu He","Xin Du","Chang-Sheng Ma"],"significance":7,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The REMAIN-2 trial showed that recaticimab added to statin therapy provides additional LDL cholesterol lowering in patients not reaching goals on statins alone, confirming the efficacy of this new PCSK9 antibody in combination therapy.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c091b6dadacc","type":"article","url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","title":"Recaticimab monotherapie bij niet-familiaire hypercholesterolemie: fase 3 REMAIN-1","title_en":"Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","select-trial","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.07.035","source_url":"https://doi.org/10.1016/j.jacc.2024.07.035","authors":["Mingtong Xu","Zhen Wang","Yumin Zhang","Yong Liu","Rongjie Huang","Xuebin Han","Zhuhua Yao","Jiao Sun","Fengsheng Tian","Xitian Hu","Liping Ma","Chunlin Lai","Xiwen Zhang","Jianlong Sheng","Qinghua Han","Chunrong Jin","Li Luo","Ruiping Zhao","Liwen Li","Biao Xu","Delu Yin","Suxin Luo","Xiaofeng Ge","Zhiyuan Liu","Ping Yang","Zheng Huang","Tianfa Li","Wei Feng","Yanqing Wu","Zhiyu Ling","Likun Ma","Chao Lv","Chanjuan Deng","Wenhua Wei","Ying Wang","Li Yan","JunBo Ge"],"significance":7,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"The REMAIN-1 trial of recaticimab, a Chinese-developed anti-PCSK9 antibody, showed significant LDL cholesterol reduction as monotherapy in nonfamilial hypercholesterolemia, expanding the global PCSK9 inhibitor landscape.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3b9fb748a8e","type":"article","url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","title":"Renale denervatie bij hypertensie: uitgebreide meta-analyse van alle trials","title_en":"Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","radiance-htn","renale-denervatie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069709","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069709","authors":["Davor Vukadinović","Lucas Lauder","David E Kandzari","Deepak L Bhatt","Ajay J Kirtane","Elazer R Edelman","Roland E Schmieder","Michel Azizi","Michael Böhm","Felix Mahfoud"],"significance":7,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This comprehensive meta-analysis of all renal denervation trials confirmed a consistent blood pressure reduction of 4-6 mmHg systolic, establishing the magnitude of benefit expected from catheter-based renal denervation as an add-on therapy.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"297470bd0787","type":"article","url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","title":"RF-renale denervatie bij ongecontroleerde hypertensie in China: gerandomiseerde trial","title_en":"Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","chronische-nierziekte","fidelio-dkd","figaro-dkd","flow-trial","radiance-htn","renale-denervatie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069215","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069215","authors":["Xiongjing Jiang","Felix Mahfoud","Wei Li","Hui Dong","Jing Yu","Shuhua Yu","Xiaoping Chen","Peijian Wang","Zhiqiang Li","Lucas Lauder","Zhifang Wang","Zheng Ji","Yifei Dong","Bing Han","Zhiming Zhu","Yulin Chen","Jianzhong Xu","Xingsheng Zhao","Weidong Fan","Wen Xie","Brad Hubbard","Xi Hu","Kazuomi Kario","Runlin Gao"],"significance":6,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This sham-controlled trial confirmed the efficacy of catheter-based radiofrequency renal denervation in Chinese patients with uncontrolled hypertension, extending the evidence for device-based therapy to the Asian hypertensive population.","created":"2026-07-03T10:31:18Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be64b1380024","type":"article","url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","title":"Complete versus culprit-only revascularisatie bij ouderen met MI met/zonder cardiogene shock","title_en":"Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.07.028","source_url":"https://doi.org/10.1016/j.jacc.2024.07.028","authors":["Marta Cocco","Gianluca Campo","Vincenzo Guiducci","Gianni Casella","Caterina Cavazza","Enrico Cerrato","Giorgio Sacchetta","Raul Moreno","Alberto Menozzi","Ignacio Amat Santos","José Luis Díez Gil","Roberto Scarsini","Andrea Picchi","Giuseppe Vadalà","Gerlando Pilato","Iginio Colaiori","Marco Barbierato","Manfredi Arioti","Rita Pavasini","Valerio Lanzilotti","Mila Menozzi","Ferdinando Varbella","Andrea Erriquez","Simone Biscaglia"],"significance":7,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This analysis confirmed the benefit of complete revascularization in older MI patients regardless of cardiogenic shock or ST-elevation status, extending the evidence to the broadest elderly MI population.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73e623b0c4cf","type":"article","url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","title":"SGLT2-remming en proteomische handtekeningen bij hartfalen: bevestiging","title_en":"Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","sglt2-remmers","vericiguat"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.07.013","source_url":"https://doi.org/10.1016/j.jacc.2024.07.013","authors":["Milton Packer","João Pedro Ferreira","Javed Butler","Gerasimos Filippatos","James L Januzzi","Sandra González Maldonado","Marina Panova-Noeva","Stuart J Pocock","Jürgen H Prochaska","Maral Saadati","Naveed Sattar","Mikhail Sumin","Stefan D Anker","Faiez Zannad"],"significance":5,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":[],"congress":"","summary_en":"A large-scale proteomic validation study within the EMPEROR programme confirmed reproducible protein expression changes induced by SGLT2 inhibition in heart failure patients. The consistent anti-inflammatory and antifibrotic proteomic signatures strengthen mechanistic understanding of SGLT2 inhibitor cardioprotection.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25850c7066d7","type":"article","url":"https://hartvaat.nl/2024/11/12/ketonester-bij-type-2-diabetes-en-hartfalen-cross-over-trial/","title":"Ketonester bij type 2 diabetes en hartfalen: cross-over trial","title_en":"Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["bisoprolol","dapagliflozine","figaro-dkd","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069732","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069732","authors":["Nigopan Gopalasingam","Kristoffer Berg-Hansen","Kristian Hylleberg Christensen","Bertil T Ladefoged","Steen Hvitfeldt Poulsen","Mads Jønsson Andersen","Barry A Borlaug","Roni Nielsen","Niels Møller","Henrik Wiggers"],"significance":6,"published":"2024-11-12","source_date":"2024-11-12","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This crossover trial showed that oral ketone ester supplementation improves cardiac efficiency in patients with type 2 diabetes and HFpEF, advancing metabolic modulation as a therapeutic approach for this common comorbidity.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bda1bad847cd","type":"article","url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","title":"FAVOR IV-QVAS: QFR versus FFR bij coronaire revascularisatiedecisies — Lancet","title_en":"Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)02175-5","source_url":"https://doi.org/10.1016/S0140-6736(24)02175-5","authors":["Birgitte Krogsgaard Andersen","Martin Sejr-Hansen","Luc Maillard","Gianluca Campo","Truls Råmunddal","Barbara E Stähli","Vincenzo Guiducci","Luigi Di Serafino","Javier Escaned","Ignacio Amat Santos","Ramón López-Palop","Ulf Landmesser","Ruthe Storgaard Dieu","Hernán Mejía-Rentería","Lukasz Koltowski","Greta Žiubrytė","Laura Cetran","Julien Adjedj","Youssef S Abdelwahed","Tommy Liu","Lone Juul Hune Mogensen","Ashkan Eftekhari","Jelmer Westra","Karsten Lenk","Gianni Casella","Eric Van Belle","Simone Biscaglia","Niels Thue Olsen","Paul Knaapen","Janusz Kochman","Ramón Calviño Santos","Roberto Scarsini","Evald Høj Christiansen","Niels Ramsing Holm"],"significance":8,"published":"2024-11-09","source_date":"2024-11-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/"],"congress":"","summary_en":"The FAVOR III Europe trial demonstrated that quantitative flow ratio (QFR) was noninferior to fractional flow reserve (FFR) for guiding coronary revascularization decisions. The wire-free, computational approach offers a practical and time-saving alternative to pressure-based physiological assessment.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"34f71d4464f9","type":"article","url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","title":"PREMIER: in-hospital start van sacubitril/valsartan bij acuut hartfalen","title_en":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","nt-probnp","sacubitril-valsartan"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae561","source_url":"https://doi.org/10.1093/eurheartj/ehae561","authors":["Atsushi Tanaka","Keisuke Kida","Yuya Matsue","Takumi Imai","Satoru Suwa","Isao Taguchi","Itaru Hisauchi","Hiroki Teragawa","Yoshiyuki Yazaki","Masao Moroi","Koichi Ohashi","Daisuke Nagatomo","Toru Kubota","Takeshi Ijichi","Yuji Ikari","Keisuke Yonezu","Naohiko Takahashi","Shigeru Toyoda","Tsutomu Toshida","Hiroshi Suzuki","Tohru Minamino","Kazutaka Nogi","Kazuki Shiina","Yu Horiuchi","Kengo Tanabe","Daisuke Hachinohe","Shunsuke Kiuchi","Kenya Kusunose","Michio Shimabukuro","Koichi Node"],"significance":7,"published":"2024-11-08","source_date":"2024-11-08","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"The PREMIER trial demonstrated that in-hospital initiation of sacubitril-valsartan during acute heart failure admission is safe and achieves rapid NT-proBNP reduction, supporting early ARNI initiation in the inpatient setting.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e2f1b5a3c89d","type":"article","url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","title":"Invasieve strategie bij ouderen met MI: gerandomiseerde trial — NEJM","title_en":"Invasive Treatment Strategy for Older Patients with Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2407791","source_url":"https://doi.org/10.1056/NEJMoa2407791","authors":["Vijay Kunadian","Helen Mossop","Carol Shields","Michelle Bardgett","Philippa Watts","M Dawn Teare","Jonathan Pritchard","Jennifer Adams-Hall","Craig Runnett","David P Ripley","Justin Carter","Julie Quigley","Justin Cooke","David Austin","Jerry Murphy","Damian Kelly","James McGowan","Murugapathy Veerasamy","Dirk Felmeden","Hussain Contractor","Sanjay Mutgi","John Irving","Steven Lindsay","Gavin Galasko","Kelvin Lee","Ayyaz Sultan","Amardeep G Dastidar","Shazia Hussain","Iftikhar Ul Haq","Mark de Belder","Martin Denvir","Marcus Flather","Robert F Storey","David E Newby","Stuart J Pocock","Keith A A Fox"],"significance":9,"published":"2024-11-07","source_date":"2024-11-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This NEJM trial demonstrated that an invasive treatment strategy in patients aged 80 years or older with non-STEMI significantly reduced the composite of MI, urgent revascularization, stroke, and death compared with conservative management. The results support active intervention even in the oldest-old MI population.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"966872badc5d","type":"article","url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","title":"Complete versus culprit-only bij ouderen met STEMI: gerandomiseerde trial","title_en":"Complete Versus Culprit-Only Revascularization in Older Patients With ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["percutane-coronaire-interventie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.071493","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.071493","authors":["Gianluca Campo","Felix Böhm","Thomas Engstrøm","Pieter C Smits","Islam Y Elgendy","Gerry P McCann","David A Wood","Matteo Serenelli","Stefan James","Dan Eik Høfsten","Bianca M Boxm-de Klerk","Adrian Banning","John A Cairns","Rita Pavasini","Goran Stankovic","Petr Kala","Henning Kelbæk","Emanuele Barbato","Ilija Srdanovic","Mohamed Hamza","Amerjeet S Banning","Simone Biscaglia","Shamir Mehta"],"significance":8,"published":"2024-11-05","source_date":"2024-11-05","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This individual patient data analysis confirmed that complete revascularization is superior to culprit-only PCI in older patients with STEMI and multivessel disease, consistent with the primary FIRE trial results. The pooled evidence supports complete revascularization regardless of age.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"802396e08d19","type":"article","url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","title":"Bioadaptor implantaat versus drug-eluting stent bij stabiel coronairlijden","title_en":"Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)02227-X","source_url":"https://doi.org/10.1016/S0140-6736(24)02227-X","authors":["David Erlinge","Jonas Andersson","Ole Fröbert","Mattias Törnerud","Mehmet Hamid","Thomas Kellerth","Per Grimfjärd","Oscar Winnberg","Juliane Jurga","Henrik Wagner","Sammy Zwackman","Martin Adielsson","Patrik Alström","Elli Masoe","Anders Ulvenstam","Jonas Millgård","Felix Böhm","Claes Held","Henrik Renlund","Jonas Oldgren","Pieter C Smits","Candace Elek","Andrea Abizaid","Stefan James"],"significance":6,"published":"2024-11-02","source_date":"2024-11-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This Swedish randomized trial of the DynamX bioadaptor implant versus conventional DES tested a next-generation coronary device that adapts to vessel physiology, aiming to improve long-term outcomes beyond static stent platforms.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93ff6b32d7f0","type":"article","url":"https://hartvaat.nl/2024/11/01/multipoint-pacing-verbetert-crt-prognose-en-respons/","title":"Multipoint pacing verbetert CRT-prognose en respons","title_en":"Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae259","source_url":"https://doi.org/10.1093/europace/euae259","authors":["Calò Leonardo","De Ruvo Ermenegildo","Kolb Christof","Janmohamed Amir","Marques Pedro","Defaye Pascal","Marquie Christelle","Piot Olivier","Grammatico Andrea","Lee Kwangdeok","Lin Wenjiao","Burri Haran","Sperzel Johannes","Thibault Bernard","Rinaldi Christopher","Leclercq Christophe"],"significance":6,"published":"2024-11-01","source_date":"2024-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"This MORE-CRT study showed that multipoint pacing improves CRT response rates and prognosis compared with conventional biventricular pacing, supporting programmable multi-electrode stimulation for optimizing resynchronization.","created":"2026-07-03T10:31:17Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"440c0ba02232","type":"article","url":"https://hartvaat.nl/2024/11/01/cultureel-aangepaste-leefstijlinterventie-voor-zuid-aziatische-volwassenen-met-c/","title":"Cultureel aangepaste leefstijlinterventie voor Zuid-Aziatische volwassenen met CV-risico","title_en":"Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2526","source_url":"https://doi.org/10.1001/jamacardio.2024.2526","authors":["Namratha R Kandula","Nirav S Shah","Santosh Kumar","Michael Charley","Margaret Clauson","Nicola Lancki","Emily A Finch","Linda Ehrlich-Jones","Goutham Rao","Bonnie Spring","Nilay S Shah","Juned Siddique"],"significance":6,"published":"2024-11-01","source_date":"2024-11-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The SAHELI trial tested a culturally adapted lifestyle intervention for South Asian adults with cardiovascular risk factors, demonstrating feasibility and effectiveness of ethnically tailored prevention in a high-risk population.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5d8de4175543","type":"article","url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","title":"Sacubitril/valsartan vermindert alle hospitalisaties bij hartfalen: post-hoc analyse","title_en":"Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","hfref","sacubitril-valsartan","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2566","source_url":"https://doi.org/10.1001/jamacardio.2024.2566","authors":["Henri Lu","Brian L Claggett","Milton Packer","Carolyn S P Lam","Karl Swedberg","Jean Rouleau","Michael R Zile","Martin Lefkowitz","Akshay S Desai","Pardeep Jhund","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":6,"published":"2024-11-01","source_date":"2024-11-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This PARADIGM-HF post-hoc analysis showed that sacubitril-valsartan reduces not only heart failure-specific but all-cause hospitalizations, demonstrating a broader healthcare utilization benefit beyond cardiac events.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T18:39:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4fcedba81cc8","type":"article","url":"https://hartvaat.nl/2024/11/01/optimale-antihypertensieve-systolische-bloeddruk-meta-analyse/","title":"Optimale antihypertensieve systolische bloeddruk: meta-analyse","title_en":"Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","baxdrostat","bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23597","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23597","authors":["Paul K Whelton","Samantha O'Connell","Katherine T Mills","Jiang He"],"significance":7,"published":"2024-11-01","source_date":"2024-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"This comprehensive meta-analysis defined the optimal systolic blood pressure target at 120-130 mmHg for maximum cardiovascular protection, providing the quantitative foundation for contemporary blood pressure guidelines.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf70a82c97ac","type":"article","url":"https://hartvaat.nl/2024/11/01/bloeddrukverlagende-medicatie-en-natriumbeperking-gecombineerd-effect/","title":"Bloeddrukverlagende medicatie en natriumbeperking: gecombineerd effect","title_en":"Blood Pressure-Lowering Medications, Sodium Reduction, and Blood Pressure.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23382","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23382","authors":["Jing Song","Liangkai Chen","Hui Xiong","Yuan Ma","Sonia Pombo-Rodrigues","Graham A MacGregor","Feng J He"],"significance":6,"published":"2024-11-01","source_date":"2024-11-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that combining blood pressure-lowering medications with sodium reduction produces greater blood pressure reduction than either alone, with additive effects supporting dual intervention strategies.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e86ab1b3df59","type":"article","url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","title":"IRONMAN: adjudicatie van hospitalisaties en sterfgevallen — heranalyse","title_en":"Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.052","source_url":"https://doi.org/10.1016/j.jacc.2024.08.052","authors":["John G F Cleland","Pierpaolo Pellicori","Fraser J Graham","Rebecca Lane","Mark C Petrie","Fozia Ahmed","Iain B Squire","Andrew Ludman","Alan Japp","Abdallah Al-Mohammad","Andrew L Clark","Ben Szwejkowski","Chris Critoph","Victor Chong","Rebekah Schiff","Thuraia Nageh","Jason Glover","John J V McMurray","Elizabeth A Thomson","Michele Robertson","Ian Ford","Philip A Kalra","Paul R Kalra"],"significance":8,"published":"2024-10-29","source_date":"2024-10-29","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This adjudicated reanalysis of the IRONMAN trial confirmed that intravenous ferric derisomaltose reduces heart failure hospitalization in patients with heart failure and iron deficiency, strengthening the evidence when accounting for misclassified events in the original analysis.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb91ad082dff","type":"article","url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","title":"Asymptomatische versus symptomatische hypotensie bij sacubitril/valsartan en HFrEF","title_en":"Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.012","source_url":"https://doi.org/10.1016/j.jacc.2024.08.012","authors":["Shingo Matsumoto","Li Shen","Alasdair D Henderson","Michael Böhm","Akshay S Desai","Lars Køber","Martin P Lefkowitz","Milton Packer","Jean L Rouleau","Scott D Solomon","Karl Swedberg","Muthiah Vaduganathan","Orly Vardeny","Adriaan A Voors","Michael R Zile","Pardeep S Jhund","John J V McMurray"],"significance":6,"published":"2024-10-29","source_date":"2024-10-29","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This analysis showed that asymptomatic hypotension during sacubitril-valsartan therapy in HFrEF is common but not associated with worse outcomes, supporting continued ARNI therapy despite low blood pressure readings.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f4e23695322c","type":"article","url":"https://hartvaat.nl/2024/10/29/reset-bp-minder-sedentair-gedrag-verlaagt-bloeddruk-bij-kantoorwerkers/","title":"RESET-BP: minder sedentair gedrag verlaagt bloeddruk bij kantoorwerkers","title_en":"Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.068564","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.068564","authors":["Bethany Barone Gibbs","Subashan Perera","Kimberly A Huber","Joshua L Paley","Molly B Conroy","John M Jakicic","Matthew F Muldoon"],"significance":6,"published":"2024-10-29","source_date":"2024-10-29","image":"","kennis":["https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/"],"congress":"","summary_en":"The RESET-BP trial showed that reducing sedentary behavior in office workers significantly lowers blood pressure, demonstrating that simply standing more during the workday has measurable cardiovascular benefit.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ffe79af12142","type":"article","url":"https://hartvaat.nl/2024/10/28/g-csf-voor-stamcelmobilisatie-na-acuut-mi-meta-analyse/","title":"G-CSF voor stamcelmobilisatie na acuut MI: meta-analyse","title_en":"Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-323926","source_url":"https://doi.org/10.1136/heartjnl-2024-323926","authors":["Felice Achilli","Stefano Maggiolini","Fabiana Madotto","Beatrice Bassetti","Francesco Gentile","Aldo Pietro Maggioni","Gualtiero I Colombo","Giulio Pompilio"],"significance":5,"published":"2024-10-28","source_date":"2024-10-28","image":"","kennis":[],"congress":"","summary_en":"The STEM-AMI OUTCOME trial assessed whether early granulocyte colony-stimulating factor administration after large ST-elevation myocardial infarction improves clinical outcomes. G-CSF did not reduce cardiac mortality or morbidity, confirming that stem cell mobilisation offers no proven benefit post-MI.","created":"2026-07-03T10:31:16Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"99056ef56a12","type":"article","url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","title":"FINEARTS-HF: finerenon bij HFmrEF/HFpEF — NEJM","title_en":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["dapa-hf","finearts-hf","finerenon-hartfalen-nierziekte","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2407107","source_url":"https://doi.org/10.1056/NEJMoa2407107","authors":["Scott D Solomon","John J V McMurray","Muthiah Vaduganathan","Brian Claggett","Pardeep S Jhund","Akshay S Desai","Alasdair D Henderson","Carolyn S P Lam","Bertram Pitt","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Imran Zainal Abidin","Marco Antonio Alcocer-Gamba","John J Atherton","Johann Bauersachs","Ma Chang-Sheng","Chern-En Chiang","Ovidiu Chioncel","Vijay Chopra","Josep Comin-Colet","Gerasimos Filippatos","Cândida Fonseca","Grzegorz Gajos","Sorel Goland","Eva Goncalvesova","Seokmin Kang","Tzvetana Katova","Mikhail N Kosiborod","Gustavs Latkovskis","Alex Pui-Wai Lee","Gerard C M Linssen","Guillermo Llamas-Esperón","Vyacheslav Mareev","Felipe A Martinez","Vojtěch Melenovský","Béla Merkely","Savina Nodari","Mark C Petrie","Clara Inés Saldarriaga","Jose Francisco Kerr Saraiva","Naoki Sato","Morten Schou","Kavita Sharma","Richard Troughton","Jacob A Udell","Heikki Ukkonen","Orly Vardeny","Subodh Verma","Dirk von Lewinski","Leonid Voronkov","Mehmet Birhan Yilmaz","Shelley Zieroth","James Lay-Flurrie","Ilse van Gameren","Flaviana Amarante","Peter Kolkhof","Prabhakar Viswanathan"],"significance":10,"published":"2024-10-24","source_date":"2024-10-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"The FINEARTS-HF trial demonstrated that finerenone significantly reduced heart failure events in patients with HFmrEF and HFpEF, extending the benefit of mineralocorticoid receptor antagonism beyond HFrEF. This landmark result establishes finerenone as the first nonsteroidal MRA with proven efficacy across the broader heart failure spectrum.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e17ef45b2ab6","type":"article","url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","title":"Semaglutide en cardiale structuur/functie bij HFpEF: STEP-HFpEF echoanalyse","title_en":"Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["echocardiografie","hfpef","hfref","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.021","source_url":"https://doi.org/10.1016/j.jacc.2024.08.021","authors":["Scott D Solomon","John W Ostrominski","Xiaowen Wang","Sanjiv J Shah","Barry A Borlaug","Javed Butler","Melanie J Davies","Dalane W Kitzman","Subodh Verma","Steen Z Abildstrøm","Mette Nygaard Einfeldt","Søren Rasmussen","Walter P Abhayaratna","Fozia Z Ahmed","Tuvia Ben-Gal","Vijay Chopra","Hiroshi Ito","Bela Merkely","Julio Núñez","Michele Senni","Peter van der Meer","Dennis Wolf","Mark C Petrie","Mikhail N Kosiborod"],"significance":7,"published":"2024-10-22","source_date":"2024-10-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/"],"congress":"","summary_en":"This echocardiographic STEP-HFpEF analysis demonstrated that semaglutide improves LV mass, left atrial volume, and diastolic function parameters in obesity-related HFpEF, showing that weight loss translates to favorable cardiac structural changes.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e102ff29a93","type":"article","url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"AF en semaglutide bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","obesitas","step-hfpef","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.023","source_url":"https://doi.org/10.1016/j.jacc.2024.08.023","authors":["Subodh Verma","Javed Butler","Barry A Borlaug","Melanie J Davies","Dalane W Kitzman","Mark C Petrie","Sanjiv J Shah","Thomas Jon Jensen","Søren Rasmussen","Cecilia Rönnbäck","Bela Merkely","Evan O'Keefe","Mikhail N Kosiborod"],"significance":6,"published":"2024-10-22","source_date":"2024-10-22","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that semaglutide favorably influences AF outcomes in obesity-related HFpEF, with weight loss reducing the atrial mechanical and inflammatory substrate that drives arrhythmia in the obesity phenotype.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c71de50159c","type":"article","url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","title":"Inflammatie bij obesitas-gerelateerd HFpEF: STEP-HFpEF mechanistisch inzicht","title_en":"Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hs-crp","obesitas","step-hfpef","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.028","source_url":"https://doi.org/10.1016/j.jacc.2024.08.028","authors":["Subodh Verma","Mark C Petrie","Barry A Borlaug","Javed Butler","Melanie J Davies","Dalane W Kitzman","Sanjiv J Shah","Cecilia Rönnbäck","Steen Z Abildstrøm","Karoline Liisberg","Dennis Wolf","Dirk von Lewinski","Malgorzata Lelonek","Vojtech Melenovsky","Michele Senni","Mikhail N Kosiborod"],"significance":7,"published":"2024-10-22","source_date":"2024-10-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This STEP-HFpEF analysis showed that semaglutide significantly reduces systemic inflammation (hsCRP, IL-6) in obesity-related HFpEF, supporting the anti-inflammatory mechanism as a key pathway for the cardiovascular benefit of GLP-1 agonists in this phenotype.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d636b55a419d","type":"article","url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","title":"FLOW: semaglutide vermindert hartfalen bij diabetes en CKD","title_en":"Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","cystatine-c","dapagliflozine","diabetes-en-hart","empagliflozine","fidelio-dkd","figaro-dkd","flow-trial","glp1-semaglutide-cardiovasculair","ijzertekort","liraglutide","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial","tirzepatide"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.08.004","source_url":"https://doi.org/10.1016/j.jacc.2024.08.004","authors":["Richard E Pratley","Katherine R Tuttle","Peter Rossing","Søren Rasmussen","Vlado Perkovic","Olav Wendelboe Nielsen","Johannes F E Mann","Richard J MacIsaac","Mikhail N Kosiborod","Zdravko Kamenov","Thomas Idorn","Marco Bo Hansen","Samy Hadjadj","George Bakris","Florian M M Baeres","Kenneth W Mahaffey"],"significance":8,"published":"2024-10-22","source_date":"2024-10-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This FLOW subanalysis demonstrated that semaglutide significantly reduces heart failure events in patients with type 2 diabetes and chronic kidney disease. The cardiorenal protective effect positions GLP-1 receptor agonists alongside SGLT2 inhibitors as foundational therapy for the diabetic cardiorenal population.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"766a5fe23b2c","type":"article","url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","title":"Dieet en AF-risico: systematische review","title_en":"Diet and risk of atrial fibrillation: a systematic review.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae551","source_url":"https://doi.org/10.1093/eurheartj/ehae551","authors":["Monika Gawałko","Melissa E Middeldorp","Arnela Saljic","John Penders","Thomas Jespersen","Christine M Albert","Gregory M Marcus","Christopher X Wong","Prashanthan Sanders","Dominik Linz"],"significance":6,"published":"2024-10-21","source_date":"2024-10-21","image":"","kennis":[],"congress":"","summary_en":"This systematic review showed that the Mediterranean diet is protective against AF, while alcohol increases risk. The findings support dietary counseling as a component of comprehensive AF prevention.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dfcdcd70da50","type":"article","url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","title":"Shensong Yangxin voorkomt AF-recidief na ablatie bij persisterend AF","title_en":"Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae532","source_url":"https://doi.org/10.1093/eurheartj/ehae532","authors":["He Huang","Yu Liu","Wei Shuai","Chenyang Jiang","Menghe Zhang","Xiufen Qu","Wenqing Zheng","Hao Yang","Fan Liu","Bo Yu","Manhua Chen","Bin Mu","Chen Yao","Yanhong Tang","Congxin Huang","Feifan Ouyang","Zhenhua Jia"],"significance":6,"published":"2024-10-21","source_date":"2024-10-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-ckd/"],"congress":"","summary_en":"This randomized trial showed that Shensong Yangxin, a traditional Chinese medicine, reduces AF recurrence after ablation for persistent AF, providing randomized evidence for an herbal anti-arrhythmic approach.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed55583a1fdd","type":"article","url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","title":"Lage-dosis triple combinatiepil bij milde hypertensie: gerandomiseerde trial","title_en":"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01744-6","source_url":"https://doi.org/10.1016/S0140-6736(24)01744-6","authors":["Anthony Rodgers","Abdul Salam","Aletta E Schutte","William C Cushman","H Asita de Silva","Gian Luca Di Tanna","Diederick E Grobbee","Krzysztof Narkiewicz","Dike B Ojji","Neil R Poulter","Markus P Schlaich","Suzanne Oparil","Wilko Spiering","Bryan Williams","Jackson T Wright","P Lakshman","W Uluwattage","P Hay","T Pereira","N Amarasena","G Ranasinghe","Chris Gianacas","Mathangi Shanthakumar","Xiaoqiu Liu","Nelson Wang","Sonali R Gnanenthiran","Paul K Whelton"],"significance":7,"published":"2024-10-19","source_date":"2024-10-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This randomized trial of a low-dose triple single-pill combination (telmisartan/amlodipine/indapamide) demonstrated effective blood pressure lowering in mild hypertension with fewer side effects than individual standard-dose agents.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5286eee1f62","type":"article","url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","title":"BRIGHT-4 bevestiging: bivalirudine superieur aan heparine bij STEMI","title_en":"Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.07.045","source_url":"https://doi.org/10.1016/j.jacc.2024.07.045","authors":["Gregg W Stone","Marco Valgimigli","David Erlinge","Yaling Han","Philippe Gabriel Steg","Rod H Stables","Enrico Frigoli","Stefan K James","Yi Li","Patrick Goldstein","Roxana Mehran","Ghazaleh Mehdipoor","Aaron Crowley","Shmuel Chen","Björn Redfors","Clayton Snyder","Zhipeng Zhou","Behnood Bikdeli"],"significance":7,"published":"2024-10-15","source_date":"2024-10-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"Confirmatory analysis of BRIGHT-4 validated that bivalirudin reduces mortality and bleeding compared with heparin during primary PCI for STEMI, strengthening the evidence for bivalirudin as the preferred anticoagulant in high-risk primary PCI.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fe96f657349e","type":"article","url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","title":"AHA Scientific Statement: nierdisfunctie bij gevorderd hartfalen","title_en":"Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["nt-probnp"],"journal":"Circulation","doi":"10.1161/CIR.0000000000001273","source_url":"https://doi.org/10.1161/CIR.0000000000001273","authors":["W H Wilson Tang","Marie A Bakitas","Xingxing S Cheng","James C Fang","Savitri E Fedson","Amy G Fiedler","Pieter Martens","Wendy I McCallum","Modele O Ogunniyi","Janani Rangaswami","Nisha Bansal"],"significance":7,"published":"2024-10-15","source_date":"2024-10-15","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This AHA scientific statement provided a comprehensive framework for evaluating and managing kidney dysfunction in advanced heart failure, addressing the complex cardiorenal interactions that drive morbidity in this population.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44cfc4da9cff","type":"article","url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","title":"ECLS-SHOCK eenjaarsresultaten: ECMO bij cardiogene shock blijft negatief","title_en":"Routine extracorporeal life support in infarct-related cardiogenic shock: 1-year results of the ECLS-SHOCK trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae610","source_url":"https://doi.org/10.1093/eurheartj/ehae610","authors":["Steffen Desch","Uwe Zeymer","Ibrahim Akin","Michael Behnes","Daniel Duerschmied","Tienush Rassaf","Amir Abbas Mahabadi","Ralf Lehmann","Ingo Eitel","Tobias Graf","Tim Seidler","Andreas Schuster","Tharusan Thevathasan","Carsten Skurk","Peter Clemmensen","Marcus Hennersdorf","Stephan Fichtlscherer","Ingo Voigt","Melchior Seyfarth","Stefan John","Sebastian Ewen","Axel Linke","Eike Tigges","Peter Nordbeck","Leonhard Bruch","Christian Jung","Jutta Franz","Philipp Lauten","Marko Noc","Georg Fuernau","Hans-Josef Feistritzer","Janine Pöss","Eva Kirchhof","Taoufik Ouarrak","Steffen Schneider","Anne Freund","Holger Thiele"],"significance":7,"published":"2024-10-14","source_date":"2024-10-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"One-year ECLS-SHOCK results confirmed that ECMO provides no survival benefit in infarct-related cardiogenic shock, with the initial negative finding persisting over extended follow-up.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e7f9ec7db48","type":"article","url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","title":"REDUCE-AMI: bètablokkers na MI met behouden EF niet nodig — bevestiging","title_en":"Beta-Blocker Interruption or Continuation after Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2404204","source_url":"https://doi.org/10.1056/NEJMoa2404204","authors":["Johanne Silvain","Guillaume Cayla","Emile Ferrari","Grégoire Range","Etienne Puymirat","Nicolas Delarche","Paul Guedeney","Thomas Cuisset","Fabrice Ivanes","Thibault Lhermusier","Thibault Petroni","Gilles Lemesle","François Bresoles","Jean-Noël Labeque","Thibaut Pommier","Jean-Guillaume Dillinger","Florence Leclercq","Franck Boccara","Pascal Lim","Timothée Besseyre des Horts","Thierry Fourme","François Jourda","Alain Furber","Benoit Lattuca","Nassim Redjimi","Christophe Thuaire","Pierre Deharo","Niki Procopi","Raphaelle Dumaine","Michel Slama","Laurent Payot","Mohamad El Kasty","Karim Aacha","Abdourahmane Diallo","Eric Vicaut","Gilles Montalescot"],"significance":10,"published":"2024-10-10","source_date":"2024-10-10","image":"","kennis":[],"congress":"","summary_en":"The REDUCE-AMI trial showed that continuation versus interruption of long-term beta-blocker therapy after myocardial infarction in patients with preserved ejection fraction made no difference in the composite of death or MI. Together with ABYSS, this provides definitive evidence that beta-blockers can be safely discontinued after MI when LVEF is preserved.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec86c8105876","type":"article","url":"https://hartvaat.nl/2024/10/07/semaglutide-en-bloeddruk-ipd-meta-analyse/","title":"Semaglutide en bloeddruk: IPD meta-analyse","title_en":"Semaglutide and blood pressure: an individual patient data meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae564","source_url":"https://doi.org/10.1093/eurheartj/ehae564","authors":["Cormac Kennedy","Peter Hayes","Arrigo F G Cicero","Stephan Dobner","Carel W Le Roux","John W McEvoy","Lina Zgaga","Martina Hennessy"],"significance":8,"published":"2024-10-07","source_date":"2024-10-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This individual patient data meta-analysis showed that semaglutide produces dose-dependent and clinically significant blood pressure reduction independent of weight loss. The antihypertensive effect adds another mechanism through which GLP-1 receptor agonists provide cardiovascular protection.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a68ddc2c268","type":"article","url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","title":"2024 ESC-richtlijn voor management van hypertensie","title_en":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aprocitentan","bloeddrukbehandeling","richtlijnen-esc"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae178","source_url":"https://doi.org/10.1093/eurheartj/ehae178","authors":["John William McEvoy","Cian P McCarthy","Rosa Maria Bruno","Sofie Brouwers","Michelle D Canavan","Claudio Ceconi","Ruxandra Maria Christodorescu","Stella S Daskalopoulou","Charles J Ferro","Eva Gerdts","Henner Hanssen","Julie Harris","Lucas Lauder","Richard J McManus","Gerard J Molloy","Kazem Rahimi","Vera Regitz-Zagrosek","Gian Paolo Rossi","Else Charlotte Sandset","Bart Scheenaerts","Jan A Staessen","Izabella Uchmanowicz","Maurizio Volterrani","Rhian M Touyz"],"significance":10,"published":"2024-10-07","source_date":"2024-10-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/"],"congress":"","summary_en":"The 2024 ESC hypertension guidelines lowered the treatment threshold to 130/80 mmHg and set a target of 120–129/70–79 mmHg for most patients, converging with the evidence from SPRINT and STEP. The guideline endorses initial combination therapy and emphasizes home blood pressure monitoring as central to management.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3eb268899ed2","type":"article","url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","title":"IV ferricarboxymaltose en inspanningscapaciteit bij HFpEF met ijzerdeficiëntie","title_en":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfmref","hfpef","hfref","ijzersuppletie","ijzertekort"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae479","source_url":"https://doi.org/10.1093/eurheartj/ehae479","authors":["Stephan von Haehling","Wolfram Doehner","Ruben Evertz","Tania Garfias-Veitl","Carlotta Derad","Monika Diek","Mahir Karakas","Ralf Birkemeyer","Gerasimos Fillippatos","Mitja Lainscak","Javed Butler","Piotr Ponikowski","Michael Böhm","Tim Friede","Stefan D Anker"],"significance":6,"published":"2024-10-05","source_date":"2024-10-05","image":"","kennis":[],"congress":"","summary_en":"This study of IV ferric carboxymaltose in HFpEF with iron deficiency showed improvement in iron parameters but not exercise capacity, suggesting that the IV iron benefit may be specific to the HFrEF phenotype.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"751e06d7422b","type":"article","url":"https://hartvaat.nl/2024/10/03/uitgebreide-versus-standaard-remote-monitoring-bij-crt-en-hartfalen/","title":"Uitgebreide versus standaard remote monitoring bij CRT en hartfalen","title_en":"Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae233","source_url":"https://doi.org/10.1093/europace/euae233","authors":["Cédric Klein","Claude Kouakam","Arnaud Lazarus","Pascal de Groote","Christophe Bauters","Eloi Marijon","Frédéric Mouquet","Bruno Degand","Yves Guyomar","Jacques Mansourati","Christophe Leclercq","Laurence Guédon-Moreau"],"significance":5,"published":"2024-10-03","source_date":"2024-10-03","image":"","kennis":[],"congress":"","summary_en":"The ECOST-CRT study compared comprehensive remote monitoring — including patient questionnaires and heart failure-specific alerts — with standard remote monitoring in CRT patients. Comprehensive monitoring did not significantly improve clinical outcomes over standard device monitoring.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"313274ef6b89","type":"article","url":"https://hartvaat.nl/2024/10/03/geisoleerde-versus-hybride-thoracoscopische-ablatie-bij-af-korte-en-langetermijn/","title":"Geïsoleerde versus hybride thoracoscopische ablatie bij AF: korte en langetermijn","title_en":"Short- and long-term outcomes in isolated vs. hybrid thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae232","source_url":"https://doi.org/10.1093/europace/euae232","authors":["Luca Aerts","Michal J Kawczynski","Elham Bidar","Justin G L Luermans","Sevasti-Maria Chaldoupi","Mark La Meir","Mariusz Kowalewski","Jos G Maessen","Samuel Heuts","Bart Maesen"],"significance":5,"published":"2024-10-03","source_date":"2024-10-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"A systematic review and individual patient data meta-analysis compared isolated thoracoscopic with hybrid thoracoscopic ablation for atrial fibrillation. The hybrid approach showed superior long-term freedom from atrial tachyarrhythmias, though it involves greater procedural complexity and careful patient selection.","created":"2026-07-03T10:31:14Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"825ed081fc97","type":"article","url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","title":"Patiromer faciliteert RAAS-remmer-optitratie bij HFrEF met hyperkaliëmie","title_en":"Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.079","source_url":"https://doi.org/10.1016/j.jacc.2024.05.079","authors":["Bertram Pitt","Stefan D Anker","Lars H Lund","Andrew J S Coats","Gerasimos Filippatos","Patrick Rossignol","Matthew R Weir","Tim Friede","Mikhail N Kosiborod","Marco Metra","Michael Böhm","Justin A Ezekowitz","Antoni Bayes-Genis","Robert J Mentz","Piotr Ponikowski","Michele Senni","Ileana L Piña","Fausto J Pinto","Peter van der Meer","Cecilia Bahit","Jan Belohlavek","Jasper J Brugts","Amandine Perrin","Sandra Waechter","Jeffrey Budden","Javed Butler"],"significance":7,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This study confirmed that patiromer enables optimization of RAAS inhibitor and MRA therapy in HFrEF patients with hyperkalemia, addressing the potassium barrier that limits guideline-directed heart failure treatment.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da20ab1bef8a","type":"article","url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","title":"Lage-dosis drievoudige pil versus standaardzorg bij hypertensie in Nigeria","title_en":"Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.18080","source_url":"https://doi.org/10.1001/jama.2024.18080","authors":["Dike B Ojji","Abdul Salam","Mahmoud U Sani","Okechukwu S Ogah","Aletta E Schutte","Mark D Huffman","Rashmi Pant","Arpita Ghosh","Rupasvi Dhurjati","Josyula K Lakshmi","Nanna R Ripiye","Ikechukwu A Orji","Shehu A Kana","Tijjani Abdussalam","Abdulgafar L Olawumi","Isiaka M Alfa","Olanike Allison Orimolade","Moses O Ajayi","Anthony Rodgers"],"significance":7,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This randomized trial in Nigeria showed that a low-dose triple combination pill significantly improves blood pressure control compared with standard care, demonstrating the effectiveness of simplified combination therapy in sub-Saharan Africa.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea809623945d","type":"article","url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","title":"PULSE-MI: prehospitale puls-dosis glucocorticoïd bij STEMI","title_en":"Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2298","source_url":"https://doi.org/10.1001/jamacardio.2024.2298","authors":["Jasmine Melissa Madsen","Thomas Engstrøm","Laust Emil Roelsgaard Obling","Yan Zhou","Lars Nepper-Christensen","Rasmus Paulin Beske","Niels Grove Vejlstrup","Lia Evi Bang","Christian Hassager","Fredrik Folke","Kasper Kyhl","Lars Bredevang Andersen","Helle Collatz Christensen","Laura Rytoft","Ketina Arslani","Lene Holmvang","Frants Pedersen","Ole Ahlehoff","Reza Jabbari","Charlotte Barfod","Mikkel Hougaard","Mikko Minkkinen","Hans-Henrik Tilsted","Rikke Sørensen","Jacob Thomsen Lønborg"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":[],"congress":"","summary_en":"The PULSE-MI trial tested prehospital high-dose methylprednisolone in STEMI to attenuate the acute inflammatory response, exploring whether early anti-inflammatory intervention before reperfusion reduces myocardial damage.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f191019c1152","type":"article","url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","title":"AMETHYST: verinurad plus allopurinol bij HFpEF — negatieve trial","title_en":"Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2435","source_url":"https://doi.org/10.1001/jamacardio.2024.2435","authors":["Dalane W Kitzman","Adriaan A Voors","Robert J Mentz","Gregory D Lewis","Shira Perl","Robin Myte","Grace Kaguthi","C David Sjöström","Christian Källgren","Sanjiv J Shah"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"The AMETHYST trial showed that dual uric acid lowering (verinurad plus allopurinol) in HFpEF does not improve clinical outcomes, confirming that uric acid is a biomarker rather than a therapeutic target in heart failure.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8cd6d0bfd7cc","type":"article","url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","title":"Plotse dood na MI: inzichten uit VALIANT en PARADISE-MI","title_en":"Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2356","source_url":"https://doi.org/10.1001/jamacardio.2024.2356","authors":["James P Curtain","Marc A Pfeffer","Eugene Braunwald","Brian L Claggett","Christopher B Granger","Lars Køber","Eldrin F Lewis","Aldo P Maggioni","Doug L Mann","Jean L Rouleau","Scott D Solomon","Philippe Gabriel Steg","Peter V Finn","Alberto Fernandez","Karola S Jering","John J V McMurray"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":[],"congress":"","summary_en":"This analysis of VALIANT and PARADISE-MI showed that sudden death risk after MI has decreased with modern therapy but remains significant, informing the ongoing debate about ICD candidacy and timing after acute coronary events.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2a78b9c1952","type":"article","url":"https://hartvaat.nl/2024/10/01/lage-dosis-doac-versus-dapt-na-laa-occlusie-gerandomiseerde-trial/","title":"Lage-dosis DOAC versus DAPT na LAA-occlusie: gerandomiseerde trial","title_en":"Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["dubbele-trombocytenremming"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2335","source_url":"https://doi.org/10.1001/jamacardio.2024.2335","authors":["Xavier Freixa","Ignacio Cruz-González","Pedro Cepas-Guillén","Xavi Millán","Pablo Antúnez-Muiños","Eduardo Flores-Umanzor","Lluís Asmarats","Ander Regueiro","Sergio López-Tejero","Chi-Hion Pedro Li","Laura Sanchis","Josep Rodés-Cabau","Dabit Arzamendi"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized trial compared low-dose DOAC with DAPT after LAA occlusion, providing the first randomized comparison of antithrombotic regimens in the post-LAAO setting.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6af11e8b3286","type":"article","url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","title":"Draadloos ultrasound-gebaseerd CRT-systeem bij hartfalen","title_en":"Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2050","source_url":"https://doi.org/10.1001/jamacardio.2024.2050","authors":["Jagmeet P Singh","Christopher A Rinaldi","Prashanthan Sanders","Spencer H Kubo","Simon James","Imran K Niazi","Timothy Betts","Christian Butter","Toshimasa Okabe","Ryan Cunnane","Emad Aziz","Mauro Biffi","Amir Zaidi","Jeffrey Alison","Pascal Defaye","Angelo Aurrichio","Michael R Gold","JoAnn Lindenfeld","Tyson Rogers","Mary Norine Walsh"],"significance":7,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study presented a wireless, leadless ultrasound-based cardiac resynchronization system as an alternative to conventional CRT, addressing the 40% of eligible heart failure patients who fail to respond to or cannot receive traditional CRT devices.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"07ee31bb67a5","type":"article","url":"https://hartvaat.nl/2024/10/01/binge-alcoholconsumptie-verhoogt-sympathische-bloeddrukrespons-rct/","title":"Binge-alcoholconsumptie verhoogt sympathische bloeddrukrespons: RCT","title_en":"Binge Alcohol Consumption Elevates Sympathetic Transduction to Blood Pressure: A Randomized Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23416","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23416","authors":["Jeremy A Bigalke","Ian M Greenlund","Tatiana X Solis-Montenegro","John J Durocher","Michael J Joyner","Jason R Carter"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"A randomised controlled trial showed that binge alcohol consumption acutely increases sympathetic vasoconstrictor transduction and blood pressure. This mechanism helps explain the well-established association between alcohol excess and acute cardiovascular events.","created":"2026-07-03T10:31:13Z","updated":"2026-07-03T13:30:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1ed40bcce2b3","type":"article","url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","title":"Neurofilament light chain en CVA-risico bij AF","title_en":"Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069440","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069440","authors":["Julia Aulin","Karl Sjölin","Johan Lindbäck","Alexander P Benz","John W Eikelboom","Ziad Hijazi","Kim Kultima","Jonas Oldgren","Lars Wallentin","Joachim Burman"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that neurofilament light chain, a marker of neuronal damage, predicts stroke risk in AF patients beyond the CHA₂DS₂-VASc score, advancing biomarker-based stroke risk assessment in atrial fibrillation.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T13:30:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c0f716e73a89","type":"article","url":"https://hartvaat.nl/2024/10/01/oraal-butyraat-verlaagt-bloeddruk-bij-hypertensie-rct/","title":"Oraal butyraat verlaagt bloeddruk bij hypertensie: RCT","title_en":"Effects of Oral Butyrate on Blood Pressure in Patients With Hypertension: A Randomized, Placebo-Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22437","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22437","authors":["Barbara J H Verhaar","Madelief Wijdeveld","Koen Wortelboer","Elena Rampanelli","Johannes H M Levels","Didier Collard","Marianne Cammenga","Vanasa Nageswaran","Arash Haghikia","Ulf Landmesser","Xinmin S Li","Joseph A DiDonato","Stanley L Hazen","Ingrid M Garrelds","A H Jan Danser","Bert-Jan H van den Born","Max Nieuwdorp","Majon Muller"],"significance":6,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This randomized trial showed that oral butyrate supplementation reduces blood pressure in hypertensive patients, providing the first interventional evidence for targeting the gut microbiome-blood pressure axis.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a6e4818bdbd","type":"article","url":"https://hartvaat.nl/2024/10/01/af-ablatie-verbetert-uitkomsten-bij-hartfalen-geactualiseerde-meta-analyse/","title":"AF-ablatie verbetert uitkomsten bij hartfalen: geactualiseerde meta-analyse","title_en":"Catheter ablation of atrial fibrillation improves outcomes in heart failure: An updated meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfref","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14919","source_url":"https://doi.org/10.1002/ehf2.14919","authors":["Shingo Kato","Mai Azuma","Sho Kodama","Nobuyuki Horita","Daisuke Utsunomiya"],"significance":7,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This updated meta-analysis confirmed the survival benefit of AF catheter ablation in heart failure patients, with the combined evidence from all available randomized trials providing the strongest case for rhythm control in the HF-AF overlap population.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69e57c6a563a","type":"article","url":"https://hartvaat.nl/2024/10/01/bdnf-en-hartfalen-systematische-review-en-meta-analyse/","title":"BDNF en hartfalen: systematische review en meta-analyse","title_en":"Circulating brain-derived neurotrophic factor levels and heart failure: A systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14916","source_url":"https://doi.org/10.1002/ehf2.14916","authors":["Amir Hossein Behnoush","Amirmohammad Khalaji","Andarz Fazlollahpour-Naghibi","Kimia Bagheri","Parmis Goshtasbi","Ghazal Mohseni","Aouatif Erasmia El Kanty","Caterina Vinciguerra","Alessandro Cannavo"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis demonstrated that brain-derived neurotrophic factor levels are reduced in heart failure and associated with worse outcomes. The neurocardiac axis offers a potentially novel pathophysiological perspective on heart failure progression.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T13:30:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ffa92ec21a7b","type":"article","url":"https://hartvaat.nl/2024/10/01/natriuretische-peptiden-en-crp-bij-hartfalen-en-ondervoeding-systematische-revie/","title":"Natriuretische peptiden en CRP bij hartfalen en ondervoeding: systematische review","title_en":"Natriuretic peptides and C-reactive protein in in heart failure and malnutrition: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cystatine-c","hs-crp","nt-probnp","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14851","source_url":"https://doi.org/10.1002/ehf2.14851","authors":["Konstantinos Prokopidis","Krzysztof Irlik","Hironori Ishiguchi","Willemina Rietsema","Gregory Y H Lip","Rajiv Sankaranarayanan","Masoud Isanejad","Katarzyna Nabrdalik"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"A systematic review explored the interaction between natriuretic peptides, C-reactive protein, and nutritional status in heart failure. Malnutrition influences the interpretation of natriuretic peptide levels, which is clinically relevant for diagnostic and therapeutic decision-making.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2cd7c493313c","type":"article","url":"https://hartvaat.nl/2024/10/01/crt-bij-inotroop-afhankelijk-hartfalen-meta-analyse/","title":"CRT bij inotroop-afhankelijk hartfalen: meta-analyse","title_en":"Cardiac resynchronization therapy in inotrope-dependent heart failure: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14835","source_url":"https://doi.org/10.1002/ehf2.14835","authors":["Nader J Al-Shakarchi","Jamie S Y Ho","Jonathan J H Bray","Fabrizio D'Ascenzo","Edward Duffy","Jack Hewett","Divine Adegbie","Faizullah Khan","Niraj S Kumar","Neal Patel","Mahmood Ahmad","Amitava Banerjee","Ikram Haq","Rui Providencia"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This meta-analysis examined cardiac resynchronisation therapy in patients with inotrope-dependent heart failure. CRT may break inotrope dependence and improve survival, although the available evidence is limited and of low quality.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d240e1331bbf","type":"article","url":"https://hartvaat.nl/2024/10/01/galectine-3-en-langetermijnuitkomsten-bij-hartfalen-meta-analyse/","title":"Galectine-3 en langetermijnuitkomsten bij hartfalen: meta-analyse","title_en":"Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hfref","myocardinfarct","nt-probnp","troponine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14813","source_url":"https://doi.org/10.1002/ehf2.14813","authors":["Wenke Cheng","Rosolowski Maciej","Holger Thiele","Petra Büttner"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"A meta-analysis confirmed that circulating galectin-3 levels predict long-term all-cause mortality and hospitalisation in heart failure patients. The fibrosis biomarker provides additional prognostic value beyond natriuretic peptides and troponin.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T18:39:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8cfa40c91b4c","type":"article","url":"https://hartvaat.nl/2024/10/01/zink-en-koperbiomarkers-en-hartfalen-meta-analyse/","title":"Zink- en koperbiomarkers en hartfalen: meta-analyse","title_en":"Association between biomarkers of zinc and copper status and heart failure: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14837","source_url":"https://doi.org/10.1002/ehf2.14837","authors":["Ruixin Liu","Jiali Yao","Kexian Chen","Wei Peng"],"significance":5,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This meta-analysis found that heart failure patients have lower serum zinc and altered copper levels compared to healthy controls. The clinical utility of these trace elements as biomarkers or therapeutic targets in heart failure requires further investigation.","created":"2026-07-03T10:31:12Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"135be1c52e12","type":"article","url":"https://hartvaat.nl/2024/10/01/catheterablatie-voor-af-bij-hartfalen-meta-analyse-van-rct-s-geactualiseerd/","title":"Catheterablatie voor AF bij hartfalen: meta-analyse van RCT's — geactualiseerd","title_en":"Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfpef","hfref","katheterablatie","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14814","source_url":"https://doi.org/10.1002/ehf2.14814","authors":["Zhongyin Zhang","Yan Zheng","Wenxiu He","Jiahe Wei","Pengzhan Li","Guoqiang Zhong","Zhiyuan Jiang"],"significance":8,"published":"2024-10-01","source_date":"2024-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This updated meta-analysis of randomized trials confirmed that catheter ablation for AF in heart failure significantly reduces mortality and heart failure hospitalization compared with medical therapy, providing the most comprehensive evidence supporting ablation in this dual-disease population.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"65999122bd63","type":"article","url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","title":"2024 ESC-richtlijn voor management van atriumfibrilleren","title_en":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["richtlijnen-esc"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae176","source_url":"https://doi.org/10.1093/eurheartj/ehae176","authors":["Isabelle C Van Gelder","Michiel Rienstra","Karina V Bunting","Ruben Casado-Arroyo","Valeria Caso","Harry J G M Crijns","Tom J R De Potter","Jeremy Dwight","Luigina Guasti","Thorsten Hanke","Tiny Jaarsma","Maddalena Lettino","Maja-Lisa Løchen","R Thomas Lumbers","Bart Maesen","Inge Mølgaard","Giuseppe M C Rosano","Prashanthan Sanders","Renate B Schnabel","Piotr Suwalski","Emma Svennberg","Juan Tamargo","Otilia Tica","Vassil Traykov","Stylianos Tzeis","Dipak Kotecha"],"significance":10,"published":"2024-09-29","source_date":"2024-09-29","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"","summary_en":"The 2024 ESC atrial fibrillation guidelines introduced the AF-CARE pathway (Comorbidities and risk factors, Anticoagulation, Rate and Rhythm control, Evaluation and reassessment) as a structured management approach. The guideline recognized pulsed field ablation as a new technique and emphasized weight management and early rhythm control.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"acef615d3bbe","type":"article","url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","title":"ISCHEMIA: atherosclerosekwantificering en CV-risico","title_en":"Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["atherosclerose","biomarkers-cardiovasculair","dyslipidemie","perifeer-vaatlijden","plaquekarakterisatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae471","source_url":"https://doi.org/10.1093/eurheartj/ehae471","authors":["Nick S Nurmohamed","James K Min","Rebecca Anthopolos","Harmony R Reynolds","James P Earls","Tami Crabtree","G B John Mancini","Jonathon Leipsic","Matthew J Budoff","Cameron J Hague","Sean M O'Brien","Gregg W Stone","Jeffrey S Berger","Robert Donnino","Mandeep S Sidhu","Jonathan D Newman","William E Boden","Bernard R Chaitman","Peter H Stone","Sripal Bangalore","John A Spertus","Daniel B Mark","Leslee J Shaw","Judith S Hochman","David J Maron"],"significance":7,"published":"2024-09-29","source_date":"2024-09-29","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/"],"congress":"","summary_en":"This ISCHEMIA analysis showed that coronary atherosclerosis burden (total plaque volume on CTA) predicts cardiovascular risk independently of treatment strategy, establishing quantitative plaque assessment as a prognostic tool beyond ischemia testing.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6fa322763263","type":"article","url":"https://hartvaat.nl/2024/09/25/obesitasmaten-en-hypertensieve-zwangerschapsstoornissen-meta-analyse-en-mr/","title":"Obesitasmaten en hypertensieve zwangerschapsstoornissen: meta-analyse en MR","title_en":"Impact of multiple obesity metrics on hypertensive disorders of pregnancy: a meta-analysis and Mendelian randomisation study.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["obesitas","select-trial","zwangerschap-hart"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324038","source_url":"https://doi.org/10.1136/heartjnl-2024-324038","authors":["Mengting Sun","Ming Gao","Manjun Luo","Tingting Wang","Xiaorui Ruan","Jiapeng Tang","Qian Chen","Hanjun Liu","Liuxuan Li","Jiabi Qin"],"significance":6,"published":"2024-09-25","source_date":"2024-09-25","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This meta-analysis and Mendelian randomization study showed that multiple obesity metrics (BMI, waist circumference, visceral adiposity) causally increase the risk of hypertensive disorders of pregnancy.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d955e13b3a1d","type":"article","url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","title":"REALITY subanalyse: restrictief transfusiebeleid bij MI en anemie — langere follow-up","title_en":"Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069917","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069917","authors":["Tabassome Simon","Brandon M Herbert","Maria Mori Brooks","Shaun G Goodman","John H Alexander","Philippe Gabriel Steg","Renato D Lopes","Shahab Ghafghazi","Claire Bouleti","Howard A Cooper","Eric L McCamant","Kevin R Bainey","Herbert D Aronow","J Dawn Abbott","Caroline Alsweiler","Marnie Bertolet","Dean A Fergusson","Andrew M Goldsweig","Paul C Hébert","Jeffrey L Carson"],"significance":6,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":[],"congress":"","summary_en":"Extended REALITY follow-up confirmed that restrictive transfusion (hemoglobin <8 g/dL) does not worsen 6-month outcomes in MI patients with anemia, supporting conservative transfusion thresholds in acute coronary care.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d54d7eaed91","type":"article","url":"https://hartvaat.nl/2024/09/24/tight-k-kaliumsuppletie-voorkomt-af-na-hartchirurgie-rct/","title":"TIGHT K: kaliumsuppletie voorkomt AF na hartchirurgie — RCT","title_en":"Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.17888","source_url":"https://doi.org/10.1001/jama.2024.17888","authors":["Benjamin O'Brien","Niall G Campbell","Elizabeth Allen","Zahra Jamal","Joanna Sturgess","Julie Sanders","Charles Opondo","Neil Roberts","Jonathan Aron","Maria Rita Maccaroni","Richard Gould","Bilal H Kirmani","Ben Gibbison","Gudrun Kunst","Alexander Zarbock","Maren Kleine-Brüggeney","Christian Stoppe","Keith Pearce","Mark Hughes","Laura Van Dyck","Richard Evans","Hugh E Montgomery","Diana Elbourne"],"significance":7,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":[],"congress":"","summary_en":"The TIGHT K trial showed that intensive potassium supplementation targeting serum levels ≥4.5 mmol/L significantly reduces postoperative atrial fibrillation after cardiac surgery, validating a simple, low-cost prophylactic strategy.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3fcc1199fd8","type":"article","url":"https://hartvaat.nl/2024/09/24/colchicine-en-coronaire-plaquestabiliteit-na-acs-oct-studie/","title":"Colchicine en coronaire plaquestabiliteit na ACS: OCT-studie","title_en":"Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","colchicine","colcot-trial","intracoronaire-beeldvorming"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069808","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069808","authors":["Miao Yu","Yong Yang","Si-Lai Dong","Chen Zhao","Fen Yang","Yuan-Fan Yuan","Yu-Hua Liao","Shao-Lin He","Kun Liu","Fen Wei","Hai-Bo Jia","Bo Yu","Xiang Cheng"],"significance":7,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This OCT study demonstrated that colchicine improves coronary plaque stability after ACS by increasing fibrous cap thickness, providing a mechanistic explanation for the cardiovascular event reduction observed in COLCOT and CLEAR SYNERGY.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6023854775b5","type":"article","url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","title":"2024 ACC beslispad: klinische beoordeling en trajectmanagement bij HFpEF","title_en":"2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.002","source_url":"https://doi.org/10.1016/j.jacc.2024.06.002","authors":["Steven M Hollenberg","Lynne Warner Stevenson","Tariq Ahmad","Biykem Bozkurt","Javed Butler","Leslie L Davis","Mark H Drazner","James N Kirkpatrick","Alanna A Morris","Robert Lee Page","Hasan Khalid Siddiqi","Alan B Storrow","John R Teerlink"],"significance":8,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The 2024 ACC Expert Consensus provided a structured decision pathway for clinical assessment, management, and trajectory of HFpEF patients during hospitalization, including fluid management, SGLT2 inhibitor initiation, and transition to outpatient care.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ec7eb39ce28","type":"article","url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","title":"Dapagliflozine verbetert arteriële en veneuze compliantie bij HFpEF","title_en":"Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","hfpef","hfref"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.068788","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.068788","authors":["Atsushi Tada","Daniel Burkhoff","Jwan A Naser","Tomonari Harada","Bianca Pourmussa","Yogesh N V Reddy","Michael D Jensen","Rickey E Carter","Ryan T Demmer","Jeffrey M Testani","Julio A Chirinos","Barry A Borlaug"],"significance":6,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This mechanistic study showed that dapagliflozin enhances both arterial and venous compliance during exercise in HFpEF, providing a hemodynamic explanation for improved exercise tolerance with SGLT2 inhibition.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4afee39ee3cc","type":"article","url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","title":"MRA bij hartfalen: IPD meta-analyse bevestigt overlevingsvoordeel","title_en":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01733-1","source_url":"https://doi.org/10.1016/S0140-6736(24)01733-1","authors":["Pardeep S Jhund","Atefeh Talebi","Alasdair D Henderson","Brian L Claggett","Muthiah Vaduganathan","Akshay S Desai","Carolyn S P Lam","Bertram Pitt","Michele Senni","Sanjiv J Shah","Adriaan A Voors","Faiez Zannad","Scott D Solomon","John J V McMurray"],"significance":9,"published":"2024-09-21","source_date":"2024-09-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that mineralocorticoid receptor antagonists significantly improve survival in patients with HFrEF, with consistent benefit across subgroups. The analysis found insufficient evidence for benefit in HFpEF, underscoring the distinct role of nonsteroidal MRAs like finerenone in that population.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aad3199c0c17","type":"article","url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","title":"Sotagliflozine en gezondheidsstatus bij verslechterend hartfalen: SOLOIST-WHF","title_en":"Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["bisoprolol","canagliflozine","empagliflozine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.036","source_url":"https://doi.org/10.1016/j.jacc.2024.06.036","authors":["Ankeet S Bhatt","Deepak L Bhatt","Ph Gabriel Steg","Michael Szarek","Christopher P Cannon","Lawrence A Leiter","Darren K McGuire","Julia B Lewis","Matthew C Riddle","Adriaan A Voors","Marco Metra","Lars H Lund","Jeffrey M Testani","Christopher S Wilcox","Michael Davies","Bertram Pitt","Mikhail N Kosiborod"],"significance":7,"published":"2024-09-17","source_date":"2024-09-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This SOLOIST-WHF analysis showed that sotagliflozin significantly improves health status (symptoms, function, quality of life) in patients with worsening heart failure and diabetes, complementing the hard clinical endpoints with patient-centered outcomes.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7143712b1610","type":"article","url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","title":"2024 ACC/AHA kwaliteitsmaatstaven voor hartfalen geactualiseerd","title_en":"2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.014","source_url":"https://doi.org/10.1016/j.jacc.2024.05.014","authors":["Michelle M Kittleson","Khadijah Breathett","Boback Ziaeian","David Aguilar","Vanessa Blumer","Biykem Bozkurt","Rebecca L Diekemper","Michael P Dorsch","Paul A Heidenreich","Corrine Y Jurgens","Prateeti Khazanie","George Augustine Koromia","Harriette G C Van Spall"],"significance":7,"published":"2024-09-17","source_date":"2024-09-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The updated 2024 ACC/AHA heart failure quality measures integrate SGLT2 inhibitors, intravenous iron, and pulmonary artery pressure monitoring as performance benchmarks, reflecting the evolution of guideline-directed therapy.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8daee1e87cee","type":"article","url":"https://hartvaat.nl/2024/09/16/langetermijn-hartfalenrisico-bij-volwassen-kankeroverlevenden-meta-analyse/","title":"Langetermijn hartfalenrisico bij volwassen kankeroverlevenden: meta-analyse","title_en":"Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","kanker-en-hart","laminopathie","myocardinfarct","nt-probnp","primaire-preventie","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324301","source_url":"https://doi.org/10.1136/heartjnl-2024-324301","authors":["Joshua Wong","Cheng Hwee Soh","Benjamen Wang","Thomas Marwick"],"significance":6,"published":"2024-09-16","source_date":"2024-09-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/nhg-standaard-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This meta-analysis documented the significantly elevated long-term heart failure risk in adult cancer survivors, supporting lifelong cardiovascular surveillance in the growing population of cancer survivorship.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9ab692e23059","type":"article","url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","title":"Tirzepatide en bloeddrukverlaging: SURMOUNT-1 gestratificeerde analyse","title_en":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","obesitas","select-trial","summit-trial"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324170","source_url":"https://doi.org/10.1136/heartjnl-2024-324170","authors":["Harlan M Krumholz","James A de Lemos","Naveed Sattar","Bruno Linetzky","Palash Sharma","Casey J Mast","Nadia N Ahmad","Mathijs C Bunck","Adam Stefanski"],"significance":7,"published":"2024-09-16","source_date":"2024-09-16","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/witte-jas-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This SURMOUNT-1 stratified analysis showed that tirzepatide dose-dependently lowers blood pressure in overweight and obese patients, with the antihypertensive effect contributing to the cardiovascular benefit of incretin-based weight management.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"845c9410110b","type":"article","url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","title":"Spironolacton en urinaire proteomics: evidence uit HOMAGE","title_en":"Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-323796","source_url":"https://doi.org/10.1136/heartjnl-2023-323796","authors":["Yu-Ling Yu","Justyna Siwy","De-Wei An","Arantxa González","Tine Hansen","Agnieszka Latosinska","Pierpaolo Pellicori","Susana Ravassa","Beatrice Mariottoni","Job Aj Verdonschot","Fozia Ahmed","Johannes Petutschnigg","Patrick Rossignol","Stephane Heymans","Joe J Cuthbert","Nicolas Girerd","Andrew L Clark","Peter Verhamme","Tim S Nawrot","Stefan Janssens","John G Cleland","Faiez Zannad","Javier Diez","Harald Mischak","João Pedro Ferreira","Jan A Staessen"],"significance":5,"published":"2024-09-16","source_date":"2024-09-16","image":"","kennis":[],"congress":"","summary_en":"Proteomic analysis from the HOMAGE trial revealed that spironolactone alters specific urinary peptide patterns, predominantly collagen-derived fragments. These findings provide insight into the antifibrotic mechanism and potential biomarkers for predicting mineralocorticoid receptor antagonist response.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee70a4c10e76","type":"article","url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","title":"OCT-geleide versus angiografie-geleide PCI bij ACS: gerandomiseerde trial","title_en":"Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01454-5","source_url":"https://doi.org/10.1016/S0140-6736(24)01454-5","authors":["Sung-Jin Hong","Seung-Jun Lee","Sang-Hyup Lee","Jong-Young Lee","Deok-Kyu Cho","Jin Won Kim","Sang Min Kim","Seung-Ho Hur","Jung Ho Heo","Ji-Yong Jang","Jin Sin Koh","Hoyoun Won","Jun-Won Lee","Soon Jun Hong","Dong-Kie Kim","Jeong Cheon Choe","Jin Bae Lee","Soo-Joong Kim","Tae-Hyun Yang","Jung-Hee Lee","Young Joon Hong","Jong-Hwa Ahn","Yong-Joon Lee","Chul-Min Ahn","Jung-Sun Kim","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Byeong-Keuk Kim"],"significance":6,"published":"2024-09-14","source_date":"2024-09-14","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"This randomized trial comparing OCT-guided with angiography-guided PCI in ACS showed improved procedural results with OCT but no significant reduction in clinical events, consistent with the main ILUMIEN IV findings.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d3998ea70f7","type":"article","url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","title":"Drug-coated balloon versus intended stenting bij de novo coronairlaesies","title_en":"Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01594-0","source_url":"https://doi.org/10.1016/S0140-6736(24)01594-0","authors":["Chao Gao","Xingqiang He","Fan Ouyang","Zhihui Zhang","Guidong Shen","Mingxing Wu","Ping Yang","Likun Ma","Feng Yang","Zheng Ji","Hua Wang","Yanqing Wu","Zhenfei Fang","Hong Jiang","Shangyu Wen","Yi Liu","Fei Li","Jingyu Zhou","Bin Zhu","Yunpeng Liu","Ruining Zhang","Tingting Zhang","Ping Wang","Jianzheng Liu","Zhiwei Jiang","Jielai Xia","Robert-Jan van Geuns","Davide Capodanno","Scot Garg","Yoshinobu Onuma","Duolao Wang","Patrick W Serruys","Ling Tao"],"significance":6,"published":"2024-09-14","source_date":"2024-09-14","image":"","kennis":[],"congress":"","summary_en":"This study compared drug-coated balloon angioplasty with rescue stenting versus intended stenting for de novo coronary lesions, evaluating the leave-nothing-behind approach for native coronary disease.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d7a21ce3032d","type":"article","url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","title":"Temporaire mechanische circulatie bij cardiogene shock: IPD meta-analyse","title_en":"Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01448-X","source_url":"https://doi.org/10.1016/S0140-6736(24)01448-X","authors":["Holger Thiele","Jacob E Møller","Jose P S Henriques","Margriet Bogerd","Melchior Seyfarth","Daniel Burkhoff","Petr Ostadal","Richard Rokyta","Jan Belohlavek","Steffen Massberg","Marcus Flather","Matthias Hochadel","Steffen Schneider","Steffen Desch","Anne Freund","Hans Eiskjær","Norman Mangner","Janine Pöss","Amin Polzin","P Christian Schulze","Carsten Skurk","Uwe Zeymer","Christian Hassager"],"significance":8,"published":"2024-09-14","source_date":"2024-09-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/klepprothese-mechanisch-biologisch/"],"congress":"","summary_en":"This individual patient data meta-analysis of mechanical circulatory support in cardiogenic shock showed that Impella CP (from DanGer Shock) provides survival benefit, while ECMO (from ECLS-SHOCK) does not. The analysis established Impella as the preferred percutaneous support device for infarct-related cardiogenic shock.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"588c46b3947d","type":"article","url":"https://hartvaat.nl/2024/09/14/sekseverschillen-in-fh-behandeling-meta-analyse/","title":"Sekseverschillen in FH-behandeling: meta-analyse","title_en":"Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bloeddrukbehandeling","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","fractional-flow-reserve","ldl-cholesterol","ouderen","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae417","source_url":"https://doi.org/10.1093/eurheartj/ehae417","authors":["Iulia Iatan","Leo E Akioyamen","Isabelle Ruel","Amanda Guerin","Lindsay Hales","Thais Coutinho","Liam R Brunham","Jacques Genest"],"significance":6,"published":"2024-09-14","source_date":"2024-09-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This meta-analysis documented that women with FH achieve significantly lower LDL-cholesterol targets than men despite similar cardiovascular risk, highlighting a sex-based treatment gap in genetic hypercholesterolemia.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da5e3bcf1ca3","type":"article","url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"Semaglutide en diureticagebruik bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfpef","hfref","obesitas","select-trial","step-hfpef","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae322","source_url":"https://doi.org/10.1093/eurheartj/ehae322","authors":["Sanjiv J Shah","Kavita Sharma","Barry A Borlaug","Javed Butler","Melanie Davies","Dalane W Kitzman","Mark C Petrie","Subodh Verma","Shachi Patel","Khaja M Chinnakondepalli","Mette N Einfeldt","Thomas J Jensen","Søren Rasmussen","Rabea Asleh","Tuvia Ben-Gal","Mikhail N Kosiborod"],"significance":6,"published":"2024-09-14","source_date":"2024-09-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This STEP-HFpEF pooled analysis showed that semaglutide reduces diuretic use in obesity-related HFpEF, suggesting that weight loss improves volume status and reduces the need for pharmacological decongestion.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"15b71d8bc293","type":"article","url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","title":"Zodasiran: siRNA tegen ANGPTL3 bij gemengde hyperlipidemie — NEJM","title_en":"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","niet-statine-therapie","ras-remmers","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2404147","source_url":"https://doi.org/10.1056/NEJMoa2404147","authors":["Robert S Rosenson","Daniel Gaudet","Robert A Hegele","Christie M Ballantyne","Stephen J Nicholls","Kathryn J Lucas","Javier San Martin","Rong Zhou","Ma'an Muhsin","Ting Chang","Jennifer Hellawell","Gerald F Watts"],"significance":9,"published":"2024-09-12","source_date":"2024-09-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"This NEJM trial of zodasiran, an siRNA targeting ANGPTL3, demonstrated significant reductions in triglycerides, LDL cholesterol, and non-HDL cholesterol in patients with mixed hyperlipidemia. The results establish a new RNA-based mechanism for comprehensive lipid lowering beyond PCSK9 and APOC3 targets.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c585698e223b","type":"article","url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","title":"Plozasiran: siRNA tegen APOC3 bij gemengde hyperlipidemie — NEJM","title_en":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","niet-statine-therapie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2404143","source_url":"https://doi.org/10.1056/NEJMoa2404143","authors":["Christie M Ballantyne","Szilard Vasas","Masoud Azizad","Peter Clifton","Robert S Rosenson","Ting Chang","Stacey Melquist","Rong Zhou","Ma'an Mushin","Nicholas J Leeper","Jennifer Hellawell","Daniel Gaudet"],"significance":9,"published":"2024-09-12","source_date":"2024-09-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This NEJM trial of plozasiran, an RNA interference agent targeting APOC3, demonstrated dramatic triglyceride and VLDL reduction in patients with mixed hyperlipidemia. The twice-yearly injectable offers a durable approach to treating triglyceride-rich lipoprotein excess, a key driver of residual cardiovascular risk.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a1c5e562dff","type":"article","url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","title":"Triglyceriden, alirocumab en CV-uitkomsten na ACS","title_en":"Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","hypertriglyceridemie","ldl-cholesterol","lipidenverlaging"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.035","source_url":"https://doi.org/10.1016/j.jacc.2024.06.035","authors":["Doron Zahger","Gregory G Schwartz","Weiming Du","Michael Szarek","Deepak L Bhatt","Vera A Bittner","Andrzej J Budaj","Rafael Diaz","Shaun G Goodman","J Wouter Jukema","Robert G Kiss","Robert A Harrington","Patrick M Moriarty","Michel Scemama","Garen Manvelian","Robert Pordy","Harvey D White","Andreas M Zeiher","Sergio Fazio","Gregory P Geba","Ph Gabriel Steg"],"significance":6,"published":"2024-09-10","source_date":"2024-09-10","image":"","kennis":[],"congress":"","summary_en":"This ODYSSEY OUTCOMES analysis showed that higher triglycerides are associated with greater residual cardiovascular risk after ACS, but alirocumab does not specifically modify the triglyceride-related component of risk.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bebc0413893d","type":"article","url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","title":"TACT-2: chelatietherapie na MI bij diabetes — negatieve trial","title_en":"Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["soul-trial"],"journal":"JAMA","doi":"10.1001/jama.2024.11463","source_url":"https://doi.org/10.1001/jama.2024.11463","authors":["Gervasio A Lamas","Kevin J Anstrom","Ana Navas-Acien","Robin Boineau","Hayley Nemeth","Zhen Huang","Jun Wen","Yves Rosenberg","Mario Stylianou","Teresa L Z Jones","Bonnie R Joubert","Qilu Yu","Regina M Santella","Ana C Mon","Francisco Ujueta","Esteban Escolar","David M Nathan","Vivian A Fonseca","Y Wady Aude","Jonathan K Ehrman","Thomas Elliott","Rakesh Prashad","Eldrin F Lewis","Renato D Lopes","Michael E Farkouh","Anne-Marie Elliott","Jonathan D Newman","Daniel B Mark"],"significance":7,"published":"2024-09-10","source_date":"2024-09-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The TACT-2 trial showed that EDTA-based chelation therapy after MI in diabetic patients did not significantly reduce cardiovascular events, failing to replicate the positive signal from the original TACT trial.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9318a5f26d9a","type":"article","url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","title":"De-escalatie naar ticagrelor monotherapie bij diabetespatiënten na ACS","title_en":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["diabetes-en-hart","diabetes-type-1"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01616-7","source_url":"https://doi.org/10.1016/S0140-6736(24)01616-7","authors":["Marco Valgimigli","Sung-Jin Hong","Felice Gragnano","Konstantina Chalkou","Anna Franzone","Bruno R da Costa","Usman Baber","Byeong-Keuk Kim","Yangsoo Jang","Shao-Liang Chen","Gregg W Stone","Joo-Yong Hahn","Stephan Windecker","Michael C Gibson","Young Bin Song","Zhen Ge","Pascal Vranckx","Shamir Mehta","Hyeon-Cheol Gwon","Renato D Lopes","George D Dangas","Eùgene P McFadden","Dominick J Angiolillo","Sergio Leonardi","Dik Heg","Paolo Calabrò","Peter Jüni","Roxana Mehran","Myeong-Ki Hong"],"significance":6,"published":"2024-09-07","source_date":"2024-09-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This analysis confirmed that de-escalation to ticagrelor monotherapy after short DAPT is equally safe and effective in diabetic and non-diabetic ACS patients, supporting the strategy across glycemic status.","created":"2026-07-03T10:31:09Z","updated":"2026-07-03T13:30:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04cf1a35c7c0","type":"article","url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","title":"Semaglutide bij HFmrEF/HFpEF: gerandomiseerde trial","title_en":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["dapa-hf","select-trial","step-hfpef","summit-trial"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01643-X","source_url":"https://doi.org/10.1016/S0140-6736(24)01643-X","authors":["Mikhail N Kosiborod","John Deanfield","Richard Pratley","Barry A Borlaug","Javed Butler","Melanie J Davies","Scott S Emerson","Steven E Kahn","Dalane W Kitzman","Ildiko Lingvay","Kenneth W Mahaffey","Mark C Petrie","Jorge Plutzky","Søren Rasmussen","Cecilia Rönnbäck","Sanjiv J Shah","Subodh Verma","Peter E Weeke","A Michael Lincoff"],"significance":9,"published":"2024-09-07","source_date":"2024-09-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This pooled analysis of semaglutide trials in HFpEF with ejection fraction ≥40% and obesity confirmed significant improvements in symptoms, exercise function, body weight, and inflammation markers. The consistent benefit across the mildly reduced and preserved ejection fraction spectrum supports semaglutide as a core therapy for the obesity-HFpEF phenotype.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e0556a1eea7","type":"article","url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","title":"AUGUSTUS 4-weg vergelijking: antitrombotische strategieën bij AF na ACS/PCI","title_en":"Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.022","source_url":"https://doi.org/10.1016/j.jacc.2024.06.022","authors":["Otavio Berwanger","Daniel M Wojdyla","Alexander C Fanaroff","Andrzej Budaj","Christopher B Granger","Roxana Mehran","Ronald Aronson","Stephan Windecker","Shaun G Goodman","John H Alexander","Renato D Lopes"],"significance":7,"published":"2024-09-03","source_date":"2024-09-03","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This comprehensive AUGUSTUS four-way comparison confirmed that apixaban plus a P2Y12 inhibitor (without aspirin) is the optimal antithrombotic strategy for AF patients after ACS and/or PCI, providing the definitive analysis of the 2×2 factorial design.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"293599ee221a","type":"article","url":"https://hartvaat.nl/2024/09/01/dapagliflozine-en-rv-pulmonale-interactie-bij-hfpef/","title":"Dapagliflozine en RV-pulmonale interactie bij HFpEF","title_en":"Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","dapagliflozine","empagliflozine"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1914","source_url":"https://doi.org/10.1001/jamacardio.2024.1914","authors":["Yogesh N V Reddy","Rickey E Carter","Hidemi Sorimachi","Massar Omar","Dejana Popovic","Alessio Alogna","Michael D Jensen","Barry A Borlaug"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that dapagliflozin improves the right ventricular-pulmonary vascular interaction during exercise in HFpEF, demonstrating that SGLT2 inhibition benefits the right heart hemodynamics in preserved ejection fraction.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"935cc2fff4b2","type":"article","url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","title":"ADAPTABLE: bijdrage van klinische trial-data naar databron","title_en":"Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.2019","source_url":"https://doi.org/10.1001/jamacardio.2024.2019","authors":["Jennifer A Rymer","Hillary Mulder","Lisa M Wruck","Daniel Muñoz","Sunil Kripalani","Mark B Effron","Kamal Gupta","Eileen Handberg","Sandeep Jain","Saket Girotra","Jeffrey Whittle","Rachel Hess","Catherine P Benziger","Kirk U Knowlton","Lesley H Curtis","Matthew T Roe","Bradley G Hammill","Russell L Rothman","Robert Harrington","Adrian Hernandez","W Schuyler Jones"],"significance":5,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":[],"congress":"","summary_en":"A methodological analysis of the ADAPTABLE trial assessed the contribution of different data sources to clinical endpoint ascertainment in pragmatic trials. Electronic health records and insurance claims provided complementary information, informing future pragmatic trial design.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"474bf3230c74","type":"article","url":"https://hartvaat.nl/2024/09/01/strip-20-jaarsresultaten-van-dieetinterventie-vanaf-de-zuigelingenleeftijd/","title":"STRIP: 20-jaarsresultaten van dieetinterventie vanaf de zuigelingenleeftijd","title_en":"Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae423","source_url":"https://doi.org/10.1093/eurheartj/ehae423","authors":["Oskari Repo","Markus Juonala","Harri Niinikoski","Suvi Rovio","Juha Mykkänen","Hanna Lagström","Carol Y Cheung","Dawei Yang","Hanna Vaahtoranta-Lehtonen","Antti Jula","Jaakko Nevalainen","Tapani Rönnemaa","Jorma Viikari","Olli Raitakari","Robyn Tapp","Katja Pahkala"],"significance":7,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/"],"congress":"","summary_en":"This 20-year STRIP follow-up showed that dietary intervention from infancy produces lasting favorable effects on cardiovascular risk factors and retinal microvasculature, demonstrating that lifelong cardiovascular health begins with childhood nutrition.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de5c7174c2e3","type":"article","url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","title":"Aspirinedosering voor secundaire preventie bij mannen versus vrouwen","title_en":"Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts"],"tags":["aspirine"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1712","source_url":"https://doi.org/10.1001/jamacardio.2024.1712","authors":["Catherine P Benziger","Amanda Stebbins","Lisa M Wruck","Mark B Effron","Guillaume Marquis-Gravel","Peter M Farrehi","Saket Girotra","Kamal Gupta","Sunil Kripalani","Daniel Munoz","Tamar S Polonsky","Amber Sharlow","Jeffrey Whittle","Robert A Harrington","Russell L Rothman","Adrian F Hernandez","W Schuyler Jones"],"significance":5,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This ADAPTABLE secondary analysis examined whether aspirin dose (81 mg vs 325 mg) for secondary cardiovascular prevention differs in effectiveness by sex. No significant sex-based differences were found, supporting standard low-dose aspirin for both men and women.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"071965354dc5","type":"article","url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","title":"ELDERCARE-AF subanalyse: dosisreductie edoxaban bij ≥80-jarigen met AF","title_en":"Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1793","source_url":"https://doi.org/10.1001/jamacardio.2024.1793","authors":["André Zimerman","Eugene Braunwald","Jan Steffel","Nicolas M Van Mieghem","Michael G Palazzolo","Sabina A Murphy","Cathy Zi Li Chen","Martin Unverdorben","Christian T Ruff","Elliott M Antman","Robert P Giugliano"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This ELDERCARE-AF post-hoc analysis confirmed that the 15 mg edoxaban dose remains effective and safe across different clinical scenarios in very elderly AF patients, supporting low-dose anticoagulation in the oldest population.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"488bd1424c25","type":"article","url":"https://hartvaat.nl/2024/09/01/lerodalcibep-bij-ascvd-of-hoog-risico-fase-3-resultaten/","title":"Lerodalcibep bij ASCVD of hoog risico: fase 3 resultaten","title_en":"Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1659","source_url":"https://doi.org/10.1001/jamacardio.2024.1659","authors":["Eric Q Klug","Sara Llerena","Lesley J Burgess","Nyda Fourie","Russell Scott","Jeff Vest","Kate Caldwell","David Kallend","Evan A Stein"],"significance":7,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"Phase 3 data for lerodalcibep showed sustained LDL cholesterol reduction in patients with or at high risk of ASCVD. The monthly subcutaneous PCSK9 fusion protein offers a new dosing interval option in the evolving lipid-lowering landscape.","created":"2026-07-03T10:31:08Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37d65fb80a1e","type":"article","url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","title":"POST-PCI subanalyse: routine stresstesten niet zinvol bij ACS noch stabiel","title_en":"Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome: A Secondary Analysis of the POST-PCI Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1556","source_url":"https://doi.org/10.1001/jamacardio.2024.1556","authors":["Jinho Lee","Do-Yoon Kang","Hoyun Kim","Yeonwoo Choi","Sangyong Jo","Jung-Min Ahn","Seonok Kim","Yong-Hoon Yoon","Seung-Ho Hur","Cheol Hyun Lee","Won-Jang Kim","Se Hun Kang","Chul Soo Park","Bong-Ki Lee","Jung-Won Suh","Jae Woong Choi","Kee-Sik Kim","Su Nam Lee","Seung-Jung Park","Duk-Woo Park"],"significance":5,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":[],"congress":"","summary_en":"A POST-PCI subanalysis confirmed that routine functional stress testing 12 months after PCI provides no incremental benefit in either acute coronary syndrome or stable patients. Symptom-guided follow-up is sufficient for both groups.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d57d35172420","type":"article","url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","title":"Multifactorieel intensief bloeddrukmodel bij ouderen en jongeren","title_en":"Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1449","source_url":"https://doi.org/10.1001/jamacardio.2024.1449","authors":["Xiaofan Guo","Nanxiang Ouyang","Guozhe Sun","Naijin Zhang","Zhao Li","Xingang Zhang","Guangxiao Li","Chang Wang","Lixia Qiao","Ying Zhou","Zihan Chen","Chuning Shi","Songyue Liu","Wei Miao","Danxi Geng","Pengyu Zhang","Yingxian Sun"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This randomized study showed that non-physician community healthcare practitioner-led intensive blood pressure intervention is comparably effective in older and younger individuals with hypertension, supporting scalable models for aggressive BP control.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b9fdbba4c802","type":"article","url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","title":"Ticagrelor monotherapie na ACS: IPD meta-analyse van vier trials","title_en":"Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae249","source_url":"https://doi.org/10.1093/eurheartj/ehae249","authors":["Yong-Joon Lee","Sanghoon Shin","Sung Woo Kwon","Yongsung Suh","Kyeong Ho Yun","Tae Soo Kang","Jun-Won Lee","Deok-Kyu Cho","Jong-Kwan Park","Jang-Whan Bae","Woong Cheol Kang","Seunghwan Kim","Seung-Jun Lee","Sung-Jin Hong","Chul-Min Ahn","Jung-Sun Kim","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Yangsoo Jang","Myeong-Ki Hong"],"significance":8,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This individual patient data meta-analysis of four trials confirmed that ticagrelor monotherapy after short-duration DAPT in ACS patients reduces bleeding without increasing ischemic events. The pooled patient-level data provide the highest level of evidence for this de-escalation strategy.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40267e452de5","type":"article","url":"https://hartvaat.nl/2024/09/01/periprocedureel-mi-na-pci-en-langetermijnmortaliteit-meta-analyse/","title":"Periprocedureel MI na PCI en langetermijnmortaliteit: meta-analyse","title_en":"Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae266","source_url":"https://doi.org/10.1093/eurheartj/ehae266","authors":["Luca Paolucci","Fabio Mangiacapra","Sara Sergio","Annunziata Nusca","Carlo Briguori","Emanuele Barbato","Gian Paolo Ussia","Francesco Grigioni"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This meta-analysis confirmed that periprocedural MI after PCI is associated with increased long-term mortality, with the risk proportional to the biomarker elevation, supporting the prognostic significance of procedural myocardial injury.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e59858b12ea8","type":"article","url":"https://hartvaat.nl/2024/09/01/hypertensieduur-en-effect-van-intensieve-bloeddrukbehandeling/","title":"Hypertensieduur en effect van intensieve bloeddrukbehandeling","title_en":"Impact of Hypertension Duration on the Cardiovascular Benefit of Intensive Blood Pressure Control.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23439","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23439","authors":["Qianhui Ling","Xilan Dong","Jingjing Bai","Yue Deng","Qirui Song","Jun Cai"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/"],"congress":"","summary_en":"This analysis showed that the cardiovascular benefit of intensive blood pressure control is consistent regardless of hypertension duration, supporting aggressive treatment even in long-standing hypertension.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21bf6617fcbb","type":"article","url":"https://hartvaat.nl/2024/09/01/nieuwe-metabolieten-geassocieerd-met-bloeddrukrespons-op-dieetinterventies/","title":"Nieuwe metabolieten geassocieerd met bloeddrukrespons op dieetinterventies","title_en":"Novel Metabolites Associated With Blood Pressure After Dietary Interventions.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["metabole-acidose"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.22999","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.22999","authors":["Yixi Sun","Ruiyuan Zhang","Ling Tian","Yang Pan","Xiao Sun","Zhijie Huang","Jia Fan","Jing Chen","Kai Zhang","Shengxu Li","Wei Chen","Lydia A Bazzano","Tanika N Kelly","Jiang He","Joshua D Bundy","Changwei Li"],"significance":5,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":[],"congress":"","summary_en":"A metabolomics study identified novel metabolites associated with blood pressure changes following dietary interventions including DASH and sodium restriction. These biomarkers may help predict individual responsiveness to dietary blood pressure-lowering strategies.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e6d4c03b5693","type":"article","url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","title":"Troponine, NT-proBNP en cognitieve uitkomsten in SPRINT","title_en":"High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","nt-probnp","trombocytenaggregatieremmers","troponine"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.22876","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.22876","authors":["Devin Haney","Yuan Ma","Djhenne Dalmacy","Nicholas M Pajewski","Ihab Hajjar","James A de Lemos","Wenxin Zhang","Elsayed Z Soliman","Christie M Ballantyne","Vijay Nambi","Naveed Sattar","Anthony A Killeen","Joachim H Ix","Michael G Shlipak","Jarett D Berry","Simon B Ascher"],"significance":6,"published":"2024-09-01","source_date":"2024-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/"],"congress":"","summary_en":"This SPRINT analysis showed that higher cardiac biomarkers (troponin, NT-proBNP) at baseline are associated with worse cognitive outcomes, linking subclinical cardiac injury to brain health in hypertensive patients.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03b107baad4a","type":"article","url":"https://hartvaat.nl/2024/08/30/simultane-hybride-ablatie-versus-thoracoscopische-chirurgische-ablatie-bij-persi/","title":"Simultane hybride ablatie versus thoracoscopische chirurgische ablatie bij persisterend AF","title_en":"Comparing simultaneous hybrid ablation with stand-alone thoracoscopic surgical ablation for the treatment of non-paroxysmal atrial fibrillation: a prospective randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae226","source_url":"https://doi.org/10.1093/europace/euae226","authors":["Zhe Zheng","Yan Yao","Haojie Li","Chunyu Yu","Lihui Zheng","Ligang Ding","Lingmin Wu","Sipeng Chen","Hengqiang Lin","Ying Meng"],"significance":6,"published":"2024-08-30","source_date":"2024-08-30","image":"","kennis":[],"congress":"","summary_en":"This study showed that simultaneous hybrid ablation (combined surgical and catheter approaches in one session) is superior to stand-alone thoracoscopic surgical ablation for non-paroxysmal AF.","created":"2026-07-03T10:31:07Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41b54fa42242","type":"article","url":"https://hartvaat.nl/2024/08/27/stop-semaglutide-vermindert-epicardiaal-vetweefsel-bij-type-2-diabetes/","title":"STOP: semaglutide vermindert epicardiaal vetweefsel bij type 2 diabetes","title_en":"Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","figaro-dkd","select-trial","semaglutide","soul-trial","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.065","source_url":"https://doi.org/10.1016/j.jacc.2024.05.065","authors":["Venkat Sanjay Manubolu","Suvasini Lakshmanan","April Kinninger","Khadije Ahmad","Shriraj Susarla","Hoon J Seok","Sajad Hamal","Suraj Dahal","Sion K Roy","Matthew J Budoff"],"significance":6,"published":"2024-08-27","source_date":"2024-08-27","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The STOP trial showed that semaglutide significantly reduces epicardial adipose tissue in patients with type 2 diabetes, providing mechanistic insight into how GLP-1 agonists may protect the heart through pericardial fat reduction.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2263b581e52d","type":"article","url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","title":"STEP-HFpEF: semaglutide even effectief bij mannen en vrouwen","title_en":"Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.001","source_url":"https://doi.org/10.1016/j.jacc.2024.06.001","authors":["Subodh Verma","Javed Butler","Barry A Borlaug","Melanie Davies","Dalane W Kitzman","Sanjiv J Shah","Mark C Petrie","Eric Barros","Cecilia Rönnbäck","Lene Sommer Vestergaard","Morten Schou","Justin A Ezekowitz","Kavita Sharma","Shachi Patel","Khaja M Chinnakondepalli","Mikhail N Kosiborod"],"significance":6,"published":"2024-08-27","source_date":"2024-08-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This sex-stratified STEP-HFpEF analysis confirmed that semaglutide provides equal benefit in men and women with obesity-related HFpEF, addressing the important question of sex-equal efficacy in the female-predominant HFpEF population.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f6dad34ee9e","type":"article","url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","title":"SELECT subanalyse: semaglutide verbetert CV-uitkomsten bij obesitas met hartfalen","title_en":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","empagliflozine","glp1-semaglutide-cardiovasculair","hfref","obesitas","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01498-3","source_url":"https://doi.org/10.1016/S0140-6736(24)01498-3","authors":["John Deanfield","Subodh Verma","Benjamin M Scirica","Steven E Kahn","Scott S Emerson","Donna Ryan","Ildiko Lingvay","Helen M Colhoun","Jorge Plutzky","Mikhail N Kosiborod","G Kees Hovingh","Søren Hardt-Lindberg","Ofir Frenkel","Peter E Weeke","Søren Rasmussen","Assen Goudev","Chim C Lang","Miguel Urina-Triana","Mikko Pietilä","A Michael Lincoff"],"significance":8,"published":"2024-08-24","source_date":"2024-08-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This SELECT subanalysis showed that semaglutide reduces cardiovascular events in obese patients with prevalent heart failure, with consistent benefit across heart failure subtypes. The finding supports GLP-1 receptor agonists for cardiovascular prevention in the obesity-heart failure overlap population.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4c0dd335d436","type":"article","url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","title":"PA-drukmonitoring bij chronisch hartfalen: effecten over klinische subgroepen","title_en":"Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["chronische-nierziekte","hfmref","hfpef","hfref","step-hfpef","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae323","source_url":"https://doi.org/10.1093/eurheartj/ehae323","authors":["Pascal R D Clephas","Victor W Zwartkruis","Jishnu Malgie","Marco W F van Gent","Hans-Peter Brunner-La Rocca","Mariusz K Szymanski","Vokko P van Halm","M Louis Handoko","Wouter E M Kok","Folkert W Asselbergs","Roland R J van Kimmenade","Olivier C Manintveld","Nicolas M D A van Mieghem","Saskia L M A Beeres","Marco C Post","C Jan Willem Borleffs","Raymond Tukkie","Arend Mosterd","Gerard C M Linssen","Ruud F Spee","Mireille E Emans","Tom D J Smilde","Jan van Ramshorst","Charles J H J Kirchhof","Margriet W Feenema-Aardema","Carlos A da Fonseca","Mieke van den Heuvel","Ronald Hazeleger","Martijn van Eck","Loek van Heerebeek","Eric Boersma","Michiel Rienstra","Rudolf A de Boer","Jasper J Brugts"],"significance":7,"published":"2024-08-21","source_date":"2024-08-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This MONITOR-HF analysis showed that pulmonary artery pressure monitoring provides benefit across all clinically relevant heart failure subgroups, including HFrEF, HFmrEF, and HFpEF, supporting universal hemodynamic-guided management.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44530ab64959","type":"article","url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","title":"Tadalafil bij gecombineerde post- en precapillaire PH en HFpEF","title_en":"Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069340","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069340","authors":["Marius M Hoeper","Britta Oerke","Max Wissmüller","Hanno Leuchte","Christian Opitz","Michael Halank","Hans-Juergen Seyfarth","Stephan Baldus","Johann Bauersachs","Michael Böhm","Hossein-Ardeschir Ghofrani","Stavros Konstantinides","Karen M Olsson","Rolf Wachter","Carolyn S P Lam","Behnaz Aminossadati","Stephan Rosenkranz"],"significance":6,"published":"2024-08-20","source_date":"2024-08-20","image":"","kennis":[],"congress":"","summary_en":"This study evaluated tadalafil for combined pre- and post-capillary pulmonary hypertension in HFpEF, showing modest hemodynamic improvement but failing to demonstrate robust clinical benefit for phosphodiesterase-5 inhibition in this phenotype.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"667f8271c47f","type":"article","url":"https://hartvaat.nl/2024/08/16/impella-cp-bij-door-mi-gecompliceerde-cardiogene-shock-journal-scan/","title":"Impella CP bij door MI gecompliceerde cardiogene shock: journal scan","title_en":"Weekly Journal Scan: Impella CP in myocardial infarction complicated by cardiogenic shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae306","source_url":"https://doi.org/10.1093/eurheartj/ehae306","authors":["Rocco Vergallo","Daniela Pedicino"],"significance":5,"published":"2024-08-16","source_date":"2024-08-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"An overview of the DanGer Shock trial results discussed the clinical implications of Impella CP mechanical circulatory support in myocardial infarction complicated by cardiogenic shock. Impella CP is the first mechanical support device with demonstrated mortality benefit in this setting.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"729be151c9d4","type":"article","url":"https://hartvaat.nl/2024/08/13/anti-il-6-therapie-bij-acuut-mi-fase-iia-trial/","title":"Anti-IL-6 therapie bij acuut MI: fase IIa trial","title_en":"Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069396","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069396","authors":["Antonio Abbate","Benjamin Van Tassell","Vlad Bogin","Roshanak Markley","Dmitry V Pevzner","Paul C Cremer","Imad Meray","Dmitry V Privalov","Angela Taylor","Sergey A Grishin","Alina N Egorova","Ekaterina G Ponomar","Yan Lavrovsky","Mikhail Yu Samsonov"],"significance":7,"published":"2024-08-13","source_date":"2024-08-13","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This phase IIa trial of interleukin-6 blockade in acute MI demonstrated significant reduction in hsCRP, testing a more targeted anti-inflammatory approach than IL-1β inhibition for attenuating the acute inflammatory response after myocardial infarction.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c16b9e8abd6c","type":"article","url":"https://hartvaat.nl/2024/08/06/perioperatief-management-van-antitrombotische-therapie-actueel-overzicht/","title":"Perioperatief management van antitrombotische therapie: actueel overzicht","title_en":"Perioperative Management of Antithrombotic Therapy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["anticoagulantia","bloeddrukbehandeling","trombose"],"journal":"JAMA","doi":"10.1001/jama.2024.5880","source_url":"https://doi.org/10.1001/jama.2024.5880","authors":["Maureen D Lyons","Bailey Pope","Jason Alexander"],"significance":6,"published":"2024-08-06","source_date":"2024-08-06","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/linkerhartoorkluiting/"],"congress":"","summary_en":"This JAMA Clinical Guidelines Synopsis summarized the ACCP guidelines on perioperative management of antithrombotic therapy, providing practical guidance for bridging anticoagulants and managing antiplatelets around surgical procedures.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a8eb96977e61","type":"article","url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","title":"RACING subanalyse: matige statine plus ezetimibe voor secundaire preventie","title_en":"Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065520","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065520","authors":["Katsumi Miyauchi","Hiroshi Iwata","Yuji Nishizaki","Teruo Inoue","Atsushi Hirayama","Kazuo Kimura","Yukio Ozaki","Toyoaki Murohara","Kenji Ueshima","Yoshihiro Kuwabara","Sachiko Tanaka-Mizuno","Naotake Yanagisawa","Tosiya Sato","Hiroyuki Daida"],"significance":7,"published":"2024-08-06","source_date":"2024-08-06","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"","summary_en":"This RACING subanalysis confirmed that moderate-intensity statin plus ezetimibe is equally effective as high-intensity statin for secondary cardiovascular prevention, with consistent results across different patient subgroups.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d560042ed8f","type":"article","url":"https://hartvaat.nl/2024/08/06/doac-bij-heartmate-3-lvad-eerste-gerandomiseerde-trial/","title":"DOAC bij HeartMate 3 LVAD: eerste gerandomiseerde trial","title_en":"A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["pathfinder-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069726","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069726","authors":["Ivan Netuka","Zuzana Tucanova","Peter Ivak","Stanislav Gregor","Dushan Michael Kolesar","Tomas Marek","Vojtech Melenovsky","Jana Binova","Zora Dorazilova","Marketa Hegarova","Martina Podolec","Hynek Riha","Jean M Connors","Mandeep R Mehra"],"significance":7,"published":"2024-08-06","source_date":"2024-08-06","image":"","kennis":[],"congress":"","summary_en":"This first randomized trial of DOAC therapy in patients with the HeartMate 3 LVAD explored whether direct oral anticoagulants can replace warfarin for anticoagulation in mechanically supported patients, potentially simplifying long-term management.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"840dd5a235ea","type":"article","url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","title":"Device-algoritmen voor RV-pacingminimalisatie: meta-analyse van uitkomsten","title_en":"Systematic review and meta-analysis on the impact on outcomes of device algorithms for minimizing right ventricular pacing.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae212","source_url":"https://doi.org/10.1093/europace/euae212","authors":["Davide Antonio Mei","Jacopo Francesco Imberti","Marco Vitolo","Niccolò Bonini","Kevin Serafini","Marta Mantovani","Enrico Tartaglia","Chiara Birtolo","Marco Zuin","Matteo Bertini","Giuseppe Boriani"],"significance":6,"published":"2024-08-03","source_date":"2024-08-03","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that device algorithms minimizing right ventricular pacing improve clinical outcomes including reduced AF and heart failure, supporting the programming of RV pacing avoidance modes in pacemaker patients.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0a7577af4fe","type":"article","url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","title":"Dagontslag versus overnachting na AF-ablatie: uitgebreide meta-analyse","title_en":"Same-day discharge vs. overnight stay following catheter ablation for atrial fibrillation: a comprehensive review and meta-analysis by the European Heart Rhythm Association Health Economics Committee.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae200","source_url":"https://doi.org/10.1093/europace/euae200","authors":["Maura M Zylla","Jacopo F Imberti","Francisco Leyva","Ruben Casado-Arroyo","Frieder Braunschweig","Helmut Pürerfellner","José L Merino","Giuseppe Boriani"],"significance":6,"published":"2024-08-03","source_date":"2024-08-03","image":"","kennis":[],"congress":"","summary_en":"This comprehensive meta-analysis confirmed that same-day discharge after AF catheter ablation is safe and equivalent to overnight observation, supporting outpatient ablation as a standard approach.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35928a4fcaea","type":"article","url":"https://hartvaat.nl/2024/08/03/cardiale-shockwave-therapie-bij-cabg-verbetert-myocardfunctie/","title":"Cardiale shockwave-therapie bij CABG verbetert myocardfunctie","title_en":"Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bradycardie","cardiogene-shock","hypertrofische-cardiomyopathie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae341","source_url":"https://doi.org/10.1093/eurheartj/ehae341","authors":["Johannes Holfeld","Felix Nägele","Leo Pölzl","Clemens Engler","Michael Graber","Jakob Hirsch","Sophia Schmidt","Agnes Mayr","Felix Troger","Mathias Pamminger","Markus Theurl","Michael Schreinlechner","Nikolay Sappler","Elfriede Ruttmann-Ulmer","Wolfgang Schaden","John P Cooke","Hanno Ulmer","Axel Bauer","Can Gollmann-Tepeköylü","Michael Grimm"],"significance":6,"published":"2024-08-03","source_date":"2024-08-03","image":"","kennis":[],"congress":"","summary_en":"This study showed that cardiac shockwave therapy as an adjunct to CABG improves myocardial function in ischemic regions, exploring a non-invasive mechanical stimulation approach for enhancing surgical revascularization outcomes.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"026f4fe6c3b8","type":"article","url":"https://hartvaat.nl/2024/08/03/anticoagulatie-bij-postoperatief-af-na-geisoleerde-cabg-meta-analyse/","title":"Anticoagulatie bij postoperatief AF na geïsoleerde CABG: meta-analyse","title_en":"Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","rivaroxaban"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae267","source_url":"https://doi.org/10.1093/eurheartj/ehae267","authors":["Mileen R D van de Kar","Thomas J van Brakel","Marcel Van't Veer","Gijs J van Steenbergen","Edgar J Daeter","Harry J G M Crijns","Dennis van Veghel","Lukas R C Dekker","Luuk C Otterspoor"],"significance":6,"published":"2024-08-03","source_date":"2024-08-03","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated anticoagulation for post-operative AF after CABG, finding limited but suggestive evidence that anticoagulation may reduce stroke risk in patients who develop AF after cardiac surgery.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09c138d17b5f","type":"article","url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","title":"Catheterablatie bij persisterend AF: recidiefpatronen en kwaliteit van leven","title_en":"Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilization.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae291","source_url":"https://doi.org/10.1093/eurheartj/ehae291","authors":["Rose Crowley","David Chieng","Hariharan Sugumar","Liang-Han Ling","Louise Segan","Jeremy William","Sandeep Prabhu","Aleksandr Voskoboinik","Geoffrey Wong","Joseph B Morton","Geoffrey Lee","Alex J McLellan","Michael Wong","Rajeev K Pathak","Laurence Sterns","Matthew Ginks","Prashanthan Sanders","Jonathan M Kalman","Peter M Kistler"],"significance":5,"published":"2024-08-03","source_date":"2024-08-03","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study characterised recurrence patterns following catheter ablation for persistent atrial fibrillation and their impact on quality of life. Despite arrhythmia recurrences, quality of life improved significantly, broadening the definition of ablation success beyond rhythm control alone.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"441d62c36be7","type":"article","url":"https://hartvaat.nl/2024/08/01/baroreflexactivatietherapie-bij-resistente-hypertensie-sham-gecontroleerde-pilot/","title":"Baroreflexactivatietherapie bij resistente hypertensie: sham-gecontroleerde pilotstudie","title_en":"Sham-Controlled Randomized Pilot Trial on Baroreflex Activation Therapy in Resistant Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23088","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23088","authors":["Johan R Simonsen","Leena Vikatmaa","Pirkka Vikatmaa","Mika Laine","Hanna Granroth-Wilding","Per-Henrik Groop","Ilkka Tikkanen","Daniel Gordin"],"significance":6,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This sham-controlled pilot study of baroreflex activation therapy in resistant hypertension showed significant blood pressure reduction, providing early evidence for this device-based neuromodulation approach.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c295a2865e58","type":"article","url":"https://hartvaat.nl/2024/08/01/sociale-determinanten-en-hypertensie-uitkomsten-systematische-review/","title":"Sociale determinanten en hypertensie-uitkomsten: systematische review","title_en":"Impact of Social Determinants of Health on Hypertension Outcomes: A Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","primaire-preventie","stress-psychosociaal","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22571","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22571","authors":["Faith E Metlock","Thomas Hinneh","Chitchanok Benjasirisan","Abeer Alharthi","Oluwabunmi Ogungbe","Ruth-Alma N Turkson-Ocran","Cheryl R Himmelfarb","Yvonne Commodore-Mensah"],"significance":5,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/psychosociale-risicofactoren-hart/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This systematic review documented the impact of social determinants of health on hypertension outcomes. Socioeconomic status, race/ethnicity, and healthcare access significantly influence blood pressure control, underscoring the need for targeted public health interventions.","created":"2026-07-03T10:31:05Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"50a1b3190d1b","type":"article","url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","title":"Sarcopenie en intensieve bloeddrukbehandeling: SPRINT subanalyse","title_en":"Relationship Between Sarcopenia and Intensive Blood Pressure Control Efficacy and Safety: A Secondary Analysis of SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.23011","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23011","authors":["Saeid Mirzai","Ian Persits","Richard Kazibwe","Mohanad Gabani","Austin Seals","Matthew J Singleton","Rishi Rikhi","Parag A Chevli","Salvatore Carbone","W H Wilson Tang","Joseph Yeboah","Jeff D Williamson","Dalane W Kitzman","David M Herrington","Michael D Shapiro"],"significance":5,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"A SPRINT secondary analysis assessed whether sarcopenia modifies the efficacy and safety of intensive blood pressure treatment. Sarcopenic patients experienced comparable cardiovascular benefit and safety, supporting intensive blood pressure targets in this vulnerable population.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c12461c228a9","type":"article","url":"https://hartvaat.nl/2024/08/01/alcohol-en-hypertensierisico-dosis-respons-meta-analyse-van-niet-experimentele-s/","title":"Alcohol en hypertensierisico: dosis-respons meta-analyse van niet-experimentele studies","title_en":"Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["alcoholgebruik"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.22703","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.22703","authors":["Marta Cecchini","Tommaso Filippini","Paul K Whelton","Inga Iamandii","Silvia Di Federico","Giuseppe Boriani","Marco Vinceti"],"significance":6,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This comprehensive dose-response meta-analysis confirmed that any alcohol consumption increases hypertension risk with no safe threshold, reinforcing alcohol reduction as a blood pressure management strategy.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T18:39:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d753e6f5b4e","type":"article","url":"https://hartvaat.nl/2024/08/01/adaptieve-atriale-pacing-gereguleerd-door-bloeddruk-pilotstudie/","title":"Adaptieve atriale pacing gereguleerd door bloeddruk: pilotstudie","title_en":"Safety and efficacy of adaptive atrial pacing regulated by blood pressure during low-level exercise: a proof-of-concept study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["bloeddrukbehandeling"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14854","source_url":"https://doi.org/10.1002/ehf2.14854","authors":["Michael Burnam","Robert Develle","Leo Polosajian","Shakeh Nalbandian","Kenneth Ellenbogen","Eli Gang"],"significance":5,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":[],"congress":"","summary_en":"This proof-of-concept study evaluated a novel pacing algorithm that modulates atrial pacing rate based on blood pressure measurements during exercise. The approach was feasible and may improve physiological responses in pacemaker patients with heart failure with preserved ejection fraction.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"846e99169008","type":"article","url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","title":"Candesartan dosering bij mannen versus vrouwen met chronisch hartfalen","title_en":"Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14715","source_url":"https://doi.org/10.1002/ehf2.14715","authors":["Hailun Qin","Pooja Dewan","Bernadet T Santema","Jozine M Ter Maaten","Karl Swedberg","John J V McMurray","Adriaan A Voors"],"significance":5,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"Analysis of the CHARM programme showed that women with heart failure achieved lower doses of candesartan than men yet experienced comparable clinical benefit. These findings support consideration of lower dose targets in women with heart failure.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9989c55bce31","type":"article","url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","title":"Coronaire microvasculaire disfunctie bij HFpEF: meta-analyse","title_en":"Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["microcirculatie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14626","source_url":"https://doi.org/10.1002/ehf2.14626","authors":["Domenico D'Amario","Renzo Laborante","Emiliano Bianchini","Giuseppe Ciliberti","Donato Antonio Paglianiti","Mattia Galli","Attilio Restivo","Davide Stolfo","Rocco Vergallo","Giuseppe M C Rosano","Filippo Crea","Carolyn S P Lam","Lars H Lund","Marco Metra","Giuseppe Patti","Gianluigi Savarese"],"significance":6,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis documented that coronary microvascular dysfunction is highly prevalent in HFpEF and is associated with worse exercise capacity and prognosis, supporting the microvascular hypothesis of HFpEF pathophysiology.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bf95f719b2f6","type":"article","url":"https://hartvaat.nl/2024/08/01/echocardiografische-monitoring-bij-heartmate-3-systematische-review/","title":"Echocardiografische monitoring bij HeartMate 3: systematische review","title_en":"Echocardiographic haemodynamic monitoring in the context of HeartMate 3™ therapy: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14759","source_url":"https://doi.org/10.1002/ehf2.14759","authors":["Linus Ohlsson","Joanna-Maria Papageorgiou","Tino Ebbers","Meriam Åström Aneq","Éva Tamás","Hans Granfeldt"],"significance":5,"published":"2024-08-01","source_date":"2024-08-01","image":"","kennis":[],"congress":"","summary_en":"A systematic review summarised echocardiographic haemodynamic monitoring strategies in patients with the HeartMate 3 left ventricular assist device. Standardised echocardiographic protocols are essential for optimal device management and early detection of complications.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e3f926f646e","type":"article","url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","title":"ARTESIA: apixaban versus aspirine naar CHA₂DS₂-VASc bij subclinisch AF","title_en":"Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.002","source_url":"https://doi.org/10.1016/j.jacc.2024.05.002","authors":["Renato D Lopes","Christopher B Granger","Daniel M Wojdyla","William F McIntyre","Marco Alings","Thenmozhi Mani","Chinthanie Ramasundarahettige","Lena Rivard","Dan Atar","David H Birnie","Giuseppe Boriani","Guy Amit","Peter Leong-Sit","Claus Rinne","Gabor Z Duray","Michael R Gold","Stefan H Hohnloser","Valentina Kutyifa","Juan Benezet-Mazuecos","Jens Cosedis Nielsen","Christian Sticherling","Alexander P Benz","Cecilia Linde","Joseph Kautzner","Philippe Mabo","Georges H Mairesse","Stuart J Connolly","Jeff S Healey"],"significance":7,"published":"2024-07-23","source_date":"2024-07-23","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"","summary_en":"This ARTESIA subanalysis showed that the benefit of apixaban over aspirin for device-detected subclinical AF increases with higher CHA₂DS₂-VASc scores, supporting risk-stratified anticoagulation decisions for subclinical arrhythmia.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42271dbade4e","type":"article","url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","title":"Snelle optitratie van neurohormonale blokkade en duurzame decongestie bij HF","title_en":"Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","carvedilol","nt-probnp"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.055","source_url":"https://doi.org/10.1016/j.jacc.2024.04.055","authors":["Jan Biegus","Alexandre Mebazaa","Beth Davison","Gad Cotter","Christopher Edwards","Jelena Čelutkienė","Ovidiu Chioncel","Alain Cohen-Solal","Gerasimos Filippatos","Maria Novosadova","Karen Sliwa","Marianna Adamo","Mattia Arrigo","Carolyn S P Lam","Jozine M Ter Maaten","Benjamin Deniau","Marianela Barros","Kamilė Čerlinskaitė-Bajorė","Albertino Damasceno","Rafael Diaz","Etienne Gayat","Antoine Kimmoun","Peter S Pang","Matteo Pagnesi","Hadiza Saidu","Koji Takagi","Daniela Tomasoni","Adriaan A Voors","Marco Metra","Piotr Ponikowski"],"significance":6,"published":"2024-07-23","source_date":"2024-07-23","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study showed that rapid up-titration of neurohormonal blockade during heart failure hospitalization durably improves decongestion and reduces residual congestion, supporting the STRONG-HF approach of aggressive inpatient optimization.","created":"2026-07-03T10:31:04Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a34347d5fa58","type":"article","url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","title":"Sacubitril/valsartan en cognitieve functie bij HFpEF","title_en":"Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","bloeddrukbehandeling","sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.068774","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.068774","authors":["Pooja Dewan","Li Shen","João Pedro Ferreira","Pardeep S Jhund","Inder S Anand","Alvin Chandra","Lu-May Chiang","Brian Claggett","Akshay S Desai","Jianjian Gong","Carolyn S P Lam","Martin P Lefkowitz","Aldo P Maggioni","Felipe Martinez","Milton Packer","Margaret M Redfield","Jean L Rouleau","Dirk J van Veldhuisen","Faiez Zannad","Michael R Zile","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2024-07-23","source_date":"2024-07-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This analysis confirmed that sacubitril-valsartan does not impair cognitive function in HFpEF patients, addressing the theoretical concern that neprilysin inhibition might affect amyloid-beta clearance in the brain.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"268e9899b8fe","type":"article","url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","title":"ILUMIEN IV: OCT-geleide PCI bij complexe laesies — subanalyse","title_en":"OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.037","source_url":"https://doi.org/10.1016/j.jacc.2024.04.037","authors":["Ziad A Ali","Ulf Landmesser","Akiko Maehara","Doosup Shin","Koshiro Sakai","Mitsuaki Matsumura","Richard A Shlofmitz","David Leistner","Paolo Canova","Fernando Alfonso","Franco Fabbiocchi","Giulio Guagliumi","Matthew J Price","Jonathan M Hill","Takashi Akasaka","Francesco Prati","Hiram G Bezerra","William Wijns","Robert J McGreevy","Robert W McNutt","Hong Nie","Kanitha Phalakornkule","Jana Buccola","Gregg W Stone"],"significance":6,"published":"2024-07-23","source_date":"2024-07-23","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"This ILUMIEN IV substudy in complex lesions showed a trend toward better outcomes with OCT-guided PCI, suggesting that intravascular imaging may be most valuable when anatomical complexity demands optimized stent deployment.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a6a9338da15b","type":"article","url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","title":"Anatomische versus viabiliteitsgerichte completeness van revascularisatie","title_en":"Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.043","source_url":"https://doi.org/10.1016/j.jacc.2024.04.043","authors":["Saad M Ezad","Margaret McEntegart","Matthew Dodd","Matthaios Didagelos","Novalia Sidik","Matthew Li Kam Wa","Holly P Morgan","Antonis Pavlidis","Roshan Weerackody","Simon J Walsh","James C Spratt","Julian Strange","Peter Ludman","Amedeo Chiribiri","Tim Clayton","Mark C Petrie","Peter O'Kane","Divaka Perera"],"significance":6,"published":"2024-07-23","source_date":"2024-07-23","image":"","kennis":[],"congress":"","summary_en":"This analysis compared anatomical versus viability-guided complete revascularization in ischemic cardiomyopathy, showing that viability-guided strategy is at least as effective, supporting targeted intervention based on myocardial viability.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5225f4b99812","type":"article","url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","title":"SBP <120 versus <140 mmHg bij hoog CV-risico: meta-analyse van intensieve behandeling","title_en":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","farmaco-economie","fidelity","fractional-flow-reserve","obesitas","ouderen","secundaire-preventie","slaapapneu","summit-trial","supraventriculaire-tachycardie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)01028-6","source_url":"https://doi.org/10.1016/S0140-6736(24)01028-6","authors":["Jiamin Liu","Yan Li","Jinzhuo Ge","Xiaofang Yan","Haibo Zhang","Xin Zheng","Jiapeng Lu","Xi Li","Yan Gao","Lubi Lei","Jing Liu","Jing Li"],"significance":8,"published":"2024-07-20","source_date":"2024-07-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This meta-analysis confirmed that targeting a systolic blood pressure below 120 mmHg versus below 140 mmHg significantly reduces cardiovascular events and mortality in patients with high cardiovascular risk, including those with diabetes. The data reinforce aggressive blood pressure targets.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ffbea3d7129","type":"article","url":"https://hartvaat.nl/2024/07/16/rich-life-gelijkwaardige-hypertensiezorg-voor-achtergestelde-populaties/","title":"RICH LIFE: gelijkwaardige hypertensiezorg voor achtergestelde populaties","title_en":"Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","cardiorenal-behandelstrategie","chronische-nierziekte","renale-denervatie","vrouwen","zwangerschap-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069622","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069622","authors":["Lisa A Cooper","Jill A Marsteller","Kathryn A Carson","Katherine B Dietz","Romsai T Boonyasai","Carmen Alvarez","Deidra C Crews","Cheryl R Dennison Himmelfarb","Chidinma A Ibe","Lisa Lubomski","Edgar R Miller","Nae-Yuh Wang","Gideon D Avornu","Deven Brown","Debra Hickman","Michelle Simmons","Ariella Apfel Stein","Hsin-Chieh Yeh"],"significance":7,"published":"2024-07-16","source_date":"2024-07-16","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"The RICH LIFE cluster-randomized trial demonstrated that a multifactorial intervention targeting health equity improves blood pressure control and patient-reported outcomes in underserved communities with hypertension disparities.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6839c92ce6be","type":"article","url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","title":"Revascularisatiestrategieën na MI: systematische review en meta-analyse","title_en":"Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.051","source_url":"https://doi.org/10.1016/j.jacc.2024.04.051","authors":["Rohin K Reddy","James P Howard","Yasser Jamil","Mahesh V Madhavan","Michael G Nanna","Alexandra J Lansky","Martin B Leon","Yousif Ahmad"],"significance":7,"published":"2024-07-16","source_date":"2024-07-16","image":"","kennis":[],"congress":"","summary_en":"This systematic review and network meta-analysis compared PCI strategies after MI (complete vs culprit, FFR-guided vs routine), confirming that complete revascularization provides the best outcomes with either physiological or angiographic guidance.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7425a2e325e3","type":"article","url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","title":"Interventie voor evidence-based zorg bij diabetes en CV-risico","title_en":"Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","ezetimibe","farmaco-economie","fidelio-dkd","figaro-dkd","liraglutide","obesitas","primaire-preventie","select-trial","semaglutide","soul-trial","summit-trial","tirzepatide"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.068962","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.068962","authors":["Manasi Tannu","Lisa Kaltenbach","Neha J Pagidipati","Darren K McGuire","Vanita R Aroda","Rodica Pop-Busui","Nitin Kondamudi","Hussein R Al-Khalidi","Renato D Lopes","Matthew A Cavender","Adam J Nelson","Julienne Kirk","Ildiko Lingvay","Melissa Magwire","Caroline Regina Richardson","Laura Webb","Monica Leyva","Ambarish Pandey","Alana Washington","Jonathan Pak","Tanya Gaynor","Waqar Khan","Patrick Weston","Christopher B Granger","Jennifer Green"],"significance":6,"published":"2024-07-16","source_date":"2024-07-16","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This study evaluated an intervention to improve evidence-based therapy in diabetic patients with cardiovascular risk, demonstrating that structured cardiology clinic-based programs increase prescription of cardiometabolic medications.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9aa126f0aa70","type":"article","url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"Semaglutide en NYHA-klasse bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas","select-trial","step-hfpef","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.038","source_url":"https://doi.org/10.1016/j.jacc.2024.04.038","authors":["Morten Schou","Mark C Petrie","Barry A Borlaug","Javed Butler","Melanie J Davies","Dalane W Kitzman","Sanjiv J Shah","Subodh Verma","Shachi Patel","Khaja M Chinnakondepalli","Signe Harring","Steen Z Abildstrøm","Karoline Liisberg","Mikhail N Kosiborod"],"significance":7,"published":"2024-07-16","source_date":"2024-07-16","image":"","kennis":[],"congress":"","summary_en":"This STEP-HFpEF analysis showed that semaglutide significantly improves NYHA functional class in obesity-related HFpEF, with more patients achieving NYHA class I and fewer remaining in class III, demonstrating meaningful functional improvement.","created":"2026-07-03T10:31:03Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5158b555199e","type":"article","url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","title":"CONVINCE: langetermijn colchicine voor preventie van recidief niet-cardioembolisch CVA — Lancet","title_en":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00968-1","source_url":"https://doi.org/10.1016/S0140-6736(24)00968-1","authors":["Peter Kelly","Robin Lemmens","Christian Weimar","Cathal Walsh","Francisco Purroy","Mark Barber","Ronan Collins","Simon Cronin","Anna Czlonkowska","Philippe Desfontaines","Adinda De Pauw","Nicholas Richard Evans","Urs Fischer","Catarina Fonseca","John Forbes","Michael D Hill","Dalius Jatuzis","Janika Kõrv","Peter Kraft","Christina Kruuse","Catherine Lynch","Dominick McCabe","Robert Mikulik","Sean Murphy","Paul Nederkoorn","Martin O'Donnell","Peter Sandercock","Bernadette Schroeder","Gek Shim","Katrina Tobin","David J Williams","Christopher Price"],"significance":8,"published":"2024-07-13","source_date":"2024-07-13","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"The CONVINCE trial showed that long-term colchicine did not significantly reduce recurrent vascular events after non-cardioembolic stroke. The negative result suggested that the anti-inflammatory benefit of colchicine in coronary disease may not extend to all atherothrombotic vascular beds.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efb957692132","type":"article","url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","title":"Evinacumab bij homozygote FH: langetermijn veiligheid en effectiviteit","title_en":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae325","source_url":"https://doi.org/10.1093/eurheartj/ehae325","authors":["Daniel Gaudet","Susanne Greber-Platzer","Laurens F Reeskamp","Gabriella Iannuzzo","Robert S Rosenson","Samir Saheb","Claudia Stefanutti","Erik Stroes","Albert Wiegman","Traci Turner","Shazia Ali","Poulabi Banerjee","Tiera Drewery","Jennifer McGinniss","Alpana Waldron","Richard T George","Xue-Qiao Zhao","Robert Pordy","Jian Zhao","Eric Bruckert","Frederick J Raal"],"significance":7,"published":"2024-07-12","source_date":"2024-07-12","image":"","kennis":[],"congress":"","summary_en":"Long-term data confirmed the sustained safety and efficacy of evinacumab in homozygous FH, with durable LDL cholesterol reduction and no emergence of late adverse effects, supporting long-term ANGPTL3 inhibition for this severe genetic disorder.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e6e6c1d1b56a","type":"article","url":"https://hartvaat.nl/2024/07/12/aerobe-kracht-of-gecombineerde-training-en-cv-risicoprofiel-bij-obesitas/","title":"Aerobe, kracht- of gecombineerde training en CV-risicoprofiel bij obesitas","title_en":"Aerobic, resistance, or combined exercise training and its outcomes on cardiovascular risk profile in overweight or obese adults via a CardioRACE trial: a gap.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":["obesitas"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae233","source_url":"https://doi.org/10.1093/eurheartj/ehae233","authors":["André Pontes-Silva","André Luiz Lopes"],"significance":5,"published":"2024-07-12","source_date":"2024-07-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This review summarised the cardiovascular risk reduction effects of aerobic, resistance, and combined exercise training in overweight or obese adults. Combined aerobic and resistance training offered the broadest benefits across blood pressure, lipids, and insulin sensitivity.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8420c9b01a92","type":"article","url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","title":"NSTE-ACS na CABG: meta-analyse van behandelstrategieën","title_en":"Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae245","source_url":"https://doi.org/10.1093/eurheartj/ehae245","authors":["Matthew Kelham","Rohan Vyas","Rohini Ramaseshan","Krishnaraj Rathod","Robbert J de Winter","Ruben W de Winter","Bjorn Bendz","Holger Thiele","Geir Hirlekar","Nuccia Morici","Aung Myat","Lampros K Michalis","Juan Sanchis","Vijay Kunadian","Colin Berry","Anthony Mathur","Daniel A Jones"],"significance":5,"published":"2024-07-12","source_date":"2024-07-12","image":"","kennis":[],"congress":"","summary_en":"A meta-analysis compared invasive versus conservative management of non-ST-elevation acute coronary syndromes in patients with previous coronary artery bypass grafting. Outcomes were worse than in native coronary disease, and the optimal strategy varies by individual patient characteristics.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b3b7465d8a0","type":"article","url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","title":"FLOW: semaglutide beschermt nieren bij type 2 diabetes en CKD — NEJM-gerelateerd","title_en":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","cystatine-c","diabetes-en-hart","diabetes-type-2","fidelio-dkd","figaro-dkd","flow-trial","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2403347","source_url":"https://doi.org/10.1056/NEJMoa2403347","authors":["Vlado Perkovic","Katherine R Tuttle","Peter Rossing","Kenneth W Mahaffey","Johannes F E Mann","George Bakris","Florian M M Baeres","Thomas Idorn","Heidrun Bosch-Traberg","Nanna Leonora Lausvig","Richard Pratley"],"significance":10,"published":"2024-07-11","source_date":"2024-07-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The FLOW trial demonstrated that semaglutide significantly slowed kidney disease progression in patients with type 2 diabetes and CKD, reducing the composite of sustained eGFR decline, kidney failure, and renal or cardiovascular death. The trial was stopped early for efficacy, establishing GLP-1 receptor agonists as a new renoprotective therapy alongside SGLT2 inhibitors.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0d683185adb","type":"article","url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","title":"Intracoronaire trombolyse bij STEMI: meta-analyse","title_en":"Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324078","source_url":"https://doi.org/10.1136/heartjnl-2024-324078","authors":["Rajan Rehan","Sohaib Virk","Christopher C Y Wong","Freda Passam","Jamie Layland","Anthony Keech","Andy Yong","Harvey D White","William Fearon","Martin Ng"],"significance":5,"published":"2024-07-10","source_date":"2024-07-10","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This meta-analysis evaluated adjunctive intracoronary thrombolytic therapy during primary PCI for ST-elevation myocardial infarction. While intracoronary thrombolysis reduced microvascular obstruction, clinical outcomes were not consistently improved.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62e77988f7f6","type":"article","url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","title":"Bempedoïnezuur versus statines: vergelijking van CV-voordelen","title_en":"Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["clear-outcomes"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.048","source_url":"https://doi.org/10.1016/j.jacc.2024.04.048","authors":["A Michael Lincoff","Kausik K Ray","William J Sasiela","Tariq Haddad","Stephen J Nicholls","Na Li","Leslie Cho","Denise Mason","Peter Libby","Shaun G Goodman","Steven E Nissen"],"significance":7,"published":"2024-07-09","source_date":"2024-07-09","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This comparative analysis showed that bempedoic acid provides similar cardiovascular risk reduction per unit of LDL cholesterol lowering as statins, confirming that the LDL-lowering hypothesis holds regardless of the pharmacological mechanism.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9be46703e7c9","type":"article","url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","title":"Cangrelor en infarctgrootte bij STEMI: gerandomiseerde trial","title_en":"Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aperitif-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.068938","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.068938","authors":["Heerajnarain Bulluck","Jun Hua Chong","Jennifer Bryant","Annitha Annathurai","Ping Chai","Mervyn Chan","Ashish Chawla","Chee Yang Chin","Yiu-Cho Chung","Fei Gao","Hee Hwa Ho","Andrew Fu Wah Ho","John Hoe","Syed Saqib Imran","Chi-Hang Lee","Benji Lim","Soo Teik Lim","Swee Han Lim","Boon Wah Liew","Patrick Lim Zhan Yun","Marcus Eng Hock Ong","Valeria Paradies","Xuan Ming Pung","Julian Cheong Kiat Tay","Lynette Teo","Boon Ping Ting","Aaron Wong","Evelyn Wong","Timothy Watson","Mark Y Chan","Yeo Khung Keong","Jack W C Tan","Derek J Hausenloy"],"significance":6,"published":"2024-07-09","source_date":"2024-07-09","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that cangrelor at reperfusion does not significantly reduce infarct size in STEMI compared with standard care, a negative result for intravenous antiplatelet therapy as a cardioprotective adjunct.","created":"2026-07-03T10:31:02Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4dffcfefcd5","type":"article","url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","title":"Selectieve aldosereductaseremmer bij diabetische cardiomyopathie: RCT","title_en":"Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","figaro-dkd","gedilateerde-cardiomyopathie","iaso-dcm"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.380","source_url":"https://doi.org/10.1016/j.jacc.2024.03.380","authors":["James L Januzzi","Javed Butler","Stefano Del Prato","Justin A Ezekowitz","Nasrien E Ibrahim","Carolyn S P Lam","Gregory D Lewis","Thomas H Marwick","Riccardo Perfetti","Julio Rosenstock","Scott D Solomon","W H Wilson Tang","Faiez Zannad"],"significance":6,"published":"2024-07-09","source_date":"2024-07-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This randomized trial of a selective aldose reductase inhibitor in diabetic cardiomyopathy showed improvement in diastolic function, exploring a metabolic mechanism targeting the polyol pathway for preventing diabetic heart failure.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc0d66613086","type":"article","url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","title":"Upgrade RV-naar CRT-pacing bij hartfalen met AF: voordelen bevestigd","title_en":"Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae179","source_url":"https://doi.org/10.1093/europace/euae179","authors":["Béla Merkely","Robert Hatala","Eperke Merkel","Mátyás Szigeti","Boglárka Veres","Alexandra Fábián","István Osztheimer","László Gellér","Michal Sasov","Jerzy K Wranicz","Csaba Földesi","Gábor Duray","Scott D Solomon","Valentina Kutyifa","Attila Kovács","Annamária Kosztin"],"significance":6,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":[],"congress":"","summary_en":"This study confirmed that upgrading from RV pacing to biventricular CRT in heart failure patients with AF improves LV function and clinical outcomes, supporting resynchronization in the pacing-dependent AF population.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca42de849dc0","type":"article","url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","title":"Closed-loop stimulatie vermindert AHRE's versus conventionele rate-adaptieve pacing","title_en":"Closed loop stimulation reduces the incidence of atrial high-rate episodes compared with conventional rate-adaptive pacing in patients with sinus node dysfunctions.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae175","source_url":"https://doi.org/10.1093/europace/euae175","authors":["Ennio C L Pisanò","Valeria Calvi","Miguel Viscusi","Antonio Rapacciuolo","Ludovico Lazzari","Luca Bontempi","Gemma Pelargonio","Giuseppe Arena","Vincenzo Caccavo","Chun-Chieh Wang","Béla Merkely","Lian-Yu Lin","Il-Young Oh","Emanuele Bertaglia","Davide Saporito","Maurizio Menichelli","Antonino Nicosia","Domenico M Carretta","Aldo Coppolino","Chi Keong Ching","Álvaro Marco Del Castillo","Xi Su","Martina Del Maestro","Daniele Giacopelli","Alessio Gargaro","Giovanni L Botto"],"significance":6,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":[],"congress":"","summary_en":"This study showed that closed-loop stimulation pacing reduces atrial high-rate episodes compared with conventional rate-adaptive pacing, suggesting that physiological heart rate adaptation may have antiarrhythmic properties.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"90fb4a05ae58","type":"article","url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","title":"PFA versus thermale ablatie bij paroxysmaal AF: aritmielastanalyse","title_en":"Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["pulsed-field-ablatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.001","source_url":"https://doi.org/10.1016/j.jacc.2024.05.001","authors":["Vivek Y Reddy","Moussa Mansour","Hugh Calkins","Andre d'Avila","Larry Chinitz","Christopher Woods","Sanjaya K Gupta","Jamie Kim","Zayd A Eldadah","Robert A Pickett","Jeffrey Winterfield","Wilber W Su","Jonathan W Waks","Christopher W Schneider","Elizabeth Richards","Elizabeth M Albrecht","Brad S Sutton","Edward P Gerstenfeld"],"significance":6,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":[],"congress":"","summary_en":"This ADVENT analysis showed that the arrhythmia burden after pulsed field ablation is comparable to thermal ablation for paroxysmal AF, confirming equivalent rhythm control with the newer tissue-selective technology.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"13fa4c223995","type":"article","url":"https://hartvaat.nl/2024/07/02/thuisbloeddruktelemonitoring-en-nurse-case-management-na-cva-jama-rct/","title":"Thuisbloeddruktelemonitoring en nurse case management na CVA: JAMA RCT","title_en":"Home Blood Pressure Telemonitoring and Nurse Case Management in Black and Hispanic Patients With Stroke: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.6609","source_url":"https://doi.org/10.1001/jama.2024.6609","authors":["Gbenga Ogedegbe","Jeanne A Teresi","Stephen K Williams","Adebayo Ogunlade","Chigozirim Izeogu","Joseph P Eimicke","Jian Kong","Stephanie A Silver","Olajide Williams","Helen Valsamis","Susan Law","Steven R Levine","Salina P Waddy","Tanya M Spruill"],"significance":7,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":[],"congress":"","summary_en":"This JAMA trial demonstrated that home blood pressure telemonitoring combined with nurse case management significantly improves blood pressure control in Black and Hispanic stroke survivors, addressing the persistent disparities in hypertension management.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"160644bde458","type":"article","url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","title":"Semaglutide en NT-proBNP bij HFpEF met obesitas: STEP-HFpEF programma","title_en":"Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["cagrisema","nt-probnp","obesitas","select-trial","step-hfpef","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.022","source_url":"https://doi.org/10.1016/j.jacc.2024.04.022","authors":["Mark C Petrie","Barry A Borlaug","Javed Butler","Melanie J Davies","Dalane W Kitzman","Sanjiv J Shah","Subodh Verma","Thomas Jon Jensen","Mette Nygaard Einfeldt","Karoline Liisberg","Eduardo Perna","Kavita Sharma","Justin A Ezekowitz","Michael Fu","Vojtěch Melenovský","Hiroshi Ito","Małgorzata Lelonek","Mikhail N Kosiborod"],"significance":7,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"This STEP-HFpEF analysis showed that semaglutide significantly reduces NT-proBNP in patients with obesity-related HFpEF, providing a biomarker-based confirmation of the drug's cardiac benefit beyond symptoms and weight loss.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db3151c82fe1","type":"article","url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","title":"ORBITA-2 subanalyse: symptomen voorspellen PCI-effect bij stabiel coronairlijden","title_en":"Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.016","source_url":"https://doi.org/10.1016/j.jacc.2024.04.016","authors":["Florentina A Simader","Christopher A Rajkumar","Michael J Foley","Fiyyaz Ahmed-Jushuf","Shayna Chotai","Nina Bual","Arif Khokhar","Aisha Gohar","Ioannis Lampadakis","Sashiananthan Ganesananthan","Rachel H Pathimagaraj","Alexandra Nowbar","John R Davies","Tom R Keeble","Peter D O'Kane","Peter Haworth","Helen Routledge","Tushar Kotecha","James C Spratt","Rupert Williams","Sukhjinder S Nijjer","Sayan Sen","Nick Curzen","Manas Sinha","James P Howard","Graham Cole","Frank E Harrell","Darrel P Francis","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":7,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This ORBITA-2 subanalysis showed that patients with more severe symptoms derive greater placebo-controlled benefit from PCI, supporting symptom severity as a selection criterion for revascularization in stable coronary disease.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f45a741aa8f","type":"article","url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","title":"Vroege versus late DOAC na CVA met hemorrhagische transformatie bij AF","title_en":"Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069324","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069324","authors":["Roman Rohner","Markus Kneihsl","Martina B Goeldlin","Arsany Hakim","Mattia Branca","Stefanie Abend","Waldo Valenzuela Pinilla","Sabine Fenzl","Beata Rezny-Kasprzak","Daniel Strbian","Sven Trelle","Maurizio Paciaroni","Götz Thomalla","Patrik Michel","Krassen Nedeltchev","Thomas Gattringer","Else C Sandset","Leo Bonati","Diana Aguiar de Sousa","P N Sylaja","George Ntaios","Masatoshi Koga","Zuzana Gdovinova","Robin Lemmens","Natan M Bornstein","Peter Kelly","Mira Katan","Thomas Horvath","Jesse Dawson","Urs Fischer"],"significance":7,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This analysis showed that early DOAC initiation after ischemic stroke with hemorrhagic transformation in AF patients is safe, even in the presence of bleeding changes on brain imaging, supporting a move toward earlier anticoagulation.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55aebfb921c6","type":"article","url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","title":"N-of-1 trial voor anginaverificatie vóór PCI","title_en":"N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.001","source_url":"https://doi.org/10.1016/j.jacc.2024.04.001","authors":["Christopher A Rajkumar","Michael J Foley","Fiyyaz Ahmed-Jushuf","Florentina A Simader","Muhammad Mohsin","Sashiananthan Ganesananthan","Alexandra N Nowbar","Shayna Chotai","Sayan Sen","Ricardo Petraco","Sukhjinder S Nijjer","Joban Sehmi","Neil Ruparelia","Jason N Dungu","Alamgir Kabir","Kare Tang","Reto Gamma","John R Davies","Tushar Kotecha","Graham D Cole","James P Howard","Thomas R Keeble","Gerald Clesham","Peter D O'Kane","Frank E Harrell","Darrel P Francis","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":7,"published":"2024-07-02","source_date":"2024-07-02","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This innovative N-of-1 trial used blinded placebo-controlled medication phases to verify whether symptoms attributed to angina were truly medication-responsive before PCI. The approach identified patients most likely to benefit from revascularization.","created":"2026-07-03T10:31:01Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7de9d2018b8","type":"article","url":"https://hartvaat.nl/2024/07/01/dubbele-versus-enkele-cardioversie-bij-af-en-obesitas-jama-cardiology-rct/","title":"Dubbele versus enkele cardioversie bij AF en obesitas: JAMA Cardiology RCT","title_en":"Dual vs Single Cardioversion of Atrial Fibrillation in Patients With Obesity: A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["obesitas"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.1091","source_url":"https://doi.org/10.1001/jamacardio.2024.1091","authors":["Joshua D Aymond","Alexandra M Sanchez","Michael R Castine","Michael L Bernard","Sammy Khatib","A Elise Hiltbold","Glenn M Polin","Paul A Rogers","Paari S Dominic","Cruz Velasco-Gonzalez","Daniel P Morin"],"significance":7,"published":"2024-07-01","source_date":"2024-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized trial showed that dual simultaneous cardioversion using two defibrillators improves success rates for AF termination in obese patients, providing a practical solution for the common problem of cardioversion failure in obesity.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"619663121899","type":"article","url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","title":"Plozasiran: siRNA tegen APOC3 bij ernstige hypertriglyceridemie — SHASTA-2","title_en":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["statines"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0959","source_url":"https://doi.org/10.1001/jamacardio.2024.0959","authors":["Daniel Gaudet","Denes Pall","Gerald F Watts","Stephen J Nicholls","Robert S Rosenson","Karen Modesto","Javier San Martin","Jennifer Hellawell","Christie M Ballantyne"],"significance":8,"published":"2024-07-01","source_date":"2024-07-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/fibraten-bij-hypertriglyceridemie/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"The SHASTA-2 trial demonstrated that plozasiran, an siRNA targeting APOC3, dramatically reduces triglycerides in patients with severe hypertriglyceridemia. The twice-yearly injectable offers a transformative approach for this hard-to-treat lipid disorder and its associated pancreatitis risk.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb176553eea8","type":"article","url":"https://hartvaat.nl/2024/07/01/bloeddrukverlaging-en-polsgolfsnelheid-meta-analyse/","title":"Bloeddrukverlaging en polsgolfsnelheid: meta-analyse","title_en":"Influence of Blood Pressure Reduction on Pulse Wave Velocity in Primary Hypertension: A Meta-Analysis and Comparison With an Acute Modulation of Transmural Pressure.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22436","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22436","authors":["Ryan J McNally","Andrii Boguslavskyi","Rayka Malek","Christopher N Floyd","Marina Cecelja","Abdel Douiri","Rosa-Maria Bruno","Bushra Farukh","Phil Chowienczyk","Luca Faconti"],"significance":5,"published":"2024-07-01","source_date":"2024-07-01","image":"","kennis":[],"congress":"","summary_en":"A meta-analysis examined the effect of antihypertensive treatment on aortic pulse wave velocity. Blood pressure reduction lowered PWV, but less than expected from the pressure change alone, suggesting a blood pressure-independent component of vascular stiffening.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eae021e993ee","type":"article","url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","title":"VALUE-trial: CV-uitkomsten bij hypertensie met perifeer vaatlijden","title_en":"Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","perifeer-vaatlijden"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.124.22832","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.124.22832","authors":["Mislav Vrsalovic","Sondre Heimark","Camilla L Søraas","Maria H Mehlum","Sverre E Kjeldsen","Giuseppe Mancia","Stevo Julius","Michael A Weber"],"significance":5,"published":"2024-07-01","source_date":"2024-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This VALUE trial subanalysis revealed that hypertensive patients with peripheral artery disease carry a very high cardiovascular risk. Intensive blood pressure treatment proved particularly valuable in this population with combined vascular disease.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fdee9887065","type":"article","url":"https://hartvaat.nl/2024/07/01/af-screening-tijdens-bloeddrukmeting-diagnostische-nauwkeurigheid/","title":"AF-screening tijdens bloeddrukmeting: diagnostische nauwkeurigheid","title_en":"Atrial Fibrillation Screening During Routine Automated Office, Home, and Ambulatory Blood Pressure Measurement: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22563","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22563","authors":["Konstantinos G Kyriakoulis","Anastasios Kollias","Ariadni Menti","Panagiotis Chardouvelis","George S Stergiou"],"significance":6,"published":"2024-07-01","source_date":"2024-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This diagnostic study evaluated AF screening during routine blood pressure measurements in office, home, and ambulatory settings, showing that automated AF detection can be effectively integrated into standard BP monitoring.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f820318a6bf0","type":"article","url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","title":"Vasculair zorgteam versus educatie bij perifeer arterieel vaatlijden","title_en":"Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["perifeer-vaatlijden","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.04.034","source_url":"https://doi.org/10.1016/j.jacc.2024.04.034","authors":["Connie N Hess","Ashley Daffron","Mark R Nehler","Justin T Morrison","Cullen E Buchanan","Michael Szarek","Victoria E Anderson","Christopher P Cannon","Judith Hsia","Joseph J Saseen","Marc P Bonaca"],"significance":6,"published":"2024-06-25","source_date":"2024-06-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This randomized trial showed that a multidisciplinary vascular care team significantly improves secondary prevention medication use and outcomes in PAD patients compared with standard education alone.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"121fe2ed65c8","type":"article","url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","title":"RAAS-blokkade bij hartfalen: voordeel onafhankelijk van etniciteit — JAMA meta-analyse","title_en":"Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.6774","source_url":"https://doi.org/10.1001/jama.2024.6774","authors":["Li Shen","Matthew M Y Lee","Pardeep S Jhund","Christopher B Granger","Inder S Anand","Aldo P Maggioni","Marc A Pfeffer","Scott D Solomon","Karl Swedberg","Salim Yusuf","John J V McMurray"],"significance":8,"published":"2024-06-25","source_date":"2024-06-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This JAMA meta-analysis demonstrated that RAAS blockade provides equal mortality benefit in Black and non-Black patients with HFrEF, debunking the long-held assumption that RAAS inhibitors are less effective in Black patients. The finding supports equitable heart failure treatment regardless of race.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ff3a8dceaac","type":"article","url":"https://hartvaat.nl/2024/06/18/sildenafil-dosisvergelijking-bij-pulmonale-arteriele-hypertensie/","title":"Sildenafil dosisvergelijking bij pulmonale arteriële hypertensie","title_en":"Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["bloeddrukbehandeling","pulmonale-hypertensie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.068107","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.068107","authors":["Marius M Hoeper","Ralf Ewert","Pavel Jansa","Yuriy Sirenko","Andris Skride","Cecile Balagtas","Sarah Hackley","Susanne Vogt","Paula Abreu","Scott Haughie","Tarek Hassan","Ronald J Oudiz"],"significance":6,"published":"2024-06-18","source_date":"2024-06-18","image":"","kennis":[],"congress":"","summary_en":"This randomized study compared different sildenafil doses for pulmonary arterial hypertension, finding that higher doses do not provide significantly better outcomes than the approved dose, informing optimal dosing strategies.","created":"2026-07-03T10:31:00Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5aacf65be07b","type":"article","url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","title":"MRA bij hartfalen met nierfunctiestoornissen: veiligheid en effectiviteit","title_en":"Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.426","source_url":"https://doi.org/10.1016/j.jacc.2024.03.426","authors":["Shingo Matsumoto","Alasdair D Henderson","Li Shen","Mingming Yang","Karl Swedberg","Muthiah Vaduganathan","Dirk J van Veldhuisen","Scott D Solomon","Bertram Pitt","Faiez Zannad","Pardeep S Jhund","John J V McMurray"],"significance":7,"published":"2024-06-18","source_date":"2024-06-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This analysis showed that MRA therapy can be safely used in heart failure patients with impaired renal function when potassium and creatinine are monitored, addressing a common barrier to optimal neurohormonal blockade in CKD patients.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a492e033cbe","type":"article","url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","title":"Invasief versus conservatief bij ouderen met NSTE-ACS: IPD meta-analyse","title_en":"Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["hartkatheterisatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae151","source_url":"https://doi.org/10.1093/eurheartj/ehae151","authors":["Christos P Kotanidis","Gregory B Mills","Bjørn Bendz","Erlend S Berg","David Hildick-Smith","Geir Hirlekar","Dejan Milasinovic","Nuccia Morici","Aung Myat","Nicolai Tegn","Juan Sanchis","Stefano Savonitto","Stefano De Servi","Keith A A Fox","Stuart Pocock","Vijay Kunadian"],"significance":8,"published":"2024-06-14","source_date":"2024-06-14","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that early invasive management reduces MI and repeat revascularization in older patients with NSTE-ACS compared with conservative management. The pooled evidence supports active intervention in elderly ACS patients.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fe56384cc3e0","type":"article","url":"https://hartvaat.nl/2024/06/11/effort-ertugliflozine-bij-functionele-mitralisinsufficientie-en-hartfalen/","title":"EFFORT: ertugliflozine bij functionele mitralisinsufficiëntie en hartfalen","title_en":"Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","canagliflozine","carvedilol","cystatine-c","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","mitralisinsufficiëntie","nt-probnp","sglt2-remmers","step-hfpef","vericiguat"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069144","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069144","authors":["Duk-Hyun Kang","Sung-Ji Park","Sung-Hee Shin","In-Chang Hwang","Yeonyee Elizabeth Yoon","Hyung-Kwan Kim","Mijin Kim","Min-Seok Kim","Sung-Cheol Yun","Jong-Min Song","Seok-Min Kang"],"significance":7,"published":"2024-06-11","source_date":"2024-06-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The EFFORT trial explored whether the SGLT2 inhibitor ertugliflozin reduces functional mitral regurgitation in heart failure, testing the hypothesis that volume management through SGLT2 inhibition can improve secondary valvular disease.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c6599591b98","type":"article","url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","title":"EMPACT-MI: LV-functie, congestie en empagliflozine-effect na MI","title_en":"Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.405","source_url":"https://doi.org/10.1016/j.jacc.2024.03.405","authors":["Jacob A Udell","Mark C Petrie","W Schuyler Jones","Stefan D Anker","Josephine Harrington","Michaela Mattheus","Svenja Seide","Offer Amir","M Cecilia Bahit","Johann Bauersachs","Antoni Bayes-Genis","Yundai Chen","Vijay K Chopra","Gemma Figtree","Junbo Ge","Shaun G Goodman","Nina Gotcheva","Shinya Goto","Tomasz Gasior","Waheed Jamal","James L Januzzi","Myung Ho Jeong","Yuri Lopatin","Renato D Lopes","Béla Merkely","Monica Martinez-Traba","Puja B Parikh","Alexander Parkhomenko","Piotr Ponikowski","Xavier Rossello","Morten Schou","Dragan Simic","Philippe Gabriel Steg","Joanna Szachniewicz","Peter van der Meer","Dragos Vinereanu","Shelley Zieroth","Martina Brueckmann","Mikhail Sumin","Deepak L Bhatt","Adrian F Hernandez","Javed Butler"],"significance":6,"published":"2024-06-11","source_date":"2024-06-11","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that empagliflozin after MI primarily benefits patients with LV dysfunction and congestion, refining the target population for post-MI SGLT2 inhibitor therapy.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"44514d3144ce","type":"article","url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","title":"Remote beoordeling na ACS: gerandomiseerde trial","title_en":"Randomized Trial of Remote Assessment of Patients After an Acute Coronary Syndrome.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.398","source_url":"https://doi.org/10.1016/j.jacc.2024.03.398","authors":["Nasser S Alshahrani","Adam Hartley","James Howard","Reza Hajhosseiny","Saud Khawaja","Henry Seligman","Tamim Akbari","Badr A Alharbi","Paul Bassett","Rasha Al-Lamee","Darrel Francis","Amit Kaura","Mihir A Kelshiker","Nicholas S Peters","Ramzi Khamis"],"significance":6,"published":"2024-06-11","source_date":"2024-06-11","image":"","kennis":[],"congress":"","summary_en":"This randomized trial demonstrated that remote follow-up after ACS is as safe as conventional clinic visits, supporting telecardiology as a viable model for post-acute coronary care delivery.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T13:30:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b12804e9537","type":"article","url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","title":"TARGET BP I: alcohol-gemedieerde renale denervatie bij hypertensie","title_en":"Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","lipidenverlaging","renale-denervatie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069291","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069291","authors":["David E Kandzari","Michael A Weber","Atul Pathak","James P Zidar","Manish Saxena","Shukri W David","Roland E Schmieder","Adam J Janas","Christopher Langer","Alexandre Persu","Farrell O Mendelsohn","Koen Ameloot","Malcolm Foster","Tim A Fischell","Helen Parise","Felix Mahfoud"],"significance":7,"published":"2024-06-11","source_date":"2024-06-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"The TARGET BP I trial evaluated alcohol-mediated renal denervation, a novel technique, showing significant blood pressure reduction in patients on antihypertensive medications. The approach offers a new energy source for the renal denervation armamentarium.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7a0fd740711","type":"article","url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","title":"SMART: zelf-expanderend versus ballonexpandeerbaar TAVR bij kleine annulus — NEJM","title_en":"Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2312573","source_url":"https://doi.org/10.1056/NEJMoa2312573","authors":["Howard C Herrmann","Roxana Mehran","Daniel J Blackman","Stephen Bailey","Helge Möllmann","Mohamed Abdel-Wahab","Walid Ben Ali","Paul D Mahoney","Hendrik Ruge","David A Wood","Sabine Bleiziffer","Basel Ramlawi","Hemal Gada","Anna Sonia Petronio","Charles D Resor","William Merhi","Bruno Garcia Del Blanco","Guilherme F Attizzani","Wayne B Batchelor","Linda D Gillam","Mayra Guerrero","Toby Rogers","Joshua D Rovin","Molly Szerlip","Brian Whisenant","G Michael Deeb","Kendra J Grubb","Ratnasari Padang","Myra T Fan","Andrew D Althouse","Didier Tchétché"],"significance":8,"published":"2024-06-06","source_date":"2024-06-06","image":"","kennis":[],"congress":"","summary_en":"The SMART trial showed that balloon-expandable TAVR achieved significantly better hemodynamic performance than self-expanding TAVR in patients with a small aortic annulus. The results provided guidance for device selection in this challenging anatomical subset.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36d053e13770","type":"article","url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","title":"ApoA-I infusie na MI: geen effect op recidief ischemische events","title_en":"Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.396","source_url":"https://doi.org/10.1016/j.jacc.2024.03.396","authors":["Thomas J Povsic","Serge Korjian","M Cecilia Bahit","Gerald Chi","Danielle Duffy","John H Alexander","Dragos Vinereanu","Pierluigi Tricoci","Sojaita Jenny Mears","Lawrence I Deckelbaum","Marc Bonaca","Paul M Ridker","Shaun G Goodman","Jan H Cornel","Basil S Lewis","Alexander Parkhomenko","Renato D Lopes","Philip Aylward","A Michael Lincoff","Mark Heise","Frank Sacks","Jose C Nicolau","Bela Merkely","Jaroslaw Trebacz","Peter Libby","Stephen J Nicholls","Stuart Pocock","Deepak L Bhatt","John Kastelein","Christoph Bode","Kenneth W Mahaffey","P Gabriel Steg","Michal Tendera","Kevin R Bainey","Robert A Harrington","Roxana Mehran","Daniel Duerschmied","Bronwyn A Kingwell","C Michael Gibson"],"significance":6,"published":"2024-06-04","source_date":"2024-06-04","image":"","kennis":[],"congress":"","summary_en":"This AEGIS-II confirmation trial showed that reconstituted apoA-I infusion does not reduce recurrent ischemic events after MI, definitively closing the therapeutic approach of acute HDL augmentation for secondary prevention.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edba8d7956cf","type":"article","url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","title":"Sacubitril/valsartan bij hartfalen over het nierfunctiespectrum","title_en":"Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","bisoprolol","carvedilol","empagliflozine","hfref","ijzertekort","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.392","source_url":"https://doi.org/10.1016/j.jacc.2024.03.392","authors":["Safia Chatur","Brendon L Neuen","Brian L Claggett","Iris E Beldhuis","Finnian R Mc Causland","Akshay S Desai","Jean L Rouleau","Michael R Zile","Martin P Lefkowitz","Milton Packer","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":6,"published":"2024-06-04","source_date":"2024-06-04","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This analysis confirmed that sacubitril-valsartan is effective and safe across the full spectrum of renal impairment in heart failure, with consistent benefit maintained even in advanced CKD.","created":"2026-07-03T10:30:59Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"808c34c2abdf","type":"article","url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","title":"DRIVE: remote management verbetert richtlijnmedicatie bij hartfalen","title_en":"Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069494","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069494","authors":["Alexander J Blood","Lee-Shing Chang","Shahzad Hassan","Jacqueline Chasse","Gretchen Stern","Daniel Gabovitch","David Zelle","Caitlin Colling","Samuel J Aronson","Christian Figueroa","Emma Collins","Ryan Ruggiero","Emily Zacherle","Joshua Noone","Carey Robar","Jorge Plutzky","Thomas A Gaziano","Christopher P Cannon","Deborah J Wexler","Benjamin M Scirica"],"significance":7,"published":"2024-06-04","source_date":"2024-06-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The DRIVE trial showed that a remote management program significantly improves guideline-directed medication use and dosing in heart failure patients, demonstrating that technology-assisted remote optimization can bridge the gap between guidelines and practice.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b47c6c3675a2","type":"article","url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","title":"SGLT2-remmers en MACE: SMART-C collaboratieve mega-meta-analyse","title_en":"Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","empagliflozine","sglt2-remmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069568","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069568","authors":["Siddharth M Patel","Yu Mi Kang","KyungAh Im","Brendon L Neuen","Stefan D Anker","Deepak L Bhatt","Javed Butler","David Z I Cherney","Brian L Claggett","Robert A Fletcher","William G Herrington","Silvio E Inzucchi","Meg J Jardine","Kenneth W Mahaffey","Darren K McGuire","John J V McMurray","Bruce Neal","Milton Packer","Vlado Perkovic","Scott D Solomon","Natalie Staplin","Muthiah Vaduganathan","Christoph Wanner","David C Wheeler","Faiez Zannad","Yujie Zhao","Hiddo J L Heerspink","Marc S Sabatine","Stephen D Wiviott"],"significance":10,"published":"2024-06-04","source_date":"2024-06-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"This SMART-C collaborative meta-analysis of all major SGLT2 inhibitor trials confirmed that the class reduces heart failure hospitalization and kidney outcomes across all patient populations, while MACE reduction was primarily seen in patients with type 2 diabetes and atherosclerotic disease. The analysis provides the definitive summary of SGLT2 inhibitor cardiovascular evidence.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"811e870fa294","type":"article","url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","title":"EAST-AFNET 4: natriumkanaalblokkers veilig en effectief voor langetermijn ritmecontrole","title_en":"Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae121","source_url":"https://doi.org/10.1093/europace/euae121","authors":["Andreas Rillig","Lars Eckardt","Katrin Borof","A John Camm","Harry J G M Crijns","Andreas Goette","Günter Breithardt","Marc D Lemoine","Andreas Metzner","Laura Rottner","Ulrich Schotten","Eik Vettorazzi","Karl Wegscheider","Antonia Zapf","Hein Heidbuchel","Stephan Willems","Larissa Fabritz","Renate B Schnabel","Christina Magnussen","Paulus Kirchhof"],"significance":7,"published":"2024-06-03","source_date":"2024-06-03","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"This EAST-AFNET 4 analysis confirmed that sodium channel blockers (flecainide, propafenone) are safe and effective for long-term early rhythm control in AF patients with cardiovascular comorbidities, addressing concerns about proarrhythmic effects.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94b40e93900c","type":"article","url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","title":"Complete versus culprit-only revascularisatie bij ouderen met MI en hoog bloedingsrisico","title_en":"Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0804","source_url":"https://doi.org/10.1001/jamacardio.2024.0804","authors":["Andrea Erriquez","Gianluca Campo","Vincenzo Guiducci","Javier Escaned","Raul Moreno","Gianni Casella","Mila Menozzi","Enrico Cerrato","Giorgio Sacchetta","Alberto Menozzi","Ignacio Amat Santos","Enrique Gutiérrez Ibañes","Roberto Scarsini","Giuseppe Vadalà","Giuseppe Andò","José Luis Díez-Gil","Sergio Musto d'Amore","Alessandro Capecchi","Iginio Colaiori","Francesco Gallo","Rita Pavasini","Andrea Marrone","Graziella Pompei","Valerio Lanzilotti","Dariusz Dudek","Emanuele Barbato","Matteo Tebaldi","Simone Biscaglia"],"significance":7,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":[],"congress":"","summary_en":"This RCT showed that complete revascularization reduces ischemic events compared with culprit-only PCI even in older MI patients with high bleeding risk, demonstrating that the benefit persists despite the higher procedural risk.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5398dc99e7fe","type":"article","url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","title":"AF-ablatie bij HFrEF versus HFpEF: meta-analyse","title_en":"Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0675","source_url":"https://doi.org/10.1001/jamacardio.2024.0675","authors":["Alireza Oraii","William F McIntyre","Ratika Parkash","Krzysztof Kowalik","Ghazal Razeghi","Alexander P Benz","Emilie P Belley-Côté","David Conen","Stuart J Connolly","Anthony S L Tang","Jeff S Healey","Jorge A Wong"],"significance":7,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis compared AF ablation efficacy in HFrEF versus HFpEF, finding that ablation improves outcomes in both phenotypes, extending the evidence for rhythm control across the heart failure ejection fraction spectrum.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"060f53791ec6","type":"article","url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","title":"REDUCE LAP-HF II: atriaal shuntdevice bij HFpEF — cardiale effecten","title_en":"Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","hfpef","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0520","source_url":"https://doi.org/10.1001/jamacardio.2024.0520","authors":["Ravi B Patel","Frank E Silvestry","Jan Komtebedde","Scott D Solomon","Gerd Hasenfuß","Sheldon E Litwin","Barry A Borlaug","Matthew J Price","Rami Kawash","Scott L Hummel","Donald E Cutlip","Martin B Leon","Dirk J van Veldhuisen","Andreas J Rieth","Scott McKenzie","Heiko Bugger","Jeremy A Mazurek","Samir R Kapadia","Marc Vanderheyden","Bonnie Ky","Sanjiv J Shah"],"significance":6,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diastolische-disfunctie-mechanisme/"],"congress":"","summary_en":"This REDUCE LAP-HF II subanalysis examined the cardiac structural effects of the atrial shunt device in HFpEF, showing favorable hemodynamic changes despite the neutral primary clinical endpoint.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b62b74b63e95","type":"article","url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","title":"OPT-BIRISK: clopidogrel monotherapie bij ACS met hoog ischemisch én bloedingsrisico","title_en":"Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["trombocytenaggregatieremmers"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0534","source_url":"https://doi.org/10.1001/jamacardio.2024.0534","authors":["Yi Li","Jing Li","Bin Wang","Quanmin Jing","Yujie Zeng","Aijie Hou","Zhifang Wang","Aijun Liu","Jinliang Zhang","Yaojun Zhang","Ping Zhang","Daming Jiang","Bin Liu","Jiamao Fan","Jun Zhang","Li Li","Guohai Su","Ming Yang","Weihong Jiang","Peng Qu","Hesong Zeng","Lu Li","Miaohan Qiu","Leisheng Ru","Shaoliang Chen","Yujie Zhou","Shubin Qiao","Gregg W Stone","Dominick J Angiolillo","Yaling Han"],"significance":7,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"The OPT-BIRISK trial showed that extended clopidogrel monotherapy is as effective as DAPT in ACS patients with both high ischemic and high bleeding risk, supporting a simplified single-agent approach in this challenging dual-risk population.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0bcc60836f3a","type":"article","url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","title":"INVESTED: griepvaccin immuunrespons bij hoog-risico CV-patiënten","title_en":"Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0468","source_url":"https://doi.org/10.1001/jamacardio.2024.0468","authors":["Alexander Peikert","Brian L Claggett","Jacob A Udell","Jacob Joseph","Sheila M Hegde","KyungMann Kim","Lu Mao","Tuo Wang","Thomas C Havighurst","Michael E Farkouh","Deepak L Bhatt","Matthew C Tattersall","Lawton S Cooper","Scott D Solomon","Orly Vardeny"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":[],"congress":"","summary_en":"Secondary analysis of the INVESTED trial compared immune responses to high-dose trivalent versus standard-dose quadrivalent influenza vaccine in patients with high-risk cardiovascular disease. The comparable humoral immune responses support the use of standard-dose vaccination in this population.","created":"2026-07-03T10:30:58Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69e60ea51b7d","type":"article","url":"https://hartvaat.nl/2024/06/01/pah-behandeling-ipd-netwerk-meta-analyse-van-alle-therapieen/","title":"PAH-behandeling: IPD netwerk-meta-analyse van alle therapieën","title_en":"Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae049","source_url":"https://doi.org/10.1093/eurheartj/ehae049","authors":["Jude Moutchia","Robyn L McClelland","Nadine Al-Naamani","Dina H Appleby","John H Holmes","Jasleen Minhas","Jeremy A Mazurek","Harold I Palevsky","Corey E Ventetuolo","Steven M Kawut"],"significance":8,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":[],"congress":"","summary_en":"This individual participant data network meta-analysis of all PAH therapies demonstrated that initial combination therapy, including regimens with sotatercept, was superior to monotherapy for improving exercise capacity and clinical outcomes. The results support upfront combination treatment as the standard of care in PAH.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fdf803109a63","type":"article","url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","title":"Bloeddrukverlaging bij centrale hypertensie: gerandomiseerde trial","title_en":"Blood Pressure Lowering in Patients With Central Hypertension: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","figaro-dkd"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21653","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21653","authors":["James E Sharman","Petr Otahal","Michael Stowasser","Tony Stanton","Christopher M Reid","Mark Nolan","Philip Roberts-Thomson","Kazuaki Negishi","Robert Greenough","Simon Stewart","Thomas H Marwick","Walter P Abhayaratna"],"significance":6,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This randomized trial investigated blood pressure lowering specifically in patients with central hypertension (elevated aortic pressure despite normal brachial readings), testing a targeted approach to vascular-specific blood pressure management.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T18:39:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"972bf5a2c122","type":"article","url":"https://hartvaat.nl/2024/06/01/renale-denervatie-langetermijn-bloeddrukeffect-bevestigd-meta-analyse/","title":"Renale denervatie: langetermijn bloeddrukeffect bevestigd — meta-analyse","title_en":"Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["figaro-dkd","renale-denervatie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22314","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22314","authors":["Gianni Sesa-Ashton","Janis M Nolde","Ida Muente","Revathy Carnagarin","Vaughan G Macefield","Tye Dawood","Elisabeth A Lambert","Gavin W Lambert","Antony Walton","Murray D Esler","Markus P Schlaich"],"significance":7,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This meta-analysis confirmed the long-term blood pressure-lowering effect of catheter-based renal denervation, with sustained reductions maintained for at least 3 years, supporting the durability of the device-based approach.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c9cc44ee6067","type":"article","url":"https://hartvaat.nl/2024/06/01/zwangerschapsdiabetes-en-hypertensierisico-meta-analyse-met-dosis-respons/","title":"Zwangerschapsdiabetes en hypertensierisico: meta-analyse met dosis-respons","title_en":"Association Between Gestational Diabetes Mellitus and Hypertension: A Systematic Review and Meta-Analysis of Cohort Studies With a Quantitative Bias Analysis of Uncontrolled Confounding.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","figaro-dkd","obesitas","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22418","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22418","authors":["Xinyue Liu","Roch A Nianogo","Carla Janzen","Zhe Fei","Marissa J Seamans","Renee Wen","Xiang Li","Liwei Chen"],"significance":6,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This meta-analysis confirmed a significant association between gestational diabetes and subsequent hypertension development, with a dose-dependent relationship that identifies GDM as a long-term cardiovascular risk marker.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"477c04328589","type":"article","url":"https://hartvaat.nl/2024/06/01/nieuwe-antihyperglycemische-middelen-en-cv-uitkomsten-bij-diabetes-meta-analyse/","title":"Nieuwe antihyperglycemische middelen en CV-uitkomsten bij diabetes: meta-analyse","title_en":"Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","diabetes-en-hart","diabetes-type-2","ezetimibe","fidelio-dkd","fidelity","figaro-dkd","select-trial","semaglutide","sglt2-remmers","soul-trial","statines","tirzepatide"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14726","source_url":"https://doi.org/10.1002/ehf2.14726","authors":["Zijing Zhou","Min Zheng","Zhihong Zuo","Ting Wu"],"significance":7,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This meta-analysis compared cardiovascular outcomes of new antihyperglycemic agents in type 2 diabetes, showing that SGLT2 inhibitors and GLP-1 receptor agonists both reduce cardiovascular events while DPP-4 inhibitors are cardiovascularly neutral.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:30:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7898e47d82c4","type":"article","url":"https://hartvaat.nl/2024/06/01/s2i2n0-3-score-voorspelt-mortaliteit-bij-hfref-guide-it-subanalyse/","title":"S2I2N0-3 score voorspelt mortaliteit bij HFrEF: GUIDE-IT subanalyse","title_en":"S2I2N0-3 score predicts short- and long-term mortality and morbidity in HFrEF: a post-hoc analysis of the GUIDE-IT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14689","source_url":"https://doi.org/10.1002/ehf2.14689","authors":["Junyi Sun","Zhengshuo Xie","Min Ye","He Xu","Yugang Dong","Chen Liu","Wengen Zhu"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"Post-hoc analysis of the GUIDE-IT trial validated the S2I2N0-3 score — incorporating stroke history, insulin-treated diabetes, and NT-proBNP — as a reliable predictor of short- and long-term mortality and morbidity in patients with heart failure with reduced ejection fraction.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc5aa97c5490","type":"article","url":"https://hartvaat.nl/2024/06/01/prognostische-modellen-voor-hfpef-systematische-review/","title":"Prognostische modellen voor HFpEF: systematische review","title_en":"Prognostic models for patients suffering a heart failure with a preserved ejection fraction: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14696","source_url":"https://doi.org/10.1002/ehf2.14696","authors":["Ying-Ying Jia","Nian-Qi Cui","Ting-Ting Jia","Jian-Ping Song"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review evaluated prognostic models for heart failure with preserved ejection fraction. Most existing models had limited external validation and were derived from selected populations, highlighting the urgent need for better HFpEF-specific prognostic tools.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93d1e2da3d6c","type":"article","url":"https://hartvaat.nl/2024/06/01/triglyceride-glucose-index-en-cv-uitkomsten-na-pci-chinese-meta-analyse/","title":"Triglyceride-glucose-index en CV-uitkomsten na PCI: Chinese meta-analyse","title_en":"Triglyceride-glucose index's link to cardiovascular outcomes post-percutaneous coronary intervention in China: a meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14679","source_url":"https://doi.org/10.1002/ehf2.14679","authors":["ChangXin Sun","LanQing Hu","XiaoYa Li","XiaoNan Zhang","JiYe Chen","DeXiu Li","JingYi Zhang","LongTao Liu","Min Wu"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"A meta-analysis of Chinese studies demonstrated that the triglyceride-glucose index, a simple surrogate marker of insulin resistance, predicts major adverse cardiovascular events after percutaneous coronary intervention. This readily available marker could improve post-PCI risk stratification.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64686abedb85","type":"article","url":"https://hartvaat.nl/2024/06/01/glycemische-variabiliteit-en-mortaliteit-bij-hartfalen-meta-analyse/","title":"Glycemische variabiliteit en mortaliteit bij hartfalen: meta-analyse","title_en":"A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14627","source_url":"https://doi.org/10.1002/ehf2.14627","authors":["Xiaoxiao Fu","Yang Wei","Jun Fang"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis found that greater glycaemic variability is associated with increased mortality in patients with heart failure. The findings suggest that stable glucose control may be prognostically more favourable than aggressive glucose lowering accompanied by fluctuations.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b573b5c6f82","type":"article","url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","title":"RIGHT-2: ambulancebloeddrukverlaging bij hyperacuut CVA — NEJM vervolgresultaten","title_en":"Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2314741","source_url":"https://doi.org/10.1056/NEJMoa2314741","authors":["Gang Li","Yapeng Lin","Jie Yang","Craig S Anderson","Chen Chen","Feifeng Liu","Laurent Billot","Qiang Li","Xiaoying Chen","Xiaoqiu Liu","Xinwen Ren","Chunfang Zhang","Ping Xu","Lijun Wu","Feng Wang","Daijun Qiu","Mei Jiang","Yiqian Peng","Chaohui Li","Yiyang Huang","Xiaohui Zhao","Jiye Liang","Yao Wang","Xiangjun Wu","Xiaoyun Xu","Guofang Chen","Dongya Huang","Yue Zhang","Lian Zuo","Guozhao Ma","Yumei Yang","Junjie Hao","Xiahong Xu","Xinli Xiong","Yueyu Tang","Yijia Guo","Jianping Yu","Shuping Li","Song He","Fengkai Mao","Quandan Tan","Song Tan","Nengwei Yu","Ruxiang Xu","Mingwei Sun","Binghu Li","Jiang Guo","Leibo Liu","Hueiming Liu","Menglu Ouyang","Lei Si","Hisatomi Arima","Philip M Bath","Gary A Ford","Thompson Robinson","Else Charlotte Sandset","Jeffrey L Saver","Nikola Sprigg","H Bart van der Worp","Lili Song"],"significance":8,"published":"2024-05-30","source_date":"2024-05-30","image":"","kennis":[],"congress":"","summary_en":"This NEJM trial evaluated intensive ambulance-delivered blood pressure reduction in the hyperacute stroke phase, before distinction between ischemic and hemorrhagic subtypes. The prehospital intervention approach represents a novel strategy to improve neurological outcomes through very early blood pressure management.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db20a606e31e","type":"article","url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","title":"PRO-HF: routine PROM-meting in hartfalenpolikliniek verbetert uitkomsten","title_en":"Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["hfpef","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069624","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069624","authors":["Alexander T Sandhu","Jamie Calma","Megan Skye","Neil Kalwani","Jimmy Zheng","Jessica Schirmer","Natasha Din","Cati Brown Johnson","Anshal Gupta","Roy Lan","Brian Yu","John A Spertus","Paul A Heidenreich"],"significance":7,"published":"2024-05-28","source_date":"2024-05-28","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"The PRO-HF trial showed that routine assessment of patient-reported outcome measures in heart failure clinics improves quality of life without increasing healthcare utilization, supporting the integration of PROMs into standard heart failure care.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8f69e3a19222","type":"article","url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","title":"NUDGE-FLU: elektronische nudges verhogen griepvaccinatie na MI","title_en":"Electronic nudges increase influenza vaccination utilization after myocardial infarction: the nationwide NUDGE-FLU implementation trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae235","source_url":"https://doi.org/10.1093/eurheartj/ehae235","authors":["Ankeet S Bhatt","Niklas Dyrby Johansen","Daniel Modin","Brian L Claggett","Erica L Dueger","Sandrine I Samson","Matthew M Loiacono","Lars Køber","Scott D Solomon","Pradeesh Sivapalan","Jens Ulrik Stæhr Jensen","Cyril Jean-Marie Martel","Muthiah Vaduganathan","Tor Biering-Sørensen"],"significance":6,"published":"2024-05-27","source_date":"2024-05-27","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"The NUDGE-FLU nationwide implementation trial showed that simple electronic nudges significantly increase influenza vaccination rates in post-MI patients, demonstrating a scalable behavioral intervention for cardiovascular prevention.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f267f9b5ee4","type":"article","url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","title":"EMPACT-MI: empagliflozine en hartfalenuitkomsten na MI","title_en":"Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","dapa-hf","empagliflozine","emperor-trials","hfref"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069217","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069217","authors":["Adrian F Hernandez","Jacob A Udell","W Schuyler Jones","Stefan D Anker","Mark C Petrie","Josephine Harrington","Michaela Mattheus","Svenja Seide","Isabella Zwiener","Offer Amir","M Cecilia Bahit","Johann Bauersachs","Antoni Bayes-Genis","Yundai Chen","Vijay K Chopra","Gemma A Figtree","Junbo Ge","Shaun G Goodman","Nina Gotcheva","Shinya Goto","Tomasz Gasior","Waheed Jamal","James L Januzzi","Myung Ho Jeong","Yuri Lopatin","Renato D Lopes","Béla Merkely","Puja B Parikh","Alexander Parkhomenko","Piotr Ponikowski","Xavier Rossello","Morten Schou","Dragan Simic","Philippe Gabriel Steg","Joanna Szachniewicz","Peter van der Meer","Dragos Vinereanu","Shelley Zieroth","Martina Brueckmann","Mikhail Sumin","Deepak L Bhatt","Javed Butler"],"significance":7,"published":"2024-05-21","source_date":"2024-05-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This EMPACT-MI subanalysis showed that empagliflozin after acute MI did not significantly reduce heart failure-specific outcomes, consistent with the neutral primary endpoint and limiting the role of early post-MI SGLT2 inhibition to patients with established heart failure.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b64f6b0aacf5","type":"article","url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","title":"DAPA-HF: dapagliflozine en dagen in volledige gezondheid","title_en":"Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["canagliflozine","dapa-hf","dapagliflozine","empagliflozine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.385","source_url":"https://doi.org/10.1016/j.jacc.2024.03.385","authors":["Toru Kondo","Ulrik M Mogensen","Atefeh Talebi","Samvel B Gasparyan","Ross T Campbell","Kieran F Docherty","Rudolf A de Boer","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Felipe A Martinez","Marc S Sabatine","Olof Bengtsson","Mikaela Sjöstrand","Muthiah Vaduganathan","Scott D Solomon","Pardeep S Jhund","John J V McMurray"],"significance":6,"published":"2024-05-21","source_date":"2024-05-21","image":"","kennis":[],"congress":"","summary_en":"This DAPA-HF analysis quantified the benefit of dapagliflozin in terms of days of full health gained, showing meaningful improvements in health-adjusted time alive beyond traditional event-based endpoints.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64947f6dcbc2","type":"article","url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","title":"ANNEXA-I: andexanet alfa bij factor Xa-remmer-geassocieerde intracerebrale bloeding — NEJM","title_en":"Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","edoxaban","rivaroxaban"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2313040","source_url":"https://doi.org/10.1056/NEJMoa2313040","authors":["Stuart J Connolly","Mukul Sharma","Alexander T Cohen","Andrew M Demchuk","Anna Członkowska","Arne G Lindgren","Carlos A Molina","Daniel Bereczki","Danilo Toni","David J Seiffge","David Tanne","Else Charlotte Sandset","Georgios Tsivgoulis","Hanne Christensen","Jan Beyer-Westendorf","Jonathan M Coutinho","Mark Crowther","Peter Verhamme","Pierre Amarenco","Risto O Roine","Robert Mikulik","Robin Lemmens","Roland Veltkamp","Saskia Middeldorp","Thompson G Robinson","Truman John Milling","Vitor Tedim-Cruz","Wilfried Lang","Anders Himmelmann","Per Ladenvall","Mikael Knutsson","Ella Ekholm","Andrew Law","Amanda Taylor","Tetyana Karyakina","Lizhen Xu","Kate Tsiplova","Sven Poli","Bernd Kallmünzer","Christoph Gumbinger","Ashkan Shoamanesh"],"significance":10,"published":"2024-05-16","source_date":"2024-05-16","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antidota-anticoagulantia/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"The ANNEXA-I trial demonstrated that andexanet alfa, a factor Xa inhibitor reversal agent, significantly reduced hematoma expansion compared with usual care in patients with acute intracerebral hemorrhage while taking factor Xa inhibitors. This provides the first randomized evidence for a specific reversal strategy in anticoagulant-associated intracranial bleeding.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c493fe8264db","type":"article","url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","title":"Olezarsen bij hypertriglyceridemie en hoog CV-risico: NEJM","title_en":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","hypertriglyceridemie","ldl-cholesterol","niet-statine-therapie","select-trial","statines"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2402309","source_url":"https://doi.org/10.1056/NEJMoa2402309","authors":["Brian A Bergmark","Nicholas A Marston","Thomas A Prohaska","Veronica J Alexander","André Zimerman","Filipe A Moura","Sabina A Murphy","Erica L Goodrich","Shuanglu Zhang","Daniel Gaudet","Ewa Karwatowska-Prokopczuk","Sotirios Tsimikas","Robert P Giugliano","Marc S Sabatine"],"significance":9,"published":"2024-05-16","source_date":"2024-05-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/fibraten-bij-hypertriglyceridemie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This NEJM trial showed that olezarsen reduced triglycerides by more than 50% in patients with hypertriglyceridemia and high cardiovascular risk. Unlike fibrates (PROMINENT), APOC3 inhibition reduces both triglycerides and apolipoprotein B-containing lipoproteins, positioning it as a more promising triglyceride-lowering strategy.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6483e543f190","type":"article","url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","title":"Olezarsen bij familiaire chylomicronemie: NEJM fase 3","title_en":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2400201","source_url":"https://doi.org/10.1056/NEJMoa2400201","authors":["Erik S G Stroes","Veronica J Alexander","Ewa Karwatowska-Prokopczuk","Robert A Hegele","Marcello Arca","Christie M Ballantyne","Handrean Soran","Thomas A Prohaska","Shuting Xia","Henry N Ginsberg","Joseph L Witztum","Sotirios Tsimikas"],"significance":9,"published":"2024-05-16","source_date":"2024-05-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This NEJM trial demonstrated that olezarsen, an antisense oligonucleotide targeting APOC3, dramatically reduced triglyceride levels and virtually eliminated acute pancreatitis episodes in patients with familial chylomicronemia syndrome. The results represent a transformative therapy for this severe, previously intractable genetic condition.","created":"2026-07-03T10:30:56Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c53949dd005","type":"article","url":"https://hartvaat.nl/2024/05/13/nitrate-cin-nitraat-beschermt-tegen-contrastnefropathie-na-acs/","title":"NITRATE-CIN: nitraat beschermt tegen contrastnefropathie na ACS","title_en":"Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae100","source_url":"https://doi.org/10.1093/eurheartj/ehae100","authors":["Daniel A Jones","Anne-Marie Beirne","Matthew Kelham","Lucinda Wynne","Mervyn Andiapen","Krishnaraj S Rathod","Tipparat Parakaw","Jessica Adams","Annastazia Learoyd","Kamran Khan","Thomas Godec","Paul Wright","Sotiris Antoniou","Andrew Wragg","Muhammad Yaqoob","Anthony Mathur","Amrita Ahluwalia"],"significance":7,"published":"2024-05-13","source_date":"2024-05-13","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"The NITRATE-CIN trial demonstrated that inorganic nitrate reduces contrast-induced nephropathy after coronary angiography in ACS patients, providing a simple, cost-effective renal protective strategy during contrast-enhanced procedures.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5443045e7f6","type":"article","url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","title":"IVUS-ACS: IVUS-geleide PCI bij ACS superieur — Lancet","title_en":"Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00282-4","source_url":"https://doi.org/10.1016/S0140-6736(24)00282-4","authors":["Xiaobo Li","Zhen Ge","Jing Kan","Muhammed Anjum","Ping Xie","Xiang Chen","Hamid Sharif Khan","Xiaomei Guo","Tahir Saghir","Jing Chen","Badar Ul Ahad Gill","Ning Guo","Imad Sheiban","Afsar Raza","Yongyue Wei","Feng Chen","Gary S Mintz","Jun-Jie Zhang","Gregg W Stone","Shao-Liang Chen"],"significance":9,"published":"2024-05-11","source_date":"2024-05-11","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"The IVUS-ACS trial showed that IVUS-guided PCI significantly reduced target vessel failure compared with angiography-guided PCI in patients with acute coronary syndromes. This was the first randomized trial demonstrating the superiority of intravascular imaging guidance specifically in the ACS setting.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21a957e11148","type":"article","url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","title":"Ticagrelor monotherapie versus DAPT na 1 maand bij ACS: Lancet RCT","title_en":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["dubbele-trombocytenremming"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00473-2","source_url":"https://doi.org/10.1016/S0140-6736(24)00473-2","authors":["Zhen Ge","Jing Kan","Xiaofei Gao","Afsar Raza","Jun-Jie Zhang","Bilal S Mohydin","Fentang Gao","Yibing Shao","Yan Wang","Hesong Zeng","Feng Li","Hamid Sharif Khan","Naeem Mengal","Hongliang Cong","Mingliang Wang","Lianglong Chen","Yongyue Wei","Feng Chen","Gregg W Stone","Shao-Liang Chen"],"significance":8,"published":"2024-05-11","source_date":"2024-05-11","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"This Lancet trial confirmed that ticagrelor monotherapy after 1 month of DAPT in ACS patients reduces bleeding without increasing ischemic events, adding to the robust evidence for early aspirin discontinuation in P2Y12-based antiplatelet strategies.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dce1bce5fd69","type":"article","url":"https://hartvaat.nl/2024/05/07/mandibulaire-advancementsplint-versus-cpap-voor-bloeddrukverlaging-bij-osa/","title":"Mandibulaire advancementsplint versus CPAP voor bloeddrukverlaging bij OSA","title_en":"Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.359","source_url":"https://doi.org/10.1016/j.jacc.2024.03.359","authors":["Yi-Hui Ou","Juliana Tereza Colpani","Crystal S Cheong","Weiqiang Loke","As Tar Thant","E' Ching Shih","Frank Lee","Siew-Pang Chan","Ching-Hui Sia","Chieh-Yang Koo","Serene Wong","Aiping Chua","Chin-Meng Khoo","William Kong","Calvin W Chin","Pipin Kojodjojo","Philip E Wong","Mark Y Chan","A Mark Richards","Peter A Cistulli","Chi-Hang Lee"],"significance":6,"published":"2024-05-07","source_date":"2024-05-07","image":"","kennis":[],"congress":"","summary_en":"This study showed that mandibular advancement devices are noninferior to CPAP for blood pressure reduction in obstructive sleep apnea, providing a practical alternative for the common hypertension-OSA overlap.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72b2be6fe491","type":"article","url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","title":"Sacubitril/valsartan en hypotensie bij HFpEF/HFmrEF","title_en":"Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","sacubitril-valsartan","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.02.035","source_url":"https://doi.org/10.1016/j.jacc.2024.02.035","authors":["Alberto Foà","Muthiah Vaduganathan","Brian L Claggett","Maria A Pabon","Henri Lu","Marc A Pfeffer","Milton Packer","Orly Vardeny","Jean L Rouleau","Martin Lefkowitz","Robert J Mentz","Pardeep S Jhund","Akshay S Desai","John J V McMurray","Scott D Solomon"],"significance":6,"published":"2024-05-07","source_date":"2024-05-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This analysis characterized hypotension with sacubitril-valsartan in HFpEF, showing that symptomatic hypotension occurs but is manageable and does not negate the clinical benefit of ARNI therapy.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b49add0c9b39","type":"article","url":"https://hartvaat.nl/2024/05/07/orale-ketonester-bij-hfref-gerandomiseerde-trial/","title":"Orale ketonester bij HFrEF: gerandomiseerde trial","title_en":"Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","emperor-trials","soul-trial","step-hfpef","summit-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067971","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067971","authors":["Kristoffer Berg-Hansen","Nigopan Gopalasingam","Kristian Hylleberg Christensen","Bertil Ladefoged","Mads Jønsson Andersen","Steen Hvitfeldt Poulsen","Barry A Borlaug","Roni Nielsen","Niels Møller","Henrik Wiggers"],"significance":6,"published":"2024-05-07","source_date":"2024-05-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This randomized trial of oral ketone ester therapy in HFrEF showed that exogenous ketone supplementation increases cardiac output, exploring metabolic modulation as a novel heart failure treatment approach.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"50624441332c","type":"article","url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","title":"PREVENT: preventieve PCI versus medicatie bij kwetsbare coronaire plaques — Lancet","title_en":"Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["percutane-coronaire-interventie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00413-6","source_url":"https://doi.org/10.1016/S0140-6736(24)00413-6","authors":["Seung-Jung Park","Jung-Min Ahn","Do-Yoon Kang","Sung-Cheol Yun","Young-Keun Ahn","Won-Jang Kim","Chang-Wook Nam","Jin-Ok Jeong","In-Ho Chae","Hiroki Shiomi","Hsien-Li Kao","Joo-Yong Hahn","Sung-Ho Her","Bong-Ki Lee","Tae Hoon Ahn","Ki-Yuk Chang","Jei Keon Chae","David Smyth","Gary S Mintz","Gregg W Stone","Duk-Woo Park"],"significance":9,"published":"2024-05-04","source_date":"2024-05-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"The PREVENT trial demonstrated that preventive PCI of vulnerable atherosclerotic plaques identified by intravascular imaging (IVUS/OCT) reduced future coronary events compared with optimal medical therapy alone. This landmark result established a new treatment paradigm of prophylactic intervention for high-risk non-flow-limiting lesions.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b8484ec61f3","type":"article","url":"https://hartvaat.nl/2024/05/02/preventieve-substraatablatie-vermindert-icd-interventies-bij-ischemische-cmp/","title":"Preventieve substraatablatie vermindert ICD-interventies bij ischemische CMP","title_en":"Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiogene-shock","fractional-flow-reserve","iaso-dcm","icd-implantatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae109","source_url":"https://doi.org/10.1093/europace/euae109","authors":["David Žižek","Miha Mrak","Matevž Jan","Anja Zupan Mežnar","Maja Ivanovski","Tadej Žlahtič","Nina Kajdič","Bor Antolič","Luka Klemen","Rafael Skale","Jurij Avramovič Gregorič","Jernej Štublar","Andrej Pernat","Matjaž Šinkovec"],"significance":7,"published":"2024-05-02","source_date":"2024-05-02","image":"","kennis":[],"congress":"","summary_en":"This study showed that preventive substrate ablation in patients with ischemic cardiomyopathy and coronary chronic total occlusion significantly reduces ICD interventions, supporting prophylactic ablation in this high-risk device population.","created":"2026-07-03T10:30:55Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de42e7b0e14d","type":"article","url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","title":"STYLE-AF: veneuze closure device versus figuur-van-acht hechting na AF-ablatie","title_en":"Venous vascular closure system vs. figure-of-eight suture following atrial fibrillation ablation: the STYLE-AF Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae105","source_url":"https://doi.org/10.1093/europace/euae105","authors":["Roland Richard Tilz","Marcel Feher","Julia Vogler","Kerstin Bode","Alexandru Ionut Duta","Angela Ortolan","Lisbeth Delgado Lopez","Mirco Küchler","Roman Mamaev","Evgeny Lyan","Philipp Sommer","Martin Braun","Vanessa Sciacca","Thomas Demming","Vera Maslova","Karl-Heinz Kuck","Christian-Hendrik Heeger","Charlotte Eitel","Sorin Stefan Popescu"],"significance":5,"published":"2024-05-02","source_date":"2024-05-02","image":"","kennis":[],"congress":"","summary_en":"The STYLE-AF study compared a venous vascular closure system with the standard figure-of-eight suture technique for achieving haemostasis following single-shot pulmonary vein isolation. The closure device reduced time to haemostasis and improved patient comfort without increasing vascular access complications.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32bdd216c2a0","type":"article","url":"https://hartvaat.nl/2024/05/02/decaaf-ii-af-last-en-symptoomreductie-na-ablatie/","title":"DECAAF II: AF-last en symptoomreductie na ablatie","title_en":"Comprehensive atrial fibrillation burden and symptom reduction post-ablation: insights from DECAAF II.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae104","source_url":"https://doi.org/10.1093/europace/euae104","authors":["Charbel Noujaim","Ala Assaf","Chanho Lim","Han Feng","Hadi Younes","Mario Mekhael","Nour Chouman","Ghaith Shamaileh","Abdel Hadi El Hajjar","Tarek Ayoub","Nino Isakadze","Mihail G Chelu","Nassir Marrouche","Eoin Donnellan"],"significance":5,"published":"2024-05-02","source_date":"2024-05-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"Analysis of the DECAAF II trial demonstrated that catheter ablation significantly reduces atrial fibrillation burden and symptom severity in persistent AF patients, regardless of whether fibrosis-guided or standard pulmonary vein isolation was performed. The clinical benefit of ablation extends beyond simple rhythm control to meaningful improvements in patient-reported outcomes.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f1c08e5b9920","type":"article","url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","title":"AEGIS-II: apoA1-infusie na acuut MI verbetert uitkomsten niet — NEJM","title_en":"Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2400969","source_url":"https://doi.org/10.1056/NEJMoa2400969","authors":["C Michael Gibson","Danielle Duffy","Serge Korjian","M Cecilia Bahit","Gerald Chi","John H Alexander","A Michael Lincoff","Mark Heise","Pierluigi Tricoci","Lawrence I Deckelbaum","Sojaita Jenny Mears","Jose C Nicolau","Renato D Lopes","Bela Merkely","Basil S Lewis","Jan H Cornel","Jaroslaw Trebacz","Alexander Parkhomenko","Peter Libby","Frank M Sacks","Thomas J Povsic","Marc Bonaca","Shaun G Goodman","Deepak L Bhatt","Michal Tendera","P Gabriel Steg","Paul M Ridker","Philip Aylward","John J P Kastelein","Christoph Bode","Kenneth W Mahaffey","Stephen J Nicholls","Stuart J Pocock","Roxana Mehran","Robert A Harrington"],"significance":8,"published":"2024-05-02","source_date":"2024-05-02","image":"","kennis":[],"congress":"","summary_en":"The AEGIS-II trial showed that infusion of recombinant apolipoprotein A1 (CSL112) after acute MI did not reduce the risk of MACE compared with placebo. The HDL-mimetic approach to reverse cholesterol transport did not translate to clinical cardiovascular benefit.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e75a55186989","type":"article","url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","title":"RENOVATE-COMPLEX-PCI: beeldvorming-geleide PCI bij vrouwen versus mannen","title_en":"Intravascular Imaging-Guided Optimization of Complex Percutaneous Coronary Intervention by Sex: A Subgroup Analysis of the RENOVATE-COMPLEX-PCI Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0291","source_url":"https://doi.org/10.1001/jamacardio.2024.0291","authors":["Ji Hyun Cha","Joo Myung Lee","Ki Hong Choi","Jong-Young Lee","Seung-Jae Lee","Sang Yeub Lee","Sang Min Kim","Kyeong Ho Yun","Jae Young Cho","Chan Joon Kim","Hyo-Suk Ahn","Chang-Wook Nam","Hyuck-Jun Yoon","Yong Hwan Park","Jin-Ok Jeong","Pil Sang Song","Joon-Hyung Doh","Sang-Ho Jo","Chang-Hwan Yoon","Min Gyu Kang","Jin-Sin Koh","Kwan Yong Lee","Young-Hyo Lim","Yun-Hyeong Cho","Jin-Man Cho","Woo Jin Jang","Kook-Jin Chun","David Hong","Taek Kyu Park","Jeong Hoon Yang","Seung-Hyuk Choi","Hyeon-Cheol Gwon","Joo-Yong Hahn","Wang Soo Lee","Young Bin Song"],"significance":6,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/"],"congress":"","summary_en":"This RENOVATE-COMPLEX-PCI subanalysis showed that the benefit of intravascular imaging-guided PCI for complex lesions is consistent in both men and women, supporting sex-equal use of imaging guidance.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1881491beca","type":"article","url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","title":"P2Y12-monotherapie versus DAPT na PCI: IPD meta-analyse","title_en":"Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["clopidogrel","dubbele-trombocytenremming"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0133","source_url":"https://doi.org/10.1001/jamacardio.2024.0133","authors":["Marco Valgimigli","Felice Gragnano","Mattia Branca","Anna Franzone","Bruno R da Costa","Usman Baber","Takeshi Kimura","Yangsoo Jang","Joo-Yong Hahn","Qiang Zhao","Stephan Windecker","Charles M Gibson","Hirotoshi Watanabe","Byeong-Keuk Kim","Young Bin Song","Yunpeng Zhu","Pascal Vranckx","Shamir Mehta","Kenji Ando","Sung Jin Hong","Hyeon-Cheol Gwon","Patrick W Serruys","George D Dangas","Eùgene P McFadden","Dominick J Angiolillo","Dik Heg","Paolo Calabrò","Peter Jüni","Roxana Mehran"],"significance":8,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"This patient-level meta-analysis confirmed that P2Y12 inhibitor monotherapy (ticagrelor or clopidogrel) after a short course of DAPT reduces major bleeding compared with standard 12-month DAPT without increasing ischemic events. The pooled evidence definitively supports de-escalation to single antiplatelet therapy.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2603675f7ba9","type":"article","url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","title":"Angiografie versus IVUS voor DES-implantatie: gerandomiseerde trial","title_en":"Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0059","source_url":"https://doi.org/10.1001/jamacardio.2024.0059","authors":["Pil Hyung Lee","Soon Jun Hong","Hyun-Sook Kim","Young Won Yoon","Jong-Young Lee","Seung-Jin Oh","Ji Sung Lee","Soo-Jin Kang","Young-Hak Kim","Seong-Wook Park","Seung-Whan Lee","Cheol Whan Lee"],"significance":6,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/"],"congress":"","summary_en":"This randomized trial confirmed that IVUS-guided DES implantation achieves better procedural results than angiography-guided PCI, supporting routine intravascular imaging for coronary stenting optimization.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3667f2f44eb","type":"article","url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","title":"QUARTET: therapeutische inertie bij lage-dosis viervoudige combinatietherapie","title_en":"Therapeutic Inertia With Initial Low-Dose Quadruple Combination Therapy for Hypertension: Results From the QUARTET Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22284","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22284","authors":["Nelson Wang","Amy Von Huben","Simone Marschner","Mark R Nelson","Janis M Nolde","Markus P Schlaich","Gemma Figtree","Graham S Hillis","Tim Usherwood","Christopher M Reid","John Chalmers","Shirley Jansen","Emily R Atkins","Laurent Billot","Clara Chow","Anthony Rodgers"],"significance":6,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/"],"congress":"","summary_en":"This QUARTET analysis showed that initial low-dose quadruple combination therapy for hypertension reduces therapeutic inertia compared with standard care, as clinicians are less reluctant to continue simplified combination treatment.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"071a75edf351","type":"article","url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","title":"SSaSS secundaire analyse: kaliumverrijkt zout en cardiale uitkomsten","title_en":"Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22410","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22410","authors":["Jie Yu","Clare Arnott","Qiang Li","Gian Luca Di Tanna","Maoyi Tian","Liping Huang","Xuejun Yin","Xinyi Zhang","Sallie-Anne Pearson","Darwin R Labarthe","Paul Elliott","Lijing L Yan","Bo Zhou","Yangfeng Wu","Bruce Neal"],"significance":7,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This secondary SSaSS analysis showed that potassium-enriched salt substitution reduces cardiac events in addition to the previously demonstrated stroke reduction, broadening the cardiovascular benefit of this simple dietary intervention.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"340a5346db84","type":"article","url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","title":"Bloeddrukstreefwaarden en residueel risico: systematische review en meta-regressie","title_en":"Revisiting Cardiovascular Benefits of Blood Pressure Reduction in Primary and Secondary Prevention: Focus on Targets and Residual Risk-A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["polygene-risicoscore","primaire-preventie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22610","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22610","authors":["Eleni Manta","Costas Thomopoulos","Maria Kariori","Dimitrios Polyzos","Constantinos Mihas","Dimitrios Konstantinidis","Dimitrios Farmakis","Giuseppe Mancia","Konstantinos Tsioufis"],"significance":6,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This systematic review examined residual cardiovascular risk after achieving blood pressure targets, finding that even at optimal blood pressure levels, significant residual risk remains, supporting comprehensive risk factor management.","created":"2026-07-03T10:30:54Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b0b1c8f68f7","type":"article","url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","title":"SPYRAL HTN-ON MED: renale denervatie en medicatiewijzigingen","title_en":"Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22251","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22251","authors":["Raymond R Townsend","Keith C Ferdinand","David E Kandzari","Kazuomi Kario","Felix Mahfoud","Michael A Weber","Roland E Schmieder","Stuart Pocock","Konstantinos Tsioufis","Shukri David","Susan Steigerwalt","Antony Walton","Ingrid Hopper","Barry Bertolet","Faisal Sharif","Karl Fengler","Martin Fahy","Douglas A Hettrick","Sandeep Brar","Michael Böhm"],"significance":6,"published":"2024-05-01","source_date":"2024-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This SPYRAL HTN-ON MED subanalysis showed that renal denervation reduces the need for antihypertensive medications, with some patients able to decrease their pill burden after the procedure.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd945e489c52","type":"article","url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","title":"Ticagrelor plus aspirine en ledematenuitkomsten bij diabetes met atherosclerose","title_en":"Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["ezetimibe","soul-trial","statines","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.03.377","source_url":"https://doi.org/10.1016/j.jacc.2024.03.377","authors":["Marc P Bonaca","Deepak L Bhatt","Tabassome Simon","Kim Michael Fox","Shamir Mehta","Robert A Harrington","Lawrence A Leiter","Warren H Capell","Claes Held","Anders Himmelmann","Wilhelm Ridderstråle","Jersey Chen","Jane J Lee","Yang Song","Marielle Andersson","Jayne Prats","Mikhail Kosiborod","Darren K McGuire","Ph Gabriel Steg"],"significance":6,"published":"2024-04-30","source_date":"2024-04-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This analysis showed that ticagrelor plus aspirin reduces adverse limb outcomes in diabetic patients with atherosclerosis, extending the dual antiplatelet benefit to peripheral vascular events in the diabetic population.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c6b98b0a5f2","type":"article","url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","title":"Semaglutide bij HFpEF met obesitas: Lancet gepoolde analyse van twee NEJM-trials","title_en":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["flow-trial","obesitas","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial","summit-trial","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00469-0","source_url":"https://doi.org/10.1016/S0140-6736(24)00469-0","authors":["Javed Butler","Sanjiv J Shah","Mark C Petrie","Barry A Borlaug","Steen Z Abildstrøm","Melanie J Davies","G Kees Hovingh","Dalane W Kitzman","Daniél Vega Møller","Subodh Verma","Mette Nygaard Einfeldt","Marie L Lindegaard","Søren Rasmussen","Walter Abhayaratna","Fozia Z Ahmed","Tuvia Ben-Gal","Vijay Chopra","Justin A Ezekowitz","Michael Fu","Hiroshi Ito","Małgorzata Lelonek","Vojtěch Melenovský","Bela Merkely","Julio Núñez","Eduardo Perna","Morten Schou","Michele Senni","Kavita Sharma","Peter van der Meer","Dirk Von Lewinski","Dennis Wolf","Mikhail N Kosiborod"],"significance":9,"published":"2024-04-27","source_date":"2024-04-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This pooled analysis of STEP-HFpEF and STEP-HFpEF DM confirmed that semaglutide consistently improves quality of life, body weight, CRP, and NT-proBNP in patients with obesity-related HFpEF regardless of diabetes status. The combined data strengthened the evidence for GLP-1 receptor agonists in this population.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"191adb9921c5","type":"article","url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","title":"FRAME-AMI: FFR-geleide versus complete PCI bij MI — NEJM","title_en":"FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2314149","source_url":"https://doi.org/10.1056/NEJMoa2314149","authors":["Felix Böhm","Brynjölfur Mogensen","Thomas Engstrøm","Goran Stankovic","Ilija Srdanovic","Jacob Lønborg","Sammy Zwackman","Mehmet Hamid","Thomas Kellerth","Jörg Lauermann","Olli A Kajander","Jonas Andersson","Rikard Linder","Oskar Angerås","Henrik Renlund","Andrejs Ērglis","Madhav Menon","Carl Schultz","Mika Laine","Claes Held","Andreas Rück","Ollie Östlund","Stefan James"],"significance":9,"published":"2024-04-25","source_date":"2024-04-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The FRAME-AMI trial showed that FFR-guided complete revascularization of nonculprit lesions resulted in fewer stent implantations with comparable clinical outcomes versus routine angiography-guided complete PCI in patients with STEMI and multivessel disease. FFR guidance may reduce overtreatment without compromising safety.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de4880c93313","type":"article","url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","title":"DAPA-MI: empagliflozine na acuut MI zonder HF of diabetes — NEJM","title_en":"Empagliflozin after Acute Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","dapagliflozine","empagliflozine","emperor-trials"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2314051","source_url":"https://doi.org/10.1056/NEJMoa2314051","authors":["Javed Butler","W Schuyler Jones","Jacob A Udell","Stefan D Anker","Mark C Petrie","Josephine Harrington","Michaela Mattheus","Isabella Zwiener","Offer Amir","M Cecilia Bahit","Johann Bauersachs","Antoni Bayes-Genis","Yundai Chen","Vijay K Chopra","Gemma Figtree","Junbo Ge","Shaun G Goodman","Nina Gotcheva","Shinya Goto","Tomasz Gasior","Waheed Jamal","James L Januzzi","Myung Ho Jeong","Yuri Lopatin","Renato D Lopes","Béla Merkely","Puja B Parikh","Alexander Parkhomenko","Piotr Ponikowski","Xavier Rossello","Morten Schou","Dragan Simic","P Gabriel Steg","Joanna Szachniewicz","Peter van der Meer","Dragos Vinereanu","Shelley Zieroth","Martina Brueckmann","Mikhail Sumin","Deepak L Bhatt","Adrian F Hernandez"],"significance":9,"published":"2024-04-25","source_date":"2024-04-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"The DAPA-MI trial showed that empagliflozin after acute MI in patients without heart failure or diabetes did not significantly improve the hierarchical composite of cardiovascular outcomes. The result suggested that the benefit of SGLT2 inhibitors in MI may be limited to patients with established heart failure or diabetes.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"08fa4e4ad054","type":"article","url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","title":"Lp(a) en CV-risicoreductie met icosapent ethyl: REDUCE-IT analyse","title_en":"Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.02.016","source_url":"https://doi.org/10.1016/j.jacc.2024.02.016","authors":["Michael Szarek","Deepak L Bhatt","Michael Miller","Eliot A Brinton","Terry A Jacobson","Jean-Claude Tardif","Christie M Ballantyne","R Preston Mason","Steven B Ketchum","Armando Lira Pineda","Ralph T Doyle","Ph Gabriel Steg"],"significance":6,"published":"2024-04-23","source_date":"2024-04-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This REDUCE-IT analysis showed that higher Lp(a) levels are associated with increased cardiovascular risk but that the benefit of icosapent ethyl is consistent regardless of Lp(a) status.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16cf24556ba9","type":"article","url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","title":"PCI versus CABG bij linker hoofdstam met en zonder diabetes: PRECOMBAT follow-up","title_en":"Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065571","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065571","authors":["Prakriti Gaba","Joseph F Sabik","Sabina A Murphy","Andrea Bellavia","Patrick T O'Gara","Peter K Smith","Patrick W Serruys","A Pieter Kappetein","Seung-Jung Park","Duk-Woo Park","Evald H Christiansen","Niels R Holm","Per H Nielsen","Marc S Sabatine","Gregg W Stone","Brian A Bergmark"],"significance":7,"published":"2024-04-23","source_date":"2024-04-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This long-term analysis comparing PCI with CABG for left main disease stratified by diabetes confirmed that CABG remains superior in diabetic patients, consistent with the overall evidence favoring surgery for complex coronary disease with diabetes.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea09edafca95","type":"article","url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","title":"IRONMAN: ijzerdeficiëntiedefinities en klinische respons op IV-ijzer bij HF","title_en":"Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae086","source_url":"https://doi.org/10.1093/eurheartj/ehae086","authors":["John G F Cleland","Philip A Kalra","Pierpaolo Pellicori","Fraser J Graham","Paul W X Foley","Iain B Squire","Peter J Cowburn","Alison Seed","Andrew L Clark","Ben Szwejkowski","Prithwish Banerjee","Justin Cooke","Mark Francis","Piers Clifford","Aaron Wong","Colin Petrie","John J V McMurray","Elizabeth A Thomson","Kirsty Wetherall","Michele Robertson","Ian Ford","Paul R Kalra"],"significance":6,"published":"2024-04-21","source_date":"2024-04-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This IRONMAN subanalysis explored which iron deficiency definition best predicts clinical response to IV iron in heart failure, informing patient selection for iron repletion therapy.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ee25cfe66aab","type":"article","url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","title":"ORBITA-COSMIC: coronaire sinusreducer bij refractaire angina — sham-gecontroleerd","title_en":"Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(24)00256-3","source_url":"https://doi.org/10.1016/S0140-6736(24)00256-3","authors":["Michael J Foley","Christopher A Rajkumar","Fiyyaz Ahmed-Jushuf","Florentina A Simader","Shayna Chotai","Rachel H Pathimagaraj","Muhammad Mohsin","Ahmed Salih","Danqi Wang","Prithvi Dixit","John R Davies","Tom R Keeble","Claudia Cosgrove","James C Spratt","Peter D O'Kane","Ranil De Silva","Jonathan M Hill","Sukhjinder S Nijjer","Sayan Sen","Ricardo Petraco","Ghada W Mikhail","Ramzi Khamis","Tushar Kotecha","Frank E Harrell","Peter Kellman","Darrel P Francis","James P Howard","Graham D Cole","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":7,"published":"2024-04-20","source_date":"2024-04-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The ORBITA-COSMIC placebo-controlled trial showed that the coronary sinus reducer device did not significantly improve angina compared with a sham procedure in patients with refractory angina, calling into question this structural approach to symptom relief.","created":"2026-07-03T10:30:53Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19508daaa7aa","type":"article","url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","title":"ABYSS: bètablokkers na MI met behouden EF niet nodig — NEJM","title_en":"Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2401479","source_url":"https://doi.org/10.1056/NEJMoa2401479","authors":["Troels Yndigegn","Bertil Lindahl","Katarina Mars","Joakim Alfredsson","Jocelyne Benatar","Lisa Brandin","David Erlinge","Ola Hallen","Claes Held","Patrik Hjalmarsson","Pelle Johansson","Patric Karlström","Thomas Kellerth","Toomas Marandi","Annica Ravn-Fischer","Johan Sundström","Ollie Östlund","Robin Hofmann","Tomas Jernberg"],"significance":10,"published":"2024-04-18","source_date":"2024-04-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The ABYSS trial showed that long-term beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction did not reduce the composite of death, MI, or stroke. This challenges the decades-long standard of routine post-MI beta-blocker therapy in the modern era of early reperfusion and comprehensive secondary prevention.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4caeceb85bde","type":"article","url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","title":"DanGer Shock: Impella versus standaardzorg bij cardiogene shock — NEJM","title_en":"Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2312572","source_url":"https://doi.org/10.1056/NEJMoa2312572","authors":["Jacob E Møller","Thomas Engstrøm","Lisette O Jensen","Hans Eiskjær","Norman Mangner","Amin Polzin","P Christian Schulze","Carsten Skurk","Peter Nordbeck","Peter Clemmensen","Vasileios Panoulas","Sebastian Zimmer","Andreas Schäfer","Nikos Werner","Martin Frydland","Lene Holmvang","Jesper Kjærgaard","Rikke Sørensen","Jacob Lønborg","Matias G Lindholm","Nanna L J Udesen","Anders Junker","Henrik Schmidt","Christian J Terkelsen","Steffen Christensen","Evald H Christiansen","Axel Linke","Felix J Woitek","Ralf Westenfeld","Sven Möbius-Winkler","Kristian Wachtell","Hanne B Ravn","Jens F Lassen","Søren Boesgaard","Oke Gerke","Christian Hassager"],"significance":10,"published":"2024-04-18","source_date":"2024-04-18","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/klepprothese-mechanisch-biologisch/"],"congress":"","summary_en":"The DanGer Shock trial demonstrated that the Impella CP microaxial flow pump significantly reduced 180-day all-cause mortality compared with standard care in patients with STEMI-related cardiogenic shock. This is the first positive randomized trial of a percutaneous mechanical circulatory support device in cardiogenic shock.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3efc32446d4","type":"article","url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","title":"STEP-HFpEF-DM: semaglutide bij HFpEF met obesitas en type 2 diabetes — NEJM","title_en":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["obesitas","select-trial","soul-trial","step-hfpef","summit-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2313917","source_url":"https://doi.org/10.1056/NEJMoa2313917","authors":["Mikhail N Kosiborod","Mark C Petrie","Barry A Borlaug","Javed Butler","Melanie J Davies","G Kees Hovingh","Dalane W Kitzman","Daniél V Møller","Marianne B Treppendahl","Subodh Verma","Thomas J Jensen","Karoline Liisberg","Marie L Lindegaard","Walter Abhayaratna","Fozia Z Ahmed","Tuvia Ben-Gal","Vijay Chopra","Justin A Ezekowitz","Michael Fu","Hiroshi Ito","Małgorzata Lelonek","Vojtěch Melenovský","Bela Merkely","Julio Núñez","Eduardo Perna","Morten Schou","Michele Senni","Kavita Sharma","Peter van der Meer","Dirk Von Lewinski","Dennis Wolf","Sanjiv J Shah"],"significance":10,"published":"2024-04-18","source_date":"2024-04-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"The STEP-HFpEF-DM trial demonstrated that semaglutide 2.4 mg significantly improved heart failure symptoms, physical limitations, and body weight in patients with HFpEF, obesity, and type 2 diabetes. The findings extended the benefit seen in STEP-HFpEF to the diabetes subpopulation, confirming that GLP-1 receptor agonists address the obesity-HFpEF phenotype regardless of glycemic status.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4cf984eddf35","type":"article","url":"https://hartvaat.nl/2024/04/16/sglt2-remming-waterconservatie-domineert-over-osmotische-diurese-bij-hf/","title":"SGLT2-remming: waterconservatie domineert over osmotische diurese bij HF","title_en":"Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.02.020","source_url":"https://doi.org/10.1016/j.jacc.2024.02.020","authors":["Adriana Marton","Seyed Ehsan Saffari","Manfred Rauh","Ruo-Ning Sun","Armin M Nagel","Peter Linz","Tzy Tiing Lim","Kaoru Takase-Minegishi","Anastacia Pajarillaga","Sharon Saw","Norihiko Morisawa","Wan Keat Yam","Shintaro Minegishi","John J Totman","Serena Teo","Louis L Y Teo","Choon Ta Ng","Kento Kitada","Johannes Wild","Jean-Paul Kovalik","Friedrich C Luft","Peter J Greasley","Calvin W L Chin","David K L Sim","Jens Titze"],"significance":6,"published":"2024-04-16","source_date":"2024-04-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This mechanistic study showed that the osmotic diuretic potential of SGLT2 inhibitors in heart failure is attenuated by compensatory renal water conservation, suggesting that the cardiac benefit operates through mechanisms beyond volume reduction.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e0edcf21d86e","type":"article","url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","title":"2024 ACC Expert Consensus: behandeling van HFrEF — beslispad geactualiseerd","title_en":"2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.12.024","source_url":"https://doi.org/10.1016/j.jacc.2023.12.024","authors":["Thomas M Maddox","James L Januzzi","Larry A Allen","Khadijah Breathett","Sara Brouse","Javed Butler","Leslie L Davis","Gregg C Fonarow","Nasrien E Ibrahim","JoAnn Lindenfeld","Frederick A Masoudi","Shweta R Motiwala","Estefania Oliveros","Mary Norine Walsh","Alan Wasserman","Clyde W Yancy","Quentin R Youmans"],"significance":9,"published":"2024-04-16","source_date":"2024-04-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The 2024 ACC Expert Consensus for HFrEF endorsed simultaneous initiation of four-pillar therapy (SGLT2 inhibitor, ARNI, beta-blocker, MRA) rather than sequential titration, with practical algorithms for rapid optimization, including in-hospital initiation during heart failure admissions.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4cb4df46cd49","type":"article","url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","title":"Postprocedurale anticoagulatie na primaire PCI voor STEMI: multicenter studie","title_en":"Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["anticoagulantia","rivaroxaban"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067079","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067079","authors":["Yan Yan","Jincheng Guo","Xiao Wang","Guozhong Wang","Zeyuan Fan","Delu Yin","Zhifang Wang","Fuchun Zhang","Changming Tian","Wei Gong","Jiamin Liu","Jiapeng Lu","Yongjun Li","Changsheng Ma","Eric Vicaut","Gilles Montalescot","Shaoping Nie"],"significance":6,"published":"2024-04-16","source_date":"2024-04-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This study showed that routine post-procedural anticoagulation after primary PCI for STEMI does not reduce ischemic events but increases bleeding, arguing against this common practice.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f30785fc0b16","type":"article","url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","title":"Dapagliflozine bij acuut hartfalen: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","canagliflozine","carvedilol","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfref","nt-probnp","sacubitril-valsartan","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.02.009","source_url":"https://doi.org/10.1016/j.jacc.2024.02.009","authors":["Zachary L Cox","Sean P Collins","Gabriel A Hernandez","A Thomas McRae","Beth T Davidson","Kirkwood Adams","Mark Aaron","Luke Cunningham","Cathy A Jenkins","Christopher J Lindsell","Frank E Harrell","Christina Kampe","Karen F Miller","William B Stubblefield","JoAnn Lindenfeld"],"significance":7,"published":"2024-04-09","source_date":"2024-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This study confirmed the efficacy and safety of dapagliflozin started during acute heart failure hospitalization, showing improved decongestion and favorable effects on guideline-directed therapy optimization during the index admission.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0267041e3873","type":"article","url":"https://hartvaat.nl/2024/04/04/pragmatische-trial-van-hospitalisatieratio-bij-ckd-nejm/","title":"Pragmatische trial van hospitalisatieratio bij CKD — NEJM","title_en":"Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["chronische-nierziekte","credence-trial","flow-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2311708","source_url":"https://doi.org/10.1056/NEJMoa2311708","authors":["Miguel A Vazquez","George Oliver","Ruben Amarasingham","Venkatraghavan Sundaram","Kevin Chan","Chul Ahn","Song Zhang","Perry Bickel","Samir M Parikh","Barbara Wells","R Tyler Miller","Susan Hedayati","Jeffrey Hastings","Adeola Jaiyeola","Tuan-Minh Nguyen","Brett Moran","Noel Santini","Blake Barker","Ferdinand Velasco","Lynn Myers","Thomas P Meehan","Chester Fox","Robert D Toto"],"significance":7,"published":"2024-04-04","source_date":"2024-04-04","image":"","kennis":[],"congress":"","summary_en":"This NEJM pragmatic trial evaluated whether structured CKD care with nephrological involvement reduces hospitalization in patients with chronic kidney disease, type 2 diabetes, and hypertension, testing a disease management approach for the cardiorenal population.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fff1e428b4b","type":"article","url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","title":"aMAZE: PVI met of zonder LAA-ligatie bij AF — JAMA RCT","title_en":"Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2024.3026","source_url":"https://doi.org/10.1001/jama.2024.3026","authors":["Dhanunjaya R Lakkireddy","David J Wilber","Suneet Mittal","David Tschopp","Christopher R Ellis","Abdi Rasekh","Troy Hounshell","Rudy Evonich","Sheetal Chandhok","Ronald D Berger","Rodney Horton","Michael H Hoskins","Hugh Calkins","Steven J Yakubov","Pamela Simons","Benjamin R Saville","Randall J Lee"],"significance":7,"published":"2024-04-02","source_date":"2024-04-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The aMAZE trial showed that adding epicardial left atrial appendage ligation to pulmonary vein isolation during AF catheter ablation did not significantly reduce AF recurrence, arguing against routine LAA ligation as an adjunct to rhythm control.","created":"2026-07-03T10:30:52Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26612b122f1e","type":"article","url":"https://hartvaat.nl/2024/04/02/ivus-versus-oct-versus-angiografie-voor-pci-begeleiding-meta-analyse/","title":"IVUS versus OCT versus angiografie voor PCI-begeleiding: meta-analyse","title_en":"Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067583","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067583","authors":["Daniele Giacoppo","Claudio Laudani","Giovanni Occhipinti","Marco Spagnolo","Antonio Greco","Carla Rochira","Federica Agnello","Davide Landolina","Maria Sara Mauro","Simone Finocchiaro","Placido Maria Mazzone","Nicola Ammirabile","Antonino Imbesi","Carmelo Raffo","Sergio Buccheri","Davide Capodanno"],"significance":7,"published":"2024-04-02","source_date":"2024-04-02","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This comprehensive meta-analysis comparing IVUS, OCT, and angiography-guided PCI confirmed that both intravascular imaging modalities are superior to angiography alone, with IVUS and OCT showing comparable outcomes to each other.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d112aba1041d","type":"article","url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","title":"Polygene risicoscore voor aortastenose naast klinische risicofactoren","title_en":"Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortadissectie","aortainsufficiëntie","aortastenose","biomarkers-cardiovasculair","gepersonaliseerde-geneeskunde","laminopathie","lipoproteïne-a","perifeer-vaatlijden","polygene-risicoscore","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2024.0011","source_url":"https://doi.org/10.1001/jamacardio.2024.0011","authors":["Aeron M Small","Giorgio E M Melloni","Frederick K Kamanu","Brian A Bergmark","Marc P Bonaca","Michelle L O'Donoghue","Robert P Giugliano","Benjamin M Scirica","Deepak Bhatt","Elliott M Antman","Itamar Raz","Stephen D Wiviott","Buu Truong","Peter W F Wilson","Kelly Cho","Christopher J O'Donnell","Eugene Braunwald","Steve A Lubitz","Patrick Ellinor","Gina M Peloso","Christian T Ruff","Marc S Sabatine","Pradeep Natarajan","Nicholas A Marston"],"significance":6,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/","https://hartvaat.nl/kennis/kleplijden/tavi-transcatheter-aortaklepimplantatie/"],"congress":"","summary_en":"This study developed a novel polygenic risk score for aortic stenosis that improves risk prediction beyond clinical factors alone, advancing the potential for genetics-guided screening in valvular disease.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b535ae85c3a9","type":"article","url":"https://hartvaat.nl/2024/04/01/interventies-voor-optimalisatie-van-richtlijnmedicatie-bij-hartfalen-systematisc/","title":"Interventies voor optimalisatie van richtlijnmedicatie bij hartfalen: systematische review","title_en":"Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","farmaco-economie","hartrevalidatie","primaire-preventie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.5627","source_url":"https://doi.org/10.1001/jamacardio.2023.5627","authors":["Amber B Tang","Nicholas K Brownell","Jacob S Roberts","Amier Haidar","Antonia Osuna-Garcia","David J Cho","Pooya Bokhoor","Gregg C Fonarow"],"significance":6,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-polikliniek-opzet/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This systematic review identified that multidisciplinary team-based approaches and clinical decision support are the most effective interventions for optimizing guideline-directed medical therapy in heart failure.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"942887c4bf95","type":"article","url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","title":"Lp(a) en hsCRP als CV-risicofactoren: primaire en secundaire preventie","title_en":"Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","inflammatie","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","secundaire-preventie","slaapapneu"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.5605","source_url":"https://doi.org/10.1001/jamacardio.2023.5605","authors":["Aeron M Small","Ashley Pournamdari","Giorgio E M Melloni","Benjamin M Scirica","Deepak L Bhatt","Itamar Raz","Eugene Braunwald","Robert P Giugliano","Marc S Sabatine","Gina M Peloso","Nicholas A Marston","Pradeep Natarajan"],"significance":7,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This analysis showed that Lp(a) and hsCRP independently predict cardiovascular risk in both primary and secondary prevention populations, supporting measurement of both biomarkers for comprehensive residual risk assessment.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"49f38c4a2bd8","type":"article","url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","title":"Bètablokkerstaken verbetert inspanningscapaciteit bij HFpEF","title_en":"β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.5500","source_url":"https://doi.org/10.1001/jamacardio.2023.5500","authors":["Patricia Palau","Rafael de la Espriella","Julia Seller","Enrique Santas","Eloy Domínguez","Vicent Bodí","Juan Sanchis","Eduardo Núñez","Antoni Bayés-Genís","Vicente Bertomeu-González","Markus Meyer","Julio Núñez"],"significance":7,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"This study showed that withdrawing beta-blockers in HFpEF patients improves exercise capacity and chronotropic response, supporting the concept that beta-blocker-induced chronotropic incompetence contributes to exercise limitation in this population.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a86097156db5","type":"article","url":"https://hartvaat.nl/2024/04/01/notion-10-jaar-tavr-versus-chirurgie-bij-laagrisico-aortastenose/","title":"NOTION 10 jaar: TAVR versus chirurgie bij laagrisico aortastenose","title_en":"Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aortastenose"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae043","source_url":"https://doi.org/10.1093/eurheartj/ehae043","authors":["Hans Gustav Hørsted Thyregod","Troels Højsgaard Jørgensen","Nikolaj Ihlemann","Daniel Andreas Steinbrüchel","Henrik Nissen","Bo Juel Kjeldsen","Petur Petursson","Ole De Backer","Peter Skov Olsen","Lars Søndergaard"],"significance":8,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"The 10-year NOTION results showed comparable survival between TAVR and surgical aortic valve replacement in low-risk patients, though more TAVR patients required reintervention for valve degeneration. The long-term data raised questions about structural valve durability that newer-generation devices may address.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42142d2751c5","type":"article","url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","title":"Icosapent ethyl na ACS: REDUCE-IT subanalyse","title_en":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["acuut-coronair-syndroom"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad889","source_url":"https://doi.org/10.1093/eurheartj/ehad889","authors":["Neila Sayah","Deepak L Bhatt","Michael Miller","Eliot A Brinton","Terry A Jacobson","Steven B Ketchum","Lixia Jiao","Armando Lira Pineda","Ralph T Doyle","Jean Claude Tardif","Christie M Ballantyne","Ph Gabriel Steg"],"significance":6,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This REDUCE-IT subanalysis in patients with recent ACS confirmed the cardiovascular benefit of icosapent ethyl in this high-risk post-acute setting.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eecc79aded63","type":"article","url":"https://hartvaat.nl/2024/04/01/cardiorace-aeroob-krachttraining-of-gecombineerd-en-cardiovasculair-risicoprofie/","title":"CardioRACE: aeroob, krachttraining of gecombineerd en cardiovasculair risicoprofiel","title_en":"Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["hartrevalidatie","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad827","source_url":"https://doi.org/10.1093/eurheartj/ehad827","authors":["Duck-Chul Lee","Angelique G Brellenthin","Lorraine M Lanningham-Foster","Marian L Kohut","Yehua Li"],"significance":7,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The CardioRACE trial compared aerobic, resistance, and combined exercise training on cardiovascular risk profile in overweight adults, finding that combined training provides the most comprehensive cardiovascular risk factor improvement.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5c7ab336eca","type":"article","url":"https://hartvaat.nl/2024/04/01/space-raas-remmers-stoppen-versus-continueren-voor-niet-cardiale-chirurgie/","title":"SPACE: RAAS-remmers stoppen versus continueren voor niet-cardiale chirurgie","title_en":"Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad716","source_url":"https://doi.org/10.1093/eurheartj/ehad716","authors":["Gareth L Ackland","Akshaykumar Patel","Tom E F Abbott","Salma Begum","Priyanthi Dias","David R Crane","Sameer Somanath","Alexander Middleditch","Stuart Cleland","Ana Gutierrez Del Arroyo","David Brealey","Rupert M Pearse"],"significance":7,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":[],"congress":"","summary_en":"The SPACE trial showed that continuing RAAS inhibitors before non-cardiac surgery is safe with comparable hemodynamic stability, addressing the common clinical dilemma of perioperative medication management.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4989e0e22dd","type":"article","url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","title":"Inspanningstraining en hoog-sensitief troponine I bij HFrEF","title_en":"Exercise training and high-sensitivity cardiac troponin-I in patients with heart failure with reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","cardiogene-shock","hartrevalidatie","myocardinfarct","troponine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14674","source_url":"https://doi.org/10.1002/ehf2.14674","authors":["Egil Riveland","Torstein Valborgland","Anastasia Ushakova","Øyvind Skadberg","Trine Karlsen","Torstein Hole","Asbjørn Støylen","Håvard Dalen","Vibeke Videm","Elias Koppen","Axel Linke","Charles Delagardelle","Emeline M Van Craenenbroeck","Paul Beckers","Eva Prescott","Martin Halle","Torbjørn Omland","Øyvind Ellingsen","Alf Inge Larsen"],"significance":5,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/"],"congress":"","summary_en":"This SMARTEX substudy found that exercise training does not significantly reduce high-sensitivity troponin I in HFrEF, suggesting that the exercise benefit operates through mechanisms other than subclinical myocardial injury reduction.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"742e19cc4648","type":"article","url":"https://hartvaat.nl/2024/04/01/halp-score-hemoglobine-albumine-lymfocyten-trombocyten-en-mortaliteit-bij-hartfa/","title":"HALP-score (hemoglobine, albumine, lymfocyten, trombocyten) en mortaliteit bij hartfalen","title_en":"Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14662","source_url":"https://doi.org/10.1002/ehf2.14662","authors":["Ling Liu","Benbingdi Gong","Wei Wang","Kai Xu","Kaoshan Wang","Guixian Song"],"significance":5,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This study showed that the HALP score (combining hemoglobin, albumin, lymphocytes, and platelets) predicts mortality in heart failure, establishing a simple, widely available composite laboratory marker for HF prognosis.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26e9435fc0f6","type":"article","url":"https://hartvaat.nl/2024/04/01/veiligheid-van-sglt2-remmers-bij-hartfalen-meta-analyse/","title":"Veiligheid van SGLT2-remmers bij hartfalen: meta-analyse","title_en":"Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["empagliflozine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14633","source_url":"https://doi.org/10.1002/ehf2.14633","authors":["Hamidreza Soleimani","Behrad Saeedian","Yeganeh Pasebani","Nastaran Babajani","Amirreza Pashapour Yeganeh","Pegah Bahirai","Hossein Navid","Ahmad Amin","Marc D Samsky","Micheal G Nanna","Kaveh Hosseini"],"significance":6,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This meta-analysis confirmed the favorable safety profile of SGLT2 inhibitors in heart failure, with no increase in serious adverse events including diabetic ketoacidosis, genital infections, or hypotension-related events.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5a79d0e2646","type":"article","url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","title":"IV ferricarboxymaltose verbetert linkeratriale strain bij hartfalen: Myocardial-IRON","title_en":"Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfref","ijzersuppletie","ijzertekort","myocardinfarct"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14630","source_url":"https://doi.org/10.1002/ehf2.14630","authors":["Enrique Santas","Irene Del Canto","Ingrid Cardells","Gema Miñana","Pau Llàcer","Luis Almenar","Lorenzo Fácila","Alicia M Maceira","Juan Sanchis","Julio Núñez"],"significance":5,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/echocardiografie-bij-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"This Myocardial-IRON subanalysis showed that IV ferric carboxymaltose improves left atrial strain in heart failure with iron deficiency, demonstrating atrial functional benefit from iron repletion.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb0382c8d2e7","type":"article","url":"https://hartvaat.nl/2024/03/30/qdot-by-lawt-gepersonaliseerde-pvi-gestuurd-door-linkeratriale-wanddikte/","title":"QDOT-by-LAWT: gepersonaliseerde PVI gestuurd door linkeratriale wanddikte","title_en":"Personalized pulmonary vein isolation with very high-power short-duration lesions guided by left atrial wall thickness: the QDOT-by-LAWT randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae087","source_url":"https://doi.org/10.1093/europace/euae087","authors":["Giulio Falasconi","Diego Penela","David Soto-Iglesias","Pietro Francia","Andrea Saglietto","Dario Turturiello","Daniel Viveros","Aldo Bellido","Jose Alderete","Fatima Zaraket","Paula Franco-Ocaña","Marina Huguet","Óscar Cámara","Radu Vătășescu","José-Tomás Ortiz-Pérez","Julio Martí-Almor","Antonio Berruezo"],"significance":6,"published":"2024-03-30","source_date":"2024-03-30","image":"","kennis":[],"congress":"","summary_en":"This randomized trial tested whether personalizing RF ablation energy delivery based on left atrial wall thickness improves pulmonary vein isolation outcomes for paroxysmal AF.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5053e5a27f1d","type":"article","url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","title":"Sacubitril/valsartan bij gedecompenseerd hartfalen tijdens opname","title_en":"Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","bisoprolol","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.01.027","source_url":"https://doi.org/10.1016/j.jacc.2024.01.027","authors":["David A Morrow","Eric J Velazquez","Akshay S Desai","Adam D DeVore","Serge Lepage","Jeong-Gun Park","Kavita Sharma","Scott D Solomon","Randall C Starling","Jonathan H Ward","Kristin M Williamson","Shelley Zieroth","Adrian F Hernandez","Robert J Mentz","Eugene Braunwald"],"significance":6,"published":"2024-03-26","source_date":"2024-03-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This study confirmed the safety and efficacy of initiating sacubitril-valsartan during hospitalization for decompensated heart failure across the ejection fraction spectrum, supporting inpatient ARNI start.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c660bf4987cb","type":"article","url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","title":"GRADE: CV-uitkomsten van glucoseverlagende middelen bij type 2 diabetes","title_en":"Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066604","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066604","authors":["Jennifer B Green","Brendan M Everett","Alokananda Ghosh","Naji Younes","Heidi Krause-Steinrauf","Joshua Barzilay","Cyrus Desouza","Silvio E Inzucchi","Yashashwi Pokharel","David Schade","Alexandra Scrymgeour","Meng H Tan","Kristina M Utzschneider","Sunder Mudaliar"],"significance":7,"published":"2024-03-26","source_date":"2024-03-26","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"The GRADE cardiovascular outcomes analysis showed that liraglutide offered the most favorable cardiovascular profile among the four glucose-lowering agents tested (glimepiride, sitagliptin, liraglutide, insulin glargine) when added to metformin in type 2 diabetes.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5f38b894ad9","type":"article","url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","title":"DOAC's bij device-gedetecteerd AF: meta-analyse NOAH-AFNET 6 en ARTESIA","title_en":"Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067512","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067512","authors":["William F McIntyre","Alexander P Benz","Nina Becher","Jeffrey S Healey","Christopher B Granger","Lena Rivard","A John Camm","Andreas Goette","Antonia Zapf","Marco Alings","Stuart J Connolly","Paulus Kirchhof","Renato D Lopes"],"significance":8,"published":"2024-03-26","source_date":"2024-03-26","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/hasbled-score/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis of NOAH-AFNET 6 and ARTESIA showed that DOACs modestly reduce stroke in patients with device-detected subclinical AF but significantly increase bleeding. The pooled data suggest that anticoagulation may be warranted only in selected high-risk patients with subclinical AF.","created":"2026-07-03T10:30:50Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"203dc9924b32","type":"article","url":"https://hartvaat.nl/2024/03/23/photon-aflibercept-8-mg-bij-diabetisch-macula-oedeem-verlengd-doseerinterval/","title":"PHOTON: aflibercept 8 mg bij diabetisch macula-oedeem — verlengd doseerinterval","title_en":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.","category":"preventie","category_label":"Preventie","professions":["internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02577-1","source_url":"https://doi.org/10.1016/S0140-6736(23)02577-1","authors":["David M Brown","David S Boyer","Diana V Do","Charles C Wykoff","Taiji Sakamoto","Peter Win","Sunir Joshi","Hani Salehi-Had","András Seres","Alyson J Berliner","Sergio Leal","Robert Vitti","Karen W Chu","Kimberly Reed","Rohini Rao","Yenchieh Cheng","Wei Sun","Delia Voronca","Rafia Bhore","Ursula Schmidt-Ott","Thomas Schmelter","Andrea Schulze","Xin Zhang","Boaz Hirshberg","George D Yancopoulos","Sobha Sivaprasad"],"significance":6,"published":"2024-03-23","source_date":"2024-03-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The PHOTON trial showed that high-dose aflibercept 8 mg with extended dosing intervals up to 16 weeks is noninferior to standard aflibercept for diabetic macular edema, reducing treatment burden for this chronic eye condition.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a108e8ae1ed1","type":"article","url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","title":"Heropname na revascularisatie voor hoofdstamziekte: incidentie en impact","title_en":"Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.01.012","source_url":"https://doi.org/10.1016/j.jacc.2024.01.012","authors":["Ioanna Kosmidou","Bahira Shahim","Ovidiu Dressler","Björn Redfors","Marie-Claude Morice","John D Puskas","David E Kandzari","Dimitri Karmpaliotis","W Morris Brown","Nicholas J Lembo","Adrian P Banning","Arie Pieter Kappetein","Patrick W Serruys","Joseph F Sabik","Gregg W Stone"],"significance":5,"published":"2024-03-19","source_date":"2024-03-19","image":"","kennis":[],"congress":"","summary_en":"This study documented the frequency and prognostic impact of hospital readmission after left main revascularization, showing that early readmission is common and associated with worse long-term survival.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e78ebe7c16c1","type":"article","url":"https://hartvaat.nl/2024/03/19/nierschade-na-minimale-contrasttoediening-bij-acs/","title":"Nierschade na minimale contrasttoediening bij ACS","title_en":"Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["chronische-nierziekte"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.01.016","source_url":"https://doi.org/10.1016/j.jacc.2024.01.016","authors":["Carlo Briguori","Cristina Quintavalle","Enrica Mariano","Alessandro D'Agostino","Mario Scarpelli","Amelia Focaccio","Giuseppe Biondi Zoccai","Salvatore Evola","Giovanni Esposito","Giuseppe Massimo Sangiorgi","Gerolama Condorelli"],"significance":6,"published":"2024-03-19","source_date":"2024-03-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hypertriglyceridemie/"],"congress":"","summary_en":"This study showed that even minimal contrast administration during PCI for ACS can cause kidney injury, particularly in patients with pre-existing renal impairment, informing ultra-low contrast strategies.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3fe308da456","type":"article","url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","title":"COMBINE AF: NOAC's versus warfarine over BMI-spectrum bij AF","title_en":"Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["obesitas"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066279","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066279","authors":["Siddharth M Patel","Eugene Braunwald","Jan Steffel","Giuseppe Boriani","Michael G Palazzolo","Elliott M Antman","Erin A Bohula","Anthony P Carnicelli","Stuart J Connolly","John W Eikelboom","Baris Gencer","Christopher B Granger","David A Morrow","Manesh R Patel","Lars Wallentin","Christian T Ruff","Robert P Giugliano"],"significance":7,"published":"2024-03-19","source_date":"2024-03-19","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This COMBINE AF patient-level analysis confirmed that NOACs maintain superior efficacy and safety compared with warfarin across the full BMI spectrum in AF, providing reassurance for DOAC use in both normal-weight and obese patients.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56743f6a4bd9","type":"article","url":"https://hartvaat.nl/2024/03/16/firstmappp-sunitinib-bij-metastatische-feochromocytomen-en-paragangliomen/","title":"FIRSTMAPPP: sunitinib bij metastatische feochromocytomen en paragangliomen","title_en":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02554-0","source_url":"https://doi.org/10.1016/S0140-6736(23)02554-0","authors":["Eric Baudin","Bernard Goichot","Alfredo Berruti","Julien Hadoux","Salma Moalla","Sandrine Laboureau","Svenja Nölting","Christelle de la Fouchardière","Tina Kienitz","Timo Deutschbein","Stefania Zovato","Laurence Amar","Magalie Haissaguerre","Henri Timmers","Patricia Niccoli","Antongiulio Faggiano","Moussa Angokai","Livia Lamartina","Florina Luca","Deborah Cosentini","Stefanie Hahner","Felix Beuschlein","Marie Attard","Matthieu Texier","Martin Fassnacht"],"significance":6,"published":"2024-03-16","source_date":"2024-03-16","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This Lancet trial of sunitinib for metastatic phaeochromocytomas/paragangliomas is relevant to cardiology due to the cardiovascular effects of catecholamine-secreting tumors and the cardiotoxicity profile of tyrosine kinase inhibitors.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae410fd97ec8","type":"article","url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","title":"RAPID NSTEMI: zeer vroege invasieve strategie bij hoger risico NSTEMI","title_en":"Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-323513","source_url":"https://doi.org/10.1136/heartjnl-2023-323513","authors":["Thomas A Kite","Andrew Ladwiniec","John P Greenwood","Chris P Gale","Brijesh Anantharam","Ranjit More","Simon Lee Hetherington","Sohail Q Khan","Peter O'Kane","Roby Rakhit","Alexander Chase","Shaun Barber","Ghazala Waheed","Colin Berry","Marcus Flather","Gerry P McCann","Nick Curzen","Adrian P Banning","Anthony H Gershlick"],"significance":6,"published":"2024-03-12","source_date":"2024-03-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/nstemi-en-instabiele-angina/"],"congress":"","summary_en":"The RAPID NSTEMI trial tested a very early invasive strategy (within 2 hours) for higher-risk NSTEMI, finding that ultra-early intervention does not significantly improve outcomes over standard-timing invasive care.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"628ff98a1875","type":"article","url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","title":"MRA's verminderen AF-risico: meta-analyse van klinische trials","title_en":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["abelacimab","aperitif-trial","colcot-trial","farmaco-economie","finerenon","finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","rivaroxaban"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad811","source_url":"https://doi.org/10.1093/eurheartj/ehad811","authors":["Alireza Oraii","Jeff S Healey","Krzysztof Kowalik","Avinash K Pandey","Alexander P Benz","Jorge A Wong","David Conen","William F McIntyre"],"significance":7,"published":"2024-03-07","source_date":"2024-03-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/mineralocorticoid-antagonisten-farmacologie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis of clinical trials showed that mineralocorticoid receptor antagonists reduce the risk of atrial fibrillation in heart failure patients, suggesting that the antifibrotic and anti-remodeling effects of MRAs extend to the atrial substrate.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2956223d0863","type":"article","url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","title":"PARADISE-MI: sacubitril/valsartan bij STEMI versus NSTEMI","title_en":"Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.01.002","source_url":"https://doi.org/10.1016/j.jacc.2024.01.002","authors":["Douglas L Mann","Johny Nicolas","Brian Claggett","Zi Michael Miao","Christopher B Granger","Prafulla Kerkar","Lars Køber","Eldrin F Lewis","John J V McMurray","Aldo P Maggioni","Julio Núñez","Mpiko Ntsekhe","Jean-Lucien Rouleau","David Sim","Scott D Solomon","Philippe Gabriel Steg","Peter van der Meer","Eugene Braunwald","Marc A Pfeffer","Roxana Mehran"],"significance":6,"published":"2024-03-05","source_date":"2024-03-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This subanalysis compared the effects of sacubitril-valsartan in STEMI versus NSTEMI after acute MI, showing comparable neurohormonal effects regardless of the acute MI subtype.","created":"2026-07-03T10:30:49Z","updated":"2026-07-03T13:29:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14304b9ffa17","type":"article","url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","title":"RADIANCE gepoolde analyse: ultrageluid renale denervatie na medicatie-optitratie","title_en":"Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["fidelity","radiance-htn","renale-denervatie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066941","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066941","authors":["Michel Azizi","Andrew S P Sharp","Naomi D L Fisher","Michael A Weber","Melvin D Lobo","Joost Daemen","Philipp Lurz","Felix Mahfoud","Roland E Schmieder","Jan Basile","Michael J Bloch","Manish Saxena","Yale Wang","Kintur Sanghvi","J Stephen Jenkins","Chandan Devireddy","Florian Rader","Philippe Gosse","Lisa Claude","Dimitri A Augustin","Candace K McClure","Ajay J Kirtane"],"significance":7,"published":"2024-03-05","source_date":"2024-03-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This pooled patient-level RADIANCE analysis confirmed that ultrasound renal denervation provides additive blood pressure reduction when initiated after medication optimization, demonstrating a consistent device effect on top of pharmacotherapy.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2fa18aaf3b76","type":"article","url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","title":"Gelijktijdige LAA-occlusie en TAVR bij AF: haalbaarheid","title_en":"Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067312","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067312","authors":["Samir R Kapadia","Amar Krishnaswamy","Brian Whisenant","Srinivasa Potluri","Vijay Iyer","Joseph Aragon","Philip Gideon","Justin Strote","Robert Leonardi","Himanshu Agarwal","German Larrain","Carlos Sanchez","Sidakpal S Panaich","James Harvey","Torsten Vahl","Venu Menon","Kathy Wolski","Qiuqing Wang","Martin B Leon"],"significance":6,"published":"2024-03-05","source_date":"2024-03-05","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This study demonstrated the feasibility and safety of concurrent LAA occlusion during TAVR in AF patients, exploring a combined structural intervention that addresses both valve disease and stroke prevention in a single procedure.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d88d2f03cca6","type":"article","url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","title":"Intravasculaire beeldvorming bij DES-implantatie: Lancet netwerk-meta-analyse","title_en":"Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02454-6","source_url":"https://doi.org/10.1016/S0140-6736(23)02454-6","authors":["Gregg W Stone","Evald H Christiansen","Ziad A Ali","Lene N Andreasen","Akiko Maehara","Yousif Ahmad","Ulf Landmesser","Niels R Holm"],"significance":8,"published":"2024-03-02","source_date":"2024-03-02","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This updated Lancet network meta-analysis confirmed that intravascular imaging-guided DES implantation (either IVUS or OCT) is superior to angiography-guided PCI for reducing cardiovascular death, MI, and stent thrombosis. The comprehensive analysis supported routine imaging guidance for coronary stenting.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42d00a18acf2","type":"article","url":"https://hartvaat.nl/2024/03/01/svc-isolatie-bij-paroxysmaal-af-zonder-geinduceerde-svc-aritmieen/","title":"SVC-isolatie bij paroxysmaal AF zonder geïnduceerde SVC-aritmieën","title_en":"Role of electroanatomical mapping-guided superior vena cava isolation in paroxysmal atrial fibrillation patients without provoked superior vena cava triggers: a randomized controlled study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae039","source_url":"https://doi.org/10.1093/europace/euae039","authors":["Yan Dong","Dongsheng Zhao","Xinguang Chen","Linshen Shi","Qiushi Chen","Haiyan Zhang","Yue Yu","Inam Ullah","Pipin Kojodjojo","Fengxiang Zhang"],"significance":5,"published":"2024-03-01","source_date":"2024-03-01","image":"","kennis":[],"congress":"","summary_en":"This study found that empirical superior vena cava isolation during AF ablation does not improve outcomes in paroxysmal AF patients without demonstrated SVC triggers, arguing against routine SVC isolation.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"607ca086966a","type":"article","url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","title":"DELIVER: dapagliflozine vermindert plotse hartdood bij verbeterde EF","title_en":"Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bisoprolol","dapa-hf","dapagliflozine","empagliflozine","hfref"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.5318","source_url":"https://doi.org/10.1001/jamacardio.2023.5318","authors":["Orly Vardeny","Akshay S Desai","Pardeep S Jhund","James C Fang","Brian Claggett","Rudolf A de Boer","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe A Martinez","Sanjiv J Shah","Finnian R Mc Causland","Mark C Petrie","Muthiah Vaduganathan","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2024-03-01","source_date":"2024-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This DELIVER post-hoc analysis showed that dapagliflozin favorably affects the mode of death in patients with heart failure and improved ejection fraction, including a potential reduction in sudden cardiac death in this previously understudied population.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09490902052c","type":"article","url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","title":"CLEAR Outcomes: bempedoïnezuur vermindert totale CV-events bij statine-intolerantie","title_en":"Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","clear-outcomes"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.5155","source_url":"https://doi.org/10.1001/jamacardio.2023.5155","authors":["Stephen J Nicholls","Adam J Nelson","A Michael Lincoff","Danielle Brennan","Kausik K Ray","Leslie Cho","Venu Menon","Na Li","LeAnne Bloedon","Steven E Nissen"],"significance":8,"published":"2024-03-01","source_date":"2024-03-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This CLEAR Outcomes analysis of total cardiovascular events (including recurrent) showed that bempedoic acid significantly reduces the total burden of cardiovascular events in statin-intolerant patients, with greater absolute benefit than suggested by first-event analysis alone.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"06b467182422","type":"article","url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","title":"POST-PCI: routine stresstesten bij diabetespatiënten na PCI niet zinvol","title_en":"Routine stress testing in diabetic patients after percutaneous coronary intervention: the POST-PCI trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["soul-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad722","source_url":"https://doi.org/10.1093/eurheartj/ehad722","authors":["Hoyun Kim","Do-Yoon Kang","Jinho Lee","Yeonwoo Choi","Jung-Min Ahn","Seonok Kim","Yong-Hoon Yoon","Seung-Ho Hur","Cheol Hyun Lee","Won-Jang Kim","Se Hun Kang","Chul Soo Park","Bong-Ki Lee","Jung-Won Suh","Jae Woong Choi","Kee-Sik Kim","Su Nam Lee","Seung-Jung Park","Duk-Woo Park"],"significance":7,"published":"2024-03-01","source_date":"2024-03-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/"],"congress":"","summary_en":"The POST-PCI trial confirmed that routine stress testing in diabetic patients after PCI does not improve clinical outcomes compared with a symptom-guided approach, arguing against surveillance testing even in this high-risk population.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T13:29:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"09f3db6043df","type":"article","url":"https://hartvaat.nl/2024/03/01/thuisbloeddruk-geleide-farmacotherapie-via-telezorg-meta-analyse-van-vs-trials/","title":"Thuisbloeddruk-geleide farmacotherapie via telezorg: meta-analyse van VS-trials","title_en":"Self-Measured Blood Pressure-Guided Pharmacotherapy: A Systematic Review and Meta-Analysis of United States-Based Telemedicine Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","thuisbloeddrukmeting"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.22109","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.22109","authors":["Sameer Acharya","Gagan Neupane","Austin Seals","Madhav Kc","Dean Giustini","Sharan Sharma","Yhenneko J Taylor","Deepak Palakshappa","Jeff D Williamson","Justin B Moore","Hayden B Bosworth","Yashashwi Pokharel"],"significance":6,"published":"2024-03-01","source_date":"2024-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This meta-analysis of US-based telehealth trials confirmed that self-measured blood pressure-guided pharmacotherapy significantly improves blood pressure control compared with usual care, supporting the implementation of telemedicine hypertension management.","created":"2026-07-03T10:30:48Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be1c3fc4fb3d","type":"article","url":"https://hartvaat.nl/2024/02/23/ar-brillen-voor-ef-schatting-bij-hartfalen-haalbaarheidstudie/","title":"AR-brillen voor EF-schatting bij hartfalen: haalbaarheidstudie","title_en":"Accuracy of visual estimation of ejection fraction in patients with heart failure using augmented reality glasses.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-323067","source_url":"https://doi.org/10.1136/heartjnl-2023-323067","authors":["Sungwoo Choi","Sangun Nah","Young Soon Cho","Inki Moon","Jae Wook Lee","Choung Ah Lee","Ji Eun Moon","Sangsoo Han"],"significance":5,"published":"2024-02-23","source_date":"2024-02-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"This study evaluated augmented reality glasses for improving visual estimation of ejection fraction in heart failure, testing whether wearable display technology enhances bedside cardiac assessment.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12faea3a61b4","type":"article","url":"https://hartvaat.nl/2024/02/20/zoutvervanger-voorkomt-hypertensie-bij-normotensieve-volwassenen/","title":"Zoutvervanger voorkomt hypertensie bij normotensieve volwassenen","title_en":"Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","ezetimibe","figaro-dkd","perifeer-vaatlijden","precision-trial","primaire-preventie","renale-denervatie","select-trial","summit-trial","vrouwen","zwangerschap-hart"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.12.013","source_url":"https://doi.org/10.1016/j.jacc.2023.12.013","authors":["Xianghui Zhang","Yifang Yuan","Chenglong Li","Xiangxian Feng","Hongxia Wang","Qianku Qiao","Ruijuan Zhang","Aoming Jin","Jiayu Li","Huijuan Li","Yangfeng Wu"],"significance":7,"published":"2024-02-20","source_date":"2024-02-20","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/"],"congress":"","summary_en":"This randomized trial showed that a potassium-enriched salt substitute significantly reduces the incidence of hypertension in normotensive adults, demonstrating that population-level dietary sodium-potassium modification can prevent blood pressure elevation before it starts.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2c4e664fdf86","type":"article","url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","title":"STOPDAPT-3: aspirinevrij versus standaard DAPT na coronaire stenting","title_en":"An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066720","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066720","authors":["Masahiro Natsuaki","Hirotoshi Watanabe","Takeshi Morimoto","Ko Yamamoto","Yuki Obayashi","Ryusuke Nishikawa","Kenji Ando","Takenori Domei","Satoru Suwa","Manabu Ogita","Tsuyoshi Isawa","Hiroyuki Takenaka","Takashi Yamamoto","Tetsuya Ishikawa","Itaru Hisauchi","Kohei Wakabayashi","Yuko Onishi","Kiyoshi Hibi","Kazuya Kawai","Ruka Yoshida","Hiroshi Suzuki","Gaku Nakazawa","Takanori Kusuyama","Itsuro Morishima","Koh Ono","Takeshi Kimura"],"significance":8,"published":"2024-02-20","source_date":"2024-02-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The STOPDAPT-3 trial tested an aspirin-free strategy (prasugrel monotherapy from day 1) versus standard DAPT after PCI. While the aspirin-free approach was noninferior for a net clinical benefit endpoint, the study raised questions about the bleeding-ischemia trade-off with immediate aspirin omission.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d916d778e3e","type":"article","url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","title":"T-PASS: ticagrelor monotherapie binnen 1 maand na stenting bij ACS","title_en":"Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066943","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066943","authors":["Sung-Jin Hong","Seung-Jun Lee","Yongsung Suh","Kyeong Ho Yun","Tae Soo Kang","Sanghoon Shin","Sung Woo Kwon","Jun-Won Lee","Deok-Kyu Cho","Jong-Kwan Park","Jang-Whan Bae","Woong Cheol Kang","Seunghwan Kim","Yong-Joon Lee","Chul-Min Ahn","Jung-Sun Kim","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Yangsoo Jang","Myeong-Ki Hong"],"significance":8,"published":"2024-02-20","source_date":"2024-02-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/cardiometabool/peripartum-cardiomyopathie/"],"congress":"","summary_en":"The T-PASS trial showed that stopping aspirin within 1 month after DES implantation for ticagrelor monotherapy in ACS patients was noninferior to 12-month DAPT for ischemic events and reduced major bleeding. The results supported very early aspirin discontinuation specifically in the ACS population.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"195e51f4edb8","type":"article","url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","title":"Ticagrelor monotherapie na ACS: IPD meta-analyse van vroege aspirinestop","title_en":"Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067283","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067283","authors":["Usman Baber","Yangsoo Jang","Angelo Oliva","Davide Cao","Birgit Vogel","George Dangas","Samantha Sartori","Alessandro Spirito","Kenneth F Smith","Mattia Branca","Timothy Collier","Stuart Pocock","Marco Valgimigli","Byeong-Keuk Kim","Myeong-Ki Hong","Roxana Mehran"],"significance":8,"published":"2024-02-20","source_date":"2024-02-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that early aspirin cessation with ticagrelor monotherapy after ACS and PCI is safe with significantly less bleeding, without increasing the risk of ischemic events. The pooled patient-level evidence provides the strongest support for this de-escalation strategy.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e78e7ae607d1","type":"article","url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","title":"CIRCA-DOSE: AF-progressie na cryoablatie versus RF-ablatie","title_en":"Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: the CIRCA-DOSE trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad572","source_url":"https://doi.org/10.1093/eurheartj/ehad572","authors":["Jason G Andrade","Marc W Deyell","Paul Khairy","Jean Champagne","Peter Leong-Sit","Paul Novak","Lawrence Sterns","Jean-Francois Roux","John Sapp","Richard Bennett","Matthew Bennett","Nathaniel Hawkins","Prashanthan Sanders","Laurent Macle"],"significance":6,"published":"2024-02-16","source_date":"2024-02-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"The CIRCA-DOSE trial showed that AF progression from paroxysmal to persistent is comparable between cryoballoon and radiofrequency ablation, suggesting that the energy source does not significantly influence the natural history of AF.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1954ce99c4be","type":"article","url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","title":"Implanteerbare hemodynamische monitoren verbeteren overleving bij HFrEF","title_en":"Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","thuisbloeddrukmeting"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.11.030","source_url":"https://doi.org/10.1016/j.jacc.2023.11.030","authors":["JoAnn Lindenfeld","Maria Rosa Costanzo","Michael R Zile","Anique Ducharme","Richard Troughton","Alan Maisel","Mandeep R Mehra","Sara Paul","Samuel F Sears","Frank Smart","Nessa Johnson","John Henderson","Philip B Adamson","Akshay S Desai","William T Abraham"],"significance":8,"published":"2024-02-13","source_date":"2024-02-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/cardiogene-shock/"],"congress":"","summary_en":"This analysis demonstrated that implantable pulmonary artery pressure monitors not only reduce heart failure hospitalization but also improve survival in patients with HFrEF. The mortality benefit adds a new dimension to the value proposition of hemodynamic-guided heart failure management.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3d8326f5dc6","type":"article","url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","title":"Bariatrische chirurgie en bloeddruk na 5 jaar: gerandomiseerde trial","title_en":"Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","obesitas","select-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.11.032","source_url":"https://doi.org/10.1016/j.jacc.2023.11.032","authors":["Carlos A Schiavon","Alexandre B Cavalcanti","Juliana D Oliveira","Rachel H V Machado","Eliana V Santucci","Renato N Santos","Julia S Oliveira","Lucas P Damiani","Débora Junqueira","Helio Halpern","Frederico de L J Monteiro","Patricia M Noujaim","Ricardo V Cohen","Marcio G de Sousa","Luiz A Bortolotto","Otavio Berwanger","Luciano F Drager"],"significance":7,"published":"2024-02-13","source_date":"2024-02-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This 5-year randomized trial confirmed that bariatric surgery provides superior long-term blood pressure reduction compared with lifestyle intervention alone in obese hypertensive patients, supporting surgical weight loss as an effective antihypertensive strategy.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"07a2adaa4542","type":"article","url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","title":"POP-HT: bloeddrukzelfmanagement verbetert cardiale remodelling na hypertensieve zwangerschap","title_en":"Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["atriale-cardiomyopathie","bloeddrukbehandeling","peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067597","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067597","authors":["Jamie Kitt","Samuel Krasner","Logan Barr","Annabelle Frost","Katherine Tucker","Paul A Bateman","Katie Suriano","Yvonne Kenworthy","Winok Lapidaire","Miriam Lacharie","Rebecca Mills","Cristian Roman","Lucy Mackillop","Alexandra Cairns","Christina Aye","Vanessa Ferreira","Stefan Piechnik","Elena Lukaschuk","Basky Thilaganathan","Lucy C Chappell","Adam J Lewandowski","Richard J McManus","Paul Leeson"],"significance":7,"published":"2024-02-13","source_date":"2024-02-13","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This POP-HT follow-up showed that physician-guided blood pressure self-management after hypertensive pregnancy reduces adverse cardiac remodeling, providing evidence that early postpartum blood pressure control can mitigate long-term cardiovascular structural changes.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"31bb5cbdcbfe","type":"article","url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","title":"SWISS-APERO: Amulet versus Watchman na 1 jaar voor LAA-sluiting","title_en":"One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067599","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067599","authors":["Roberto Galea","Nicolas Meneveau","Federico De Marco","Adel Aminian","Dik Heg","Konstantina Chalkou","Christoph Gräni","Frederic Anselme","Anna Franzone","Pascal Vranckx","Urs Fischer","Francesco Bedogni","Lorenz Räber","Marco Valgimigli"],"significance":6,"published":"2024-02-06","source_date":"2024-02-06","image":"","kennis":[],"congress":"","summary_en":"One-year SWISS-APERO results showed comparable efficacy and safety between the Amulet and Watchman FLX devices for percutaneous LAA closure, informing device selection in clinical practice.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"928742587a03","type":"article","url":"https://hartvaat.nl/2024/02/01/sequentiele-hybride-ablatie-versus-chirurgische-cryomaze-bij-af-met-structurele-/","title":"Sequentiële hybride ablatie versus chirurgische CryoMaze bij AF met structurele hartziekte","title_en":"Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae040","source_url":"https://doi.org/10.1093/europace/euae040","authors":["Alan Bulava","Dan Wichterle","Aleš Mokráček","Pavel Osmančík","Petr Budera","Petr Kačer","Linda Vetešková","Petr Němec","Tomáš Skála","Petr Šantavý","Jan Chovančík","Piotr Branny","Vitalii Rizov","Miroslav Kolesár","Iva Šafaříková","Marian Rybář"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":[],"congress":"","summary_en":"This multicenter RCT showed that sequential hybrid ablation (combining surgical and catheter approaches) provides superior rhythm control compared with surgical CryoMaze alone in AF patients with structural heart disease.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef3147a9082a","type":"article","url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","title":"Pulmonaalvenenstenose na PFA versus thermale ablatie: vergelijking","title_en":"Pulmonary vein narrowing after pulsed field versus thermal ablation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["advent-trial","katheterablatie","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euae038","source_url":"https://doi.org/10.1093/europace/euae038","authors":["Moussa Mansour","Edward P Gerstenfeld","Chinmay Patel","Andrea Natale","William Whang","Frank A Cuoco","Stavros E Mountantonakis","Douglas N Gibson","John D Harding","Scott K Holland","Anitha B Achyutha","Christopher W Schneider","Andrew S Mugglin","Elizabeth M Albrecht","Kenneth M Stein","John W Lehmann","Vivek Y Reddy"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"This study showed that pulsed field ablation causes significantly less pulmonary vein narrowing than thermal ablation for AF, demonstrating a key safety advantage of the tissue-selective PFA technology.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"512be1f0729d","type":"article","url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","title":"TALOS-AMI: DAPT de-escalatie veilig bij MI met hoog ischemisch risico","title_en":"Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4587","source_url":"https://doi.org/10.1001/jamacardio.2023.4587","authors":["Myunhee Lee","Sungwook Byun","Sungmin Lim","Eun Ho Choo","Kwan Yong Lee","Donggyu Moon","Ik Jun Choi","Byung-Hee Hwang","Chan Joon Kim","Mahn-Won Park","Yun Seok Choi","Hee-Yeol Kim","Ki-Dong Yoo","Doo-Soo Jeon","Hyeon Woo Yim","Kiyuk Chang"],"significance":7,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"This TALOS-AMI post-hoc analysis confirmed that de-escalation from ticagrelor to clopidogrel after 1 month is safe even in high-ischemic-risk MI patients, extending the de-escalation evidence to the population with the greatest concern about reducing antiplatelet potency.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0a2a65d424e5","type":"article","url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","title":"MESSAGE-HF: geautomatiseerde sms na hartfalenopname verbetert uitkomsten niet","title_en":"Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4501","source_url":"https://doi.org/10.1001/jamacardio.2023.4501","authors":["Luis E Rohde","Marciane M Rover","Conrado R Hoffmann Filho","Eneida Rejane Rabelo-Silva","Odilson M Silvestre","Silvia M Martins","Luiz C S Passos","José A de Figueiredo Neto","Luiz C Danzmann","Fábio S Silveira","Cezar Eumann Mesas","Mauro E Hernandes","Lidia Z Moura","Marcus V Simões","Luiz E F Ritt","Fábio Akio Nishijuka","Eduardo G Bertoldi","Frederico T C Dall Orto","Ellen Hettwer Magedanz","Ricardo Mourilhe-Rocha","Miguel M Fernandes-Silva","Almir Sergio Ferraz","Pedro Schwartzmann","Fábio M de Castilho","Antonio Carlos Pereira Barretto","Edval Gomes Dos Santos Júnior","Paulo Roberto Nogueira","Manoel Canesin","Luis Beck-da-Silva","Maísa de Carvalho Silva","Mario Sergio Adolfi Júnior","Renato H N Santos","Amanda Ferreira","Danielle Pereira","Leticia López Pedraza","Flávia C S Kojima","Viviane Campos","Pedro G M de Barros E Silva","Mariana Blacher","Alexandre B Cavalcanti","Felix Ramires"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The MESSAGE-HF trial showed that automated text messaging after heart failure hospitalization does not significantly reduce readmissions or mortality, highlighting the limitations of simple digital interventions for complex disease management.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e378af941d9c","type":"article","url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","title":"TRANSFORM-HF: torsemide versus furosemide bij nieuw vs chronisch hartfalen","title_en":"Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["diuretica","furosemide","hfmref","hfref"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4776","source_url":"https://doi.org/10.1001/jamacardio.2023.4776","authors":["Selim R Krim","Senthil Anand","Stephen J Greene","Anqi Chen","Daniel Wojdyla","Juan Vilaro","Herbert Haught","John M Herre","Eric L Eisenstein","Kevin J Anstrom","Bertram Pitt","Eric J Velazquez","Robert J Mentz"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"This TRANSFORM-HF substudy showed no difference between torsemide and furosemide in either new-onset or worsening chronic heart failure, confirming loop diuretic equivalence across HF presentations.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3b7bec48d64a","type":"article","url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","title":"DELIVER: eGFR-dip na dapagliflozine bij HFpEF is veilig","title_en":"Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","hfpef","hfref","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4664","source_url":"https://doi.org/10.1001/jamacardio.2023.4664","authors":["Finnian R Mc Causland","Brian L Claggett","Muthiah Vaduganathan","Akshay Desai","Pardeep Jhund","Orly Vardeny","James C Fang","Rudolf A de Boer","Kieran F Docherty","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Jose F Kerr Saraiva","Martina M McGrath","Sanjiv J Shah","Subodh Verma","Anna Maria Langkilde","Magnus Petersson","John J V McMurray","Scott D Solomon"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This DELIVER subanalysis confirmed that the initial eGFR decline after dapagliflozin initiation in HFpEF is hemodynamic rather than nephrotoxic and is not associated with worse outcomes, supporting continued therapy despite early creatinine changes.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e40a67b8a99b","type":"article","url":"https://hartvaat.nl/2024/02/01/acyl-ghreline-verbetert-cardiac-output-met-behoud-van-rv-pa-koppeling-bij-hf/","title":"Acyl-ghreline verbetert cardiac output met behoud van RV-PA koppeling bij HF","title_en":"Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["diabetes-en-hart","ventrikelfibrilleren"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14580","source_url":"https://doi.org/10.1002/ehf2.14580","authors":["Mikael Erhardsson","Ulrika L Faxén","Ashwin Venkateshvaran","Camilla Hage","Gianluigi Pironti","Tonje Thorvaldsen","Dominic-Luc Webb","Per M Hellström","Daniel C Andersson","Marcus Ståhlberg","Lars H Lund"],"significance":5,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study confirmed that acyl ghrelin increases cardiac output in HFrEF while preserving right ventricular-pulmonary arterial coupling, supporting the safety of this metabolic hormone for hemodynamic augmentation.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"302805d59c87","type":"article","url":"https://hartvaat.nl/2024/02/01/maggic-score-voor-mortaliteitsvoorspelling-bij-klepziekte/","title":"MAGGIC-score voor mortaliteitsvoorspelling bij klepziekte","title_en":"Meta-Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14586","source_url":"https://doi.org/10.1002/ehf2.14586","authors":["Junxing Lv","Haiyan Xu","Yunqing Ye","Zhe Li","Weiwei Wang","Bin Zhang","Qinghao Zhao","Haitong Zhang","Zhenyan Zhao","Qingrong Liu","Bincheng Wang","Zhenya Duan","Zikai Yu","Shuai Guo","Yanyan Zhao","Runlin Gao","Junbo Ge","Yongjian Wu"],"significance":5,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":[],"congress":"","summary_en":"This study validated the MAGGIC risk score for mortality prediction in valvular heart disease patients with heart failure, showing acceptable discrimination for this important clinical subgroup.","created":"2026-07-03T10:30:46Z","updated":"2026-07-03T13:29:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dfe5eeea4bd8","type":"article","url":"https://hartvaat.nl/2024/02/01/nieuwe-kaliumbinders-verbeteren-raas-remmer-gebruik-bij-hartfalen-meta-analyse/","title":"Nieuwe kaliumbinders verbeteren RAAS-remmer-gebruik bij hartfalen: meta-analyse","title_en":"The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["bisoprolol","carvedilol","empagliflozine","hfref","ras-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14588","source_url":"https://doi.org/10.1002/ehf2.14588","authors":["Mohamed Abuelazm","Amr Badr","Mustafa Turkmani","Mostafa Atef Amin","Ahmed Mazen Amin","Aya Aboutaleb","Ibrahim Gowaily","Youssef Soliman","Basel Abdelazeem"],"significance":7,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis confirmed that new potassium binders (patiromer, sodium zirconium cyclosilicate) safely enable optimization of RAAS inhibitor therapy in heart failure by preventing hyperkalemia, addressing a key barrier to reaching target doses.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1d43363d90c","type":"article","url":"https://hartvaat.nl/2024/02/01/ivabradine-vermindert-mr-getriggerde-atriale-fibrose-niet-versus-carvedilol/","title":"Ivabradine vermindert MR-getriggerde atriale fibrose niet versus carvedilol","title_en":"Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["carvedilol"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14577","source_url":"https://doi.org/10.1002/ehf2.14577","authors":["Wei-Chieh Lee","Yu-Wen Lin","Jhih-Yuan Shih","Zhih-Cherng Chen","Nan-Chun Wu","Wei-Ting Chang"],"significance":5,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This study compared ivabradine with carvedilol in heart failure with mitral regurgitation, finding that carvedilol was more effective in reducing atrial fibrosis and fibrillation, suggesting that beta-blockade provides broader anti-remodeling benefit.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3e156c388dc1","type":"article","url":"https://hartvaat.nl/2024/02/01/hydralazine-bij-ernstige-systolische-disfunctie-en-mitralisinsufficientie/","title":"Hydralazine bij ernstige systolische disfunctie en mitralisinsufficiëntie","title_en":"Hydralazine combined with conventional therapy improved outcomes in severe systolic dysfunction and mitral regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","diuretica","mitralisinsufficiëntie","mitralisstenose"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14564","source_url":"https://doi.org/10.1002/ehf2.14564","authors":["Shih-Hung Hsiao","Chao-Sheng Hsiao","Jau-Wen Shiau","Kuan-Rau Chiou"],"significance":5,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"This study showed that adding hydralazine to conventional heart failure therapy improves outcomes in patients with severe systolic dysfunction and significant mitral regurgitation, supporting vasodilator therapy for afterload reduction in severe HF.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"869baa33d3d2","type":"article","url":"https://hartvaat.nl/2024/02/01/urinezuur-als-biomarker-maar-niet-therapeutisch-doel-bij-hartfalen-meta-analyse/","title":"Urinezuur als biomarker maar niet therapeutisch doel bij hartfalen: meta-analyse","title_en":"Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14535","source_url":"https://doi.org/10.1002/ehf2.14535","authors":["Shiwei Qin","Meilin Xiang","Lei Gao","Xiaocheng Cheng","Dongying Zhang"],"significance":6,"published":"2024-02-01","source_date":"2024-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This meta-analysis confirmed that uric acid is a strong prognostic biomarker in heart failure but that uric acid-lowering therapy does not improve clinical outcomes, distinguishing the biomarker role from the therapeutic target role.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f6d19416613","type":"article","url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","title":"Edoxaban versus warfarine bij chronische trombo-embolische pulmonale hypertensie","title_en":"A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067528","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067528","authors":["Kazuya Hosokawa","Hiroko Watanabe","Yu Taniguchi","Nobutaka Ikeda","Takumi Inami","Satoshi Yasuda","Toyoaki Murohara","Masaru Hatano","Yuichi Tamura","Jun Yamashita","Koichiro Tatsumi","Ichizo Tsujino","Yuko Kobayakawa","Shiro Adachi","Nobuhiro Yaoita","Shun Minatsuki","Koji Todaka","Keiichi Fukuda","Hiroyuki Tsutsui","Kohtaro Abe"],"significance":7,"published":"2024-01-30","source_date":"2024-01-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/"],"congress":"","summary_en":"This randomized trial showed that edoxaban is noninferior to warfarin for preventing thromboembolic events in patients with chronic thromboembolic pulmonary hypertension, providing a DOAC option for anticoagulation in this pulmonary vascular disease.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eddf9c65e9fa","type":"article","url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","title":"ORION-5: inclisiran bij homozygote FH","title_en":"Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063460","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063460","authors":["Frederick Raal","Ronen Durst","Ran Bi","Zsolt Talloczy","Pierre Maheux","Anastasia Lesogor","John J P Kastelein"],"significance":7,"published":"2024-01-30","source_date":"2024-01-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"The ORION-5 trial showed that inclisiran significantly lowers LDL cholesterol in patients with homozygous familial hypercholesterolemia, though the effect is smaller than in heterozygous FH due to reduced LDL receptor activity. The twice-yearly injection provides a new treatment option for the most severe genetic dyslipidemia.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c261a1d49a10","type":"article","url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","title":"Switchen van VKA naar NOAC bij fragiele ouderen met AF: veilig","title_en":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066485","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066485","authors":["Linda P T Joosten","Sander van Doorn","Peter M van de Ven","Bart T G Köhlen","Melchior C Nierman","Huiberdina L Koek","Martin E W Hemels","Menno V Huisman","Marieke Kruip","Laura M Faber","Nynke M Wiersma","Wim F Buding","Rob Fijnheer","Henk J Adriaansen","Kit C Roes","Arno W Hoes","Frans H Rutten","Geert-Jan Geersing"],"significance":7,"published":"2024-01-23","source_date":"2024-01-23","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This study showed that switching from VKA to NOAC in frail elderly AF patients is safe and associated with fewer serious bleeding events, addressing the clinical uncertainty about anticoagulant transition in the most vulnerable population.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"160e6bcd3ef5","type":"article","url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","title":"RAFT langetermijn: CRT-D bij hartfalen — NEJM 14-jaarsresultaten","title_en":"Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2304542","source_url":"https://doi.org/10.1056/NEJMoa2304542","authors":["John L Sapp","Soori Sivakumaran","Calum J Redpath","Habib Khan","Ratika Parkash","Derek V Exner","Jeff S Healey","Bernard Thibault","Laurence D Sterns","Nhat Hung N Lam","Jaimie Manlucu","Ahmed Mokhtar","Glen Sumner","Stuart McKinlay","Shane Kimber","Blandine Mondesert","Mario Talajic","Jean Rouleau","C Elizabeth McCarron","George Wells","Anthony S L Tang"],"significance":8,"published":"2024-01-18","source_date":"2024-01-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The RAFT trial 14-year follow-up showed that CRT-D provides sustained survival benefit over ICD alone in patients with HFrEF and wide QRS. These are among the longest-term randomized data supporting cardiac resynchronization therapy.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"284877074808","type":"article","url":"https://hartvaat.nl/2024/01/16/connect-palliatieve-telezorg-verbetert-kwaliteit-van-leven-bij-hartfalen-jama/","title":"CONNECT: palliatieve telezorg verbetert kwaliteit van leven bij hartfalen — JAMA","title_en":"Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"JAMA","doi":"10.1001/jama.2023.24035","source_url":"https://doi.org/10.1001/jama.2023.24035","authors":["David B Bekelman","William Feser","Brianne Morgan","Carolyn H Welsh","Elizabeth C Parsons","Grady Paden","Anna Baron","Brack Hattler","Connor McBryde","Andrew Cheng","Allison V Lange","David H Au"],"significance":7,"published":"2024-01-16","source_date":"2024-01-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The CONNECT trial demonstrated that palliative telecare delivered by nurses and social workers significantly improves quality of life in patients with COPD, heart failure, or interstitial lung disease, supporting scalable remote palliative care models.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c018be58e45a","type":"article","url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","title":"WATCHFUL: leefstijl-wandelinterventie bij HFrEF","title_en":"Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067395","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067395","authors":["Tomas Vetrovsky","Michal Siranec","Tereza Frybova","Iulian Gant","Iveta Svobodova","Ales Linhart","Jiri Parenica","Marie Miklikova","Lenka Sujakova","David Pospisil","Radek Pelouch","Daniela Odrazkova","Petr Parizek","Jan Precek","Martin Hutyra","Milos Taborsky","Jiri Vesely","Martin Griva","Miroslav Semerad","Vaclav Bunc","Karolina Hrabcova","Adela Vojkuvkova","Michal Svoboda","Jan Belohlavek"],"significance":6,"published":"2024-01-16","source_date":"2024-01-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"The WATCHFUL trial showed that a structured walking program improves daily physical activity and quality of life in HFrEF patients, demonstrating that low-intensity, lifestyle-integrated exercise provides meaningful functional benefit.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"194dcd38b074","type":"article","url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","title":"Residuele lekkage na LAA-occlusie en uitkomsten: meta-analyse","title_en":"Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad828","source_url":"https://doi.org/10.1093/eurheartj/ehad828","authors":["Athanasios Samaras","Andreas S Papazoglou","Charalampos Balomenakis","Alexandra Bekiaridou","Dimitrios V Moysidis","Vasiliki Patsiou","Antonios Orfanidis","George Giannakoulas","George Kassimis","Nikolaos Fragakis","Jacqueline Saw","Ulf Landmesser","Mohamad Adnan Alkhouli","Apostolos Tzikas"],"significance":6,"published":"2024-01-14","source_date":"2024-01-14","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that residual leaks after LAA occlusion are associated with higher thromboembolic risk, particularly larger leaks, informing the importance of complete device sealing and post-procedural surveillance.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"df6672ddc5ef","type":"article","url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","title":"ARTESIA: apixaban bij subclinisch AF — NEJM","title_en":"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2310234","source_url":"https://doi.org/10.1056/NEJMoa2310234","authors":["Jeff S Healey","Renato D Lopes","Christopher B Granger","Marco Alings","Lena Rivard","William F McIntyre","Dan Atar","David H Birnie","Giuseppe Boriani","A John Camm","David Conen","Julia W Erath","Michael R Gold","Stefan H Hohnloser","John Ip","Josef Kautzner","Valentina Kutyifa","Cecilia Linde","Philippe Mabo","Georges Mairesse","Juan Benezet Mazuecos","Jens Cosedis Nielsen","Francois Philippon","Marco Proietti","Christian Sticherling","Jorge A Wong","David J Wright","Ignatius G Zarraga","Shelagh B Coutts","Andrew Kaplan","Marta Pombo","Felix Ayala-Paredes","Lizhen Xu","Kim Simek","Sandra Nevills","Rajibul Mian","Stuart J Connolly"],"significance":10,"published":"2024-01-11","source_date":"2024-01-11","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/atriumfibrilleren/hasbled-score/"],"congress":"","summary_en":"The ARTESIA trial showed that apixaban reduced the risk of stroke and systemic embolism by 37% compared with aspirin in patients with subclinical atrial fibrillation detected by implanted cardiac devices, but at the cost of increased major bleeding. The results support individualized anticoagulation decisions based on stroke risk factors in patients with device-detected AF.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d36a2cc85c06","type":"article","url":"https://hartvaat.nl/2024/01/02/2023-af-richtlijn-op-een-blik-samenvatting/","title":"2023 AF-richtlijn op een blik: samenvatting","title_en":"2023 Atrial Fibrillation Guideline-at-a-Glance.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.10.021","source_url":"https://doi.org/10.1016/j.jacc.2023.10.021","authors":["Barbara S Wiggins","Morgane Cibotti-Sun","Mykela M Moore"],"significance":7,"published":"2024-01-02","source_date":"2024-01-02","image":"","kennis":[],"congress":"","summary_en":"This guideline-at-a-glance provided a concise visual summary of the 2023 ACC/AHA atrial fibrillation guidelines, distilling the key recommendations including the new staging system and early rhythm control approach into a practical quick-reference format.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55c4237f6f81","type":"article","url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","title":"2023 ACC/AHA AF-richtlijn: JACC-editie","title_en":"2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.08.017","source_url":"https://doi.org/10.1016/j.jacc.2023.08.017","authors":["José A Joglar","Mina K Chung","Anastasia L Armbruster","Emelia J Benjamin","Janice Y Chyou","Edmond M Cronin","Anita Deswal","Lee L Eckhardt","Zachary D Goldberger","Rakesh Gopinathannair","Bulent Gorenek","Paul L Hess","Mark Hlatky","Gail Hogan","Chinwe Ibeh","Julia H Indik","Kazuhiko Kido","Fred Kusumoto","Mark S Link","Kathleen T Linta","Gregory M Marcus","Patrick M McCarthy","Nimesh Patel","Kristen K Patton","Marco V Perez","Jonathan P Piccini","Andrea M Russo","Prashanthan Sanders","Megan M Streur","Kevin L Thomas","Sabrina Times","James E Tisdale","Anne Marie Valente","David R Van Wagoner"],"significance":10,"published":"2024-01-02","source_date":"2024-01-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The 2023 ACC/AHA/ACCP/HRS AF guideline (JACC edition) provides comprehensive updated recommendations for atrial fibrillation, including a new staging classification, early rhythm-control strategy, catheter ablation as first-line therapy in selected patients, and integrated management of AF risk factors including obesity.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"654788968f4f","type":"article","url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","title":"2023 ACC/AHA/ACCP/HRS AF-richtlijn: nieuwe classificatie en behandelaanpak","title_en":"2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIR.0000000000001193","source_url":"https://doi.org/10.1161/CIR.0000000000001193","authors":["José A Joglar","Mina K Chung","Anastasia L Armbruster","Emelia J Benjamin","Janice Y Chyou","Edmond M Cronin","Anita Deswal","Lee L Eckhardt","Zachary D Goldberger","Rakesh Gopinathannair","Bulent Gorenek","Paul L Hess","Mark Hlatky","Gail Hogan","Chinwe Ibeh","Julia H Indik","Kazuhiko Kido","Fred Kusumoto","Mark S Link","Kathleen T Linta","Gregory M Marcus","Patrick M McCarthy","Nimesh Patel","Kristen K Patton","Marco V Perez","Jonathan P Piccini","Andrea M Russo","Prashanthan Sanders","Megan M Streur","Kevin L Thomas","Sabrina Times","James E Tisdale","Anne Marie Valente","David R Van Wagoner"],"significance":10,"published":"2024-01-02","source_date":"2024-01-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline introduced a new four-stage classification system (stages 1–4), emphasized early rhythm control, endorsed catheter ablation as a first-line option for selected patients, and highlighted weight management as a disease-modifying intervention. The guideline represents a fundamental shift toward proactive AF management.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1497e83ea14","type":"article","url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","title":"Clopidogrel versus aspirine als langetermijnmonotherapie na PCI: bevestiging","title_en":"Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine","clear-outcomes","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.10.013","source_url":"https://doi.org/10.1016/j.jacc.2023.10.013","authors":["Hirotoshi Watanabe","Takeshi Morimoto","Masahiro Natsuaki","Ko Yamamoto","Yuki Obayashi","Ryusuke Nishikawa","Kenji Ando","Koh Ono","Kazushige Kadota","Satoru Suwa","Itsuro Morishima","Ruka Yoshida","Yoshiki Hata","Masaharu Akao","Masahiro Yagi","Nobuhiro Suematsu","Yoshihiro Morino","Takafumi Yokomatsu","Itaru Takamisawa","Toshiyuki Noda","Masayuki Doi","Hideki Okayama","Yuichi Nakamura","Kiyoshi Hibi","Hiroki Sakamoto","Teruo Noguchi","Takeshi Kimura"],"significance":7,"published":"2024-01-02","source_date":"2024-01-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This study confirmed that clopidogrel monotherapy remains superior to aspirin beyond 1 year after PCI, with sustained ischemic benefit and similar bleeding rates, reinforcing clopidogrel as the preferred long-term single antiplatelet agent.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4c48f851377b","type":"article","url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","title":"Verkorte DAPT bij hoog bloedingsrisico: geen sekseverschillen","title_en":"Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4316","source_url":"https://doi.org/10.1001/jamacardio.2023.4316","authors":["Antonio Landi","Mirvat Alasnag","Dik Heg","Enrico Frigoli","Fazila Tun Nesa Malik","Ivan Gomez-Blazquez","Suzanne Pourbaix","Alaide Chieffo","Christian Spaulding","Fermin Sainz","Helen Routledge","Giuseppe Andò","Luca Testa","Alessandro Sciahbasi","Hussain Contractor","Nigel Jepson","Juan Mieres","Syed Saqib Imran","Husam Noor","Pieter C Smits","Marco Valgimigli"],"significance":6,"published":"2024-01-01","source_date":"2024-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"This subanalysis confirmed that abbreviated DAPT in high-bleeding-risk patients provides equal benefit in women and men, supporting sex-neutral antiplatelet de-escalation decisions.","created":"2026-07-03T10:30:44Z","updated":"2026-07-03T13:29:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ef9131dcbcf","type":"article","url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","title":"Tafamidis en cardiale functie bij ATTR-CM: post-hoc ATTR-ACT analyse","title_en":"Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aritmogene-cardiomyopathie","atriale-cardiomyopathie","cardiale-amyloidose","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","ouderen","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.4147","source_url":"https://doi.org/10.1001/jamacardio.2023.4147","authors":["Sanjiv J Shah","Nowell Fine","Pablo Garcia-Pavia","Allan L Klein","Fabio Fernandes","Neil J Weissman","Mathew S Maurer","Kurt Boman","Balarama Gundapaneni","Marla B Sultan","Perry Elliott"],"significance":7,"published":"2024-01-01","source_date":"2024-01-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This ATTR-ACT post-hoc analysis demonstrated that tafamidis slows the progression of cardiac dysfunction in transthyretin amyloid cardiomyopathy, with echocardiographic evidence of preserved systolic and diastolic function over time.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae6627050bd5","type":"article","url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","title":"REALITY: restrictief versus liberaal transfusiebeleid bij MI en anemie — NEJM","title_en":"Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307983","source_url":"https://doi.org/10.1056/NEJMoa2307983","authors":["Jeffrey L Carson","Maria Mori Brooks","Paul C Hébert","Shaun G Goodman","Marnie Bertolet","Simone A Glynn","Bernard R Chaitman","Tabassome Simon","Renato D Lopes","Andrew M Goldsweig","Andrew P DeFilippis","J Dawn Abbott","Brian J Potter","Francois Martin Carrier","Sunil V Rao","Howard A Cooper","Shahab Ghafghazi","Dean A Fergusson","William J Kostis","Helaine Noveck","Sarang Kim","Meechai Tessalee","Gregory Ducrocq","Pedro Gabriel Melo de Barros E Silva","Darrell J Triulzi","Caroline Alsweiler","Mark A Menegus","John D Neary","Lynn Uhl","Jordan B Strom","Christopher B Fordyce","Emile Ferrari","Johanne Silvain","Frances O Wood","Benoit Daneault","Tamar S Polonsky","Manohara Senaratne","Etienne Puymirat","Claire Bouleti","Benoit Lattuca","Harvey D White","Sheryl F Kelsey","P Gabriel Steg","John H Alexander"],"significance":8,"published":"2023-12-28","source_date":"2023-12-28","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"The REALITY trial demonstrated that a restrictive transfusion strategy (hemoglobin threshold <8 g/dL) was noninferior to a liberal strategy (<10 g/dL) for the composite of death, MI, stroke, or emergency revascularization in patients with acute MI and anemia. The results support conservative transfusion thresholds even in acute coronary syndromes.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8a28f839e00c","type":"article","url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","title":"ORBITA-2: PCI versus placebo bij stabiele angina pectoris — NEJM","title_en":"A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2310610","source_url":"https://doi.org/10.1056/NEJMoa2310610","authors":["Christopher A Rajkumar","Michael J Foley","Fiyyaz Ahmed-Jushuf","Alexandra N Nowbar","Florentina A Simader","John R Davies","Peter D O'Kane","Peter Haworth","Helen Routledge","Tushar Kotecha","Reto Gamma","Gerald Clesham","Rupert Williams","Jehangir Din","Sukhjinder S Nijjer","Nick Curzen","Neil Ruparelia","Manas Sinha","Jason N Dungu","Sashiananthan Ganesananthan","Ramzi Khamis","Lal Mughal","Tim Kinnaird","Ricardo Petraco","James C Spratt","Sayan Sen","Joban Sehmi","David J Collier","Afzal Sohaib","Thomas R Keeble","Graham D Cole","James P Howard","Darrel P Francis","Matthew J Shun-Shin","Rasha K Al-Lamee"],"significance":10,"published":"2023-12-21","source_date":"2023-12-21","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"ORBITA-2, a double-blind, placebo-controlled trial in patients with stable angina who were not receiving antianginal medications, showed that PCI significantly improved angina symptoms compared with a sham procedure. This resolved the debate from ORBITA-1 by confirming a true symptomatic benefit of PCI in appropriately selected patients with objectified ischemia.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"167fc16068a2","type":"article","url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","title":"IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie: IPD meta-analyse","title_en":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","hfmref","hfpef","hfref","ijzersuppletie","ijzertekort","ivabradine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad586","source_url":"https://doi.org/10.1093/eurheartj/ehad586","authors":["Piotr Ponikowski","Robert J Mentz","Adrian F Hernandez","Javed Butler","Muhammad Shahzeb Khan","Dirk J van Veldhuisen","Bernard Roubert","Nicole Blackman","Tim Friede","Ewa A Jankowska","Stefan D Anker"],"significance":9,"published":"2023-12-21","source_date":"2023-12-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arb-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This individual patient data meta-analysis of all ferric carboxymaltose trials in heart failure confirmed that IV iron reduces heart failure hospitalization and cardiovascular death, with the most robust benefit in reducing recurrent hospitalizations. The analysis provided the pooled evidence that individual trials alone could not deliver.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2c4971592484","type":"article","url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","title":"Ticagrelor versus prasugrel en coronaire microcirculatie bij PCI","title_en":"Effects of ticagrelor and prasugrel on coronary microcirculation in elective percutaneous coronary intervention.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["percutane-coronaire-interventie"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321868","source_url":"https://doi.org/10.1136/heartjnl-2022-321868","authors":["Fabio Mangiacapra","Iginio Colaiori","Giuseppe Di Gioia","Mariano Pellicano","Alex Heyse","Luca Paolucci","Aaron Peace","Jozef Bartunek","Bernard de Bruyne","Emanuele Barbato"],"significance":5,"published":"2023-12-20","source_date":"2023-12-20","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This study compared the effects of ticagrelor and prasugrel on coronary microcirculation during elective PCI, finding similar improvements in absolute coronary blood flow with both agents.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4eaeaa73967b","type":"article","url":"https://hartvaat.nl/2023/12/19/ai-diagnostiek-bij-gehospitaliseerde-patienten-jama-vignettenstudie/","title":"AI-diagnostiek bij gehospitaliseerde patiënten: JAMA vignettenstudie","title_en":"Measuring the Impact of AI in the Diagnosis of Hospitalized Patients: A Randomized Clinical Vignette Survey Study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2023.22295","source_url":"https://doi.org/10.1001/jama.2023.22295","authors":["Sarah Jabbour","David Fouhey","Stephanie Shepard","Thomas S Valley","Ella A Kazerooni","Nikola Banovic","Jenna Wiens","Michael W Sjoding"],"significance":6,"published":"2023-12-19","source_date":"2023-12-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This JAMA vignette study demonstrated that AI-assisted diagnosis improves clinical accuracy for hospitalized patients, while also showing that algorithmic bias can introduce systematic errors if not carefully monitored.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b57336cb8ee5","type":"article","url":"https://hartvaat.nl/2023/12/19/synchronisatie-van-voetstap-en-hartfase-bij-crt-patienten/","title":"Synchronisatie van voetstap en hartfase bij CRT-patiënten","title_en":"Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","bloeddrukbehandeling","cardiale-resynchronisatie","dubbele-trombocytenremming","hfpef","hfref","ijzertekort","ivabradine","klepprothese","laminopathie","nt-probnp","secundaire-preventie","step-hfpef","supraventriculaire-tachycardie","syncope","trombocytenaggregatieremmers","ventrikelfibrilleren","vericiguat","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066170","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066170","authors":["Denis J Wakeham","Erika Ivey","Sophie A Saland","Joshua S Lewis","Dean Palmer","Margot Morris","Jeffery L Bleich","Peter G Weyand","Tiffany L Brazile","Christopher M Hearon","Satyam Sarma","James P MacNamara","Michinari Hieda","Benjamin D Levine"],"significance":5,"published":"2023-12-19","source_date":"2023-12-19","image":"","kennis":[],"congress":"","summary_en":"This innovative study tested whether synchronizing walking foot strike with the cardiac cycle improves exercise hemodynamics in CRT patients, exploring biomechanical-cardiac coupling as a novel exercise optimization strategy.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"05083b6addfd","type":"article","url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","title":"SELECT: semaglutide vermindert CV-events bij obesitas zonder diabetes — NEJM","title_en":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","ezetimibe","glp1-semaglutide-cardiovasculair","obesitas","perifeer-vaatlijden","select-trial","semaglutide","soul-trial","stride-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307563","source_url":"https://doi.org/10.1056/NEJMoa2307563","authors":["A Michael Lincoff","Kirstine Brown-Frandsen","Helen M Colhoun","John Deanfield","Scott S Emerson","Sille Esbjerg","Søren Hardt-Lindberg","G Kees Hovingh","Steven E Kahn","Robert F Kushner","Ildiko Lingvay","Tugce K Oral","Marie M Michelsen","Jorge Plutzky","Christoffer W Tornøe","Donna H Ryan"],"significance":10,"published":"2023-12-14","source_date":"2023-12-14","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with overweight or obesity and established atherosclerotic disease but without diabetes. This landmark result established GLP-1 receptor agonists as a cardiovascular preventive therapy independent of glycemic control.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"65c2c4aa74ed","type":"article","url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","title":"VOYAGER PAD: rivaroxaban plus aspirine na endovasculaire revascularisatie voor PAD","title_en":"Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["perifeer-vaatlijden"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063806","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063806","authors":["Jennifer Rymer","Sonia S Anand","E Sebastian Debus","Lloyd P Haskell","Connie N Hess","W Schuyler Jones","Eva Muehlhofer","Scott D Berkowitz","Rupert M Bauersachs","Marc P Bonaca","Manesh R Patel"],"significance":7,"published":"2023-12-12","source_date":"2023-12-12","image":"","kennis":[],"congress":"","summary_en":"This VOYAGER PAD subanalysis confirmed that rivaroxaban plus aspirin after endovascular revascularization for symptomatic PAD reduces both cardiac and limb ischemic events, supporting dual-pathway inhibition specifically in the post-revascularization peripheral vascular population.","created":"2026-07-03T10:30:43Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e66028904b35","type":"article","url":"https://hartvaat.nl/2023/12/06/gemodificeerde-transseptale-punctie-bij-laa-occlusie-rct/","title":"Gemodificeerde transseptale punctie bij LAA-occlusie: RCT","title_en":"Angioplasty Guidewire-Assisted vs. Conventional Transseptal Puncture for Left Atrial Appendage Occlusion: a multicentre randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad349","source_url":"https://doi.org/10.1093/europace/euad349","authors":["Feng Hu","Bin Xu","Zhiqing Qiao","Fuyu Cheng","Zien Zhou","Zhiguo Zou","Minhua Zang","Song Ding","Jun Hong","Yuquan Xie","Yong Zhou","JianFeng Huang","Jun Pu"],"significance":5,"published":"2023-12-06","source_date":"2023-12-06","image":"","kennis":[],"congress":"","summary_en":"This RCT showed that an angioplasty guidewire-assisted transseptal puncture technique for LAA occlusion improves procedural efficiency and precision compared with the conventional approach.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T13:29:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce94cf2ec3d2","type":"article","url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","title":"Intravasculaire beeldvorming versus functionele versus angiografische PCI-begeleiding vergeleken","title_en":"Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.09.823","source_url":"https://doi.org/10.1016/j.jacc.2023.09.823","authors":["Toshiki Kuno","Yuko Kiyohara","Akiko Maehara","Hiroki A Ueyama","Polydoros N Kampaktsis","Hisato Takagi","Roxana Mehran","Gregg W Stone","Deepak L Bhatt","Gary S Mintz","Sripal Bangalore"],"significance":7,"published":"2023-12-05","source_date":"2023-12-05","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/"],"congress":"","summary_en":"This comprehensive meta-analysis compared intravascular imaging, functional testing (FFR/iFR), and angiography-guided PCI, finding that imaging guidance provides the best outcomes, followed by physiological guidance, with angiography alone yielding the worst results.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T13:29:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b41307503a0c","type":"article","url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","title":"Bloeddruk- en zuurstofstreefwaarden en nierschade na hartstilstand","title_en":"Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066012","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066012","authors":["Sebastian Buhl Rasmussen","Karoline Korsholm Jeppesen","Jesper Kjaergaard","Christian Hassager","Henrik Schmidt","Simon Mølstrøm","Rasmus Paulin Beske","Johannes Grand","Hanne Berg Ravn","Matilde Winther-Jensen","Martin Abild Stengaard Meyer","Jacob Eifer Møller"],"significance":6,"published":"2023-12-05","source_date":"2023-12-05","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that higher MAP targets protect against acute kidney injury after cardiac arrest, informing hemodynamic management strategies for renal preservation in the post-resuscitation period.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T13:29:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6fc6573669e4","type":"article","url":"https://hartvaat.nl/2023/12/01/kaliummagnesiumcitraat-versus-kaliumchloride-bij-thiazide-bijwerkingen/","title":"Kaliummagnesiumcitraat versus kaliumchloride bij thiazide-bijwerkingen","title_en":"Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21932","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21932","authors":["Wanpen Vongpatanasin","John M Giacona","Danielle Pittman","Ashley Murillo","Ghazi Khan","Jijia Wang","Talon Johnson","Jimin Ren","Orson W Moe","Charles C Y Pak"],"significance":5,"published":"2023-12-01","source_date":"2023-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This study showed that potassium magnesium citrate is superior to potassium chloride for correcting the metabolic side effects of chlorthalidone, providing a more comprehensive electrolyte replacement strategy during thiazide therapy.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T13:29:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"329890dbd727","type":"article","url":"https://hartvaat.nl/2023/12/01/step-trial-diastolische-bloeddruk-beinvloedt-effect-van-intensieve-behandeling/","title":"STEP-trial: diastolische bloeddruk beïnvloedt effect van intensieve behandeling","title_en":"Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering: Results From the STEP Randomized Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","step-hfpef"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21892","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21892","authors":["Ruixue Yang","Rongjie Huang","Liangqing Zhang","Dongfeng Li","Jiehong Luo","Jun Cai"],"significance":6,"published":"2023-12-01","source_date":"2023-12-01","image":"","kennis":[],"congress":"","summary_en":"This STEP subanalysis showed that intensive blood pressure lowering is most effective in patients with higher baseline diastolic pressure, informing the identification of patients who derive the greatest absolute benefit from aggressive treatment.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T18:39:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a2738e9ad8fe","type":"article","url":"https://hartvaat.nl/2023/12/01/adaptieve-servoventilatie-en-hypoxemische-belasting-bij-hartfalen/","title":"Adaptieve servoventilatie en hypoxemische belasting bij hartfalen","title_en":"Hypoxaemic burden in heart failure patients receiving adaptive servo-ventilation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","hartrevalidatie","hfmref","hfpef","hfref","ijzersuppletie","ijzertekort","slaapapneu","step-hfpef","ventrikelfibrilleren","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14556","source_url":"https://doi.org/10.1002/ehf2.14556","authors":["Mathias Baumert","Dominik Linz","Michael Pfeifer","Maria Tafelmeier","Philippe Felfeli","Michael Arzt","Sobhan S Shahrbabaki"],"significance":5,"published":"2023-12-01","source_date":"2023-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study showed that adaptive servo-ventilation effectively reduces the hypoxemic burden in heart failure patients with central sleep apnea, despite the safety concerns raised by the SERVE-HF trial.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db51f72bdf67","type":"article","url":"https://hartvaat.nl/2023/12/01/acute-nierschade-bij-hartfalen-incidentie-mortaliteit-en-voorspellers-meta-analy/","title":"Acute nierschade bij hartfalen: incidentie, mortaliteit en voorspellers — meta-analyse","title_en":"Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","nierfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14520","source_url":"https://doi.org/10.1002/ehf2.14520","authors":["Song-Chao Ru","Shu-Bin Lv","Zhi-Juan Li"],"significance":6,"published":"2023-12-01","source_date":"2023-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"This systematic review documented that acute kidney injury in heart failure occurs in 25-30% of patients and significantly worsens prognosis, highlighting the importance of renal monitoring during heart failure management.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f846f80edc31","type":"article","url":"https://hartvaat.nl/2023/12/01/nierziekteverloop-na-acute-nierschade-prospectieve-cohortstudie/","title":"Nierziekteverloop na acute nierschade: prospectieve cohortstudie","title_en":"A comprehensive description of kidney disease progression after acute kidney injury from a prospective, parallel-group cohort study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","chronische-nierziekte","flow-trial","nierfalen"],"journal":"Kidney international","doi":"10.1016/j.kint.2023.08.005","source_url":"https://doi.org/10.1016/j.kint.2023.08.005","authors":["Kerry L Horne","Daniela Viramontes-Hörner","Rebecca Packington","John Monaghan","Susan Shaw","Aleli Akani","Timothy Reilly","Thomas Trimble","Grazziela Figueredo","Nicholas M Selby"],"significance":5,"published":"2023-12-01","source_date":"2023-12-01","image":"","kennis":[],"congress":"","summary_en":"This prospective study documented the trajectory of kidney disease progression after AKI, showing significant CKD development risk particularly after severe episodes, informing post-AKI nephrological follow-up.","created":"2026-07-03T10:30:42Z","updated":"2026-07-03T13:29:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95c31e4878e3","type":"article","url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","title":"POP-HT: zelfmanagement van bloeddruk na hypertensieve zwangerschap — JAMA RCT","title_en":"Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","zwangerschap-hart"],"journal":"JAMA","doi":"10.1001/jama.2023.21523","source_url":"https://doi.org/10.1001/jama.2023.21523","authors":["Jamie Kitt","Rachael Fox","Annabelle Frost","Milensu Shanyinde","Katherine Tucker","Paul A Bateman","Katie Suriano","Yvonne Kenworthy","Annabelle McCourt","William Woodward","Winok Lapidaire","Miriam Lacharie","Mauro Santos","Cristian Roman","Lucy Mackillop","Christian Delles","Basky Thilaganathan","Lucy C Chappell","Adam J Lewandowski","Richard J McManus","Paul Leeson"],"significance":7,"published":"2023-11-28","source_date":"2023-11-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The POP-HT trial demonstrated that physician-guided blood pressure self-management after hypertensive pregnancy improves long-term blood pressure control, addressing the increased cardiovascular risk that follows pregnancy hypertension.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0598bed11e73","type":"article","url":"https://hartvaat.nl/2023/11/27/slaapgerelateerde-ademhalingsstoornissen-en-cv-ziekte-wie-testen-en-hoe-behandel/","title":"Slaapgerelateerde ademhalingsstoornissen en CV-ziekte: wie testen en hoe behandelen","title_en":"Sleep-disordered breathing and cardiovascular disease: who and why to test and how to intervene?","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","slaapapneu"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2019-316375","source_url":"https://doi.org/10.1136/heartjnl-2019-316375","authors":["Ali Vazir","Chris J Kapelios"],"significance":5,"published":"2023-11-27","source_date":"2023-11-27","image":"","kennis":[],"congress":"","summary_en":"This review summarized the relationship between sleep-disordered breathing and cardiovascular disease, addressing screening indications, diagnostic approaches, and treatment considerations for the common SDB-HF overlap.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec2a44581965","type":"article","url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","title":"ZENITH-CKD: zibotentan plus dapagliflozine bij CKD — Lancet","title_en":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["dapagliflozine","figaro-dkd"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02230-4","source_url":"https://doi.org/10.1016/S0140-6736(23)02230-4","authors":["Hiddo J L Heerspink","Arihiro Kiyosue","David C Wheeler","Min Lin","Emma Wijkmark","Glenn Carlson","Anne-Kristina Mercier","Magnus Åstrand","Sebastian Ueckert","Peter J Greasley","Phil Ambery"],"significance":8,"published":"2023-11-25","source_date":"2023-11-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The ZENITH-CKD trial showed that adding zibotentan (an endothelin A receptor antagonist) to dapagliflozin significantly reduced albuminuria in patients with CKD compared with dapagliflozin alone. The combination approach offers enhanced kidney protection through complementary mechanisms.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6bf6118812f","type":"article","url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","title":"Biodegradeerbare versus duurzame polymeer DES bij STEMI: langetermijndata","title_en":"Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02197-9","source_url":"https://doi.org/10.1016/S0140-6736(23)02197-9","authors":["Juan F Iglesias","Marco Roffi","Sylvain Losdat","Olivier Muller","Sophie Degrauwe","David J Kurz","Laurent Haegeli","Daniel Weilenmann","Christoph Kaiser","Maxime Tapponnier","Stéphane Cook","Florim Cuculi","Dik Heg","Stephan Windecker","Thomas Pilgrim"],"significance":6,"published":"2023-11-25","source_date":"2023-11-25","image":"","kennis":[],"congress":"","summary_en":"Long-term data confirmed that biodegradable polymer sirolimus-eluting stents provide comparable outcomes to durable polymer everolimus-eluting stents in STEMI patients, supporting either platform for primary PCI.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"416efd011cab","type":"article","url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","title":"PARTNER 3 vijfjaarsresultaten: TAVR vergelijkbaar met chirurgie bij laagrisico — NEJM","title_en":"Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307447","source_url":"https://doi.org/10.1056/NEJMoa2307447","authors":["Michael J Mack","Martin B Leon","Vinod H Thourani","Philippe Pibarot","Rebecca T Hahn","Philippe Genereux","Susheel K Kodali","Samir R Kapadia","David J Cohen","Stuart J Pocock","Michael Lu","Roseann White","Molly Szerlip","Julien Ternacle","S Chris Malaisrie","Howard C Herrmann","Wilson Y Szeto","Mark J Russo","Vasilis Babaliaros","Craig R Smith","Philipp Blanke","John G Webb","Raj Makkar"],"significance":9,"published":"2023-11-23","source_date":"2023-11-23","image":"","kennis":[],"congress":"","summary_en":"The 5-year PARTNER 3 follow-up confirmed that outcomes after TAVR remained comparable to surgical aortic valve replacement in low-risk patients with severe aortic stenosis. Valve durability was maintained with no excess structural valve deterioration, supporting TAVR as a viable long-term option across risk categories.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62e316e9b5d8","type":"article","url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","title":"EARLY-UNLOAD: vroege LV-ontlading bij VA-ECMO — gerandomiseerde trial","title_en":"Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066179","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066179","authors":["Min Chul Kim","Yongwhan Lim","Seung Hun Lee","Yoonmin Shin","Joon Ho Ahn","Dae Young Hyun","Kyung Hoon Cho","Doo Sun Sim","Young Joon Hong","Ju Han Kim","Myung Ho Jeong","Yong Hun Jung","In-Seok Jeong","Youngkeun Ahn"],"significance":7,"published":"2023-11-14","source_date":"2023-11-14","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The EARLY-UNLOAD trial showed that early left ventricular unloading during VA-ECMO support for cardiogenic shock improves LV recovery compared with conventional management, supporting proactive mechanical strategies to facilitate cardiac recovery.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94a744c86585","type":"article","url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","title":"Rate control bij AF: calciumantagonisten versus bètablokkers","title_en":"Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["amlodipine","betablokkers","bisoprolol","bloeddrukbehandeling","calciumantagonisten"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-322635","source_url":"https://doi.org/10.1136/heartjnl-2023-322635","authors":["Tim Koldenhof","Isabelle C Van Gelder","Harry Jgm Crijns","Michiel Rienstra","Robert G Tieleman"],"significance":6,"published":"2023-11-10","source_date":"2023-11-10","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/atriumfibrilleren/betablokkers-bij-af/"],"congress":"","summary_en":"This study showed that non-dihydropyridine calcium channel blockers provide better rate control than beta-blockers in non-permanent AF, supporting calcium antagonists as an alternative first-line rate control strategy.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"264c607d45e8","type":"article","url":"https://hartvaat.nl/2023/11/10/transcatheter-asd-sluiting-bij-ouderen-systematische-review-en-meta-analyse/","title":"Transcatheter ASD-sluiting bij ouderen: systematische review en meta-analyse","title_en":"Transcatheter closure of atrial septal defect in the elderly: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["congenitale-hartafwijking"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-322529","source_url":"https://doi.org/10.1136/heartjnl-2023-322529","authors":["Amalia Baroutidou","Alexandra Arvanitaki","Ioannis T Farmakis","Vasiliki Patsiou","Andreas Giannopoulos","Georgios Efthimiadis","Antonios Ziakas","George Giannakoulas"],"significance":6,"published":"2023-11-10","source_date":"2023-11-10","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/flecainide-en-propafenon/","https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This meta-analysis confirmed that transcatheter ASD closure in elderly patients is safe and effective with significant hemodynamic improvement, supporting device closure even at advanced age.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5606e1756b48","type":"article","url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","title":"Renale denervatie veilig en effectief bij patiënten op antihypertensiva","title_en":"Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","chronische-nierziekte","credence-trial","cystatine-c","diuretica","fidelio-dkd","fidelity","figaro-dkd","flow-trial","radiance-htn","renale-denervatie","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.08.045","source_url":"https://doi.org/10.1016/j.jacc.2023.08.045","authors":["David E Kandzari","Raymond R Townsend","Kazuomi Kario","Felix Mahfoud","Michael A Weber","Roland E Schmieder","Stuart Pocock","Konstantinos Tsioufis","Dimitrios Konstantinidis","James Choi","Cara East","Lucas Lauder","Debbie L Cohen","Taisei Kobayashi","Axel Schmid","David P Lee","Adrian Ma","Joachim Weil","Tolga Agdirlioglu","Markus P Schlaich","Sharad Shetty","Chandan M Devireddy","Janice Lea","Jiro Aoki","Andrew S P Sharp","Richard Anderson","Martin Fahy","Vanessa DeBruin","Sandeep Brar","Michael Böhm"],"significance":7,"published":"2023-11-07","source_date":"2023-11-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This pooled analysis confirmed that renal denervation significantly reduces blood pressure in patients already taking antihypertensive medications, supporting the device-based approach as an add-on therapy for inadequately controlled hypertension.","created":"2026-07-03T10:30:41Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"529ea93d59dc","type":"article","url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","title":"Colchicine vermindert perioperatief AF na thoraxchirurgie: Lancet RCT","title_en":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["colchicine","pericarditis"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)01689-6","source_url":"https://doi.org/10.1016/S0140-6736(23)01689-6","authors":["David Conen","Michael Ke Wang","Ekaterine Popova","Matthew T V Chan","Giovanni Landoni","Juan P Cata","Cara Reimer","Sean R McLean","Sadeesh K Srinathan","Juan Carlos Trujillo Reyes","Ascension Martín Grande","Anna Gonzalez Tallada","Daniel I Sessler","Edith Fleischmann","Barbara Kabon","Luca Voltolini","Patrícia Cruz","Donna E Maziak","Laura Gutiérrez-Soriano","William F McIntyre","Vikas Tandon","Elisabeth Martínez-Téllez","Juan Jose Guerra-Londono","Deborah DuMerton","Randolph H L Wong","Anna L McGuire","Biniam Kidane","Diego Parise Roux","Yaron Shargall","Jennifer R Wells","Sandra N Ofori","Jessica Vincent","Lizhen Xu","Zhuoru Li","John W Eikelboom","Sanjit S Jolly","Jeff S Healey","P J Devereaux"],"significance":7,"published":"2023-11-04","source_date":"2023-11-04","image":"","kennis":[],"congress":"","summary_en":"This Lancet trial showed that colchicine reduces perioperative atrial fibrillation and myocardial injury after major thoracic surgery in patients with preexisting cardiovascular disease, extending the anti-inflammatory benefit to the perioperative setting.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edd8917be9f6","type":"article","url":"https://hartvaat.nl/2023/11/02/duurzaamheid-van-pvi-bij-af-meta-analyse/","title":"Duurzaamheid van PVI bij AF: meta-analyse","title_en":"Durability of pulmonary vein isolation for atrial fibrillation: a meta-analysis and systematic review.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad335","source_url":"https://doi.org/10.1093/europace/euad335","authors":["Teodor Serban","Diego Mannhart","Qurrat-Ul-Ain Abid","Andres Höchli","Sorin Lazar","Philipp Krisai","Arianna Sofia Bettelini","Sven Knecht","Michael Kühne","Christian Sticherling","Jeanne du Fay de Lavallaz","Patrick Badertscher"],"significance":6,"published":"2023-11-02","source_date":"2023-11-02","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/"],"congress":"","summary_en":"This meta-analysis documented that pulmonary vein reconnection after PVI is common (up to 60%) but that clinical outcomes are influenced more by durability of isolation than by initial procedure success, informing the follow-up strategy.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b32c4852eeb","type":"article","url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","title":"ADVENT: pulsed field ablatie non-inferieur aan thermale ablatie bij AF — NEJM","title_en":"Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["advent-trial","pulsed-field-ablatie","pulsed-field-ablatie-atriumfibrilleren"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307291","source_url":"https://doi.org/10.1056/NEJMoa2307291","authors":["Vivek Y Reddy","Edward P Gerstenfeld","Andrea Natale","William Whang","Frank A Cuoco","Chinmay Patel","Stavros E Mountantonakis","Douglas N Gibson","John D Harding","Christopher R Ellis","Kenneth A Ellenbogen","David B DeLurgio","Jose Osorio","Anitha B Achyutha","Christopher W Schneider","Andrew S Mugglin","Elizabeth M Albrecht","Kenneth M Stein","John W Lehmann","Moussa Mansour"],"significance":9,"published":"2023-11-02","source_date":"2023-11-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"The ADVENT trial demonstrated that pulsed field ablation was noninferior to conventional thermal ablation (radiofrequency or cryoablation) for the treatment of paroxysmal atrial fibrillation, with a comparable safety profile. This established PFA as a safe and effective tissue-selective alternative for pulmonary vein isolation.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad5b39f77a68","type":"article","url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","title":"Enterisch-gecoat versus ongecoat aspirine: geen verschil in GI-bloedingen — ADAPTABLE","title_en":"Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.3364","source_url":"https://doi.org/10.1001/jamacardio.2023.3364","authors":["Amber Sleem","Mark B Effron","Amanda Stebbins","Lisa M Wruck","Guillaume Marquis-Gravel","Daniel Muñoz","Richard N Re","Kamal Gupta","Carl J Pepine","Sandeep K Jain","Saket Girotra","Jeffrey Whittle","Catherine P Benziger","Peter M Farrehi","Kirk U Knowlton","Tamar S Polonsky","Matthew T Roe","Russell L Rothman","Robert A Harrington","W Schuyler Jones","Adrian F Hernandez"],"significance":7,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/preventie/secundaire-preventie-overzicht/"],"congress":"","summary_en":"This ADAPTABLE secondary analysis found no difference in gastrointestinal bleeding between enteric-coated and uncoated aspirin in cardiovascular secondary prevention, challenging the widespread belief that enteric coating provides GI protection.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3125691b5b62","type":"article","url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","title":"Posterior wand-isolatie bij AF-ablatie en systolisch hartfalen: CASTLE-AF subanalyse","title_en":"The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","hfref"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.3208","source_url":"https://doi.org/10.1001/jamacardio.2023.3208","authors":["Jeremy William","David Chieng","Hariharan Sugumar","Liang-Han Ling","Louise Segan","Rose Crowley","Ahmed Al-Kaisey","Joshua Hawson","Sandeep Prabhu","Aleksandr Voskoboinik","Geoffrey Wong","Joseph B Morton","Geoffrey Lee","Alex J McLellan","Michael Wong","Rajeev K Pathak","Laurence Sterns","Matthew Ginks","Christopher M Reid","Prashanthan Sanders","Jonathan M Kalman","Peter M Kistler"],"significance":6,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This CASTLE-AF subanalysis showed that adding posterior wall isolation to AF catheter ablation in HFrEF patients does not provide additional benefit over standard PVI, consistent with the neutral findings in the broader AF population.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"426106ee3d62","type":"article","url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","title":"Beta3-LVH: mirabegron bij linkerventrikel hypertrofie — fase 2b RCT","title_en":"Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.3003","source_url":"https://doi.org/10.1001/jamacardio.2023.3003","authors":["Jean-Luc Balligand","Dulce Brito","Oana Brosteanu","Barbara Casadei","Christophe Depoix","Frank Edelmann","Vanessa Ferreira","Gerasimos Filippatos","Bernhard Gerber","Damien Gruson","Dirk Hasenclever","Kristian Hellenkamp","Ignatios Ikonomidis","Bartosz Krakowiak","Renaud Lhommel","Masliza Mahmod","Stefan Neubauer","Alexandre Persu","Stefan Piechnik","Burkert Pieske","Elisabeth Pieske-Kraigher","Fausto Pinto","Piotr Ponikowski","Michele Senni","Jean-Noël Trochu","Nancy Van Overstraeten","Rolf Wachter","Anne-Catherine Pouleur"],"significance":6,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"This phase 2b trial of mirabegron (a beta-3 adrenergic agonist) in patients with LV hypertrophy did not significantly reduce LV mass, a negative result for this repurposed bladder medication as a cardiac therapy.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4fd706e286a","type":"article","url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","title":"Evinacumab bij refractaire hypercholesterolemie: langetermijn effectiviteit en veiligheid","title_en":"Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","bempedoïnezuur","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pelacarsen","statines","yellow-iii"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.2921","source_url":"https://doi.org/10.1001/jamacardio.2023.2921","authors":["Robert S Rosenson","Lesley J Burgess","Christoph F Ebenbichler","Seth J Baum","Erik S G Stroes","Shazia Ali","Nagwa Khilla","Jennifer McGinniss","Daniel Gaudet","Robert Pordy"],"significance":7,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Longer-term data on evinacumab confirmed sustained LDL cholesterol reduction in patients with refractory hypercholesterolemia, providing reassurance about the durability and safety of ANGPTL3 inhibition over extended treatment periods.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b2bb026e6f4","type":"article","url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","title":"iFR versus FFR en vijfjaarsmortaliteit: SWEDEHEART en DEFINE FLAIR","title_en":"Instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART and DEFINE FLAIR.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve","perifeer-vaatlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad582","source_url":"https://doi.org/10.1093/eurheartj/ehad582","authors":["Ashkan Eftekhari","Emil Nielsen Holck","Jelmer Westra","Niels Thue Olsen","Niels Henrik Bruun","Lisette Okkels Jensen","Thomas Engstrøm","Evald Høj Christiansen"],"significance":7,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"Five-year pooled data from iFR-SWEDEHEART and DEFINE-FLAIR confirmed that iFR-guided revascularization has the same long-term mortality as FFR-guided treatment, providing the most robust evidence for the equivalence of these physiological assessment tools.","created":"2026-07-03T10:30:40Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a16e906cb5d1","type":"article","url":"https://hartvaat.nl/2023/11/01/covid-19-en-vertraagde-cardiovasculaire-zorg-in-europa-lancet-systematische-revi/","title":"COVID-19 en vertraagde cardiovasculaire zorg in Europa: Lancet systematische review","title_en":"Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["covid-hart"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)02117-7","source_url":"https://doi.org/10.1016/S0140-6736(23)02117-7","authors":["Yasmine Khan","Nick Verhaeghe","Brecht Devleesschauwer","Lisa Cavillot","Sylvie Gadeyne","Nele S Pauwels","Laura Van den Borre","Delphine De Smedt"],"significance":7,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":[],"congress":"","summary_en":"This Lancet systematic review documented the impact of the COVID-19 pandemic on delayed cardiovascular care across Europe, quantifying reduced presentations, longer treatment delays, and excess cardiovascular mortality during pandemic waves.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d62ce8e38ab","type":"article","url":"https://hartvaat.nl/2023/11/01/gemaskeerde-hypertensie-bij-kinderen-prevalentie-en-cv-risico-meta-analyse/","title":"Gemaskeerde hypertensie bij kinderen: prevalentie en CV-risico — meta-analyse","title_en":"Prevalence of Pediatric Masked Hypertension and Risk of Subclinical Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.20967","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.20967","authors":["Jason Chung","Cal Robinson","Lauren Sheffield","Prathayini Paramanathan","Andrew Yu","Joycelyne Ewusie","Stephanie Sanger","Mark Mitsnefes","Rulan S Parekh","Manish D Sinha","Myanca Rodrigues","Lehana Thabane","Janis Dionne","Rahul Chanchlani"],"significance":6,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This meta-analysis showed that masked hypertension in children occurs in approximately 10% and is associated with subclinical cardiovascular damage, supporting ambulatory monitoring for pediatric blood pressure assessment.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"815913c7d13a","type":"article","url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","title":"Tijd-in-streefwaarde van bloeddruk en AF: SPRINT-inzichten","title_en":"Systolic Blood Pressure Time in Target Range and Incident Atrial Fibrillation in Patients With Hypertension: Insights From the SPRINT Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21651","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21651","authors":["Jue Wang","Chao Jiang","Sitong Li","Zhiyan Wang","Yufeng Wang","Yiwei Lai","Zhen Wang","Wenhe Lv","Yu Bai","Zejun Yang","Qi Guo","Lihong Huang","Liu He","Xueyuan Guo","Songnan Li","Nian Liu","Chenxi Jiang","Ribo Tang","Deyong Long","Xin Du","Caihua Sang","Jianzeng Dong","Changsheng Ma"],"significance":6,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT analysis showed that greater time with systolic blood pressure at target is associated with lower incident AF, supporting sustained blood pressure control as a strategy for atrial fibrillation prevention.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1da31a0f70e7","type":"article","url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","title":"Sekseverschillen in effect van bloeddrukverlaging: IPD meta-analyse","title_en":"Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21496","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21496","authors":["Zeinab Bidel","Milad Nazarzadeh","Dexter Canoy","Emma Copland","Eva Gerdts","Mark Woodward","Ajay K Gupta","Christopher M Reid","William C Cushman","Kristian Wachtell","Koon Teo","Barry R Davis","John Chalmers","Carl J Pepine","Kazem Rahimi"],"significance":7,"published":"2023-11-01","source_date":"2023-11-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that the relative cardiovascular benefit of blood pressure lowering is similar in men and women, supporting equal treatment regardless of sex when blood pressure thresholds are met.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"647f8bd76770","type":"article","url":"https://hartvaat.nl/2023/10/31/antitrombotische-therapie-na-laa-occlusie-netwerk-meta-analyse/","title":"Antitrombotische therapie na LAA-occlusie: netwerk-meta-analyse","title_en":"Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","trombose"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.08.010","source_url":"https://doi.org/10.1016/j.jacc.2023.08.010","authors":["Pedro E P Carvalho","Douglas M Gewehr","Isabele A Miyawaki","Alleh Nogueira","Nicole Felix","Philippe Garot","Arthur Darmon","Patrizio Mazzone","Alberto Preda","Bruno R Nascimento","Luiz F Kubrusly","Rhanderson Cardoso"],"significance":6,"published":"2023-10-31","source_date":"2023-10-31","image":"","kennis":[],"congress":"","summary_en":"This network meta-analysis compared antithrombotic regimens after LAA occlusion, showing that DOAC monotherapy may offer a better safety-efficacy profile than traditional DAPT for post-LAAO management.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a735bfea08e7","type":"article","url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","title":"CTS-AMI: Tongxinluo bij acuut MI — JAMA mega-trial","title_en":"Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2023.19524","source_url":"https://doi.org/10.1001/jama.2023.19524","authors":["Yuejin Yang","Xiangdong Li","Guihao Chen","Ying Xian","Haitao Zhang","Yuan Wu","Yanmin Yang","Jianhua Wu","Chuntong Wang","Shenghu He","Zhong Wang","Yixin Wang","Zhifang Wang","Hui Liu","Xiping Wang","Minzhou Zhang","Jun Zhang","Jia Li","Tao An","Hao Guan","Lin Li","Meixia Shang","Chen Yao","Yaling Han","Boli Zhang","Runlin Gao","Eric D Peterson"],"significance":8,"published":"2023-10-24","source_date":"2023-10-24","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"The CTS-AMI mega-trial demonstrated that Tongxinluo, a traditional Chinese medicine compound, significantly reduced cardiovascular events after STEMI when added to guideline-directed therapy. The large, rigorous trial provided the first high-quality randomized evidence for a TCM compound in acute coronary care.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5347c36df057","type":"article","url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","title":"LAAOS III: LAA-occlusie en anticoagulatiegebruik","title_en":"Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060315","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060315","authors":["Stuart J Connolly","Jeff S Healey","Emilie P Belley-Cote","Kumar Balasubramanian","Domenico Paparella","Katheryn Brady","Wilko Reents","Bernhard C Danner","P J Devereaux","Mukul Sharma","Chinthanie Ramasundarahettige","Salim Yusuf","Richard P Whitlock"],"significance":7,"published":"2023-10-24","source_date":"2023-10-24","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This LAAOS III subanalysis showed that surgical LAA occlusion reduces ischemic stroke independently of postoperative oral anticoagulation use, supporting the additive benefit of structural and pharmacological stroke prevention.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4b16aca109c","type":"article","url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","title":"Graftfalen na CABG: individuele-patiëntdata meta-analyse","title_en":"Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064090","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064090","authors":["Mario Gaudino","Sigrid Sandner","Kevin R An","Arnaldo Dimagli","Antonino Di Franco","Katia Audisio","Lamia Harik","Roberto Perezgrovas-Olaria","Giovanni Soletti","Stephen E Fremes","David L Hare","Alexander Kulik","Andre Lamy","Joyce Peper","Marc Ruel","Jurrien M Ten Berg","Laura M Willemsen","Qiang Zhao","Daniel M Wojdyla","Deepak L Bhatt","John H Alexander","Bjorn Redfors"],"significance":7,"published":"2023-10-24","source_date":"2023-10-24","image":"","kennis":[],"congress":"","summary_en":"This individual patient data meta-analysis documented the predictors and clinical consequences of graft failure after CABG, showing that venous graft failure is common and significantly impacts long-term outcomes, reinforcing the value of arterial conduits.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea3a30bdc4d1","type":"article","url":"https://hartvaat.nl/2023/10/24/inhalatief-epoprostenol-versus-no-bij-rechterventrikel-falen-na-hartchirurgie/","title":"Inhalatief epoprostenol versus NO bij rechterventrikel falen na hartchirurgie","title_en":"Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062464","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062464","authors":["Kamrouz Ghadimi","Jhaymie L Cappiello","Mary Cooter Wright","Jerrold H Levy","Benjamin S Bryner","Adam D DeVore","Jacob N Schroder","Chetan B Patel","Sudarshan Rajagopal","Svati H Shah","Carmelo A Milano"],"significance":6,"published":"2023-10-24","source_date":"2023-10-24","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared inhaled epoprostenol with nitric oxide for right ventricular failure after major cardiac surgery, finding comparable efficacy for both pulmonary vasodilators in this critical post-surgical setting.","created":"2026-07-03T10:30:39Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f59702636ca","type":"article","url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","title":"PROMPT-AHF: EPD-alerts verbeteren hartfalenmedicatie bij ontslag","title_en":"Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad512","source_url":"https://doi.org/10.1093/eurheartj/ehad512","authors":["Lama Ghazi","Yu Yamamoto","Michael Fuery","Kyle O'Connor","Sounok Sen","Marc Samsky","Ralph J Riello","Ravi Dhar","Joanna Huang","Temitope Olufade","James McDermott","Silvio E Inzucchi","Eric J Velazquez","Francis Perry Wilson","Nihar R Desai","Tariq Ahmad"],"significance":7,"published":"2023-10-21","source_date":"2023-10-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"The PROMPT-AHF trial showed that electronic health record alerts at hospital discharge significantly increase prescription of guideline-directed medical therapy (including SGLT2 inhibitors) for acute heart failure, demonstrating the effectiveness of automated clinical decision support.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"965aea903547","type":"article","url":"https://hartvaat.nl/2023/10/21/lerodalcibep-bij-familiaire-hypercholesterolemie-liberate-hefh-langetermijndata/","title":"Lerodalcibep bij familiaire hypercholesterolemie: LIBerate-HeFH langetermijndata","title_en":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipidenverlaging","lipoproteïne-a","pcsk9-remmers","pelacarsen","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad596","source_url":"https://doi.org/10.1093/eurheartj/ehad596","authors":["Frederick Raal","Nyda Fourie","Russell Scott","Dirk Blom","Matthys De Vries Basson","Meral Kayikcioglu","Kate Caldwell","David Kallend","Evan Stein"],"significance":7,"published":"2023-10-21","source_date":"2023-10-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"Long-term data on lerodalcibep, a novel small recombinant fusion protein PCSK9 inhibitor, showed sustained LDL cholesterol reduction in heterozygous FH patients. The monthly subcutaneous injection offers a new dosing interval between biweekly antibodies and biannual siRNA.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18bd75dd229d","type":"article","url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","title":"Minimalisatie van atriale pacing bij sinusknoopziekte vermindert AF","title_en":"Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","supraventriculaire-tachycardie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad564","source_url":"https://doi.org/10.1093/eurheartj/ehad564","authors":["Mads Brix Kronborg","Maria Hee Jung Park Frausing","Jerzy Malczynski","Sam Riahi","Jens Haarbo","Katja Fiedler Holm","Charlotte Ellen Larroudé","Andi Eie Albertsen","Lene Svendstrup","Ulrik Hintze","Ole Dyg Pedersen","Ulla Davidsen","Thomas Fischer","Jens Brock Johansen","Jens Kristensen","Christian Gerdes","Jens Cosedis Nielsen"],"significance":7,"published":"2023-10-21","source_date":"2023-10-21","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"This randomized trial showed that minimizing atrial pacing in sinus node dysfunction reduces the risk of new-onset atrial fibrillation, suggesting that unnecessary atrial pacing may itself contribute to AF development.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"290a755d84fd","type":"article","url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","title":"Upgrade van RV-pacing naar CRT bij hartfalen: gerandomiseerde trial","title_en":"Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiale-resynchronisatie","harttransplantatie","pathfinder-trial","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad591","source_url":"https://doi.org/10.1093/eurheartj/ehad591","authors":["Béla Merkely","Robert Hatala","Jerzy K Wranicz","Gábor Duray","Csaba Földesi","Zoltán Som","Marianna Németh","Kinga Goscinska-Bis","László Gellér","Endre Zima","István Osztheimer","Levente Molnár","Júlia Karády","Gerhard Hindricks","Ilan Goldenberg","Helmut Klein","Mátyás Szigeti","Scott D Solomon","Valentina Kutyifa","Attila Kovács","Annamária Kosztin"],"significance":7,"published":"2023-10-21","source_date":"2023-10-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This randomized trial demonstrated that upgrading right ventricular pacing to CRT-D in heart failure patients improves LV function and clinical outcomes, confirming the benefit of resynchronization in pacing-induced cardiomyopathy.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T18:39:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8ce3ad482f80","type":"article","url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","title":"ILUMIEN IV: OCT-geleide versus angiografie-geleide PCI — NEJM","title_en":"Optical Coherence Tomography-Guided versus Angiography-Guided PCI.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2305861","source_url":"https://doi.org/10.1056/NEJMoa2305861","authors":["Ziad A Ali","Ulf Landmesser","Akiko Maehara","Mitsuaki Matsumura","Richard A Shlofmitz","Giulio Guagliumi","Matthew J Price","Jonathan M Hill","Takashi Akasaka","Francesco Prati","Hiram G Bezerra","William Wijns","David Leistner","Paolo Canova","Fernando Alfonso","Franco Fabbiocchi","Ozgen Dogan","Robert J McGreevy","Robert W McNutt","Hong Nie","Jana Buccola","Nick E J West","Gregg W Stone"],"significance":8,"published":"2023-10-19","source_date":"2023-10-19","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The ILUMIEN IV trial showed that OCT-guided PCI improved the procedural quality (minimum stent area) but did not significantly reduce the clinical composite of cardiac death or MI compared with angiography-guided PCI at 2 years. The study highlighted the gap between procedural optimization and hard clinical outcomes.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb22a1e4b719","type":"article","url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","title":"OCTOBER: OCT-geleide PCI bij complexe bifurcatielaesies — NEJM","title_en":"OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307770","source_url":"https://doi.org/10.1056/NEJMoa2307770","authors":["Niels R Holm","Lene D Andreasen","Omeed Neghabat","Peep Laanmets","Indulis Kumsars","Johan Bennett","Niels T Olsen","Jacob Odenstedt","Pavel Hoffmann","Jo Dens","Saqib Chowdhary","Peter O'Kane","Søren-Haldur Bülow Rasmussen","Matthias Heigert","Ole Havndrup","Jan P Van Kuijk","Simone Biscaglia","Lone J H Mogensen","Loghman Henareh","Francesco Burzotta","Christian H Eek","Darren Mylotte","Miquel S Llinas","Lukasz Koltowski","Paul Knaapen","Slobodan Calic","Nils Witt","Irene Santos-Pardo","Stuart Watkins","Jacob Lønborg","Andreas T Kristensen","Lisette O Jensen","Fredrik Calais","James Cockburn","Andrew McNeice","Olli A Kajander","Ton Heestermans","Stephan Kische","Ashkan Eftekhari","James C Spratt","Evald H Christiansen"],"significance":9,"published":"2023-10-19","source_date":"2023-10-19","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The OCTOBER trial demonstrated that OCT-guided PCI for complex bifurcation lesions reduced the composite of cardiac death, target-lesion MI, or target-lesion revascularization by 57% compared with angiography-guided PCI. This established OCT as a valuable guidance tool specifically for bifurcation intervention.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"37d91cedf608","type":"article","url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","title":"Orthostatische hypotensie en intensieve bloeddrukbehandeling: IPD meta-analyse in JAMA","title_en":"Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"JAMA","doi":"10.1001/jama.2023.18497","source_url":"https://doi.org/10.1001/jama.2023.18497","authors":["Stephen P Juraschek","Jiun-Ruey Hu","Jennifer L Cluett","Anthony M Ishak","Carol Mita","Lewis A Lipsitz","Lawrence J Appel","Nigel S Beckett","Ruth L Coleman","William C Cushman","Barry R Davis","Greg Grandits","Rury R Holman","Edgar R Miller","Ruth Peters","Jan A Staessen","Addison A Taylor","Lutgarde Thijs","Jackson T Wright","Kenneth J Mukamal"],"significance":8,"published":"2023-10-17","source_date":"2023-10-17","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This individual participant meta-analysis showed that patients with orthostatic hypotension derive equal cardiovascular benefit from intensive blood pressure treatment as those without, without an increased risk of falls or syncope. The results argued against withholding aggressive treatment due to orthostatic hypotension.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"346666b0a253","type":"article","url":"https://hartvaat.nl/2023/10/17/million-hearts-betaald-cv-risicomanagement-vermindert-mi-en-cva-jama-rct/","title":"Million Hearts: betaald CV-risicomanagement vermindert MI en CVA — JAMA RCT","title_en":"Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2023.19597","source_url":"https://doi.org/10.1001/jama.2023.19597","authors":["Laura Blue","Keith Kranker","Amanda R Markovitz","Rhea E Powell","Malcolm V Williams","Jia Pu","David J Magid","Nancy McCall","Allison Steiner","Kate A Stewart","Julia M Rollison","Patricia Markovich","G Greg Peterson"],"significance":7,"published":"2023-10-17","source_date":"2023-10-17","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"The Million Hearts Model trial showed that paying healthcare organizations for structured cardiovascular risk management significantly reduced MI and stroke in high-risk patients, demonstrating that financial incentives for prevention translate to clinical outcomes.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daa461a1fd96","type":"article","url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","title":"Antiplaatjesmonotherapie na PCI: clopidogrel versus aspirine naar risicoprofiel","title_en":"Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["aspirine","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.07.031","source_url":"https://doi.org/10.1016/j.jacc.2023.07.031","authors":["Seokhun Yang","Jeehoon Kang","Kyung Woo Park","Seung-Ho Hur","Nam Ho Lee","Doyeon Hwang","Han-Mo Yang","Hyo-Suk Ahn","Kwang Soo Cha","Sang-Ho Jo","Jae Kean Ryu","Il-Woo Suh","Hyun-Hee Choi","Seong-Ill Woo","Jung-Kyu Han","Eun-Seok Shin","Bon-Kwon Koo","Hyo-Soo Kim"],"significance":7,"published":"2023-10-17","source_date":"2023-10-17","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This analysis confirmed clopidogrel's superiority over aspirin as antiplatelet monotherapy after PCI across a range of clinical, ischemic, and bleeding risk profiles, supporting clopidogrel as the default long-term post-PCI antiplatelet agent.","created":"2026-07-03T10:30:38Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"478786242097","type":"article","url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","title":"Bivalirudine versus heparine bij NSTEMI: IPD meta-analyse","title_en":"Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.063946","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.063946","authors":["Behnood Bikdeli","David Erlinge","Marco Valgimigli","Adnan Kastrati","Yaling Han","Philippe Gabriel Steg","Rod H Stables","Roxana Mehran","Stefan K James","Enrico Frigoli","Patrick Goldstein","Yi Li","Adeel Shahzad","Stefanie Schüpke","Ghazaleh Mehdipoor","Shmuel Chen","Björn Redfors","Aaron Crowley","Zhipeng Zhou","Gregg W Stone"],"significance":7,"published":"2023-10-17","source_date":"2023-10-17","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that bivalirudin causes less major bleeding than heparin during PCI for NSTEMI without increasing ischemic events, providing the most robust comparative data for anticoagulation in this setting.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"639ba091615d","type":"article","url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","title":"OCTIVUS: OCT-geleide versus IVUS-geleide PCI — non-inferioriteit bevestigd","title_en":"Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.066429","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.066429","authors":["Do-Yoon Kang","Jung-Min Ahn","Sung-Cheol Yun","Seung-Ho Hur","Yun-Kyeong Cho","Cheol Hyun Lee","Soon Jun Hong","Subin Lim","Sang-Wook Kim","Hoyoun Won","Jun-Hyok Oh","Jeong Cheon Choe","Young Joon Hong","Yong-Hoon Yoon","Hoyun Kim","Yeonwoo Choi","Jinho Lee","Young Won Yoon","Soo-Joong Kim","Jang-Ho Bae","Duk-Woo Park","Seung-Jung Park"],"significance":8,"published":"2023-10-17","source_date":"2023-10-17","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"The OCTIVUS trial demonstrated that OCT-guided PCI was noninferior to IVUS-guided PCI for clinical outcomes. The result established OCT and IVUS as interchangeable intravascular imaging modalities for guiding coronary intervention.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea3dd5ee212c","type":"article","url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","title":"VA-ECMO bij cardiogene shock: IPD meta-analyse — Lancet","title_en":"Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)01607-0","source_url":"https://doi.org/10.1016/S0140-6736(23)01607-0","authors":["Uwe Zeymer","Anne Freund","Matthias Hochadel","Petr Ostadal","Jan Belohlavek","Richard Rokyta","Steffen Massberg","Stefan Brunner","Enzo Lüsebrink","Marcus Flather","David Adlam","Kris Bogaerts","Amerjeet Banning","Manel Sabaté","Ibrahim Akin","Alexander Jobs","Steffen Schneider","Steffen Desch","Holger Thiele"],"significance":9,"published":"2023-10-14","source_date":"2023-10-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that VA-ECMO does not improve survival in patients with infarct-related cardiogenic shock, with pooled data from randomized trials showing no mortality benefit but increased limb complications. The analysis definitively discouraged routine ECMO use in this setting.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03992bd7b00d","type":"article","url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","title":"MULTISTARS AMI: timing van complete revascularisatie bij STEMI — NEJM","title_en":"Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307823","source_url":"https://doi.org/10.1056/NEJMoa2307823","authors":["Barbara E Stähli","Ferdinando Varbella","Axel Linke","Bettina Schwarz","Stephan B Felix","Moritz Seiffert","Rahel Kesterke","Peter Nordbeck","Bernhard Witzenbichler","Irene M Lang","Mirjam Kessler","Christian Valina","Alban Dibra","Miklos Rohla","Marco Moccetti","Matteo Vercellino","Luise Gaede","Lorenz Bott-Flügel","Philipp Jakob","Julia Stehli","Alessandro Candreva","Christian Templin","Matthias Schindler","Manfred Wischnewsky","Greca Zanda","Giorgio Quadri","Norman Mangner","Aurel Toma","Giulia Magnani","Peter Clemmensen","Thomas F Lüscher","Thomas Münzel","P Christian Schulze","Karl-Ludwig Laugwitz","Wolfgang Rottbauer","Kurt Huber","Franz-Josef Neumann","Steffen Schneider","Franz Weidinger","Stephan Achenbach","Gert Richardt","Adnan Kastrati","Ian Ford","Willibald Maier","Frank Ruschitzka"],"significance":9,"published":"2023-10-12","source_date":"2023-10-12","image":"","kennis":[],"congress":"","summary_en":"The MULTISTARS AMI trial showed that immediate complete revascularization during the index primary PCI procedure was superior to staged revascularization within 45 days for reducing cardiovascular death or MI in patients with STEMI and multivessel disease. The results support a one-stop-shop approach when feasible.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3b7630d56416","type":"article","url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","title":"CASTLE-HTx: AF-ablatie bij eindstadium hartfalen — NEJM","title_en":"Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfref","katheterablatie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2306037","source_url":"https://doi.org/10.1056/NEJMoa2306037","authors":["Christian Sohns","Henrik Fox","Nassir F Marrouche","Harry J G M Crijns","Angelika Costard-Jaeckle","Leonard Bergau","Gerhard Hindricks","Nikolaos Dagres","Samuel Sossalla","Rene Schramm","Thomas Fink","Mustapha El Hamriti","Maximilian Moersdorf","Vanessa Sciacca","Frank Konietschke","Volker Rudolph","Jan Gummert","Jan G P Tijssen","Philipp Sommer"],"significance":10,"published":"2023-10-12","source_date":"2023-10-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/"],"congress":"","summary_en":"The CASTLE-HTx trial demonstrated that catheter ablation for atrial fibrillation in patients with end-stage heart failure (on LVAD or transplant waiting list) dramatically improved survival, with a 44% relative reduction in the composite of death, LVAD implantation, or urgent heart transplantation. The results extend the benefit of AF ablation to the most severely ill heart failure patients.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d76ed9ad0e02","type":"article","url":"https://hartvaat.nl/2023/10/12/aromi-prehospitale-copeptine-versnelt-mi-uitsluiting/","title":"AROMI: prehospitale copeptine versnelt MI-uitsluiting","title_en":"Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad447","source_url":"https://doi.org/10.1093/eurheartj/ehad447","authors":["Claus Kjær Pedersen","Carsten Stengaard","Morten Thingemann Bøtker","Hanne Maare Søndergaard","Karen Kaae Dodt","Christian Juhl Terkelsen"],"significance":7,"published":"2023-10-12","source_date":"2023-10-12","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"The AROMI study showed that prehospital copeptin measurement combined with in-hospital troponin can accelerate AMI rule-out in the ambulance setting, potentially enabling earlier triage and reducing unnecessary emergency department evaluations.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eba1cd609313","type":"article","url":"https://hartvaat.nl/2023/10/12/anticoagulatie-bij-af-na-eerdere-intracraniele-bloeding-meta-analyse/","title":"Anticoagulatie bij AF na eerdere intracraniële bloeding: meta-analyse","title_en":"Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","rivaroxaban"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2023-322492","source_url":"https://doi.org/10.1136/heartjnl-2023-322492","authors":["Huiya Cai","Guoquan Chen","Wei Hu","Chunjiao Jiang"],"significance":7,"published":"2023-10-12","source_date":"2023-10-12","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis showed that resuming anticoagulation (preferably with DOACs) in AF patients after intracranial hemorrhage is associated with fewer ischemic events and lower mortality without a significant increase in recurrent ICH, supporting cautious anticoagulation restart.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3aa7c1c4f52b","type":"article","url":"https://hartvaat.nl/2023/10/07/inte-africa-geintegreerd-management-van-hiv-diabetes-en-hypertensie-lancet/","title":"INTE-AFRICA: geïntegreerd management van HIV, diabetes en hypertensie — Lancet","title_en":"Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)01573-8","source_url":"https://doi.org/10.1016/S0140-6736(23)01573-8","authors":["Sokoine Kivuyo","Josephine Birungi","Joseph Okebe","Duolao Wang","Kaushik Ramaiya","Samafilan Ainan","Faith Tumuhairwe","Simple Ouma","Ivan Namakoola","Anupam Garrib","Erik van Widenfelt","Gerald Mutungi","Gerard Abou Jaoude","Neha Batura","Joshua Musinguzi","Mina Nakawuka Ssali","Bernard Michael Etukoit","Kenneth Mugisha","Meshack Shimwela","Omary Said Ubuguyu","Abel Makubi","Caroline Jeffery","Stephen Watiti","Jolene Skordis","Luis Cuevas","Nelson K Sewankambo","Geoff Gill","Anne Katahoire","Peter G Smith","Max Bachmann","Jeffrey V Lazarus","Sayoki Mfinanga","Moffat J Nyirenda","Shabbar Jaffar"],"significance":7,"published":"2023-10-07","source_date":"2023-10-07","image":"","kennis":[],"congress":"","summary_en":"The INTE-AFRICA trial showed that integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa is feasible and may improve care quality, testing a model for addressing the growing burden of noncommunicable diseases alongside HIV.","created":"2026-07-03T10:30:37Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ad3cb057aa1","type":"article","url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","title":"MORE-CRT MPP: multipoint pacing bij CRT non-responders","title_en":"Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad294","source_url":"https://doi.org/10.1093/europace/euad294","authors":["Christophe Leclercq","Haran Burri","Peter Paul Delnoy","Christopher A Rinaldi","Johannes Sperzel","Leonardo Calò","Joaquin Fernandez Concha","Antonio Fusco","Faisal Al Samadi","Kwangdeok Lee","Bernard Thibault"],"significance":6,"published":"2023-10-05","source_date":"2023-10-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"The MORE-CRT MPP trial evaluated whether multipoint pacing can convert CRT non-responders to responders, testing programmable stimulation optimization as a salvage strategy for patients who fail conventional biventricular pacing.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7840245af09d","type":"article","url":"https://hartvaat.nl/2023/10/05/rivaroxaban-dosering-bij-af-on-label-versus-off-label-in-azie-en-niet-azie/","title":"Rivaroxaban dosering bij AF: on-label versus off-label in Azië en niet-Azië","title_en":"Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad288","source_url":"https://doi.org/10.1093/europace/euad288","authors":["Yi-Hsin Chan","Chih-Yu Chan","Shao-Wei Chen","Tze-Fan Chao","Gregory Y H Lip"],"significance":6,"published":"2023-10-05","source_date":"2023-10-05","image":"","kennis":[],"congress":"","summary_en":"This study compared on-label with off-label rivaroxaban dosing in AF across Asian and non-Asian populations, confirming that off-label underdosing is associated with worse ischemic outcomes without meaningful bleeding reduction.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6017dcf440d5","type":"article","url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","title":"ECLS-SHOCK: ECMO bij infarctgerelateerde cardiogene shock — NEJM","title_en":"Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2307227","source_url":"https://doi.org/10.1056/NEJMoa2307227","authors":["Holger Thiele","Uwe Zeymer","Ibrahim Akin","Michael Behnes","Tienush Rassaf","Amir Abbas Mahabadi","Ralf Lehmann","Ingo Eitel","Tobias Graf","Tim Seidler","Andreas Schuster","Carsten Skurk","Daniel Duerschmied","Peter Clemmensen","Marcus Hennersdorf","Stephan Fichtlscherer","Ingo Voigt","Melchior Seyfarth","Stefan John","Sebastian Ewen","Axel Linke","Eike Tigges","Peter Nordbeck","Leonhard Bruch","Christian Jung","Jutta Franz","Philipp Lauten","Tomaz Goslar","Hans-Josef Feistritzer","Janine Pöss","Eva Kirchhof","Taoufik Ouarrak","Steffen Schneider","Steffen Desch","Anne Freund"],"significance":10,"published":"2023-10-05","source_date":"2023-10-05","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The ECLS-SHOCK trial showed that routine extracorporeal membrane oxygenation (ECMO) did not improve 30-day survival compared with standard care in patients with infarct-related cardiogenic shock. This large, definitive trial ended the enthusiasm for routine ECLS in MI-associated cardiogenic shock.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40783730c310","type":"article","url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","title":"Vijf modificeerbare risicofactoren en mondiale CV-sterfte: NEJM PURE-analyse","title_en":"Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2206916","source_url":"https://doi.org/10.1056/NEJMoa2206916","authors":["Christina Magnussen","Francisco M Ojeda","Darryl P Leong","Jesus Alegre-Diaz","Philippe Amouyel","Larissa Aviles-Santa","Dirk De Bacquer","Christie M Ballantyne","Antonio Bernabé-Ortiz","Martin Bobak","Hermann Brenner","Rodrigo M Carrillo-Larco","James de Lemos","Annette Dobson","Marcus Dörr","Chiara Donfrancesco","Wojciech Drygas","Robin P Dullaart","Gunnar Engström","Marco M Ferrario","Jean Ferrières","Giovanni de Gaetano","Uri Goldbourt","Clicerio Gonzalez","Guido Grassi","Allison M Hodge","Kristian Hveem","Licia Iacoviello","M Kamran Ikram","Vilma Irazola","Modou Jobe","Pekka Jousilahti","Pontiano Kaleebu","Maryam Kavousi","Frank Kee","Davood Khalili","Wolfgang Koenig","Anna Kontsevaya","Kari Kuulasmaa","Karl J Lackner","David M Leistner","Lars Lind","Allan Linneberg","Thiess Lorenz","Magnus Nakrem Lyngbakken","Reza Malekzadeh","Sofia Malyutina","Ellisiv B Mathiesen","Olle Melander","Andres Metspalu","J Jaime Miranda","Marie Moitry","Joseph Mugisha","Mahdi Nalini","Vijay Nambi","Toshiharu Ninomiya","Karen Oppermann","Eleonora d'Orsi","Andrzej Pająk","Luigi Palmieri","Demosthenes Panagiotakos","Arokiasamy Perianayagam","Annette Peters","Hossein Poustchi","Andrew M Prentice","Eva Prescott","Ulf Risérus","Veikko Salomaa","Susana Sans","Satoko Sakata","Ben Schöttker","Aletta E Schutte","Sadaf G Sepanlou","Sanjib Kumar Sharma","Jonathan E Shaw","Leon A Simons","Stefan Söderberg","Abdonas Tamosiunas","Barbara Thorand","Hugh Tunstall-Pedoe","Raphael Twerenbold","Diego Vanuzzo","Giovanni Veronesi","Julia Waibel","S Goya Wannamethee","Masafumi Watanabe","Philipp S Wild","Yao Yao","Yi Zeng","Andreas Ziegler","Stefan Blankenberg"],"significance":9,"published":"2023-10-05","source_date":"2023-10-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/"],"congress":"","summary_en":"This PURE study analysis demonstrated that five modifiable risk factors (hypertension, dyslipidemia, diabetes, obesity, and smoking) account for the majority of cardiovascular disease and mortality worldwide, with regional variation in their relative contributions. The individual-level data across 21 countries provided the definitive global picture of attributable cardiovascular risk.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba49558c2065","type":"article","url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","title":"eGFR en albuminurie voorspellen CV-events: IPD mega-meta-analyse","title_en":"Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair"],"journal":"JAMA","doi":"10.1001/jama.2023.17002","source_url":"https://doi.org/10.1001/jama.2023.17002","authors":["Morgan E Grams","Josef Coresh","Kunihiro Matsushita","Shoshana H Ballew","Yingying Sang","Aditya Surapaneni","Natalia Alencar de Pinho","Amanda Anderson","Lawrence J Appel","Johan Ärnlöv","Fereidoun Azizi","Nisha Bansal","Samira Bell","Henk J G Bilo","Nigel J Brunskill","Juan J Carrero","Steve Chadban","John Chalmers","Jing Chen","Elizabeth Ciemins","Massimo Cirillo","Natalie Ebert","Marie Evans","Alejandro Ferreiro","Edouard L Fu","Masafumi Fukagawa","Jamie A Green","Orlando M Gutierrez","William G Herrington","Shih-Jen Hwang","Lesley A Inker","Kunitoshi Iseki","Tazeen Jafar","Simerjot K Jassal","Vivekanand Jha","Aya Kadota","Ronit Katz","Anna Köttgen","Tsuneo Konta","Florian Kronenberg","Brian J Lee","Jennifer Lees","Adeera Levin","Helen C Looker","Rupert Major","Cheli Melzer Cohen","Makiko Mieno","Mariko Miyazaki","Olivier Moranne","Isao Muraki","David Naimark","Dorothea Nitsch","Wonsuk Oh","Michelle Pena","Tanjala S Purnell","Charumathi Sabanayagam","Michihiro Satoh","Simon Sawhney","Elke Schaeffner","Ben Schöttker","Jenny I Shen","Michael G Shlipak","Smeeta Sinha","Benedicte Stengel","Keiichi Sumida","Marcello Tonelli","Jose M Valdivielso","Arjan D van Zuilen","Frank L J Visseren","Angela Yee-Moon Wang","Chi-Pang Wen","David C Wheeler","Hiroshi Yatsuya","Kunihiro Yamagata","Jae Won Yang","Ann Young","Haitao Zhang","Luxia Zhang","Andrew S Levey","Ron T Gansevoort"],"significance":8,"published":"2023-10-03","source_date":"2023-10-03","image":"","kennis":[],"congress":"","summary_en":"This mega-scale individual participant data meta-analysis confirmed that low eGFR and albuminuria independently and additively predict cardiovascular events and mortality. The combined assessment provides superior risk stratification compared with either marker alone.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"23be4915720e","type":"article","url":"https://hartvaat.nl/2023/10/03/cpap-therapietrouw-en-recidief-cv-events-meta-analyse/","title":"CPAP-therapietrouw en recidief CV-events: meta-analyse","title_en":"Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2023.17465","source_url":"https://doi.org/10.1001/jama.2023.17465","authors":["Manuel Sánchez-de-la-Torre","Esther Gracia-Lavedan","Ivan D Benitez","Alicia Sánchez-de-la-Torre","Anna Moncusí-Moix","Gerard Torres","Kelly Loffler","Richard Woodman","Robert Adams","Gonzalo Labarca","Jorge Dreyse","Christine Eulenburg","Erik Thunström","Helena Glantz","Yüksel Peker","Craig Anderson","Doug McEvoy","Ferran Barbé"],"significance":7,"published":"2023-10-03","source_date":"2023-10-03","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/"],"congress":"","summary_en":"This meta-analysis demonstrated that only adherent CPAP users (≥4 hours/night) experience a reduction in recurrent cardiovascular events in obstructive sleep apnea, suggesting that the neutral results of CPAP trials may be explained by suboptimal adherence.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d1dc55762cca","type":"article","url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","title":"Vericiguat bij HFrEF is kosteneffectief: VICTORIA analyse","title_en":"Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063602","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063602","authors":["Derek S Chew","Yanhong Li","Robert Bigelow","Patricia A Cowper","Kevin J Anstrom","Melanie R Daniels","Linda Davidson-Ray","Adrian F Hernandez","Christopher M O'Connor","Paul W Armstrong","Daniel B Mark"],"significance":6,"published":"2023-10-03","source_date":"2023-10-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This VICTORIA cost-effectiveness analysis showed that vericiguat is cost-effective in high-risk HFrEF patients with recent heart failure events, supporting the value proposition of sGC stimulation as a fifth pillar of heart failure therapy.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"486824c2255e","type":"article","url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","title":"ADVOR: nierfunctie en decongestie met acetazolamide","title_en":"Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","sacubitril-valsartan"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad557","source_url":"https://doi.org/10.1093/eurheartj/ehad557","authors":["Evelyne Meekers","Jeroen Dauw","Pieter Martens","Sebastiaan Dhont","Frederik H Verbrugge","Petra Nijst","Jozine M Ter Maaten","Kevin Damman","Alexandre Mebazaa","Gerasimos Filippatos","Frank Ruschitzka","Wai Hong Wilson Tang","Matthias Dupont","Wilfried Mullens"],"significance":7,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This ADVOR analysis showed that acetazolamide improves decongestion without significantly worsening renal function in acute heart failure, with the initial eGFR decline reflecting hemodynamic effects rather than tubular injury.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8bee317bb751","type":"article","url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","title":"PRECISE: uitgesteld testen bij stabiel coronairlijden is veilig","title_en":"Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["stabiel-coronairlijden"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.2614","source_url":"https://doi.org/10.1001/jamacardio.2023.2614","authors":["James E Udelson","Michelle D Kelsey","Michael G Nanna","Christopher B Fordyce","Eric Yow","Robert M Clare","Daniel B Mark","Manesh R Patel","Campbell Rogers","Nick Curzen","Gianluca Pontone","Pál Maurovich-Horvat","Bernard De Bruyne","John P Greenwood","Victor Marinescu","Jonathon Leipsic","Gregg W Stone","Ori Ben-Yehuda","Colin Berry","Shea E Hogan","Bjorn Redfors","Ziad A Ali","Robert A Byrne","Christopher M Kramer","Robert W Yeh","Beth Martinez","Sarah Mullen","Whitney Huey","Kevin J Anstrom","Hussein R Al-Khalidi","Karen Chiswell","Sreekanth Vemulapalli","Pamela S Douglas"],"significance":7,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/"],"congress":"","summary_en":"This PRECISE trial analysis showed that deferring non-invasive testing in stable outpatients with suspected coronary artery disease and low pretest probability is safe, validating the guideline recommendation to avoid unnecessary testing.","created":"2026-07-03T10:30:36Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a281a58f43ec","type":"article","url":"https://hartvaat.nl/2023/10/01/mra-plus-sglt2-remmer-bij-hartfalen-meta-analyse-toont-synergistisch-voordeel/","title":"MRA plus SGLT2-remmer bij hartfalen: meta-analyse toont synergistisch voordeel","title_en":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["dapagliflozine","empagliflozine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad522","source_url":"https://doi.org/10.1093/eurheartj/ehad522","authors":["Mainak Banerjee","Indira Maisnam","Rimesh Pal","Satinath Mukhopadhyay"],"significance":8,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This meta-analysis showed that combining an MRA with an SGLT2 inhibitor in heart failure provides additive reductions in cardiovascular death and heart failure hospitalization beyond either drug class alone. The findings support the four-pillar approach including dual neurohormonal and metabolic modulation.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"52b5b5e367f9","type":"article","url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","title":"PA-drukmonitoring bij chronisch hartfalen: meta-analyse van drie RCT's","title_en":"Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad346","source_url":"https://doi.org/10.1093/eurheartj/ehad346","authors":["Pascal R D Clephas","Sumant P Radhoe","Eric Boersma","John Gregson","Pardeep S Jhund","William T Abraham","John J V McMurray","Rudolf A de Boer","Jasper J Brugts"],"significance":8,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"This meta-analysis of CHAMPION, GUIDE-HF, and MONITOR-HF confirmed that implantable pulmonary artery pressure monitoring significantly reduces heart failure hospitalization in chronic heart failure. The pooled evidence across three continents supported the clinical utility of hemodynamic monitoring.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3081eef49c7","type":"article","url":"https://hartvaat.nl/2023/10/01/trimetazidine-bij-hfpef-gerandomiseerde-cross-over-trial/","title":"Trimetazidine bij HFpEF: gerandomiseerde cross-over trial","title_en":"Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","step-hfpef","summit-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14418","source_url":"https://doi.org/10.1002/ehf2.14418","authors":["Arno A van de Bovenkamp","Kiki T J Geurkink","Frank T P Oosterveer","Frances S de Man","Wouter E M Kok","Patrick N A Bronzwaer","Cor P Allaart","Aart J Nederveen","Albert C van Rossum","Adrianus J Bakermans","M Louis Handoko"],"significance":6,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This cross-over trial of trimetazidine in HFpEF showed no significant improvement in cardiac function or exercise capacity, a negative result for metabolic modulation in the preserved ejection fraction phenotype.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3a386b1bcfd8","type":"article","url":"https://hartvaat.nl/2023/10/01/baroreflexactivatietherapie-bij-hfref-systematische-review/","title":"Baroreflexactivatietherapie bij HFrEF: systematische review","title_en":"Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14473","source_url":"https://doi.org/10.1002/ehf2.14473","authors":["Juan Máximo Molina-Linde","David Cordero-Pereda","Elena Baños-Álvarez","Maria Piedad Rosario-Lozano","Juan Antonio Blasco-Amaro"],"significance":5,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This systematic review evaluated baroreflex activation therapy as an adjunctive treatment for HFrEF, showing symptom improvement and NT-proBNP reduction with this neuromodulation device.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T13:29:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7e64e4e9b08a","type":"article","url":"https://hartvaat.nl/2023/10/01/alcoholconsumptie-en-bloeddruk-dosis-respons-meta-analyse/","title":"Alcoholconsumptie en bloeddruk: dosis-respons meta-analyse","title_en":"Alcohol Intake and Blood Pressure Levels: A Dose-Response Meta-Analysis of Nonexperimental Cohort Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21224","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21224","authors":["Silvia Di Federico","Tommaso Filippini","Paul K Whelton","Marta Cecchini","Inga Iamandii","Giuseppe Boriani","Marco Vinceti"],"significance":7,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This dose-response meta-analysis showed a linear relationship between alcohol consumption and blood pressure elevation with no safe threshold, supporting alcohol reduction as a blood pressure management strategy at any intake level.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ef3dda26540","type":"article","url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","title":"Ivabradine bij hoogrisico hartfalenpatiënten: SHIFT-analyse","title_en":"Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfref","ivabradine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14455","source_url":"https://doi.org/10.1002/ehf2.14455","authors":["Amr Abdin","Michel Komajda","Jeffrey S Borer","Ian Ford","Luigi Tavazzi","Cécile Batailler","Karl Swedberg","Giuseppe M C Rosano","Felix Mahfoud","Michael Böhm"],"significance":6,"published":"2023-10-01","source_date":"2023-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/"],"congress":"","summary_en":"This SHIFT post-hoc analysis showed that ivabradine provides the greatest benefit in HFrEF patients with the highest risk profiles (higher heart rate, lower LVEF, recent hospitalization), supporting risk-based patient selection for heart rate lowering.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6c4104fb770","type":"article","url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","title":"AdaptResponse: adaptieve versus conventionele CRT bij hartfalen — Lancet","title_en":"Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00912-1","source_url":"https://doi.org/10.1016/S0140-6736(23)00912-1","authors":["Bruce L Wilkoff","Gerasimos Filippatos","Christophe Leclercq","Michael R Gold","Ahmad S Hersi","Kengo Kusano","Wilfried Mullens","G Michael Felker","Charan Kantipudi","Mikhael F El-Chami","Vidal Essebag","Bertrand Pierre","Francois Philippon","Francisco Perez-Gil","Eugene S Chung","Juan Sotomonte","Stanley Tung","Balbir Singh","Babak Bozorgnia","Satish Goel","Hans Holger Ebert","Niraj Varma","Kara J Quan","Fiorella Salerno","Bart Gerritse","Janelle van Wel","Daniel E Schaber","Dedra H Fagan","David Birnie"],"significance":7,"published":"2023-09-30","source_date":"2023-09-30","image":"","kennis":[],"congress":"","summary_en":"The AdaptResponse trial showed that adaptive CRT (automatic optimization with LV-only pacing when appropriate) is noninferior to conventional biventricular CRT, supporting intelligent pacing algorithms that simplify device management.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14ac906afdc4","type":"article","url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","title":"NOAH-AFNET 6: edoxaban bij atriaal high-rate episodes — NEJM","title_en":"Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2303062","source_url":"https://doi.org/10.1056/NEJMoa2303062","authors":["Paulus Kirchhof","Tobias Toennis","Andreas Goette","A John Camm","Hans Christoph Diener","Nina Becher","Emanuele Bertaglia","Carina Blomstrom Lundqvist","Martin Borlich","Axel Brandes","Nuno Cabanelas","Melanie Calvert","Gregory Chlouverakis","Gheorghe-Andrei Dan","Joris R de Groot","Wolfgang Dichtl","Borys Kravchuk","Andrzej Lubiński","Eloi Marijon","Béla Merkely","Lluís Mont","Ann-Kathrin Ozga","Kim Rajappan","Andrea Sarkozy","Daniel Scherr","Rafał Sznajder","Vasil Velchev","Dan Wichterle","Susanne Sehner","Emmanuel Simantirakis","Gregory Y H Lip","Panos Vardas","Ulrich Schotten","Antonia Zapf"],"significance":10,"published":"2023-09-28","source_date":"2023-09-28","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/hasbled-score/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"The NOAH-AFNET 6 trial found that edoxaban did not significantly reduce cardiovascular events compared with placebo in patients with device-detected atrial high-rate episodes (AHREs) but without clinical atrial fibrillation, while increasing major bleeding. The results do not support routine anticoagulation for subclinical atrial arrhythmias detected by cardiac devices.","created":"2026-07-03T10:30:35Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6019e86167e","type":"article","url":"https://hartvaat.nl/2023/09/28/pijn-op-de-borst-bij-mi-met-en-zonder-diabetes-meta-analyse/","title":"Pijn op de borst bij MI met en zonder diabetes: meta-analyse","title_en":"Chest pain symptoms during myocardial infarction in patients with and without diabetes: a systematic review and meta-analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-322289","source_url":"https://doi.org/10.1136/heartjnl-2022-322289","authors":["Abhinav Kumar","Amrit Sanghera","Balpreet Sanghera","Tahira Mohamed","Ariella Midgen","Sophie Pattison","Louise Marston","Melvyn M Jones"],"significance":6,"published":"2023-09-28","source_date":"2023-09-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This meta-analysis showed that diabetic patients more often present with atypical MI symptoms, but chest pain remains the most common presentation even in diabetes, informing triage and diagnostic approaches.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5acd4e7fc5ac","type":"article","url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","title":"Biodegradeerbare versus duurzame polymeer-stents bij hoog bloedingsrisico","title_en":"Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065448","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065448","authors":["Marco Valgimigli","Adrian Wlodarczak","Ralph Tölg","Béla Merkely","Henning Kelbæk","Jacek Legutko","Stefano Galli","Matthieu Godin","Gabor G Toth","Thibault Lhermusier","Benjamin Honton","Peter Laurenz Dietrich","Francis Stammen","Bert Ferdinande","Johanne Silvain","Davide Capodanno","Guillaume Cayla"],"significance":6,"published":"2023-09-26","source_date":"2023-09-26","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/vasculair/antistolling-bij-vte/"],"congress":"","summary_en":"This randomized trial comparing biodegradable with durable polymer DES in high-bleeding-risk patients showed equivalent outcomes with both platforms, supporting either technology for short-DAPT strategies.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d2faf3745a87","type":"article","url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","title":"Geblindeerde stopstudie: voordelen empagliflozine verdwijnen na staken bij HF","title_en":"Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","emperor-trials"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065748","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065748","authors":["Milton Packer","Javed Butler","Cordula Zeller","Stuart J Pocock","Martina Brueckmann","João Pedro Ferreira","Gerasimos Filippatos","Muhammad Shariq Usman","Faiez Zannad","Stefan D Anker"],"significance":7,"published":"2023-09-26","source_date":"2023-09-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This blinded withdrawal study from EMPEROR showed that the benefits of empagliflozin in heart failure rapidly diminish after treatment discontinuation, with NT-proBNP and clinical deterioration markers worsening within weeks. The findings underscore the need for continuous SGLT2 inhibitor therapy.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"530e1a49b5bf","type":"article","url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","title":"STEP-HFpEF: semaglutide bij HFpEF en obesitas — NEJM","title_en":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["select-trial","step-hfpef","summit-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2306963","source_url":"https://doi.org/10.1056/NEJMoa2306963","authors":["Mikhail N Kosiborod","Steen Z Abildstrøm","Barry A Borlaug","Javed Butler","Søren Rasmussen","Melanie Davies","G Kees Hovingh","Dalane W Kitzman","Marie L Lindegaard","Daniél V Møller","Sanjiv J Shah","Marianne B Treppendahl","Subodh Verma","Walter Abhayaratna","Fozia Z Ahmed","Vijay Chopra","Justin Ezekowitz","Michael Fu","Hiroshi Ito","Małgorzata Lelonek","Vojtech Melenovsky","Bela Merkely","Julio Núñez","Eduardo Perna","Morten Schou","Michele Senni","Kavita Sharma","Peter Van der Meer","Dirk von Lewinski","Dennis Wolf","Mark C Petrie"],"significance":10,"published":"2023-09-21","source_date":"2023-09-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The STEP-HFpEF trial showed that weekly semaglutide 2.4 mg in patients with HFpEF and obesity dramatically improved heart failure symptoms, physical limitations, and quality of life, with a mean 13% body weight reduction. This landmark result established GLP-1 receptor agonists as a transformative therapy for the obesity-HFpEF phenotype.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9f7f40ff69ff","type":"article","url":"https://hartvaat.nl/2023/09/19/uspstf-evidence-review-screening-op-hypertensieve-zwangerschapsstoornissen/","title":"USPSTF evidence review: screening op hypertensieve zwangerschapsstoornissen","title_en":"Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["bloeddrukbehandeling","primaire-preventie","summit-trial","zwangerschap-hart"],"journal":"JAMA","doi":"10.1001/jama.2023.4934","source_url":"https://doi.org/10.1001/jama.2023.4934","authors":["Jillian T Henderson","Elizabeth M Webber","Rachel G Thomas","Kimberly K Vesco"],"significance":6,"published":"2023-09-19","source_date":"2023-09-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This USPSTF systematic review supported blood pressure screening throughout pregnancy as an effective method for detecting preeclampsia and related disorders, confirming the maternal and fetal benefits of early detection.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f118f4f1c7c8","type":"article","url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","title":"USPSTF: screening op hypertensieve zwangerschapsstoornissen aanbevolen","title_en":"Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["primaire-preventie","zwangerschap-hart"],"journal":"JAMA","doi":"10.1001/jama.2023.16991","source_url":"https://doi.org/10.1001/jama.2023.16991","authors":["Michael J Barry","Wanda K Nicholson","Michael Silverstein","Michael D Cabana","David Chelmow","Tumaini Rucker Coker","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Li Li","Gbenga Ogedegbe","Goutham Rao","John M Ruiz","James Stevermer","Joel Tsevat","Sandra Millon Underwood","John B Wong"],"significance":7,"published":"2023-09-19","source_date":"2023-09-19","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The USPSTF reaffirmed the recommendation to screen for hypertensive disorders at every prenatal visit, reflecting the rising incidence of preeclampsia and gestational hypertension as leading causes of maternal morbidity.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5caeeba11844","type":"article","url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","title":"FAME 3 driejaarsresultaten: FFR-geleide PCI versus CABG bij drievatslijden","title_en":"Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065770","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065770","authors":["Frederik M Zimmermann","Victoria Y Ding","Nico H J Pijls","Zsolt Piroth","Albert H M van Straten","Laszlo Szekely","Giedrius Davidavicius","Gintaras Kalinauskas","Samer Mansour","Rajesh Kharbanda","Nikolaos Östlund-Papadogeorgos","Adel Aminian","Keith G Oldroyd","Nawwar Al-Attar","Nikola Jagic","Jan-Henk E Dambrink","Petr Kala","Oskar Angeras","Philip MacCarthy","Olaf Wendler","Filip Casselman","Nils Witt","Kreton Mavromatis","Steven E S Miner","Jaydeep Sarma","Thomas Engstrøm","Evald H Christiansen","Pim A L Tonino","Michael J Reardon","Hisao Otsuki","Yuhei Kobayashi","Mark A Hlatky","Kenneth W Mahaffey","Manisha Desai","Y Joseph Woo","Alan C Yeung","Bernard De Bruyne","William F Fearon"],"significance":8,"published":"2023-09-19","source_date":"2023-09-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"Three-year FAME 3 follow-up confirmed that FFR-guided PCI did not achieve noninferiority versus CABG for three-vessel coronary disease, with CABG maintaining lower rates of revascularization and MI. The extended data reinforced CABG as the standard for complex multivessel disease.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"089807296c9d","type":"article","url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","title":"ISCHEMIA: impact van complete revascularisatie op uitkomsten","title_en":"Impact of Complete Revascularization in the ISCHEMIA Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.06.015","source_url":"https://doi.org/10.1016/j.jacc.2023.06.015","authors":["Gregg W Stone","Ziad A Ali","Sean M O'Brien","Grace Rhodes","Philippe Genereux","Sripal Bangalore","Kreton Mavromatis","Jennifer Horst","Ovidiu Dressler","Kian Keong Poh","Ranjit K Nath","Nagaraja Moorthy","Adam Witkowski","Sudhanshu K Dwivedi","Olga Bockeria","Jiyan Chen","Paola E P Smanio","Michael H Picard","Bernard R Chaitman","Daniel S Berman","Leslee J Shaw","William E Boden","Harvey D White","Stephen E Fremes","Yves Rosenberg","Harmony R Reynolds","John A Spertus","Judith S Hochman","David J Maron"],"significance":7,"published":"2023-09-19","source_date":"2023-09-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/","https://hartvaat.nl/kennis/vasculair/kritieke-ischemie-been/"],"congress":"","summary_en":"This ISCHEMIA subanalysis showed that among patients randomized to invasive management, achieving complete revascularization improved long-term outcomes compared with incomplete revascularization, supporting thorough intervention when an invasive approach is chosen.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f0932779c5c","type":"article","url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","title":"HEART-FID: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — NEJM","title_en":"Ferric Carboxymaltose in Heart Failure with Iron Deficiency.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","dapa-hf","iaso-dcm","ijzersuppletie","ijzertekort","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2304968","source_url":"https://doi.org/10.1056/NEJMoa2304968","authors":["Robert J Mentz","Jyotsna Garg","Frank W Rockhold","Javed Butler","Carmine G De Pasquale","Justin A Ezekowitz","Gregory D Lewis","Eileen O'Meara","Piotr Ponikowski","Richard W Troughton","Yee Weng Wong","Lilin She","Josephine Harrington","Robert Adamczyk","Nicole Blackman","Adrian F Hernandez"],"significance":9,"published":"2023-09-14","source_date":"2023-09-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The HEART-FID trial showed that intravenous ferric carboxymaltose in patients with HFrEF and iron deficiency did not significantly improve the hierarchical composite of death, heart failure hospitalization, and 6-minute walk distance. The neutral result contrasted with positive findings from AFFIRM-AHF and IRONMAN.","created":"2026-07-03T10:30:34Z","updated":"2026-07-03T18:39:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"781180027215","type":"article","url":"https://hartvaat.nl/2023/09/13/prognostische-modellen-voor-hartfalen-bij-type-2-diabetes-systematische-review/","title":"Prognostische modellen voor hartfalen bij type 2 diabetes: systematische review","title_en":"Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","diabetes-en-hart","diabetes-type-1","diabetes-type-2","nt-probnp","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-322044","source_url":"https://doi.org/10.1136/heartjnl-2022-322044","authors":["Georgios Kostopoulos","Ioannis Doundoulakis","Konstantinos A Toulis","Thomas Karagiannis","Apostolos Tsapas","Anna-Bettina Haidich"],"significance":5,"published":"2023-09-13","source_date":"2023-09-13","image":"","kennis":[],"congress":"","summary_en":"This systematic review evaluated prognostic models for heart failure in type 2 diabetes, finding that most models have limited discrimination and need validation in diverse diabetic populations.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39607af33d58","type":"article","url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","title":"AF-ablatie vermindert psychologische distress: JAMA RCT","title_en":"Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["stress-psychosociaal"],"journal":"JAMA","doi":"10.1001/jama.2023.14685","source_url":"https://doi.org/10.1001/jama.2023.14685","authors":["Ahmed M Al-Kaisey","Ramanathan Parameswaran","Christina Bryant","Robert D Anderson","Joshua Hawson","David Chieng","Louise Segan","Aleksandr Voskoboinik","Hariharan Sugumar","Geoffrey R Wong","Sue Finch","Stephen A Joseph","Alex McLellan","Liang-Han Ling","Joseph Morton","Paul Sparks","Prashanthan Sanders","Geoffrey Lee","Peter M Kistler","Jonathan M Kalman"],"significance":7,"published":"2023-09-12","source_date":"2023-09-12","image":"","kennis":[],"congress":"","summary_en":"This JAMA trial demonstrated that AF catheter ablation significantly reduces psychological distress, including anxiety and depression, compared with medical therapy, establishing the mental health co-benefit of successful rhythm control.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"066d6106b4c2","type":"article","url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","title":"FIRE: complete revascularisatie bij ouderen ≥75 jaar met MI — NEJM","title_en":"Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2300468","source_url":"https://doi.org/10.1056/NEJMoa2300468","authors":["Simone Biscaglia","Vincenzo Guiducci","Javier Escaned","Raul Moreno","Valerio Lanzilotti","Andrea Santarelli","Enrico Cerrato","Giorgio Sacchetta","Alfonso Jurado-Roman","Alberto Menozzi","Ignacio Amat Santos","José Luis Díez Gil","Marco Ruozzi","Marco Barbierato","Luca Fileti","Andrea Picchi","Veronica Lodolini","Giuseppe Biondi-Zoccai","Elisa Maietti","Rita Pavasini","Paolo Cimaglia","Carlo Tumscitz","Andrea Erriquez","Carlo Penzo","Iginio Colaiori","Gianluca Pignatelli","Gianni Casella","Gianmarco Iannopollo","Mila Menozzi","Ferdinando Varbella","Giorgio Caretta","Dariusz Dudek","Emanuele Barbato","Matteo Tebaldi","Gianluca Campo"],"significance":9,"published":"2023-09-07","source_date":"2023-09-07","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The FIRE trial demonstrated that complete revascularization reduced cardiovascular death or MI compared with culprit-only PCI in patients aged 75 or older with MI and multivessel disease. The results extended the benefit of complete revascularization to the elderly population previously excluded from major trials.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc0ac291aa0a","type":"article","url":"https://hartvaat.nl/2023/09/07/orforglipron-dagelijkse-orale-glp-1-agonist-bij-obesitas-nejm/","title":"Orforglipron: dagelijkse orale GLP-1-agonist bij obesitas — NEJM","title_en":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2302392","source_url":"https://doi.org/10.1056/NEJMoa2302392","authors":["Sean Wharton","Thomas Blevins","Lisa Connery","Julio Rosenstock","Sohini Raha","Rong Liu","Xiaosu Ma","Kieren J Mather","Axel Haupt","Deborah Robins","Edward Pratt","Christof Kazda","Manige Konig"],"significance":9,"published":"2023-09-07","source_date":"2023-09-07","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This NEJM phase 2 trial demonstrated that orforglipron, an oral nonpeptide GLP-1 receptor agonist, produced dose-dependent weight loss of up to 14.7% in adults with obesity. The results positioned oral GLP-1 therapy as a practical alternative to injectable formulations for obesity treatment.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36fab078c8fe","type":"article","url":"https://hartvaat.nl/2023/09/05/best-ii-bloeddrukmanagement-na-trombectomie-bij-cva-jama/","title":"BEST-II: bloeddrukmanagement na trombectomie bij CVA — JAMA","title_en":"Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"JAMA","doi":"10.1001/jama.2023.14330","source_url":"https://doi.org/10.1001/jama.2023.14330","authors":["Eva A Mistry","Kimberly W Hart","Larry T Davis","Yue Gao","Charles J Prestigiacomo","Shilpi Mittal","Tapan Mehta","Hayden LaFever","Pablo Harker","Hilary E Wilson-Perez","Kalli A Beasley","Neeharika Krothapalli","Emily Lippincott","Heather Stefek","Michael Froehler","Rohan Chitale","Matthew Fusco","Aaron Grossman","Peyman Shirani","Matthew Smith","Matthew N Jaffa","Sharon D Yeatts","Gregory W Albers","Jonathan P Wanderer","Juliana Tolles","Christopher J Lindsell","Roger J Lewis","Gordon R Bernard","Pooja Khatri"],"significance":7,"published":"2023-09-05","source_date":"2023-09-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The BEST-II trial showed that moderate blood pressure lowering (SBP <140 mmHg) was superior to intensive (SBP <120 mmHg) after successful endovascular thrombectomy, with better functional outcomes at the moderate target.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c672f9418660","type":"article","url":"https://hartvaat.nl/2023/09/05/optimal-bp-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-jama/","title":"OPTIMAL-BP: intensieve bloeddrukverlaging na trombectomie bij CVA — JAMA","title_en":"Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"JAMA","doi":"10.1001/jama.2023.14590","source_url":"https://doi.org/10.1001/jama.2023.14590","authors":["Hyo Suk Nam","Young Dae Kim","JoonNyung Heo","Hyungwoo Lee","Jae Wook Jung","Jin Kyo Choi","Il Hyung Lee","In Hwan Lim","Soon-Ho Hong","Minyoul Baik","Byung Moon Kim","Dong Joon Kim","Na-Young Shin","Bang-Hoon Cho","Seong Hwan Ahn","Hyungjong Park","Sung-Il Sohn","Jeong-Ho Hong","Tae-Jin Song","Yoonkyung Chang","Gyu Sik Kim","Kwon-Duk Seo","Kijeong Lee","Jun Young Chang","Jung Hwa Seo","Sukyoon Lee","Jang-Hyun Baek","Han-Jin Cho","Dong Hoon Shin","Jinkwon Kim","Joonsang Yoo","Kyung-Yul Lee","Yo Han Jung","Yang-Ha Hwang","Chi Kyung Kim","Jae Guk Kim","Chan Joo Lee","Sungha Park","Hye Sun Lee","Sun U Kwon","Oh Young Bang","Craig S Anderson","Ji Hoe Heo"],"significance":7,"published":"2023-09-05","source_date":"2023-09-05","image":"","kennis":[],"congress":"","summary_en":"The OPTIMAL-BP trial found no significant difference between intensive and conventional blood pressure lowering after endovascular thrombectomy for acute ischemic stroke, consistent with ENCHANTED2/MT results arguing against very aggressive post-procedure BP reduction.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8d6d51b8bcad","type":"article","url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","title":"CAMEO-DAPA: cardiale en metabole effecten van dapagliflozine bij HFpEF","title_en":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.065134","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.065134","authors":["Barry A Borlaug","Yogesh N V Reddy","Amanda Braun","Hidemi Sorimachi","Massar Omar","Dejana Popovic","Alessio Alogna","Michael D Jensen","Rickey Carter"],"significance":6,"published":"2023-09-05","source_date":"2023-09-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The CAMEO-DAPA trial showed that dapagliflozin improves cardiac efficiency and metabolic parameters in HFpEF, advancing the mechanistic understanding of SGLT2 inhibitor benefit in preserved ejection fraction heart failure.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"85630fd7f53b","type":"article","url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","title":"Matige statine plus ezetimibe bij zeer hoog ASCVD-risico: non-inferioriteitstudie","title_en":"Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","niet-statine-therapie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.2222","source_url":"https://doi.org/10.1001/jamacardio.2023.2222","authors":["Seung-Jun Lee","Jung-Joon Cha","Woong Gil Choi","Wang-Soo Lee","Jin-Ok Jeong","Seonghoon Choi","Yoon-Haeng Cho","Woojung Park","Chang-Hwan Yoon","Yong-Joon Lee","Sung-Jin Hong","Chul-Min Ahn","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Soon Jun Hong","Jung-Sun Kim"],"significance":7,"published":"2023-09-01","source_date":"2023-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This study confirmed that moderate-intensity statin with ezetimibe is noninferior to high-intensity statin in patients at very high cardiovascular risk, extending the combination therapy evidence to the highest-risk population.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"78f186c6e448","type":"article","url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","title":"Drempelwaarde voor aortale polsgolfsnelheid en CV-events: IPD meta-analyse","title_en":"Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity: An Individual-Participant Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["perifeer-vaatlijden"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21318","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21318","authors":["De-Wei An","Tine W Hansen","Lucas S Aparicio","Babangida Chori","Qi-Fang Huang","Fang-Fei Wei","Yi-Bang Cheng","Yu-Ling Yu","Chang-Sheng Sheng","Natasza Gilis-Malinowska","José Boggia","Wiktoria Wojciechowska","Teemu J Niiranen","Valérie Tikhonoff","Edoardo Casiglia","Krzysztof Narkiewicz","Katarzyna Stolarz-Skrzypek","Kalina Kawecka-Jaszcz","Antti M Jula","Wen-Yi Yang","Angela J Woodiwiss","Jan Filipovský","Ji-Guang Wang","Marek W Rajzer","Peter Verhamme","Tim S Nawrot","Jan A Staessen","Yan Li"],"significance":6,"published":"2023-09-01","source_date":"2023-09-01","image":"","kennis":[],"congress":"","summary_en":"This individual participant data meta-analysis established an outcome-driven threshold for aortic pulse wave velocity at 10 m/s, identifying a clinically actionable cutoff for vascular stiffness-based cardiovascular risk assessment.","created":"2026-07-03T10:30:33Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0220fe3c7a69","type":"article","url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","title":"STEP-substudie: intensieve bloeddrukverlaging verbetert LVH bij ouderen","title_en":"Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie","dubbele-trombocytenremming","farmaco-economie","lipidenverlaging","obesitas","step-hfpef","summit-trial"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20732","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20732","authors":["Yue Deng","Wei Liu","Xinchun Yang","Zihong Guo","Juyan Zhang","Rongjie Huang","Xiaomin Yang","Chunli Yu","Jing Yu","Jun Cai"],"significance":7,"published":"2023-09-01","source_date":"2023-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"This STEP substudy showed that intensive blood pressure lowering (SBP <130 mmHg) regresses left ventricular hypertrophy in older hypertensive patients, providing cardiac structural evidence supporting aggressive blood pressure targets in the elderly.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8229489ce9ee","type":"article","url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","title":"STREAM-2: halve-dosis tenecteplase bij ouderen met STEMI","title_en":"STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064521","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064521","authors":["Frans Van de Werf","Arsen D Ristić","Oleg V Averkov","Alexandra Arias-Mendoza","Yves Lambert","José F Kerr Saraiva","Pablo Sepulveda","Fernando Rosell-Ortiz","John K French","Ljilja B Musić","Katleen Vandenberghe","Kris Bogaerts","Cynthia M Westerhout","Alain Pagès","Thierry Danays","Kevin R Bainey","Peter Sinnaeve","Patrick Goldstein","Robert C Welsh","Paul W Armstrong"],"significance":7,"published":"2023-08-29","source_date":"2023-08-29","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The STREAM-2 trial demonstrated that half-dose tenecteplase followed by PCI is a viable pharmaco-invasive strategy for older STEMI patients (≥60 years) when timely primary PCI is unavailable, with safety comparable to primary PCI.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ac275c9c85d","type":"article","url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","title":"REPRIEVE: pitavastatine vermindert CV-events bij HIV — NEJM","title_en":"Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2304146","source_url":"https://doi.org/10.1056/NEJMoa2304146","authors":["Steven K Grinspoon","Kathleen V Fitch","Markella V Zanni","Carl J Fichtenbaum","Triin Umbleja","Judith A Aberg","Edgar T Overton","Carlos D Malvestutto","Gerald S Bloomfield","Judith S Currier","Esteban Martinez","Jhoanna C Roa","Marissa R Diggs","Evelynne S Fulda","Kayla Paradis","Stephen D Wiviott","Borek Foldyna","Sara E Looby","Patrice Desvigne-Nickens","Beverly Alston-Smith","Jorge Leon-Cruz","Sara McCallum","Udo Hoffmann","Michael T Lu","Heather J Ribaudo","Pamela S Douglas"],"significance":10,"published":"2023-08-24","source_date":"2023-08-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The REPRIEVE trial demonstrated that pitavastatin reduced major cardiovascular events by 35% in people living with HIV who had low-to-moderate cardiovascular risk. The trial was stopped early for efficacy, providing the first definitive evidence for statin therapy in primary cardiovascular prevention among HIV-infected individuals.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26eb9bcb8978","type":"article","url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","title":"Vaste-dosiscombinatietherapie voor primaire CV-preventie: IPD meta-analyse","title_en":"Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-322278","source_url":"https://doi.org/10.1136/heartjnl-2022-322278","authors":["Gilles R Dagenais","Prem Pais","Peggy Gao","Gholamreza Roshandel","Reza Malekzadeh","Philip Joseph","Salim Yusuf"],"significance":8,"published":"2023-08-24","source_date":"2023-08-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"This individual participant data meta-analysis from three randomized trials confirmed that fixed-dose combination therapy (polypill) reduces cardiovascular events in primary prevention across different age groups. The consistent benefit supports the polypill strategy as a population-level intervention.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T13:29:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47491b7b4ace","type":"article","url":"https://hartvaat.nl/2023/08/24/fysieke-activiteitsniveaus-bij-hartfalen-meta-analyse/","title":"Fysieke activiteitsniveaus bij hartfalen: meta-analyse","title_en":"Habitual physical activity levels of adults with heart failure: systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["ivabradine"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321943","source_url":"https://doi.org/10.1136/heartjnl-2022-321943","authors":["Cara Jordan","Sarah J Charman","Alan Mark Batterham","Darren Flynn","David Houghton","Linda Errington","Guy MacGowan","Leah Avery"],"significance":5,"published":"2023-08-24","source_date":"2023-08-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis quantified the very low habitual physical activity levels (3,000-4,000 steps/day) in heart failure patients, establishing the scale of sedentary behavior and the opportunity for activity promotion.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f7d8419d554","type":"article","url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","title":"CVA bij hartfalen met gereduceerde versus behouden ejectiefractie","title_en":"Stroke in patients with heart failure and reduced or preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","anticoagulantia","bloeddrukbehandeling","cerebrovasculair","dapa-hf","hfmref","hfpef","hfref","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad338","source_url":"https://doi.org/10.1093/eurheartj/ehad338","authors":["Mingming Yang","Toru Kondo","Jawad H Butt","William T Abraham","Inder S Anand","Akshay S Desai","Lars Køber","Milton Packer","Marc A Pfeffer","Jean L Rouleau","Marc S Sabatine","Scott D Solomon","Karl Swedberg","Michael R Zile","Pardeep S Jhund","John J V McMurray"],"significance":6,"published":"2023-08-14","source_date":"2023-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This study compared stroke risk between HFrEF and HFpEF, showing elevated risk in both phenotypes but with different underlying mechanisms (cardiac embolism in HFrEF, atrial cardiomyopathy in HFpEF).","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f548b6cac6d","type":"article","url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","title":"STRONG-HF: NT-proBNP-geleide intensieve optitratie na acuut HF","title_en":"NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","nt-probnp","troponine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad335","source_url":"https://doi.org/10.1093/eurheartj/ehad335","authors":["Marianna Adamo","Matteo Pagnesi","Alexandre Mebazaa","Beth Davison","Christopher Edwards","Daniela Tomasoni","Mattia Arrigo","Marianela Barros","Jan Biegus","Jelena Celutkiene","Kamilė Čerlinskaitė-Bajorė","Ovidiu Chioncel","Alain Cohen-Solal","Albertino Damasceno","Rafael Diaz","Gerasimos Filippatos","Etienne Gayat","Antoine Kimmoun","Carolyn S P Lam","Maria Novosadova","Peter S Pang","Piotr Ponikowski","Hadiza Saidu","Karen Sliwa","Koji Takagi","Jozine M Ter Maaten","Adriaan Voors","Gad Cotter","Marco Metra"],"significance":7,"published":"2023-08-14","source_date":"2023-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This STRONG-HF analysis showed that NT-proBNP-guided intensive up-titration of heart failure medications after discharge improves outcomes, demonstrating that biomarker monitoring adds value to the aggressive post-discharge optimization strategy.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42df1f8a55ad","type":"article","url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","title":"Telemonitoring bij hartfalen: meta-analyse van alle strategieën","title_en":"Telemonitoring for heart failure: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad280","source_url":"https://doi.org/10.1093/eurheartj/ehad280","authors":["Niels T B Scholte","Muhammed T Gürgöze","Dilan Aydin","Dominic A M J Theuns","Olivier C Manintveld","Eelko Ronner","Eric Boersma","Rudolf A de Boer","Robert M A van der Boon","Jasper J Brugts"],"significance":7,"published":"2023-08-14","source_date":"2023-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This comprehensive meta-analysis of telemonitoring in heart failure showed that structured telemonitoring reduces hospitalizations but has inconsistent effects on mortality, with benefit dependent on the specific technology and implementation model.","created":"2026-07-03T10:30:32Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bcdd82197d08","type":"article","url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","title":"Sacubitril/valsartan bij HFmrEF/HFpEF: gepoolde analyse van drie trials","title_en":"Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","dapa-hf","fidelity","sacubitril-valsartan","step-hfpef","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad344","source_url":"https://doi.org/10.1093/eurheartj/ehad344","authors":["Muthiah Vaduganathan","Robert J Mentz","Brian L Claggett","Zi Michael Miao","Ian J Kulac","Jonathan H Ward","Adrian F Hernandez","David A Morrow","Randall C Starling","Eric J Velazquez","Kristin M Williamson","Akshay S Desai","Shelley Zieroth","Martin Lefkowitz","John J V McMurray","Eugene Braunwald","Scott D Solomon"],"significance":8,"published":"2023-08-14","source_date":"2023-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This participant-level pooled analysis of PARAGON-HF, PARADIGM-HF, and PARAGLIDE-HF confirmed that sacubitril-valsartan reduces NT-proBNP and heart failure events in patients with HFmrEF and HFpEF (EF ≥40%), particularly those with lower LVEF within this range.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1322da8ef645","type":"article","url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","title":"Dapagliflozine versus metolazone bij diureticaresistent hartfalen","title_en":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["bisoprolol","dapa-hf","dapagliflozine","empagliflozine","emperor-trials"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad341","source_url":"https://doi.org/10.1093/eurheartj/ehad341","authors":["Su Ern Yeoh","Joanna Osmanska","Mark C Petrie","Katriona J M Brooksbank","Andrew L Clark","Kieran F Docherty","Paul W X Foley","Kaushik Guha","Crawford A Halliday","Pardeep S Jhund","Paul R Kalra","Gemma McKinley","Ninian N Lang","Matthew M Y Lee","Alex McConnachie","James J McDermott","Elke Platz","Peter Sartipy","Alison Seed","Bethany Stanley","Robin A P Weir","Paul Welsh","John J V McMurray","Ross T Campbell"],"significance":7,"published":"2023-08-14","source_date":"2023-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This study compared dapagliflozin with metolazone as adjunctive therapy in loop diuretic-resistant heart failure, finding comparable diuretic efficacy with a potentially better safety profile for the SGLT2 inhibitor approach.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7cc7318df53","type":"article","url":"https://hartvaat.nl/2023/08/12/retatrutide-triple-gip-glp-1-glucagonagonist-bij-type-2-diabetes-lancet-fase-2/","title":"Retatrutide: triple GIP/GLP-1/glucagonagonist bij type 2 diabetes — Lancet fase 2","title_en":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-type-2","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)01053-X","source_url":"https://doi.org/10.1016/S0140-6736(23)01053-X","authors":["Julio Rosenstock","Juan Frias","Ania M Jastreboff","Yu Du","Jitong Lou","Sirel Gurbuz","Melissa K Thomas","Mark L Hartman","Axel Haupt","Zvonko Milicevic","Tamer Coskun"],"significance":9,"published":"2023-08-12","source_date":"2023-08-12","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/semaglutide-gewichtsverlies-hart/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This Lancet phase 2 trial of retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, demonstrated up to 24% weight loss and dramatic HbA1c improvement in patients with type 2 diabetes. The results surpassed those of dual incretin agonists, establishing triple agonism as the next frontier in metabolic therapeutics.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc2c5d45e0c8","type":"article","url":"https://hartvaat.nl/2023/08/08/stop-ca-atorvastatine-beschermt-tegen-antracycline-cardiotoxiciteit/","title":"STOP-CA: atorvastatine beschermt tegen antracycline-cardiotoxiciteit","title_en":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["clear-outcomes","kanker-en-hart","rosuvastatine"],"journal":"JAMA","doi":"10.1001/jama.2023.11887","source_url":"https://doi.org/10.1001/jama.2023.11887","authors":["Tomas G Neilan","Thiago Quinaglia","Takeshi Onoue","Syed S Mahmood","Zsofia D Drobni","Hannah K Gilman","Amanda Smith","Julius C Heemelaar","Priya Brahmbhatt","Jor Sam Ho","Supraja Sama","Jakub Svoboda","Donna S Neuberg","Jeremy S Abramson","Ephraim P Hochberg","Jefferey A Barnes","Philippe Armand","Eric D Jacobsen","Caron A Jacobson","Austin I Kim","Jacob D Soumerai","Yuchi Han","Robb S Friedman","Ann S Lacasce","Bonnie Ky","Dan Landsburg","Sunita Nasta","Raymond Y Kwong","Michael Jerosch-Herold","Robert A Redd","Lanqi Hua","James L Januzzi","Aarti Asnani","Negareh Mousavi","Marielle Scherrer-Crosbie"],"significance":8,"published":"2023-08-08","source_date":"2023-08-08","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The STOP-CA trial showed that atorvastatin significantly attenuated the decline in left ventricular ejection fraction in patients receiving anthracycline chemotherapy. The result established statins as a potential cardioprotective strategy during cancer treatment.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5859a4b6d0b5","type":"article","url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","title":"GLP-1-agonisten met en zonder SGLT2-remmers bij type 2 diabetes: JACC analyse","title_en":"GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-2","ezetimibe","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.05.048","source_url":"https://doi.org/10.1016/j.jacc.2023.05.048","authors":["João Sérgio Neves","Marta Borges-Canha","Francisco Vasques-Nóvoa","Jennifer B Green","Lawrence A Leiter","Christopher B Granger","Davide Carvalho","Adelino Leite-Moreira","Adrian F Hernandez","Stefano Del Prato","John J V McMurray","João Pedro Ferreira"],"significance":8,"published":"2023-08-08","source_date":"2023-08-08","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This analysis demonstrated that GLP-1 receptor agonists and SGLT2 inhibitors provide complementary cardiovascular benefits when used together in type 2 diabetes, with additive reductions in MACE and heart failure events. The findings support dual cardiometabolic therapy in eligible patients.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"933454326775","type":"article","url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","title":"Gerichte LV-leadplaatsing bij CRT: meta-analyse van beeldvorming- en elektrisch geleide benaderingen","title_en":"Targeted left ventricular lead positioning to the site of latest activation in cardiac resynchronization therapy: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad267","source_url":"https://doi.org/10.1093/europace/euad267","authors":["Daniel Benjamin Fyenbo","Henrik Laurits Bjerre","Maria Hee Jung Park Frausing","Charlotte Stephansen","Anders Sommer","Rasmus Borgquist","Zoltan Bakos","Michael Glikson","Anat Milman","Roy Beinart","Radka Kockova","Kamil Sedlacek","Dan Wichterle","Samir Saba","Sandeep Jain","Alaa Shalaby","Mads Brix Kronborg","Jens Cosedis Nielsen"],"significance":7,"published":"2023-08-02","source_date":"2023-08-02","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"This meta-analysis confirmed that targeted LV lead placement at the site of latest electrical activation improves CRT response compared with empirical positioning, supporting imaging or electrical mapping-guided lead deployment.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1084a4d5e50c","type":"article","url":"https://hartvaat.nl/2023/08/02/af-ablatie-bij-hypertrofische-cardiomyopathie-meta-analyse/","title":"AF-ablatie bij hypertrofische cardiomyopathie: meta-analyse","title_en":"Catheter ablation of atrial fibrillation in patients with and without hypertrophic cardiomyopathy: systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aritmogene-cardiomyopathie","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad256","source_url":"https://doi.org/10.1093/europace/euad256","authors":["Fatima M Ezzeddine","Kolade M Agboola","Leslie C Hassett","Ammar M Killu","Freddy Del-Carpio Munoz","Christopher V DeSimone","Gurukripa N Kowlgi","Abhishek J Deshmukh","Konstantinos C Siontis"],"significance":6,"published":"2023-08-02","source_date":"2023-08-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis showed that AF catheter ablation in HCM patients has higher recurrence rates than in non-HCM patients but still provides significant benefit, supporting ablation as a treatment option for the AF-HCM overlap.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04fc2b5668ca","type":"article","url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","title":"Peri-device lekkage bij LAA-occluders: mechanismen en voorspellers","title_en":"Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad237","source_url":"https://doi.org/10.1093/europace/euad237","authors":["Dhanunjaya Lakkireddy","Jens Erik Nielsen-Kudsk","Stephan Windecker","David Thaler","Matthew J Price","Alok Gambhir","Nigel Gupta","Konstantinos Koulogiannis","Leo Marcoff","Anuj Mediratta","Jordan A Anderson","Ryan Gage","Christopher R Ellis"],"significance":6,"published":"2023-08-02","source_date":"2023-08-02","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/"],"congress":"","summary_en":"This Amulet IDE analysis characterized the mechanisms, predictors, and evolution of peri-device leak after LAA occlusion, providing practical guidance for device selection and follow-up imaging after appendage closure.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a0bfa52b3fa1","type":"article","url":"https://hartvaat.nl/2023/08/02/decaaf-ii-fibroselocatie-beinvloedt-af-recidief-na-ablatie/","title":"DECAAF II: fibroselocatie beïnvloedt AF-recidief na ablatie","title_en":"Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad199","source_url":"https://doi.org/10.1093/europace/euad199","authors":["Ala Assaf","Mario Mekhael","Charbel Noujaim","Nour Chouman","Hadi Younes","Han Feng","Abdelhadi ElHajjar","Botao Shan","Peter Kistler","Omar Kreidieh","Nassir Marrouche","Eoin Donnellan"],"significance":6,"published":"2023-08-02","source_date":"2023-08-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This DECAAF II subanalysis showed that the location of atrial fibrosis influences AF recurrence after ablation, with posterior and septal fibrosis carrying the highest risk, informing targeted ablation strategies.","created":"2026-07-03T10:30:31Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19a4a0c606ab","type":"article","url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","title":"Mondiale vergelijking van heropnamepercentages bij hartfalen","title_en":"Global Comparison of Readmission Rates for Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.05.040","source_url":"https://doi.org/10.1016/j.jacc.2023.05.040","authors":["Farid Foroutan","Daniel G Rayner","Heather J Ross","Tamara Ehler","Ananya Srivastava","Sheojung Shin","Abdullah Malik","Harsukh Benipal","Clarissa Yu","Tsz Hin Alexander Lau","Joshua G Lee","Rodolfo Rocha","Peter C Austin","Daniel Levy","Jennifer E Ho","John J V McMurray","Faiez Zannad","George Tomlinson","John A Spertus","Douglas S Lee"],"significance":6,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":[],"congress":"","summary_en":"This international comparison revealed substantial variation in heart failure readmission rates across countries, identifying healthcare system factors that may explain differences and offering benchmarks for quality improvement.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00e87b21fc7e","type":"article","url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","title":"Atrial flow regulator en overleving bij hartfalen: voorspelde impact","title_en":"Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","hfpef","hfref","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14384","source_url":"https://doi.org/10.1002/ehf2.14384","authors":["Lucas Lauder","Martin W Bergmann","Christina Paitazoglou","Ramazan Özdemir","Christos Iliadis","Jozef Bartunek","Alexander Lauten","Thomas Keller","Stephan Weber","Horst Sievert","Stefan D Anker","Felix Mahfoud"],"significance":5,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/wat-is-atriumfibrilleren/"],"congress":"","summary_en":"This modeling study predicted the potential survival impact of the atrial flow regulator device in heart failure, providing theoretical estimates of benefit to guide clinical development.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"792ab5698038","type":"article","url":"https://hartvaat.nl/2023/08/01/hfa-peff-score-voor-hfpef-diagnose-validatie-meta-analyse/","title":"HFA-PEFF score voor HFpEF-diagnose: validatie meta-analyse","title_en":"Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14421","source_url":"https://doi.org/10.1002/ehf2.14421","authors":["Shu Li","Xiaomei Zhu","Yunlong Zhang","Fengjie Li","Shubin Guo"],"significance":6,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis validated the HFA-PEFF diagnostic score for HFpEF, confirming good diagnostic accuracy and supporting its clinical utility for standardized evaluation of suspected heart failure with preserved ejection fraction.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7817cf05b831","type":"article","url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","title":"Combinatietabletten voor intensieve bloeddrukbehandeling: SPRINT analyse","title_en":"Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21132","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21132","authors":["Jordan B King","Catherine G Derington","Jennifer S Herrick","Joshua A Jacobs","Alexander R Zheutlin","Molly B Conroy","William C Cushman","Adam P Bress"],"significance":5,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/"],"congress":"","summary_en":"This SPRINT analysis showed that many intensive blood pressure treatment regimens are available as single-pill combinations, supporting the practical implementation of aggressive multi-drug therapy in a single tablet.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"88361d2b4759","type":"article","url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","title":"Bloeddrukstreefwaarden bij type 2 diabetes: netwerk-meta-analyse","title_en":"Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","diabetes-en-hart","diabetes-type-1","obesitas"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.20954","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.20954","authors":["Qianqian Yang","Ruizhi Zheng","Siyu Wang","Jiamin Zhu","Mian Li","Tiange Wang","Zhiyun Zhao","Min Xu","Jieli Lu","Yuhong Chen","Guang Ning","Weiqing Wang","Yufang Bi","Yu Xu"],"significance":7,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This network meta-analysis explored optimal blood pressure targets for type 2 diabetes, finding that intensive control (SBP <130 mmHg) reduces major cardiovascular events, supporting aggressive targets specifically for the diabetic population.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T13:29:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58c20c8dd9af","type":"article","url":"https://hartvaat.nl/2023/08/01/bio-impedantieanalyse-bij-overgewicht-en-acuut-hartfalen-pilotstudie/","title":"Bio-impedantieanalyse bij overgewicht en acuut hartfalen: pilotstudie","title_en":"The role of bioimpedance analysis in overweight and obese patients with acute heart failure: a pilot study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","klepprothese"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14398","source_url":"https://doi.org/10.1002/ehf2.14398","authors":["Ana Venegas-Rodríguez","Ana María Pello","Marta López-Castillo","Mikel Taibo Urquía","Jorge Balaguer-Germán","Alicia Munté","Guillermo González-Martín","Sol María Carriazo-Julio","Juan Martínez-Milla","Andrea Kallmeyer","Óscar González Lorenzo","Hans Paul Gaebelt Slocker","José Tuñón","Emilio González-Parra","Álvaro Aceña"],"significance":5,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This pilot study evaluated bioimpedance analysis for detecting residual congestion at hospital discharge in overweight acute heart failure patients, where standard assessment is less reliable due to body habitus.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T18:39:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"24b7a35d2771","type":"article","url":"https://hartvaat.nl/2023/08/01/telerevalidatie-haalbaar-voor-hartfalenpatienten-zonder-toegang-tot-poliklinisch/","title":"Telerevalidatie haalbaar voor hartfalenpatiënten zonder toegang tot poliklinische revalidatie","title_en":"Feasibility of telerehabilitation for heart failure patients inaccessible for outpatient rehabilitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","hartrevalidatie","nierfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14405","source_url":"https://doi.org/10.1002/ehf2.14405","authors":["Kari Margrethe Lundgren","Knut Asbjørn Rise Langlo","Øyvind Salvesen","Paolo Zanaboni","Elisa Cittanti","Rune Mo","Øyvind Ellingsen","Håvard Dalen","Inger-Lise Aamot Aksetøy"],"significance":5,"published":"2023-08-01","source_date":"2023-08-01","image":"","kennis":[],"congress":"","summary_en":"This study confirmed the feasibility and acceptance of telerehabilitation for chronic heart failure patients who cannot access outpatient cardiac rehabilitation, addressing a major implementation barrier.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1d2b67c5e1f","type":"article","url":"https://hartvaat.nl/2023/07/29/cradle-4-geplande-bevalling-versus-afwachten-bij-laat-preterm-pre-eclampsie-in-l/","title":"CRADLE-4: geplande bevalling versus afwachten bij laat-preterm pre-eclampsie in LMIC's","title_en":"Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["zwangerschap-hart"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00688-8","source_url":"https://doi.org/10.1016/S0140-6736(23)00688-8","authors":["Alice Beardmore-Gray","Nicola Vousden","Paul T Seed","Bellington Vwalika","Sebastian Chinkoyo","Victor Sichone","Alexander B Kawimbe","Umesh Charantimath","Geetanjali Katageri","Mrutyunjaya B Bellad","Laxmikant Lokare","Kasturi Donimath","Shailaja Bidri","Shivaprasad Goudar","Jane Sandall","Lucy C Chappell","Andrew H Shennan"],"significance":7,"published":"2023-07-29","source_date":"2023-07-29","image":"","kennis":[],"congress":"","summary_en":"This Lancet trial compared planned delivery with expectant management for late preterm preeclampsia in low- and middle-income countries, addressing a critical evidence gap for managing hypertensive pregnancy complications in resource-limited settings.","created":"2026-07-03T10:30:30Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db1d8eb209a5","type":"article","url":"https://hartvaat.nl/2023/07/29/luspatercept-versus-epoetine-alfa-bij-mds-gerelateerde-anemie-lancet-trial/","title":"Luspatercept versus epoëtine alfa bij MDS-gerelateerde anemie: Lancet-trial","title_en":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00874-7","source_url":"https://doi.org/10.1016/S0140-6736(23)00874-7","authors":["Uwe Platzbecker","Matteo Giovanni Della Porta","Valeria Santini","Amer M Zeidan","Rami S Komrokji","Jake Shortt","David Valcarcel","Anna Jonasova","Sophie Dimicoli-Salazar","Ing Soo Tiong","Chien-Chin Lin","Jiahui Li","Jennie Zhang","Ana Carolina Giuseppi","Sandra Kreitz","Veronika Pozharskaya","Karen L Keeperman","Shelonitda Rose","Jeevan K Shetty","Sheida Hayati","Sadanand Vodala","Thomas Prebet","Andrius Degulys","Stefania Paolini","Thomas Cluzeau","Pierre Fenaux","Guillermo Garcia-Manero"],"significance":5,"published":"2023-07-29","source_date":"2023-07-29","image":"","kennis":[],"congress":"","summary_en":"This Lancet trial showing luspatercept superiority over epoetin alfa for anemia in MDS patients is relevant to CKD and cardiovascular medicine through shared erythropoiesis pathways and iron metabolism.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"81dad8024694","type":"article","url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","title":"Omega-3 biomarkers en incident AF: IPD analyse","title_en":"Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.05.024","source_url":"https://doi.org/10.1016/j.jacc.2023.05.024","authors":["Frank Qian","Nathan Tintle","Paul N Jensen","Rozenn N Lemaitre","Fumiaki Imamura","Tobias Rudholm Feldreich","Sarah Oppeneer Nomura","Weihua Guan","Federica Laguzzi","Eunjung Kim","Jyrki K Virtanen","Marinka Steur","Christian S Bork","Yoichiro Hirakawa","Michelle L O'Donoghue","Aleix Sala-Vila","Andres V Ardisson Korat","Qi Sun","Eric B Rimm","Bruce M Psaty","Susan R Heckbert","Nita G Forouhi","Nicholas J Wareham","Matti Marklund","Ulf Risérus","Lars Lind","Johan Ärnlöv","Parveen Garg","Michael Y Tsai","James Pankow","Jeffrey R Misialek","Bruna Gigante","Karin Leander","Julie A Pester","Christine M Albert","Maryam Kavousi","Arfan Ikram","Trudy Voortman","Erik B Schmidt","Toshiharu Ninomiya","David A Morrow","Antoni Bayés-Genís","James H O'Keefe","Kwok Leung Ong","Jason H Y Wu","Dariush Mozaffarian","William S Harris","David S Siscovick"],"significance":7,"published":"2023-07-25","source_date":"2023-07-25","image":"","kennis":[],"congress":"","summary_en":"This individual patient data analysis found a positive association between higher omega-3 fatty acid biomarker levels and incident atrial fibrillation, contributing to the growing safety concern about omega-3 supplementation and arrhythmia risk.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b3e09c52496","type":"article","url":"https://hartvaat.nl/2023/07/21/rood-vlees-cardiovasculaire-ziekte-en-diabetes-systematische-review/","title":"Rood vlees, cardiovasculaire ziekte en diabetes: systematische review","title_en":"Red meat consumption, cardiovascular diseases, and diabetes: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","anemie-ckd","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","dyslipidemie","ezetimibe","farmaco-economie","figaro-dkd","microbioom","obesitas","ouderen","perifeer-vaatlijden","roken","slaapapneu","soul-trial","supraventriculaire-tachycardie","tirzepatide","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad336","source_url":"https://doi.org/10.1093/eurheartj/ehad336","authors":["Wenming Shi","Xin Huang","C Mary Schooling","Jie V Zhao"],"significance":7,"published":"2023-07-21","source_date":"2023-07-21","image":"","kennis":[],"congress":"","summary_en":"This systematic review and meta-analysis confirmed a modest but consistent association between red meat consumption and cardiovascular disease and diabetes, though the effect size was smaller than commonly assumed.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bee1fd641e99","type":"article","url":"https://hartvaat.nl/2023/07/21/vegetarisch-of-veganistisch-dieet-en-bloedlipiden-meta-analyse-van-rct-s/","title":"Vegetarisch of veganistisch dieet en bloedlipiden: meta-analyse van RCT's","title_en":"Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","lipidenverlaging"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad211","source_url":"https://doi.org/10.1093/eurheartj/ehad211","authors":["Caroline A Koch","Emilie W Kjeldsen","Ruth Frikke-Schmidt"],"significance":7,"published":"2023-07-21","source_date":"2023-07-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"This meta-analysis of RCTs showed that vegetarian and vegan diets significantly lower total and LDL cholesterol compared with omnivorous diets, supporting plant-based dietary patterns for cardiovascular risk reduction.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eda94fb1c50d","type":"article","url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","title":"Zilebesiran: RNA-interferentietherapie voor hypertensie — NEJM","title_en":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2208391","source_url":"https://doi.org/10.1056/NEJMoa2208391","authors":["Akshay S Desai","David J Webb","Jorg Taubel","Sarah Casey","Yansong Cheng","Gabriel J Robbie","Don Foster","Stephen A Huang","Sean Rhyee","Marianne T Sweetser","George L Bakris"],"significance":10,"published":"2023-07-20","source_date":"2023-07-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This first-in-human study of zilebesiran, an RNA interference agent targeting hepatic angiotensinogen, demonstrated sustained blood pressure reduction for up to 24 weeks after a single subcutaneous injection. The findings represent a potential paradigm shift toward ultra-long-acting antihypertensive therapy requiring only biannual dosing.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6f6a13e59d5b","type":"article","url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","title":"NI006: antilichaam voor afbraak van cardiale transthyretine-amyloid — NEJM fase 1","title_en":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-amyloidose"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2303765","source_url":"https://doi.org/10.1056/NEJMoa2303765","authors":["Pablo Garcia-Pavia","Fabian Aus dem Siepen","Erwan Donal","Olivier Lairez","Peter van der Meer","Arnt V Kristen","Michele F Mercuri","Aubin Michalon","Robert J A Frost","Jan Grimm","Roger M Nitsch","Christoph Hock","Peter C Kahr","Thibaud Damy"],"significance":9,"published":"2023-07-20","source_date":"2023-07-20","image":"","kennis":[],"congress":"","summary_en":"This first-in-human phase 1 trial showed that NI006, a monoclonal antibody targeting transthyretin amyloid deposits, can reduce cardiac amyloid burden in patients with ATTR cardiomyopathy. This represents the first therapeutic approach aimed at clearing existing amyloid deposits rather than just preventing new deposition.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b758741a0ba","type":"article","url":"https://hartvaat.nl/2023/07/18/uspstf-evidence-review-lipidescreening-bij-kinderen-geactualiseerd/","title":"USPSTF evidence review: lipidescreening bij kinderen geactualiseerd","title_en":"Screening for Lipid Disorders in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["dyslipidemie","lipidenverlaging","niet-statine-therapie","plaquekarakterisatie","primaire-preventie","vrouwen","yellow-iii"],"journal":"JAMA","doi":"10.1001/jama.2023.8867","source_url":"https://doi.org/10.1001/jama.2023.8867","authors":["Janelle M Guirguis-Blake","Corinne V Evans","Erin L Coppola","Nadia Redmond","Leslie A Perdue"],"significance":6,"published":"2023-07-18","source_date":"2023-07-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/cascadescreening-fh/"],"congress":"","summary_en":"This USPSTF systematic review confirmed that lipid screening in children can detect dyslipidemia effectively, but the long-term clinical benefit of early treatment remains uncertain, limiting the strength of screening recommendations.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c788656aa5d1","type":"article","url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","title":"USPSTF: screening op lipidestoornissen bij kinderen en adolescenten","title_en":"Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["primaire-preventie"],"journal":"JAMA","doi":"10.1001/jama.2023.11330","source_url":"https://doi.org/10.1001/jama.2023.11330","authors":["Michael J Barry","Wanda K Nicholson","Michael Silverstein","David Chelmow","Tumaini Rucker Coker","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Li Li","Gbenga Ogedegbe","Goutham Rao","John M Ruiz","James Stevermer","Joel Tsevat","Sandra Millon Underwood"],"significance":7,"published":"2023-07-18","source_date":"2023-07-18","image":"","kennis":[],"congress":"","summary_en":"The USPSTF concluded that evidence is insufficient to determine whether universal lipid screening in children and adolescents improves health outcomes, maintaining the 'I' statement despite ongoing concern about familial hypercholesterolemia underdiagnosis.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"61a6c325e7da","type":"article","url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","title":"Bioresorbeerbare coronaire scaffolds: vijfjaarsuitkomsten met verbeterde techniek","title_en":"5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.05.003","source_url":"https://doi.org/10.1016/j.jacc.2023.05.003","authors":["Gregg W Stone","Dean J Kereiakes","Tommaso Gori","D Christopher Metzger","Bernardo Stein","Matthew Erickson","Jan Torzewski","Ameer Kabour","Guy Piegari","Jeffrey Cavendish","Barry Bertolet","Kelly A Stockelman","Nick E J West","Ori Ben-Yehuda","James W Choi","Steven O Marx","John A Spertus","Stephen G Ellis"],"significance":6,"published":"2023-07-18","source_date":"2023-07-18","image":"","kennis":[],"congress":"","summary_en":"These 5-year data showed that bioresorbable scaffolds implanted with improved technique (proper sizing, high-pressure post-dilation) have better outcomes than earlier experience, though metallic DES remain the standard of care.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e8574ce68c4","type":"article","url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","title":"SGLT2-remmers verbeteren kwaliteit van leven gelijk bij zwarte en witte hartfalenpatiënten","title_en":"Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["canagliflozine","empagliflozine","sglt2-remmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063263","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063263","authors":["Kashvi Gupta","John A Spertus","Mary Birmingham","Kensey L Gosch","Mansoor Husain","Dalane W Kitzman","Bertram Pitt","Sanjiv J Shah","James L Januzzi","Ildiko Lingvay","Javed Butler","Mikhail Kosiborod","David E Lanfear"],"significance":6,"published":"2023-07-18","source_date":"2023-07-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This patient-level analysis showed that SGLT2 inhibitors equally improve quality of life in Black and White heart failure patients, addressing the important question of equitable treatment benefit across racial groups.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f24c2982bd79","type":"article","url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","title":"Vroege versus late AF-ablatie: impact op aritmierecidief","title_en":"Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad247","source_url":"https://doi.org/10.1093/eurheartj/ehad247","authors":["Jonathan M Kalman","Ahmed M Al-Kaisey","Ramanathan Parameswaran","Joshua Hawson","Robert D Anderson","Michael Lim","David Chieng","Stephen A Joseph","Alex McLellan","Joseph B Morton","Paul B Sparks","Geoffrey Lee","Prashanthan Sanders","Peter M Kistler"],"significance":7,"published":"2023-07-14","source_date":"2023-07-14","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study showed that early catheter ablation (within 1 year of AF diagnosis) results in fewer arrhythmia recurrences than delayed ablation, reinforcing the early rhythm control paradigm from EAST-AFNET 4.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"53b8aa080ebd","type":"article","url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","title":"TRAVERSE: testosteronsubstitutie cardiovasculair veilig bij hypogonadisme","title_en":"Cardiovascular Safety of Testosterone-Replacement Therapy.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["summit-trial","vrouwen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2215025","source_url":"https://doi.org/10.1056/NEJMoa2215025","authors":["A Michael Lincoff","Shalender Bhasin","Panagiotis Flevaris","Lisa M Mitchell","Shehzad Basaria","William E Boden","Glenn R Cunningham","Christopher B Granger","Mohit Khera","Ian M Thompson","Qiuqing Wang","Kathy Wolski","Deborah Davey","Vidyasagar Kalahasti","Nader Khan","Michael G Miller","Michael C Snabes","Anna Chan","Elena Dubcenco","Xue Li","Tingting Yi","Bidan Huang","Karol M Pencina","Thomas G Travison","Steven E Nissen"],"significance":9,"published":"2023-07-13","source_date":"2023-07-13","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"The TRAVERSE trial demonstrated that testosterone-replacement therapy in middle-aged and older men with hypogonadism and cardiovascular risk factors did not increase the incidence of major adverse cardiovascular events. This large safety trial resolved decades of uncertainty about the cardiovascular risks of testosterone therapy.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aee289cbd657","type":"article","url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","title":"P2Y12-monotherapie versus aspirine voor langetermijnsecundaire preventie: meta-analyse","title_en":"P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["aspirine","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.04.051","source_url":"https://doi.org/10.1016/j.jacc.2023.04.051","authors":["Felice Gragnano","Davide Cao","Leah Pirondini","Anna Franzone","Hyo-Soo Kim","Moritz von Scheidt","Alf-Åge R Pettersen","Qiang Zhao","Mark Woodward","Mauro Chiarito","Eugene P McFadden","Kyung Woo Park","Adnan Kastrati","Ingebjørg Seljeflot","Yunpeng Zhu","Stephan Windecker","Jeehoon Kang","Heribert Schunkert","Harald Arnesen","Deepak L Bhatt","Philippe Gabriel Steg","Paolo Calabrò","Stuart Pocock","Roxana Mehran","Marco Valgimigli"],"significance":8,"published":"2023-07-11","source_date":"2023-07-11","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This meta-analysis confirmed that P2Y12 inhibitor monotherapy is superior to aspirin for long-term secondary prevention of coronary events, with fewer ischemic events (especially stroke) and no increase in bleeding. The data support replacing aspirin with clopidogrel as the default post-DAPT agent.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21132825f84b","type":"article","url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","title":"Ondervoeding verslechtert prognose bij hartfalen en MR: COAPT-analyse","title_en":"Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.04.047","source_url":"https://doi.org/10.1016/j.jacc.2023.04.047","authors":["Andrea Scotti","Augustin Coisne","Juan F Granada","Elissa Driggin","Mahesh V Madhavan","Zhipeng Zhou","Björn Redfors","Saibal Kar","D Scott Lim","David J Cohen","JoAnn Lindenfeld","William T Abraham","Michael J Mack","Federico M Asch","Gregg W Stone"],"significance":6,"published":"2023-07-11","source_date":"2023-07-11","image":"","kennis":[],"congress":"","summary_en":"This COAPT analysis showed that malnutrition independently predicts worse outcomes in heart failure with secondary MR, highlighting the importance of nutritional assessment in the MitraClip decision-making process.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb9e6e80104f","type":"article","url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","title":"TRANSFORM-HF: torsemide versus furosemide — geen verschil in symptomen","title_en":"Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["diuretica","furosemide"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064842","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064842","authors":["Stephen J Greene","Eric J Velazquez","Kevin J Anstrom","Robert M Clare","Tracy A DeWald","Mitchell A Psotka","Andrew P Ambrosy","Gerin R Stevens","John J Rommel","Tamas Alexy","Fassil Ketema","Dong-Yun Kim","Patrice Desvigne-Nickens","Bertram Pitt","Eric L Eisenstein","Robert J Mentz"],"significance":7,"published":"2023-07-11","source_date":"2023-07-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This TRANSFORM-HF symptom analysis confirmed that torsemide offers no advantage over furosemide for symptoms and quality of life in hospitalized heart failure patients, supporting either loop diuretic as an equivalent clinical choice.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1165b188dffb","type":"article","url":"https://hartvaat.nl/2023/07/04/cognitieve-gedragstherapie-verbetert-kwaliteit-van-leven-bij-symptomatisch-af/","title":"Cognitieve gedragstherapie verbetert kwaliteit van leven bij symptomatisch AF","title_en":"Cognitive Behavioral Therapy Improves Quality of Life in Patients With Symptomatic Paroxysmal Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["perifeer-vaatlijden","soul-trial","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.04.044","source_url":"https://doi.org/10.1016/j.jacc.2023.04.044","authors":["Josefin Särnholm","Helga Skúladóttir","Christian Rück","Erland Axelsson","Marianne Bonnert","Maria Bragesjö","Ashwin Venkateshvaran","Eva Ólafsdóttir","Susanne S Pedersen","Brjánn Ljótsson","Frieder Braunschweig"],"significance":7,"published":"2023-07-04","source_date":"2023-07-04","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/abc-pad-af/"],"congress":"","summary_en":"This randomized trial showed that cognitive behavioral therapy significantly improves quality of life and reduces AF symptom burden in patients with symptomatic paroxysmal AF, establishing psychological intervention as a complementary approach to rhythm management.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5fa7d23446b","type":"article","url":"https://hartvaat.nl/2023/07/04/colchicine-voorkomt-postoperatief-af-na-hartchirurgie-meta-analyse/","title":"Colchicine voorkomt postoperatief AF na hartchirurgie: meta-analyse","title_en":"Safety and efficacy of colchicine for the prevention of post-operative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["colchicine","pericarditis"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad169","source_url":"https://doi.org/10.1093/europace/euad169","authors":["Siddharth Agarwal","Christopher W Beard","Jagjit Khosla","Shari Clifton","Muhammad Faraz Anwaar","Asad Ghani","Kassem Farhat","Nikolaos Pyrpyris","Joud Momani","Muhammad Bilal Munir","Christopher V DeSimone","Abhishek Deshmukh","Stavros Stavrakis","Warren M Jackman","Sunny Po","Zain Ul Abideen Asad"],"significance":7,"published":"2023-07-04","source_date":"2023-07-04","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that colchicine significantly reduces post-operative atrial fibrillation after cardiac surgery, supporting its use as a prophylactic anti-inflammatory agent in the perioperative setting.","created":"2026-07-03T10:30:28Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a008f08b1f5","type":"article","url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","title":"Sacubitril/valsartan bij HFmrEF/HFpEF met verslechterend hartfalen","title_en":"Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","bisoprolol","carvedilol","empagliflozine","hfmref","hfpef","hfref","ijzertekort","nt-probnp","sacubitril-valsartan","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.04.019","source_url":"https://doi.org/10.1016/j.jacc.2023.04.019","authors":["Robert J Mentz","Jonathan H Ward","Adrian F Hernandez","Serge Lepage","David A Morrow","Samiha Sarwat","Kavita Sharma","Randall C Starling","Eric J Velazquez","Kristin M Williamson","Akshay S Desai","Shelley Zieroth","Scott D Solomon","Eugene Braunwald"],"significance":7,"published":"2023-07-04","source_date":"2023-07-04","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This analysis showed that sacubitril-valsartan benefits patients with HFmrEF/HFpEF and worsening heart failure (recent hospitalization or elevated natriuretic peptides), supporting ARNI use in the higher-risk phenotype within this population.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"906e786d66aa","type":"article","url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","title":"INTERACT3: bundeled care bij acute intracerebrale bloeding — Lancet","title_en":"The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00806-1","source_url":"https://doi.org/10.1016/S0140-6736(23)00806-1","authors":["Lu Ma","Xin Hu","Lili Song","Xiaoying Chen","Menglu Ouyang","Laurent Billot","Qiang Li","Alejandra Malavera","Xi Li","Paula Muñoz-Venturelli","Asita de Silva","Nguyen Huy Thang","Kolawole W Wahab","Jeyaraj D Pandian","Mohammad Wasay","Octavio M Pontes-Neto","Carlos Abanto","Antonio Arauz","Haiping Shi","Guanghai Tang","Sheng Zhu","Xiaochun She","Leibo Liu","Yuki Sakamoto","Shoujiang You","Qiao Han","Bernard Crutzen","Emily Cheung","Yunke Li","Xia Wang","Chen Chen","Feifeng Liu","Yang Zhao","Hao Li","Yi Liu","Yan Jiang","Lei Chen","Bo Wu","Ming Liu","Jianguo Xu","Chao You","Craig S Anderson"],"significance":8,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":[],"congress":"","summary_en":"The INTERACT3 trial showed that a goal-directed care bundle with early intensive blood pressure lowering improved functional outcomes in patients with acute intracerebral hemorrhage. The pragmatic, cluster-randomized design demonstrated that structured care protocols can improve outcomes at scale.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41a7eb18f5cf","type":"article","url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","title":"DELIVER: dapagliflozine verbetert individuele KCCQ-componenten bij HFpEF","title_en":"Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.1342","source_url":"https://doi.org/10.1001/jamacardio.2023.1342","authors":["Alexander Peikert","Alvin Chandra","Mikhail N Kosiborod","Brian L Claggett","Akshay S Desai","Pardeep S Jhund","Carolyn S P Lam","Silvio E Inzucchi","Felipe A Martinez","Rudolf A de Boer","Adrian F Hernandez","Sanjiv J Shah","Stefan P Janssens","Jan Belohlávek","C Jan Willem Borleffs","Dan Dobreanu","Anna Maria Langkilde","Olof Bengtsson","Magnus Petersson","John J V McMurray","Scott D Solomon","Muthiah Vaduganathan"],"significance":6,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This detailed DELIVER analysis showed that dapagliflozin improves all individual components of the Kansas City Cardiomyopathy Questionnaire in HFpEF — symptoms, physical limitations, and quality of life — providing a comprehensive symptom benefit.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"99e3c1830254","type":"article","url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","title":"TiNO-gecoate versus everolimus-eluting stents bij ACS: TIDES-ACS vijfjaarsdata","title_en":"Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.1373","source_url":"https://doi.org/10.1001/jamacardio.2023.1373","authors":["Frederic Bouisset","Jussi Sia","Takuya Mizukami","Pasi P Karjalainen","Pim A L Tonino","Nico H J Pijls","Jan Van der Heyden","Hannu Romppanen","Kari Kervinen","Juhani K E Airaksinen","Jacques Lalmand","Peter Frambach","Bruno Roza da Costa","Carlos Collet","Bernard De Bruyne"],"significance":6,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"Five-year TIDES-ACS results showed that titanium-nitride-oxide-coated stents provide comparable outcomes to everolimus-eluting stents in ACS, with faster strut coverage offering a potential advantage for shortened DAPT.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94a011d56a1a","type":"article","url":"https://hartvaat.nl/2023/07/01/statinoplaaddosis-voor-cabg-gerandomiseerde-trial/","title":"Statinoplaaddosis voor CABG: gerandomiseerde trial","title_en":"Statin loading before coronary artery bypass grafting: a randomized trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["newton-cabg"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad238","source_url":"https://doi.org/10.1093/eurheartj/ehad238","authors":["Oliver J Liakopoulos","Elmar W Kuhn","Martin Hellmich","Markus Schlömicher","Justus Strauch","Wilko Reents","Anno Diegeler","Matthias Thielmann","Daniel Wendt","Jochen Börgermann","Jan F Gummert","Christian Stoppe","Andreas Goetzenich","Sven Martens","Hermann Reichenspurner","Jens Wippermann","Hannes Reuter","Yeong-Hoon Choi","Thorsten Wahlers"],"significance":6,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"This randomized trial showed that high-dose statin loading before CABG does not improve outcomes, in contrast to the proven benefit before PCI, suggesting different mechanisms of perioperative benefit between surgical and percutaneous revascularization.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a16d6aea248c","type":"article","url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","title":"Timing van antihypertensiva: meta-analyse van RCT's bevestigt flexibiliteit","title_en":"Timing of Antihypertensive Drug Therapy: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20862","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20862","authors":["Muhammad Haisum Maqsood","Franz H Messerli","Adam H Skolnick","Jonathan D Newman","Jeffrey S Berger","Sripal Bangalore"],"significance":7,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This meta-analysis of RCTs confirmed that the timing of antihypertensive drug administration (morning vs evening) has no significant effect on blood pressure control or cardiovascular outcomes, adding to the TIME and BedMed evidence.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e2815ab5233","type":"article","url":"https://hartvaat.nl/2023/07/01/familiair-hyperaldosteronisme-type-1-therapeutische-opties-en-langetermijnuitkom/","title":"Familiair hyperaldosteronisme type 1: therapeutische opties en langetermijnuitkomsten","title_en":"Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["diabetes-type-1","familiaire-hypercholesterolemie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21054","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21054","authors":["Shu Ting Tan","Veronica Boyle","Marianne S Elston"],"significance":5,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This systematic review summarized the treatment options and long-term outcomes of familial hyperaldosteronism type 1, the first identified monogenic cause of primary aldosteronism.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bb83210074e0","type":"article","url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","title":"Leeftijdsbias draagt bij aan therapeutische inertie bij bloeddrukmanagement","title_en":"Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","bradycardie","hartrevalidatie","lichaamsbeweging","lichamelijke-inactiviteit","ouderen","summit-trial","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.21323","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.21323","authors":["Alexander R Zheutlin","Daniel K Addo","Joshua A Jacobs","Catherine G Derington","Jennifer S Herrick","Tom Greene","Eric L Stulberg","Dan R Berlowitz","Jeff D Williamson","Nicholas M Pajewski","Mark A Supiano","Adam P Bress"],"significance":6,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/"],"congress":"","summary_en":"This SPRINT analysis showed that age bias contributes to therapeutic inertia in blood pressure management, with clinicians being less aggressive in intensifying treatment for older patients despite equal evidence of benefit.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f58a43d2c310","type":"article","url":"https://hartvaat.nl/2023/07/01/metabolomics-en-bloeddrukrespons-op-dash-dieet/","title":"Metabolomics en bloeddrukrespons op DASH-dieet","title_en":"Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["dyslipidemie","metabole-acidose"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.123.20901","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.123.20901","authors":["Hyunju Kim","Lawrence J Appel","Alice H Lichtenstein","Kari E Wong","Nilanjan Chatterjee","Eugene P Rhee","Casey M Rebholz"],"significance":5,"published":"2023-07-01","source_date":"2023-07-01","image":"","kennis":[],"congress":"","summary_en":"This metabolomics analysis from the DASH trials identified specific metabolic profiles associated with blood pressure response to the DASH diet, revealing biochemical pathways underlying dietary cardiovascular benefit.","created":"2026-07-03T10:30:27Z","updated":"2026-07-03T13:29:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e554ae15002","type":"article","url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","title":"ELAN: vroege versus late anticoagulatie na CVA bij AF — NEJM","title_en":"Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2303048","source_url":"https://doi.org/10.1056/NEJMoa2303048","authors":["Urs Fischer","Masatoshi Koga","Daniel Strbian","Mattia Branca","Stefanie Abend","Sven Trelle","Maurizio Paciaroni","Götz Thomalla","Patrik Michel","Krassen Nedeltchev","Leo H Bonati","George Ntaios","Thomas Gattringer","Else-Charlotte Sandset","Peter Kelly","Robin Lemmens","P N Sylaja","Diana Aguiar de Sousa","Natan M Bornstein","Zuzana Gdovinova","Takeshi Yoshimoto","Marjaana Tiainen","Helen Thomas","Manju Krishnan","Gek C Shim","Christoph Gumbinger","Jochen Vehoff","Liqun Zhang","Kosuke Matsuzono","Espen Kristoffersen","Philippe Desfontaines","Peter Vanacker","Angelika Alonso","Yusuke Yakushiji","Caterina Kulyk","Dimitri Hemelsoet","Sven Poli","Ana Paiva Nunes","Nicoletta Caracciolo","Peter Slade","Jelle Demeestere","Alexander Salerno","Markus Kneihsl","Timo Kahles","Daria Giudici","Kanta Tanaka","Silja Räty","Rea Hidalgo","David J Werring","Martina Göldlin","Marcel Arnold","Cecilia Ferrari","Seraina Beyeler","Christian Fung","Bruno J Weder","Turgut Tatlisumak","Sabine Fenzl","Beata Rezny-Kasprzak","Arsany Hakim","Georgia Salanti","Claudio Bassetti","Jan Gralla","David J Seiffge","Thomas Horvath","Jesse Dawson"],"significance":10,"published":"2023-06-29","source_date":"2023-06-29","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The ELAN trial showed that early initiation of DOACs (within 48 hours for mild stroke, within 6–7 days for moderate stroke) after ischemic stroke in patients with atrial fibrillation was safe and associated with fewer recurrent strokes compared with later initiation. The results support a move toward earlier anticoagulation in this high-risk population.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T13:29:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef85ba064c43","type":"article","url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","title":"SGLT2-remmers en CV-uitkomsten over patiëntpopulaties: JACC overzicht","title_en":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","sglt2-remmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.04.034","source_url":"https://doi.org/10.1016/j.jacc.2023.04.034","authors":["Muhammad Shariq Usman","Tariq Jamal Siddiqi","Stefan D Anker","George L Bakris","Deepak L Bhatt","Gerasimos Filippatos","Gregg C Fonarow","Stephen J Greene","James L Januzzi","Muhammad Shahzeb Khan","Mikhail N Kosiborod","Darren K McGuire","Ileana L Piña","Julio Rosenstock","Muthiah Vaduganathan","Subodh Verma","Shelley Zieroth","Javed Butler"],"significance":8,"published":"2023-06-27","source_date":"2023-06-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This comprehensive JACC review summarized the effects of SGLT2 inhibitors across all studied populations — HFrEF, HFpEF, CKD, and type 2 diabetes — providing a unified overview of their cardiovascular and renal benefits and positioning them as foundational cardiometabolic therapy.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T13:29:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"472fce716fe2","type":"article","url":"https://hartvaat.nl/2023/06/26/opioiden-bij-dyspneu-en-hartfalen-meta-analyse-toont-geen-voordeel/","title":"Opioïden bij dyspneu en hartfalen: meta-analyse toont geen voordeel","title_en":"Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","alcoholgebruik","bisoprolol","carvedilol","empagliflozine","nt-probnp"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-322074","source_url":"https://doi.org/10.1136/heartjnl-2022-322074","authors":["Jan Gaertner","Tanja Fusi-Schmidhauser","Stephanie Stock","Waldemar Siemens","Vera Vennedey"],"significance":7,"published":"2023-06-26","source_date":"2023-06-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This meta-analysis found that opioids do not significantly improve breathlessness in heart failure despite their widespread use, challenging the traditional practice of opioid administration for dyspnea in acute heart failure.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f68243ef6631","type":"article","url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","title":"Dapagliflozine en perifeer arterieel vaatlijden bij hartfalen: DAPA-HF/DELIVER meta-analyse","title_en":"Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfpef","hfref","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad276","source_url":"https://doi.org/10.1093/eurheartj/ehad276","authors":["Jawad H Butt","Toru Kondo","Mingming Yang","Pardeep S Jhund","Kieran F Docherty","Muthiah Vaduganathan","Brian L Claggett","Adrian F Hernandez","Carolyn S P Lam","Silvio E Inzucchi","Felipe A Martinez","Rudolf A de Boer","Mikhail N Kosiborod","Akshay S Desai","Lars Køber","Piotr Ponikowski","Marc S Sabatine","Sanjiv J Shah","Natalia Zaozerska","Ulrica Wilderäng","Olof Bengtsson","Scott D Solomon","John J V McMurray"],"significance":7,"published":"2023-06-25","source_date":"2023-06-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This patient-level meta-analysis of DAPA-HF and DELIVER confirmed that dapagliflozin does not increase the risk of amputation in heart failure patients, addressing the safety concern raised by the earlier canagliflozin CANVAS results.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21d57d48c536","type":"article","url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","title":"Cystatine C voor GFR-schatting bij hartfalen: PARADIGM-HF analyse","title_en":"Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["chronische-nierziekte","cystatine-c","hfref","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad210","source_url":"https://doi.org/10.1093/eurheartj/ehad210","authors":["Paolo Tolomeo","Jawad H Butt","Toru Kondo","Gianluca Campo","Akshay S Desai","Pardeep S Jhund","Lars Køber","Martin P Lefkowitz","Jean L Rouleau","Scott D Solomon","Karl Swedberg","Muthiah Vaduganathan","Michael R Zile","Milton Packer","John J V McMurray"],"significance":6,"published":"2023-06-25","source_date":"2023-06-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This PARADIGM-HF analysis showed that the combined creatinine-cystatin C eGFR formula provides more accurate kidney function estimation in heart failure than creatinine alone, with implications for drug dosing and risk assessment.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"873f6ca6e978","type":"article","url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","title":"MONITOR-HF: PA-drukmonitoring bij hartfalen effectief in Europa — Lancet RCT","title_en":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00923-6","source_url":"https://doi.org/10.1016/S0140-6736(23)00923-6","authors":["Jasper J Brugts","Sumant P Radhoe","Pascal R D Clephas","Dilan Aydin","Marco W F van Gent","Mariusz K Szymanski","Michiel Rienstra","Mieke H van den Heuvel","Carlos A da Fonseca","Gerard C M Linssen","C Jan Willem Borleffs","Eric Boersma","Folkert W Asselbergs","Arend Mosterd","Hans-Peter Brunner-La Rocca","Rudolf A de Boer"],"significance":9,"published":"2023-06-24","source_date":"2023-06-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The MONITOR-HF trial confirmed that remote pulmonary artery pressure monitoring (CardioMEMS) improved quality of life and reduced heart failure hospitalization in European patients with chronic heart failure treated with contemporary guideline-directed therapy. The results extended the evidence from the US-based CHAMPION trial.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3517e2d01f1a","type":"article","url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","title":"LOOP-substudie: NT-proBNP verbetert AF-screeningsopbrengst","title_en":"Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["nt-probnp"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064361","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064361","authors":["Lucas Yixi Xing","Søren Zöga Diederichsen","Søren Højberg","Derk W Krieger","Claus Graff","Ruth Frikke-Schmidt","Morten S Olesen","Axel Brandes","Lars Køber","Ketil Jørgen Haugan","Jesper Hastrup Svendsen"],"significance":7,"published":"2023-06-13","source_date":"2023-06-13","image":"","kennis":[],"congress":"","summary_en":"This LOOP trial secondary analysis showed that NT-proBNP improves the yield of AF screening with implantable cardiac monitors, supporting a biomarker-enriched approach to identifying patients most likely to benefit from intensive arrhythmia monitoring.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T13:29:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d2a4b6c14fdf","type":"article","url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","title":"ADVOR: bicarbonaatwaarden en decongestie-effect van acetazolamide","title_en":"Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad236","source_url":"https://doi.org/10.1093/eurheartj/ehad236","authors":["Pieter Martens","Frederik H Verbrugge","Jeroen Dauw","Petra Nijst","Evelyne Meekers","Silvio Nunes Augusto","Jozine M Ter Maaten","Line Heylen","Kevin Damman","Alexandre Mebazaa","Gerasimos Filippatos","Frank Ruschitzka","Wai Hong Wilson Tang","Matthias Dupont","Wilfried Mullens"],"significance":6,"published":"2023-06-09","source_date":"2023-06-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This ADVOR subanalysis showed that higher baseline bicarbonate levels predict better response to acetazolamide in acute heart failure, identifying a biomarker-guided approach to sequential nephron blockade.","created":"2026-07-03T10:30:26Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"800caf7a12a2","type":"article","url":"https://hartvaat.nl/2023/06/09/acyl-ghreline-verbetert-hartfunctie-bij-hartfalen/","title":"Acyl-ghreline verbetert hartfunctie bij hartfalen","title_en":"Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["empagliflozine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad100","source_url":"https://doi.org/10.1093/eurheartj/ehad100","authors":["Lars H Lund","Camilla Hage","Gianluigi Pironti","Tonje Thorvaldsen","Ulrika Ljung-Faxén","Stanislava Zabarovskaja","Kambiz Shahgaldi","Dominic-Luc Webb","Per M Hellström","Daniel C Andersson","Marcus Ståhlberg"],"significance":5,"published":"2023-06-09","source_date":"2023-06-09","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This translational study demonstrated that acylated ghrelin improves cardiac function in heart failure through a calcium-independent mechanism, exploring appetite hormone signaling as a novel HF therapeutic approach.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fca71cb7976a","type":"article","url":"https://hartvaat.nl/2023/06/08/behandeling-van-vroeg-gediagnosticeerde-zwangerschapsdiabetes-nejm-trial/","title":"Behandeling van vroeg gediagnosticeerde zwangerschapsdiabetes: NEJM trial","title_en":"Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["select-trial","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2214956","source_url":"https://doi.org/10.1056/NEJMoa2214956","authors":["David Simmons","Jincy Immanuel","William M Hague","Helena Teede","Christopher J Nolan","Michael J Peek","Jeff R Flack","Mark McLean","Vincent Wong","Emily Hibbert","Alexandra Kautzky-Willer","Jürgen Harreiter","Helena Backman","Emily Gianatti","Arianne Sweeting","Viswanathan Mohan","Joanne Enticott","N Wah Cheung"],"significance":8,"published":"2023-06-08","source_date":"2023-06-08","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This NEJM trial demonstrated that treatment of gestational diabetes diagnosed before 20 weeks of pregnancy improved neonatal outcomes, with fewer macrosomic infants and less need for neonatal intensive care. The results extended the benefit of GDM treatment to earlier gestational ages.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5dda5dec10ea","type":"article","url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","title":"STRONG-HF: optitratie effectief over het hele EF-spectrum na HF-opname","title_en":"Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfmref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.03.426","source_url":"https://doi.org/10.1016/j.jacc.2023.03.426","authors":["Matteo Pagnesi","Marco Metra","Alain Cohen-Solal","Christopher Edwards","Marianna Adamo","Daniela Tomasoni","Carolyn S P Lam","Ovidiu Chioncel","Rafael Diaz","Gerasimos Filippatos","Piotr Ponikowski","Karen Sliwa","Adriaan A Voors","Antoine Kimmoun","Maria Novosadova","Koji Takagi","Marianela Barros","Albertino Damasceno","Hadiza Saidu","Etienne Gayat","Peter S Pang","Jelena Celutkiene","Gad Cotter","Alexandre Mebazaa","Beth Davison"],"significance":8,"published":"2023-06-06","source_date":"2023-06-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This STRONG-HF subanalysis showed that rapid up-titration of guideline-directed therapy after heart failure hospitalization was effective across the entire ejection fraction spectrum, including patients with HFpEF. The results expanded the aggressive post-discharge optimization approach beyond HFrEF.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a8dca96e051d","type":"article","url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","title":"COMBINE AF: DOAC's versus warfarine over het nierfunctiespectrum — IPD meta-analyse","title_en":"Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","anticoagulatie-kwetsbare-ouderen","rivaroxaban"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062752","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062752","authors":["Josephine Harrington","Anthony P Carnicelli","Kaiyuan Hua","Lars Wallentin","Manesh R Patel","Stefan H Hohnloser","Robert P Giugliano","Keith A A Fox","Ziad Hijazi","Renato D Lopes","Sean D Pokorney","Hwanhee Hong","Christopher B Granger"],"significance":8,"published":"2023-06-06","source_date":"2023-06-06","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"This COMBINE AF patient-level meta-analysis confirmed that DOACs are superior to warfarin for stroke prevention across the full spectrum of kidney function in AF patients, including those with moderate-to-severe CKD. The data address a key uncertainty in anticoagulation management.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38dd94af8b09","type":"article","url":"https://hartvaat.nl/2023/06/01/intensieve-bloeddrukcontrole-en-geleidingsziekten-sprint-post-hoc-analyse/","title":"Intensieve bloeddrukcontrole en geleidingsziekten: SPRINT post-hoc analyse","title_en":"Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie","thuisbloeddrukmeting","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.0845","source_url":"https://doi.org/10.1001/jamacardio.2023.0845","authors":["Emilie K Frimodt-Møller","Eric Vittinghoff","Gurbani Kaur","Tor Biering-Sørensen","Elsayed Z Soliman","Gregory M Marcus"],"significance":6,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This SPRINT post-hoc analysis showed that intensive blood pressure control is not associated with increased left ventricular conduction disease, addressing a safety concern about aggressive blood pressure management.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T18:39:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"300876628e08","type":"article","url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","title":"Lage-dosis drievoudige/viervoudige combinatiepil versus monotherapie bij hypertensie: meta-analyse","title_en":"Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","fidelity","lorundrostat"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.0720","source_url":"https://doi.org/10.1001/jamacardio.2023.0720","authors":["Nelson Wang","Phidias Rueter","Emily Atkins","Ruth Webster","Mark Huffman","Asita de Silva","Clara Chow","Anushka Patel","Anthony Rodgers"],"significance":8,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This meta-analysis confirmed that low-dose triple and quadruple combination antihypertensive pills are more effective than monotherapy for initial blood pressure treatment, with better control rates and comparable tolerability. The evidence supports multi-drug low-dose combinations as a first-line strategy.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa0b2048c999","type":"article","url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","title":"Genetische bijdrage aan aortastenose: dyslipidemie, inflammatie en verkalking","title_en":"Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["aortastenose","cardiovasculaire-genetica","diabetes-type-1","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","laminopathie","ldl-cholesterol","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pcsk9-remmers","pelacarsen","statines","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad142","source_url":"https://doi.org/10.1093/eurheartj/ehad142","authors":["Hao Yu Chen","Christian Dina","Aeron M Small","Christian M Shaffer","Rebecca T Levinson","Anna Helgadóttir","Romain Capoulade","Hans Markus Munter","Andreas Martinsson","Benjamin J Cairns","Linea C Trudsø","Mary Hoekstra","Hannah A Burr","Thomas W Marsh","Scott M Damrauer","Line Dufresne","Solena Le Scouarnec","David Messika-Zeitoun","Dilrini K Ranatunga","Rachel A Whitmer","Amélie Bonnefond","Garðar Sveinbjornsson","Ragnar Daníelsen","David O Arnar","Gudmundur Thorgeirsson","Unnur Thorsteinsdottir","Daníel F Gudbjartsson","Hilma Hólm","Jonas Ghouse","Morten Salling Olesen","Alex H Christensen","Susan Mikkelsen","Rikke Louise Jacobsen","Joseph Dowsett","Ole Birger Vesterager Pedersen","Christian Erikstrup","Sisse R Ostrowski","Christopher J O'Donnell","Matthew J Budoff","Vilmundur Gudnason","Wendy S Post","Jerome I Rotter","Mark Lathrop","Henning Bundgaard","Bengt Johansson","Johan Ljungberg","Ulf Näslund","Thierry Le Tourneau","J Gustav Smith","Quinn S Wells","Stefan Söderberg","Kári Stefánsson","Jean-Jacques Schott","Daniel J Rader","Robert Clarke","James C Engert","George Thanassoulis"],"significance":7,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This genome-wide association study identified novel genetic loci for aortic stenosis implicating pathways of dyslipidemia (including Lp(a)), inflammation, calcification, and adiposity, advancing the understanding of the genetic etiology of calcific aortic valve disease.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"405b3e592195","type":"article","url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","title":"COAPT vijfjaarsresultaten: MitraClip duurzaam effectief bij secundaire MR","title_en":"Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitralisinsufficiëntie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2300213","source_url":"https://doi.org/10.1056/NEJMoa2300213","authors":["Gregg W Stone","William T Abraham","JoAnn Lindenfeld","Saibal Kar","Paul A Grayburn","D Scott Lim","Jacob M Mishell","Brian Whisenant","Michael Rinaldi","Samir R Kapadia","Vivek Rajagopal","Ian J Sarembock","Andreas Brieke","Steven O Marx","David J Cohen","Federico M Asch","Michael J Mack"],"significance":9,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"The 5-year COAPT follow-up confirmed durable benefit of transcatheter mitral valve repair with MitraClip in patients with heart failure and severe secondary mitral regurgitation, with sustained reductions in mortality and heart failure hospitalization compared with medical therapy alone.","created":"2026-07-03T10:30:25Z","updated":"2026-07-03T13:29:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47c51903ba77","type":"article","url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","title":"IGFBP7 en LV-massaregressie met empagliflozine: EMPA-HEART subanalyse","title_en":"IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14335","source_url":"https://doi.org/10.1002/ehf2.14335","authors":["Pankaj Puar","Nikhil Mistry","Kim A Connelly","Andrew T Yan","Adrian Quan","Hwee Teoh","Yi Pan","Raj Verma","David A Hess","Subodh Verma","C David Mazer"],"significance":5,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":[],"congress":"","summary_en":"This EMPA-HEART subanalysis showed that IGFBP7 levels may identify patients who derive greater cardiorenal benefit from empagliflozin, advancing biomarker-guided patient selection for SGLT2 inhibitor therapy.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db0b96ad192f","type":"article","url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","title":"NLR en cardiale remodelling met empagliflozine: EMPA-HEART subanalyse","title_en":"Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","cardiale-amyloidose","colchicine","empagliflozine","emperor-trials","farmaco-economie","gepersonaliseerde-geneeskunde","hs-crp","inflammatie","laminopathie","menopauze","microbioom","ouderen","slaapapneu","ventrikelfibrilleren"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14351","source_url":"https://doi.org/10.1002/ehf2.14351","authors":["Raj Verma","Michael Moroney","Makoto Hibino","Cyril David Mazer","Kim A Connelly","Andrew T Yan","Adrian Quan","Hwee Teoh","Subodh Verma","Pankaj Puar"],"significance":5,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This subanalysis showed that the neutrophil-to-lymphocyte ratio modifies the cardiac remodeling response to empagliflozin, suggesting that baseline inflammation status influences SGLT2 inhibitor benefit.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ba79bcc8d738","type":"article","url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","title":"Diabetesduur beïnvloedt LV-massaregressie met empagliflozine","title_en":"Impact of diabetes duration on left ventricular mass regression with empagliflozin.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","canagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","emperor-trials","ezetimibe","figaro-dkd","obesitas","slaapapneu","soul-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14357","source_url":"https://doi.org/10.1002/ehf2.14357","authors":["Michael Moroney","Raj Verma","Makoto Hibino","C David Mazer","Kim A Connelly","Andrew T Yan","Adrian Quan","Hwee Teoh","Subodh Verma","Pankaj Puar"],"significance":5,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPA-HEART subanalysis showed that diabetes duration modifies the cardiac remodeling response to empagliflozin, with patients with shorter diabetes duration experiencing greater LV mass regression.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c620693e7912","type":"article","url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","title":"Remote ischemische conditionering bij milde hypertensie zonder medicatie: RCT","title_en":"Chronic Remote Ischemic Conditioning on Mild Hypertension in the Absence of Antihypertensive Medication: A Multicenter, Randomized, Double-Blind, Proof-of-Concept Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20934","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20934","authors":["Wenting Guo","Wenbo Zhao","Dong Li","Haiying Jia","Changhong Ren","Sijie Li","Jing Zhao","Bingxin Yu","Jian Dong","Rongfen Guo","Kun Zhu","Yu Cao","Yan Wang","Ying Wang","Zunshan Li","Zhen Wang","Dan Wang","Chengbei Hou","Derek J Hausenloy","Xi Chu","Xunming Ji"],"significance":5,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This multicenter RCT showed that chronic remote ischemic conditioning does not significantly lower blood pressure in patients with mild hypertension without antihypertensive medication, limiting enthusiasm for this non-pharmacological approach.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T13:29:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b733d090c2f","type":"article","url":"https://hartvaat.nl/2023/06/01/betablokkers-bij-systolisch-hartfalen-en-pacemakerritme-mortaliteitseffect/","title":"Bètablokkers bij systolisch hartfalen en pacemakerritme: mortaliteitseffect","title_en":"Beta-blocker use and mortality among patients with systolic heart failure and pacemaker rhythm.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","betablokkers","bisoprolol","bloeddrukbehandeling","carvedilol","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14353","source_url":"https://doi.org/10.1002/ehf2.14353","authors":["Andrew S Perry","Aldo P Maggioni","Luigi Tavazzi","Wayne C Levy"],"significance":6,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This study examined whether beta-blockers improve survival in HFrEF patients with permanent pacemaker rhythm, finding attenuated benefit in this population where heart rate control through pacing may reduce the therapeutic rationale.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"207c749dd8a7","type":"article","url":"https://hartvaat.nl/2023/06/01/sglt2-remmers-bij-hartfalen-systematisch-overzicht-van-mechanismen-en-kliniek/","title":"SGLT2-remmers bij hartfalen: systematisch overzicht van mechanismen en kliniek","title_en":"Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","empagliflozine","fidelity","hfref","nt-probnp","sglt2-remmers","vericiguat"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14355","source_url":"https://doi.org/10.1002/ehf2.14355","authors":["Buena Aziri","Edin Begic","Slobodan Jankovic","Zorica Mladenovic","Bojan Stanetic","Tamara Kovacevic-Preradovic","Amer Iglica","Aida Mujakovic"],"significance":6,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This systematic review summarized the current understanding of SGLT2 inhibitor mechanisms in heart failure, covering natriuresis, osmotic diuresis, ketone body metabolism, and cardiac energy substrate optimization.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T13:29:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03a3c7755adf","type":"article","url":"https://hartvaat.nl/2023/06/01/hartfalentherapie-bij-hfmref-netwerk-meta-analyse/","title":"Hartfalentherapie bij HFmrEF: netwerk-meta-analyse","title_en":"The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["bisoprolol","carvedilol","empagliflozine","hfmref","hfpef","hfref","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14284","source_url":"https://doi.org/10.1002/ehf2.14284","authors":["Marta Leite","Francisco Sampaio","Francisca A Saraiva","Sílvia O Diaz","António S Barros","Ricardo Fontes-Carvalho"],"significance":7,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This network meta-analysis investigated the efficacy of heart failure therapies specifically in HFmrEF (LVEF 41-49%), finding that SGLT2 inhibitors, ARNI, and beta-blockers provide benefit in this intermediate ejection fraction group.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec8b536c45f3","type":"article","url":"https://hartvaat.nl/2023/06/01/team-based-care-bij-hypertensie-meta-analyse-bevestigt-effectiviteit-en-kostenef/","title":"Team-based care bij hypertensie: meta-analyse bevestigt effectiviteit en kosteneffectiviteit","title_en":"Effectiveness and Cost-Effectiveness of Team-Based Care for Hypertension: A Meta-Analysis and Simulation Study.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling","farmaco-economie","hartrevalidatie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20292","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20292","authors":["Kelsey B Bryant","Aditi S Rao","Laura P Cohen","Nadine Dandan","Ian M Kronish","Nikita Barai","Valy Fontil","Yiyi Zhang","Andrew E Moran","Brandon K Bellows"],"significance":7,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hypertensie/calciumantagonisten-hypertensie/"],"congress":"","summary_en":"This meta-analysis and simulation study showed that team-based care for hypertension significantly improves blood pressure control and is cost-effective, supporting the implementation of pharmacist and nurse-led hypertension management models.","created":"2026-07-03T10:30:24Z","updated":"2026-07-03T13:29:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9781422ba08e","type":"article","url":"https://hartvaat.nl/2023/06/01/eindorgaanschade-bij-kinderen-met-primaire-hypertensie-meta-analyse/","title":"Eindorgaanschade bij kinderen met primaire hypertensie: meta-analyse","title_en":"Risk of Target Organ Damage in Children With Primary Ambulatory Hypertension: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","renale-denervatie","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20190","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20190","authors":["Jason Chung","Cal H Robinson","Andrew Yu","Abdulaziz A Bamhraz","Joycelyne E Ewusie","Stephanie Sanger","Mark Mitsnefes","Rulan S Parekh","Rupesh Raina","Lehana Thabane","Janis M Dionne","Rahul Chanchlani"],"significance":6,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/"],"congress":"","summary_en":"This meta-analysis showed that target organ damage (LVH, increased vascular stiffness, elevated carotid IMT) is prevalent in children with primary ambulatory hypertension, supporting early cardiovascular assessment in pediatric blood pressure elevation.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d49f29c53ac7","type":"article","url":"https://hartvaat.nl/2023/06/01/natriuretisch-peptide-screening-voor-lv-disfunctie-diagnostische-nauwkeurigheid/","title":"Natriuretisch peptide screening voor LV-disfunctie: diagnostische nauwkeurigheid","title_en":"Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","iaso-dcm","laminopathie","nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14314","source_url":"https://doi.org/10.1002/ehf2.14314","authors":["Clare R Goyder","Andrea K Roalfe","Nicholas R Jones","Kathy S Taylor","Charles D Plumptre","Olivia James","Thomas R Fanshawe","F D Richard Hobbs","Clare J Taylor"],"significance":7,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This systematic review confirmed that natriuretic peptide screening in the community can effectively rule out left ventricular systolic dysfunction, supporting a biomarker-first strategy for early heart failure detection in primary care.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T18:39:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"226eaba03894","type":"article","url":"https://hartvaat.nl/2023/06/01/angiotensinepathways-onder-empagliflozine-bij-chronisch-hartfalen/","title":"Angiotensinepathways onder empagliflozine bij chronisch hartfalen","title_en":"Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","dapagliflozine","empagliflozine","emperor-trials","hfref","sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14313","source_url":"https://doi.org/10.1002/ehf2.14313","authors":["Agnes Bosch","Marko Poglitsch","Dennis Kannenkeril","Julie Kolwelter","Kristina Striepe","Christian Ott","Manfred Rauh","Mario Schiffer","Stephan Achenbach","Roland E Schmieder"],"significance":5,"published":"2023-06-01","source_date":"2023-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/","https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"This study characterized the effects of empagliflozin on angiotensin pathway components in chronic heart failure, showing that SGLT2 inhibition modulates RAAS activation beyond its diuretic-natriuretic effects.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc5f17b5ebed","type":"article","url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","title":"Complicaties van AF-ablatie: actueel overzicht","title_en":"Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.03.418","source_url":"https://doi.org/10.1016/j.jacc.2023.03.418","authors":["Karim Benali","Paul Khairy","Nefissa Hammache","Adrian Petzl","Antoine Da Costa","Atul Verma","Jason G Andrade","Laurent Macle"],"significance":6,"published":"2023-05-30","source_date":"2023-05-30","image":"","kennis":[],"congress":"","summary_en":"This comprehensive review of procedure-related complications of AF catheter ablation documented declining complication rates over time, providing current safety benchmarks and prevention strategies for the most common procedural risks.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0196b9665211","type":"article","url":"https://hartvaat.nl/2023/05/30/empagliflozine-en-cardiale-energiestofwisseling-bij-hartfalen-empa-vision/","title":"Empagliflozine en cardiale energiestofwisseling bij hartfalen: EMPA-VISION","title_en":"Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bisoprolol","carvedilol","dapa-hf","diabetes-en-hart","empagliflozine","emperor-trials","farmaco-economie","fidelity","hfmref","hfpef","hfref","microbioom","obesitas","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062021","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062021","authors":["Moritz J Hundertmark","Amanda Adler","Charalambos Antoniades","Ruth Coleman","Julian L Griffin","Rury R Holman","Hanan Lamlum","Jisoo Lee","Daniel Massey","Jack J J J Miller","Joanne E Milton","Shveta Monga","Ferenc E Mózes","Areesha Nazeer","Betty Raman","Oliver Rider","Christopher T Rodgers","Ladislav Valkovič","Eleanor Wicks","Masliza Mahmod","Stefan Neubauer"],"significance":6,"published":"2023-05-30","source_date":"2023-05-30","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The EMPA-VISION trial used cardiac MR spectroscopy to investigate whether empagliflozin changes myocardial energy metabolism in heart failure, exploring the metabolic mechanism hypothesis for SGLT2 inhibitor cardioprotection.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"42d5e5c1a211","type":"article","url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","title":"AFFIRM-AHF: hemoglobine beïnvloedt IV-ijzereffect bij acuut hartfalen","title_en":"Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["ijzersuppletie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060757","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060757","authors":["Gerasimos Filippatos","Piotr Ponikowski","Dimitrios Farmakis","Stefan D Anker","Javed Butler","Vincent Fabien","Bridget-Anne Kirwan","Iain C Macdougall","Marco Metra","Giuseppe Rosano","Frank Ruschitzka","Peter van der Meer","Sandra Wächter","Ewa A Jankowska"],"significance":6,"published":"2023-05-30","source_date":"2023-05-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This AFFIRM-AHF subanalysis showed that intravenous ferric carboxymaltose is most effective in acute HF patients with iron deficiency and without severe anemia, informing patient selection for IV iron therapy.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c574d4566395","type":"article","url":"https://hartvaat.nl/2023/05/27/best-cli-veneuze-bypass-versus-endovasculair-bij-chronische-kritieke-ischemie/","title":"BEST-CLI: veneuze bypass versus endovasculair bij chronische kritieke ischemie","title_en":"A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00462-2","source_url":"https://doi.org/10.1016/S0140-6736(23)00462-2","authors":["Andrew W Bradbury","Catherine A Moakes","Matthew Popplewell","Lewis Meecham","Gareth R Bate","Lisa Kelly","Ian Chetter","Athanasios Diamantopoulos","Arul Ganeshan","Jack Hall","Simon Hobbs","Kim Houlind","Hugh Jarrett","Suzanne Lockyer","Jonas Malmstedt","Jai V Patel","Smitaa Patel","S Tawqeer Rashid","Athanasios Saratzis","Gemma Slinn","D Julian A Scott","Hany Zayed","Jonathan J Deeks"],"significance":8,"published":"2023-05-27","source_date":"2023-05-27","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/kritieke-ischemie-been/","https://hartvaat.nl/kennis/kleplijden/aortaregurgitatie/"],"congress":"","summary_en":"The BEST-CLI trial demonstrated that vein bypass surgery was superior to endovascular therapy as the initial revascularization strategy for patients with chronic limb-threatening ischemia when a good-quality great saphenous vein was available. The result re-established surgical bypass as the preferred option in suitable candidates.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"521e364f64ca","type":"article","url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","title":"Prognose van ischemisch CVA onder orale anticoagulatie bij AF","title_en":"Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad200","source_url":"https://doi.org/10.1093/eurheartj/ehad200","authors":["Alexander P Benz","Stefan H Hohnloser","John W Eikelboom","Anthony P Carnicelli","Robert P Giugliano","Christopher B Granger","Josephine Harrington","Ziad Hijazi","David A Morrow","Manesh R Patel","David J Seiffge","Ashkan Shoamanesh","Lars Wallentin","Qilong Yi","Stuart J Connolly"],"significance":7,"published":"2023-05-21","source_date":"2023-05-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This study characterized the outcomes of AF patients who suffer ischemic stroke despite oral anticoagulation, showing poor prognosis and highlighting the residual stroke risk that persists even with guideline-directed anticoagulation.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e11a2c7e05bc","type":"article","url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","title":"Drie substraatstrategieën voor persisterend AF vergeleken: multicenter RCT","title_en":"Multi-centre, prospective randomized comparison of three different substrate ablation strategies for persistent atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad090","source_url":"https://doi.org/10.1093/europace/euad090","authors":["Kaige Li","Changhao Xu","Xiyao Zhu","Xinhua Wang","Ping Ye","Weifeng Jiang","Shaohui Wu","Kai Xu","Xiangting Li","Ying Wang","Qidong Zheng","Yanzhe Wang","Lihua Leng","Zengtang Zhang","Bing Han","Yu Zhang","Mu Qin","Xu Liu"],"significance":6,"published":"2023-05-19","source_date":"2023-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This multicenter RCT compared three substrate ablation strategies for persistent AF, finding that no additional strategy (empirical linear lesions or voltage-guided ablation) significantly improved outcomes over PVI plus empirical lines.","created":"2026-07-03T10:30:23Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bdc567bd9cf8","type":"article","url":"https://hartvaat.nl/2023/05/19/slokdarmkoeling-voorkomt-oesofagale-schade-bij-af-ablatie-meta-analyse/","title":"Slokdarmkoeling voorkomt oesofagale schade bij AF-ablatie: meta-analyse","title_en":"Role of oesophageal cooling in the prevention of oesophageal injury in atrial fibrillation catheter ablation: a systematic review and meta-analysis of randomized controlled trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["lichamelijke-inactiviteit","stress-psychosociaal"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad080","source_url":"https://doi.org/10.1093/europace/euad080","authors":["Mohamed Hamed","Sheref A Elseidy","Mohamed Abdelazeem","Ramez Morcos","Ahmed Abdallah","Yasser Sammour","Amr F Barakat","Wissam Khalife","Vijay Ramu","Mamas A Mamas","Ayman Elbadawi"],"significance":6,"published":"2023-05-19","source_date":"2023-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This meta-analysis showed that active esophageal cooling during AF catheter ablation significantly reduces the risk of thermal esophageal injury, supporting protective cooling as a safety adjunct during left atrial ablation procedures.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4af5811e08d4","type":"article","url":"https://hartvaat.nl/2023/05/19/fluoroscopievrije-cryoballonablatie-met-ice-begeleiding-bij-af/","title":"Fluoroscopievrije cryoballonablatie met ICE-begeleiding bij AF","title_en":"Safety and efficacy of intracardiac echocardiography-guided zero-fluoroscopic cryoballoon ablation for atrial fibrillation: a prospective randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad086","source_url":"https://doi.org/10.1093/europace/euad086","authors":["Jinhee Ahn","Dong Geum Shin","Sang-Jin Han","Hong Euy Lim"],"significance":6,"published":"2023-05-19","source_date":"2023-05-19","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This prospective RCT confirmed that zero-fluoroscopy cryoballoon ablation guided by intracardiac echocardiography is safe and effective for AF, eliminating radiation exposure for both patients and operators.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"594c9ff5c0b6","type":"article","url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","title":"EAST-AFNET 4: vroege ritmecontrole bij AF is kosteneffectief","title_en":"Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad051","source_url":"https://doi.org/10.1093/europace/euad051","authors":["Sophie Gottschalk","Shinwan Kany","Hans-Helmut König","Harry Jgm Crijns","Panos Vardas","A John Camm","Karl Wegscheider","Andreas Metzner","Andreas Rillig","Paulus Kirchhof","Judith Dams"],"significance":7,"published":"2023-05-19","source_date":"2023-05-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This EAST-AFNET 4 economic analysis showed that early rhythm control for atrial fibrillation is cost-effective compared with usual care, with the clinical benefits translating to favorable health economic outcomes.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd70cb3f7694","type":"article","url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","title":"Geleidingssysteempacing in Europa: inzichten uit klinische praktijk","title_en":"Conduction system pacing, a European survey: insights from clinical practice.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euad019","source_url":"https://doi.org/10.1093/europace/euad019","authors":["Daniel Keene","Frédéric Anselme","Haran Burri","Óscar Cano Pérez","Karol Čurila","Michael Derndorfer","Paul Foley","László Gellér","Michael Glikson","Wim Huybrechts","Marek Jastrzebski","Krzysztof Kaczmarek","Grigorios Katsouras","Jonathan Lyne","Pablo Peñafiel Verdú","Christian Restle","Sergio Richter","Stefan Timmer","Kevin Vernooy","Zachary Whinnett"],"significance":5,"published":"2023-05-19","source_date":"2023-05-19","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This European survey documented the current landscape of conduction system pacing practice, showing growing adoption of His bundle and left bundle branch area pacing with variability in technique and indications.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bae7b7e9f1e7","type":"article","url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","title":"TRILUMINATE: transcatheter tricuspidaliskleprepair bij ernstige TR — NEJM","title_en":"Transcatheter Repair for Patients with Tricuspid Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip","tricuspidalisinsufficiëntie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2300525","source_url":"https://doi.org/10.1056/NEJMoa2300525","authors":["Paul Sorajja","Brian Whisenant","Nadira Hamid","Hursh Naik","Raj Makkar","Peter Tadros","Matthew J Price","Gagan Singh","Neil Fam","Saibal Kar","Jonathan G Schwartz","Shamir Mehta","Richard Bae","Nishant Sekaran","Travis Warner","Moody Makar","George Zorn","Erin M Spinner","Phillip M Trusty","Raymond Benza","Ulrich Jorde","Patrick McCarthy","Vinod Thourani","Gilbert H L Tang","Rebecca T Hahn","David H Adams"],"significance":9,"published":"2023-05-18","source_date":"2023-05-18","image":"","kennis":[],"congress":"","summary_en":"The TRILUMINATE trial demonstrated that transcatheter edge-to-edge repair (TriClip) for severe tricuspid regurgitation was safe and significantly reduced regurgitation severity, though it did not meet the primary composite endpoint of death or tricuspid-related surgery. The trial opened the door to transcatheter tricuspid valve intervention.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"21604545703d","type":"article","url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","title":"Afschaffen eigen bijdrage medicatie vermindert cardiovasculair risico bij ouderen","title_en":"Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","diabetes-en-hart","ezetimibe","farmaco-economie","hartrevalidatie","microbioom","obesitas","ouderen","richtlijnen-esc","roken","slaapapneu","voeding-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064188","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064188","authors":["David J T Campbell","Chad Mitchell","Brenda R Hemmelgarn","Marcello Tonelli","Peter Faris","Jianguo Zhang","Ross T Tsuyuki","Jane Fletcher","Flora Au","Scott Klarenbach","Derek V Exner","Braden J Manns"],"significance":7,"published":"2023-05-16","source_date":"2023-05-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This randomized trial showed that eliminating medication copayments for low-income older adults at high cardiovascular risk significantly improves medication adherence and reduces cardiovascular events, demonstrating the clinical impact of financial barriers to care.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c860f81a3e00","type":"article","url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","title":"Zelfmanagement via reclameprincipes bij ouderen met hoog CV-risico","title_en":"Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.","category":"preventie","category_label":"Preventie","professions":["huisarts"],"tags":["ezetimibe","farmaco-economie","gedilateerde-cardiomyopathie","hartrevalidatie","laminopathie","ouderen","secundaire-preventie","slaapapneu"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064189","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064189","authors":["David J T Campbell","Marcello Tonelli","Brenda R Hemmelgarn","Peter Faris","Jianguo Zhang","Flora Au","Ross T Tsuyuki","Chad Mitchell","Raj Pannu","Tavis Campbell","Noah Ivers","Jane Fletcher","Derek V Exner","Braden J Manns"],"significance":5,"published":"2023-05-16","source_date":"2023-05-16","image":"","kennis":["https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This RCT showed that a self-management support intervention using advertising-derived engagement principles improves cardiovascular risk factors in older low-income adults at high cardiovascular risk.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"771b99c9e20c","type":"article","url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","title":"Implanteerbare hemodynamische monitoring bij hartfalen: meta-analyse over EF-spectrum","title_en":"Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfmref","hfpef","hfref","step-hfpef"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321885","source_url":"https://doi.org/10.1136/heartjnl-2022-321885","authors":["James P Curtain","Matthew M Y Lee","John Jv McMurray","Roy S Gardner","Mark C Petrie","Pardeep S Jhund"],"significance":7,"published":"2023-05-15","source_date":"2023-05-15","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This meta-analysis showed that implantable pulmonary artery pressure monitoring reduces heart failure hospitalization across the full ejection fraction spectrum, including HFpEF, supporting hemodynamic-guided management regardless of LVEF.","created":"2026-07-03T10:30:22Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e86cb1add68","type":"article","url":"https://hartvaat.nl/2023/05/14/prehospitale-troponine-voor-uitsluiting-nste-acs-gerandomiseerde-trial/","title":"Prehospitale troponine voor uitsluiting NSTE-ACS: gerandomiseerde trial","title_en":"Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad056","source_url":"https://doi.org/10.1093/eurheartj/ehad056","authors":["Cyril Camaro","Goaris W A Aarts","Eddy M M Adang","Roger van Hout","Gijs Brok","Anouk Hoare","Laura Rodwell","Frank de Pooter","Walter de Wit","Gilbert E Cramer","Roland R J van Kimmenade","Peter Damman","Eva Ouwendijk","Martijn Rutten","Erwin Zegers","Robert-Jan M van Geuns","Marc E R Gomes","Niels van Royen"],"significance":7,"published":"2023-05-14","source_date":"2023-05-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-acs-2023/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"This trial explored whether a single prehospital troponin measurement can safely rule out NSTE-ACS in the ambulance setting, potentially enabling faster triage and reducing unnecessary emergency department transfers.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a4f52f38ad6b","type":"article","url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","title":"2023 ACC Expert Consensus: management van HFpEF","title_en":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.03.393","source_url":"https://doi.org/10.1016/j.jacc.2023.03.393","authors":["Michelle M Kittleson","Gurusher S Panjrath","Kaushik Amancherla","Leslie L Davis","Anita Deswal","Dave L Dixon","James L Januzzi","Clyde W Yancy"],"significance":8,"published":"2023-05-09","source_date":"2023-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"The 2023 ACC Expert Consensus provided a structured decision pathway for HFpEF management, positioning SGLT2 inhibitors as a cornerstone therapy alongside diuretics for volume management, GLP-1 receptor agonists for obesity, and targeted treatment of comorbidities.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16e817f232dc","type":"article","url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","title":"RENOVATE-COMPLEX-PCI: intravasculaire beeldvorming versus angiografie bij complexe PCI","title_en":"Intravascular Imaging-Guided or Angiography-Guided Complex PCI.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2216607","source_url":"https://doi.org/10.1056/NEJMoa2216607","authors":["Joo Myung Lee","Ki Hong Choi","Young Bin Song","Jong-Young Lee","Seung-Jae Lee","Sang Yeub Lee","Sang Min Kim","Kyeong Ho Yun","Jae Young Cho","Chan Joon Kim","Hyo-Suk Ahn","Chang-Wook Nam","Hyuck-Jun Yoon","Yong Hwan Park","Wang Soo Lee","Jin-Ok Jeong","Pil Sang Song","Joon-Hyung Doh","Sang-Ho Jo","Chang-Hwan Yoon","Min Gyu Kang","Jin-Sin Koh","Kwan Yong Lee","Young-Hyo Lim","Yun-Hyeong Cho","Jin-Man Cho","Woo Jin Jang","Kook-Jin Chun","David Hong","Taek Kyu Park","Jeong Hoon Yang","Seung-Hyuk Choi","Hyeon-Cheol Gwon","Joo-Yong Hahn"],"significance":9,"published":"2023-05-04","source_date":"2023-05-04","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/intravasculaire-echografie-ivus-oct/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"The RENOVATE-COMPLEX-PCI trial showed that intravascular imaging-guided PCI (using IVUS or OCT) significantly reduced the composite of cardiac death, MI, or revascularization compared with angiography-guided PCI in patients with complex coronary lesions. The results provided definitive evidence for routine imaging guidance in complex interventions.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3ee4b008b12","type":"article","url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","title":"Korte versus standaard DAPT na PCI met moderne DES: meta-analyse","title_en":"Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064264","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064264","authors":["Jung-Kyu Han","Doyeon Hwang","Seokhun Yang","Sang-Hyeon Park","Jeehoon Kang","Han-Mo Yang","Kyung Woo Park","Hyun-Jae Kang","Bon-Kwon Koo","Seung-Ho Hur","Weon Kim","Seok Yeon Kim","Sang-Hyun Park","Seung Hwan Han","Sang-Hyun Kim","Sanghoon Shin","Yong Hoon Kim","Kyungil Park","Namho Lee","Seung Jin Lee","Jin Won Kim","Hyo-Soo Kim"],"significance":7,"published":"2023-05-02","source_date":"2023-05-02","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This meta-analysis of contemporary drug-eluting stents confirmed that 3-6 months of DAPT is as safe as 12 months for ischemic outcomes while reducing bleeding, supporting shortened antiplatelet duration with third-generation DES technology.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"60f7a1ebf553","type":"article","url":"https://hartvaat.nl/2023/05/02/gepersonaliseerde-beslisondersteuning-verhoogt-statinegebruik-bij-ascvd/","title":"Gepersonaliseerde beslisondersteuning verhoogt statinegebruik bij ASCVD","title_en":"Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":["stress-psychosociaal","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.064226","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.064226","authors":["Salim S Virani","David J Ramsey","Dax Westerman","Mark K Kuebeler","Liang Chen","Julia M Akeroyd","Glenn T Gobbel","Christie M Ballantyne","Laura A Petersen","Alexander Turchin","Michael E Matheny"],"significance":6,"published":"2023-05-02","source_date":"2023-05-02","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/dyslipidemie-overzicht/"],"congress":"","summary_en":"This cluster-randomized trial showed that personalized clinical decision support significantly increases statin prescribing in patients with established ASCVD, demonstrating the effectiveness of AI-assisted prescribing prompts.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"650f7a1be27b","type":"article","url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","title":"AWARE: uitgebreide ablatie vermindert AF-recidief niet boven standaard PVI","title_en":"Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.0212","source_url":"https://doi.org/10.1001/jamacardio.2023.0212","authors":["Girish M Nair","David H Birnie","Pablo B Nery","Calum J Redpath","Jean-Francois Sarrazin","Jean-Francois Roux","Ratika Parkash","Martin Bernier","Laurence D Sterns","John Sapp","Paul Novak","George Veenhuyzen","Carlos A Morillo","Sheldon M Singh","Mouhannad M Sadek","Mehrdad Golian","Andres Klein","Marcio Sturmer","Vijay S Chauhan","Paul Angaran","Martin S Green","Jordan Bernick","George A Wells","Vidal Essebag"],"significance":7,"published":"2023-05-01","source_date":"2023-05-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The AWARE trial showed that augmented ablation (PVI plus posterior wall and septum isolation) was not superior to standard PVI for reducing AF recurrence in paroxysmal AF, arguing against routine extensive ablation beyond pulmonary vein isolation.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d929bf99f45","type":"article","url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","title":"Cardiale biomarkers en CV-events bij diabetes: DECLARE-TIMI 58 subanalyse","title_en":"Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-2","nt-probnp","soul-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.0019","source_url":"https://doi.org/10.1001/jamacardio.2023.0019","authors":["Thomas A Zelniker","Stephen D Wiviott","Ofri Mosenzon","Erica L Goodrich","Petr Jarolim","Avivit Cahn","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John Wilding","Oleg Averkov","Andrzej Budaj","Alexander Parkhomenko","Kausik K Ray","Ingrid Gause-Nilsson","Anna Maria Langkilde","Martin Fredriksson","Itamar Raz","Marc S Sabatine","David A Morrow"],"significance":6,"published":"2023-05-01","source_date":"2023-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"This analysis showed that NT-proBNP and troponin levels predict both cardiovascular risk and treatment response to dapagliflozin in high-risk diabetic patients, supporting biomarker-guided patient selection for SGLT2 inhibitor therapy.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b26934403cd3","type":"article","url":"https://hartvaat.nl/2023/05/01/dyslipidemie-en-pre-eclampsierisico-mendeliaanse-randomisatie/","title":"Dyslipidemie en pre-eclampsierisico: Mendeliaanse randomisatie","title_en":"Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20426","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20426","authors":["Hillary Hosier","Heather S Lipkind","Humaira Rasheed","Andrew T DeWan","Tormod Rogne"],"significance":6,"published":"2023-05-01","source_date":"2023-05-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This Mendelian randomization study suggested a causal link between genetically determined dyslipidemia (particularly elevated LDL) and preeclampsia risk, identifying lipid metabolism as a potential modifiable pathway in pregnancy hypertension.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"76f023231f95","type":"article","url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","title":"MK-0616: eerste orale PCSK9-remmer in fase 2b","title_en":"Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["enlicitide","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.02.018","source_url":"https://doi.org/10.1016/j.jacc.2023.02.018","authors":["Christie M Ballantyne","Puja Banka","Gustavo Mendez","Raymundo Garcia","Julio Rosenstock","Anthony Rodgers","Geraldine Mendizabal","Yale Mitchel","Alberico L Catapano"],"significance":9,"published":"2023-04-25","source_date":"2023-04-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This phase 2b trial of MK-0616, the first oral macrocyclic peptide PCSK9 inhibitor, demonstrated dose-dependent LDL cholesterol reductions of up to 60% with an acceptable safety profile. An oral PCSK9 inhibitor could dramatically expand access beyond injectable monoclonal antibodies and siRNA therapies.","created":"2026-07-03T10:30:21Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e12b14fad259","type":"article","url":"https://hartvaat.nl/2023/04/21/cardiometabole-gezondheid-bij-kinderen-geboren-na-ivf/","title":"Cardiometabole gezondheid bij kinderen geboren na IVF","title_en":"Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["diabetes-en-hart","farmaco-economie","gepersonaliseerde-geneeskunde","hartrevalidatie","menopauze","obesitas","ouderen","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac726","source_url":"https://doi.org/10.1093/eurheartj/ehac726","authors":["Ahmed Elhakeem","Amy E Taylor","Hazel M Inskip","Jonathan Y Huang","Toby Mansell","Carina Rodrigues","Federica Asta","Sophia M Blaauwendraad","Siri E Håberg","Jane Halliday","Margreet W Harskamp-van Ginkel","Jian-Rong He","Vincent W V Jaddoe","Sharon Lewis","Gillian M Maher","Yannis Manios","Fergus P McCarthy","Irwin K M Reiss","Franca Rusconi","Theodosia Salika","Muriel Tafflet","Xiu Qiu","Bjørn O Åsvold","David Burgner","Jerry K Y Chan","Luigi Gagliardi","Romy Gaillard","Barbara Heude","Maria C Magnus","George Moschonis","Deirdre Murray","Scott M Nelson","Daniela Porta","Richard Saffery","Henrique Barros","Johan G Eriksson","Tanja G M Vrijkotte","Deborah A Lawlor"],"significance":5,"published":"2023-04-21","source_date":"2023-04-21","image":"","kennis":[],"congress":"","summary_en":"This multi-cohort analysis showed that children born after assisted reproductive technology have a slightly less favorable cardiometabolic profile compared with naturally conceived children, warranting long-term cardiovascular follow-up.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"360bc73b27eb","type":"article","url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","title":"STELLAR: sotatercept bij pulmonale arteriële hypertensie — NEJM fase 3","title_en":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2213558","source_url":"https://doi.org/10.1056/NEJMoa2213558","authors":["Marius M Hoeper","David B Badesch","H Ardeschir Ghofrani","J Simon R Gibbs","Mardi Gomberg-Maitland","Vallerie V McLaughlin","Ioana R Preston","Rogerio Souza","Aaron B Waxman","Ekkehard Grünig","Grzegorz Kopeć","Gisela Meyer","Karen M Olsson","Stephan Rosenkranz","Yayun Xu","Barry Miller","Marcie Fowler","John Butler","Joerg Koglin","Janethe de Oliveira Pena","Marc Humbert"],"significance":10,"published":"2023-04-20","source_date":"2023-04-20","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"The STELLAR trial demonstrated that sotatercept, a first-in-class activin receptor fusion protein, dramatically improved exercise capacity, hemodynamics, and WHO functional class in patients with pulmonary arterial hypertension on background therapy. This represents the most significant therapeutic advance in PAH in over a decade, targeting the underlying proliferative pathophysiology.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f4af1440869","type":"article","url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","title":"AHA Scientific Statement: gestructureerde inspanningstraining bij HFpEF","title_en":"Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.02.012","source_url":"https://doi.org/10.1016/j.jacc.2023.02.012","authors":["Vandana Sachdev","Kavita Sharma","Steven J Keteyian","Charina F Alcain","Patrice Desvigne-Nickens","Jerome L Fleg","Viorel G Florea","Barry A Franklin","Maya Guglin","Martin Halle","Eric S Leifer","Gurusher Panjrath","Emily A Tinsley","Renee P Wong","Dalane W Kitzman"],"significance":7,"published":"2023-04-18","source_date":"2023-04-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This AHA scientific statement reviewed the evidence for supervised exercise training in HFpEF, confirming it as the only proven intervention to improve exercise capacity in this population and providing practical implementation guidance.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b27ffd8ed35a","type":"article","url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","title":"Gecoördineerde zorg optimaliseert CV-preventie bij type 2 diabetes: JAMA RCT","title_en":"Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","primaire-preventie","select-trial","soul-trial"],"journal":"JAMA","doi":"10.1001/jama.2023.2854","source_url":"https://doi.org/10.1001/jama.2023.2854","authors":["Neha J Pagidipati","Adam J Nelson","Lisa A Kaltenbach","Monica Leyva","Darren K McGuire","Rodica Pop-Busui","Matthew A Cavender","Vanita R Aroda","Melissa L Magwire","Caroline R Richardson","Ildiko Lingvay","Julienne K Kirk","Hussein R Al-Khalidi","Laura Webb","Tanya Gaynor","Jonathan Pak","Cagri Senyucel","Renato D Lopes","Jennifer B Green","Christopher B Granger"],"significance":7,"published":"2023-04-18","source_date":"2023-04-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This JAMA trial demonstrated that coordinated, multidisciplinary care significantly increases the use of evidence-based cardiovascular preventive therapies in patients with type 2 diabetes, translating guideline recommendations into clinical practice.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6574b98379b1","type":"article","url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","title":"Optimaal bereikt LDL-cholesterol en langetermijn CV-uitkomsten: FOURIER analyse","title_en":"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","cetp-remmers","diabetes-en-hart","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","hdl-cholesterol","ldl-cholesterol","lipidenverlaging","pcsk9-remmers","pelacarsen","plaquekarakterisatie","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063399","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063399","authors":["Prakriti Gaba","Michelle L O'Donoghue","Jeong-Gun Park","Stephen D Wiviott","Dan Atar","Julia F Kuder","KyungAh Im","Sabina A Murphy","Gaetano M De Ferrari","Zbigniew A Gaciong","Kalman Toth","Ioanna Gouni-Berthold","Jose Lopez-Miranda","François Schiele","François Mach","Jose H Flores-Arredondo","J Antonio G López","Mary Elliott-Davey","Bei Wang","Maria Laura Monsalvo","Siddique Abbasi","Robert P Giugliano","Marc S Sabatine"],"significance":8,"published":"2023-04-18","source_date":"2023-04-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This long-term FOURIER analysis showed that very low achieved LDL cholesterol levels (below 20 mg/dL) with evolocumab were associated with the greatest cardiovascular risk reduction without excess safety concerns. The data supported pushing LDL targets as low as achievable.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"52e750db0ae4","type":"article","url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","title":"DAPT de-escalatie na ACS: IPD meta-analyse","title_en":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["dubbele-trombocytenremming"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac829","source_url":"https://doi.org/10.1093/eurheartj/ehac829","authors":["Jeehoon Kang","Konstantinos D Rizas","Kyung Woo Park","Jaewook Chung","Wout van den Broek","Daniel M F Claassens","Eun Ho Choo","Dániel Aradi","Steffen Massberg","Doyeon Hwang","Jung-Kyu Han","Han-Mo Yang","Hyun-Jae Kang","Kiyuk Chang","Jur M Ten Berg","Dirk Sibbing","Bon-Kwon Koo","Hyo-Soo Kim"],"significance":8,"published":"2023-04-17","source_date":"2023-04-17","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/farmacologie/p2y12-remmers-vergelijking/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that de-escalation from potent P2Y12 inhibitors to clopidogrel after the acute phase of ACS safely reduces bleeding without increasing ischemic events. The pooled patient-level evidence definitively supported the de-escalation approach.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"930953017d9e","type":"article","url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","title":"In-stent restenose: tienjaarsuitkomsten plain balloon vs DCB vs DES — ISAR-DESIRE 3","title_en":"Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad026","source_url":"https://doi.org/10.1093/eurheartj/ehad026","authors":["Daniele Giacoppo","Hector A Alvarez-Covarrubias","Tobias Koch","Salvatore Cassese","Erion Xhepa","Thorsten Kessler","Jens Wiebe","Michael Joner","Willibald Hochholzer","Karl-Ludwig Laugwitz","Heribert Schunkert","Adnan Kastrati","Sebastian Kufner"],"significance":6,"published":"2023-04-17","source_date":"2023-04-17","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"Ten-year ISAR-DESIRE 3 results showed that drug-eluting stents remain superior to drug-coated balloons and plain balloons for treating DES in-stent restenosis, providing the longest-term comparative data for this common PCI challenge.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ff40fd709b69","type":"article","url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","title":"Inflammatie en cholesterol als CV-voorspellers onder statinetherapie: Lancet analyse","title_en":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","hdl-cholesterol","hs-crp","inflammatie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","rosuvastatine","statines"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00215-5","source_url":"https://doi.org/10.1016/S0140-6736(23)00215-5","authors":["Paul M Ridker","Deepak L Bhatt","Aruna D Pradhan","Robert J Glynn","Jean G MacFadyen","Steven E Nissen"],"significance":8,"published":"2023-04-15","source_date":"2023-04-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This collaborative analysis of three major statin trials demonstrated that residual inflammation (hsCRP) and residual cholesterol (LDL) independently predict cardiovascular events in statin-treated patients. Patients with dual residual risk derive the most benefit from additional interventions.","created":"2026-07-03T10:30:20Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a22bd59b1f37","type":"article","url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","title":"CLEAR Outcomes: bempedoïnezuur vermindert CV-events bij statine-intolerantie","title_en":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","clear-outcomes","niet-statine-therapie","rosuvastatine","statines","trombocytenaggregatieremmers"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2215024","source_url":"https://doi.org/10.1056/NEJMoa2215024","authors":["Steven E Nissen","A Michael Lincoff","Danielle Brennan","Kausik K Ray","Denise Mason","John J P Kastelein","Paul D Thompson","Peter Libby","Leslie Cho","Jorge Plutzky","Harold E Bays","Patrick M Moriarty","Venu Menon","Diederick E Grobbee","Michael J Louie","Chien-Feng Chen","Na Li","LeAnne Bloedon","Paula Robinson","Maggie Horner","William J Sasiela","Jackie McCluskey","Deborah Davey","Pedro Fajardo-Campos","Predrag Petrovic","Jan Fedacko","Witold Zmuda","Yury Lukyanov","Stephen J Nicholls"],"significance":10,"published":"2023-04-13","source_date":"2023-04-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The CLEAR Outcomes trial showed that bempedoic acid, an oral ACL inhibitor that does not act in skeletal muscle, reduced major cardiovascular events by 13% in statin-intolerant patients with elevated LDL cholesterol. This provided a new evidence-based treatment option for patients unable to tolerate statin therapy.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8156d3b0f255","type":"article","url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","title":"Heterogeniteit in bloeddrukrespons op antihypertensiva: JAMA cross-over RCT","title_en":"Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lorundrostat","precision-trial"],"journal":"JAMA","doi":"10.1001/jama.2023.3322","source_url":"https://doi.org/10.1001/jama.2023.3322","authors":["Johan Sundström","Lars Lind","Shamim Nowrouzi","Emil Hagström","Claes Held","Per Lytsy","Bruce Neal","Kerstin Marttala","Ollie Östlund"],"significance":9,"published":"2023-04-11","source_date":"2023-04-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/"],"congress":"","summary_en":"This randomized crossover trial revealed substantial individual heterogeneity in blood pressure response to four different antihypertensive drug classes, with rotation of medications identifying the best-responding agent for each patient. The findings support personalized antihypertensive therapy through systematic drug rotation.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7121427a8690","type":"article","url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","title":"Matige statine plus ezetimibe bij ouderen met atherosclerose: JACC-studie","title_en":"Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["ezetimibe","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.02.007","source_url":"https://doi.org/10.1016/j.jacc.2023.02.007","authors":["Sang-Hyup Lee","Yong-Joon Lee","Jung Ho Heo","Seung-Ho Hur","Hyun Hee Choi","Kyung-Jin Kim","Ju Han Kim","Keun-Ho Park","Jung Hee Lee","Yu Jeong Choi","Seung-Jun Lee","Sung-Jin Hong","Chul-Min Ahn","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Jung-Sun Kim"],"significance":7,"published":"2023-04-11","source_date":"2023-04-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This study confirmed that moderate-intensity statin combined with ezetimibe provides comparable cardiovascular protection to high-intensity statin monotherapy in elderly patients with atherosclerosis, offering a better-tolerated alternative.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"526ae00102dc","type":"article","url":"https://hartvaat.nl/2023/04/11/ambulante-beslisondersteuning-verbetert-mra-voorschrijving-bij-hfref/","title":"Ambulante beslisondersteuning verbetert MRA-voorschrijving bij HFrEF","title_en":"Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["mra-aldosteronantagonisten"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.02.005","source_url":"https://doi.org/10.1016/j.jacc.2023.02.005","authors":["Amrita Mukhopadhyay","Harmony R Reynolds","Lawrence M Phillips","Arielle R Nagler","William C King","Adam Szerencsy","Archana Saxena","Rod Aminian","Nathan Klapheke","Leora I Horwitz","Stuart D Katz","Saul Blecker"],"significance":6,"published":"2023-04-11","source_date":"2023-04-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/mra-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This cluster-randomized trial showed that ambulatory clinical decision support tools significantly increase MRA prescribing in HFrEF, demonstrating that automated prompts can overcome treatment inertia for underused heart failure medications.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e1466a67e21","type":"article","url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","title":"BIOVASC: directe versus gestageerde complete revascularisatie bij ACS met meervatslijden","title_en":"Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(23)00351-3","source_url":"https://doi.org/10.1016/S0140-6736(23)00351-3","authors":["Roberto Diletti","Wijnand K den Dekker","Johan Bennett","Carl E Schotborgh","Rene van der Schaaf","Manel Sabaté","Raúl Moreno","Koen Ameloot","Rutger van Bommel","Daniele Forlani","Bert van Reet","Giovanni Esposito","Maurits T Dirksen","Willem P T Ruifrok","Bert R C Everaert","Carlos Van Mieghem","Jacob J Elscot","Paul Cummins","Mattie Lenzen","Salvatore Brugaletta","Eric Boersma","Nicolas M Van Mieghem"],"significance":8,"published":"2023-04-08","source_date":"2023-04-08","image":"","kennis":[],"congress":"","summary_en":"The BIOVASC trial showed that immediate complete revascularization during the index procedure was noninferior to staged complete PCI in patients with ACS and multivessel coronary disease, with similar rates of the composite primary endpoint at 1 year.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7162a8c0155f","type":"article","url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","title":"LODESTAR: treat-to-target versus hoge-dosis statine bij coronairlijden","title_en":"Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bloeddrukbehandeling","ezetimibe","lipidenverlaging","niet-statine-therapie","rosuvastatine","statines"],"journal":"JAMA","doi":"10.1001/jama.2023.2487","source_url":"https://doi.org/10.1001/jama.2023.2487","authors":["Sung-Jin Hong","Yong-Joon Lee","Seung-Jun Lee","Bum-Kee Hong","Woong Chol Kang","Jong-Young Lee","Jin-Bae Lee","Tae-Hyun Yang","Junghan Yoon","Chul-Min Ahn","Jung-Sun Kim","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Yangsoo Jang","Myeong-Ki Hong"],"significance":8,"published":"2023-04-04","source_date":"2023-04-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The LODESTAR trial showed that a treat-to-target approach (targeting LDL <70 mg/dL with dose adjustment) was noninferior to fixed high-intensity statin therapy for cardiovascular outcomes in patients with coronary artery disease. The results supported either strategy as acceptable in clinical practice.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62362b737160","type":"article","url":"https://hartvaat.nl/2023/04/04/genetisch-risico-op-primair-aldosteronisme-en-bijdrage-aan-hypertensie-gwas-meta/","title":"Genetisch risico op primair aldosteronisme en bijdrage aan hypertensie: GWAS meta-analyse","title_en":"Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["gepersonaliseerde-geneeskunde","lorundrostat","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062349","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062349","authors":["Tatsuhiko Naito","Kosuke Inoue","Kyuto Sonehara","Ryuta Baba","Takaya Kodama","Yu Otagaki","Akira Okada","Kiyotaka Itcho","Kazuhiro Kobuke","Shinji Kishimoto","Kenichi Yamamoto","Takayuki Morisaki","Yukihito Higashi","Nobuyuki Hinata","Koji Arihiro","Noboru Hattori","Yukinori Okada","Kenji Oki"],"significance":7,"published":"2023-04-04","source_date":"2023-04-04","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This cross-ancestry GWAS meta-analysis identified genetic loci for primary aldosteronism and quantified their contribution to hypertension, establishing the genetic architecture of this common form of secondary hypertension.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3605d57b0302","type":"article","url":"https://hartvaat.nl/2023/04/01/parable-sacubitril-valsartan-vermindert-linkeratriumvolume-bij-pre-hfpef/","title":"PARABLE: sacubitril/valsartan vermindert linkeratriumvolume bij pre-HFpEF","title_en":"Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","bloeddrukbehandeling","hfpef","hfref","sacubitril-valsartan","step-hfpef","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2023.0065","source_url":"https://doi.org/10.1001/jamacardio.2023.0065","authors":["Mark Ledwidge","Jonathan D Dodd","Fiona Ryan","Claire Sweeney","Katherine McDonald","Rebecca Fox","Elizabeth Shorten","Shuaiwei Zhou","Chris Watson","Joseph Gallagher","Niall McVeigh","David J Murphy","Kenneth McDonald"],"significance":7,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"The PARABLE trial showed that sacubitril-valsartan reduces left atrial volume in patients with pre-HFpEF compared with valsartan, suggesting potential for early intervention to prevent the structural atrial changes that characterize established HFpEF.","created":"2026-07-03T10:30:19Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b15a05cb034e","type":"article","url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","title":"Dapagliflozine verlaagt urinezuur en vermindert jichtaanvallen bij hartfalen","title_en":"Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["bisoprolol","canagliflozine","dapagliflozine","empagliflozine","emperor-trials","sglt2-remmers"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.5608","source_url":"https://doi.org/10.1001/jamacardio.2022.5608","authors":["Jawad H Butt","Kieran F Docherty","Brian L Claggett","Akshay S Desai","Magnus Petersson","Anna Maria Langkilde","Rudolf A de Boer","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Lars Køber","Carolyn S P Lam","Felipe A Martinez","Piotr Ponikowski","Marc S Sabatine","Sanjiv J Shah","Muthiah Vaduganathan","Pardeep S Jhund","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This analysis showed that dapagliflozin reduces uric acid levels and decreases the need for uric acid-lowering therapy and colchicine in heart failure patients, demonstrating an anti-gout co-benefit of SGLT2 inhibition.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T13:29:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5c6030a07aa","type":"article","url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","title":"Lichaamshouding en orthostatische hypotensie bij hypertensie: Syst-Eur analyse","title_en":"Body Position and Orthostatic Hypotension in Hypertensive Adults: Results from the Syst-Eur Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","summit-trial","supraventriculaire-tachycardie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20602","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20602","authors":["Ben Grobman","Ruth-Alma N Turkson-Ocran","Jan A Staessen","Yu-Ling Yu","Lewis A Lipsitz","Kenneth J Mukamal","Stephen P Juraschek"],"significance":5,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/albumine-creatinine-ratio/"],"congress":"","summary_en":"This Syst-Eur analysis showed that orthostatic hypotension measurement results depend on the starting position (seated vs supine), informing the standardization of OH assessment in hypertensive patients.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ff97b2b0c815","type":"article","url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","title":"Intraveneus ijzer bij hartfalen: meta-analyse op studieniveau","title_en":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","ijzersuppletie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14310","source_url":"https://doi.org/10.1002/ehf2.14310","authors":["Husam M Salah","Gianluigi Savarese","Giuseppe M C Rosano","Andrew P Ambrosy","Robert J Mentz","Marat Fudim"],"significance":7,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This study-level meta-analysis confirmed that intravenous iron in heart failure with iron deficiency reduces the risk of heart failure hospitalization, with the strongest evidence from the largest trials (AFFIRM-AHF, IRONMAN).","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T18:39:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efb6dea7f6cf","type":"article","url":"https://hartvaat.nl/2023/04/01/sglt2-remmers-raas-remmers-en-arni-vergeleken-bij-hartfalen-meta-analyse/","title":"SGLT2-remmers, RAAS-remmers en ARNI vergeleken bij hartfalen: meta-analyse","title_en":"The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","ace-remmers","acuut-hartfalen","biomarkers-cardiovasculair","canagliflozine","cardio-renaal-metabool","cardiorenal-behandelstrategie","dapagliflozine","empagliflozine","ezetimibe","fidelity","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","microbioom","pcsk9-remmers","ras-remmers","sglt2-remmers","statines","supraventriculaire-tachycardie","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14298","source_url":"https://doi.org/10.1002/ehf2.14298","authors":["Peng-Juan Ji","Zhuo-Ya Zhang","Qi Yan","Hui-Li Cao","Ya-Jing Zhao","Bin Yang","Jin Li"],"significance":7,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This comprehensive meta-analysis compared the cardiovascular effects of SGLT2 inhibitors, RAAS inhibitors, and sacubitril-valsartan (ARNI) in heart failure, finding that all three drug classes contribute to the contemporary quadruple therapy framework.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd9ad29e4abe","type":"article","url":"https://hartvaat.nl/2023/04/01/indirecte-vergelijking-van-sglt2-remmers-bij-hartfalen-bayesiaanse-analyse/","title":"Indirecte vergelijking van SGLT2-remmers bij hartfalen: Bayesiaanse analyse","title_en":"Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","empagliflozine","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14297","source_url":"https://doi.org/10.1002/ehf2.14297","authors":["Hai-Bin Chen","Yao-Lin Yang","Rong-Sen Meng","Xue-Wei Liu"],"significance":7,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This Bayesian network meta-analysis found no significant differences between individual SGLT2 inhibitors (empagliflozin, dapagliflozin, sotagliflozin) for heart failure outcomes, supporting a class effect without meaningful agent-level superiority.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T13:29:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f188895328c3","type":"article","url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","title":"Mesenchymale stamcellen bij ischemisch hartfalen: Deense fase II trial","title_en":"Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14281","source_url":"https://doi.org/10.1002/ehf2.14281","authors":["Abbas Ali Qayyum","Mette Mouridsen","Brian Nilsson","Ida Gustafsson","Morten Schou","Olav Wendelboe Nielsen","Jens Dahlgaard Hove","Anders Bruun Mathiasen","Erik Jørgensen","Steffen Helqvist","Francis Richard Joshi","Ellen Mønsted Johansen","Bjarke Follin","Morten Juhl","Lisbeth Drozd Højgaard","Mandana Haack-Sørensen","Annette Ekblond","Jens Kastrup"],"significance":5,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"This Danish phase II trial of adipose tissue-derived mesenchymal stromal cells in ischemic HFrEF showed safety but no significant improvement in LV function, adding to the neutral stem cell therapy evidence.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T13:29:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb30044a33d1","type":"article","url":"https://hartvaat.nl/2023/04/01/aspirine-in-primaire-preventie-en-hartfalenrisico-meta-analyse/","title":"Aspirine in primaire preventie en hartfalenrisico: meta-analyse","title_en":"Aspirin in primary prevention and the risk of heart failure: a systematic review and meta-analysis of controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["aspirine","primaire-preventie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14269","source_url":"https://doi.org/10.1002/ehf2.14269","authors":["Ana Beatrice Magalhães de Oliveira","Beatriz Luchiari","Isabella Bonilha","Joaquim Barreto","Ana Claudia Cavalcante Nogueira","Guilherme Duprat Ceniccola","Carisi Anne Polanczyk","Andrei Carvalho Sposito","Luiz Sérgio Fernandes de Carvalho"],"significance":5,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis found that aspirin in primary prevention does not significantly increase or decrease the risk of heart failure, clarifying a neutral relationship between aspirin and HF development.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T13:29:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e0cd3e01b35f","type":"article","url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","title":"Natriumzirconiumcyclosilicaat bij hyperkaliëmie en hartfalen","title_en":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14268","source_url":"https://doi.org/10.1002/ehf2.14268","authors":["Jean-Claude Tardif","Jean Rouleau","Glenn M Chertow","Ayman Al-Shurbaji","Vera Lisovskaja","Stephanie Gustavson","Yanli Zhao","Nadia Bouabdallaoui","Akshay S Desai","Alexander Chernyavskiy","Maria Evsina","Béla Merkely","John J V McMurray","Marc A Pfeffer"],"significance":6,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This study showed that sodium zirconium cyclosilicate effectively lowers potassium in HFrEF patients, enabling higher RAAS inhibitor and MRA doses, addressing the hyperkalemia barrier to optimal heart failure pharmacotherapy.","created":"2026-07-03T10:30:18Z","updated":"2026-07-03T13:29:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"682f3a5b703c","type":"article","url":"https://hartvaat.nl/2023/04/01/multicomponent-geintegreerde-zorg-bij-chronisch-hartfalen-meta-analyse/","title":"Multicomponent geïntegreerde zorg bij chronisch hartfalen: meta-analyse","title_en":"Multicomponent integrated care for patients with chronic heart failure: systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","hfref","ivabradine","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14207","source_url":"https://doi.org/10.1002/ehf2.14207","authors":["Ya-Feng Yang","Jia-Xin Hoo","Jia-Yin Tan","Lee-Ling Lim"],"significance":6,"published":"2023-04-01","source_date":"2023-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis confirmed that multicomponent integrated care programs improve clinical outcomes in chronic heart failure, supporting comprehensive disease management over isolated pharmacological or device interventions.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7885bb306df3","type":"article","url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","title":"Ablatie versus antiaritmica voor vermindering van ziekenhuisbezoeken bij AF","title_en":"Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac253","source_url":"https://doi.org/10.1093/europace/euac253","authors":["Prapa Kanagaratnam","James McCready","Muzahir Tayebjee","Ewen Shepherd","Thiagarajah Sasikaran","Derick Todd","Nicholas Johnson","Andreas Kyriacou","Sajad Hayat","Neil A Hobson","Ian Mann","Richard Balasubramaniam","Zachary Whinnett","Mark Earley","Sanjiv Petkar","Rick Veasey","Senthil Kirubakaran","Clare Coyle","Min-Young Kim","Phang Boon Lim","James O'Neill","D Wyn Davies","Nicholas S Peters","Daphne Babalis","Nicholas Linton","Emanuela Falaschetti","Mark Tanner","Jaymin Shah","Neil Poulter"],"significance":7,"published":"2023-03-30","source_date":"2023-03-30","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This prospective randomized trial demonstrated that catheter ablation significantly reduces total AF-related hospital episodes compared with antiarrhythmic drug therapy, providing health economic data beyond traditional clinical endpoints.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T13:29:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5ff68dfd0eb","type":"article","url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","title":"Biatriale tachycardieën: ablatiestrategie en linkeratriale epicardiale geleiding","title_en":"Revisiting the characteristics and ablation strategy of biatrial tachycardias: a case series and systematic review.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aritmogene-cardiomyopathie","bradycardie","cardiale-resynchronisatie","cardiogene-shock","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","pulsed-field-ablatie-atriumfibrilleren","supraventriculaire-tachycardie","takotsubo","ventriculaire-tachycardie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac231","source_url":"https://doi.org/10.1093/europace/euac231","authors":["Yiwei Lai","Qi Guo","Caihua Sang","Mingyang Gao","Lihong Huang","Song Zuo","Zhibing Lu","Chenxi Jiang","Songnan Li","Xueyuan Guo","Wei Wang","Nian Liu","Changyi Li","Xiaoxia Liu","Xin Zhao","Ribo Tang","Deyong Long","Xin Du","Jianzeng Dong","Changsheng Ma"],"significance":5,"published":"2023-03-30","source_date":"2023-03-30","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This study and systematic review described the role of left atrial epicardial conduction in biatrial tachycardias, providing ablation strategy guidance for this complex arrhythmia mechanism.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"415a5bee8ecf","type":"article","url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","title":"Upgrade van RV-pacemaker naar CRT of geleidingssysteempacing: meta-analyse","title_en":"Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","linkerbundeltakpacing"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac188","source_url":"https://doi.org/10.1093/europace/euac188","authors":["Nandita Kaza","Varanand Htun","Alejandra Miyazawa","Florentina Simader","Bradley Porter","James P Howard","Ahran D Arnold","Akriti Naraen","David Luria","Michael Glikson","Carsten Israel","Darrel P Francis","Zachary I Whinnett","Matthew J Shun-Shin","Daniel Keene"],"significance":7,"published":"2023-03-30","source_date":"2023-03-30","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"This meta-analysis showed that upgrading right ventricular pacemakers to biventricular or conduction system pacing improves left ventricular function and clinical outcomes, supporting upgrade consideration in pacemaker-dependent patients with reduced LV function.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c02f865a587","type":"article","url":"https://hartvaat.nl/2023/03/28/secundaire-hypertensie-bij-kinderen-jama-klinische-diagnostiek/","title":"Secundaire hypertensie bij kinderen: JAMA klinische diagnostiek","title_en":"Does This Child With High Blood Pressure Have Secondary Hypertension?: The Rational Clinical Examination Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["vrouwen"],"journal":"JAMA","doi":"10.1001/jama.2023.3184","source_url":"https://doi.org/10.1001/jama.2023.3184","authors":["James T Nugent","Kuan Jiang","Melissa C Funaro","Ishan Saran","Chelsea Young","Lama Ghazi","Christine Y Bakhoum","F Perry Wilson","Jason H Greenberg"],"significance":6,"published":"2023-03-28","source_date":"2023-03-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/witte-jas-hypertensie/"],"congress":"","summary_en":"This JAMA systematic review identified clinical factors that predict secondary hypertension in children, providing a rational evaluation framework for the workup of pediatric blood pressure elevation.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d6013a09ee56","type":"article","url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","title":"Culprit-interventie bij cardiogene shock met hartstilstand","title_en":"Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock With Cardiac Arrest.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bradycardie","cardiogene-shock","myocardinfarct","percutane-coronaire-interventie","plotse-hartdood"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2023.01.029","source_url":"https://doi.org/10.1016/j.jacc.2023.01.029","authors":["Uwe Zeymer","Brunilda Alushi","Marko Noc","Mamas A Mamas","Gilles Montalescot","Georg Fuernau","Kurt Huber","Janine Poess","Suzanne de Waha-Thiele","Steffen Schneider","Taoufik Ouarrak","Steffen Desch","Alexander Lauten","Holger Thiele"],"significance":6,"published":"2023-03-28","source_date":"2023-03-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This analysis examined the role of culprit lesion intervention in cardiogenic shock complicated by cardiac arrest, showing that primary PCI remains beneficial even in the most critically ill resuscitated patients.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"129e18a8549c","type":"article","url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","title":"AMPLITUDE-O: dosisrespons van efpeglenatide op CV-uitkomsten bij diabetes","title_en":"Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","semaglutide","soul-trial","tirzepatide"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.063716","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.063716","authors":["Hertzel C Gerstein","Zhuoru Li","Chinthanie Ramasundarahettige","Seungjae Baek","Kelley R H Branch","Stefano Del Prato","Carolyn S P Lam","Renato D Lopes","Richard Pratley","Julio Rosenstock","Naveed Sattar"],"significance":6,"published":"2023-03-28","source_date":"2023-03-28","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This AMPLITUDE-O analysis explored the dose-response relationship between efpeglenatide and cardiovascular outcomes in type 2 diabetes, informing the optimal dosing of this GLP-1 receptor agonist for cardiovascular protection.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6f0aef042ed3","type":"article","url":"https://hartvaat.nl/2023/03/21/genetische-varianten-geassocieerd-met-syncope-neurale-en-autonome-processen/","title":"Genetische varianten geassocieerd met syncope: neurale en autonome processen","title_en":"Genetic variants associated with syncope implicate neural and autonomic processes.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":["gepersonaliseerde-geneeskunde","laminopathie","syncope","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad016","source_url":"https://doi.org/10.1093/eurheartj/ehad016","authors":["Hildur M Aegisdottir","Rosa B Thorolfsdottir","Gardar Sveinbjornsson","Olafur A Stefansson","Bjarni Gunnarsson","Vinicius Tragante","Gudmar Thorleifsson","Lilja Stefansdottir","Thorgeir E Thorgeirsson","Egil Ferkingstad","Patrick Sulem","Gudmundur Norddahl","Gudrun Rutsdottir","Karina Banasik","Alex Hoerby Christensen","Christina Mikkelsen","Ole Birger Pedersen","Søren Brunak","Mie Topholm Bruun","Christian Erikstrup","Rikke Louise Jacobsen","Kaspar Rene Nielsen","Erik Sørensen","Michael L Frigge","Kristjan E Hjorleifsson","Erna V Ivarsdottir","Anna Helgadottir","Solveig Gretarsdottir","Valgerdur Steinthorsdottir","Asmundur Oddsson","Hannes P Eggertsson","Gisli H Halldorsson","David A Jones","Jeffrey L Anderson","Kirk U Knowlton","Lincoln D Nadauld","Magnus Haraldsson","Gudmundur Thorgeirsson","Henning Bundgaard","David O Arnar","Unnur Thorsteinsdottir","Daniel F Gudbjartsson","Sisse R Ostrowski","Hilma Holm","Kari Stefansson"],"significance":6,"published":"2023-03-21","source_date":"2023-03-21","image":"","kennis":[],"congress":"","summary_en":"This GWAS identified genetic loci associated with syncope that implicate neural and autonomic nervous system pathways, providing the first genomic insights into the pathophysiology of this common clinical condition.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0712c47958b3","type":"article","url":"https://hartvaat.nl/2023/03/21/coronairangiografie-na-hartstilstand-zonder-stemi-netwerk-meta-analyse/","title":"Coronairangiografie na hartstilstand zonder STEMI: netwerk-meta-analyse","title_en":"Coronary angiography after cardiac arrest without ST-elevation myocardial infarction: a network meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["hartkatheterisatie","stabiel-coronairlijden"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac611","source_url":"https://doi.org/10.1093/eurheartj/ehac611","authors":["Sebastian Heyne","Sascha Macherey","Max M Meertens","Simon Braumann","Franz S Nießen","Tobias Tichelbäcker","Stephan Baldus","Christoph Adler","Samuel Lee"],"significance":7,"published":"2023-03-21","source_date":"2023-03-21","image":"","kennis":[],"congress":"","summary_en":"This network meta-analysis confirmed that early coronary angiography after cardiac arrest without STEMI provides no survival advantage over a selective, delayed approach, consistent with the COACT and TOMAHAWK trial results.","created":"2026-07-03T10:30:17Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"55231f8aaea6","type":"article","url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","title":"Intensieve bloeddrukinterventie door niet-artsen in lage-inkomenslanden: Lancet RCT","title_en":"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02603-4","source_url":"https://doi.org/10.1016/S0140-6736(22)02603-4","authors":["Jiang He","Nanxiang Ouyang","Xiaofan Guo","Guozhe Sun","Zhao Li","Jianjun Mu","Dao Wen Wang","Lixia Qiao","Liying Xing","Guocheng Ren","Chunxia Zhao","Ruihai Yang","Zuyi Yuan","Chang Wang","Chuning Shi","Songyue Liu","Wei Miao","Guangxiao Li","Chung-Shiuan Chen","Yingxian Sun"],"significance":8,"published":"2023-03-18","source_date":"2023-03-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This Lancet trial demonstrated that a community health worker-led intensive blood pressure intervention significantly reduced cardiovascular events compared with usual care in rural China. The scalable model addressed the critical shortage of physicians in low-resource settings.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b6974a43dd1","type":"article","url":"https://hartvaat.nl/2023/03/14/real-time-remote-monitoring-voorspelt-maligne-ventriculaire-aritmieen/","title":"Real-time remote monitoring voorspelt maligne ventriculaire aritmieën","title_en":"Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["icd-implantatie","plotse-hartdood","ventrikelfibrilleren"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.12.024","source_url":"https://doi.org/10.1016/j.jacc.2022.12.024","authors":["Curtis Ginder","Jin Li","Jonathan L Halperin","Joseph G Akar","David T Martin","Ishanu Chattopadhyay","Gaurav A Upadhyay"],"significance":6,"published":"2023-03-14","source_date":"2023-03-14","image":"","kennis":[],"congress":"","summary_en":"This study showed that real-time remote monitoring of ICD patients can predict malignant ventricular arrhythmias based on changes in heart rate, activity, and impedance parameters, advancing proactive rhythm management.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d6909be1716","type":"article","url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","title":"Matige statine plus ezetimibe versus hoge-dosis statine bij diabetes en ASCVD","title_en":"Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-type-2","ezetimibe","figaro-dkd","niet-statine-therapie","rosuvastatine","soul-trial","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac709","source_url":"https://doi.org/10.1093/eurheartj/ehac709","authors":["Yong-Joon Lee","Jae Young Cho","Seng Chan You","Yong-Ho Lee","Kyeong Ho Yun","Yun-Hyeong Cho","Won-Yong Shin","Sang Wook Im","Woong Chol Kang","Yongwhi Park","Sung Yoon Lee","Seung-Jun Lee","Sung-Jin Hong","Chul-Min Ahn","Byeong-Keuk Kim","Young-Guk Ko","Donghoon Choi","Myeong-Ki Hong","Yangsoo Jang","Jung-Sun Kim"],"significance":7,"published":"2023-03-14","source_date":"2023-03-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This subanalysis in diabetic patients with ASCVD confirmed that moderate-intensity statin plus ezetimibe is noninferior to high-intensity statin monotherapy for cardiovascular outcomes, supporting combination therapy as an alternative in diabetes.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38a3dc2c58ec","type":"article","url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","title":"DAPT-duur na PCI bij hoog bloedingsrisico: meta-analyse van RCT's","title_en":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["dubbele-trombocytenremming"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac706","source_url":"https://doi.org/10.1093/eurheartj/ehac706","authors":["Francesco Costa","Claudio Montalto","Mattia Branca","Sung-Jin Hong","Hirotoshi Watanabe","Anna Franzone","Pascal Vranckx","Joo-Yong Hahn","Hyeon-Cheol Gwon","Fausto Feres","Yangsoo Jang","Giuseppe De Luca","Elvin Kedhi","Davide Cao","Philippe Gabriel Steg","Deepak L Bhatt","Gregg W Stone","Antonio Micari","Stephan Windecker","Takeshi Kimura","Myeong-Ki Hong","Roxana Mehran","Marco Valgimigli"],"significance":7,"published":"2023-03-14","source_date":"2023-03-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This meta-analysis of RCTs confirmed that abbreviated DAPT (1-3 months) after PCI in high-bleeding-risk patients safely reduces bleeding without increasing ischemic events, consolidating the evidence for shortened antiplatelet therapy in vulnerable patients.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc76c328f3e0","type":"article","url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","title":"Mondiale prevalentie, uitkomsten en kosten van hartfalen: CaReMe-studie","title_en":"Prevalence, outcomes and costs of a contemporary, multinational population with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321702","source_url":"https://doi.org/10.1136/heartjnl-2022-321702","authors":["Anna Norhammar","Johan Bodegard","Marc Vanderheyden","Navdeep Tangri","Avraham Karasik","Aldo Pietro Maggioni","Kari Anne Sveen","Tiago Taveira-Gomes","Manuel Botana","Lukas Hunziker","Marcus Thuresson","Amitava Banerjee","Johan Sundström","Andreas Bollmann"],"significance":7,"published":"2023-03-10","source_date":"2023-03-10","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/nhg-standaard-hartfalen-2021/"],"congress":"","summary_en":"The CaReMe study used digital healthcare data to estimate global heart failure prevalence, finding substantial disease burden with high hospitalization rates and healthcare costs, informing the scale of the heart failure epidemic.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ddd28b1559da","type":"article","url":"https://hartvaat.nl/2023/03/07/mesenchymale-precursorcellen-bij-hfref-gerandomiseerde-trial/","title":"Mesenchymale precursorcellen bij HFrEF: gerandomiseerde trial","title_en":"Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.11.061","source_url":"https://doi.org/10.1016/j.jacc.2022.11.061","authors":["Emerson C Perin","Kenneth M Borow","Timothy D Henry","Farrell O Mendelsohn","Leslie W Miller","Elizabeth Swiggum","Eric D Adler","David H Chang","R David Fish","Alain Bouchard","Margaret Jenkins","Alex Yaroshinsky","Jack Hayes","Olga Rutman","Christopher W James","Eric Rose","Silviu Itescu","Barry Greenberg"],"significance":6,"published":"2023-03-07","source_date":"2023-03-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This randomized trial of allogeneic mesenchymal precursor cells in HFrEF showed a trend toward fewer heart failure events without reaching statistical significance, providing preliminary data on cell-based immunomodulation for heart failure.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da1ed4887e1f","type":"article","url":"https://hartvaat.nl/2023/03/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-met-pacemaker/","title":"Gepersonaliseerde versnelde pacing bij HFpEF met pacemaker","title_en":"Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","step-hfpef","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.5320","source_url":"https://doi.org/10.1001/jamacardio.2022.5320","authors":["Margaret Infeld","Kramer Wahlberg","Jillian Cicero","Timothy B Plante","Sean Meagher","Alexandra Novelli","Nicole Habel","Anand Muthu Krishnan","Daniel N Silverman","Martin M LeWinter","Daniel L Lustgarten","Markus Meyer"],"significance":7,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This trial investigated whether a personalized higher pacemaker backup rate improves symptoms and physical activity in HFpEF patients with pacemakers, exploring chronotropic optimization as a therapeutic strategy in this population.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4870b4335fed","type":"article","url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","title":"Diastolische bloeddruk en cognitie bij intensieve behandeling: SPRINT MIND","title_en":"Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20112","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20112","authors":["Chao Jiang","Sitong Li","Yufeng Wang","Yiwei Lai","Yu Bai","Manlin Zhao","Liu He","Yu Kong","Xueyuan Guo","Songnan Li","Nian Liu","Chenxi Jiang","Ribo Tang","Caihua Sang","Deyong Long","Xin Du","Jianzeng Dong","Craig S Anderson","Changsheng Ma"],"significance":7,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This SPRINT MIND analysis showed that the cognitive benefit of intensive systolic blood pressure control is maintained even in patients with low diastolic blood pressure, addressing the concern that aggressive systolic lowering might compromise cerebral perfusion.","created":"2026-07-03T10:30:16Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa6758ffbfcd","type":"article","url":"https://hartvaat.nl/2023/03/01/renale-denervatie-en-sympathische-activiteit-systematische-review/","title":"Renale denervatie en sympathische activiteit: systematische review","title_en":"Effects of Renal Denervation on Sympathetic Nerve Traffic and Correlates in Drug-Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["renale-denervatie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20503","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20503","authors":["Annalisa Biffi","Raffaella Dell'Oro","Fosca Quarti-Trevano","Cesare Cuspidi","Giovanni Corrao","Giuseppe Mancia","Guido Grassi"],"significance":6,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This systematic review examined whether renal denervation actually reduces sympathetic nerve activity, finding heterogeneous evidence for central sympathoinhibition as the mechanism of blood pressure lowering.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87f06efd2271","type":"article","url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","title":"Antihypertensieve regimes in SPRINT gedetailleerd beschreven","title_en":"Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lorundrostat"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20373","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20373","authors":["Catherine G Derington","Adam P Bress","Andrew E Moran","William S Weintraub","Jennifer S Herrick","William C Cushman","Ian M Kronish","Barry Stults","Daichi Shimbo","Paul Muntner","Tom Greene","Jeffrey T Bates","Tara I Chang","Lois Anne Katz","Shakaib U Rehman","Christianne L Roumie","Leonardo Tamariz","Jordan B King"],"significance":6,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/","https://hartvaat.nl/kennis/hypertensie/centrale-middelen-hypertensie/"],"congress":"","summary_en":"This detailed description of antihypertensive regimens used in SPRINT showed that the intensive group required more RAAS inhibitors and diuretics, contextualizing the treatment strategy behind the landmark trial's results.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef03c1032830","type":"article","url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","title":"Korttermijn bloeddrukmetingen voorspellen langetermijneffect van behandeling","title_en":"Clinical Utility of Short-Term Blood Pressure Measures to Inform Long-Term Blood Pressure Management.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lipidenverlaging"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20458","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20458","authors":["Nelson Wang","Katie Harris","Mark Woodward","Stephen Harrap","Giuseppe Mancia","Neil Poulter","John Chalmers","Anthony Rodgers"],"significance":6,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This study showed that blood pressure measurements taken shortly after starting antihypertensive therapy reliably predict long-term effects, supporting early assessment to guide medication adjustments.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25294f043b46","type":"article","url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","title":"RADIANCE II: ultrageluid renale denervatie bij milde tot matige hypertensie","title_en":"Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"JAMA","doi":"10.1001/jama.2023.0713","source_url":"https://doi.org/10.1001/jama.2023.0713","authors":["Michel Azizi","Manish Saxena","Yale Wang","J Stephen Jenkins","Chandan Devireddy","Florian Rader","Naomi D L Fisher","Roland E Schmieder","Felix Mahfoud","Jason Lindsey","Kintur Sanghvi","Thomas M Todoran","John Pacella","John Flack","Joost Daemen","Andrew S P Sharp","Philipp Lurz","Michael J Bloch","Michael A Weber","Melvin D Lobo","Jan Basile","Lisa Claude","Helen Reeve-Stoffer","Candace K McClure","Ajay J Kirtane"],"significance":8,"published":"2023-02-28","source_date":"2023-02-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"The RADIANCE II trial confirmed that ultrasound renal denervation significantly reduced blood pressure compared with a sham procedure in patients with mild-to-moderate hypertension, replicating the findings from RADIANCE-HTN SOLO with a refined study design.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T13:29:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3fe3e858c8b9","type":"article","url":"https://hartvaat.nl/2023/02/28/incidenteel-coronair-calcium-op-ct-thorax-ai-gestuurde-screening-verbetert-stati/","title":"Incidenteel coronair calcium op CT-thorax: AI-gestuurde screening verbetert statinegebruik","title_en":"Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project).","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["calciumscore","coronaire-ct-angiografie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062746","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062746","authors":["Alexander T Sandhu","Fatima Rodriguez","Summer Ngo","Bhavik N Patel","Domenico Mastrodicasa","David Eng","Nishith Khandwala","Sujana Balla","Doug Sousa","David J Maron"],"significance":8,"published":"2023-02-28","source_date":"2023-02-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The NOTIFY study demonstrated that AI-detected coronary artery calcium on non-gated chest CT scans, when reported to clinicians and patients, significantly increased statin prescribing. The opportunistic screening approach leveraged existing imaging to improve cardiovascular prevention without additional testing.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4500f5d9a8b5","type":"article","url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","title":"CT-coronairangiografie bij ≥75-jarigen met NSTE-ACS","title_en":"Coronary CT and timing of invasive coronary angiography in patients ≥75 years old with non-ST segment elevation acute coronary syndromes.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","coronaire-ct-angiografie"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321640","source_url":"https://doi.org/10.1136/heartjnl-2022-321640","authors":["Hanna Ratcovich","Golnaz Sadjadieh","Jesper J Linde","Francis R Joshi","Henning Kelbæk","Klaus F Kofoed","Lars Køber","Peter Riis Hansen","Christian Torp-Pedersen","Hanne Elming","Gunnar Hilmar Gislason","Dan Eik Høfsten","Thomas Engstrøm","Lene Holmvang"],"significance":6,"published":"2023-02-23","source_date":"2023-02-23","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"This study showed that coronary CT angiography can reliably rule out significant coronary disease in elderly NSTE-ACS patients, supporting a non-invasive-first approach for older adults with suspected acute coronary syndromes.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7f8600e6704","type":"article","url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","title":"Technieken om cardioversiesucces bij AF te verbeteren: meta-analyse","title_en":"Techniques improving electrical cardioversion success for patients with atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","atleten","bradycardie","cardiogene-shock","farmaco-economie","hartrevalidatie","laminopathie","microbioom","myocardinfarct","obesitas","ouderen","slaapapneu","supraventriculaire-tachycardie","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac199","source_url":"https://doi.org/10.1093/europace/euac199","authors":["Stephanie T Nguyen","Emilie P Belley-Côté","Omar Ibrahim","Kevin J Um","Alexandra Lengyel","Taranah Adli","Yuan Qiu","Michael Wong","Serena Sibilio","Alexander P Benz","Alex Wolf","Nicola J Whitlock","Juan Gabriel Acosta","Jeff S Healey","Adrian Baranchuk","William F McIntyre"],"significance":5,"published":"2023-02-16","source_date":"2023-02-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrische-cardioversie/"],"congress":"","summary_en":"This meta-analysis evaluated techniques for improving electrical cardioversion success in AF, finding that anteroposterior electrode position, higher initial energy, and pad-based delivery improve conversion rates.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e9ad856cb2fa","type":"article","url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","title":"P-golfduur voorspelt AF-recidief na catheterablatie: meta-analyse","title_en":"P-wave duration and atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["katheterablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac210","source_url":"https://doi.org/10.1093/europace/euac210","authors":["Stergios Intzes","Konstantinos Zagoridis","Marianthi Symeonidou","Emmanouil Spanoudakis","Arash Arya","Borislav Dinov","Nikolaos Dagres","Gerhard Hindricks","Andreas Bollmann","Emmanuel Kanoupakis","Emmanuel Koutalas","Sotirios Nedios"],"significance":5,"published":"2023-02-16","source_date":"2023-02-16","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that prolonged P-wave duration on ECG independently predicts AF recurrence after catheter ablation, supporting this simple measure as a pre-ablation risk stratification tool.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7f9538959774","type":"article","url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","title":"Hoog vermogen korte duur versus laag vermogen langere duur posteriore ablatie bij AF","title_en":"Higher power short duration vs. lower power longer duration posterior wall ablation for atrial fibrillation and oesophageal injury outcomes: a prospective multi-centre randomized controlled study (Hi-Lo HEAT trial).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac190","source_url":"https://doi.org/10.1093/europace/euac190","authors":["David Chieng","Louise Segan","Hariharan Sugumar","Ahmed Al-Kaisey","Joshua Hawson","Benjamin M Moore","Michael C Y Nam","Aleksandr Voskoboinik","Sandeep Prabhu","Liang-Han Ling","Jer Fuu Ng","Gregor Brown","Geoffrey Lee","Joseph Morton","Henry Debinski","Jonathan M Kalman","Peter M Kistler"],"significance":6,"published":"2023-02-16","source_date":"2023-02-16","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that high-power short-duration RF ablation of the posterior wall reduces esophageal thermal injury compared with conventional power settings, improving safety for this anatomically challenging ablation target.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72cb030e6303","type":"article","url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","title":"Catheterablatie verbetert CV-uitkomsten bij AF en hartfalen: meta-analyse van RCT's","title_en":"Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","carvedilol","cerebrovasculair","farmaco-economie","hartkatheterisatie","hartrevalidatie","harttransplantatie","hfpef","hfref","ijzertekort","katheterablatie","laminopathie","myocardinfarct","ouderen","pathfinder-trial","perifeer-vaatlijden","primaire-preventie","sacubitril-valsartan","secundaire-preventie","step-hfpef","supraventriculaire-tachycardie","ventrikelfibrilleren","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac173","source_url":"https://doi.org/10.1093/europace/euac173","authors":["Florentina A Simader","James P Howard","Yousif Ahmad","Keenan Saleh","Akriti Naraen","Jack W Samways","Jagdeep Mohal","Rohin K Reddy","Nandita Kaza","Daniel Keene","Matthew J Shun-Shin","Darrel P Francis","Zachary I Whinnett","Ahran D Arnold"],"significance":8,"published":"2023-02-16","source_date":"2023-02-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis of randomized trials confirmed that catheter ablation for atrial fibrillation in heart failure patients significantly improves cardiovascular outcomes, including reductions in mortality and heart failure hospitalization. The pooled evidence strengthened the indication for AF ablation in the HF population.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8f9f8ff8189","type":"article","url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","title":"Sekseverschillen in tienjaarsuitkomsten na PCI: DECADE-samenwerking","title_en":"Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062049","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062049","authors":["J J Coughlan","Lorenz Räber","Salvatore Brugaletta","Sebastian Kufner","Michael Maeng","Lisette Okkels Jensen","Luis Ortega-Paz","Sarah Bär","Karl-Ludwig Laugwitz","Morten Madsen","Dik Heg","Alp Aytekin","Stephan Windecker","Kevin Kris Warnakula Olesen","Manel Sabaté","Adnan Kastrati","Salvatore Cassese"],"significance":6,"published":"2023-02-14","source_date":"2023-02-14","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This 10-year analysis showed that women have higher long-term mortality after PCI than men, primarily driven by older age and more comorbidities at presentation rather than the intervention itself.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d495c027b757","type":"article","url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","title":"P2Y12-monotherapie versus DAPT na complexe PCI","title_en":"P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.11.041","source_url":"https://doi.org/10.1016/j.jacc.2022.11.041","authors":["Felice Gragnano","Roxana Mehran","Mattia Branca","Anna Franzone","Usman Baber","Yangsoo Jang","Takeshi Kimura","Joo-Yong Hahn","Qiang Zhao","Stephan Windecker","Charles M Gibson","Byeong-Keuk Kim","Hirotoshi Watanabe","Young Bin Song","Yunpeng Zhu","Pascal Vranckx","Shamir Mehta","Sung-Jin Hong","Kenji Ando","Hyeon-Cheol Gwon","Paolo Calabrò","Patrick W Serruys","George D Dangas","Eùgene P McFadden","Dominick J Angiolillo","Dik Heg","Marco Valgimigli"],"significance":7,"published":"2023-02-14","source_date":"2023-02-14","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This analysis showed that P2Y12 inhibitor monotherapy preserves ischemic protection while reducing bleeding risk compared with DAPT even after complex PCI, extending the de-escalation approach to the highest-complexity interventions.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12a92fe12c35","type":"article","url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","title":"Cryoballon PVI als eerstelijnsbehandeling voor typisch atriumflutter","title_en":"Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie","pulmonaalvenenisolatie"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321729","source_url":"https://doi.org/10.1136/heartjnl-2022-321729","authors":["Dhiraj Gupta","Wern Yew Ding","Peter Calvert","Emmanuel Williams","Moloy Das","Lilith Tovmassian","Muzahir H Tayebjee","Guy Haywood","Claire A Martin","Kim Rajappan","Matthew G D Bates","Ian Peter Temple","Tobias Reichlin","Zhong Chen","Richard N Balasubramaniam","Christina Ronayne","Nichola Clarkson","Maureen Morgan","Janet Barton","Ian Kemp","Saagar Mahida","Christian Sticherling"],"significance":7,"published":"2023-02-14","source_date":"2023-02-14","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"This study compared cryoballoon pulmonary vein isolation with standard CTI ablation as first-line treatment for typical atrial flutter, finding that PVI provides additional AF prevention while treating the flutter, potentially offering a more comprehensive rhythm strategy.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"388ab546d761","type":"article","url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","title":"REDO-FIRM: FIRM-geleide ablatie verbetert uitkomst niet bij recidief-AF","title_en":"Randomized evaluation of redo ablation procedures of atrial fibrillation with focal impulse and rotor modulation-guided procedures: the REDO-FIRM study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac122","source_url":"https://doi.org/10.1093/europace/euac122","authors":["Stefan G Spitzer","John M Miller","Philipp Sommer","Tamas Szili-Torok","Vivek Y Reddy","Georg Nölker","Chris Williams","Anne Sarver","David J Wilber"],"significance":6,"published":"2023-02-08","source_date":"2023-02-08","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"The REDO-FIRM trial showed that focal impulse and rotor modulation-guided redo ablation does not improve outcomes over conventional redo ablation for recurrent AF, a negative result for the rotor-mapping technology in repeat procedures.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa5264c30465","type":"article","url":"https://hartvaat.nl/2023/02/08/voorspellers-van-af-recidief-na-ablatie-en-cardioversie-umbrella-review/","title":"Voorspellers van AF-recidief na ablatie en cardioversie: umbrella review","title_en":"Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac143","source_url":"https://doi.org/10.1093/europace/euac143","authors":["Emmanouil Charitakis","Elena Dragioti","Maria Stratinaki","Dafni Korela","Stylianos Tzeis","Henrik Almroth","Ioan Liuba","Anders Hassel Jönsson","Georgios Charalambous","Lars O Karlsson","Dimitrios Tsartsalis"],"significance":6,"published":"2023-02-08","source_date":"2023-02-08","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This umbrella review of meta-analyses identified the strongest predictors of AF recurrence after catheter ablation and cardioversion — left atrial size, AF duration, age, and body mass index — providing a practical risk assessment framework.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T13:29:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00a787d87306","type":"article","url":"https://hartvaat.nl/2023/02/08/stolling-en-atriumfibrilleren-systematische-review-en-meta-analyse/","title":"Stolling en atriumfibrilleren: systematische review en meta-analyse","title_en":"The association of coagulation and atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["laminopathie","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac130","source_url":"https://doi.org/10.1093/europace/euac130","authors":["Martijn J Tilly","Sven Geurts","Angelo M Pezzullo","Wichor M Bramer","Natasja M S de Groot","Maryam Kavousi","Moniek P M de Maat"],"significance":6,"published":"2023-02-08","source_date":"2023-02-08","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"This meta-analysis examined the bidirectional relationship between coagulation activation and AF, suggesting that coagulation may not only be a consequence but also a contributor to atrial fibrillation development.","created":"2026-07-03T10:30:14Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"50c05c6f589a","type":"article","url":"https://hartvaat.nl/2023/02/07/inspanningsgerichte-hartrevalidatie-bij-coronairlijden-geactualiseerde-meta-anal/","title":"Inspanningsgerichte hartrevalidatie bij coronairlijden: geactualiseerde meta-analyse","title_en":"Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","farmaco-economie","fidelity","hartkatheterisatie","hartrevalidatie","harttransplantatie","ivabradine","laminopathie","myocardinfarct","ouderen","stabiel-coronairlijden","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac747","source_url":"https://doi.org/10.1093/eurheartj/ehac747","authors":["Grace O Dibben","James Faulkner","Neil Oldridge","Karen Rees","David R Thompson","Ann-Dorthe Zwisler","Rod S Taylor"],"significance":7,"published":"2023-02-07","source_date":"2023-02-07","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/revalidatie-na-hartinfarct/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This updated meta-analysis confirmed that exercise-based cardiac rehabilitation for coronary heart disease reduces cardiovascular mortality and hospital readmission, with benefits extending to contemporary patient populations and interventions.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f26b26cab542","type":"article","url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","title":"FFR-geleide versus angiografie-geleide PCI bij acuut MI met meervatslijden","title_en":"Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac763","source_url":"https://doi.org/10.1093/eurheartj/ehac763","authors":["Joo Myung Lee","Hyun Kuk Kim","Keun Ho Park","Eun Ho Choo","Chan Joon Kim","Seung Hun Lee","Min Chul Kim","Young Joon Hong","Sung Gyun Ahn","Joon-Hyung Doh","Sang Yeub Lee","Sang Don Park","Hyun-Jong Lee","Min Gyu Kang","Jin-Sin Koh","Yun-Kyeong Cho","Chang-Wook Nam","Bon-Kwon Koo","Bong-Ki Lee","Kyeong Ho Yun","David Hong","Hyun Sung Joh","Ki Hong Choi","Taek Kyu Park","Jeong Hoon Yang","Young Bin Song","Seung-Hyuk Choi","Hyeon-Cheol Gwon","Joo-Yong Hahn"],"significance":7,"published":"2023-02-07","source_date":"2023-02-07","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This randomized trial comparing FFR-guided with angiography-guided PCI of nonculprit vessels in acute MI showed that FFR guidance results in fewer stent implantations but similar clinical outcomes, consistent with other FFR-in-MI trials.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T13:29:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f7369c13777c","type":"article","url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","title":"ECMO-CS: ECMO bij cardiogene shock verbetert overleving niet","title_en":"Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["cardiogene-shock"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062949","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062949","authors":["Petr Ostadal","Richard Rokyta","Jiri Karasek","Andreas Kruger","Dagmar Vondrakova","Marek Janotka","Jan Naar","Jana Smalcova","Marketa Hubatova","Milan Hromadka","Stefan Volovar","Miroslava Seyfrydova","Jiri Jarkovsky","Michal Svoboda","Ales Linhart","Jan Belohlavek"],"significance":8,"published":"2023-02-07","source_date":"2023-02-07","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"The ECMO-CS trial showed that veno-arterial ECMO in cardiogenic shock was not associated with improved survival compared with standard medical therapy, consistent with the ECLS-SHOCK results. The negative finding discourages routine ECMO use in non-infarction cardiogenic shock.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T13:29:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"104a39f1f4df","type":"article","url":"https://hartvaat.nl/2023/02/02/baxdrostat-aldosteronsynthaseremmer-bij-resistente-hypertensie-nejm-fase-2/","title":"Baxdrostat: aldosteronsynthaseremmer bij resistente hypertensie — NEJM fase 2","title_en":"Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","bax24-trial","baxdrostat","bloeddrukbehandeling","lorundrostat","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2213169","source_url":"https://doi.org/10.1056/NEJMoa2213169","authors":["Mason W Freeman","Yuan-Di Halvorsen","William Marshall","Mackenzie Pater","Jon Isaacsohn","Catherine Pearce","Brian Murphy","Nicholas Alp","Ajay Srivastava","Deepak L Bhatt","Morris J Brown"],"significance":9,"published":"2023-02-02","source_date":"2023-02-02","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This phase 2 NEJM trial of baxdrostat, the first selective aldosterone synthase inhibitor, demonstrated dose-dependent blood pressure reduction in patients with treatment-resistant hypertension. The results validated a new pharmacological target for the hardest-to-treat hypertension population.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94fd5da9d2af","type":"article","url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","title":"Fysieke revalidatie bij fragiele ouderen met acuut hartfalen","title_en":"Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","empagliflozine","ijzertekort"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4903","source_url":"https://doi.org/10.1001/jamacardio.2022.4903","authors":["Ambarish Pandey","Dalane W Kitzman","M Benjamin Nelson","Amy M Pastva","Pamela Duncan","David J Whellan","Robert J Mentz","Haiying Chen","Bharathi Upadhya","Gordon R Reeves"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This secondary analysis showed that multidomain physical rehabilitation improves quality of life and functional capacity in frail older patients hospitalized for acute heart failure, supporting rehabilitation even in the most vulnerable HF population.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9e8e1ddc504","type":"article","url":"https://hartvaat.nl/2023/02/01/cv-risicomodellen-bij-hiv-patienten-systematische-review/","title":"CV-risicomodellen bij HIV-patiënten: systematische review","title_en":"Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4873","source_url":"https://doi.org/10.1001/jamacardio.2022.4873","authors":["Cullen Soares","Michael Kwok","Kent-Andrew Boucher","Mohammed Haji","Justin B Echouffo-Tcheugui","Christopher T Longenecker","Gerald S Bloomfield","David Ross","Eric Jutkowtiz","Jennifer L Sullivan","James L Rudolph","Wen-Chih Wu","Sebhat Erqou"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This meta-analysis showed that standard cardiovascular risk models underestimate risk in people living with HIV, supporting the development of HIV-specific risk calculators that account for the unique inflammatory and metabolic factors in this population.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T13:29:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d6f1d2092aab","type":"article","url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","title":"NYHA-klasse versus objectieve metingen bij mild hartfalen: PARADIGM-HF analyse","title_en":"Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfmref","hfpef","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4427","source_url":"https://doi.org/10.1001/jamacardio.2022.4427","authors":["Luis E Rohde","André Zimerman","Muthiah Vaduganathan","Brian L Claggett","Milton Packer","Akshay S Desai","Michael Zile","Jean Rouleau","Karl Swedberg","Martin Lefkowitz","Victor Shi","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This PARADIGM-HF analysis showed that NYHA functional classification correlates poorly with objective measures (BNP, exercise capacity) in HFrEF, questioning the reliability of NYHA class as a treatment decision tool.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"52d9f1164ad8","type":"article","url":"https://hartvaat.nl/2023/02/01/clorotic-thiazide-toevoegen-aan-lisdiureticum-bij-acuut-hartfalen/","title":"CLOROTIC: thiazide toevoegen aan lisdiureticum bij acuut hartfalen","title_en":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["diuretica","furosemide"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac689","source_url":"https://doi.org/10.1093/eurheartj/ehac689","authors":["Joan Carles Trullàs","José Luis Morales-Rull","Jesús Casado","Margarita Carrera-Izquierdo","Marta Sánchez-Marteles","Alicia Conde-Martel","Melitón Francisco Dávila-Ramos","Pau Llácer","Prado Salamanca-Bautista","José Pérez-Silvestre","Miguel Ángel Plasín","José Manuel Cerqueiro","Paloma Gil","Francesc Formiga","Luis Manzano"],"significance":8,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/lisdiuretica-furosemide-bumetanide/"],"congress":"","summary_en":"The CLOROTIC trial showed that adding hydrochlorothiazide to furosemide in acute decompensated heart failure improved weight loss and urine output compared with furosemide alone, though it did not affect dyspnea or all-cause mortality. The results supported sequential nephron blockade as a diuretic strategy.","created":"2026-07-03T10:30:13Z","updated":"2026-07-03T13:29:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0daa36edf57f","type":"article","url":"https://hartvaat.nl/2023/02/01/hypertensieve-zwangerschapscomplicaties-en-dementierisico-meta-analyse/","title":"Hypertensieve zwangerschapscomplicaties en dementierisico: meta-analyse","title_en":"Association Between Hypertensive Disorders of Pregnancy and Dementia: a Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","bradycardie","hypertrofische-cardiomyopathie","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19399","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19399","authors":["Karen C Schliep","Hailey Mclean","Bin Yan","Fares Qeadan","Lauren H Theilen","Adam de Havenon","Jennifer J Majersik","Truls Østbye","Surendra Sharma","Michael W Varner"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This meta-analysis showed that hypertensive disorders of pregnancy are associated with increased risk of later dementia, establishing gestational hypertension as a risk factor for long-term neurodegenerative disease.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fafb5ce7f395","type":"article","url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","title":"Aspirine en cardiovasculaire uitkomsten bij chronische nierziekte","title_en":"Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","aficamten","anemie-ckd","aspirine","biomarkers-cardiovasculair","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","fidelio-dkd","figaro-dkd","flow-trial","ijzertekort","inflammatie","menopauze","myocardinfarct","obesitas","ouderen","richtlijnen-esc","roken","slaapapneu","trombocytenaggregatieremmers"],"journal":"Kidney international","doi":"10.1016/j.kint.2022.09.023","source_url":"https://doi.org/10.1016/j.kint.2022.09.023","authors":["Johannes F E Mann","Philip Joseph","Peggy Gao","Prem Pais","Jessica Tyrwhitt","Denis Xavier","Tony Dans","Patricio Lopez Jaramillo","Habib Gamra","Salim Yusuf"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/"],"congress":"","summary_en":"This study evaluated aspirin for cardiovascular event prevention in CKD patients, showing modest ischemic benefit offset by increased bleeding risk, consistent with the general aspirin primary prevention evidence.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T18:39:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b17d0b664d93","type":"article","url":"https://hartvaat.nl/2023/02/01/nnt-van-nieuwe-antidiabetica-voor-cv-uitkomsten-meta-analyse/","title":"NNT van nieuwe antidiabetica voor CV-uitkomsten: meta-analyse","title_en":"Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14213","source_url":"https://doi.org/10.1002/ehf2.14213","authors":["Georg Wolff","Yingfeng Lin","Cihan Akbulut","Maximilian Brockmeyer","Claudio Parco","Alexander Hoss","Alexander Sokolowski","Ralf Westenfeld","Malte Kelm","Michael Roden","Sabrina Schlesinger","Oliver Kuss"],"significance":7,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis calculated the numbers needed to treat (NNT) for SGLT2 inhibitors and GLP-1 receptor agonists across cardiovascular outcomes, providing absolute treatment effect estimates useful for clinical decision-making and cost-effectiveness analysis.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d70d0cdf9bb4","type":"article","url":"https://hartvaat.nl/2023/02/01/hartfalenrisicoscores-vergelijking-voor-mortaliteit-en-heropname/","title":"Hartfalenrisicoscores: vergelijking voor mortaliteit en heropname","title_en":"Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14208","source_url":"https://doi.org/10.1002/ehf2.14208","authors":["Xiangwei Bo","Yahao Zhang","Yang Liu","Naresh Kharbuja","Lijuan Chen"],"significance":5,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This study compared the performance of multiple heart failure risk scores for predicting 1-year mortality and readmission, finding variable discrimination that depends on the population and outcome assessed.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b5b20395edb4","type":"article","url":"https://hartvaat.nl/2023/02/01/nifedipine-retard-intrapartum-bij-ernstige-pre-eclampsie-preventietrial/","title":"Nifedipine retard intrapartum bij ernstige pre-eclampsie: preventietrial","title_en":"Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19751","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19751","authors":["Erin M Cleary","Nicholas W Racchi","K Grace Patton","Meghana Kudrimoti","Maged M Costantine","Kara M Rood"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This trial showed that intrapartum extended-release nifedipine reduces severe hypertension in women with preeclampsia, providing an evidence-based prophylactic strategy for the most dangerous intrapartum blood pressure elevations.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c0d750f41d1","type":"article","url":"https://hartvaat.nl/2023/02/01/multifactoriele-optimalisatie-van-chronisch-hartfalen-gerandomiseerde-studie/","title":"Multifactoriële optimalisatie van chronisch hartfalen: gerandomiseerde studie","title_en":"Effects of multifaceted optimization management for chronic heart failure: a multicentre, randomized controlled study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["hfref","ivabradine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14170","source_url":"https://doi.org/10.1002/ehf2.14170","authors":["Guangming Pan","Weiqiang Ji","Xia Wang","Song Li","Chaoyang Zheng","Weihui Lyu","Xiaoyan Feng","Yu Xia","Zhihua Xiong","Haohong Shan","Haiyu Yang","Xu Zou"],"significance":5,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"This multicenter RCT tested a multifaceted optimization program integrating traditional Chinese and Western medicine for chronic heart failure management, showing improved outcomes with the structured approach.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed5d2bae993d","type":"article","url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","title":"Diabetes en sacubitril/valsartan-titratie bij hartfalen na opname","title_en":"Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","diabetes-en-hart","diabetes-type-1","sacubitril-valsartan","soul-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14166","source_url":"https://doi.org/10.1002/ehf2.14166","authors":["Klaus K Witte","Rolf Wachter","Michele Senni","Jan Belohlavek","Ewa Straburzynska-Migaj","Candida Fonseca","Eva Lonn","Adele Noè","Heike Schwende","Dmytro Butylin","YannTong Chiang","Domingo Pascual-Figal"],"significance":6,"published":"2023-02-01","source_date":"2023-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study showed that diabetes complicates sacubitril-valsartan up-titration during heart failure hospitalization but that the clinical benefit is maintained, supporting ARNI initiation efforts even in diabetic HF patients.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8e33d0a122e9","type":"article","url":"https://hartvaat.nl/2023/01/31/tromboseprofylaxe-bij-fontan-circulatie-aspirine-warfarine-of-noac/","title":"Tromboseprofylaxe bij Fontan-circulatie: aspirine, warfarine of NOAC","title_en":"Thromboprophylaxis in Patients With Fontan Circulation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["doacs","trombocytenaggregatieremmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.10.037","source_url":"https://doi.org/10.1016/j.jacc.2022.10.037","authors":["Jef Van den Eynde","Mathias Possner","Fares Alahdab","Gruschen Veldtman","Bryan H Goldstein","Rahul H Rathod","Arvind K Hoskoppal","Anita Saraf","Brian Feingold","Tarek Alsaied"],"significance":7,"published":"2023-01-31","source_date":"2023-01-31","image":"","kennis":[],"congress":"","summary_en":"This randomized study compared aspirin, warfarin, and a NOAC as thromboprophylaxis in patients with Fontan circulation, providing the first randomized data to guide antithrombotic strategy in this unique congenital heart disease population.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c29f2c33f32c","type":"article","url":"https://hartvaat.nl/2023/01/31/hfpef-inspanningsbeperking-niet-alleen-door-hemodynamiek/","title":"HFpEF: inspanningsbeperking niet alleen door hemodynamiek","title_en":"Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","hfpef","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061828","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061828","authors":["Satyam Sarma","James P MacNamara","Bryce N Balmain","Christopher M Hearon","Denis J Wakeham","Andrew R Tomlinson","Linda S Hynan","Tony G Babb","Benjamin D Levine"],"significance":7,"published":"2023-01-31","source_date":"2023-01-31","image":"","kennis":[],"congress":"","summary_en":"This study challenged the hemodynamic hypothesis in HFpEF by showing that exercise intolerance is not fully explained by elevated wedge pressures, suggesting peripheral and skeletal muscle limitations contribute significantly to functional impairment.","created":"2026-07-03T10:30:12Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae7244b159ad","type":"article","url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","title":"PCSK9-remming bij COVID-19: anti-inflammatoir potentieel onderzocht","title_en":"PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["covid-hart"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.10.030","source_url":"https://doi.org/10.1016/j.jacc.2022.10.030","authors":["Eliano P Navarese","Przemysław Podhajski","Paul A Gurbel","Klaudyna Grzelakowska","Eleonora Ruscio","Udaya Tantry","Przemysław Magielski","Aldona Kubica","Piotr Niezgoda","Piotr Adamski","Roman Junik","Grzegorz Przybylski","Marta Pilaczyńska-Cemel","Manali Rupji","Giuseppe Specchia","Jarosław Pinkas","Robert Gajda","Diana A Gorog","Felicita Andreotti","Jacek Kubica"],"significance":5,"published":"2023-01-24","source_date":"2023-01-24","image":"","kennis":[],"congress":"","summary_en":"This study tested PCSK9 inhibition as an anti-inflammatory intervention during COVID-19 infection, based on the hypothesis that PCSK9 modulates the inflammatory response through lipid-immune pathway interactions.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebb2d4db8291","type":"article","url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","title":"AXADIA-AFNET 8: apixaban versus VKA bij AF op hemodialyse","title_en":"A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062779","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062779","authors":["Holger Reinecke","Christiane Engelbertz","Rupert Bauersachs","Günter Breithardt","Hans-Herbert Echterhoff","Joachim Gerß","Karl Georg Haeusler","Bernd Hewing","Joachim Hoyer","Sabine Juergensmeyer","Thomas Klingenheben","Guido Knapp","Lars Christian Rump","Hans Schmidt-Guertler","Christoph Wanner","Paulus Kirchhof","Dennis Goerlich"],"significance":7,"published":"2023-01-24","source_date":"2023-01-24","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"The AXADIA trial comparing apixaban with phenprocoumon in AF patients on hemodialysis was underpowered for clinical outcomes, illustrating the ongoing challenge of generating definitive anticoagulation evidence in end-stage kidney disease.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ecd6c3049bf7","type":"article","url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","title":"EMPA-HEART 2: empagliflozine vermindert LV-massa niet bij patiënten zonder diabetes of HF","title_en":"Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","canagliflozine","cardiorenal-behandelstrategie","dapa-hf","dapagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","emperor-trials","figaro-dkd","pathfinder-trial","slaapapneu","soul-trial","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062769","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062769","authors":["Kim A Connelly","C David Mazer","Pankaj Puar","Hwee Teoh","Chao-Hung Wang","Tamique Mason","Farhad Akhavein","Ching-Wen Chang","Min-Hui Liu","Ning-I Yang","Wei-Siang Chen","Yu-Hsiang Juan","Erika Opingari","Yaseen Salyani","William Barbour","Aryan Pasricha","Shamon Ahmed","Andrew Kosmopoulos","Raj Verma","Michael Moroney","Ehab Bakbak","Aishwarya Krishnaraj","Deepak L Bhatt","Javed Butler","Mikhail N Kosiborod","Carolyn S P Lam","David A Hess","Otavio Rizzi Coelho-Filho","Myriam Lafreniere-Roula","Kevin E Thorpe","Adrian Quan","Lawrence A Leiter","Andrew T Yan","Subodh Verma"],"significance":7,"published":"2023-01-24","source_date":"2023-01-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The EMPA-HEART 2 trial showed that empagliflozin did not significantly reduce left ventricular mass in patients with coronary artery disease without diabetes or heart failure, suggesting that SGLT2 inhibitor cardiac remodeling benefits may be specific to diabetic or heart failure populations.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa8efb8386e7","type":"article","url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","title":"GDF-15 en cardiovasculair risico: IPD meta-analyse","title_en":"Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","diabetes-type-2","fractional-flow-reserve","inflammatie","richtlijnen-esc"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac577","source_url":"https://doi.org/10.1093/eurheartj/ehac577","authors":["Eri Toda Kato","David A Morrow","Jianping Guo","David D Berg","Michael A Blazing","Erin A Bohula","Marc P Bonaca","Christopher P Cannon","James A de Lemos","Robert P Giugliano","Petr Jarolim","Tibor Kempf","L Kristin Newby","Michelle L O'Donoghue","Marc A Pfeffer","Nader Rifai","Stephen D Wiviott","Kai C Wollert","Eugene Braunwald","Marc S Sabatine"],"significance":6,"published":"2023-01-21","source_date":"2023-01-21","image":"","kennis":[],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that GDF-15 is a strong, independent predictor of diverse cardiovascular outcomes, establishing this stress-responsive cytokine as a powerful risk biomarker.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"08018d658378","type":"article","url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","title":"TRANSFORM-HF: torsemide biedt geen overlevingsvoordeel boven furosemide","title_en":"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","carvedilol","diuretica","dubbele-trombocytenremming","furosemide","hfpef","hfref","ijzertekort","step-hfpef"],"journal":"JAMA","doi":"10.1001/jama.2022.23924","source_url":"https://doi.org/10.1001/jama.2022.23924","authors":["Robert J Mentz","Kevin J Anstrom","Eric L Eisenstein","Shelly Sapp","Stephen J Greene","Shelby Morgan","Jeffrey M Testani","Amanda H Harrington","Vandana Sachdev","Fassil Ketema","Dong-Yun Kim","Patrice Desvigne-Nickens","Bertram Pitt","Eric J Velazquez"],"significance":9,"published":"2023-01-17","source_date":"2023-01-17","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"The TRANSFORM-HF trial found no difference in all-cause mortality between torsemide and furosemide in patients hospitalized for heart failure. This definitive pragmatic trial ended the long-standing hypothesis that torsemide's anti-aldosterone properties might confer a survival advantage over furosemide.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2efbc1cfdaa8","type":"article","url":"https://hartvaat.nl/2023/01/17/option-indobufen-als-aspirine-alternatief-in-dapt-na-pci/","title":"OPTION: indobufen als aspirine-alternatief in DAPT na PCI","title_en":"Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062762","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062762","authors":["Hongyi Wu","Lili Xu","Xin Zhao","Huanyi Zhang","Kang Cheng","Xiaoyan Wang","Manhua Chen","Guangping Li","Jiangnan Huang","Jun Lan","Guanghe Wei","Chi Zhang","Yinman Wang","Juying Qian","Junbo Ge"],"significance":6,"published":"2023-01-17","source_date":"2023-01-17","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"The OPTION trial showed that indobufen, a reversible COX inhibitor, is noninferior to aspirin when combined with clopidogrel after coronary DES implantation, providing an alternative antiplatelet backbone with potentially fewer GI side effects.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T13:29:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f451774d5846","type":"article","url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","title":"ADVOR: acetazolamide effectief over het hele EF-spectrum bij acuut hartfalen","title_en":"Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","empagliflozine","emperor-trials","hfmref","hfpef","hfref","sacubitril-valsartan","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062486","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062486","authors":["Pieter Martens","Jeroen Dauw","Frederik H Verbrugge","Petra Nijst","Evelyne Meekers","Silvio Nunes Augusto","Jozine M Ter Maaten","Kevin Damman","Alexandre Mebazaa","Gerasimos Filippatos","Frank Ruschitzka","W H Wilson Tang","Matthias Dupont","Wilfried Mullens"],"significance":7,"published":"2023-01-17","source_date":"2023-01-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This ADVOR subanalysis confirmed that adjunctive acetazolamide improves decongestion in acute heart failure regardless of left ventricular ejection fraction, supporting sequential nephron blockade across the heart failure spectrum.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"91f230e06b78","type":"article","url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","title":"STROKESTOP: AF-screening is kosteneffectief bij 75-76-jarigen","title_en":"Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac547","source_url":"https://doi.org/10.1093/eurheartj/ehac547","authors":["Johan Lyth","Emma Svennberg","Lars Bernfort","Mattias Aronsson","Viveka Frykman","Faris Al-Khalili","Leif Friberg","Mårten Rosenqvist","Johan Engdahl","Lars-Åke Levin"],"significance":8,"published":"2023-01-14","source_date":"2023-01-14","image":"","kennis":[],"congress":"","summary_en":"The STROKESTOP cost-effectiveness analysis showed that population-level screening for atrial fibrillation in 75-76-year-olds using intermittent ECG recordings is cost-effective, with favorable incremental cost per QALY gained. The economic evaluation complemented the clinical benefit demonstrated in the main trial.","created":"2026-07-03T10:30:11Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18e8aaa8284a","type":"article","url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","title":"EARLY-AF 2 jaar: cryoablatie vertraagt AF-progressie beter dan antiaritmica","title_en":"Progression of Atrial Fibrillation after Cryoablation or Drug Therapy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["abelacimab","cryoablatie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2212540","source_url":"https://doi.org/10.1056/NEJMoa2212540","authors":["Jason G Andrade","Marc W Deyell","Laurent Macle","George A Wells","Matthew Bennett","Vidal Essebag","Jean Champagne","Jean-Francois Roux","Derek Yung","Allan Skanes","Yaariv Khaykin","Carlos Morillo","Umjeet Jolly","Paul Novak","Evan Lockwood","Guy Amit","Paul Angaran","John Sapp","Stephan Wardell","Sandra Lauck","Julia Cadrin-Tourigny","Simon Kochhäuser","Atul Verma"],"significance":9,"published":"2023-01-12","source_date":"2023-01-12","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"The 2-year EARLY-AF results showed that initial cryoablation therapy not only maintained better rhythm control but also significantly reduced progression from paroxysmal to persistent atrial fibrillation compared with antiarrhythmic drugs. This disease-modifying effect strengthened the case for early ablation intervention.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69401437857f","type":"article","url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","title":"EMPA-KIDNEY: empagliflozine beschermt nieren bij brede CKD-populatie","title_en":"Empagliflozin in Patients with Chronic Kidney Disease.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["chronische-nierziekte","credence-trial","cystatine-c","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","fidelio-dkd","figaro-dkd","flow-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2204233","source_url":"https://doi.org/10.1056/NEJMoa2204233","authors":["William G Herrington","Natalie Staplin","Christoph Wanner","Jennifer B Green","Sibylle J Hauske","Jonathan R Emberson","David Preiss","Parminder Judge","Kaitlin J Mayne","Sarah Y A Ng","Emily Sammons","Doreen Zhu","Michael Hill","Will Stevens","Karl Wallendszus","Susanne Brenner","Alfred K Cheung","Zhi-Hong Liu","Jing Li","Lai Seong Hooi","Wen Liu","Takashi Kadowaki","Masaomi Nangaku","Adeera Levin","David Cherney","Aldo P Maggioni","Roberto Pontremoli","Rajat Deo","Shinya Goto","Xavier Rossello","Katherine R Tuttle","Dominik Steubl","Michaela Petrini","Dan Massey","Jens Eilbracht","Martina Brueckmann","Martin J Landray","Colin Baigent","Richard Haynes"],"significance":10,"published":"2023-01-12","source_date":"2023-01-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"The EMPA-KIDNEY trial demonstrated that empagliflozin reduced kidney disease progression and cardiovascular death in a broad population of patients with chronic kidney disease, including those without diabetes and those with only mildly reduced eGFR. The trial was stopped early for efficacy and extended the renal protection of SGLT2 inhibitors to virtually all CKD patients.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7a739eaa35b9","type":"article","url":"https://hartvaat.nl/2023/01/11/metamfetamine-geassocieerd-hartfalen-systematische-review/","title":"Metamfetamine-geassocieerd hartfalen: systematische review","title_en":"Methamphetamine-associated heart failure: a systematic review of observational studies.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfmref","hfref"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321610","source_url":"https://doi.org/10.1136/heartjnl-2022-321610","authors":["Veena Manja","Ananya Nrusimha","Ya Gao","Aleesha Sheikh","Mark McGovern","Paul A Heidenreich","Alex Tarlochan Singh Sandhu","Steven Asch"],"significance":6,"published":"2023-01-11","source_date":"2023-01-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/echocardiografie-bij-hartfalen/"],"congress":"","summary_en":"This systematic review characterized methamphetamine-associated heart failure as a distinct clinical entity affecting younger patients with unique pathophysiology, raising awareness of this emerging cause of cardiomyopathy.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7b00d7c736c","type":"article","url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","title":"Inadequate NOAC-dosering bij AF: uitkomsten en oorzaken — meta-analyse","title_en":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321114","source_url":"https://doi.org/10.1136/heartjnl-2022-321114","authors":["Valeria Caso","Joris R de Groot","Marcelo Sanmartin Fernandez","Tomás Segura","Carina Blomström-Lundqvist","David Hargroves","Sotiris Antoniou","Helen Williams","Alice Worsley","James Harris","Amrit Caleyachetty","Burcu Vardar","Paul Field","Christian T Ruff"],"significance":7,"published":"2023-01-11","source_date":"2023-01-11","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-ouderen/"],"congress":"","summary_en":"This systematic review documented that inappropriate NOAC dosing (particularly underdosing) in AF is prevalent and associated with worse outcomes, highlighting the importance of adherence to recommended dose criteria for stroke prevention.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d67c08785f7","type":"article","url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","title":"CAPLA: posterior wand-isolatie verbetert uitkomst niet bij persisterend AF","title_en":"Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2022.23722","source_url":"https://doi.org/10.1001/jama.2022.23722","authors":["Peter M Kistler","David Chieng","Hariharan Sugumar","Liang-Han Ling","Louise Segan","Sonia Azzopardi","Ahmed Al-Kaisey","Ramanathan Parameswaran","Robert D Anderson","Joshua Hawson","Sandeep Prabhu","Aleksandr Voskoboinik","Geoffrey Wong","Joseph B Morton","Bhupesh Pathik","Alex J McLellan","Geoffrey Lee","Michael Wong","Sue Finch","Rajeev K Pathak","Deep Chandh Raja","Laurence Sterns","Matthew Ginks","Christopher M Reid","Prashanthan Sanders","Jonathan M Kalman"],"significance":8,"published":"2023-01-10","source_date":"2023-01-10","image":"","kennis":[],"congress":"","summary_en":"The CAPLA trial showed that adding posterior left atrial wall isolation to standard pulmonary vein isolation did not significantly reduce AF recurrence in patients with persistent atrial fibrillation. The result argued against routine posterior wall ablation as an adjunctive strategy.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0506af28f16c","type":"article","url":"https://hartvaat.nl/2023/01/10/dagelijkse-stappen-en-cardiovasculaire-ziekte-geharmoniseerde-meta-analyse/","title":"Dagelijkse stappen en cardiovasculaire ziekte: geharmoniseerde meta-analyse","title_en":"Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["atleten","biomarkers-cardiovasculair","farmaco-economie","gepersonaliseerde-geneeskunde","obesitas","ouderen","richtlijnen-esc","slaapapneu"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061288","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061288","authors":["Amanda E Paluch","Shivangi Bajpai","Marcel Ballin","David R Bassett","Thomas W Buford","Mercedes R Carnethon","Ariel Chernofsky","Erin E Dooley","Ulf Ekelund","Kelly R Evenson","Deborah A Galuska","Barbara J Jefferis","Lingsong Kong","William E Kraus","Martin G Larson","I-Min Lee","Charles E Matthews","Robert L Newton","Anna Nordström","Peter Nordström","Priya Palta","Alpa V Patel","Kelley Pettee Gabriel","Carl F Pieper","Lisa Pompeii","Erika Rees-Punia","Nicole L Spartano","Ramachandran S Vasan","Peter H Whincup","Shengping Yang","Janet E Fulton"],"significance":8,"published":"2023-01-10","source_date":"2023-01-10","image":"","kennis":[],"congress":"","summary_en":"This harmonized meta-analysis demonstrated a dose-response relationship between daily step count and cardiovascular disease risk, with as few as 2,000-3,000 steps per day providing measurable benefit. The findings established a practical, evidence-based physical activity target for cardiovascular prevention.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"41a9f7f97554","type":"article","url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","title":"HOST-EXAM Extended: clopidogrel superieur aan aspirine als monotherapie na PCI","title_en":"Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine","trombocytenaggregatieremmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062770","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062770","authors":["Jeehoon Kang","Kyung Woo Park","Huijin Lee","Doyeon Hwang","Han-Mo Yang","Seung-Woon Rha","Jang-Whan Bae","Nam Ho Lee","Seung-Ho Hur","Jung-Kyu Han","Eun-Seok Shin","Bon-Kwon Koo","Hyo-Soo Kim"],"significance":8,"published":"2023-01-10","source_date":"2023-01-10","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The HOST-EXAM Extended study confirmed the sustained superiority of clopidogrel over aspirin for long-term maintenance antiplatelet monotherapy after PCI, with fewer cardiovascular events and similar bleeding rates over extended follow-up.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03948f2cae67","type":"article","url":"https://hartvaat.nl/2023/01/05/nejm-interventie-voor-snelle-ambulante-follow-up-na-acuut-hartfalen/","title":"NEJM: interventie voor snelle ambulante follow-up na acuut hartfalen","title_en":"Trial of an Intervention to Improve Acute Heart Failure Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2211680","source_url":"https://doi.org/10.1056/NEJMoa2211680","authors":["Douglas S Lee","Sharon E Straus","Michael E Farkouh","Peter C Austin","Monica Taljaard","Alice Chong","Christine Fahim","Stephanie Poon","Peter Cram","Stuart Smith","Robert S McKelvie","Liane Porepa","Michael Hartleib","Peter Mitoff","Robert M Iwanochko","Andrea MacDougall","Steven Shadowitz","Howard Abrams","Esam Elbarasi","Jiming Fang","Jacob A Udell","Michael J Schull","Susanna Mak","Heather J Ross"],"significance":7,"published":"2023-01-05","source_date":"2023-01-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"This NEJM trial tested whether an intervention combining rapid clinical assessment, structured decision support, and early post-discharge follow-up improves outcomes in acute heart failure, addressing the persistent challenge of high readmission rates.","created":"2026-07-03T10:30:10Z","updated":"2026-07-03T13:29:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"85c10f9e3b14","type":"article","url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","title":"Aficamten bij obstructieve hypertrofische cardiomyopathie: fase 2 resultaten","title_en":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","aritmogene-cardiomyopathie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.10.020","source_url":"https://doi.org/10.1016/j.jacc.2022.10.020","authors":["Martin S Maron","Ahmad Masri","Lubna Choudhury","Iacopo Olivotto","Sara Saberi","Andrew Wang","Pablo Garcia-Pavia","Neal K Lakdawala","Sherif F Nagueh","Florian Rader","Albree Tower-Rader","Aslan T Turer","Caroline Coats","Michael A Fifer","Anjali Owens","Scott D Solomon","Hugh Watkins","Roberto Barriales-Villa","Christopher M Kramer","Timothy C Wong","Sharon L Paige","Stephen B Heitner","Stuart Kupfer","Fady I Malik","Lisa Meng","Amy Wohltman","Theodore Abraham"],"significance":8,"published":"2023-01-03","source_date":"2023-01-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This phase 2 study of aficamten, a next-generation cardiac myosin inhibitor, showed dose-dependent reduction of the LVOT gradient and symptom improvement in patients with obstructive hypertrophic cardiomyopathy. The results advanced aficamten toward phase 3 development as an alternative to mavacamten.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ea45f944b352","type":"article","url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","title":"Rosuvastatine versus voedingssupplementen voor lipidenmanagement","title_en":"Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["lipidenverlaging","niet-statine-therapie","rosuvastatine","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.10.013","source_url":"https://doi.org/10.1016/j.jacc.2022.10.013","authors":["Luke J Laffin","Dennis Bruemmer","Michelle Garcia","Danielle M Brennan","Ellen McErlean","Douglas S Jacoby","Erin D Michos","Paul M Ridker","Tracy Y Wang","Karol E Watson","Howard G Hutchinson","Steven E Nissen"],"significance":8,"published":"2023-01-03","source_date":"2023-01-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This JACC study compared low-dose rosuvastatin with six popular dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice) for lipid and inflammatory biomarker effects. Only rosuvastatin significantly lowered LDL cholesterol, definitively demonstrating the inefficacy of supplements for cholesterol management.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T13:29:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eece633bcb74","type":"article","url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","title":"ISCHEMIA langetermijn: geen overlevingsverschil invasief versus conservatief bij stabiel coronairlijden","title_en":"Survival After Invasive or Conservative Management of Stable Coronary Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ouderen","stabiel-coronairlijden"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062714","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062714","authors":["Judith S Hochman","Rebecca Anthopolos","Harmony R Reynolds","Sripal Bangalore","Yifan Xu","Sean M O'Brien","Stavroula Mavromichalis","Michelle Chang","Aira Contreras","Yves Rosenberg","Ruth Kirby","Balram Bhargava","Roxy Senior","Ann Banfield","Shaun G Goodman","Renato D Lopes","Radosław Pracoń","José López-Sendón","Aldo Pietro Maggioni","Jonathan D Newman","Jeffrey S Berger","Mandeep S Sidhu","Harvey D White","Andrea B Troxel","Robert A Harrington","William E Boden","Gregg W Stone","Daniel B Mark","John A Spertus","David J Maron"],"significance":9,"published":"2023-01-03","source_date":"2023-01-03","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/coronairlijden/stabiele-angina-pectoris/"],"congress":"","summary_en":"Extended ISCHEMIA follow-up confirmed that an initial invasive strategy provided no survival benefit over conservative management in patients with stable coronary disease and moderate-to-severe ischemia. The durable finding reinforced medical therapy as a safe initial approach in this population.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T13:29:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b9b783244b7","type":"article","url":"https://hartvaat.nl/2023/01/01/nudging-verhoogt-statinevoorschrijving-bij-zowel-arts-als-patient/","title":"Nudging verhoogt statinevoorschrijving bij zowel arts als patiënt","title_en":"Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4373","source_url":"https://doi.org/10.1001/jamacardio.2022.4373","authors":["Srinath Adusumalli","Genevieve P Kanter","Dylan S Small","David A Asch","Kevin G Volpp","Sae-Hwan Park","Yevgeniy Gitelman","David Do","Damien Leri","Corinne Rhodes","Christine VanZandbergen","John T Howell","Mika Epps","Ann M Cavella","Michael Wenger","Tory O Harrington","Kayla Clark","Julie E Westover","Christopher K Snider","Mitesh S Patel"],"significance":6,"published":"2023-01-01","source_date":"2023-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This cluster-randomized trial showed that behavioral nudges targeting clinicians, patients, or both significantly increase statin prescribing for eligible individuals, demonstrating the effectiveness of decision architecture for cardiovascular prevention.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T13:29:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4096c3429fde","type":"article","url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","title":"Vitamine D voorkomt statine-gerelateerde spierklachten niet","title_en":"Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":["anemie-ckd","chronische-nierziekte","clear-outcomes","dyslipidemie","ezetimibe","niet-statine-therapie","rosuvastatine","statines"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4250","source_url":"https://doi.org/10.1001/jamacardio.2022.4250","authors":["Mark A Hlatky","Pedro Engel Gonzalez","JoAnn E Manson","Julie E Buring","I-Min Lee","Nancy R Cook","Samia Mora","Vadim Bubes","Neil J Stone"],"significance":7,"published":"2023-01-01","source_date":"2023-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This randomized study showed that vitamin D supplementation does not reduce the incidence of statin-associated muscle symptoms in new statin users, arguing against routine vitamin D for preventing statin intolerance.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T13:29:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8b410c44aae6","type":"article","url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","title":"DELIVER: dapagliflozine beschermt ook de nieren bij HFpEF","title_en":"Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","cystatine-c","dapa-hf","dapagliflozine","empagliflozine","hfpef","hfref","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.4210","source_url":"https://doi.org/10.1001/jamacardio.2022.4210","authors":["Finnian R Mc Causland","Brian L Claggett","Muthiah Vaduganathan","Akshay S Desai","Pardeep Jhund","Rudolf A de Boer","Kieran Docherty","James Fang","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Jose F Kerr Saraiva","Martina M McGrath","Sanjiv J Shah","Subodh Verma","Anna Maria Langkilde","Magnus Petersson","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2023-01-01","source_date":"2023-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This DELIVER analysis showed that dapagliflozin slows kidney function decline in patients with HFpEF, demonstrating renoprotective effects of SGLT2 inhibition that extend to the preserved ejection fraction heart failure population.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad63f1b7d1c8","type":"article","url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","title":"EMPULSE: empagliflozine verbetert decongestie bij acuut hartfalen","title_en":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","canagliflozine","carvedilol","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","sacubitril-valsartan","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac530","source_url":"https://doi.org/10.1093/eurheartj/ehac530","authors":["Jan Biegus","Adriaan A Voors","Sean P Collins","Mikhail N Kosiborod","John R Teerlink","Christiane E Angermann","Jasper Tromp","Joao Pedro Ferreira","Michael E Nassif","Mitchell A Psotka","Martina Brueckmann","Afshin Salsali","Jonathan P Blatchford","Piotr Ponikowski"],"significance":8,"published":"2023-01-01","source_date":"2023-01-01","image":"","kennis":[],"congress":"","summary_en":"This EMPULSE subanalysis showed that empagliflozin started during acute heart failure hospitalization significantly improved decongestion markers, including weight loss and hemoconcentration, supporting SGLT2 inhibitors as an adjunctive decongestion strategy.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ac2c017b22b","type":"article","url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","title":"Opleiding, intelligentie en cognitie: onafhankelijke verbanden met hypertensie","title_en":"Independent Associations of Education, Intelligence, and Cognition With Hypertension and the Mediating Effects of Cardiometabolic Risk Factors: A Mendelian Randomization Study.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","diabetes-en-hart","lichamelijke-inactiviteit","obesitas","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20286","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20286","authors":["Yiying Wang","Chaojie Ye","Lijie Kong","Jie Zheng","Min Xu","Yu Xu","Mian Li","Zhiyun Zhao","Jieli Lu","Yuhong Chen","Weiqing Wang","Guang Ning","Yufang Bi","Tiange Wang"],"significance":5,"published":"2023-01-01","source_date":"2023-01-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/risicofactoren-cardiovasculair/","https://hartvaat.nl/kennis/preventie/esc-richtlijn-cardiovasculaire-preventie-2021/"],"congress":"","summary_en":"This Mendelian randomization study showed that lower educational attainment is independently associated with hypertension risk, partially mediated by cognitive factors and cardiovascular risk behaviors.","created":"2026-07-03T10:30:09Z","updated":"2026-07-03T18:38:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a44c6d984a68","type":"article","url":"https://hartvaat.nl/2022/12/29/chloortalidon-versus-hydrochloorthiazide-geen-verschil-in-cv-events/","title":"Chloortalidon versus hydrochloorthiazide: geen verschil in CV-events","title_en":"Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2212270","source_url":"https://doi.org/10.1056/NEJMoa2212270","authors":["Areef Ishani","William C Cushman","Sarah M Leatherman","Robert A Lew","Patricia Woods","Peter A Glassman","Addison A Taylor","Cynthia Hau","Alison Klint","Grant D Huang","Mary T Brophy","Louis D Fiore","Ryan E Ferguson"],"significance":9,"published":"2022-12-29","source_date":"2022-12-29","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"This large pragmatic NEJM trial in 13,000 hypertensive veterans demonstrated that chlorthalidone was not superior to hydrochlorothiazide for preventing major cardiovascular events. The results challenged the assumption of chlorthalidone's superiority and supported continued use of either thiazide diuretic.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c0400d3607f1","type":"article","url":"https://hartvaat.nl/2022/12/22/orthostatische-bloeddruk-en-intensieve-behandeling-sprint-inzichten/","title":"Orthostatische bloeddruk en intensieve behandeling: SPRINT-inzichten","title_en":"Relationship between orthostatic blood pressure changes and intensive blood pressure management in patients with hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321276","source_url":"https://doi.org/10.1136/heartjnl-2022-321276","authors":["Junyu Pei","Hao Zhang","Yanan Li","Jiafu Yan","Keyang Zheng","Xiaopu Wang","Xi-Long Zheng","Xinqun Hu"],"significance":6,"published":"2022-12-22","source_date":"2022-12-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This SPRINT analysis showed that intensive blood pressure treatment does not significantly increase the risk of orthostatic hypotension, providing reassurance for aggressive blood pressure management in the elderly.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"79c9bb754226","type":"article","url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","title":"ORION-11: inclisiran verlaagt LDL effectief bij primaire preventie","title_en":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bempedoïnezuur","dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac615","source_url":"https://doi.org/10.1093/eurheartj/ehac615","authors":["Kausik K Ray","David Kallend","Lawrence A Leiter","Frederick J Raal","Wolfgang Koenig","Mark J Jaros","Gregory G Schwartz","Ulf Landmesser","Lorena Garcia Conde","R Scott Wright"],"significance":7,"published":"2022-12-21","source_date":"2022-12-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/inclisiran-sirna/","https://hartvaat.nl/kennis/lipiden/pcsk9-mechanisme/"],"congress":"","summary_en":"This ORION-11 subanalysis showed that inclisiran effectively lowers LDL cholesterol in primary prevention patients on statins, demonstrating the twice-yearly injection's utility beyond the secondary prevention population.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"22c389402f97","type":"article","url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","title":"Bloeddrukverlaging en dementiepreventie: IPD meta-analyse","title_en":"Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac584","source_url":"https://doi.org/10.1093/eurheartj/ehac584","authors":["Ruth Peters","Ying Xu","Oisin Fitzgerald","Htein Linn Aung","Nigel Beckett","Christopher Bulpitt","John Chalmers","Francoise Forette","Jessica Gong","Katie Harris","Peter Humburg","Fiona E Matthews","Jan A Staessen","Lutgarde Thijs","Christophe Tzourio","Jane Warwick","Mark Woodward","Craig S Anderson"],"significance":8,"published":"2022-12-21","source_date":"2022-12-21","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This individual patient data meta-analysis demonstrated that blood pressure lowering reduces the risk of incident dementia, with no evidence of a U-shaped relationship at lower blood pressure levels. The analysis provided the strongest evidence yet for blood pressure control as a dementia prevention strategy.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2014541a69c6","type":"article","url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","title":"Empagliflozine en het circulerend proteoom bij hartfalen: EMPEROR-mechanismen","title_en":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["empagliflozine","emperor-trials"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac495","source_url":"https://doi.org/10.1093/eurheartj/ehac495","authors":["Faiez Zannad","João Pedro Ferreira","Javed Butler","Gerasimos Filippatos","James L Januzzi","Mikhail Sumin","Matthias Zwick","Maral Saadati","Stuart J Pocock","Naveed Sattar","Stefan D Anker","Milton Packer"],"significance":6,"published":"2022-12-21","source_date":"2022-12-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This proteomics analysis of EMPEROR program data revealed that empagliflozin significantly alters circulating protein profiles in heart failure, identifying molecular pathways that may explain SGLT2 inhibitor cardioprotection beyond diuresis.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ef91d0be4027","type":"article","url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","title":"IRONMAN: intraveneus ijzer bij hartfalen met ijzerdeficiëntie — Lancet RCT","title_en":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["ijzersuppletie","ijzertekort"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02083-9","source_url":"https://doi.org/10.1016/S0140-6736(22)02083-9","authors":["Paul R Kalra","John G F Cleland","Mark C Petrie","Elizabeth A Thomson","Philip A Kalra","Iain B Squire","Fozia Z Ahmed","Abdallah Al-Mohammad","Peter J Cowburn","Paul W X Foley","Fraser J Graham","Alan G Japp","Rebecca E Lane","Ninian N Lang","Andrew J Ludman","Iain C Macdougall","Pierpaolo Pellicori","Robin Ray","Michele Robertson","Alison Seed","Ian Ford"],"significance":9,"published":"2022-12-17","source_date":"2022-12-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The IRONMAN trial showed a trend toward reduced heart failure hospitalization and cardiovascular death with intravenous ferric derisomaltose in patients with heart failure and iron deficiency, though the primary endpoint did not reach statistical significance. COVID-19 pandemic disruptions affected enrollment and follow-up.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebdc26982909","type":"article","url":"https://hartvaat.nl/2022/12/13/micronutrientensuppletie-en-cardiovasculair-risico-jacc-systematische-review/","title":"Micronutriëntensuppletie en cardiovasculair risico: JACC systematische review","title_en":"Micronutrient Supplementation to Reduce Cardiovascular Risk.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts"],"tags":["biomarkers-cardiovasculair","farmaco-economie","menopauze","microbioom","roken","voeding-hart"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.09.048","source_url":"https://doi.org/10.1016/j.jacc.2022.09.048","authors":["Peng An","Sitong Wan","Yongting Luo","Junjie Luo","Xu Zhang","Shuaishuai Zhou","Teng Xu","Jingjing He","Jeffrey I Mechanick","Wen-Chih Wu","Fazheng Ren","Simin Liu"],"significance":7,"published":"2022-12-13","source_date":"2022-12-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This systematic review of micronutrient supplementation and cardiovascular risk found that only folate and omega-3 fatty acids (specifically in REDUCE-IT) show evidence of CV benefit, while other supplements lack convincing efficacy data.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca12db02e7a5","type":"article","url":"https://hartvaat.nl/2022/12/10/urbanisatie-en-cardiometabool-risico-bij-inheemse-braziliaanse-volkeren/","title":"Urbanisatie en cardiometabool risico bij inheemse Braziliaanse volkeren","title_en":"The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","farmaco-economie","hartrevalidatie","inflammatie","lichaamsbeweging","menopauze","microbioom","obesitas","ouderen","primaire-preventie","roken","select-trial","slaapapneu","soul-trial","tirzepatide","vrouwen"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00625-0","source_url":"https://doi.org/10.1016/S0140-6736(22)00625-0","authors":["Caroline K Kramer","Cristiane B Leitão","Luciana V Viana"],"significance":6,"published":"2022-12-10","source_date":"2022-12-10","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This Lancet study documented the cardiometabolic impact of urbanization on Indigenous Brazilian peoples, showing rapid increases in hypertension, diabetes, and dyslipidemia following nutritional transition from traditional to modern diets.","created":"2026-07-03T10:30:08Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3910d6eafd87","type":"article","url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","title":"Ideale blankingperiode na AF-ablatie: bewijs voor herziening","title_en":"Evidence-based insights on ideal blanking period duration following atrial fibrillation catheter ablation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac098","source_url":"https://doi.org/10.1093/europace/euac098","authors":["Andrea Saglietto","Andrea Ballatore","Henri Xhakupi","Federico Rubat Baleuri","Massimo Magnano","Fiorenzo Gaita","Gaetano Maria De Ferrari","Matteo Anselmino"],"significance":6,"published":"2022-12-09","source_date":"2022-12-09","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/elektrisch-remodellering-atrium/"],"congress":"","summary_en":"This review examined the evidence for the standard 3-month blanking period after AF ablation, showing that early recurrences within the blanking period are associated with late outcomes and may warrant earlier therapeutic consideration.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"10653d4b1f49","type":"article","url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","title":"Apixaban bij AF op hemodialyse: eerste gerandomiseerde trial","title_en":"Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.054990","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.054990","authors":["Sean D Pokorney","Glenn M Chertow","Hussein R Al-Khalidi","Dianne Gallup","Pat Dignacco","Kurt Mussina","Nisha Bansal","Crystal A Gadegbeku","David A Garcia","Samira Garonzik","Renato D Lopes","Kenneth W Mahaffey","Kelly Matsuda","John P Middleton","Jennifer A Rymer","George H Sands","Ravi Thadhani","Kevin L Thomas","Jeffrey B Washam","Wolfgang C Winkelmayer","Christopher B Granger"],"significance":8,"published":"2022-12-06","source_date":"2022-12-06","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This first randomized trial of apixaban in AF patients on hemodialysis showed no significant improvement over usual care (mostly warfarin) for stroke prevention, with similar rates of bleeding and thrombotic events. The result highlighted the persistent evidence gap in anticoagulation for dialysis patients with AF.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"79be1fe70690","type":"article","url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","title":"PARADISE-MI: sacubitril/valsartan vermindert coronaire events niet na MI","title_en":"The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060841","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060841","authors":["Roxana Mehran","Philippe Gabriel Steg","Marc A Pfeffer","Karola Jering","Brian Claggett","Eldrin F Lewis","Christopher Granger","Lars Køber","Aldo Maggioni","Douglas L Mann","John J V McMurray","Jean-Lucien Rouleau","Scott D Solomon","Gregory Ducrocq","Otavio Berwanger","Carmine G De Pasquale","Ulf Landmesser","Mark Petrie","David Sim Kheng Leng","Peter van der Meer","Martin Lefkowitz","Yinong Zhou","Eugene Braunwald"],"significance":7,"published":"2022-12-06","source_date":"2022-12-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This PARADISE-MI analysis confirmed that sacubitril-valsartan does not reduce major coronary events compared with ramipril after acute MI, consistent with the neutral primary endpoint and limiting ARNI use to established heart failure.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4d564506a7f5","type":"article","url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","title":"PRECISION: aprocitentan bij resistente hypertensie — eerste endothelineantagonist","title_en":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aprocitentan","bloeddrukbehandeling","endothelineantagonisten","lorundrostat","precision-trial","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02034-7","source_url":"https://doi.org/10.1016/S0140-6736(22)02034-7","authors":["Markus P Schlaich","Marc Bellet","Michael A Weber","Parisa Danaietash","George L Bakris","John M Flack","Roland F Dreier","Mouna Sassi-Sayadi","Lloyd P Haskell","Krzysztof Narkiewicz","Ji-Guang Wang"],"significance":9,"published":"2022-12-03","source_date":"2022-12-03","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/"],"congress":"","summary_en":"The PRECISION trial showed that aprocitentan, a dual endothelin receptor antagonist, significantly reduced blood pressure in patients with resistant hypertension on triple therapy. This was the first positive phase 3 trial of an endothelin antagonist for systemic hypertension, opening a new mechanism of action for treatment-resistant blood pressure.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"193915d5f61b","type":"article","url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","title":"STRONG-HF: snelle optitratie van hartfalenmedicatie na ziekenhuis is veilig en effectief","title_en":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["step-hfpef"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02076-1","source_url":"https://doi.org/10.1016/S0140-6736(22)02076-1","authors":["Alexandre Mebazaa","Beth Davison","Ovidiu Chioncel","Alain Cohen-Solal","Rafael Diaz","Gerasimos Filippatos","Marco Metra","Piotr Ponikowski","Karen Sliwa","Adriaan A Voors","Christopher Edwards","Maria Novosadova","Koji Takagi","Albertino Damasceno","Hadiza Saidu","Etienne Gayat","Peter S Pang","Jelena Celutkiene","Gad Cotter"],"significance":10,"published":"2022-12-03","source_date":"2022-12-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The STRONG-HF trial demonstrated that rapid, intensive up-titration of guideline-directed medical therapy (beta-blocker, RAAS inhibitor, MRA) within two weeks of hospital discharge for acute heart failure was safe and significantly reduced heart failure readmission and death compared with usual care. The study established early, aggressive optimization as the standard post-discharge approach.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ec06faa53900","type":"article","url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","title":"RADIANCE-HTN TRIO: renale denervatie effectief na medicatie-optitratie","title_en":"Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.3904","source_url":"https://doi.org/10.1001/jamacardio.2022.3904","authors":["Michel Azizi","Felix Mahfoud","Michael A Weber","Andrew S P Sharp","Roland E Schmieder","Philipp Lurz","Melvin D Lobo","Naomi D L Fisher","Joost Daemen","Michael J Bloch","Jan Basile","Kintur Sanghvi","Manish Saxena","Philippe Gosse","J Stephen Jenkins","Terry Levy","Alexandre Persu","Benjamin Kably","Lisa Claude","Helen Reeve-Stoffer","Candace McClure","Ajay J Kirtane"],"significance":7,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This RADIANCE-HTN TRIO prespecified analysis confirmed that ultrasound renal denervation significantly reduces blood pressure in patients with confirmed resistant hypertension even after medication escalation, supporting device-based therapy as an adjunct to optimized pharmacotherapy.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3619a4ff1df6","type":"article","url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","title":"Serieel hoog-sensitief troponine T voorspelt CV-events na ACS: ODYSSEY analyse","title_en":"Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","hs-crp"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.3627","source_url":"https://doi.org/10.1001/jamacardio.2022.3627","authors":["Siddharth M Patel","Arman Qamar","Robert P Giugliano","Petr Jarolim","Nicholas A Marston","Jeong-Gun Park","Michael A Blazing","Christopher P Cannon","Eugene Braunwald","David A Morrow"],"significance":6,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This ODYSSEY OUTCOMES analysis showed that serial high-sensitivity troponin T measurements after ACS improve cardiovascular event prediction beyond baseline values, supporting dynamic biomarker monitoring for post-ACS risk assessment.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"14c436befbc4","type":"article","url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","title":"DELIVER: snel voordeel van dapagliflozine bij HFpEF — binnen weken merkbaar","title_en":"Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","empagliflozine","hfpef","hfref","metoprolol","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.3750","source_url":"https://doi.org/10.1001/jamacardio.2022.3750","authors":["Muthiah Vaduganathan","Brian L Claggett","Pardeep Jhund","Rudolf A de Boer","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Sanjiv J Shah","Akshay S Desai","Sheila M Hegde","Daniel Lindholm","Magnus Petersson","Anna Maria Langkilde","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This DELIVER analysis demonstrated that dapagliflozin achieves clinical benefit within 13 days of initiation in HFpEF, establishing SGLT2 inhibitors as one of the fastest-acting therapies for heart failure across the ejection fraction spectrum.","created":"2026-07-03T10:30:07Z","updated":"2026-07-03T13:29:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94e3c1d4f8dd","type":"article","url":"https://hartvaat.nl/2022/12/01/apotheker-geleide-telezorg-versus-poliklinische-zorg-bij-ongecontroleerde-hypert/","title":"Apotheker-geleide telezorg versus poliklinische zorg bij ongecontroleerde hypertensie","title_en":"Comparing Pharmacist-Led Telehealth Care and Clinic-Based Care for Uncontrolled High Blood Pressure: The Hyperlink 3 Pragmatic Cluster-Randomized Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":["bloeddrukbehandeling","thuisbloeddrukmeting"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19816","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19816","authors":["Karen L Margolis","Anna R Bergdall","A Lauren Crain","Meghan M JaKa","Jeffrey P Anderson","Leif I Solberg","JoAnn Sperl-Hillen","MarySue Beran","Beverly B Green","Patricia Haugen","Christine K Norton","Amy J Kodet","Rashmi Sharma","Deepika Appana","Nicole K Trower","Pamala A Pawloski","Daniel J Rehrauer","Maria L Simmons","Zeke J McKinney","Thomas E Kottke","Jeanette Y Ziegenfuss","Rae Ann Williams","Patrick J O'Connor"],"significance":6,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/therapietrouw-hypertensie/"],"congress":"","summary_en":"The Hyperlink 3 trial showed that pharmacist-led telehealth care achieves comparable blood pressure control to clinic-based care in uncontrolled hypertension, validating remote team-based management models.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa528965fbcc","type":"article","url":"https://hartvaat.nl/2022/12/01/klebsiella-pneumoniae-als-mogelijke-oorzaak-van-hypertensie/","title":"Klebsiella pneumoniae als mogelijke oorzaak van hypertensie","title_en":"Causality of Opportunistic Pathogen Klebsiella pneumoniae to Hypertension Development.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["endocarditis","microbioom"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.18878","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.18878","authors":["Jing Li","Qiannan Gao","Yiyangzi Ma","Yue Deng","Shuangyue Li","Na Shi","Haitao Niu","Xin-Yu Liu","Jun Cai"],"significance":5,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/witte-jas-hypertensie/"],"congress":"","summary_en":"This translational study suggested a causal relationship between the gut pathogen Klebsiella pneumoniae and hypertension development, advancing the microbiome-hypertension hypothesis with species-level specificity.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c25bcc66b859","type":"article","url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","title":"Finerenon: bloeddrukeffecten en cardiorenale uitkomsten bij CKD en diabetes","title_en":"Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bloeddrukbehandeling","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","diabetes-en-hart","diabetes-type-2","fidelio-dkd","fidelity","figaro-dkd","ijzertekort"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19744","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19744","authors":["Luis M Ruilope","Rajiv Agarwal","Stefan D Anker","Gerasimos Filippatos","Bertram Pitt","Peter Rossing","Pantelis Sarafidis","Roland E Schmieder","Amer Joseph","Nicole Rethemeier","Christina Nowack","George L Bakris"],"significance":7,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This analysis showed that finerenone modestly lowers blood pressure in patients with CKD and type 2 diabetes, but the cardiorenal benefit is independent of blood pressure reduction, operating through direct mineralocorticoid receptor-mediated organ protection.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9403a61252d8","type":"article","url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","title":"Hartfalen tijdens de COVID-19-pandemie: klinische en organisatorische dilemma's","title_en":"Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","covid-hart"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14118","source_url":"https://doi.org/10.1002/ehf2.14118","authors":["Alberto Palazzuoli","Marco Metra","Sean P Collins","Marianna Adamo","Andrew P Ambrosy","Laura E Antohi","Tuvia Ben Gal","Dimitrios Farmakis","Finn Gustafsson","Loreena Hill","Yuri Lopatin","Francesco Tramonte","Alexander Lyon","Josep Masip","Oscar Miro","Brenda Moura","Wilfried Mullens","Razvan I Radu","Magdy Abdelhamid","Stefan Anker","Ovidiu Chioncel"],"significance":5,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This review described the multifaceted impact of COVID-19 on heart failure care, covering delayed presentations, disrupted diagnostic pathways, telemedicine adoption, and the long-term cardiovascular consequences of SARS-CoV-2 infection.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b30e6de72dd2","type":"article","url":"https://hartvaat.nl/2022/12/01/immuuncelsubsets-voorspellen-incident-hartfalen-in-populatiestudies/","title":"Immuuncelsubsets voorspellen incident hartfalen in populatiestudies","title_en":"Association of immune cell subsets with incident heart failure in two population-based cohorts.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14140","source_url":"https://doi.org/10.1002/ehf2.14140","authors":["Arjun Sinha","Colleen M Sitlani","Margaret F Doyle","Alison E Fohner","Petra Buzkova","James S Floyd","Sally A Huber","Nels C Olson","Joyce N Njoroge","Jorge R Kizer","Joseph A Delaney","Sanjiv S Shah","Russell P Tracy","Bruce Psaty","Matthew Feinstein"],"significance":5,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":[],"congress":"","summary_en":"This population-based study showed that specific immune cell subsets (monocytes, neutrophils) predict incident heart failure, establishing immune profiling as a novel approach to HF risk assessment.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"40e7c8d9c078","type":"article","url":"https://hartvaat.nl/2022/12/01/digitale-hartrevalidatie-bij-hartfalen-systematische-review/","title":"Digitale hartrevalidatie bij hartfalen: systematische review","title_en":"Efficacy and safety of digital therapeutics-based cardiac rehabilitation in heart failure patients: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bisoprolol","carvedilol","empagliflozine","hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14145","source_url":"https://doi.org/10.1002/ehf2.14145","authors":["Xiu Zhang","Zeruxin Luo","Mengxuan Yang","Wei Huang","Pengming Yu"],"significance":5,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This systematic review confirmed that digital therapeutics-based cardiac rehabilitation improves functional capacity and quality of life in heart failure, supporting virtual programs as a viable alternative during and after the COVID-19 pandemic.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"79ebafdc3930","type":"article","url":"https://hartvaat.nl/2022/12/01/langetermijnmortaliteit-bij-hfmref-systematische-review-en-meta-analyse/","title":"Langetermijnmortaliteit bij HFmrEF: systematische review en meta-analyse","title_en":"Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14125","source_url":"https://doi.org/10.1002/ehf2.14125","authors":["Deep Chandh Raja","Indira Samarawickrema","Souvik Das","Abhinav Mehta","Lukah Tuan","Sanjiv Jain","Sanjay Dixit","Frank Marchlinski","Walter P Abhayaratna","Prashanthan Sanders","Rajeev K Pathak"],"significance":6,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis confirmed that long-term mortality in HFmrEF is intermediate between HFrEF and HFpEF, supporting the classification of mid-range ejection fraction as a distinct prognostic category.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5fc216bd3825","type":"article","url":"https://hartvaat.nl/2022/12/01/daprodustat-bij-anemie-en-hartfalen-met-ckd-gerandomiseerde-studie/","title":"Daprodustat bij anemie en hartfalen met CKD: gerandomiseerde studie","title_en":"Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","chronische-nierziekte","dapagliflozine","figaro-dkd","finearts-hf","flow-trial","hfpef","hfref","ijzertekort","nierfalen","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14109","source_url":"https://doi.org/10.1002/ehf2.14109","authors":["Takashi Iso","Yuya Matsue","Akira Mizukami","Takashi Tokano","Kikuo Isoda","Satoru Suwa","Katsumi Miyauchi","Naotake Yanagisawa","Yasuo Okumura","Tohru Minamino"],"significance":6,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This randomized study of daprodustat in patients with heart failure, CKD, and anemia showed that the HIF-PH inhibitor improves hemoglobin with an acceptable safety profile, exploring oral anemia therapy in the cardio-renal population.","created":"2026-07-03T10:30:06Z","updated":"2026-07-03T18:38:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e92b327771b","type":"article","url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","title":"Vericiguat en NT-proBNP bij HFrEF: VICTORIA subanalyse","title_en":"Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14050","source_url":"https://doi.org/10.1002/ehf2.14050","authors":["Michele Senni","Jose Lopez-Sendon","Alain Cohen-Solal","Piotr Ponikowski","Richard Nkulikiyinka","Cecilia Freitas","Vanja Miodrag Vlajnic","Lothar Roessig","Burkert Pieske"],"significance":6,"published":"2022-12-01","source_date":"2022-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This VICTORIA subanalysis showed that vericiguat's benefit in HFrEF is consistent across NT-proBNP levels, with patients at the highest natriuretic peptide levels having the greatest absolute benefit from sGC stimulation.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f61dfc2a208","type":"article","url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","title":"FAVOR III: QFR-geleide PCI verbetert tweejaarsuitkomsten","title_en":"2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.09.007","source_url":"https://doi.org/10.1016/j.jacc.2022.09.007","authors":["Lei Song","Bo Xu","Shengxian Tu","Changdong Guan","Zening Jin","Bo Yu","Guosheng Fu","Yujie Zhou","Jian'an Wang","Yundai Chen","Jun Pu","Lianglong Chen","Xinkai Qu","Junqing Yang","Xuebo Liu","Lijun Guo","Chengxing Shen","Yaojun Zhang","Qi Zhang","Hongwei Pan","Rui Zhang","Jian Liu","Yanyan Zhao","Yang Wang","Kefei Dou","Ajay J Kirtane","Yongjian Wu","William Wijns","Weixian Yang","Martin B Leon","Shubin Qiao","Gregg W Stone"],"significance":7,"published":"2022-11-29","source_date":"2022-11-29","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/fractional-flow-reserve/","https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"Two-year FAVOR III results confirmed that angiographic QFR-guided PCI maintains superior outcomes compared with conventional angiography guidance, supporting the durability of wire-free physiological assessment for coronary intervention decisions.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b8eaabe6581","type":"article","url":"https://hartvaat.nl/2022/11/26/triple-gip-glp-1-glucagonreceptoragonist-bij-type-2-diabetes-fase-1b/","title":"Triple GIP/GLP-1/glucagonreceptoragonist bij type 2 diabetes: fase 1b","title_en":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","semaglutide","tirzepatide"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02033-5","source_url":"https://doi.org/10.1016/S0140-6736(22)02033-5","authors":["Shweta Urva","Tamer Coskun","Mei Teng Loh","Yu Du","Melissa K Thomas","Sirel Gurbuz","Axel Haupt","Charles T Benson","Martha Hernandez-Illas","David A D'Alessio","Zvonko Milicevic"],"significance":8,"published":"2022-11-26","source_date":"2022-11-26","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This phase 1b trial of a triple GIP/GLP-1/glucagon receptor agonist (retatrutide) demonstrated dramatic HbA1c reduction and weight loss in patients with type 2 diabetes. The triple agonism concept showed additive metabolic benefit beyond dual GIP/GLP-1 agonists.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6524884587fb","type":"article","url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","title":"Bivalirudine versus heparine bij primaire PCI voor STEMI: Lancet-trial","title_en":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01999-7","source_url":"https://doi.org/10.1016/S0140-6736(22)01999-7","authors":["Yi Li","Zhenyang Liang","Lei Qin","Mian Wang","Xianzhao Wang","Huanyi Zhang","Yin Liu","Yan Li","Zhisheng Jia","Limin Liu","Hongyan Zhang","Jun Luo","Songwu Dong","Jincheng Guo","Hengqing Zhu","Shengli Li","Haijun Zheng","Lijun Liu","Yanqing Wu","Yiming Zhong","Miaohan Qiu","Yaling Han","Gregg W Stone"],"significance":7,"published":"2022-11-26","source_date":"2022-11-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/kleplijden/mitralisregurgitatie/"],"congress":"","summary_en":"This Lancet trial compared bivalirudin with high-dose infusion versus heparin monotherapy in STEMI patients undergoing primary PCI, providing updated safety and efficacy data for anticoagulation during primary percutaneous coronary intervention.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7cc1eb83f3fd","type":"article","url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","title":"PROMINENT: pemafibrate verlaagt triglyceriden maar vermindert CV-events niet","title_en":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-en-hart","dyslipidemie","ezetimibe","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obesitas","select-trial","soul-trial","stride-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2210645","source_url":"https://doi.org/10.1056/NEJMoa2210645","authors":["Aruna Das Pradhan","Robert J Glynn","Jean-Charles Fruchart","Jean G MacFadyen","Elaine S Zaharris","Brendan M Everett","Stuart E Campbell","Ryu Oshima","Pierre Amarenco","Dirk J Blom","Eliot A Brinton","Robert H Eckel","Marshall B Elam","João S Felicio","Henry N Ginsberg","Assen Goudev","Shun Ishibashi","Jacob Joseph","Tatsuhiko Kodama","Wolfgang Koenig","Lawrence A Leiter","Alberto J Lorenzatti","Boris Mankovsky","Nikolaus Marx","Børge G Nordestgaard","Dénes Páll","Kausik K Ray","Raul D Santos","Handrean Soran","Andrey Susekov","Michal Tendera","Koutaro Yokote","Nina P Paynter","Julie E Buring","Peter Libby","Paul M Ridker"],"significance":10,"published":"2022-11-24","source_date":"2022-11-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/"],"congress":"","summary_en":"The PROMINENT trial showed that pemafibrate, a selective PPARα agonist, effectively lowered triglycerides but did not reduce cardiovascular events in patients with type 2 diabetes and elevated triglycerides despite statin therapy. This definitive negative result, together with earlier fibrate failures, largely closed the door on triglyceride lowering as a cardiovascular prevention strategy.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ece78811e0a5","type":"article","url":"https://hartvaat.nl/2022/11/24/protecct-ct-bij-verdenking-acs-met-intermediaire-troponinewaarden/","title":"PROTECCT: CT bij verdenking ACS met intermediaire troponinewaarden","title_en":"Prospective RandOmised Trial of Emergency Cardiac Computerised Tomography (PROTECCT).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-320990","source_url":"https://doi.org/10.1136/heartjnl-2022-320990","authors":["Waqar Aziz","Holly Morgan","Ozan M Demir","Aish Sinha","Tiago Rua","Ronak Rajani","Ai-Lee Chang","Eric Woo","Sze Mun Mak","Giulia Benedetti","Adriana Villa","Rebecca Preston","Roshan Navin","Kevin O'Kane","Laura Hunter","Tevfik Ismail","Gerry Carr-White","Nick Beckley-Hoelscher","Janet Peacock","Michael Marber","Reza Razavi","Divaka Perera"],"significance":7,"published":"2022-11-24","source_date":"2022-11-24","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"The PROTECCT trial evaluated whether coronary CT angiography can improve the diagnostic pathway for patients with suspected ACS and intermediate troponin levels, exploring the role of CCTA in the diagnostic gray zone.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ef997b6113d","type":"article","url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","title":"EES versus CABG bij meervatslijden: langetermijn follow-up van RCT's","title_en":"Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["newton-cabg"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.062188","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.062188","authors":["Jung-Min Ahn","Do-Yoon Kang","Sung-Cheol Yun","Seung Ho Hur","Hun-Jun Park","Damras Tresukosol","Woong Chol Kang","Hyuck Moon Kwon","Seung-Woon Rha","Do-Sun Lim","Myung-Ho Jeong","Bong-Ki Lee","He Huang","Young Hyo Lim","Jang Ho Bae","Byung Ok Kim","Tiong Kiam Ong","Sung Gyun Ahn","Cheol-Hyun Chung","Duk-Woo Park","Seung-Jung Park"],"significance":8,"published":"2022-11-22","source_date":"2022-11-22","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/kleplijden/endocarditis-profylaxe/"],"congress":"","summary_en":"This extended follow-up of multiple randomized trials comparing PCI with everolimus-eluting stents versus CABG for multivessel disease confirmed that CABG provides superior long-term outcomes, particularly for complex coronary anatomy. The results reinforced CABG as the preferred strategy for extensive multivessel disease.","created":"2026-07-03T10:30:05Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3b305af0db1","type":"article","url":"https://hartvaat.nl/2022/11/22/cva-risicoscores-bij-af-vergeleken-cha2ds2-vasc-blijft-de-beste/","title":"CVA-risicoscores bij AF vergeleken: CHA₂DS₂-VASc blijft de beste","title_en":"Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac096","source_url":"https://doi.org/10.1093/europace/euac096","authors":["Vera H W van der Endt","Jet Milders","Bas B L Penning de Vries","Serge A Trines","Rolf H H Groenwold","Olaf M Dekkers","Marco Trevisan","Juan J Carrero","Merel van Diepen","Friedo W Dekker","Ype de Jong"],"significance":7,"published":"2022-11-22","source_date":"2022-11-22","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This comprehensive meta-analysis of 6.3 million AF patients compared multiple stroke risk prediction scores, confirming that CHA₂DS₂-VASc remains the best-validated and most practical tool for thromboembolic risk stratification in clinical practice.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7dc7d56fffc5","type":"article","url":"https://hartvaat.nl/2022/11/22/athena-subanalyse-dronedaron-effectief-ongeacht-leeftijd-en-geslacht-bij-af/","title":"ATHENA-subanalyse: dronedaron effectief ongeacht leeftijd en geslacht bij AF","title_en":"Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab208","source_url":"https://doi.org/10.1093/europace/euab208","authors":["Anne B Curtis","Emily P Zeitler","Aysha Malik","Andrew Bogard","Nidhi Bhattacharyya","John Stewart","Stefan H Hohnloser"],"significance":6,"published":"2022-11-22","source_date":"2022-11-22","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This ATHENA post-hoc analysis confirmed that dronedarone maintains consistent efficacy and safety across age and sex subgroups in AF, supporting its use as a rhythm control agent regardless of patient demographics.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c63c3b71294","type":"article","url":"https://hartvaat.nl/2022/11/19/sglt2-remmers-en-nieruitkomsten-diabetes-maakt-niet-uit-lancet-meta-analyse/","title":"SGLT2-remmers en nieruitkomsten: diabetes maakt niet uit — Lancet meta-analyse","title_en":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","empagliflozine","fidelio-dkd","figaro-dkd","sglt2-remmers","soul-trial"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)02074-8","source_url":"https://doi.org/10.1016/S0140-6736(22)02074-8","authors":[],"significance":9,"published":"2022-11-19","source_date":"2022-11-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This collaborative meta-analysis of major SGLT2 inhibitor trials demonstrated that the kidney-protective effects of SGLT2 inhibition are independent of diabetes status and baseline kidney function. The findings support SGLT2 inhibitors as a universal renoprotective therapy across diverse CKD populations.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"feb7ce74561d","type":"article","url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","title":"Olpasiran: siRNA verlaagt lipoproteïne(a) spectaculair in fase 2 trial","title_en":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2211023","source_url":"https://doi.org/10.1056/NEJMoa2211023","authors":["Michelle L O'Donoghue","Robert S Rosenson","Baris Gencer","J Antonio G López","Norman E Lepor","Seth J Baum","Elmer Stout","Daniel Gaudet","Beat Knusel","Julia F Kuder","Xinhui Ran","Sabina A Murphy","Huei Wang","You Wu","Helina Kassahun","Marc S Sabatine"],"significance":10,"published":"2022-11-17","source_date":"2022-11-17","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The OCEAN(a)-DOSE trial demonstrated that olpasiran, a small interfering RNA targeting hepatic apolipoprotein(a) synthesis, reduced lipoprotein(a) levels by more than 95% in patients with established atherosclerotic cardiovascular disease. This represented the first pharmacological agent capable of near-complete Lp(a) elimination, opening a new therapeutic frontier.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5217cb710825","type":"article","url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","title":"COAPT: MitraClip vermindert hospitalisaties bij secundaire MR en hartfalen","title_en":"Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitraclip"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.08.803","source_url":"https://doi.org/10.1016/j.jacc.2022.08.803","authors":["Gennaro Giustino","Anton Camaj","Samir R Kapadia","Saibal Kar","William T Abraham","JoAnn Lindenfeld","D Scott Lim","Paul A Grayburn","David J Cohen","Björn Redfors","Zhipeng Zhou","Stuart J Pocock","Federico M Asch","Michael J Mack","Gregg W Stone"],"significance":8,"published":"2022-11-15","source_date":"2022-11-15","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"Long-term COAPT analysis confirmed that transcatheter edge-to-edge repair (MitraClip) durably reduces hospitalizations and mortality in patients with heart failure and severe secondary mitral regurgitation, with sustained benefit beyond the initial follow-up period.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"11e0de37fdb9","type":"article","url":"https://hartvaat.nl/2022/11/15/fgf21-sirtuin-3-hoe-inspanning-beschermt-tegen-diabetische-cardiomyopathie/","title":"FGF21-Sirtuin 3: hoe inspanning beschermt tegen diabetische cardiomyopathie","title_en":"FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059631","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059631","authors":["Leigang Jin","Leiluo Geng","Lei Ying","Lingling Shu","Kevin Ye","Ranyao Yang","Yan Liu","Yao Wang","Yin Cai","Xue Jiang","Qin Wang","Xingqun Yan","Boya Liao","Jie Liu","Fuyu Duan","Gary Sweeney","Connie Wai Hong Woo","Yu Wang","Zhengyuan Xia","Qizhou Lian","Aimin Xu"],"significance":5,"published":"2022-11-15","source_date":"2022-11-15","image":"","kennis":[],"congress":"","summary_en":"This translational study revealed that exercise protects against diabetic cardiomyopathy through the FGF21-Sirtuin 3 axis, which governs mitochondrial dynamics and cardiac metabolic homeostasis.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d8569dbca08","type":"article","url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","title":"mTOR-remming bij STEMI: sirolimus vermindert infarctgrootte niet","title_en":"Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.08.747","source_url":"https://doi.org/10.1016/j.jacc.2022.08.747","authors":["Barbara E Stähli","Roland Klingenberg","Dik Heg","Mattia Branca","Robert Manka","Ioannis Kapos","Oliver Müggler","Andrea Denegri","Rahel Kesterke","Florence Berger","Julia Stehli","Alessandro Candreva","Arnold von Eckardstein","David Carballo","Christian Hamm","Ulf Landmesser","François Mach","Tiziano Moccetti","Christian Jung","Malte Kelm","Thomas Münzel","Giovanni Pedrazzini","Lorenz Räber","Stephan Windecker","Christian Templin","Christian M Matter","Thomas F Lüscher","Frank Ruschitzka"],"significance":6,"published":"2022-11-08","source_date":"2022-11-08","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This randomized trial tested whether mTOR inhibition with sirolimus reduces infarct size after STEMI through anti-inflammatory mechanisms, exploring immunomodulation as an adjunct to primary PCI reperfusion.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7e38c35a2ad8","type":"article","url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","title":"ENCHANTED2/MT: intensieve bloeddrukverlaging na trombectomie bij CVA is schadelijk","title_en":"Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01882-7","source_url":"https://doi.org/10.1016/S0140-6736(22)01882-7","authors":["Pengfei Yang","Lili Song","Yongwei Zhang","Xiaoxi Zhang","Xiaoying Chen","Yunke Li","Lingli Sun","Yingfeng Wan","Laurent Billot","Qiang Li","Xinwen Ren","Hongjian Shen","Lei Zhang","Zifu Li","Pengfei Xing","Yongxin Zhang","Ping Zhang","Weilong Hua","Fang Shen","Yihan Zhou","Bing Tian","Wenhuo Chen","Hongxing Han","Liyong Zhang","Chenghua Xu","Tong Li","Ya Peng","Xincan Yue","Shengli Chen","Changming Wen","Shu Wan","Congguo Yin","Ming Wei","Hansheng Shu","Guangxian Nan","Sheng Liu","Wenhua Liu","Yiling Cai","Yi Sui","Maohua Chen","Yu Zhou","Qiao Zuo","Dongwei Dai","Rui Zhao","Qiang Li","Qinghai Huang","Yi Xu","Benqiang Deng","Tao Wu","Jianping Lu","Xia Wang","Mark W Parsons","Ken Butcher","Bruce Campbell","Thompson G Robinson","Mayank Goyal","Diederik Dippel","Yvo Roos","Charles Majoie","Longde Wang","Yongjun Wang","Jianmin Liu","Craig S Anderson"],"significance":9,"published":"2022-11-05","source_date":"2022-11-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/"],"congress":"","summary_en":"The ENCHANTED2/MT trial demonstrated that intensive blood pressure lowering to <120 mmHg after endovascular thrombectomy for acute ischemic stroke worsened functional outcomes compared with a higher target. The trial was stopped early for futility and potential harm.","created":"2026-07-03T10:30:04Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3623b687ae4","type":"article","url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","title":"Complete revascularisatie bij STEMI verbetert angina-gerelateerde kwaliteit van leven","title_en":"Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","ouderen","perifeer-vaatlijden","stabiel-coronairlijden"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.3032","source_url":"https://doi.org/10.1001/jamacardio.2022.3032","authors":["Shamir R Mehta","Jia Wang","David A Wood","John A Spertus","David J Cohen","Roxana Mehran","Robert F Storey","Philippe Gabriel Steg","Natalia Pinilla-Echeverri","Tej Sheth","Kevin R Bainey","Sripal Bangalore","Warren J Cantor","David P Faxon","Laurent J Feldman","Sanjit S Jolly","Vijay Kunadian","Shahar Lavi","Jose Lopez-Sendon","Mina Madan","Raul Moreno","Sunil V Rao","Josep Rodés-Cabau","Goran Stankovic","Shrikant I Bangdiwala","John A Cairns"],"significance":7,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/coronairlijden/revalidatie-na-hartinfarct/"],"congress":"","summary_en":"This substudy demonstrated that complete revascularization improves angina-related quality of life compared with culprit-only PCI in STEMI patients with multivessel disease, adding patient-centered outcomes to the clinical event reduction.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd69100e3c2f","type":"article","url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","title":"Empagliflozine vermindert albuminurie bij hartfalen: EMPEROR-Pooled analyse","title_en":"Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","anemie-ckd","bisoprolol","canagliflozine","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","fidelity","hfmref","hfpef","hfref","sacubitril-valsartan","sglt2-remmers","statines","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.2924","source_url":"https://doi.org/10.1001/jamacardio.2022.2924","authors":["João Pedro Ferreira","Faiez Zannad","Javed Butler","Gerasimos Filippatos","Stuart J Pocock","Martina Brueckmann","Dominik Steubl","Elke Schueler","Stefan D Anker","Milton Packer"],"significance":7,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This pooled EMPEROR analysis showed that empagliflozin significantly reduces albuminuria across the heart failure spectrum (both HFrEF and HFpEF), providing evidence of kidney-protective effects of SGLT2 inhibition in heart failure beyond eGFR preservation.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f6498cec239","type":"article","url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","title":"DELIVER: dapagliflozine effectief bij HFpEF ongeacht atriumfibrilleren","title_en":"Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfpef","hfref","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.08.718","source_url":"https://doi.org/10.1016/j.jacc.2022.08.718","authors":["Jawad H Butt","Toru Kondo","Pardeep S Jhund","Josep Comin-Colet","Rudolf A de Boer","Akshai S Desai","Adrian F Hernandez","Silvio E Inzucchi","Stefan P Janssens","Mikhail N Kosiborod","Carolyn S P Lam","Anna Maria Langkilde","Daniel Lindholm","Felipe Martinez","Magnus Petersson","Sanjiv J Shah","Jorge Thierer","Muthiah Vaduganathan","Subodh Verma","Ulrica Wilderäng","Brian C Claggett","Scott D Solomon","John J V McMurray"],"significance":7,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This DELIVER subanalysis confirmed that dapagliflozin reduces heart failure events in HFpEF patients regardless of whether they have concurrent atrial fibrillation, an important finding given the high prevalence of AF in this population.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f0471e66196","type":"article","url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","title":"EMMY: empagliflozine na acuut myocardinfarct verbetert NT-proBNP en remodelling","title_en":"Empagliflozin in acute myocardial infarction: the EMMY trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","canagliflozine","dapagliflozine","empagliflozine","emperor-trials","myocardinfarct","nt-probnp"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac494","source_url":"https://doi.org/10.1093/eurheartj/ehac494","authors":["Dirk von Lewinski","Ewald Kolesnik","Norbert J Tripolt","Peter N Pferschy","Martin Benedikt","Markus Wallner","Hannes Alber","Rudolf Berger","Michael Lichtenauer","Christoph H Saely","Deddo Moertl","Pia Auersperg","Christian Reiter","Thomas Rieder","Jolanta M Siller-Matula","Gloria M Gager","Matthias Hasun","Franz Weidinger","Thomas R Pieber","Peter M Zechner","Markus Herrmann","Andreas Zirlik","Rury R Holman","Abderrahim Oulhaj","Harald Sourij"],"significance":8,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The EMMY trial showed that empagliflozin started after acute MI significantly reduced NT-proBNP levels and attenuated left ventricular remodeling compared with placebo. The results provided early evidence of SGLT2 inhibitor cardioprotection in the acute post-MI setting.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"746b19d95bad","type":"article","url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","title":"VIP-ACS: dubbele-dosis griepvaccinatie na ACS verbetert uitkomsten niet","title_en":"Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac472","source_url":"https://doi.org/10.1093/eurheartj/ehac472","authors":["Henrique Andrade R Fonseca","Remo Holanda M Furtado","André Zimerman","Pedro A Lemos","Marcelo Franken","Frederico Monfardini","Rodrigo P Pedrosa","Rodrigo de Lemos S Patriota","Luiz Carlos S Passos","Frederico Toledo C Dall'Orto","Conrado R Hoffmann Filho","Bruno Ramos Nascimento","Felipe A Baldissera","Cesar Augusto C Pereira","Paulo Ricardo A Caramori","Pedro Beraldo de Andrade","Carlos Esteves","Elke Ferreira Salim","Jefferson Henrique da Silva","Izabela Chave Pedro","Mariana Castaldi R Silva","Ewerton Hernandes de Pedri","Ana Carla R D Carioca","Luciana Pereira A de Piano","Camila Santos N Albuquerque","Diogo D F Moia","Roberta Grazzielli R A P Momesso","Felipe P Machado","Lucas P Damiani","Ronaldo Vicente P Soares","Guilherme P Schettino","Luiz V Rizzo","José Carlos Nicolau","Otávio Berwanger"],"significance":7,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/"],"congress":"","summary_en":"The VIP-ACS trial showed that double-dose influenza vaccination during ACS hospitalization was not superior to standard-dose outpatient vaccination for preventing cardiovascular events, testing whether enhanced immunogenicity provides clinical benefit in the acute setting.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d5e62144e44e","type":"article","url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","title":"DIAMOND: patiromer maakt RAAS-remmer-optitratie bij HFrEF met hyperkaliëmie mogelijk","title_en":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac401","source_url":"https://doi.org/10.1093/eurheartj/ehac401","authors":["Javed Butler","Stefan D Anker","Lars H Lund","Andrew J S Coats","Gerasimos Filippatos","Tariq Jamal Siddiqi","Tim Friede","Vincent Fabien","Mikhail Kosiborod","Marco Metra","Ileana L Piña","Fausto Pinto","Patrick Rossignol","Peter van der Meer","Cecilia Bahit","Jan Belohlavek","Michael Böhm","Jasper J Brugts","John G F Cleland","Justin Ezekowitz","Antoni Bayes-Genis","Israel Gotsman","Assen Goudev","Irakli Khintibidze","Joann Lindenfeld","Robert J Mentz","Bela Merkely","Eliodoro Castro Montes","Wilfried Mullens","Jose C Nicolau","Aleksandr Parkhomenko","Piotr Ponikowski","Petar M Seferovic","Michele Senni","Evgeny Shlyakhto","Alain Cohen-Solal","Peter Szecsödy","Klaus Jensen","Fabio Dorigotti","Matthew R Weir","Bertram Pitt"],"significance":8,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"The DIAMOND trial showed that patiromer effectively reduced serum potassium in patients with HFrEF, enabling more patients to reach target doses of RAAS inhibitors without hyperkalemia-related dose reductions. The results addressed a key barrier to optimal heart failure pharmacotherapy.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2fda2725e242","type":"article","url":"https://hartvaat.nl/2022/11/01/checkpoint-remmers-verhogen-korttermijnrisico-op-hypertensie-niet-meta-analyse/","title":"Checkpoint-remmers verhogen korttermijnrisico op hypertensie niet: meta-analyse","title_en":"Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","ras-remmers"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19865","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19865","authors":["Shintaro Minegishi","Sho Kinguchi","Nobuyuki Horita","Ho Namkoong","Alexandros Briasoulis","Tomoaki Ishigami","Kouichi Tamura","Akira Nishiyama","Yuichiro Yano"],"significance":5,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nsaids-en-nierziekte/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This meta-analysis showed that immune checkpoint inhibitors do not increase the short-term risk of hypertension in cancer patients, providing reassurance on this specific cardiovascular safety concern during immunotherapy.","created":"2026-07-03T10:30:03Z","updated":"2026-07-03T13:29:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e4c59c6d7f8","type":"article","url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","title":"Antihypertensieve combinaties bij Afrikaanse patiënten: CREOLE secundaire analyse","title_en":"Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","dubbele-trombocytenremming"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18333","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18333","authors":["Dike B Ojji","Victoria Cornelius","Giles Partington","Veronica Francis","Shahiemah Pandie","Wynand Smythe","Nicky Hickman","Felix Barasa","Albertino Damasceno","Anastase Dzudie","Erika Jones","Prossie Merab Ingabire","Charles Mondo","Okechukwu Ogah","Elijah Ogola","Mahmoud U Sani","Gabriel Lamkur Shedul","Grace Shedul","Brian Rayner","Karen Sliwa","Neil Poulter"],"significance":6,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This CREOLE secondary analysis compared blood pressure variability among three antihypertensive combinations in Black African patients, showing that the calcium channel blocker-containing combinations provide more stable blood pressure control.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce190e75e4d4","type":"article","url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","title":"Radiale versus femorale toegang bij coronairangiografie: meta-analyse toont mortaliteitsvoordeel","title_en":"Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061527","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061527","authors":["Giuseppe Gargiulo","Daniele Giacoppo","Sanjit S Jolly","John Cairns","Michel Le May","Ivo Bernat","Enrico Romagnoli","Sunil V Rao","Maarten A H van Leeuwen","Shamir R Mehta","Olivier F Bertrand","George A Wells","Thomas A Meijers","George C M Siontis","Giovanni Esposito","Stephan Windecker","Peter Jüni","Marco Valgimigli"],"significance":8,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"This comprehensive meta-analysis confirmed that radial artery access for coronary angiography and PCI is associated with lower mortality and fewer major bleeding events compared with femoral access. The pooled evidence supported transradial access as the default approach for coronary procedures.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T13:29:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cbff4fa58eac","type":"article","url":"https://hartvaat.nl/2022/11/01/arteriele-stijfheid-en-endotheeldysfunctie-bij-anca-geassocieerde-vasculitis/","title":"Arteriële stijfheid en endotheeldysfunctie bij ANCA-geassocieerde vasculitis","title_en":"Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["perifeer-vaatlijden"],"journal":"Kidney international","doi":"10.1016/j.kint.2022.07.026","source_url":"https://doi.org/10.1016/j.kint.2022.07.026","authors":["Tariq E Farrah","Vanessa Melville","Alicja Czopek","Henry Fok","Lorraine Bruce","Nicholas L Mills","Matthew A Bailey","David J Webb","James W Dear","Neeraj Dhaun"],"significance":5,"published":"2022-11-01","source_date":"2022-11-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study showed that patients with ANCA-associated vasculitis have increased arterial stiffness and endothelial dysfunction, identifying vascular pathogenic mechanisms that contribute to their elevated cardiovascular risk.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T13:29:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8673375fc10c","type":"article","url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","title":"PCI versus CABG bij drievatslijden met proximale LAD-betrokkenheid","title_en":"Mortality after multivessel revascularisation involving the proximal left anterior descending artery.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-320934","source_url":"https://doi.org/10.1136/heartjnl-2022-320934","authors":["Masafumi Ono","Hironori Hara","Chao Gao","Hideyuki Kawashima","Rutao Wang","Neil O'Leary","Joanna J Wykrzykowska","Jan J Piek","Michael J Mack","David Holmes","Marie-Claude Morice","Stuart Head","Arie Pieter Kappetein","Thilo Noack","Piroze M Davierwala","Friedrich W Mohr","Scot Garg","Yoshinobu Onuma","Patrick W Serruys"],"significance":7,"published":"2022-10-28","source_date":"2022-10-28","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/"],"congress":"","summary_en":"This study confirmed that CABG provides superior long-term survival compared with PCI in patients with three-vessel disease involving the proximal LAD, reinforcing the importance of surgical revascularization when this critical territory is involved.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T13:29:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f98ac66cc35","type":"article","url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","title":"2022 ACC/AHA datadefinities voor pijn op de borst en acuut myocardinfarct","title_en":"2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["myocardinfarct"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.05.012","source_url":"https://doi.org/10.1016/j.jacc.2022.05.012","authors":["H V Skip Anderson","Sofia Carolina Masri","Mouin S Abdallah","Anna Marie Chang","Mauricio G Cohen","Islam Y Elgendy","Martha Gulati","Kathleen LaPoint","Nidhi Madan","Issam D Moussa","Jorge Ramirez","April W Simon","Vikas Singh","Stephen W Waldo","Marlene S Williams"],"significance":5,"published":"2022-10-25","source_date":"2022-10-25","image":"","kennis":[],"congress":"","summary_en":"This ACC/AHA document standardized data elements and definitions for chest pain and acute MI research and quality improvement, enabling consistent data collection across registries and clinical trials.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T13:29:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8b0696b4023e","type":"article","url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","title":"TIME: avonddosering antihypertensiva biedt geen voordeel boven ochtenddosering","title_en":"Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","anemie-ckd","bloeddrukbehandeling"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01786-X","source_url":"https://doi.org/10.1016/S0140-6736(22)01786-X","authors":["Isla S Mackenzie","Amy Rogers","Neil R Poulter","Bryan Williams","Morris J Brown","David J Webb","Ian Ford","David A Rorie","Greg Guthrie","J W Kerr Grieve","Filippo Pigazzani","Peter M Rothwell","Robin Young","Alex McConnachie","Allan D Struthers","Chim C Lang","Thomas M MacDonald"],"significance":9,"published":"2022-10-22","source_date":"2022-10-22","image":"","kennis":[],"congress":"","summary_en":"The TIME trial showed that evening dosing of antihypertensive medications offered no cardiovascular benefit over morning dosing in hypertensive adults, definitively refuting the chronotherapy hypothesis. The pragmatic result simplified clinical practice by confirming that dosing time does not matter.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b0f64cddcae","type":"article","url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","title":"SYMPLICITY HTN-3: langetermijn follow-up renale denervatie bij resistente hypertensie","title_en":"Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01787-1","source_url":"https://doi.org/10.1016/S0140-6736(22)01787-1","authors":["Deepak L Bhatt","Muthiah Vaduganathan","David E Kandzari","Martin B Leon","Krishna Rocha-Singh","Raymond R Townsend","Barry T Katzen","Suzanne Oparil","Sandeep Brar","Vanessa DeBruin","Martin Fahy","George L Bakris"],"significance":7,"published":"2022-10-22","source_date":"2022-10-22","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"Long-term SYMPLICITY HTN-3 follow-up confirmed the safety but not the efficacy of the first-generation renal denervation system, with the negative result attributed to procedural limitations that were subsequently addressed by newer-generation devices.","created":"2026-07-03T10:30:02Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fcac607dce4e","type":"article","url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","title":"BOX: bloeddrukdoelen bij comateuze overlevenden van hartstilstand","title_en":"Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2208687","source_url":"https://doi.org/10.1056/NEJMoa2208687","authors":["Jesper Kjaergaard","Jacob E Møller","Henrik Schmidt","Johannes Grand","Simon Mølstrøm","Britt Borregaard","Søren Venø","Laura Sarkisian","Dmitry Mamaev","Lisette O Jensen","Benjamin Nyholm","Dan E Høfsten","Jakob Josiassen","Jakob H Thomsen","Jens J Thune","Laust E R Obling","Matias G Lindholm","Martin Frydland","Martin A S Meyer","Matilde Winther-Jensen","Rasmus P Beske","Ruth Frikke-Schmidt","Sebastian Wiberg","Søren Boesgaard","Søren A Madsen","Vibeke L Jørgensen","Christian Hassager"],"significance":8,"published":"2022-10-20","source_date":"2022-10-20","image":"","kennis":[],"congress":"","summary_en":"The BOX trial found no difference between a high (77 mmHg) versus low (63 mmHg) mean arterial pressure target in comatose survivors of out-of-hospital cardiac arrest. The result indicated that there is a broad acceptable blood pressure range in post-cardiac arrest intensive care.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T13:29:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fbb1648662d7","type":"article","url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","title":"Dosisrespons van sacubitril/valsartan bij HFrEF","title_en":"Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.08.737","source_url":"https://doi.org/10.1016/j.jacc.2022.08.737","authors":["Reza Mohebi","Yuxi Liu","Ileana L Piña","Margaret F Prescott","Javed Butler","G Michael Felker","Jonathan H Ward","Scott D Solomon","James L Januzzi"],"significance":7,"published":"2022-10-18","source_date":"2022-10-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/"],"congress":"","summary_en":"This study showed that even lower-than-target doses of sacubitril-valsartan provide meaningful clinical benefit in HFrEF, with a dose-response relationship where any dose is better than no exposure. The finding supports initiating ARNI therapy even when target dose cannot be achieved.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T13:29:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1746c6bf5c50","type":"article","url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","title":"Intensieve bloeddrukverlaging bij maligne linkerventrikel hypertrofie","title_en":"Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie","hypertrofische-cardiomyopathie","nt-probnp","obesitas","summit-trial","troponine","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.08.735","source_url":"https://doi.org/10.1016/j.jacc.2022.08.735","authors":["Simon B Ascher","James A de Lemos","MinJae Lee","Elaine Wu","Elsayed Z Soliman","Ian J Neeland","Dalane W Kitzman","Christie M Ballantyne","Vijay Nambi","Anthony A Killeen","Joachim H Ix","Michael G Shlipak","Jarett D Berry"],"significance":7,"published":"2022-10-18","source_date":"2022-10-18","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This analysis showed that patients with malignant left ventricular hypertrophy (elevated troponin and BNP) have the highest cardiovascular risk but also derive the greatest absolute benefit from intensive blood pressure lowering, supporting targeted aggressive treatment.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be6845ee80b9","type":"article","url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","title":"Asundexian (factor XIa-remmer) na ACS: fase 2 dosisfindingsstudie","title_en":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061612","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061612","authors":["Sunil V Rao","Bodo Kirsch","Deepak L Bhatt","Andrzej Budaj","Rosa Coppolecchia","John Eikelboom","Stefan K James","W Schuyler Jones","Bela Merkely","Lars Keller","Renicus S Hermanides","Gianluca Campo","José Luis Ferreiro","Taro Shibasaki","Hardi Mundl","John H Alexander"],"significance":7,"published":"2022-10-18","source_date":"2022-10-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/"],"congress":"","summary_en":"This phase 2 trial of the oral factor XIa inhibitor asundexian after ACS showed dose-dependent suppression of thrombin generation with minimal bleeding increase, providing early safety and pharmacodynamic data that preceded the larger AF trial.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T13:29:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e46316b348b6","type":"article","url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","title":"DELIVER: dapagliflozine effectief ongeacht frailteit bij HFpEF","title_en":"Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["dapa-hf","dapagliflozine","hfpef","hfref","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061754","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061754","authors":["Jawad H Butt","Pardeep S Jhund","Jan Belohlávek","Rudolf A de Boer","Chern-En Chiang","Akshai S Desai","Jarosław Drożdż","Adrian F Hernandez","Silvio E Inzucchi","Tzvetana Katova","Masafumi Kitakaze","Mikhail N Kosiborod","Carolyn S P Lam","Anna Maria Langkilde","Daniel Lindholm","Erasmus Bachus","Felipe Martinez","Béla Merkely","Magnus Petersson","Jose F Kerr Saraiva","Sanjiv J Shah","Muthiah Vaduganathan","Orly Vardeny","Ulrica Wilderäng","Brian L Claggett","Scott D Solomon","John J V McMurray"],"significance":8,"published":"2022-10-18","source_date":"2022-10-18","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This DELIVER subanalysis demonstrated that dapagliflozin provides similar relative benefit in frail and non-frail patients with HFpEF, with even greater absolute benefit in frail patients due to their higher baseline risk. The results supported SGLT2 inhibitor use regardless of frailty status.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"324f502e4cbd","type":"article","url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","title":"dal-GenE: farmacogenetica-geleide dalcetrapib na ACS","title_en":"Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["cardiovasculaire-genetica","gepersonaliseerde-geneeskunde"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac374","source_url":"https://doi.org/10.1093/eurheartj/ehac374","authors":["Jean Claude Tardif","Marc A Pfeffer","Simon Kouz","Wolfgang Koenig","Aldo P Maggioni","John J V McMurray","Vincent Mooser","David D Waters","Jean C Grégoire","Philippe L L'Allier","J Wouter Jukema","Harvey D White","Therese Heinonen","Donald M Black","Fouzia Laghrissi-Thode","Sylvie Levesque","Marie Claude Guertin","Marie Pierre Dubé"],"significance":7,"published":"2022-10-14","source_date":"2022-10-14","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"The dal-GenE trial tested a pharmacogenetics-guided approach with dalcetrapib after ACS, targeting patients with a specific ADCY9 genotype predicted to respond to CETP inhibition. The trial explored precision medicine in the lipid-lowering space.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T13:29:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7d32ed5bca64","type":"article","url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","title":"REVIVED-BCIS2: PCI verbetert overleving niet bij ischemische LV-disfunctie","title_en":"Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2206606","source_url":"https://doi.org/10.1056/NEJMoa2206606","authors":["Divaka Perera","Tim Clayton","Peter D O'Kane","John P Greenwood","Roshan Weerackody","Matthew Ryan","Holly P Morgan","Matthew Dodd","Richard Evans","Ruth Canter","Sophie Arnold","Lana J Dixon","Richard J Edwards","Kalpa De Silva","James C Spratt","Dwayne Conway","James Cotton","Margaret McEntegart","Amedeo Chiribiri","Pedro Saramago","Anthony Gershlick","Ajay M Shah","Andrew L Clark","Mark C Petrie"],"significance":10,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The REVIVED-BCIS2 trial showed that PCI did not improve survival or left ventricular function compared with optimal medical therapy in patients with severe ischemic cardiomyopathy and viable myocardium. The result challenged the long-held assumption that revascularization improves outcomes in ischemic left ventricular dysfunction and supports a medical-therapy-first approach.","created":"2026-07-03T10:30:01Z","updated":"2026-07-03T13:29:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"02963f01b5da","type":"article","url":"https://hartvaat.nl/2022/10/13/low-voltage-substraatmodificatie-bij-af-ablatie-meta-analyse/","title":"Low-voltage substraatmodificatie bij AF-ablatie: meta-analyse","title_en":"Low-voltage area substrate modification for atrial fibrillation ablation: a systematic review and meta-analysis of clinical trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac089","source_url":"https://doi.org/10.1093/europace/euac089","authors":["Joey Junarta","Muhammad U Siddiqui","Joshua M Riley","Sean J Dikdan","Akash Patel","Daniel R Frisch"],"significance":6,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated the additional value of low-voltage area substrate modification beyond pulmonary vein isolation for AF ablation, finding mixed results for this targeted approach to substrate-based ablation.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T13:29:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d2c81a9790f6","type":"article","url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","title":"Voorbehandeling met antiaritmica voor cardioversie bij AF: netwerk-meta-analyse","title_en":"Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","cardiogene-shock","farmaco-economie","fidelity","fractional-flow-reserve","hartrevalidatie","inflammatie","laminopathie","microbioom","myocardinfarct","obesitas","ouderen","secundaire-preventie","slaapapneu","supraventriculaire-tachycardie","ventrikelfibrilleren","vrouwen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac063","source_url":"https://doi.org/10.1093/europace/euac063","authors":["Kevin J Um","William F McIntyre","Pablo A Mendoza","Omar Ibrahim","Stephanie T Nguyen","Sabrina H Lin","Emmanuelle Duceppe","Bram Rochwerg","Jeff S Healey","Alex Koziarz","Alexandra P Lengyel","Akash Bhatnagar","Guy Amit","Victor A Chu","Richard P Whitlock","Emilie P Belley-Côté"],"significance":6,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/"],"congress":"","summary_en":"This network meta-analysis compared different antiarrhythmic drugs as pretreatment before electrical cardioversion of AF, identifying vernakalant and flecainide as the most effective agents for enhancing cardioversion success.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T18:38:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"759a81a56beb","type":"article","url":"https://hartvaat.nl/2022/10/13/gecombineerde-epicardiale-en-endocardiale-redo-ablatie-bij-persisterend-af/","title":"Gecombineerde epicardiale en endocardiale redo-ablatie bij persisterend AF","title_en":"Combined epicardial and endocardial approach for redo radiofrequency catheter ablation in patients with persistent atrial fibrillation: a randomized clinical trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","atleten","biomarkers-cardiovasculair","farmaco-economie","gedilateerde-cardiomyopathie","hartkatheterisatie","hypertrofische-cardiomyopathie","myocardinfarct","ouderen","secundaire-preventie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac058","source_url":"https://doi.org/10.1093/europace/euac058","authors":["Kwang No Lee","Do Young Kim","Ki Yung Boo","Yun Gi Kim","Seung Young Roh","Jaemin Shim","Jong Il Choi","Young Hoon Kim"],"significance":6,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This randomized trial tested whether adding an epicardial approach to endocardial redo ablation for persistent AF improves outcomes, evaluating the value of hybrid surgical-catheter strategies for recurrent arrhythmia.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8689c56c88f","type":"article","url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","title":"Intensieve bloeddrukcontrole bij AF: inzichten uit SPRINT","title_en":"Effects of intensive blood pressure control on cardiovascular and cognitive outcomes in patients with atrial fibrillation: insights from the SPRINT trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","farmaco-economie","obesitas","ouderen","summit-trial"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac059","source_url":"https://doi.org/10.1093/europace/euac059","authors":["Chao Jiang","Yiwei Lai","Xin Du","Yufeng Wang","Sitong Li","Liu He","Rong Hu","Qiang Lv","Jiahui Wu","Li Feng","Man Ning","Yanfei Ruan","Xu Li","Changqi Jia","Wenli Dai","Xueyuan Guo","Chenxi Jiang","Ribo Tang","Caihua Sang","Deyong Long","Hisatomi Arima","Jianzeng Dong","Craig S Anderson","Changsheng Ma"],"significance":7,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/atriumflutter/","https://hartvaat.nl/kennis/atriumfibrilleren/digoxine-bij-af/"],"congress":"","summary_en":"This SPRINT substudy in patients with atrial fibrillation showed that intensive blood pressure control reduces cardiovascular events even in the AF population, while also potentially reducing cognitive decline.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a720020cb4df","type":"article","url":"https://hartvaat.nl/2022/10/13/dagopname-na-af-ablatie-even-veilig-als-overnachting-meta-analyse/","title":"Dagopname na AF-ablatie even veilig als overnachting: meta-analyse","title_en":"Efficacy and safety of same-day discharge after atrial fibrillation ablation compared with post-procedural overnight stay: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac068","source_url":"https://doi.org/10.1093/europace/euac068","authors":["Pok Tin Tang","Mark Davies","Yaver Bashir","Timothy R Betts","Michala Pedersen","Kim Rajappan","Matthew R Ginks","Rohan S Wijesurendra"],"significance":6,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This meta-analysis confirmed that same-day discharge after AF catheter ablation is as safe as overnight observation, supporting the cost-effective approach of outpatient ablation procedures.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68bd520a189e","type":"article","url":"https://hartvaat.nl/2022/10/13/ffr-geleide-versus-angiografie-geleide-revascularisatie-meta-analyse-van-rct-s/","title":"FFR-geleide versus angiografie-geleide revascularisatie: meta-analyse van RCT's","title_en":"Fractional flow reserve versus angiography alone in guiding myocardial revascularisation: a systematic review and meta-analysis of randomised trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["farmaco-economie","stabiel-coronairlijden"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320768","source_url":"https://doi.org/10.1136/heartjnl-2021-320768","authors":["Ayman Elbadawi","Ramy Sedhom","Alexander T Dang","Mohamed M Gad","Faisal Rahman","Emmanouil S Brilakis","Islam Y Elgendy","Hani Jneid"],"significance":7,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-farmacologie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This meta-analysis confirmed that FFR-guided revascularization results in fewer stent implantations than angiography-guided treatment without compromising clinical outcomes, supporting the value of physiological assessment for treatment selection.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"375837514bbe","type":"article","url":"https://hartvaat.nl/2022/10/13/cerebrale-microbloedingen-en-risico-bij-af-systematische-review/","title":"Cerebrale microbloedingen en risico bij AF: systematische review","title_en":"Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":["abelacimab","bloeddrukbehandeling","microcirculatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac028","source_url":"https://doi.org/10.1093/europace/euac028","authors":["Bernadette Corica","Giulio Francesco Romiti","Valeria Raparelli","Roberto Cangemi","Stefania Basili","Marco Proietti"],"significance":6,"published":"2022-10-13","source_date":"2022-10-13","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This meta-analysis documented the prevalence of cerebral microbleeds in AF patients and their association with increased intracranial hemorrhage risk, informing the bleeding risk assessment for anticoagulation decisions.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fb746b359b72","type":"article","url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","title":"Langetermijn evolocumab bij atherosclerotisch vaatlijden: open-label extensie FOURIER","title_en":"Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["atherosclerose","bempedoïnezuur","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","gedilateerde-cardiomyopathie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pelacarsen","perifeer-vaatlijden","plaquekarakterisatie","statines","vrouwen","yellow-iii"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.061620","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.061620","authors":["Michelle L O'Donoghue","Robert P Giugliano","Stephen D Wiviott","Dan Atar","Anthony Keech","Julia F Kuder","KyungAh Im","Sabina A Murphy","Jose H Flores-Arredondo","J Antonio G López","Mary Elliott-Davey","Bei Wang","Maria Laura Monsalvo","Siddique Abbasi","Marc S Sabatine"],"significance":7,"published":"2022-10-11","source_date":"2022-10-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The open-label FOURIER extension showed that long-term evolocumab use (up to 5 years) maintains sustained LDL cholesterol reduction with a favorable safety profile, providing the longest-term safety data for PCSK9 monoclonal antibody therapy.","created":"2026-07-03T10:30:00Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"18fb03fd0981","type":"article","url":"https://hartvaat.nl/2022/10/08/all-heart-allopurinol-verbetert-cv-uitkomsten-niet-bij-ischemische-hartziekte/","title":"ALL-HEART: allopurinol verbetert CV-uitkomsten niet bij ischemische hartziekte","title_en":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","aspirine","bradycardie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01657-9","source_url":"https://doi.org/10.1016/S0140-6736(22)01657-9","authors":["Isla S Mackenzie","Christopher J Hawkey","Ian Ford","Nicola Greenlaw","Filippo Pigazzani","Amy Rogers","Allan D Struthers","Alan G Begg","Li Wei","Anthony J Avery","Jaspal S Taggar","Andrew Walker","Suzanne L Duce","Rebecca J Barr","Jennifer S Dumbleton","Evelien D Rooke","Jonathan N Townend","Lewis D Ritchie","Thomas M MacDonald"],"significance":8,"published":"2022-10-08","source_date":"2022-10-08","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The ALL-HEART trial showed that allopurinol did not improve cardiovascular outcomes in patients with ischemic heart disease without gout, despite its theoretical benefits on endothelial function and oxidative stress. The large, pragmatic negative result argued against using allopurinol for cardiovascular prevention.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"95cae36387f2","type":"article","url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","title":"Empagliflozine bij HFpEF: gelijk effect bij vrouwen en mannen","title_en":"Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","emperor-trials","hfpef","hfref","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059755","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059755","authors":["Javed Butler","Gerasimos Filippatos","Tariq Jamal Siddiqi","João Pedro Ferreira","Martina Brueckmann","Edimar Bocchi","Michael Böhm","Vijay K Chopra","Nadia Giannetti","Tomoko Iwata","James L Januzzi","Sanjay Kaul","Ileana L Piña","Piotr Ponikowski","Ursula Rauch-Kröhnert","Sanjiv J Shah","Michele Senni","Mikhail Sumin","Subodh Verma","Jian Zhang","Stuart J Pocock","Faiez Zannad","Milton Packer","Stefan D Anker"],"significance":7,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Preserved sex-stratified analysis confirmed that empagliflozin reduces heart failure events equally in women and men with HFpEF, a reassuring finding given the female predominance in the HFpEF population.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"96fb8ae89819","type":"article","url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","title":"PARADISE-MI: sacubitril/valsartan versus ramipril na acuut MI — echocardiografie","title_en":"Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","answer-hf","ramipril","sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059210","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059210","authors":["Amil M Shah","Brian Claggett","Narayana Prasad","Guichu Li","Mayra Volquez","Karola Jering","Maja Cikes","Attila Kovacs","Wilfried Mullens","Jose C Nicolau","Lars Køber","Peter van der Meer","Pardeep S Jhund","Ghionul Ibram","Martin Lefkowitz","Yinong Zhou","Scott D Solomon","Marc A Pfeffer"],"significance":7,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This PARADISE-MI echocardiographic substudy showed that sacubitril-valsartan did not significantly improve left ventricular remodeling compared with ramipril after acute MI, consistent with the neutral clinical primary endpoint.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa83237edfd5","type":"article","url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","title":"TIMING: vroege versus late NOAC-start na ischemisch CVA bij AF","title_en":"Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060666","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060666","authors":["Jonas Oldgren","Signild Åsberg","Ziad Hijazi","Per Wester","Maria Bertilsson","Bo Norrving"],"significance":8,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"The Swedish TIMING trial demonstrated that early NOAC initiation (within 4 days) after acute ischemic stroke in patients with AF was safe and noninferior to delayed start (5-10 days) for the composite of stroke, major bleeding, or death. The results supported a move toward earlier anticoagulation.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f2e9efe809d","type":"article","url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","title":"DELIVER: dapagliflozine effectief bij recent gehospitaliseerde HFpEF-patiënten","title_en":"Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","hfpef","hfref","step-hfpef"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.021","source_url":"https://doi.org/10.1016/j.jacc.2022.07.021","authors":["Jonathan W Cunningham","Muthiah Vaduganathan","Brian L Claggett","Ian J Kulac","Akshay S Desai","Pardeep S Jhund","Rudolf A de Boer","David DeMets","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Sanjiv J Shah","Martina M McGrath","Eileen O'Meara","Ulrica Wilderäng","Daniel Lindholm","Magnus Petersson","Anna Maria Langkilde","John J V McMurray","Scott D Solomon"],"significance":8,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DELIVER subanalysis confirmed that dapagliflozin is effective in patients recently hospitalized for heart failure with mildly reduced or preserved ejection fraction, with early benefit seen within weeks of treatment initiation. The data supported in-hospital SGLT2 inhibitor use in HFpEF.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4370563dc147","type":"article","url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","title":"2022 ACC Expert Consensus: niet-statine therapieën voor LDL-verlaging bij ASCVD","title_en":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["ezetimibe","lipidenverlaging","niet-statine-therapie","pcsk9-remmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.006","source_url":"https://doi.org/10.1016/j.jacc.2022.07.006","authors":["Donald M Lloyd-Jones","Pamela B Morris","Christie M Ballantyne","Kim K Birtcher","Ashleigh M Covington","Sondra M DePalma","Margo B Minissian","Carl E Orringer","Sidney C Smith","Ashley Arana Waring","John T Wilkins"],"significance":9,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The 2022 ACC Expert Consensus updated the decision pathway for nonstatin lipid-lowering therapies, integrating evidence on bempedoic acid and inclisiran alongside ezetimibe and PCSK9 monoclonal antibodies. The document provided practical algorithms for escalating therapy to achieve LDL-cholesterol targets.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"107d08c08fab","type":"article","url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","title":"Sekseverschillen in AF-risico: VITAL Rhythm studie","title_en":"Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["slaapapneu"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.2825","source_url":"https://doi.org/10.1001/jamacardio.2022.2825","authors":["Hasan K Siddiqi","Manickavasagar Vinayagamoorthy","Baris Gencer","Chee Ng","Julie Pester","Nancy R Cook","I-Min Lee","Julie Buring","JoAnn E Manson","Christine M Albert"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/coagulatiescascade/"],"congress":"","summary_en":"The VITAL Rhythm Study confirmed that women have significantly lower AF incidence than men even after adjusting for cardiovascular risk factors, establishing sex as an independent determinant of arrhythmia risk.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5332672887c1","type":"article","url":"https://hartvaat.nl/2022/10/01/smartphone-app-thuisbloeddrukmeting-versus-kantoor-en-ambulante-meting/","title":"Smartphone-app thuisbloeddrukmeting versus kantoor- en ambulante meting","title_en":"Smartphone Application-Assisted Home Blood Pressure Monitoring Compared With Office and Ambulatory Blood Pressure Monitoring in Patients With Hypertension: the AMUSE-BP Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["digitale-gezondheid","thuisbloeddrukmeting"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19685","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19685","authors":["Eline H Groenland","Jean-Paul A C Vendeville","Remy H H Bemelmans","Houshang Monajemi","Michiel L Bots","Frank L J Visseren","Wilko Spiering"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This study showed that smartphone app-assisted home blood pressure monitoring provides measurements comparable to ambulatory monitoring, supporting standardized digital home BP assessment as a practical alternative.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce027150bdba","type":"article","url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","title":"Bloeddruk in hogere versus lagere arm en CV-uitkomsten: INTERPRESS-IPD meta-analyse","title_en":"Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18921","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18921","authors":["Christopher E Clark","Fiona C Warren","Kate Boddy","Sinéad T J McDonagh","Sarah F Moore","Maria Teresa Alzamora","Rafel Ramos Blanes","Shao-Yuan Chuang","Michael H Criqui","Marie Dahl","Gunnar Engström","Raimund Erbel","Mark Espeland","Luigi Ferrucci","Maëlenn Guerchet","Andrew Hattersley","Carlos Lahoz","Robyn L McClelland","Mary M McDermott","Jackie Price","Henri E Stoffers","Ji-Guang Wang","Jan Westerink","James White","Lyne Cloutier","Rod S Taylor","Angela C Shore","Richard J McManus","Victor Aboyans","John L Campbell"],"significance":7,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This individual patient data meta-analysis confirmed that the higher arm blood pressure reading provides better cardiovascular risk prediction, supporting the guideline recommendation to measure blood pressure in both arms and use the higher reading for clinical decisions.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"560bc827a50f","type":"article","url":"https://hartvaat.nl/2022/10/01/alfa-antagonisten-en-cardiovasculaire-uitkomsten-meta-analyse-nuanceert-risico/","title":"Alfa-antagonisten en cardiovasculaire uitkomsten: meta-analyse nuanceert risico","title_en":"Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","aperitif-trial","biomarkers-cardiovasculair","bloeddrukbehandeling","carvedilol","endothelineantagonisten","farmaco-economie","fidelity","figaro-dkd","voeding-hart"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14012","source_url":"https://doi.org/10.1002/ehf2.14012","authors":["José Pedro Sousa","Diogo Mendonça","Rogério Teixeira","Lino Gonçalves"],"significance":5,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated whether alpha-1 adrenergic antagonists increase cardiovascular risk in heart failure, finding insufficient evidence to confirm the long-held safety concern about these commonly avoided medications.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"253c4e07138d","type":"article","url":"https://hartvaat.nl/2022/10/01/financiele-prikkels-verbeteren-hypertensiecontrole-chinese-rct/","title":"Financiële prikkels verbeteren hypertensiecontrole: Chinese RCT","title_en":"Effect of Financial Incentives on Hypertension Control: A Multicenter Randomized Controlled Trial in China.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["bloeddrukbehandeling","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19568","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19568","authors":["Liqiang Zheng","Sitong Liu","Yundi Jiao","Yani Wu","Yali Wang","Zhecong Yu","Jiahui Xu","Yingxian Sun","Zhaoqing Sun"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/therapietrouw-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This multicenter Chinese trial showed that financial incentives for hypertensive patients significantly improve blood pressure control, demonstrating that behavioral economic strategies can overcome medication non-adherence.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7893bf02c8cd","type":"article","url":"https://hartvaat.nl/2022/10/01/bloedbiomerkers-voor-prognose-bij-hypertrofische-cardiomyopathie-meta-analyse/","title":"Bloedbiomerkers voor prognose bij hypertrofische cardiomyopathie: meta-analyse","title_en":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["abelacimab","biomarkers-cardiovasculair","bloeddrukbehandeling","laminopathie","nt-probnp","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14073","source_url":"https://doi.org/10.1002/ehf2.14073","authors":["Mark Jansen","Sila Algül","Laurens P Bosman","Michelle Michels","Jolanda van der Velden","Rudolf A de Boer","J Peter van Tintelen","Folkert W Asselbergs","Annette F Baas"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"This meta-analysis identified BNP, NT-proBNP, and troponin as reliable prognostic biomarkers in hypertrophic cardiomyopathy, providing a blood-based approach to risk stratification in this genetic heart disease.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"803e15b491da","type":"article","url":"https://hartvaat.nl/2022/10/01/intraveneus-tolvaptan-versus-orale-formulering-bij-congestief-hartfalen/","title":"Intraveneus tolvaptan versus orale formulering bij congestief hartfalen","title_en":"Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14021","source_url":"https://doi.org/10.1002/ehf2.14021","authors":["Naoki Sato","Shingo Uno","Yuka Kurita","Seongryul Kim"],"significance":5,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This phase III trial confirmed the non-inferiority of intravenous tolvaptan versus oral tolvaptan for congestive heart failure, providing a parenteral aquaretic option for patients unable to take oral medications.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc3e25929a87","type":"article","url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","title":"MitraClip bij secundaire mitralisklepinsufficiëntie: meta-analyse ischemisch vs niet-ischemisch","title_en":"Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["mitralisinsufficiëntie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13772","source_url":"https://doi.org/10.1002/ehf2.13772","authors":["Mauro Chiarito","Jorge Sanz-Sanchez","Michele Pighi","Francesco Cannata","Antonio Popolo Rubbio","Andrea Munafò","Davide Cao","Fausto Roccasalva","Daniela Pini","Paolo A Pagnotta","Federica Ettori","Anna Sonia Petronio","Corrado Tamburino","Bernhard Reimers","Antonio Colombo","Carlo Di Mario","Carmelo Grasso","Roxana Mehran","Cosmo Godino","Giulio G Stefanini"],"significance":7,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-mri/"],"congress":"","summary_en":"This meta-analysis compared MitraClip plus medical therapy versus medical therapy alone for secondary mitral regurgitation, incorporating data from both the positive COAPT and the neutral MITRA-FR to provide a balanced assessment.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56cd2871f19b","type":"article","url":"https://hartvaat.nl/2022/10/01/bnp-nt-probnp-stratificeert-prognose-gelijk-met-en-zonder-hartfalen-meta-analyse/","title":"BNP/NT-proBNP stratificeert prognose gelijk met en zonder hartfalen: meta-analyse","title_en":"Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14019","source_url":"https://doi.org/10.1002/ehf2.14019","authors":["Stefanie Hendricks","Iryna Dykun","Bastian Balcer","Matthias Totzeck","Tienush Rassaf","Amir A Mahabadi"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"This meta-analysis confirmed that BNP and NT-proBNP levels stratify prognosis equally well in patients with and without heart failure, supporting universal natriuretic peptide measurement for cardiovascular risk assessment.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ae37dd9ec29","type":"article","url":"https://hartvaat.nl/2022/10/01/orale-ijzersuppletie-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Orale ijzersuppletie bij hartfalen: systematische review en meta-analyse","title_en":"Oral iron supplementation in patients with heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","hfmref","hfpef","hfref","ijzersuppletie","ivabradine","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14020","source_url":"https://doi.org/10.1002/ehf2.14020","authors":["Zhiping Song","Mingyang Tang","Gang Tang","Guoqi Fu","Dengke Ou","Fengyou Yao","Xingzhi Hou","Denghong Zhang"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis showed that oral iron supplementation in heart failure with iron deficiency improves iron parameters but does not consistently improve clinical outcomes, supporting the superiority of intravenous over oral iron.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T18:38:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"851828690658","type":"article","url":"https://hartvaat.nl/2022/10/01/inspanningshemodynamiek-bij-hfpef-systematische-review-en-meta-analyse/","title":"Inspanningshemodynamiek bij HFpEF: systematische review en meta-analyse","title_en":"Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","hfpef","hfref","step-hfpef","summit-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13979","source_url":"https://doi.org/10.1002/ehf2.13979","authors":["Claudia Baratto","Sergio Caravita","Davide Soranna","Céline Dewachter","Antoine Bondue","Antonella Zambon","Luigi P Badano","Gianfranco Parati","Jean-Luc Vachiéry"],"significance":6,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This meta-analysis of exercise right heart catheterization in HFpEF confirmed that exercise-induced pulmonary wedge pressure elevation reliably diagnoses HFpEF, providing hemodynamic benchmarks for this diagnostic gold standard.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9af77eb92035","type":"article","url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","title":"Verschillende trainingsvormen en HDL-functie bij HFpEF: OptimEx substudie","title_en":"Impact of different training modalities on high-density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hartrevalidatie","hfpef","hfref","lipidenverlaging","step-hfpef","summit-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14032","source_url":"https://doi.org/10.1002/ehf2.14032","authors":["Pamela W Sowa","Ephraim B Winzer","Jennifer Hommel","Anita Männel","Emeline M van Craenenbroeck","Ulrik Wisløff","Burkert Pieske","Martin Halle","Axel Linke","Volker Adams"],"significance":5,"published":"2022-10-01","source_date":"2022-10-01","image":"","kennis":[],"congress":"","summary_en":"This OptimEx substudy showed that exercise training modality (HIIT vs moderate continuous) differentially affects HDL function in HFpEF, with both improving nitric oxide-mediated endothelial function through different mechanisms.","created":"2026-07-03T10:29:58Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"535d7dbeda27","type":"article","url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","title":"ADVOR: acetazolamide bij acuut gedecompenseerd hartfalen met volumeoverbelasting","title_en":"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","bloeddrukbehandeling","carvedilol","dapagliflozine","dubbele-trombocytenremming","emperor-trials","sacubitril-valsartan","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2203094","source_url":"https://doi.org/10.1056/NEJMoa2203094","authors":["Wilfried Mullens","Jeroen Dauw","Pieter Martens","Frederik H Verbrugge","Petra Nijst","Evelyne Meekers","Katrien Tartaglia","Fabien Chenot","Samer Moubayed","Riet Dierckx","Philippe Blouard","Pierre Troisfontaines","David Derthoo","Walter Smolders","Liesbeth Bruckers","Walter Droogne","Jozine M Ter Maaten","Kevin Damman","Johan Lassus","Alexandre Mebazaa","Gerasimos Filippatos","Frank Ruschitzka","Matthias Dupont"],"significance":10,"published":"2022-09-29","source_date":"2022-09-29","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The ADVOR trial showed that adding intravenous acetazolamide to loop diuretics in patients hospitalized for acute decompensated heart failure significantly improved decongestion success at 3 days compared with placebo. This pragmatic result revived interest in combination diuretic strategies and provided the first large-scale evidence for sequential nephron blockade in acute heart failure.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d2a3985d416b","type":"article","url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","title":"Verkorte antiplaatjestherapie na stenting bij hoog bloedingsrisico en ACS","title_en":"Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","percutane-coronaire-interventie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.016","source_url":"https://doi.org/10.1016/j.jacc.2022.07.016","authors":["Pieter C Smits","Enrico Frigoli","Pascal Vranckx","Yukio Ozaki","Marie-Claude Morice","Bernard Chevalier","Yoshinobu Onuma","Stephan Windecker","Pim A L Tonino","Marco Roffi","Maciej Lesiak","Felix Mahfoud","Jozef Bartunek","David Hildick-Smith","Antonio Colombo","Goran Stankovic","Andrés Iñiguez","Carl Schultz","Ran Kornowski","Paul J L Ong","Mirvat Alasnag","Alfredo E Rodriguez","Valeria Paradies","Petr Kala","Sasko Kedev","Amar Al Mafragi","Willem Dewilde","Dik Heg","Marco Valgimigli"],"significance":7,"published":"2022-09-27","source_date":"2022-09-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This meta-analysis showed that abbreviated antiplatelet therapy (1-3 months DAPT followed by monotherapy) is safe and effective in high-bleeding-risk patients with ACS after coronary stenting, reducing bleeding without increasing ischemic events.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"33f07bf70c78","type":"article","url":"https://hartvaat.nl/2022/09/27/linkerbundeltakpacing-versus-biventriculaire-pacing-voor-crt-gerandomiseerde-tri/","title":"Linkerbundeltakpacing versus biventriculaire pacing voor CRT: gerandomiseerde trial","title_en":"Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","linkerbundeltakpacing","summit-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.019","source_url":"https://doi.org/10.1016/j.jacc.2022.07.019","authors":["Yao Wang","Haojie Zhu","Xiaofeng Hou","Zhao Wang","Fengwei Zou","Zhiyong Qian","Yongyue Wei","Xiang Wang","Longyao Zhang","Xiaofei Li","Zhimin Liu","Siyuan Xue","Chaotong Qin","Jiaxin Zeng","Hui Li","Hongping Wu","Hong Ma","Kenneth A Ellenbogen","Michael R Gold","Xiaohan Fan","Jiangang Zou"],"significance":8,"published":"2022-09-27","source_date":"2022-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"This first randomized trial comparing left bundle branch area pacing with biventricular pacing for cardiac resynchronization therapy showed that LBBP achieved comparable or superior echocardiographic response with a simpler implantation procedure. The results positioned LBBP as a viable CRT alternative.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03641f437109","type":"article","url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","title":"MOMENTUM 3: vijfjaarsresultaten HeartMate 3 versus axiale LVAD","title_en":"Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2022.16197","source_url":"https://doi.org/10.1001/jama.2022.16197","authors":["Mandeep R Mehra","Daniel J Goldstein","Joseph C Cleveland","Jennifer A Cowger","Shelley Hall","Christopher T Salerno","Yoshifumi Naka","Douglas Horstmanshof","Joyce Chuang","AiJia Wang","Nir Uriel"],"significance":9,"published":"2022-09-27","source_date":"2022-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/lvad-ventrikelondersteunende-systemen/"],"congress":"","summary_en":"The 5-year MOMENTUM 3 results confirmed sustained superiority of the HeartMate 3 over the HeartMate II, with significantly better event-free survival and fewer device-related complications. These long-term data solidified the HeartMate 3 as the definitive standard in durable mechanical circulatory support.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T13:29:04Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d2fd3ba1513","type":"article","url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","title":"IJzerdeficiëntie bij hartfalen en het effect van dapagliflozine: DAPA-HF","title_en":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","nt-probnp","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060511","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060511","authors":["Kieran F Docherty","Paul Welsh","Subodh Verma","Rudolf A De Boer","Eileen O'Meara","Olof Bengtsson","Lars Køber","Mikhail N Kosiborod","Ann Hammarstedt","Anna Maria Langkilde","Daniel Lindholm","Dustin J Little","Mikaela Sjöstrand","Felipe A Martinez","Piotr Ponikowski","Marc S Sabatine","David A Morrow","Morten Schou","Scott D Solomon","Naveed Sattar","Pardeep S Jhund","John J V McMurray"],"significance":7,"published":"2022-09-27","source_date":"2022-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This DAPA-HF analysis showed that iron deficiency is prevalent in HFrEF and associated with worse outcomes, but that dapagliflozin's heart failure benefit is independent of iron status, not mediating its protective effect through iron metabolism.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efb4fc55d5c2","type":"article","url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","title":"Zoutvervangers verminderen cardiovasculaire events: systematische review","title_en":"Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bradycardie","cardiogene-shock","farmaco-economie","fractional-flow-reserve","hartrevalidatie","hypertrofische-cardiomyopathie","inflammatie","lichaamsbeweging","obesitas","ouderen","plotse-hartdood","richtlijnen-esc","roken","secundaire-preventie","select-trial","slaapapneu"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2022-321332","source_url":"https://doi.org/10.1136/heartjnl-2022-321332","authors":["Xuejun Yin","Anthony Rodgers","Adam Perkovic","Liping Huang","Ka-Chun Li","Jie Yu","Yangfeng Wu","J H Y Wu","Matti Marklund","Mark D Huffman","J Jaime Miranda","Gian Luca Di Tanna","Darwin Labarthe","Paul Elliott","Maoyi Tian","Bruce Neal"],"significance":8,"published":"2022-09-26","source_date":"2022-09-26","image":"","kennis":[],"congress":"","summary_en":"This systematic review and meta-analysis confirmed that potassium-enriched salt substitutes lower blood pressure and reduce cardiovascular events and all-cause mortality, reinforcing the SSaSS results and supporting salt substitution as a scalable public health intervention.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e5371335e9d","type":"article","url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","title":"Smartphone-detectie van AF via fotoplethysmografie: meta-analyse","title_en":"Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["digitale-gezondheid"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320417","source_url":"https://doi.org/10.1136/heartjnl-2021-320417","authors":["Simrat Gill","Karina V Bunting","Claudio Sartini","Victor Roth Cardoso","Narges Ghoreishi","Hae-Won Uh","John A Williams","Kiliana Suzart-Woischnik","Amitava Banerjee","Folkert W Asselbergs","Mjc Eijkemans","Georgios V Gkoutos","Dipak Kotecha"],"significance":7,"published":"2022-09-26","source_date":"2022-09-26","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that smartphone cameras using photoplethysmography detect atrial fibrillation with high sensitivity and specificity, supporting the potential of consumer smartphone technology as a scalable AF screening tool.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T13:29:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f6d56c03b512","type":"article","url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","title":"GRADE: vergelijking glucoseverlagende middelen op microvasculaire en CV-uitkomsten","title_en":"Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","fidelio-dkd","figaro-dkd","obesitas","ouderen","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2200436","source_url":"https://doi.org/10.1056/NEJMoa2200436","authors":["David M Nathan","John M Lachin","Ionut Bebu","Henry B Burch","John B Buse","Andrea L Cherrington","Stephen P Fortmann","Jennifer B Green","Steven E Kahn","M Sue Kirkman","Heidi Krause-Steinrauf","Mary E Larkin","Lawrence S Phillips","Rodica Pop-Busui","Michael Steffes","Margaret Tiktin","Mark Tripputi","Deborah J Wexler","Naji Younes"],"significance":9,"published":"2022-09-22","source_date":"2022-09-22","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"The GRADE trial compared four glucose-lowering agents added to metformin over 5 years and found that liraglutide and insulin glargine were most durable for glycemic control, while liraglutide had the most favorable cardiovascular profile. The results provided comparative effectiveness data to guide second-line agent selection in type 2 diabetes.","created":"2026-07-03T10:29:57Z","updated":"2026-07-03T13:29:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5bbd94bd3de9","type":"article","url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","title":"DELIVER: dapagliflozine effectief bij HFmrEF en HFpEF","title_en":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","canagliflozine","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","hfmref","hfpef","hfref","step-hfpef","summit-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2206286","source_url":"https://doi.org/10.1056/NEJMoa2206286","authors":["Scott D Solomon","John J V McMurray","Brian Claggett","Rudolf A de Boer","David DeMets","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Sanjiv J Shah","Akshay S Desai","Pardeep S Jhund","Jan Belohlavek","Chern-En Chiang","C Jan Willem Borleffs","Josep Comin-Colet","Dan Dobreanu","Jaroslaw Drozdz","James C Fang","Marco Antonio Alcocer-Gamba","Waleed Al Habeeb","Yaling Han","Jose Walter Cabrera Honorio","Stefan P Janssens","Tzvetana Katova","Masafumi Kitakaze","Béla Merkely","Eileen O'Meara","Jose Francisco Kerr Saraiva","Sergey N Tereshchenko","Jorge Thierer","Muthiah Vaduganathan","Orly Vardeny","Subodh Verma","Vinh Nguyen Pham","Ulrica Wilderäng","Natalia Zaozerska","Erasmus Bachus","Daniel Lindholm","Magnus Petersson","Anna Maria Langkilde"],"significance":10,"published":"2022-09-22","source_date":"2022-09-22","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The DELIVER trial demonstrated that dapagliflozin significantly reduced the composite of worsening heart failure or cardiovascular death in patients with heart failure and an ejection fraction above 40%, regardless of diabetes status. Together with EMPEROR-Preserved, this confirmed the benefit of SGLT2 inhibitors across the full ejection fraction spectrum.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de42cca98d1e","type":"article","url":"https://hartvaat.nl/2022/09/21/riociguat-bij-pulmonale-hypertensie-en-hfpef-haemodynamic-trial/","title":"Riociguat bij pulmonale hypertensie en HFpEF: haemoDYNAMIC-trial","title_en":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","dapa-hf","pulmonale-hypertensie","step-hfpef","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac389","source_url":"https://doi.org/10.1093/eurheartj/ehac389","authors":["Theresa Marie Dachs","Franz Duca","René Rettl","Christina Binder-Rodriguez","Daniel Dalos","Luciana Camuz Ligios","Andreas Kammerlander","Ekkehard Grünig","Ingrid Pretsch","Regina Steringer-Mascherbauer","Klemens Ablasser","Manfred Wargenau","Julia Mascherbauer","Irene M Lang","Christian Hengstenberg","Roza Badr-Eslam","Johannes Kastner","Diana Bonderman"],"significance":7,"published":"2022-09-21","source_date":"2022-09-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/rechtsventrikelfalen/"],"congress":"","summary_en":"The haemoDYNAMIC trial showed that riociguat improves hemodynamic parameters in patients with pulmonary hypertension and HFpEF, exploring sGC stimulation as a targeted approach for the pulmonary vascular component of this challenging phenotype.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f9a43f2c341","type":"article","url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","title":"Sacubitril/valsartan en frailteit bij HFpEF: PARAGON-HF analyse","title_en":"Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.06.037","source_url":"https://doi.org/10.1016/j.jacc.2022.06.037","authors":["Jawad H Butt","Pooja Dewan","Pardeep S Jhund","Inder S Anand","Dan Atar","Junbo Ge","Akshay S Desai","Luis E Echeverria","Lars Køber","Carolyn S P Lam","Aldo P Maggioni","Felipe Martinez","Milton Packer","Jean L Rouleau","David Sim","Dirk J Van Veldhuisen","Bojan Vrtovec","Faiez Zannad","Michael R Zile","Jianjian Gong","Martin P Lefkowitz","Adel R Rizkala","Scott D Solomon","John J V McMurray"],"significance":7,"published":"2022-09-20","source_date":"2022-09-20","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This PARAGON-HF analysis showed that sacubitril-valsartan is effective in HFpEF regardless of frailty status, with frail patients potentially deriving greater absolute benefit due to their higher baseline event rates.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"605dceae5392","type":"article","url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","title":"Recombinant LCAT bij acuut STEMI: fase 2b trial","title_en":"Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059325","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059325","authors":["Marc P Bonaca","David A Morrow","Brian A Bergmark","David D Berg","Joao A C Lima","Udo Hoffmann","Yoko Kato","Michael T Lu","Julia Kuder","Sabina A Murphy","Jindrich Spinar","Ton Oude Ophuis","Róbert G Kiss","Jose Lopez-Sendon","Oleg Averkov","Stephen B Wheatcroft","Jacek Kubica","Jose Carlos Nicolau","Remo H M Furtado","Liron Abuhatzira","Boaz Hirshberg","Sami A Omar","Andrea L Vavere","Yi-Ting Chang","Richard T George","Marc S Sabatine"],"significance":6,"published":"2022-09-20","source_date":"2022-09-20","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"This phase 2b trial of recombinant human LCAT in acute STEMI tested whether enhancing HDL function through enzyme augmentation provides cardioprotection in the acute MI setting.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a50a8d70315","type":"article","url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","title":"Harmonisatie van ACC/AHA en ESC/ESH bloeddrukrichtlijnen","title_en":"Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.005","source_url":"https://doi.org/10.1016/j.jacc.2022.07.005","authors":["Paul K Whelton","Robert M Carey","Giuseppe Mancia","Reinhold Kreutz","Joshua D Bundy","Bryan Williams"],"significance":8,"published":"2022-09-20","source_date":"2022-09-20","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This harmonization document analyzed the similarities and differences between the ACC/AHA and ESC/ESH hypertension guidelines, highlighting converging evidence on treatment initiation thresholds and targets while acknowledging remaining disagreements on classification and risk assessment.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f893c3a2366","type":"article","url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","title":"INVICTUS: rivaroxaban versus warfarine bij reumatische hartziekte en AF","title_en":"Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["aperitif-trial","rivaroxaban"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2209051","source_url":"https://doi.org/10.1056/NEJMoa2209051","authors":["Stuart J Connolly","Ganesan Karthikeyan","Mpiko Ntsekhe","Abraham Haileamlak","Ahmed El Sayed","Alaa El Ghamrawy","Albertino Damasceno","Alvaro Avezum","Antonio M L Dans","Bernard Gitura","Dayi Hu","Emmanuel R Kamanzi","Fathi Maklady","Golden Fana","J Antonio Gonzalez-Hermosillo","John Musuku","Khawar Kazmi","Liesl Zühlke","Lillian Gondwe","Changsheng Ma","Maria Paniagua","Okechukwu S Ogah","Onkabetse J Molefe-Baikai","Peter Lwabi","Pilly Chillo","Sanjib K Sharma","Tantchou T J Cabral","Wadea M Tarhuni","Alexander Benz","Martin van Eikels","Amy Krol","Divya Pattath","Kumar Balasubramanian","Sumathy Rangarajan","Chinthanie Ramasundarahettige","Bongani Mayosi","Salim Yusuf"],"significance":10,"published":"2022-09-15","source_date":"2022-09-15","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-kankerpatienten/"],"congress":"","summary_en":"The INVICTUS trial showed that rivaroxaban was inferior to warfarin for preventing cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation, with higher rates of stroke, systemic embolism, and death. This landmark negative result confirmed that DOACs cannot replace warfarin in valvular AF due to rheumatic heart disease.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d8d3ae5374f4","type":"article","url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","title":"Polypill voor secundaire cardiovasculaire preventie: SECURE-trial in NEJM","title_en":"Polypill Strategy in Secondary Cardiovascular Prevention.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aspirine","figaro-dkd","kanker-en-hart","ramipril","rosuvastatine"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2208275","source_url":"https://doi.org/10.1056/NEJMoa2208275","authors":["Jose M Castellano","Stuart J Pocock","Deepak L Bhatt","Antonio J Quesada","Ruth Owen","Antonio Fernandez-Ortiz","Pedro L Sanchez","Francisco Marin Ortuño","Jose M Vazquez Rodriguez","Alexandra Domingo-Fernández","Iñigo Lozano","Maria C Roncaglioni","Marta Baviera","Andreana Foresta","Luisa Ojeda-Fernandez","Furio Colivicchi","Stefania A Di Fusco","Wolfram Doehner","Antje Meyer","François Schiele","Fiona Ecarnot","Aleš Linhart","Jean-Claude Lubanda","Gyorgy Barczi","Bela Merkely","Piotr Ponikowski","Marta Kasprzak","Juan M Fernandez Alvira","Vicente Andres","Hector Bueno","Timothy Collier","Frans Van de Werf","Pablo Perel","Moises Rodriguez-Manero","Angeles Alonso Garcia","Marco Proietti","Mikkel M Schoos","Tabassome Simon","Jose Fernandez Ferro","Nicolas Lopez","Ettore Beghi","Yannick Bejot","David Vivas","Alberto Cordero","Borja Ibañez","Valentin Fuster"],"significance":10,"published":"2022-09-15","source_date":"2022-09-15","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/polypil-cardiovasculair/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The SECURE trial demonstrated that a cardiovascular polypill containing aspirin, ramipril, and atorvastatin reduced major adverse cardiovascular events by 24% compared with separate medications in patients after myocardial infarction. The benefit was attributed to improved adherence, validating the polypill as a practical secondary prevention strategy.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3235cd817b6","type":"article","url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","title":"EAST-AFNET4: vroege ritmecontrole effectief ook bij hoge comorbiditeit","title_en":"Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","ouderen","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060274","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060274","authors":["Andreas Rillig","Katrin Borof","Günter Breithardt","A John Camm","Harry J G M Crijns","Andreas Goette","Karl-Heinz Kuck","Andreas Metzner","Panos Vardas","Eik Vettorazzi","Karl Wegscheider","Antonia Zapf","Paulus Kirchhof"],"significance":8,"published":"2022-09-13","source_date":"2022-09-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"This EAST-AFNET4 subanalysis showed that early rhythm control reduces cardiovascular events even in AF patients with high comorbidity burden, including those with heart failure, diabetes, and chronic kidney disease. The benefit was not attenuated by comorbidity complexity.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c48728bc8265","type":"article","url":"https://hartvaat.nl/2022/09/10/statines-en-spiersymptomen-lancet-ipd-meta-analyse-ontkracht-breed-probleem/","title":"Statines en spiersymptomen: Lancet IPD meta-analyse ontkracht breed probleem","title_en":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01545-8","source_url":"https://doi.org/10.1016/S0140-6736(22)01545-8","authors":[],"significance":10,"published":"2022-09-10","source_date":"2022-09-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This individual participant data meta-analysis of large-scale, double-blind statin trials in the Lancet showed that statins cause only a small excess of muscle symptoms (about 11 per 1,000 patients over 5 years), with most patient-reported muscle complaints being attributable to the nocebo effect. The findings provide robust reassurance for clinicians managing statin-associated myalgia concerns.","created":"2026-07-03T10:29:56Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2388915e9482","type":"article","url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","title":"POST-PCI: routine functionele testen versus standaardzorg na PCI bij hoog risico","title_en":"Routine Functional Testing or Standard Care in High-Risk Patients after PCI.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2208335","source_url":"https://doi.org/10.1056/NEJMoa2208335","authors":["Duk-Woo Park","Do-Yoon Kang","Jung-Min Ahn","Sung-Cheol Yun","Yong-Hoon Yoon","Seung-Ho Hur","Cheol Hyun Lee","Won-Jang Kim","Se Hun Kang","Chul Soo Park","Bong-Ki Lee","Jung-Won Suh","Jung Han Yoon","Jae Woong Choi","Kee-Sik Kim","Si Wan Choi","Su Nam Lee","Seung-Jung Park"],"significance":8,"published":"2022-09-08","source_date":"2022-09-08","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"The POST-PCI trial demonstrated that routine functional testing after PCI in high-risk patients did not improve clinical outcomes compared with standard care at 2 years. The results argued against routine surveillance testing as a post-PCI follow-up strategy.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"666688e852b6","type":"article","url":"https://hartvaat.nl/2022/09/07/aortastenose-bij-homozygote-familiaire-hypercholesterolemie-paradigmaverschuivin/","title":"Aortastenose bij homozygote familiaire hypercholesterolemie: paradigmaverschuiving","title_en":"Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["aortastenose","cardiovasculaire-genetica","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","ldl-cholesterol","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac339","source_url":"https://doi.org/10.1093/eurheartj/ehac339","authors":["Alexandre M Bélanger","Leo E Akioyamen","Isabelle Ruel","Lindsay Hales","Jacques Genest"],"significance":7,"published":"2022-09-07","source_date":"2022-09-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This review described the paradigm shift in homozygous familial hypercholesterolemia, where improved lipid-lowering therapy has transformed early atherosclerotic death into longer survival complicated by progressive aortic stenosis from lipid deposition.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b76e22eb3c21","type":"article","url":"https://hartvaat.nl/2022/09/07/prevalentie-van-statine-intolerantie-meta-analyse-nuanceert-het-probleem/","title":"Prevalentie van statine-intolerantie: meta-analyse nuanceert het probleem","title_en":"Prevalence of statin intolerance: a meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac015","source_url":"https://doi.org/10.1093/eurheartj/ehac015","authors":["Ibadete Bytyçi","Peter E Penson","Dimitri P Mikhailidis","Nathan D Wong","Adrian V Hernandez","Amirhossein Sahebkar","Paul D Thompson","Mohsen Mazidi","Jacek Rysz","Daniel Pella","Željko Reiner","Peter P Toth","Maciej Banach"],"significance":8,"published":"2022-09-07","source_date":"2022-09-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This meta-analysis estimated that true statin intolerance affects 7-29% of patients depending on the definition used, with nocebo-confirmed intolerance rates being much lower. The data highlighted the gap between perceived and actual statin intolerance and supported rechallenge strategies.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"99dfc1175bfe","type":"article","url":"https://hartvaat.nl/2022/09/06/klinisch-beslisondersteuning-vermindert-acute-nierschade-bij-coronairangiografie/","title":"Klinisch beslisondersteuning vermindert acute nierschade bij coronairangiografie","title_en":"Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","atleten","bradycardie","farmaco-economie","hartkatheterisatie","hartrevalidatie","myocardinfarct","ouderen","perifeer-vaatlijden","select-trial","stabiel-coronairlijden","vrouwen"],"journal":"JAMA","doi":"10.1001/jama.2022.13382","source_url":"https://doi.org/10.1001/jama.2022.13382","authors":["Matthew T James","Bryan J Har","Benjamin D Tyrrell","Peter D Faris","Zhi Tan","John A Spertus","Stephen B Wilton","William A Ghali","Merril L Knudtson","Tolulope T Sajobi","Neesh I Pannu","Scott W Klarenbach","Michelle M Graham"],"significance":6,"published":"2022-09-06","source_date":"2022-09-06","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This randomized trial showed that clinical decision support with audit and feedback reduces contrast-associated acute kidney injury during coronary angiography and PCI, demonstrating the effectiveness of automated safety systems.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be439ab09a4e","type":"article","url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","title":"SGLT2-remmers bij hartfalen: mega-meta-analyse van vijf grote trials","title_en":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","canagliflozine","dapa-hf","dapagliflozine","empagliflozine","emperor-trials","finearts-hf","hfmref","hfpef","hfref","step-hfpef","vericiguat"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)01429-5","source_url":"https://doi.org/10.1016/S0140-6736(22)01429-5","authors":["Muthiah Vaduganathan","Kieran F Docherty","Brian L Claggett","Pardeep S Jhund","Rudolf A de Boer","Adrian F Hernandez","Silvio E Inzucchi","Mikhail N Kosiborod","Carolyn S P Lam","Felipe Martinez","Sanjiv J Shah","Akshay S Desai","John J V McMurray","Scott D Solomon"],"significance":10,"published":"2022-09-03","source_date":"2022-09-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This comprehensive meta-analysis of five major SGLT2 inhibitor trials in heart failure (DAPA-HF, EMPEROR-Reduced, DELIVER, EMPEROR-Preserved, SOLOIST-WHF) confirmed that SGLT2 inhibition reduces heart failure hospitalization and cardiovascular death across the full range of ejection fraction. The analysis provided definitive class-level evidence supporting their use in all heart failure phenotypes.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d90b02bafb70","type":"article","url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","title":"FLAVOUR: FFR versus IVUS voor PCI-beslissingen bij coronairlijden","title_en":"Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2201546","source_url":"https://doi.org/10.1056/NEJMoa2201546","authors":["Bon-Kwon Koo","Xinyang Hu","Jeehoon Kang","Jinlong Zhang","Jun Jiang","Joo-Yong Hahn","Chang-Wook Nam","Joon-Hyung Doh","Bong-Ki Lee","Weon Kim","Jinyu Huang","Fan Jiang","Hao Zhou","Peng Chen","Lijiang Tang","Wenbing Jiang","Xiaomin Chen","Wenming He","Sung-Gyun Ahn","Myeong-Ho Yoon","Ung Kim","Joo-Myung Lee","Doyeon Hwang","You-Jeong Ki","Eun-Seok Shin","Hyo-Soo Kim","Seung-Jea Tahk","Jian'an Wang"],"significance":9,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The FLAVOUR trial demonstrated that FFR-guided PCI was noninferior to IVUS-guided PCI for the composite of death, MI, or revascularization at 24 months in patients with intermediate coronary stenoses. The results validated both physiological and anatomical guidance strategies as acceptable approaches.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0c86e68657aa","type":"article","url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","title":"Collaterale schade van COVID-19 aan cardiovasculaire zorg: meta-analyse","title_en":"The collateral damage of COVID-19 to cardiovascular services: a meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["covid-hart"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac227","source_url":"https://doi.org/10.1093/eurheartj/ehac227","authors":["Ramesh Nadarajah","Jianhua Wu","Ben Hurdus","Samira Asma","Deepak L Bhatt","Giuseppe Biondi-Zoccai","Laxmi S Mehta","C Venkata S Ram","Antonio Luiz P Ribeiro","Harriette G C Van Spall","John E Deanfield","Thomas F Lüscher","Mamas Mamas","Chris P Gale"],"significance":7,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/insulineresistentie-mechanisme/"],"congress":"","summary_en":"This meta-analysis quantified the collateral damage of COVID-19 on cardiovascular services, showing significant reductions in ACS hospitalizations, prolonged door-to-balloon times, and increased cardiovascular mortality during pandemic waves.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5d59d354df7","type":"article","url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","title":"Dapagliflozine effectief ongeacht CV-achtergrondmedicatie: DECLARE subanalyse","title_en":"Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","canagliflozine","dapa-hf","dapagliflozine","diabetes-type-2","dubbele-trombocytenremming","empagliflozine","emperor-trials","farmaco-economie","sglt2-remmers","soul-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.2006","source_url":"https://doi.org/10.1001/jamacardio.2022.2006","authors":["Kazuma Oyama","Itamar Raz","Avivit Cahn","Erica L Goodrich","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John P H Wilding","Ingrid A M Gause-Nilsson","Ofri Mosenzon","Marc S Sabatine","Stephen D Wiviott"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DECLARE-TIMI 58 subanalysis confirmed that dapagliflozin's cardiovascular and renal benefits in type 2 diabetes are consistent regardless of background cardiovascular medication use, supporting additive benefit on top of standard therapy.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d5406ad8e22c","type":"article","url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","title":"ORBITA-substudie: inspanningstesten en PCI-effectiviteit","title_en":"Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac260","source_url":"https://doi.org/10.1093/eurheartj/ehac260","authors":["Sashiananthan Ganesananthan","Christopher A Rajkumar","Michael Foley","David Thompson","Alexandra N Nowbar","Henry Seligman","Ricardo Petraco","Sayan Sen","Sukhjinder Nijjer","Simon A Thom","Roland Wensel","John Davies","Darrel Francis","Matthew Shun-Shin","James Howard","Rasha Al-Lamee"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This ORBITA substudy showed that cardiopulmonary exercise test parameters can predict the symptomatic response to PCI, establishing CPET as a functional tool for selecting patients most likely to benefit from coronary intervention.","created":"2026-07-03T10:29:55Z","updated":"2026-07-03T13:29:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82746703c978","type":"article","url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","title":"Timing van invasieve strategie bij NSTE-ACS: meta-analyse van RCT's","title_en":"Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","cardiale-resynchronisatie","farmaco-economie","hartkatheterisatie","myocardinfarct","ouderen","primaire-preventie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac213","source_url":"https://doi.org/10.1093/eurheartj/ehac213","authors":["Thomas A Kite","Sameer A Kurmani","Vasiliki Bountziouka","Nicola J Cooper","Selina T Lock","Chris P Gale","Marcus Flather","Nick Curzen","Adrian P Banning","Gerry P McCann","Andrew Ladwiniec"],"significance":7,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/nstemi-en-instabiele-angina/","https://hartvaat.nl/kennis/kleplijden/mitraclip-transcatheter-mitralisreparatie/"],"congress":"","summary_en":"This meta-analysis of randomized trials on the timing of invasive strategy in NSTE-ACS found that very early intervention (within 12 hours) may benefit high-risk patients but does not improve outcomes universally, supporting risk-stratified timing decisions.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T13:29:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0bf64c401485","type":"article","url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","title":"AF voorspelt cognitieve achteruitgang: meta-analyse van 2,8 miljoen personen","title_en":"Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac003","source_url":"https://doi.org/10.1093/europace/euac003","authors":["Yu Han Koh","Leslie Z W Lew","Kyle B Franke","Adrian D Elliott","Dennis H Lau","Anand Thiyagarajah","Dominik Linz","Margaret Arstall","Phillip J Tully","Bernhard T Baune","Dian A Munawar","Rajiv Mahajan"],"significance":7,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/atriumfibrilleren/chadsvasc-score/"],"congress":"","summary_en":"This large meta-analysis of 2.8 million persons confirmed that atrial fibrillation is an independent risk factor for cognitive decline and dementia, with the association persisting even in anticoagulated patients, suggesting mechanisms beyond cardioembolism.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T13:29:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"484de21d9696","type":"article","url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","title":"Bloeddruk beïnvloedt opbrengst van AF-screening: LOOP-substudie","title_en":"Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["ambulante-bloeddrukmeting","atleten","bloeddrukbehandeling","primaire-preventie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19333","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19333","authors":["Lucas Yixi Xing","Søren Zöga Diederichsen","Søren Højberg","Derk W Krieger","Claus Graff","Morten Salling Olesen","Axel Brandes","Lars Køber","Ketil Jørgen Haugan","Jesper Hastrup Svendsen"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/holter-monitoring-bij-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This LOOP trial substudy showed that higher systolic blood pressure increases the detection rate of AF during long-term continuous monitoring, informing the selection of patients most likely to benefit from intensive arrhythmia surveillance.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d70575a0a855","type":"article","url":"https://hartvaat.nl/2022/09/01/obstructief-slaapapneu-sympathische-activiteit-en-bloeddruk-meta-analyse/","title":"Obstructief slaapapneu, sympathische activiteit en bloeddruk: meta-analyse","title_en":"Influence of Obstructive Sleep Apnea Severity on Muscle Sympathetic Nerve Activity and Blood Pressure: a Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","bradycardie","slaapapneu"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19288","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19288","authors":["Lauren E Maier","Brittany A Matenchuk","Ana Vucenovic","Allison Sivak","Margie H Davenport","Craig D Steinback"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/secundaire-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This meta-analysis established a dose-response relationship between obstructive sleep apnea severity and both sympathetic nerve activity and blood pressure, supporting the neurogenic mechanism linking OSA to hypertension.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T18:38:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0997b9796b5e","type":"article","url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","title":"Bloeddrukinterventie en -controle in SPRINT nader geanalyseerd","title_en":"Blood Pressure Intervention and Control in SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17233","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17233","authors":["William C Cushman","Robert J Ringer","Carlos J Rodriguez","Gregory W Evans","Jeffrey T Bates","Jeffrey A Cutler","Amret Hawfield","Dalane W Kitzman","Ilya M Nasrallah","Suzanne Oparil","John Nord","Vasilios Papademetriou","Karen Servilla","Peter Van Buren","Paul K Whelton","Jeff Whittle","Jackson T Wright"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This detailed SPRINT analysis described the pharmacological strategy used to achieve intensive blood pressure control, showing that on average 2.8 antihypertensives were needed versus 1.8 for standard treatment.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9224ff905281","type":"article","url":"https://hartvaat.nl/2022/09/01/primair-aldosteronisme-in-de-zwangerschap-systematische-review/","title":"Primair aldosteronisme in de zwangerschap: systematische review","title_en":"Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts","internist"],"tags":["aldosteronsynthaseremmers","baxdrostat","lorundrostat","mra-aldosteronantagonisten","resistente-hypertensie-aldosteronremmers","spironolacton"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18858","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18858","authors":["Viola Sanga","Giacomo Rossitto","Teresa Maria Seccia","Gian Paolo Rossi"],"significance":5,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/centrale-middelen-hypertensie/"],"congress":"","summary_en":"This systematic review documented the diagnostic and therapeutic challenges of primary aldosteronism during pregnancy, providing practical guidance for managing this uncommon but serious gestational condition.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ecf5a919f1a1","type":"article","url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","title":"Biomarkers voorspellen complexe coronaire revascularisatie in FOURIER","title_en":"Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","endotheel","fractional-flow-reserve","inflammatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.05.051","source_url":"https://doi.org/10.1016/j.jacc.2022.05.051","authors":["Antonio Fagundes","David A Morrow","Kazuma Oyama","Remo H M Furtado","Thomas A Zelniker","Minao Tang","Julia F Kuder","Sabina A Murphy","Andrew Hamer","Anthony C Keech","Peter Sever","Robert P Giugliano","Marc S Sabatine","Brian A Bergmark"],"significance":6,"published":"2022-08-30","source_date":"2022-08-30","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"","summary_en":"This FOURIER substudy showed that cardiovascular biomarkers (NT-proBNP, troponin, IL-6) predict the need for complex coronary revascularization, informing risk stratification beyond traditional clinical variables.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e5f0738341d6","type":"article","url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","title":"RIPCORD 2: routinematige FFR-meting versus conventionele angiografie","title_en":"Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057793","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057793","authors":["Rodney H Stables","Liam J Mullen","Mostafa Elguindy","Zoe Nicholas","Yousra H Aboul-Enien","Ian Kemp","Peter O'Kane","Alex Hobson","Thomas W Johnson","Sohail Q Khan","Stephen B Wheatcroft","Scot Garg","Azfar G Zaman","Mamas A Mamas","James Nolan","Sachin Jadhav","Colin Berry","Stuart Watkins","David Hildick-Smith","Julian Gunn","Dwayne Conway","Angels Hoye","Iftikhar A Fazal","Colm G Hanratty","Bernard De Bruyne","Nick Curzen"],"significance":7,"published":"2022-08-30","source_date":"2022-08-30","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"The RIPCORD 2 trial showed that routine FFR measurement during diagnostic coronary angiography frequently changes the management plan but does not improve clinical outcomes compared with conventional angiography-guided decision-making.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5a4266fa0465","type":"article","url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","title":"ApoB en residueel CV-risico na ACS: effect van alirocumab","title_en":"Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["ezetimibe","hdl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","voeding-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057807","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057807","authors":["Emil Hagström","P Gabriel Steg","Michael Szarek","Deepak L Bhatt","Vera A Bittner","Nicolas Danchin","Rafael Diaz","Shaun G Goodman","Robert A Harrington","J Wouter Jukema","Evangelos Liberopoulos","Nikolaus Marx","Jennifer McGinniss","Garen Manvelian","Robert Pordy","Michel Scemama","Harvey D White","Andreas M Zeiher","Gregory G Schwartz"],"significance":7,"published":"2022-08-30","source_date":"2022-08-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"This ODYSSEY OUTCOMES analysis showed that apolipoprotein B is a stronger predictor of residual cardiovascular risk after ACS than LDL cholesterol, and that alirocumab's benefit correlates more closely with apoB reduction, supporting apoB as a treatment target.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3e6f6fe966c","type":"article","url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","title":"Empagliflozine bij HFpEF: consistent effect met en zonder diabetes","title_en":"Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","empagliflozine","emperor-trials","hfpef","hfref","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059785","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059785","authors":["Gerasimos Filippatos","Javed Butler","Dimitrios Farmakis","Faiez Zannad","Anne Pernille Ofstad","João Pedro Ferreira","Jennifer B Green","Julio Rosenstock","Sven Schnaidt","Martina Brueckmann","Stuart J Pocock","Milton Packer","Stefan D Anker"],"significance":8,"published":"2022-08-30","source_date":"2022-08-30","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This EMPEROR-Preserved subanalysis confirmed that empagliflozin's benefit on heart failure outcomes in HFpEF is consistent regardless of diabetes status, extending the evidence for SGLT2 inhibitors as a universal heart failure therapy beyond glycemic management.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c78136f6a3b6","type":"article","url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","title":"Aflibercept versus bevacizumab-eerst bij diabetisch macula-oedeem","title_en":"Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.","category":"preventie","category_label":"Preventie","professions":["internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2204225","source_url":"https://doi.org/10.1056/NEJMoa2204225","authors":["Chirag D Jhaveri","Adam R Glassman","Frederick L Ferris","Danni Liu","Maureen G Maguire","John B Allen","Carl W Baker","David Browning","Matthew A Cunningham","Scott M Friedman","Lee M Jampol","Dennis M Marcus","Daniel F Martin","Carin M Preston","Cynthia R Stockdale","Jennifer K Sun"],"significance":7,"published":"2022-08-25","source_date":"2022-08-25","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This NEJM trial compared aflibercept monotherapy with a stepped approach starting with bevacizumab for diabetic macular edema, evaluating the cost-effectiveness of different anti-VEGF treatment strategies for this common diabetic complication.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0efc3857d0e5","type":"article","url":"https://hartvaat.nl/2022/08/23/uspstf-evidence-review-statines-voor-primaire-cv-preventie-geactualiseerd/","title":"USPSTF evidence review: statines voor primaire CV-preventie geactualiseerd","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["hartrevalidatie","ouderen","primaire-preventie"],"journal":"JAMA","doi":"10.1001/jama.2022.12138","source_url":"https://doi.org/10.1001/jama.2022.12138","authors":["Roger Chou","Amy Cantor","Tracy Dana","Jesse Wagner","Azrah Y Ahmed","Rongwei Fu","Maros Ferencik"],"significance":8,"published":"2022-08-23","source_date":"2022-08-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/"],"congress":"","summary_en":"This updated USPSTF evidence review reaffirmed that statin use for primary cardiovascular prevention is associated with reduced cardiovascular events and mortality, supporting continued recommendation for statin therapy in adults at elevated 10-year CVD risk.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"697f480b9f9a","type":"article","url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","title":"USPSTF-aanbeveling: statinegebruik voor primaire cardiovasculaire preventie","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["atleten","biomarkers-cardiovasculair","hartrevalidatie","ouderen","primaire-preventie","secundaire-preventie","slaapapneu"],"journal":"JAMA","doi":"10.1001/jama.2022.13044","source_url":"https://doi.org/10.1001/jama.2022.13044","authors":["Carol M Mangione","Michael J Barry","Wanda K Nicholson","Michael Cabana","David Chelmow","Tumaini Rucker Coker","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Martha Kubik","Li Li","Gbenga Ogedegbe","Lori Pbert","John M Ruiz","James Stevermer","John B Wong"],"significance":9,"published":"2022-08-23","source_date":"2022-08-23","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"The 2022 USPSTF reaffirmation recommended statin use for primary cardiovascular prevention in adults aged 40-75 with at least one CVD risk factor and a 10-year CVD risk of 10% or greater, maintaining the 2016 recommendation with updated evidence review.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:29:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd382966a5fc","type":"article","url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","title":"Impact van therapieontrouw op duale antiplaatjestherapie in klinische trial","title_en":"Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["farmaco-economie","soul-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.04.065","source_url":"https://doi.org/10.1016/j.jacc.2022.04.065","authors":["Marco Valgimigli","Enrico Frigoli","Pascal Vranckx","Yukio Ozaki","Marie-Claude Morice","Bernard Chevalier","Yoshinobu Onuma","Stephan Windecker","Laurent Delorme","Petr Kala","Sasko Kedev","Rajpal K Abhaichand","Vasil Velchev","Willem Dewilde","Jakub Podolec","Gregor Leibundgut","Dragan Topic","Carl Schultz","Goran Stankovic","Astin Lee","Thomas Johnson","Pim A L Tonino","Aneta Klotzka","Maciej Lesiak","Renato D Lopes","Pieter C Smits","Dik Heg"],"significance":6,"published":"2022-08-23","source_date":"2022-08-23","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This TWILIGHT analysis showed that medication non-adherence in a clinical trial of DAPT after PCI is common and significantly impacts outcomes, highlighting adherence as a critical determinant of antiplatelet therapy effectiveness.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"60c08b5bea35","type":"article","url":"https://hartvaat.nl/2022/08/23/klinische-verslechtering-als-surrogaat-voor-mortaliteit-bij-pulmonale-arteriele-/","title":"Klinische verslechtering als surrogaat voor mortaliteit bij pulmonale arteriële hypertensie","title_en":"Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","figaro-dkd","ouderen","pathfinder-trial","perifeer-vaatlijden","pulmonale-hypertensie","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.058635","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.058635","authors":["Élodie Tremblay","Camille Gosselin","Vicky Mai","Annie C Lajoie","Roubi Kilo","Jason Weatherald","Yves Lacasse","Sebastien Bonnet","Jean-Christophe Lega","Steeve Provencher"],"significance":6,"published":"2022-08-23","source_date":"2022-08-23","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/therapietrouw-hypertensie/"],"congress":"","summary_en":"This meta-analysis validated clinical worsening as a surrogate endpoint for mortality in PAH trials, supporting its use as a composite outcome in drug development programs for pulmonary arterial hypertension.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"70163f2672e2","type":"article","url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","title":"CABANA: catheterablatie bij AF is kosteneffectief vergeleken met antiaritmica","title_en":"Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.058575","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.058575","authors":["Derek S Chew","Yanhong Li","Patricia A Cowper","Kevin J Anstrom","Jonathan P Piccini","Jeanne E Poole","Melanie R Daniels","Kristi H Monahan","Linda Davidson-Ray","Tristram D Bahnson","Hussein R Al-Khalidi","Kerry L Lee","Douglas L Packer","Daniel B Mark"],"significance":7,"published":"2022-08-16","source_date":"2022-08-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This CABANA cost-effectiveness analysis showed that catheter ablation for AF is cost-effective compared with antiarrhythmic drug therapy, despite the neutral primary intention-to-treat result, driven by quality-of-life improvements and reduced long-term healthcare utilization.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"99444e74ea6b","type":"article","url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","title":"Obesitas en dapagliflozine bij type 2 diabetes: DECLARE-TIMI 58 subanalyse","title_en":"Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","dapagliflozine","diabetes-en-hart","diabetes-type-2","empagliflozine","obesitas"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab530","source_url":"https://doi.org/10.1093/eurheartj/ehab530","authors":["Kazuma Oyama","Itamar Raz","Avivit Cahn","Julia Kuder","Sabina A Murphy","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John P H Wilding","Kyong Soo Park","Assen Goudev","Rafael Diaz","Jindřich Špinar","Ingrid A M Gause-Nilsson","Ofri Mosenzon","Marc S Sabatine","Stephen D Wiviott"],"significance":7,"published":"2022-08-14","source_date":"2022-08-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/vericiguat-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/"],"congress":"","summary_en":"This DECLARE-TIMI 58 subanalysis showed that dapagliflozin's cardiovascular and renal benefits are consistent across the BMI spectrum in type 2 diabetes, supporting SGLT2 inhibitor use regardless of obesity status.","created":"2026-07-03T10:29:53Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a6a042e76a72","type":"article","url":"https://hartvaat.nl/2022/08/11/prevalentie-incidentie-en-overleving-bij-hartfalen-wereldwijde-systematische-rev/","title":"Prevalentie, incidentie en overleving bij hartfalen: wereldwijde systematische review","title_en":"Prevalence, incidence and survival of heart failure: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","primaire-preventie","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320131","source_url":"https://doi.org/10.1136/heartjnl-2021-320131","authors":["Sophia Emmons-Bell","Catherine Johnson","Gregory Roth"],"significance":7,"published":"2022-08-11","source_date":"2022-08-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This comprehensive systematic review documented the global epidemiology of heart failure, finding that prevalence ranges from 1-3% in the general population and exceeds 10% in those over 70, with improving survival but persistently high morbidity.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b509f719c683","type":"article","url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","title":"Ticagrelor DAPT en veneuze graftfalen na CABG: systematische review","title_en":"Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-bypass","dubbele-trombocytenremming","newton-cabg"],"journal":"JAMA","doi":"10.1001/jama.2022.11966","source_url":"https://doi.org/10.1001/jama.2022.11966","authors":["Sigrid Sandner","Björn Redfors","Dominick J Angiolillo","Katia Audisio","Stephen E Fremes","Paul W A Janssen","Alexander Kulik","Roxana Mehran","Joyce Peper","Marc Ruel","Jacqueline Saw","Giovanni Jr Soletti","Andrew Starovoytov","Jurrien M Ten Berg","Laura M Willemsen","Qiang Zhao","Yunpeng Zhu","Mario Gaudino"],"significance":6,"published":"2022-08-09","source_date":"2022-08-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"This meta-analysis evaluated the effect of ticagrelor-based dual antiplatelet therapy on saphenous vein graft failure after CABG, assessing whether more potent platelet inhibition improves graft patency.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3768681df0f","type":"article","url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","title":"Vertraagde-afgifteformulering van ivabradine bij systolisch hartfalen","title_en":"Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["hfref","ivabradine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.05.027","source_url":"https://doi.org/10.1016/j.jacc.2022.05.027","authors":["Feiming Ye","Xiaofeng Wang","Shulin Wu","Shumei Ma","Yu Zhang","Gang Liu","Kunshen Liu","Zhiming Yang","Xiaohua Pang","Li Xue","Shijuan Lu","Ming Zhong","Jing Li","Hao Yu","Donghua Lou","Dongyang Cui","Xiaojie Xie","Jian'an Wang"],"significance":6,"published":"2022-08-09","source_date":"2022-08-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This study of a sustained-release ivabradine formulation in systolic heart failure demonstrated that once-daily dosing achieves comparable heart rate reduction to the twice-daily formulation, potentially improving adherence.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fdc30ff5b355","type":"article","url":"https://hartvaat.nl/2022/08/09/renale-en-vasculaire-effecten-van-gecombineerde-sglt2-en-ace-remming/","title":"Renale en vasculaire effecten van gecombineerde SGLT2- en ACE-remming","title_en":"Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","dapagliflozine","empagliflozine","fidelio-dkd","fidelity","figaro-dkd","flow-trial","ras-remmers","renale-denervatie","sglt2-remmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059150","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059150","authors":["Yuliya Lytvyn","Karen Kimura","Nuala Peter","Vesta Lai","Josephine Tse","Leslie Cham","Bruce A Perkins","Nima Soleymanlou","David Z I Cherney"],"significance":7,"published":"2022-08-09","source_date":"2022-08-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"This mechanistic study showed that empagliflozin combined with ramipril provides additive renal and vascular protective effects in type 2 diabetes, supporting the rationale for combining SGLT2 inhibitors with RAAS inhibitors for cardiorenal protection.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f5a055d714da","type":"article","url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","title":"Initiële eGFR-dip na start dapagliflozine bij HFrEF: DAPA-HF analyse","title_en":"Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["dapa-hf","hfpef","hfref"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.058910","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.058910","authors":["Carly Adamson","Kieran F Docherty","Hiddo J L Heerspink","Rudolf A de Boer","Kevin Damman","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Felipe A Martinez","Mark C Petrie","Piotr Ponikowski","Marc S Sabatine","Morten Schou","Scott D Solomon","Subodh Verma","Olof Bengtsson","Anna Maria Langkilde","Mikaela Sjöstrand","Muthiah Vaduganathan","Pardeep S Jhund","John J V McMurray"],"significance":8,"published":"2022-08-09","source_date":"2022-08-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DAPA-HF post-hoc analysis showed that the initial eGFR decline ('dip') commonly seen after dapagliflozin initiation is not associated with worse clinical outcomes and is followed by a slower long-term rate of kidney function decline. The finding provided reassurance about the hemodynamic kidney effects of SGLT2 inhibitors.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7713c586a7f0","type":"article","url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","title":"REDUCE-IT: icosapent ethyl vermindert inflammatiemarkers","title_en":"Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","inflammatie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059410","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059410","authors":["Paul M Ridker","Nader Rifai","Jean MacFadyen","Robert J Glynn","Lixia Jiao","Ph Gabriel Steg","Michael Miller","Eliot A Brinton","Terry A Jacobson","Jean-Claude Tardif","Christie M Ballantyne","R Preston Mason","Deepak L Bhatt"],"significance":7,"published":"2022-08-02","source_date":"2022-08-02","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"This REDUCE-IT substudy demonstrated that icosapent ethyl significantly reduces inflammatory biomarkers (IL-1β, IL-6, CRP) and oxidized LDL compared with mineral oil placebo, suggesting that anti-inflammatory effects contribute to the cardiovascular benefit beyond triglyceride lowering.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3913fdf97fdf","type":"article","url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","title":"Rivaroxaban monotherapie versus combinatie met plaatjesremmers bij AF en coronairlijden","title_en":"Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["aperitif-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.1561","source_url":"https://doi.org/10.1001/jamacardio.2022.1561","authors":["Ryo Naito","Katsumi Miyauchi","Satoshi Yasuda","Koichi Kaikita","Masaharu Akao","Junya Ako","Tetsuya Matoba","Masato Nakamura","Nobuhisa Hagiwara","Kazuo Kimura","Atsushi Hirayama","Kunihiko Matsui","Hisao Ogawa"],"significance":7,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This study showed that rivaroxaban monotherapy provides comparable protection against thrombotic events with less bleeding than combination therapy with antiplatelets in AF patients with stable coronary disease, supporting anticoagulant monotherapy after the initial period.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"72740c719ee1","type":"article","url":"https://hartvaat.nl/2022/08/01/schone-kookbrandstof-en-bloeddruk-tijdens-zwangerschap-hapin-trial/","title":"Schone kookbrandstof en bloeddruk tijdens zwangerschap: HAPIN-trial","title_en":"Effects of a Liquefied Petroleum Gas Stove Intervention on Gestational Blood Pressure: Intention-to-Treat and Exposure-Response Findings From the HAPIN Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19362","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19362","authors":["Wenlu Ye","Kyle Steenland","Ashlinn Quinn","Jiawen Liao","Kalpana Balakrishnan","Ghislaine Rosa","Florien Ndagijimana","Jean de Dieu Ntivuguruzwa","Lisa M Thompson","John P McCracken","Anaité Díaz-Artiga","Joshua P Rosenthal","Aris Papageorghiou","Victor G Davila-Roman","Ajay Pillarisetti","Michael Johnson","Jiantong Wang","Laura Nicolaou","William Checkley","Jennifer L Peel","Thomas F Clasen"],"significance":5,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"The HAPIN trial tested whether replacing biomass fuel with LPG cooking stoves improves gestational blood pressure, exploring household air pollution reduction as a modifiable environmental risk factor for pregnancy hypertension.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T13:28:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39755a06c156","type":"article","url":"https://hartvaat.nl/2022/08/01/ramipril-bij-hypertensieve-kinderen-op-hemodialyse-search-trial/","title":"Ramipril bij hypertensieve kinderen op hemodialyse: SEARCH-trial","title_en":"Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":["aprocitentan","bloeddrukbehandeling","figaro-dkd","precision-trial","radiance-htn","ramipril","sacubitril-valsartan","select-trial","soul-trial"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19312","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19312","authors":["Areej Mohamed Ateya","Ihab El Hakim","Sara Mahmoud Shahin","Radwa El Borolossy","Reinhold Kreutz","Nagwa Ali Sabri"],"significance":6,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"The SEARCH trial showed that ramipril improves endothelial dysfunction and inflammation biomarkers in hypertensive children on hemodialysis, supporting RAAS inhibition for vascular protection in the pediatric renal population.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9f96f511376","type":"article","url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","title":"Hele-genoomsequencing onthult nieuwe bloeddruk-loci","title_en":"Insights From a Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood Pressure, and Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.19324","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.19324","authors":["Tanika N Kelly","Xiao Sun","Karen Y He","Michael R Brown","Sarah A Gagliano Taliun","Jacklyn N Hellwege","Marguerite R Irvin","Xuenan Mi","Jennifer A Brody","Nora Franceschini","Xiuqing Guo","Shih-Jen Hwang","Paul S de Vries","Yan Gao","Arden Moscati","Girish N Nadkarni","Lisa R Yanek","Tali Elfassy","Jennifer A Smith","Ren-Hua Chung","Amber L Beitelshees","Amit Patki","Stella Aslibekyan","Brandon M Blobner","Juan M Peralta","Themistocles L Assimes","Walter R Palmas","Chunyu Liu","Adam P Bress","Zhijie Huang","Lewis C Becker","Chii-Min Hwa","Jeffrey R O'Connell","Jenna C Carlson","Helen R Warren","Sayantan Das","Ayush Giri","Lisa W Martin","W Craig Johnson","Ervin R Fox","Erwin P Bottinger","Alexander C Razavi","Dhananjay Vaidya","Lee-Ming Chuang","Yen-Pei C Chang","Take Naseri","Deepti Jain","Hyun Min Kang","Adriana M Hung","Vinodh Srinivasasainagendra","Beverly M Snively","Dongfeng Gu","May E Montasser","Muagututi'a Sefuiva Reupena","Benjamin D Heavner","Jonathon LeFaive","James E Hixson","Kenneth M Rice","Fei Fei Wang","Jonas B Nielsen","Jianfeng Huang","Alyna T Khan","Wei Zhou","Jovia L Nierenberg","Cathy C Laurie","Nicole D Armstrong","Mengyao Shi","Yang Pan","Adrienne M Stilp","Leslie Emery","Quenna Wong","Nicola L Hawley","Ryan L Minster","Joanne E Curran","Patricia B Munroe","Daniel E Weeks","Kari E North","Russell P Tracy","Eimear E Kenny","Daichi Shimbo","Aravinda Chakravarti","Stephen S Rich","Alex P Reiner","John Blangero","Susan Redline","Braxton D Mitchell","Dabeeru C Rao","Yii-Der Ida Chen","Sharon L R Kardia","Robert C Kaplan","Rasika A Mathias","Jiang He","Bruce M Psaty","Myriam Fornage","Ruth J F Loos","Adolfo Correa","Eric Boerwinkle","Jerome I Rotter","Charles Kooperberg","Todd L Edwards","Gonçalo R Abecasis","Xiaofeng Zhu","Daniel Levy","Donna K Arnett","Alanna C Morrison"],"significance":6,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/classificatie-bloeddruk-esc-2024/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This large-scale whole-genome sequencing study identified novel genetic loci associated with blood pressure and hypertension, including rare coding variants that provide insights into blood pressure biology and potential drug targets.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T13:28:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7ea58aa6ead3","type":"article","url":"https://hartvaat.nl/2022/08/01/cardiorenaal-syndroom-en-fitheid-bij-hartfalen-telerevalidatie-trial/","title":"Cardiorenaal syndroom en fitheid bij hartfalen: telerevalidatie-trial","title_en":"Cardiorenal syndrome and the association with fitness: Data from a telerehabilitation randomized clinical trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardio-renaal-metabool","cardiorenal-behandelstrategie","hartrevalidatie","ijzertekort","pathfinder-trial","step-hfpef","summit-trial","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13985","source_url":"https://doi.org/10.1002/ehf2.13985","authors":["Knut Asbjørn Rise Langlo","Kari Margrethe Lundgren","Paolo Zanaboni","Rune Mo","Øyvind Ellingsen","Stein Ivar Hallan","Inger-Lise Aamot Aksetøy","Håvard Dalen"],"significance":5,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-en-nierfunctie/"],"congress":"","summary_en":"This telerehabilitation trial data showed that cardiorenal syndrome is strongly associated with reduced cardiorespiratory fitness in chronic heart failure, linking combined cardiac and renal impairment to exercise intolerance.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c161dcf2bf8","type":"article","url":"https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/","title":"Empagliflozine vermindert nierletselmarkers bij acuut hartfalen","title_en":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","bisoprolol","canagliflozine","complementremmers","cystatine-c","dapagliflozine","empagliflozine","emperor-trials","ezetimibe","hfmref","hfpef","hfref","ijzersuppletie","nt-probnp","primaire-preventie","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13955","source_url":"https://doi.org/10.1002/ehf2.13955","authors":["Kirsten Thiele","Matthias Rau","Niels-Ulrik Korbinian Hartmann","Marcus Möller","Julia Möllmann","Joachim Jankowski","András P Keszei","Michael Böhm","Jürgen Floege","Nikolaus Marx","Michael Lehrke"],"significance":6,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This exploratory study showed that empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure, suggesting renal protective effects of SGLT2 inhibition despite initial eGFR dip.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc77f79bc757","type":"article","url":"https://hartvaat.nl/2022/08/01/sekseverschillen-in-effectiviteit-van-hartfalenmedicatie-meta-analyse/","title":"Sekseverschillen in effectiviteit van hartfalenmedicatie: meta-analyse","title_en":"Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","empagliflozine","farmaco-economie","hfref","ivabradine","sacubitril-valsartan","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13974","source_url":"https://doi.org/10.1002/ehf2.13974","authors":["Cecilia Danielson","Gabriele Lileikyte","Wouter Ouwerkerk","Carolyn S P Lam","David Erlinge","Tiew-Hwa Katherine Teng"],"significance":7,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis identified important sex differences in the efficacy of pharmacological therapies for HFrEF, with some agents (particularly ACE inhibitors) showing attenuated benefit in women compared with men, warranting sex-stratified prescribing approaches.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46ab69c42932","type":"article","url":"https://hartvaat.nl/2022/08/01/b-lijnen-geleide-hartfalenbehandeling-verbetert-uitkomsten-na-ontslag/","title":"B-lijnen-geleide hartfalenbehandeling verbetert uitkomsten na ontslag","title_en":"Impact of B-lines-guided intensive heart failure management on outcome of discharged heart failure patients with residual B-lines.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13988","source_url":"https://doi.org/10.1002/ehf2.13988","authors":["Yunlong Zhu","Na Li","Mingxing Wu","Zhiliu Peng","Haobo Huang","Wenjiao Zhao","Liqing Yi","Min Liao","Zhican Liu","Yiqun Peng","Yuying Zhou","Jinxin Lu","Guohua Li","Jianping Zeng"],"significance":6,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/harttransplantatie-indicaties/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study showed that B-lines-guided intensive heart failure management using lung ultrasound improves outcomes in discharged HF patients with residual pulmonary congestion, supporting imaging-guided decongestion monitoring.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"549582d03eac","type":"article","url":"https://hartvaat.nl/2022/08/01/thuisrevalidatie-met-ict-voor-fragiele-hartfalenpatienten/","title":"Thuisrevalidatie met ICT voor fragiele hartfalenpatiënten","title_en":"Home-based cardiac rehabilitation using information and communication technology for heart failure patients with frailty.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13934","source_url":"https://doi.org/10.1002/ehf2.13934","authors":["Yuta Nagatomi","Tomomi Ide","Tae Higuchi","Tomoyuki Nezu","Takeo Fujino","Takeshi Tohyama","Takuya Nagata","Taiki Higo","Toru Hashimoto","Shouji Matsushima","Keisuke Shinohara","Tomiko Yokoyama","Aika Eguchi","Ayumi Ogusu","Masataka Ikeda","Yusuke Ishikawa","Fumika Yamashita","Shintaro Kinugawa","Hiroyuki Tsutsui"],"significance":5,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated the feasibility and safety of ICT-supported home-based cardiac rehabilitation for frail heart failure patients, showing that technology can overcome the access barriers that prevent vulnerable patients from participating in exercise programs.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8816a2a1b291","type":"article","url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","title":"Matige statine plus ezetimibe versus hoge-dosis statine bij coronairlijden: Lancet-studie","title_en":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["statines"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00916-3","source_url":"https://doi.org/10.1016/S0140-6736(22)00916-3","authors":["Byeong-Keuk Kim","Sung-Jin Hong","Yong-Joon Lee","Soon Jun Hong","Kyeong Ho Yun","Bum-Kee Hong","Jung Ho Heo","Seung-Woon Rha","Yun-Hyeong Cho","Seung-Jun Lee","Chul-Min Ahn","Jung-Sun Kim","Young-Guk Ko","Donghoon Choi","Yangsoo Jang","Myeong-Ki Hong"],"significance":8,"published":"2022-07-30","source_date":"2022-07-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This Lancet long-term study demonstrated that moderate-intensity statin combined with ezetimibe was equally effective as high-intensity statin monotherapy for preventing cardiovascular events, with fewer adverse effects. The results supported combination therapy as an alternative to high-dose statins.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T13:28:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"966b76e9d4e5","type":"article","url":"https://hartvaat.nl/2022/07/27/veiligheid-van-pcsk9-remmers-systematische-review-en-meta-analyse/","title":"Veiligheid van PCSK9-remmers: systematische review en meta-analyse","title_en":"Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["enlicitide","figaro-dkd","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","tirzepatide"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320556","source_url":"https://doi.org/10.1136/heartjnl-2021-320556","authors":["Jing Li","Heyue Du","Yang Wang","Bert Aertgeerts","Gordon Guyatt","Qiukui Hao","Yanjiao Shen","Ling Li","Na Su","Nicolas Delvaux","Geertruida Bekkering","Safi U Khan","Irbaz B Riaz","Per Olav Vandvik","Baihai Su","Haoming Tian","Sheyu Li"],"significance":7,"published":"2022-07-27","source_date":"2022-07-27","image":"","kennis":[],"congress":"","summary_en":"This comprehensive meta-analysis confirmed the favorable safety profile of PCSK9 inhibitors, finding no significant increase in serious adverse events, diabetes, neurocognitive effects, or cancer with evolocumab and alirocumab therapy.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T13:28:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"17049a967361","type":"article","url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","title":"Langetermijneffect van antihypertensiva op bloeddruk: meta-analyse op individueel niveau","title_en":"Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320171","source_url":"https://doi.org/10.1136/heartjnl-2021-320171","authors":["Dexter Canoy","Emma Copland","Milad Nazarzadeh","Rema Ramakrishnan","Ana-Catarina Pinho-Gomes","Abdul Salam","Jamie P Dwyer","Farshad Farzadfar","Johan Sundström","Mark Woodward","Barry R Davis","Kazem Rahimi"],"significance":7,"published":"2022-07-27","source_date":"2022-07-27","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"This individual-level meta-analysis of antihypertensive drug effects on long-term blood pressure found that sustained blood pressure reduction beyond the initial treatment period depends on continued drug therapy, with blood pressure returning toward baseline after discontinuation.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2594e41a0060","type":"article","url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","title":"USPSTF: gedragsinterventies voor gezonde leefstijl bij cardiovasculaire preventie","title_en":"Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bloeddrukbehandeling","diabetes-en-hart","diabetes-type-2","farmaco-economie","fractional-flow-reserve","gepersonaliseerde-geneeskunde","hartrevalidatie","hfpef","lichaamsbeweging","obesitas","ouderen","primaire-preventie","richtlijnen-esc","secundaire-preventie","select-trial","slaapapneu","supraventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"JAMA","doi":"10.1001/jama.2022.10951","source_url":"https://doi.org/10.1001/jama.2022.10951","authors":["Carol M Mangione","Michael J Barry","Wanda K Nicholson","Michael Cabana","Tumaini Rucker Coker","Karina W Davidson","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Martha Kubik","Li Li","Gbenga Ogedegbe","Lori Pbert","John M Ruiz","James Stevermer","John B Wong"],"significance":8,"published":"2022-07-26","source_date":"2022-07-26","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"This USPSTF systematic review confirmed that behavioral counseling on diet and physical activity produces modest but consistent cardiovascular risk factor improvements in adults. The evidence supported population-level lifestyle counseling as a component of cardiovascular prevention.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"987882a757d2","type":"article","url":"https://hartvaat.nl/2022/07/26/chinees-hartgezond-dieet-verlaagt-bloeddruk-effectief-gerandomiseerde-trial/","title":"Chinees hartgezond dieet verlaagt bloeddruk effectief: gerandomiseerde trial","title_en":"Effects of Cuisine-Based Chinese Heart-Healthy Diet in Lowering Blood Pressure Among Adults in China: Multicenter, Single-Blind, Randomized, Parallel Controlled Feeding Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059045","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059045","authors":["Yanfang Wang","Lin Feng","Guo Zeng","Huilian Zhu","Jianqin Sun","Pei Gao","Jihong Yuan","Xi Lan","Shuyi Li","Yanfang Zhao","Xiayan Chen","Hongli Dong","Si Chen","Zhen Li","Yidan Zhu","Ming Li","Xiang Li","Zhenquan Yang","Huijuan Li","Hai Fang","Gaoqiang Xie","Pao-Hwa Lin","Junshi Chen","Yangfeng Wu"],"significance":7,"published":"2022-07-26","source_date":"2022-07-26","image":"","kennis":["https://hartvaat.nl/kennis/preventie/leefstijladvisering-cardiologie/"],"congress":"","summary_en":"This multicenter trial developed and tested an evidence-based heart-healthy diet adapted to Chinese cuisine that significantly lowered blood pressure. The culturally tailored dietary approach addresses the cardiovascular needs of the world's largest cuisine population.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:57Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5101b0a42c02","type":"article","url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","title":"EMPAG-HF: vroege empagliflozine bij acuut hartfalen verbetert diurese","title_en":"Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","answer-hf","bisoprolol","dapa-hf","dapagliflozine","diuretica","empagliflozine","emperor-trials","finearts-hf","hfmref","hfpef","hfref","ijzertekort","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059038","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059038","authors":["P Christian Schulze","Jürgen Bogoviku","Julian Westphal","Pawel Aftanski","Franz Haertel","Sissy Grund","Stephan von Haehling","Ulrike Schumacher","Sven Möbius-Winkler","Martin Busch"],"significance":8,"published":"2022-07-26","source_date":"2022-07-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The EMPAG-HF trial demonstrated that early empagliflozin initiation in acute decompensated heart failure significantly increased urinary output without worsening kidney function. The results supported SGLT2 inhibitors as a useful adjunct to loop diuretics for decongestion.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fd2b32adaee4","type":"article","url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","title":"EMPULSE: empagliflozine verbetert symptomen en kwaliteit van leven bij acuut hartfalen","title_en":"Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bisoprolol","dapagliflozine","empagliflozine","emperor-trials","hfref"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059725","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059725","authors":["Mikhail N Kosiborod","Christiane E Angermann","Sean P Collins","John R Teerlink","Piotr Ponikowski","Jan Biegus","Josep Comin-Colet","João Pedro Ferreira","Robert J Mentz","Michael E Nassif","Mitchell A Psotka","Jasper Tromp","Martina Brueckmann","Jonathan P Blatchford","Afshin Salsali","Adriaan A Voors"],"significance":9,"published":"2022-07-26","source_date":"2022-07-26","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The EMPULSE trial demonstrated that empagliflozin initiated during hospitalization for acute heart failure significantly improved a hierarchical composite of death, heart failure events, and symptoms compared with placebo. The results support in-hospital initiation of SGLT2 inhibitors in acute heart failure.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2f28958db48","type":"article","url":"https://hartvaat.nl/2022/07/21/posterior-wand-isolatie-met-cryoballon-bij-persisterend-af-meerwaarde-onderzocht/","title":"Posterior wand-isolatie met cryoballon bij persisterend AF: meerwaarde onderzocht","title_en":"Does isolation of the left atrial posterior wall using cryoballoon ablation improve clinical outcomes in patients with persistent atrial fibrillation? A prospective randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie","katheterablatie","pulmonaalvenenisolatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac005","source_url":"https://doi.org/10.1093/europace/euac005","authors":["Jinhee Ahn","Dong Geum Shin","Sang Jin Han","Hong Euy Lim"],"significance":6,"published":"2022-07-21","source_date":"2022-07-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This randomized trial tested whether adding posterior wall isolation to cryoballoon-based PVI improves outcomes in persistent AF, finding no significant incremental benefit from this additional ablation target.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5ee0c1b15ba","type":"article","url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","title":"Permanente pacemaker na TAVI: langetermijneffect op klinische uitkomsten","title_en":"Long-term clinical impact of permanent pacemaker implantation in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aortastenose","tavi"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac008","source_url":"https://doi.org/10.1093/europace/euac008","authors":["Andrea Zito","Giuseppe Princi","Marco Lombardi","Domenico D'Amario","Rocco Vergallo","Cristina Aurigemma","Enrico Romagnoli","Gemma Pelargonio","Piergiorgio Bruno","Carlo Trani","Francesco Burzotta","Filippo Crea"],"significance":7,"published":"2022-07-21","source_date":"2022-07-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This meta-analysis confirmed that permanent pacemaker implantation after TAVR is associated with higher long-term mortality and more heart failure hospitalizations, highlighting the importance of minimizing conduction complications during transcatheter valve procedures.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"08241fe4c60d","type":"article","url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","title":"METEORIC-HF: omecamtiv mecarbil verbetert inspanningscapaciteit niet bij HFrEF","title_en":"Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","hfpef","hfref"],"journal":"JAMA","doi":"10.1001/jama.2022.11016","source_url":"https://doi.org/10.1001/jama.2022.11016","authors":["Gregory D Lewis","Adriaan A Voors","Alain Cohen-Solal","Marco Metra","David J Whellan","Justin A Ezekowitz","Michael Böhm","John R Teerlink","Kieran F Docherty","Renato D Lopes","Punag H Divanji","Stephen B Heitner","Stuart Kupfer","Fady I Malik","Lisa Meng","Amy Wohltman","G Michael Felker"],"significance":8,"published":"2022-07-19","source_date":"2022-07-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"The METEORIC-HF trial showed that omecamtiv mecarbil did not improve exercise capacity in patients with HFrEF, despite its positive effects on heart failure events in GALACTIC-HF. The disconnect between clinical outcomes and functional capacity measures remains unexplained.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e077241a5984","type":"article","url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","title":"VT-ablatie versus antiaritmica bij myocardinfarct: locatie maakt uit","title_en":"Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["aperitif-trial","myocardinfarct","ventriculaire-tachycardie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab298","source_url":"https://doi.org/10.1093/europace/euab298","authors":["Michelle Samuel","Lena Rivard","Isabelle Nault","Lorne Gula","Vidal Essebag","Ratika Parkash","Laurence D Sterns","Paul Khairy","John L Sapp"],"significance":7,"published":"2022-07-15","source_date":"2022-07-15","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/ranolazine-bij-angina/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This VANISH substudy showed that the comparative effectiveness of VT ablation versus escalated antiarrhythmic drugs varies by infarct location, with anterior infarcts potentially responding differently to ablation than inferior infarcts.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f448be644443","type":"article","url":"https://hartvaat.nl/2022/07/15/wereldwijde-trends-in-orale-antistollingsgebruik-bij-af-2010-2018/","title":"Wereldwijde trends in orale antistollingsgebruik bij AF (2010-2018)","title_en":"Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab303","source_url":"https://doi.org/10.1093/europace/euab303","authors":["Maxim Grymonprez","Cynthia Simoens","Stephane Steurbaut","Tine L De Backer","Lies Lahousse"],"significance":7,"published":"2022-07-15","source_date":"2022-07-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"This systematic review documented the worldwide shift from vitamin K antagonists to NOACs for atrial fibrillation between 2010 and 2018, showing substantial geographic variation in adoption rates and overall DOAC market penetration.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3e127c5e141b","type":"article","url":"https://hartvaat.nl/2022/07/15/geindividualiseerde-versus-standaard-cryoballonablatie-bij-paroxysmaal-af/","title":"Geïndividualiseerde versus standaard cryoballonablatie bij paroxysmaal AF","title_en":"Individualized or fixed approach to pulmonary vein isolation utilizing the fourth-generation cryoballoon in patients with paroxysmal atrial fibrillation: the randomized INDI-FREEZE trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab305","source_url":"https://doi.org/10.1093/europace/euab305","authors":["Christian Hendrik Heeger","Sorin Stefan Popescu","Roza Saraei","Bettina Kirstein","Sascha Hatahet","Omar Samara","Anna Traub","Marcel Fehe","Gabriele D'Ambrosio","Ahmad Keelani","Michael Schlüter","Charlotte Eitel","Julia Vogler","Karl Heinz Kuck","Roland Richard Tilz"],"significance":6,"published":"2022-07-15","source_date":"2022-07-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/flecainide-en-propafenon/"],"congress":"","summary_en":"This randomized trial compared individualized cryoballoon dosing with a standardized freeze protocol for AF ablation, finding comparable outcomes and supporting both approaches as acceptable energy delivery strategies.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"028528a5f1c6","type":"article","url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","title":"RACE 3 langetermijnresultaten: gerichte behandeling bij vroeg persisterend AF en hartfalen","title_en":"Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab270","source_url":"https://doi.org/10.1093/europace/euab270","authors":["Bao Oanh Nguyen","Harry J G M Crijns","Jan G P Tijssen","Bastiaan Geelhoed","Anne H Hobbelt","Martin E W Hemels","W J Myke Mol","Bob Weijs","Marco Alings","Marcelle D Smit","Robert G Tieleman","Raymond Tukkie","Dirk J Van Veldhuisen","Isabelle C Van Gelder","Michiel Rienstra"],"significance":7,"published":"2022-07-15","source_date":"2022-07-15","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"Long-term RACE 3 follow-up showed that targeted therapy of underlying conditions (obesity, physical inactivity, hypertension) in patients with early persistent AF and heart failure maintains sinus rhythm better than usual care over extended follow-up.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"937f9a2f9daa","type":"article","url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","title":"GUIDE-HF en de impact van COVID-19 op hartfalenuitkomsten","title_en":"The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","covid-hart","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac114","source_url":"https://doi.org/10.1093/eurheartj/ehac114","authors":["Michael R Zile","Akshay S Desai","Maria Rosa Costanzo","Anique Ducharme","Alan Maisel","Mandeep R Mehra","Sara Paul","Samuel F Sears","Frank Smart","Christopher Chien","Ashrith Guha","Jason L Guichard","Shelley Hall","Orvar Jonsson","Nessa Johnson","Poornima Sood","John Henderson","Philip B Adamson","JoAnn Lindenfeld"],"significance":7,"published":"2022-07-14","source_date":"2022-07-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This GUIDE-HF analysis demonstrated that the COVID-19 pandemic significantly influenced heart failure event rates, confounding the trial's primary results and highlighting the importance of accounting for pandemic effects in contemporary cardiovascular trial interpretation.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d460700eecd","type":"article","url":"https://hartvaat.nl/2022/07/13/atriumfibrilleren-na-transcatheter-asd-sluiting-systematische-review/","title":"Atriumfibrilleren na transcatheter ASD-sluiting: systematische review","title_en":"Atrial fibrillation following transcatheter atrial septal defect closure: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319794","source_url":"https://doi.org/10.1136/heartjnl-2021-319794","authors":["Jonah Daniel Himelfarb","Healey Shulman","Christopher James Olesovsky","Rawan K Rumman","Laura Oliva","Joshua Friedland","Ashley Farrell","Ella Huszti","Eric Horlick","Lusine Abrahamyan"],"significance":6,"published":"2022-07-13","source_date":"2022-07-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis showed that new-onset AF is a relevant complication after transcatheter closure of atrial septal defects, informing the follow-up monitoring and anticoagulation considerations after ASD device closure.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6d5063398fac","type":"article","url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","title":"Frailteit beïnvloedt effect van inspanningstraining bij hartfalen: HF-ACTION analyse","title_en":"Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","hfref","step-hfpef","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059983","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059983","authors":["Ambarish Pandey","Matthew W Segar","Sumitabh Singh","Gordon R Reeves","Christopher O'Connor","Ileana Piña","David Whellan","William E Kraus","Robert J Mentz","Dalane W Kitzman"],"significance":7,"published":"2022-07-12","source_date":"2022-07-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This HF-ACTION analysis showed that frail patients with HFrEF derive greater absolute benefit from exercise training than non-frail patients, supporting exercise rehabilitation as particularly important for the most vulnerable heart failure population.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25070feaa907","type":"article","url":"https://hartvaat.nl/2022/07/05/deep-lipidomics-cardiometabool-risico-en-effect-van-voedingsvet/","title":"Deep lipidomics: cardiometabool risico en effect van voedingsvet","title_en":"Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","cardio-renaal-metabool","diabetes-en-hart","dyslipidemie","fidelity","lipide-aferese","obesitas","plaquekarakterisatie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056805","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056805","authors":["Fabian Eichelmann","Laury Sellem","Clemens Wittenbecher","Susanne Jäger","Olga Kuxhaus","Marcela Prada","Rafael Cuadrat","Kim G Jackson","Julie A Lovegrove","Matthias B Schulze"],"significance":6,"published":"2022-07-05","source_date":"2022-07-05","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/insulineresistentie-mechanisme/"],"congress":"","summary_en":"This deep lipidomics analysis identified specific lipid species associated with cardiometabolic disease risk that change with dietary fat modulation, advancing precision nutrition through molecular lipid profiling.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4f8042a1123a","type":"article","url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","title":"AUGUSTUS-analyse: apixaban versus warfarine bij AF na ACS of PCI","title_en":"Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.1166","source_url":"https://doi.org/10.1001/jamacardio.2022.1166","authors":["M Cecilia Bahit","Amit N Vora","Zhuokai Li","Daniel M Wojdyla","Laine Thomas","Shaun G Goodman","Ronald Aronson","J Dedrick Jordan","Brad J Kolls","Keith E Dombrowski","Dragos Vinereanu","Sigrun Halvorsen","Otavio Berwanger","Stephan Windecker","Roxana Mehran","Christopher B Granger","John H Alexander","Renato D Lopes"],"significance":7,"published":"2022-07-01","source_date":"2022-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This AUGUSTUS subanalysis confirmed that apixaban versus warfarin reduces cerebrovascular ischemic events and major bleeding in AF patients with recent ACS or PCI, reinforcing the preference for DOAC-based antithrombotic strategies.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cfd31ed9a9e5","type":"article","url":"https://hartvaat.nl/2022/07/01/behandeling-van-acuut-coronair-syndroom-in-ruraal-australie-moracs-trial/","title":"Behandeling van acuut coronair syndroom in ruraal Australië: MORACS-trial","title_en":"Management of Acute Coronary Syndromes in Patients in Rural Australia: The MORACS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","atleten","bradycardie","hartkatheterisatie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.1188","source_url":"https://doi.org/10.1001/jamacardio.2022.1188","authors":["Fiona Dee","Lindsay Savage","James W Leitch","Nicholas Collins","Conrad Loten","Peter Fletcher","John French","Natasha Weaver","Olivia Watson","Helen Orvad","Kerry J Inder","Dawn McIvor","Trent Williams","Allan J Davies","John Attia","John Wiggers","Aaron L Sverdlov","Andrew J Boyle"],"significance":6,"published":"2022-07-01","source_date":"2022-07-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/ecg-bij-acs/"],"congress":"","summary_en":"The MORACS trial tested telementored ECG interpretation for STEMI management in rural Australia, evaluating whether remote specialist guidance improves the quality of care for acute MI in geographically isolated settings.","created":"2026-07-03T10:29:49Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ea242978e8c","type":"article","url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","title":"Pulsatiele hemodynamiek voorspelt bloeddrukrespons op renale denervatie","title_en":"Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","dialyse","diuretica","endotheel","figaro-dkd","flow-trial","katheterablatie","radiance-htn","renale-denervatie","thuisbloeddrukmeting"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18641","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18641","authors":["Thomas Weber","Siegfried Wassertheurer","Christopher C Mayer","Bernhard Hametner","Kathrin Danninger","Raymond R Townsend","Felix Mahfoud","Kazuomi Kario","Martin Fahy","Vanessa DeBruin","Nicole Peterson","Manuela Negoita","Michael A Weber","David E Kandzari","Roland E Schmieder","Konstantinos P Tsioufis","Ronald K Binder","Michael Böhm"],"significance":6,"published":"2022-07-01","source_date":"2022-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This SPYRAL HTN-OFF MED analysis showed that 24-hour pulsatile hemodynamic parameters predict the blood pressure response to renal denervation, enabling individualized patient selection for device-based therapy.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8a1fad3e2f6","type":"article","url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","title":"Hoog-sensitief troponine en myocardinfarct bij nierfunctiestoornissen","title_en":"High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["myocardinfarct","troponine"],"journal":"Kidney international","doi":"10.1016/j.kint.2022.02.019","source_url":"https://doi.org/10.1016/j.kint.2022.02.019","authors":["Peter J Gallacher","Eve Miller-Hodges","Anoop S V Shah","Tariq E Farrah","Nynke Halbesma","James P Blackmur","Andrew R Chapman","Philip D Adamson","Atul Anand","Fiona E Strachan","Amy V Ferry","Kuan Ken Lee","Colin Berry","Iain Findlay","Anne Cruickshank","Alan Reid","Alasdair Gray","Paul O Collinson","Fred S Apple","David A McAllister","Donogh Maguire","Keith A A Fox","Catriona Keerie","Christopher J Weir","David E Newby","Nicholas L Mills","Neeraj Dhaun"],"significance":7,"published":"2022-07-01","source_date":"2022-07-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This study evaluated the performance of high-sensitivity cardiac troponin I for MI diagnosis in patients with kidney impairment, addressing the clinical challenge of distinguishing acute ischemic injury from chronic troponin elevation in CKD.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0f69073ef0e8","type":"article","url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","title":"MRI-geleide fibroseablatie versus conventionele ablatie bij persisterend AF","title_en":"Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2022.8831","source_url":"https://doi.org/10.1001/jama.2022.8831","authors":["Nassir F Marrouche","Oussama Wazni","Christopher McGann","Tom Greene","J Michael Dean","Lilas Dagher","Eugene Kholmovski","Moussa Mansour","Francis Marchlinski","David Wilber","Gerhard Hindricks","Christian Mahnkopf","Darryl Wells","Pierre Jais","Prashanthan Sanders","Johannes Brachmann","Jeroen J Bax","Leonie Morrison-de Boer","Thomas Deneke","Hugh Calkins","Christian Sohns","Nazem Akoum"],"significance":8,"published":"2022-06-21","source_date":"2022-06-21","image":"","kennis":[],"congress":"","summary_en":"The DECAAF II trial showed that MRI-guided fibrosis ablation did not improve freedom from atrial arrhythmia compared with conventional catheter ablation in patients with persistent AF. The negative result suggested that current MRI-based fibrosis mapping does not reliably guide ablation targets.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4ae8254d8dbb","type":"article","url":"https://hartvaat.nl/2022/06/21/timing-van-vt-ablatie-bij-icd-patienten-partita-trial/","title":"Timing van VT-ablatie bij ICD-patiënten: PARTITA-trial","title_en":"Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["iaso-dcm","ventriculaire-tachycardie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059598","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059598","authors":["Paolo Della Bella","Francesca Baratto","Pasquale Vergara","Patrizia Bertocchi","Matteo Santamaria","Pasquale Notarstefano","Leonardo Calò","Daniela Orsida","Luca Tomasi","Marcello Piacenti","Stefano Sangiorgio","Francesco Pentimalli","Etienne Pruvot","João De Sousa","Frederic Sacher","Massimo Tritto","Luca Rebellato","Thomas Deneke","Salvo Andrea Romano","Martina Nesti","Alessio Gargaro","Daniele Giacopelli","Giovanni Peretto","Andrea Radinovic"],"significance":8,"published":"2022-06-21","source_date":"2022-06-21","image":"","kennis":[],"congress":"","summary_en":"The PARTITA trial demonstrated that early VT ablation after the first appropriate ICD shock reduced the composite of heart failure hospitalization or death compared with delayed ablation after subsequent shocks. The results supported a proactive ablation strategy rather than waiting for recurrent VT.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6abcd673ce82","type":"article","url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","title":"EuroHeart datastandaarden voor hartfalenregistraties","title_en":"Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac151","source_url":"https://doi.org/10.1093/eurheartj/ehac151","authors":["Suleman Aktaa","Gorav Batra","John G F Cleland","Andrew Coats","Lars H Lund","Theresa McDonagh","Giuseppe Rosano","Petar Seferovic","Peter Vasko","Lars Wallentin","Aldo P Maggioni","Barbara Casadei","Chris P Gale"],"significance":5,"published":"2022-06-14","source_date":"2022-06-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/"],"congress":"","summary_en":"The EuroHeart project established standardized data definitions for heart failure registries and clinical trials across Europe, enabling unified outcomes assessment and quality-of-care comparison.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T18:38:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0dbe4960e2cd","type":"article","url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","title":"Omecamtiv mecarbil bij hartfalen met en zonder atriumfibrilleren: GALACTIC-HF","title_en":"Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["aficamten","hfref"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac144","source_url":"https://doi.org/10.1093/eurheartj/ehac144","authors":["Scott D Solomon","Brian L Claggett","Zi Michael Miao","Rafael Diaz","G Michael Felker","John J V McMurray","Marco Metra","Ramon Corbalan","Gerasimos Filippatos","Assen R Goudev","Viatcheslav Mareev","Pranas Serpytis","Thomas Suter","Mehmet B Yilmaz","Faiez Zannad","Stuart Kupfer","Stephen B Heitner","Fady I Malik","John R Teerlink"],"significance":6,"published":"2022-06-14","source_date":"2022-06-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This GALACTIC-HF subanalysis confirmed that omecamtiv mecarbil is equally effective in HFrEF patients with and without atrial fibrillation, supporting cardiac myosin activation regardless of rhythm status.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T13:28:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9e95afda3d57","type":"article","url":"https://hartvaat.nl/2022/06/10/echogeleide-lvad-snelheidsoptimalisatie-voor-betere-inspanningstolerantie/","title":"Echogeleide LVAD-snelheidsoptimalisatie voor betere inspanningstolerantie","title_en":"Echo-guided left ventricular assist device speed optimisation for exercise maximisation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aortainsufficiëntie","aortastenose","echocardiografie","klepprothese","perifeer-vaatlijden","slaapapneu","ventrikelfibrilleren"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320495","source_url":"https://doi.org/10.1136/heartjnl-2021-320495","authors":["Maciej Stapor","Adam Pilat","Andrzej Gackowski","Agnieszka Misiuda","Izabela Gorkiewicz-Kot","Michal Kaleta","Pawel Kleczynski","Krzysztof Zmudka","Jacek Legutko","Boguslaw Kapelak","Karol Wierzbicki"],"significance":6,"published":"2022-06-10","source_date":"2022-06-10","image":"","kennis":[],"congress":"","summary_en":"This study explored whether echo-guided LVAD speed optimization during exercise improves exercise capacity, testing individualized hemodynamic programming as a strategy to overcome the fixed-speed limitation of current devices.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T13:28:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"728c5eaabc8e","type":"article","url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","title":"Voorspelling van atriumfibrilleren in elektronische gezondheidsdossiers: systematische review","title_en":"Prediction of incident atrial fibrillation in community-based electronic health records: a systematic review with meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["ventrikelfibrilleren"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320036","source_url":"https://doi.org/10.1136/heartjnl-2021-320036","authors":["Ramesh Nadarajah","Eman Alsaeed","Ben Hurdus","Suleman Aktaa","David Hogg","Matthew G D Bates","Campbel Cowan","Jianhua Wu","Chris P Gale"],"significance":6,"published":"2022-06-10","source_date":"2022-06-10","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This systematic review evaluated prediction models for AF in community-based electronic health records, finding that existing models have moderate discrimination and identifying opportunities for AI-enhanced prediction.","created":"2026-07-03T10:29:48Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce15693f888e","type":"article","url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","title":"Elektronische alerts verbeteren hartfalenbehandeling in de polikliniek","title_en":"Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["acuut-hartfalen","hfpef","hfref","nt-probnp","step-hfpef","ventrikelfibrilleren"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.03.338","source_url":"https://doi.org/10.1016/j.jacc.2022.03.338","authors":["Lama Ghazi","Yu Yamamoto","Ralph J Riello","Claudia Coronel-Moreno","Melissa Martin","Kyle D O'Connor","Michael Simonov","Joanna Huang","Temitope Olufade","James McDermott","Ravi Dhar","Silvio E Inzucchi","Eric J Velazquez","F Perry Wilson","Nihar R Desai","Tariq Ahmad"],"significance":7,"published":"2022-06-07","source_date":"2022-06-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This cluster-randomized trial showed that electronic alerts in the electronic health record significantly increased the prescription of guideline-directed medical therapy for HFrEF, demonstrating the effectiveness of clinical decision support for heart failure care quality.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16d7184605c1","type":"article","url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","title":"RAFT-AF: ablatie versus rate control bij hartfalen en atriumfibrilleren","title_en":"Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","nt-probnp"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057095","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057095","authors":["Ratika Parkash","George A Wells","Jean Rouleau","Mario Talajic","Vidal Essebag","Allan Skanes","Stephen B Wilton","Atul Verma","Jeffrey S Healey","Laurence Sterns","Matthew Bennett","Jean-Francois Roux","Lena Rivard","Peter Leong-Sit","Mats Jensen-Urstad","Umjeet Jolly","Francois Philippon","John L Sapp","Anthony S L Tang"],"significance":8,"published":"2022-06-07","source_date":"2022-06-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"The RAFT-AF trial showed that ablation-based rhythm control improved left ventricular function and NT-proBNP levels compared with rate control in patients with heart failure and AF, though it did not significantly reduce the composite of mortality and heart failure events. The echocardiographic benefit supported ablation for AF in heart failure.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7977e3b4de6e","type":"article","url":"https://hartvaat.nl/2022/06/01/digitale-gamificatie-interventie-verhoogt-lichaamsbeweging-na-hypertensieve-zwan/","title":"Digitale gamificatie-interventie verhoogt lichaamsbeweging na hypertensieve zwangerschap","title_en":"Effectiveness of a Text-Based Gamification Intervention to Improve Physical Activity Among Postpartum Individuals With Hypertensive Disorders of Pregnancy: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","bloeddrukbehandeling","bradycardie","ezetimibe","obesitas","peripartum-cardiomyopathie","vrouwen","zwangerschap-hart"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.0553","source_url":"https://doi.org/10.1001/jamacardio.2022.0553","authors":["Jennifer Lewey","Samantha Murphy","Dazheng Zhang","Mary E Putt","Michal A Elovitz","Valerie Riis","Mitesh S Patel","Lisa D Levine"],"significance":6,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This trial showed that a text-based gamification intervention significantly increased physical activity in women after hypertensive pregnancy, addressing the elevated long-term cardiovascular risk through behavioral change.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"203cc9c29630","type":"article","url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","title":"Edoxaban 15 mg bij zeer oude patiënten met atriumfibrilleren: ELDERCARE subanalyse","title_en":"Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","ouderen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.0480","source_url":"https://doi.org/10.1001/jamacardio.2022.0480","authors":["Masaru Kuroda","Eiji Tamiya","Takahisa Nose","Akiyoshi Ogimoto","Junki Taura","Yuki Imamura","Masayuki Fukuzawa","Takuya Hayashi","Masaharu Akao","Takeshi Yamashita","Gregory Y H Lip","Ken Okumura"],"significance":7,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-ouderen/"],"congress":"","summary_en":"This ELDERCARE-AF age-stratified analysis confirmed that low-dose edoxaban (15 mg) maintains its favorable benefit-risk profile across age strata in patients aged 80 years and older with atrial fibrillation, supporting anticoagulation in the very elderly.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T13:28:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d2fb19150d7","type":"article","url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","title":"Lage-dosis drievoudige combinatietherapie bij hypertensie: TRIUMPH secundaire analyse","title_en":"Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["aprocitentan","bloeddrukbehandeling","fidelity","lorundrostat","precision-trial","resistente-hypertensie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.0471","source_url":"https://doi.org/10.1001/jamacardio.2022.0471","authors":["Sonali R Gnanenthiran","Nelson Wang","Gian Luca Di Tanna","Abdul Salam","Ruth Webster","H Asita de Silva","Rama Guggilla","Stephen Jan","Pallab K Maulik","Nitish Naik","Vanessa Selak","Simon Thom","Dorairaj Prabhakaran","Aletta E Schutte","Anushka Patel","Anthony Rodgers"],"significance":7,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/","https://hartvaat.nl/kennis/farmacologie/polypil-cardiovasculair/"],"congress":"","summary_en":"This TRIUMPH secondary analysis showed that a low-dose triple combination pill significantly increased time at target blood pressure compared with usual care, demonstrating that simplified combination therapy improves sustained blood pressure control.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T13:28:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0d236ebd0c30","type":"article","url":"https://hartvaat.nl/2022/06/01/finger-trial-multidomein-leefstijlinterventie-verlaagt-cardiovasculair-risico-bi/","title":"FINGER-trial: multidomein-leefstijlinterventie verlaagt cardiovasculair risico bij ouderen","title_en":"Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["atleten","hartrevalidatie","lichaamsbeweging","stride-trial","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab922","source_url":"https://doi.org/10.1093/eurheartj/ehab922","authors":["Jenni Lehtisalo","Minna Rusanen","Alina Solomon","Riitta Antikainen","Tiina Laatikainen","Markku Peltonen","Timo Strandberg","Jaakko Tuomilehto","Hilkka Soininen","Miia Kivipelto","Tiia Ngandu"],"significance":7,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The FINGER trial, originally designed for cognitive outcomes, also demonstrated cardiovascular risk reduction from a multi-domain lifestyle intervention (diet, exercise, cognitive training, vascular risk management) in older adults at risk for dementia.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T13:28:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"27a0bfeb8d8e","type":"article","url":"https://hartvaat.nl/2022/06/01/vijf-jaar-inspanningstraining-verbetert-cardiovasculair-risicoprofiel-bij-oudere/","title":"Vijf jaar inspanningstraining verbetert cardiovasculair risicoprofiel bij ouderen","title_en":"Effect of 5 years of exercise training on the cardiovascular risk profile of older adults: the Generation 100 randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","atleten","biomarkers-cardiovasculair","bloeddrukbehandeling","bradycardie","diabetes-en-hart","diabetes-type-2","farmaco-economie","fractional-flow-reserve","hartrevalidatie","lichaamsbeweging","obesitas","ouderen","perifeer-vaatlijden","richtlijnen-esc","roken","secundaire-preventie","slaapapneu","summit-trial","supraventriculaire-tachycardie","ventrikelfibrilleren"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab721","source_url":"https://doi.org/10.1093/eurheartj/ehab721","authors":["Jon Magne Letnes","Ida Berglund","Kristin E Johnson","Håvard Dalen","Bjarne M Nes","Stian Lydersen","Hallgeir Viken","Erlend Hassel","Sigurd Steinshamn","Elisabeth Kleivhaug Vesterbekkmo","Asbjørn Støylen","Line S Reitlo","Nina Zisko","Fredrik H Bækkerud","Atefe R Tari","Jan Erik Ingebrigtsen","Silvana B Sandbakk","Trude Carlsen","Sigmund A Anderssen","Maria A Fiatarone Singh","Jeff S Coombes","Jorunn L Helbostad","Øivind Rognmo","Ulrik Wisløff","Dorthe Stensvold"],"significance":7,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"The Generation 100 trial showed that 5 years of supervised exercise training in adults aged 70-77 improved several cardiovascular risk factors including blood pressure, lipids, and body composition, demonstrating the sustained cardiovascular benefit of structured exercise in the elderly.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c3989d6138be","type":"article","url":"https://hartvaat.nl/2022/06/01/milrinone-versus-dobutamine-bij-hartfalen-meta-analyse/","title":"Milrinone versus dobutamine bij hartfalen: meta-analyse","title_en":"Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["emperor-trials"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13812","source_url":"https://doi.org/10.1002/ehf2.13812","authors":["Lukasz Szarpak","Piotr Szwed","Aleksandra Gasecka","Zubaid Rafique","Michal Pruc","Krzysztof J Filipiak","Milosz J Jaguszewski"],"significance":5,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hartfalen-stadiumindeling-nyha/"],"congress":"","summary_en":"This meta-analysis compared milrinone with dobutamine in acute decompensated heart failure, finding comparable efficacy and safety profiles for these two commonly used inotropic agents.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e8f89f20580","type":"article","url":"https://hartvaat.nl/2022/06/01/sglt2-remmers-bij-hartfalen-geupdatete-meta-analyse-bevestigt-breed-voordeel/","title":"SGLT2-remmers bij hartfalen: geüpdatete meta-analyse bevestigt breed voordeel","title_en":"Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","canagliflozine","cardiorenal-behandelstrategie","dapagliflozine","empagliflozine","fidelity","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13905","source_url":"https://doi.org/10.1002/ehf2.13905","authors":["Yang Cao","Pengxiao Li","Yi Li","Yaling Han"],"significance":8,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This updated meta-analysis confirmed that SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization in both HFrEF and HFpEF, with the magnitude of benefit consistent across the ejection fraction spectrum regardless of diabetes status.","created":"2026-07-03T10:29:47Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c18246e9bff7","type":"article","url":"https://hartvaat.nl/2022/06/01/interatriale-shuntdevices-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Interatriale shuntdevices bij hartfalen: systematische review en meta-analyse","title_en":"Haemodynamic changes of interatrial shunting devices for heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfmref","hfpef","hfref","ventrikelfibrilleren","vericiguat"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13911","source_url":"https://doi.org/10.1002/ehf2.13911","authors":["Tieci Yi","Min Li","Fangfang Fan","Lin Qiu","Zhi Wang","Haoyu Weng","Xiaoke Shang","Changdong Zhang","Wei Ma","Yan Zhang","Yong Huo"],"significance":6,"published":"2022-06-01","source_date":"2022-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/transthoracale-echocardiografie/"],"congress":"","summary_en":"This meta-analysis of interatrial shunt devices for heart failure showed significant reductions in pulmonary wedge pressure and improvements in hemodynamic parameters, though clinical outcomes trials subsequently yielded mixed results.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T18:38:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"105ff3260dd0","type":"article","url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","title":"Langetermijneffect van metformine en leefstijlinterventie op cardiovasculaire events","title_en":"Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["biomarkers-cardiovasculair","diabetes-en-hart","diabetes-type-1","diabetes-type-2","farmaco-economie","figaro-dkd","hartrevalidatie","obesitas","ouderen","primaire-preventie","roken","secundaire-preventie","select-trial","slaapapneu","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056756","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056756","authors":["Ronald B Goldberg","Trevor J Orchard","Jill P Crandall","Edward J Boyko","Matthew Budoff","Dana Dabelea","Kishore M Gadde","William C Knowler","Christine G Lee","David M Nathan","Karol Watson","Marinella Temprosa"],"significance":8,"published":"2022-05-31","source_date":"2022-05-31","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"After 21 years of follow-up in the Diabetes Prevention Program, neither lifestyle intervention nor metformin reduced the incidence of cardiovascular events compared with placebo, despite their proven diabetes prevention effects. The result indicated that metabolic prevention alone does not translate to cardiovascular event reduction.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"692aea8daf68","type":"article","url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","title":"Kwaliteit van leven na FFR-geleide PCI versus coronaire bypasschirurgie","title_en":"Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.060049","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.060049","authors":["William F Fearon","Frederik M Zimmermann","Victoria Y Ding","Jo M Zelis","Zsolt Piroth","Giedrius Davidavicius","Samer Mansour","Rajesh Kharbanda","Nikolaos Östlund-Papadogeorgos","Keith G Oldroyd","Olaf Wendler","Michael J Reardon","Y Joseph Woo","Alan C Yeung","Nico H J Pijls","Bernard De Bruyne","Manisha Desai","Mark A Hlatky"],"significance":7,"published":"2022-05-31","source_date":"2022-05-31","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This FAME 3 quality-of-life analysis showed that FFR-guided PCI provided similar quality-of-life improvement as CABG at 1 year for three-vessel disease, despite inferior clinical outcomes, suggesting symptom relief is comparable between strategies.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e9e8bfaedee1","type":"article","url":"https://hartvaat.nl/2022/05/25/jbs-richtlijn-management-van-hartstilstand-in-het-cathlab/","title":"JBS-richtlijn: management van hartstilstand in het cathlab","title_en":"Joint British Societies' guideline on management of cardiac arrest in the cardiac catheter laboratory.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-320588","source_url":"https://doi.org/10.1136/heartjnl-2021-320588","authors":["Joel Dunning","Andrew Archbold","Joseph Paul de Bono","Liz Butterfield","Nick Curzen","Charles D Deakin","Ellie Gudde","Thomas R Keeble","Alan Keys","Mike Lewis","Niall O'Keeffe","Jaydeep Sarma","Martin Stout","Paul Swindell","Simon Ray"],"significance":6,"published":"2022-05-25","source_date":"2022-05-25","image":"","kennis":[],"congress":"","summary_en":"This Joint British Societies guideline provided practical recommendations for managing cardiac arrest in the catheterization laboratory, addressing the unique challenges of resuscitation during invasive cardiovascular procedures.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3fede62b2a4c","type":"article","url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","title":"Hydratie ter preventie van nierschade na primaire PCI: gerandomiseerde trial","title_en":"Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319716","source_url":"https://doi.org/10.1136/heartjnl-2021-319716","authors":["Yong Liu","Ning Tan","Yong Huo","Shiqun Chen","Jin Liu","Yun-Dai Chen","Keng Wu","Guifu Wu","Kaihong Chen","Jianfeng Ye","Yan Liang","Xinwu Feng","Shaohong Dong","Qiming Wu","Xianhua Ye","Hesong Zeng","Minzhou Zhang","Min Dai","Chong-Yang Duan","Guoli Sun","Yibo He","Feier Song","Zhaodong Guo","Ping-Yan Chen","Junbo Ge","Ying Xian","Jiyan Chen"],"significance":5,"published":"2022-05-25","source_date":"2022-05-25","image":"","kennis":[],"congress":"","summary_en":"This randomized trial tested aggressive versus general hydration for preventing contrast-induced kidney injury after primary PCI for acute MI, evaluating a simple intervention for renal protection during emergent procedures.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5397c3211286","type":"article","url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","title":"Dapagliflozine naar baseline bloeddruk bij diabetes type 2: DECLARE-TIMI 58","title_en":"Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.058103","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.058103","authors":["Remo H M Furtado","Itamar Raz","Erica L Goodrich","Sabina A Murphy","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John P H Wilding","Philip Aylward","Anthony J Dalby","Mikael Dellborg","Doina Dimulescu","José C Nicolau","Anthonius J M Oude Ophuis","Avivit Cahn","Ofri Mosenzon","Ingrid Gause-Nilsson","Anna Maria Langkilde","Marc S Sabatine","Stephen D Wiviott"],"significance":5,"published":"2022-05-24","source_date":"2022-05-24","image":"","kennis":[],"congress":"","summary_en":"This DECLARE-TIMI 58 analysis showed that dapagliflozin's efficacy in type 2 diabetes is consistent across baseline blood pressure levels, supporting SGLT2 inhibitor use regardless of blood pressure status.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"32e8c8c15155","type":"article","url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","title":"Latent pulmonaal vaatlijden en respons op atriale shunt bij HF","title_en":"Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059486","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059486","authors":["Barry A Borlaug","John Blair","Martin W Bergmann","Heiko Bugger","Dan Burkhoff","Leonhard Bruch","David S Celermajer","Brian Claggett","John G F Cleland","Donald E Cutlip","Ira Dauber","Jean-Christophe Eicher","Qi Gao","Thomas M Gorter","Finn Gustafsson","Chris Hayward","Jan van der Heyden","Gerd Hasenfuß","Scott L Hummel","David M Kaye","Jan Komtebedde","Joseph M Massaro","Jeremy A Mazurek","Scott McKenzie","Shamir R Mehta","Mark C Petrie","Marco C Post","Ajith Nair","Andreas Rieth","Frank E Silvestry","Scott D Solomon","Jean-Noël Trochu","Dirk J Van Veldhuisen","Ralf Westenfeld","Martin B Leon","Sanjiv J Shah"],"significance":5,"published":"2022-05-24","source_date":"2022-05-24","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that latent pulmonary vascular disease alters the response to the IASD interatrial shunt device in heart failure, identifying a subgroup where right heart hemodynamics limit the benefit of left atrial decompression.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"feaf71044a42","type":"article","url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","title":"Dorpsarts-geleide multifacet-interventie voor bloeddrukcontrole in ruraal China: Lancet","title_en":"A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00325-7","source_url":"https://doi.org/10.1016/S0140-6736(22)00325-7","authors":["Yingxian Sun","Jianjun Mu","Dao Wen Wang","Nanxiang Ouyang","Liying Xing","Xiaofan Guo","Chunxia Zhao","Guocheng Ren","Ning Ye","Ying Zhou","Jun Wang","Zhao Li","Guozhe Sun","Ruihai Yang","Chung-Shiuan Chen","Jiang He"],"significance":7,"published":"2022-05-21","source_date":"2022-05-21","image":"","kennis":[],"congress":"","summary_en":"This Lancet cluster-randomized trial showed that a village doctor-led multifaceted intervention (health coaching, treatment algorithm, home BP monitoring) significantly improves blood pressure control in rural China, providing a scalable model for low-resource settings.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7442cc21800","type":"article","url":"https://hartvaat.nl/2022/05/21/bariatrische-chirurgie-en-cardiovasculaire-ziekte-meta-analyse/","title":"Bariatrische chirurgie en cardiovasculaire ziekte: meta-analyse","title_en":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["obesitas"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac071","source_url":"https://doi.org/10.1093/eurheartj/ehac071","authors":["Sophie L van Veldhuisen","Thomas M Gorter","Gijs van Woerden","Rudolf A de Boer","Michiel Rienstra","Eric J Hazebroek","Dirk J van Veldhuisen"],"significance":8,"published":"2022-05-21","source_date":"2022-05-21","image":"","kennis":[],"congress":"","summary_en":"This systematic review and meta-analysis showed that bariatric surgery is associated with significant reductions in cardiovascular events and cardiovascular mortality compared with nonsurgical management of obesity. The quantified cardiovascular benefit supports consideration of bariatric surgery as a cardiovascular prevention strategy.","created":"2026-07-03T10:29:46Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed5b8a53fa21","type":"article","url":"https://hartvaat.nl/2022/05/17/voedingscholesterol-serumcholesterol-en-eiconsumptie-en-mortaliteit-meta-analyse/","title":"Voedingscholesterol, serumcholesterol en eiconsumptie en mortaliteit: meta-analyse","title_en":"Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["dyslipidemie","ezetimibe","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057642","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057642","authors":["Bin Zhao","Lu Gan","Barry I Graubard","Satu Männistö","Demetrius Albanes","Jiaqi Huang"],"significance":6,"published":"2022-05-17","source_date":"2022-05-17","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated the associations of dietary cholesterol, serum cholesterol, and egg consumption with mortality, providing a nuanced perspective on the complex relationship between dietary cholesterol intake and cardiovascular outcomes.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"38590fcf8181","type":"article","url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","title":"Kosteneffectiviteit van zoutsubstitutie: SSaSS analyse","title_en":"Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059573","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059573","authors":["Ka-Chun Li","Liping Huang","Maoyi Tian","Gian Luca Di Tanna","Jie Yu","Xinyi Zhang","Xuejun Yin","Yishu Liu","Zhixin Hao","Bo Zhou","Xiangxian Feng","Zhifang Li","Jianxin Zhang","Jixin Sun","Yuhong Zhang","Yi Zhao","Ruijuan Zhang","Yan Yu","Nicole Li","Lijing L Yan","Darwin R Labarthe","Paul Elliott","Yangfeng Wu","Bruce Neal","Thomas Lung","Lei Si"],"significance":6,"published":"2022-05-17","source_date":"2022-05-17","image":"","kennis":[],"congress":"","summary_en":"This SSaSS cost-effectiveness analysis showed that household salt substitution is highly cost-effective for cardiovascular prevention, supporting the economic case for this population-level dietary intervention.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"94eccb4e7b5a","type":"article","url":"https://hartvaat.nl/2022/05/12/behandeling-van-milde-chronische-hypertensie-in-de-zwangerschap-nejm-chap/","title":"Behandeling van milde chronische hypertensie in de zwangerschap: NEJM CHAP","title_en":"Treatment for Mild Chronic Hypertension during Pregnancy.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["zwangerschap-hart"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2201295","source_url":"https://doi.org/10.1056/NEJMoa2201295","authors":["Alan T Tita","Jeff M Szychowski","Kim Boggess","Lorraine Dugoff","Baha Sibai","Kirsten Lawrence","Brenna L Hughes","Joseph Bell","Kjersti Aagaard","Rodney K Edwards","Kelly Gibson","David M Haas","Lauren Plante","Torri Metz","Brian Casey","Sean Esplin","Sherri Longo","Matthew Hoffman","George R Saade","Kara K Hoppe","Janelle Foroutan","Methodius Tuuli","Michelle Y Owens","Hyagriv N Simhan","Heather Frey","Todd Rosen","Anna Palatnik","Susan Baker","Phyllis August","Uma M Reddy","Wendy Kinzler","Emily Su","Iris Krishna","Nicki Nguyen","Mary E Norton","Daniel Skupski","Yasser Y El-Sayed","Dotum Ogunyemi","Zorina S Galis","Lorie Harper","Namasivayam Ambalavanan","Nancy L Geller","Suzanne Oparil","Gary R Cutter","William W Andrews"],"significance":10,"published":"2022-05-12","source_date":"2022-05-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The CHAP trial demonstrated that treatment of mild chronic hypertension during pregnancy (targeting blood pressure <140/90 mmHg) significantly reduced the risk of preeclampsia and preterm birth with no adverse fetal effects. This landmark result reversed the prevailing watchful-waiting approach and established active treatment as beneficial in pregnancy-associated hypertension.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7436d916ffb5","type":"article","url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","title":"SMS voor medicatietrouw en secundaire preventie na ACS: TEXTMEDS","title_en":"Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056161","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056161","authors":["Clara K Chow","Harry Klimis","Aravinda Thiagalingam","Julie Redfern","Graham S Hillis","David Brieger","John Atherton","Ravinay Bhindi","Derek P Chew","Nicholas Collins","Michael Andrew Fitzpatrick","Craig Juergens","Nadarajah Kangaharan","Andrew Maiorana","Michele McGrady","Rohan Poulter","Pratap Shetty","Jonathon Waites","Christian Hamilton Craig","Peter Thompson","Sandrine Stepien","Amy Von Huben","Anthony Rodgers"],"significance":6,"published":"2022-05-10","source_date":"2022-05-10","image":"","kennis":[],"congress":"","summary_en":"The TEXTMEDS trial showed that automated text messages improve medication adherence after acute coronary syndrome, demonstrating a low-cost, scalable digital intervention for secondary cardiovascular prevention.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7bd12eead3d","type":"article","url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","title":"Alirocumab plus statine op coronaire atherosclerose na MI: JAMA PACMAN-AMI","title_en":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["rosuvastatine","statines"],"journal":"JAMA","doi":"10.1001/jama.2022.5218","source_url":"https://doi.org/10.1001/jama.2022.5218","authors":["Lorenz Räber","Yasushi Ueki","Tatsuhiko Otsuka","Sylvain Losdat","Jonas D Häner","Jacob Lonborg","Gregor Fahrni","Juan F Iglesias","Robert-Jan van Geuns","Anna S Ondracek","Maria D Radu Juul Jensen","Christian Zanchin","Stefan Stortecky","David Spirk","George C M Siontis","Lanja Saleh","Christian M Matter","Joost Daemen","François Mach","Dik Heg","Stephan Windecker","Thomas Engstrøm","Irene M Lang","Konstantinos C Koskinas"],"significance":8,"published":"2022-05-10","source_date":"2022-05-10","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"The PACMAN-AMI trial demonstrated that adding alirocumab to high-intensity statin therapy after acute MI produced greater reductions in coronary plaque volume and improved plaque composition on multimodality intravascular imaging compared with statin alone. The results provided direct evidence that early PCSK9 inhibition favorably modifies vulnerable plaques.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64820d2350a7","type":"article","url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","title":"Zelfmeting bloeddruk en hypertensie-diagnose bij risicozwangerschap: JAMA BUMP 1","title_en":"Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["bloeddrukbehandeling"],"journal":"JAMA","doi":"10.1001/jama.2022.4712","source_url":"https://doi.org/10.1001/jama.2022.4712","authors":["Katherine L Tucker","Sam Mort","Ly-Mee Yu","Helen Campbell","Oliver Rivero-Arias","Hannah M Wilson","Julie Allen","Rebecca Band","Alison Chisholm","Carole Crawford","Greig Dougall","Lazarina Engonidou","Marloes Franssen","Marcus Green","Sheila Greenfield","Lisa Hinton","James Hodgkinson","Layla Lavallee","Paul Leeson","Christine McCourt","Lucy Mackillop","Jane Sandall","Mauro Santos","Lionel Tarassenko","Carmelo Velardo","Lucy Yardley","Lucy C Chappell","Richard J McManus"],"significance":7,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The BUMP 1 trial demonstrated that blood pressure self-monitoring during higher-risk pregnancy does not significantly increase detection of hypertension compared with usual care, though it may improve overall blood pressure awareness.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36c2b6470210","type":"article","url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","title":"Zelfmeting bloeddruk en bloeddrukcontrole bij risicozwangerschap: JAMA BUMP 2","title_en":"Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2022.4726","source_url":"https://doi.org/10.1001/jama.2022.4726","authors":["Lucy C Chappell","Katherine L Tucker","Ushma Galal","Ly-Mee Yu","Helen Campbell","Oliver Rivero-Arias","Julie Allen","Rebecca Band","Alison Chisholm","Carole Crawford","Greig Dougall","Lazarina Engonidou","Marloes Franssen","Marcus Green","Sheila Greenfield","Lisa Hinton","James Hodgkinson","Layla Lavallee","Paul Leeson","Christine McCourt","Lucy Mackillop","Jane Sandall","Mauro Santos","Lionel Tarassenko","Carmelo Velardo","Hannah Wilson","Lucy Yardley","Richard J McManus"],"significance":7,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The BUMP 2 trial showed that blood pressure self-monitoring in higher-risk pregnancies improves blood pressure control, supporting the use of home monitoring as an adjunct to clinical assessment in obstetric hypertension.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e0d914deac9b","type":"article","url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","title":"Icosapent-ethyl en CV-preventie bij eerder MI: REDUCE-IT","title_en":"Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.02.035","source_url":"https://doi.org/10.1016/j.jacc.2022.02.035","authors":["Prakriti Gaba","Deepak L Bhatt","Ph Gabriel Steg","Michael Miller","Eliot A Brinton","Terry A Jacobson","Steven B Ketchum","Rebecca A Juliano","Lixia Jiao","Ralph T Doyle","Craig Granowitz","Jean-Claude Tardif","Robert P Giugliano","Fabrice M A C Martens","C Michael Gibson","Christie M Ballantyne"],"significance":6,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This REDUCE-IT subanalysis confirmed that icosapent ethyl provides significant cardiovascular event reduction in patients with prior MI, the highest-risk population within the statin-treated triglyceridemic cohort.","created":"2026-07-03T10:29:45Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d73c700b81be","type":"article","url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: executive summary","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.12.011","source_url":"https://doi.org/10.1016/j.jacc.2021.12.011","authors":["Paul A Heidenreich","Biykem Bozkurt","David Aguilar","Larry A Allen","Joni J Byun","Monica M Colvin","Anita Deswal","Mark H Drazner","Shannon M Dunlay","Linda R Evers","James C Fang","Savitri E Fedson","Gregg C Fonarow","Salim S Hayek","Adrian F Hernandez","Prateeti Khazanie","Michelle M Kittleson","Christopher S Lee","Mark S Link","Carmelo A Milano","Lorraine C Nnacheta","Alexander T Sandhu","Lynne Warner Stevenson","Orly Vardeny","Amanda R Vest","Clyde W Yancy"],"significance":9,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"Executive summary of the 2022 AHA/ACC/HFSA heart failure guideline, providing key recommendations, decision pathways, and the four-pillar treatment algorithm for HFrEF including SGLT2 inhibitors, ARNI, beta-blockers, and MRAs.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8044aaa0a36","type":"article","url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: JACC-editie","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.12.012","source_url":"https://doi.org/10.1016/j.jacc.2021.12.012","authors":["Paul A Heidenreich","Biykem Bozkurt","David Aguilar","Larry A Allen","Joni J Byun","Monica M Colvin","Anita Deswal","Mark H Drazner","Shannon M Dunlay","Linda R Evers","James C Fang","Savitri E Fedson","Gregg C Fonarow","Salim S Hayek","Adrian F Hernandez","Prateeti Khazanie","Michelle M Kittleson","Christopher S Lee","Mark S Link","Carmelo A Milano","Lorraine C Nnacheta","Alexander T Sandhu","Lynne Warner Stevenson","Orly Vardeny","Amanda R Vest","Clyde W Yancy"],"significance":10,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"The 2022 AHA/ACC/HFSA heart failure guideline published in JACC replaced the 2013 guidelines and integrated contemporary evidence on SGLT2 inhibitors and ARNI into structured treatment algorithms for heart failure across the ejection fraction spectrum.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7b7c0f2e1730","type":"article","url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","title":"Vupanorsen en non-HDL-cholesterol bij statinebehandelde patiënten: TRANSLATE-TIMI 70","title_en":"Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","niet-statine-therapie","rosuvastatine","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.122.059266","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.122.059266","authors":["Brian A Bergmark","Nicholas A Marston","Candace R Bramson","Madelyn Curto","Vesper Ramos","Alexandra Jevne","Julia F Kuder","Jeong-Gun Park","Sabina A Murphy","Subodh Verma","Wojtek Wojakowski","Steven G Terra","Marc S Sabatine","Stephen D Wiviott"],"significance":7,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The TRANSLATE-TIMI 70 trial showed that vupanorsen (targeting ANGPTL3) modestly reduced non-HDL cholesterol in statin-treated patients but was associated with hepatic steatosis, raising safety concerns that ultimately led to discontinuation of its development.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4d63b9e50c5e","type":"article","url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","title":"Korte interfererende RNA tegen Lp(a): JAMA fase-1 dosisstudie","title_en":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2022.5050","source_url":"https://doi.org/10.1001/jama.2022.5050","authors":["Steven E Nissen","Kathy Wolski","Craig Balog","Daniel I Swerdlow","Alison C Scrimgeour","Curtis Rambaran","Rosamund J Wilson","Malcom Boyce","Kausik K Ray","Leslie Cho","Gerald F Watts","Michael Koren","Traci Turner","Erik S Stroes","Carrie Melgaard","Giles V Campion"],"significance":7,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This JAMA phase 1 dose-escalation study of an siRNA targeting lipoprotein(a) production demonstrated potent and durable Lp(a) reduction, advancing the most promising Lp(a)-lowering mechanism toward clinical development.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"602d8dc5a2da","type":"article","url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: Circulation-editie","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIR.0000000000001063","source_url":"https://doi.org/10.1161/CIR.0000000000001063","authors":["Paul A Heidenreich","Biykem Bozkurt","David Aguilar","Larry A Allen","Joni J Byun","Monica M Colvin","Anita Deswal","Mark H Drazner","Shannon M Dunlay","Linda R Evers","James C Fang","Savitri E Fedson","Gregg C Fonarow","Salim S Hayek","Adrian F Hernandez","Prateeti Khazanie","Michelle M Kittleson","Christopher S Lee","Mark S Link","Carmelo A Milano","Lorraine C Nnacheta","Alexander T Sandhu","Lynne Warner Stevenson","Orly Vardeny","Amanda R Vest","Clyde W Yancy"],"significance":10,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The 2022 AHA/ACC/HFSA heart failure guideline was the first comprehensive update since 2013, integrating SGLT2 inhibitors, sacubitril-valsartan, and vericiguat into guideline-directed medical therapy. The document codified the four-pillar approach to HFrEF and provided new recommendations for HFpEF management based on emerging evidence.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ffc999e2eaeb","type":"article","url":"https://hartvaat.nl/2022/05/03/triventriculaire-pacing-bij-hf-strive-hf-gerandomiseerde-trial/","title":"Triventriculaire pacing bij HF: STRIVE HF gerandomiseerde trial","title_en":"Standard care vs. TRIVEntricular pacing in Heart Failure (STRIVE HF): a prospective multicentre randomized controlled trial of triventricular pacing vs. conventional biventricular pacing in patients with heart failure and intermediate QRS left bundle branch block.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["step-hfpef","summit-trial"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab267","source_url":"https://doi.org/10.1093/europace/euab267","authors":["Justin Gould","Simon Claridge","Thomas Jackson","Benjamin J Sieniewicz","Baldeep S Sidhu","Bradley Porter","Mark K Elliott","Vishal Mehta","Steven Niederer","Humra Chadwick","Ravi Kamdar","Shaumik Adhya","Nikhil Patel","Shoaib Hamid","Dominic Rogers","William Nicolson","Cheuk F Chan","Zachary Whinnett","Francis Murgatroyd","Pier D Lambiase","Christopher A Rinaldi"],"significance":5,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"The STRIVE HF trial tested triventricular pacing (adding a right ventricular septal lead to conventional BiV pacing) for heart failure, evaluating whether three-site stimulation improves CRT response.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"837d994f103e","type":"article","url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","title":"Multimodaliteitsbeeldvorming-geleide LV-leadplaatsing bij CRT: langetermijn","title_en":"Long-term outcomes in a randomized controlled trial of multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab314","source_url":"https://doi.org/10.1093/europace/euab314","authors":["Daniel Benjamin Fyenbo","Anders Sommer","Bjarne Linde Nørgaard","Mads Brix Kronborg","Jens Kristensen","Christian Gerdes","Henrik Kjærulf Jensen","Jesper Møller Jensen","Jens Cosedis Nielsen"],"significance":5,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"This trial reported long-term outcomes of multimodality imaging-guided LV lead placement for CRT, showing that combining imaging techniques for optimal lead positioning reduces heart failure events over extended follow-up.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e3a1052c175","type":"article","url":"https://hartvaat.nl/2022/05/03/af-risico-bij-laag-matig-alcoholgebruik-naar-geslacht-en-regio-meta-analyse/","title":"AF-risico bij laag-matig alcoholgebruik naar geslacht en regio: meta-analyse","title_en":"Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab266","source_url":"https://doi.org/10.1093/europace/euab266","authors":["Lingzhi Yang","Huaqiao Chen","Tingting Shu","Mingyong Pan","Wei Huang"],"significance":6,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that the association between low-to-moderate alcohol consumption and incident AF varies by sex, geographic region, and type of alcoholic beverage, providing nuanced guidance on alcohol-AF risk counseling.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c7f7675f1cdd","type":"article","url":"https://hartvaat.nl/2022/05/03/radiale-strain-geleide-leadplaatsing-voor-crt-bij-ischemisch-hf/","title":"Radiale strain geleide leadplaatsing voor CRT bij ischemisch HF","title_en":"Radial strain imaging-guided lead placement for improving response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy: the Raise CRT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab253","source_url":"https://doi.org/10.1093/europace/euab253","authors":["Michael Glikson","Roy Beinart","Gregory Golovchiner","Alon Bar Sheshet","Moshe Swissa","Munther Bolous","Raphael Rosso","Aharon Medina","Moti Haim","Paul Friedman","Vladimir Khalamaizer","Shlomit Benzvi","Saki Ito","Ilan Goldenberg","Robert Klempfner","Ori Vaturi","Jae K Oh"],"significance":5,"published":"2022-05-03","source_date":"2022-05-03","image":"","kennis":[],"congress":"","summary_en":"This study evaluated radial strain imaging-guided LV lead placement for improving CRT response in ischemic heart failure, testing whether targeting the latest activated non-scarred segment improves resynchronization.","created":"2026-07-03T10:29:44Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc6abf65ad15","type":"article","url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","title":"Nierdisfunctie en uitkomsten bij HF met MR: COAPT","title_en":"Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehac026","source_url":"https://doi.org/10.1093/eurheartj/ehac026","authors":["Nirat Beohar","Gorav Ailawadi","Lak N Kotinkaduwa","Björn Redfors","Matheus Simonato","Zixuan Zhang","Loren Garrison Morgan","Esteban Escolar","Saibal Kar","David Scott Lim","Jacob M Mishell","Brian K Whisenant","William T Abraham","JoAnn Lindenfeld","Michael J Mack","Gregg W Stone"],"significance":6,"published":"2022-05-01","source_date":"2022-05-01","image":"","kennis":[],"congress":"","summary_en":"This COAPT analysis showed that baseline renal dysfunction worsens outcomes in heart failure with severe MR, but that MitraClip provides consistent relative benefit regardless of kidney function status.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"927a54de4497","type":"article","url":"https://hartvaat.nl/2022/05/01/antihypertensivaklasse-en-uitkomsten-in-sprint/","title":"Antihypertensivaklasse en uitkomsten in SPRINT","title_en":"Impact of Antihypertensive Drug Class on Outcomes in SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18369","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18369","authors":["Douglas D DeCarolis","Amy Gravely","Christine M Olney","Areef Ishani"],"significance":6,"published":"2022-05-01","source_date":"2022-05-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT analysis examined whether any specific antihypertensive drug class was associated with better outcomes under intensive blood pressure control, informing the drug selection component of aggressive treatment strategies.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fa610a44db7d","type":"article","url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","title":"Risicostratificatie door kruisclassificatie van centrale en brachiale systolische bloeddruk","title_en":"Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18773","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18773","authors":["Yi-Bang Cheng","Lutgarde Thijs","Lucas S Aparicio","Qi-Fang Huang","Fang-Fei Wei","Yu-Ling Yu","Jessica Barochiner","Chang-Sheng Sheng","Wen-Yi Yang","Teemu J Niiranen","José Boggia","Zhen-Yu Zhang","Katarzyna Stolarz-Skrzypek","Natasza Gilis-Malinowska","Valérie Tikhonoff","Wiktoria Wojciechowska","Edoardo Casiglia","Krzysztof Narkiewicz","Jan Filipovský","Kalina Kawecka-Jaszcz","Ji-Guang Wang","Yan Li","Jan A Staessen"],"significance":5,"published":"2022-05-01","source_date":"2022-05-01","image":"","kennis":[],"congress":"","summary_en":"This study used cross-classification of central and brachial systolic blood pressure for cardiovascular risk stratification, testing whether discordant central-peripheral readings identify patients at differential risk.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63ad8f847719","type":"article","url":"https://hartvaat.nl/2022/05/01/antihypertensieve-behandeling-en-cerebrale-bloedflow-meta-analyse/","title":"Antihypertensieve behandeling en cerebrale bloedflow: meta-analyse","title_en":"Effect of Antihypertensive Treatment on Cerebral Blood Flow in Older Adults: a Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18255","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18255","authors":["Anniek E van Rijssel","Bram C Stins","Lucy C Beishon","Marit L Sanders","Terence J Quinn","Jurgen A H R Claassen","Rianne A A de Heus"],"significance":6,"published":"2022-05-01","source_date":"2022-05-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated the effect of antihypertensive treatment on cerebral blood flow in older adults, addressing the concern that blood pressure lowering may compromise brain perfusion in the elderly.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9781e92c6b6a","type":"article","url":"https://hartvaat.nl/2022/05/01/remote-ischemische-conditionering-bij-stemi-registergebaseerde-gerandomiseerde-t/","title":"Remote ischemische conditionering bij STEMI: registergebaseerde gerandomiseerde trial","title_en":"Remote ischaemic conditioning in ST elevation myocardial infarction: a registry-based randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319455","source_url":"https://doi.org/10.1136/heartjnl-2021-319455","authors":["Kevin R Bainey","Yinggan Zheng","Richard Coulden","Emer Sonnex","Richard Thompson","Junyi Mei","Alexandra Bastiany","Robert Welsh"],"significance":5,"published":"2022-05-01","source_date":"2022-05-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"This registry-based randomized trial of remote ischemic conditioning in STEMI tested cardioprotection at the population level, evaluating whether the benefits seen in controlled trials translate to routine clinical practice.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"89d5fedf281c","type":"article","url":"https://hartvaat.nl/2022/04/30/abiraterone-bij-gemetastaseerd-castratiegevoelig-prostaatkanker-peace-1/","title":"Abiraterone bij gemetastaseerd castratiegevoelig prostaatkanker: PEACE-1","title_en":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00367-1","source_url":"https://doi.org/10.1016/S0140-6736(22)00367-1","authors":["Karim Fizazi","Stéphanie Foulon","Joan Carles","Guilhem Roubaud","Ray McDermott","Aude Fléchon","Bertrand Tombal","Stéphane Supiot","Dominik Berthold","Philippe Ronchin","Gabriel Kacso","Gwenaëlle Gravis","Fabio Calabro","Jean-François Berdah","Ali Hasbini","Marlon Silva","Antoine Thiery-Vuillemin","Igor Latorzeff","Loïc Mourey","Brigitte Laguerre","Sophie Abadie-Lacourtoisie","Etienne Martin","Claude El Kouri","Anne Escande","Alvar Rosello","Nicolas Magne","Friederike Schlurmann","Frank Priou","Marie-Eve Chand-Fouche","Salvador Villà Freixa","Muhammad Jamaluddin","Isabelle Rieger","Alberto Bossi"],"significance":5,"published":"2022-04-30","source_date":"2022-04-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/","https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/"],"congress":"","summary_en":"The PEACE-1 Lancet trial of abiraterone for metastatic prostate cancer is relevant to cardio-oncology due to the hypertension and hypokalemia side effects of androgen-pathway manipulation.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e90221ac0230","type":"article","url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","title":"Aspirine voor CV-preventie: USPSTF aanbeveling 2022","title_en":"Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["aspirine"],"journal":"JAMA","doi":"10.1001/jama.2022.4983","source_url":"https://doi.org/10.1001/jama.2022.4983","authors":["Karina W Davidson","Michael J Barry","Carol M Mangione","Michael Cabana","David Chelmow","Tumaini Rucker Coker","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Alex H Krist","Martha Kubik","Li Li","Gbenga Ogedegbe","Lori Pbert","John M Ruiz","James Stevermer","Chien-Wen Tseng","John B Wong"],"significance":10,"published":"2022-04-26","source_date":"2022-04-26","image":"","kennis":[],"congress":"","summary_en":"The 2022 USPSTF recommendation statement downgraded the role of aspirin in primary cardiovascular prevention, advising against initiation in adults 60 years or older and recommending individualized decision-making in those aged 40–59 with elevated CVD risk. This reflected accumulating evidence from ASPREE, ARRIVE, and ASCEND showing unfavorable bleeding-to-benefit ratios.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2071c46c02c3","type":"article","url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","title":"Externe validatie van de FREEDOM-score voor PCI versus CABG","title_en":"External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.01.049","source_url":"https://doi.org/10.1016/j.jacc.2022.01.049","authors":["Kuniaki Takahashi","Patrick W Serruys","Valentin Fuster","Michael E Farkouh","John A Spertus","David J Cohen","Seung-Jung Park","Duk-Woo Park","Jung-Min Ahn","Yoshinobu Onuma","David M Kent","Ewout W Steyerberg","David van Klaveren"],"significance":6,"published":"2022-04-19","source_date":"2022-04-19","image":"","kennis":[],"congress":"","summary_en":"This external validation of the FREEDOM score confirmed its ability to predict individual benefit from CABG versus PCI, supporting the tool for personalized revascularization decision-making in diabetic multivessel disease.","created":"2026-07-03T10:29:43Z","updated":"2026-07-03T13:28:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b0c4337ec4ec","type":"article","url":"https://hartvaat.nl/2022/04/19/substraatablatie-versus-antiaritmica-bij-symptomatische-vt/","title":"Substraatablatie versus antiaritmica bij symptomatische VT","title_en":"Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["supraventriculaire-tachycardie","ventriculaire-tachycardie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.01.050","source_url":"https://doi.org/10.1016/j.jacc.2022.01.050","authors":["Ángel Arenal","Pablo Ávila","Javier Jiménez-Candil","Luis Tercedor","David Calvo","Fernando Arribas","Javier Fernández-Portales","José Luis Merino","Antonio Hernández-Madrid","Francisco J Fernández-Avilés","Antonio Berruezo"],"significance":7,"published":"2022-04-19","source_date":"2022-04-19","image":"","kennis":[],"congress":"","summary_en":"This study compared substrate-based catheter ablation with antiarrhythmic drug therapy for symptomatic ventricular tachycardia in patients with ischemic cardiomyopathy and an ICD, evaluating the optimal rhythm management approach.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"909b54440bb9","type":"article","url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","title":"Therapeutische doelen voor HF via proteomics en Mendeliaanse randomisatie","title_en":"Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056663","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056663","authors":["Albert Henry","María Gordillo-Marañón","Chris Finan","Amand F Schmidt","João Pedro Ferreira","Ravi Karra","Johan Sundström","Lars Lind","Johan Ärnlöv","Faiez Zannad","Anders Mälarstig","Aroon D Hingorani","R Thomas Lumbers"],"significance":6,"published":"2022-04-19","source_date":"2022-04-19","image":"","kennis":[],"congress":"","summary_en":"This study used proteomics and Mendelian randomization to identify novel therapeutic targets for heart failure, discovering disease-associated proteins that could be drugged for HF prevention or treatment.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6b552931f0cc","type":"article","url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","title":"Alirocumab na ACS bij patiënten met HF-voorgeschiedenis: ODYSSEY OUTCOMES","title_en":"Alirocumab after acute coronary syndrome in patients with a history of heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab804","source_url":"https://doi.org/10.1093/eurheartj/ehab804","authors":["Harvey D White","Gregory G Schwartz","Michael Szarek","Deepak L Bhatt","Vera A Bittner","Chern-En Chiang","Rafael Diaz","Shaun G Goodman","Johan Wouter Jukema","Megan Loy","Neha Pagidipati","Robert Pordy","Arsen D Ristić","Andreas M Zeiher","Daniel M Wojdyla","Philippe Gabriel Steg"],"significance":6,"published":"2022-04-19","source_date":"2022-04-19","image":"","kennis":[],"congress":"","summary_en":"This ODYSSEY OUTCOMES subanalysis showed that alirocumab benefits ACS patients with a history of heart failure, a population previously thought to not respond to lipid-lowering therapy based on statin trial data.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc89681a5adf","type":"article","url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","title":"Coronaire flowreserve en cardiovasculaire uitkomsten: meta-analyse","title_en":"Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab775","source_url":"https://doi.org/10.1093/eurheartj/ehab775","authors":["Mihir A Kelshiker","Henry Seligman","James P Howard","Haseeb Rahman","Michael Foley","Alexandra N Nowbar","Christopher A Rajkumar","Matthew J Shun-Shin","Yousif Ahmad","Sayan Sen","Rasha Al-Lamee","Ricardo Petraco"],"significance":7,"published":"2022-04-19","source_date":"2022-04-19","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This meta-analysis quantified the association between reduced coronary flow reserve and cardiovascular outcomes, establishing impaired coronary microvascular function as an independent predictor of adverse events across multiple measurement modalities.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2f6e6c1221f2","type":"article","url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","title":"Renale denervatie met antihypertensiva: Lancet SPYRAL HTN-ON MED langetermijn","title_en":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie","sacubitril-valsartan"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00455-X","source_url":"https://doi.org/10.1016/S0140-6736(22)00455-X","authors":["Felix Mahfoud","David E Kandzari","Kazuomi Kario","Raymond R Townsend","Michael A Weber","Roland E Schmieder","Konstantinos Tsioufis","Stuart Pocock","Kyriakos Dimitriadis","James W Choi","Cara East","Richard D'Souza","Andrew S P Sharp","Sebastian Ewen","Antony Walton","Ingrid Hopper","Sandeep Brar","Pamela McKenna","Martin Fahy","Michael Böhm"],"significance":7,"published":"2022-04-09","source_date":"2022-04-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"Long-term SPYRAL HTN-ON MED results confirmed sustained blood pressure reduction with renal denervation in the presence of antihypertensive medications, providing durable efficacy and safety data for device-based therapy in medicated patients.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f3813c6f5bb7","type":"article","url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","title":"Asundexian (factor XIa-remmer) versus apixaban bij AF: Lancet PACIFIC-AF","title_en":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["abelacimab","aperitif-trial","rivaroxaban"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00456-1","source_url":"https://doi.org/10.1016/S0140-6736(22)00456-1","authors":["Jonathan P Piccini","Valeria Caso","Stuart J Connolly","Keith A A Fox","Jonas Oldgren","W Schuyler Jones","Diana A Gorog","Václav Durdil","Thomas Viethen","Christoph Neumann","Hardi Mundl","Manesh R Patel"],"significance":8,"published":"2022-04-09","source_date":"2022-04-09","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doacs-overzicht/","https://hartvaat.nl/kennis/antistolling/antidota-anticoagulantia/"],"congress":"","summary_en":"The PACIFIC-AF phase 2 trial showed that asundexian, an oral factor XIa inhibitor, had significantly less bleeding than apixaban in AF patients while maintaining preliminary signals of anticoagulant efficacy. This early positive result set the stage for the subsequent (failed) OCEANIC-AF phase 3 trial.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b3be955bda4","type":"article","url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","title":"Natriumreductie <100 mmol bij hartfalen: Lancet SODIUM-HF","title_en":"Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["carvedilol","finearts-hf","hfpef","hfref"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00369-5","source_url":"https://doi.org/10.1016/S0140-6736(22)00369-5","authors":["Justin A Ezekowitz","Eloisa Colin-Ramirez","Heather Ross","Jorge Escobedo","Peter Macdonald","Richard Troughton","Clara Saldarriaga","Wendimagegn Alemayehu","Finlay A McAlister","JoAnne Arcand","John Atherton","Robert Doughty","Milan Gupta","Jonathan Howlett","Shahin Jaffer","Andrea Lavoie","Mayanna Lund","Thomas Marwick","Robert McKelvie","Gordon Moe","A Shekhar Pandey","Liane Porepa","Miroslaw Rajda","Haunnah Rheault","Jitendra Singh","Mustafa Toma","Sean Virani","Shelley Zieroth"],"significance":8,"published":"2022-04-09","source_date":"2022-04-09","image":"","kennis":[],"congress":"","summary_en":"The SODIUM-HF trial showed that strict dietary sodium restriction (<100 mmol/day) in heart failure patients did not significantly reduce the composite of cardiovascular hospitalization, emergency department visit, or death compared with usual care. The neutral result questioned the clinical benefit of intensive sodium restriction.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da7c90b7b17e","type":"article","url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","title":"ApoC-III-reductie bij matige hypertriglyceridemie met hoog CV-risico","title_en":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","hdl-cholesterol","hypertriglyceridemie","lipoproteïne-a","yellow-iii"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab820","source_url":"https://doi.org/10.1093/eurheartj/ehab820","authors":["Jean-Claude Tardif","Ewa Karwatowska-Prokopczuk","Eric St Amour","Christie M Ballantyne","Michael D Shapiro","Patrick M Moriarty","Seth J Baum","Eunju Hurh","Victoria J Bartlett","Joyce Kingsbury","Amparo L Figueroa","Veronica J Alexander","Joseph Tami","Joseph L Witztum","Richard S Geary","Louis St L O'Dea","Sotirios Tsimikas","Daniel Gaudet"],"significance":7,"published":"2022-04-06","source_date":"2022-04-06","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hypertriglyceridemie/"],"congress":"","summary_en":"This clinical trial evaluated olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting apoC-III, in patients with moderate hypertriglyceridemia and high cardiovascular risk, demonstrating significant triglyceride reduction with a favorable safety profile.","created":"2026-07-03T10:29:42Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4b4783cf0387","type":"article","url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","title":"Nierfunctiebeoordeling en eindpuntbepaling in klinische trials: EHJ","title_en":"Kidney function assessment and endpoint ascertainment in clinical trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab832","source_url":"https://doi.org/10.1093/eurheartj/ehab832","authors":["Muhammad Shahzeb Khan","George L Bakris","Milton Packer","Izza Shahid","Stefan D Anker","Gregg C Fonarow","Christoph Wanner","Matthew R Weir","Faiez Zannad","Javed Butler"],"significance":5,"published":"2022-04-06","source_date":"2022-04-06","image":"","kennis":[],"congress":"","summary_en":"This EHJ review addressed the heterogeneity in kidney function assessment and endpoint definitions in clinical trials, proposing standardized approaches to improve cross-trial comparability for renal outcomes.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e493464bfb2c","type":"article","url":"https://hartvaat.nl/2022/04/06/langetermijn-veiligheid-en-werkzaamheid-van-anacetrapib-ehj/","title":"Langetermijn veiligheid en werkzaamheid van anacetrapib: EHJ","title_en":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["cetp-remmers","ezetimibe","obicetrapib"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab863","source_url":"https://doi.org/10.1093/eurheartj/ehab863","authors":["E Sammons","J C Hopewell","F Chen","W Stevens","K Wallendszus","E Valdes-Marquez","R Dayanandan","C Knott","K Murphy","E Wincott","A Baxter","R Goodenough","M Lay","M Hill","S Macdonnell","G Fabbri","D Lucci","M Fajardo-Moser","S Brenner","D Hao","H Zhang","J Liu","B Wuhan","S Mosegaard","W Herrington","C Wanner","C Angermann","G Ertl","A Maggioni","P Barter","B Mihaylova","Y Mitchel","R Blaustein","S Goto","J Tobert","P DeLucca","Y Chen","Z Chen","A Gray","R Haynes","J Armitage","C Baigent","S Wiviott","C Cannon","E Braunwald","R Collins","L Bowman","M Landray"],"significance":6,"published":"2022-04-06","source_date":"2022-04-06","image":"","kennis":[],"congress":"","summary_en":"This long-term analysis of anacetrapib in atherosclerotic vascular disease confirmed sustained efficacy and safety beyond the initial REVEAL trial period, providing extended data on CETP inhibition with the only agent to show cardiovascular benefit.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f51a250efeb8","type":"article","url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","title":"Antistolling, comorbiditeitsbehandeling en vroege ritmecontrole: EAST-AFNET 4 patronen","title_en":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab200","source_url":"https://doi.org/10.1093/europace/euab200","authors":["Andreas Metzner","Anna Suling","Axel Brandes","Günter Breithardt","A John Camm","Harry J G M Crijns","Lars Eckardt","Arif Elvan","Andreas Goette","Laurent M Haegeli","Hein Heidbuchel","Josef Kautzner","Karl-Heinz Kuck","Luis Mont","G Andre Ng","Lukasz Szumowski","Sakis Themistoclakis","Isabelle C van Gelder","Panos Vardas","Karl Wegscheider","Stephan Willems","Paulus Kirchhof"],"significance":6,"published":"2022-04-05","source_date":"2022-04-05","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/"],"congress":"","summary_en":"This detailed EAST-AFNET 4 analysis examined treatment patterns for anticoagulation, comorbidity management, and rhythm control, confirming that the cardiovascular benefit was driven by the rhythm control strategy rather than differences in other treatments.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"103282e63f06","type":"article","url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","title":"Prasugrel dosis-de-escalatie na complexe PCI bij ACS: JAMA Cardiology","title_en":"Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2022.0052","source_url":"https://doi.org/10.1001/jamacardio.2022.0052","authors":["Doyeon Hwang","Young-Hyo Lim","Kyung Woo Park","Kook Jin Chun","Jung-Kyu Han","Han-Mo Yang","Hyun-Jae Kang","Bon-Kwon Koo","Jeehoon Kang","Yun-Kyeong Cho","Soon Jun Hong","Sanghyun Kim","Sang-Ho Jo","Yong Hoon Kim","Weon Kim","Sung Yun Lee","Young Dae Kim","Seok Kyu Oh","Jung-Hee Lee","Hyo-Soo Kim"],"significance":6,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"This analysis of prasugrel dose de-escalation after complex PCI in ACS showed that reducing the maintenance dose improves the bleeding-ischemia balance, supporting dose-reduction as an alternative to agent switching.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"112312593e47","type":"article","url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","title":"Clopidogrel monotherapie na 1-2 maanden DAPT versus 12 maanden DAPT: JAMA Cardiology","title_en":"Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["clopidogrel"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.5244","source_url":"https://doi.org/10.1001/jamacardio.2021.5244","authors":["Hirotoshi Watanabe","Takeshi Morimoto","Masahiro Natsuaki","Ko Yamamoto","Yuki Obayashi","Manabu Ogita","Satoru Suwa","Tsuyoshi Isawa","Takenori Domei","Kyohei Yamaji","Shojiro Tatsushima","Hiroki Watanabe","Masanobu Ohya","Hideo Tokuyama","Tomohisa Tada","Hiroki Sakamoto","Hiroyoshi Mori","Hiroshi Suzuki","Tenjin Nishikura","Kohei Wakabayashi","Kiyoshi Hibi","Mitsuru Abe","Kazuya Kawai","Koichi Nakao","Kenji Ando","Kengo Tanabe","Yuji Ikari","Yoshihiro Morino","Kazushige Kadota","Yutaka Furukawa","Yoshihisa Nakagawa","Takeshi Kimura"],"significance":7,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"This analysis compared clopidogrel monotherapy after 1-2 months of DAPT with standard 12-month DAPT, providing additional evidence for ultra-short antiplatelet strategies with clopidogrel as the preferred single agent after PCI.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d03cce2c71c5","type":"article","url":"https://hartvaat.nl/2022/04/01/sglt2-remmers-bij-hfref-of-hfpef-meta-analyse/","title":"SGLT2-remmers bij HFrEF of HFpEF: meta-analyse","title_en":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["empagliflozine","hfmref","hfpef","hfref","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13805","source_url":"https://doi.org/10.1002/ehf2.13805","authors":["Arjun K Pandey","Nitish K Dhingra","Makoto Hibino","Vijay Gupta","Subodh Verma"],"significance":8,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This meta-analysis of SGLT2 inhibitors across the heart failure spectrum confirmed class-wide benefit on cardiovascular death and heart failure hospitalization in both HFrEF and HFpEF, providing the pooled evidence supporting universal SGLT2 inhibitor use in heart failure.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"254e0f6a5b40","type":"article","url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","title":"ICD bij niet-ischemisch systolisch HF met coronaire atherosclerose: DANISH","title_en":"Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hartkatheterisatie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13810","source_url":"https://doi.org/10.1002/ehf2.13810","authors":["Christina Byrne","Ole Ahlehoff","Marie Bayer Elming","Frants Pedersen","Steen Pehrson","Jens C Nielsen","Hans Eiskjaer","Lars Videbaek","Jesper Hastrup Svendsen","Jens Haarbo","Anna Margrethe Thøgersen","Lars Køber","Jens Jakob Thune"],"significance":5,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"This DANISH subanalysis showed that the presence of concomitant coronary atherosclerosis does not modify the ICD benefit in non-ischemic heart failure, supporting the neutral primary finding regardless of coronary disease status.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"897e57fc91b4","type":"article","url":"https://hartvaat.nl/2022/04/01/glucoseverlagende-middelen-bij-niet-diabetisch-hf-bayesiaanse-netwerkmeta-analys/","title":"Glucoseverlagende middelen bij niet-diabetisch HF: Bayesiaanse netwerkmeta-analyse","title_en":"Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-en-hart"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13822","source_url":"https://doi.org/10.1002/ehf2.13822","authors":["Trevor Yeong","Aaron Shengting Mai","Oliver Z H Lim","Cheng Han Ng","Yip Han Chin","Phoebe Tay","Chaoxing Lin","Mark Muthiah","Chin Meng Khoo","Mayank Dalakoti","Poay-Huan Loh","Mark Chan","Tiong-Cheng Yeo","Roger Foo","Raymond Wong","Nicholas W S Chew","Weiqin Lin"],"significance":7,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"This Bayesian network meta-analysis explored whether glucose-lowering medications, particularly SGLT2 inhibitors and GLP-1 agonists, improve outcomes in non-diabetic heart failure patients, finding evidence supporting SGLT2 inhibitor use independent of glycemic indication.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3757209db5a3","type":"article","url":"https://hartvaat.nl/2022/04/01/dpp-4-remming-en-catecholamines-tijdens-ace-remming/","title":"DPP-4-remming en catecholamines tijdens ACE-remming","title_en":"DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18348","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18348","authors":["Jessica R Wilson","Erica M Garner","Mona Mashayekhi","Scott A Hubers","Claudia E Ramirez Bustamante","Scott Jafarian Kerman","Hui Nian","Cyndya A Shibao","Nancy J Brown"],"significance":5,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that DPP-4 inhibition increases catecholamine levels without raising blood pressure during concurrent ACE inhibition, providing mechanistic data on the cardiovascular safety of DPP-4 inhibitors.","created":"2026-07-03T10:29:41Z","updated":"2026-07-03T13:28:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"66d85ea1937e","type":"article","url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","title":"5-jaarsfollow-up van intracoronaire celtherapie na MI: REGENERATE-AMI","title_en":"Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13786","source_url":"https://doi.org/10.1002/ehf2.13786","authors":["Anthony Mathur","Doo Sun Sim","Fizzah Choudry","Jessry Veerapen","Martina Colicchia","Tymoteusz Turlejski","Mohsin Hussain","Stephen Hamshere","Didier Locca","Roby Rakhit","Tom Crake","Jens Kastrup","Samir Agrawal","Daniel A Jones","John Martin"],"significance":5,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":[],"congress":"","summary_en":"The 5-year REGENERATE-AMI follow-up showed no sustained improvement in cardiac function from intracoronary autologous bone marrow cell therapy after acute MI, adding to the long-term negative evidence for post-infarction stem cell treatment.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b254da630e51","type":"article","url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","title":"Robuustheid van SGLT2-remmer HF-trials: evaluatie","title_en":"Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13785","source_url":"https://doi.org/10.1002/ehf2.13785","authors":["Muhammad Shariq Usman","Muhammad Shahzeb Khan","Gregg C Fonarow","Stephen J Greene","Tim Friede","Muthiah Vaduganathan","Gerasimos Filippatos","Andrew J Stewart Coats","Stefan D Anker","Javed Butler"],"significance":5,"published":"2022-04-01","source_date":"2022-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This evaluation confirmed the robustness of outcomes across SGLT2 inhibitor heart failure trials, showing consistent benefit regardless of analytical methods and sensitivity analyses used.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b4374bf3b5b3","type":"article","url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","title":"Amphilimus versus zotarolimus stents bij diabetes: SUGAR gerandomiseerde trial","title_en":"Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["select-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab790","source_url":"https://doi.org/10.1093/eurheartj/ehab790","authors":["Rafael Romaguera","Pablo Salinas","Josep Gomez-Lara","Salvatore Brugaletta","Antonio Gómez-Menchero","Miguel A Romero","Sergio García-Blas","Raymundo Ocaranza","Pascual Bordes","Marcelo Jiménez Kockar","Neus Salvatella","Victor A Jiménez-Díaz","Mar Alameda","Ramiro Trillo","Dae Hyun Lee","Pedro Martín","María López-Benito","Alfonso Freites","Virginia Pascual-Tejerina","Felipe Hernández-Hernández","Bruno García Del Blanco","Mohsen Mohandes","Francisco Bosa","Eduardo Pinar","Gerard Roura","Josep Comin-Colet","Antonio Fernández-Ortiz","Carlos Macaya","Xavier Rossello","Manel Sabate","Stuart J Pocock","Joan A Gómez-Hospital"],"significance":6,"published":"2022-03-31","source_date":"2022-03-31","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The SUGAR randomized trial compared amphilimus-eluting with zotarolimus-eluting stents in diabetic patients with coronary disease, testing a newer polymer-free technology designed for improved healing in the diabetic vasculature.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"58acc797dd22","type":"article","url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","title":"Enkele of meervoudige arteriële CABG versus PCI bij drievaten/hoofdstam: meta-analyse","title_en":"Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab537","source_url":"https://doi.org/10.1093/eurheartj/ehab537","authors":["Piroze M Davierwala","Chao Gao","Daniel J F M Thuijs","Rutao Wang","Hironori Hara","Masafumi Ono","Thilo Noack","Scot Garg","Neil O'leary","Milan Milojevic","Arie Pieter Kappetein","Marie-Claude Morice","Michael J Mack","Robert-Jan van Geuns","David R Holmes","Mario Gaudino","David P Taggart","Yoshinobu Onuma","Friedrich Wilhelm Mohr","Patrick W Serruys"],"significance":7,"published":"2022-03-31","source_date":"2022-03-31","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis compared single and multiple arterial CABG with PCI for three-vessel or left main coronary disease, showing that multiple arterial grafts provide the best long-term survival while PCI carries higher revascularization rates.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5befd3ddfb97","type":"article","url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","title":"AF-screening bij ouderen in de huisartsenpraktijk: VITAL-AF gerandomiseerde trial","title_en":"Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057014","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057014","authors":["Steven A Lubitz","Steven J Atlas","Jeffrey M Ashburner","Ana T Trisini Lipsanopoulos","Leila H Borowsky","Wyliena Guan","Shaan Khurshid","Patrick T Ellinor","Yuchiao Chang","David D McManus","Daniel E Singer"],"significance":7,"published":"2022-03-29","source_date":"2022-03-29","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"The VITAL-AF pragmatic trial of point-of-care AF screening during primary care visits showed that single-time-point screening modestly increases AF detection but has limited yield in the broader older adult population.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3b5a213b177","type":"article","url":"https://hartvaat.nl/2022/03/29/insuline-voorkomt-hypercholesterolemie-via-12-gehydroxyleerde-galzuren/","title":"Insuline voorkomt hypercholesterolemie via 12α-gehydroxyleerde galzuren","title_en":"Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","statines"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.045373","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.045373","authors":["Ivana Semova","Amy E Levenson","Joanna Krawczyk","Kevin Bullock","Mary E Gearing","Alisha V Ling","Kathryn A Williams","Ji Miao","Stuart S Adamson","Dong-Ju Shin","Satyapal Chahar","Mark J Graham","Rosanne M Crooke","Lee R Hagey","David Vicent","Sarah D de Ferranti","Srividya Kidambi","Clary B Clish","Sudha B Biddinger"],"significance":5,"published":"2022-03-29","source_date":"2022-03-29","image":"","kennis":[],"congress":"","summary_en":"This mechanistic study showed that insulin prevents hypercholesterolemia by suppressing 12α-hydroxylated bile acids, revealing a molecular link between insulin deficiency and the extreme cardiovascular risk in type 1 diabetes.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c7326d955da9","type":"article","url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","title":"Pelacarsen op Lp(a)-cholesterol en gecorrigeerd LDL-cholesterol","title_en":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["ezetimibe","ldl-cholesterol","lipide-aferese","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","pelacarsen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.12.032","source_url":"https://doi.org/10.1016/j.jacc.2021.12.032","authors":["Calvin Yeang","Ewa Karwatowska-Prokopczuk","Fei Su","Brian Dinh","Shuting Xia","Joseph L Witztum","Sotirios Tsimikas"],"significance":7,"published":"2022-03-22","source_date":"2022-03-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This analysis quantified the effect of pelacarsen on Lp(a)-associated cholesterol and its impact on corrected LDL cholesterol measurements, demonstrating that apparent LDL cholesterol includes a substantial Lp(a)-derived component that should be accounted for in treatment decisions.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"30d4dfc5dbd0","type":"article","url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","title":"MRI-hersenlaesies en cognitie bij AF na LAA-ablatie","title_en":"MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056320","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056320","authors":["Karl Georg Haeusler","Felizitas A Eichner","Peter U Heuschmann","Jochen B Fiebach","Tobias Engelhorn","Benjamin Blank","David Callans","Arif Elvan","Massimo Grimaldi","Jim Hansen","Gerhard Hindricks","Hussein R Al-Khalidi","Lluis Mont","Jens Cosedis Nielsen","Jonathan P Piccini","Ulrich Schotten","Sakis Themistoclakis","Johan Vijgen","Luigi Di Biase","Paulus Kirchhof"],"significance":5,"published":"2022-03-22","source_date":"2022-03-22","image":"","kennis":[],"congress":"","summary_en":"This study assessed MRI-detected brain lesions and their association with cognitive function in AF patients undergoing left atrial catheter ablation, addressing the cerebral safety of this common arrhythmia procedure.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"472282216adf","type":"article","url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","title":"Vroege ritmecontrole bij AF met of zonder symptomen: EAST-AFNET 4","title_en":"Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab593","source_url":"https://doi.org/10.1093/eurheartj/ehab593","authors":["Stephan Willems","Katrin Borof","Axel Brandes","Günter Breithardt","A John Camm","Harry J G M Crijns","Lars Eckardt","Nele Gessler","Andreas Goette","Laurent M Haegeli","Hein Heidbuchel","Josef Kautzner","G André Ng","Renate B Schnabel","Anna Suling","Lukasz Szumowski","Sakis Themistoclakis","Panos Vardas","Isabelle C van Gelder","Karl Wegscheider","Paulus Kirchhof"],"significance":8,"published":"2022-03-21","source_date":"2022-03-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-en-hartfalen/"],"congress":"","summary_en":"This EAST-AFNET 4 analysis showed that early rhythm control improves outcomes in AF patients regardless of symptom status, expanding the indication beyond symptomatic patients. The finding challenged the guideline restriction of rhythm control to symptomatic AF.","created":"2026-07-03T10:29:40Z","updated":"2026-07-03T13:28:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eebbb2e3848d","type":"article","url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","title":"5-jaars iFR versus FFR-geleide PCI: DEFINE-FLAIR/iFR-SWEDEHEART","title_en":"5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.12.030","source_url":"https://doi.org/10.1016/j.jacc.2021.12.030","authors":["Matthias Götberg","Karolina Berntorp","Rebecca Rylance","Evald H Christiansen","Troels Yndigegn","Ingibjörg J Gudmundsdottir","Sasha Koul","Lennart Sandhall","Mikael Danielewicz","Lars Jakobsen","Sven-Erik Olsson","Hans Olsson","Elmir Omerovic","Fredrik Calais","Pontus Lindroos","Michael Maeng","Dimitrios Venetsanos","Stefan K James","Amra Kåregren","Jörg Carlsson","Jens Jensen","Ann-Charlotte Karlsson","David Erlinge","Ole Fröbert"],"significance":7,"published":"2022-03-15","source_date":"2022-03-15","image":"","kennis":[],"congress":"","summary_en":"Five-year results confirmed that iFR-guided PCI maintains noninferior outcomes compared with FFR-guided PCI over long-term follow-up, providing sustained evidence for the adenosine-free physiological assessment as a standard approach.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82bec070f8ea","type":"article","url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","title":"Leeftijd en uitkomsten van katheterablatie versus medicatie bij AF: CABANA","title_en":"Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055297","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055297","authors":["Tristram D Bahnson","Anna Giczewska","Daniel B Mark","Andrea M Russo","Kristi H Monahan","Hussein R Al-Khalidi","Adam P Silverstein","Jeanne E Poole","Kerry L Lee","Douglas L Packer"],"significance":6,"published":"2022-03-15","source_date":"2022-03-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/ritmestoornissen/katheterablatie-vt/"],"congress":"","summary_en":"This CABANA analysis showed that the benefit of catheter ablation versus medical therapy for AF varies by age, with younger patients potentially deriving greater benefit from ablation.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69a6a3a3c2df","type":"article","url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","title":"Periodieke repolarisatiedynamiek identificeert ICD-responders bij NICM: DANISH","title_en":"Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["iaso-dcm"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056464","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056464","authors":["Rune Boas","Nikolay Sappler","Lukas von Stülpnagel","Mathias Klemm","Ulrik Dixen","Jens Jakob Thune","Steen Pehrson","Lars Køber","Jens C Nielsen","Lars Videbæk","Jens Haarbo","Eva Korup","Niels Eske Bruun","Axel Brandes","Hans Eiskjær","Anna M Thøgersen","Berit T Philbert","Jesper Hastrup Svendsen","Jacob Tfelt-Hansen","Axel Bauer","Konstantinos D Rizas"],"significance":6,"published":"2022-03-08","source_date":"2022-03-08","image":"","kennis":[],"congress":"","summary_en":"This DANISH substudy showed that periodic repolarization dynamics, an ECG-based marker of sympathetic activity, identifies patients with nonischemic cardiomyopathy who benefit from prophylactic ICD implantation, improving patient selection.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"413d6d23a3b4","type":"article","url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","title":"Amulet versus Watchman voor LAA-sluiting: SWISS-APERO gerandomiseerde trial","title_en":"Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["linkerhartoorsluiting"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057859","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057859","authors":["Roberto Galea","Federico De Marco","Nicolas Meneveau","Adel Aminian","Frédéric Anselme","Christoph Gräni","Adrian T Huber","Emmanuel Teiger","Xavier Iriart","Flora Babongo Bosombo","Dik Heg","Anna Franzone","Pascal Vranckx","Urs Fischer","Giovanni Pedrazzini","Francesco Bedogni","Lorenz Räber","Marco Valgimigli"],"significance":7,"published":"2022-03-08","source_date":"2022-03-08","image":"","kennis":[],"congress":"","summary_en":"The SWISS-APERO randomized trial compared the Amulet with the Watchman FLX device for percutaneous LAA closure, providing the first head-to-head comparison of these leading LAA occlusion technologies.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"601bce516b49","type":"article","url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","title":"Geleide versus potente P2Y12-therapie bij ACS: netwerkmeta-analyse van 61.898 patiënten","title_en":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab836","source_url":"https://doi.org/10.1093/eurheartj/ehab836","authors":["Mattia Galli","Stefano Benenati","Francesco Franchi","Fabiana Rollini","Davide Capodanno","Giuseppe Biondi-Zoccai","Giovanni Maria Vescovo","Larisa H Cavallari","Behnood Bikdeli","Jurrien Ten Berg","Roxana Mehran","Charles Michael Gibson","Filippo Crea","Naveen L Pereira","Dirk Sibbing","Dominick J Angiolillo"],"significance":8,"published":"2022-03-07","source_date":"2022-03-07","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This network meta-analysis of nearly 62,000 ACS patients compared guided de-escalation with potent P2Y12 inhibitor therapy, finding that guided approaches reduce bleeding without increasing ischemic events. The comprehensive analysis supported precision antiplatelet strategies as a superior alternative.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a93d2ccde82","type":"article","url":"https://hartvaat.nl/2022/03/02/kenmerken-van-patienten-met-atriale-high-rate-episodes-bij-icd-crt/","title":"Kenmerken van patiënten met atriale high-rate episodes bij ICD/CRT","title_en":"Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab186","source_url":"https://doi.org/10.1093/europace/euab186","authors":["Kazuo Miyazawa","Daniele Pastori","David T Martin","Wassim K Choucair","Jonathan L Halperin","Gregory Y H Lip"],"significance":5,"published":"2022-03-02","source_date":"2022-03-02","image":"","kennis":[],"congress":"","summary_en":"This analysis characterized patients with device-detected atrial high-rate episodes, identifying clinical features that distinguish AHRE patients from those with clinical AF and informing anticoagulation decisions.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39d4057c2269","type":"article","url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","title":"Frequentiecontrolemiddelen verschillen in preventie van AF-progressie","title_en":"Rate control drugs differ in the prevention of progression of atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["hartrevalidatie","lichamelijke-inactiviteit","primaire-preventie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab191","source_url":"https://doi.org/10.1093/europace/euab191","authors":["Tim Koldenhof","Petra E P J Wijtvliet","Nikki A H A Pluymaekers","Michiel Rienstra","Richard J Folkeringa","Patrick Bronzwaer","Arif Elvan","Jan Elders","Raymond Tukkie","Justin G L M Luermans","Sander M J van Kuijk","Jan G P Tijssen","Isabelle C van Gelder","Harry J G M Crijns","Robert G Tieleman"],"significance":6,"published":"2022-03-02","source_date":"2022-03-02","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/frequentiecontrole-af/"],"congress":"","summary_en":"This study showed that different rate control drugs (verapamil, beta-blockers, digoxin) have differential effects on preventing AF progression from paroxysmal to persistent, supporting verapamil as potentially protective against disease advancement.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"62b50ca2ec86","type":"article","url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","title":"Edoxaban 15 mg naar nierfunctie bij zeer oude AF: ELDERCARE subanalyse","title_en":"Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057190","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057190","authors":["Tetsuro Yoshida","Akihiro Nakamura","Junichi Funada","Mari Amino","Wataru Shimizu","Masayuki Fukuzawa","Saori Watanabe","Takuya Hayashi","Takeshi Yamashita","Ken Okumura","Masaharu Akao"],"significance":6,"published":"2022-03-01","source_date":"2022-03-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This ELDERCARE subanalysis confirmed that low-dose edoxaban (15 mg) maintains its favorable efficacy-safety profile across different levels of renal function in very elderly AF patients.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a20ff4a5a85e","type":"article","url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","title":"Orale antihypertensiva bij niet-ernstige zwangerschapshypertensie: netwerkmeta-analyse","title_en":"Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18415","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18415","authors":["Jeffrey N Bone","Akshdeep Sandhu","Edgardo D Abalos","Asma Khalil","Joel Singer","Sarina Prasad","Shazmeen Omar","Marianne Vidler","Peter von Dadelszen","Laura A Magee"],"significance":6,"published":"2022-03-01","source_date":"2022-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/centrale-middelen-hypertensie/"],"congress":"","summary_en":"This network meta-analysis evaluated oral antihypertensives for non-severe pregnancy hypertension, comparing different drug classes to identify the most effective and safe agents for blood pressure control during pregnancy.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7154764fed65","type":"article","url":"https://hartvaat.nl/2022/03/01/bloeddruk-hypertensie-en-risico-op-aortadissectie-j-sch-en-uk-biobank/","title":"Bloeddruk, hypertensie en risico op aortadissectie: J-SCH en UK Biobank","title_en":"Blood Pressure, Hypertension, and the Risk of Aortic Dissection Incidence and Mortality: Results From the J-SCH Study, the UK Biobank Study, and a Meta-Analysis of Cohort Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["abelacimab","bloeddrukbehandeling","ras-remmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056546","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056546","authors":["Makoto Hibino","Yoichiro Otaki","Elsa Kobeissi","Han Pan","Hiromi Hibino","Henock Taddese","Azeem Majeed","Subodh Verma","Tsuneo Konta","Kunihiro Yamagata","Shouichi Fujimoto","Kazuhiko Tsuruya","Ichiei Narita","Masato Kasahara","Yugo Shibagaki","Kunitoshi Iseki","Toshiki Moriyama","Masahide Kondo","Koichi Asahi","Tsuyoshi Watanabe","Tetsu Watanabe","Masafumi Watanabe","Dagfinn Aune"],"significance":7,"published":"2022-03-01","source_date":"2022-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This large prospective Japanese study demonstrated a continuous positive relationship between blood pressure levels and the risk of aortic dissection incidence and mortality, reinforcing the importance of blood pressure control for aortic protection.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db76c6e3de9f","type":"article","url":"https://hartvaat.nl/2022/02/22/temporaire-ruggenmergstimulatie-ter-preventie-van-postoperatief-af/","title":"Temporaire ruggenmergstimulatie ter preventie van postoperatief AF","title_en":"Temporary Spinal Cord Stimulation to Prevent Postcardiac Surgery Atrial Fibrillation: 30-Day Safety and Efficacy Outcomes.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["aspirine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.078","source_url":"https://doi.org/10.1016/j.jacc.2021.08.078","authors":["Alexander Romanov","Vladimir Lomivorotov","Alexander Chernyavskiy","Vladimir Murtazin","Elena Kliver","Dmitry Ponomarev","Igor Mikheenko","Alexander Yakovlev","Marina Yakovleva","Jonathan S Steinberg"],"significance":5,"published":"2022-02-22","source_date":"2022-02-22","image":"","kennis":[],"congress":"","summary_en":"This study tested temporary spinal cord stimulation for preventing post-cardiac surgery AF, exploring neuromodulation as a novel approach to this common post-operative complication.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc04ccf98425","type":"article","url":"https://hartvaat.nl/2022/02/19/faricimab-bij-diabetisch-maculaoedeem-met-verlengde-dosering-lancet/","title":"Faricimab bij diabetisch maculaoedeem met verlengde dosering: Lancet","title_en":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.","category":"preventie","category_label":"Preventie","professions":["internist"],"tags":["soul-trial"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(22)00018-6","source_url":"https://doi.org/10.1016/S0140-6736(22)00018-6","authors":["Charles C Wykoff","Francis Abreu","Anthony P Adamis","Karen Basu","David A Eichenbaum","Zdenka Haskova","Hugh Lin","Anat Loewenstein","Shaun Mohan","Ian A Pearce","Taiji Sakamoto","Patricio G Schlottmann","David Silverman","Jennifer K Sun","John A Wells","Jeffrey R Willis","Ramin Tadayoni"],"significance":6,"published":"2022-02-19","source_date":"2022-02-19","image":"","kennis":[],"congress":"","summary_en":"This Lancet trial of faricimab, a bispecific anti-VEGF/anti-angiopoietin-2 antibody, in diabetic macular edema showed efficacy with extended dosing up to every 16 weeks, reducing treatment burden for this common diabetic eye complication.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"175deea1f4be","type":"article","url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","title":"Finerenon CV en renale uitkomsten bij diabetes met CKD: FIDELITY gepoolde analyse","title_en":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","credence-trial","diabetes-en-hart","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","flow-trial","soul-trial","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab777","source_url":"https://doi.org/10.1093/eurheartj/ehab777","authors":["Rajiv Agarwal","Gerasimos Filippatos","Bertram Pitt","Stefan D Anker","Peter Rossing","Amer Joseph","Peter Kolkhof","Christina Nowack","Martin Gebel","Luis M Ruilope","George L Bakris"],"significance":9,"published":"2022-02-10","source_date":"2022-02-10","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"The FIDELITY pooled analysis combined FIDELIO-DKD and FIGARO-DKD data to demonstrate consistent cardiovascular and kidney benefits of finerenone across the full spectrum of CKD severity in patients with type 2 diabetes. This definitive analysis established finerenone's position in the cardiorenal protection armamentarium.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b76115c0faf1","type":"article","url":"https://hartvaat.nl/2022/02/10/propionaat-vermindert-atherosclerose-via-immuunregulatie-van-intestinaal-cholest/","title":"Propionaat vermindert atherosclerose via immuunregulatie van intestinaal cholesterolmetabolisme","title_en":"Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","pcsk9-remmers","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab644","source_url":"https://doi.org/10.1093/eurheartj/ehab644","authors":["Arash Haghikia","Friederike Zimmermann","Paul Schumann","Andrzej Jasina","Johann Roessler","David Schmidt","Philipp Heinze","Johannes Kaisler","Vanasa Nageswaran","Annette Aigner","Uta Ceglarek","Roodline Cineus","Ahmed N Hegazy","Emiel P C van der Vorst","Yvonne Döring","Christopher M Strauch","Ina Nemet","Valentina Tremaroli","Chinmay Dwibedi","Nicolle Kränkel","David M Leistner","Markus M Heimesaat","Stefan Bereswill","Geraldine Rauch","Ute Seeland","Oliver Soehnlein","Dominik N Müller","Ralf Gold","Fredrik Bäckhed","Stanley L Hazen","Aiden Haghikia","Ulf Landmesser"],"significance":6,"published":"2022-02-10","source_date":"2022-02-10","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that propionate, a short-chain fatty acid produced by gut bacteria, attenuates atherosclerosis through immune-dependent regulation of intestinal cholesterol metabolism, advancing the microbiome-cardiovascular connection.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6fdbda374461","type":"article","url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","title":"1-jaars CV-events bij restrictieve versus liberale transfusie na acuut MI: REALITY","title_en":"One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057909","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057909","authors":["Jose R Gonzalez-Juanatey","Gilles Lemesle","Etienne Puymirat","Gregory Ducrocq","Marine Cachanado","Joan Albert Arnaiz","Manuel Martínez-Sellés","Johanne Silvain","Albert Ariza-Solé","Emile Ferrari","Gonzalo Calvo","Nicolas Danchin","Cristina Avendano-Solá","Alexandra Rousseau","Eric Vicaut","Teba Gonzalez-Ferrero","Philippe Gabriel Steg","Tabassome Simon"],"significance":6,"published":"2022-02-08","source_date":"2022-02-08","image":"","kennis":[],"congress":"","summary_en":"One-year REALITY results confirmed that a restrictive transfusion strategy (hemoglobin threshold <8 g/dL) is safe and noninferior to liberal transfusion after acute MI, with sustained comparable outcomes.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8f84823da58e","type":"article","url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","title":"Stress cardiale biomarkers en CV/renale uitkomsten bij canagliflozine","title_en":"Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.11.027","source_url":"https://doi.org/10.1016/j.jacc.2021.11.027","authors":["Muthiah Vaduganathan","Naveed Sattar","Jialin Xu","Javed Butler","Kenneth W Mahaffey","Bruce Neal","Wayne Shaw","Norman Rosenthal","Michael Pfeifer","Michael K Hansen","James L Januzzi"],"significance":5,"published":"2022-02-08","source_date":"2022-02-08","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/"],"congress":"","summary_en":"This analysis showed that stress cardiac biomarkers (NT-proBNP, troponin) predict both cardiovascular-renal outcomes and response to canagliflozin in diabetes, supporting biomarker-guided SGLT2 inhibitor therapy.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dd7b3417bfff","type":"article","url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","title":"Antitrombotische therapie bij AF na ACS of PCI: JACC overzicht","title_en":"Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.11.035","source_url":"https://doi.org/10.1016/j.jacc.2021.11.035","authors":["Ralf E Harskamp","Alexander C Fanaroff","Renato D Lopes","Daniel M Wojdyla","Shaun G Goodman","Laine E Thomas","Ronald Aronson","Stephan Windecker","Roxana Mehran","Christopher B Granger","John H Alexander"],"significance":7,"published":"2022-02-08","source_date":"2022-02-08","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This JACC overview of antithrombotic therapy in AF patients after ACS or PCI synthesized the evidence from AUGUSTUS, RE-DUAL PCI, and ENTRUST-AF PCI, confirming dual therapy with a DOAC and P2Y12 inhibitor as the preferred approach.","created":"2026-07-03T10:29:38Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e731da2ff404","type":"article","url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","title":"Finerenon vermindert incident HF bij CKD met diabetes: FIDELITY","title_en":"Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","chronische-nierziekte","credence-trial","dapagliflozine","diabetes-en-hart","diabetische-nefropathie","fidelio-dkd","fidelity","figaro-dkd","finerenon-hartfalen-nierziekte","ijzertekort","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057983","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057983","authors":["Gerasimos Filippatos","Stefan D Anker","Rajiv Agarwal","Luis M Ruilope","Peter Rossing","George L Bakris","Christoph Tasto","Amer Joseph","Peter Kolkhof","Andrea Lage","Bertram Pitt"],"significance":8,"published":"2022-02-08","source_date":"2022-02-08","image":"","kennis":[],"congress":"","summary_en":"This FIDELITY pooled analysis demonstrated that finerenone reduces the risk of new-onset heart failure in patients with CKD and type 2 diabetes, adding heart failure prevention to the established renal and cardiovascular benefits of nonsteroidal mineralocorticoid receptor antagonism.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c5a8bffe204f","type":"article","url":"https://hartvaat.nl/2022/02/02/cryoballon-versus-rf-bij-persisterend-af-noorse-no-pers-af-gerandomiseerde-trial/","title":"Cryoballon versus RF bij persisterend AF: Noorse NO-PERS AF gerandomiseerde trial","title_en":"Cryoballoon vs. radiofrequency catheter ablation: insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab281","source_url":"https://doi.org/10.1093/europace/euab281","authors":["Li-Bin Shi","Ole Rossvoll","Pål Tande","Peter Schuster","Eivind Solheim","Jian Chen"],"significance":6,"published":"2022-02-02","source_date":"2022-02-02","image":"","kennis":[],"congress":"","summary_en":"The NO-PERS AF Norwegian randomized study compared cryoballoon with radiofrequency ablation specifically for persistent AF, providing head-to-head data in this more challenging arrhythmia phenotype.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"29c539ce823f","type":"article","url":"https://hartvaat.nl/2022/02/02/remote-monitoring-en-klinische-uitkomsten-bij-europese-hf-met-icd-langetermijn/","title":"Remote monitoring en klinische uitkomsten bij Europese HF met ICD: langetermijn","title_en":"Effect of remote monitoring on clinical outcomes in European heart failure patients with an implantable cardioverter-defibrillator: secondary results of the REMOTE-CIED randomized trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab221","source_url":"https://doi.org/10.1093/europace/euab221","authors":["Cheyenne S L Chiu","Ivy Timmermans","Henneke Versteeg","Edgar Zitron","Philippe Mabo","Susanne S Pedersen","Mathias Meine"],"significance":5,"published":"2022-02-02","source_date":"2022-02-02","image":"","kennis":[],"congress":"","summary_en":"This long-term analysis of remote monitoring in European heart failure patients with ICDs evaluated whether sustained RPM reduces clinical events and healthcare utilization over extended follow-up.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"10041c0f81c5","type":"article","url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","title":"Thuismonitoring temporele trends en baseline risico voor HF-voorspelling bij ICD","title_en":"Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab170","source_url":"https://doi.org/10.1093/europace/euab170","authors":["Antonio D'Onofrio","Francesco Solimene","Leonardo Calò","Valeria Calvi","Miguel Viscusi","Donato Melissano","Vitantonio Russo","Antonio Rapacciuolo","Andrea Campana","Fabrizio Caravati","Paolo Bonfanti","Gabriele Zanotto","Edoardo Gronda","Antonello Vado","Vittorio Calzolari","Giovanni Luca Botto","Massimo Zecchin","Luca Bontempi","Daniele Giacopelli","Alessio Gargaro","Luigi Padeletti"],"significance":5,"published":"2022-02-02","source_date":"2022-02-02","image":"","kennis":[],"congress":"","summary_en":"This study developed and validated an algorithm combining remote monitoring temporal trends from implanted defibrillators with baseline patient risk profiles to predict heart failure hospitalizations.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3578a7af8a6c","type":"article","url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","title":"Matige hypothermie versus normothermie bij cardiogene shock met VA-ECMO: JAMA HYPERION2","title_en":"Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.24776","source_url":"https://doi.org/10.1001/jama.2021.24776","authors":["Bruno Levy","Nicolas Girerd","Julien Amour","Emmanuel Besnier","Nicolas Nesseler","Julie Helms","Clément Delmas","Romain Sonneville","Catherine Guidon","Bertrand Rozec","Helène David","David Bougon","Oussama Chaouch","Oulehri Walid","Dupont Hervé","Nicolas Belin","Lucie Gaide-Chevronnay","Patrick Rossignol","Antoine Kimmoun","Kevin Duarte","Arthur S Slutsky","Daniel Brodie","Jean-Luc Fellahi","Alexandre Ouattara","Alain Combes"],"significance":7,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The HYPERION2 trial showed that moderate hypothermia did not improve 30-day mortality compared with normothermia in patients with cardiogenic shock receiving VA-ECMO, a negative result for temperature management in this setting.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"621cb998867d","type":"article","url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","title":"Economische uitkomsten van revalidatie bij ouderen met acuut HF: REHAB-HF","title_en":"Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["farmaco-economie","hartrevalidatie"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.4836","source_url":"https://doi.org/10.1001/jamacardio.2021.4836","authors":["Derek S Chew","Yanhong Li","Michel Zeitouni","David J Whellan","Dalane Kitzman","Robert J Mentz","Pamela Duncan","Amy M Pastva","Gordon R Reeves","M Benjamin Nelson","Haiying Chen","Shelby D Reed"],"significance":6,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":[],"congress":"","summary_en":"This REHAB-HF economic analysis showed that rehabilitation therapy in older acute heart failure patients is cost-effective, with the functional improvement translating to acceptable healthcare economic value.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c128f3c0ddb5","type":"article","url":"https://hartvaat.nl/2022/02/01/optimalisatie-van-trainingsrespons-voor-vrouwen-in-hartrevalidatie-jama-cardiolo/","title":"Optimalisatie van trainingsrespons voor vrouwen in hartrevalidatie: JAMA Cardiology","title_en":"Optimizing Training Response for Women in Cardiac Rehabilitation: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["atleten","farmaco-economie","gepersonaliseerde-geneeskunde","hartrevalidatie","ouderen","pathfinder-trial","secundaire-preventie","vrouwen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.4822","source_url":"https://doi.org/10.1001/jamacardio.2021.4822","authors":["Sherrie Khadanga","Patrick D Savage","Anton Pecha","Jason Rengo","Philip A Ades"],"significance":6,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that optimizing training intensity and modality specifically for women in cardiac rehabilitation significantly improves peak aerobic capacity, addressing the sex-based response gap in standard rehabilitation programs.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e056ce12034a","type":"article","url":"https://hartvaat.nl/2022/02/01/geindividualiseerde-triggerstudies-bij-paroxysmaal-af-jama-i-stop-afib/","title":"Geïndividualiseerde triggerstudies bij paroxysmaal AF: JAMA I-STOP-AFib","title_en":"Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.5010","source_url":"https://doi.org/10.1001/jamacardio.2021.5010","authors":["Gregory M Marcus","Madelaine Faulkner Modrow","Christopher H Schmid","Kathi Sigona","Gregory Nah","Jiabei Yang","Tzu-Chun Chu","Sean Joyce","Shiffen Gettabecha","Kelsey Ogomori","Vivian Yang","Xochitl Butcher","Mellanie True Hills","Debbe McCall","Kathleen Sciarappa","Ida Sim","Mark J Pletcher","Jeffrey E Olgin"],"significance":7,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":[],"congress":"","summary_en":"The I-STOP-AFib trial investigated whether individualized identification and avoidance of patient-reported AF triggers (alcohol, caffeine, exercise, sleep deprivation) reduces AF episode frequency, exploring a personalized behavioral approach to rhythm management.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8538749fa2b2","type":"article","url":"https://hartvaat.nl/2022/02/01/luseogliflozine-en-geschat-plasmavolume-bij-hfpef/","title":"Luseogliflozine en geschat plasmavolume bij HFpEF","title_en":"Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13683","source_url":"https://doi.org/10.1002/ehf2.13683","authors":["Mitsutaka Nakashima","Toru Miyoshi","Kentaro Ejiri","Hajime Kihara","Yoshiki Hata","Toshihiko Nagano","Atsushi Takaishi","Hironobu Toda","Seiji Nanba","Yoichi Nakamura","Satoshi Akagi","Satoru Sakuragi","Taro Minagawa","Yusuke Kawai","Nobuhiro Nishii","Soichiro Fuke","Masaki Yoshikawa","Kazufumi Nakamura","Hiroshi Ito"],"significance":5,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that luseogliflozin reduces estimated plasma volume in HFpEF patients, demonstrating the diuretic-natriuretic mechanism of SGLT2 inhibition in the preserved ejection fraction phenotype.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"00a61992503f","type":"article","url":"https://hartvaat.nl/2022/02/01/myocardiale-mechanica-bij-hypertensieve-zwangerschapsaandoeningen-meta-analyse/","title":"Myocardiale mechanica bij hypertensieve zwangerschapsaandoeningen: meta-analyse","title_en":"Myocardial Mechanics in Hypertensive Disorders of Pregnancy: a Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18123","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18123","authors":["Jamie M O'Driscoll","Veronica Giorgione","Jamie J Edwards","Jonathan D Wiles","Rajan Sharma","Baskaran Thilaganathan"],"significance":5,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis evaluated myocardial mechanics (global longitudinal strain) in hypertensive disorders of pregnancy, showing that GLS detects subclinical cardiac dysfunction even when ejection fraction appears preserved.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f914314a968","type":"article","url":"https://hartvaat.nl/2022/02/01/sekse-en-gender-in-crt-studies-systematische-review/","title":"Sekse en gender in CRT-studies: systematische review","title_en":"Integrating sex and gender in studies of cardiac resynchronization therapy: a systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13733","source_url":"https://doi.org/10.1002/ehf2.13733","authors":["Omar Dewidar","Irina Podinic","Victoria Barbeau","Dilan Patel","Alba Antequera","David Birnie","Vivian Welch","George A Wells"],"significance":5,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"This systematic review documented the underrepresentation and inconsistent reporting of sex and gender in cardiac resynchronization therapy studies, highlighting the need for sex-specific CRT evidence.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dfa67013e9c2","type":"article","url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","title":"CCTA-afgeleide FFR: prognostische waarde — meta-analyse","title_en":"Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["fractional-flow-reserve"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319773","source_url":"https://doi.org/10.1136/heartjnl-2021-319773","authors":["Bjarne L Nørgaard","Sara Gaur","Timothy A Fairbairn","Pam S Douglas","Jesper M Jensen","Manesh R Patel","Abdul R Ihdayhid","Brian S H Ko","Stephanie L Sellers","Jonathan Weir-McCall","Hitoshi Matsuo","Niels Peter R Sand","Kristian A Øvrehus","Campbell Rogers","Sarah Mullen","Koen Nieman","Erik Parner","Jonathon Leipsic","Jawdat Abdulla"],"significance":6,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-ct-angiografie/","https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"This meta-analysis evaluated the prognostic value of CT-derived fractional flow reserve (FFR-CT), showing that non-invasive physiological assessment of coronary stenoses predicts future cardiovascular events beyond anatomical assessment alone.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6b7ff9a253ea","type":"article","url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-geactualiseerde-evidence-report-2022/","title":"Screening op AF: USPSTF geactualiseerde evidence report 2022","title_en":"Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.21811","source_url":"https://doi.org/10.1001/jama.2021.21811","authors":["Leila C Kahwati","Gary N Asher","Zachary O Kadro","Susan Keen","Rania Ali","Emmanuel Coker-Schwimmer","Daniel E Jonas"],"significance":7,"published":"2022-01-25","source_date":"2022-01-25","image":"","kennis":[],"congress":"","summary_en":"This updated USPSTF evidence review evaluated current screening strategies for atrial fibrillation in asymptomatic adults, including wearable devices and single-lead ECG, assessing the evidence for population-level AF screening programs.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"952715e5f2c9","type":"article","url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","title":"Screening op AF: USPSTF aanbeveling 2022","title_en":"Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.23732","source_url":"https://doi.org/10.1001/jama.2021.23732","authors":["Karina W Davidson","Michael J Barry","Carol M Mangione","Michael Cabana","Aaron B Caughey","Esa M Davis","Katrina E Donahue","Chyke A Doubeni","John W Epling","Martha Kubik","Li Li","Gbenga Ogedegbe","Lori Pbert","Michael Silverstein","James Stevermer","Chien-Wen Tseng","John B Wong"],"significance":8,"published":"2022-01-25","source_date":"2022-01-25","image":"","kennis":[],"congress":"","summary_en":"The 2022 USPSTF reaffirmed the insufficient evidence ('I' statement) for ECG screening for atrial fibrillation in asymptomatic older adults, despite advancing wearable technology, due to the lack of randomized trials demonstrating that screening-detected AF treatment improves outcomes.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"838d5faab644","type":"article","url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","title":"DOAC's versus warfarine bij AF: patiënt-niveau netwerkmeta-analyse van gerandomiseerde trials","title_en":"Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulatie-kwetsbare-ouderen","doacs"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056355","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056355","authors":["Anthony P Carnicelli","Hwanhee Hong","Stuart J Connolly","John Eikelboom","Robert P Giugliano","David A Morrow","Manesh R Patel","Lars Wallentin","John H Alexander","M Cecilia Bahit","Alexander P Benz","Erin A Bohula","Tze-Fan Chao","Leanne Dyal","Michael Ezekowitz","Keith A A Fox","Baris Gencer","Jonathan L Halperin","Ziad Hijazi","Stefan H Hohnloser","Kaiyuan Hua","Elaine Hylek","Eri Toda Kato","Julia Kuder","Renato D Lopes","Kenneth W Mahaffey","Jonas Oldgren","Jonathan P Piccini","Christian T Ruff","Jan Steffel","Daniel Wojdyla","Christopher B Granger"],"significance":9,"published":"2022-01-25","source_date":"2022-01-25","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This patient-level network meta-analysis of all four DOACs versus warfarin in atrial fibrillation confirmed the class-wide superiority of DOACs for stroke prevention with less intracranial hemorrhage. The analysis also provided the first robust head-to-head indirect comparisons between individual DOACs.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7012293817ce","type":"article","url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","title":"2021 ACC/AHA/SCAI richtlijn voor coronaire revascularisatie: executive summary","title_en":"2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.09.005","source_url":"https://doi.org/10.1016/j.jacc.2021.09.005","authors":["Jennifer S Lawton","Jacqueline E Tamis-Holland","Sripal Bangalore","Eric R Bates","Theresa M Beckie","James M Bischoff","John A Bittl","Mauricio G Cohen","J Michael DiMaio","Creighton W Don","Stephen E Fremes","Mario F Gaudino","Zachary D Goldberger","Michael C Grant","Jang B Jaswal","Paul A Kurlansky","Roxana Mehran","Thomas S Metkus","Lorraine C Nnacheta","Sunil V Rao","Frank W Sellke","Garima Sharma","Celina M Yong","Brittany A Zwischenberger"],"significance":10,"published":"2022-01-18","source_date":"2022-01-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"The 2021 ACC/AHA/SCAI coronary revascularization guideline executive summary integrated evidence from ISCHEMIA, EXCEL, NOBLE, and contemporary trials to update recommendations for PCI versus CABG decision-making. The document emphasized heart team consultation, functional ischemia testing, and patient-centered shared decision-making for complex coronary disease.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"332b27df6b1b","type":"article","url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","title":"Magnetisch gecontroleerde capsule-endoscopie voor antiplaatjestherapie GI-schade","title_en":"Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.10.028","source_url":"https://doi.org/10.1016/j.jacc.2021.10.028","authors":["Yaling Han","Zhuan Liao","Yi Li","Xianxian Zhao","Shuren Ma","Dan Bao","Miaohan Qiu","Jie Deng","Jinhai Wang","Peng Qu","Chunmeng Jiang","Shaobin Jia","Shaoqi Yang","Leisheng Ru","Jia Feng","Wei Gao","Yonghui Huang","Ling Tao","Ying Han","Kan Yang","Xiaoyan Wang","Wenjuan Zhang","Bangmao Wang","Yue Li","Youlin Yang","Junxia Li","Jiangqiu Sheng","Yitong Ma","Min Cui","Sicong Ma","Xiaozeng Wang","Zhaoshen Li","Gregg W Stone"],"significance":5,"published":"2022-01-18","source_date":"2022-01-18","image":"","kennis":[],"congress":"","summary_en":"This study used magnetically controlled capsule endoscopy to non-invasively assess antiplatelet therapy-induced gastrointestinal injury, providing a patient-friendly method for detecting subclinical GI damage.","created":"2026-07-03T10:29:36Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"594029179c19","type":"article","url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","title":"FFR-geleide PCI versus CABG: NEJM FAME 3","title_en":"Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2112299","source_url":"https://doi.org/10.1056/NEJMoa2112299","authors":["William F Fearon","Frederik M Zimmermann","Bernard De Bruyne","Zsolt Piroth","Albert H M van Straten","Laszlo Szekely","Giedrius Davidavičius","Gintaras Kalinauskas","Samer Mansour","Rajesh Kharbanda","Nikolaos Östlund-Papadogeorgos","Adel Aminian","Keith G Oldroyd","Nawwar Al-Attar","Nikola Jagic","Jan-Henk E Dambrink","Petr Kala","Oskar Angerås","Philip MacCarthy","Olaf Wendler","Filip Casselman","Nils Witt","Kreton Mavromatis","Steven E S Miner","Jaydeep Sarma","Thomas Engstrøm","Evald H Christiansen","Pim A L Tonino","Michael J Reardon","Di Lu","Victoria Y Ding","Yuhei Kobayashi","Mark A Hlatky","Kenneth W Mahaffey","Manisha Desai","Y Joseph Woo","Alan C Yeung","Nico H J Pijls"],"significance":9,"published":"2022-01-13","source_date":"2022-01-13","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The FAME 3 trial showed that FFR-guided PCI was not noninferior to CABG for the composite of death, MI, stroke, or repeat revascularization at 1 year in patients with three-vessel coronary artery disease. The result reinforced CABG as the preferred strategy for extensive multivessel disease.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"898f5a2d3d46","type":"article","url":"https://hartvaat.nl/2022/01/13/risicofactoren-voor-type-1-en-type-2-mi/","title":"Risicofactoren voor type 1 en type 2 MI","title_en":"Risk factors for type 1 and type 2 myocardial infarction.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab581","source_url":"https://doi.org/10.1093/eurheartj/ehab581","authors":["Ryan Wereski","Dorien M Kimenai","Anda Bularga","Caelan Taggart","David J Lowe","Nicholas L Mills","Andrew R Chapman"],"significance":6,"published":"2022-01-13","source_date":"2022-01-13","image":"","kennis":[],"congress":"","summary_en":"This study identified distinct risk factor profiles for type 1 versus type 2 myocardial infarction, showing that while type 1 MI is driven by traditional atherosclerotic risk factors, type 2 MI is associated with non-cardiac comorbidities.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ca826f4dc6b8","type":"article","url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","title":"4-jaars LAA-sluiting versus niet-warfarine OAC bij AF","title_en":"4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.10.023","source_url":"https://doi.org/10.1016/j.jacc.2021.10.023","authors":["Pavel Osmancik","Dalibor Herman","Petr Neuzil","Pavel Hala","Milos Taborsky","Petr Kala","Martin Poloczek","Josef Stasek","Ludek Haman","Marian Branny","Jan Chovancik","Pavel Cervinka","Jiri Holy","Tomas Kovarnik","David Zemanek","Stepan Havranek","Vlastimil Vancura","Petr Peichl","Petr Tousek","Veronika Lekesova","Jiri Jarkovsky","Martina Novackova","Klara Benesova","Petr Widimsky","Vivek Y Reddy"],"significance":7,"published":"2022-01-04","source_date":"2022-01-04","image":"","kennis":[],"congress":"","summary_en":"Four-year PRAGUE-17 results confirmed that left atrial appendage closure is noninferior to DOAC therapy for AF-related stroke prevention, providing the longest-term randomized comparison of structural versus pharmacological stroke prevention using contemporary anticoagulants.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9a655a59e50","type":"article","url":"https://hartvaat.nl/2022/01/04/sglt2-remmers-en-plotse-hartdood-ventriculaire-aritmie-meta-analyse/","title":"SGLT2-remmers en plotse hartdood/ventriculaire aritmie: meta-analyse","title_en":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab177","source_url":"https://doi.org/10.1093/europace/euab177","authors":["Dimitrios Sfairopoulos","Nan Zhang","Yueying Wang","Ziliang Chen","Konstantinos P Letsas","Gary Tse","Guangping Li","Gregory Y H Lip","Tong Liu","Panagiotis Korantzopoulos"],"significance":7,"published":"2022-01-04","source_date":"2022-01-04","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"This meta-analysis found that SGLT2 inhibitors may reduce the risk of sudden cardiac death and ventricular arrhythmias in patients with type 2 diabetes and heart failure, suggesting an antiarrhythmic component to the cardiovascular benefit of SGLT2 inhibition.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2c06f8bce76b","type":"article","url":"https://hartvaat.nl/2022/01/04/enkele-freeze-cryoballonablatie-bij-af-ehra-systematische-review/","title":"Enkele freeze cryoballonablatie bij AF: EHRA systematische review","title_en":"Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab133","source_url":"https://doi.org/10.1093/europace/euab133","authors":["Michal Miroslaw Farkowski","Michal Karlinski","Sergio Barra","Rui Providencia","Dominik Golicki","Mariusz Pytkowski","Ante Anic","Julian Kyoung Ryul Chun","Carlo de Asmundis","Deirdre Anne Lane","Serge Boveda"],"significance":5,"published":"2022-01-04","source_date":"2022-01-04","image":"","kennis":[],"congress":"","summary_en":"This EHRA systematic review confirmed that a single cryoballoon freeze application per vein achieves comparable efficacy and safety to the standard double-freeze protocol, supporting procedural simplification for AF ablation.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"125bfe1d2791","type":"article","url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","title":"Sacubitril/valsartan bij gevorderd HFrEF: JAMA Cardiology LIFE gerandomiseerde trial","title_en":"Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["answer-hf","dapa-hf","sacubitril-valsartan","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.4567","source_url":"https://doi.org/10.1001/jamacardio.2021.4567","authors":["Douglas L Mann","Michael M Givertz","Justin M Vader","Randall C Starling","Palak Shah","Steven E McNulty","Kevin J Anstrom","Kenneth B Margulies","Michael S Kiernan","Claudius Mahr","Divya Gupta","Margaret M Redfield","Anuradha Lala","Gregory D Lewis","Adam D DeVore","Patrice Desvigne-Nickens","Adrian F Hernandez","Eugene Braunwald"],"significance":7,"published":"2022-01-01","source_date":"2022-01-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"The LIFE trial showed that sacubitril-valsartan in patients with advanced (NYHA class IV) HFrEF is safe but does not provide significant clinical benefit beyond standard RAAS inhibition, defining the limits of ARNI therapy in end-stage heart failure.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68329be68ca9","type":"article","url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","title":"Omecamtiv mecarbil bij ernstig HF: GALACTIC-HF post-hoc analyse","title_en":"Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.4027","source_url":"https://doi.org/10.1001/jamacardio.2021.4027","authors":["G Michael Felker","Scott D Solomon","Brian Claggett","Rafael Diaz","John J V McMurray","Marco Metra","Inder Anand","Marisa G Crespo-Leiro","Ulf Dahlström","Eva Goncalvesova","Jonathan G Howlett","Peter MacDonald","Alexander Parkhomenko","János Tomcsányi","Siddique A Abbasi","Stephen B Heitner","Thomas Hucko","Stuart Kupfer","Fady I Malik","John R Teerlink"],"significance":6,"published":"2022-01-01","source_date":"2022-01-01","image":"","kennis":[],"congress":"","summary_en":"This GALACTIC-HF post-hoc analysis showed that omecamtiv mecarbil provides the greatest absolute benefit in patients with the most severe heart failure (lowest EF, highest NT-proBNP), identifying the target population for cardiac myosin activation.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3ba4a24e7de8","type":"article","url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","title":"Farmacologische hypertensiebehandeling bij volwassenen: WHO-richtlijn samenvatting","title_en":"Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","bloeddrukbehandeling","ras-remmers","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18192","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18192","authors":["Akram Al-Makki","Donald DiPette","Paul K Whelton","M Hassan Murad","Reem A Mustafa","Shrish Acharya","Hind Mamoun Beheiry","Beatriz Champagne","Kenneth Connell","Marie Therese Cooney","Nnenna Ezeigwe","Thomas Andrew Gaziano","Agaba Gidio","Patricio Lopez-Jaramillo","Unab I Khan","Vindya Kumarapeli","Andrew E Moran","Margaret Mswema Silwimba","Brian Rayner","Apichard Sukonthasan","Jing Yu","Nizal Saraffzadegan","K Srinath Reddy","Taskeen Khan"],"significance":9,"published":"2022-01-01","source_date":"2022-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The WHO executive summary on pharmacological hypertension treatment provided practical, globally applicable recommendations including treatment initiation thresholds, drug class selection, and follow-up strategies for resource-limited settings where the burden of uncontrolled hypertension is greatest.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2e3e7e8ef8c1","type":"article","url":"https://hartvaat.nl/2022/01/01/sglt2-remmers-over-het-cv-ziektespectrum-overzicht/","title":"SGLT2-remmers over het CV-ziektespectrum: overzicht","title_en":"Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319185","source_url":"https://doi.org/10.1136/heartjnl-2021-319185","authors":["Gaurav S Gulsin","Matthew P M Graham-Brown","Iain B Squire","Melanie J Davies","Gerry P McCann"],"significance":7,"published":"2022-01-01","source_date":"2022-01-01","image":"","kennis":[],"congress":"","summary_en":"This review summarized the cardiovascular benefits of SGLT2 inhibitors across the full spectrum of diseases — type 2 diabetes, heart failure (HFrEF and HFpEF), and CKD — providing a unified perspective on their therapeutic versatility.","created":"2026-07-03T10:29:35Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9883cb407c01","type":"article","url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","title":"Telomeerlengte en mortaliteit bij chronisch hartfalen","title_en":"Telomere length is independently associated with all-cause mortality in chronic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-318654","source_url":"https://doi.org/10.1136/heartjnl-2020-318654","authors":["Simon P R Romaine","Matthew Denniff","Veryan Codd","Mintu Nath","Andrea Koekemoer","Stefan D Anker","John G Cleland","Gerasimos Filippatos","Daniel Levin","Marco Metra","Ify R Mordi","Wouter Ouwerkerk","Jozine M Ter Maaten","Dirk J van Veldhuisen","Faiez Zannad","Leong L Ng","Pim van der Harst","Chim C Lang","Adriaan A Voors","Christopher P Nelson","Nilesh J Samani"],"significance":5,"published":"2022-01-01","source_date":"2022-01-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that leucocyte telomere length, a marker of biological aging, is independently associated with all-cause mortality in chronic heart failure, adding a measure of cellular senescence to HF risk stratification.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a9580242a94a","type":"article","url":"https://hartvaat.nl/2021/12/30/dolutegravir-als-eerste-of-tweedelijnbehandeling-voor-hiv-1-bij-kinderen-nejm/","title":"Dolutegravir als eerste- of tweedelijnbehandeling voor HIV-1 bij kinderen: NEJM","title_en":"Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.","category":"cholesterol","category_label":"Cholesterol","professions":["internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2108793","source_url":"https://doi.org/10.1056/NEJMoa2108793","authors":["Anna Turkova","Ellen White","Hilda A Mujuru","Adeodata R Kekitiinwa","Cissy M Kityo","Avy Violari","Abbas Lugemwa","Tim R Cressey","Philippa Musoke","Ebrahim Variava","Mark F Cotton","Moherndran Archary","Thanyawee Puthanakit","Osee Behuhuma","Robin Kobbe","Steven B Welch","Mutsa Bwakura-Dangarembizi","Pauline Amuge","Elizabeth Kaudha","Linda Barlow-Mosha","Shafic Makumbi","Nastassja Ramsagar","Chaiwat Ngampiyaskul","Godfrey Musoro","Lorna Atwine","Afaaf Liberty","Victor Musiime","Dickson Bbuye","Grace M Ahimbisibwe","Suwalai Chalermpantmetagul","Shabinah Ali","Tatiana Sarfati","Ben Wynne","Clare Shakeshaft","Angela Colbers","Nigel Klein","Sarah Bernays","Yacine Saïdi","Alexandra Coelho","Tiziana Grossele","Alexandra Compagnucci","Carlo Giaquinto","Pablo Rojo","Deborah Ford","Diana M Gibb"],"significance":5,"published":"2021-12-30","source_date":"2021-12-30","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/"],"congress":"","summary_en":"This NEJM trial of dolutegravir in children with HIV is relevant to cardiology through the cardiovascular-metabolic interactions of antiretroviral therapy, including effects on lipids and glucose metabolism in the pediatric population.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f611f28b121c","type":"article","url":"https://hartvaat.nl/2021/12/30/chlorthalidon-bij-hypertensie-met-gevorderde-ckd-nejm-click/","title":"Chlorthalidon bij hypertensie met gevorderde CKD: NEJM CLICK","title_en":"Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2110730","source_url":"https://doi.org/10.1056/NEJMoa2110730","authors":["Rajiv Agarwal","Arjun D Sinha","Andrew E Cramer","Mary Balmes-Fenwick","Jazmyn H Dickinson","Fangqian Ouyang","Wanzhu Tu"],"significance":9,"published":"2021-12-30","source_date":"2021-12-30","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/"],"congress":"","summary_en":"The CLICK trial demonstrated that chlorthalidone effectively lowered blood pressure in patients with advanced CKD (eGFR 15-30 mL/min), a population traditionally thought unresponsive to thiazide diuretics. This evidence-changing result supported the use of thiazide-like diuretics even in severe kidney disease.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"01eca33a8611","type":"article","url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","title":"Angiografie na buitenziekenhuis-hartstilstand zonder ST-elevatie: NEJM TOMAHAWK","title_en":"Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2101909","source_url":"https://doi.org/10.1056/NEJMoa2101909","authors":["Steffen Desch","Anne Freund","Ibrahim Akin","Michael Behnes","Michael R Preusch","Thomas A Zelniker","Carsten Skurk","Ulf Landmesser","Tobias Graf","Ingo Eitel","Georg Fuernau","Hendrik Haake","Peter Nordbeck","Fabian Hammer","Stephan B Felix","Christian Hassager","Thomas Engstrøm","Stephan Fichtlscherer","Jakob Ledwoch","Karsten Lenk","Michael Joner","Stephan Steiner","Christoph Liebetrau","Ingo Voigt","Uwe Zeymer","Michael Brand","Roland Schmitz","Jan Horstkotte","Claudius Jacobshagen","Janine Pöss","Mohamed Abdel-Wahab","Philipp Lurz","Alexander Jobs","Suzanne de Waha-Thiele","Denise Olbrich","Frank Sandig","Inke R König","Sabine Brett","Maren Vens","Kathrin Klinge","Holger Thiele"],"significance":9,"published":"2021-12-30","source_date":"2021-12-30","image":"","kennis":[],"congress":"","summary_en":"The TOMAHAWK trial confirmed that immediate coronary angiography did not improve 30-day survival compared with a delayed approach in patients resuscitated from out-of-hospital cardiac arrest without ST-segment elevation. Together with COACT, this definitively argued against routine emergent catheterization in this setting.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9235284c0d5","type":"article","url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","title":"10-jaars mortaliteit na PCI of CABG bij diabetes met complex coronairlijden","title_en":"Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab441","source_url":"https://doi.org/10.1093/eurheartj/ehab441","authors":["Rutao Wang","Patrick W Serruys","Chao Gao","Hironori Hara","Kuniaki Takahashi","Masafumi Ono","Hideyuki Kawashima","Neil O'leary","David R Holmes","Adam Witkowski","Nick Curzen","Francesco Burzotta","Stefan James","Robert-Jan van Geuns","Arie Pieter Kappetein","Marie-Angele Morel","Stuart J Head","Daniel J F M Thuijs","Piroze M Davierwala","Timothy O'Brien","Valentin Fuster","Scot Garg","Yoshinobu Onuma"],"significance":7,"published":"2021-12-28","source_date":"2021-12-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This 10-year comparison of PCI versus CABG in diabetic patients with complex coronary disease confirmed the long-term survival advantage of surgical revascularization, consistent with FREEDOM and reinforcing CABG as the preferred strategy in this population.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"692cf06547ae","type":"article","url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","title":"Sekseverschillen na CABG: gepoolde IPD analyse","title_en":"Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab504","source_url":"https://doi.org/10.1093/eurheartj/ehab504","authors":["Mario Gaudino","Antonino Di Franco","John H Alexander","Faisal Bakaeen","Natalia Egorova","Paul Kurlansky","Andreas Boening","Joanna Chikwe","Michelle Demetres","Philip J Devereaux","Anno Diegeler","Arnaldo Dimagli","Marcus Flather","Irbaz Hameed","Andre Lamy","Jennifer S Lawton","Wilko Reents","N Bryce Robinson","Katia Audisio","Mohamed Rahouma","Patrick W Serruys","Hironori Hara","David P Taggart","Leonard N Girardi","Stephen E Fremes","Umberto Benedetto"],"significance":7,"published":"2021-12-28","source_date":"2021-12-28","image":"","kennis":[],"congress":"","summary_en":"This pooled individual patient data analysis of sex differences after CABG found that women have higher perioperative complication rates but similar long-term survival compared with men, informing the ongoing discussion about sex-specific outcomes in cardiac surgery.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"36405524ce2f","type":"article","url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","title":"Langdurige omega-3 suppletie en AF-risico: meta-analyse van CV-trials","title_en":"Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","internist"],"tags":["voeding-hart"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055654","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055654","authors":["Baris Gencer","Luc Djousse","Omar T Al-Ramady","Nancy R Cook","JoAnn E Manson","Christine M Albert"],"significance":8,"published":"2021-12-21","source_date":"2021-12-21","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of randomized controlled trials confirmed that long-term marine omega-3 fatty acid supplementation is associated with a significantly increased risk of atrial fibrillation. The definitive safety signal raised concerns about the cardiovascular use of fish oil supplements.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f4edebd0f4ba","type":"article","url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","title":"IV ijzercarboxymaltose en cardiale reverse remodellering na CRT: IRON-CRT","title_en":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["ijzersuppletie","ijzertekort"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab411","source_url":"https://doi.org/10.1093/eurheartj/ehab411","authors":["Pieter Martens","Matthias Dupont","Jeroen Dauw","Petra Nijst","Lieven Herbots","Paul Dendale","Pieter Vandervoort","Liesbeth Bruckers","Wai Hong Wilson Tang","Wilfried Mullens"],"significance":7,"published":"2021-12-21","source_date":"2021-12-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/cardiale-remodellering/"],"congress":"","summary_en":"The IRON-CRT trial demonstrated that intravenous ferric carboxymaltose enhances cardiac reverse remodeling after CRT implantation in iron-deficient heart failure patients, suggesting that iron repletion and resynchronization have synergistic cardiac benefits.","created":"2026-07-03T10:29:34Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0f02c08bd26","type":"article","url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","title":"PCI met DES versus CABG bij hoofdstamlijden: Lancet PRECOMBAT 10-jaars","title_en":"Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)02334-5","source_url":"https://doi.org/10.1016/S0140-6736(21)02334-5","authors":["Marc S Sabatine","Brian A Bergmark","Sabina A Murphy","Patrick T O'Gara","Peter K Smith","Patrick W Serruys","A Pieter Kappetein","Seung-Jung Park","Duk-Woo Park","Evald H Christiansen","Niels R Holm","Per H Nielsen","Gregg W Stone","Joseph F Sabik","Eugene Braunwald"],"significance":8,"published":"2021-12-18","source_date":"2021-12-18","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"The PRECOMBAT 10-year follow-up showed no significant difference in the composite of death, MI, stroke, or revascularization between PCI with DES and CABG for left main coronary disease, though individual event rates favored CABG numerically. The long-term Korean data added to the revascularization debate.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa322482a9a8","type":"article","url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","title":"Daprodustat bij anemie bij niet-dialysepatiënten: NEJM","title_en":"Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","fidelio-dkd","flow-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2113380","source_url":"https://doi.org/10.1056/NEJMoa2113380","authors":["Ajay K Singh","Kevin Carroll","John J V McMurray","Scott Solomon","Vivekanand Jha","Kirsten L Johansen","Renato D Lopes","Iain C Macdougall","Gregorio T Obrador","Sushrut S Waikar","Christoph Wanner","David C Wheeler","Andrzej Więcek","Allison Blackorby","Borut Cizman","Alexander R Cobitz","Rich Davies","Tara L DiMino","Lata Kler","Amy M Meadowcroft","Lin Taft","Vlado Perkovic"],"significance":7,"published":"2021-12-16","source_date":"2021-12-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This NEJM trial showed that daprodustat effectively treats anemia in CKD patients not on dialysis, with cardiovascular safety comparable to darbepoetin alfa, expanding the oral HIF inhibitor option to the non-dialysis CKD population.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8314f8063c78","type":"article","url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","title":"Daprodustat bij anemie bij dialysepatiënten: NEJM","title_en":"Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","dapa-hf","flow-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2113379","source_url":"https://doi.org/10.1056/NEJMoa2113379","authors":["Ajay K Singh","Kevin Carroll","Vlado Perkovic","Scott Solomon","Vivekanand Jha","Kirsten L Johansen","Renato D Lopes","Iain C Macdougall","Gregorio T Obrador","Sushrut S Waikar","Christoph Wanner","David C Wheeler","Andrzej Więcek","Allison Blackorby","Borut Cizman","Alexander R Cobitz","Rich Davies","Jo Dole","Lata Kler","Amy M Meadowcroft","Xinyi Zhu","John J V McMurray"],"significance":7,"published":"2021-12-16","source_date":"2021-12-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This NEJM trial demonstrated that daprodustat, an oral HIF prolyl hydroxylase inhibitor, is noninferior to darbepoetin alfa for treating anemia in dialysis patients, with a favorable cardiovascular safety profile and the convenience of oral dosing.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1d91bf9ca435","type":"article","url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","title":"QFR-geleide coronaire interventie: Lancet FAVOR III China sham-gecontroleerd","title_en":"Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)02248-0","source_url":"https://doi.org/10.1016/S0140-6736(21)02248-0","authors":["Bo Xu","Shengxian Tu","Lei Song","Zening Jin","Bo Yu","Guosheng Fu","Yujie Zhou","Jian'an Wang","Yundai Chen","Jun Pu","Lianglong Chen","Xinkai Qu","Junqing Yang","Xuebo Liu","Lijun Guo","Chengxing Shen","Yaojun Zhang","Qi Zhang","Hongwei Pan","Xiaogang Fu","Jian Liu","Yanyan Zhao","Javier Escaned","Yang Wang","William F Fearon","Kefei Dou","Ajay J Kirtane","Yongjian Wu","Patrick W Serruys","Weixian Yang","William Wijns","Changdong Guan","Martin B Leon","Shubin Qiao","Gregg W Stone"],"significance":8,"published":"2021-12-11","source_date":"2021-12-11","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"The FAVOR III China trial demonstrated that angiographic quantitative flow ratio (QFR)-guided PCI significantly improved 1-year outcomes compared with angiography-guided PCI. The wire-free virtual physiological assessment offered a practical alternative to pressure wire-based FFR measurement.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d2563e2b36ce","type":"article","url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","title":"Finerenon bij nierziekte met diabetes type 2: NEJM FIGARO-DKD","title_en":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte","diabetes-en-hart","diabetes-type-2","diabetische-nefropathie","fidelio-dkd","figaro-dkd","finerenon-hartfalen-nierziekte","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2110956","source_url":"https://doi.org/10.1056/NEJMoa2110956","authors":["Bertram Pitt","Gerasimos Filippatos","Rajiv Agarwal","Stefan D Anker","George L Bakris","Peter Rossing","Amer Joseph","Peter Kolkhof","Christina Nowack","Patrick Schloemer","Luis M Ruilope"],"significance":10,"published":"2021-12-09","source_date":"2021-12-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"The FIGARO-DKD trial demonstrated that finerenone reduced cardiovascular events in patients with type 2 diabetes and a broader range of CKD severity than FIDELIO, including those with earlier-stage kidney disease and less severely elevated albuminuria. Together with FIDELIO, the FIDELITY program established finerenone's cardiorenal benefit across the full CKD spectrum in diabetes.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"03fc73711555","type":"article","url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","title":"AV-junctieablatie plus CRT bij permanent AF met smal QRS: APAF-CRT mortaliteitsanalyse","title_en":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab569","source_url":"https://doi.org/10.1093/eurheartj/ehab569","authors":["Michele Brignole","Francesco Pentimalli","Pietro Palmisano","Maurizio Landolina","Fabio Quartieri","Eraldo Occhetta","Leonardo Calò","Giuseppe Mascia","Lluis Mont","Kevin Vernooy","Vincent van Dijk","Cor Allaart","Laurent Fauchier","Maurizio Gasparini","Gianfranco Parati","Davide Soranna","Michiel Rienstra","Isabelle C Van Gelder"],"significance":8,"published":"2021-12-07","source_date":"2021-12-07","image":"","kennis":[],"congress":"","summary_en":"The APAF-CRT mortality analysis confirmed that AV junction ablation combined with cardiac resynchronization therapy significantly reduced all-cause mortality in patients with permanent atrial fibrillation, narrow QRS, and heart failure. The result established this strategy as a life-saving intervention in drug-refractory AF with HF.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9356bdad4e5b","type":"article","url":"https://hartvaat.nl/2021/12/07/minimaal-onderbroken-versus-continue-doac-bij-af-ablatie-meta-analyse/","title":"Minimaal onderbroken versus continue DOAC bij AF-ablatie: meta-analyse","title_en":"Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab175","source_url":"https://doi.org/10.1093/europace/euab175","authors":["Stijn P G van Vugt","Sjoerd W Westra","Rick H J A Volleberg","Gerjon Hannink","Rena Nakamura","Carlo de Asmundis","Gian-Battista Chierchia","Eliano P Navarese","Marc A Brouwer"],"significance":6,"published":"2021-12-07","source_date":"2021-12-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This meta-analysis compared minimally interrupted with continuous DOAC use during AF catheter ablation, showing similar safety and efficacy for both periprocedural anticoagulation strategies.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6457210cbaae","type":"article","url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","title":"GOLD FORCE multi-elektrode RF versus irrigated RF bij AF: gerandomiseerde trial","title_en":"Efficacy and safety of the GOLD FORCE multicentre randomized clinical trial: multielectrode phased radiofrequency vs. irrigated radiofrequency single-tip catheter with contact force ablation for treatment of symptomatic paroxysmal atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab168","source_url":"https://doi.org/10.1093/europace/euab168","authors":["Lisette I S Wintgens","Martijn N Klaver","Moniek Maarse","Stefan G Spitzer","Anke Langbein","Martin J Swaans","Vincent F Van Dijk","Jippe C Balt","Maurits C E F Wijffels","Jan G P Tijssen","Arif Elvan","Lucas V A Boersma"],"significance":5,"published":"2021-12-07","source_date":"2021-12-07","image":"","kennis":[],"congress":"","summary_en":"The GOLD FORCE trial compared multielectrode phased RF ablation with irrigated RF ablation for AF, evaluating a balloon-based multielectrode technology against the conventional single-tip approach.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"82f9e2229b04","type":"article","url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","title":"Posterieure pericardiotomie ter preventie van AF na hartchirurgie: Lancet PALACS","title_en":"Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","aspirine","pericarditis","secundaire-preventie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)02490-9","source_url":"https://doi.org/10.1016/S0140-6736(21)02490-9","authors":["Mario Gaudino","Tommaso Sanna","Karla V Ballman","N Bryce Robinson","Irbaz Hameed","Katia Audisio","Mohamed Rahouma","Antonino Di Franco","Giovanni J Soletti","Christopher Lau","Lisa Q Rong","Massimo Massetti","Marc Gillinov","Niv Ad","Pierre Voisine","J Michael DiMaio","Joanna Chikwe","Stephen E Fremes","Filippo Crea","John D Puskas","Leonard Girardi"],"significance":8,"published":"2021-12-04","source_date":"2021-12-04","image":"","kennis":[],"congress":"","summary_en":"The PALACS trial demonstrated that posterior left pericardiotomy, a simple 30-second surgical addition during cardiac surgery, significantly reduced the incidence of postoperative atrial fibrillation. The low-cost, low-risk intervention offered an elegant preventive strategy.","created":"2026-07-03T10:29:33Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c1aac3be3ae6","type":"article","url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","title":"Edoxaban versus VKA bij AF na TAVR: NEJM ENVISAGE-TAVI AF","title_en":"Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2111016","source_url":"https://doi.org/10.1056/NEJMoa2111016","authors":["Nicolas M Van Mieghem","Martin Unverdorben","Christian Hengstenberg","Helge Möllmann","Roxana Mehran","Diego López-Otero","Luis Nombela-Franco","Raul Moreno","Peter Nordbeck","Holger Thiele","Irene Lang","José L Zamorano","Fayaz Shawl","Masanori Yamamoto","Yusuke Watanabe","Kentaro Hayashida","Rainer Hambrecht","Felix Meincke","Pascal Vranckx","James Jin","Eric Boersma","Josep Rodés-Cabau","Patrick Ohlmann","Piera Capranzano","Hyo-Soo Kim","Thomas Pilgrim","Richard Anderson","Usman Baber","Anil Duggal","Petra Laeis","Hans Lanz","Cathy Chen","Marco Valgimigli","Roland Veltkamp","Shigeru Saito","George D Dangas"],"significance":8,"published":"2021-12-02","source_date":"2021-12-02","image":"","kennis":[],"congress":"","summary_en":"The ENVISAGE-TAVI AF trial showed that edoxaban was noninferior to vitamin K antagonists for the composite of net adverse clinical events in patients with AF after TAVR, but was associated with more gastrointestinal bleeding. The results informed DOAC use in the growing post-TAVR AF population.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7b034d9593a","type":"article","url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","title":"Ticagrelor monotherapie bij hoog bloedingsrisico na PCI: TWILIGHT-HBR","title_en":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab702","source_url":"https://doi.org/10.1093/eurheartj/ehab702","authors":["Javier Escaned","Davide Cao","Usman Baber","Johny Nicolas","Samantha Sartori","Zhongjie Zhang","George Dangas","Dominick J Angiolillo","Carlo Briguori","David J Cohen","Timothy Collier","Dariusz Dudek","Michael Gibson","Robert Gil","Kurt Huber","Upendra Kaul","Ran Kornowski","Mitchell W Krucoff","Vijay Kunadian","Shamir Mehta","David J Moliterno","E Magnus Ohman","Keith G Oldroyd","Gennaro Sardella","Samin K Sharma","Richard Shlofmitz","Giora Weisz","Bernhard Witzenbichler","Stuart Pocock","Roxana Mehran"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This TWILIGHT-HBR subanalysis confirmed that ticagrelor monotherapy after short DAPT significantly reduces bleeding in high-bleeding-risk patients undergoing PCI, with no increase in ischemic events, supporting the de-escalation approach in this vulnerable population.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b38c99055351","type":"article","url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","title":"Sacubitril/valsartan uitgebreide FDA-labeling: JAMA Cardiology implicaties","title_en":"Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.3651","source_url":"https://doi.org/10.1001/jamacardio.2021.3651","authors":["Muthiah Vaduganathan","Brian L Claggett","Stephen J Greene","Rahul Aggarwal","Ankeet S Bhatt","John J V McMurray","Gregg C Fonarow","Scott D Solomon"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This analysis estimated the potential impact of expanded FDA labeling for sacubitril-valsartan (including HF with LVEF above 40%) on the eligible US patient population, quantifying the implementation opportunity.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f40f6db5bbd8","type":"article","url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","title":"hs-troponine en natriuretische peptiden na intensieve BP-verlaging: SPRINT-biomarkers","title_en":"Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","nt-probnp","troponine"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.3187","source_url":"https://doi.org/10.1001/jamacardio.2021.3187","authors":["Jarett D Berry","Vijay Nambi","Walter T Ambrosius","Haiying Chen","Anthony A Killeen","Addison Taylor","Robert D Toto","Elsayed Z Soliman","John W McEvoy","Ambarish Pandey","Parag H Joshi","Stefan Blankenberg","Dalane W Kitzman","Christie M Ballantyne","James A de Lemos"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT biomarker analysis showed that elevated troponin and natriuretic peptide levels modify the benefit of intensive blood pressure treatment, with the highest-biomarker patients deriving the greatest cardiovascular risk reduction.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47fdeae0caed","type":"article","url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","title":"Ticagrelor monotherapie bij CKD na PCI: TWILIGHT-CKD","title_en":"Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab533","source_url":"https://doi.org/10.1093/eurheartj/ehab533","authors":["Giulio G Stefanini","Carlo Briguori","Davide Cao","Usman Baber","Samantha Sartori","Zhongjie Zhang","George Dangas","Dominick J Angiolillo","Shamir Mehta","David J Cohen","Timothy Collier","Dariusz Dudek","Javier Escaned","C Michael Gibson","Robert Gil","Kurt Huber","Upendra Kaul","Ran Kornowski","Mitchell W Krucoff","Vijay Kunadian","David J Moliterno","E Magnus Ohman","Keith G Oldroyd","Gennaro Sardella","Samin K Sharma","Richard Shlofmitz","Giora Weisz","Bernhard Witzenbichler","Stuart Pocock","Roxana Mehran"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This TWILIGHT-CKD subanalysis confirmed that ticagrelor monotherapy after PCI is safe and effective in patients with chronic kidney disease, extending the de-escalation strategy to the renally impaired population.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d98b9b4ed094","type":"article","url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","title":"Thin-cap fibroatheroom voorspelt events bij diabetes met normale FFR: COMBINE OCT-FFR","title_en":"Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab433","source_url":"https://doi.org/10.1093/eurheartj/ehab433","authors":["Elvin Kedhi","Balazs Berta","Tomasz Roleder","Renicus S Hermanides","Enrico Fabris","Alexander J J IJsselmuiden","Floris Kauer","Fernando Alfonso","Clemens von Birgelen","Javier Escaned","Cyril Camaro","Mark W Kennedy","Bruno Pereira","Michael Magro","Holger Nef","Sebastian Reith","Arif Al Nooryani","Fernando Rivero","Krzysztof Malinowski","Giuseppe De Luca","Hector Garcia Garcia","Juan F Granada","Wojciech Wojakowski"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The COMBINE OCT-FFR trial demonstrated that thin-cap fibroatheroma detected by OCT in diabetic patients with normal FFR predicts future cardiovascular events, supporting imaging-based vulnerable plaque identification for risk stratification beyond physiological assessment.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ecff8d041542","type":"article","url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","title":"Post-stenting FFR versus angiografie voor PCI-optimalisatie: TARGET-FFR","title_en":"Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab449","source_url":"https://doi.org/10.1093/eurheartj/ehab449","authors":["Damien Collison","Matthaios Didagelos","Muhammad Aetesam-Ur-Rahman","Samuel Copt","Robert McDade","Peter McCartney","Thomas J Ford","John McClure","Mitchell Lindsay","Aadil Shaukat","Paul Rocchiccioli","Richard Brogan","Stuart Watkins","Margaret McEntegart","Richard Good","Keith Robertson","Patrick O'Boyle","Andrew Davie","Adnan Khan","Stuart Hood","Hany Eteiba","Colin Berry","Keith G Oldroyd"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/"],"congress":"","summary_en":"The TARGET-FFR trial showed that post-stenting FFR-guided optimization did not significantly improve clinical outcomes compared with angiographic assessment alone, questioning the routine use of FFR to guide stent optimization.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c46968cd075b","type":"article","url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","title":"Cardiale mortaliteit bij electieve revascularisatie plus medicamenteus versus medicamenteus alleen: meta-analyse","title_en":"Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab246","source_url":"https://doi.org/10.1093/eurheartj/ehab246","authors":["Eliano P Navarese","Alexandra J Lansky","Dean J Kereiakes","Jacek Kubica","Paul A Gurbel","Diana A Gorog","Marco Valgimigli","Nick Curzen","David E Kandzari","Marc P Bonaca","Marc Brouwer","Julia Umińska","Milosz J Jaguszewski","Paolo Raggi","Ron Waksman","Martin B Leon","William Wijns","Felicita Andreotti"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-vs-cabg-afweging/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis showed that elective coronary revascularization plus medical therapy reduces cardiac mortality compared with medical therapy alone in stable coronary disease patients, a finding driven primarily by CABG rather than PCI trials.","created":"2026-07-03T10:29:32Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1255bea62afc","type":"article","url":"https://hartvaat.nl/2021/12/01/acute-aerobe-training-en-kortdurende-ambulante-bloeddrukreductie-bij-hypertensie/","title":"Acute aerobe training en kortdurende ambulante bloeddrukreductie bij hypertensie: meta-analyse","title_en":"Acute Aerobic Exercise Induces Short-Term Reductions in Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["hartrevalidatie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.18099","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.18099","authors":["Gonzalo Saco-Ledo","Pedro L Valenzuela","Miguel Ramírez-Jiménez","Javier S Morales","Adrián Castillo-García","James A Blumenthal","Luis M Ruilope","Alejandro Lucia"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This meta-analysis showed that acute aerobic exercise produces short-term reductions in ambulatory blood pressure in hypertensive patients, providing evidence for the immediate cardiovascular effects of physical activity.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T18:38:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"059fcd943dc5","type":"article","url":"https://hartvaat.nl/2021/12/01/intermitterend-levosimendan-bij-gevorderd-hf-laica-studie/","title":"Intermitterend levosimendan bij gevorderd HF: LAICA-studie","title_en":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13670","source_url":"https://doi.org/10.1002/ehf2.13670","authors":["Martín J García-González","Ana Aldea Perona","Antonio Lara Padron","José Luis Morales Rull","Manuel Martínez-Sellés","Manuel de Mora Martin","Javier López Díaz","Silvia López Fernandez","Pilar Ortiz Oficialdegui","Alejandro Jiménez Sosa"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"The LAICA study of intermittent levosimendan infusions in advanced heart failure evaluated whether repeated inotropic support reduces hospitalization and improves quality of life in patients with refractory disease.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3b9fb2b8080a","type":"article","url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-na-acuut-mi-meta-analyse/","title":"Sacubitril/valsartan na acuut MI: meta-analyse","title_en":"The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13677","source_url":"https://doi.org/10.1002/ehf2.13677","authors":["Bo Xiong","Dan Nie","Jun Qian","Yuanqing Yao","Gang Yang","Shunkang Rong","Que Zhu","Yun Du","Yonghong Jiang","Jing Huang"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This meta-analysis of sacubitril-valsartan after acute MI showed favorable effects on cardiac function and remodeling, though the clinical benefit beyond standard RAAS inhibition requires further study.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3d656ffcfbb6","type":"article","url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","title":"SGLT2-remmers en cardiale remodellering: meta-analyse van MRI-trials","title_en":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13645","source_url":"https://doi.org/10.1002/ehf2.13645","authors":["Nitish K Dhingra","Nikhil Mistry","Pankaj Puar","Raj Verma","Stefan Anker","C David Mazer","Subodh Verma"],"significance":7,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of randomized cardiac MRI studies confirmed that SGLT2 inhibitors reduce left ventricular mass and improve cardiac remodeling parameters, providing imaging evidence for the structural cardiac benefits of this drug class.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"553e4a2b7ddc","type":"article","url":"https://hartvaat.nl/2021/12/01/egfr-variabiliteit-en-uitkomsten-bij-real-world-hf/","title":"eGFR-variabiliteit en uitkomsten bij real-world HF","title_en":"Variability in estimated glomerular filtration rate and patients' outcomes in a real-world heart failure population.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["cystatine-c"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13557","source_url":"https://doi.org/10.1002/ehf2.13557","authors":["Tatsufumi Oka","Takayuki Hamano","Tomohito Ohtani","Akihiro Tanaka","Yohei Doi","Satoshi Yamaguchi","Masamitsu Senda","Yusuke Sakaguchi","Isao Matsui","Kei Nakamoto","Fusako Sera","Shungo Hikoso","Masami Nishino","Yasushi Sakata","Yoshitaka Isaka"],"significance":5,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that variability in eGFR predicts outcomes in a real-world heart failure population, establishing kidney function instability as a prognostic marker beyond baseline renal impairment.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b035797813d","type":"article","url":"https://hartvaat.nl/2021/12/01/lv-dimensies-en-cv-uitkomsten-bij-systolisch-hf-warcef/","title":"LV-dimensies en CV-uitkomsten bij systolisch HF: WARCEF","title_en":"Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13560","source_url":"https://doi.org/10.1002/ehf2.13560","authors":["Kazato Ito","Siyuan Li","Shunichi Homma","John L P Thompson","Richard Buchsbaum","Kenji Matsumoto","Stefan D Anker","Min Qian","Marco R Di Tullio"],"significance":5,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This WARCEF analysis showed that LV dimensions are independently associated with cardiovascular outcomes in systolic heart failure, supporting echocardiographic size parameters for risk stratification beyond ejection fraction.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f8813c7b981","type":"article","url":"https://hartvaat.nl/2021/12/01/empagliflozine-en-vaatfunctie-bij-chronisch-hf/","title":"Empagliflozine en vaatfunctie bij chronisch HF","title_en":"Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["anemie-ckd","answer-hf","chronische-nierziekte","dapa-hf","empagliflozine","emperor-trials"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13622","source_url":"https://doi.org/10.1002/ehf2.13622","authors":["Julie Kolwelter","Agnes Bosch","Susanne Jung","Lena Stabel","Dennis Kannenkeril","Christian Ott","Peter Bramlage","Mario Schiffer","Stephan Achenbach","Roland E Schmieder"],"significance":5,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that empagliflozin improves vascular function in chronic heart failure patients, providing mechanistic evidence that SGLT2 inhibitors reduce afterload through direct vascular effects.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7acfe0bf0e39","type":"article","url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","title":"SMS-strategie bij patiënten na recente HF-opname: studieontwerp","title_en":"Design of a multifaceted strategy based on automated text messaging in patients with recent heart failure admission.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13516","source_url":"https://doi.org/10.1002/ehf2.13516","authors":["Luis E Rohde","Conrado R Hoffmann Filho","Marciane M Rover","Eneida Rejane Rabelo-Silva","Letícia Lopez","Luiz C S Passos","Odilson M Silvestre","Silvia M Martins","José A de Figueiredo Neto","Fábio S Silveira","Manoel F Canesin","Marcus V Simões","Fábio Akio Nishijuka","Eduardo G Bertoldi","Luiz C Danzmann","Ricardo Mourilhe-Rocha","Ellen Hettwer Magedanz","Mauro Esteves","Fábio M de Castilho","Miguel M Fernandes-Silva","Luiz E F Ritt","Mariana Blacher","Rafael M Soares","Alexandre B Cavalcanti","Felix Ramirez"],"significance":4,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"The MESSAGE-HF study describes the design of a multicentre Brazilian trial evaluating an automated text messaging and telephone support telemonitoring strategy for patients recently hospitalised for heart failure with reduced ejection fraction.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fdb788f08894","type":"article","url":"https://hartvaat.nl/2021/12/01/hartfalen-en-atriumflutter-systematische-review/","title":"Hartfalen en atriumflutter: systematische review","title_en":"Heart failure and atrial flutter: a systematic review of current knowledge and practices.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13526","source_url":"https://doi.org/10.1002/ehf2.13526","authors":["Michael J Diamant","Jason G Andrade","Sean A Virani","Pardeep S Jhund","Mark C Petrie","Nathaniel M Hawkins"],"significance":5,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review addressed the under-studied relationship between heart failure and atrial flutter (as distinct from AF), identifying knowledge gaps in the management of this specific arrhythmia-HF combination.","created":"2026-07-03T10:29:31Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e7c1dafad9d0","type":"article","url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","title":"Baseline parameters en 1-jaars QoL bij HF na CRT-D: ESC HF","title_en":"Influence of baseline parameters on one-year physical, mental, and health-related quality of life in patients with heart failure and preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13593","source_url":"https://doi.org/10.1002/ehf2.13593","authors":["Judith Fitz","Frank Edelmann","Gerd Hasenfuß","Anja Sandek","Kathleen Nolte","Djawid Hashemi","Tobias D Trippel","Rolf Wachter","Christoph Herrmann-Lingen"],"significance":4,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":[],"congress":"","summary_en":"Post-hoc analysis of the Aldo-DHF trial identified baseline parameters that longitudinally influence one-year physical function, mental health, and overall quality of life in patients with HFpEF.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3e5fe10ff859","type":"article","url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","title":"Longechogeleide behandeling bij hemodialysepatiënten met hoog CV-risico: gerandomiseerde trial","title_en":"A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"Kidney international","doi":"10.1016/j.kint.2021.07.024","source_url":"https://doi.org/10.1016/j.kint.2021.07.024","authors":["Carmine Zoccali","Claudia Torino","Francesca Mallamaci","Pantelis Sarafidis","Aikaterini Papagianni","Robert Ekart","Radovan Hojs","Marian Klinger","Krzysztof Letachowicz","Danilo Fliser","Sarah Seiler-Mußler","Fabio Lizzi","Andrzej Wiecek","Agata Miskiewicz","Kostas Siamopoulos","Olga Balafa","Itzchak Slotki","Linda Shavit","Aristeidis Stavroulopoulos","Adrian Covic","Dimitrie Siriopol","Ziad A Massy","Alexandre Seidowsky","Yuri Battaglia","Alberto Martinez-Castelao","Carolina Polo-Torcal","Marie-Jeanne Coudert-Krier","Patrick Rossignol","Enrico Fiaccadori","Giuseppe Regolisti","Thierry Hannedouche","Thomas Bachelet","Kitty J Jager","Friedo W Dekker","Rocco Tripepi","Giovanni Tripepi","Luna Gargani","Rosa Sicari","Eugenio Picano","Gérard Michel London"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This randomized multicenter trial showed that lung ultrasound-guided treatment in chronic hemodialysis patients with high cardiovascular risk reduces pulmonary congestion, testing a practical imaging strategy for fluid management.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2be5bb3478d","type":"article","url":"https://hartvaat.nl/2021/12/01/predictieve-modellen-voor-cv-en-renale-uitkomsten-bij-diabetes-type-2-meta-analy/","title":"Predictieve modellen voor CV en renale uitkomsten bij diabetes type 2: meta-analyse","title_en":"Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","fidelio-dkd","figaro-dkd","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319243","source_url":"https://doi.org/10.1136/heartjnl-2021-319243","authors":["Tayler A Buchan","Abdullah Malik","Cynthia Chan","Jason Chambers","Yujin Suk","Jie Wei Zhu","Fang Zhou Ge","Le Ming Huang","Lina Abril Vargas","Qiukui Hao","Sheyu Li","Reem A Mustafa","Per Olav Vandvik","Gordon Guyatt","Farid Foroutan"],"significance":6,"published":"2021-12-01","source_date":"2021-12-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This systematic review evaluated predictive models for cardiovascular and kidney outcomes in type 2 diabetes, informing the BMJ Rapid Recommendations on SGLT2 inhibitor and GLP-1 agonist treatment decisions.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"738ee98b9fb3","type":"article","url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","title":"Voorspellers van AF-ontwikkeling bij embolic stroke of undetermined source: RE-SPECT ESUS","title_en":"Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055176","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055176","authors":["Maria Cecilia Bahit","Ralph L Sacco","J Donald Easton","Juliane Meyerhoff","Lisa Cronin","Eva Kleine","Claudia Grauer","Martina Brueckmann","Hans-Christoph Diener","Renato D Lopes","Michael Brainin","Phillippe Lyrer","Rolf Wachter","Tomas Segura","Christopher B Granger"],"significance":6,"published":"2021-11-30","source_date":"2021-11-30","image":"","kennis":[],"congress":"","summary_en":"This RE-SPECT ESUS analysis identified predictors of AF development in patients with embolic stroke of undetermined source, informing which ESUS patients should receive prolonged cardiac monitoring for occult AF detection.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12b01b4f99c5","type":"article","url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","title":"Bètablokkerstaken en functionele capaciteit bij HFpEF","title_en":"Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.073","source_url":"https://doi.org/10.1016/j.jacc.2021.08.073","authors":["Patricia Palau","Julia Seller","Eloy Domínguez","Clara Sastre","Jose María Ramón","Rafael de La Espriella","Enrique Santas","Gema Miñana","Vicent Bodí","Juan Sanchis","Alfonso Valle","F Javier Chorro","Pau Llácer","Antoni Bayés-Genís","Julio Núñez"],"significance":6,"published":"2021-11-23","source_date":"2021-11-23","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study showed that beta-blocker withdrawal in HFpEF patients improves chronotropic response and functional capacity, providing evidence that beta-blockers may be counterproductive in preserved ejection fraction heart failure.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"225ded743549","type":"article","url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","title":"Sacubitril/valsartan versus standaardtherapie op NT-proBNP en inspanningscapaciteit: JAMA PARALLAX","title_en":"Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"JAMA","doi":"10.1001/jama.2021.18463","source_url":"https://doi.org/10.1001/jama.2021.18463","authors":["Burkert Pieske","Rolf Wachter","Sanjiv J Shah","Abigail Baldridge","Peter Szeczoedy","Ghionul Ibram","Victor Shi","Ziqiang Zhao","Martin R Cowie"],"significance":7,"published":"2021-11-16","source_date":"2021-11-16","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"The PARALLAX trial demonstrated that sacubitril-valsartan reduces NT-proBNP levels compared with standard medical therapy in patients with heart failure and EF ≥40%, but did not significantly improve submaximal exercise capacity.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ce97d29cc13b","type":"article","url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","title":"Regionale en etnische invloeden op empagliflozine bij HFrEF: EMPEROR-Reduced","title_en":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["emperor-trials","hfref"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab360","source_url":"https://doi.org/10.1093/eurheartj/ehab360","authors":["Carolyn S P Lam","João Pedro Ferreira","Egon Pfarr","David Sim","Hiroyuki Tsutsui","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Stuart J Pocock","Naveed Sattar","Subodh Verma","Martina Brueckmann","Janet Schnee","Daniel Cotton","Faiez Zannad","Milton Packer"],"significance":5,"published":"2021-11-14","source_date":"2021-11-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis showed that empagliflozin's benefit in HFrEF is consistent across geographic regions and racial/ethnic groups, supporting universal SGLT2 inhibitor use regardless of population background.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d3c3831c093d","type":"article","url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","title":"Bloeddrukverlaging en risico op diabetes type 2: Lancet BPLTTC IPD meta-analyse","title_en":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01920-6","source_url":"https://doi.org/10.1016/S0140-6736(21)01920-6","authors":["Milad Nazarzadeh","Zeinab Bidel","Dexter Canoy","Emma Copland","Malgorzata Wamil","Jeannette Majert","Karl Smith Byrne","Johan Sundström","Koon Teo","Barry R Davis","John Chalmers","Carl J Pepine","Abbas Dehghan","Derrick A Bennett","George Davey Smith","Kazem Rahimi"],"significance":9,"published":"2021-11-13","source_date":"2021-11-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This BPLTTC meta-analysis revealed that pharmacological blood pressure lowering reduces the risk of new-onset type 2 diabetes, with an estimated 11% relative risk reduction per 5 mmHg systolic blood pressure decrease. The unexpected metabolic benefit adds a new dimension to the argument for aggressive blood pressure management.","created":"2026-07-03T10:29:30Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"84839401e677","type":"article","url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","title":"Tirzepatide versus insuline glargine bij diabetes type 2 met hoog CV-risico: Lancet SURPASS-4","title_en":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-type-2"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)02188-7","source_url":"https://doi.org/10.1016/S0140-6736(21)02188-7","authors":["Stefano Del Prato","Steven E Kahn","Imre Pavo","Govinda J Weerakkody","Zhengyu Yang","John Doupis","Diego Aizenberg","Alan G Wynne","Jeffrey S Riesmeyer","Robert J Heine","Russell J Wiese"],"significance":8,"published":"2021-11-13","source_date":"2021-11-13","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The SURPASS-4 trial showed that tirzepatide was superior to insulin glargine for HbA1c reduction and weight loss in patients with type 2 diabetes and increased cardiovascular risk, while demonstrating cardiovascular safety in this high-risk population.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9a876620b8b0","type":"article","url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","title":"Sacubitril/valsartan bij acuut MI: NEJM PARADISE-MI","title_en":"Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2104508","source_url":"https://doi.org/10.1056/NEJMoa2104508","authors":["Marc A Pfeffer","Brian Claggett","Eldrin F Lewis","Christopher B Granger","Lars Køber","Aldo P Maggioni","Douglas L Mann","John J V McMurray","Jean-Lucien Rouleau","Scott D Solomon","Philippe G Steg","Otavio Berwanger","Maja Cikes","Carmine G De Pasquale","Cara East","Alberto Fernandez","Karola Jering","Ulf Landmesser","Roxana Mehran","Béla Merkely","Freny Vaghaiwalla Mody","Mark C Petrie","Ivo Petrov","Morten Schou","Michele Senni","David Sim","Peter van der Meer","Martin Lefkowitz","Yinong Zhou","Jianjian Gong","Eugene Braunwald"],"significance":9,"published":"2021-11-11","source_date":"2021-11-11","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/farmacologie/ace-remmers-farmacologie/"],"congress":"","summary_en":"The PARADISE-MI trial found that sacubitril-valsartan did not significantly reduce the composite of cardiovascular death or heart failure events compared with ramipril in patients with acute MI and reduced left ventricular function. The result indicated that ARNI therapy does not provide additional benefit over ACE inhibition in the post-MI setting.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"232ab99ce440","type":"article","url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","title":"Colchicine na ACS: 2-jaars COPS follow-up","title_en":"Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.054610","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.054610","authors":["David C Tong","Jason E Bloom","Stephen Quinn","Arthur Nasis","Chin Hiew","Philip Roberts-Thomson","Heath Adams","Rumes Sriamareswaran","Nay M Htun","William Wilson","Dion Stub","William van Gaal","Laurie Howes","Allysha Yeap","Brian Yip","Sam Wu","Padeepa Perera","Nicholas Collins","Andy Yong","Ravinay Bhindi","Robert Whitbourn","Astin Lee","Manuja Premaratne","Kaleab Asrress","Melanie Freeman","John Amerena","Jamie Layland"],"significance":7,"published":"2021-11-09","source_date":"2021-11-09","image":"","kennis":[],"congress":"","summary_en":"The 2-year COPS follow-up of colchicine after ACS showed attenuation of the early mortality signal and a trend toward ischemic benefit, providing longer-term context for the initial concerning safety finding.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d0a43d26ae58","type":"article","url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","title":"FFR voor behandeling van multivatencoronairlijden: JACC","title_en":"Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.061","source_url":"https://doi.org/10.1016/j.jacc.2021.08.061","authors":["Gilles Rioufol","François Dérimay","François Roubille","Thibault Perret","Pascal Motreff","Denis Angoulvant","Yves Cottin","Ludovic Meunier","Laura Cetran","Guillaume Cayla","Brahim Harbaoui","Jean-Yves Wiedemann","Éric Van Belle","Christophe Pouillot","Nathalie Noirclerc","Jean-François Morelle","François-Xavier Soto","Christophe Caussin","Bernard Bertrand","Thierry Lefèvre","Patrick Dupouy","Pierre-François Lesault","Franck Albert","Olivier Barthelemy","René Koning","Laurent Leborgne","Pierre Barnay","Philippe Chapon","Sébastien Armero","Antoine Lafont","Christophe Piot","Camille Amaz","Bernadette Vaz","Lakhdar Benyahya","Yvonne Varillon","Michel Ovize","Nathan Mewton","Gérard Finet"],"significance":6,"published":"2021-11-09","source_date":"2021-11-09","image":"","kennis":[],"congress":"","summary_en":"This analysis evaluated the role of FFR in guiding treatment strategy for multivessel coronary disease, assessing whether physiological assessment improves revascularization decisions in complex coronary anatomy.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8c97287729b8","type":"article","url":"https://hartvaat.nl/2021/11/08/preoperatieve-tte-voor-voorspelling-van-postoperatief-af-meta-analyse/","title":"Preoperatieve TTE voor voorspelling van postoperatief AF: meta-analyse","title_en":"Role of pre-operative transthoracic echocardiography in predicting post-operative atrial fibrillation after cardiac surgery: a systematic review of the literature and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["echocardiografie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab095","source_url":"https://doi.org/10.1093/europace/euab095","authors":["Michal J Kawczynski","Martijn Gilbers","Sophie Van De Walle","Simon Schalla","Harry J Crijns","Jos G Maessen","Ulrich Schotten","Bart Maesen","Elham Bidar"],"significance":5,"published":"2021-11-08","source_date":"2021-11-08","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated preoperative echocardiographic predictors of postoperative AF after cardiac surgery, identifying LA size, LV diastolic dysfunction, and atrial remodeling markers as the strongest predictors.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3cad1184b7ff","type":"article","url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","title":"Closed loop stimulatie en cardiopulmonale variabelen bij chronisch HF met chronotrope incompetentie","title_en":"Impact of closed loop stimulation on prognostic cardiopulmonary variables in patients with chronic heart failure and severe chronotropic incompetence: a pilot, randomized, crossover study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","bradycardie","cardiale-resynchronisatie","hypertrofische-cardiomyopathie","slaapapneu"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab110","source_url":"https://doi.org/10.1093/europace/euab110","authors":["Joachim Proff","Béla Merkely","Roland Papp","Corinna Lenz","Peter Nordbeck","Christian Butter","Juergen Meyerhoefer","Michael Doering","Dean J MacCarter","Katharina Ingel","Thomas Thouet","Ulf Landmesser","Mattias J Roser"],"significance":5,"published":"2021-11-08","source_date":"2021-11-08","image":"","kennis":[],"congress":"","summary_en":"This study evaluated the impact of closed-loop stimulation on cardiopulmonary exercise variables in heart failure patients with chronotropic incompetence undergoing CRT, testing physiological rate adaptation for functional optimization.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1d2dfd55e191","type":"article","url":"https://hartvaat.nl/2021/11/02/hogere-intraoperatieve-bloeddrukstreefwaarden-en-cv-events-bij-niet-cardiale-chi/","title":"Hogere intraoperatieve bloeddrukstreefwaarden en CV-events bij niet-cardiale chirurgie","title_en":"Targeting Higher Intraoperative Blood Pressures Does Not Reduce Adverse Cardiovascular Events Following Noncardiac Surgery.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.048","source_url":"https://doi.org/10.1016/j.jacc.2021.08.048","authors":["Patrick M Wanner","Dirk U Wulff","Mirjana Djurdjevic","Wolfgang Korte","Thomas W Schnider","Miodrag Filipovic"],"significance":6,"published":"2021-11-02","source_date":"2021-11-02","image":"","kennis":[],"congress":"","summary_en":"This study showed that targeting higher intraoperative blood pressures during non-cardiac surgery does not reduce postoperative cardiovascular events, challenging the strategy of aggressive intraoperative hemodynamic augmentation.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9d11baf137ff","type":"article","url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","title":"Griepvaccinatie na MI: IAMI dubbelblinde gerandomiseerde multicenter trial","title_en":"Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057042","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057042","authors":["Ole Fröbert","Matthias Götberg","David Erlinge","Zubair Akhtar","Evald H Christiansen","Chandini R MacIntyre","Keith G Oldroyd","Zuzana Motovska","Andrejs Erglis","Rasmus Moer","Ota Hlinomaz","Lars Jakobsen","Thomas Engstrøm","Lisette O Jensen","Christian O Fallesen","Svend E Jensen","Oskar Angerås","Fredrik Calais","Amra Kåregren","Jörg Lauermann","Arash Mokhtari","Johan Nilsson","Jonas Persson","Per Stalby","Abu K M M Islam","Afzalur Rahman","Fazila Malik","Sohel Choudhury","Timothy Collier","Stuart J Pocock","John Pernow"],"significance":9,"published":"2021-11-02","source_date":"2021-11-02","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"The IAMI trial showed that influenza vaccination administered within 72 hours of myocardial infarction or high-risk coronary intervention reduced the composite of all-cause death, MI, or stent thrombosis at 12 months. This is the first large, placebo-controlled trial demonstrating the cardiovascular protective effect of influenza vaccination after acute coronary events.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"51eea428703b","type":"article","url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","title":"AF-last en QoL na AF-ablatie: CABANA-substudie","title_en":"Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.3063","source_url":"https://doi.org/10.1001/jamacardio.2021.3063","authors":["Michelle Samuel","Paul Khairy","Jean Champagne","Marc W Deyell","Laurent Macle","Peter Leong-Sit","Paul Novak","Mariano Badra-Verdu","John Sapp","Jean-Claude Tardif","Jason G Andrade"],"significance":6,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":[],"congress":"","summary_en":"This CABANA substudy showed that AF burden reduction after ablation correlates with quality-of-life improvement, supporting AF burden as a meaningful outcome measure for rhythm control interventions.","created":"2026-07-03T10:29:29Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"717f7895219c","type":"article","url":"https://hartvaat.nl/2021/11/01/inspanningstraining-en-ambulante-bloeddruk-bij-resistente-hypertensie-jama-cardi/","title":"Inspanningstraining en ambulante bloeddruk bij resistente hypertensie: JAMA Cardiology","title_en":"Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension: A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["ambulante-bloeddrukmeting","aperitif-trial","aprocitentan","bax24-trial","bloeddrukbehandeling","obesitas","select-trial","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.2735","source_url":"https://doi.org/10.1001/jamacardio.2021.2735","authors":["Susana Lopes","José Mesquita-Bastos","Catarina Garcia","Susana Bertoquini","Verónica Ribau","Manuel Teixeira","Ilda P Ribeiro","Joana B Melo","José Oliveira","Daniela Figueiredo","Guilherme V Guimarães","Linda S Pescatello","Jorge Polonia","Alberto J Alves","Fernando Ribeiro"],"significance":7,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that structured aerobic exercise training significantly reduces ambulatory blood pressure in patients with resistant hypertension, supporting exercise as an important adjunctive strategy even when blood pressure is difficult to control pharmacologically.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5f064269a595","type":"article","url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","title":"Langetermijn event-vrije en totale overleving met dapagliflozine bij HFrEF: JAMA Cardiology","title_en":"Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.2632","source_url":"https://doi.org/10.1001/jamacardio.2021.2632","authors":["Kieran F Docherty","Pardeep S Jhund","Brian Claggett","João Pedro Ferreira","Olof Bengtsson","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Anna Maria Langkilde","Felipe A Martinez","Piotr Ponikowski","Marc S Sabatine","Mikaela Sjöstrand","Scott D Solomon","John J V McMurray"],"significance":7,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":[],"congress":"","summary_en":"This DAPA-HF analysis extrapolated long-term survival benefits of dapagliflozin in HFrEF, estimating that SGLT2 inhibitor therapy translates to meaningful gains in event-free and overall survival over the patient's remaining lifetime.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5677a0fa5921","type":"article","url":"https://hartvaat.nl/2021/11/01/rustduur-voor-bloeddrukmeting-best-rest-trial/","title":"Rustduur vóór bloeddrukmeting: Best Rest Trial","title_en":"Effects of Different Rest Period Durations Prior to Blood Pressure Measurement: The Best Rest Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17496","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17496","authors":["Tammy M Brady","Jeanne Charleston","Junichi Ishigami","Edgar R Miller","Kunihiro Matsushita","Lawrence J Appel"],"significance":6,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"The Best Rest Trial evaluated different rest period durations before blood pressure measurement, providing evidence for optimizing the pre-measurement protocol to improve clinical accuracy.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed87e163c62a","type":"article","url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","title":"Bloeddrukvariabiliteit en dementie/cognitieve stoornis: meta-analyse","title_en":"Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17797","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17797","authors":["Rianne A A de Heus","Christophe Tzourio","Emily Jo Lynn Lee","Melissa Opozda","Andrew D Vincent","Kaarin J Anstey","Albert Hofman","Kazuomi Kario","Simona Lattanzi","Lenore J Launer","Yuan Ma","Rajiv Mahajan","Simon P Mooijaart","Michiaki Nagai","Ruth Peters","Deborah Turnbull","Yuichiro Yano","Jurgen A H R Claassen","Phillip J Tully"],"significance":7,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review and meta-analysis found that blood pressure variability, both short-term and long-term, is independently associated with increased risk of dementia and cognitive impairment, adding to the growing evidence linking hemodynamic instability to neurodegeneration.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"af5685e2e93e","type":"article","url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","title":"Aspirine versus P2Y12-remmer met antistolling bij AF","title_en":"Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","aspirine"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319321","source_url":"https://doi.org/10.1136/heartjnl-2021-319321","authors":["Hidehira Fukaya","Junya Ako","Satoshi Yasuda","Koichi Kaikita","Masaharu Akao","Tetsuya Matoba","Masato Nakamra","Katsumi Miyauchi","Nobuhisa Hagiwara","Kazuo Kimura","Atsushi Hirayama","Kunihiko Matsui","Hisao Ogawa"],"significance":6,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This analysis compared aspirin with P2Y12 inhibitors as the antiplatelet component of combined antithrombotic therapy in AF patients, evaluating which antiplatelet offers the best ischemia-bleeding balance alongside anticoagulation.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c8c64bc79d1c","type":"article","url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","title":"Antiplaatjestherapie bij MI zonder obstructief coronairlijden (MINOCA)","title_en":"Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-318045","source_url":"https://doi.org/10.1136/heartjnl-2020-318045","authors":["Matthias Bossard","Peggy Gao","William Boden","Gabriel Steg","Jean-Francois Tanguay","Cam Joyner","Christopher B Granger","Adnan Kastrati","David Faxon","Andrzej Budaj","Prem Pais","Giuseppe Di Pasquale","Vicent Valentin","Marcus Flather","Tiziano Moccetti","Salim Yusuf","Shamir R Mehta"],"significance":6,"published":"2021-11-01","source_date":"2021-11-01","image":"","kennis":[],"congress":"","summary_en":"This study evaluated antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA), addressing the uncertain role of intensified antithrombotic treatment in this distinct MI phenotype.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e8c1ef2f1fd5","type":"article","url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","title":"DAPT na PCI bij hoog bloedingsrisico: NEJM MASTER DAPT","title_en":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2108749","source_url":"https://doi.org/10.1056/NEJMoa2108749","authors":["Marco Valgimigli","Enrico Frigoli","Dik Heg","Jan Tijssen","Peter Jüni","Pascal Vranckx","Yukio Ozaki","Marie-Claude Morice","Bernard Chevalier","Yoshinobu Onuma","Stephan Windecker","Pim A L Tonino","Marco Roffi","Maciej Lesiak","Felix Mahfoud","Jozef Bartunek","David Hildick-Smith","Antonio Colombo","Goran Stanković","Andrés Iñiguez","Carl Schultz","Ran Kornowski","Paul J L Ong","Mirvat Alasnag","Alfredo E Rodriguez","Aris Moschovitis","Peep Laanmets","Michael Donahue","Sergio Leonardi","Pieter C Smits"],"significance":9,"published":"2021-10-28","source_date":"2021-10-28","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/","https://hartvaat.nl/kennis/coronairlijden/dual-antiplatelet-therapy-dapt/"],"congress":"","summary_en":"The MASTER DAPT trial showed that abbreviated 1-month dual antiplatelet therapy followed by single antiplatelet therapy was noninferior to standard DAPT for net adverse clinical events in high-bleeding-risk patients after drug-eluting stent implantation. The results support a shortened DAPT duration in this vulnerable population.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c53f91cb409c","type":"article","url":"https://hartvaat.nl/2021/10/26/vroege-impedantie-geleide-interventie-verbetert-langetermijn-hf-uitkomsten/","title":"Vroege impedantie-geleide interventie verbetert langetermijn HF-uitkomsten","title_en":"Early Impedance-Guided Intervention Improves Long-Term Outcome in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.036","source_url":"https://doi.org/10.1016/j.jacc.2021.08.036","authors":["Michael Kleiner Shochat","Marat Fudim","Daniel Kapustin","Mark Kazatsker","Ilia Kleiner","Jean Marc Weinstein","Gurusher Panjrath","Guy Rozen","Ariel Roguin","Simcha R Meisel"],"significance":6,"published":"2021-10-26","source_date":"2021-10-26","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that early intervention guided by thoracic impedance monitoring improves long-term outcomes in heart failure patients, supporting proactive congestion management through implanted device monitoring.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a7ec2334fcea","type":"article","url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","title":"Systematische AF-screening en klinische uitkomsten: Lancet STROKESTOP","title_en":"Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["primaire-preventie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01637-8","source_url":"https://doi.org/10.1016/S0140-6736(21)01637-8","authors":["Emma Svennberg","Leif Friberg","Viveka Frykman","Faris Al-Khalili","Johan Engdahl","Mårten Rosenqvist"],"significance":9,"published":"2021-10-23","source_date":"2021-10-23","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"The STROKESTOP trial demonstrated that systematic screening for atrial fibrillation in 75-76-year-olds using intermittent ECG recordings, followed by anticoagulation when AF was detected, reduced the composite of ischemic stroke, systemic embolism, bleeding, and death compared with no screening. This is the first randomized trial showing clinical benefit from population-level AF screening.","created":"2026-07-03T10:29:28Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b98e713dedc","type":"article","url":"https://hartvaat.nl/2021/10/21/digitale-therapeutica-bij-essentiele-hypertensie-herb-dh1-pivottrial/","title":"Digitale therapeutica bij essentiële hypertensie: HERB-DH1 pivottrial","title_en":"Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["baxdrostat","bloeddrukbehandeling","lorundrostat"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab559","source_url":"https://doi.org/10.1093/eurheartj/ehab559","authors":["Kazuomi Kario","Akihiro Nomura","Noriko Harada","Ayako Okura","Kiyose Nakagawa","Tomoyuki Tanigawa","Eisuke Hida"],"significance":7,"published":"2021-10-21","source_date":"2021-10-21","image":"","kennis":[],"congress":"","summary_en":"The HERB-DH1 pivotal trial demonstrated that a smartphone-based digital therapeutics system for lifestyle modification significantly reduces blood pressure in patients with essential hypertension, validating the concept of software-as-treatment for chronic disease management.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"04f9718d3069","type":"article","url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","title":"Diabetes met cardiomyopathie in de community: prevalentie en prognose","title_en":"Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.020","source_url":"https://doi.org/10.1016/j.jacc.2021.08.020","authors":["Matthew W Segar","Muhammad Shahzeb Khan","Kershaw V Patel","Javed Butler","W H Wilson Tang","Muthiah Vaduganathan","Carolyn S P Lam","Subodh Verma","Darren K McGuire","Ambarish Pandey"],"significance":6,"published":"2021-10-19","source_date":"2021-10-19","image":"","kennis":[],"congress":"","summary_en":"This study characterized the prevalence and prognostic significance of diabetes with cardiomyopathy in community-dwelling adults, showing that diabetic cardiomyopathy is common and predicts subsequent heart failure development.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12b654708da9","type":"article","url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","title":"Empagliflozine en verslechterende HF-events bij HFpEF: EMPEROR-Preserved analyse","title_en":"Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["emperor-trials","hfpef","hfref","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.056824","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.056824","authors":["Milton Packer","Javed Butler","Faiez Zannad","Gerasimos Filippatos","Joao Pedro Ferreira","Stuart J Pocock","Peter Carson","Inder Anand","Wolfram Doehner","Markus Haass","Michel Komajda","Alan Miller","Steen Pehrson","John R Teerlink","Sven Schnaidt","Cordula Zeller","Janet M Schnee","Stefan D Anker"],"significance":8,"published":"2021-10-19","source_date":"2021-10-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Preserved analysis detailed that empagliflozin reduced worsening heart failure events across the ejection fraction spectrum in HFpEF, with consistent benefit regardless of baseline LVEF, diabetes status, or renal function.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d02083fa0f4f","type":"article","url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","title":"Bètablokker-respons bij HF met sinusritme en AF: machine learning clusteranalyse","title_en":"Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01638-X","source_url":"https://doi.org/10.1016/S0140-6736(21)01638-X","authors":["Andreas Karwath","Karina V Bunting","Simrat K Gill","Otilia Tica","Samantha Pendleton","Furqan Aziz","Andrey D Barsky","Saisakul Chernbumroong","Jinming Duan","Alastair R Mobley","Victor Roth Cardoso","Karin Slater","John A Williams","Emma-Jane Bruce","Xiaoxia Wang","Marcus D Flather","Andrew J S Coats","Georgios V Gkoutos","Dipak Kotecha"],"significance":7,"published":"2021-10-16","source_date":"2021-10-16","image":"","kennis":[],"congress":"","summary_en":"This Lancet machine learning analysis redefined beta-blocker response in heart failure, showing that the mortality benefit of beta-blockers is driven by heart rate reduction and is absent in patients with atrial fibrillation, challenging the assumption of universal beta-blocker benefit in HFrEF.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39307ae425b1","type":"article","url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","title":"Empagliflozine bij HFpEF: NEJM EMPEROR-Preserved","title_en":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dapa-hf","emperor-trials","hfpef","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2107038","source_url":"https://doi.org/10.1056/NEJMoa2107038","authors":["Stefan D Anker","Javed Butler","Gerasimos Filippatos","João P Ferreira","Edimar Bocchi","Michael Böhm","Hans-Peter Brunner-La Rocca","Dong-Ju Choi","Vijay Chopra","Eduardo Chuquiure-Valenzuela","Nadia Giannetti","Juan Esteban Gomez-Mesa","Stefan Janssens","James L Januzzi","Jose R Gonzalez-Juanatey","Bela Merkely","Stephen J Nicholls","Sergio V Perrone","Ileana L Piña","Piotr Ponikowski","Michele Senni","David Sim","Jindrich Spinar","Iain Squire","Stefano Taddei","Hiroyuki Tsutsui","Subodh Verma","Dragos Vinereanu","Jian Zhang","Peter Carson","Carolyn Su Ping Lam","Nikolaus Marx","Cordula Zeller","Naveed Sattar","Waheed Jamal","Sven Schnaidt","Janet M Schnee","Martina Brueckmann","Stuart J Pocock","Faiez Zannad","Milton Packer"],"significance":10,"published":"2021-10-14","source_date":"2021-10-14","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"The EMPEROR-Preserved trial was the first to demonstrate that an SGLT2 inhibitor (empagliflozin) reduces heart failure hospitalization in patients with HFpEF. This landmark result extended the benefit of SGLT2 inhibition across the full ejection fraction spectrum, addressing an area with previously no proven pharmacological therapy.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"748b079a6996","type":"article","url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","title":"Empagliflozine en renale uitkomsten bij hartfalen: NEJM EMPEROR-Reduced renal","title_en":"Empagliflozin and Major Renal Outcomes in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapagliflozine","empagliflozine","emperor-trials"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMc2112411","source_url":"https://doi.org/10.1056/NEJMc2112411","authors":["Milton Packer","Javed Butler","Faiez Zannad","Stuart J Pocock","Gerasimos Filippatos","João P Ferreira","Martina Brueckmann","Waheed Jamal","Cordula Zeller","Christoph Wanner","Stefan D Anker"],"significance":8,"published":"2021-10-14","source_date":"2021-10-14","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Reduced renal analysis showed that empagliflozin slowed the decline in eGFR and reduced the risk of serious kidney outcomes in patients with heart failure, demonstrating renoprotective effects of SGLT2 inhibition in the heart failure population.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6672a9401c1d","type":"article","url":"https://hartvaat.nl/2021/10/14/lignocaine-versus-opioiden-op-antiplaatjeseffect-van-ticagrelor-local-trial/","title":"Lignocaïne versus opioïden op antiplaatjeseffect van ticagrelor: LOCAL trial","title_en":"Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab557","source_url":"https://doi.org/10.1093/eurheartj/ehab557","authors":["Himawan Fernando","Thy Duong","Kevin Huynh","Jonathan Noonan","James Shaw","Stephen J Duffy","Ziad Nehme","Karen Smith","Paul S Myles","Peter J Meikle","Karlheinz Peter","Dion Stub"],"significance":6,"published":"2021-10-14","source_date":"2021-10-14","image":"","kennis":[],"congress":"","summary_en":"The LOCAL trial showed that intravenous lignocaine avoids the antiplatelet-delaying effect of opioids on ticagrelor in ACS patients, providing an alternative analgesic strategy that preserves rapid P2Y12 inhibition.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5e0f3ff6b8c5","type":"article","url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","title":"Overbrugging van antiplaatjestherapie na PCI: JACC review","title_en":"Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.013","source_url":"https://doi.org/10.1016/j.jacc.2021.08.013","authors":["Alexander E Sullivan","Michael G Nanna","Tracy Y Wang","Deepak L Bhatt","Dominick J Angiolillo","Roxana Mehran","Subhash Banerjee","Sarah Cantrell","W Schuyler Jones","Jennifer A Rymer","Jeffrey B Washam","Sunil V Rao","E Magnus Ohman"],"significance":6,"published":"2021-10-12","source_date":"2021-10-12","image":"","kennis":[],"congress":"","summary_en":"This JACC review addressed the practical challenge of bridging antiplatelet therapy when patients with coronary stents require non-cardiac surgery, providing guidance on risk assessment and perioperative management.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b8da8a38d1b5","type":"article","url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","title":"Reductie in ischemische events door onderzoekers en adjudicatiecommissie: REDUCE-IT","title_en":"Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.009","source_url":"https://doi.org/10.1016/j.jacc.2021.08.009","authors":["Prakriti Gaba","Deepak L Bhatt","Robert P Giugliano","Ph Gabriel Steg","Michael Miller","Eliot A Brinton","Terry A Jacobson","Steven B Ketchum","Rebecca A Juliano","Lixia Jiao","Ralph T Doyle","Craig Granowitz","Jean-Claude Tardif","Christie M Ballantyne","Duane S Pinto","Matthew J Budoff","C Michael Gibson"],"significance":5,"published":"2021-10-12","source_date":"2021-10-12","image":"","kennis":[],"congress":"","summary_en":"This REDUCE-IT analysis compared investigator-reported with centrally adjudicated ischemic events, showing consistent treatment effects regardless of event ascertainment method, strengthening the trial's internal validity.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"725715de76f5","type":"article","url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","title":"Baseline LDL en klinische uitkomsten van ezetimibe plus statine: IMPROVE-IT","title_en":"Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.08.011","source_url":"https://doi.org/10.1016/j.jacc.2021.08.011","authors":["Kazuma Oyama","Robert P Giugliano","Michael A Blazing","Jeong-Gun Park","Andrew M Tershakovec","Marc S Sabatine","Christopher P Cannon","Eugene Braunwald"],"significance":6,"published":"2021-10-12","source_date":"2021-10-12","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This IMPROVE-IT analysis showed that patients with higher baseline LDL cholesterol derive greater absolute benefit from adding ezetimibe to statin therapy, supporting the treat-to-target approach based on baseline lipid levels.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2d4ae974532c","type":"article","url":"https://hartvaat.nl/2021/10/12/leefstijlmodificatie-bij-resistente-hypertensie-triumph-gerandomiseerde-trial/","title":"Leefstijlmodificatie bij resistente hypertensie: TRIUMPH gerandomiseerde trial","title_en":"Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["aprocitentan","bax24-trial","bloeddrukbehandeling","figaro-dkd","lorundrostat","precision-trial","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","select-trial","summit-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055329","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055329","authors":["James A Blumenthal","Alan L Hinderliter","Patrick J Smith","Stephanie Mabe","Lana L Watkins","Linda Craighead","Krista Ingle","Crystal Tyson","Pao-Hwa Lin","William E Kraus","Lawrence Liao","Andrew Sherwood"],"significance":7,"published":"2021-10-12","source_date":"2021-10-12","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/"],"congress":"","summary_en":"The TRIUMPH randomized trial showed that lifestyle modifications (dietary counseling, exercise, weight loss) significantly reduce blood pressure in patients with resistant hypertension already on pharmacotherapy, demonstrating that non-pharmacological approaches retain benefit even in treatment-resistant disease.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dfcacae098d9","type":"article","url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","title":"Ongeleide de-escalatie van ticagrelor naar clopidogrel na MI met PCI: Lancet TALOS-AMI","title_en":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["trombocytenaggregatieremmers"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01445-8","source_url":"https://doi.org/10.1016/S0140-6736(21)01445-8","authors":["Chan Joon Kim","Mahn-Won Park","Min Chul Kim","Eun-Ho Choo","Byung-Hee Hwang","Kwan Yong Lee","Yun Seok Choi","Hee-Yeol Kim","Ki-Dong Yoo","Doo-Soo Jeon","Eun-Seok Shin","Young-Hoon Jeong","Ki-Bae Seung","Myung Ho Jeong","Hyeon Woo Yim","Youngkeun Ahn","Kiyuk Chang"],"significance":8,"published":"2021-10-09","source_date":"2021-10-09","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The TALOS-AMI trial demonstrated that unguided de-escalation from ticagrelor to clopidogrel one month after MI reduced bleeding without increasing ischemic events. The pragmatic approach, requiring no platelet function testing, offered a simpler de-escalation strategy than guided protocols.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4ddb2b626d0","type":"article","url":"https://hartvaat.nl/2021/10/09/klinische-risicofactoren-voor-cva-bij-anticoagulantie-naieve-af-meta-analyse/","title":"Klinische risicofactoren voor CVA bij anticoagulantie-naïeve AF: meta-analyse","title_en":"A meta-analysis of clinical risk factors for stroke in anticoagulant-naïve patients with atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["abelacimab","anticoagulantia","anticoagulatie-kwetsbare-ouderen","rivaroxaban"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab087","source_url":"https://doi.org/10.1093/europace/euab087","authors":["Jean Jacques Noubiap","Vitalis Fambombi Feteh","Melissa E Middeldorp","John L Fitzgerald","Gijo Thomas","Timothy Kleinig","Dennis H Lau","Prashanthan Sanders"],"significance":6,"published":"2021-10-09","source_date":"2021-10-09","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This meta-analysis of clinical risk factors for stroke in anticoagulant-naive AF patients identified the strongest predictors of thromboembolism, informing risk stratification for anticoagulation initiation decisions.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e4935825fb42","type":"article","url":"https://hartvaat.nl/2021/10/09/voorspellers-van-sinusritme-6-weken-na-af-cardioversie-x-vert/","title":"Voorspellers van sinusritme 6 weken na AF-cardioversie: X-VeRT","title_en":"Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab084","source_url":"https://doi.org/10.1093/europace/euab084","authors":["Riccardo Cappato","Michael D Ezekowitz","Stefan H Hohnloser","Isabelle Ling Meng","Melanie Wosnitza","And Arthur John Camm"],"significance":5,"published":"2021-10-09","source_date":"2021-10-09","image":"","kennis":[],"congress":"","summary_en":"This X-VeRT post-hoc analysis identified predictors of sinus rhythm maintenance 6 weeks after cardioversion of AF, informing which patients are likely to benefit from electrical rhythm restoration.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb8198be7caf","type":"article","url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","title":"Gewichtsverlies voor AF-ablatie: SORT-AF gerandomiseerde trial","title_en":"Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab122","source_url":"https://doi.org/10.1093/europace/euab122","authors":["Nele Gessler","Stephan Willems","Daniel Steven","Jens Aberle","Ruken Oezge Akbulak","Nils Gosau","Boris A Hoffmann","Christian Meyer","Arian Sultan","Roland Tilz","Julia Vogler","Peter Wohlmuth","Susanne Scholz","Melanie A Gunawardene","Christian Eickholt","Jakob Lüker"],"significance":7,"published":"2021-10-09","source_date":"2021-10-09","image":"","kennis":[],"congress":"","summary_en":"The SORT-AF trial investigated whether structured weight reduction before AF catheter ablation improves ablation outcomes in obese patients, testing the hypothesis that upstream risk factor modification enhances procedural success.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c815032c3bd0","type":"article","url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","title":"Ketonlichamen en functionele uitkomsten na STEMI","title_en":"Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.054","source_url":"https://doi.org/10.1016/j.jacc.2021.07.054","authors":["Marie-Sophie L Y de Koning","B Daan Westenbrink","Solmaz Assa","Erwin Garcia","Margery A Connelly","Dirk J van Veldhuisen","Robin P F Dullaart","Erik Lipsic","Pim van der Harst"],"significance":5,"published":"2021-10-05","source_date":"2021-10-05","image":"","kennis":[],"congress":"","summary_en":"This study showed that circulating ketone body levels are associated with functional outcomes after STEMI, supporting the metabolic shift toward ketone utilization as a compensatory mechanism in cardiac injury.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c716f6ea76d2","type":"article","url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","title":"Paroxetine GRK2-remming versus placebo bij anterieur MI: JAMA Cardiology","title_en":"Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.2247","source_url":"https://doi.org/10.1001/jamacardio.2021.2247","authors":["Thomas Pilgrim","René Vollenbroich","Sarah Deckarm","Christoph Gräni","Stephan Dobner","Anselm W Stark","Sophie A Erne","Flora Babongo Bosombo","Kady Fischer","Stefan Stortecky","Nicole Reusser","Monika Fürholz","George C M Siontis","Dik Heg","Lukas Hunziker","Stephan Windecker","Jonas Lanz"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This trial tested paroxetine as a GRK2 inhibitor (repurposed from antidepressant) for preventing LV remodeling after anterior MI, exploring kinase inhibition for post-infarction cardioprotection.","created":"2026-07-03T10:29:26Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6eb6e1ad9bf7","type":"article","url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","title":"Ticagrelor of prasugrel na PCI voor ACS: ISAR-REACT 5 pre-gespecificeerde analyse","title_en":"Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.2228","source_url":"https://doi.org/10.1001/jamacardio.2021.2228","authors":["J J Coughlan","Alp Aytekin","Shqipdona Lahu","Gjin Ndrepepa","Maurizio Menichelli","Katharina Mayer","Jochen Wöhrle","Isabell Bernlochner","Senta Gewalt","Bernhard Witzenbichler","Willibald Hochholzer","Dirk Sibbing","Salvatore Cassese","Dominick J Angiolillo","Rayyan Hemetsberger","Christian Valina","Arne Müller","Sebastian Kufner","Christoph Liebetrau","Erion Xhepa","Alexander Hapfelmeier","Hendrik B Sager","Michael Joner","Massimiliano Fusaro","Gert Richardt","Karl Ludwig Laugwitz","Franz Josef Neumann","Heribert Schunkert","Stefanie Schüpke","Adnan Kastrati"],"significance":7,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This ISAR-REACT 5 prespecified subanalysis of ACS patients treated with PCI confirmed the superiority of prasugrel over ticagrelor for the composite of death, MI, or stroke in the interventionally managed population.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1456f1f4d8a5","type":"article","url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","title":"EBC hoofdstam-stentstudie: provisional versus systematisch dubbel stenten","title_en":"The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab283","source_url":"https://doi.org/10.1093/eurheartj/ehab283","authors":["David Hildick-Smith","Mohaned Egred","Adrian Banning","Philippe Brunel","Miroslaw Ferenc","Thomas Hovasse","Adrian Wlodarczak","Manuel Pan","Thomas Schmitz","Marc Silvestri","Andreis Erglis","Evgeny Kretov","Jens Flensted Lassen","Alaide Chieffo","Thierry Lefèvre","Francesco Burzotta","James Cockburn","Olivier Darremont","Goran Stankovic","Marie-Claude Morice","Yves Louvard"],"significance":7,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This European Bifurcation Club randomized study compared stepwise provisional stenting with systematic double stenting for left main coronary bifurcation lesions, providing data on the optimal bifurcation strategy for this critical anatomy.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ef3a66a8809","type":"article","url":"https://hartvaat.nl/2021/10/01/acute-pleiotrope-effecten-van-dapagliflozine-bij-diabetes-type-2-met-hfref-cross/","title":"Acute pleiotrope effecten van dapagliflozine bij diabetes type 2 met HFrEF: crossover","title_en":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13553","source_url":"https://doi.org/10.1002/ehf2.13553","authors":["Fahmida Ilyas","Lynette Jones","Su Ling Tee","Matthew Horsfall","Amy Swan","Fiona Wollaston","Tracy Hecker","Carla De Pasquale","Simeoni Thomas","William Chong","Steve Stranks","Arduino A Mangoni","Joseph B Selvanayagam","Derek P Chew","Carmine G De Pasquale"],"significance":6,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This crossover study characterized the acute pleiotropic effects of dapagliflozin in diabetic patients with HFrEF, showing rapid hemodynamic and metabolic changes within hours of administration.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1f2c1cbb3b93","type":"article","url":"https://hartvaat.nl/2021/10/01/aortaklepcalcificatie-en-cv-risicofactoren-bij-oudere-deense-mannen/","title":"Aortaklepcalcificatie en CV-risicofactoren bij oudere Deense mannen","title_en":"Cross-sectional study of aortic valve calcification and cardiovascular risk factors in older Danish men.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["acuut-hartfalen","aortainsufficiëntie","aortastenose","perifeer-vaatlijden","slaapapneu"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319023","source_url":"https://doi.org/10.1136/heartjnl-2021-319023","authors":["Lida Khurrami","Jacob Eifer Møller","Jes Sanddal Lindholt","Grazina Urbonaviciene","Flemming Hald Steffensen","Jess Lambrechtsen","Marek Karon","Lars Frost","Martin Busk","Kenneth Egstrup","Maise Høigaard Fredgart","Axel Cosmus Pyndt Diederichsen"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This cross-sectional study examined the relationship between aortic valve calcification and cardiovascular risk factors in older Danish men, exploring shared pathways between valvular calcification and atherosclerotic disease.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35e3fec41fcb","type":"article","url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","title":"Uitgebreide vasodilatatie en QoL bij acuut HF: substudie","title_en":"Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aperitif-trial","bloeddrukbehandeling","dapa-hf","sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13543","source_url":"https://doi.org/10.1002/ehf2.13543","authors":["Maria Belkin","Desiree Wussler","Danielle Menosi Gualandro","Samyut Shrestha","Ivo Strebel","Assen Goudev","Micha T Maeder","Joan Walter","Dayana Flores","Nikola Kozhuharov","Pedro Lopez-Ayala","Isabelle Danier","Mucio Tavares de Oliveira Junior","Richard Kobza","Hans Rickli","Tobias Breidthardt","Paul Erne","Thomas Münzel","Christian Mueller"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This quality-of-life substudy showed that a comprehensive vasodilation strategy versus usual care in acute heart failure does not improve long-term health-related quality of life, consistent with the neutral primary endpoint.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"300129c80f1b","type":"article","url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","title":"Sacubitril/valsartan in real-life Europese HFrEF: meta-analyse","title_en":"Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13547","source_url":"https://doi.org/10.1002/ehf2.13547","authors":["Stefano Giovinazzo","Luca Carmisciano","Matteo Toma","Stefano Benenati","Daniela Tomasoni","Maria Pia Sormani","Italo Porto","Marco Canepa","Michele Senni","Marco Metra","Pietro Ameri"],"significance":6,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review of European real-world evidence for sacubitril-valsartan in HFrEF showed consistent clinical benefits outside the controlled trial setting, supporting broader ARNI implementation.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d566e9e4b7aa","type":"article","url":"https://hartvaat.nl/2021/10/01/niet-invasieve-technieken-en-biomarkers-voor-poliklinisch-vochtmanagement-bij-hf/","title":"Niet-invasieve technieken en biomarkers voor poliklinisch vochtmanagement bij HF","title_en":"Use of novel non-invasive techniques and biomarkers to guide outpatient management of fluid overload and reduce hospital readmission: systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13510","source_url":"https://doi.org/10.1002/ehf2.13510","authors":["Georgios Zisis","Amera Halabi","Quan Huynh","Christopher Neil","Melinda Carrington","Thomas H Marwick"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This review evaluated novel non-invasive techniques (bioimpedance, lung ultrasound) and biomarkers for outpatient fluid management in heart failure, supporting technology-assisted congestion monitoring to reduce readmissions.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4955576677d5","type":"article","url":"https://hartvaat.nl/2021/10/01/iv-furosemide-plus-hypertone-zoutoplossing-en-hf-markers/","title":"IV furosemide plus hypertone zoutoplossing en HF-markers","title_en":"Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["furosemide"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13511","source_url":"https://doi.org/10.1002/ehf2.13511","authors":["Antonino Tuttolomondo","Carlo Maida","Alessandra Casuccio","Domenico Di Raimondo","Roberto Fonte","Valerio Vassallo","Maria Grazia Puleo","Tiziana Di Chiara","Alba Mogavero","Alessandro Del Cuore","Mario Daidone","Antonella Ortello","Antonio Pinto"],"significance":4,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This study compared the effects of intravenous furosemide combined with small-volume hypertonic saline solution versus furosemide alone on heart failure biomarkers in acute decompensated HFrEF. The combination approach may enhance diuretic efficacy.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab1e60350b5d","type":"article","url":"https://hartvaat.nl/2021/10/01/katheterablatie-als-eerstelijns-paf-therapie-meta-analyse/","title":"Katheterablatie als eerstelijns PAF-therapie: meta-analyse","title_en":"Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2021-319496","source_url":"https://doi.org/10.1136/heartjnl-2021-319496","authors":["Jacopo F Imberti","Wern Yew Ding","Agnieszka Kotalczyk","Juqian Zhang","Giuseppe Boriani","Gregory Lip","Jason Andrade","Dhiraj Gupta"],"significance":7,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"This meta-analysis of catheter ablation as first-line treatment for paroxysmal AF confirmed superior efficacy over antiarrhythmic drugs for maintaining sinus rhythm, with a favorable safety profile supporting the ablation-first approach.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7533bf7e10ad","type":"article","url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","title":"Apothekerzorg bij poliklinisch HF: meta-analyse","title_en":"The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13508","source_url":"https://doi.org/10.1002/ehf2.13508","authors":["Pia M Schumacher","Nicolas Becker","Ross T Tsuyuki","Nina Griese-Mammen","Sheri L Koshman","Michael A McDonald","Marcel Bouvy","Frans H Rutten","Ulrich Laufs","Michael Böhm","Martin Schulz"],"significance":6,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis provided evidence that pharmacist-led care for outpatients with heart failure improves medication adherence, quality of life, and clinical outcomes, supporting interprofessional HF management models.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0bc26253703","type":"article","url":"https://hartvaat.nl/2021/10/01/revalidatie-bij-chronisch-hf-systematische-review-van-inspanningsinterventies/","title":"Revalidatie bij chronisch HF: systematische review van inspanningsinterventies","title_en":"A systematic review of rehabilitation in chronic heart failure: evaluating the reporting of exercise interventions.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13498","source_url":"https://doi.org/10.1002/ehf2.13498","authors":["Amy E Harwood","Sophie Russell","Nduka C Okwose","Scott McGuire","Djordje G Jakovljevic","Gordon McGregor"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review evaluated the quality of exercise intervention reporting in chronic heart failure rehabilitation trials, finding inconsistencies that hinder reproducibility and implementation of evidence-based programs.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b78211caf6d","type":"article","url":"https://hartvaat.nl/2021/10/01/empagliflozine-en-nierprotectie-bij-acuut-mi-met-diabetes-pilot/","title":"Empagliflozine en nierprotectie bij acuut MI met diabetes: pilot","title_en":"Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13509","source_url":"https://doi.org/10.1002/ehf2.13509","authors":["Kosuke Mozawa","Yoshiaki Kubota","Yu Hoshika","Shuhei Tara","Yukichi Tokita","Kenji Yodogawa","Yu-Ki Iwasaki","Takeshi Yamamoto","Hitoshi Takano","Yayoi Tsukada","Kuniya Asai","Masaaki Miyamoto","Yasushi Miyauchi","Eitaro Kodani","Mitsunori Maruyama","Jun Tanabe","Wataru Shimizu"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study demonstrated renoprotective effects of empagliflozin in patients with acute MI and type 2 diabetes, extending the kidney-protective benefits of SGLT2 inhibitors to the acute coronary care setting.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7653002b0db9","type":"article","url":"https://hartvaat.nl/2021/10/01/sglt2-remmers-en-hf-hospitalisatie-en-hartfunctie-systematische-review/","title":"SGLT2-remmers en HF-hospitalisatie en hartfunctie: systematische review","title_en":"Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","canagliflozine","dapagliflozine","empagliflozine","hfref"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13483","source_url":"https://doi.org/10.1002/ehf2.13483","authors":["Roy Rasalam","John J Atherton","Gary Deed","Michael Molloy-Bland","Neale Cohen","Andrew Sindone"],"significance":6,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review evaluated the effects of SGLT2 inhibitors on heart failure hospitalization and cardiac function parameters, consolidating the mechanistic and clinical evidence for SGLT2 inhibitor cardioprotection.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1e3f63b3253f","type":"article","url":"https://hartvaat.nl/2021/10/01/inspiratoire-spiertraining-plus-aerobe-training-en-neurovasculaire-controle-bij-/","title":"Inspiratoire spiertraining plus aerobe training en neurovasculaire controle bij chronisch HF","title_en":"Effects of inspiratory muscle training combined with aerobic exercise training on neurovascular control in chronic heart failure patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13478","source_url":"https://doi.org/10.1002/ehf2.13478","authors":["Patricia F Trevizan","Ligia M Antunes-Correa","Denise M L Lobo","Patricia A Oliveira","Dirceu R de Almeida","Maria Cristina D Abduch","Wilson Mathias Junior","Ludhmila Abrahão Hajjar","Roberto Kalil Filho","Carlos Eduardo Negrão"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This study tested whether combining inspiratory muscle training with aerobic exercise improves neurovascular control in chronic heart failure, showing synergistic effects on sympathetic nerve activity and baroreflex sensitivity.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fe47a35c8cdb","type":"article","url":"https://hartvaat.nl/2021/10/01/niet-invasieve-thuistelemonitoring-bij-gedecompenseerd-hf-meta-analyse/","title":"Niet-invasieve thuistelemonitoring bij gedecompenseerd HF: meta-analyse","title_en":"Non-invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","ouderen","secundaire-preventie","thuisbloeddrukmeting","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13475","source_url":"https://doi.org/10.1002/ehf2.13475","authors":["Teemu E I Drews","Jari Laukkanen","Tuomo Nieminen"],"significance":6,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of non-invasive home telemonitoring in decompensated heart failure showed that remote monitoring reduces mortality and readmission, supporting technology-enabled post-discharge surveillance.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d4a6bc8c1854","type":"article","url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-verbetert-hartfunctie-bij-chinese-hf-patienten-real-world/","title":"Sacubitril/valsartan verbetert hartfunctie bij Chinese HF-patiënten: real-world","title_en":"Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13491","source_url":"https://doi.org/10.1002/ehf2.13491","authors":["Wenwen Chen","Yanlin Liu","Yuanmin Li","Heqin Dang"],"significance":4,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"A real-world study from a Chinese tertiary hospital demonstrated that sacubitril/valsartan improves cardiac function in Chinese patients with HFrEF, adding to the evidence base beyond the original PARADIGM-HF trial population.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b483ab5ee74","type":"article","url":"https://hartvaat.nl/2021/09/30/ozanimod-bij-colitis-ulcerosa-nejm/","title":"Ozanimod bij colitis ulcerosa: NEJM","title_en":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.","category":"hypertensie","category_label":"Hypertensie","professions":["internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2033617","source_url":"https://doi.org/10.1056/NEJMoa2033617","authors":["William J Sandborn","Brian G Feagan","Geert D'Haens","Douglas C Wolf","Igor Jovanovic","Stephen B Hanauer","Subrata Ghosh","AnnKatrin Petersen","Steven Y Hua","Ji Hwan Lee","Lorna Charles","Denesh Chitkara","Keith Usiskin","Jean-Frederic Colombel","Loren Laine","Silvio Danese"],"significance":5,"published":"2021-09-30","source_date":"2021-09-30","image":"","kennis":[],"congress":"","summary_en":"This NEJM trial of ozanimod for ulcerative colitis is relevant to cardiology due to the S1P receptor modulator's effects on heart rate (transient bradycardia) and the need for cardiac monitoring during treatment initiation.","created":"2026-07-03T10:29:24Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b6791bbb67d3","type":"article","url":"https://hartvaat.nl/2021/09/30/intensieve-bloeddrukcontrole-bij-oudere-patienten-met-hypertensie-nejm-step/","title":"Intensieve bloeddrukcontrole bij oudere patiënten met hypertensie: NEJM STEP","title_en":"Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","bloeddrukbehandeling"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2111437","source_url":"https://doi.org/10.1056/NEJMoa2111437","authors":["Weili Zhang","Shuyuan Zhang","Yue Deng","Shouling Wu","Jie Ren","Gang Sun","Jinfeng Yang","Yinong Jiang","Xinjuan Xu","Tzung-Dau Wang","Youren Chen","Yufeng Li","Lianchen Yao","Dianfang Li","Lixin Wang","Xiaomei Shen","Xinhua Yin","Wei Liu","Xiaoyang Zhou","Bingpo Zhu","Zihong Guo","Hualing Liu","Xiaoping Chen","Yingqing Feng","Gang Tian","Xiuyin Gao","Kazuomi Kario","Jun Cai"],"significance":10,"published":"2021-09-30","source_date":"2021-09-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The STEP trial demonstrated that intensive blood pressure control (target 110–130 mmHg) significantly reduced cardiovascular events compared with standard treatment (130–150 mmHg) in Chinese patients aged 60–80 with hypertension. The results confirmed the benefits of intensive blood pressure targets in older adults, extending the findings of SPRINT to an Asian population.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7bd821f70679","type":"article","url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","title":"Empagliflozine verbetert CV en renale uitkomsten ongeacht systolische bloeddruk bij HF","title_en":"Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","canagliflozine","cystatine-c","dapagliflozine","empagliflozine","emperor-trials","hfref","perifeer-vaatlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.049","source_url":"https://doi.org/10.1016/j.jacc.2021.07.049","authors":["Michael Böhm","Stefan D Anker","Javed Butler","Gerasimos Filippatos","João Pedro Ferreira","Stuart J Pocock","Felix Mahfoud","Martina Brueckmann","Waheed Jamal","Anne Pernille Ofstad","Elke Schüler","Piotr Ponikowski","Christoph Wanner","Faiez Zannad","Milton Packer"],"significance":6,"published":"2021-09-28","source_date":"2021-09-28","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis confirmed that empagliflozin improves cardiovascular and renal outcomes regardless of baseline systolic blood pressure, supporting SGLT2 inhibitor use even in patients with lower blood pressures.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0e883f5ed505","type":"article","url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","title":"NT-proBNP prognose en empagliflozine-effect bij EMPEROR-Reduced","title_en":"Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["emperor-trials","nt-probnp"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.046","source_url":"https://doi.org/10.1016/j.jacc.2021.07.046","authors":["James L Januzzi","Faiez Zannad","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Stuart J Pocock","João Pedro Ferreira","Naveed Sattar","Subodh Verma","Ola Vedin","Janet Schnee","Tomoko Iwata","Dan Cotton","Milton Packer"],"significance":6,"published":"2021-09-28","source_date":"2021-09-28","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis showed that baseline NT-proBNP levels have prognostic value and that empagliflozin reduces heart failure events consistently across the natriuretic peptide spectrum.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0230eaa9d36e","type":"article","url":"https://hartvaat.nl/2021/09/21/1-jaar-inspanningstraining-keert-lv-stijfheid-om-bij-stadium-b-hf/","title":"1 jaar inspanningstraining keert LV-stijfheid om bij stadium B HF","title_en":"One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["nierfalen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.054117","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.054117","authors":["Michinari Hieda","Satyam Sarma","Christopher M Hearon","James P MacNamara","Katrin A Dias","Mitchel Samels","Dean Palmer","Sheryl Livingston","Margot Morris","Benjamin D Levine"],"significance":7,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":[],"congress":"","summary_en":"This study demonstrated that one year of committed high-intensity exercise training can reverse abnormal left ventricular myocardial stiffness in patients with stage B heart failure (hypertrophy with elevated biomarkers), supporting exercise as a disease-modifying intervention before clinical HF develops.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b3f4e92b049c","type":"article","url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","title":"PCSK9-remming en geoxideerde fosfolipiden","title_en":"PCSK9 Inhibition and Oxidized Phospholipids.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["enlicitide","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.031","source_url":"https://doi.org/10.1016/j.jacc.2021.07.031","authors":["Harpreet S Bhatia","Calvin Yeang","Amos Baruch","Xiaohong Yang","Erik S G Stroes","Sotirios Tsimikas"],"significance":6,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/"],"congress":"","summary_en":"This study examined the effect of PCSK9 inhibition on oxidized phospholipids, exploring whether evolocumab reduces these atherogenic mediators as an additional mechanism of cardiovascular protection beyond LDL lowering.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ed2ea642916e","type":"article","url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","title":"Bijwerkingspatronen in crossover trial statine/placebo/geen behandeling: StatinWISE","title_en":"Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.022","source_url":"https://doi.org/10.1016/j.jacc.2021.07.022","authors":["James P Howard","Frances A Wood","Judith A Finegold","Alexandra N Nowbar","David M Thompson","Ahran D Arnold","Christopher A Rajkumar","Susan Connolly","Jaimini Cegla","Chris Stride","Peter Sever","Christine Norton","Simon A M Thom","Matthew J Shun-Shin","Darrel P Francis"],"significance":7,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":[],"congress":"","summary_en":"This StatinWISE detailed analysis of daily symptom scores showed that statin-attributed side effects are largely not reproducible under blinded conditions, with patients experiencing similar symptom levels during statin, placebo, and no-treatment periods.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"be10b9598d01","type":"article","url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","title":"Dapagliflozine en ventriculaire aritmieën en plotse dood bij HF: DAPA-HF","title_en":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab560","source_url":"https://doi.org/10.1093/eurheartj/ehab560","authors":["James P Curtain","Kieran F Docherty","Pardeep S Jhund","Mark C Petrie","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Felipe A Martinez","Piotr Ponikowski","Marc S Sabatine","Olof Bengtsson","Anna Maria Langkilde","Mikaela Sjöstrand","Scott D Solomon","John J V McMurray"],"significance":7,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":[],"congress":"","summary_en":"This DAPA-HF analysis showed that dapagliflozin does not significantly reduce the incidence of ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in HFrEF, suggesting that the mortality benefit operates primarily through heart failure-related mechanisms.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b227d806a092","type":"article","url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","title":"Sacubitril/valsartan bij schijnbaar resistente hypertensie met HFpEF","title_en":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["answer-hf","aprocitentan","bloeddrukbehandeling","lorundrostat","resistente-hypertensie","resistente-hypertensie-aldosteronremmers","sacubitril-valsartan"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab499","source_url":"https://doi.org/10.1093/eurheartj/ehab499","authors":["Alice M Jackson","Pardeep S Jhund","Inder S Anand","Hans-Dirk Düngen","Carolyn S P Lam","Marty P Lefkowitz","Gerard Linssen","Lars H Lund","Aldo P Maggioni","Marc A Pfeffer","Jean L Rouleau","Jose F K Saraiva","Michele Senni","Orly Vardeny","Magnus O Wijkman","Mehmet B Yilmaz","Yoshihiko Saito","Michael R Zile","Scott D Solomon","John J V McMurray"],"significance":6,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This study showed that sacubitril-valsartan effectively lowers blood pressure in HFpEF patients with apparent resistant hypertension, identifying a potential additional indication for ARNI therapy in the hypertension-HFpEF overlap.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5549b30f9746","type":"article","url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","title":"Kwartdosis viervoudige combinatiepil versus standaardzorg bij hypertensie: Lancet QUARTET","title_en":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lorundrostat"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01922-X","source_url":"https://doi.org/10.1016/S0140-6736(21)01922-X","authors":["Clara K Chow","Emily R Atkins","Graham S Hillis","Mark R Nelson","Christopher M Reid","Markus P Schlaich","Peter Hay","Kris Rogers","Laurent Billot","Michael Burke","John Chalmers","Bruce Neal","Anushka Patel","Tim Usherwood","Ruth Webster","Anthony Rodgers"],"significance":9,"published":"2021-09-18","source_date":"2021-09-18","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"The QUARTET trial showed that initial treatment with a quarter-dose quadruple combination blood pressure pill achieved superior blood pressure control compared with standard care monotherapy at 12 weeks. The results support ultra-low-dose combination therapy as an effective strategy to overcome treatment inertia in hypertension.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"095bd94309aa","type":"article","url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","title":"Zoutsubstitutie en CV-events en sterfte: NEJM SSaSS","title_en":"Effect of Salt Substitution on Cardiovascular Events and Death.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2105675","source_url":"https://doi.org/10.1056/NEJMoa2105675","authors":["Bruce Neal","Yangfeng Wu","Xiangxian Feng","Ruijuan Zhang","Yuhong Zhang","Jingpu Shi","Jianxin Zhang","Maoyi Tian","Liping Huang","Zhifang Li","Yan Yu","Yi Zhao","Bo Zhou","Jixin Sun","Yishu Liu","Xuejun Yin","Zhixin Hao","Jie Yu","Ka-Chun Li","Xinyi Zhang","Peifen Duan","Faxuan Wang","Bing Ma","Weiwei Shi","Gian Luca Di Tanna","Sandrine Stepien","Sana Shan","Sallie-Anne Pearson","Nicole Li","Lijing L Yan","Darwin Labarthe","Paul Elliott"],"significance":10,"published":"2021-09-16","source_date":"2021-09-16","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"The SSaSS trial showed that replacing regular salt with a potassium-enriched salt substitute in 20,995 participants significantly reduced stroke, cardiovascular events, and all-cause mortality without increasing hyperkalemia. This is the largest dietary intervention trial in cardiovascular prevention and demonstrates a scalable public health strategy.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97ffb5a6086f","type":"article","url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","title":"COPD bij AF: prevalentie, management en impact — meta-analyse","title_en":"Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab453","source_url":"https://doi.org/10.1093/eurheartj/ehab453","authors":["Giulio Francesco Romiti","Bernadette Corica","Eugenia Pipitone","Marco Vitolo","Valeria Raparelli","Stefania Basili","Giuseppe Boriani","Sergio Harari","Gregory Y H Lip","Marco Proietti"],"significance":6,"published":"2021-09-14","source_date":"2021-09-14","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis quantified the prevalence and adverse impact of COPD in AF patients, showing that respiratory comorbidity significantly worsens cardiovascular outcomes in the atrial fibrillation population.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"75374e99a2ea","type":"article","url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","title":"Hemodynamisch geleid HF-management: Lancet GUIDE-HF","title_en":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["pathfinder-trial","step-hfpef"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01754-2","source_url":"https://doi.org/10.1016/S0140-6736(21)01754-2","authors":["JoAnn Lindenfeld","Michael R Zile","Akshay S Desai","Kunjan Bhatt","Anique Ducharme","Douglas Horstmanshof","Selim R Krim","Alan Maisel","Mandeep R Mehra","Sara Paul","Samuel F Sears","Andrew J Sauer","Frank Smart","Marcel Zughaib","Paige Castaneda","Jean Kelly","Nessa Johnson","Poornima Sood","Greg Ginn","John Henderson","Philip B Adamson","Maria Rosa Costanzo"],"significance":8,"published":"2021-09-11","source_date":"2021-09-11","image":"","kennis":[],"congress":"","summary_en":"The GUIDE-HF trial of hemodynamic-guided heart failure management with implantable PA pressure sensors showed no significant overall benefit, though a pre-COVID subanalysis suggested reduced heart failure events. The results highlighted the confounding impact of the pandemic on heart failure trials.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a31e3152d808","type":"article","url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","title":"Antiaritmica bij vroeg persisterend AF met HF: RACE 3","title_en":"Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab062","source_url":"https://doi.org/10.1093/europace/euab062","authors":["Meelad I H Al-Jazairi","Bao-Oanh Nguyen","Ruben R De With","Marcelle D Smit","Bob Weijs","Anne H Hobbelt","Marco Alings","Jan G P Tijssen","Bastiaan Geelhoed","Hans L Hillege","Robert G Tieleman","Dirk J Van Veldhuisen","Harry J G M Crijns","Isabelle C Van Gelder","Yuri Blaauw","Michiel Rienstra"],"significance":6,"published":"2021-09-08","source_date":"2021-09-08","image":"","kennis":[],"congress":"","summary_en":"This RACE 3 analysis evaluated antiarrhythmic drug use in patients with early persistent AF and heart failure, showing that rhythm control drugs have limited additional benefit when combined with upstream therapy targeting risk factors.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"611a0db9b822","type":"article","url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","title":"Hartfrequentie en uitkomsten van renale denervatie bij ongecontroleerde hypertensie","title_en":"Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","bisoprolol","bloeddrukbehandeling","cardiorenal-behandelstrategie","chronische-nierziekte","cystatine-c","diuretica","endotheel","fidelity","flow-trial","ivabradine","radiance-htn","renale-denervatie","resistente-hypertensie","sacubitril-valsartan","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.06.044","source_url":"https://doi.org/10.1016/j.jacc.2021.06.044","authors":["Michael Böhm","Konstantinos Tsioufis","David E Kandzari","Kazuomi Kario","Michael A Weber","Roland E Schmieder","Raymond R Townsend","Saarraaken Kulenthiran","Christian Ukena","Stuart Pocock","Sebastian Ewen","Joachim Weil","Martin Fahy","Felix Mahfoud"],"significance":5,"published":"2021-09-07","source_date":"2021-09-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This analysis showed that baseline heart rate influences the blood pressure-lowering response to renal denervation, identifying heart rate as a predictor of RDN efficacy in uncontrolled hypertension.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T18:38:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"12f7ad5ed2cc","type":"article","url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","title":"Efpeglenatide en CV en renale uitkomsten bij diabetes type 2: NEJM AMPLITUDE-O","title_en":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-2","ezetimibe","fidelio-dkd","figaro-dkd","flow-trial","glp1-semaglutide-cardiovasculair","liraglutide","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2108269","source_url":"https://doi.org/10.1056/NEJMoa2108269","authors":["Hertzel C Gerstein","Naveed Sattar","Julio Rosenstock","Chinthanie Ramasundarahettige","Richard Pratley","Renato D Lopes","Carolyn S P Lam","Nardev S Khurmi","Laura Heenan","Stefano Del Prato","Leanne Dyal","Kelley Branch"],"significance":9,"published":"2021-09-02","source_date":"2021-09-02","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The AMPLITUDE-O trial demonstrated that efpeglenatide, an exendin-based GLP-1 receptor agonist, reduced cardiovascular events and kidney outcomes in patients with type 2 diabetes at high cardiovascular risk. This was the sixth positive GLP-1 RA cardiovascular outcomes trial, extending the class benefit to a structurally distinct agent.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"39e4a115ea00","type":"article","url":"https://hartvaat.nl/2021/09/01/million-hearts-cv-risicoreductiemodel-en-medicatie-initiatie-jama-cardiology/","title":"Million Hearts CV-risicoreductiemodel en medicatie-initiatie: JAMA Cardiology","title_en":"Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.1565","source_url":"https://doi.org/10.1001/jamacardio.2021.1565","authors":["G Greg Peterson","Jia Pu","David J Magid","Linda Barterian","Keith Kranker","Michael Barna","Leslie Conwell","Adam Rose","Laura Blue","Amanda Markovitz","Nancy McCall","Patricia Markovich"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that the Million Hearts cardiovascular risk reduction model successfully increases initiation and intensification of preventive medications, translating the pay-for-performance approach into measurable prescribing changes.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e3790293a47","type":"article","url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","title":"Sekseverschillen bij ticagrelor ± aspirine na PCI bij hoog risico: TWILIGHT","title_en":"Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.1720","source_url":"https://doi.org/10.1001/jamacardio.2021.1720","authors":["Birgit Vogel","Usman Baber","David J Cohen","Samantha Sartori","Samin K Sharma","Dominick J Angiolillo","Serdar Farhan","Ridhima Goel","Zhongjie Zhang","Carlo Briguori","Timothy Collier","George Dangas","Dariusz Dudek","Javier Escaned","Robert Gil","Ya-Ling Han","Upendra Kaul","Ran Kornowski","Mitchell W Krucoff","Vijay Kunadian","Shamir R Mehta","David Moliterno","E Magnus Ohman","Gennaro Sardella","Bernhard Witzenbichler","C Michael Gibson","Stuart Pocock","Kurt Huber","Roxana Mehran"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This TWILIGHT sex-stratified analysis showed that ticagrelor monotherapy after short DAPT reduces bleeding similarly in women and men undergoing PCI, confirming sex-equal benefit of the de-escalation strategy.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"643c9930591a","type":"article","url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","title":"Normalisatie van arteriële stijfheid en CV-events: SPARTE-studie","title_en":"SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["perifeer-vaatlijden"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17579","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17579","authors":["Stephane Laurent","Gilles Chatellier","Michel Azizi","David Calvet","Gabriel Choukroun","Nicolas Danchin","Pascal Delsart","Xavier Girerd","Philippe Gosse","Hakim Khettab","Gerard London","Jean-Jacques Mourad","Bruno Pannier","Helena Pereira","Dominique Stephan","Paul Valensi","Pedro Cunha","Krzysztof Narkiewicz","Rosa-Maria Bruno","Pierre Boutouyrie"],"significance":7,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/cardiovasculaire-risicoschatting-score2/"],"congress":"","summary_en":"The SPARTE study investigated whether targeting normalization of arterial stiffness (pulse wave velocity) reduces cardiovascular events in hypertensive patients at moderate-to-high risk, testing a biomarker-guided treatment strategy.","created":"2026-07-03T10:29:22Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"834a5b23bb57","type":"article","url":"https://hartvaat.nl/2021/09/01/ace-remmer-plus-calciumantagonist-bij-zwarte-hypertensieve-patienten/","title":"ACE-remmer plus calciumantagonist bij zwarte hypertensieve patiënten","title_en":"Cardiovascular Benefits of Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Black Hypertensive Patients.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["ace-remmers","amlodipine","aprocitentan","baxdrostat","bloeddrukbehandeling","calciumantagonisten","cardiorenal-behandelstrategie","ezetimibe","figaro-dkd","lorundrostat","precision-trial","ramipril","ras-remmers","resistente-hypertensie","sacubitril-valsartan"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17990","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17990","authors":["Robert D Brook","Niko Kaciroti","Taylor Jamerson","Kenneth A Jamerson"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This analysis showed that combination ACE inhibitor plus calcium channel blocker therapy provides superior cardiovascular benefit in Black hypertensive patients, informing drug class selection in populations with different pharmacogenomic responses.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d9dbdc6dcf0a","type":"article","url":"https://hartvaat.nl/2021/09/01/arts-apotheker-samenwerkingsmodel-en-time-in-target-bloeddruk-post-hoc-analyse/","title":"Arts-apotheker samenwerkingsmodel en time-in-target bloeddruk: post-hoc analyse","title_en":"Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17873","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17873","authors":["Dave L Dixon","William L Baker","Leo F Buckley","Teresa M Salgado","Benjamin W Van Tassell","Barry L Carter"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This post-hoc analysis showed that a physician-pharmacist collaborative care model improves blood pressure time-in-target range, demonstrating that team-based management achieves more sustained blood pressure control than usual care.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"455b26654e1b","type":"article","url":"https://hartvaat.nl/2021/09/01/zorginterventies-voor-hypertensie-bij-achtergestelde-populaties-in-de-vs-meta-an/","title":"Zorginterventies voor hypertensie bij achtergestelde populaties in de VS: meta-analyse","title_en":"Health Care Delivery Interventions for Hypertension Management in Underserved Populations in the United States: A Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.15946","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.15946","authors":["Maarya Pasha","LaPrincess C Brewer","Susie Sennhauser","Mouaz Alsawas","M Hassan Murad"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review evaluated healthcare delivery interventions for hypertension in underserved US populations, identifying team-based care, community health workers, and digital health as the most effective approaches for closing treatment disparities.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"da422aacaa5c","type":"article","url":"https://hartvaat.nl/2021/09/01/langetermijn-bloeddrukvariabiliteit-en-dementierisico-meta-analyse/","title":"Langetermijn bloeddrukvariabiliteit en dementierisico: meta-analyse","title_en":"Long-Term Blood Pressure Variability Increases Risks of Dementia and Cognitive Decline: A Meta-Analysis of Longitudinal Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17788","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17788","authors":["Pingping Jia","Helen W Y Lee","Joyce Y C Chan","Karen K L Yiu","Kelvin K F Tsoi"],"significance":7,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of longitudinal studies demonstrated that long-term blood pressure variability (visit-to-visit fluctuations) is independently associated with increased risk of dementia and cognitive decline, beyond mean blood pressure levels.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6e8d97d7ed3b","type":"article","url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","title":"Albuminurietesting bij hypertensie en diabetes: IPD meta-analyse","title_en":"Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17323","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17323","authors":["Jung-Im Shin","Alex R Chang","Morgan E Grams","Josef Coresh","Shoshana H Ballew","Aditya Surapaneni","Kunihiro Matsushita","Henk J G Bilo","Juan J Carrero","Gabriel Chodick","Kenn B Daratha","Simerjot K Jassal","Girish N Nadkarni","Robert G Nelson","Christoph Nowak","Nikita Stempniewicz","Keiichi Sumida","Jamie P Traynor","Mark Woodward","Yingying Sang","Ron T Gansevoort"],"significance":7,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This individual participant data meta-analysis from a global consortium showed that albuminuria testing provides important prognostic information in patients with hypertension and diabetes, supporting routine albuminuria screening for cardiovascular and renal risk stratification.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"64dcff1cfad1","type":"article","url":"https://hartvaat.nl/2021/09/01/slaaprestrictie-en-ambulante-en-slaap-bloeddruk-gerandomiseerde-crossover/","title":"Slaaprestrictie en ambulante en slaap-bloeddruk: gerandomiseerde crossover","title_en":"Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17622","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17622","authors":["Naima Covassin","Jan Bukartyk","Prachi Singh","Andrew D Calvin","Erik K St Louis","Virend K Somers"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This randomized crossover trial demonstrated that experimental sleep restriction increases both ambulatory and nocturnal blood pressure in healthy young adults, establishing a causal link between insufficient sleep and blood pressure elevation.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35aefd701b5e","type":"article","url":"https://hartvaat.nl/2021/09/01/bloed-hersenbarriere-kruisende-raas-middelen-en-cognitie-bij-ouderen-meta-analys/","title":"Bloed-hersenbarrière kruisende RAAS-middelen en cognitie bij ouderen: meta-analyse","title_en":"Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17049","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17049","authors":["Jean K Ho","Frank Moriarty","Jennifer J Manly","Eric B Larson","Denis A Evans","Kumar B Rajan","Elizabeth M Hudak","Lamiaa Hassan","Enwu Liu","Nobuyuki Sato","Naoyuki Hasebe","Danielle Laurin","Pierre-Hugues Carmichael","Daniel A Nation"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that blood-brain-barrier-crossing RAAS inhibitors may have superior cognitive benefits compared with non-crossing agents in elderly hypertensive patients, informing antihypertensive drug selection for neuroprotection.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d17366aa1df6","type":"article","url":"https://hartvaat.nl/2021/09/01/bloeddrukverlagende-middelen-en-antibiotica-en-aaa-groei-meta-analyse/","title":"Bloeddrukverlagende middelen en antibiotica en AAA-groei: meta-analyse","title_en":"Effect of blood pressure lowering drugs and antibiotics on abdominal aortic aneurysm growth: a systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-318192","source_url":"https://doi.org/10.1136/heartjnl-2020-318192","authors":["Jonathan Golledge","Tejas P Singh"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/"],"congress":"","summary_en":"This meta-analysis evaluated the effect of blood pressure-lowering drugs and antibiotics on abdominal aortic aneurysm growth, finding limited evidence for pharmacological slowing of aneurysm progression.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a31b0bf6bf90","type":"article","url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","title":"Colchicine bij chronisch coronairlijden met versus zonder eerder ACS","title_en":"Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.06.037","source_url":"https://doi.org/10.1016/j.jacc.2021.06.037","authors":["Tjerk S J Opstal","Aernoud T L Fiolet","Amber van Broekhoven","Arend Mosterd","John W Eikelboom","Stefan M Nidorf","Peter L Thompson","Michiel Duyvendak","J W Martijn van Eck","Eugène A van Beek","Frank den Hartog","Charley A Budgeon","Willem A Bax","Jan G P Tijssen","Saloua El Messaoudi","Jan H Cornel"],"significance":6,"published":"2021-08-31","source_date":"2021-08-31","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"This analysis of colchicine in chronic coronary disease stratified by prior ACS showed that the anti-inflammatory benefit is consistent regardless of ACS history, supporting colchicine use across the stable coronary disease population.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e98fe010da78","type":"article","url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","title":"2021 ACC consensus: ASCVD-risicoreductie bij persistente hypertriglyceridemie","title_en":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.06.011","source_url":"https://doi.org/10.1016/j.jacc.2021.06.011","authors":["Salim S Virani","Pamela B Morris","Anandita Agarwala","Christie M Ballantyne","Kim K Birtcher","Penny M Kris-Etherton","Amanda B Ladden-Stirling","Michael Miller","Carl E Orringer","Neil J Stone"],"significance":8,"published":"2021-08-31","source_date":"2021-08-31","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The 2021 ACC Expert Consensus addressed ASCVD risk reduction in patients with persistent hypertriglyceridemia, providing decision algorithms integrating icosapent ethyl, fibrates, and lifestyle modification based on the REDUCE-IT and STRENGTH evidence.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f5cb669e363","type":"article","url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","title":"De-escalatie van DAPT bij ACS: JACC review","title_en":"De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.06.012","source_url":"https://doi.org/10.1016/j.jacc.2021.06.012","authors":["Satoshi Shoji","Toshiki Kuno","Tomohiro Fujisaki","Hisato Takagi","Alexandros Briasoulis","Pierre Deharo","Thomas Cuisset","Azeem Latib","Shun Kohsaka"],"significance":7,"published":"2021-08-24","source_date":"2021-08-24","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This JACC review comprehensively summarized all available evidence on DAPT de-escalation strategies after ACS, including guided (pharmacogenomic/pharmacodynamic), unguided, dose-reduction, and early aspirin discontinuation approaches.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f39d5b1ffced","type":"article","url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","title":"IV ijzercarboxymaltose en QoL bij ijzerdeficiënt acuut HF: AFFIRM-AHF","title_en":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab234","source_url":"https://doi.org/10.1093/eurheartj/ehab234","authors":["Ewa A Jankowska","Bridget-Anne Kirwan","Mikhail Kosiborod","Javed Butler","Stefan D Anker","Theresa McDonagh","Maria Dorobantu","Jarosław Drozdz","Gerasimos Filippatos","Andre Keren","Irakli Khintibidze","Hans Kragten","Felipe A Martinez","Marco Metra","Davor Milicic","José C Nicolau","Marcus Ohlsson","Alexander Parkhomenko","Domingo A Pascual-Figal","Frank Ruschitzka","David Sim","Hadi Skouri","Peter van der Meer","Basil S Lewis","Josep Comin-Colet","Stephan von Haehling","Alain Cohen-Solal","Nicolas Danchin","Wolfram Doehner","Henry J Dargie","Michael Motro","Tim Friede","Vincent Fabien","Fabio Dorigotti","Stuart Pocock","Piotr Ponikowski"],"significance":6,"published":"2021-08-17","source_date":"2021-08-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"This AFFIRM-AHF quality-of-life analysis showed that intravenous ferric carboxymaltose significantly improves health-related quality of life in iron-deficient patients with acute heart failure, complementing the clinical event data.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d7c79f54bedf","type":"article","url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","title":"Cholesterol- en bloeddrukverlaging na HOPE-3: 8,7-jaars follow-up","title_en":"Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipidenverlaging","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab225","source_url":"https://doi.org/10.1093/eurheartj/ehab225","authors":["Jackie Bosch","Eva M Lonn","Hyejung Jung","Jun Zhu","Lisheng Liu","Patricio Lopez-Jaramillo","Prem Pais","Denis Xavier","Rafael Diaz","Gilles Dagenais","Antonio Dans","Alvaro Avezum","Leopoldo S Piegas","Alexander Parkhomenko","Kati Keltai","Matyas Keltai","Karen Sliwa","Claus Held","Ronald J G Peters","Basil S Lewis","Petr Jansky","Khalid Yusoff","Kamlesh Khunti","William D Toff","Christopher M Reid","John Varigos","Philip Joseph","Lawrence A Leiter","Salim Yusuf"],"significance":8,"published":"2021-08-17","source_date":"2021-08-17","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/"],"congress":"","summary_en":"The HOPE-3 extended 8.7-year follow-up showed that the cardiovascular benefits of rosuvastatin observed during the active treatment period persisted after trial completion, suggesting a legacy effect of intermediate-risk lipid lowering on long-term cardiovascular protection.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"11f4fe615cc2","type":"article","url":"https://hartvaat.nl/2021/08/14/tirzepatide-versus-insuline-degludec-bij-diabetes-type-2-lancet-surpass-3/","title":"Tirzepatide versus insuline degludec bij diabetes type 2: Lancet SURPASS-3","title_en":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01443-4","source_url":"https://doi.org/10.1016/S0140-6736(21)01443-4","authors":["Bernhard Ludvik","Francesco Giorgino","Esteban Jódar","Juan P Frias","Laura Fernández Landó","Katelyn Brown","Ross Bray","Ángel Rodríguez"],"significance":8,"published":"2021-08-14","source_date":"2021-08-14","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The SURPASS-3 trial demonstrated that tirzepatide was superior to insulin degludec for glycemic control and weight loss when added to metformin with or without an SGLT2 inhibitor in type 2 diabetes. The results positioned tirzepatide as a potent alternative to basal insulin.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"86b4a76f45ce","type":"article","url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","title":"Orale antiaritmica voor cardioversie van recent-onset AF: netwerkmeta-analyse","title_en":"Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab014","source_url":"https://doi.org/10.1093/europace/euab014","authors":["Omar A Ibrahim","Emilie P Belley-Côté","Kevin J Um","Adrian Baranchuk","Alexander P Benz","Shreyash Dalmia","Chang N Wang","Waleed Alhazzani","David Conen","P J Devereaux","Richard P Whitlock","Jeff S Healey","William F McIntyre"],"significance":6,"published":"2021-08-06","source_date":"2021-08-06","image":"","kennis":[],"congress":"","summary_en":"This network meta-analysis of single-dose oral antiarrhythmic drugs for recent-onset AF cardioversion identified the most effective agents and their relative efficacy, informing the pill-in-the-pocket approach to acute rhythm management.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9df957d26b5a","type":"article","url":"https://hartvaat.nl/2021/08/06/ventriculaire-aritmie-bij-crt-responders-en-super-responders-meta-analyse/","title":"Ventriculaire aritmie bij CRT-responders en super-responders: meta-analyse","title_en":"Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa414","source_url":"https://doi.org/10.1093/europace/euaa414","authors":["Matthew F Yuyun","Sebhat A Erqou","Adelqui O Peralta","Peter S Hoffmeister","Hirad Yarmohammadi","Justin B Echouffo Tcheugui","David T Martin","Jacob Joseph","Jagmeet P Singh"],"significance":5,"published":"2021-08-06","source_date":"2021-08-06","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that CRT responders and super-responders have reduced risk of ventricular arrhythmias compared with non-responders, supporting the antiarrhythmic effect of successful resynchronization.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5d3c321153a1","type":"article","url":"https://hartvaat.nl/2021/08/05/milrinone-versus-dobutamine-bij-cardiogene-shock-nejm-doremi/","title":"Milrinone versus dobutamine bij cardiogene shock: NEJM DOREMI","title_en":"Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2026845","source_url":"https://doi.org/10.1056/NEJMoa2026845","authors":["Rebecca Mathew","Pietro Di Santo","Richard G Jung","Jeffrey A Marbach","Jordan Hutson","Trevor Simard","F Daniel Ramirez","David T Harnett","Anas Merdad","Aws Almufleh","Willy Weng","Omar Abdel-Razek","Shannon M Fernando","Kwadwo Kyeremanteng","Jordan Bernick","George A Wells","Vincent Chan","Michael Froeschl","Marino Labinaz","Michel R Le May","Juan J Russo","Benjamin Hibbert"],"significance":8,"published":"2021-08-05","source_date":"2021-08-05","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/"],"congress":"","summary_en":"The DOREMI trial found no significant difference between milrinone and dobutamine for the primary outcome in patients with cardiogenic shock. As the first large head-to-head comparison of inotropes in shock, it established that neither agent is clearly superior.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63e834cfc811","type":"article","url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","title":"Lp(a) en PCSK9-remmingsvoordeel bij nominaal gecontroleerd LDL","title_en":"Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["dyslipidemie","ezetimibe","laminopathie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","statines"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.102","source_url":"https://doi.org/10.1016/j.jacc.2021.04.102","authors":["Gregory G Schwartz","Michael Szarek","Vera A Bittner","Rafael Diaz","Shaun G Goodman","J Wouter Jukema","Ulf Landmesser","Patricio López-Jaramillo","Garen Manvelian","Robert Pordy","Michel Scemama","Peter R Sinnaeve","Harvey D White","Ph Gabriel Steg"],"significance":7,"published":"2021-08-03","source_date":"2021-08-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This analysis showed that elevated Lp(a) identifies patients who benefit from PCSK9 inhibition even when LDL cholesterol appears adequately controlled, supporting Lp(a) measurement to guide treatment escalation decisions.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d33da4695961","type":"article","url":"https://hartvaat.nl/2021/08/01/aobp-na-nul-versus-vijf-minuten-rust-gerandomiseerde-trial/","title":"AOBP na nul versus vijf minuten rust: gerandomiseerde trial","title_en":"Randomized Controlled Trial Comparing Automated Office Blood Pressure Readings After Zero or Five Minutes of Rest.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17319","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17319","authors":["Sheldon W Tobe","Lisa Dubrofsky","Daniel I Nasser","Raveenie Rajasingham","Martin G Myers"],"significance":6,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This randomized trial showed that automated office blood pressure readings obtained after zero minutes of rest are comparable to those after five minutes, simplifying the measurement protocol for clinical practice.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b70f9823b15","type":"article","url":"https://hartvaat.nl/2021/08/01/fenotype-van-cpap-responders-bij-resistente-hypertensie-hiparco/","title":"Fenotype van CPAP-responders bij resistente hypertensie: HIPARCO","title_en":"Clinical Phenotype of Resistant Hypertension Responders to Continuous Positive Airway Pressure Treatment: Results From the HIPARCO Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17364","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17364","authors":["Miguel Angel Martinez-Garcia","Martino F Pengo"],"significance":5,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":[],"congress":"","summary_en":"This HIPARCO analysis characterized the clinical phenotype of resistant hypertension patients who respond to CPAP therapy, identifying which obstructive sleep apnea patients benefit most from positive airway pressure for blood pressure control.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"739f7cc4f759","type":"article","url":"https://hartvaat.nl/2021/08/01/motivational-interviewing-en-zorggebruik-en-mortaliteit-bij-hf-motivate-hf/","title":"Motivational interviewing en zorggebruik en mortaliteit bij HF: MOTIVATE-HF","title_en":"Effectiveness of motivational interviewing on health-service use and mortality: a secondary outcome analysis of the MOTIVATE-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13373","source_url":"https://doi.org/10.1002/ehf2.13373","authors":["Paolo Iovino","Paola Rebora","Giuseppe Occhino","Valentina Zeffiro","Gabriele Caggianelli","Davide Ausili","Rosaria Alvaro","Barbara Riegel","Ercole Vellone"],"significance":6,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This MOTIVATE-HF secondary analysis showed that motivational interviewing reduces healthcare service use and may improve mortality in heart failure patients, demonstrating both clinical and economic benefits of behavioral intervention.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e1377f6408ef","type":"article","url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","title":"GDF-15 en liraglutide-behandeling bij HF-patiënten","title_en":"Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13348","source_url":"https://doi.org/10.1002/ehf2.13348","authors":["Abhinav Sharma","Stephen Greene","Muthiah Vaduganathan","Marat Fudim","Andrew P Ambrosy","Jie-Lena Sun","Steven E McNulty","Adrian F Hernandez","Barry A Borlaug","Eric J Velazquez","Robert J Mentz","Adam D DeVore","Brooke Alhanti","Kenneth Margulies","G Michael Felker"],"significance":5,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":[],"congress":"","summary_en":"This analysis evaluated GDF-15 as a biomarker in heart failure patients treated with liraglutide, assessing whether this stress-responsive cytokine predicts treatment response and cardiovascular outcomes.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fbea7a3b3ece","type":"article","url":"https://hartvaat.nl/2021/08/01/geschiktheid-van-poliklinische-chronische-hf-patienten-voor-sglt2-remmers/","title":"Geschiktheid van poliklinische chronische HF-patiënten voor SGLT2-remmers","title_en":"Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","chronische-nierziekte","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13380","source_url":"https://doi.org/10.1002/ehf2.13380","authors":["Gianmarco Angelini","Miriam Albanese","Raffaella Ursi","Francesco Lisi","Maria Consiglia Bellino","Luca Amato","Margherita Ilaria Gioia","Giuseppe Parisi","Natale Daniele Brunetti","Giuseppina Piazzolla","Marco Matteo Ciccone","Massimo Iacoviello"],"significance":6,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":[],"congress":"","summary_en":"This analysis estimated the proportion of outpatient chronic heart failure patients eligible for SGLT2 inhibitors based on trial criteria, identifying the implementation opportunity and potential treatment gap.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5dfcefe023c2","type":"article","url":"https://hartvaat.nl/2021/08/01/polsgolfcalibratie-en-implicaties-voor-bloeddrukmeting-meta-analyse/","title":"Polsgolfcalibratie en implicaties voor bloeddrukmeting: meta-analyse","title_en":"Pulse Wave Calibration and Implications for Blood Pressure Measurement: Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16817","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16817","authors":["Dawid Jedrzejewski","Ewan McFarlane","Peter S Lacy","Bryan Williams"],"significance":5,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/bloeddrukmeting-thuismeting-abpm/"],"congress":"","summary_en":"This meta-analysis evaluated pulse wave calibration methods and their implications for blood pressure measurement accuracy, addressing a fundamental technical issue that affects all non-invasive BP devices.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"028717bd92a4","type":"article","url":"https://hartvaat.nl/2021/08/01/echo-optimalisatie-van-lvad-en-functionele-capaciteit-gerandomiseerde-trial/","title":"Echo-optimalisatie van LVAD en functionele capaciteit: gerandomiseerde trial","title_en":"Effects of echo-optimization of left ventricular assist devices on functional capacity, a randomized controlled trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13359","source_url":"https://doi.org/10.1002/ehf2.13359","authors":["Marzia Lilliu","Francesco Onorati","Giovanni Battista Luciani","Giuseppe Faggian"],"significance":5,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"This randomized trial tested whether echo-guided optimization of LVAD pump parameters improves exercise capacity, evaluating individualized device programming for functional benefit in mechanically supported patients.","created":"2026-07-03T10:29:19Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edb5530b1a75","type":"article","url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","title":"Klinische fenotypen zijn effectiever dan EF-categorieën voor HF-uitkomsten","title_en":"Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13344","source_url":"https://doi.org/10.1002/ehf2.13344","authors":["Andreas B Gevaert","Semra Tibebu","Mamas A Mamas","Neal G Ravindra","Shun Fu Lee","Tariq Ahmad","Dennis T Ko","James L Januzzi","Harriette G C Van Spall"],"significance":6,"published":"2021-08-01","source_date":"2021-08-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that data-driven clinical phenotype clusters stratify heart failure risk more effectively than traditional LVEF categories, supporting the move toward phenotype-based rather than EF-based classification.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9674dc6c6de4","type":"article","url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","title":"Ziekenhuis- en post-ontslagkwaliteitsinterventie bij HF: JAMA CONNECT-HF","title_en":"Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["dapa-hf"],"journal":"JAMA","doi":"10.1001/jama.2021.8844","source_url":"https://doi.org/10.1001/jama.2021.8844","authors":["Adam D DeVore","Bradi B Granger","Gregg C Fonarow","Hussein R Al-Khalidi","Nancy M Albert","Eldrin F Lewis","Javed Butler","Ileana L Piña","Larry A Allen","Clyde W Yancy","Lauren B Cooper","G Michael Felker","Lisa A Kaltenbach","A Thomas McRae","David E Lanfear","Robert W Harrison","Maghee Disch","Dan Ariely","Julie M Miller","Christopher B Granger","Adrian F Hernandez"],"significance":7,"published":"2021-07-27","source_date":"2021-07-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/"],"congress":"","summary_en":"The CONNECT-HF trial showed that a hospital and post-discharge quality improvement intervention did not significantly reduce mortality or heart failure rehospitalization, highlighting the challenges of translating guideline adherence into outcome improvement.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c4f0f9675862","type":"article","url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","title":"Heeft deze volwassene hypertensie? JAMA Rational Clinical Examination","title_en":"Does This Adult Patient Have Hypertension?: The Rational Clinical Examination Systematic Review.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.4533","source_url":"https://doi.org/10.1001/jama.2021.4533","authors":["Anthony J Viera","Yuichiro Yano","Feng-Chang Lin","David L Simel","Jonathan Yun","Gaurav Dave","Ann Von Holle","Laura A Viera","Daichi Shimbo","Shakia T Hardy","Katrina E Donahue","Alan Hinderliter","Christiane E Voisin","Daniel E Jonas"],"significance":7,"published":"2021-07-27","source_date":"2021-07-27","image":"","kennis":[],"congress":"","summary_en":"This JAMA Rational Clinical Examination review addressed how to diagnose hypertension in adults, comparing office, home, and ambulatory blood pressure measurement methods and their diagnostic accuracy.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f9140c90b2ac","type":"article","url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","title":"Multivaten-PCI geleid door FFR of angiografie bij MI: NEJM FLOWER-MI","title_en":"Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2104650","source_url":"https://doi.org/10.1056/NEJMoa2104650","authors":["Etienne Puymirat","Guillaume Cayla","Tabassome Simon","Philippe G Steg","Gilles Montalescot","Isabelle Durand-Zaleski","Alicia le Bras","Romain Gallet","Khalife Khalife","Jean-François Morelle","Pascal Motreff","Gilles Lemesle","Jean-Guillaume Dillinger","Thibault Lhermusier","Johanne Silvain","Vincent Roule","Jean-Noel Labèque","Grégoire Rangé","Grégory Ducrocq","Yves Cottin","Didier Blanchard","Anaïs Charles Nelson","Bernard De Bruyne","Gilles Chatellier","Nicolas Danchin"],"significance":9,"published":"2021-07-22","source_date":"2021-07-22","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/coronaire-angiografie-hartkatheterisatie/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The FLOWER-MI trial showed that FFR-guided complete revascularization of nonculprit lesions did not reduce the composite of death, MI, or urgent revascularization compared with angiography-guided PCI in patients with STEMI and multivessel disease. The surprising negative result questioned the added value of FFR guidance in the acute MI setting.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"331b48451b16","type":"article","url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","title":"Laaggedoseerd colchicine bij coronairlijden: meta-analyse van gerandomiseerde trials","title_en":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["colchicine","colcot-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab115","source_url":"https://doi.org/10.1093/eurheartj/ehab115","authors":["Aernoud T L Fiolet","Tjerk S J Opstal","Arend Mosterd","John W Eikelboom","Sanjit S Jolly","Anthony C Keech","Peter Kelly","David C Tong","Jamie Layland","Stefan M Nidorf","Peter L Thompson","Charley Budgeon","Jan G P Tijssen","Jan H Cornel"],"significance":8,"published":"2021-07-21","source_date":"2021-07-21","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This meta-analysis of colchicine trials in coronary disease confirmed that low-dose colchicine reduces cardiovascular events with an acceptable safety profile, integrating COLCOT, LoDoCo2, and COPS data. The pooled evidence supported colchicine as a cost-effective anti-inflammatory strategy.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0ad936dc6146","type":"article","url":"https://hartvaat.nl/2021/07/18/smartphone-ecg-voor-af-detectie-na-cerebrovasculair-event-multicenter-rct/","title":"Smartphone-ECG voor AF-detectie na cerebrovasculair event: multicenter RCT","title_en":"Smartphone electrocardiogram for detecting atrial fibrillation after a cerebral ischaemic event: a multicentre randomized controlled trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["digitale-gezondheid"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab036","source_url":"https://doi.org/10.1093/europace/euab036","authors":["Keng Tat Koh","Wan Chung Law","Win Moe Zaw","Diana Hui Ping Foo","Chen Ting Tan","Anderson Steven","Desmond Samuel","Tem Lom Fam","Ching Hua Chai","Zhai Sing Wong","Sivaraj Xaviar","Chandan Deepak Bhavnani","Jason Seng Hong Tan","Yen Yee Oon","Asri Said","Alan Yean Yip Fong","Tiong Kiam Ong"],"significance":7,"published":"2021-07-18","source_date":"2021-07-18","image":"","kennis":[],"congress":"","summary_en":"This multicenter randomized trial evaluated smartphone-based ECG for AF detection after cerebral ischemic events, exploring consumer technology as a scalable post-stroke monitoring strategy.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"87b2e9906a2c","type":"article","url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","title":"Cryoballonablatie versus antiaritmica als eerstelijns PAF-therapie","title_en":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab029","source_url":"https://doi.org/10.1093/europace/euab029","authors":["Malte Kuniss","Nikola Pavlovic","Vedran Velagic","Jean Sylvain Hermida","Stewart Healey","Giuseppe Arena","Nicolas Badenco","Christian Meyer","Jian Chen","Saverio Iacopino","Frédéric Anselme","Douglas L Packer","Heinz-Friedrich Pitschner","Carlo de Asmundis","Stephan Willems","Fabio Di Piazza","Daniel Becker","Gian-Battista Chierchia"],"significance":6,"published":"2021-07-18","source_date":"2021-07-18","image":"","kennis":[],"congress":"","summary_en":"This study compared cryoballoon ablation with antiarrhythmic drugs as first-line therapy for paroxysmal AF, providing additional evidence for the ablation-first approach as the initial treatment strategy.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"421a59f212ee","type":"article","url":"https://hartvaat.nl/2021/07/18/letselrisico-bij-vasovagale-syncope-systematische-review-en-meta-analyse/","title":"Letselrisico bij vasovagale syncope: systematische review en meta-analyse","title_en":"Likelihood of injury due to vasovagal syncope: a systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["syncope"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euab041","source_url":"https://doi.org/10.1093/europace/euab041","authors":["Juliana G Jorge","Satish R Raj","Pedro S Teixeira","Jose A C Teixeira","Robert S Sheldon"],"significance":5,"published":"2021-07-18","source_date":"2021-07-18","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis quantified the likelihood of injury due to vasovagal syncope, showing that physical injuries are more common than previously recognized, challenging the perception of VVS as uniformly benign.","created":"2026-07-03T10:29:18Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4e82842c6bea","type":"article","url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","title":"Procedurevolume en complicaties bij AF-ablatie: meta-analyse","title_en":"Relationship between procedural volume and complication rates for catheter ablation of atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa415","source_url":"https://doi.org/10.1093/europace/euaa415","authors":["Ivaylo R Tonchev","Michael Chi Yuan Nam","Alexandra Gorelik","Saurabh Kumar","Haris Haqqani","Prashanthan Sanders","Peter M Kistler","Jonathan M Kalman"],"significance":6,"published":"2021-07-18","source_date":"2021-07-18","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that higher procedural volume for AF catheter ablation is associated with lower complication rates, supporting centralization of complex electrophysiology procedures in experienced centers.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7e07a5ddc829","type":"article","url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","title":"Ultradunne versus conventionele 2e-generatie DES: langetermijn meta-analyse","title_en":"Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab280","source_url":"https://doi.org/10.1093/eurheartj/ehab280","authors":["Mahesh V Madhavan","James P Howard","Azim Naqvi","Ori Ben-Yehuda","Bjorn Redfors","Megha Prasad","Bahira Shahim","Martin B Leon","Sripal Bangalore","Gregg W Stone","Yousif Ahmad"],"significance":6,"published":"2021-07-15","source_date":"2021-07-15","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of long-term follow-up data confirmed that ultrathin-strut DES provide improved safety outcomes compared with conventional second-generation stents, supporting the continued evolution toward thinner coronary device platforms.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c271c0e63af2","type":"article","url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","title":"Fysieke revalidatie bij oudere gehospitaliseerde HF-patiënten: NEJM REHAB-HF","title_en":"Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["hartrevalidatie","step-hfpef"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2026141","source_url":"https://doi.org/10.1056/NEJMoa2026141","authors":["Dalane W Kitzman","David J Whellan","Pamela Duncan","Amy M Pastva","Robert J Mentz","Gordon R Reeves","M Benjamin Nelson","Haiying Chen","Bharathi Upadhya","Shelby D Reed","Mark A Espeland","LeighAnn Hewston","Christopher M O'Connor"],"significance":8,"published":"2021-07-15","source_date":"2021-07-15","image":"","kennis":[],"congress":"","summary_en":"The REHAB-HF trial showed that a tailored physical rehabilitation intervention improved physical function and frailty in older patients hospitalized for acute heart failure, though it did not significantly reduce rehospitalization or death. The functional benefit supports rehabilitation in elderly heart failure patients.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"db26331f6cf5","type":"article","url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","title":"Ablatie versus medicatie bij AF naar ras en etniciteit","title_en":"Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.092","source_url":"https://doi.org/10.1016/j.jacc.2021.04.092","authors":["Kevin L Thomas","Hussein R Al-Khalidi","Adam P Silverstein","Kristi H Monahan","Tristram D Bahnson","Jeanne E Poole","Daniel B Mark","Douglas L Packer"],"significance":5,"published":"2021-07-13","source_date":"2021-07-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This study showed that racial and ethnic minorities with AF have similar outcomes from catheter ablation as White patients, supporting equitable access to rhythm control procedures across diverse populations.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"73ce03cd3fea","type":"article","url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","title":"Finerenon vermindert nieuw-onset AF bij CKD met diabetes: FIDELIO-DKD","title_en":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","diabetes-en-hart","diabetische-nefropathie","fidelio-dkd","figaro-dkd","finerenon","ijzertekort"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.079","source_url":"https://doi.org/10.1016/j.jacc.2021.04.079","authors":["Gerasimos Filippatos","George L Bakris","Bertram Pitt","Rajiv Agarwal","Peter Rossing","Luis M Ruilope","Javed Butler","Carolyn S P Lam","Peter Kolkhof","Luke Roberts","Christoph Tasto","Amer Joseph","Stefan D Anker"],"significance":7,"published":"2021-07-13","source_date":"2021-07-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This FIDELIO-DKD analysis showed that finerenone reduces new-onset atrial fibrillation in patients with CKD and type 2 diabetes, revealing an unexpected antiarrhythmic benefit of nonsteroidal mineralocorticoid receptor antagonism.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d04b7066708c","type":"article","url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","title":"EF en uitkomsten bij omecamtiv mecarbil: GALACTIC-HF","title_en":"Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.065","source_url":"https://doi.org/10.1016/j.jacc.2021.04.065","authors":["John R Teerlink","Rafael Diaz","G Michael Felker","John J V McMurray","Marco Metra","Scott D Solomon","Tor Biering-Sørensen","Michael Böhm","Diana Bonderman","James C Fang","David E Lanfear","Mayanna Lund","Shin-Ichi Momomura","Eileen O'Meara","Piotr Ponikowski","Jindrich Spinar","Jose H Flores-Arredondo","Brian L Claggett","Stephen B Heitner","Stuart Kupfer","Siddique A Abbasi","Fady I Malik"],"significance":6,"published":"2021-07-13","source_date":"2021-07-13","image":"","kennis":[],"congress":"","summary_en":"This GALACTIC-HF analysis showed that omecamtiv mecarbil provides greater benefit in patients with lower ejection fractions, suggesting that the cardiac myosin activator is most effective in those with the most severely impaired contractility.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"678e27ea6a26","type":"article","url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","title":"10-jaars mortaliteit naar compleetheid van revascularisatie bij drievaten/hoofdstamlijden","title_en":"Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.046289","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.046289","authors":["Kuniaki Takahashi","Patrick W Serruys","Chao Gao","Masafumi Ono","Rutao Wang","Daniel J F M Thuijs","Michael J Mack","Nick Curzen","Friedrich-Wilhelm Mohr","Piroze Davierwala","Milan Milojevic","Joanna J Wykrzykowska","Robbert J de Winter","Faisal Sharif","Yoshinobu Onuma","Stuart J Head","Arie Pieter Kappetein","Marie-Claude Morice","David R Holmes"],"significance":7,"published":"2021-07-13","source_date":"2021-07-13","image":"","kennis":[],"congress":"","summary_en":"This 10-year analysis of all-cause mortality according to completeness of revascularization in three-vessel or left main disease showed that complete revascularization is associated with better long-term survival regardless of whether PCI or CABG was used.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bc1e076f8062","type":"article","url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","title":"Late RAPID-TnT uitkomsten: 0/1-uur hs-troponine T bij verdenking ACS","title_en":"Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["troponine"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055009","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055009","authors":["Kristina Lambrakis","Cynthia Papendick","John K French","Stephen Quinn","Andrew Blyth","Anil Seshadri","Michael J R Edmonds","Anthony Chuang","Ehsan Khan","Adam J Nelson","Deborah Wright","Matthew Horsfall","Erin Morton","Jonathan Karnon","Tom Briffa","Louise A Cullen","Derek P Chew"],"significance":6,"published":"2021-07-13","source_date":"2021-07-13","image":"","kennis":[],"congress":"","summary_en":"Late outcomes of the RAPID-TnT trial confirmed that a 0/1-hour high-sensitivity troponin protocol for suspected ACS safely reduces emergency department evaluation time without missing clinically significant MI.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"48521ad48389","type":"article","url":"https://hartvaat.nl/2021/07/10/tirzepatide-bij-diabetes-type-2-lancet-surpass-1-fase-3/","title":"Tirzepatide bij diabetes type 2: Lancet SURPASS-1 fase-3","title_en":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["diabetes-type-2"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01324-6","source_url":"https://doi.org/10.1016/S0140-6736(21)01324-6","authors":["Julio Rosenstock","Carol Wysham","Juan P Frías","Shizuka Kaneko","Clare J Lee","Laura Fernández Landó","Huzhang Mao","Xuewei Cui","Chrisanthi A Karanikas","Vivian T Thieu"],"significance":9,"published":"2021-07-10","source_date":"2021-07-10","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The SURPASS-1 trial demonstrated that tirzepatide, a novel dual GIP/GLP-1 receptor agonist, produced superior HbA1c reduction and weight loss compared with placebo as monotherapy in type 2 diabetes. These first phase 3 results foreshadowed the transformative potential of dual incretin agonism.","created":"2026-07-03T10:29:17Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d89f86948645","type":"article","url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","title":"CV-uitkomsten bij diabetes met vastgesteld of hoog-risico coronairlijden: dulaglutide","title_en":"Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","fidelio-dkd","figaro-dkd","obesitas","perifeer-vaatlijden","roken","select-trial","slaapapneu","soul-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa777","source_url":"https://doi.org/10.1093/eurheartj/ehaa777","authors":["Giulia Ferrannini","Hertzel Gerstein","Helen Martina Colhoun","Gilles R Dagenais","Rafael Diaz","Leanne Dyal","Mark Lakshmanan","Linda Mellbin","Jeffrey Probstfield","Matthew Casey Riddle","Jonathan Edward Shaw","Alvaro Avezum","Jan Neil Basile","William C Cushman","Petr Jansky","Mátyás Keltai","Fernando Lanas","Lawrence Alan Leiter","Patricio Lopez-Jaramillo","Prem Pais","Valdis Pīrāgs","Nana Pogosova","Peter Johann Raubenheimer","Wayne Huey-Herng Sheu","Lars Rydén"],"significance":6,"published":"2021-07-08","source_date":"2021-07-08","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This analysis showed that dulaglutide provides similar cardiovascular protection in diabetic patients with established versus high-risk-for coronary disease, supporting GLP-1 receptor agonist use for primary prevention in high-risk diabetes.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5028ff9bf6c2","type":"article","url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","title":"GRACE 2.0-score bij type 1 en type 2 MI","title_en":"Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa375","source_url":"https://doi.org/10.1093/eurheartj/ehaa375","authors":["John Hung","Andreas Roos","Erik Kadesjö","David A McAllister","Dorien M Kimenai","Anoop S V Shah","Atul Anand","Fiona E Strachan","Keith A A Fox","Nicholas L Mills","Andrew R Chapman","Martin J Holzmann"],"significance":5,"published":"2021-07-08","source_date":"2021-07-08","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This analysis showed that the GRACE 2.0 risk score performs well for type 1 MI but has limited accuracy for type 2 MI, suggesting the need for separate risk models for demand-type myocardial infarction.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ecbf034055c1","type":"article","url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","title":"Optimale medicamenteuze therapie en 10-jaarsmortaliteit na revascularisatie","title_en":"Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["diabetes-en-hart","farmaco-economie","lipidenverlaging","niet-statine-therapie","obesitas","ouderen","perifeer-vaatlijden","roken","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.087","source_url":"https://doi.org/10.1016/j.jacc.2021.04.087","authors":["Hideyuki Kawashima","Patrick W Serruys","Masafumi Ono","Hironori Hara","Neil O'Leary","Michael J Mack","David R Holmes","Marie-Claude Morice","Stuart J Head","Arie Pieter Kappetein","Daniel J F M Thuijs","Milan Milojevic","Thilo Noack","Friedrich-Wilhelm Mohr","Piroze M Davierwala","Faisal Sharif","John W McEvoy","Yoshinobu Onuma"],"significance":6,"published":"2021-07-06","source_date":"2021-07-06","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"","summary_en":"This analysis showed that optimal medical therapy significantly impacts 10-year mortality after coronary revascularization regardless of whether PCI or CABG was performed, reinforcing that pharmacotherapy is the foundation of long-term post-revascularization care.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"68e4c2127e54","type":"article","url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","title":"Mortaliteitsvoordeel van rivaroxaban plus aspirine bij chronisch vaatlijden: COMPASS","title_en":"Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.083","source_url":"https://doi.org/10.1016/j.jacc.2021.04.083","authors":["John W Eikelboom","Deepak L Bhatt","Keith A A Fox","Jacqueline Bosch","Stuart J Connolly","Sonia S Anand","Alvaro Avezum","Scott D Berkowitz","Kelley R H Branch","Gilles R Dagenais","Camilo Félix","Tomasz J Guzik","Robert G Hart","Aldo P Maggioni","Eva Muehlhofer","Mukul Sharma","Olga Shestakovska","Salim Yusuf"],"significance":7,"published":"2021-07-06","source_date":"2021-07-06","image":"","kennis":[],"congress":"","summary_en":"This COMPASS analysis quantified the mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease, showing that the dual-pathway strategy reduces both cardiovascular and all-cause death.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"56490ba03b1f","type":"article","url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","title":"CaMKII delta-remming en ventriculaire remodellering na MI: JAMA Cardiology","title_en":"Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["ventrikelfibrilleren"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0676","source_url":"https://doi.org/10.1001/jamacardio.2021.0676","authors":["Andrew J Boyle","Carl Schultz","Joseph B Selvanayagam","Stuart Moir","Richard Kovacs","Nabil Dib","David Zlotnick","Mohammed Al-Omary","Stuart Sugito","Aravinda Selvarajah","Nicholas Collins","Grant McLachlan"],"significance":5,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial tested a CaMKII delta inhibitor for preventing ventricular remodeling after anterior STEMI, exploring targeted kinase inhibition as a post-MI cardioprotective strategy.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b858219379fc","type":"article","url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","title":"Dapagliflozine naar nierfunctie en albuminurie bij diabetes: DECLARE","title_en":"Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0660","source_url":"https://doi.org/10.1001/jamacardio.2021.0660","authors":["Thomas A Zelniker","Itamar Raz","Ofri Mosenzon","Jamie P Dwyer","Hiddo H J L Heerspink","Avivit Cahn","Erica L Goodrich","Kyungah Im","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John P H Wilding","Ingrid Gause-Nilsson","Anna Maria Langkilde","Marc S Sabatine","Stephen D Wiviott"],"significance":7,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This DECLARE analysis showed that dapagliflozin's cardiovascular benefit is consistent across baseline kidney function and albuminuria categories, supporting SGLT2 inhibitor use regardless of renal status in type 2 diabetes.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1b4b2a65e24f","type":"article","url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","title":"Revacept GPVI-antagonist bij PCI: JAMA Cardiology","title_en":"Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0475","source_url":"https://doi.org/10.1001/jamacardio.2021.0475","authors":["Katharina Mayer","Ralph Hein-Rothweiler","Stefanie Schüpke","Marion Janisch","Isabell Bernlochner","Gjin Ndrepepa","Dirk Sibbing","Tommaso Gori","Oliver Borst","Stefan Holdenrieder","Danny Kupka","Tobias Petzold","Christian Bradaric","Rainer Okrojek","David M Leistner","Tobias D Trippel","Thomas Münzel","Ulf Landmesser","Burkert Pieske","Andreas M Zeiher","Meinrad P Gawaz","Alexander Hapfelmeier","Karl-Ludwig Laugwitz","Heribert Schunkert","Adnan Kastrati","Steffen Massberg"],"significance":6,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This trial of revacept, a novel competitive antagonist of platelet glycoprotein VI, during PCI tested a new antithrombotic mechanism that targets the collagen-platelet interaction at the site of vascular injury.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8d59aeff6444","type":"article","url":"https://hartvaat.nl/2021/07/01/transformatie-van-klinisch-onderzoek-door-patientbetrokkenheid-rate-af/","title":"Transformatie van klinisch onderzoek door patiëntbetrokkenheid: RATE-AF","title_en":"Transforming clinical research by involving and empowering patients- the RATE-AF randomized trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab098","source_url":"https://doi.org/10.1093/eurheartj/ehab098","authors":["Karina V Bunting","Mary Stanbury","Otilia Tica","Dipak Kotecha"],"significance":5,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This EHJ article highlighted the RATE-AF trial as a model for patient involvement and empowerment in cardiovascular clinical research, demonstrating how patient-centered trial design improves research quality and relevance.","created":"2026-07-03T10:29:16Z","updated":"2026-07-03T13:28:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cc96615a5791","type":"article","url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","title":"Empagliflozine en LV-volumes en functie bij HFrEF: JAMA Cardiology","title_en":"Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.6827","source_url":"https://doi.org/10.1001/jamacardio.2020.6827","authors":["Massar Omar","Jesper Jensen","Mulham Ali","Peter H Frederiksen","Caroline Kistorp","Lars Videbæk","Mikael Kjær Poulsen","Christian D Tuxen","Sören Möller","Finn Gustafsson","Lars Køber","Morten Schou","Jacob Eifer Møller"],"significance":7,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that empagliflozin is associated with improvements in left ventricular volumes, mass, and function in HFrEF, providing echocardiographic evidence of reverse cardiac remodeling with SGLT2 inhibition.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"176d843075d8","type":"article","url":"https://hartvaat.nl/2021/07/01/remote-post-ontslag-behandeling-na-mi-door-paramedici-versus-standaardzorg-jama-/","title":"Remote post-ontslag behandeling na MI door paramedici versus standaardzorg: JAMA Cardiology","title_en":"Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.6721","source_url":"https://doi.org/10.1001/jamacardio.2020.6721","authors":["Mark Y Chan","Karen W L Koh","Sock-Cheng Poh","Stephanie Marchesseau","Devinder Singh","Yiying Han","Faclin Ng","Eleanor Lim","Joseph F Prabath","Chi-Hang Lee","Hui-Wen Sim","Ruth Chen","Leonardo Carvalho","Sock-Hwee Tan","Joshua P Y Loh","Jack W C Tan","Karishma Kuwelker","R M Amanullah","Chee-Tang Chin","James W L Yip","Choy-Yee Lee","Juvena Gan","Chew-Yong Lo","Hee-Hwa Ho","Derek J Hausenloy","Bee-Choo Tai","A Mark Richards"],"significance":6,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This trial showed that remote post-discharge treatment by allied health practitioners after MI achieves comparable safety and efficacy to standard cardiologist-led care, supporting task-shifting for post-MI management.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"51bf54585cb5","type":"article","url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","title":"CV-gevolgen van stoppen met laaggedoseerd rivaroxaban bij chronisch vaatlijden","title_en":"Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["anticoagulantia","ouderen","perifeer-vaatlijden","roken","slaapapneu","stabiel-coronairlijden","ventrikelfibrilleren"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-318758","source_url":"https://doi.org/10.1136/heartjnl-2020-318758","authors":["Gilles R Dagenais","Leanne Dyal","Jacqueline J Bosch","Darryl P Leong","Victor Aboyans","Scott D Berkowitz","Deepak L Bhatt","Stuart J Connolly","Keith A A Fox","Eva Muehlhofer","Jeffrey L Probstfield","Petr Widimsky","Bernhard R Winkelmann","Salim Yusuf","John W Eikelboom"],"significance":6,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":[],"congress":"","summary_en":"This COMPASS analysis showed that discontinuing low-dose rivaroxaban in patients with chronic coronary or peripheral artery disease is associated with increased cardiovascular events, supporting the importance of treatment persistence.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25011bdec80d","type":"article","url":"https://hartvaat.nl/2021/07/01/kbp-5074-en-bloeddruk-bij-gevorderde-ckd-block-ckd/","title":"KBP-5074 en bloeddruk bij gevorderde CKD: BLOCK-CKD","title_en":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["chronische-nierziekte"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17073","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17073","authors":["George Bakris","Pablo E Pergola","Belkis Delgado","Diyan Genov","Tamar Doliashvili","Nam Vo","Y Fred Yang","James McCabe","Vincent Benn","Bertram Pitt"],"significance":6,"published":"2021-07-01","source_date":"2021-07-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The BLOCK-CKD study evaluated KBP-5074, a nonsteroidal MRA, for blood pressure lowering in advanced CKD, testing a novel mineralocorticoid receptor antagonist designed for safety in the renally impaired population.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ae4967af9d54","type":"article","url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","title":"Aspirine versus clopidogrel voor chronische monotherapie na PCI: Lancet HOST-EXAM","title_en":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":["aspirine","trombocytenaggregatieremmers"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)01063-1","source_url":"https://doi.org/10.1016/S0140-6736(21)01063-1","authors":["Bon-Kwon Koo","Jeehoon Kang","Kyung Woo Park","Tae-Min Rhee","Han-Mo Yang","Ki-Bum Won","Seung-Woon Rha","Jang-Whan Bae","Nam Ho Lee","Seung-Ho Hur","Junghan Yoon","Tae-Ho Park","Bum Soo Kim","Sang Wook Lim","Yoon Haeng Cho","Dong Woon Jeon","Sang-Hyun Kim","Jung-Kyu Han","Eun-Seok Shin","Hyo-Soo Kim"],"significance":9,"published":"2021-06-26","source_date":"2021-06-26","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/trombocytenaggregatieremmers-bij-acs/","https://hartvaat.nl/kennis/kleplijden/aortaregurgitatie/"],"congress":"","summary_en":"The HOST-EXAM trial showed that clopidogrel was superior to aspirin for chronic maintenance antiplatelet monotherapy after PCI, reducing the composite of cardiovascular death, MI, stroke, readmission for ACS, or stent thrombosis at 24 months. The result challenged aspirin as the default long-term antiplatelet agent after coronary stenting.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"85ad7df68f15","type":"article","url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","title":"Echografie renale denervatie bij triple-pilresistente hypertensie: Lancet RADIANCE-HTN TRIO","title_en":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["radiance-htn","renale-denervatie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)00788-1","source_url":"https://doi.org/10.1016/S0140-6736(21)00788-1","authors":["Michel Azizi","Kintur Sanghvi","Manish Saxena","Philippe Gosse","John P Reilly","Terry Levy","Lars C Rump","Alexandre Persu","Jan Basile","Michael J Bloch","Joost Daemen","Melvin D Lobo","Felix Mahfoud","Roland E Schmieder","Andrew S P Sharp","Michael A Weber","Marc Sapoval","Pete Fong","Atul Pathak","Pierre Lantelme","David Hsi","Sripal Bangalore","Adam Witkowski","Joachim Weil","Benjamin Kably","Neil C Barman","Helen Reeve-Stoffer","Leslie Coleman","Candace K McClure","Ajay J Kirtane"],"significance":9,"published":"2021-06-26","source_date":"2021-06-26","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/mineralocorticoid-antagonisten-hypertensie/"],"congress":"","summary_en":"The RADIANCE-HTN TRIO trial demonstrated that ultrasound-based renal denervation significantly reduced daytime ambulatory systolic blood pressure compared with a sham procedure in patients with resistant hypertension on a standardized triple combination pill. This was the first positive renal denervation trial in true resistant hypertension.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45294f103fe1","type":"article","url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","title":"Prevalentie van linkeratriumtrombus bij geanticoaguleerde AF-patiënten","title_en":"Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["abelacimab"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.036","source_url":"https://doi.org/10.1016/j.jacc.2021.04.036","authors":["Antony Lurie","Jia Wang","Kyra J Hinnegan","William F McIntyre","Emilie P Belley-Côté","Guy Amit","Jeff S Healey","Stuart J Connolly","Jorge A Wong"],"significance":6,"published":"2021-06-15","source_date":"2021-06-15","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This study documented the prevalence of left atrial thrombus in AF patients despite guideline-directed anticoagulation, showing that a clinically relevant proportion harbors thrombus even on DOACs, informing pre-procedure screening decisions.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eb80c30d5c50","type":"article","url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","title":"Plasma-renine-activiteit na renale sympathische denervatie","title_en":"Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["renale-denervatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.044","source_url":"https://doi.org/10.1016/j.jacc.2021.04.044","authors":["Felix Mahfoud","Raymond R Townsend","David E Kandzari","Kazuomi Kario","Roland E Schmieder","Konstantinos Tsioufis","Stuart Pocock","Shukri David","Kiritkumar Patel","Anjani Rao","Antony Walton","Jason E Bloom","Thomas Weber","Markus Suppan","Lucas Lauder","Sidney A Cohen","Pamela McKenna","Martin Fahy","Michael Böhm","Michael A Weber"],"significance":5,"published":"2021-06-15","source_date":"2021-06-15","image":"","kennis":[],"congress":"","summary_en":"This study characterized changes in plasma renin activity after renal denervation, providing neurohormonal evidence for the mechanism of blood pressure lowering through sympathetic ablation.","created":"2026-07-03T10:29:15Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0775dfe05825","type":"article","url":"https://hartvaat.nl/2021/06/14/gestandaardiseerde-inspanningstraining-bij-pah-en-cteph-haalbaarheid-en-veilighe/","title":"Gestandaardiseerde inspanningstraining bij PAH en CTEPH: haalbaarheid en veiligheid","title_en":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa696","source_url":"https://doi.org/10.1093/eurheartj/ehaa696","authors":["Ekkehard Grünig","Alison MacKenzie","Andrew J Peacock","Christina A Eichstaedt","Nicola Benjamin","Robert Nechwatal","Silvia Ulrich","Stéphanie Saxer","Maurizio Bussotti","Marinella Sommaruga","Stefano Ghio","Lina Gumbiene","Eglė Palevičiūtė","Elena Jurevičienė","Antonio Cittadini","Anna A Stanziola","Alberto M Marra","Gabor Kovacs","Horst Olschewski","Joan-Albert Barberà","Isabel Blanco","Martijn A Spruit","Frits M E Franssen","Anton Vonk Noordegraaf","Abílio Reis","Mário Santos","Sofia Gonçalves Viamonte","Heleen Demeyer","Marion Delcroix","Eduardo Bossone","Martin Johnson"],"significance":6,"published":"2021-06-14","source_date":"2021-06-14","image":"","kennis":[],"congress":"","summary_en":"This multicenter randomized trial confirmed that standardized exercise training is feasible, safe, and effective in patients with PAH and CTEPH, supporting supervised rehabilitation as standard of care in pulmonary hypertension management.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4f440a6af32c","type":"article","url":"https://hartvaat.nl/2021/06/08/interventies-bij-secundaire-mitralisklepinsufficientie-jama-klinisch-overzicht/","title":"Interventies bij secundaire mitralisklepinsufficiëntie: JAMA klinisch overzicht","title_en":"Interventions for Patients With Secondary Mitral Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.2741","source_url":"https://doi.org/10.1001/jama.2021.2741","authors":["Sameer Hirji","Adam S Cifu","Tsuyoshi Kaneko"],"significance":7,"published":"2021-06-08","source_date":"2021-06-08","image":"","kennis":[],"congress":"","summary_en":"This JAMA clinical review provided a comprehensive overview of interventions for secondary mitral regurgitation, integrating evidence from COAPT, MITRA-FR, and contemporary guidelines to inform clinical decision-making.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b425af3b253a","type":"article","url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","title":"10-jaarsfollow-up na revascularisatie bij oudere patiënten met complex coronairlijden","title_en":"10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["stabiel-coronairlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.04.016","source_url":"https://doi.org/10.1016/j.jacc.2021.04.016","authors":["Masafumi Ono","Patrick W Serruys","Hironori Hara","Hideyuki Kawashima","Chao Gao","Rutao Wang","Kuniaki Takahashi","Neil O'Leary","Joanna J Wykrzykowska","Faisal Sharif","Jan J Piek","Scot Garg","Michael J Mack","David R Holmes","Marie-Claude Morice","Stuart J Head","Arie Pieter Kappetein","Daniel J F M Thuijs","Thilo Noack","Piroze M Davierwala","Friedrich W Mohr","David J Cohen","Yoshinobu Onuma"],"significance":6,"published":"2021-06-08","source_date":"2021-06-08","image":"","kennis":[],"congress":"","summary_en":"This 10-year follow-up after revascularization in elderly patients with complex coronary disease provided the longest comparative data for PCI versus CABG in the older population, informing revascularization decisions at advanced age.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2f35a9a87302","type":"article","url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","title":"Linker-hartoorsluiting tijdens hartchirurgie ter preventie van CVA: NEJM LAAOS III","title_en":"Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2101897","source_url":"https://doi.org/10.1056/NEJMoa2101897","authors":["Richard P Whitlock","Emilie P Belley-Cote","Domenico Paparella","Jeff S Healey","Katheryn Brady","Mukul Sharma","Wilko Reents","Petr Budera","Andony J Baddour","Petr Fila","P J Devereaux","Alexander Bogachev-Prokophiev","Andreas Boening","Kevin H T Teoh","Georgios I Tagarakis","Mark S Slaughter","Alistair G Royse","Shay McGuinness","Marco Alings","Prakash P Punjabi","C David Mazer","Richard J Folkeringa","Andrea Colli","Álvaro Avezum","Juliet Nakamya","Kumar Balasubramanian","Jessica Vincent","Pierre Voisine","Andre Lamy","Salim Yusuf","Stuart J Connolly"],"significance":10,"published":"2021-06-03","source_date":"2021-06-03","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The LAAOS III trial demonstrated that surgical left atrial appendage occlusion performed during cardiac surgery significantly reduced the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation. This simple addition to planned cardiac surgery provides lasting stroke protection as an adjunct to anticoagulation.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"97181797b9b4","type":"article","url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","title":"Implanteerbare versus verlengde externe ECG-monitoring voor AF na ischemisch CVA: JAMA","title_en":"Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.6128","source_url":"https://doi.org/10.1001/jama.2021.6128","authors":["Brian H Buck","Michael D Hill","F Russell Quinn","Ken S Butcher","Bijoy K Menon","Sajad Gulamhusein","Muzaffar Siddiqui","Shelagh B Coutts","Thomas Jeerakathil","Eric E Smith","Khurshid Khan","Phillip A Barber","Glen Jickling","Lucy Reyes","Supriya Save","Paige Fairall","Lori Piquette","Noreen Kamal","Derek S Chew","Andrew M Demchuk","Ashfaq Shuaib","Derek V Exner"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/"],"congress":"","summary_en":"This JAMA trial compared implantable versus prolonged external ECG monitoring for AF detection after ischemic stroke, evaluating the optimal monitoring strategy for identifying occult arrhythmia as a cause of cryptogenic stroke.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b2def1c866c4","type":"article","url":"https://hartvaat.nl/2021/06/01/continue-cardiale-monitoring-versus-standaardzorg-bij-cryptogeen-cva-jama/","title":"Continue cardiale monitoring versus standaardzorg bij cryptogeen CVA: JAMA","title_en":"Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.6470","source_url":"https://doi.org/10.1001/jama.2021.6470","authors":["Richard A Bernstein","Hooman Kamel","Christopher B Granger","Jonathan P Piccini","Pramod P Sethi","Jeffrey M Katz","Carola Alfaro Vives","Paul D Ziegler","Noreli C Franco","Lee H Schwamm"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/implanteerbare-loop-recorder/"],"congress":"","summary_en":"This JAMA trial showed that long-term continuous cardiac monitoring significantly increases AF detection in patients with ischemic stroke attributed to large- or small-vessel disease, a population not traditionally considered high-risk for AF.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9bef8786b63a","type":"article","url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","title":"Dieet en natriumreductie op cardiale schade en inflammatie: DASH-Sodium","title_en":"Effects of Diet and Sodium Reduction on Cardiac Injury, Strain, and Inflammation: The DASH-Sodium Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["colcot-trial","voeding-hart"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.03.320","source_url":"https://doi.org/10.1016/j.jacc.2021.03.320","authors":["Stephen P Juraschek","Lara C Kovell","Lawrence J Appel","Edgar R Miller","Frank M Sacks","Alex R Chang","Robert H Christenson","Heather Rebuck","Kenneth J Mukamal"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This DASH-Sodium analysis showed that combining the DASH diet with sodium reduction produces additive reductions in cardiac injury biomarkers (troponin), cardiac strain (NT-proBNP), and inflammation, providing a mechanistic basis for dietary cardiovascular protection.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3364ac04762","type":"article","url":"https://hartvaat.nl/2021/06/01/katheterablatie-of-antiaritmica-als-eerstelijnstherapie-bij-af-jama-cardiology-m/","title":"Katheterablatie of antiaritmica als eerstelijnstherapie bij AF: JAMA Cardiology meta-analyse","title_en":"Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0852","source_url":"https://doi.org/10.1001/jamacardio.2021.0852","authors":["Mohit K Turagam","Daniel Musikantow","William Whang","Jacob S Koruth","Marc A Miller","Marie-Noelle Langan","Aamir Sofi","Subbarao Choudry","Srinivas R Dukkipati","Vivek Y Reddy"],"significance":8,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This JAMA Cardiology meta-analysis of randomized trials confirmed that catheter ablation as first-line therapy for atrial fibrillation is superior to antiarrhythmic drugs for maintaining sinus rhythm, with potential benefits on cardiovascular outcomes. The pooled data supported the shift toward earlier ablation.","created":"2026-07-03T10:29:14Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dcea9a445ce5","type":"article","url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","title":"Dapagliflozine bij HFrEF naar geslacht: DAPA-HF pre-gespecificeerde analyse","title_en":"Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["answer-hf","dapa-hf","step-hfpef"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0379","source_url":"https://doi.org/10.1001/jamacardio.2021.0379","authors":["Jawad H Butt","Kieran F Docherty","Mark C Petrie","Morten Schou","Mikhail N Kosiborod","Eileen O'Meara","Tzvetana Katova","Charlotta E A Ljungman","Mirta Diez","Modele O Ogunniyi","Anna Maria Langkilde","Mikaela Sjöstrand","Daniel Lindholm","Olof Bengtsson","Felipe A Martinez","Piotr Ponikowski","Marc S Sabatine","Scott D Solomon","Pardeep S Jhund","John J V McMurray","Lars Køber"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DAPA-HF analysis confirmed that dapagliflozin is equally effective and safe in women and men with HFrEF, providing reassurance about sex-specific outcomes in a drug class tested predominantly in male-majority trials.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e307dac8f7c8","type":"article","url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","title":"Geïsoleerde diastolische hypertensie: cohort en meta-analyse voor behandeldrempel","title_en":"A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab111","source_url":"https://doi.org/10.1093/eurheartj/ehab111","authors":["Alan P Jacobsen","Mahmoud Al Rifai","Kelly Arps","Seamus P Whelton","Matthew J Budoff","Khurram Nasir","Michael J Blaha","Bruce M Psaty","Roger S Blumenthal","Wendy S Post","John W McEvoy"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This cohort study and meta-analysis investigated whether isolated diastolic hypertension (as defined by the ACC/AHA 130/80 threshold) is associated with cardiovascular risk sufficient to warrant treatment, addressing a common clinical dilemma.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"19300925fc32","type":"article","url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","title":"Klinische uitkomsten en respons op vericiguat naar index HF-event: VICTORIA","title_en":"Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.6455","source_url":"https://doi.org/10.1001/jamacardio.2020.6455","authors":["Carolyn S P Lam","Anna Giczewska","Karen Sliwa","Frank Edelmann","Jens Refsgaard","Edimar Bocchi","Justin A Ezekowitz","Adrian F Hernandez","Christopher M O'Connor","Lothar Roessig","Mahesh J Patel","Burkert Pieske","Kevin J Anstrom","Paul W Armstrong"],"significance":6,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This VICTORIA analysis showed that vericiguat's benefit varies by the index heart failure event type, with patients recently hospitalized for heart failure deriving the greatest absolute benefit.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5eb2e10fe0b8","type":"article","url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","title":"Metabole effecten van empagliflozine bij HF: Empire HF Metabolic gerandomiseerde trial","title_en":"Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","emperor-trials"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.053463","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.053463","authors":["Jesper Jensen","Massar Omar","Caroline Kistorp","Christian Tuxen","Ida Gustafsson","Lars Køber","Finn Gustafsson","Jens Faber","Julie L Forman","Jacob E Møller","Morten Schou"],"significance":6,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"The Empire HF Metabolic trial characterized the metabolic effects of empagliflozin in heart failure, showing favorable shifts in ketone body utilization and energy metabolism that may underlie the cardiac benefit of SGLT2 inhibitors.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63b5a02c4004","type":"article","url":"https://hartvaat.nl/2021/06/01/aanhoudend-voordeel-van-gedragsinterventies-voor-hypertensie-gerandomiseerde-tri/","title":"Aanhoudend voordeel van gedragsinterventies voor hypertensie: gerandomiseerde trial","title_en":"Sustained Benefit of Alternate Behavioral Interventions to Improve Hypertension Control: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["select-trial"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.15192","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.15192","authors":["Maria Antonia Rodriguez","Binhuan Wang","Sangmin Hyoung","Jennifer Friedberg","Judith Wylie-Rosett","Yixin Fang","John P Allegrante","Stuart R Lipsitz","Sundar Natarajan"],"significance":6,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial demonstrated sustained blood pressure improvement with alternative behavioral interventions (motivational interviewing, health coaching), showing that lifestyle modification benefits persist beyond the active intervention period.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b1fe79ac240d","type":"article","url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","title":"CD34-antilichaam sirolimus-eluting Combo stent versus Orsiro: gerandomiseerde trial","title_en":"Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.052766","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.052766","authors":["Lars Jakobsen","Evald H Christiansen","Phillip Freeman","Johnny Kahlert","Karsten Veien","Michael Maeng","Bent Raungaard","Julia Ellert","Anton B Villadsen","Steen D Kristensen","Ole Ahlehoff","Martin K Christensen","Christian J Terkelsen","Hans Erik Bøtker","Jens Aaroe","Troels Thim","Leif Thuesen","Ahmed Aziz","Ashkan Eftekhari","Rebekka V Jensen","Nicolaj B Støttrup","Jeppe G Rasmussen","Anders Junker","Svend E Jensen","Henrik S Hansen","Lisette O Jensen"],"significance":5,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared a dual-therapy CD34 antibody-coated sirolimus stent (Combo) with the Orsiro stent, testing whether combining endothelial capture with drug elution improves stent outcomes.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a1ad44916b06","type":"article","url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","title":"Diagnostiek van hartfalen in de huisartsenpraktijk: IPD meta-analyse","title_en":"Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13311","source_url":"https://doi.org/10.1002/ehf2.13311","authors":["Andrea K Roalfe","Clare J Taylor","Johannes C Kelder","Arno W Hoes","F D Richard Hobbs"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/bnp-en-nt-probnp/"],"congress":"","summary_en":"This individual patient data meta-analysis evaluated natriuretic peptide thresholds for diagnosing heart failure in primary care, providing evidence-based cut-points for the clinical decision to refer for specialist assessment.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c85c9b9c02f","type":"article","url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","title":"Inspanningstraining en hs-troponine T bij HFrEF","title_en":"Exercise training and high-sensitivity cardiac troponin T in patients with heart failure with reduced ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["bloeddrukbehandeling","step-hfpef","summit-trial","troponine"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13310","source_url":"https://doi.org/10.1002/ehf2.13310","authors":["Elias Koppen","Torbjørn Omland","Alf Inge Larsen","Trine Karlsen","Axel Linke","Eva Prescott","Martin Halle","Håvard Dalen","Charles Delagardelle","Torstein Hole","Emeline M van Craenenbroeck","Paul Beckers","Øyvind Ellingsen","Patrick Feiereisen","Torstein Valborgland","Vibeke Videm"],"significance":5,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that exercise training reduces high-sensitivity troponin T levels in HFrEF patients, suggesting that regular physical activity decreases subclinical myocardial injury in the heart failure population.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fc7d3d312c3d","type":"article","url":"https://hartvaat.nl/2021/06/01/sglt2-remmers-versus-arni-bij-hfref-meta-analyse/","title":"SGLT2-remmers versus ARNI bij HFrEF: meta-analyse","title_en":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13313","source_url":"https://doi.org/10.1002/ehf2.13313","authors":["Yuling Yan","Bin Liu","Jun Du","Jing Wang","Xiaodong Jing","Yajie Liu","Songbai Deng","Jianlin Du","Qiang She"],"significance":7,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This meta-analysis indirectly compared SGLT2 inhibitors with sacubitril-valsartan (ARNI) in HFrEF, finding comparable effect sizes on key outcomes and supporting both as essential components of contemporary heart failure therapy.","created":"2026-07-03T10:29:13Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4a8bed98487f","type":"article","url":"https://hartvaat.nl/2021/06/01/serumkalium-en-prognose-bij-symptomatisch-hf/","title":"Serumkalium en prognose bij symptomatisch HF","title_en":"Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13295","source_url":"https://doi.org/10.1002/ehf2.13295","authors":["Camila Cristiane Toledo","Pedro Vellosa Schwartzmann","Luis Miguel Silva","Gabriel da Silva Ferreira","Fernando Bianchini Cardoso","Vinicius Citelli Ribeiro","Layde Rosane Paim","Lígia M Antunes-Correa","Andrei Carvalho Sposito","Jose Roberto Matos Souza","Rodrigo Modolo","Wilson Nadruz","Luis Sergio Fernandes de Carvalho","Otávio R Coelho-Filho"],"significance":5,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This study showed that serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical and biochemical variables, supporting potassium monitoring for risk stratification.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:21Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d54fccd3d80d","type":"article","url":"https://hartvaat.nl/2021/06/01/palliatieve-zorg-bij-ph-met-congenitaal-hartlijden-expertopinie/","title":"Palliatieve zorg bij PH met congenitaal hartlijden: expertopinie","title_en":"Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13263","source_url":"https://doi.org/10.1002/ehf2.13263","authors":["Andrew Constantine","Robin Condliffe","Paul Clift","Robert Tulloh","Konstantinos Dimopoulos"],"significance":5,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This systematic review and expert opinion addressed palliative care in pulmonary hypertension associated with congenital heart disease, filling a gap in end-of-life care guidance for this severe condition.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c2514ad7fde3","type":"article","url":"https://hartvaat.nl/2021/06/01/roken-en-hartfalen-mendeliaanse-randomisatie-en-mediatie-analyse/","title":"Roken en hartfalen: Mendeliaanse randomisatie en mediatie-analyse","title_en":"Smoking and heart failure: a Mendelian randomization and mediation analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13248","source_url":"https://doi.org/10.1002/ehf2.13248","authors":["Yunlong Lu","Zhouming Xu","Marios K Georgakis","Zhen Wang","Hefeng Lin","Liangrong Zheng"],"significance":6,"published":"2021-06-01","source_date":"2021-06-01","image":"","kennis":[],"congress":"","summary_en":"This Mendelian randomization study provided causal evidence that smoking increases heart failure risk, with mediation analysis showing that the effect operates partially through coronary artery disease and pulmonary impairment.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d71f453643de","type":"article","url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","title":"Vergelijkende effectiviteit van aspirinedoseringen bij CVD: NEJM ADAPTABLE","title_en":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":["farmaco-economie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2102137","source_url":"https://doi.org/10.1056/NEJMoa2102137","authors":["W Schuyler Jones","Hillary Mulder","Lisa M Wruck","Michael J Pencina","Sunil Kripalani","Daniel Muñoz","David L Crenshaw","Mark B Effron","Richard N Re","Kamal Gupta","R David Anderson","Carl J Pepine","Eileen M Handberg","Brittney R Manning","Sandeep K Jain","Saket Girotra","Danielle Riley","Darren A DeWalt","Jeff Whittle","Ythan H Goldberg","Veronique L Roger","Rachel Hess","Catherine P Benziger","Peter Farrehi","Li Zhou","Daniel E Ford","Kevin Haynes","Jeffrey J VanWormer","Kirk U Knowlton","Jennifer L Kraschnewski","Tamar S Polonsky","Dan J Fintel","Faraz S Ahmad","James C McClay","James R Campbell","Douglas S Bell","Gregg C Fonarow","Steven M Bradley","Anuradha Paranjape","Matthew T Roe","Holly R Robertson","Lesley H Curtis","Amber G Sharlow","Lisa G Berdan","Bradley G Hammill","Debra F Harris","Laura G Qualls","Guillaume Marquis-Gravel","Madelaine F Modrow","Gregory M Marcus","Thomas W Carton","Elizabeth Nauman","Lemuel R Waitman","Abel N Kho","Elizabeth A Shenkman","Kathleen M McTigue","Rainu Kaushal","Frederick A Masoudi","Elliott M Antman","Desiree R Davidson","Kevin Edgley","James G Merritt","Linda S Brown","Doris N Zemon","Thomas E McCormick","Jacqueline D Alikhaani","Kenneth C Gregoire","Russell L Rothman","Robert A Harrington","Adrian F Hernandez"],"significance":9,"published":"2021-05-27","source_date":"2021-05-27","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"The ADAPTABLE trial, the first large pragmatic trial comparing aspirin doses in cardiovascular disease, found no significant difference between 81 mg and 325 mg daily for preventing cardiovascular events or causing major bleeding. The results support low-dose aspirin as the standard for secondary prevention.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7188603b9ffd","type":"article","url":"https://hartvaat.nl/2021/05/25/gedragsinterventies-voor-gezond-gewicht-in-de-zwangerschap-jama-uspstf-evidence-/","title":"Gedragsinterventies voor gezond gewicht in de zwangerschap: JAMA USPSTF evidence report","title_en":"Counseling and Behavioral Interventions for Healthy Weight and Weight Gain in Pregnancy: Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"preventie","category_label":"Preventie","professions":["huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.4230","source_url":"https://doi.org/10.1001/jama.2021.4230","authors":["Amy G Cantor","Rebecca M Jungbauer","Marian McDonagh","Ian Blazina","Nicole E Marshall","Chandler Weeks","Rongwei Fu","Erin S LeBlanc","Roger Chou"],"significance":6,"published":"2021-05-25","source_date":"2021-05-25","image":"","kennis":[],"congress":"","summary_en":"This USPSTF evidence report evaluated counseling and behavioral interventions for healthy gestational weight gain, informing recommendations on lifestyle management during pregnancy for cardiovascular and metabolic health.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7bb9c3a099d6","type":"article","url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","title":"Extrapulmonale vein driver mapping bij persisterend AF bij obese patiënten","title_en":"Extra-pulmonary vein driver mapping and ablation for persistent atrial fibrillation in obese patients.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["obesitas"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa314","source_url":"https://doi.org/10.1093/europace/euaa314","authors":["Xiaofeng Hu","Weifeng Jiang","Shaohui Wu","Kai Xu","Daoliang Zhang","Yu Zhang","Xu Liu","Mu Qin"],"significance":5,"published":"2021-05-21","source_date":"2021-05-21","image":"","kennis":[],"congress":"","summary_en":"This study evaluated extrapulmonary vein driver mapping and ablation for persistent AF in obese patients, testing whether obesity-specific AF substrate requires targeted ablation beyond standard PVI.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f80a7093f52b","type":"article","url":"https://hartvaat.nl/2021/05/21/high-power-short-duration-versus-conventionele-rf-ablatie-bij-af-meta-analyse/","title":"High-power short-duration versus conventionele RF-ablatie bij AF: meta-analyse","title_en":"High-power short duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic review and meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa327","source_url":"https://doi.org/10.1093/europace/euaa327","authors":["Venkatesh Ravi","Abhushan Poudyal","Qurrat-Ul-Ain Abid","Timothy Larsen","Kousik Krishnan","Parikshit S Sharma","Richard G Trohman","Henry D Huang"],"significance":6,"published":"2021-05-21","source_date":"2021-05-21","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that high-power short-duration RF ablation for AF achieves comparable efficacy and safety to conventional lower-power approaches with shorter procedure times, supporting the accelerated protocol.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2ed1986bdb19","type":"article","url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","title":"Katheterablatie versus medicatie bij persisterend en langdurig persisterend AF: langetermijn","title_en":"Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa356","source_url":"https://doi.org/10.1093/europace/euaa356","authors":["Gang Wu","He Huang","Lin Cai","Yanzong Yang","Xu Liu","Bo Yu","Yanhong Tang","Hong Jiang","Congxin Huang"],"significance":6,"published":"2021-05-21","source_date":"2021-05-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This long-term observation compared catheter ablation with pharmacotherapy for persistent and longstanding persistent AF, providing extended follow-up data on rhythm control strategies in the most challenging AF phenotypes.","created":"2026-07-03T10:29:12Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d62ec7758b61","type":"article","url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","title":"FIRM-ablatie versus PVI bij paroxysmaal AF: gerandomiseerde resultaten","title_en":"Focal Impulse and Rotor Modulation Ablation vs. Pulmonary Vein isolation for the treatment of paroxysmal Atrial Fibrillation: results from the FIRMAP AF study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa378","source_url":"https://doi.org/10.1093/europace/euaa378","authors":["Roland R Tilz","Corinna Lenz","Philipp Sommer","Meyer-Saraei Roza","Anne E Sarver","Christopher G Williams","Christian Heeger","Gerhard Hindricks","Julia Vogler","Charlotte Eitel"],"significance":6,"published":"2021-05-21","source_date":"2021-05-21","image":"","kennis":[],"congress":"","summary_en":"This randomized trial showed that Focal Impulse and Rotor Modulation (FIRM) ablation does not improve outcomes over standard PVI for paroxysmal AF, a negative result for rotor-guided ablation technology.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"47778bc63a48","type":"article","url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","title":"Intensieve versus standaard bloeddrukcontrole: NEJM SPRINT definitief rapport","title_en":"Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa1901281","source_url":"https://doi.org/10.1056/NEJMoa1901281","authors":["Cora E Lewis","Lawrence J Fine","Srinivasan Beddhu","Alfred K Cheung","William C Cushman","Jeffrey A Cutler","Gregory W Evans","Karen C Johnson","Dalane W Kitzman","Suzanne Oparil","Mahboob Rahman","David M Reboussin","Michael V Rocco","Kaycee M Sink","Joni K Snyder","Paul K Whelton","Jeff D Williamson","Jackson T Wright","Walter T Ambrosius"],"significance":10,"published":"2021-05-20","source_date":"2021-05-20","image":"","kennis":[],"congress":"","summary_en":"The final SPRINT report, including post-trial follow-up, confirmed the durable benefit of intensive systolic blood pressure control (target <120 mmHg) versus standard treatment (target <140 mmHg) in reducing cardiovascular events and mortality. The sustained benefit after treatment cessation strengthened the case for aggressive blood pressure targets.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4fa963e39710","type":"article","url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","title":"Diabetes-factoren en ticagrelor plus aspirine: THEMIS en THEMIS-PCI","title_en":"Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.03.298","source_url":"https://doi.org/10.1016/j.jacc.2021.03.298","authors":["Lawrence A Leiter","Deepak L Bhatt","Darren K McGuire","Hwee Teoh","Kim Fox","Tabassome Simon","Shamir R Mehta","Eli I Lev","Róbert G Kiss","Anthony J Dalby","Héctor Bueno","Wilhelm Ridderstråle","Anders Himmelmann","Jayne Prats","Yuyin Liu","Jane J Lee","John Amerena","Mikhail N Kosiborod","Philippe Gabriel Steg"],"significance":6,"published":"2021-05-18","source_date":"2021-05-18","image":"","kennis":[],"congress":"","summary_en":"This THEMIS subanalysis examined diabetes-specific factors that modify the benefit of adding ticagrelor to aspirin, identifying which diabetic patients derive the greatest net clinical advantage from intensified antiplatelet therapy.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7f4daee9fc5","type":"article","url":"https://hartvaat.nl/2021/05/11/digitale-interventie-voor-depressie-bij-hypertensie-diabetes-in-brazilie-en-peru/","title":"Digitale interventie voor depressie bij hypertensie/diabetes in Brazilië en Peru: JAMA","title_en":"Effect of a Digital Intervention on Depressive Symptoms in Patients With Comorbid Hypertension or Diabetes in Brazil and Peru: Two Randomized Clinical Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.4348","source_url":"https://doi.org/10.1001/jama.2021.4348","authors":["Ricardo Araya","Paulo Rossi Menezes","Heloísa Garcia Claro","Lena R Brandt","Kate L Daley","Julieta Quayle","Francisco Diez-Canseco","Tim J Peters","Daniela Vera Cruz","Mauricio Toyama","Suzana Aschar","Liliana Hidalgo-Padilla","Hellen Martins","Victoria Cavero","Thais Rocha","George Scotton","Ivan F de Almeida Lopes","Mark Begale","David C Mohr","J Jaime Miranda"],"significance":6,"published":"2021-05-11","source_date":"2021-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This JAMA trial showed that a digital mental health intervention improves depressive symptoms in patients with comorbid hypertension or diabetes in Latin America, demonstrating scalable technology-based treatment for the depression-cardiovascular comorbidity.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3f82b542dbbb","type":"article","url":"https://hartvaat.nl/2021/05/11/geindividualiseerde-voedingsondersteuning-bij-gehospitaliseerd-chronisch-hf/","title":"Geïndividualiseerde voedingsondersteuning bij gehospitaliseerd chronisch HF","title_en":"Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","chronische-nierziekte","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.03.232","source_url":"https://doi.org/10.1016/j.jacc.2021.03.232","authors":["Lara Hersberger","Anna Dietz","Helene Bürgler","Annika Bargetzi","Laura Bargetzi","Nina Kägi-Braun","Pascal Tribolet","Filomena Gomes","Claus Hoess","Vojtech Pavlicek","Stefan Bilz","Sarah Sigrist","Michael Brändle","Christoph Henzen","Robert Thomann","Jonas Rutishauser","Drahomir Aujesky","Nicolas Rodondi","Jacques Donzé","Zeno Stanga","Beat Mueller","Philipp Schuetz"],"significance":6,"published":"2021-05-11","source_date":"2021-05-11","image":"","kennis":[],"congress":"","summary_en":"This study showed that individualized nutritional support during hospitalization for chronic heart failure improves clinical outcomes, supporting targeted nutrition assessment and intervention as part of inpatient heart failure management.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e3bfd10dfe89","type":"article","url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","title":"Intensieve bloeddruk en aortastijfheid: SPRINT-HEART","title_en":"Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16676","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16676","authors":["Bharathi Upadhya","Nicholas M Pajewski","Michael V Rocco","W Gregory Hundley","Gerard Aurigemma","Craig A Hamilton","Jeffrey T Bates","Jiang He","Jing Chen","Michel Chonchol","Steve P Glasser","Adriana M Hung","Roberto Pisoni","Henry Punzi","Mark A Supiano","Robert Toto","Addison Taylor","Dalane W Kitzman"],"significance":6,"published":"2021-05-05","source_date":"2021-05-05","image":"","kennis":[],"congress":"","summary_en":"This SPRINT-HEART analysis showed that intensive blood pressure control reduces aortic stiffness, demonstrating that aggressive blood pressure management has direct vascular benefits beyond hemodynamic lowering.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4fd8db379553","type":"article","url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","title":"Bloeddrukvariabiliteit en uitkomsten bij HFpEF","title_en":"Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16757","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16757","authors":["Fang-Fei Wei","Yuanyuan Zhou","Lutgarde Thijs","Ruicong Xue","Bin Dong","Xin He","Weihao Liang","Yuzhong Wu","Jingzhou Jiang","Weiping Tan","Jiangui He","Jan A Staessen","Yugang Dong","Jingjing Zhao","Chen Liu"],"significance":5,"published":"2021-05-05","source_date":"2021-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This study showed that visit-to-visit blood pressure variability is associated with worse clinical outcomes in HFpEF, identifying blood pressure instability as a prognostic factor in this population.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e29d884e8a7d","type":"article","url":"https://hartvaat.nl/2021/05/05/chronische-milde-slaaprestrictie-verhoogt-bloeddruk-bij-vrouwen-aha-go-red/","title":"Chronische milde slaaprestrictie verhoogt bloeddruk bij vrouwen: AHA Go Red","title_en":"Sustained Mild Sleep Restriction Increases Blood Pressure in Women: An Update From the American Heart Association Go Red for Women Strategically Focused Research Network.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16370","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16370","authors":["Nour Makarem","Faris M Zuraikat","Samantha E Scaccia","Arindam RoyChoudhury","Marie-Pierre St-Onge"],"significance":6,"published":"2021-05-05","source_date":"2021-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This AHA Go Red for Women study showed that sustained mild sleep restriction increases blood pressure in women, establishing inadequate sleep as a sex-specific modifiable cardiovascular risk factor.","created":"2026-07-03T10:29:11Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c6a32100154","type":"article","url":"https://hartvaat.nl/2021/05/05/veroorzaken-betablokkers-depressie-systematische-review-en-meta-analyse/","title":"Veroorzaken bètablokkers depressie? Systematische review en meta-analyse","title_en":"Do β-Blockers Cause Depression?: Systematic Review and Meta-Analysis of Psychiatric Adverse Events During β-Blocker Therapy.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts"],"tags":["stress-psychosociaal"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16590","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16590","authors":["Thomas G Riemer","Linda E Villagomez Fuentes","Engi A E Algharably","Marie S Schäfer","Eva Mangelsen","Marc-Alexander Fürtig","Nadine Bittner","Annalena Bär","Laila Zaidi Touis","Kristian Wachtell","Tomislav Majic","Martin J Dinges","Reinhold Kreutz"],"significance":8,"published":"2021-05-05","source_date":"2021-05-05","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This systematic review and meta-analysis found no significant association between beta-blocker therapy and increased risk of depression, debunking a widely held clinical belief. The evidence addressed one of the most common reasons patients and clinicians avoid beta-blockers.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f4b9f9e63f82","type":"article","url":"https://hartvaat.nl/2021/05/05/furosemide-voor-versneld-bloeddrukherstel-postpartum-bij-hypertensieve-zwangersc/","title":"Furosemide voor versneld bloeddrukherstel postpartum bij hypertensieve zwangerschap: RCT","title_en":"Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["huisarts"],"tags":["diuretica","furosemide","zwangerschap-hart"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16133","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16133","authors":["Joana Lopes Perdigao","Jennifer Lewey","Adi Hirshberg","Nathanael Koelper","Sindhu K Srinivas","Michal A Elovitz","Lisa D Levine"],"significance":6,"published":"2021-05-05","source_date":"2021-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This randomized trial tested whether furosemide accelerates postpartum blood pressure recovery in women with hypertensive disorders of pregnancy, evaluating a simple pharmacological strategy for the post-delivery period.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dc8bda035cdd","type":"article","url":"https://hartvaat.nl/2021/05/01/bloeddrukverlaging-voor-primaire-en-secundaire-preventie-over-alle-niveaus-lance/","title":"Bloeddrukverlaging voor primaire en secundaire preventie over alle niveaus: Lancet BPLTTC meta-analyse","title_en":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["primaire-preventie"],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)00590-0","source_url":"https://doi.org/10.1016/S0140-6736(21)00590-0","authors":[],"significance":10,"published":"2021-05-01","source_date":"2021-05-01","image":"","kennis":[],"congress":"","summary_en":"This individual-participant-data meta-analysis from the BPLTTC demonstrated that pharmacological blood pressure lowering reduces cardiovascular events across all baseline blood pressure levels, including in individuals with normal or high-normal pressure. The findings support a strategy of treating based on absolute cardiovascular risk rather than blood pressure thresholds alone.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f22698e54d0a","type":"article","url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","title":"Screening op AF bij ouderen: JAMA Cardiology gerandomiseerde trial","title_en":"Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["atleten"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2021.0038","source_url":"https://doi.org/10.1001/jamacardio.2021.0038","authors":["David J Gladstone","Rolf Wachter","Katharina Schmalstieg-Bahr","F Russell Quinn","Eva Hummers","Noah Ivers","Tamara Marsden","Andrea Thornton","Angie Djuric","Johanna Suerbaum","Doris von Grünhagen","William F McIntyre","Alexander P Benz","Jorge A Wong","Fatima Merali","Sam Henein","Chris Nichol","Stuart J Connolly","Jeff S Healey"],"significance":7,"published":"2021-05-01","source_date":"2021-05-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial of systematic AF screening in the older population evaluated the yield and downstream clinical impact of screening for previously undiagnosed atrial fibrillation.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0dfe7fc4c749","type":"article","url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","title":"Time to clinical benefit van dapagliflozine bij HFrEF: DAPA-HF","title_en":"Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.7585","source_url":"https://doi.org/10.1001/jamacardio.2020.7585","authors":["David D Berg","Pardeep S Jhund","Kieran F Docherty","Sabina A Murphy","Subodh Verma","Silvio E Inzucchi","Lars Køber","Mikhail N Kosiborod","Anna Maria Langkilde","Felipe A Martinez","Olof Bengtsson","Piotr Ponikowski","Mikaela Sjöstrand","Scott D Solomon","John J V McMurray","Marc S Sabatine"],"significance":7,"published":"2021-05-01","source_date":"2021-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DAPA-HF analysis showed that dapagliflozin achieves clinical benefit within weeks of initiation in HFrEF, with earlier benefit in patients with prior heart failure hospitalization, supporting prompt SGLT2 inhibitor initiation.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3587e088f934","type":"article","url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","title":"MCP-1 en cardiovasculaire mortaliteit: populatie-gebaseerde meta-analyse","title_en":"Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.5392","source_url":"https://doi.org/10.1001/jamacardio.2020.5392","authors":["Marios K Georgakis","James A de Lemos","Colby Ayers","Biqi Wang","Harry Björkbacka","Tiberiu A Pana","Barbara Thorand","Caroline Sun","Lana Fani","Rainer Malik","Josée Dupuis","Gunnar Engström","Marju Orho-Melander","Olle Melander","S Matthijs Boekholdt","Astrid Zierer","Mohamed A Elhadad","Wolfgang Koenig","Christian Herder","Ron C Hoogeveen","Maryam Kavousi","Christie M Ballantyne","Annette Peters","Phyo K Myint","Jan Nilsson","Emelia J Benjamin","Martin Dichgans"],"significance":5,"published":"2021-05-01","source_date":"2021-05-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that circulating MCP-1 (monocyte chemoattractant protein-1) is independently associated with cardiovascular mortality in population-based studies, supporting its role as an inflammatory risk biomarker.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"46cbf3317ec0","type":"article","url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","title":"Vroegtijdig permanent staken van apixaban of warfarine bij AF","title_en":"Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-317229","source_url":"https://doi.org/10.1136/heartjnl-2020-317229","authors":["Anthony P Carnicelli","Sana M Al-Khatib","Denis Xavier","Frederik Dalgaard","Peter D Merrill","Daniel M Wojdyla","Basil S Lewis","Michael Hanna","John H Alexander","Renato D Lopes","Lars Wallentin","Christopher B Granger"],"significance":6,"published":"2021-05-01","source_date":"2021-05-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This ARISTOTLE analysis showed that premature discontinuation of both apixaban and warfarin is associated with worse outcomes in AF, with similar rates of permanent discontinuation but different reasons across the two agents.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"7fde6c0921e2","type":"article","url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-evidence-update-2021/","title":"Screening op hypertensie bij volwassenen: USPSTF evidence update 2021","title_en":"Screening for Hypertension in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2020.21669","source_url":"https://doi.org/10.1001/jama.2020.21669","authors":["Janelle M Guirguis-Blake","Corinne V Evans","Elizabeth M Webber","Erin L Coppola","Leslie A Perdue","Meghan Soulsby Weyrich"],"significance":7,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":[],"congress":"","summary_en":"This updated USPSTF evidence review confirmed that screening for hypertension in adults followed by appropriate treatment reduces cardiovascular events and mortality, supporting the continued recommendation for routine blood pressure screening.","created":"2026-07-03T10:29:10Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2bb523083dba","type":"article","url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","title":"Screening op hypertensie bij volwassenen: USPSTF herbevestiging 2021","title_en":"Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.4987","source_url":"https://doi.org/10.1001/jama.2021.4987","authors":["Alex H Krist","Karina W Davidson","Carol M Mangione","Michael Cabana","Aaron B Caughey","Esa M Davis","Katrina E Donahue","Chyke A Doubeni","Martha Kubik","Li Li","Gbenga Ogedegbe","Lori Pbert","Michael Silverstein","James Stevermer","Chien-Wen Tseng","John B Wong"],"significance":7,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":[],"congress":"","summary_en":"The 2021 USPSTF reaffirmed the recommendation for screening for hypertension in adults, maintaining a Grade A recommendation for office blood pressure measurement as part of routine care.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"69db8bb658c1","type":"article","url":"https://hartvaat.nl/2021/04/27/groepsmedisch-consult-en-microfinanciering-bij-diabetes-hypertensie-in-kenia/","title":"Groepsmedisch consult en microfinanciering bij diabetes/hypertensie in Kenia","title_en":"Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["anemie-ckd","diabetes-en-hart"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.03.002","source_url":"https://doi.org/10.1016/j.jacc.2021.03.002","authors":["Rajesh Vedanthan","Jemima H Kamano","Stavroula A Chrysanthopoulou","Richard Mugo","Benjamin Andama","Gerald S Bloomfield","Cleophas W Chesoli","Allison K DeLong","David Edelman","Eric A Finkelstein","Carol R Horowitz","Simon Manyara","Diana Menya","Violet Naanyu","Vitalis Orango","Sonak D Pastakia","Thomas W Valente","Joseph W Hogan","Valentin Fuster"],"significance":6,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This study tested a combined group medical visit and microfinance intervention for patients with diabetes or hypertension in Kenya, addressing social determinants of health through an integrated care delivery model.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"8dfe1dc7dd5a","type":"article","url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","title":"Patiëntselectie voor intensieve bloeddrukbehandeling naar voordeel en bijwerkingen","title_en":"Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.02.058","source_url":"https://doi.org/10.1016/j.jacc.2021.02.058","authors":["Adam P Bress","Tom Greene","Catherine G Derington","Jincheng Shen","Yizhe Xu","Yiyi Zhang","Jian Ying","Brandon K Bellows","William C Cushman","Paul K Whelton","Nicholas M Pajewski","David Reboussin","Srinivasan Beddu","Rachel Hess","Jennifer S Herrick","Zugui Zhang","Paul Kolm","Robert W Yeh","Sanjay Basu","William S Weintraub","Andrew E Moran"],"significance":7,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/behandeldoelen-bloeddruk/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This analysis developed a framework for identifying patients who benefit most from intensive blood pressure treatment based on the balance between cardiovascular event prevention and adverse effects, supporting personalized blood pressure management.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1c7beb1637d4","type":"article","url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","title":"Pneumonie-incidentie en uitkomsten bij hartfalen","title_en":"Incidence and Outcomes of Pneumonia in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.03.001","source_url":"https://doi.org/10.1016/j.jacc.2021.03.001","authors":["Li Shen","Pardeep S Jhund","Inder S Anand","Ankeet S Bhatt","Akshay S Desai","Aldo P Maggioni","Felipe A Martinez","Marc A Pfeffer","Adel R Rizkala","Jean L Rouleau","Karl Swedberg","Muthiah Vaduganathan","Orly Vardeny","Dirk J van Veldhuisen","Faiez Zannad","Michael R Zile","Milton Packer","Scott D Solomon","John J V McMurray"],"significance":5,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":[],"congress":"","summary_en":"This study showed that pneumonia incidence and outcomes differ between HFrEF and HFpEF patients, highlighting the infection vulnerability of heart failure and the need for vaccination and prevention strategies.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e52268d41303","type":"article","url":"https://hartvaat.nl/2021/04/27/empagliflozine-en-pulmonalisdruk-bij-hf-embrace-hf/","title":"Empagliflozine en pulmonalisdruk bij HF: EMBRACE-HF","title_en":"Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["answer-hf","bloeddrukbehandeling","dapa-hf","emperor-trials","step-hfpef"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.052503","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.052503","authors":["Michael E Nassif","Mohammed Qintar","Sheryl L Windsor","Rita Jermyn","David M Shavelle","Fengming Tang","Sumant Lamba","Kunjan Bhatt","John Brush","Andrew Civitello","Robert Gordon","Orvar Jonsson","Brent Lampert","Jamie Pelzel","Mikhail N Kosiborod"],"significance":7,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":[],"congress":"","summary_en":"The EMBRACE-HF trial showed that empagliflozin reduces pulmonary artery pressure in heart failure patients with implantable hemodynamic monitors, providing direct hemodynamic evidence of SGLT2 inhibitor-mediated cardiac decompression.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b86c3941cdd","type":"article","url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","title":"2021 ACC/AHA kerngegevenselementen voor hartfalen","title_en":"2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.012","source_url":"https://doi.org/10.1016/j.jacc.2020.11.012","authors":["Biykem Bozkurt","Ray E Hershberger","Javed Butler","Kathleen L Grady","Paul A Heidenreich","Maria Lizza Isler","James K Kirklin","William S Weintraub"],"significance":5,"published":"2021-04-27","source_date":"2021-04-27","image":"","kennis":[],"congress":"","summary_en":"This ACC/AHA document defined standardized key data elements and definitions for heart failure research and quality improvement, enabling consistent data collection across registries and clinical trials.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"63ce21d20d26","type":"article","url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","title":"IL-6-receptorremming bij acuut STEMI: gerandomiseerde trial","title_en":"Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.02.049","source_url":"https://doi.org/10.1016/j.jacc.2021.02.049","authors":["Kaspar Broch","Anne Kristine Anstensrud","Sindre Woxholt","Kapil Sharma","Ingvild Maria Tøllefsen","Bjørn Bendz","Svend Aakhus","Thor Ueland","Brage Høyem Amundsen","Jan Kristian Damås","Erlend Sturle Berg","Elisabeth Bjørkelund","Christina Bendz","Einar Hopp","Ola Kleveland","Knut Haakon Stensæth","Anders Opdahl","Nils-Einar Kløw","Ingebjørg Seljeflot","Geir Øystein Andersen","Rune Wiseth","Pål Aukrust","Lars Gullestad"],"significance":7,"published":"2021-04-20","source_date":"2021-04-20","image":"","kennis":[],"congress":"","summary_en":"This randomized trial of tocilizumab (IL-6 receptor inhibitor) in acute STEMI showed reduced C-reactive protein and troponin T release, demonstrating the feasibility and mechanistic promise of anti-inflammatory therapy in the acute MI setting.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"513ce845d1f3","type":"article","url":"https://hartvaat.nl/2021/04/20/natriumreductie-en-bloeddruk-dosis-respons-meta-analyse-van-experimentele-studie/","title":"Natriumreductie en bloeddruk: dosis-respons meta-analyse van experimentele studies","title_en":"Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.050371","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.050371","authors":["Tommaso Filippini","Marcella Malavolti","Paul K Whelton","Androniki Naska","Nicola Orsini","Marco Vinceti"],"significance":7,"published":"2021-04-20","source_date":"2021-04-20","image":"","kennis":[],"congress":"","summary_en":"This dose-response meta-analysis of experimental studies quantified the blood pressure effect of sodium reduction, showing a linear relationship between dietary sodium decrease and blood pressure lowering across the range of intake levels.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5031f2242169","type":"article","url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","title":"Geleide versus standaard antiplaatjestherapie na PCI: Lancet meta-analyse","title_en":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)00533-X","source_url":"https://doi.org/10.1016/S0140-6736(21)00533-X","authors":["Mattia Galli","Stefano Benenati","Davide Capodanno","Francesco Franchi","Fabiana Rollini","Domenico D'Amario","Italo Porto","Dominick J Angiolillo"],"significance":8,"published":"2021-04-17","source_date":"2021-04-17","image":"","kennis":[],"congress":"","summary_en":"This Lancet meta-analysis showed that guided antiplatelet therapy selection (pharmacogenomic or pharmacodynamic testing) after PCI reduces ischemic and bleeding events compared with standard unguided therapy. The results supported precision medicine approaches to antiplatelet management.","created":"2026-07-03T10:29:09Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9b3e818eea05","type":"article","url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","title":"2020 ESC-richtlijn voor NSTE-ACS management","title_en":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","richtlijnen-esc"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa575","source_url":"https://doi.org/10.1093/eurheartj/ehaa575","authors":["Jean-Philippe Collet","Holger Thiele","Emanuele Barbato","Olivier Barthélémy","Johann Bauersachs","Deepak L Bhatt","Paul Dendale","Maria Dorobantu","Thor Edvardsen","Thierry Folliguet","Chris P Gale","Martine Gilard","Alexander Jobs","Peter Jüni","Ekaterini Lambrinou","Basil S Lewis","Julinda Mehilli","Emanuele Meliga","Béla Merkely","Christian Mueller","Marco Roffi","Frans H Rutten","Dirk Sibbing","George C M Siontis"],"significance":10,"published":"2021-04-07","source_date":"2021-04-07","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/esc-richtlijn-kleplijden-2021/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"The 2020 ESC Guidelines for non-ST-elevation acute coronary syndromes updated risk stratification, timing of invasive management, and antithrombotic strategies incorporating evidence from ISCHEMIA, TWILIGHT, and contemporary trials. The guideline refined the balance between ischemic protection and bleeding risk in ACS patients.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d27bde006579","type":"article","url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","title":"Ventriculaire aritmie bij niet-ischemisch HF: prevalentie en prognose — DANISH","title_en":"Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa341","source_url":"https://doi.org/10.1093/europace/euaa341","authors":["Rune Boas","Jens Jakob Thune","Steen Pehrson","Lars Køber","Jens C Nielsen","Lars Videbæk","Jens Haarbo","Eva Korup","Niels Eske Bruun","Axel Brandes","Hans Eiskjær","Anna M Thøgersen","Berit T Philbert","Jesper Hastrup Svendsen","Ulrik Dixen"],"significance":6,"published":"2021-04-06","source_date":"2021-04-06","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This DANISH analysis characterized the prevalence and prognostic significance of ventricular arrhythmias in non-ischemic heart failure, providing risk stratification data for ICD selection in this debated indication.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6ab48fed97b1","type":"article","url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","title":"PVI alleen versus uitgebreide ablatie bij persisterend AF: meta-analyse","title_en":"Pulmonary vein isolation alone vs. more extensive ablation with defragmentation and linear ablation of persistent atrial fibrillation: the EARNEST-PVI trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa293","source_url":"https://doi.org/10.1093/europace/euaa293","authors":["Koichi Inoue","Shungo Hikoso","Masaharu Masuda","Yoshio Furukawa","Akio Hirata","Yasuyuki Egami","Tetsuya Watanabe","Hitoshi Minamiguchi","Miwa Miyoshi","Nobuaki Tanaka","Takafumi Oka","Masato Okada","Takashi Kanda","Yasuhiro Matsuda","Masato Kawasaki","Kenichi Hayashi","Tetsuhisa Kitamura","Tomoharu Dohi","Akihiro Sunaga","Hiroya Mizuno","Daisaku Nakatani","Yasushi Sakata"],"significance":6,"published":"2021-04-06","source_date":"2021-04-06","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis confirmed that PVI alone achieves similar outcomes to more extensive ablation (defragmentation and linear lesions) for persistent AF, supporting the simpler approach as the standard first procedure.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ac0bc30c886c","type":"article","url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","title":"ERO/LVEDV-ratio en respons op MitraClip: JAMA Cardiology","title_en":"Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.7200","source_url":"https://doi.org/10.1001/jamacardio.2020.7200","authors":["JoAnn Lindenfeld","William T Abraham","Paul A Grayburn","Saibal Kar","Federico M Asch","D Scott Lim","Hong Nie","Pooja Singhal","Kartik S Sundareswaran","Neil J Weissman","Michael J Mack","Gregg W Stone"],"significance":6,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This analysis showed that the effective regurgitation orifice area to LV end-diastolic volume ratio (ERO/LVEDV) predicts the response to transcatheter mitral valve repair, establishing a quantitative echocardiographic criterion for MitraClip patient selection.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0dd1830bef12","type":"article","url":"https://hartvaat.nl/2021/04/01/aerobe-training-bevordert-angiogenese-en-verlaagt-bloeddruk-bij-hypertensie-exca/","title":"Aerobe training bevordert angiogenese en verlaagt bloeddruk bij hypertensie: EXCAVATION-CHN","title_en":"Promotion of Aerobic Exercise Induced Angiogenesis Is Associated With Decline in Blood Pressure in Hypertension: Result of EXCAVATION-CHN1.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16107","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16107","authors":["Jianwen Liang","Xiaoyu Zhang","Wenhao Xia","Xinzhu Tong","Yanxia Qiu","Yumin Qiu","Jiang He","Bingbo Yu","Hui Huang","Jun Tao"],"significance":6,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/farmacologie/aldosteron-en-raas-farmacologie/"],"congress":"","summary_en":"This study showed that aerobic exercise training promotes angiogenesis that is associated with blood pressure reduction in hypertensive patients, providing a vascular mechanism linking physical activity to blood pressure improvement.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aa758c0bbed6","type":"article","url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","title":"Canagliflozine naar diureticagebruik: CANVAS post-hoc analyse","title_en":"Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13236","source_url":"https://doi.org/10.1002/ehf2.13236","authors":["Jie Yu","Clare Arnott","Brendon L Neuen","Hiddo L Heersprink","Kenneth W Mahaffey","Christopher P Cannon","Sadiya S Khan","Abigail S Baldridge","Sanjiv J Shah","Yuli Huang","Chao Li","Gemma A Figtree","Vlado Perkovic","Meg J Jardine","Bruce Neal","Mark D Huffman"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This CANVAS post-hoc analysis showed that the cardiovascular and renal effects of canagliflozin differ by baseline diuretic use, providing practical insights for prescribing SGLT2 inhibitors alongside volume management.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9fc4be621b87","type":"article","url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","title":"Intensieve versus standaard bloeddruk op CVA-subtypes: SPRINT","title_en":"Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16027","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16027","authors":["Clinton B Wright","Alexander P Auchus","Alan Lerner","Walter T Ambrosius","Hakan Ay","Jeffrey T Bates","Jing Chen","James F Meschia","Suchita Pancholi","Vasilios Papademetriou","Anjay Rastogi","Mary Sweeney","James J Willard","Jerry Yee","Suzanne Oparil"],"significance":6,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT analysis examined the effect of intensive blood pressure control on specific stroke subtypes, showing differential risk reduction for ischemic versus hemorrhagic stroke with aggressive blood pressure management.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5846c86e9869","type":"article","url":"https://hartvaat.nl/2021/04/01/sarcopenie-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Sarcopenie bij hartfalen: systematische review en meta-analyse","title_en":"Sarcopenia in heart failure: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13255","source_url":"https://doi.org/10.1002/ehf2.13255","authors":["Yan Zhang","Jia Zhang","Wenqing Ni","Xueli Yuan","Hongmin Zhang","Ping Li","Jian Xu","Zhiguang Zhao"],"significance":6,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis quantified the prevalence and clinical impact of sarcopenia in heart failure patients, establishing muscle wasting as a common comorbidity associated with worse functional capacity and outcomes.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2442ac74229f","type":"article","url":"https://hartvaat.nl/2021/04/01/lv-longitudinale-systolische-functieparameters-als-voorspellers-bij-hfpef/","title":"LV longitudinale systolische functieparameters als voorspellers bij HFpEF","title_en":"Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13247","source_url":"https://doi.org/10.1002/ehf2.13247","authors":["Anna Gozdzik","Thomas H Marwick","Monika Przewlocka-Kosmala","Ewa A Jankowska","Piotr Ponikowski","Wojciech Kosmala"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/echocardiografie-bij-hartfalen/"],"congress":"","summary_en":"This study compared different LV longitudinal systolic function parameters (GLS, MAPSE, S') for predicting adverse outcomes in HFpEF, informing the optimal echocardiographic measure for risk stratification.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"244ebbacd78f","type":"article","url":"https://hartvaat.nl/2021/04/01/cardio-microstroomdevice-bij-chronisch-hf-eerste-klinische-studie/","title":"Cardio-microstroomdevice bij chronisch HF: eerste klinische studie","title_en":"Cardio-microcurrent device for chronic heart failure: first-in-human clinical study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hypertrofische-cardiomyopathie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13242","source_url":"https://doi.org/10.1002/ehf2.13242","authors":["Dragana Kosevic","Dominik Wiedemann","Petar Vukovic","Velibor Ristic","Julia Riebandt","Una Radak","Kersten Brandes","Peter Goettel","Hans-Dirk Duengen","Elvis Tahirovic","Tatjana Kottmann","Hans Werner Voss","Marija Zdravkovic","Svetozar Putnik","Jan D Schmitto","Johannes Mueller","Jesus Eduardo Rame","Miodrag Peric"],"significance":4,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"The first-in-human study of a cardio-microcurrent device for chronic heart failure demonstrated feasibility and safety of chronic electrical microcurrent application to the heart. The results inform the design of a future randomised controlled trial.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ebeb651c5720","type":"article","url":"https://hartvaat.nl/2021/04/01/sglt2-remmers-bij-hfref-meta-analyse-van-vier-effectmodificatoren/","title":"SGLT2-remmers bij HFrEF: meta-analyse van vier effectmodificatoren","title_en":"Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13241","source_url":"https://doi.org/10.1002/ehf2.13241","authors":["Mei Qiu","Liang-Liang Ding","Ze-Lin Zhan","Hai-Rong Zhou"],"significance":7,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis examined four factors (diabetes status, baseline eGFR, NT-proBNP, and blood pressure) that may modify the efficacy of SGLT2 inhibitors in HFrEF, finding consistent benefit across all subgroups.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"2b04c60d85d5","type":"article","url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","title":"TELEREH-HF: etiologie-subanalyse van telerevalidatie bij hartfalen","title_en":"An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13189","source_url":"https://doi.org/10.1002/ehf2.13189","authors":["Dominika Szalewska","Renata Główczyńska","Ryszard Piotrowicz","Ilona Kowalik","Michael J Pencina","Grzegorz Opolski","Wojciech Zaręba","Maciej Banach","Piotr Orzechowski","Sławomir Pluta","Robert Irzmański","Zbigniew Kalarus","Ewa Piotrowicz"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This TELEREH-HF subanalysis evaluated hybrid telerehabilitation by heart failure etiology, assessing whether ischemic and non-ischemic HF patients derive differential benefit from remote exercise programs.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b312ce7c9b0","type":"article","url":"https://hartvaat.nl/2021/04/01/ventriculaire-aritmie-of-overlijden-na-stemi-versus-takotsubo/","title":"Ventriculaire aritmie of overlijden na STEMI versus takotsubo","title_en":"Risk of in-hospital life-threatening ventricular arrhythmia or death after ST-elevation myocardial infarction vs. the Takotsubo syndrome.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["ventriculaire-tachycardie"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13208","source_url":"https://doi.org/10.1002/ehf2.13208","authors":["Rickard Zeijlon","Jasmina Chamat","Israa Enabtawi","Sandeep Jha","Mohammed Munir Mohammed","Johan Wågerman","Vina Le","Aaron Shekka Espinosa","Erik Nyman","Elmir Omerovic","Björn Redfors"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":["https://hartvaat.nl/kennis/ritmestoornissen/sport-en-ritmestoornissen/"],"congress":"","summary_en":"This study compared the risk of life-threatening ventricular arrhythmias between STEMI and Takotsubo syndrome, showing that arrhythmic risk is lower in Takotsubo despite similar acute presentation.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6b82d07cbd09","type":"article","url":"https://hartvaat.nl/2021/04/01/eiwitrijk-versus-standaard-dieet-bij-obees-hf-met-diabetes/","title":"Eiwitrijk versus standaard dieet bij obees HF met diabetes","title_en":"High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","select-trial","soul-trial"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13213","source_url":"https://doi.org/10.1002/ehf2.13213","authors":["Lorraine S Evangelista","Mini M Jose","Hanaa Sallam","Hani Serag","George Golovko","Kamil Khanipov","Michele A Hamilton","Gregg C Fonarow"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This study compared high-protein versus standard-protein diets in overweight heart failure patients with diabetes, evaluating whether protein intake influences cardiometabolic risk factors in this dual-disease population.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f05b1a4870dd","type":"article","url":"https://hartvaat.nl/2021/04/01/betrokkenheid-van-huisartsenzorg-bij-multidisciplinair-hf-management-meta-analys/","title":"Betrokkenheid van huisartsenzorg bij multidisciplinair HF-management: meta-analyse","title_en":"Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13152","source_url":"https://doi.org/10.1002/ehf2.13152","authors":["Willem Raat","Miek Smeets","Stefan Janssens","Bert Vaes"],"significance":7,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis showed that multidisciplinary heart failure disease management programs with primary care involvement achieve better adherence to guidelines and clinical outcomes, supporting integrated care models that bridge hospital and community settings.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"979eb67d7d52","type":"article","url":"https://hartvaat.nl/2021/04/01/va-ecls-bij-harttransplantatie-en-vad-centra-meta-analyse/","title":"VA-ECLS bij harttransplantatie en VAD-centra: meta-analyse","title_en":"Veno-Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta-analysis.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13080","source_url":"https://doi.org/10.1002/ehf2.13080","authors":["Mariusz Kowalewski","Kamil Zieliński","Mirosław Gozdek","Giuseppe Maria Raffa","Michele Pilato","Musab Alanazi","Martijn Gilbers","Sam Heuts","Ehsan Natour","Elham Bidar","Rick Schreurs","Thijs Delnoij","Rob Driessen","Jan Willem Sels","Marcel van de Poll","Paul Roekaerts","Michał Pasierski","Paolo Meani","Jos Maessen","Piotr Suwalski","Roberto Lorusso"],"significance":5,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis of VA-ECLS outcomes at heart transplant and VAD centers showed that center expertise significantly influences survival, supporting regionalization of mechanical support for cardiogenic shock.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3e6a8e79dccb","type":"article","url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","title":"Dapagliflozine en mortaliteit bij CKD: DAPA-CKD pre-gespecificeerde analyse","title_en":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["dapagliflozine","fidelio-dkd","flow-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehab094","source_url":"https://doi.org/10.1093/eurheartj/ehab094","authors":["Hiddo J L Heerspink","C David Sjöström","Niels Jongs","Glenn M Chertow","Mikhail Kosiborod","Fan Fan Hou","John J V McMurray","Peter Rossing","Ricardo Correa-Rotter","Raisa Kurlyandskaya","Bergur V Stefansson","Robert D Toto","Anna Maria Langkilde","David C Wheeler"],"significance":8,"published":"2021-03-31","source_date":"2021-03-31","image":"","kennis":[],"congress":"","summary_en":"This pre-specified DAPA-CKD mortality analysis confirmed that dapagliflozin significantly reduces all-cause mortality in patients with chronic kidney disease, independent of diabetes status. The survival benefit strengthened the case for universal SGLT2 inhibitor use in CKD.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a79bc37229c3","type":"article","url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","title":"MRA en empagliflozine interactie bij HF: EMPEROR-Reduced","title_en":"Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["emperor-trials"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.01.044","source_url":"https://doi.org/10.1016/j.jacc.2021.01.044","authors":["João Pedro Ferreira","Faiez Zannad","Stuart J Pocock","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Martina Brueckmann","Waheed Jamal","Dominik Steubl","Elke Schueler","Milton Packer"],"significance":6,"published":"2021-03-23","source_date":"2021-03-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis showed that the benefit of empagliflozin in heart failure is consistent regardless of concomitant MRA use, confirming additive cardioprotection when combining SGLT2 inhibitors with mineralocorticoid antagonists.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"890daf971fce","type":"article","url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","title":"Empagliflozine bij HFrEF met volume-overbelasting: EMPEROR-Reduced","title_en":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","empagliflozine","emperor-trials","hfref"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.01.033","source_url":"https://doi.org/10.1016/j.jacc.2021.01.033","authors":["Milton Packer","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Joao Pedro Ferreira","Stuart J Pocock","Naveed Sattar","Martina Brueckmann","Waheed Jamal","Daniel Cotton","Tomoko Iwata","Faiez Zannad"],"significance":6,"published":"2021-03-23","source_date":"2021-03-23","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis confirmed that empagliflozin provides consistent benefit in heart failure patients with volume overload and congestion, addressing the mechanism hypothesis that SGLT2 inhibitors act primarily through diuretic effects.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de80969e0321","type":"article","url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","title":"Omega-3 en vitamine D en incident AF: JAMA VITAL-AF","title_en":"Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.1489","source_url":"https://doi.org/10.1001/jama.2021.1489","authors":["Christine M Albert","Nancy R Cook","Julie Pester","M Vinayaga Moorthy","Claire Ridge","Jacqueline S Danik","Baris Gencer","Hasan K Siddiqi","Chee Ng","Heike Gibson","Samia Mora","Julie E Buring","JoAnn E Manson"],"significance":8,"published":"2021-03-16","source_date":"2021-03-16","image":"","kennis":[],"congress":"","summary_en":"The VITAL-AF trial unexpectedly showed that marine omega-3 fatty acid supplementation was associated with increased risk of atrial fibrillation, while vitamin D had no effect. The pro-arrhythmic signal contradicted the assumed cardiovascular benefit of fish oil supplements.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1bb65d9dee5c","type":"article","url":"https://hartvaat.nl/2021/03/16/systolische-bloeddruk-time-in-target-en-cv-uitkomsten-bij-hypertensie/","title":"Systolische bloeddruk time-in-target en CV-uitkomsten bij hypertensie","title_en":"Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","bloeddrukbehandeling"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.01.014","source_url":"https://doi.org/10.1016/j.jacc.2021.01.014","authors":["Nayyra Fatani","Dave L Dixon","Benjamin W Van Tassell","John Fanikos","Leo F Buckley"],"significance":7,"published":"2021-03-16","source_date":"2021-03-16","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This study introduced systolic blood pressure time-in-target-range as a novel metric for assessing blood pressure control quality, showing that sustained time within the target range predicts cardiovascular outcomes better than single measurements.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"1efa17e0f1d7","type":"article","url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","title":"Plaatjesreactiviteit bij ACS in afwachting van chirurgische revascularisatie","title_en":"Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.01.015","source_url":"https://doi.org/10.1016/j.jacc.2021.01.015","authors":["Carlos A K Nakashima","Luis A O Dallan","Luiz A F Lisboa","Fabio B Jatene","Ludhmila A Hajjar","Alexandre M Soeiro","Remo H M Furtado","Talia F Dalçoquio","Luciano M Baracioli","Felipe G Lima","Roberto R C V Giraldez","Bianca A Silva","Mateus S S Costa","Celia M C Strunz","Luis R P Dallan","Carlos J D G Barbosa","Flavia A B Britto","Michael E Farkouh","Paul A Gurbel","Jose C Nicolau"],"significance":5,"published":"2021-03-16","source_date":"2021-03-16","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"","summary_en":"This study characterized platelet reactivity in ACS patients awaiting CABG after P2Y12 inhibitor discontinuation, informing the optimal timing of surgery after antiplatelet withdrawal.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"596886dd2ed6","type":"article","url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","title":"Alirocumab naar bereikte LDL na ACS: ODYSSEY OUTCOMES","title_en":"Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["lipide-aferese"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.049447","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.049447","authors":["Gregory G Schwartz","Philippe Gabriel Steg","Deepak L Bhatt","Vera A Bittner","Rafael Diaz","Shaun G Goodman","J Wouter Jukema","Yong-Un Kim","Qian H Li","Garen Manvelian","Robert Pordy","Timothée Sourdille","Harvey D White","Michael Szarek"],"significance":7,"published":"2021-03-16","source_date":"2021-03-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"This ODYSSEY OUTCOMES analysis showed that alirocumab continues to reduce cardiovascular events at very low achieved LDL levels after ACS, with no safety concerns down to LDL cholesterol below 25 mg/dL.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c65954e4b2bf","type":"article","url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","title":"Duurzame versus biodegradeerbare polymer DES bij ACS: meta-analyse","title_en":"Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.051700","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.051700","authors":["Hyo-Soo Kim","Jeehoon Kang","Doyeon Hwang","Jung-Kyu Han","Han-Mo Yang","Hyun-Jae Kang","Bon-Kwon Koo","Seok Yeon Kim","Keun-Ho Park","Seung-Woon Rha","Won-Yong Shin","Hong-Seok Lim","Kyungil Park","Kyung Woo Park"],"significance":6,"published":"2021-03-16","source_date":"2021-03-16","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis comparing durable polymer with biodegradable polymer DES specifically in ACS patients found similar safety and efficacy, supporting either polymer technology for acute coronary intervention.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9bdffc124783","type":"article","url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","title":"Spironolacton bij HFpEF met verslechterende nierfunctie: TOPCAT","title_en":"Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.12.057","source_url":"https://doi.org/10.1016/j.jacc.2020.12.057","authors":["Iris E Beldhuis","Peder L Myhre","Michael Bristow","Brian Claggett","Kevin Damman","James C Fang","Jerome L Fleg","Sonja McKinlay","Eldrin F Lewis","Eileen O'Meara","Bertram Pitt","Sanjiv J Shah","Orly Vardeny","Adriaan A Voors","Marc A Pfeffer","Scott D Solomon","Akshay S Desai"],"significance":6,"published":"2021-03-09","source_date":"2021-03-09","image":"","kennis":[],"congress":"","summary_en":"This TOPCAT analysis showed that spironolactone maintains its benefit in HFpEF patients who develop worsening renal function during treatment, supporting continuation of MRA therapy despite transient creatinine rises.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a5652930f973","type":"article","url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","title":"Halve versus volle dosis edoxaban bij AF: gerandomiseerde vergelijking","title_en":"Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.12.053","source_url":"https://doi.org/10.1016/j.jacc.2020.12.053","authors":["Jan Steffel","Christian T Ruff","Ophelia Yin","Eugene Braunwald","Jeong-Gun Park","Sabina A Murphy","Stuart Connolly","Elliott M Antman","Robert P Giugliano"],"significance":7,"published":"2021-03-09","source_date":"2021-03-09","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This randomized comparison of half-dose versus full-dose edoxaban in over 14,000 AF patients showed that appropriately reduced dosing maintains stroke prevention efficacy with less bleeding, confirming the pharmacokinetic rationale for dose reduction.","created":"2026-07-03T10:29:06Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"861e675b79eb","type":"article","url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","title":"10-jaarsfollow-up EES versus BMS bij STEMI: EXAMINATION","title_en":"10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.12.059","source_url":"https://doi.org/10.1016/j.jacc.2020.12.059","authors":["Salvatore Brugaletta","Josep Gomez-Lara","Luis Ortega-Paz","Victor Jimenez-Diaz","Marcelo Jimenez","Pilar Jiménez-Quevedo","Roberto Diletti","Vicente Mainar","Gianluca Campo","Antonio Silvestro","Jaume Maristany","Xacobe Flores","Loreto Oyarzabal","Antonio De Miguel-Castro","Andrés Iñiguez","Antonio Serra","Luis Nombela-Franco","Alfonso Ielasi","Maurizio Tespili","Mattie Lenzen","Nieves Gonzalo","Pascual Bordes","Matteo Tebaldi","Simone Biscaglia","Juan Jose Rodriguez-Arias","Soheil Al-Shaibani","Victor Arevalos","Rafael Romaguera","Joan Antoni Gomez-Hospital","Patrick W Serruys","Manel Sabaté"],"significance":7,"published":"2021-03-09","source_date":"2021-03-09","image":"","kennis":[],"congress":"","summary_en":"The 10-year EXAMINATION follow-up confirmed the sustained superiority of everolimus-eluting stents over bare-metal stents in STEMI patients, providing the longest randomized comparison of DES versus BMS in primary PCI.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9baf4a0beb75","type":"article","url":"https://hartvaat.nl/2021/03/09/bloeddrukverlagende-medicatie-naar-hypertensierichtlijn-in-lage-middeninkomensla/","title":"Bloeddrukverlagende medicatie naar hypertensierichtlijn in lage/middeninkomenslanden","title_en":"Variation in the Proportion of Adults in Need of Blood Pressure-Lowering Medications by Hypertension Care Guideline in Low- and Middle-Income Countries: A Cross-Sectional Study of 1 037 215 Individuals From 50 Nationally Representative Surveys.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","bloeddrukbehandeling","lorundrostat","perifeer-vaatlijden","ras-remmers","renale-denervatie","sacubitril-valsartan","vrouwen"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.051620","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.051620","authors":["Nikkil Sudharsanan","Michaela Theilmann","Tabea K Kirschbaum","Jennifer Manne-Goehler","Sina Azadnajafabad","Pascal Bovet","Simiao Chen","Albertino Damasceno","Jan-Walter De Neve","Maria Dorobantu","Cara Ebert","Farshad Farzadfar","Gladwell Gathecha","Mongal Singh Gurung","Kosar Jamshidi","Jutta M A Jørgensen","Demetre Labadarios","Julia Lemp","Nuno Lunet","Joseph K Mwangi","Sahar Saeedi Moghaddam","Silver K Bahendeka","Zhaxybay Zhumadilov","Till Bärnighausen","Sebastian Vollmer","Rifat Atun","Justine I Davies","Pascal Geldsetzer"],"significance":6,"published":"2021-03-09","source_date":"2021-03-09","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/alfa-blokkers-hypertensie/"],"congress":"","summary_en":"This analysis showed substantial variation in the proportion of adults requiring antihypertensive medication across different international guidelines, highlighting how guideline differences affect treatment eligibility at the population level.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e9dad3a016f0","type":"article","url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","title":"Katheterablatie om AF-progressie te vertragen: ATTEST gerandomiseerde trial","title_en":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa298","source_url":"https://doi.org/10.1093/europace/euaa298","authors":["Karl-Heinz Kuck","Dmitry S Lebedev","Evgeny N Mikhaylov","Alexander Romanov","László Gellér","Oskars Kalējs","Thomas Neumann","Karapet Davtyan","Young Keun On","Sergey Popov","Maria Grazia Bongiorni","Michael Schlüter","Stephan Willems","Feifan Ouyang"],"significance":7,"published":"2021-03-08","source_date":"2021-03-08","image":"","kennis":[],"congress":"","summary_en":"The ATTEST trial investigated whether catheter ablation can delay the progression from paroxysmal to persistent AF compared with antiarrhythmic drugs, testing the disease-modifying potential of early ablation intervention.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cb3b33f2b85e","type":"article","url":"https://hartvaat.nl/2021/03/08/multi-katheter-cryotherapie-versus-rf-ablatie-bij-langdurig-persisterend-af-gera/","title":"Multi-katheter cryotherapie versus RF-ablatie bij langdurig persisterend AF: gerandomiseerde trial","title_en":"Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa289","source_url":"https://doi.org/10.1093/europace/euaa289","authors":["Mark M Gallagher","Gang Yi","Hanney Gonna","Lisa W M Leung","Idris Harding","Banu Evranos","Rachel Bastiaenen","Rajan Sharma","Sue Wright","Mark Norman","Zia Zuberi","A John Camm"],"significance":6,"published":"2021-03-08","source_date":"2021-03-08","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared multi-catheter cryotherapy with radiofrequency ablation for longstanding persistent AF, testing whether a balloon-based approach can match point-by-point RF ablation in the most challenging arrhythmia phenotype.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ab94078be306","type":"article","url":"https://hartvaat.nl/2021/03/03/verminderde-verkeersgerelateerde-luchtvervuiling-en-bloeddruk-gerandomiseerde-cr/","title":"Verminderde verkeersgerelateerde luchtvervuiling en bloeddruk: gerandomiseerde crossover trial","title_en":"Effect of Reducing Ambient Traffic-Related Air Pollution on Blood Pressure: A Randomized Crossover Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.15580","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.15580","authors":["Neelakshi Hudda","Misha Eliasziw","Scott O Hersey","Ellin Reisner","Robert D Brook","Wig Zamore","John L Durant","Doug Brugge"],"significance":6,"published":"2021-03-03","source_date":"2021-03-03","image":"","kennis":[],"congress":"","summary_en":"This randomized crossover trial demonstrated that reducing traffic-related air pollution exposure (using HEPA filters and residential relocation) lowers blood pressure, establishing a causal link between ambient air quality and hypertension.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"57230526253a","type":"article","url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","title":"3-jaarsuitkomsten van transcatheter mitraalklepherstel bij HF: COAPT","title_en":"3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.12.047","source_url":"https://doi.org/10.1016/j.jacc.2020.12.047","authors":["Michael J Mack","JoAnn Lindenfeld","William T Abraham","Saibal Kar","D Scott Lim","Jacob M Mishell","Brian K Whisenant","Paul A Grayburn","Michael J Rinaldi","Samir R Kapadia","Vivek Rajagopal","Ian J Sarembock","Andreas Brieke","Jason H Rogers","Steven O Marx","David J Cohen","Neil J Weissman","Gregg W Stone"],"significance":8,"published":"2021-03-02","source_date":"2021-03-02","image":"","kennis":[],"congress":"","summary_en":"The COAPT 3-year results confirmed sustained benefit of transcatheter mitral valve repair with MitraClip in heart failure with severe secondary mitral regurgitation, with persistent reductions in hospitalization and mortality beyond the 2-year primary endpoint.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"01c90ac5c8e8","type":"article","url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","title":"Genoomwijde analyse identificeert nieuwe MI-gevoeligheidsloci","title_en":"Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa1040","source_url":"https://doi.org/10.1093/eurheartj/ehaa1040","authors":["Jaana A Hartiala","Yi Han","Qiong Jia","James R Hilser","Pin Huang","Janet Gukasyan","William S Schwartzman","Zhiheng Cai","Subarna Biswas","David-Alexandre Trégouët","Nicholas L Smith","Marcus Seldin","Calvin Pan","Margarete Mehrabian","Aldons J Lusis","Peter Bazeley","Yan V Sun","Chang Liu","Arshed A Quyyumi","Markus Scholz","Joachim Thiery","Graciela E Delgado","Marcus E Kleber","Winfried März","Laurence J Howe","Folkert W Asselbergs","Marion van Vugt","Georgios J Vlachojannis","Riyaz S Patel","Leo-Pekka Lyytikäinen","Mika Kähönen","Terho Lehtimäki","Tuomo V M Nieminen","Pekka Kuukasjärvi","Jari O Laurikka","Xuling Chang","Chew-Kiat Heng","Rong Jiang","William E Kraus","Elizabeth R Hauser","Jane F Ferguson","Muredach P Reilly","Kaoru Ito","Satoshi Koyama","Yoichiro Kamatani","Issei Komuro","Lindsey K Stolze","Casey E Romanoski","Mohammad Daud Khan","Adam W Turner","Clint L Miller","Redouane Aherrahrou","Mete Civelek","Lijiang Ma","Johan L M Björkegren","S Ram Kumar","W H Wilson Tang","Stanley L Hazen","Hooman Allayee"],"significance":6,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":[],"congress":"","summary_en":"This genome-wide association study identified novel genetic susceptibility loci specifically for myocardial infarction beyond coronary atherosclerosis, advancing the understanding of thrombotic and plaque rupture genetics.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3155c057bd8a","type":"article","url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","title":"Objectieve risicobeoordeling versus standaardzorg bij ACS: JAMA Cardiology","title_en":"Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.6314","source_url":"https://doi.org/10.1001/jamacardio.2020.6314","authors":["Derek P Chew","Karice Hyun","Erin Morton","Matt Horsfall","Graham S Hillis","Clara K Chow","Stephen Quinn","Mario D'Souza","Andrew T Yan","Chris P Gale","Shaun G Goodman","Keith Fox","David Brieger"],"significance":6,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial compared objective risk assessment (using the GRACE risk score) with standard clinical judgment for managing ACS patients, testing whether systematic risk scoring improves treatment decisions and outcomes.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"929a6d90fb37","type":"article","url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","title":"KDIGO 2021 bloeddruk bij CKD: executive summary","title_en":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"Kidney international","doi":"10.1016/j.kint.2020.10.026","source_url":"https://doi.org/10.1016/j.kint.2020.10.026","authors":["Alfred K Cheung","Tara I Chang","William C Cushman","Susan L Furth","Fan Fan Hou","Joachim H Ix","Gregory A Knoll","Paul Muntner","Roberto Pecoits-Filho","Mark J Sarnak","Sheldon W Tobe","Charles R V Tomson","Lyubov Lytvyn","Jonathan C Craig","David J Tunnicliffe","Martin Howell","Marcello Tonelli","Michael Cheung","Amy Earley","Johannes F E Mann"],"significance":8,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"Executive summary of the KDIGO 2021 blood pressure guideline for chronic kidney disease, providing concise recommendations on targets, treatment strategies, and the integration of SPRINT evidence for CKD patients not receiving dialysis.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0b14af966048","type":"article","url":"https://hartvaat.nl/2021/03/01/kdigo-2021-richtlijn-voor-bloeddrukmanagement-bij-ckd/","title":"KDIGO 2021 richtlijn voor bloeddrukmanagement bij CKD","title_en":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","chronische-nierziekte"],"journal":"Kidney international","doi":"10.1016/j.kint.2020.11.003","source_url":"https://doi.org/10.1016/j.kint.2020.11.003","authors":[],"significance":9,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"The KDIGO 2021 guideline for blood pressure management in chronic kidney disease updated targets, recommending systolic <120 mmHg for most CKD patients. The guideline integrated SPRINT and DAPA-CKD evidence to provide a unified approach to cardiorenal protection through blood pressure control.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a853cd64a977","type":"article","url":"https://hartvaat.nl/2021/03/01/langetermijn-overlevingsvoordeel-van-ramipril-bij-mi-met-hf/","title":"Langetermijn overlevingsvoordeel van ramipril bij MI met HF","title_en":"Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-316823","source_url":"https://doi.org/10.1136/heartjnl-2020-316823","authors":["Jianhua Wu","Alistair S Hall","Chris P Gale"],"significance":6,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":[],"congress":"","summary_en":"This long-term analysis confirmed the sustained survival benefit of ramipril in patients with MI complicated by heart failure, providing the extended follow-up data supporting lifelong ACE inhibitor use after post-MI heart failure.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"999dca1ea5d6","type":"article","url":"https://hartvaat.nl/2021/03/01/bnp-en-cardiale-remodellering-na-mi-gerandomiseerde-trial/","title":"BNP en cardiale remodellering na MI: gerandomiseerde trial","title_en":"B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["acuut-hartfalen","bloeddrukbehandeling","farmaco-economie","myocardinfarct","nt-probnp","secundaire-preventie","summit-trial"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2020-317182","source_url":"https://doi.org/10.1136/heartjnl-2020-317182","authors":["Scott A Hubers","John A Schirger","S Jeson Sangaralingham","Yang Chen","John C Burnett","David Hodge","Horng H Chen"],"significance":5,"published":"2021-03-01","source_date":"2021-03-01","image":"","kennis":[],"congress":"","summary_en":"This randomized trial tested whether BNP-guided therapy improves cardiac remodeling after MI, exploring natriuretic peptide monitoring as a treatment titration strategy in the post-infarction period.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"159747bdad4f","type":"article","url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","title":"Myocardinfarct in de ISCHEMIA-trial: impact van verschillende MI-definities","title_en":"Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["colcot-trial","myocardinfarct"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.047987","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.047987","authors":["Bernard R Chaitman","Karen P Alexander","Derek D Cyr","Jeffrey S Berger","Harmony R Reynolds","Sripal Bangalore","William E Boden","Renato D Lopes","Marcin Demkow","Gian Piero Perna","Robert K Riezebos","Edward O McFalls","Subhash Banerjee","Akshay Bagai","Gilbert Gosselin","Sean M O'Brien","Frank W Rockhold","David D Waters","Kristian A Thygesen","Gregg W Stone","Harvey D White","David J Maron","Judith S Hochman"],"significance":7,"published":"2021-02-23","source_date":"2021-02-23","image":"","kennis":[],"congress":"","summary_en":"This ISCHEMIA analysis examined how different myocardial infarction definitions affect the trial's conclusions, showing that the treatment comparison is sensitive to whether periprocedural MI is counted, a finding with important implications for trial design.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5c196ecfb26f","type":"article","url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","title":"Progressie van tricuspidalisinsufficiëntie na chirurgie voor ischemische MR","title_en":"Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["tricuspidalisinsufficiëntie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.066","source_url":"https://doi.org/10.1016/j.jacc.2020.11.066","authors":["Philippe B Bertrand","Jessica R Overbey","Xin Zeng","Robert A Levine","Gorav Ailawadi","Michael A Acker","Peter K Smith","Vinod H Thourani","Emilia Bagiella","Marissa A Miller","Lopa Gupta","Michael J Mack","A Marc Gillinov","Gennaro Giustino","Alan J Moskowitz","Annetine C Gelijns","Michael E Bowdish","Patrick T O'Gara","James S Gammie","Judy Hung"],"significance":5,"published":"2021-02-16","source_date":"2021-02-16","image":"","kennis":[],"congress":"","summary_en":"This analysis documented the progression of tricuspid regurgitation after surgery for ischemic mitral regurgitation, informing the debate about concomitant tricuspid repair during mitral valve operations.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"3443e0eabad8","type":"article","url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","title":"2021 ACC HF-behandeloptimalisatie update: antwoorden op 10 cruciale vragen","title_en":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.022","source_url":"https://doi.org/10.1016/j.jacc.2020.11.022","authors":["Thomas M Maddox","James L Januzzi","Larry A Allen","Khadijah Breathett","Javed Butler","Leslie L Davis","Gregg C Fonarow","Nasrien E Ibrahim","JoAnn Lindenfeld","Frederick A Masoudi","Shweta R Motiwala","Estefania Oliveros","J Herbert Patterson","Mary Norine Walsh","Alan Wasserman","Clyde W Yancy","Quentin R Youmans"],"significance":9,"published":"2021-02-16","source_date":"2021-02-16","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"The 2021 ACC Expert Consensus update addressed 10 pivotal questions on heart failure treatment optimization, integrating evidence for SGLT2 inhibitors across the ejection fraction spectrum, vericiguat in recently decompensated HFrEF, and practical implementation of quadruple therapy.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c497d90dd5d","type":"article","url":"https://hartvaat.nl/2021/02/16/2021-acc-consensus-same-day-ontslag-na-pci/","title":"2021 ACC consensus: same-day ontslag na PCI","title_en":"2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.013","source_url":"https://doi.org/10.1016/j.jacc.2020.11.013","authors":["Sunil V Rao","Mladen I Vidovich","Ian C Gilchrist","Rajiv Gulati","J Antonio Gutierrez","Connie N Hess","Prashant Kaul","Sara C Martinez","Jennifer Rymer"],"significance":6,"published":"2021-02-16","source_date":"2021-02-16","image":"","kennis":[],"congress":"","summary_en":"This ACC expert consensus provided a structured decision pathway for same-day discharge after PCI, defining eligibility criteria and safety protocols for shortening the post-procedural hospitalization.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4776d1ba95ce","type":"article","url":"https://hartvaat.nl/2021/02/13/transdermaal-oestradiol-bij-prostaatkanker-langetermijn-cv-uitkomsten-lancet/","title":"Transdermaal oestradiol bij prostaatkanker: langetermijn CV-uitkomsten — Lancet","title_en":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Lancet (London, England)","doi":"10.1016/S0140-6736(21)00100-8","source_url":"https://doi.org/10.1016/S0140-6736(21)00100-8","authors":["Ruth E Langley","Duncan C Gilbert","Trinh Duong","Noel W Clarke","Matthew Nankivell","Stuart D Rosen","Stephen Mangar","Archie Macnair","Subramanian Kanaga Sundaram","Marc E Laniado","Sanjay Dixit","Sanjeev Madaan","Caroline Manetta","Alvan Pope","Christopher D Scrase","Stephen Mckay","Iqtedar A Muazzam","Gerald N Collins","Jane Worlding","Simon T Williams","Edgar Paez","Angus Robinson","Jonathan McFarlane","John V Deighan","John Marshall","Silvia Forcat","Melanie Weiss","Roger Kockelbergh","Abdulla Alhasso","Howard Kynaston","Mahesh Parmar"],"significance":6,"published":"2021-02-13","source_date":"2021-02-13","image":"","kennis":[],"congress":"","summary_en":"This Lancet long-term analysis showed that transdermal estradiol for androgen suppression in prostate cancer has favorable cardiovascular outcomes compared with LHRH agonists, relevant to the growing field of cardio-oncology.","created":"2026-07-03T10:29:04Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"45cff576b6a0","type":"article","url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","title":"Neprilysineremming en empagliflozine bij chronisch HFrEF: EMPEROR-Reduced interactie","title_en":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa968","source_url":"https://doi.org/10.1093/eurheartj/ehaa968","authors":["Milton Packer","Stefan D Anker","Javed Butler","Gerasimos Filippatos","Joao Pedro Ferreira","Stuart J Pocock","Hans-Peter Brunner-La Rocca","Stefan Janssens","Hiroyuki Tsutsui","Jian Zhang","Martina Brueckmann","Waheed Jamal","Daniel Cotton","Tomoko Iwata","Janet Schnee","Faiez Zannad"],"significance":7,"published":"2021-02-11","source_date":"2021-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Reduced analysis showed that the benefit of empagliflozin is consistent regardless of whether patients are also taking sacubitril-valsartan, confirming that SGLT2 inhibitors provide additive benefit on top of ARNI therapy.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"75c2d2e0a539","type":"article","url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","title":"Empagliflozine en inspanningsvermogen bij HFrEF en HFpEF: EMPERIAL","title_en":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["dapa-hf","emperor-trials","step-hfpef","summit-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa943","source_url":"https://doi.org/10.1093/eurheartj/ehaa943","authors":["William T Abraham","JoAnn Lindenfeld","Piotr Ponikowski","Piergiuseppe Agostoni","Javed Butler","Akshay S Desai","Gerasimos Filippatos","Jacek Gniot","Michael Fu","Lars Gullestad","Jonathan G Howlett","Stephen J Nicholls","Josep Redon","Isabelle Schenkenberger","José Silva-Cardoso","Stefan Störk","Jerzy Krzysztof Wranicz","Gianluigi Savarese","Martina Brueckmann","Waheed Jamal","Matias Nordaby","Barbara Peil","Ivana Ritter","Anastasia Ustyugova","Cordula Zeller","Afshin Salsali","Stefan D Anker"],"significance":7,"published":"2021-02-11","source_date":"2021-02-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The EMPERIAL trials evaluated the effect of empagliflozin on exercise ability (6-minute walk distance) and symptoms in patients with both HFrEF and HFpEF, finding modest improvements in symptom burden but no significant change in exercise capacity.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"93fc383ca3a0","type":"article","url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","title":"Spironolacton en cardiovasculaire functie bij risico op HF: EHJ","title_en":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","biomarkers-cardiovasculair","menopauze","roken","slaapapneu"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa758","source_url":"https://doi.org/10.1093/eurheartj/ehaa758","authors":["John G F Cleland","João Pedro Ferreira","Beatrice Mariottoni","Pierpaolo Pellicori","Joe Cuthbert","Job A J Verdonschot","Johannes Petutschnigg","Fozia Z Ahmed","Franco Cosmi","Hans-Peter Brunner La Rocca","Mamas A Mamas","Andrew L Clark","Frank Edelmann","Burkert Pieske","Javed Khan","Ken McDonald","Philippe Rouet","Jan A Staessen","Blerim Mujaj","Arantxa González","Javier Diez","Mark Hazebroek","Stephane Heymans","Roberto Latini","Stéphanie Grojean","Anne Pizard","Nicolas Girerd","Patrick Rossignol","Tim J Collier","Faiez Zannad"],"significance":6,"published":"2021-02-11","source_date":"2021-02-11","image":"","kennis":[],"congress":"","summary_en":"This study showed that spironolactone reduces fibrosis markers and improves cardiac function in people at increased risk of developing heart failure, supporting early MRA use for heart failure prevention.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"4cf278f51181","type":"article","url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","title":"Restrictieve versus liberale transfusie bij acuut MI: JAMA REALITY","title_en":"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2021.0135","source_url":"https://doi.org/10.1001/jama.2021.0135","authors":["Gregory Ducrocq","Jose R Gonzalez-Juanatey","Etienne Puymirat","Gilles Lemesle","Marine Cachanado","Isabelle Durand-Zaleski","Joan Albert Arnaiz","Manuel Martínez-Sellés","Johanne Silvain","Albert Ariza-Solé","Emile Ferrari","Gonzalo Calvo","Nicolas Danchin","Cristina Avendaño-Solá","Jerome Frenkiel","Alexandra Rousseau","Eric Vicaut","Tabassome Simon","Philippe Gabriel Steg"],"significance":7,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This JAMA REALITY trial preliminary analysis compared restrictive versus liberal transfusion strategies in patients with acute MI and anemia, addressing the optimal hemoglobin threshold for transfusion in this high-risk population.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"26dbf2ca833a","type":"article","url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","title":"HIIT, matig continu of richtlijnadvies en piek-VO2 bij HFrEF: JAMA SMARTEX-HF","title_en":"Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA","doi":"10.1001/jama.2020.26812","source_url":"https://doi.org/10.1001/jama.2020.26812","authors":["Stephan Mueller","Ephraim B Winzer","André Duvinage","Andreas B Gevaert","Frank Edelmann","Bernhard Haller","Elisabeth Pieske-Kraigher","Paul Beckers","Anna Bobenko","Jennifer Hommel","Caroline M Van de Heyning","Katrin Esefeld","Pia von Korn","Jeffrey W Christle","Mark J Haykowsky","Axel Linke","Ulrik Wisløff","Volker Adams","Burkert Pieske","Emeline M van Craenenbroeck","Martin Halle"],"significance":8,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":[],"congress":"","summary_en":"The SMARTEX-HF trial showed that high-intensity interval training was not superior to moderate continuous training for improving peak VO2 in patients with HFrEF. The result supported moderate exercise as safe and effective, without an incremental benefit from more intense training in heart failure.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"583b74da1828","type":"article","url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","title":"10-jaarsmortaliteit na PCI of CABG bij totale coronairocclusie","title_en":"Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["coronaire-bypass","perifeer-vaatlijden"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.055","source_url":"https://doi.org/10.1016/j.jacc.2020.11.055","authors":["Hideyuki Kawashima","Kuniaki Takahashi","Masafumi Ono","Hironori Hara","Rutao Wang","Chao Gao","Faisal Sharif","Michael J Mack","David R Holmes","Marie-Claude Morice","Stuart J Head","Arie Pieter Kappetein","Daniel J F M Thuijs","Milan Milojevic","Thilo Noack","Friedrich-Wilhelm Mohr","Piroze M Davierwala","Patrick W Serruys","Yoshinobu Onuma"],"significance":6,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/coronairlijden/cabg-bypasschirurgie/"],"congress":"","summary_en":"This 10-year mortality comparison of PCI versus CABG in patients with total coronary occlusions provided the longest follow-up data for revascularization strategy selection in this challenging anatomy.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9ac9b0c18b2e","type":"article","url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","title":"2020 ACC consensus: anticoagulatie en antiplaatjestherapie bij AF of VTE","title_en":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.09.011","source_url":"https://doi.org/10.1016/j.jacc.2020.09.011","authors":["Dharam J Kumbhani","Christopher P Cannon","Craig J Beavers","Deepak L Bhatt","Adam Cuker","Ty J Gluckman","Joseph E Marine","Roxana Mehran","Steven R Messe","Nimesh S Patel","Benjamin E Peterson","Kenneth Rosenfield","Sarah A Spinler","Vinod H Thourani"],"significance":8,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"The 2020 ACC Expert Consensus provided a comprehensive decision pathway for managing antithrombotic therapy in patients with atrial fibrillation or venous thromboembolism who require antiplatelet agents, with practical algorithms for diverse clinical scenarios.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"6507c3492a78","type":"article","url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","title":"Finerenon en cardiovasculaire uitkomsten bij CKD met diabetes type 2: FIDELIO-DKD","title_en":"Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anemie-ckd","cardio-renaal-metabool","cardiorenal-behandelstrategie","chronische-nierziekte","dapagliflozine","diabetes-en-hart","diabetes-type-2","fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","ijzertekort","menopauze","mra-aldosteronantagonisten","roken","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.051898","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.051898","authors":["Gerasimos Filippatos","Stefan D Anker","Rajiv Agarwal","Bertram Pitt","Luis M Ruilope","Peter Rossing","Peter Kolkhof","Patrick Schloemer","Ingo Tornus","Amer Joseph","George L Bakris"],"significance":10,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"The FIDELIO-DKD trial demonstrated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both kidney failure progression and cardiovascular events in patients with chronic kidney disease and type 2 diabetes. This established finerenone as a new therapeutic pillar in cardiorenal protection alongside SGLT2 inhibitors and GLP-1 receptor agonists.","created":"2026-07-03T10:29:03Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"9c1cf6317423","type":"article","url":"https://hartvaat.nl/2021/02/09/omega-3-vetzuren-bij-oudere-mi-patienten-omemi-gerandomiseerde-trial/","title":"Omega-3 vetzuren bij oudere MI-patiënten: OMEMI gerandomiseerde trial","title_en":"Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.052209","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.052209","authors":["Are Annesønn Kalstad","Peder Langeland Myhre","Kristian Laake","Sjur Hansen Tveit","Erik Berg Schmidt","Paal Smith","Dennis Winston Trygve Nilsen","Arnljot Tveit","Morten Wang Fagerland","Svein Solheim","Ingebjørg Seljeflot","Harald Arnesen"],"significance":7,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":[],"congress":"","summary_en":"The OMEMI randomized trial found that omega-3 fatty acid supplementation did not reduce cardiovascular events in elderly patients after myocardial infarction, consistent with the negative findings of other recent omega-3 trials in secondary prevention.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"86d5325d4229","type":"article","url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","title":"Empagliflozine en LV-volumes bij diabetes/prediabetes met HFrEF: SUGAR-DM-HF","title_en":"Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.052186","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.052186","authors":["Matthew M Y Lee","Katriona J M Brooksbank","Kirsty Wetherall","Kenneth Mangion","Giles Roditi","Ross T Campbell","Colin Berry","Victor Chong","Liz Coyle","Kieran F Docherty","John G Dreisbach","Catherine Labinjoh","Ninian N Lang","Vera Lennie","Alex McConnachie","Clare L Murphy","Colin J Petrie","John R Petrie","Iain A Speirits","Steven Sourbron","Paul Welsh","Rosemary Woodward","Aleksandra Radjenovic","Patrick B Mark","John J V McMurray","Pardeep S Jhund","Mark C Petrie","Naveed Sattar"],"significance":7,"published":"2021-02-09","source_date":"2021-02-09","image":"","kennis":[],"congress":"","summary_en":"The SUGAR-DM-HF trial demonstrated that empagliflozin reduces left ventricular end-diastolic and end-systolic volumes in patients with diabetes or prediabetes and HFrEF, providing evidence for reverse remodeling with SGLT2 inhibition.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"0114720b0e72","type":"article","url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","title":"LAA-isolatie tijdens AF-ablatie: geactualiseerde meta-analyse","title_en":"Efficacy and safety of left atrial appendage electrical isolation during catheter ablation of atrial fibrillation: an updated meta-analysis.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa266","source_url":"https://doi.org/10.1093/europace/euaa266","authors":["Jorge Romero","Mohamed Gabr","Kavisha Patel","David Briceno","Juan Carlos Diaz","Isabella Alviz","Chintan Trivedi","Sanghamitra Mohanty","Dalvert Polanco","Domenico Giovanni Della Rocca","Dhanunjaya Lakkireddy","Andrea Natale","Luigi Di Biase"],"significance":6,"published":"2021-02-05","source_date":"2021-02-05","image":"","kennis":[],"congress":"","summary_en":"This updated meta-analysis of left atrial appendage electrical isolation during AF ablation confirmed improved freedom from arrhythmia recurrence with LAAEI, supporting this technique as an adjunctive strategy in non-paroxysmal AF.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"25848998f711","type":"article","url":"https://hartvaat.nl/2021/02/05/slokdarmbescherming-met-temperatuurcontroleren-bij-af-ablatie-impact/","title":"Slokdarmbescherming met temperatuurcontroleren bij AF-ablatie: IMPACT","title_en":"Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa276","source_url":"https://doi.org/10.1093/europace/euaa276","authors":["Lisa W M Leung","Abhay Bajpai","Zia Zuberi","Anthony Li","Mark Norman","Riyaz A Kaba","Zaki Akhtar","Banu Evranos","Hanney Gonna","Idris Harding","Manav Sohal","Nawaf Al-Subaie","John Louis-Auguste","Jamal Hayat","Mark M Gallagher"],"significance":5,"published":"2021-02-05","source_date":"2021-02-05","image":"","kennis":[],"congress":"","summary_en":"The IMPACT randomized trial evaluated an esophageal temperature control device during AF ablation, testing active esophageal protection as a strategy to prevent thermal injury during posterior wall ablation.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c95caa8de638","type":"article","url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","title":"Dalend hemoglobine en prognose bij ACS-hospitalisatie","title_en":"Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.11.046","source_url":"https://doi.org/10.1016/j.jacc.2020.11.046","authors":["Sergio Leonardi","Felice Gragnano","Greta Carrara","Giuseppe Gargiulo","Enrico Frigoli","Pascal Vranckx","Dario Di Maio","Vanessa Spedicato","Emanuele Monda","Luigi Fimiani","Vincenzo Fioretti","Fabrizio Esposito","Marisa Avvedimento","Fabio Magliulo","Attilio Leone","Salvatore Chianese","Michele Franzese","Martina Scalise","Alessandra Schiavo","Paolo Mazzone","Giovanni Esposito","Giuseppe Andò","Paolo Calabrò","Stephan Windecker","Marco Valgimigli"],"significance":5,"published":"2021-02-02","source_date":"2021-02-02","image":"","kennis":[],"congress":"","summary_en":"This study showed that hemoglobin decline during ACS hospitalization, even without overt bleeding, independently predicts worse outcomes, supporting hemoglobin monitoring as a prognostic tool beyond clinical bleeding events.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:11Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b7e54c019252","type":"article","url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","title":"Zelfzorginterventie en 90-daags uitkomsten bij acuut HF na SEH-ontslag: JAMA Cardiology","title_en":"Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":["answer-hf","dapa-hf","summit-trial"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.5763","source_url":"https://doi.org/10.1001/jamacardio.2020.5763","authors":["Sean P Collins","Dandan Liu","Cathy A Jenkins","Alan B Storrow","Phillip D Levy","Peter S Pang","Anna Marie Chang","Douglas Char","Deborah J Diercks","Gregory J Fermann","Jin H Han","Brian Hiestand","Christopher Hogan","Christina J Kampe","Yosef Khan","Sangil Lee","JoAnn Lindenfeld","Jennifer Martindale","Candace D McNaughton","Karen F Miller","Carolyn Miller-Reilly","Kelly Moser","W Frank Peacock","Chad Robichaux","Russell Rothman","Jon Schrock","Wesley H Self","Adam J Singer","Sarah A Sterling","Michael J Ward","Cheryl Walsh","Javed Butler"],"significance":6,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":[],"congress":"","summary_en":"This trial of a self-care intervention for patients with acute heart failure discharged from the emergency department showed improved 90-day outcomes, addressing the underserved population of non-hospitalized AHF patients.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"35c7c926cbdf","type":"article","url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","title":"SGLT2-remmers en CV/renale uitkomsten bij diabetes type 2: JAMA Cardiology meta-analyse","title_en":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":["canagliflozine","diabetes-type-2","sglt2-remmers"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.4511","source_url":"https://doi.org/10.1001/jamacardio.2020.4511","authors":["Darren K McGuire","Weichung J Shih","Francesco Cosentino","Bernard Charbonnel","David Z I Cherney","Samuel Dagogo-Jack","Richard Pratley","Michelle Greenberg","Shuai Wang","Susan Huyck","Ira Gantz","Steven G Terra","Urszula Masiukiewicz","Christopher P Cannon"],"significance":8,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/"],"congress":"","summary_en":"This JAMA Cardiology meta-analysis updated the evidence on SGLT2 inhibitor cardiovascular and kidney outcomes in type 2 diabetes, confirming class-consistent reductions in heart failure hospitalization, cardiovascular death, and kidney disease progression across all available agents.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"190d4628c6d5","type":"article","url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","title":"Evolocumab bij metabool syndroom na ACS: FOURIER","title_en":"Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2020.3151","source_url":"https://doi.org/10.1001/jamacardio.2020.3151","authors":["Prakash Deedwania","Sabina A Murphy","Andre Scheen","Jolita Badariene","Armando Lira Pineda","Narimon Honarpour","Anthony C Keech","Peter S Sever","Terje R Pedersen","Marc S Sabatine","Robert P Giugliano"],"significance":6,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This FOURIER analysis confirmed that evolocumab provides consistent cardiovascular event reduction in patients with metabolic syndrome, showing that the PCSK9 inhibitor benefit extends to this high-risk metabolic phenotype.","created":"2026-07-03T10:29:02Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5d0b35e7033b","type":"article","url":"https://hartvaat.nl/2021/02/01/therapietrouw-aan-single-pill-versus-vrije-combinatietherapie-bij-hypertensie-me/","title":"Therapietrouw aan single-pill versus vrije combinatietherapie bij hypertensie: meta-analyse","title_en":"Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.15781","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.15781","authors":["Gianfranco Parati","Sverre Kjeldsen","Antonio Coca","William C Cushman","Jiguang Wang"],"significance":8,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/combinatietherapie-hypertensie/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"This meta-analysis demonstrated that single-pill combination therapy achieves significantly higher adherence compared with free-equivalent combinations of the same drugs in hypertension. The data provided the pharmacological rationale for recommending fixed-dose combinations as the preferred prescribing strategy.","created":"2026-07-03T10:29:01Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"80911c6e3e6d","type":"article","url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","title":"Polsdruk, prognose en sacubitril/valsartan bij HFpEF: PARAGON-HF","title_en":"Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16277","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16277","authors":["Kota Suzuki","Brian Claggett","Masatoshi Minamisawa","Kotaro Nochioka","Gary F Mitchell","Inder S Anand","Faiez Zannad","Sanjiv J Shah","Martin Lefkowitz","Victor Shi","Marc A Pfeffer","John J V McMurray","Scott D Solomon"],"significance":5,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/"],"congress":"","summary_en":"This PARAGON-HF analysis showed that pulse pressure is a prognostic marker and may modify the effect of sacubitril-valsartan in HFpEF, linking arterial stiffness to treatment response in preserved ejection fraction.","created":"2026-07-03T10:29:01Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"98fa19810f4c","type":"article","url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","title":"Urinezuur, bloeddruk en CV-ziekte: Mendeliaanse randomisatie en meta-analyse","title_en":"Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.16547","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.16547","authors":["Dipender Gill","Alan C Cameron","Stephen Burgess","Xue Li","Daniel J Doherty","Ville Karhunen","Azmil H Abdul-Rahim","Martin Taylor-Rowan","Verena Zuber","Philip S Tsao","Derek Klarin","Evangelos Evangelou","Paul Elliott","Scott M Damrauer","Terence J Quinn","Abbas Dehghan","Evropi Theodoratou","Jesse Dawson","Ioanna Tzoulaki"],"significance":6,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":[],"congress":"","summary_en":"This Mendelian randomization and meta-analysis study showed that genetically determined serum urate levels are not causally associated with blood pressure or cardiovascular disease, suggesting that the observational association is confounded.","created":"2026-07-03T10:29:01Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"16217e73274f","type":"article","url":"https://hartvaat.nl/2021/02/01/revascularisatie-bij-ernstig-verminderde-lvef-korte-en-langetermijnuitkomsten/","title":"Revascularisatie bij ernstig verminderde LVEF: korte- en langetermijnuitkomsten","title_en":"Short-term and long-term outcomes of revascularization interventions for patients with severely reduced left ventricular ejection fraction: a meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","diabetes-en-hart","ouderen","vrouwen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13141","source_url":"https://doi.org/10.1002/ehf2.13141","authors":["Junyu Pei","Xiaopu Wang","Zhenhua Xing","Keyang Zheng","Xinqun Hu"],"significance":5,"published":"2021-02-01","source_date":"2021-02-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis compared CABG with PCI outcomes in patients with severely reduced LVEF, providing evidence to guide revascularization strategy selection in the most depressed ventricular function.","created":"2026-07-03T10:29:01Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"5b67d2d4fb08","type":"article","url":"https://hartvaat.nl/2021/01/28/inhalatietreprostinil-bij-pulmonale-hypertensie-door-interstitiele-longziekte-ne/","title":"Inhalatietreprostinil bij pulmonale hypertensie door interstitiële longziekte: NEJM INCREASE","title_en":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog"],"tags":["pulmonale-hypertensie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2008470","source_url":"https://doi.org/10.1056/NEJMoa2008470","authors":["Aaron Waxman","Ricardo Restrepo-Jaramillo","Thenappan Thenappan","Ashwin Ravichandran","Peter Engel","Abubakr Bajwa","Roblee Allen","Jeremy Feldman","Rahul Argula","Peter Smith","Kristan Rollins","Chunqin Deng","Leigh Peterson","Heidi Bell","Victor Tapson","Steven D Nathan"],"significance":8,"published":"2021-01-28","source_date":"2021-01-28","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/therapietrouw-hypertensie/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"The INCREASE trial demonstrated that inhaled treprostinil improved exercise capacity in patients with pulmonary hypertension associated with interstitial lung disease. This was the first therapy proven effective for this specific, previously untreatable form of pulmonary hypertension.","created":"2026-07-03T10:29:01Z","updated":"2026-07-03T13:28:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f0286e6faef9","type":"article","url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","title":"Cryoablatie of medicatie als initiële AF-behandeling: NEJM STOP AF First","title_en":"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa2029980","source_url":"https://doi.org/10.1056/NEJMoa2029980","authors":["Jason G Andrade","George A Wells","Marc W Deyell","Matthew Bennett","Vidal Essebag","Jean Champagne","Jean-Francois Roux","Derek Yung","Allan Skanes","Yaariv Khaykin","Carlos Morillo","Umjeet Jolly","Paul Novak","Evan Lockwood","Guy Amit","Paul Angaran","John Sapp","Stephan Wardell","Sandra Lauck","Laurent Macle","Atul Verma"],"significance":9,"published":"2021-01-28","source_date":"2021-01-28","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/esc-richtlijn-af-2024/"],"congress":"","summary_en":"The STOP AF First trial confirmed that cryoablation was superior to antiarrhythmic drug therapy as initial treatment for paroxysmal atrial fibrillation, with significantly fewer patients experiencing treatment failure at 1 year. Together with EARLY-A